_ . ·.

. .·' .'.• :... · : ..·.-' ·'\.:

.
·.' · ..:· .':· .':.' .; ' : ·�.,· ...- .· .
't ' ' ' '•
· -·;'- ;·;.. . . ..'. . ... ' . · . :.
..
· ·- .- ,
, ,-·, -. ·,. _ .'_ _ . · : . - · .- _- _ ·_ ·, ..
.'
.
· '

,.: . :--
.. :._
,

' . . .' \. .
. . _. .

--·.... -
.· ·- _- ·'_-.·· ... .. _ ·.- · . . .. .. .-- '.- . . . .·....' ' . . .·..·- .;,,··'- _-. .. .._- ·' ·- .'...
_
,.
.
_.

- . - .. . . _ ' ·_ .., ;
';. . - .··;·. .
.
. _ - -;.
. . ..

-'.�. '. . .. · - . .
· . . . _ . . . . '- _.. :, .-· �--.: .
. . . :_ ,
• • .•-•.-.. • • •• ... . . . .
· . : .. .
.-:...:..· .- .. ...
.
..

· ·'. .. · .".- ''_.·- _· .·_ .. . - . · - . ·

. .

...·. .
.

. . .... . .
II praises �nd gratitude be to Almighty Atlah S _ \Jbhanahu wa ta'ala,the blessings of whom made us enable to ··• . . . ·<···
.
.. � ·.,.- .
·.;.; z.�_ ,,; . · · .
·

publish QIMP-17th edition. Although,after a tong and hard work we could present thjs edition to our worthy readers, :
. .
we still apologize sincerely for unwilling delay in publishing this issue. · ·

· ·� , · ·

QIMP (Quick lnde)\ of Medical Products & Problems) is primarily an index for rapid references of clinical problems and
7 -;_ - - -�
. - -� -�
therapeutic information of different pharmacologicaJ products. This book has been prepared with the intention to- · .· · ,
-' . 5;- 's� :
-
-
provide updated but brief prec::cribing information of . the drugs manufactured locally: .. and imported from abroad; : .·
and also to provide. recent & comprehensive manage'ment schedule of the common rn�dical problems simultaneou-.· ;. -• �.;· ; .·:; . . ·
.. · . ·
.···
.
sly, to the medicaf· gractitioners and professionals. ·. .. ·
. · . . .: /
. · · .
. '
·. . .. .·. · · : · .· : · . · · . · : . . . .::· :.. . .· . : : . . : . · .
· , . .·.

: .. : ; :: :{: : .. : .... : � ; . - · - -. . . .·
)c
Dear reader, y�5f' tf !w, QIMP has been publiS�lti{, ih �wo parts, Clinical & Th�����Utic since 14th edition anU \. . ,

in three parts including 'Doctors Directory' from ·16th edition due to it's gradual-increasing in volume every · ·· · ·· ·· ··.�� ·.
• •• . .
year. This year, wf! also decided to continue providing 'QIMP ...17 Doctors Direetory' as complimentary with· > S;: ...
. . . . . �· - ·' · · .
the main therapeautic part as last year. In this issue, we could not continue the seC.tion of 'Research & Devel...
opment' for some technical reason. We hope, in the following issues, we would be able to include the same
lnsha-Allah.

... .'
.
In the therapeutic part,we tried to incorporate the current & latest information of important drugs & preparations of • · f{::� ·
· · . ..·
different pharmaceutical manufacturers & importers; as was available at the time of editi·on.ln every issue, a number · · · _ :r\ > _
. •. • •
of new products are-·always missing which are launching during the period of publicatioo & after publication; there is ·. ·
{
.. .·.
· · ··
no way to make .th�m available in the current issu·e>�ut to wait for the next edition. <· · c';. '° . · · ·
· . . . . (� %'
.�
xi i.;
.
' ii � fi };i t;Wj
.· . . - , \· -- - · . .· . · . · · . • · ·. · . · · . . · · · . .· , . ., ·.· · .· · . · · \"
' ·• · • '.· ··'.,; ,-- ·.-· ·._ ·· .- :.: . .. . . ;. • \ c ;· . • ··. .
· ' .· o · - · • ; , - · /
- > •
. . . · ,, : - . ..
· •
. ' ·- :_". ,-_' .,: '_ -·,·--- .-.',.'. '. _.:<·_ .o.- . _ , '. . . . , .. :..- -
. .:. : \: ,. , • ,.-' .· ': �
.

,: : :.:� : ._ :
.. f
The QIMP, as is rnt:�_,;ded to be a desk book for rapid reference, cannot contain alt the\information necessary for ' :,_ : . ;::;
' ·, ;
treatment and p'rescribing medicines. The information should be supplemented as .necessary from specialized \..\ �,W ; ·
·
publications and addltional information may be collected from manufacturers or importers concerned. Price rates of ";· ;{�' ·
. . �'--. � .
··.

different medical products given here in the book are of the time of price list collection.These are subject to change
at any time.

In preparing the manuscript of this book, we took help from different textbooks,magazines, periodicals,formulary, '·� •·
. · · · '..-
.. ·

guides and manufacturers literature. In the reference list,we acknowledged them. We would also like to express our · •. �:� 2 : •<
gratitude to the respective authors & publishers. · · · . · ··. · ·
.. . · , •
.. ·.. ·. - ·. • •
• · . · . :
{'_::
. ' .
.• • .--- - .·' ·- . .• • • • • • - ·; · . • · . . , . . . .:.·-:· .. . . . . ··
• •
·· _ . · ' •- , :" •·•.•,.•:-•\· '·.•• '-. ,· . .
.

· .• _. · _•· ., •_.• .
·..

. . . • • • - •
· • .

· - . .· . . ' . · , . ·
.

• .' -
· .
. . . ·' . .· · ; ·,· :..;-. :..'.. ; . . .. . . . . ".
- o \;. • '• . • • · . . . · .
__
-
'
· . . '... .... "" .
· ·, .:,_', ._ .· ·.. . : . . . ' . ' " . . . '. . : ... • , .
·. .
. _ . .· :_ ..
.
. _ -
' ·
- ' . ·. _ - ·
- , . \ · . • • •
:> • ..
- , . . . - . ' . . -· .
- .
·- ' .
. - . :
-
· . -.. . . . .. . .
•

- - :: '; . . . . .
Dear readers, despite 6ur all efforts & means to make the text as accurate as possiple,there is likelihood of so many .. ·· · ..·· :· · ;. " · ·.
·..· · ·. ·
errors & mistakes in sorting innumerable information of such a big publication. Therefore, we do welcome and
· · . •
.
·

request the readers to send us their comments and constructive criticism regarding errors and inaccuracies. For pro- :· . ··

- c • •
gressive improvement of such a work, a feed back is essential. -

This edition of QIMP has also become possible with the help and cooperation of some of my friends and colleagues. I
am so much grateful & indebted to them. l would also like to express many tha-nks to the advertisers who have
extended their cordial cooperation. .
. .
c;_. -
. ' - . . ';:·_... '.... ..
. ,- . .
''. .\ ; · .· . · .
.
last of all we furtb'.€r submit our all praises and worship to the Almighty Allah, the grac� .�ncl blessings of whom made ; :; �•; • ·
, : i� ..,Jr-;':. · .. · . · ·• > · .·
•

·
>

it possible to coT1tfnt.1e•the publication until this.ti.rt"\��···:' .· · · ··

. : . . . .•· .
· ·• ·; ·
. . . - . . . ' .·- · - · - .··- " . . .. . . . ... .' .. . . .. . . . .
. . . -. .'., . . . . . . . . . .
:

. . '.\ ',- ·:-,. . .·. ·- . · · . . . •: . ·- • • • . • ' t- . .

·

_. , ...· . � .- ... -. . .
·.' '. .� . . .. ..
..

. . . ... . . . ·- .- .. _- - . . . .
·
-
. - ··. .· . . . . . .: . . _. _
Februarv1 2014 .·. .. . Editor
-

. ..• .
... .
- · .·_.. .·,,"\
'._ . .
.. .
·
. . . :·,·.: : .- . .
.:.
: · .' .- .· · ..· -.· - .
·.

· . _\ · .:. .
. . · - - .· .'-:: ... :
' ., � ·� ...: ..
• •-
· · .- "

- .:· .: · .
�
. • -;: :.o.• • •.
. · .·' ·. .. .· .
.
. . . . . - .. .- ..
. ...
.
.

. •. .

• ·.. - '.
. ' ._.' ... . . ..
. ,"_...,.:. .. . ·- - . .
' · �.- :- '· .. ..
' .. .

. .·._.- · .. .

· .

. .. . .

-
�- ---

I Ct1rrent Medical D1agnos1s &Treatment-20 l 0, 49th Edit1011 b)' Stephen
J. McPhee, MD, Prof. ot'Med1crne. Department ot' Medic1ne. l Int\ ersity
of California, San Francisco; Maxine A. Papadakis, MD, Prot·. of Clinical
Medicine, School of Medicine, University of California, San Francisco &
soine of the previous editions. Published by McGraw-H1ll Compa11ies,
Inc, USA.
2. Devidson's Pn11ciples &Practice ot· Medicine-20 I 0, 21st Edit1011 by
Nicki R. Colledge. BSc. FRCP (Ed), Br1an R Walker. BSc. MD FRCP
(Ed), &Stuart H. Ralston, MD FRCP FMedSci FRSE, and some of the
previous editions. Publisl1ed by Churchill Livingstone Else 1ier, an in1pr1nt
of Elsevier Ltd,UK.
3. Clinical Medici11e. 4tl1 Edition, by Parveen Kumar &Michael Clark &
previous edition.
4. Harrison's Principles of Internal Medicine, 1 3t11 Edition
5. Macleod's Clinical Exa111ination, 9th Edition. by John Monro &
Chnstopher Ed\vards.
6. Bailey &Love's Short Practice of Surgery, 1 9th Edition (? ).
Revised by Cl1arles V Mann. R.C G Russell, Norman S. William .
7-12. References belongi11g to these nt1mbers are not coi1cerned w1th the
therapeutic part of QIMP.
13. Nelson Textbook of Pediat1ics, I 3tl1 Fdit1on. by Beh11nar1 and
Vaughan.
1 4.Current Ped1atr1c Diagnosis &Treatment, 13th Edition Fd1t1ed h\'
William W. Hay, Jr. Jessie R. Groothu1s. Antl1ony R. Hay\\ ard. Mv·ron J.
Levir1.
1 5. Signs And Syt1dro111es 111 Cli111cal Medici11e, 1 s t Ed1tio11 by Dr. Y
An1n.
16. Tropical Paediatrics Handbook, by Nestle Nt1trit1on Set" ices. Edited
by Dr. Philippe Goyens, Dr. Paul-JacqL1es Latnotte.
17. Essence of Paediatrics, 2nd Edition (&previous ed1tio11). by Prof.
M.R. Khan &Dr. M. Ekl1lasur Rahman.
18. A Text book of Ophtl1almology (Author's name could not be collected
due to absence ot· t11e conce1ned editorial assistant).
19. A Text book of ENT (Author's name could not be collected d11e to
absence of the concerned editorial assistant).
20. Lecture notes on Paediatrics by Prof. M.R Khan &Prof. i\.1 Q K.
Talukder.
21. BNF- Brit1sl1 National Formulary �un1ber 65 March-Septe111ber 20 Ii
&Previous editions, by British Medical Association and the Royal
Pharmaceutical Society of Great Britain.
22. Clinical Pharmacology, 8th Edition, by D.R. Laurence. P.N Ben11etr &
M . .J. Brown.
23. Goth's Medical Pharmacology, 12th edition
24. MIMS Bangladesh. Issue-2, 2006. by Wong Mei Cr1an. CMPMed1ca
Asia Pte. Ltd.
25. MIMS Annt1al, Mya11mar 1997, by Medi Media, Asia Ptc. Ltd.
26. Literatt1re provided by the lncepta Pharn1aceut1cals Ltd Dl1aka
27. Prof. M.N Alain. Tl1e Orion' medical journal, VolL1me-6, 11ay 2000.
28. Lecture notes on Surgery &Orthopaedics by different srl1olers.
29. Lecture notes 011 Ophthalmology by dife
f rent scholers
30. Lecture notes on ENT by different scholers.
31. Hutchison's Practical Paediatric Problems, Last edition (?) ( ( Llrrentlv.
Children medicine &surgery).
32. Paediatric Yade-Mect1m, 12th edition 1990, edited by Jacl� lnsley�
Pt1blished by Arnold, A member of the Hodder Headline Grot1p, London.
Sydney, Auckland.
33. Compilation from literature of different concerned mant1tact11nng
authorities.
�4. T,iterature provided by the General Pharmaceuticals Ltd. Dl1aka.
.)5 I 1tcratlrre pro,·ided by the Sanofi Anentis, Dhaka.
�6 l 1terature provided by the Aristopl1anna I .td, Dhaka.
..
37 Literature of Malesci, Provided b)' the local agent M.C. Roy
Cho\vdhu1y &Co Ltd. Dhaka.
)8. I 1terature prov·ided b)' the Hamdard I.aborator1es (Waqf) Bangladesh,
Dhaka.
39 I iterah1. re provided by tl1e Jayson Pharmacet1t1cals Ltd Dl1aka.
40. Literature provided by the Organon Bangladesh Ltd (curre11tly
Nuvista Pharn1a I.imited), Dl1aka.
41. Literature provided by the Hoechst Marion Roussel Ltd. Dhaka.
42 l iterature provided by the Square Pha1�naceuticals Ltd, Dhaka
43. Literature provided by the Sonear Laborato11es Ltd, Dhaka. 44.
I iterature provided by the Sun Pl1armacet1tical Indttstnes Ltd. Dhaka
45. Literature pro\rided by the Opsonm Chen1ical lndt1stries Ltd, Dhaka.
46. Literature provided by Tl1e Acme I.aboratories Ltd, Dhaka.
47. Literature provided by the GlaxoSmithKline Bangladesh Ltd. Dhaka.
48. Literature provided by the Bexi1nco Pharmaceuticals Ltd, Dhaka.
49. Literature of Abbott T aboratories USA, provided b y the local agent,
Un1Health Limited, Dhaka.
50. Literature provided by the Roche Bangladesh Limited, Dhaka
51. Literature of Bristol-Myers Squibb of Pakiastan, provided by the local
agent Kapricorn Enterprise Ltd, Dhaka.
52. L1terature provided by the ACI Ltd, Dl1aka.
53. Literature provided by the Servier Laborato11es Ltd, Bangladesh
Office, Dhaka.
54. I.iterature pro\ ided by the Novartis (Bangladesh) Ltd, Dhaka.
55. Literature provided by the Jayson Natural Products Ltd, Dhaka
56 Literature of Human Drug Com, provided by the local agent City
Overseas Pro1notion Office, Dhaka.
57. Literature provided by tl1e Sanofi Aventis, Dhaka.
58. Literature of Gedeon Richter, provided by the local agent, Cit)
Overseas Promotion Office, Dhaka.
59 I.iterature of Slo' akofarma, pro,·ided by the local agent, Cit) 0\ erseas
Promotion Office. Dhaka.
60 Literature of Pfizer-Pharmacia p1·0, 1ded by the local agent, Janata
Healthcare, Dhaka.
61. L1tcrature of Apll1a Therapet1t1c Corporation USA. provided by tl1e
local agent Shuvro Ltd, Dhaka.
62. I iterature pro\·idcd by the Renata Limited, Dhaka
63 Literature of Abbott Laboratories Pakistan, provided by the local agent
U111Health Limited. Dhaka.
64. Literature provided by A. H. Janakalyan Pharmaceuticals (Waqf)
Bangladesh, Dhaka.
65. Literatl1re provided by the Eskayef Bangladesh I.td, Dhaka. 66.
Literature provided by the Amico Laborator ies Limited, Dhaka
67 Literature of H. Lt1ndbeck AS. Denmark, pro\1ided by the local agent
Lilac Private Limited, Dhaka.
68. Literature of N orgine Limited U.K, pro\ 1ded b)' the local agent Lilac
Private Limited, Dhaka.
69. Literature of Chino1n Phannaceut1cals lJtd Hungary, provided by the
local agent, City Overseas Ltd, Dhaka.
70 Literature of Serono Laboratories (LJ.K) I td, provided by the local
agent Janata Healthcare, Dl1aka.
71. Literature ot' Scl1er1ng-Plough Ltd, I't O\- 1ded by the local agent Janata
flealthcare, Dhaka.
72. a) I iterature pro\ idcd by the City Overseas Promotion Office,
Dhaka.
b) I iterature of B1ogal provided by tl1c c:1ty Overseas Promotion
..
Office, Dhaka.
71 L1terature of Leo Pharmacet1t1cals. pro ·ided by the local agent
Kapr1com Enterprise Ltd, Dhaka.
74. Literature of Sea1le Pakistan, pro' ided b)' the local agent �1 S
Meclina111, Dl1aka.
75. I iterature provided by the Pha1n1adesl1 1,aboratories l,im1ted. Dhaka.
76 Literature provided by the Hoechst Marton Roussel Ltd. Dhaka.
77. I iterature of Grune11thal, provided by the local agent UniHealth Ltd.
Dhaka.
78. literature prov·ided by the Navana Pha1maceuticals Ltd. Dhaka.
79 l 1terature of Menar1ni International Italy, provided by the local agent,
 M.C. Roy Chowdhury & Co. Ltd, Dhaka.
80. Literature of Efroze Chemical Pakistan, provided by the local agent
City Overseas Ltd, Dhaka.
81. Literature ofStiefel Labs Ltd, provided by the local agent UniMed
Pharma Limited, Dhaka, Currently GlaxoSmithKline Dhaka.
82. Literature provided by the Sandoz Bangladesl1 Office, Dhaka.
83. Literatt1re of· S.K. Beechan1, provided by the local agent GlaxoSmith­
Kline Bangladesh, Dhaka.
84. Literature of ICN Pharmaceuticals Inc, provided by the local agent
Janata Healthcare, Dhaka.
85. Literature provided by the Mundi Pharma Ltd, Dhaka.
86. Literature provided by the Pacific Pharmaceuticals Ltd, Dhaka.
87. Literature provided by tl1e Orion Pharma Ltd, Dhaka.
88. Literature of Lab. Doms Adrian, provided by the local agent M.H
Multiplex Ltd, Dhaka.
89. Literature ofTeijin, provided by the local agent Janata Healthcare,
Dhaka.
90. 1.iterature provided by the Edruc Ltd, Dhaka.
91. Literature of Green Cross, provided by the local agent Shuvro Ltd,
Dhaka.
92. Literature ofAlpha Therapeutic Corporation. USA, provided by the
local agent Shuvro Ltd, Dhaka.
93. Literature ofPharmachemie, provided by the local agent S.B Traders,
Dhaka.
94. Literature ofMedochemic Litnited, provided by the local agent
Hyeimpex Ltd, Dhaka.
95. Literature of Zeneca, provided by the local agent ACI Ltd, Dhaka.
a) Literature of Ely Lilly Pakistan Ltd, provided by the local agent
International Age11cies (BD) Ltd, Dhaka.
96. Literature ofAsta Medica Ltd, provided by the local agent Sanofi
Aventis, Dhaka.
97. Literature ofMSD, provided by the local agent Sclavo (Bangladesh)
Ltd, Dhaka.
98. Literature ofConnaught, provided by the local agent Sanofi Aventis,
Dhaka.
99. Literatltre ofGr1fols S.A, provided by the local agent Shuvro Ltd,
Dhaka.
J 00. Literature of Altana Pharma, provided by the local agent M/S. Ultra
Pha1ma, Dhaka.
10 I . Literature provided by the Opsosaline Ltd, Dhaka.
102. Literature of A Icon Laboratories (U.K) Ltd, provided by the local
agent Globex, Dhaka.
103. Literature provided by the Reman Drug Laboratories Ltd, Dhaka.
104. Literature ofBioche1n1e Austria, provided by the local agent MIS.
Swadesh. Dhaka.
105. Lippincott's Illustrated Reviews: Pharmacology, 2nd edition by Mary·
J. Mycek, Richard A, Harvey & Pamela C. Champe, Published by
Lippincott-Raven Publishers, Philadelphia, New York.
J 06. Literature of Janssen-Cilag Austria, provided by the local agent MJS
UniHealth Limited, Dhaka.
107. Literature ofEisai Co. Ltd. of Japan, provided by the local agent
Square Phar111acet1ticals Ltd, Dhaka.
108. Literature of Bayer Pharma Ltd, provided by the local agent
Square Pharmaceuticals Ltd, Dhaka.
109. Literature ofUCB India Ltd, provided by the local agent ACI Ltd,
Dhaka.
110. Literature of Rhodia Organic Fine Ltd, provided by the local agent
H1·1mpex Ltd, Dhaka.
111 .a) Literature of Janssen, Belgium, provided by the local agent Tajarat
..
Health Care, Dhaka.
111. b) Literature of Cilag Ag Switzerland, provided by the local agent
Ta Jarat Health Care, Dhaka.
112. Literature ofNebo a/s, Denmark, provided by the local agent Tajarat
Healtl1 Care, Dhaka.
113 Literature provided by the Gonoshasthaya Pharmaceuticals, Dhaka.
114. LiteratL1re ofAlfa Wassermann s.p.A Italy, provided by the local
agent Hyeitnpex Limited, Dhaka.
115. Literature ofPharmachemie, provided by the local agent S.B Traders,
Dhaka.
116. Literature ofGreen Cross Plasma Derivatives Corp. Korea, provided
I
by the local agent rfajarat Health Care, Dhaka.
117. BDNF- Bangladesh National Formulary, 1st Edition, November 2001
by Directorate ofDrug Administration, Bangladesh Medical Association
and Bangladesh Pharmaceutical Society, Dhaka.
118. Literature of Fresemus Kabi, provided by the local agent Hyeimpex
International Limited, Dhaka.
119. Literature ofBaxter Bio Sc1ence Viem1a/Austria, provided by the
· . local agent Ultra Phan11a, Dhaka.
120. Literature provided by the Alco Pha1ma, Dhaka.
121. Literature ofDBL, provided by the local agent M/S Globex, Dhaka.
122. Literature ofNovo Nordisk, provided by the Novo Nordisk local
office dhaka; and by the local agent, International Agencies, New
Eskaton, Dhaka & MIS Transcom, Dhaka.
123. Literature of Biotest, provided by the local agent UniMed/UniHealth
Limited, Dhaka.
. 124. Literature provided by the Delta Pharma Ltd, Dhaka.
125. Literature of Pfizer, provided by the local agent Janata Healthcare
Limited, Dhaka.
126. Literature provided by the Gaco Phar1naceuticals Ltd, Dhaka.
127. Literature provided by The Ibn Sina Pharmaceuticals Ltd, Db aka.
128. Literature provided by The Peoples Pharma Ltd, Dhaka. 129.
Literature provided by the UniMed/UniHealth manu·facturers Ltd, Dhaka.
130. Literature provided by the Drug International Limited, Dhaka.
131. Literature of 'Biotech', provided by the local agent Roche Bangladesh
Ltd, Dhaka.
132. Literature provided by the Hallmark Pharmaceuticals Limited,
Dhaka.
133. Literature provided by the Popular Pharmaceuticals Limited, Dhaka.
134. Literature provided by the Techno Drugs, Dhaka.
135. Literature provided by the Healthcare Pharmaceuticals Limited,
Dhaka.
136. Literature provided by the Aexim Pharmaceuticals L1m1te4 Dhaka.
137. Literature ofMerck KGaA, provided b y the local agent Techno
Drugs, Dhaka.
138. Literature provided by the Beacon Pharmaceuticals Limited, Dhaka.
139. Literature provided by the Silva Pharmacet1ticals Limited, Dhaka.
140. Literature ofActavis U.K, provided by the local agent Tajarat Health
Care, Dl1aka.
141. Literature provided by the Apex Pharma Limited, Dhaka.
142. Literature provided by the Deep-Laid Pharmaco Limited, Dhaka.
143. Literature of Allergan, India, provided by t11e local agent City
overseas Ltd. Dhaka.
I 44. Literatu1e of Dermagenics, Europa BV, provided by the local agent
Unimed Ltd. Dhaka.
145. Internet sources. •
146. Literature provided by the Phatmasia Lin11ted, Dhaka
14 7. Literature of· Cipla lillllted, Mumbai, India, provided by the local
agent Bangladesh Thalassemia Foundation, Dhaka.
148. Literature provided b y the Ziska Pharmaceuticals Limited, Dhaka.
149 (a). LiteratL1re provided by the Kumudini Pharma Limited, Dhaka.
149 (b). Literature of Solvay Pham1a provided by the local agent
Unihealth Ltd, Dhaka.
150. Literature provided by the Kemiko Pharmaceuticals Limited, Dhaka.
151. Bangladesh Paediatric Association- Modified Immunization
Schedule.
152. Literature provided by the MonicoPharma Limited, Dhaka.
153. Literature provided b y the Amulet Pharmaceuticals Limited, Dhaka.
154. Literature provided by the Nipro JMI Pharma Limited, Dhaka.
155. Literature provided by the SharifPharrnaceuticals Limited, Dhaka.
156. Literature of wyeth, (a subsidiary ofpfizer inc.) provided by the local
agent, Janata Healthcare, Dhaka..
157. Literature ofB. Braun, Melsungen AG, Germany, provided by the
local agent, City Overseas Ltd, Dhaka.
158. Literature of Purnava Ltd, provided by the local agent, Renata Ltd,
Dhaka.
159. Literatt1re provided by the ·Radiant Pharmaceuticals Limited, Dhaka.
. 160. Literature provided by the VN Ayurvedic & Neutraceuticals Limited,
Dhaka.
161. FDA Pregnancy categories: www.drugs.com/pregnancy-categories.
---�- ,�,,,_,.
,_,_..
.._ -:--.·"'���.,•,
.. >··•r•••�,."•�-�
-,;o..<,..�·<-'-.,�"'-"'•"'··�•• ·•••"� r .r. � • •��r·�·" . o �·�··•�·•,•,yy ,y rMnrY"
,..,. ,,..,
,.,, 'i'""""
,.,,.
'
 . ,
, . .

-.
-• -

I. -

· ·.
-

.- .

Preface
Reference '
I\
Index

lX
.· . . .

Section-1
Therapeutics (Chapter 1-22)
I
Missing Drugs (Chapter 23) F I 1 • r I I 3 JUl llll •• I I I

..\...5_8
\ .- _..?
1111 Ill F

Section-2
Indigenous Medicines ,
588
"''. " " '
..."'". ""
....
,.."'""'"
. . ....
. .·-""' - """'"'"
_,,,., ' " "'
'"___........ ..
,
... ' '"
"' " "
'' '
"'- "' ....

l·M'>�tlMO-�
,..

Section-3
Appendices 11111
I n.... .. I I .
•1•11•..
II7••• •SHI 111111 I lII I• SblWI Irs II I I I I I oO' 'O
o

"\II 0.!?....
I I
II r I

Hematological Values
I ..

I II t•

CSF Picture in diferent Meningitis \

6I9
"'"'""""" "'""'" "" " II 11",.
"""' ,
. """""""'""'" " """""'" """' ""
11'"'""'"11 "''"" ""'
"'""'"'"""""'"""""""'""'""""" """ ' """""II""'

Immunization Schedule ,0,!.?..,.

111111t•11111
111e;11111u;�

., '
•O 04
".,
OI 040
OU OUW IU Oo
...0
IOo
O 110mnllO110o
0 11.
0 m
110
..•1••0
'"""'"
'•oolOIOO•l•OIOO•o.
AOoo x
11
o mo
o1
o ..
•••••
o '"'
' o
° "OW•'1
•o
l•noo
"'Oii•On
111i
0 i •110
0 UOU 0OIO "0 0 0 0 0 0" 0 0 0 0I
0'\.

FDA Pregnancy Categories

O" O
0 U U

620
IW I•

\
'q

EDD & Obstetric table

•••

620
L
I I I 11 II 1 I 1 1 lfl I IMM'•1f1HH••1111111 SllllllUlll 11111111
1111 lllLJl 11111N•
1J11
lfl:l• 1-•R1
.. I I 1SiiR I 1 l II

\....
'

Indices
Pharmaceutical Company Directory \
6 )( I
1111"'""'" I llOllllOh
II"'"""'"'"'"" " "" """'
"'""""
'"'"" '"'"""
'*-''''''
"''"""'"""""""""'"'""'"""'"'"' '" "'"""'"""" '"'"""'"''"'

'
'

Alphabetic Therapeutic Index

Ull
1111:
1I
HlltM
..Gtl�lfM'llU
Il
fi �
l

IOldlU llUIUIHUOl lHlOI

O•o ..
••u• n lll
o•l •l•IO" m U I O O OIOIO"OHi

62 5
dM ""
" '
,_"""'
°"
°"""""" "'°"'""'
IW""" " """
'"""'° I '
" OI
ol hhll04
*"\
"

llllJ
l fttHIF111111111111 111�--

I
 QIMP-17 (IX) INNER INDEX

I..
,
. . .. .
I.
.
.

I
I •I . . .
.
.
.
I'
,
.

22. Peripheral vasodilator drugs 79

Section-I 23. Intermittent claudication 79
r

. ...
. . . . . 24. Drugs for muscular energy • •
· . : :. .
. .
.. . . .: · . · .
· ··· · . · ·· · :. -...· ..: . .' ··· .
. ·•.
. RAP
THE.
. · :·.
E u : · T .
• : ·1: · .
c . P'
' . .......· .., .' ..: .' . :. .. ·: ... .. ... .. : . .
- .: , · . ·
; '. ; .A· .
c· · · · E· · ··IN · ·· ·
· n ·
. . ..· .E · x metabolism 79
··
;

·
.

.
· : '. .
'

25. Sympathomimetics 80
26. Inotropic sympathomimetics 80
1. Gastro..-inte.stinal Drugs ··· · . l.
.. .
27. VasoconstrictorNenotonic 81
1. Antacids 1 28. Anticoagulants 81
· ····· ···•· ·
2. Antacids with laxative action 29. Antiplatelet drugs 83
· 5
3. ..· Anti-dyspeptic & carminatives . 5 30. Fibrinolytic drugs 86 ""-•!•

4 . . ·. Anti-spasmodics /Antimuscarinics 6 31. Antifibrinolytic drugs 86

5. .. • Anticholinergic & anti-psychotic 32. Coagulant IHemostatic drugs 86
combination products . 11 33. Antihemophilic factor 88 •
•
34. Lipid regulating drugs 88
� .

. 11 �J�200.+.w.
'" "--- :.

1
6. Motility stimulants · ; +
� Af�me400 ..,..
� !\
,,
- _,.,..
,.'-0.,,.

..
j. �: ��'"'::,;- ..., j�;
7 ..
Asiof'I<
14
:

Ulcer healing drugs 4J. 'l'lf:

. �.�.;:_��.1�.":!">.'! "'.°"' �:"""'·
-
··'.
.t �'!�4f
'
'3
. . !f!!"
·
. ll".i�!?.t:':
t
. if
.�
'"'
- --

�?;� ��- -.�-��"':;.:;'.. �· ,-,!'�:. ��.

# A.s"lltlC f.
Drugs used in Respiratory · ·
�--
3. .....�-"'!"��,...

8. H 2-Receptor antagonists 14 . •" . �. �.

diseases 95
9. .Prostaglandin analogues 16
10. Proton pump inhibitors 17 1. Bronchodilators 96
..· ..
'
,

11. Chelating complexes . 28 2. Adrenoceptor stimulants 96 .

;

.
. ; ;.
':
.. .

12. Therapy forH. Pylory. . .. 28 3. Antimuscarinic bronchodilators 102

··
13. Anti-diarrhoeal drugs · 29 4. Theophylline & related drugs 103
14. Antimotility drugs 29 5. Prophylactics of asthma 105
.. 15. Anti-diarrhoeal antimicrobial drugs 29 6. Respiratory corticosteroids 110 .
·
�\..

-��\-�''-:Jl•i� '
· 16. Anti-diarrhoeal antiprotozoal drugs 29 7. Anti-allergic, anti-infammatory & ·
17. Water purifying agents 31 hyposensitisation drugs 117
Trusted
18. Drugs for chronic inflammatory 8. Cough preparations 118
bowel disease 31 9. Respiratory antihistaminics 123 oral 3rd generation
19. Drugs for Ulcerative colitis 31 10. Respiratory stimulants I Analeptics 123
20. Irritable bowel syndrome (IBS) 32 11. Pulmonary surfactants 123 cephalosporin with
21. Laxatives & Purgatives 32 · 12. Morphine & other narcotic
22. Abdominal gas adsorbents 36 analgesic antagonists 124
excellent coverage
23. Preparations for Aphthous ulcer 36 13. Aromatic inhalations 124
24. Local preparations for anal & rectal ..
4. Drugs used in CNS diseases 124
disorders 36
25. Drugs affecting exocrine & •
1. Hypnotics/Benzodiazepines 124
intestinal secretions 37 126
2. Barbiturates
26. Treatment of dry mouth 38
3. Trichloroethanol derivatives 126
27. Digestive Enzyme 38 Cefuroxime 250 mg, 500 mg Tablet & 70 ml PFS
4. Sedative & Tranquillisers I
28. Anti-gallstone drugs 38
Anxiolytics 128
..

. . . . . .. . 5. Antipsychotic drugs 131

2. Drugs acting on Cardio·v�scula.r
6. Antimanic drugs 137
System · 39
7. Antidepressant drugs 137
1. Anti-arrhythmic drugs 39 8. Tricyclic antidepressants 138
2. Positive inotropic drugs 41 9. Monoamine-oxidase inhibitors 139
3. Cardiac glycosides . 41 10. SSRis & related antidepressants 139
4. Anti-hypertensive drugs 41 11. Combined antidepressant prepns. 145
5. Centrally acting antihypertensives 41 12. C.N.S stimulant drugs 145
6. Beta-adrenoceptor blocking drugs 42 13. Drugs used in nausea, vomiting &
7. · Alpha-adrenoceptor blocking drugs 47 vertigo 146
8. · Drugs affecting the renin- 14. Drugs used in vestibuler disorders 146
angiotensin system 48 15. Drugs for Meniere's disease 148
9. Angiotensin-converting enzyme 16. Drugs used in nausea & vomiting
(ACE) inhibitors 48 in pregnancy 149
10. Angiotensin-11 receptor blocker 17. Symptomatic relief of nausea &
(ARB) 50 vomiting from underlying diseases 149
11. Vasodilator antihypertensive drugs 55 . 18. Drugs used in nausea & vomiting
· 12. Diuretics 55 induced by chemotherapy &
13. Drugs for pulmonary arterial radiotherapy 149
hypertension 59 19. Anticonvulsant/Antiepileptic drugs 153
14. Combined antihypertensive prepns. 60 20. Drugs used in parkinsonism 163 Triple coverage with
15. Renin inhibitors 70 21. Dopaminergic drugs 163
16. Anti-anginal drugs 70 22. Antimuscarinic drugs 166 excellent efficacy
17. Coronary vasodilators 70 23. Drugs used in essential tremor,
18. Calcium channel blocker 72 chorea & tics · 167 • •
'
19. Potassium channel activator 75 24. Appetite suppressants 168
20. Cerebral vasodilator drugs 78 25. Antiobesity drugs 168
21. Neurosensory oxygenator 78 26. Pancreatic lipase inhibitor 168
INNER INDEX QIMP-17 (X)

27. Centrally acting appetite 2. Non-opioid analgesics 318

suppressants 169 3. Opioid analgesics 325
28. Drugs used in stroke 169 4. Anti-migraine drugs 328
29. Drugs for dementia 170 5. Trigeminal neuralgia 331
30. Drugs used in substance 6. Drugs used in oral & dental pain 331
dependence 172 7. Embrocations 332
31. Alcohol & opioid dependence 172 8. Analgesic & muscle relaxants for
32. Drugs for cessation of smoking 172 topical use 3 32
. .
Flupentixol BP 0.5 mg + Melitracen INN 10 mg s,. Drugs us.ed in Endocrine diseases. 173 9.. ABti-.rheumati:c & Anti-
in.ftcammatnry drugs 3-34
1. Antidiabetic drugs 173
2. Insulin preparations 173 1. Drugs used in rheumatic diseases 334
3. Oral hypoglycemic agents 179 2. Non-steroid anti-inflammatory
4. Thyroid & antithyroid drugs 198 drugs 334
5. Corticosteroid drugs 200 3. Drugs which suppress rheumatic
6. Sex Hormones 204 disease process 353
7. Female sex hor1nones 204 4. Disease-modifying antirheumatic
8. Drugs for menopausal symptoms 209 drugs (DMRD) 353
9. Hormone replacement therapy 209 5. Drugs used in gout 354
10. Male sex horn1ones I Androgens 211 6. Drugs used in neuromuscular
11. Anabolic androgens 212 disorders 356
12. Hypothalamic & pituitary 7. Drugs used in myasthenia gravis 356
hormones & anti-estrogens 212 8. Drugs used in cerebral palsy 356
13. Drugs for Sterility 212 9. Skeletal muscle relaxants 357
14. Drugs for growth failure 216 10. Drugs used in soft-tissue
15. Growth hormone antagonists 216 inflammation 359
16. Pineal hormone 217
'I t 6. Drugs used in Allergic disorders. 36tJ
.

:;:
\.
..

17. Hormonal drugs affecting bone

::,.; .'; \• '." \.i,••

metabolism 218
..

..:�,"
-

1. Antihistamines 360
18. Drugs for milk suppression 218
2. Sedating antihistamines 360
A new dimension 19. Drugs affecting gonadotrophins 219
3.
20. Non-hormone sex stimulant drugs 220 Non-sedative newer antihistamines 363
for treating 4. Antihistamine-Decongestant
6.. c·oatraceptive· Methods & Prepns.222 combined prepns. 372
anxiety & depression
1. Contraceptive methods 222 11 .. Drugs acting on the Skin 374
2. Oral Contraceptive prepns. 222
1. Topical Antihistamine prepns. 374
3. Emergency contraceptive pill 225
2. Local Antipruritics 374
1·., Systemic Antimicrobial drugs 225 3. Local Anesthetics 374
4. Topical Antibiotic prepns. 375
1. Antimicrobial drugs 225
5. Topical Anti-viral prepns. 377
2. Antibacterial drugs 225
6. Topical Anti-fungal drugs 377
Montelukast 10 mg Tablet
3. Penicillin group of drugs 225 380
7. Parasiticidal prepns.
4. Cephalosporins & Cephamycins 237 380
8. Anti-scabies drugs
5. Tetracycline group of drugs 269 9. Topical anti-infective & anesthetic
6. Aminoglycosides 270
combined prepns. 3 82
7. Macrolides 271
10. Topical steroid prepns. 382
8. Clindamycin 279
11. Topical steroid & combined prepns. 382
9. Some other anti-bacterials 280
12. Preparations for eczema & psoriasis 390
10. Oxazolidinones 280
13. Preparations for warts & calluses 395
11. Sulphonamides & Trimethoprim 284 395
14. Drugs for acne & rosacea
12. 4-Quinolories & Fluoroquinolones 286
15. Drugs for ichthyosis & scaly skin 400
13. Antituberculous drugs 296 401
16. Drugs for skin scars
14. Anti-leprotic drugs 297
17. Drugs for hyperpigmentation 401
15. Anti-viral drugs/Anti-AIDS drugs 297 18. Protection of skin from solar
16. Drugs for Herpes simplex & 403
radiation
Varicella zoster 297
19. Shampoos & other scalp prepns. 403
17. Anti-retroviral drugs 299 20. Anti-dandruff preparations 403
18. Drug for chronic viral hepatitis-B 302 403
21. Preparations for Hair loss
19. Drug for chronic viral hepatitis-C 304 22. 404
Antiseptics & Skin disinfectants
20. Drug for influenza virus 305
23. Iodine compounds: Povidone-iodine405 •

21. Anti-fungal drugs 306

24. Dressing & Healing products for
22. Anti-protozoa! drugs 310
wounds, bum & ulcers 407
23. Antimalarial drugs 313
25. Cosmetic treatment of facial
Reliance for 24. Anti-kala-azar drugs 315
wrinkles & frowning 408
25. Anthe1mintics 315
asthma patients 26. Filaricidal drugs 317
26. Drugs for excessive perspiration
of the palms, soles & axillae 408
27. Parasiticidal diugs 317
.

• • 12. Drugs used in Anemias & some

8. Analgesics & Antipyreties 318 other specific blood disorders. 409

1. Analgesics 318 1. Drugs used in Anaemias 409

'

QIMP-17 (XI) INNER INDEX

2. Oral Iron preparations. 409 41. Special milk formulations .. 465

3. Non-ionic iron preparation 410 42. Parenteral nutritional prepns. 466
4. Parenteral Iron Preparations 411 43. Protein (Amino acids) prepns. 466
5. Iron+ Folic acid prepn. 413 44. Fat (Fatty acids) prepns. 468
6. Iron+ Folic +Vitamin prepn. 414 45. Parenteral vitamin prepns. 468
7. Iron+ Vitamin +Mineral prepn. 416
8. Drugs used in Megaloblastic ·14. Water & Electrolytes repl:acement
anemias 422 & plasm.a ;su
; bstitute·s 469 • •
•

9. Drugs used in Hemolytic,

Hypoplastic & Renal anaemias 423 1. Oral electrolyte prepns. 469 Pantoprazole INN 20 mg & 40 mg Tablet
10. Drugs in platelet disorders (ITP) 425 2. Oral saline 469
3. Tasty oral saline 470
13� ·Drugs used in Vitamin, Mineral & 4. Ric-based oral saline 470
Nutritional deficiency disorders -426 5. Potassium salts prepns. 470
6. Intravenous fluid preparation.s 471
1. Vitamin preparations 427 7. Saline & electrolyte prepns. 471 •

8. Plasma substitutes/expanders 473

2. Vitamin AI Vitamin D 427
3. Multivitamin & Cod liver oil prep. 429
431 .IS. Drugs us�d In Rune fo·rmatitln
4. Vitamin-B group
5. Vitamin C 438 & Bone disorders -475
6. Vitamin EI Vitamin-K 439
I. Drugs used in bone for1nation 475
7. Vitamin B+Vitamin C 440
2. Hormone in bone formation 475
8. Vitamin C+Vitamin D+Folic Acid 440
3. Vitamins in bone formation 475
9. Antioxidant multivitamin prepns. 441 4. Minerals in bone formation 476
10. Multivitamin Cap & Tab prepns. 442
5. Bisphosphonate preparations 476
11. Multivitamin SyrupI Drop prepns. 442
6. Stimulation of cartilage formation 481
12. Specific mineral prepns. 442
7. Drugs used in inflammatory
13. Specific mineral & vitamin
diseases of bones & joints 482
combined prepns. 443
I 14. Calcium Salts prepns. 443
If
16. Carcinotkemotlttrapeutit drugs
: &
15. Calcium+ Vitamin C 445 :
CytotoXJit lmmunnsup.presstt·ttts ,4�
16. Calcium+ Vitamin D 446
17. Calcium+ Vitamin C +Vitamin D 449
A novel
1. Cytotoxic drugs 483
18. Calcium+ Vitamin D+Minerals 449 2. Cytotoxic alkylating drugs 483 proton pump inhibitor
19. Calcium+ Vitamin C + Vitamin D 3. Drugs for urothelial toxicity 484
+ Vitamin E+Multimineral 450 4. Cytotoxic antibiotics 484
20. Magnesium salts 451 5. Cytotoxic antimetabolites 486
21. Zinc preparations 451 6. Methotraxate antidote 488
22. Zinc+ Folic Acid 454 7. Cytotoxic vinca alkaloids &
23. Zinc+ Vitamin B complex 454 Etoposide 489
24. Nonspecific multivitamin & 8. Other cytotoxic antineoplastic drugs490
multimineral combined prepns. 455 9. Drugs effecting the Immune
25. Multivitamin+ Multimineral prepn. 455 response 498
26. Super Antioxidant vitamin+ 10. Cytotoxic Immunosuppressants 498 Esomeprazole 2 ·mg Tablet
multimineral prepns. 456 11. Corticosteroids & other
27. Specialised multivitamin & immunosuppressants 499
multimineral prepns. 457 12. Rituximab 501
28. Multivitamin-multimineral A-Z 13. Immunosuppressants: Interferon 502
fo1mula for prenatal supplement 457 14. Sex hor111ones in malignant diseases502
29. Multivitamin-multimineral A-Z 15. Sex ho1n1one antagonists 502
formula for infants & children 16. Drugs used in breast cancer 502
up to 5 years of age 457 17. Drugs used in prostate cancer 503
30. Multivitamin-multimineral A-Z 18. Hormone antagonists 503
• formula for growing children 458 19. Drugs for chemotherapy
31. Multivitamin-multimineral A-Z ' induced neutropenia 504
fo11nula for children to all aged
people 458 17. lmmunoio:gi'tat products
32. Multivitamin & multimineral & Vaccines 59:5
A-Z formula for teen boys/girls 459
33. Multivitamin & multimineral 1. Chicken pox vaccine 505
A-Z Gold prepns. 459 2. Cholera I Diphtheria vaccine 506
34. Multivitamin & multimineral 3. DPT I Influenzae vaccine 506
A-Z Silver prepns. 462 4. DPT+ Poliomyelitis+
35. Multivitamin & multimineral Hemophilus in:fluenzae vaccine 507
A-Z formula fo the junior 463 5. DPT + Poliomyelitis+ Hemophilus
The gold standard
36. Multivitamin & multimineral influenzae+ Hepatitis-B vaccine 507
preparations for nursing mother 463 6. Hepatitis-A vaccine 508 PPI for GERD
38. Multivitamin & multimineral prep. 7. Hepatitis-B vaccine 509
for pregnancy & nursing mother 463 8. Human Papilloma virus vaccine 509 • •

39. Nutritional & energy supplement 464 9. MeaslesI Meningococcal vaccine 509
40. Sweetening agents for diabetic 10. Mumps I MMR vaccine 510
patients 465 11. Pertussis I Pneumococcal vaccine 510
 INNER INDEX QIMP-17 (XII)

12. Poliomyelitis vaccine 511 22. Drugs used in the treatment

13. Rabies vaccine 512
'

586
'

-
of Poisoning
14. Rabies Immune globulin 513
'

15. Rotavirus vaccine 513

16. Tetanus vaccine I Tetanus antitoxin 514 1. Organophosphate Poisoning 586

- • 17. Tuberculosis I Typhoid vaccine 515

! 18. Immunoglobulin prepns. 515 23.- Chapter for missing drugs 587
19. Human anti-tetanus
immunoglobulin (TIG) 516 1. Missing drugs 587
Etoricoxib INN 60 mg, 90 mg & 120 mg Tablet 20. Human anti-D immunoglobulins 517

18� Anesthetics & Muscle relaxants 517 Section-2

1. General anesthetics 517 INDIGENOUS MEDICINES

2. Antimuscarinic drugs 521
3. Sedative & Analgesic 1. Indigenous antacid, anti-dyspeptic
peri-operative drugs 522 & carminative prepns. 588
4. Muscle relaxants 527 2. Indigenous baby carn1inative
5. Recovary from general anesthesia 530 prepns. 590
6. Anticholinesterases used in 3. Anti-diarrhoeal & anti-dysenteric
recovary from general anesthesia 530 prepns. 590
7. Local anesthetics 531 4. Herbal laxative preparations 591
8. Reversal of hypotension induced 6. Herbal products for liver disorders 592
by Spinal or epidural anaesthesia 533 7. Herbal appetite stimulasts 594
8. Blood lipid level & blood pressure
19. Drugs acting on Urogenital system 533 lowering prepns. 595
9. Cough & respiratory prepns. 595
1. Urinary anti-infectives 534
10. Neurotonic preparations 598
2. Irrigation solution 535
11. Prepns. with hormone-like activity 601
3. Urinary retention: Benign
12. Analgesic, antipyretic & diuretic
prostatic hyperplasia 535
prepns. 603
4. Urinary incontinence: Overactive
13. Drugs for rheumatic disorders 604
bladder 539
14. Preparations for soft-tissue
5. Anti-kidney stone preparations 540
The fittest COX- 2 6. Drugs used in chronic kidney
inflammation & pain 604
15. Preparations for skin diseases 605
selective painkiller diseases 540
16. Indigenous immunoactivator 606
7. Drugs used in end stage renal
17. Diabetes & Urinary problems 607
diseases 540
18. Herbal remedy for nocturnal
8. Hemodialysis solutions 540
em1ss1on 608
• •

9. Peritoneal dialysis solution 541

19. Uterotonic & pregnancy
• 10. Drugs using in genital problems 542
protective prepns. 608
11. Drugs acting on the uterus 542
20. Preparations for menopausal
12. Drugs for endometriosis &
symptoms 610
Uterine fibroids 544
21. Indigenous hematinic prepns. 610 .
Ketorolac Tromethamine USP 10 mg 13. Drugs using in vaginal &
22. Indigenous tonics & vitamin prepns.610
vulval conditions 544
23. Food supplement for Bone &
20. Drugs in Ophthalmic problems 548 Cartilage formation 614
24. Prepns. for mouth & dental care 614
2X10 Tablets 1. Anti-infective preparations 548 25. Natural Honey preparations 614
Surpim USP 10mg
2. Antibacterial eye products 548 26. Herbal prepns. for ophthalmic care615
�<AICTio;••••
3. Antifungal eye products 554 27. Herbal hair oil 615
<jj Asiatic • 4. Antiviral eye products 555 28. Probiotics & Prebiotics 615
5. Anti-inflammatory/allergic prepns. 555 29. Sweetening products for diabetic
6. Steroid & steroid-antibiotic prepns. 555 patients 616
7. Non-steroid drugs 561
•

8. Mydriatics & cycloplegics 565

9. Myotics & glaucoma drugs 566 Section-3
10. Drugs in dry eyes 570
11. Drugs for corneal edema 573
12. Antioxidant vitamins & minerals APPENDICES & INDICES
for eye health 574
13. Drugs for lens opacification 574 Appendix: 1 Hematological Values 617
14. Treatment for age related macular Appendix: 2 C.S.F Picture in
degeneratoin (AMD) 575 different Meningitis 619
15. Ocular peri-operative drugs 576 Appendix: 3 Immunization schedule 619
16. Diagnostics & prepns. Appendix: 4 Infectious diseases table 620
for ophthalmic exam. 577 Appendix: 5 EDD & obstetrie table 620
Index:1 Phar111aceutical company
21,. Dr°'gs using in E.N,.T problems 578 directory 621
Index:2 Alphabetic therapeutic index 625
• •

1. Aural preparations 578

• • •
2. Nasal preparations 582

•
 """ '' " ""' . ...
"
..
"

Section - I

�
Classification: Antacids are classified as: Dosage & admin: See below under individual
i. Systemic antacids: Which are usually absorbed preparations.
from the gut so, these are preferable as blood al­
DRUGS ACTING ON kaliser to combat acidosis rather than antacids,
such as, sodim bicarbonate, sodium citrate, s Sugar Free •
THE ALIMENTARY odium acetate, potassium citrate.
M 21,22,2 3
SYSTE ii. Non-systemic antacids: These are not signifi­
cantly absorbed from the gut and mainly used as Magaldrate & Simethicone USP suspension
antacids such as, aluminum hydroxide, magne­ & chewable tablet
The drugs and preparations acting on the ali­ sium hydroxide, magnesium trisilicate.
mentary system are classified iqt� the follow- Sl(+f
... .
'
- . " . .
-

.. . .
"

..··. .. ''.... H.•·.··• '..

ing broad groups:
. .... ... ... . ..
AL
..

... ...
. . .
"
+MAGNESIUM . "..
+ ACEDONE-Z Tab. Zenith
1. Antacids & other ant�dyspeptic ·drugs.
ANTACIDS21,33 Dried aluminium hydroxide gel & magnesium
2. Antispasmodics (anticholinergics).
3. Anticholinergic & anti-psychotic hydroxide BP: tablet.
ALUMINIUM+ MAGNESIUM ANTACID: Dose: 1-2 tabs. chewed half to 1 hour after or
combination products.
Tablet/Suspension inbetween meals & at bed time or as required.
4. Motility stimulants/Dopamine antagonists.
Aluminum & magnesium antacid preparations are Child: Not recommended.
5. Ulcer-healing drugs.
non-systemic antacids. These are not significantly 250's pack: 132.50 MRP
6. Antidiarrhoeal drugs.
absorbed from the gut and mainly used as + ACEDONE-Z Susp. Zenith
7. Drugs in chronic inflammatory bowel
antacids such as, aluminum hydroxide, magne­ Aluminium hydroxide gel BP & magnesium hy­
diseases.
sium hydroxide, magnesium trisilicate. droxide BP: suspension
8. Preparations for aphthous ulcer.
Mode of action: When antacids are ingested, Dose: 2-4 tsf half to 1 hour after meals or when
9. · Laxatives, purgatives & lubricants.
these salts dissociate to neutralize gastric acid and required and at bedtime.
10. Local preparations for anal and rectal
form neutral salts within the stomach. Thus, the 200ml bot: 40.00 MRP
disorders.
goal of antacid use is to increase the pH of gastric + ACEDONE.-Z Plus Susp. Zenith
11. Drugs affecting exocrine &.intestinal secre-
contents to a range of 3.5 to 4.5, at which pepsin Aluminium hydroxide gel BP & magnesium hy­
tions.
···

activity is greatly diminished. Pain usually occurs droxide BP + siniethicone: suspension

when pH is below 3.5. There is good evidence Dose: 2-4 tsf half to 1 hour after meals and at
1. ANTACIDS & 01'8ER ANTI­ from the clinical trials that antacids do not accel­ bedtime or as required
erate the rate of healing in gasttic ulcer, but in
DYSPEPTIC DRUGS duodenal ulcer, where very high doses of antacids
200ml bot: 65.00 MRP
+ ALGEX Tab. Doctor's
such as 200-300ml of aluminium hydroxide daily Dried aluminium hydroxide gel & magnesium
1.1 Antacids
in divided doses at frequent intervals well pro­ hydroxide as tablet.
1.2 Antacids with laxative action
mote ulcer healing, but such treatment is incon­ Dose: 1-2 tabs. chewed half to 1 hour after or
1.3 Anti-dyspeptic & Carminatives
venient to the patient. inbetween meals & at bed time or as required.
Ind: Hyperacidity, gastric & duodenal ulcer, gas­ Child: Not recommended.
ANT A C I11s21,2 2 ,2 3 ,3 3 tritis, heartburn, dyspepsia, gastro-oesophageal re­ 200's pack: 100.00 MRP
flux disease, flatulence. + ALGEX Susp. Doctor's
Definition: Antacids are the most useful drugs C/I: Hypophosphataemia; if simethicone is Aluminium hydroxide gel 380mg & magnesium
added, contra-indicated i11 renal failure, severely '
. for relief of hyperacidity & associated pain.
' '

hydroxide l25mg/5ml: suspension

'
debilitated patients, 1st trimester of pregnancy.
. ·Antacid preparations are weakly ]:)asic and consist
'

Dose: 2�4 tsf 3 or 4 times daily half to 1 hour

of metal salts, most comffionly aliiminium hy­ S/E: Diarrhoea, constipation, nausea, vomiting. after or inbetween meals and at bedtime.
droxide, magnesium hydroxide, calcium carbon­ Cautions: Renal dysfunction, low phosphate diet, 200ml bot: 32.30 MRP
ate, or sodium bicarbonate. prolonged use.
+ ALUCIL-S Tab. Opsonin
GASTRO-INTESTINAL DRUGS
Dried aluminium oxide gel BP & magnesium hy­
droxide BP & simethicone (activated dime­
thicone) 30mg/tablet.
Dose: 1-2 tabs. chewed half to 1 hour after
. droxide BP: suspension
meals or as required & at bedtime.
IOO's pack: 175.94 MRP
+ ALUCIL-S Susp. Opsonin
Aluminium hydroxide gel BP & magnesium hy­
droxide BP+ simethicone: suspension.·
Dose: 2-4 tsf half to 1 hour after meals and at
bedtime or as required
200ml bot: 65.98 MRP
f ALUGEL Tab. Cosmic
Dried aluminium hydroxide gel BP 250mg &
magnesium hydroxide BP 400mg /tablet.
Dose: Adults: 1-2 tabs. chewed half to 1 hour
after or inbetween meals and at bed time or as
required.
200's pack: 102.00 MRP
+ ANCIDPLUS (DS) Susp. Renata
Aluminium hydroxide gel BP & magnesium hy­
droxide BP: suspension
Dose: 2-4 tsf half to 1 hour after meals and at
bedtime or as required.
200ml bot: 46.00 MRP
t ANTACID MAX Tab. Beximco
Dried aluminium hydroxide gel 400mg + magne­
sium hydroxide 400mg & simetbicone (activated
dimethicone) 30mg/tablet.
Dose: 1-2 tablets chewed half to 1 hour after
meals or as required & at bedtime.
200's pack: 400.00 MRP
t ANTAMEAL Tab. Alco Pharma
Dried aluminium hydroxide gel & magnesium
hydroxide BP: tablet
Dose: 2-4 tabets chewed or sucked with water
half to 1 hour after meals or as required.
Child, over 6 yrs. half adult dose.
200's pack: 100.00 MRP
t ANTANIL Tab. lbn Sina
Dried aluminium hydroxide gel BP 250mg &
magnesium hydroxide BP 400mg/tablet.
Dose: 2-4 tabs chewed or sucked with water
half to 1 hour after meals or as reqd. Child,
over 6 yrs. half adult dose.
200's pack: 104.00 MRP
t ANTANIL Susp. lbn Sina
Alum.hydroxide gel 200mg & magnesium hy­
droxide 400mg/5ml: suspension.
Dose: 1-2 tsf 3 or 4 times daily half to 1 hour
after or inbetween meals & at bedtime.
200ml bot: 33.00 MRP
+ ANTANIL Plus Tab. lbn Sina
Dried aluminium hydroxide 400mg, magnesium
hydroxide 400mg & simethicone (activated dime­
thicone) 30mg/tablet.
Dose: 1 -2 tabs. chewed half to 1 hour after
meals or as required & at bedtime
l OO's pack: 150.00 IP
+ ANTANIL Plus Susp. Ibo Sina
Aluminium hydroxide gel 400mg, magnesium
hydroxide 400mg & simethicone 30mg/5ml:
suspension.
•
Dose: 2-4 tsf. half to 1 hour after meals or
when required & at bedtime.
.
. ....
QIMP-17 (2)
200ml bot: 65.00 IP 200ml bot: 65.00 MRP
+ DUOMEAL Tab. Ad-din
t APEDROX Susp. APC Pharma
Aluminium hydroxide gel BP & magnesium hy­ Dried alu.minium hydroxide gel BP 250mg &
magnesium hydroxide BP 200mg/tablet.
Dose: 1-2 tabs. half to 1 hour after or between
Dose: 2-4 tsf half to 1 hour after meals and at
bedtime or as required meals and at bedtime
200ml bot: 30.00 MRP 200's pack: 106.00 MRP
+ DUOMEAL Su.sp. Ad-din
t AVLOCID Plus Susp.ACI
Aluminium hydroxide gel 400mg, magnesium Aluminium hydroxide gel BP. 250mg & magne­
sium hydroxide BP l 25mg in 5ml: suspension
hydroxide 400mg & simethicone 30mg/5ml:
•
Dose: 2-4 tsf half to 1 hour or between meals
suspension.
Dose: 2-4 tsf. half to 1 hour after meals·or and at bedtime.
when required & at bedtime. 200ml bot: 32.00 MRP
200ml bot: 75�00 MRP t ENTACYD Tab. Square
Dried aluminium hydroxide gel BP 250mg, mag­
t BIOCID Tab. Biopharma
nesium hydroxide BP 200mg & magnesium trisil­
Dried aluminium hydroxide gel BP & magnesium
icate 370mg/tablet.
hydroxide BP: tablet
Dose: 1-2 tabs. half to 1 hour after or between
Dose: 1-2 tabs. chewed half to 1 hour after
meals or as required & at bedtime.
meals and at bedtime
200's pack: I00.00 MRP 200's pack: 160.00 MRP
t ENTACYD Susp. Square
t BIOCID MH Susp. Biopharma
Aluminium hydroxide gel BP & magnesium hy­ Aluminium hydroxide gel BP. 250 mg, magne­
sium hydroxide BP 125mg in 5ml: suspension
droxide BP: suspension
Dose: 2-4 tsf half to 1 hour after meals and at Dose: 2-4 tsf half to 1 hour or between meals
bedtime or as required and at bedtime.
200ml bot: 32.42 MRP 200ml bot: 55.00 MRP ·
+ ENTACYD Plus Tab. Square
+ BIOCID Plus Tab. Biopharma
Dried alumin. hydroxide gel USP 400mg + mag­
Dried aluminium hydroxide gel BP & magnesium
hydroxide BP & simethicone (activated dime­ nesium hydroxide- USP 400mg + simethicone
USP 30mg/tablet.
thicone) 30mg/tablet.
Dose: 1-2 tabs. chewed half to 1 hour after
Dose: 1-2 tabs. chewed half to 1 hour after
meals or as required & at bedtime meals & at bed time.
200's pack: 400.00 MRP 200's pack: 400.00 MRP
t ENTACYD Plus Susp. Square
+ BIOCID Plus Susp. Biopharma
Aluminium hydroxide gel USP 200mg+ magne­
Aluminium hydroxide gel BP & magnesium hy­
siu.m hydroxide USP 400mg + simethicone USP
droxide BP & simethicone 30mg/5ml:
•
30mg/5ml: suspension.
suspension.
Dose: 2-4 tsf half to 1 hour after meals or when
Dose: 2-4 tsf. half to 1 hour after meals or
when required & at bedtime. required & at bed time.
200ml bot: 75.00 MRP 200ml bot: 75.00 MRP
t EPAZEL Plus Susp. Edruc
+ CYTOCID Susp. CPL
Aluminium hydroxide gel 300mg, magnesium Aluminium oxide USP + magnesium hydroxide
hydroxide 1OOmg in 5ml: Suspension BP+ simethicone BP 30mg/5ml: suspension.
Dose: 2-4 tsf half to 1 hour after meals or when
Dose: 2-4 tsf half to 1 hour after meals and at
required & at bed time.
bedtime or as required. '
..
200ml bot: 32.00 MRP 200ml bot: 75.00 MRP
t DROXIGEL-Plus Tab. Modern t FLATAMEAL-DS Susp. Beximco
Alumin. oxide 200mg + magnesiilln hydroxide
Dried. aluminium hydroxide BP 400mg, magne­
400mg+ Simethicone 30mg/5ml: suspension.
sium hydroxide BP 400mg & simethicone
Dose: 2-4 tsf half to 1 hour after meals or when
30mg/tablet.
required & at bed time.
Dose: 1-2 tablets chewed half to 1 hour after
200ml bot: 75.00 MRP
meals & at bed time.
200's pack: 180.00 MRP + G-ANTACID Tab. Gonoshasthaya
t DROXIGEL-S Susp. Modern Dried aluminium hydroxide gel 250mg & magne­
Aluminium hydroxide gel BP 2.00gm & magne­ sium trisilicate 500mg + mannitol 120mg/tablet.
sium hydroxide paste BP 334mg/5ml: suspension. Dose: 1-2 tabs chewed or sucked with water
Dose: 2-4 tsf half to 1 hour after meals or when half to 1 hour after meals or when required.
required & at bed time. 250's strip pack: 132.50 MRP
200ml bot: 32.88 MRP IOOO's pot: 310.00 MRP
t DROXIGEL-Plus Susp. Modern + G-ANTACID Susp. Gonosbastbaya.
Aluminium hydroxide gel BP 2.00gm, magne­ Aluminium hydroxide gel l 25mg & magnesium
sium hydroxide BP paste 1330mg & simethicone trisilicate 500mg in 5ml: suspension
Dose: 2-4 tsf half to 1 hour after or between
30mg/5ml: suspension.
Dose: 2-4 tsf half to 1 hour after meals or when meals and at bedtime.
required & at bed time. 200ml bot: 28.15 MRP
.9' vice ?Jlff,f
•••
•••
r:&l
lQJ !�'!,.�E�!/11 . S lTO.
SJJ.HlltAC>ESH
www.squarepharma.com.bd •••
SQUARE
--
 QIMP-17 (3) GASTRO-INTESTINAL DRUGS

t G-ANTACID MH Tab. Gonoshasthaya 200's pack: 106.00 MRP Hydroxy magnesium aluminate or magaldrate
Dried aluminium hydroxide gel & magnesium t LACTAMEAL Susp. Beximco 480mg+simethicone 20mg/5ml USP, 200ml bot:
hydroxide BP: tablet. Aluminium oxide BP l 75mg +magnesium hy­ magaldrate suspension.
Dose: 1-2 tabs chewed or sucked with water
. --
.. . droxide BP 225mg/5ml: suspension.. Dose: 2-4 tsf 3 or 4 times daily half to 1 hour
haH to 1 hour a.fter meals or when required. Dose: 2-4 tsf 3 or 4 times daily haH to 1 hour after or between meals and at bedtime.
200's pack: 106.00 MRP after meals and at bedtime. 1OOml bot: 55. 00 MRP
t GASTID Chewable Tab. SK+F 200ml bot: 33.00 MRP 200ml bot: 100. 00 MRP
Magaldrate BP 480mg +simethicone USP t MAGACIL Susp. Opsonin t MAGNOGEL Tab. Amico
20mg/tablet (chewable). Hydroxy magnesium aluminate or magaldrate: Dried aluminium/magnesium hydroxide BP
Dose: 1-2 tablets haH to 1 hour after meals & suspension. prepn: antacid tablet
•

at bed time or as directed by the physician. Dose: 2-4 tsf 3 or 4 times daily haH to 1 hour Dose: 1-2 tabs 3 or 4 times daily haH to 1 hour
60's pack: 180.00 MRP after or between meals and at bedtime. after meals and at bedtime.
1--
t GASTID Susp. SK+F 200ml bot: 43.97 MRP 200's pack: 104.00 MRP

1 Hydroxy magnesium aluminate or magaldrate +

simethicone: suspension.
t MAGACIL Plus Susp. Opsonin
Hydroxy magnesium aluminate or magaldrate+
t MAGNOGEL Susp. Amico
Alumini11m hydroxide & magnesium hydroxide
I
. Dose: 2-4 tsf 3 or 4 times daily haH to 1 hour simethicone: suspension. gel prepn: antacid suspension
after or between meals and at bedtime. Dose: 2-4 tsf 3 or 4 times daily haH to 1 hour Dose: 2-4 tsf 3 or 4 times daily haH to 1 hour·
'

I 200ml bot: 100.00 MRP after or between meals and at bedtime. after meals and at bedtime.
I 200ml bot: 87.93 MRP 200ml bot: 32.00 MRP
l t MAGADRATE-Plus Tab. Aexim t MARLOX Tab. Incepta
® Dried aluminium magnesium polyhydroxy
Sug.Jr Free • Dried aluminium magnesium polyhydroxy com­
plex USP & magnesium carbonate: magaldrate complex USP & magnesium carbonate: magal­
I
•
preparation drate preparation
! Dose: 1-2 tabs 3 or 4 times daily haH to 1 hour Dose: 1-2 tablets by chewing half to 1 hour
Mag aldrate & Simethicone USP suspension
& chewable tablet after or between meals & at bedtime. after meals or when required.
l OO's pack: 80.00 MRP 200's pack: 200.00 MRP
SK•F t MAGADRATE-Plus Susp. Aexim t MARLOX Plus Tab. lncepta
Hydroxy magnesium aluminate or magaldrate Each tablet contains magaldrate BP 480mg and
t GASTOLIN Susp. Belsen USP 444mg/5ml: magaldrate suspension. simethicone USP 20mg.
Aluminium hydroxide gel & magnesium trisili­ Dose: 2-4 tsf 3 or 4 times daily haH to 1 hour Dose: 1-2 tablets haH to 1 hour after meals &
cate BP: suspension after or between meals and at bedtime. at bed time or as directed by the physician.
Dose: 2-4 tsf half to 1 hour after or between 200ml bot: 50.00 MRP 1OO's pack: 300.00 MRP
meals and at bedtime. t MAGADROX Plus Tab. Gaco t MARLOX Plus Susp. Incepta
200ml bot: 60.00 MRP Aluminium hydroxide dried gel 250mg, mag. Each 5ml suspension contains magaldrate BP
t GELUDROX HS Susp. Drug Inter trisilicate 400mg +Simethicone 30mg/tablet. 480mg & simethicone USP 20mg.
Al11minium hydroxide compressed gel. BP equiv­ Dose: 1-2 tabs haH to 1 hour after meals or Dose: 2-4 tsf half to 1 hour after meals and at
alent to aluminium oxide 200mg, magnesium hy­ when required. bedtime or as directed by the physician. Shake
droxide BP 400mg & simethicone 30mg/5ml: l OO's pack: 90.00 MRP the suspension well before each use.
suspension
•

t MAGADROX Plus Susp. Gaco 200ml bot: 100.00 MRP

Dose: 2-4 tsf half to 1 hour after meal and at Alumini11m hydroxide gel BP magnesi11m hy­ t MUCOGEL Susp. Medicon
bedtime. droxide BP & simethicone 30mg/5ml: Aluminium hydroxide & magnesium hydroxide
gel prepn: antacid suspension
•

200ml bot: 60.00 MRP suspension

t HYDROCID Susp. Millat Dose: 2-4 tsf haH to 1 hour after meal and at Dose: 2-4 tsf 3 or 4 times daily half to 1 hour
Aluminium hydroxide gel BP+magnesium hy­ bedtime. after meals and at bedtime.
droxide BP: suspension 200ml bot: 75.00 MRP 200ml bot: 50.00 MRP
Dose: 2-4 tsf half to 1 hour after meals and at t MAGANTA Plus Tab. Square t NEUTRAL S Susp. Hallmark
bedtime. Hydroxy magnesium aluminate or magaldrate Aluminium hydroxide compressed gel + magne­
200ml bot: 32.57 MRP USP 480mg +simethicone 20mg/tablet. sium hydroxide paste+simethicone: antacid sus-
Dose: 1-2 tablets half to 1 hour after meals &
•

t JPDROX Tab. Jayson pension

Dried alumini11m hydroxide gel + magnesium hy­ at bed time or as directed by the physician. Dose: 2-4 tsf 3 or 4 times daily haH to 1 hour
droxide BP prepn: antacid tablet l OO's pack: 300.00 MRP • after meals and at bedtime.
Dose: 1-2 tabs half to 1 hour after meals or + MAGANTA Plus Susp. Square 200ml bot: 75.00 MRP
when required. Hydroxy magnesium aluminate or magaldrate + NOCID Tab. Medimet
200's pack: 106.00 MRP USP 480mg +simethicone 20mg/5ml, 200ml bot: Antacid preparation: tablet
t JPDROX-S Tab. Jayson magaldrate suspension. Dose: 1-2 tabs 3 or 4 times daily haH to 1 hour
Dried aluminium hydroxide gel + magnesium hy­ Dose: 2-4 tsf 3 or 4 times daily half to 1 hour after or between meals & at bedtime.
droxide BP+Simethicone: antacid tablet after or between meals and at bedtime. 200's pack: 200.00 MRP
..

Dose: 1-2 tabs half to 1 hour after meals or 200ml bot: 100.00 MRP t NOCID Plus Tab. Medimet
when required. t MAGAPLUS Susp. Kemiko Antacid preparation with simethicone: tablet
l OO's pack: 140.00 IP Aluminium magnesium polyhydroxy complex or Dose: 1-2 tabs 3 or 4 times daily haH to 1 hour

t LACTAMEAL Tab. Beximco magaldrate USP 400mg/5ml: suspension
Dried aluminium hydroxide gel BP 250mg + Dose: 2-4 tsf 3 or 4 times daily half to 1 hour
magnesium hydroxide BP 400mg/tablet. after or between meals and at bedtime.
Dose: 1-2 tablets 3 or 4 times daily half to 1 200ml bot: 54.20 MRP
hour after meals and at bedtime. t MAGAPLUS-X Susp. Kemiko
after or between meals & at bedtime.
200's pack: 280.00 MRP
t NOCID-N Susp. Medimet
Antacid liquid prepn: suspension.
Dose: 2-4 tsf 3 or 4 times daily haH to 1 hour

Magaplus- Suspension
Magaldrate USP 480 mg & Simethicone USP 20 mg
KEMIKO PHARMACEUTICALS LTD. Effectively controls Indigestion, Heartburn, Hyperacidity & Flatulence

I
 :. .:·:..: : :" . ::
.' ...-.. . ..... .- ....-·..... ..-..........··.·-.···. . ....
........ -. . . . .
.. . ... . .
, '.'. ' ..

.
• ..
: "'.'"'.'. !''!" '" . " ,. -
. ..
..
"
•

' ' · · ·

--·-- -. . .._ . ..-,,.

'
··. -
•
•

.
••

GASTRO-INTESTINAL DRUGS , QIMP-17 (4)

. -. ..
.
-

. .
.

;;
.. . .
.. ...

' :'.'.: "• •

! "'. •·:
:
·· :·1•·:· ·•·'..; b· o • .. ..· ·:.:• •.·.•..:.:.:..•......::",'. •
.

. , ..,"...•.. .>
! "
•. t· · · .
-- "!
. ..2
.

•
· o o' m .
· · ·· · . ... . · ·. • ·
•
. .. .. - · .,_, .

..
'
. : .·<· · · ·. > ·• · · · / : . ·· . · . ... ::: " . :.: .. :.' ··
' .
'

· · . •• •·
" '. !" ''. !""

200ml bo�:.75.0()MlY>:H
'.

· 33 ooMRP
'.

after meals and at bedtjlll� or as required. . ..... . '.• · · . · • · · · .

·

. · · •

.' •
•

•
'

··· · . · ·
·

· · · ·
·

. :. · : .. 1· i
·
1
· > · t · · : . · .: :: : ;.' :. • :··· ··.. · ·
200riil bot: 40.ooMRP I • >. .. .. •·• · · ··· •• •·• · · · • uuEL .1,;ab
s•
··. .: :t
� . · � . · Pac f c . . . . ··. • .
_

• + PEPTACii>Ta.1>�1\lllico · · ·· · � .
:
'

.. . · . .
•

:
_

+ NOCID Plus Susp. Medimet Dried aluminium/magnesium hydroxide gel Dried aluminium hydroxide BP + magnesium• by� · •· ·
. gel + magne-
Aluminium hydroxide compr��sed dtoxide BP: tablet.
preparation with simethicone: antacid tablet
,

si11tri hydroxide paste + simetliicone: antacid sus- ·'' .. Ind: Dyspepsi� hyperacidity, peptic ulcer, flatu- Dose: 1�2 tabs chewed or sucked with
penSion.... .. .... . ... water half to 1 hour after or between meals j . - .. .
•

·· lence. - .
·
and at. bedtime. ··· ·· ·•·•· ... ·•··· · ·
,

Dose: 24 tsf3 or 4times da�y half to 1 hour

. __
,,,

D()se: 1-2 tablets3 or .4 times .daily• half t() l .

.• · • ·· ·
. ··- . . after n.;te.a�s and at bedtime. . .. ·
.. ·· . · · • ·. . ltour after meals & at bedtim ·
.• • ·
e·•. · •·••• •.· •. ''•• · · · ····. .
· 2 oo·s· P.�ck.� 1 00.00 .MRP . ·
. ·· . · · . ••
,,
2001lll��ti60.00,MRP . .· · ········· ··· . . • ·· · • . ·+.
·•·
. I ·.. < . u· • ···
.
H

.. ·+ SU��L$usp� Pacific , ·, "

.
. · . .
. · • ,, .
· .
... . loo's pack:100 0.o. M.ro>
"

. -. ·. . ._
•·•

•· . .
' D
�

+ NOVELTA Chewable !ab� ?-non Pharma Alun1itfi"tih1 hydroxide gel B}> +Magnesium hy­
,

·
.

· + PEPTACID Susp. Amico .... •.• .·

Magaldrate .BP 480mg + s1methicone USP droxide BP:suspension··· ·. ·· . . :.:• .- ·
Aluminium hydroxide&magnesi11m hydroxide - · · . ·-
20mg/tablet (chewable). gel + simethicone 30mg/5ml: antacid suspension Dose: 2-4tsf3 to4 times daily half to 1 hour ·•· · _,
•

Dose: !:-2 tablets half to 1 hour after meals & Dose: 2-4tsf3 or4 times daily half to.- ·hour after nieals and as required.
at bed time or as directed by . the physician. . · •.•. after meals and at bedtime. • · 2ootnl bot: · 32.00 MRP ·•··· ·· ...·•.···.· · ·
H

. . .. . •·· • •• . . . .... ..- .. -- . .. . . .. . ... .. ·.

...

.
H :

•
.

IOO's pack: 300.00MRP... .

H

· .·.········· · ••..· <• · • T RICID Tab. Kumudini

.

• 200ml bot· 55 00MRP · . • · •· .

· · · •· ... . .· .• •. •·•. ••... .. •. •. ·····

..

·. ·. •••
.. ..

Dried..· al.t�futniuriilmagn
. . . . . . .. . i e�itirti h ydroxide
.... BP
+ NOY.EtTA susp. Orion Pharma
. •• . + i- H.ARMAt
m;susp. Pharmadesb . •
. . .
.
... .· · .. .
. .. . .
.
. .

. . . .•.
·
.
.

Magaldfate BP 480mg + simefyic()ne USP pr-epn; anta�id tablet

.

..
.• •·.• ·.. Aluminium hydtoxide gel BP 200mg +·magne-
·· ·
··· >

20mg/5ml:. suspension. ··.. · · sium hydroxide BP 125mg/ Sml:suspensipn

Dose: .1-2 tabs half to 1 hour after meals or
Dose: 2-4tsf half to 1 hour'after meals and at Dose: 2 tsf3 or 4times daily half to 1 hour when required.
bedtime or as directed by the physician. Shake 200's pack: 104.00MRP
after meals and at bedtime.
the suspension well before each use. 200ml bot: 33.00MRP + Z-ANTACID Tab. Ziska .. .
Dtj�q"aluminium hydroxide �el BP + magnesium
..... ".. ;66:·.. �·•.•.•.·o• . :� �.�i6oM� .
.. .
. ....
. . . . : ..
. .
.·
. ·
·· · .>•
•
•··· ·
·
+ �HA�;CID·Plus 1:ab. Phar��de��> ·
> •· · ••• · ··· ·.· . Dned alumllllwn hydroxide gel. BP 400@.g
• .
···
& · ··
hydroxide BP· tablet . , , - � · ··· ·
. ... . ..
. ... . . · · > · �
.· ·

+ ?XE�ONE Tab. �cme. . · . .. · ... ... .

... . . . ; . •..···· • magnesium hyd!oXide BP 400mg + simetliicone •nrise:. 1:�•tab . cliewed 3 ti�iies daily half to 1
.•
.
Dned a1Um11. hydroxide gel 250mg &magnesium · · ·.. • 30mg/tablet. ··.•· ·•• • .·.·• · ...· · •·· · · · · hour •rt�r Dieals and as required.
·
hydroxide 400mg/tablet . Dose: 1-2 tab�3 or4times daily half to 1 hour 200's pack:100.00 MRP
Dose: 1-2 tabs3 or4times daily half to 1 hour after meals aiid as required.
after or between meals & at bedtime. 200's pack: 360.00MRP ·.... ·· CALCIUMANTAClll42
..
IOO's p�ck:53.00MRP + PHARMACIDP.lus Snsp. Pharmadesh• ·
.' . .

. ...... .. ... . ..
+ ?XE(:;O�� M Tab� A��e Aluminiun:i·hydr,()�ide compress�d g�lfOOmg +, . .,,.'_ .'" -. ... '. ". . . .
·.. .. . . _, -
... ·
_
. . .. ,,.. ..
. .•
'

.
Dned alUlll.lruum magnes1um polyhydroxy com- magnesium hydi()Xide 400mg+ simetbicone . ... · ·
CALCIUM CARBONATE ANTACID: Tablet

.
.: . .. .
. - . . .

· ·
· :.
plex USP&magnesium carbonate: magaldrate 30mg/5ml: antacid suspension (chewable) · .···· ·.... - ·.
-·.- · -· -
_ - -
_ .

Calcium carbonate antacid preparation is avail-

, ,

prepar�tion Dose: 2-4tsf3 or4times daily half to 1 hour

Dose: 1-2 tabs3 or4ti�es daily half to 1 hour after meals and at bedtime. able as calcium carbonate BP 1 OOOmg chewable
after or between meals & at bedtime. 200ml bot:72�00 MRP tablet.
.
IOO's pack:100.00MRP . . Mode of action: Calcium carbonate antacid
+ RECOCID Plus Tab. Rephco .. .
+ !?XEC�NE S Ta�. Acme · ·H··...· .•··
Antacid prepn. +. S.imethicone: til1l�t wprl{s by simple acid-base neutralization reac­
. .
... .
.

. .
Dned a��· hydrox1�e gel 400mg&magnesium • tio& Thlis; it consumes the excess stomach acid
·.

.
. ..· · Dose: 1-2 tablets 3. or4 times'(laity half to 1· ····
hydroxide 400mg + suneth1cone 30mg/tablet
. .. .... &reli�yes' the hyperacidity related symptoms.
.

hour after meals & at bedtime. . .

•...

Ind: Dyspepsia, hyperacidity, peptic ulcer, flatu- 200's pack:400.00MRP

Ind: It.is indicated for the management of condi­
lence. tions associated with hyperacidity and for fast re­
.
.. .. . + RECOCID Plus Susp. Rephco
Dose: 1-2 tabs chewed half to.1 hour after meal Aluminium hydroxide compressed gel + magne- lief of acid indigestion, heartburn, sour stomach
or as required & at be.dtime. and upset stomach. ..
...... . sium hydroxide paste + simethicone: antacid sus-
10.0's pack: 200.00 MRP · pension
C/I: Kn()wn l1.ypersensitivity to calcium carbon-
> . . . . _
+.. OXECONE Susp, �c111e ·· Dose: 2-4 tsf3 ()r4. times daily half to J. hour .. ate or any of its ingredi�11ts �<i lll: hyper-cal­
.
.
· . <
·
Aluminium hydroxide compressed gel 200mg&.. · ·:···• after meals arid •t bedtime. ce�a,. renal calculi, hypotphbSphatemia.
.

. ·.·
magnesium hydroxide 125mg/5ml: suspension · S!E: Generally well tolerated. Occasionally it
"' 200ml bot:75.00 MRP . .. · ..
D·ose: 2-4 tsf3 or4times daily half to 1 hour may produce nausea and constipation in few pa­
.

+ SEEMACID-MH Susp. Seema

after meals & at bedtime • .
Aluminium hydroxide gel BP: suspension tients� but it can be relieved by reducing the dose
200ml bot: 33.01MRP . .. Dose: 2-4tsf3 times daily half to 1 hour &frequency.
. after
+ OXE,(:ONE M Susp. Acnie .. . . . · · ····••·· meals and as req-uired. Pregna11cy & lactation: Calci'um carbonate
. · ·
.•

Aluraj��ll1n magnesium polyhydr()�y.complex · antacids are thought to be th� safest antacids dur;.
U�P&magnesituncarbonate: magaldrate prepa-•
.
. ·· 200ml bot:64.00·MRP
.
.
· ....
·
• . . · . . . -_. .
· ••· · · ·
,

. ·' .• SEEMACID Plus·s usp. Seema ing pregri

.. ancy & lactation·since
. . both the baby & · ·
· · .·· . .. --- - -- .
ratJ.on ... .
-- -

: . Antacid liquid ptepn. BP + simethicone: mother need calcium to cievelpp

. .. -. properly&
, "'.

.
.

. .

Dose: 2-4 tsf3 or4times daily half to 1 hour ···

suspension maintain their health.
after or,between meals and at bedtimes. Dose: 2-4tsf3 or4times daily half to 1 hour Dos,age & admin: 2-3 tablet(s) when symptoms ... .
200ml bot: 54.20MRP after meals and at bedtime. ·
. . · occur;. . may
. be repeated hourly, or as required•. .. .• · ·
200ml bot: 75.00MRP
. _ ,-. .. .
.
,,
+ O��ONE MS Susp.Acme . .. ·· .
Drug mter: Iron supplement$ should not be .. . • . ·
.. .. .. . Each. ?t.11,l �uspension contains magaldrate BP + STOMACID·.Ta b.�Ambee ··••· · . .
.· ta,I(e,q at the same time of the day with calcium . .. · . • · : ·
.

.. .. ."' . ·
480mg&sitnethicone USP 2Qqig.. .. . .. Dried alwriimurrt hydroxide BP + ma�esium hy-
.
· ..
• • ... . .
- .. -
.
· caroonate, which may decrease the absorption of .
Dose: 24 tsf half to 1 hour a.rter meals and at droxide BP: tablet. .•. ·· ·
. -· .. iron. Alld· tetracycline antibiotics should not be
bedtime or as directed by the physician. Shake . Dose: 1-2 tabs chewed or sucked with water
taken at the same time of the day with calcium
the suspension well before each use. half to 1 hour after or between meals and at
carbonat.e, because calcium decreases their ab-
200ml bot: 100.00MRP •

bedtime.
. sorption�· . .
1 OO's pack: 53.00 MRP .
'

+ OXE(;O� S Susp� Acme . . "

. .
Aluminium hydroxide gel 40()w.g &magnesium +. STOMACID SllSP.�Ambee ., •.. +-��I.PT.ab. (Ch�wable) Squar, · · · · · · · · ..
. .
•• . . . • . .. . . . . ..•

hydroxide 400mg USP + sim.�llii69ne 30ing/5ml: · Aluffiiin um hycif()�de ge1 BP +Magnesium hy- · •· Calcium carbonate BP 1 OOQ111glt�blet· (chewable).
.. .. ... .. . . . . -· . .
suspension. ... . ..• ••. . · · droxide BP; suspension Dosage & admin: 2-3 tablet($) when symptoms
. . ..
Dose: Z-4tsf3 or4 times daily half to 1 hour Dose: 2-4 tsf3 to4times daily half to t hour occur; may be repeated hourly, or as required.
..

after mea\ls and at bedtime. after meals and as required. 50's pack: 100.50MRP

..
. . ... .
_,,. . . . ..·-. . ... -..·.-
-.' ..". . .".....' .. ... .. -. . .. .. .. ...
. ..... . . .. .. .: ,;::. · .· ....;.: · ...· . , : .· : .. . ..
- ' .

. .
... . . .... . .... .. ....... . '".;,: ;:::· : :. .. ..•; . ......... . . . ....... ..
..

·
- '
'

.. .. . .
.. . '

... ....
·· :. '"

... - " . .. .
. ' ... _.

. ... ...' ....

,,;

!:
. .- ' . "
,,
·�' " "
' "

.. ...
-
' .

. _;

I
 ... . ''. .. . " .. .. ...; ,. .., ., ,, " .. .' .. . .. .
. .
.
.. '
.
..

"
.
.
.
. . .. .....
: .. ...:....::'::.
. . :":···· :·. ; : . .
. ., . ;
,
:· :�;
·.
. .

:.....:.::....
....
. ..

:'. ..::::..
. ....

. :i:��. �:��i'.'.:: . . : . . . .... .......

. .. ...... .. . ..
.
. ' ..: ·.:··:.·.. ... ..:... ..:··.. .::.....: .; ..... .. :. . .
. .. .
::;;::.:.;;;:·
· : "
' "
;. �: :: :·:::::·:·: :�·
.. · .' ..·... -....-. : . :. ..... .· '.·' . .
.'.:_.

. :· ·�...... ...... . -.. :··· · ...· ; • · .. .

...
,•

··::: ··: . .. ;..: . .

; ', ,
..
. ..
, . ' .­

-..
.

-. . . . . .... .
�:

.
- . . ,·- -. - -
- .
:

. ··.-··:-.::,::
-··- ::�;::
-····- -:: -
-

· ·. .
. : .:: ·::::.. :·
·

.. ·• ....
... .
. .
:·=::'. . _ :
.. QIMP-17 (5) GASTR�INTESTINAL DRUGS ' .
· .;..
..;.. · ------'!""""'-- """ ""--------------�---- ··- -� ---.---..,;
- ·
· .-,.. · ; '.. � � ·
· ·· .·· : .
.·; . :'.: ::· - -

;. .

... . . .- .
•
.....� .
-----
·______________

,_ ., .. ..
·· -· ·� . ----��� · � _....
.. . .
_' . ,' .
,
... .. · ; · . ·· · · . . . .
- -
· .. .: . . .. .... .. . . · . .. . ..
. . ·• ·· • . .. . .. -+ ALGICI,D Susp• MagtJ;esitjlJl hydroxide BP� 4ClOfugJSml: suspensio� . ·
·
•:.: · · ......... . .. .. .
lil�e.pta
. . . ......• : . .. .
:

· 1 t4fht hbt 60 00MRP. J. '

.. . •·•• . .
·son1iJM: ALGINATE+· · • •• ' . ... . . .... .... :. .. ... Sodium alginate BPH50.0mg +potassiµrq bicar.. '..
f

.
. ..'
· . :.. . . · · .
···•.· ..
. : .
.

·· ··· · ·•· > .. .. ' · . ..

• ..
.

·
· .. . . . •
..

J'oTAsSlcM. BICA�BO.iiTE26 · ... . . I •- ··· bonate BP I OOtnglSDJl:. suspension.

. ...
·

" . . :- ::-
· ··:• ·
·
•... • ..
··

...·.
· ·
AC
.
·S ILK {)FNfA��ES�
· ····· · ·· . . Plus S�sJ>. ..
.-
.
·+ �; M . .
200ml bot: 125.00MRP ·
-

• Acme. · · · ·· · · ·
. . /
SODIUM ALGINATE + • + ALGISUM TaJ>� Opsonin •. Magnesium hydroxide BP 300mg +liquid paraffin
POTAS.SIUM BICARBONATE: Chewable . . Sodium alginate BP SOOmg +potassium !>icar- l .25ml/5ml: suspension
- . :. .. .. .
Tablet/�uspension . .. . : · ..·. bonate BP IOOmg/table!.(chewable). .
·
·· l 20ml bot: 95.00 MRP · .. .. . . .
This�m�ined preparation.of sodiµm a1ginate & ·· • •
·· · · - •• • S.Q's pack: 153.95, MitP;· .. . . . . .• •. . . . .. .
..
·· ..
.

· . . • LAXEFIN Eniul. Sharif : . . .... .• . .. . ·· ·

.. .. . · ······ ··· · ..
· . · ·
. · .:
poth$siij���carbonate h.#� �eeµ •round usefull in .�· •• .• . �H.A.LGISU'M:Susp� Opsonin . . ·
. . ·· · MagfJ.,es • • ·:: !.-·
i\lni hydioXj,�e B.P 300.tng f liquid · paraffinH <, •.
:
•;
. .
,

. H H ff .. H ·
the tieatriterit of symptotn.$9f.gastrooesophageal .
Sodium alginate BP 500mg + potassiun.J. bicar�:
.. .
·
l .25ml/5ml:
. . . ;: . . :
emulsion ·· · · ..· · ·
· · ·
· · · ... . ..: . .. . ·· · · . ..'
...
- ·::. · · · ·
} ·:
··
reflfil(, such as acid regurgitation, heartburn and bonate BP 1 OOmg/5.ntl: suspension. IOOml.bot; 95.00MRP
·
••··

indigestion. The preparations·are available as- 200ri11 bot: 109.96 .MRP + MAGALAX Emul. Orion Pharma
..
· ·
.� ::::·
: ..
chewabl�.ta}Jlet & suspension. Each chewable Magn�sium hydroxide BP 300ing + liquid paraffin
;:·.. ... + ASYNTA Susp Square .
tablet contains sodium alginate BP 500mg & . -: . ..· :
l .25ml5 / ml: emulsion .
••

Sodium alginate BP 500mg +potassium ])icar­

·
.. .. .
:;; ·.· . - .: :;.:
·- ·•··
pot��siJ.�t.n bicarbonate BP iOOmg; each. 5ml sus-. . . . · .· bonate BP 10Qmg!5·ml: �uspension.
' . .
1 OOml bot: 85..00MRP . ....•• ··�- :,. · .· ..
. .::
.

· ..
. • ·• . .. . . · . : .,_ :. . •
peris1ondontains sodium alginate BP 500m g &. • >> .;; · 200ml bot· 125 00 MR.P ...•.. • . . . ... •. · . · • •..•.•• . ...
. ..•.

· • · ... . + MAGMIL �usp. Pa.�ifi¢. ; . ···. ······ •

> · • '· •
.
potassi�fu bicarbon�te :BP l OO�g. • · : C t ·: hydroxide BP 49.qµig/5ml: suspensi6tl : : ·
·- ,'
!,

. · _Magnesium
,

: + XERO ID �b. Novel�a ···

.•
. ... · ·· · ·· ·· ·· ·
. . ... .. . . ..
Mode ofattion: This combined preparation ·
: Sodium alginate BP 500mg + potassiulli bicar-
··- · .
l·OOtnl bot: 60.00MRP · ······· ···· · ····
:: ;- ; :;: :-
works by forming a raft (thick layer) on top of the
·
bonate BP l OOmg/tablet (chewable). 200ml bot: 100.00MRP · ·· : . ;

stomacJi,.i;ontents soon after it has made contact .. SO's pack: 175.00MRP + MAGNASON Susp. Jayson
with th�·stomach acid. The rait:�cts as a strong · + XEROCID Su�p.. Novelt� . Magnesium hydroxide BP 400ing/5ml: suspension •
. . .
physicaI, barrier and helps ke¢� ��!the compo-· · · · • ·: Sodium alginate ll� 5Q0mg + potassi\ltri bicar­
..· · ..
.
.. .
.. JOQll).I·pq�: ?0.00 IP
... ..

.... · · ··••·•· ··
..
.

·
. .. .··
nents of:the stomach cont�nt$ i,���� stoma9h . · .· ·· · · · b.2n.ate BP i-oOmgl$m�; suspension.· · • · · ·· · • . . ·
oc ·
·:.
• . .
. . .
,·

+- �K OF MAGN).tSIA SU.sp� ... . ··

·• t ��
•. . ·. . .
.. ·· · ··· D o . t
..
$.
where th�y ·work, not letti11g them seep back up '
" 200ml bot: 12 s . ••· .· ·· ··••• . " M�gne�1titrt hydroxide BP 4 12nigl5ml: suspension : . ···. ·
• ..
,

· \ .· ·.
into the esophagus where they hurt� · ·· · ··· ·
· ··
· ····
.
:MRP
· · ·
..
···· · · · · ·
• ·
•. oo .
l 14ml bot: 28 00MRP ·•· ·.
.
• · • . .
·
·· • . •
. .· · ·.
•
•·
•
Ind: Treatment of symptoms o( gastrooe- .
··
· ·. ··· ··· · ··· + MILK OF MAGNESIA Susp. Millat
. ..
·
.
·

sophage�I reflux, such as acid regurgitation, Antacids With La.iative action Magnesium hydroxide BP: suspension.
.

heartburn and indigestion (related to reflux), for ·· 1OOml bot: 28.00MRP .

example, following meals or during pregnancy or 21,,z2,i3 33
E
MAGN SIUM HYDRO XJDE , + MILK OF MAGNESIA Susp. Modern . . ...
in patients with symptoms r�lated to reflux . .• ·· <
·

.. . ... . ... . Magri.e,s.ium hydroxide BP 8o/cf w/w: suspension. •·· · · ···· •• • ··· . :· ,
..
..
..

· •
. .. .
esophagitis. , .· • · ·· :: :. . • . . · · ·. ·
•.
•.

··
. •. .. - · · •· · ·L K. . lOOml bot: 60,00MRP .
.
. : ' : ;' .
. . ····=
· Ml
·
�/I:. . .. • ' · :
.
. · :
•••
; . . � ; . .. .
.
.
·
• UM • HYD R .. : ' .. ... .
;• · :. : · •
•
algm�te an�. po•ta�: �• i�m
::: : : : :.._ s· 1
· 0 D.
bicarbonate• ;.:•
. · . .-: :::. ..•· �.; : - , • .. : :.. MAG NEy• . XI E OR. . :: OF .
Sotif
;
: : : : : : ... . . . · ··-·• .
; '
: :
:

200mlbot: 100.00MRP ..·· . . ···•·

•
. - . . ' .
.. . '
·
. : :·
. . . ..
: ,
. . , . .
. MAGNES : Suspensi n · • •
IA o : •.:; ::·: ·::>. : 1'.••::·: ·:
is co��mdicated pat1e�ts with known hyper-
11:1 .
+ MILK OF MAGNESIA Susp. Orlon Pharma··· . . .
MAGNESIUM HYDROXIDE O R MILK OF
sens1t1v1ty t these mgredi�nts Magnesium hydroxide BP: suspension.
�. �.
· ··
MAGNESIA+ LIQUID p : Susp.
S/E: In addition to the desrred �ffect of the drug, . . & . . lOOml bot: 50.00MRP
. C· ompos1tion ·. action: An aqueous suspension . . ·
some _ s1ge effects may appear sue h as. nausea, . ..
·

.
· . · . . · ·
. +·MILK OF MAGNESIA Susp� Pharmadesh . ·: ....
.

.. . .. of magnesium ·· ·
· .h. Y.u.i:ox1de containing a· ou 10 t
. . · ·
rh�a �r. heaHd�c
. . · . b · go/ .
constt· p��1.?� dia r . he. 1n these cases •.
.
Ma.gt�$it•fu
.. :..J 4.
hydroxide su.spel l sion
·· · ·
.
.
.H� > ··..
. ; . >hydrated magne�i l
i m: oxide, also known milk · ,
c 1 A 1 • ..
.

t
.
d h
.
.
.
.

•>
114nii:.bot�45.00MRP
as· ·. : . ···· .. · < · ·. ···
..
·
ati� ��- T
·
1ax
.
of ma esia is ecti ve osm otic h is
..

���:! 8ii; ��� ::��:�� :ke:T��= : : � ·�ff a? . · ·· ··

t

·.
u

i·g •.
.•.

�
·
-

(
r . l . 19· RP · :-
... t: M
·• ·
20 0m bo 50 . - • .
.
.
a
magnesium salt 1s useful where rapid bqwel evac-
0
.·
appear ··
a sensation
·
· of swellin g..In. th'1s case i't is·. ···· . .· . . . . · ··
··-•• . . : .. > . •
.. · :

+ MOM Susp. Opsonin

ative
· .· · ··. ···
uatt on is requrre<i & acts as an osmotic iax •
· · ···
ad visable to consu1t a ph ysic1an.
·

·
.

. . Magnesium hydroxide BP: suspension . .

.
· •
·· l
. . . . .. . by retammg water w1 n t ·thi h e gut. Th'is is aso an
This combmed preparation should
·. · .

Precautions: . 1 14ml bot: 24.73MRP ..

. . . . . . euective antaci.d and bowe1 disturbances are nun-
be prescn1>ed with caution . m patients with renal
a.
. .
·

. + NESIFIN Emul. Opsonin

w en com me wi t ent1a:1 y cons t'-
·
uruze . d h b' d . "th po i.1 1
· ··· .
•1
. ..
nnpamner1t and congest1re car 1ac . 1ai ure.
.· · ·· · .
. ..... ... Ma;gllesium: hydroxide BP +liquid paraffm: or�l . . . • . .
· · · · .
· . .c.
.
. . .•· ·• ·•· · •
H
•··
a·
. p a mg a1um . · .. • .1. . .
.
· ·

Pregn•ncy& J actat on : This.combined prepa . r a- ;: . t : ���t � . . · .. ·. th··· ·

. · em'" . � ·
•
1s ·i' ·
·
o ..
:;
. n·••. .. · . < ·L •• · . ·- •: .• •.• ·••···.· : .
·
: i
· · .. <·• •• t •, s ome manu1actUters · · · ··
·. · · .· : : · . ..·:....:: .: . . · . · . ..... .
.
· '· · :.
d 1 d
.
a dd ·e para111n
.
1qu1
.

·
· ..
·
.
· tion· ·• • · caii be given · · · ·
• ·:�: ::::�:;:. : : ;::.::: .
:• ·
.
··· . · :W •
· i4:
...
�·
, · ·
·
.
.
in pregnant & lactating women.. :
. .
.
·
.

•
.
·
•
.

. ;:
• • Wt
•

·
.
·

. ·
·
:
. . . • •
< � ' '' '
: · ·

- &··· ... . milk of magnesia for better laxative action. .

•.•
•

1
•

.
·
· • ·
o :
.
. . . ··•
.
·

Dosage& · adnun. Dail y 4

· · n·mes, a11.er mea s �· .
heart- bum, gas naqs�a.
·
Constip�t1on,
•.•.

.
·
Ind:
• .

b fi bedtim
·

·· ·· & ;:�����!.1'u1.����t� . .- . . -· - . . ..
Magnesium hydroxide BP +•liquid paraffm: oral· ·
· ·
.

Acute chronic constipation due to hyperacidity

�
c�::ble tabl�: & peptic ulcer.
emulsion ... .
Adult&. child over 12 years: 1-2 table s. t . ; IOOntl .hot: 95.00MRP
. C/I: Do not use where use f o laxative is contra-
Child 6-1·2 years. ·. 1 abl·e ... . . .,. t .t .
1n d"lcate. d ; acute gastro-1ntest1na 1 con d" -1t1 11.s; rena 1 .
. ..- .
. ..· 1 ·� ··... . ..
·
.
· · ·
... . . · · · g · .
. • ..

Suspensio1 . .' ..
' • . . . . . .
.... ..... .... . ......... .
-·· ·-
ia1·1 ure (nsk of. magn�s1 ... . F acc�u1 at'toll?
.
• ' . : .... . .c.
.
· \..

. · · .. .
·

. •

. ···\
.
··;
Adult a)ld child over·t21y���;S-lOml. . •
'.
.

.•
� · S/E: Diarrhoea;
. abdommal colic.
Child 2 12 yeti ar � 2 ·5-S m1 L/.· .· .•.· ···. . ··· .
..
Caution: Hepatic impairment elder ly & debilita-
. · ·:

. ··
· .·
.

hll
•
•
�
•

This prepara on ls not recommended 1or c · -

ted; heart block, myocardial disease; pregnancy.
. . ·

� � �
: .
dren na er 2 ear 0 f a e. SIME1'BICO NE 26•42
� .. Doses: Adults& older children- S to 10 tsf in a
Dru mter: If one ts taking o_ther medicines con-
·

. .
�
. , : single dose or in divi ded doses with a·.giass of
:
... .. ·

com1tan��y, or has �ust cqm�leted � oth � r dru g . . .•··•• . •

. · . . .. • ·· •
· ·. · · . SIMEtmCONE: Drop. ..
· · · .
.
treatment? should inform tu,� p�ys1c1an m order to
. . · . . .. .
·

· ·
water
· .
.
··: 3·. � ·e ·. . . Simethicone is an effective an.titlatulent. It is use.d : .
·
.. .

ffi · ..· . ··C ·· · blld .

. ... 6_1,- 1 o . f 1. · :ie> a · · s
fr om drug · • . . ·. . · ·
·n
prevent· h azard s or ine · tC · ae� · · · · · · �rising ·
· · ren . . .. . years,
... .•
..
. t . 11.
.,
•
s n a s1
·
ea t 0- .
. . .
. 2.;.s : ·.• · .· · .1 t o·· ·3 · · · • · · . for reliel-of the painful symptoms of excess gas .•. , •. · ·
. . . . . . .. . ..
.. .. . . . .
• .
> : .... .. .. .. . .
.... . ..
· ·

·
·

Il· lterac
. •t· ·�ns.
' · . · . · · ;
_ .._ .. . or
• I n dt.vid ed.• d.. o,s.es ,,.,.:th wa :L t er, . y�ars,
· . · . . . · ··
.
. . .. . . ... .
· . · .. .. . · ... .
.
·
· ·· · •
.
-.
�

m the dig�stive
.. · . . .
tract. Such gas is frequently ··... ....· .• • • .
..
· · · •·•
. · ·
••
. . ··
. .
. .
.

·
.·.

·• . . · ···.
- sf in divided doses
· ·
,

: In a single tdos� or "1 t h

+ ALGICID Tab Incetp a ·
.
· wate.r ·· .. ··· caused by excessive swallow�g of air or by eat.;. · · · •.• ···• · • ·
· ·
Sodi11m· alginate BP 500mg + potassium bicar- ing foods that disagree, or leading to indigestion.
.

··

bonate :SP lOOmg/tablet (chewable). + AC:ME'S MILK OF MAGNESIA Susp. Mode of action: Simethicone acts in the stomach
.. .
•· ..

l OO's paclc: 350.00MRP ... and int�es to change the ��e tension of .
·

. :: :; :".-:;• .:: : ..: .

Acme
·--·· ··- . .
·- . ·.:. .... . :
. •

. -�..:.:'... . ..'
. �
; ; ;

.. ·.-s-- - . : .
_,
. .. - ..

: ',. ;

......"..·-·.·. . ........ .
...······
. . . ' : :.:' .
. ;·
,

� �.1$1 •••
•••
Ui:l
[g !'!�!!E�!A BANGLADESH
L$ LTD. www.squarepharma.com.bd •••
$QUARE

.. .. ... . . .. ... . ·- . .
. . . ....'..-..-....-:. :'.. :-:.:::.::
. .. :; .
�
''' .. .... .. .. · .... : ·..· ·
.� . . .
::.::::,:·::::: :...:::;:: .: :..:
.. ....'' .... ....
. · ·- . . . . .. - . ..····.-.··...- ...·-- .'.
. . .. .
... ·-·· '...
. ... .. ...-'....."..:;:.- . . --:. .
··..... '. ·. ..··.. . '
.. ... -.... . . -.....
'
. ·: ·· ···· ' ' ......
··: : . . :...· . : : ·:.. . :. . . ' ;;:'.: j'.�: ::.. i'.i:::< : .
....... . .. .. .
......
. . :: :: . ::; .". ..
-····...... .. . . .
•

; : :. . ·
· · ..
·

· ..·. ::.... ·.......: ..

..
.

....···· . . : .-. .·: .:...

. . ... .
..

.. .... · ·...-····....· :.:: : �;: : ; ;; ;.. :. �: ;;_ . :;; . .

. . . -. ,.. _.. .
. ..

.
.

· ··
.

'..... ····· . ..· · .·:--.··; ...• ::.-

:
,.

..
.. ·· .
•;.
.
' ;
,

,
 GASTRO-INTESTINAL DRUGS
gas bubbles, enabling them to coalesce, thus gas
is freed and eliminated more easily by belching or
passing flatus. Its defoaming action relieves flatu­
lence by dispersing .and preventing the form-ation
of mucous surrounded gas pockets in the.O.I
· tract.
Ind: 1. Flatulence, abdominal distention, fullness,
gas and windy colic. Simethicone drop is spe-
· ·. ·.
cially used in infants.
2. Postoperative gas pains- simethicone aids in
the elimination of gas from the G.I tract and can
be used to reduce postoperative gas pains.
2. Large bowel preparation- addition of simethi­
cone to a polyethylene glycol bowel preparation
produces symptom<:ttic improvement prior to in­
vestigation in patients undergoing colonoscopy.
3. Treatment of poisoning- simethicone has an an­
ecdotal use as an antif oaming agent in the man­
agement of accidental ingestion of foaming
. .. detergents. .
.
C/I: Contra-indicated in renal failure, severely
debilitated patients, 1st trimester of pregnancy.
S/E: Silllethicone is physiologically inert. and no
adverse effect has been noted after oral ingestion.
Precaution: Do not exceed 12 doses per day ex­
cept under the advice and supervision of a physi­
cian. Keep the medicine out of the reach of
children.
Pregnancy & lactation: No data are available to
suggest any harmful effect in pregnancy, still it is
not advised to give in the 1st trimester. Excretion
of simethicone in breast milk has not been estab­
lished, and is also unlikely.
Dosage & Admin: Children less than 2 yeal".S
of age- 20mg (0.3ml or 5 drops) 4 times daily
up to 240mg (3.6ml or 55 drops)/day.
Children 2-12 years of age- 40mg (0.6ml or 10
drops) 4 times daily �· ·
.··
Adults- 40-80mg (0.6ml-1.2ml or 10-20 drops)
4 times daily, up to 500mg (7.5ml)/day.
Take all the dosages after meals and at bed-
· Cautions: Renal impairment; patient on a
time. Incase of infants, can be given with feeds. .
··
Shake the bottle well before each use.
Durg inte: There is no evidence that simethicone
modifies the effect of .other drugs. The defoaming
. .
effect of simethicone is reduced by antacids such
as aluminium hydroxide and magnesium carbon­
ate, which absorb the silicone.
+AEROPAC Drop Amico
Simethicone USP 67mg/ml: drop
15ml drop: 25.00 MRP
. ..
+FLACOL Drop Square . spasm, v. colicky abdominal pain, vi. diverticuli­
Simethicone USP 67mg/ml: drop
l 5ml drop: 30.11 MRP
t FLATULEX Drop OpsQnln
Simethicone USP 67mg/ml: drop
15ml drop: 26.49 MRP
+GASNIL Drop SK+F
Simethicone USP 67mg/ml: drop
15ml drop: 30,00 MRP
+LEFOAM Drop Incepta
Simethicone USP 67mg/ml: drop
15ml drop: 30.00 MRP
+NEODROP Drop Beximco
Simethicone USP 67mg/ml: drop
15ml drop: 30.00 IP ..
. 3
+OROCURE Drop Edruc
Simethicone USP 67mg/ml: drop
15ml drop: 30.00 MRP
t PEDICON Drop Orion Pharma
QIMP-17 (6)
Simethicone USP 67mg/ml: drop
lOml drop: 25.09 MRP
20ml drop: 30.11 MRP
t PEDIGAS Drop Globe
Simethicone USP 67mg/ml: <.Irop
l 5ml drop: 30.00 MRP
+SEMECON Drop Drug Inter.
Simethicone USP 67mg/ml: drop
. ·· 15ml drop: 35.00 MRP
+SIMECOL Drop Alco Pharma
Simethicone USP 67mg/ml: drop
l 5ml drop: 28.00 MRP
+SIME T Drop ACI
Simethicone USP 67mg/ml: drop
15ml drop: 30.11 MRP
CARM1NATIVE PREPARATIONS21•38
CA�ATIVE MIXTURE: Liquid . .
Sodium bicarbonate, chloroform, Tr. gingb. fort,
Menthapip, Peppermint, Camphor, Tr. card Co.
. Ind: Dyspepsia, hyperacidity, indigestion, gas
···
formation in the stomach & intestine.
Dose: 1 tablespoonful diluted with water 3
times daily or when required.
.. Preparation: May .be available in the pharmacies :
as mixrure.
SODA MIN T Tablet. ..
Sodium l,)icarbonate 300mg, contains about
4mmol Na+/tablet.
Ind: Rapid relief of dyspepsia.
Cautions: Renal impairment; patient on a
sodium-restricted diet; avoid prolonged use.
S/E: Belching, alkalosis etc. .
Dose: 2-6 tablets sucked when required.
t S.ODICURB Tab. Popular . ...
Sodium bicarbonate 300mg (contains about
4mmol Na+)/tablet.
Ind: Rapid relief of dyspepsia.
sodium-restricted diet; avoid prolonged use.
S/E: Belching, alkalosis etc.
Dose: 2-6 tablets sucked when required.
60 tabs pack: 361 ;20 MRP
2. ANTISPASMODICS
... . .
(Antlchollnerglcs)
2.1 Antimuscarinics
a) Tertiary amines viz:
Atropine sulphate, Dicycloverine (Dicy­
clomine) hydrochloride
b) .· Quaternary ammonium
compounds viz:
Hyoscine butylbromide, Propantheline
2.2 Other anti$pasmodics viz:
Alverine citrate, Drotaverine, Mebeverine,
Oxyphencycllmine, Oxyphenonlum bro­
mUle, Timon/um etc.
. ocular tension, urinary hesitancy, palpitations,
·. '
· Andmuscarinics
ATROPINE SULPBATE 21•3
ATROPINE SULPHATE: Tablet/ Injection.
Ind: Aid in peptic ulcer treatment, g.i spasm,
-·.. ... renal & biliary
. colic. . .
C/I: Glaucoma, paralytic ileus, pyloric stenosis,
prostatic enlargement, intestinal obstruction.
S/E: Dry mouth with difficulty in swallowing &
· ·
. • •·· .· thirst; dilatation of pupils with loss of accommo­
dation and sensitivity to light, increased intraoc­
ular pressure, flushing, dry skin, bradycardia,
followed by tachycardia, palpitations & arrhyth­
mias, difficulty witll micturition and constipation.
Cautions: Elderly patient; urinary retention,
tachycardia, cardiac insufficiency; and during
. ... .. breast feeding. . .
Dosage & admin: By mouth, 0.25-2 mg daily in
single or diVided doses, dosage should be grad­
ually increased to the max. tolerated. By inj.
0.25-2 mg sC or i.m. injection.
+ATROPINE lnj. Chemist
Atropine sulphate 0.6mg/ lml ampoule: injection
. 50 amps pack: 126:00 MRP .
+ATROPINE-Jayson Inj. Jayson
Atropine sulphate 0.6mg/ lml ampoule: injection
.. 10 amps pack: 50.00 IP
· ··· · · ..
t ATROPINE Sulph. Inj. Edruc
Atropine sulphate 0.6mg/lml ampoule: injection
10 amps pack: 50.00 MRP
··
+G-ATROPINE Sulph. lnj. Gonoshas. .
Atropine sulphate Q.6mg/ lml ampoule: injection
10 amps pack: 30.10 MRP
DICYCLOVERINE26•42
DICYCLOVERINE HCl: Tablet/Syrup
Dicycloverine hydrochloride is an antimuscarinic
(anticholinergic) antispasmodic agent, used to re­
lieve smooth muscle spasm of the gastrointesti­
nal tract. It is avail�ble as dicycloverine
hydro-chloride BP IOmg/tablet and 1Omg/5ml
syrup.
Mode of action: It works at specific receptors,
···· called cholinergic (or muscarinic) receptors, lo­
·
cated on the involuntary muscles in the walls of
the gut. By binding to these receptors dicy­
cloverine prevents.
... certain chemicals produced by
'
the body from interacting with these receptors.
This causes the gut muscle to relax, relieving the
pain of colic produced by gut muscle contraction
and spasm.
Ind: i. Functional or irritable bowel syndrome, ii.
urinary incontinence secondary to unstable detru­
sor muscle, iii. infantile colic, iv. gastro-intestinal
tis, and vii. abdominal colic.
C/I: i. Obstructive uropathy, ii. obstructive dis­
ease of the gastrointestinal tract, iii. severe ulcera­
tive colitis, iv. reflux esophagitis, v. unsta-ble
cardiovascular status in acute hemorrhage, vi.
glaucoma, vii. myasthenia gravis, viii. evidence
· . of prior hypersensitivity to dicycloverine hydro­
.
chloride or other ingredients of this formulation,
and ix. infants less than 6 months of age.
S/E: Insomnia, mydriasis, cycloplegia, increased
dyspnea.
Precaution: Use with caution in patients with au­
tonom�c neuropathy, hepatic or renal disease, ul­
cerative colitis, coronary heart disease,
conges-tive heart failure, cardiac tachyarrhyth­
mia, hiatal hernia, known or suspected prostatic hy­
pertrophy..
 ' , , " .......

QIMP-17 (7) GASTRO-INTES'I'INAL DRUGS .

However, in human pregnancy it should be used + IBSPA Tab. Pacific + COLIPAN Inj. Medimet
only if clearly needed. Dicycloverine hydrochloride BP 1Omg/tablet Hyoscine butylbromide 20mg/1ml amp: injection
There are evidences on the secretion of dicy­ lOO's paclc 200.00 MRP 10 amps pack: 78.50 MRP
cloverine into breast milk. So, it should not be + IBSPA Syp. Pacific + G-HYOSCINE Tab. Gonoshas
used in case of lactating mother.42 Dicycloverine hydrochloride BP 1Omg/5ml: syrup Hyoscine butylbromide 1Omg/tablet.
Dosage & admin: By mouth: Adults- 10 to 50ml bot: 25.00 MRP . lOmg x l·OO's pack: 335.00 MRP
20mg 3 times a day� Maximum recommended, + LOVERIN Tab . Beximco •. + G-HYOSCINE Inj. Gonoshas
.
oral dose is 160mg daily in divided doses. Dicycloyerine hydrochloride BP IOmg/tablet Hyoscihe butylbromide 20mg/ l ml amp: injection
Children over 6 months of age-. 5 to lOmg 3. . 5.0's pack: 100.SOIP
·
· 10 amps pack: -77.5 MRP
times a day. . ... . + LOVERIN Syp. Beximco + HYB UCIN Tab. Supreme
By i.m injection: Usual recommended dose is Dicycloverine hydrochloride BP 1Omg/5ml: syrup Hyoscirie-butylbromide 1Omg/tablet.
80mg daily by i.m route in 4 divided doses. 50ml bot: 30.00 IP lOmg x lOO's pack: 340.00 MRP
Drug inter: The following agents may increase + WINSPA Tab. Apex + HYSIN 10 Tab. Edruc
certain actions or side-effects of dicycloverine­ Dicycloverine hydrochloride BP 1Omg/tablet Hyoscine butylbromide 1Omg/tablet.
amantadine antiarrhythmic agents of class (e.g 50's pack: 100.00 MRP lOmg x IOO's pack: 348.00 MRP
quinidine ), antihistamine antipsychotic agents + WIN SPA Syp.. Apex + HYSIN Inj. Edruc
(e.g phenothiazines), benzodiazepines, MAO in­ Dicycloverine hydrochloride BP 1Omg/5ml: syrup Hyoscine butylbromide lOmg/lml amp: injection
hibitors, narcotic analgesics (e.g meperidine), ni­ 50ml bot: 30.00 MRP 10 amps pack: 100.00 MRP
trates and nitrites, sympathomimetic agents, + HYSOCIN Tab. Pharmadesh
tricyclic antidepressants, and other drugs having Hyoscine butylbromide 1Omg/tablet.
anticholinergic activity.
HYOSCINE BUTYLBROMIDE21.33
lOmg x lOO's pack: 344.00 MRP
. ... + HYSOM.A Tab. Modern
' '''. '.. .',' '
+ ABDORIN Tab. Opsonin •· •
· ·
.
.• '
' '
HYOSCINE BUT. .YLB.RO . MID E: Tablet/ Tine-
' ' ' ' ' ' Hyoscine bµ:tylbromide 1Omg/tablet.
Dicycloverine hydrochloride J3.P l 0mg/tablet ture/ Injction� · . · • ·· · · ·
' ' ' ' _,

...
'

'' '
. .. . . lOmg x - -IOO's
'
pack: 167.00 MRP
50's pack: 88.41 MRP Ind: Aid in peptic ul�r treatment, spasmodic
'

·
' "

+ HYSO�IDE Tab. Opsonin

+ ABDORIN Syp. Opsonin pain, gastro-intestinal spasm, biliary and spas- Hyoscine butylbromide 1Omg & 20mg/tablet.
Dicycloverine hydrochloride BP 10mg/5ml: syrup modic dysmenorthoea.
. . .
lOmg x lOO's pack: 301.73 MRP
50ml bot: 26.49 MRP C/I; S/E; Cautions: Same as atropine sulphate 20mg x 1OO's pack: 308.77 MRP
+ COLICON Tab. Square (above). t HYSOMIDE Inj. Opsonin
Dicycloverine hydrochloride BP 1Omg/tablet Dose: By mouth, adult- 20mg 4 times daily. Hyoscine butylbromide 20mg/l ml amp: injection
1OO's pack: 201.00 MRP Child- under 6 years not recommended, 6-12 25 amps pack: 173.52 MRP
+ COLICON Syp. Square yrs. lOmg 3 times daily. By injection, 20mg + SAPEN Tab. SAPL
Dicycloverine hydrochloride BP 10mg/5ml: syrup i.m. or i.v inj.(in acute pain or spasm), re­ - Hyoscine butylbromide 1Omg/tablet.
50ml bot: 30.11 MRP . peated after 30 minutes if necessary. IOmg X: lOO's pack: 180.00 MRP
t COLICON Inj. Square .• ·.
+ SPANIL Tab. Beximco
.
Dicycloverine hydrochloride B.J.> Z()µlg/2ml am­ + ANCOPAN Tab.
. Bristol
. ' ' ' ' ' '

Hyoscine butylbromide 1Omg/tablet.

poule: i.m injection.
. . . ·. •..
Hyoscine butylbromide
. . . 1Omg & 20mg/tablet
BP . .
lOmg x lOO's pack: 344.00 MRP
10 amps pack: 60.20 MRP ... • ••· · lOmg x lOO's pack,;180.00 MRP
· ·
•

.. + SPASM()SON Tab. Jayson

20mg x SO's p<i.ckc· 175.00 MRP
" ' ' ' ' '

+ CYCLOPAN Tab. Incepta . -

' ''
HycJscine butylbromide 1Omg/tablet.
':

Dicycloverine hydrochloride BP 1Oing/tablet + ANTIPEN Tab. Nipa

lOmg x lOO's pack: 340.00 MRP
1OO's pack: 200.00 MRP Hyoscine butylbromide BP IOmg/tablet
t SPASMOSON Inj. Jayson
+ CYCLOPAN Syp. Incepta lOmg x IOO's pack: 162.00 MRP
Hyoscine butylbromide 20mg/ l ml ampoule: in-
Dicycloverine hydrochloride BP 1Omg/5ml: syrup + BROSPAN Tab. Gaco
jection.
50ml liot: 30.00 MRP Hyoscine-n-butylbromide BP 1Omg/tablet.
l ml amp x 1O's pack: 78.80 MRP
+ CYCLOPAN Inj. Incepta IOmg x lOO's pack: 182.00 MRP
+ SPASMOZEN Tab. Zenith
Dicycloverine hydrochloride BP 20mg/2ml am­ + BROSPAN Inj. Gaco
Hyoscine butylbromide 1Omg/tablet.
poule: i.m injection. Hyoscine butylbromide 20mg/ l m1 amp: injection
lOmg x IOO's pack: 343.00 MRP
5 amps pack: 40.00 MRP 1 ampoule: 7 .84 MRP

t CYCLOVIN Tab. Somatec + BUSCON Tab. Ibo Sina

Dicycloverine hydrochloride BP 1Omg/tablet Hyoscine butylbromide 1Omg/tablet. PROPANTHELJNE21,13s
lOO's pack: 201.00 MRP lOmg x lOO's pack: 344.00 MRP

t CYCLOVIN Syp� SonI,atec ... + BUSCON Inj. lbn Sina ... PROPANTHELINE: Tablet. .
Hyoscine bl:;ltylbromide 20mg/lml amp:· injection ... ... • Propantheline is an anticholin"ergic drug, which
Dicycloverine hydrochloride BP 1Omg/5m1: syrup . .
·
50ml bot: 30.11 MRP 10 amps pack: 11.00 MRP reduces .the effect of acetylcholine. Propantheline
+ DIRIN Tab. Alco Pharma + BUTALPEN Tab. Desh Pharma is used to treat or prevent spasm in the muscles of
Dicycloverine hydrochloride BP 1Omg/tablet Hyoscine butylbromide BP 1Omg/tablet. the gastrointestinal tract in the irritable bowel
lOO's pack: 200.00 MRP IOmg x 1OO's pack: 300.00 MRP syndrome.In addition, propantheline inhibits gas-
+ DIRIN Syp. Alco Pharma 10mg x 500's pack: 1500.00 MRP trointestinal propulsive motility and decreases
Dicycloverine hydrochloride BP 1Omg/5ml: syrup + BUTAPAN Tab. Sanofi-aventis gastric acid secretion and controls excessive pha-
50ml bot: 40.00 MRP Hyoscine butylbromide 1Omg & 20mg/tablet. ryngeal, tracheal and bronchial secretions. It is
+ DIVERIN Tab. ACI 1Omg x 500's pack: 1710.00 MRP available as- propantheline bromide USP
Dicycloverine hydrochloride BP IOmg & 20mg x 1OO's pack: 600.00 MRP l 5mg/tablet.
20mg/tablet + BUTAPAN Inj. Sanofi-aventis Mode of action: Action of propantheline is
lOmg x 50's pack: 100.50 MRP Hyoscine butylbromide 20mg/lml amp: injection achieved via a dual mechanism: i. a specific anti-
20mg x 50's pack: 175.50 MRP l ml amp x lO's pack: 78.87 MRP cholinergic effect (antimuscarinic) at the acetyl-
t DIVERIN Syp. ACI + COLIK Tab.
. ACI choline�receptor sites and, ii. a direct effect upon
.
Dicycloverine hydrochloride BP 1Omg/5ml: syrup Hyoscine butylbromide 1Omg/tablet. smooth muscles (musculotropic).
50ml bot: 30.11 MRP lOmg x IOO's pack: 344.00 MRP Ind: Propantheline is indicated as an adjunctive
t ERASPA Tab. MST Phrama · + COLIPAN Tab. Medimet -

therapy in the treatment of peptic ulcer and for the

Dicycloverine hydrochloride BP 1Omg/tablet Hyoscine butylbromide 1Omg/tablet. relief of symptoms of gastritis;
50's pack: 100.00 MRP IOmg x 1OO's pack: 300.00 MRP Spastic and inflammatory diseases of the gastro-
1 . ::::::.:�;;'''.:""� ::: ..............
;;
""'". ·:::·::::;;;.::::1""" "' . . . ... . ..
. ... ......... .. :' . ' .
. ::. ..
.
. ... .. ........... .
.
... . . . .
. . .
· "' ...
. . ..

.
"

.. ..: ·. . ·:
.�: : :.:
. .
.
. ... . .
�

,;
•
• .
'. .

.. .
.;:::� :::;::
,
... ... ..
.

.... .... .....

�.
.
, . . .......
... . '
.
.
.
..

t
.
I.
......
..... .. . ; '
(

' ...

. ..
,
. .
..

Il ..
: ...

'.

..... . .. . .
..
.. .. ..
... .......
. ...
.. .

· .· MEBEVE
· RJNE:n�6,33 .. . . ........ .. .
. ...
. '. . .
. . .. .· . · : .
. ..
:1�::
. . '

·:.. :. �. .'
..

:
. : . ; : .'
'
:: � .
.
.. ·
, ·:: ..

.
. .. . '. .. . ...... .. . ...
"
.

MEBEVERINE HCI: Tablet/Capsule/Syrup.

Mebeverine hydrochloride is a musculotropic

' ".
.
.

....., . .... . . . .. .. . .... ...

. ...
..
.
.

: :. . .
,
.•

. .. .
. :·
'
.
'

....
·:

. . ..... .
.... .

"'. : . ·
; .

.. .. .. . ...
... . . .. .

antispasmodic agent used to relieve cramps or
spasms of the stomach and intestine (gut). It is
particularly useful in treating irritable bowel
syndrome (IBS) and similar conditions. It is
available as- Mmbeverine hydrochloride BP
135mg tablet & 200mg SR (sustained release)
capsule. It may be available as liquid preparation.
Mode of action: Mebeverine hydrochloride
works by relaxing the muscles and helping
restore the normal movement of the gut.
Ind: For the symptomatic treatment of irritable
bowel syndrome (IBS).
Other conditions include- chronic irritable colon,
spastic constipation, mucous colitis, colicky
abdominal pain, persistent non-specific diarrhoea.
C/I: Not known.
S/E: Generally mebeverine is well tolerated. But,
a few side-effects like skin rash, urticaria and
angioedema may appear.
Precautions: Paralytic ileus. Caution also should
be exercised in porphyria (better to avoid in
porphyria) or allergic reaction to this or any other
medicine of this group.
Pregnancy & lactation: No teratogenicity has
been shown in animal experiments. However, the
usual precautions concerning the administration
of any drug during pregnancy should be
exercised. Mebeverine does not excrete in the
breast milk after administering at therapeutic dose.
Dosage & admin: Adults, elderly & children
over.JO years: 1 tablet (135mg) three times, or
1 SR (sustained release) capsule (200mg) twice
daily. Mebeverine is most effective when taken
20-30 minutes before meals.After several weeks
when the desired effect has been obtained, the
dosage may be gradually reduced.
Missed dose: If a dose of this medicine is
missed, that should be taken as soon as
possible. However, if it is almost time for the
next dose, then skip the missed dose and the
regular dosing schedule should be maintained.
Dose should not be doubled at the same time
to compensate the missing dose.
Children under 10 years: Not recommended.
Drug inter: Not known.
+EVARIN Tab. Delta Pharma
Mebeverine hydrochloride 135mg/tablet.
135mg x 50's pack: 300.00 MRP
+ IRIBAN Tab. Incepta
Mebeverine hydrochloride l 35mg/tablet.
l 35mg x 50's pack: 300.00 MRP
+ IRIBAN SR 200 Tab. Incepta
Mebeverine hydrochloride 200mg/tablet
(sustained release).
200mg x 30's pack: 300.00 MRP
+IRISYN Tab. Ibn Sina
Mebeverine hydrochloride 135mg/tablet.
135mg x 50's pack: 350.00 IP
+MAVE Tab. Opsonin
Mebeverine hydrochloride 135mg/tablet.
135mg x 50's pack: 264.97 MRP
+MAVE SR 200 Cap. Opsonin
Mebeverine hydrochloride 200mg/capsule
(sustained release).
200mg x 30's pack: 264.97 MRP
+MEBIZ SR Cap. Sun Pharma
Mebeverine hydrochloride 200mg/capsule
(sustained release).
200mg x 30's pack: 241.50 MRP
+MESPA Tab.Ambee
QIMP-17 (9)
Mebeverine hydrochloride 135mg/tablet.
135mg x 50's pack: 301.00 MRP
+MEVERINE Tab. Drug Inter.
Mebeverine hydrochloride 135mg/tablet.
135mg x 50's pack: 300.00 MRP
+MEVERINE SR Cap. Drug Inter.
Mebeverine hydrochloride BP 200mg/capsule
(sustained release).
200mg x 30's pack: 300.00 MRP
+MEVIN Tab. Square
Mebeverine hydrochloride 135mg/tablet.
135mg x 50's pack: 300.00 MRP
+ROSTIL Tab. Beximco
Mebeverine hydrochloride 135mg/tablet.
135mg x 50's pack: 350.00 IP
+VERIPEL SR Cap. Beacon
Mebeverine hydrochloride BP 250mg/capsule
(sustained release).
250mg x 32's p.ack: 288.00 MRP
+VERON Tab. SK+F
Mebeverine hydrochloride 135mg/tablet.
135mg x 50's pack: 300.00 MRP
OXYPHENONIUM BROMIDE 21,33
OXYPHENONIUM BROMIDE: Tablet
Ind: Aid in peptic ulcer treatment, spasmodic
pain, gastro-intestinal spasm, biliary and
spasmodic dysmenorrhoea.
C/l; S/E: See under hyoscine butyl bromide.
Adult: 1-2 tabs. several times daily, if
necessary. Child: over 6yrs, 1/2 to 1 tablet 1-3
times daily.
+ANT RENEX Tab. Opsonin
Oxyphenonium bromide 5mg/tablet.
IOO's pack: 109.96 MRP
+ANTRENYL Tab. Sandoz
Oxyphenonium bromide 5mg/tablet.
IOO's pack: 400.00 MRP
+ ISONIL Tab.Amico
Oxyphenonium bromide 5mg/tablet.
IOO's pack: 141.00 MRP
PEPPERMINT OIL34
PEPPERMINT OIL: �apsule (Gelatin capsule)
Peppermint & peppermint oil are the ingredients
of carminatives. Peppermint oil is found effective
in the symptomatic relief of abdominal pain,
distension, flatulence and gas associated with the
irritable bowel syndrome (JBS). It is available as­
liquid-filled enteric-coated gelatin capsule
containing peppermint oil USP 0.2ml/capsule.
Mode of action: Peppermint oil is able to cause
direct relaxation of smooth muscles found in the
gut and gallbladder wall too by blocking the so
called calcium channels that help in the contrac­
tion of these muscles. It thus helps tone the stom­
ach, liver and intestine while strengthening and
toning the nervous system. Peppermint oil's dou­
ble action helps relive both the painful abdominal
spasm and uncomfortable bloating of IBS. Firstly
peppermint oil has a relaxing effect in the bowel
muscle to relieve the knotted feeling & cramping
pain in the stomach. At the same time peppermint
oil helps disperse the pockets of trapped wind
that can cause the uncomfortable bloating
feeling. It is also proposed that peppermint oil
helps in relaxation of the esophageal sphincter,
GASTRO-INTESTINAL DRUGS
leading to release of gas pressure in the stomach.
Peppermint and its main active agent, menthol
are effective decongestants. Because menthol
,
thins mucus, it is also a good expectorant,
meaning that it helps loosen and breaks up
coughs with phlegm.
Ind: Peppermint oil is indicated in the sympto­
matic relief of abdominal pain, distension,
flatulence and gas associated with the irritable
bowel syndrome (JBS). Because it has a calming
and numbing effect, it has been used to treat
headaches, menstrual cramps and flatulence. It is
also widely used to treat symptoms of the com­
mon cold & ·coughs with phlegm. Peppermint oil
may help the body break down gallstones.
C/I: Do not administer with meals or to patients
with achlorhydria.
S/E: Peppermint oil is usually well tolerated,
though very occasionally heartburn and irritation
can occur.
Precautions: Peppermint oil should not be
administered to patients with heartburn or active
gastric ulcers as symptoms may be exacerbated.
Do not administer to patients allergic to
peppermint, menthol, arachis (peanut) oil or
similar essential oils. Do not chew or break the
capsules as local irritation of the mouth,
esophagus and stomach may occur.
Pregnancy & lactation: There are no data
available to establish the safety of peppermint oil
in pregnancy; therefore it should be used only if
the possible benefits outweigh the possible
hazards. Levels of menthol were not detectable in
plasma or saliva following administration of
. peppermint oil indicating rapid first pass
metabolism. Significant levels of menthol in
breast milk are thought to be unlikely.
Dosage & admin: Adults: 1 capsule 3 times a
day with a small quantity of water. Increase
dosage to 2 capsules 3 times a day if required.
Take 30 to 60 minutes before meals. Do not
chew. Do not take immediately after meals or
with food.
Children over 8 years: 1 capsule 3 times a day
swallowed whole with a small quantity of
water.
Drug Inter: Indigestion remedies s.hould not be
taken at the same time with peppermint oil.
+LIQUMINT Cap. Beacon
Peppermint oil BP 0.2ml/capsule (enteric-coated
soft gelatin capsule).
0.2ml cap x 50's pack: 200.00 MRP
+MINTEK Cap. Drug Inter.
Peppermint oil BP 0.2ml/capsule (enteric-coated
soft gelatin capsule).
0.2ml cap x 30's pack: 180.00 MRP
+MINTOL Cap. General
Peppermint oil BP 0.2ml/capsule (enteric-coated
soft gelatin capsule).
0.2ml cap x 30's pack: 210.90 MRP
TIEMO,NIUM 2 I ,40,s2
T IEMONIUM METHYLSULFATE: Tablet/
Syrup/Injection/Suppository
Tiemonium is an antispasmodic drug with anti­
cbolinergic effects which reduces visceral smooth
muscles spasm & used for the relief of muscular
& visceral pain. It is available as tiemonium
 •
®
QIMP-17 (10)

Tiemonium Methytsulphate
50mg Tablet t PANIUM Tab. Navana
�
•

......
I"s I
�
•10mg/5ml Syrup t TIMOVIS Tab. Kumudini
•5mg/2ml Injection Tiemonium methylsulfate INN 50mg/tablet Tiemonium methylsulfate INN 50mg/tablet
50's pack: 250.00 MRP
Reliably relieves ArJrJr1rr1inal P;:iir1 ��� t PARILLEX Tab. Drug inter.
50's pack: 200.00 MRP
t TIMOZIN Tab. lncepta
Tiemonium methylsulfate INN 50mg/tablet Tiemonium methylsulfate INN 50mg/tablet
methylsulfate INN in tablet, syrup, injection & 50's pack: 200.00 MRP 50's pack: 200.00 MRP
suppository preparation. + PREVIP Tab. General t TIMOZIN Inj. Incepta
Ind: Acute spasmodic pain in gastrointestial and Tiemonium methylsulfate INN 50mg/tablet Tiemonium methylsulfate INN 5mg/2ml ampoule:
biliary diseases, and in urology and 50's pack: 201.00 MRP i.m/i.v injection
gynaecological origin. t RELVIS Tab. Biopharma 5 amps pack: 75.00 MRP
C/I: Glaucoma; difficulty to urinate (disorders of Tiemonium methylsulfate INN 50mg/tablet
t T INILUX SO Tab. Sharif
prostate or bladder). 50's· pack: 250.00 MRP Tiemonium methylsulfate INN 50mg/tablet
S/E: See under atropine; risk of hypotension & + RELVIS Inj. Biopharma 30's pack: �20.00 MRP
tachycardia; occasional retention of urine in Tiemonium methylsulfate INN 5mg/2ml
t TINIMET Tab. Rephco
excessive or overdoses. ampoule: i.m/i.v injection Tiemonium methylsulfate INN 50mg/tablet
Caution: See under atropine; avoid taking this 10 amps pack: 150.00 MRP 50's pack: 250.00 MRP
I drug without medical advice during pregnancy or t SPANIUM Tab. Z iska + T INIMET lnj. Rephco •

breast feeding. Tie1nonium methylsulfate INN 50mg/tablet Tiemonium methylsulfate INN 5mg/2ml
Dosage & admin: Adult: By mouth, the usual 50's pack: 200.00 MRP ampoule: i.m/i.v injection
dosage is 100-300mg (2 to 6 tablets or 4 to 12
t SPANIUM Inj. Ziska 10 amps pack: 200.00 MRP
tsf) daily in divided doses as required; by Tiemonium methylsulfate INN 5mg/2ml
+ TINO Tab. Delta Pharma
injection usual dosage is Smg by slow i.m or ampoule: i.m/i.v injection Tiemonium methylsulfate INN 50mg/tablet
i.v injection 3 times daily. 5 amps pack: 75.00 MRP 50's pack: 200.00 MRP
By suppository: Suppository can be used as an
+ SPAZIN Tab Euro Pharma
•.
t TISPA Tab. Concord
alternative of oral tablet preparation, where it Tiemonium methylsulfate INN 50mg/tablet Tiemonium methylsulfate INN 50mg/tablet
necessary.
•

ts
50's pack: 250.00 MRP
50's pack: 250.00 MRP
+ TIEMO Tab. Alco Pharma
t ALGIN Tab. Renata + TITOS Tab. Novo Healthcare
Tiemonium methylsulfate INN 50mg/tablet Tiemonium methylsulfate INN 50mg/tablet
Tiemonium methylsulfate INN 50mg/tablet (f.c)
30's pack: 120.00 MRP
50's pack: 300.00 MRP 30's pack: 150.00 MRP
t ALGIN Syp. Renata t TIENUM Tab. Chemist t T IUM Tab. Ad-din
I Tiemonium methylsulfate INN 1Omg/5ml: syrup Tiemonium methylsulfate INN 50mg/tablet Tiemonium methylsulfate INN 50mg/tablet
I OOml bot: 90.00 MRP 50's pack: 200.00 MRP 30's pack: 105.00 MRP
•

+ ALGIN Inj. Renata t TIENUM Inj. Chemist t T I VIS Tab. Beacon

Tiemonium methylsulfate INN 5mg/2ml Tiemonium methylsulfate INN 50mg/tablet
Tiemonium methylsulfate INN 5mg/2ml
ampoule: i.m/i. v injection ampoule: i.m/i.v injection 50's pack: 250.00 MRP
5 amps pack: 75.00 MRP
5 amps pack: 125.00 MRP + TMS Tab. Medicon
+ DYSMA Tab. Rangs pharma t TIMEM Tab. Silva Tiemonium methylsulfate INN 50mg/tablet
Tiemonium methylsulfate INN 50mg/tablet (f.c) Tiemonium methylsulfate INN 50mg/tablet 50's pack: 250.00 MRP
30's pack: 120.00 MRP
50's pack: 250.00 MRP t T YNIUM Tab. ACI
50's pack: 200.00 MRP

II t EMOGIN Tab. Somatec Tiemonium methylsulfate INN 50mg/tablet

Tiemonium methylsulfate INN 50mg/tablet t TIMETH Tab. Edruc 50's pack: 250.00 MRP
50's pack: 250.00 MRP Tiemonium methylsulfate INN 50mg/tablet
t TYNIUM Syp. ACI
1 50's pack: 200.00 MRP
t EMONIUM Tab. Beximco Tiemonium methylsulfate INN 1Omg/5ml: syrup
Tiemonium methylsulfate INN 50mg/tablet t TIMOLAX Tab. SAPL I OOml bot: 85.00 MRP
50's pack: 250.00 IP Tiemonium methylsulfate INN 50mg/tablet
t TYNIUM lnj. ACI
50's pack: 200.00 MRP
+ EMONIUM lnj. Beximco Tiemonium methylsulfate INN 5mg/2ml
Tiemonium methylsulfate INN 5mg/2ml t TIMONAC Tab. RAK Pharma ampoule: i.m/i. v injection
Tiemonium methylsulfate INN 50mg/tablet
ampoule: i.m/i.v injection 5 amps pack: 75.30 MRP
5 amps pack: 75.00 IP 50's pack: 200.00 MRP
+ VERALGIN Tab. Aristopharma
t NORVIS Tab. Square t TIMONAC lnj. RAK Pharma Tiemonium methylsulfate INN 50mg/tablet
Tiemonium methylsulfate INN 50mg/tablet Tiemonium methylsulfate INN 5mg/2ml
50's pack: 300.00 MRP
50's pack: 250.00 MRP ampoule: i.rn/i.v injection
+ VERALGIN lnj. Aristopharma
10 amps pack: 200.00 MRP Tiemonium methylsulfate INN 5mg/2ml
t NORVIS Syp. Square
Tiemonium methylsulfate INN 1Omg/5ml: syrup t TIMONIL Tab. Popular ampoule: i.m/i.v injection
IOOml bot: 87.00 MRP Tiemonium methylsulfate INN 50mg/tablet 2ml amp x lO's pack: 150.00 MRP
50's pack: 201.00 MRP
t NORVIS Inj. Square + VISARIN Tab. Pharmasia
Tiemonium methylsulfate INN 5mg/2ml t TIMONIL Inj. Popular Tiemonium methylsulfate INN 50mg/tablet
Tiemonium methylsulfate INN 5mg/2ml
ampoule: i.m/i.v injection 50's pack: 200.00 MRP
10 amps pack: 150.50 MRP ampoule: i.m/i.v injection
+ VISCER Tab. Techno Drugs
5 amps pack: 75.30 MRP Tiemonium methylsulfate INN 50mg/tablet
+ ONIUM Tab. Ori�n Pharma '

Tiemonium methylsulfate INN 50mg/tablet t TIMOPA Tab. Cosmic 50's pack: 175.00 MRP
50's pack: 251.00 MRP Tiemonium methylsulfate INN 50mg/tablet
t VISCER Inj. Techno Drugs
50's pack: 250.00 MRP
t ONIUM Inj. Orion Pharma­ Tiemonium methylsulfate INN 5mg/2ml
Tiemonium methylsulfate INN 5mg/2ml + TIMOTHY Tab. SK+F ampoule: i.m/i. v injection
ampoule: i.rn/i.v injection Tiemonium methylsulfate INN 50mg/tablet 2ml amp x lO's pack: 120.00 MRP
5 amps pack: 75.30 MRP 50's pack: 200.00 MRP t VISCERAL Tab. Ibo Sina
Tiemonium methylsulfate INN 50mg/tablet (f.c)
+ ONIUM Syp. Orion Pharma t TIMOTHYinj. SK+F
Tiemonium methylsulfate INN I Omg/5ml: syrup Tiemonium methylsulfate INN 5mg/2ml 50's pack: 225.00 IP

50ml bot: 50.00 MRP ampoule: i.m/i.v injection + VISCERAL Inj. Ibo Sina
I OOml bot: 85.00 MRP 5 amps pack: 75.00 MRP Tiemonium methylsulfate INN 5mg/2ml
 QIMP-17 (11) GASTRO-INTES'I'INAL DRUGS

ampoule: i.m/i.v injection and increases synchronization between electro­
10 amps pack: 160.00 IP physiological spikes and contractions in isolated
+ VISCERALGINE Tab. Nuvista guinea pig strips of colon and ileum. However, it
Tiemonium methylsulfate INN 50mg/tablet (f.c) does not alter normal motility, but regulates
50's pack: 412.50 MRP abnormal intestinal activity.
+ VISCERALGINE Inj. Nuvista Ind: I. Treatment and relief of symptoms
Tiemonium methylsulfate INN 5mg/2ml associated with irritable bowel syndrome (spastic
ampoule: i.m/i.v injection colon). 2. Postoperative paralytic ileus in order to
10 amps pack: 394.50 MRP accelerate the resumption of the intestinal transit
+ VISEGIN Tab. UniMed & UniHealth following abdominal surgery.
Tiemonium methylsulfate INN 50mg/tablet C/I: Patients with known hypersensitivity to
30's pack: 150.00 MRP trimebutine maleate or any excipient.
+ VISET Tab. Healthcare AIR: Trimebutine maleate is generally well
Tiemonium methylsulfate INN 50mg/tablet tolerated. The infrequently reported adverse
50's pack: 300.00 MRP effects are as following- dry mouth, foul taste,
+ VISET Syp. Healthcare diarrhea, dyspepsia, epigastric pain, nausea,
Tiemonium methylsulfate INN 1 Omg/5ml: syrup constipation, drowsiness, fatigue, dizziness,
50ml bot: 55.00 MRP hot/cold sensations, headache etc.
lOOml bot: 90.00 MRP Precautions: Pregnancy & lactation: Although
+ VISET Inj. Healthcare teratological studies have not shown any drug
Tiemonium methylsulfate INN 5mg/2ml ampoule: related adverse effects on the course and outcome
i.m/i.v injection of pregnancy, the use of trimebutine maleate in
10 amps pack: 250.00 MRP pregnant women is not recommended. It is not
+ VISNIL Tab. NIPR O JMI known if trimebutine maleate passes into breast
Tiemonium methylsulfate INN 50mg/tablet milk. This medication should be used while
30's pack: 120.00 MRP breast feeding only if the potential benefits out­
+ VISNOR Tab. Apex weigh risks to the nursing infants.
Tiemonium methylsulfate INN 50mg/tablet Dosage & admin: Adults: 100mg-200mg, 3
50's pack: 200.00 MRP times daily before meals.
+ VISNOR lnj. Apex ·
Drug inter: Trimebutine maleate increases the
Tiemonium methylsulfate INN 5mg/2ml ampoule: duration of d-tubocurarine-induced curarization.
i.m/i.v injection No other drug interactions have been observed
10 amps pack: 150.00 MRP during clinical trials or otherwise reported.
site in the chemoreceptor trigger zone.
Ind: In adult- i. prevention and symptomatic
relief of acute nausea and vomiting from any
cause including cytotoxic therapy, radiotherapy
and anti-parkinsonism therapy; ii. functional
yspepsia; not recommended for routine
prophylaxis of post-operative vomiting or for
chronic administration.
In children, the use of domperidone is restricted to
nausea and vomiting following cytotoxic or radio­
therapy only; not recommended for other causes.
C/I: Hypersensitivity to this drug; neonates.
S/E: Domperidone may cause increased prolactin
production (1.3o/o), which may result in
galactorrhoea, gynaecomastia; soreness and
reduced libido. Other side-effects may include­
dry mouth, nervousness, drowsiness, skin rash
and itching. Extra-pyramidal reactions are also
reported very rarely in some clinical studies.
Cautions: Domperidone should be used with
absolute caution in case of young children,
because there may be an increased risk of extra­
pyramidal reactions, since drug may enter into
the central nervous system due to an
incompletely developed blood-brain barrier.
Pregnancy & lactation: The safety of
domperidone has not been proven and hence it is
not recommended during pregnancy. In lactating
mother, domperidone may precipitate
galactorrhoea & improve post natal lactation; it
is also secreted in breast milk but in very small
quantities insufficient to be considered harmful;
but its use in lactating mother should be very

+ VISPAM Tab. Everest cautiously observed.

+ TIMOTOR Tab. Square
Tiemonium methylsulfate INN 50mg/tablet Dosage & admin: By mouth: Adults: Acute
Trimebutine maleate INN l OOmg/tablet (f.c)
50's pack: 200.00 MRP nausea and vomiting (including drug
1OOmg x 50's pack: 250.50 MRP
+ VISPAZIN Tab. G lobe induced), 10-20mg every 3-4 times daily orally
Tiemonium methylsulfate INN 50mg/tablet before meal; maximum period of treatment is
50's pack: 200.00 MRP 12 weeks. Functional dyspepsia, 10-20mg 3
3. ANTICHOLINERGIC &
+ VISPAZIN lnj. G lobe times daily orally before meals & at night;
Tiemonium methylsulfate INN 5mg/2ml ampoule: ANTI-PSYCHOTIC COMBI­ maximum period of treatment is 12 weeks.
Children: Nausea and vomiting following
i.m/i.v injection N ATION PRODUCTS
10 amps pack: 100.00 MRP cytotoxic or radiotherapy only, 0.2-0.4mg/kg

+ VISRAL Tab. Opsonin every 4-8 hours daily. Functional dyspepsia­

T here is no defmite product molecules in this
Tiemonium methylsulfate INN 50mg/tablet not recommended.
group. This is an innovative group of combi­
50's pack: 219.92 MRP (Domperidone oral preparation should be
ned preparations. • •
!

+ VISRAL Syp. Opsonin -·

.'
- taken 15-30 minutes before a meal.)
Tiemonium methylsulfate INN 1 Omg/5ml: syrup Suppositories: Adult: 30 to 60mg every 4 to 8
TRIFLUOPERAZINE + hours.
1 OOml bot: 70.38 MRP
+ VISRAL Inj. Opsonin ISOPROPAMIDE65 Children: Maximum daily dose 30mg for the
Tiemonium methylsulfate INN 5mg/2ml ampoule: babies of 10-15kg body weight. Suppositories
i.m/i.v injection TRIFLUOPERAZINE + ISOPR OPAMIDE: are to be inserted per rectum. During
5 amps pack: 66.24 MRP Tablet insertion patient should lie on his/her left with

+ VISRAL Suppo. Opsonin Preparation: This combination product is not flexed right hip and knee.

Tiemonium methylsulfate INN 20mg/suppository available now. Drug inter: Domperidone may reduce the
1 O's pack: 70.38 MRP hypoprolactinaemic effect of bromocriptine. The

+ ZEUM 50 Tab. Sandoz action of domperidone on g.i function may be

4. MOTILITY STIMULANTS/ antagonized by anti-muscarinics and opioid
Tiemonium methylsulfate INN 50mg/tablet
50's pack: 325.00 MRP DOPAMINE ANTAGONISTS analgesics.

TRIMEBUTINE42 DOMPERIDONE21,26,65
•
®
TRIMEBUTINE MALEATE: Tablet DOMPERIDONE:Tablet/Suspension/Drop/
Trimebutine maleate is a noncompetitive Suppositories
Domperidone tablet, suspension & effervescent granules
spasmolytic agent. It is available as trimebutine Introduction & mode of action: Domperidone
maleate INN 1OOmg film coated tablet. is a dopamine antagonist. It acts peripherally
Mode of action: Trimebutine maleate possesses rather than central action; since it can't readily
SK•F '

moderate opiate receptor affinity and has marked enter the central nervous system due to blood­
anti-serotonin activity especially on 'mu' recep­ brain barrier, its effects are confmed to the + ADEGUT Tab. Supreme
tors. It induces regulation of spontaneous activity periphery and acts principally at the receptor Domperidone maleate I Omg/tablet
GASTRO-INTES'I'INAL DRUGS
50's pack: 1 00.00 MRP
t ADEGUT Susp. Supreme
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t ADOREX Tab. Ambee .
Domperidone maleate 1 Omg/tablet
1 OO's pack: 96.00 MRP
t ADOREX Susp. Ambee
Domperidone 5mg/5ml: suspension
60ml bot: 28.10 MRP
l OOml bot: 38. 1 4 MRP
t ADOREX Drop Ambee
Domperidone 5mg/ml: drop
l 5ml drop: 20.07 MRP
t ANET Tab. Kemiko
Domperidone maleate IOmg/tablet
1 OO's pack: 200.00 MRP
+ ANET Susp. Kemiko
Domperidone 5mg/5ml: suspension
60ml bot: 35.00 MRP
t APEDOM Tab. Apollo
Domperidone maleate 1 Omg/tablet
1 OO's pack: 200.00 IP
t APEDOM Susp. Apollo
Domperidone 5mg/5ml: suspension
60ml bot: 27.00 IP
t APULDON Tab. Aristopharma
Domp·eridone maleate 1Omg/tablet
•
IOO's pack: 200.00 MRP
+ APULDON Susp. Aristopharma
Domperidone 5mg/5ml: suspension
60ml bot: 35.00 MRP
+ APULDON Drop Aristopharma
Domperidone 5mg/ml: drop
1 5ml drop: 25.00 MRP
+ APULDON Suppo. Aristopharma
Domperidone l 5mg & 30mg/suppository.
1 5mg suppository x l O's pack: 60.00 MRP
30mg suppository x l O's pack: 90.00 MRP
t ATIDON Tab. Asiatic
Domperidone maleate IOmg/tablet
50's pack: 1 00.00 MRP
t ATIDON Susp. Asiatic
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t AVOMIT Tab. Chemist
Domperidone maleate IOmg/tablet
l OO's pack: 200.00 MRP
t AVOMIT Susp. Chemist
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t BEDOM Tab. Bengal Drugs
Domperidone maleate BP I Omg/tablet
1 OO's pack: 200.00 MRP
t BEDOM Susp. Bengal Drugs
Domperidone BP 5mg/5ml: suspension
60ml bot: 28.00 MRP
t BERIDOM Tab. Belsen
Domperidone maleate 1 Omg/tablet
1 OO's pack: 200.00 MRP
t . BERIDOM Susp. Belsen
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t BPDON Tab. Bristol
Domperidone maleate IOmg/tablet
l OO's pack: 1 00.00 MRP
+ COSY Tab. Orion Pharma
Domperidone maleate 1 Omg/tablet
1 OO's pack: 20 1 .00 MRP
+ COSY Susp. Orion Pharma
QIMP-17 (12)
Domperidone 5mg/5ml: suspension
60ml bot: 28. 1 0 MRP
l OOml bot: 38.14 MRP
+ CPDOM Tab. Cosmo Pharma
Domperidone maleate I Omg/tablet
IOO's pack: 200.00 IP
tDEDOM Tab. Decent
Domperidone maleate 1 Omg/tablet
l OO's pack: 1 90.00 MRP
t DEDOM Susp. Decent
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t DEFLUX Tab. Beximco
Domperidone maleate 1 Omg/tablet
1 50's pack: 375.00 IP
t DEFLUX DT Tab. Bexi.mco
Domperidone maleate 1 Omg/tablet (dispersible)
1 OO's pack: 200.00 IP
t DEFLUX Susp. Beximco
Domperidone 5mg/5ml: suspension
l OOml bot: 38.00 IP
+ DEFLUX Drop Beximco
Domperidone 5mg/ml: drop
1 5ml drop: 20.00 IP
t DEGUT Tab. Delta Pharma
Domperidone maleate 1 Omg/tablet
IOO's pack: 200.00 MRP
t DOMAR Tab. Pacific
Domperidone maleate 1 Omg/tablet
1 OO's pack: 300.00 MRP
+ DOMAR Susp. Pacific
Domperidone 5mg/5ml: suspension
60ml bot: 25.00 MRP
1 OOml bot: 40.00 MRP
t DOMIDON Tab. Ziska
Domperidone maleate 1Omg/tablet
l OO's pack: 200.00 MRP
t DOMIDON Susp. Ziska
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
+ DOMILIN Tab. General
Domperidone maleate 1 Omg/tablet
100.'s pack: 201 .00 MRP
+ DOMILIN Susp. General
Domperidone 5mg/5ml: suspension
l OOml bot: 40.15 MRP
t DOMILUX Tab. Popular
Domperidone maleate 1 Omg/tablet
200's pack: 302.00 MRP
+ DOMILUX Susp. Popular
Domperidone 5mg/5ml: suspension
60ml bot: 35.00 MRP
t DOMIN Tab. Opsonin
Domperidone maleate 1 Omg/tablet
l OO's pack: 176.04 MRP
+ DOMIN Susp. Opsonin
Domperidone 5mg/5ml: suspension
60ml bot: 24. 73 MRP
+ DOMIN Drop Opsonin
Domperidone 5mg/ml: drop
15ml drop: 1 7.67 MRP
+ DOMIN Suppo. Opsonin
Domperidone l 5mg & 30mg/suppository.
15mg suppository x l O's pack: 44.16 MRP
30mg suppository x 1 O's pack: 70.64 MRP
t DOMINAT Tab. Nipa
. . . .. .
,,
. .
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
t DOMINAT Susp. Nipa
Domperidone 5mg/5ml: suspension
..
60ml bot: 27.00 MRP
t DOMINOL Tab. White Horse
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
t DOMIREN Tab. Renata
Domperidone maleate 1 Omg/tablet
1 20's pack: 240.00 MRP
t DOMIREN Susp. Renata
Domperidone 5mg/5ml: suspension
60ml bot: 35.00 MRP
1 OOml bot: 38.00 MRP
t DOMIREN Drop Renata
Domperidone 5mg/ml: drop
.
1 5ml drop: 25.00 MRP
t DOMPA Tab. Seema
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP •
t DOMPA-S Susp. Seema
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t DOMPEN Tab. Millat
Domperidone maleate 1 Omg/tablet
1 OO's pack: 250.00 MRP
+ DOMPI Tab. Alco Pharma
Domperidone maleate 1 Omg/tablet
I OO's pack: 200.00 MRP
+ DOMPI Susp. Alco Pharma
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t DOMSIL Tab. Silva
Domperidone maleate 1 Omg/tablet
IOO's pack: 201 .00 MRP
t DOMSIL DT Tab. Silva
Domperidone maleate 20mg/dispersible tablet
IOO's pack: 201 .00 MRP
t DOMSIL Susp. Silva
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
IOOml bot: 38.00 MRP
t DOMSTAL Tab. APC Pharma
Domperidone maleate IOmg/tablet
50's pack: 1 00.00 MRP
t DOMSTAL Susp. APC Pharma
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t DOPADON Tab. Ibo Sina
Domperidone maleate IOmg/tabl.et
l OO's pack: 225.00 IP
t DOPADON Susp. Ibo Sina
Domperidone 5mg/5ml: suspension
60ml bot: 30.00 IP
t DOPAGUT Tab. Concord
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
t DOPAGUT Susp. Concord
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t DOPON Tab. SAPL
Domperidone maleate 1 Omg/tablet
50's pack: 100.00 MRP
t DORIDON Tab. Medicon
Domperidone maleate 1 Omg/tablet
IOO's pack: 200.00 MRP
t DORIDON Drop Medicon
Domperidone 5mg/ml: drop
15ml drop: 25.00 MRP
t DP DONE Tab. CPL
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
t DP DONE Susp. CPL
I
•
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t DUDON Tab. Kumudini
Domperidone maleate 1 Omg/tablet
1OO's pack: 200.00 MRP
t DUDON Susp. Kumudini
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t DYSNOV Tab. UniMed & UniHealth
Domperidone maleate 1 Omg/tablet
50's pack: 100.00 MRP
t DYSNOV Susp. UniMed & UniHealth
Domperidone 5mg/5ml: suspension
l OOml bot: 38.00 MRP
t DYSNOV Drop UniMed & UniHealth
Domperidone 5mg/ml: drop
15ml drop: 20.00 MRP
t EDONE Tab. Zenith
Domperidone maleate 1 Omg/tablet
l OO's pack: 201.00 MRP
t EDONE Susp. Zenith
Domperidone 5mg/5ml: suspension
60ml bot: 28.11 MRP
l OOml bot: 38.14 MRP
+ EGUT Tab. Euro Pharma
Domperidone maleate 1 Omg/tablet
IOO's pack: 200.00 MRP
+ EGUT Susp. Euro Pharma
Domperidone 5mg/5ml: suspension
60ml bot: 35.00 MRP
t EMEDON Tab. Cosmic
Domperidone maleate 1Omg/tablet
IOO's pack: 154.00 MRP
+ EMIDOM Tab. Somatec
Domperidone maleate 1Omg/tablet
l OO's pack: 201.00 MRP
t EMIDOM Susp. Somatec
Domperidone 5mg/5ml: suspension
60ml bot: 28.11 MRP
+ ERIDON Tab. Doctor's
Domperidone maleate 1Omg/tablet
l OO's pack: 100.00 MRP
+ ERIDON Susp. Doctor's
Domperidone 5mg/5ml: suspension
60ml bot: 25.00 MRP
t ESOGUT Tab. Biopharma
.
Domperidone maleate 1Omg/tablet
l OO's pack: 201.00 MRP
t ESOGUT Susp. Biopharma
Domperidone 5mg/5ml: suspension
60ml bot: 28.11 MRP
t ESOGUT Drop Biopharma
Domperidone 5mg/ml: drop
15ml drop: 20.08 MRP
t EVDOM Tab. Everest
Domperidone maleate 1Omg/tablet
l OO's pack: 150.00 MRP
+ EVDOM Susp. Everest
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t GIDONIC Tab. Novelta
Domperidone maleate BP 1Omg/tablet
I OO's pack: 200.00 MRP
t GIDONIC Susp. Novelta
Domperidone BP 5mg/5ml: suspension
·
60ml bot: 28.00 MRP
t GIDOR A Tab. Rephco
Domperidone maleate 1 Omg/tablet
1 OO's pack: 200.00 MRP
t GIDOR A Susp. Rephco
QIMP-17 (13)
Domperidone 5mg/5ml: suspension
60ml bot: 30.00 MRP
t GUTSET Tab. Ad-din
Domperidone maleate 1Omg/tablet
1 OO's pack: 200.00 MRP
t GUTSET Drop Ad-din
Domperidone 5mg/ml: drop
15ml drop: 20.00 MRP
t LORIDON Tab. Modern
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
t LORIDON Susp. Modern
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t LORIDON Drop. Modern
Domperidone 5mg/ml: drop
l 5ml drop: 20.00 MRP
+ LOVAL Tab. Jayson
Domperidone maleate 1 Omg/tablet
l OO's pack: 201.00 IP
+ LOVAL Susp. Jayson
Domperidone 5mg/5ml: suspension
60ml bot: 28.10 IP
1 OOml bot: 38.15 IP
t MERIN Tab. Edruc
·oomperidone maleate 1 Omg/tablet
l OO's pack: 150.00 MRP
+ MERIN Susp. Edruc
Domperidone 5mg/5ml: suspension
l OOml bot: 38.00 MRP
t MOTIDOM Tab. Medimet
Domperidone maleate 1 Omg/tablet
IOO's pack: 150.00 MRP
t MOTIFAST Tab. Square
Domperidone maleate 1 Omg/tablet
l OO's pack: 250.00 MRP
+ MOTIGEN Tab. Novo Healthcare
Domperidone maleate 1 Omg/tablet
1 OO's pack: 200.00 MRP
+ MOTIGEN Susp. Novo Healthcare
Domperidone 5mg/5ml: suspension
60ml bot:.28.00 MRP
t MOTIGUT Tab. Square
Domperidone maleate 1Omg/tablet
150's pack: 375.00 MRP
t MOTIGUT Susp. Square
Domperidone 5mg/5ml: suspension
60ml bot: 35.00 MRP
t MOTIGUT Drop Square
Domperidone 5mg/ml: drop
15ml drop: 25.00 MRP
t MOTIL Tab. Hallmark
Domperidone maleate 1 Omg/tablet
1OO's pack: 200.00 MRP
+ MOTIL Susp. Hallmark
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t MOTILEX Tab. Techno Drugs
Domperidone maleate 1 Omg/tablet
50's pack: 75.00 MRP
+ MOTILEX Susp. Techno Drugs
Domperidone 5mg/5ml: suspension
60ml bot: 35.00 MRP
t MOTINORM Tab. Sharif
Domperidone maleate 1 Omg/tablet
1OO's pack: 200.00 MRP
t MOTIPER Tab. Mystic
Domperidone maleate 1 Omg/tablet
50's pack: 100.00 MRP
t MOTIPER Susp. Mystic
. .
GASTRO-INTESTINAL DRUGS
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t MYODON Tab. Peoples
Domperidone maleate 1 Omg/tablet
1OO's pack: 200.00 MRP
t MYODON Susp. Peoples
Domperidone 5mg/5ml: suspension
60ml bot: 25.00 MRP
t NOBUR N Tab. Beacon
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
t NORMOGUT Tab. Rangs Pharma
Domperidone maleate 1 Omg/tablet
50's pack: 100.00 MRP
t NORMOGUT Susp. Rangs Pharma
Domperidone 5mg/5ml: suspension
l OOml bot: 38.00 MRP
+ NUDON Tab. Organic Health
Domperidone maleate 1Omg/tablet
1OO's pack: 200.00 MRP
+ OMID Tab. Desh Pharma
Domperidone maleate 1 Omg/tablet
lOO's pack: 150.00 MRP
+ OMID Susp. Desh Pharma
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t OMIDON Tab. Incepta
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
t OMIDON D Tab. Incepta
Domperidone maleate 20mg/dispersible tablet
l OO's pack: 200.00 MRP
+ OMIDON Susp. Incepta
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
1 OOml bot: 38.00 MRP
+ OMIDON Drop Incepta
Domperidone 5mg/ml: drop
15ml drop: 20.00 MRP
+ PARIDON Tab. Drug inter.
Domperidone maleate 1 Omg/tablet
1 OO's pack: 200.00 MRP
+ PARIDON Susp. Drug inter.
Domperidone 5mg/5ml: suspension
1OOml bot: 32.00 MRP
+ P-DON Tab. Pharmadesh
Domperidone maleate 1Omg/tablet
IOO's pack: 150.00 MRP
+ P-DON Susp. Pharmadesh
Domperidone 5mg/5ml: suspension
60ml bot: 27.00 MRP
+ PERI Tab. Hudson
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
+ PERI Susp. Hudson
Domperidone 5mg/5ml: suspension
l OOml bot: 35.00 MRP
t PERIDONE Tab. Astra
Domperidone maleate 1 Omg/tablet
30's pack: 60.00 MRP
t PERION Tab. Globe
Domperidone maleate 1Omg/tablet
l OO's pack: 200.00 MRP
t PERION Susp. Globe
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
. 1 OOml bot: 38.00 MRP
t PROKINET Tab. NIPRO JMI
Domperidone maleate BP 1Omg/tablet
1OO's pack: 201.00 MRP

Restores the normal wave of GI tract
makes meal more enjoyable
t PROKINET Susp. NIPRO JMI
Domperidone BP 5mg/5snl: suspension
60ml bot: 35.00 MRP
+ REGUT Tab. Reliance
Domperidone maleate 1Omg/tablet
l OO's pack: 206.00 MRP
t REMADON Tab. Reman
Domperidone maleate 1Omg/tablet
lOO's pack: 195.00 MRP
t RIDON Tab. SK+F
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
t RIDON EG SK+F
Domperidone maleate 1Omg/sachet (effervescent
granules)
20's pack: 100.00 MRP
t RIDON Susp. SK+F
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
+ SANDOM Tab. Sanofi-aventis
Domperidone maleate 1Omg/tablet
l OO's pack: 201.00 MRP
+ SANDOM Susp. Sanofi-aventis
Domperidone 5mg/5ml: suspension
60ml bot: 28.10 MRP
+ SANDOM Drop Sanofi-aventis
Domperidone 5mg/ml: drop
15ml drop: 20.07 MRP
t SYDON Tab. MST Pharma
Domperidone maleate 1 Omg/tablet
l OO's pack: 200.00 MRP
t SYDON Susp. MST Pharma
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t VAVE Tab. ACI
Domperidone maleate l Omg/tablet (f.c).
150's pack: 301.50 MRP
t specific or cytotoxic nausia and vomiting.
VAVE OD Tab. ACI
Domperidone maleate 1 Omg/tablet (orodisper­
sible).
l OO's pack: 500.00 MRP
t abdominal surgery, Parkinsonism & children.
VAVE Susp. ACI
Domperidone 5mg/5ml: suspension
60ml bot: 28.11 MRP
l OOml bot: 38.14 MRP
t lmg 2 or 3 times daily; 3-5 yrs. 2mg 2 or 3
VAVE Drop ACI
Domperidone 5mg/ml: drop
15ml drop: 20.07 MRP
+ VEGADON Tab. Pharmasia
Domperidone maleate l Omg/tablet (f.c).
1 OO's pack: 200.00 IP
+ VEGADON Susp. Pharmasia
, .
Domperidone 5mg/5ml: suspension
60ml bot: 28. l 0 IP
t VIRDON 10 Tab. Virgo
Domperidone maleate l Omg/tablet (f.c).
l OO's pack: 200.00 MRP
t VIRDON Susp. Virgo
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t VIRDON Drop Virgo
Domperidone 5mg/ml: drop
15ml drop: 20.00 MRP
+ VOMINO Tab. MonicoPharma
Domperidone maleate l Omg/tablet (f.c).
QIMP-17 (14)
l OO's pack: 200.00 MRP
+ VOMINO Susp. MonicoPharma
•
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t VOMITOP Tab. Navana
Domperidone maleate l Omg/tablet (f.c).
l OO's pack: 200.00 MRP
t VOMITOP Susp. Navana
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
t VOMITOP Drop Navana
Domperidone 5mg/ml: drop
l 5ml drop: 20.08 MRP
t XEPADON Tab. Amico
Domperidone maleate 1 Omg/tablet (f.c).
50's pack: 100.00 MRP
t XEPADON Susp. Amico
Domperidone 5mg/5ml: suspension
60ml bot: 25.00 MRP
t XEPADON Drop Amico
Domperidone 5mg/ml: drop
15ml drop: 18.00 MRP
t XERIDON Tab. RAK Pharma
Domperidone maleate l Omg/tablet (f.c).
1 OO's pack: 200.00 MRP
t XERIDON Susp. RAK Pharma
Domperidone 5mg/5ml: suspension
60ml bot: 28.00 MRP
METOCLOPRAMIDE21,23
METOCLOP RAMIDE HCI: Tablet/ syrup/
drop/injection
It is an effective anti-emetic drug. It has got a
central anti-emetic effect & a peripheral action
on the gut as dopamine antagonist, as a result it
enhances motility of the upper gastrointestinal
tract & thus hastens gastric emptying.
Ind: Non ulcer dyspepsia, for speeding the
transit of barium during intestinal follow through
examination, reflux oesophagitis and also in non
S/E: Extrapyramidal reactions, drowsiness,
constipation, gynaecomastia, galactorrhoea.
Cautions: Renal impairment, immediately after
Dosage & admin: Adult: 15 to 20 years 5-
lOmg; others, lOmg. B9th 3 times daily.
Child: Under 1 yr,1 mg twice daily; 1-3 yrs.
times daily; 5-14 yrs. 2.5-5mg 3 times daily.
All orally,i.m or i.v. Usual max. doses,all ages
0.5mg/kg body-wt . daily .
Preparations: See under CNS products.
4. ULCER HEALIN'G DRUGS
4.1 H2 -receptor antagonists
4.2 Selective antimuscarinics
4.3 Chelates and complexes
4.4 Prostaglandin analogues
4.5 Proton pump inhibitors
4.6 Therapy for H. Pylori eradication
4.7 Other ulcer-heali.ng drugs
Hi-Receptor antagonists
CIMETIDINE21,33
· ------
• •
CIMETIDINE: Tablet/Syrup/Injection
Ind: Peptic ulceration, recurrent & stomal ulcera­
tion, Zollinger-Ellison syndrome; Reflux oesoph­
agitis & conditions where a reductation of gastric
acid is beneficial; erosive gastritis with bleeding.
Cautions: Impaired renal functions (reduce
dosage), exclude malignant disease, as cimetidine
• •
may mask symptoms & delay treatment; long
term treatment should be avoided, otherwise the
patient should be kept under observation or
monitored; avoid abrupt withdrawal of treatment,
concurrent admin. of anticoagulants or phenytoin.
S/E: Occasional diarrhoea, dizziness, rashes,
rarely mental confusion and gynaecomastia.
Dosage & admin: By mouth: Duodenal &
benign gastric ulcer,400mg,2 times daily with
breakfast & at bed time or 800mg at bedtime
for minimun 4 weeks,then 400mg. once or
twice daily as maintenance dose. Reflux
oesophagitis- 400mg 4 times a day after meals.
By injection: 200mg i.m. or slow i. v.( 100-
150mg/hour) 4-6 hourly,max. dose 2gm daily.
Preparations: May not be available.
FAMOTIDINE21,33
FAMOTIDINE: Tablet
Ind: Benign gastric & duodenal ulcer, reflux
oesophagitis, Zollinger- Ellison syndrome.
S/E: See under cimetidine
Cautions: see under cimetidine; does not inhibit
hepatic microsomal drug metabolism.
Dose: Benign gastric and duodenal ulceration,
treatment, 40mg at night for 4-8 weeks;
.....
maintenance, 20mg at night.
Reflux oesophagitis, 20-40mg twice daily for
6-12 weeks.
Zollinger-Ellison s�drome,20mg every 6 hrs.
•
(higher dose in those who have previously
been receiving another H2-antagonist).
t FAMOTACK Tab. Square
Famotidine 20mg & 40mg/tablet
20mg x 1 OO's pack: 200.00 MRP
40mg x 50's pack: 200.00 MRP
t FAMOTID Tab. Drug inter.
Famotidine 20mg & 40mg/tablet
20mg x l OO's pack: 200.00 MRP
40mg x l OO's pack: 400.00 MRP
+ NACID Tab. Sonear
Famotidine 20mg/tablet
20mg x l OO's pack: 205.00 MRP
t SERVIPEP Tab. Sandoz
Famotidine 20mg & 40mg/tablet
20mg x 50's pack: 200.00 MRP
40mg x 50's pack: 300.00 MRP
t YAMADIN Tab. Beximco
Famotidine 20mg & 40mg/tablet
• 20mg x 200's pack: 380.00 IP
40mg x l OO's pack: 382.00 IP
t ZACTROL Tab. Peoples
Famotidine USP 40mg/tablet
40mg x 1 OO's pack: 300.00 MRP
RANITIDINE21,33
RANI'I'IDINE: Tablet/Syrup/Injection
Ind: Duodenal, benign gastric and postoperative
ulceration, reflux oesophagitis, Zollinger- Ellison
 QIMP-17 (15) • •
GASTRO-INTES'I'INAL DRUGS

syndrome and other conditions where a reduction 150mg x lOO's pack: 200.00 MRP +INRAN -150 Tab. MonicoPharma
of gastric acid is beneficial. t BEDINE Tab. Bengal Drugs Ranitidine l 50mg/tablet.
Parenteral administration is specially indicated Ranitidine USP l 50mg/tablet lOO's pack: 200.00 MRP
•

for the treatment of hospitalized patients with 1 50mg x lOO's pack: 200.00 MRP +INRAN I.M/l.V Inj. MonicoPharma
pathological hypersecretory conditions, t DENITINE Tab. Doctor's Ranitidine 50mg/2ml ampoule: i.m/i.v injection
intractable duodenal ulcers, & to prevent acid Ranitidine l 50mg/tablet 10 amps pack: 60.00 MRP
aspiration in obstetric patients at delivery. lOO's pack: 200.00 MRP
•

t INSEAC Tab. Ibo Sina

S/E: No serious adverse reactions, but rare & t DETAC-150 Tab. Desh Pharma Ranitidine l 50mg & 300mg/tablet
transient nausea, headache, dizziness and Ranitidine l 50mg/tablet l 50mg x l 50's pack: 300.00 IP
diarrhoea may occur. Anaphylactoid reactions & IOO's pack: 100.00 IP 300mg x 48's pack: 192.00 IP
skin rashes have been reported rarely. 150's pack: 150.00 IP
t LIBRET I.V Inf. Libra
Caution: Caution should be taken in case of renal t DUGAL Tab. Reman
Ranitidine hydrochloride 50mg in 1OOml
impairment, pregnancy, lactation; exclude malig­ Ranitidine 150mg & 300mg/tablet
(0.5mg/ml) bottle: i.v infusion
nant diseases before treatment. Carry out periodic 150mg x l 50's pack: 172.50 MRP
1OOml bot: 5 5. 21 MRP
axaminations of patients on prolonged therapy. +D URAN Syp. Techno Drugs
+LUMERAN Tab. Aristopharma
Dosage & admin: By mouth: Adult, Benign Ranitidine 75mg/5ml: syrup
•

Ranitidine 150mg/tablet
gastric and duodenal ulcer- 150mg (1 tab or 2 lOOml bot: 45.00 MRP
150mg x lOO's pack: 200.00 MRP
tst) b.i.d in the morning and at bed time; or +D URAN I.V Inf. Techno Drugs
t MYSTIN-R Tab. Mystic
300mg at bed time for 4 weeks; maintenance Ranitidine hydrochloride 50mg in 1OOml
Ranitidine 150mg/tablet.
therapy, 150mg at bed time. (0.5mg/ml) bottle: i.v infusion
1OO's pack: 200.00 MRP
Reflux oesophagitis- 150mg b.i.d for upto 8 wks. lOOml bot: 60.00 MRP
t NEOCEPTIN-R Tab. Beximco
Zollinger-Ellison syndrome- the starting dose t EDITIN-R Tab. Edruc •

Ranitidine 150mg & 300mg/tablet

is 150mg t.d.s and may be increased as Ranitidine USP 1 50mg/tablet
150mg x 150's pack: 375.00 IP
necessary to 900mg (six tablets). lOO's pack: 2 23.00 MRP
300mg x lOO's pack: 400.00 IP
Child- Over 8 years upto 150mg twice daily. t EDITIN-R Inj. Edruc
t NEOCEP'I'IN-R Syp. Bexinico
Parenteral administration: By injection, adult- Ranitidine USP 50mg/2ml ampoule: injection
Ranitidine 75mg/5ml: syrup
50mg i.m or by slow i. v injection or infusion, 10 amps pack: 1 20.00 MRP
lOOml bot: 45.00 IP
repeated 6 to 8 hourly. t E-TACK Tab. Reliance
t NEOCEPTIN-R lnj. Beximco
By i. v infusion, 25mg (or 50ml)/hour for 2 Ranitidine 150mg/tablet
Ranitidine 50mg/2ml ampoule: injection
hours; may be repeated every 6-8 hours. 1OO's pack: 238.00 MRP
10 amps pack: 60.00 IP
Prophylaxis of stress ulceration, initially slow t EUCON Tab. Pacific
+NEOCEPTIN-R I.V Inf. Beximco
i.v infusion of SOmg (as above) then continuous Ranitid.ine 150mg/tablet
Ranitidine hydrochloride 50mg in 1OOml
infusion of 125-250mcg/kg per hour. 1OO's pack: 190.00 MRP
(0.5mg/ml) bottle: i.v infusion
In patients with severely impaired renal +EVRAN Tab. Everest
lOOml bot: 101.00 IP
function having a creatinine clearance less Ranitidine 150mg/tablet
than 50ml/min, the recommended dosage is
t NEOPEP Tab. CPL
lOO's pack: 150.00 MRP
Ranitidine l 50mg/tablet
SOmg every 18-24 hours. If the patient's +EXAC Tab. Hallmark
150mg x lOO's pack: 200.00 MRP
condition requires, the frequency of dosing Ranitidine 150mg/tablet
may be increased to every 12 hours or even
t NEOSETINE-R Tab. Bristol
1OO's pack: 200.00 MRP
Ranitidine 150mg/tablet
further with caution. t GASTAB Tab. NIPRO JMI
150mg x lOO's pack: 150.00 MRP
Ranitidine USP 150mg/tablet
t ACEPTIN-R Tab. Asiatic t NEOTACK Tab. Square
lOO's pack: 200.00 MRP
Ranitidine 150mg/tablet Ranitidine 150mg & 300mg/tablet
t GASTAB Syp. NIPRO JMI
lOO's pack: 200.00 MRP 150mg x 1 50's pack: 375.00 MRP
Ranitidine USP 75mg/5ml: syrup
+ACIN Tab. Biopharma 300mg x lOO's pack: 450.00 MRP
1OOml bot: 45.17 MRP
Ranitidine 150mg & 300mg/tablet t NEOTACK Syp. Square
t GASTROLOC Tab. Beacon
150mg x 1 50's pack: 301. 50 MRP Ranitidine 75mg/5ml: syrup
•

Ranitidine 150mg/tablet
300mg x 50's pack: 175.50 MRP lOOml bot: 45.16 MRP
1OO's pack: 200.00 MRP
+ACIN Syp. Biopharma t NEOTACK Inj. Square
+ GEPIN Tab. General
Ranitidine 75mg/5ml: syrup Ranitidine 50mg/2ml ampoule: injection
Ranitidine l 50mg/tablet
lOOml bot: 45.17 MRP 10 amps pack: 100.00 MRP
lOO's pack: 201.00 MRP
t ALIN Tab. Rephco t NEOTID Tab. Modern
t GEPIN Syp. General
Ranitidine 150mg/tablet Ranitidine 150mg/tablet
Ranitidine 75mg/5ml: syrup
1OO's pack: 2 50.00 MRP lOO's pack: 200.00 MRP
lOOml bot: 45.17 MRP
+AMURAN Tab. Amulet t NEOTIN Tab. Nipa
200ml bot: 80.30 MRP
Ranitidine l 50mg/tablet Ranitidine l 50mg/tablet
+GEPIN I.V Inj. General
•
1OO's pack: 200.00 MRP lOO's pack: 2 50.00 MRP
•
I Ranitidine 50mg/2ml ampoule: i.v injection
t ANTAC Tab. Ambee t NORMACID Tab. Kemiko
10 amps pack: 100.00 MRP
I Ranitidine 150mg/tablet Ranitidine hydrochloride USP 150mg/tablet
t G-RANI'I'IDIN Tab. Gonoshas
lOO's pack: 181.00 MRP lOO's pack: 2 50.00 MRP
i t ANTAC Syp. Ambee
Ranitidine l 50mg/tablet.
lOO's pack: 140.00 MRP
+NORMACID Syp. Kemiko
•

"
Ranitidine 75mg/5ml: syrup Ranitidine hydrochloride USP 75mg/5ml: syrup
+H2-150 Tab. Apollo
1OOml bot: 40 .15 MRP lOOml bot: 45.00 MRP
Ranitidine l 50mg/tablet.
I t ANTAC lnj. Ambee
Ranitidine 50mg/2ml ampoule: injection
150's pack: 300.00 IP
+NORMACID lnj. Kemiko
Ranitidine 50mg/2ml ampoule: i.m/i.v injection
I 10 amps pack: 53.20 MRP t H-BLOK Tab. RAK Pharma l 0 amps pack: 60.00 MRP
.

Ranitidine l 50mg/tablet.
l
+ASINAR Tab. Sanofi-aventis +NORMA-ff Tab. Renata
Ranitidine 150mg/tablet 1OO's pack: 200.00 MRP Ranitidine l 50mg/tablet
150mg x lOO's pack: 2 50.00 MRP t HI-TAC Tab. Hudson 150mg x lOO's pack: 2 2 5.00 MRP
t ASTAC Tab. Astra Ranitidine l 50mg/tablet. +OFF-H Tab. Organic Health
Ranitidine l 50mg/tablet lOO's pack: 200.00 MRP Ranitidine l 50mg/tablet

I
 ®
•
QIMP-17 (16) . .
.

Ranitidine
+ RANITAB Tab. Sonear Ranitidine l 50mg & 300mg/tablet.
Ranitidine 150mg/tablet 150mg x IOO's pack: 250.00 MRP
IOO's pack: 205.00 MRP 300mg x 50's pack: 200.00 MRP
+ RANITACK Tab. Ad-din + ULTAC Tab. Aexim
Ranitidine 150mg/tablet Ranitidine l 50mg/tablet
l 50mg x 1OO's pack: 250.00 MRP
150's pack: 225.00 MRP IOO's pack: 150.00 MRP
+ ORTAC Tab. Orion Pharma + RANITEC-150 Tab. APC Pharma + ULTRADIN-150 Tab. Globe
Ranitidine l 50mg/tablet .
Ranitidine 150mg/tablet Ranitidine l 50mg/tablet.
lOO's pack: 201.00 MRP
IOO's pack: 200.00 MRP 1OO's pack: 200.00 MRP
+ ORTAC Inj. Orion Pharma + RANITID Tab. Opsonin + UNITAC Tab. Gaco
Ranitidine 50mg/2ml ampoule: i.m/i.v injection
Ranitidine 150mg & 300mg/tablet. Ranitidine 150 mg/tablet.
10 amps pack: 60.20 MRP
150mg x 150's pack: 329.88 MRP lOO's pack: 180.00 MRP
+ ORTAC I.V Inf. Orion Infusion 300mg lOO's pack: 353.64 MRP
x + VIRDIN Tab. Virgo
Ranitidine hydrochloride 50mg in 1OOml
+ RANITID Syp. Opsonin Ranitidine USP 150 mg/tablet.
(0.5mg/ml) bottle: i.v infusion
Ranitidine 75mg/5ml: syrup IOO's pack: 200.00 MRP
1OOml bot: 60.23 MRP
•

lOOml bot: 39.73 MRP + WINTACK Tab. White Horse

+ PEPTIDIN-150 Tab. Cosmic + RANITID Inj. Opsonin Ranitidine 150 mg/tablet.
Ranitidine 150mg/tablet Ranitidine 50mg/2ml ampoule: i.m/i.v injection IOO's pack: 200.00 MRP
IOO's pack: 200.00 MRP 50 amps pack: 264.79 MRP + XANTID Tab. ACI
+ PEPTIL-H Tab. SK+F + RANITOR Tab. Popular Ranitidine 150mg/tablet.
Ranitidine l 50mg/tablet
Ranitidine 150mg/tablet. 150mg x 150's pack: �01.50 MRP
150mg x 150's pack: 345.00 MRP
150's pack: 300.00 MRP + XANTID-HS Tab. ACI
+ PEPTIL-H Syp. SK+F + RANIX Inj. Chemist
'

Ranitidine 300mg/tablet (higher strength).

Ranitidine 75mg/5ml: syrup
Ranitidine 50mg/lml ampoule: i.m/i.v injection· 300mg x lOO's pack: 402.00 MRP
IOOml bot: 45.00 MRP
I 0 amps pack: 50.00 MRP + XANTID Inj. ACI
+ PEPTIL-H Inj. SK+F + RANTEC Tab. Medimet. Ranitidine 50mg/2ml ampoule: i.m/i.v injection
Ranitidine 50mg/2ml ampoule: i.m/i.v injection
Ranitidine 150mg & 300mg/tablet 2ml amp x IO's pack: 75.30 MRP
10 amps pack: 60.00 MRP ·.
150mg x IOO's pack: 200.00 MRP + XARDIN Tab. Sharif
+ PEPTONIL-R Tab. Decent 300mg x 50's pack: 175.00 MRP Ranitidine 150mg/tablet.
Ranitidine l 50mg/tablet
+ RANTIN Tab. Seema 150mg x IOO's pack: 150.00 MRP
1OO's pack: 200.00 MRP
Ranitidine 150mg/tablet + ZANTAC Tab. GlaxoSmithKline
+ PEPTOSOL I.V Inf. Opso Saline 150's pack: 300.00 MRP Ranitidine 150mg/tablet.
Ranitidine hydrochloride 50mg in 1OOml bottle,
+ RAN TOP Tab. Novus 150mg x IOO's pack: 405.53 MRP
for i.v administration as a single dose.
Ranitidine 150mg/tablet + ZENIDINE Tab. Zenith
lOOml bot: 35.13 MRP
1OO's pack: 200.00 MRP Ranitidine 150mg/tablet.
+ RANBEX Tab. Novo Healthcare + RANUL Tab. Apex 1OO's pack: 200.00 MRP
Ranitidine l 50mg/tablet
Ranitidine 150mg/tablet + ZENIL Tab. Rangs Pharma
lOO's pack: 125.00 MRP
1OO's pack: I 00.00 MRP Ranitidine 150mg/tablet.
+ RANI Tab. Cosmo Pharma + R AVIA Tab. Pharmasia IOO's pack: 200.00 MRP
Ranitidine l 50mg/tablet
Ranitidine l 50mg/tablet + ZODIN Tab. Somatec
·

lOO's pack: 202.00 IP

IOO's pack: 100.00 MRP Ranitidine 150mg/tablet.
+ RANI-150 Tab. Alco Pharma 150's pack: 150.00 MRP lOO's pack: 201.00 MRP
Ranitidine 150mg/tablet
+ RECODIN-150 Tab. Concord + ZODIN Syp. Somatec
IOO's pack: 200.00 MRP
Ranitidine 150mg/tablet. Ranitidine 75mg/5ml: syrup
+ RANICARE 150 Tab. Novelta 150's pack: 225.00 MRP 1OOml bot: 40.15 MRP
Ranitidine BP l 50mg/tablet
+ REETAC-R Tab. N avana + ZOREP Tab. Amico •

1OO's pack: 200.00 MRP

Ranitidine 150mg/tablet. Ranitidine 150mg & 300mg/tablet.
+ RANID Tab. Ziska 150mg x IOO's pack: 200.00 MRP 150mg x IOO's pack: 150.00 MRP
•

Ranitidine l 50mg/tablet
+ RENETE Tab. Euro Pharma
lOO's pack: 110.00 MRP
Ranitidine l 50mg/tablet.
+ RANID Inj. Ziska 150's pack: 375.00 MRP Prostaglandin Analogues
Ranitidine 50mg/2ml ampoule: i.m/i.v injection
+ RENICON Tab. Medicon •

10 amps pack: 60.00 MRP

Ranitidine l 50mg/tablet.
MISOPROSTOL2 6,42
+ RANILOC Tab. Kumudini lOO's pack: 200.00 MRP
Ranitidine 150mg/tablet
+ RHINE Tab. Healthc are
150's pack: 300.00 MRP MISOPROSTOL: Tablet
Ranitidine l 50mg/tablet.
+ RANIMIL Tab. Millat Misoprostol is a synthetic prostaglandin El ana­
1OO's pack: 300.00 IP
Ranitidine l 50mg/tablet logue that has gastric antisecretory, mucosa! pro­
+ RT 150 Tab. Silva
1OO's pack: 250.00 MRP tective and uterine contractibility properties. It is
Ranitidine 150mg/tablet.
+ RANISON Tab. Jayson available as- Misoprostol INN 1OOmcg &
IOO's pack: 200.00 MRP ..

Ranitidine 150mg/tablet 200mcg tablet for oral administration.

+ SADIN Tab. SAPL
lOO's pack: 173.00 IP Mode of action: After absorption, misoprostol
Ranitidine l 50mg/tablet.
+ RANISON Inj. Jayson undergoes rapid de-esterification to its free acid,
lOO's pack: 200.00 MRP
Ranitidine 50mg/2ml ampoule: i.m/i.v injection which is responsible for its clinical activity and,
+ SUTAC Tab. Supreme
10 amps pack: 100.00 IP unlike the parent compound, is detectable in plas­
Ranitidine 150mg/tablet.
+ RANISYN Tab. MST Pharma ma. NSAIDs inhibit prostaglandin synthesis, and
lOO's pack: 200.00 MRP
Ranitidine 150mg/tablet a deficiency of prostaglandins within the gastric
+ TINADIN Tab. Delta Pharma mucosa may lead to diminishing bicarbonate and
IOO's pack: 210.00 MRP
Ranitidine l 50mg/tablet
+ RANIT Tab. Pharmadesh mucus secretion & may contribute to the mucosa!
200's pack: 220.00 MRP
Ranitidine 150mg/tablet. damage caused b y these agents. The antisecretory
1OO's pack: 200.00 MRP + ULCAR Tab. Drug Inter. activity and uterine contractibility of misoprostol

is mediated through a class of high aflinity E­
type prostaglandin receptors on the surface of
gastric parietal cells and uterus respectively.
Misoprostol achieves cytoprotection by increasing
gastric mucus secretion, duodenal bicarbonate
secretion and gastric mucosal blood flow.
Ind: Antiulcerant indication:
Misoprostol is indicated for reducing the risk of
NSAID-induced gastric ulcers in patients at high
risk of complications from gastric ulcer, e.g the
elderly and patients with concomitant debilitating
disease, as well as patients at high risk of devel­
oping gastric ulceration, such as patients with a
history of ulcer. Misoprostol has not been shown
to reduce the risk of duodenal ulcers in patients
taking NSAIDs. Misoprostol should be taken for
the duration of NSAID therapy. It had no effect,
compared to placebo, on gastrointestinal pain or
discomfort associated with NSAID use.
Gynecological indication:
Induction of labor (in unfavorable cervical
conditions); prevention & treatment of
postpartum hemorrhage (PPH).
·
C/I: Misoprostol is contraindicated to anyone
with a history of allergy to prostaglandins.
S/E: Generally, misoprostol is well tolerated. The
most frequent adverse effects associated with
misoprostol therapy involve the GI tract such as,
diarrhea, abdominal pain, dyspepsia, flatulence,
nausea, vomiting, rashes and dizziness. The
incidence of diarrhea may be minimized by
administering the drug after meal and at bedtime
and by avoiding concomitant administration with
a magnesium-containing or other laxative antacid.
Precautions: Incase of prevention and treatment
ofNSAID-induced gastric & duodenal ulcer:
Misoprostol is contraindicated in women who are
pregnant, and should not be used in women of
child bearing potential unless the patient requires
NSAID therapy. Women of child bearing
potential should be told that they must not be
pregnant when misoprostol therapy is initiated
and they must use an effective contraceptive
method while taking misoprostol.
Pregnancy & lactation: Misoprostol is
contraindicated in pregnant women. It should not
be used in women in child bearing potential
unless the patient requires NSAID therapy or is
at high risk of developing gastric ulceration.
Misoprostol is prescribed if patient has had a
negative serum pregnancy test within 2 weeks
prior to beginning of therapy.
Dosage & admin: Benign gastric and duodenal
ulceration and NSAID associated ulceration:
The recommended adult dose of misoprostol is
200mcg four times daily (or, 800mcg daily in
2-4 divided doses) with breakfast or main
meals and at bedtime; treatment should be
continued for at least 4 weeks and may be
continued for upto 8 weeks if required.
Misoprostol should be taken with a meal, and
the last dose of the day should be at bedtime.
Prophylaxis of NSAID-induced gastric ulcer:
200mcg 2-4 times daily taken with NSAID. If
this dose cannot be tolerated, a dose of
1 OOmcg can be used. Misoprostol should be
taken for the duration of NSAID therapy as
prescribed by the physician.
r
Induction of labor: See, gynecological chapter.
•
•
Children: Use of misoprostol in children below
t•.
•
QIMP-17 (17) • •
the age of 18 years have not been.established.
Drug inter: There is no evidence of clinically
significant interaction between misoprostol and
cardiac, pulmonary, CNS drugs and NSAID's.
Bioavailability of misoprostol is decreased with
high doses of antacid.
+ CYTOMIS Tab. Incepta
Misoprostol INN I OOmcg & 200mcg/tablet.
IOOmcg x 30's pack: 240.00 MRP
200mcg x 3·o·s pack: 450.00 MRP
+ G-MISOPROSTOL Tab. Gonoshas
Misoprostol INN 200mcg/tablet.
200mcg x 30's pack: 300.00 MRP
+ ISOVENT Tab. Square
Misoprostol INN 200mcg & 600mcg/tablet.
200mcg x 30's pack: 451.50 MRP
600mcg x l O's pack: 400.00 MRP
+ MISOCLEAR Tab. Acme
Misoprostol INN 200mcg/tablet.
200mcg x 30's pack: 450.00 MRP
+ MISOPA Tab. Beximco
Misoprostol INN 1 OOmcg, 200mcg &
600mcg/tablet.
1 OOmcg x 30's pack: 240.00 MRP
200mcg x 30's pack: 450.00 MRP
600mcg x IO's pack: 400.00 MRP
+ MISOTAB Tab. Euro Pharma
Misoprostol INN 200mcg/tablet.
200mcg x 30's pack: 450.00 MRP
+ MISOTOL Tab. Ziska
Misoprostol INN 200mcg/tablet.
200mcg x 20's pack: 300.00 MRP
•
Proton Pump Inhibitorsi1.26,33
The important 'proton pump inhibitors' include­
Omeprazole, Lansoprazole, Pantoprazole,
Rabeprazole & Esomeprazole.
Mode of action: 'Proton pump inhibitors'
interfere in the final stage of gastric acid
production by blocking i.e forming a covalent
bond to two sites of the H+, K+ -ATPase
enzyme system ('proton pump') at the secretory
surfaces of the gastric parietal cells. This leads to
inhibition of both basal and stimulated gastric
acid secretion irrespective of the stimulus. The
binding to the H+ K+ - ATPase enzyme system
,
results in an antisecretory effect of long duration
persisting more than 24 hours.
OMEPRAZOLE21.26,33,I 39
OMEPRAZOLE: Tablet/Capsule/Suspension/
Injection
Mode of action: See above under the text of
'proton pump inhibitors'.
Ind: Benign gastric & duodenal ulcer (including
NSAID complicating), Zollinger- Ellison
syndrome, reflux oesophagitis.
S/E: Diarrhoea, headache (both may be severe);
also nausea, constipation, flatulence, dizziness,
somnolence, malaise, insomnia and paraesthesia;
rashes, urticaria, bullous eruption, erythema mul­
tiforme, angioedema, alopecia and photosensitiv­
ity reported; muscle and joint pain, blurred
vision, peripheral oedema, gynaecomastia and
rarely impotence, loss of taste, stomatitis, gastro-
intestinal candidiasis, leucopenia,
thrombocytopenia, fever, bronchospasm,
interstitial nephritis, liver enzyme changes and
liver dysfunction also reported, reversible mental
confusion, agitation, depression and
hallucinations have been noted in the severely ill.
Cautions: Exclude gastric malignancy; severe
liver disease, avoid in pregnancy & nursing.
Pregnancy .& lactation: There are no adequate &
well-controlled studies on the use of omeprazole
in pregnant women. Therapeutic doses during
pregnancy are unlikely to cause a substantial ter­
atogenic risk. Omeprazole should be used during
pregnancy only if the potential benefit to pregnant
women justifies the potential risk to the fetus.
Omeprazole is excreted in human milk. Thus, a
decision should be taken to. discontinue nursing
or to discontinue the drug, taking into account
the importance of the drug to the mother.
Dosage & admin: By mouth (tablet, capsule,
suspension):
·
Benign gastric and duodenal ulcers (including
those complicating NSAID therapy) 20mg
daily for 4 weeks in duodenal ulceration or 8
weeks in gastric ulceration; in severe cases
increase to 40mg daily; long-term use not
recommended.
Zollinger-Ellison syndrome, initially 60mg
once daily; usual ranger 20-120mg daily
(above 80mg in 2 divided doses).
Reflux oesophagitis, 20mg daily for 4 weeks,
followed by a further 4-8 weeks if not fully
healed; 40mg daily has been given for 8 weeks
in reflux oesophagitis refractory to other
treatment; may be continued at 20mg daily.
Preparation of suspension: Whole contents of
the packet should be taken into a small glass
containing 2-3 tsf of water. Other liquids or
foods should not be used. The mixer should be
stirred well and drink immediately. The glass
should be refilled with water and drink.
If the suspension is to be administered
through a nasogastric or orogastric tube, the
suspension should be constituted with about
20ml of water, and an approximately sized
syringe should be used to instill the suspension
in the tube. The suspension should be washed
through the tube with about 20ml of water.
By i. v injection:
In patients with duodenal ulcer, gastric ulcer
or reflux oesophagitis where oral medication is
inappropriate, omeprazole i. v 40mg once daily
is recommended. In patients with Zollinger­
Ellison syndrome the recommended initial
dose of omeprazole given i. v is 60mg daily.
Higher daily doses may be required and the
dose should be adjusted individually. When
doses exceed 60mg daily, the dose should be
divided and given twice daily.
Impaired renal function: Dose adjustment is
not needed in patients with impaired renal ·
function.
Impaired hepatic functi.on: As plasma half-life
of omeprazole is increased in patients with
impaired hepatic function a daily dose of
10-20mg may be sufficient •
 GASTRO-INTES11NAL DRUGS QIMP-17 (18) . .
.

Elderly: Dose adjustment is not needed in the + HK-20 Cap. Apollo

elderly. Omeprazole 20mg/capsule
20mg x 1 OO's pack: 500.00 IP
t INHIBITA Cap. Delta Pharma
Omeprazole 20mg & 40mg/capsule
20mg x 60's pack: 240.00 MRP
40mg x 20's pack: 140.00 MRP
Omeprazole USP + INPRO Cap. Biopharma
Omeprazole 20mg & 40mg/capsule

SK•F 20mg x 96's pack: 385.92 MRP

40mg x 20's pack: 140.60 MRP
+ INPRO Inj. Biopharma
+ ANASEC Cap. Novo Healthcare Omeprazole BP 40mg/ampoule: i.v injection
Omeprazole BP 20mg/capsule
1 amp's pack: 70.00 MRP
20mg x 60's pack: 300.00 MRP t LOMESEC 20 Cap. Aexim
+ ANASEC Inj. Novo Healthcare Omeprazole 20mg/capsule
Omeprazole BP 40mg/ampoule: i.v injection 20mg x 60's pack: 180.00 MRP
1 amp's pack: 70.00 MRP t LOSECTIL,Cap. SK+F
t ASPRA Cap. Apex
•

Omeprazole I Omg, 20mg & 40mg/capsule

Omeprazole 20mg/capsule . . lOmg x 48's pack: 96.00 MRP
20mg x 40's pack: 200.00 MRP . :I Omeprazole
·

.
-·"'
"" 20mg x 1OO's pack: 400.00 MRP
+ AU-20 Cap. Decent 40mg x 48's pack: 336.00 MRP
Omeprazole 20mg/capsule ... . . .
.

. .

..
.
. . . .
. . . . . .

' . ' .

. t LOSECTIL 20 Susp. SK+F

.

.
' . . ' . .

. . ' . . . .

MRP
. . '
.
.
. . . -

20mg 1OO's pack: 400.00

• ' • ' I ' ' ' • ' ' ' ' ' ' ' . .

x . . .
.. . ..
. '

Omeprazole 20mg powder for suspension in

:
' . . . .
. . . .
. . . . . � .

.
. .
.. .
. . . . . . . ' . . .

+ . . ..
.
' . . . . .

AUMI Cap. Hudson

.
. . . . . . . . .
,. . . .

. . each packet.
. . . . . . . . . . .

.
. . .. .. . . . ..
' , - �
-
� , . - - .

. . . . -

Omeprazole 20mg & 40mg/capsule

. . . . . .

. . • . . . . ,. . . . . . � .
.. . . .

Dose & admin: See above under the text.

· ·· · · · · ·

,
�
. '

20mg x 60's pack: 240.00 MRP

.
.

20mg packet x 30's pack: 150.00 MRP

40mg x 20's pack: 150.00 MRP t LOSECTIL 40 Susp. SK+F
, , .
- .. .. .. . .. .. � . . .. .. ., ... _

.. .. ..
t BESEC'I'IL Cap. Bengal Drugs
. .
.. .. .. ..
,, ,, _ _ _ ,
·· - �
. 1 . .. . . . ,,.

Omeprazole 40mg powder for suspension in

.. . � .

Omeprazole BP 20mg/capsule
each packet.
20mg x 1OO's pack: 400.00 MRP 40mg packet x 30's pack: 240.00 MRP
t COSEC Cap. Drug Inter.
t LOSECTIL lnj. SK+F
Omeprazole 20mg & 40mg/capsule
Omeprazole BP 40mg/ampoule: i. v injection
20mg x 1OO's pack: 500.00 MRP •
•

•
'
<

'
.
�
>
"'
• •

.. 1 amp's pack: 70.00 MRP

336.00 MRP
.

40mg 42's pack:

-. ' . - '

x • - •
2.40 1 • 'I
•

t LOSEK Cap. Bristol

• ' " . • 1 "
>. • • • •
• - " ·, , ..

t COSEC-40 I.V Inj. Drug Inter.

• •

- TestOrug
• � •

Omeprazole 20mg & 40mg/capsule

' • . • •
• ' • • •
1 • . • •

Omeprazole BP 40mg/ampoule: i.v injection 1.80 - Research

> • •

MRP
'· 'f.

20mg
• •

60's pack: 240.00

" •

• •
•

� x
- <
•
• ' • • •

MRP
,.
. ""

1 amp's pack: 70.00

• • ..
• .
e Ill .l

30's pack: 210.00 MRP

.
> • •

40mg
• ' ' .
x
..
•

8
• • • . . "
.
1.20
+ DEU 20 Cap. MonicoPharma -�
•
. • • • •

" •
'
•
AUC :::i
•
..
•
•
•

t NEOPRA 20 Cap. Supreme

•

• • ' -·. .. ..

I
• �
• • •
Omeprazole 20mg/capsule
s • • • •
� • . . '
.
0.60 Omeprazole 20mg/capsule
�
...
• • • •
• " 1'I I

MRP
' u • •

20mg 1OO's pack: 400.00

• •

: ,!:
' ,.
x
�
. II 1"
:c·
"
60's pack: 300.00 MRP
. �

20mg
• • "'

x
� , • II \o

+
• � , ¥ •
.
DEU-40 I.V Inj. MonicoPharma o.oo+-------,.--�--r---,
� � . '

t NORAIN Cap. GlaxoSmithKline

� -· • • • •
'
• •
.-
0
'. . .
"' • • • •
. •�•• • 6 12 18 24
Omeprazole BP 40mg/ampoule: i.v injection
• • •
• •

'
Omeprazole 20mg/capsule
• • . .

Time(m)
"" � • • •
.. ..

1 amp's pack: 70.00 MRP

. "

-:.

MRP
.. "
-·:· ..- ... "'
.. i
• •
20mg x 60's pack: 300.00
t EMEZ Cap. Edruc
t NUPRAZOL Cap. Nuvista
Omeprazole 20mg/capsule
Omeprazole 20mg/capsule
20mg x 60's pack: 240.00 MRP 20mg x 50's pack: 343.00 MRP
+ EPZ-40 Cap. Reman + 0-20 Cap. Asiatic
Omeprazole 40mg/capsule
Omeprazole 20mg/capsule
40mg 20's pack: 150.40 MRP
x
20mg x 1OO's pack: 500.00 MRP
+ EUPI-20 Cap. Pharmasia
+ 0-40 Cap. Asiatic
Omeprazole 20mg/capsule
Omeprazole 40mg/capsule
20mg x 60's pack: 300.00 MRP 40mg x 20's pack: 140.00 MRP
+ EUPl-40 I.V lnj� Pharmasia t OC-20 Cap. CPL
Omeprazole BP 40mg/ampoule: i.v injection
Omeprazole 20mg/capsule
1 amp's pack: 80.00 MRP 20mg x 60's pack: 240.00 MRP
+ GAP-20 Cap. Euro Pharma
+ OMAG-DR Tab. Rangs Pharma
Omeprazole 20mg/capsule
Omeprazole magnesium 20mg/tablet (delayed
20mg x 60's pack: 300.00 MRP
release)
t GEM-20 Cap. Millat 20mg x 1 OO's pack: 400.00 MRP
Omeprazole 20mg/capsule
+ OMAPRIN-20 Cap. Doctor's
20mg x 60's pack: 300.00 MRP Omeprazole 20m:g/capsule
+ G-OMEPRAZOLE Cap. Gonoshasthaya 20mg x 40's pack: 120.00 MRP
Omeprazole 20mg/capsule
20mg x 40's pack: 120.00 MRP t OM-CAPSULE Cap. Ambee
Omeprazole 20mg & 40mg/capsule
t G-OMEPRAZO LE Inj. Gonos'1asthaya
Omeprazole BP 40mg/ampoule: i.v injection
20mg x 40's pack: 120.80 MRP
40mg x 20's pack: 100.20 MRP
1 amp's pack: 65.00 MRP
t HEALER Cap. Amico + OME Cap. Somatec
Omeprazole 20mg/capsule Omeprazole 20mg & 40mg/capsule
20mg x 50's pack: 200.00 MRP 20mg x 60's pack: 240.00 M.RP

I
 QIMP-17 (19) • •

40mg x 20's pack: 160.00 MRP lyophilized powder for solution): i.v injection.
t OMECAP-20 Cap. Chemist 40mg vial x l's pack: 90.00 MRP
Omeprazole 20mg/capsule + OMEP Cap. Aristopharma
20mg x l OO's pack: 400.00 MRP Omeprazole 1Omg, 20mg & 40mg/capsule
t OMECARE Cap. Novelta lOmg x 48's pack: 96.00 MRP
Omeprazole BP 20mg & 40mg/capsule 20mg x lOO's pack: 500.00 MRP release).
20mg x 60's pack: 240.00 MRP 40mg x 30's pack: 210.00 MRP 20mg x 60's pack: 240.00 MRP
40mg x 30's pack: 240.00 MRP t OMEP I.V Inj. Aristopharma t OMESIL IR 40 Cap. Silva
t OMECRON Cap. NIPRO JMI Omeprazole sodium BP 40mg/vial, (as Each capsule contains omeprazole BP 40mg &
Omeprazole 20mg & 40mg/capsule lyophilized powder for solution): i.v injection. sodium bicarbonate BP 11OOmg (immediate
20mg x 50's pack: 300.00 MRP 40mg vial x l's pack: 80.00 MRP release).
40mg x 40's pack: 320.00 MRP + OMEPRA Cap. Alco Pharma 40mg x 28's pack: 196.00 MRP
t OMEGUT Cap. Popular Omeprazole 20mg & 40mg/capsule + OMET-20 Cap. Pharmadesh
Omeprazole 20mg & 40mg/capsule 20mg x 50's pack: 200.00 MRP Omeprazole 20mg/capsule
20mg x IOO's pack: 500.00 MRP 40mg x 30's pack: 210.00 MRP 20mg x 60's pack: 210.00 MRP
40mg x 32's pack: 351.51 MRP t OMEPRAZOLE-20 Cap. APC Pharma t OMETAC Cap. Navana
t OMEGUT lnj. Popular Omeprazole 20mg/capsule Omeprazole 20mg & 40mg/capsule
Omeprazole 40mg/ampoule: i.v injection 20mg x 60's pack: I 50.00 MRP 20mg x lOO's pack: 402.00 MRP
l amp's pack: 80.00 MRP t OMEPROL Cap. Ziska 40mg x 24's pack: 144.48 MRP
+ OMEL-20 Cap. Medicon Omeprazole 20mg & 40mg/capsule t OME'I'ID Cap. Opsonin
Omeprazole �Omg/capsule 20mg x 56's pack: 224.00 MRP Omeprazole 20mg & 40mg/capsule
20mg x IOO's pack: 500.00 MRP 40mg x 28's pack: 196.00 MRP 20mg x 90's pack: 395.87 MRP
t OMELET Cap. Amulet t OMEPROL Inj. Z iska 40mg x 30's pack: 185.53 MRP
Omeprazole 20mg & 40mg/capsule Omeprazole 40mg/ampoule: i. v injection t OME'fID 40 I.V lnj. Opsonin
20mg x 60's pack: 300.00 MRP l amp's pack: 70.00 MRP Omeprazole sodium BP 40mg/vial, (as
40mg x 30's pack: 210.00 MRP t OMESIL Cap. Silva lyophilized powder for solution): i.v injection.

. ·•·

.
' ·

.
.

' ..

-­

omeprazole • ·�

·
Beautlfuti:·Enteric coated Pellets that cures
a 20 mg Capsule
40 mg Capsule l,.a
.

• Avallable"'both as injection & oral a .... �

· •Start witrt<lnjectlon continue with oral a 40 mg Injection BIO PHARMA

.-

+ OMENIX Cap. lncepta Omeprazole 20mg & 40mg/capsule 40mg ( lOml) vial x l's pack: 61.81 MRP
Omeprazole 20mg & 40mg/capsule 20mg x 60's pack: 300.00 MRP t OMETOP-20 Cap. Novus
20mg x 80's pack: 400.00 MRP 40mg x 20's pack: 159.00 MRP Omeprazole 20mg/capsule
40mg x 30's pack: 240.00 MRP t OMESIL Tab. Silva 20mg x 30's pack: 120.00 MRP
+ OMENIX 20 Susp. Incepta Omeprazole 20mg & 40mg/tablet t OMETOR Cap. Astra
Omeprazole 20mg powder for suspension in 20mg x 60's pack: 240.00 MRP Omeprazole 20mg/capsule
each packet. 40mg x 30's pack: 210.00 MRP 20mg x 28's pack: 112.00 MRP
Dose & admin: See above under the text. t OMESIL Fast 20 Susp. Silva t OMEVIR 20 Cap. Virgo
20mg packet x 30's pack: I 50.00 MRP Omeprazole 20mg powder for suspension in each Omeprazole BP 20mg/capsule
+ OMENIX 40 Susp. Incepta packet. 20mg x 60's pack: 240.00 MRP
Omeprazole 40mg powder for suspension in Dose & admin: See above under the text. t OMEX Cap. Kemiko
each packet. 20mg packet x 30's pack: 150.00 MRP Omeprazole 20mg & 40mg/capsule
Dose & admin: See above under the text. t OMESIL Fast 40 Susp. Silva 20mg x 60's pack: 300.00 MRP
40mg packet x 30's pack: 240.00 MRP Omeprazole 40mg powder for suspension in each 40mg x 20's pack: 140.00 MRP
t OMENIX 40 I.V Inj. Incepta packet. t OMEZOLE Cap. Medimet
Omeprazole sodi\1m BP 40mg/vial, (as Dose & admin: See above under the text. Omeprazole 20mg/capsule
lyophilized powder for solution): i.v injection. 40mg packet x 30's pack: 240.00 MRP 20mg x 50's pack: 200.00 MRP
40mg vial x 1's pack: 70.00 MRP t OMESIL IR 20 Cap. Silva 20mg x 56's pack: 224.00 MRP
t OMENTA I.V Inj. RAK Pharma Each capsule contains omeprazole BP 20mg & 20mg x 1OO's pack: 400.00 MRP
Omeprazole sodium BP 40mg/vial, (as sodium bicarbonate BP 11OOmg (immediate t OMIDEX Cap. Modern
 . .
GASTRO-INTESTINAL DRUGS
Omeprazole 20mg/capsule
20mg x 40's pack: 120.00 MRP
20mg x lOO's pack: 400.00 MRP
+ OMILOC 20 Cap. Kumudini
Omeprazole 20mg/capsule
20mg x 1OO's pack: 500.00 MRP
+ OMIREX Cap. Jayson ·
Omeprazole 20mg & 40mg/capsule
20mg x 1OO's pack: 500.00 IP
40mg x 20's pack: 160.00 IP
+ OMITAC-20 Cap. Gaco
Omeprazole 20mg/capsule
20mg x 60's pack: 240.00 MRP
+ OMITIN Cap. Nipa
Omeprazole 20mg & 40mg/capsule
20mg x 60's pack: 240.00 MRP
40mg x 30's pack: 210.00 MRP
+ OMIZIT-20 Cap. White Horse
Omeprazole 20mg/capsule
20mg x 30's pack: 120.00 MRP
+ OMPA-20 Cap. Seema
Omeprazole 20mg/capsule
20mg x 60's pack: 300.00 MRP
+ OMRAZOL Cap. Ad-din
Omeprazole 20mg & 40mg/capsule
20mg x 1OO's pack: 450.00 MRP
40mg x 20's pack: 140.00 MRP
+ OMSEC Cap. Techno Drugs
Omeprazole 20mg/capsule
20mg x 60's pack: 300.00 MRP
+ OMSEC 40 I.V Inj. Techno Drugs
Omeprazole sodium BP 40mg/vial,
lyophilized powder for solution): i.v injection.
40mg (lOml) vial x l's pack: 70.00 MRP
+ OMTRIC-20 Cap. Belsen
Omeprazole 20mg/capsule
20mg x 1OO's pack: 500.00 MRP
+ OP-20 Cap. Globe
Omeprazole 20mg/capsule
20mg x 60's pack: 240.00 MRP
+ OP-40 Cap. Globe
Omeprazole 40mg/capsule
40mg x 40's pack: 280.00 MRP
+ OP-40 I.V Inj. Globe
Omeprazole sodium BP 40mg/vial, (as
lyophilized powder for solution): i.v injection.
40mg (lOml) vial x l's pack: 70.00 MRP
+ OPAL Cap. Healthcare
Omeprazole 20mg & 40mg/capsule
20mg 60's pack: 300.00 MRP
40mg x 30's pack: 256.00 MRP
+ OPAL I.V Inj. Healthcare
Omeprazole sodium BP 40mg/vial, (as
lyophilized powder for solution): i.v injection.
40mg (lOml) vial x l's pack: 95.00 MRP
+ OPEZEN Tab. Zenith
Omeprazole 20mg & 40mg/tablet
20mg x 60's pack: 240.60 MRP
40mg x 20's pack: 140.40 MRP
+ OP MAX Cap. Concord
Omeprazole 20mg & 40mg/capsule
20mg x lOO's pack: 400.00 MRP
40mg x 40's pack: 280.00 MRP
+ OPRA Cap. Cosmo Pharma
Omeprazole 20mg/capsule
20mg x 50's pack: 202.00 MRP
+ OSYN-20 Cap. MST Pharma
Omeprazole 20mg/capsule
20mg x 60's pack: 240.00 MRP
+ OZOLE Cap. Peoples
QIMP-17 (20) • •
Omeprazole BP 20mg/capsule
20mg x 90's pack: 405.00 MRP
+ PEPT RAL 20 Cap. Labaid Pharma
Omeprazole BP 20mg/capsule
20mg x 60's pack: 300.00 MRP
+ PPI Cap. Acme
Omeprazole 20mg & 40mg/capsule
20mg x 1 OO's pack: 500 MRP
I
40mg x 20's pack: 160.00 MRP
+ PPI I.V Inj. Acme .
Omeprazole sodium BP 40mg/vial, (as
lyophilized powder for solution): i.v injection.
40mg vial x l's pack: 70.26 MRP
+ PRAM Cap. Mystic
Omeprazole 20mg/capsule
20mg x 28's pack: 105.00 MRP
+ PRAZO 20 Tab. Pacific
Omeprazole 20mg/tablet
� Tll 20mg x IOO's pack: 250.00 MRP
+ PRAZO 20 Cap. Pacific
Omeprazole 20mg/capsule
( )
- � 20mg x lOO's pack: 299.00 MRP
\ Omeprazole BP 20mg x 200's pack: 598.00 MRP
+ PRAZO Plus Cap. Pacific
Each capsule contains omeprazole BP 20mg &
sodium bicarbonate BP 11 OOmg.
20mg x 32's pack: 160.00 MRP
+ PRAZOLE Cap. Renata
Omeprazole 20mg/capsule
20mg x 60's pack: 241.20 MRP
+ PRESEC Cap. Unimed & unihealth
(as Omeprazole 20mg/capsule
20mg x 28's pack: 112.00 MRP
+ PREVAS Cap. General
Omeprazole 20mg & 40mg/capsule
20mg x 50's pack: 201.00 MRP
40mg x 30's pack: 210.90 MRP
+ PREV ENCID Cap. Rangs Pharma
Omeprazole 20mg & 40mg/capsule
20mg x 60's pack: 300.00 MRP
40mg x 20's pack: 160.00 MRP
+ PROBITOR Cap. Sandoz
Omeprazole 20mg & 40mg/capsule
20mg x 80's pack: 560.00 MRP
40mg x 28's pack: 280.00 MRP
+ PROCAP Cap. Orion Pharma
Omeprazole 20mg & 40mg/capsule
20mg x IOO's pack: 500.00 MRP
40mg x 20's pack: 160.00 MRP
.
+ PROCAP 40 I.V lnj. Orion Pharma
.
Omeprazole sodium BP 40mg/vial, (as •
lyophilized powder for solution): i.v injection.
40mg (1Oml) vial x 1's pack: 90.00 MRP
+ PROCEPTIN Cap. Beximco
Omeprazole 20mg & 40mg/capsule
20mg x 60's pack: 300.00 IP
20mg x lOO's pack: 500.00 IP
40mg x 30's pack: 240.00 IP
+ PROCEP'I'IN 40 I.V lnj. Beximco
Omeprazole sodium BP 40mg/vial, (as
lyophilized powder for solution): i.v injection.
Dose & admin: See above under the text.
40mg vial x 1's pack: 100.00 MRP
+ PROLOK Cap. Ibn Sina
Omeprazole 20mg/capsule
20mg x lOO's pack: 400.00 IP
+ PROLOK 40 I.V Inj. lbn Sina
Omeprazole sodium BP 40mg/vial, (as
lyophilized powder for solution): i.v injection.
Dose & admin: See above under the text.
•

40mg vial x l's pack: 90.00 IP
+ PROMISEC Cap. Sharif
Omeprazole 20mg & 40mg/capsule
20mg x 40's pack: 200.00 MRP
40mg x 20's pack: 140.00 MRP
+ PROPIN Cap. Hallmark
Omeprazole 20mg & 40mg/capsule
20mg x 28's pack: 112.00 MRP
20mg x 40's pack: 200.00 MRP
40mg x 20's pack: 150.60 MRP
+ RE-20 Cap. Reman
Omeprazole 20mg/capsule
20mg x 40's pack: 200.00 IP
•
+ REGERD Cap. Organic Health
Omeprazole BP 20mg & 40mg/capsule
20mg x 60's pack: 300.00 MRP .
40mg x 28's pack: 196.00 MRP
+ ROCEPTIN-20 Cap. Desh Pharma
Omeprazole 20mg/capsule
20mg x 60's pack: 180.00 MRP
+ ROME-20 Cap. Rephco
Omeprazole 20mg/capsule
20mg x 1OO's pack: 500.00 MRP
+ ROMILOK Cap. Reliance
Omeprazole 20mg/capsule
20mg x 60's pack: 240.00 MRP
+ SECLO Cap. Square
Omeprazole 20mg & 40mg/capsule
20mg x lOO's pack: 500.00 MRP
40mg x 30's pack: 240.00 MRP
+ SECLO DR Tab. Square
Omeprazole magnesium 20mg/tablet (delayed
release)
20mg x 60's pack: 300.00 MRP
+ SECLO 40 I.V Inj. Square
Omeprazole sodium BP 40mg/vial, (as
lyophilized powder for solution): i.v injection.
40mg vial x l's pack: 80.00 MRP
+ SEC'l'IL Cap. Cosmic
Omeprazole 20mg & 40mg/capsule
20mg x l OO's pack: 412.00 MRP
40mg x 40's pack: 280.00 MRP
+ SOM-20 Cap. SAPL
Omeprazole 20mg/capsule
20mg x 60's pack: 270.00 MRP
+ S-OME Tab. Somatec
Esomeprazole
Pur:e:l!IH to MSUr•
QIMP-17 (21) •
• •
..
.
Omeprazole 20mg & 40mg/tablet
20mg x 50's pack: 200.50 MRP
40mg x 30's pack: 210.90 MRP
+ XELDRIN Cap. ACI
Omeprazole 1 Omg, 20mg & 40mg/capsule
1 Omg x 48's pack: 96.48 MRP
lOmg x 50's pack: 100.50 MRP
20mg x 1OO's pack: 500.00 MRP
40mg x 40's pack: 320.00 MRP
+ XELDRIN 40 I. V lnj. ACI
Omeprazole sodium BP 40mg/vial, (as
lyophilized powder for solution): i.v injection.
Dose & admin: See above under the text.
40mg vial x l 's pack: 70.26 MRP
+ XELOPES Cap. Beacon
Omeprazole 20mg & 40mg/capsule
20mg x 120's pack: 600.00 MRP
40mg x 30's pack: 210.00 MRP
+ XELOPES Inj. Beacon
Omeprazole sodium BP 40mg/vial, (as
lyophilized powder for solution): i.v injection.
Dose & admin: See above under the text.
40mg vial x 1's pack: 90.00 MRP
+ XEROSEC Cap. Sanofi-aventis
Omeprazole 20mg & 40mg/capsule
20mg x IOO's pack: 500.00 MRP
40mg x 30's pack: 240.90 MRP
+ ZD.ON Cap. Radiant
Omeprazole 20mg & 40mg/capsule
20mg x 60's pack: 300.00 MRP
40mg x 24's pack: 180.00 MRP
+ ZOOM Cap. Everest
Omeprazole 20mg & 40mg/capsule
20mg x 50's pack: 175.00 MRP
40mg x 30's pack: 210.00 MRP
ESOMEPRAZOLE26,42
ESOMEPRAZOLE: Tablet/Injection
Esomeprazole is the newest proton pump
inhibitor. It is available as esomeprazole
magnesium oral tablet & esomeprazole sodium
parenteral i.v injection.
Mode of action: See above under the text of
'proton pump inhibitors'.
mg Tablet
20
40mgTablet
A Enterprise
&id ccmtroJ --�' -�- _ _
GASTRO-INTESTINAL DRUGS
Ind: Esomeprazole is indicated for the relief of
heartburn and other symptoms associated with
gastroesophageal reflux disease (GERD) and for
the healing of erosive esophagitis, a potentially
serious condition associated with GERD; acid
related dyspepsia; duodenal and gastric ulcer;
Zolinger-Ellison syndrome.
Esomeprazole is also approved for using in com­
bination of 'triple therapy' with amoxycillin and
clarithromycin for the eradication of Helicobacter
pylori infection in patients with duodenal ulcer
disease.
C/I: Known hypersensitivity to any component
of the formulation.
S/E: Side-effects may include- headache,
diarrhoea, abdominal pain etc.
Precaution: Exclude the possibility of
malignancy when gastric ulcer is suspected and
before treatment for dyspepsia. When using in
'triple therapy' refer to the prescribing
information of the respective antibiotics.
Precautions & warnings: No dosage adjustment
is necessary for geriatric patients; no dosage
adjustment is necessary in renal insufficiency &
in patients with mild to moderate liver impair­
ment; patients with severe liver impairment, a
dose of 20mg of esomeprazole should not be
exceeded. In paediatric patient, safety and
effectiveness have not yet been established.
Dosage & admin: By mouth:
Gastroesophageal reflux disease (GERD): i.
Symptomatic gastroesophageal reflux- 20mg
once daily for 4 weeks; if symptoms do not
resolve completely after 4 weeks, an additional
4 weeks of treatment may be considered. ii.
Healing of erosive esophagitis- 20mg or 40mg
once daily for 4 to 8 weeks; patients who do
not heal after 8 weeks, an additional 4-8 weeks
treatment may be considered. iii . Maintenance
of healing of erosive esophagitis- 20mg once
daily for up to not beyond six months.
Triple therapy for H. pylori eradication:
Esomeprazole 40mg once daily for 10 days
with Amoxycillin lgm twice daily for 10 days
& Clarithromycin 500mg twice daily for 10
days.
•
mg Capsule
I
20
40 mg IV lnj.
•

® QIMP-17 (22) . ,
•

Esomeprazole 20mg x 60's pack: 420.00 MRP

t ERAZOLE-20 Tab. Kemiko
Esomeprazole 20mg/tablet (e.c)
20mg x 30's pack: 150.00 MRP
+ ES MAX 20 Tab. Concord
By injection: Esomeprazole 20mg/tablet (e.c)
Duodenal ulcer, gastric ulcer, gastrointestinal
20mg x 60's pack: 300.00 MRP
lesions refractory to Hi blockers, Zollinger­
+ ES MAX Cap. Concord
Ellison syndrome: 40mg/day intravenously.
Esomeprazole 20mg & 40mg/capsule
Reflux esophagitis: 20-40mg/day intravenously.
20mg x 60's pack: 360.00 MRP
(Reconstitution of solution: Injection solution
40mg x 20's pack: 160.00 MRP
is prepared by adding 5ml of 0.90/o S odium
t ESMOTAC Tab. Gaco
chloride for intravenous injection into the vial.
Esomeprazole 20mg & 40mg/tablet (e.c)
IV injection must be administered intrave­
20mg x 30's pack: 120.00 MRP
nously over a period of at least 3 minutes).
40mg x 20's pack: 140.00 MRP
Drug inter: Esomeprazole appears to be a
+ ES0-20 Tab. Asiatic
selective inhibitor of the cytochrome P-450
Esomeprazole 20mg/tablet (e.c)
mono-oxygenase system; there may be an effect
20mg x 30's pack: 150.00 MRP
on hepatic clearance, but there have been no
t ESOCARE Cap. Novelta
•

reports to date of clinically relevant interactions.

Esomeprazole USP 20mg & 40mg/capsule
There is some uncertainty over the effect of
20mg x 50's pack: 300.00 MRP
esomeprazole on the oral combined contraceptive
40mg x 30's pack: 270.00 MRP •

pill. Physiological changes similar to those found

t ESOCON Tab. Biopharma
with omeprazole are likely to take place because
Esomeprazole 20mg & 40mg/tablet (e.c)
of the reduction in gastric acid, which is likely to
20mg x 60's pack: 241.20 MRP
influence the bacterial colonization of the stomach
40mg x 40's pack: 281.20 MRP
and duodenum and also vitamin B12 absorption.
t ESOCON I.V Inj. Biopharma
. Esomeprazole sodium 40mg/vial: i.v injection
+ ALTON Tab. General
40mg vial x l's combipack: 65.00 MRP
Esomeprazole BP 20mg & 40mg/tablet (e.c)
20mg x 30's pack: 150.00 MRP t ESOGAP Tab. Euro Pharma
Esomeprazole 20mg & 40mg/tablet (e.c)
40mg x 30's pack: 240.00 MRP
20mg x 50's pack: 200.00 MRP
+ ASECTOR Cap. Novo Healthcare
40mg x 50's pack: 350.00 MRP
Esomeprazole BP 20mg & 40mg/capsule (e.c)
20mg x 60's pack: 420.00 MRP
t ESOGEL Cap. Organic Health
Esomeprazole 20mg & 40mg/capsule
40mg x 28's pack: 252.00 MRP
20mg x 30's pack: 180.00 MRP
t ASECTOR I.V Inj. Novo Healthcare
40mg x 28's pack: 224.00 MRP
Esomeprazole sodium 40mg/vial: i.v injection
40mg vial x l's pack: 90.00 MRP
t ESOLOK Cap. Ibo Sina
Esomeprazole 20mg & 40mg/capsule
t ASOZIT-20 Cap. White Horse
20mg x lOO's pack: 650.00 IP
Esomeprazole BP 20mg/capsule
40mg x 48's pack: 384.00 IP
20mg x 30's pack: 210.00 MRP
t ESOLOK Tab. Ibo Sina
t CURACID Tab. Rangs Pharma
Esomeprazole 20mg & 40mg/tablet (e.c)
Esomeprazole BP 20mg & 40mg/tablet (e.c)
20mg x lOO's pack: 400.00 IP
20mg x 28's pack: 168.00 MRP
40mg x 30's pack: 210.00 IP
40mg x 20's pack: 180.00 MRP
t ESOLOK I.V lnj. Ibo Sina
t EMA Tab. Globe
Esomeprazole sodium 40mg/vial: i.v injection
Esomeprazole BP 20mg & 40mg/tablet (e.c)
40mg vial x l's combipack: 100.00 IP
20mg x 30's pack: 142.50 MRP
40mg x 30's pack: 210.00 MRP
t ESOM-E 20 Tab. Edruc
Esomeprazole USP 20mg/tablet (e.c)
t EMA-40 I.V Inj. Globe
•
20mg x 30's pack: 120.00 MRP
Esomeprazole sodium 40mg/vial: i.v injection
40mg vial x l's combipack: 70.00 MRP
t ESOMENTA Cap. RAK Pharma
Esomeprazole 20mg & 40mg/capsule
+ EMEP Tab. Aristopharma
20mg x 50's pack: 350.00 MRP
Esomeprazole BP 20mg/tablet (e.c)
40mg x 30's pack: 300.00 MRP
20mg x 60's pack: 300.00 MRP
t ESOMEP Tab. ACI
+ EMEP Cap. Aristopharma
Esomeprazole 20mg & 40mg/tablet (e.c)
Esomeprazole BP 20mg & 40mg/capsule
20mg x 50's pack: 201.00 MRP
20mg x 60's pack: 420.00 MRP
40mg x 30's pack: 210.90 MRP
40mg x 40's pack: 360.00 MRP
t ESOMEP Cap. ACI
+ EMEP I.V Inj. Aristopharma
Esomeprazole 20mg & 40mg/capsule
Esomeprazole sodium 40mg/vial: i.v injection
20mg x 50's pack: 350.00 MRP •

40mg vial x l's combipack: 90.00 MRP

40mg x 40's pack: 360.00 MRP
+ EM0-20 Tab. Pharmadesh
Esomeprazole 20mg/tablet (e.c)
t ESOMEP IV Inj. ACI
Esomeprazole sodium 40mg/vial: i.v injection
20mg x 30's pack: 135.00 MRP
40mg vial x l's combipack: 90.00 MRP
t EPA Tab. Zenith
Esomeprazole 20mg/tablet (e.c) t ESOMILOC Tab. Kumudini
Organic Health Care Ltd.
20mg x 50's pack: 200.50 MRP Esomeprazole 20mg/tablet (e.c)
20mg x 50's pack: 250.00 MRP
•

t EPRAZOL 20 Tab. Labaid Pharma

Esomeprazole 20mg/tablet (e.c) t ESOMO Cap. Amulet
•

•
 QIMP-17 (23) GASTRO-INTES'I'INAL DRUGS
• •

Esomeprazole BP 20mg & 40mg/capsule 20mg x lOO's pack: 500.00 MRP Esomeprazole 20mg & 40mg/capsule.
20mg x 60's pack: 360.00 MRP 40mg x 30's pack: 210.90 MRP 20mg x 50's pack: 300.00 MRP
40mg x 30's pack: 240.00 MRP + ESO'I'ID Tab. Opsonin 40mg x 30's pack: 270.00 MRP
+ ESONIX Tab. Incepta Esomeprazole 20mg & 40mg/tablet (e.c) + EXOR-40 I.V Inj. Orion Pharma
Esomeprazole BP 20mg & 40mg/tablet (e.c) 20mg x l 5's pack: 220.08 MRP Esomeprazole sodium 40mg/vial: injection
20mg x 50's pack: 250.00 MRP 40mg x 50's pack: 351.88 MRP 40mg vial x l's pack: 100.00 MRP
240.00 MRP
I

40mg x 30's pack: + ESO'I'ID Cap. Opsonin + EZ-20 Cap. Modem

+ ESONIX Cap. lncepta Esomeprazole 20mg & 40mg/capsule. Esomeprazole 20mg/capsule
Esomeprazole BP 20mg & 40mg/capsule 20mg x 90's pack: 476.62 MRP 20mg x 30's pack: 150.00 MRP
20mg x 56's pack: 392.00 MRP 40mg x 30's pack: 238.31 MRP + EZOOM Tab. Everest
40mg x 30's pack: 270.00 MRP + ESOTID IV Inj. Opsonin Esomeprazole 20mg/tablet
+ ESONIX I.V Inj. lncepta Esomeprazole sodium 40mg/vial: i. v injection 20mg x 50's pack: 200.00 MRP
Esomeprazole sodium 40mg/vial: i.v injection 40mg vial x l's combipack: 61.81 MRP + iMAX 20 .Cap. Delta Pharma
40mg vial x 1 's combipack: 70.00 MRP + ESOTOR Tab. NIPRO JMI Esomeprazole 20mg/capsule
+ ESOPIN 20 Tab. Hallmark Esomeprazole 20mg & 40mg/tablet (e.c) 20mg x 60's pack: 300.00 MRP
Esomeprazole 20mg/tablet (e.c) 20mg x 50's pack: 250.00 MRP + MAXIMA Cap. Acme
20mg x 30's pack: 150.00 MRP 40mg x 30's pack: 240.00 MRP Esomeprazole 20mg & 40mg/capsule
20mg x 50's pack: 250.00 MRP + ESOVIR Tab. Virgo 20mg x 40's pack: 280.00 MRP
+ ESOPRA-20 Tab. Rephco Esomeprazole USP 20mg/tablet (e.c) · 4()mg x 20's pack: 180.00 MRP
Esomeprazole mag. trihydrate 20mg/tablet (e.c) 20mg x 60's pack: 300.00 MRP + Inj. Aclne
20mg x 50's pack: 200.00 MRP + ESOZ Tab. Astra Esomeprazole sodium 40mg/vial: injection
+ ESOPRA-20 Tab. Alco Pharma Esomeprazole 20mg/tablet (e.c) 40mg vial x l's pack: 90.00 MRP
Esomeprazole 20mg & 40mg/tablet (e.c) 20mg x 30's pack: 150.00 MRP + MAXPRO Tab. Renata
20mg x 30's pack: 120.00 MRP + ESOZOL Tab. Medicon Esomeprazole 20mg & 40mg/tablet (e.c)
40mg x 30's pack: 210.00 MRP Esomeprazole 20mg/tablet (e.c) 20mg x I OO's pack: 500.00 MRP
+ ESOPREX Cap. Beacon 20mg x 50's pack: 300.00 MRP 40mg x 30's pack: 240.00 MRP

A.".,SANDOZ
Novartis company
. .::. .- '
;'
. ...
', .-
' .- -· - -
.-·-·
...•.
. ;

·�
;

� . ...
,
,,_,
_

. .

.
-
.
.- .

�effer than ·esomeprazofe tabfet

.
_

·
ch
. .
-� - .
.. .. . :' - . --
• -

. . .
. ; . .
.
- -

.- . ' · .· • . IS\ · J�<'tbn be given to pregnant mother&

- -'> -

.
.
�
•

,
- •

· \W
.

·
...

: .
..

..
:., ,

: .
•

.-[_
.

..
. ·
. .
lactating -m,otner .. ·

' - .
-

. ·-�:·-�· :- .
'ci' :''..Mcrnufctttored
..,,.

Esom.eprazol· e. 2b mg & d40 mg

• •

Capsule . .
,, · -
-

_;
.. · .. . in murtinationar pfant . - ----·
"-.
·
'
.
,
-

- -

.
' ______
'

-.� -.:·:t.
Th,e trusted.Esomepr:azole brand.
..

I • ...

.- -. :
-
-

Esomeprazole 20mg & 40mg/capsule. + ESPRAM Tab. Mystic + MAXPRO Cap. Renata
20mg x 56's pack: 336.00 MRP Esomeprazole 20mg/tablet (e.c) Esomeprazole 20mg & 40mg/capsule
40mg x 30's pack: 240.00 MRP 20mg x 30's pack: 120.00 MRP 20mg x 60's pack: 420.00 MRP
+ ESOPROL Cap. Ziska + ESPJµZO Cap. Pacific 40mg x 30's pack: 300.00 MRP
Esomeprazole 20mg & 40mg/capsule. Esomeprazole 20mg/capsule
+ MAXPRO Inj. Renata
20mg x 56's pack: 280.00 MRP 20mg x 30's pack: 150.00 MRP Esomeprazole sodium 40mg/vial: injection
40mg x 28's pack: 224.00 MRP + ESRU-20 Tab. Doctor's 40mg vial x l 's pack: 90.00 MRP
+ ESORAL Tab. SK+F Esomeprazole 20mg/tablet
Esomeprazole 20mg & 40mg/tablet (e.c) 20mg x 50's pack: 200.00 MRP + NEPTOR Cap. Sandoz
20mg x 80's pack: 400.00 MRP Esomeprazole 20mg & 40mg/capsule
+ EXIUM Cap. Radiant Pharma
40mg x 30's pack: 240.00 MRP 20mg x 60's pack: 480.00 MRP
Esomeprazole 20mg & 40mg/capsule.
40mg x 30's pack: 360.00 MRP
+ ESORAL Cap. SK+F 20mg x IOO's pack: 750.00 MRP
Esomeprazole 20mg & 40mg/capsule 40mg x 60's pack: 570.00 MRP + NEXCAP DR Cap. UniMed & UniHealth
20mg x 50's pack: 350.00 MRP + EXMART-20 Tab. MST Pharma Esomeprazole 20mg & 40mg/capsule (delayed
40mg x 30's pack: 270.00 MRP Esomeprazole 20mg/tablet (e.c) release).
+ ESORAL I.V lnj. SK+F 20mg x 30's pack: 150.00 MRP Dosage & admin: Dosages are same as normal
Esomeprazole sodium 40mg/vial: injection + EXOME Tab. Chemist tablet or capsule preparations - see above
40mg vial x l's combipack: 90.00 MRP Esomeprazole 20mg/tablet under the text.
t ESOTAC Tab. Navana 20mg x 50's pack: 200.00 MRP 20mg x 28's pack: 196.00 MRP
Esomeprazole 20mg & 40mg/tablet (e.c) + EXOR Cap. Orion Pharma 40mg x 28's pack: 252.00 MRP

Erazole-20 Tablet
Esomeprazole INN 20 mg

KEMIKO PHARMACEUTICALS LTD. Drug of choice in GERO

I
 -

QIMP-17 (24)
. ..

Esomeprazole 20 mg & 40 mg Tablet & 20 mg Capsule 20mg x 50's pack: 250.00 MRP
The fastest PPI + XELPRO Tab. Pharmasia
with longer action Esomeprazole magnesium 20mg & 40mg/tablet
AJ)eX
)
! , 1 l• t l : ' -l
(e.c) •

20mg x 50's pack: 250.00 MRP

+ NEXE Tab. Apex 40mg x 30's pack: 240.00 MRP
Esomeprazole 20mg & 40mg/tablet ( e.c) Omeprazole 20 & 40 mg
20mg x 30's pack: 150.00 MRP
LANSOPRAZOLE21,34
40mg x 30's pack: 240.00 MRP
+ NEXUM Tab. Square
Esomeprazole 20mg & 40mg/tablet (e.c) LANSOPRAZOLE: Capsule

The tested and trusted Mode of action: See above under the text of
20mg x 50's pack: 250.50 MRP
'proton pump inhibitors'.
40mg x 30's pack: 241.20 MRP Omeprazole brand
Ind: Lansoprazole is indicated in the treatment
+ NEXUM Cap. Square
of conditions where a reduction of gastric acid
Esomeprazole 20mg & 40mg/capsule
secretion is required, such as- duodenal ulcer,
20mg x 60's pack: 361.20 MRP
gastric ulcer, peptic ulcer associated with
40mg x 30's pack: 270.90 MRP
Helicobacter pylori, NSAID associated peptic
+ NEXUM I.V Inj. Square
® ulcer, gastro-oesophageal reflux disease, acid­
Esomeprazole sodium 40mg/vial: i. v injection
related dyspepsia & Zollinger-Ellison syndrome.
40mg vial x l 's pack: 90.00 MRP
C/I: Hypersensitivity to the ingredients of this
+ OPTON Tab. Beximco
Esomeprazole 20 & 40 mg drug.
Esomeprazole 20mg & 40mg/tablet (e.c)
S/E: These include- headache, diarrhoea, rashes,
20mg x 30's pack: 150.00 IP
pruritus, dizziness, urticaria, nausea & vomiting,
20mg x 60's pack: 300.00 IP
Optically pure PPI to ensure constipation, flatulence & abdominal pain.
40mg x 30's pack: 240.00 IP
optimum acid control Precaution & warnings: Lansoprazole should
+ OPTON IV Inj. Beximco
be administered with care in the following
Esomeprazole sodium 40mg/vial: i.v injection
patients- i. patients with a history of drug
40mg vial x l 's pack: 100.00 MRP
hypersensitivity, ii. patients with hepatic
+ PROGUT Tab. Popular
dysfunction, iii. in pregnant women or women
Esomeprazole 20mg & 40mg/tablet (e.c)
having possibilities of being pregnant only if the
20mg x 50's pack: 250.00 MRP
expected therapeutic benefit is thought to
40mg x 30's pack: 240.00 MRP
outweigh any possible risk, iv. it is advisable to
+ PROGUT Cap. Popular
avoid in nursing mothers, v. the safety of
Esomeprazole 20mg & 40mg/capsule.
lansoprazole in children has not been established.
20mg x 1 OO's pack: 700.00 MRP
Dosage & admin: Benign gastric ulcer- 30mg
40mg x 50's pack: 450.00 MRP
daily in the morning for 8 weeks.
+ PROGUT I.V Inj. Popular
A definition of fast antiulcerant Duodenal ulcer- 30mg daily in the morning for
Esomeprazole sodium 40mg/vial: injection
4 weeks; maintenance 15mg daily. NSAID
40mg vial x l's combipack: 90.00 MRP
associated duodenal or gastric ulcer- 15mg to
+ PRONEX Tab. Drug Inter.
30mg once daily for 4 weeks, followed by a
Esomeprazole INN 20mg & 40mg/tablet (e.c)
further 4 weeks if not healed completely.
20mg x 50's pack: 250.00 MRP
Zollinger-Ellison syndrome (and other hyper­
40mg x 50's pack: 400.00 MRP
secretory conditions)- initially 60mg once daily
+ PRONEX-40 I.V Inj. Drug Inter.
adjusted according to response; daily doses
Esomeprazole sodium INN 40mg/vial: injection
of 120mg or more is given in two divided
40mg vial x l's combipack: 70.00 MRP
doses. Gastro-oesophageal reflux disease-
+ SERGEL Cap. Healthcare
30mg daily in the morning for 4 weeks,
Esomeprazole 20mg & 40mg/capsule
followed by a further 4 weeks if not fully
20mg x 90's pack: 630.00 MRP Pantoprazole 20 & 40 mg
healed; maintenance therapy may be required,
40mg x 30's pack: 270.00 MRP
15-30mg daily. Acid-related dyspepsia- 15mg
+ SOMPRAZ Tab. Healthcare
to 30mg daily in the morning for 2-4 weeks.
Esomeprazole 20mg & 40mg/tablet (e.c) Proven in Research
20mg x 30's pack: 210.00 MRP proven in practice Drug Inter: In clinical studies lansoprazole
40mg x 30's pack: 270.00 MRP does not show any significant interactions with
+ SERGEL I.V Inj. Healthcare warfarin, indomethacin, aspirin, ibuprofen,
Esomeprazole sodium 40mg/vial: injection phenytoin, prednisolone, antacids, or diazepam in
40mg vial x l's combipack: 100.00 MRP healthy subjects; but when administered concom­

+ SOMAZOLE Cap. Ad-din itantly with theophylline, a minor increase (10%)

Esomeprazole 20mg/capsule in the clearance of theophylline was seen, which
20mg x l OO's pack: 500.00 MRP is unlikely to be of clinical importance.

+ SOMPRAZ Tab. Sun Pharma

+ ENSO Cap. Kemiko
Esomeprazole 20mg & 40mg/tablet (e.c)
Lansoprazole 15mg & 30mg/capsule
20mg x 50's pack: 250.00 MRP
15mg x 20's pack: 60.00 MRP
40mg x 50's pack: 400.00 MRP
30mg x 20's pack: 100.00 MRP
+ SOMPRAZOL Cap. Sharif + LANOZOLE Cap. Medimet
Esomeprazole 20mg & 40mg/capsule
Lansoprazole 15mg & 30mg/capsule
20mg x 60's pack: 360.00 MRP
15mg x 40's pack: 120.00 MRP
40mg x 20's pack: 180.00 MRP
30mg x 20's pack: l 00.00 MRP
+ VERSAL Tab. Cosmic + LANSEC Cap. Drug Inter.
Esomeprazole INN 20mg/tablet (e.c) Lansoprazole l 5mg & 30mg/capsule

15mg x 60's pack: 210.00 MRP
30mg x 60's pack: 360.00 MRP
t LANSINA Cap. Ibo Sina
Lansoprazole 30mg/capsule
30mg x 25's pack: 150.00 IP
t LANSO Cap. S quare
Lansoprazole l 5mg & 30mg/capsule
15mg x 50's pack: 175.50 MRP
30mg x 30's pack: 180.60 MRP
t LANSODIN Cap. Acme
Lansoprazole 15mg & 30mg/capsule
l 5mg x 28's pack: 98.00 MRP
30mg x 28's pack: 168.00 MRP
t LANSOPRIL Cap. Amico
Lansoprazole INN 30mg/capsule
30ing x 30's pack: 150.00 MRP
• LANSOPROL Cap. Z iska
Lansoprazole INN 30mg/capsule
•
I
30mg x 20's pack: 80.00 MRP
t LANTID Cap. Opsonin
Lansoprazole 15mg & 30mg/capsule
l 5mg x 20's pack: 52.95 MRP
30mg x 18's pack: 79.49 MRP
t LANZOL-30 Cap. Doctor's
Lansoprazole 30mg/capsule
30mg x 40's pack: 200.00 MRP
t LAP Cap. Ambee
Lansoprazole 30mg/capsule
30mg x 28's pack: 140.28 MRP
t LASOCON Cap. Biopharma
Lansoprazole 30mg/capsule
30mg x 28's pack: 168.00 MRP
t LAZ0-30 Cap. Desh Pharma
Lansoprazole 30mg/capsule
30mg x 30's pack: 150.00 MRP
t PROTOLAN Cap. Beximco
Lansoprazole 15mg & 30mg/capsule
15mg x 30's pack: 120.00 IP
30mg x 30's pack: 180.00 IP
t ZOTON Cap. General
Lansoprazole 15mg & 30mg/capsule
15mg x 30's pack: 105.30 MRP
30mg x 20's pack: 120.40 MRP
PANTOPRAZOLE21,26,133
PANTOPRAZOLE: Tablet/Capsule/Injection
Pantoprazole is a 'proton pump inhibitor', and
chemically a benzimidazole derivative.. It is
available as pantoprazole sodium sesquihydrate
20mg & 40mg tablet & capsule for oral
administration and also as 40mg injection vial for
i.v. administration.
Mode of action: See above under the text of
'proton pump inhibitors'.
Ind: Pantoprazole is indicated where suppression
of acid secretion is of therapeutic benefit, such
as- peptic ulcer diseases (PUD); gastro­
oesopha,geal reflux diseases (GERD); treatment
of ulcer resistant to H2 receptor antagonists
(H2RAs); treatment of ulcers induced by non­
steroidal anti-inflammatory drugs (NSAIDs);
gastrointestinal bleeding from stress or acid
peptic diseases; eradication of helicobacter pylori
QIMP-17 (25)
• •
(in combination with antibiotics); Zollinger­
Ellison syndrome; prophylaxis for acid aspiration
syndrome during induction of anaesthsia.
C/I: Hypersensitivity to any of the product.
S/E: No serious adverse reactions have been
reported yet. There are two commonest sympto­
matic adverse effects are reported, headache
(1.3%) and diarrhoea (1.5%). Other side-effects
may include abdominal pain, dizziness, nausea,
epigastric discomfort, flatulence, skin rash,
pruritus etc. Peripheral oedema has occasionally
been reported in female patients.
Precautions & warnings: Cautions: Exclude
gastric malignancy & severe liver disease before
treatment is started. No dosage adjustment of
pantoprazole is required in patients with mild,
moderate or severe renal insufficiency or in
elderly patients. No dosage adjustment is needed
in patients with mild or moderate hepatic
impairment, but in hepatic cirrhosis, the dosing is
reduced to every other day.
Pregnancy & lactation: There are no data are
available on administration of pantoprazole to
pregnant women & lactating mother, therefore, it
is better to avoid in pregnancy and breast
feeding. This drug could only be used during
pregnancy & lac.tation if it is clearly needed to
safe the mo.ther; in the case of lactating mother
nursing may be discontinued.
Dosage & Admin: By mouth: The usual
recommended adult oral dose is 40mg once
daily, preferably in the morning with or
without food. The duration of therapy is
ranging from 2-8 weeks.
In duodenal ulcers, pantoprazole 40mg once
daily given for 2-4 weeks; it generally heals
within 2 weeks.
In gastric ulcers, pantoprazole 40mg once
daily given for 4-8 weeks; it usually heals
within 4 weeks.
In reflux oesophagitis, pantoprazole 40mg
once daily given for 4-8 weeks; it also heals
within 4 weeks of treatment.
In resistant ulcers, 40mg once daily given for
8 weeks.
In ulcers induced by NS AIDs, 40mg once
daily, in patients receiving continuous
treatment with NS AIDs.
In gastrointestinal bleeding from stress or acid
peptic diseases, usual adult dosage; if req uired
the dosage may be increased.
Eradication ofHelicobacter pylori- pantopra­
zole 40mg twice daily in 'triple therapy' in
combination with appropriate antibiotic for 1
week achieved eradication rates of 90-1000/o.
Z ollinger-Ellison syndrome- pantoprazole
160mg (40mg x 4 tablets) per day; once con­
trol of acid secretion has been achieved, the
dose should be gradually reduced to the lowest
effective dose that maintains acid control.
Prophylaxis for acid aspiration syndrome dur­
ing induction of anesthesia- pantoprazole 40-
80mg should be given the evening before sur­
gery & repeated again the morning of surgery.
Maintenance therapy: Maintenance treatment
.9'- HN
rm
� =:!A
-
GAS'I'RO-INTES'I'INAL DRUGS
should be the lowest effective dose of the
drug. Pantoprazole 20mg or 40mg, both are
safe and effective in maintaining patients with
healed reflux oesophagitis and peptic ulcer
disease (PUD) in remission.
By i.v injection: Usual recommended adult
dose: Duodenal ulcer- 40mg once daily for 2-4
weeks; Gastric ulcer- 40mg once daily for 4-8
weeks; Gastro-esophageal reflux disease-
40mg once daily for 4 weeks.
I.V injection should be given slowly by •
diluting in 10 ml of sterile water for injection
to make 10 ml solution containing 4mg/ml of
pantoprazole approximately. S ubsequently
add 10 ml of reconstituted solution to 90 ml of
normal saline or s�. dertrose solution to make
100 ml solution of 0.4 mg/ml of pantoprazole
approximately. The resultant infusion should
be giv.en i.v over a period of 2-15 minutes.
Drug inter: No significant interactions.
t AUP-20 Tab. Decent
Pantoprazole sodium sesquihydrate 20mg/tablet.
20mg x 30's pack: 90.00 MRP
t AUP-40 Tab. Decent
Pantoprazole sodium sesquihydrate 40mg/tablet.
40mg x 30's pack: 150.00 MRP
t COS PR A 20 Tab. Cosmo Pharma
Pantoprazole sodium sesquihydrate 20mg/tablet
20mg x 50's pack: 125.00 IP
t DETONIX-20 Tab. Desh Pharma
Pantoprazole sodium sesquihydrate 20mg/tablet
20mg x 50's pack: 200.00 IP
20mg x lOO's pack: 400.00 IP
t EUROPAN-20 Tab. Globe
Pantoprazole sodi1un sesquihydrate 20mg/tablet.
20mg x 30's pack: 120.00 MRP
t EUROPAN-40 Tab. Globe
Pantoprazole sodium sesquihydrate 40mg/tablet.
40mg x 30's pack: 180.00 MRP
t EUROPAN-40 Inj. Globe
Pantoprazole sodium sesquihydrate
40mg/ampoule: i.v injection
40mg amp x l's pack: 70.00 MRP
t EXOPAN Tab. Edruc
Pantoprazole sodium sesquihydrate 20mg/tablet
20mg x 50's pack: 150.00 MRP
t NEOPANTA Tab. S upreme
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 30's pack: 120.00 MRP
40mg x 50's pack: 300.00 MRP
t NIXPAN Tab. Ad-din
Pantoprazole sodium sesquihydrate 20mg/tablet
20mg x 30's pack: 90.00 MRP
t OTONIX Tab. Peoples
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 50's pack: 150.00 MRP
40mg x 50's pack: 250.00 MRP
t P-20 Tab. Asiatic
Pantoprazole sodium sesquihydrate 20mg/tablet
20mg x 50's pack: 200.00 MRP
t P-40 Tab. Asiatic
Pantoprazole sodi11m sesquihydrate 40mg/tablet
•••
•••
BANGLAl'•tlH
.. • I.TD. www.squarepharmacom.bd •••
.......

Pantoprazole
'
40mg x 50's pack: 300.00 MRP
t PAGERD Tab. Organic Health
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 50's pack: 200.00 MRP
40mg x 50's pack: 300.00 MRP
t PAMEL-20 Tab. Medicon
Pantoprazole sodium sesquihydrate 20mg/tablet
20mg x 50's pack: 200.00 MRP
t PAME L-40 Tab. Medicon
Pantoprazole sodium sesquihydrate 40mg/tablet
40mg x 50's pack: 250.00 MRP
t PANLOC Tab. Kumudini
Pantoprazole soditun sesquihydrate 20mg &
40mg/tablet
20mg x 50's pack: 200.00 MRP
40mg x 30's pack: 180.00 MRP
t PANORAL Tab. SK+F
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 40's pack: 160.00 MRP
40mg x 40's pack: 240.00 MRP
t PANOZ Tab. Astra
Pantoprazole sodium sesquihydrate 20mg/tablet
20mg x 30's pack: 120.00 MRP
t PANPRO Tab. Biophar111a
Pantopr�le sodium sesquihydrate 20mg &
40mg/tablet
20mg x 1OO's pack: 400.00 MRP
40mg x 50's pack: 300.00 MRP
t PANPRO Inj. Biopharma
Pantoprazole sodium sesquihydrate
40mg/ampoule: i.v injection
40mg amp x l's pack: 70.00 MRP
t PANSEC Tab. Drug Inter.
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 50's pack: 200.00 MRP
40mg x IOO's pack: 600.00 MRP
t PANSEC-40 Inj. Drug Inter.
Pantoprazole sodium sesquihydrate
40mg/ampoule: i.v injection
40mg amp x l's pack: 70.00 MRP
t PANSOS Tab. NIPRO JMI
Pantoprazole sodium sesquihydrate USP 20mg &
40mg/tablet
20mg x 50's pack: 150.00 MRP
40mg x 50's pack: 250.00 MRP
t PANTAC Tab. Navana
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 60's pack: 180.60 MRP
40mg x 30's pack: 150.60 MRP
t PANT ALOC 40 Tab. Aexim
Pantoprazole sodium sesquihydrate 40mg/tablet
40mg x 30's pack: 105.00 MRP
t PANTEX Tab. ACI
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet.
20mg x 50's pack: 200.00 MRP
QIMP-17 (26)
40mg x 30's pack: 180.00 MRP
t PANTE X Cap. ACI
Pantoprazole sodium sesquihydrate
40mg/capsule.
40mg x 40's pack: 200.80 MRP
t PANTEX I.V Inj. ACI
Pantoprazole sodi11m sesquihydrate
40mg/ampoule: i.v injection
40mg amp x l 's pack: 70.26 MRP
t PANTID Tab. Opsonin
Pantoprazo le sodi1nn sesquihydrate 20mg &
40mg/tablet.
20mg x lOO's pack: 351.88 MRP
40mg x 50's pack: 263.90 MRP
t PANTID I.V Inj. Opsonin
Pantoprazole sodium sesquihydrate
40mg/ampoule: i.v injection
40mg amp x l 's pack: 61.81 MRP
t PANTIUM Tab. Radiant
Pantoprazole sodium sesquihydrate 20mg/tablet.
20mg x 60's pack: 420.00 MRP
t PANTO Tab. Somatec
Pantoprazole sodium sesquihydrate INN 20mg &
40mg/tablet
20mg x 50's pack: 200.00 MRP
40mg x 30's pack: 180.00 MRP
t PANTOBEX Tab. Beximco
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 1OO's pack: 500.00 IP
40mg x 1OO's pack: 700.00 IP
t PANTOBEX I.V lnj. Beximco
Pantoprazole sodium sesquihydrate
40mg/ampoule: i.v injection.
40mg amp x l 's pack: 110.00 MRP
t PANTOCHEM Tab. Chemist
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 50's pack: 150.00 MRP
40mg x 50's pack: 250.00 MRP
t PANTODAC Tab. Ziska
Pantoprazole sodi11m sesquihydrate INN 20mg &
40mg/tablet
20mg x 60's pack: 180.00 MRP
40mg x 30's pack: 150.00 MRP
t PANTOGEN Tab. General
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 50's pack: 150.50 MRP
40mg x 50's pack: 251.00 MRP
t PANTOGUT Tab. Popular
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 1OO's pack: 400.00 MRP
40mg x 50's pack: 300.00 MRP
t PANTOGUT I .V lnj. Popular
Pantoprazole sodium sesquihydrate
40mg/ampoule: i.v injection.
40mg amp x l's pack: 70.00 MRP
t PANTOLOK Tab. Ibo Sina
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x l OO's pack: 400.00 IP
40mg x 50's pack: 250.00 IP
t PANTOLOK I.V lnj. Ibo Sina
••
Paotoprazole sodium sesquihydrate
40mg/ampoule: i.v injection.
40mg amp x l 's pack: 80.00 IP
t PANTON-AX Tab. Bristol
Pantoprazole sodi11m sesquihydrate 20mg &
40mg/tablet
•
20mg x 50's pack: 150.00 MRP
40mg x 50's pack: 450.00 MRP
t PANTONIX Tab. lncepta
Paotoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 70's pack: 350.00 MRP
40mg x 70's pack: 490.00 MRP
t PANTONIX I.V Inj. Incepta
Paotoprazole sodium sesquihydrate
40mg/ampoule: i.v injection
40mg amp x 1's pack: 70.00 MRP
t PANTOPR A Tab. Alco Pharma
Pantoprazole sodi11m sesquihydrate 20mg &
40mg/tablet
20mg x 30's pack: 90.00 MRP
40mg x 30's pack: 150.00 MRP
t PANTO-SP Tab. Seema
Pantoprazole sodium sesquihydrate 20mg/tablet
20mg x 50's pack: 150.00 MRP
t PANTOSIL Tab. Silva
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 50's pack: 150.00 MRP
40tng x 50's pack: 250.00 MRP
t PANTOZOL Tab. Gaco
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 20's pack: 60.00 MRP
40mg x 20's pack: 100.00 MRP
t PANTROL Tab. Apex
Pantoprazole sodium sesquihydrate 20mg/tablet
20mg x 50's pack: 150.00 MRP
t PANZER Tab. Sun Pharma
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 50's pack: 200.00 MRP
40mg x 50's pack: 300.00 MRP
t PANZOL Tab. Amico
Pantoprazole sodium sesquihydrate 40mg &
40mg/tablet
20mg x 30's pack: 105.00 MRP
40mg x 30's pack: 165.00 MRP
t PANZUM Tab. Everest •
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
20mg x 50's pack: 150.00 MRP
40mg x 50's pack: 250.00 MRP
t PC-20 Tab. CPL
Pantoprazole sodium sesquihydrate BP
20mg/tablet
20mg x 50's pack: 200.00 MRP
t PENTOSA Tab. Pharmasia
Paotoprazole sodium sesquihydrate 20mg &
40mg/tablet
.. •
20mg x 30's pack: 120.00 MRP
40mg x 30's pack: 180.00 MRP
t PRAMAX Tab. Concord
Pantoprazole sodium sesquihydrate 20mg &
40mg/tablet
 QIMP-17 (27) ' •

20mg x 50's pack: 200.00 MRP Pantoprazole sodium sesquihydrate 20mg &
40mg x 30's pack: 180.00 MRP 40mg/tablet
t PRAZO LIN Tab. Rephco
'

20mg x 30's pack: 90.00 IP

Pantoprazole sodi11m sesquihydrate 20mg & 40mg x 30's pack: 150.60 IP
,. ACME- •

40mg/tablet t TRUPAN Tab. Square

20mg x 50's pack: 200.00 MRP Pantoprazole sodi11m sesquihydrate 20mg & Rare- bloody diarrhea, cholangitis, duodenitis
40mg x 50's pack: 300.00 MRP 40mg/tablet gastrointestinal hemorrhage, hepatic encephal;,_
+ PREGEL Tab. Healthcare 20mg x 60's pack: 240.00 MRP p�y, hepatitis, hepatoma, liver fatty deposit,
Pantoprazole sodium sesquihydrate 20mg & 40mg x 60's pack: 360.00 MRP salivary gland enlargement, thirst.
40mg/tablet t T RUPAN I.V lnj. Square Endocrine system: Hyperthyroidism,
20mg x 50's pack: 250.00 MRP Pantoprazole sodium sesquihydrate 40mg/vial: hypothyroidism.
40mg x 30's pack: 210.00 MRP i.v Injection H�tinic & lymphatic system: Anemia, ecchy­
t PRETONIX Tab. Pharmadesh 40mg vial x 1's pack: 80.00 MRP mostS, lymphadenopathy, hypochromic anemia
Pantoprazole sodium sesquihydrate 20mg & t WPAN Tab. Kemiko Metabolic.& nutritional diorders: Peripheral
40mg/tablet Pantoprazole sodium sesquihydrate 20mg & edema, edema, weight gain, gout, dehydration,
20mg x 50's pack: 175.00 MRP 40mg/tablet weight loss.
40mg x 30's pack: 172.50 MRP 20mg x SO's pack: 200.00 MRP Musculo-skeletal system: Myalgia, arthritis, leg
t PROPENTA-20 Tab. SAPL 40mg x 50's pack: 300.00 MRP cramps, bone pain, arthrosis, bursitis. Rare­
Pantoprazole sodium sesquihydrate 20mg/tablet twitching.
20mg x 50's pack: 175.00 MRP Nervous system: Insomnia, anxiety, dizzines,s
RABEPRAZOLE 52
t PROTIUM Tab. UniMed & UniHealth depression, nervousness , somnolence, hypertonia,
Pantoprazole sodium sesquihydrate 20mg & neuralgia, vertigo, convulsion, abnormal dreams
RABEPRAZOLE: Tablet
40mg/tablet libido decreased, neuropathy, paresthesia, tremo;.
Rabeprazole sodium INN 20mg/tablet
20mg x 28's pack: 140.00 MRP Rare- agitation, amnesia, confusion,
Ind: l . Short-term treatment (4 to 8 weeks) in
40mg x 28's pack: 252.00 MRP extrapyramidal syndrome, hyperkinesia.
the healing & symptomatic relief of 'erosive or
t PROTOCID Tab. Acme Respiratory system: Dyspnea, asthma, epistaxis
ulcerative gastro-esophageal reflux diseases
Pantoprazole sodium sesquihydrate 20mg & laryngitis, hiccup, hyperven-tilation. Rare- apne'a '
(GERD)'.
40mg/tablet hypoventilation.
2. Treatment for maintaining healing and
20mg x 50's pack: 200.00 MRP Ski� & appendages: Rash, pruritus, sweating,
40mg x 50's pack: 300.00 MRP
�eduction in relapse rates of heart burn symptoms .
urt1cana, alopecia. Rare- dry skin, herpes zoster
m patients with 'erosive or ulcerative gastro­
'

t PROTOCID I.V Inj. Acme psoriasis, skin discoloration.

esophageal reflux diseases (GERD)'.
Pantoprazole sodium sesquihydrate Special senses: Cataract, amblyopia, g laucoma,
3. Healing of duodenal ulcers: Short-term (up to
40mg/ampoule: i.v injection. dry eyes, abnormal vision, tinnitus, otitis media.
4 weeks) treatment in the healing and
40mg amp x l's pack: 70.26 MRP Rare- corneal opacity, blurry visio� diplopia,
symptomatic relief of duodenal ulcers. Most
t PROTOLOC Tab. Beacon deafness, eye pain, retinal degeneration,
patients heal within 4 weeks.
Pantoprazole sodium sesquihydrate 20mg & strabismus.
4. Long-tenn treatment of pathological
40mg/tablet Urogenital system: Cystitis, urinary frequency,
hypersecretory conditions including Zollinger­
20mg x 50's pack: 200.00 MRP dysmenorrhea, dysuria, kidney calculus,
Ellison syndrome.
40mg x 50's pack: 300.00 MRP metrorrhagia, polyuria. Rare- breast enlargement
C/I: Known hypersensitivity to the drug or
t PROTONIL Tab. Renata h� impotence, leukorrhea, menorrbagia, '
substituted benzimidazoles. Symptomatic _
Pantoprazole sodium sesquihydrate 20mg & orchitts, urmary incontinence.
response to therapy does not preclude the
40mg/tablet Caution & warnings: No dosage adjustment is
presence of gastric malignancy.
20mg x 50's pack: 200.00 MRP necessary in elderly patients, in patients with
S/E: Generally rabeprazole is well tolerated in
40mg x 30's pack: 180 . 00 MRP renal disease or in patients with mild to moderate
both short-term and long-term trials. The follow­
t PROTON-P Tab. Aristopharma hepatic impairment. Due to the lack of clinical
ing adverse events were reported with rabepra­
Pantoprazole sodium sesquihydrate 20mg & data on rabeprazole in patients with severe
zole in both short-term and long-term treatments.
40mg/tablet hepatic impairment, caution should be exercised.
20mg x 50's pack: 250.00 MRP
�ody as_ a whole: Asthenia, fever, allergic reac­
�o� .chills, malaise, chest pain (substemal), neck Pregnancy & lactation: No adequate and
40mg x 50's pack: 350.00 MRP wellcontrolled studies in pregnant women. In
ngidity, photosensitivity reaction. Rarely,
t PROTON-P I.V lnj. Aristopharma animal studies have revealed no eVidence of
abdomen enlarg� face edema, hangover effect.
Pantoprazole sodium sesquihydrate 40mg/vial: impaired fertility or harm to the fetus due to
i.v Injection
c_ar�iovascular �stem: HypertCnsion, myocar­
�al mfarct, electrocardiogram abnormal, migr­ rabepramle. Since many drugs are excreted in the
40mg vial x l 's pack: 80.00 MRP milk, and there are potential for adverse
ame, syncope, angina pectoris, bundle branch
t PROTOPA-20 Tab. Apollo r�ions to nursing infants from rabepramle, a
block, palpitation, sinus bradycardia, tachycardia. .
Pantoprazole sodium sesquihydrate 20mg/tablet
Rare- bradycardia, pulmonary embolus, dec�1on s�ould be made to discontinue nursing
20mg x 30's pack: 120.00 MRP or dtSCOOtmue the drag, taking into account the
supraventricular tachycardia, thrombophlebitis
t PROTOZIN Tab. Euro Pharma vasodilation, QTC prolongation and ventricubr importance of the drug to the mother.
Pantoprazole sodi11m sesquihydrate 20mg & Dosage & admin: Healing of 'erosive or ulcer­
tachycardia.
40mg/tablet ative gast1'0esophageal reflux diseues
Digestive system: Diarrhea, nausea, abdominal
20mg x SO's pack: 200.00 MRP
pain, vomiting, dyspepsia, flatulence, constipation, (G�RD)': The recommended dose is 20mg
40mg x 50's pack: 250.00 MRP
dry mouth, eructation, gastroenteritis, rectal hem­ daily for 4 to 8 weeks. Patients who have not
+ PZ-20 Tab. Modern orrhage, melena, anorexia, cholelithiasis, mouth healed after 8 weeks of treatment., an addi­
Pantoprazole sodium sesquihydrate 20mg/tablet
ul�tion, stomatitis, dysphagia, gingivitis, chole­ tional 8-weeks coune may be considered.
20mg x 50's pack: 200.00 MRP _ creased appetite, abnor111al stools, coli­ ·
�ystitis, m Maintaining healing & reduction in relapse
+ TOPR A Tab. Jayson tis, esoP.hagitis, glossitis, pancreatitis, proctitis. rates of heart burn symptoms in patients with

.
,
•

nlfllllSI PPI .
·
-·

.
. .
�-�
.,ff.':-�: �
··- ;-· ., .., ..
. , !:-0 ". �;.'i!!�t.,�
� · \'<.�-*."r-'-• � , ":"'-:o'.�
"�.';.' "'i-
- • •- •
" ·- _'"<-:

Esomeprazole 20 mg & 40 mg Tablet & 20 ·;r,g · wnl11·11r acdon-

.:"
.

·' 15lJ
.11e

ACME
'erosive or ulcerative gashoesophageal reflu
diseases (GERD)': T he recommended dose is
20mg daily.
Healing of duodenal ulcers: The recommended
dose is 20mg daily in the morning for 4 weeks.
Treatment of pathological hypersecretory con­
ditions including Zollinger-Ellison syndrome:
The dosage of rabeprazole in patients with
pathologic hypersecretory conditions varies
with the individual patient. T he recommended
starting dose is 60mg once day. Doses should
be adjusted to individual patient's need and
continued for as long as clinically indicated.
Some patients may require divided doses.
Doses up to lOOmg divided in to 4 times and
60mg in to 2 times daily may be administered.
Some patients with Zollinger-Ellison
syndrome have been treated continuously with
rabeprazole for up to one year.
Rabeprazole tablets should be swallowed
whole, and not be chewed crushed, or split.
Drug inter: Rabeprazole is metabolized by the
cytochrome P450 drug metabolizing enzyme
system, but it does not have clinically significant
interactions with other drugs metabolized by the
CYP450 enzyme system, such as warfarin,
theophylline, diaz.epam, phenytoin etc.
t ACIFIX Tab. Beximco
Rabeprazole sodi11m INN 20mg/tablet
20mg x 50's pack: 250.00 MRP
t FINIX Tab. Opsonin
Rabeprazole sodium INN 20mg/tablet
20mg x lOO's pack: 441.60 MRP
t PARICEL Tab. ACI
Rabeprazole sodi1un INN 20mg/tablet
20mg x 60's pack: 301.20 MRP
t RABE-20 Tab. Aristopharma
Rabeprazole sodi11m INN 20mg/tablet
20mg x 60's pack: 300.00 MRP
t RABECA Tab. Square
Rabeprazole sodi11m INN 20mg/tablet
20mg x 30's pack: 150.00 MRP
+ RABECON Tab. Biopharma
Rabeprazole sodi11m INN 20mg/tablet
20mg x 60's pack: 300.00 MRP
t RABEPROL Tab. Somatec
Rabeprazole sodi11m INN 20mg/tablet
20mg x 50's pack: 250.00 MRP
t RABESEC Tab. Drug Inter.
Rabeprazole sodi11m INN 20mg/tablet
20mg x 50's pack: 250.00 MRP
t RABETAC Tab. Navana
Rabeprazole sodi11m INN 20mg/tablet
20mg x 30's pack: 150.00 MRP
t RABIFAST Tab. SK+F
Rabeprazole sodium 20mg/tablet
20mg x 50's pack: 250.00 MRP
t RABIGUT Tab. Popular
Rabeprazole sodi11m 20mg/tablet
QIMP-17 (28)
20mg x lOO's pack: 500.00 MRP
t RADIUM Tab. Cosmic
Rabeprazole sodi11m INN 20mg/tablet
20mg x 50's pack: 250.00 MRP
t RABIZOL Tab. Acme
Rabeprazole sodi11m INN 20mg/tablet
20mg x 50's pack: 250.00 MRP
t RABONAC Tab. Sharif
Rabeprazole sodi11m INN 20mg/tablet
20mg x 60's pack: 300.00 MRP
t RASONIX Tab. lncepta
Rabeprazole sodi11m INN 20mg/tablet
20mg x 30's pack: 150.00 MRP
t RAZOLE-20 Tab. Kemiko
Rabeprazole sodi11m INN 20mg/tablet
20mg x 50's pack: 250.00 MRP
Chelating complexes
SUCRALFATE2I,33
SUCRALFATE: Tablet
Ind: Duodenal & gastric ulcer, chronic gastritis.
S/E: Constipation, diarrhoea, nausia, indigestion,
dry mouth, rash, pruritus, back pain, dizziness,
insomnia, vertigo, gastric discomfort.
Cautions: Renal impairment; concurrent admin.
of tetracyclines. If any adverse effect, special
reporting to committee on safety of medicine is
requested. Antacid should not be taken half an
hour before or after a dose.
Dosage & admin: Adult: Usually SOOmg to
1OOOmg 4 times daily before meals for
minimum 4 weeks.
Children: Not recommended.
t ANTEPSIN-1000 Tab. Kemiko
Sucralfate l OOOmg/tablet.
l OOOmg x lOO's pack: 550.00 MRP
t GASTALFET Tab. Beximco
Sucralfate 500mg/tablet.
500mg x lOO's pack: 402.00 IP
t ULSEC Tab. Asiatic
Sucralfate l OOOmg/tablet.
l OOOmg x 24's pack: 96.00 MRP
Therapy for H. Pylori
eradication
TRIPLE THERAPY2,21,34
The recommended therapeutic regimens for
eradication ofH. pylori in peptic ulcer patients
who are positive, include a combination of triple
drugs, which are - a proton p11mp inhibitor
omeprazole, lansoprazole or rabeprazole) & two
antibiotics (from amoxycillin, clarithromycin,
tetracycline & metronidazole), known as 'triple
therapy'.
Omeprazole, lansoprazole, rabeprazole or other
products of this family are gastric proton pump
' l
inhibitors which act on active proton p11mp.
Amoxicillin is a broad-spectrum antibiotic;
Clarithromycin is an antibiotic of the macrolide
family, highly effective against a wide variety of
-
aerobic and anaerobic gram-positive pathogens. fi.
�
Tetracycline is a broad-spectrum antibiotic, •
effective against infections due to gram+ve and •
gram-ve bacteria, but recently its use has become ���,,.,
..
limited owing to increasing bacterial resistance.
" II'
··t.'
Metronidazole is an antimicrobial drug with high ?:t >
•
activity against anaerobic bacteria and protozoa. -
•
I
•
-�
...,
It is also included in triple therapy as an
alternative to amoxicillin.
Mode of action: Proton pump inhibitors suppress
gastric acid secretion by inhibiting the gastric
H+/K+-ATPase at the secretory surface of the
gastric parietal cells.Amoxicillin works by
inhibiting bacterial cell wall synthesis &
clarithromycin acts by inhibiting microsomal
protein synthesis in susceptible organisms mainly
by binding to the donor site on the SOS sub11nit of
the bacterial ribosome and preventing
translocation to that site.
Ind: For eradication ofH. pylori in active
chronic gastritis, duodenal and gastric ulcers.
Triple therapy is not indicated for non-ulcer
dyspepsia because of cancer risk.
C/I: Known hypersensitivity to any of its
components.
AIR: Adverse reactions which are reported as
possibly or probably related to treatment (<3%)
in clinical trials when all three components of
this therapy are given concomitantly are listed
below under different systems:
Digestive system- nausea, vomiting, diarrhoea,
dark stools, dry mouth, glossitis, oral moniliasis,
stomatitis, tongue discoloration;
Musculoskeletal system- myalgia;
Nervous system- confusion, headache, dizziness;
Skin- skin reactions;
Urogenital system- vaginitis, vaginal moniliasis.
Precautions: Serious and occasionally fatal
hypersensitivity ( anaphylactoid) reactions have
been reported in patients on amoxycillin therapy.
These reactions are more apt to occur in indivi­
duals with a history of penicillin hypersensitivity.
Elderly patients may suffer from asymptomatic
renal and hepatic dysfunction. Care should be
taken when administering 'triple therapy' kit to
•
this group of patients.
Pregnancy & lactation: There are no adequate
and well controlled studies of 'triple therapy' kit
in pregnant women. But metronidazole is contra­
indicated in pregnancy specially in the l st
trimester. Therefore, 'triple therapy' kit containing
metronidazole should not be given during l st
trimester of pregnancy; thereafter only it can be
(viz. used in the rest period of pregnancy if the potent­
ial benefit justifies the potential risk to the mother
& fetus.
Clarithromycin should not be used in pregnant
women except in clinical circumstances where no
alternative therapy is appropriate.
Amoxycillin is excreted in human milk in very
www.squarepharmacom.bd l�
....'...;•.."''
IVi '
"
<
,.
(.
.
•
.
•,
•
 QIMP-17 (29) GASTRO-INTES'I'INAL DRUGS
' . .
•

small amounts. Because of the potential for 5.3 Anti-diarrhoeal antimicrobial drugs 200's pack: 200.00 MRP
serious adverse reactions in nursing infants from 5.4 Anti-diarrhoeal Antiprotozoal drugs + LOPAMID Cap. Acme
'I
'triple therapy' kit, a decision should be made 5.5 Water purifying agents Loperamide hydrochlor 2 mg/capsule.
whether to discontinue nursing or to discontinue IOO's pack: 100.00 MRP
the drug therapy, taking into account the + LOPERIN Cap. Opsonin
importance of the therapy to the mother. Adsorbents & bulk forming Loperamide hydrochlor. 2mg/capsule.
Dosage & admin: Each 'triple therapy' kit 1 OO's pack: 87.97 MRP
drugs
twice daily for 7-14 days or as per the + LORAMID E Cap. Bristol
physician's advice. Loperamide hydrochlor. 2mg/capsule.
Use in geriatrics: Elderly patients may suffer Adsorbents & bulk forming drugs, when taken 200's pack: 100.00 MRP
from asymptomatic renal and hepatic dysfunc­ with a minimum amount of water are useful in + NOMOTIL Cap. Ziska
tion. Care should be taken when administering controlling faecal consistency in diarrhoea, Loperamide hydrochlor. 2mg/capsule.
triple therapy' kit to this patients population. ileostomy and colostomy. 200's pack: 120.00 MRP
Drug inter: Proton pump inhibitors, such as,
omeprazole, lansoprazole or rabeprazole are
ISPAGHULA HUSK21,33 Anti-diarrhoeal Antimicrobial
- -
'
metabolized through the cytochrome P450
>

system, specifically through the CYP3A and drugs21

ISPAGHUL A HUSK: Non-proprietory bran of
CYP2C 19 isozymes. Studies have shown that,
topical seeds granules.
these have no clinically significant interactions
Ind: Diarrhoea, constipation, IBS, anal fissure,
with other drugs metabolized by the cytochrome In simple gastroenteritis, antimicrobial agents are
haemorrhoides.
P450 system, such as warfarin, antipyrine, generally unnecessary.When the bacterial cause
C/I: Intestinal obstruction, colonic atony.
indomethacin, ibuprofen, phenytoin, propranolol, is suspected and isolated, appropriate
S/E: Flatulence, abdominal distension.
prednisolone, diazepam, clarithromycin, ·or antimicrobial drugs are needed. Such as-
Caution: Adequate water intake should be
terfenadine in healthy subjects. a. Erythromycin- is the drug of choice for
maintained incase of constipation. In diarrhoea it
Use of clarithromycin in patients who are treating enteritis caused by camphylobacter spp.
should be taken with minimum amount of water
receiving theophylline may be associated with an b. Cotrimoxazole- is used to treat both
& should not be taken immediately before going
increase of serum theophylline concentrations. salmonella and shigella gastroenteritis.
to bed.
There have been reports of interactions of c. Nalidixic acid- is used to treat shigellosis with
Dosage & admin: Adult: 1-2 tsf in water twice
erythromycin and/or clarithromycin with a severe involvement.
or thrice daily with meals or just after meals.
carbamaze-pine, cyclosporine, tactrolimus. d. Ciprojloxacin- for severe form of salmonella,
In diarrhoea water should be minimum.
hexobarbital, phenytoin, alfentanil, disopyramide, shigella, camphylobacter gastroenteritis.
Preparations: See under laxatives.
lovastatin, bromocriptine, valproate, terfenadine, e. Pivmecillinam- also drug of choice for
cisapride, pimozide & astemizole. salmonellosis & shigellosis
METHYL CELLULOSE f. Furazolidone- a miscellaneous antimicrobial,
+HELICON Kit Strip General
used in bacterial and protozoa! gastroenteritis
Each Helicon kit strip contains- 1 lansoprazole
MET HYL CELLULOSE: Tablet and diarrhoea.
INN 30mg capsule, 2 amoxycillin BP 500mg
Ind: Diarrhoea, ileostomy, colostomy control, Preparations: See systemic antimicrobial drugs.
capsules & 1 clarithromycin USP 500mg tablet.
constipation, obesity.
Dosage & admin: Each Helicon kit strip twice
C/I; S/E; Cautions: See below under laxatives.
daily for 7-14 days or as per the physician's
Dose: See below under laxatives. Anti-diarrhoeal Antiprotozoal
advice.
Preparations: See below under laxatives. drugs21,42
Helicon Kit strip x 14's pack: 772.94 MRP
+ NEOKIT Strip Beximco
Some protozoa are olso responsible for human
Each Neokit strip contains- 1 omeprazole 20mg
Antimotility drugs diarrhoea by causing intestinal infections. The
capsule, 1 clarithromycin 500mg tablet & 1
most common pathogens responsible for
metronidazole 400mg tablet.
In acute diarrhoea antimotility drugs have a very protozoa! diarrhoea are- Cryptosporidium
Dosage: Each Neokit twice daily for 7-14 days
limited role as adjuncts to fluid and electrolyte parvum, Giardia intestinalis, Giardia lamblia and
or as per the physician's advice.
replacement. They are not recommended for Entamoeba histolytica ..
Neokit strip x 14's pack: 770.00 IP
acute diarrhoea in young children. In chronic The drugs available and effective against these
+ PYLOCURE Strip Opsonin
diarrhoea, sometimes it may be necessary but protozoa are:
Each Pylocure strip contains- One rabeprazole
prolonged use may aggravate the condition. a. Metronidazole- is the drug of choice for
sodium INN 20mg tablet, two amoxycillin BP
treating diarrhoea caused by Giardia and
500mg capsules and one clarithromycin ·usp
Entamoeba histolytica ..
500mg tablet.
LOPERAMJDE2t,33 b. Nitazoxanide- recent study shows that
Dosage: Each Pylocure strip twice daily for 7-
nitazoxanide is highly effective against all these
14 days or as per the physician's advice.
LOPERAMIDE: Capsule above pathogenic protozoa.
Pylocure strip x 7's pack: 339.92 MRP
Ind: Adjunct to rehydration in acute diarrhoea
+ PYLOTRIP Strip Square
in adult and children over 4 years; chronic
Each Pylotrip blister strip contains- lansoprazole NITAZOXANJDE42,87
diarrhoea in adult only.
30mg, amoxycillin BP 500mg & clarithromycin
-
S/E: Occasional dry mouth, dizziness, headache,
USP lgm.
'

gastro-intestinal disturbances and rashes NITAZOXANIDE INN: Tablet/Syrup

Dosage: Each Pylotrip strip twice daily for 7- Nitazoxanide is an antiprotozoal antidiarrhoeal
Dosage & admin: Adult: Acute diarrhoea, ini­
14 days or as per the physician's advi�e. drug. It is available as- nitazoxanide INN
tially 2 caps. then 1 at each loose stool, (usual­
Pylotrip strip x 7's pack: 385.00 MRP 500mg/tablet and 100mg/5ml syrup.
ly 3-4 daily). Max. 8 daily. Chronic diarrhoea,
initially 2-4 caps. daily in divided doses. Mode of action: The antiprotozoal activity of
nitazoxanide is believed to be due to the
5.ANTI-D OEAL Child: Acute diarrhoea, under 4 years, not
rcommended; 4-8 yrs. 1/2 of 1 capsule; 9-12 interference with the pyruvate: ferredoxin
DRUGS •

yrs 1 capsule. Both four times daily. oxidoreductase enzyme-dependent electron

transfer reaction which is essential to anaerobic
5.1 Adsorbents & bulk forming drugs + IMOTIL Cap. Square energy metabolism.
5.2 Antimotility drugs Loperamide hydrochl0ride 2mg/capsule. Ind: Nitazoxanide is indicated for the treatment

•
 I I.
GASTRO-INTESTINAL DRUGS QIMP-17 (30)

of diarrhoea caused by cryptosporidium parvwn 28's pack: 280.00 MRP + NITOXIN Susp. Aristopharma
and giardia lamblia in paediatric & adult patients. t NIAZID Susp. Apex Nitazoxanide INN 100mg/5ml: suspension
S/E: Nitazoxanide is well tolerated and minimt1m Nitazoxanide INN 100mg/5ml: suspension 30ml bot: 36.00 MRP
side effects, such as- abdominal discomfort, 30ml bot: 35.00 MRP 60ml bot: 50.00 MRP
diarrhoea, nausea and headache. The side effects + NICUD Susp. MonicoPharma t NIXAR Tab. Sharif
are typically mild and transient in nature. Nitazoxanide INN 100mg/5ml: suspension Nitazoxanide INN 500mg/tablet (f.c ).
C/I: Known case of hypersensitivity to 30ml bot: 35.00 MRP 20's pack: 200.00 MRP
-

nitazoxanide. + NIDOR-500 Tab. Pharmasia t NIXAR Susp. Sharif

Pregnancy & lactation: The safety of nitazoxa­ Nitazoxanide INN 500mg/tablet. Nitazoxanide INN 100mg/5ml: suspension
nide in pregnancy and lactation is yet unproven. 18's pack: 180.72 MRP 30ml bot: 35.00 MRP
So, this drug should be used in pregnancy and + NIDOR Susp. Pharmasia t NIXONID Tab. Rephco
lactation with great caution if it is clearly needed. Nitazoxanide INN 100mg/5ml: suspension Nitazoxanide INN 500mg/tablet (f.c).
Dosage & admin: Age 12-47 months: lOOmg 30ml bot: 35.00 MRP
•
20's pack: 200.00 MRP
(Sml) every 12 hours for 3 days. 60ml bot: 50.00 MRP + NIZONID Tab. Medicon
Age 4- 11years- 200mg (lOml) every 12 hours t NIDOZOX 500 Tab. Acme Nitazoxanide INN 500mg/tablet (f.c).
for 3 days. Nitazoxanide INN 500mg/tablet. 12's pack: 120.00 MRP
'

Adults & adolescents: 500mg (1tablet or 18's pack: 180.72 MRP + NIZONID Susp. Medicon
25ml) every 12 hours for 3 days. t NIDOZOX Susp. Acme Nitazoxanide INN 100mg/5ml: suspension
The drug should be taken with food. Nitazoxanide INN 100mg/5ml: suspension 30ml bot: 35.00 MRP
Drug inter: No interactions with other medicinal 30ml bot: 35.14 MRP t NIZOX Tab. Somatec
products have been reported by patients using t NITALET Tab. Amulet Nitazoxanide INN 500mg/tablet (f.c).
nitazoxanide. Nitazoxanide INN 500mg/tablet. 12's pack: 120.36 MRP
12's pack: 120.00 MRP + NIZOX Susp. Somatec
+ ADNIX Tab. Alco Pharma
t NITANID Tab. Drug Inter. Nitazoxanide INN 100mg/5ml: suspension
Ni�oxanide � 500mg/tablet.
Nitazoxanide INN 500mg/tablet. 30ml bot: 30.11 MRP
12's pack: 120.00 MRP
20's pack: 200.00 MRP + NTZ Susp. Asiatic
+ ADNIX Susp. Alco Pharma
t NITANID Susp. Drug Inter. Nitazoxanide INN 100mg/5ml: suspension
Nitazoxanide INN 100mg/5ml: suspension
Nitazoxanide INN 100mg/5ml: suspension 30ml bot: 35.00 MRP
30ml bot: 35.00 MRP
60ml bot: 50.00 MRP 60ml bot: 50.00 MRP
+ ALINIX Tab. Healthcare
t NITASOL Tab. Ibo Sina t PROXA-A Tab. Ad-din
Nitazoxanide INN 500mg/tablet.
Nitazoxanide INN 500mg/tablet. Nitazoxanide INN 500mg/tablet (f.c).
30's pack: 300.00 MRP
12's pack: 132.00 IP 20's pack: 180.00 MRP
+ ALINIX Susp. Healthcare
t NITASOL Susp. Ibo Sina t TAZONID Tab. Popular
Nitazoxanide INN 100mg/5ml: suspension
Nitazoxanide INN I 00mg/5ml: suspension Nitazoxanide INN 500mg/tablet (f.c).
30ml bot: 35.00 MRP
30ml bot: 36.00 IP 30's pack: 301.20 MRP
60ml bot: 50.00 MRP
60ml bot: 50.00 IP + TAZONID Susp. Popular
t ANTIZOA Tab. RAK Pharma
+ NITAX Tab. Delta Pharma Nitazoxanide INN 100mg/5ml: suspension
Nitazoxanide INN 500mg/tablet.
Nitazoxanide INN 500mg/tablet. 30ml bot: 32.00 MRP
30's pack: 300.00 MRP
lO's pack: 80.00 M.RP + TAZOX Tab. Novo Healthcare
t ANTIZOA Susp. RAK Pharma
+ NITAXIDE Tab. Beximco Nitazoxanide INN 500mg/tablet (f.c).
Nitazoxanide INN 100mg/5ml: suspension
Nitazoxanide INN 500mg/tablet. 12's pack: 120.00 MRP
30ml bot: 35.00 MRP
20's pack: 200.00 MRP + TAZOX Susp. Novo Healthcare
t ATINID Tab. Biopharma
t NITAXIDE Susp. Beximco Nitazoxanide INN 100mg/5ml: suspension
Nitazoxanide INN 500mg/tablet.
Nitazoxanide INN I 00mg/5ml: suspension 30ml bot: 35.00 MRP
20's pack: 200.80 MRP
30ml bot: 35.00 IP t TOZA Tab. SK+F
+ ATINID Susp. Biopharma
60ml bot: 50.00 IP Nitazoxanide INN 500mg/tablet (f.c).
Nitazoxanide INN 100mg/5ml: suspension
t NITAZET Tab. Organic Health 12's pack: 120.00 MRP
30ml bot: 35.13 MRP
Nitazoxanide INN 500mg/tablet. t TOZA Susp. SK+F
60ml bot: 50.19 MRP
30's pack: 300.00 MRP Nitazoxanide INN 100mg/5ml: suspension
t DIANIDE Tab. General
t NITAZET Susp. Organic Health 30ml bot: 35.00 MRP
Nitazoxanide INN 500mg/tablet.
Nitazoxanide INN 100mg/5ml: suspension 60ml bot: 50.00 MRP
6's pack: 60.23 MRP
30ml bot: 35.00 MRP t XANIDE Tab. Globe
+ DIANIDE Susp. General
60ml bot: 50.00 MRP Nitazoxanide INN 500mg/tablet (f.c).
Nitazoxanide INN 100mg/5ml: suspension
t NITAZOX Tab. Incepta 12's pack: 120.00 MRP
30ml bot: 35.14 MRP
Nitazoxanide INN 500mg/tablet. + XANIDE Susp. Globe
60ml bot: 50.19 MRP
30's pack: 300.00 MRP Nitazoxanide INN 100mg/5ml: suspension
t DIAR Tab. ACI
t NITAZOX Susp. lncepta 30ml bot: 35.00 MRP
Nitazoxanide INN 500mg/tablet.
Nitazoxanide INN 100mg/5ml: suspension 60ml bot: 50.00 MRP
lO's pack: 100.40 MRP
30ml bot: 35.00 MRP + XANITA Tab. Renata
t DIAR Susp. ACI
60ml bot: 50.00 MRP Nitazoxanide INN 500mg/tablet (f.c).
Nitazoxanide INN 100mg/5ml: suspension '

t NI'I'IDE Tab. NIPRO JMI 18's pack: 180.72 MRP

30ml bot: 35.13 MRP
Nitazoxanide INN 500mg/tablet (f.c). + XANITA Susp. Renata
60ml bot: 50.19 MRP
30's pack: 300.00 MRP Nitazoxanide INN 100mg/5ml: suspension
t DIAZOX Tab. Kumudini
30ml bot: 40.00 MRP
Nitazoxanide INN 500mg/tablet. t NITIDE Susp. NIPRO JMI
Nitazoxanide INN 100mg/5ml: suspension 60ml bot: 58.00 MRP
12's pack: 120.00 MRP
t DIAZOX Susp. Kumudini 30ml bot: 35.00 MRP + ZOANA Tab. Orion Pharma
Nitazoxanide INN 100mg/5ml: suspension 60ml bot: 50.00 MRP Nitazoxanide INN 500mg/tablet.
30ml bot: 35.00 MRP 12's pack: 120.48 MRP
t NITOXIN Tab. Aristopharma
t NIAZID Tab. Apex Nitazoxanide INN 500mg/tablet (f.c). + ZOANA Susp. Orion Pharma
Nitazoxanide INN 500mg/tablet. 30's pack: 300.00 MRP Nitazoxanide INN 100mg/5ml: suspension
 '

QIMP-17 (31) I �. GASTRO-INTESTINAL DRUGS

32ml bot: 35.13 MRP violently with many substances, causing fire and
62ml bot: 50.19 MRP explosion hazard. Ulcerative Colitis
+ ZOX Tab. Square A/E: Skin contact: There may be irritation and
Nitazoxanide INN 500mg/tablet. redness at the site of contact. Repeated or
30's pack: 301.20 MRP prolonged contact may cause dermatitis. Eye
MESALAZINE (MESALAMINE)21,44,146
+ ZOX Susp. Square contact: There may be severe pain, redness and
' MESALAZINE (MESALAMINE):
f
Nitazoxanide INN 100mg/5ml: suspension irritation. Ingestion: There may be nausea and
Tablet/Capsule
30ml bot: 35.14 MRP vomiting, occasionally with abdominal pain.
Mesalazine (or 5-aminosalicylic acid), also
60ml bot: 50.20 MRP Inhalation: Mild poisoning causes cough,
known as mesalamine, is the active component of
'

+ ZOXAN Tab. Opsonin irritation of the throat and shortness of breath.

sulfasalazine. It is a drug of choice for treating
Nitazoxanide INN 500mg/tablet. Very toxic to aquatic organisms, may cause long
ulcerative colitis. It is currently available as
18's pack: 158.98 MRP term adverse effects in the aquatic environment.
250mg, 400mg & 500mg tablet or capsule for
+ ZOXAN Susp. Opsonin Precautions & warnings: Harmful if swallowed.
oral adminisqation.
Nitazoxanide INN 100mg/5ml: suspension If tablet is swallowed seek medical advice
Mode of action: The specific mechanism of
30ml bot: 30.90 MRP immediately. Keep away from other materials,
action of mesalazine is unknown; however, it is
60ml bot: 44.16 MRP especially from flammable materials. Slit off the
thought that it modulates local chemical
tablets only before use. Store in a cool & dry
-

t ZOXANID Tab. Silva

•

mediators of the inflammatory response,

Nitazoxanide INN 500mg/tablet.
30's pack: 301.00 MRP
t ZOXANID Susp. Silva
Nitazoxanide INN l 00mg/5ml: suspension
30ml bot: 35.00 MRP
60ml bot: 50.00 MRP
Water Purifying agent'
place, protected from light and moisture. Keep
specially leukotrienes; action appears topical
out of the reach of children.
rather than systemic.
Dosage & admin: For drinking water: 17mg 1
Ind: Treatment and maintenance of remission of
tablet to 1 liter of water or 51mg 1 tablet to 3
ulcerative colitis.
liters of water.
C/I: Salicylate hypersensitivity; renal impairment
For fruits, vegetables washing water: 17mg 3
(nephrotoxic).
tablets or 51mg 1 tablet to 1 liter of water.
S/E: Nausea, diarrhoea, and abdominal pain;
Double the amount of tablets if the water is
headache; exacerbation of symptoms of colitis;
·
,

HALAZONE2I,43
+ HALOTAB Tab. Sonear
Halazone USP 7.5mg, 15mg & 50mg/tablet.
Ind: Water purification.
Use: Dissolve 7.5mg tablet in 1.5 litres, 15mg
tablet in 3 litres & 50mg tablet in 10 litres of
(suspected contaminated) drinking water &
use half to 1 hour after preparation.
7.5mg x 1OO's pack: 66.00 MRP
l 5mg x 1OO's pack: 100.00 MRP
50mg x lOO's pack: 200.00 MRP
t TIDOTAB Tab. Sonear
Sodium thiosulph. BP 7.5mg & 15mg/tablet.
Ind: To remove smell of Chlorine from drinking
water liberated from Halazone tablet.
Use: Dissolve 7.5mg tab. alongwith 7.5mg
Halazone tab. in 1.5 litres & 15mg tab.
alongwith 15mg Halazone tab. in 3 litres of
drinking water respectively & use half to 1
hour after prepn.
7.5mg x 1OO's pack: 60.00 MRP
15mg x lOO's pack: 95.00 MRP
SODIUM
DICHLOROISOCYANURATE42
SODIUM DICHLOROISOCYANURATE:
Tablet (effervescent)
Sodium dichloroisocyanurate is a disinfectant
with the general properties of chlorine and .
sodium hypochlorite. It contains about 65%; of
heavily contaminated.
Leave for 15 (fifteen) minutes before use.
Drug inter: Store away from calcium or sodium
hypochlorite. Store away from acids and
compounds containing ammonia.
t PEURITAR 1 Effer. Tab. Square
. Sodium dichloroisocyanurate INN 17mg/tablet
(effervescent).
Ind & Use: Water purification. Washing fruits
and vegetables, and for cleaning teeth.
Dosage & admin: For drinking water: 17mg
(1 tablet) to 1 liter of water.
For fruits, vegetables washing water: 17mg 3
tablets to 1 liter of water.
Double the amount of tablets if. the water is
heavily contaminated.
Leave for 15 (fifteen) minutes before use.
Price: 17mg x 1OO's pack: 51.00 MRP
t PEURITAR 3 Effer. Tab. Square
Sodium dichloroisocyanurate INN 51mg/tablet
(effervescent).
Ind & Use: Water purification. Washing fruits
and vegetables, and for cleaning teeth.
Dosage & admin: For drinking water: 51mg
(1 tablet) to 3 liters of water.
For fruits, vegetables washing water: 51mg (1
tablet) to 1 liter of water.
Double the amount of tablets if the water is
heavily contaminated.
Leave for 15 (fifteen) minutes before use.
Price: 51mg x 30's pack: 28.80 MRP
6. DRUGS for CHRONIC
rarely reversible pancreatitis, hepatitis, and
interstitial nephritis; leucopenia, neutropenia,
thrombocytopenia and aplastic anaemia reported;
myocarditis, lupus phenomenon, fibrosing
alveolitis also reported.
Precautions & warning: Treatment with mesa­
lazine may cause an acute intolerance syndrome
(cramping, acute abdominal pain, bloody
diarrhea; sometimes fever, headache, rash);
discontinue if this occurs. Patients with pyloric
stenosis may have prolonged gastric retention of
tablets, delaying the release of mesalamine in the
colon. Pericarditis should be considered in
patients with chest pain or new abdominal
complaints. Use caution in patients with impaired
renal or hepatic function. Postmarketing reports
suggest an increased incidence of blood
dyscrasias in patients >65 years of age.
Pregnancy & lactation: Pregnancy category B.
There are no adequate and well-controlled
studies in pregnant & nursing women for either
sulfasalazine or 5-ASA. Therefore, during
pregnancy this drug should only be given if it is
clearly needed; and nursing should not be
undertaken whil� a patient is on this drug since
many drugs are excreted in human milk.
Dosage: Acuteattack- lgm 3-4 times daily;
maintenance of remission- 250-400 or 500mg 4
times daily. Usual course of therapy is 3-8
weeks.
Child, not recommended.
t MESACOL 400 Tab. Sun Pharma
Mesalazine or 5-aminosalicylic acid (also known
as mesalamine) 40Qµig/tablet. _

400mg x 50's pack: 377.50 MRP

available chlorine. It rapidly dissolves into water INFLAMMATORY BOWEL
+ MESAMIN 250 Cap. Pharmasia
to kill micro-organisms. This product is available
DISEASE Mesalamine or 5-aminosalicylic acid (also
as sodium dichloroisocyanurate INN 17mg &
known as mesalazine) USP 250mg/capsule
5 l mg/tablet (effervescent).
250mg x 28's pack: 280.00 MRP
Ind & Use: Effervescent water purifying tablets 6.1 Ulcerative colitis
make water safer by destroying h armful micro­ 6.2 Crohn's disease
organisms. It can also be used for washing fruits 6.3 Irritable bowel syndrome
•
SULPHASALAZINE21,45
and vegetables, and for cleaning teeth. 6.4 Malabsorption syndromes
· ·

C/I: Do not use with other products. It may 6.5 Antibiotic-associated colitis SULPHASALAZINE: Tablet/Suppository
release dangerous gases (chlorine). It may react 6.6 Diverticular disease Ind: Ulcerative colitis, crohn's disease, rheuma-
 •

GASTRO-INTES'l'INAL DRUGS QIMP-17 (32) ' .

>

'" .
•••
toid arthritis. Pregnancy & lactation: Since limited experi­ sodium, glycerol (glycerine), senna (sennoside),
Precautions: Impaired renal or hepatic function. ence in pregnant women, use of tegaserod du­ sodium picosulfate.
Regular blood check and liver function test ring pregnancy is not recommended. It is also not
should be done. recommended to prescribe for nursing women.
S/E: Nausea, headache, rash, fever, loss of Pediatric patients: Safety and efficacy have not
BISACODYl}l,33
appetite. been established in pediatric patients.
BISACODYL: Tablet
Dosage & admin: By mouth: Inflammatory Dosage: The recommended dose is 6mg orally •

Ind: Constipation, bowel evacuation before

bowel diseases: Adults: 2-4 tablets 4 times
daily; maintenance, 4 tablets daily in divided
doses.
Rheumatoid arthritis: Initially 1 tablet daily for
one week increasing by one each week to
maximum 6 daily in divided doses.
Children: Under 2 years not recommended.
Over 2 years 40-60mg/kg daily; maintenance,
20-30 mg/kg daily.
By suppository: Suppository can be used as an
twice daily prior to meal. No dosage
adjustment is required in elderly patients.
Drug inter: Based on the currently available
data, dosage adjustment is not required for either
drug when tegaserod is coadministered with
other drugs.
+ DORESA Tab. lncepta
Tegaserod maleate INN 6mg/tablet
50's pack: 300.00 MRP
radio-logical procedures, endoscopy, surgery and
labour.
C/I: Intestinal obstruction.
S/E: May cause gastro-intestinal disturbance and
abdominal cramp.
Caution: Prolonged use should be avoided as
they can eventually precipitate the onset of an
atonic nonfunctioning colon and hypokalaemia.
Adult: 1-2 tabs. after meal usufily at night.
'

alternative of oral tablet preparation, where it

+ TEGARID Tab. Renata Child: Under 10 yrs. 1 tab. at night; over 10
Tegaserod maleate INN 6mg/tablet yrs. same as adult. Avoid taking with milk
1s necessary.
•

30's pack: 180.00 MRP and antacids.

+ REUMAZIN Tab. Aristopharma + TESOD Tab. Square
Tegaserod maleate INN 6mg/tablet + DURALAX Tab. Opsonin
Sulphasalazine 500mg/tablet
Bisacodyl 5mg/tablet.
·s o's pack: 260.00 MRP 30's pack: 150.30 MRP
200's pack: 123.09 MRP
+ SALAZINE Tab. Opsonin + ZILED Tab. Kemiko
Sulphasalazine 500mg/tablet Tegaserod maleate INN 6mg/tablet
50's pack: 229.60 MRP 30's pack: 180.00 MRP GLYCERINE21
+ SALAZINE Suppo. Opsonin
Sulphasalazine 500mg/suppository GLYCERINE Suppository
1O's pack: 87 .97 MRP
7. LAXATIVES, PURGATIVES
Glycerine suppositories sticks are available as­
+ SULFACOL Tab. Drug Inter. & LUBRICANTS21 adult site (2.30gm/stick) & children size
Sulphasalazine USP 500mg/tablet (1.15gm/stick).
30's pack: 150.00 MRP 7.1 Bulk-forming laxatives Use & application: 1 suppository to be
+
..

SULFAZIN Tab. Popular
Sulphasalazine 500mg/tablet
30's pack: 156.60 MRP
Irritable Bowel Syndrome
TEGASEROD26,54
TEGASER OD: Tablet.
Tegaserod is an amino guanidine-indole with
selective and partial 5-HT4 receptor agonistic
activity. It is available as tegaserod maleate INN
. equivalent to tegaserod 6mg/tablet.
Mode of action: It binds to 5-HT4 receptors in
gastrointestinal tract and stimulates
gastrointestinal motility and intestinal peristaltic
reflex, and inhibits intestinal sensitivity.
Ind: Treatment of constipation predominantly in
patients of irritable bowel syndrome, whose main
symptoms are constipation, abdominal pain and
discomfort.
C/I: Hypersensitivity to the active substance or
to any of the excipients.
A/E: The adverse events are similar to that
observed with placebo, with the exception of
diarrhoea. The frequency of most other adverse
events are also similar as placebo-trial. They
7.2 Stimulant laxatives
7 .3 Faecal softeners
7.4 Osmotic laxatives
7.5 Enema & Bowel cleansing solutions
7.6 Peripheral opioid-receptor antagonists
7.7 5HT 4 receptor agonists
Bulk-forming laxadvesi1
T hese include:lspaghula husk,
methylcellulose, stercula.
ISPAGHULA HUSK21
ISPAGHULA HUSK: Sachet.
Non-proprietory bran of tropical seeds (Oesufgue
bhushi): granules.
Ind: Constipation caused by inadequate fibre
intake, diverticuler disease,
chronic diarrhoea; irritable colon syndrome,
colostomy control, heamorrhoids.
C/I: Intestinal obstruction and colonic atony
S/E: Flatulence, abdominal distension, intestinal
obstruction.
Caution: Adequate water intake should be
maintained; caution in ulcerative colitis.
Adult: 2 tsf (1 Oml) in water once or twice daily
inserted per rectum when requird. Moistened
with water before use. During insertion
patient should lie on his/her left with flexed
right hip and knee.
Preparations: See below.
+ GLYSUP Suppository Square
Glycerine suppositories sticks, available in 2
sizes: adult size (2.30gm/stick) & children size
( l .15gm/stick).
l .15gm stick (child size) x 30's pack: 90.00 MRP
2.30gm stick (adult size) x 20's pack: 100.00 MRP
SENNOSIDE21,47
SENNOSIDE: Tablet.
Ind: Constipation; bowel evacuation before
abdominal radiological procedures, endoscopy,
surgery and labour.
C/I; S�; Cautions: Same as Bisacodyl (above);
the urine may be coloured red.
Adult: 2-4 tabs. at bedtime.
Child: under 2 years, not recommended; 2-6
yrs. l/4th and over 6 yrs. 1/2 adult dose. Both
ages take in the morning.
+ LAXENNA Tab. GlaxoSmithKline
Sennoside B 12mg/tablet.
250's pack: 313.68 MRP ..
•

with meals.
include abdominal pain, nausea, flatulence,
Child: half adult dose.
headache, dizziness, back pain and influenza-like Faecal softeners 21
symptoms. + LAXATE Sachet Medimet
Precautions & warnings: Usually no dosage
.

lspaghula husk granules 3.5gm/sachet T hese include: A.rachis oil (peanut oil) enema,
adjustment is required in patients with mild to 12's pack: 84.00 MRP liquid paraffin.
moderate hepatic impairment & mild, moderate
or severe renal impairment.
Special care is necessary in patients with severe Sdmulant laxatives21 LIQUID P ARAFFJN 21
hepatic impairment & patients with lactose
intolerance. T hese include: Bisacodyl, dantron, docusate LIQUID PARAFFIN: Mineral Oil Prepn.

Liquid paraffin, an unabsorbable lubricant
mineral oil which act as faecal softeners by
affecting intestinal electrolyte transport.
Ind: Constipation, management of haemorrhoids
(piles) and anal fissure.
Cautions: avoid prolonged use.
S/E: Anal seepage of paraffin and consequent
anal irritation after prolonged use, granuloma­
tous reactions caused by absorption of small
quantities of liquid paraffin, lipoid pneumonia
and interference with absorption of fat soluble
vitamins.
Dose: 2 tsf (lOml) at night and morning or
after meals; Child, half adult dose.
Preparations: Available in the market.
Osmotic Laxativ es21
These include: Lactitol, lactulose, lubiprostone
(?),polyethylene glycol (macrogol), magnesium
salts (magnesium hydroxide or milk of
magnesia, magnesium sulfate), phosphates
(rectal), sodium citrate (rectal),
LACTITOL 65, 127
LACTITOL: Oral solution/Powder in Sachet
for solution
Lactitol is an osmotic laxative. It is a disaccha­
ride derivative consisting of galactose and
sorbitol. It is available as- lactitol monohydrate
BP 10gm/15ml solution, & l Ogm/sachet powder
for solution.
Mode of action: As an osmotic laxative, lactitol
is not digested (i.e not hydrolysed by the disac­
charidases of the GIT) and thus not absorbed to a
significant extent in the small intestine. When it
reaches the colon, it is fermented by colonic bac­
teria. The products of this fermentation are short
chain fatty acids, carbon dioxide and hydrogen.
These products increase the osmotic power of the
original non-absorbed hydrocarbonate, and
because they are not absorbed at same rate, make
the contents of the colon more viscous by water
retention. Because lactitol is an excellent energy
source for the saccharolytic bacteria in the colon,
also the bacterial mass increases which results in
an increase of dry substance of the faeces, which
has also a positive influence on defeacation.
Ind: Lactitol is used for the treatment of two dif­
ferent syndromes namely- constipation & hepatic
encephalopathy or portal systemic encephalo­
pathy. These diseases are a result of malfunction
of the liver what is often caused by alcohol abuse
but also by hepatitis and other causes.
C/I: Galactosaemia (unable to metabolize
galactose), intestinal obstruction.
S/E: Reported side effects are abdominal
distension, flatulence and abdominal c ramps
leading to diarrhoea in case of overdose. A dose
reduction promptly corrects the latter. The
untoward effects tend to diminish with continued
use, probably as a reflection of shift in the
composition of the colonic flora. It is preferable
to administer lactitol in a single daily dose; this
diminished the incidence and intensity of
untoward abdominal effects.
Precaution: Should be taken carefully in case of
lactose intolerance.
QIMP-17 (33) •, .
•
GASTRO-INTESTINAL DRUGS
Pregnancy & lactation: Lactitol belongs to + ACTILAC Syp. Healthcare
pregnancy category B. Animal studies did not Lactulose concentrate oral solution; 1 tsf ( 5ml)
reveal any embryotoxic or teratogenic effe.cts. contains 3.4gm of lactulose USP: syrup.
Although the passage of lactitol into breast milk I OOml bot: 125.00 MRP
has not been studied, it appears unlikely to have 200ml bot: 230.00 MRP
any clinical relevance since it is only minimally + ACTULOSE Syp. Silva
absorbed. Lactulose concentrate oral solution; ltsf (5ml)
Dosage & admin: Adults: The initial daily contains 3.4gm of lactulose USP: syrup.
dosage should be 20gm (30ml oral solution or 1 OOml bot: 60.00 MRP
2 sachets) to be taken in a single dose with 200ml bot: 120.00 MRP
morning or evening meal. This dose can be + ASILAC Syp. Asiatic
reduced to lOgm (15ml solution or 1 sachet)/ Lactulose concentrate oral solution; 1tsf (5ml)
day when desired effect has been obtained. contains 3.35gm of lactulose: syrup.
Children: 2-6 years old, 2.5-5gm (5-lOml oral I OOml bot:· I 00.00 MRP
solution or Yz sachet) per day; 6-12 years old, 200ml bot: 230.00 MRP
5-lOgm (10-15ml oral solution or 1 sachet) per + AVOLAC Solo. Aristopharma
day; 12-16 years old, 10-20gm (15-30ml oral Lactulose concentrate oral solution; I tsf (5ml)
solution or 1-2 sachets) per day. contains 3.35gm of lactulose: syrup.
l OOml bot: 120.00 MRP
t LAXITOL Oral Solo. SK+F 200ml bot: 230.00 MRP
Lactitol monohydrate BP 10gm/15ml: oral + COMFORT Syp. APC Pharma
solution. Lactulose concentrate oral solution BP; 1 tsf
50ml bot: 65.00 MRP (5ml) contains 3.35gm of lactulose: syrup.
1 OOml bot: 120.00 MRP l OOml bot: 120.00 MRP
+ LAXITOL Sachet SK+F + CONLAX Soln. UniMed & UniHealth
Lactitol monohydrate BP 1Ogm/sachet: powder Lactulose concentrate oral solution; ltsf (5ml)
for solution. contains 3.35gm of lactulose: syrup.
IO's pack: 120.00 MRP 1 OOml bot: 100.00 MRP
+ MAXILAX Sachet Opsonin 200ml bot: 200.00 MRP
Lactitol monohydrate BP 1 Ogm/sachet: powder + DLAC Soln. Drug Inter.
for solution. ·
Lactulose concentrate oral solution; I tsf (5ml)
IO's pack: 105.57 MRP contains lactulose BP 3.35gm: syrup.
+ SINALAX Sachet lbn Sina 50ml bot: 70.00 MRP
Lactitol monohydrate BP 1 Ogm/sachet: powder l OOml bot: 120.00 MRP
for solution. 200ml bot: 220.00 MRP
IO's pack: 130.00 IP + ELAX Syp. Edruc
+ TITOLAX Sachet Renata Lactulose concentrate oral solution; 1 tsf (5ml)
Lactitol monohydrate BP 1 Ogm/sachet: powder contains 3.4gm of lactulose USP: syrup.
for solution. 1 OOml bot: 100. 00 MRP
IO's pack: 120.00 MRP + EZYLAX Solo. Orion Pharma
Lactulose concentrate oral solution; 1tsf (5ml)
contains 3.35gm of lactulose: syrup.
LACTULOSE21,33
50ml bot: 50.19 MRP
l OOml bot: 100.38 MRP
LACTULOSE: Liquid
+ HEPALAC Solo. Supreme
Lactulose is a semisynthetic disaccharide which
Lactulose concentrate oral solution; ltsf (Sml)
is not absorbed from the gastrointestinal tract. It
contains 3.35gm of lactulose BP: syrup.
produces an osmotic diarrhoea of low faecal pH
I OOml bot: 120.00 MRP
and discourages the proliferation of ammonia
200ml bot: 230.00 MRP
producing organisms. It is therefore useful in the
+ INOLAC Soln. Incepta
treatment of hepatic encephalopathy.
Lactulose concentrate oral solution; ltsf (Sml)
Ind: Constipation, hepatic encephalopathy
contains 3.4gm of lactulose USP: syrup.
C/I: Galactosaemia, intestinal obstruction.
l OOml bot: 95.00 MRP
S/E: Flatulence, cramp, abdominal discomfort.
+ ISOLAC Solo. Concord
Dose: Constipation- adult, initially 15ml twice
Lactulose concentrate oral solution; 1 tsf (5ml)
daily then gradually reduced according to
contains 3.35gm of lactulose: syrup.
patient's needs; child, under 1 year 2.5ml, 1-5
lOOml bot: 120.00 MRP
years 5ml, 6-12 years lOml, all twice daily,
+ LACLOSE Solo. Opsonin
gradually reduced.
Lactulose concentrate oral solution; 1tsf (5ml)
Hepatic encephalopathy- 30-SOml 3 times
contains 3.4gm of lactulose USP: syrup.
daily, subsequently adjusted to produce 2-3
l OOml bot: 105.57 MRP
soft stools daily.
200ml bot: 202.33 MRP
+ LACTOLAX Solo. Pharmasia
Lactulose concentrate oral solution; I tsf (5ml)
contains 3.35gm of lactulose USP: syrup.
l OOml bot: 100.00 MRP
Lactulose BP Oral Solution + LACTOMOSE Solo. MonicoPharma
Lactulose concentrate oral solution; 1tsf (5ml)
(c(\) DRUG INTERNATIONAL LTD.
contains 3.4gm of lactulose USP: syrup.
.., TONGl-GAZIPUR
l OOml bot: 100.00 MRP
 GASTRO-INTESTINAL DRUGS QIMP-17 (34) ·..
.

+ LACTU Solo. Biopharma contains 3.35gm of lactulose BP: syrup. administration of food with lubiprostone may
Lactulose concentrate oral solution; 1tsf (5ml) 1OOml bot: 120.00 MRP reduce symptoms of nausea. ii. Lubiprostone
contains 3.4gm of lactulose USP: syrup. + SINALAC Soln. Ibo Sina should not be prescribed to patients that have
lOOml bot: 120.00 MRP Lactulose concentrate oral solution; 1tsf (5ml) severe diarrhea. iii. In patients with symptoms
200ml bot: 200.00 MRP contains 3.35gm of lactulose BP: syrup. suggestive of mechanical gastrointestinal obstruc­
+ LAX Solo. Medicon 60ml bot: 70.00 IP tion, confmn the absence of such an obstruction
Lactulose concentrate oral solution; I tsf (5ml) 1OOml bot: 120.00 IP prior to initiating therapy with lubiprostone.
contains 3.4gm of lactulose USP: syrup. 200ml bot: 230.00 IP Pregnancy & lactation: Pregnancy category C.
l OOml bot: 120.00 MRP 450ml bot: 425.00 IP Lubiprostone should be used in pregnant woman
+ LAXATIV Solo. Rangs Pharma + SIVOLAC Syp. Sharif if the potential benefit justifies the potential risk
Lactulose concentrate oral solution; 1tsf (5ml) Lactulose concentrate oral solution; ltsf (5ml) to the fetus. It is also not known whether
contains 3.4gm of lactulose USP: syrup. contains 3.4gm of lactulose USP: syrup lubiprostone is excreted in human milk.
l OOml bot: 100.00 MRP lOOml bot: 100.00 MRP Dosage: Chronic idiopatihic constipation:
200ml bot: 200.00 MRP + TULAC Solo. SK+F Lubiprostone 24mcg twice daily orally with
+ LAXOLAC Soln. Globe Lactulose concentrate oral solution; l tsf (5ml) food and water.
Lactulose concentrate oral solution; 1tsf (5ml) contains 3.5gm of lactulose USP: syrup. Opioid-induced constipation: Lubiprostone
contains 3.35gm of lactulose USP: syrup. 50ml bot: 65.00 MRP 24mcg twice daily orally with food and water.
l OOml bot: 115.00 MRP l OOml bot: 100.00 MRP lrritllble bowel syndrome with constipation:
+ LEA.XE Solo. Alco Pharma 200ml bot: 120.00 MRP Lubiprostone 8mcg should be taken twice
Lactulose concentrate oral solution; 1tsf (5ml) + TULOS Soln. Acme daily orally with food and water.
contains 3.35gm of lactulose USP: syrup. Lactulose concentrate oral solution; 1tsf (5ml) Geriatric use: Irritable bowel symdrome with
lOOml bot: 120.00 MRP contains 3.5gm of lactulose USP: syrup. constipation: The safety and efficacy of
200ml bot: 230.00 MRP l OOml bot: 120.00 MRP lubiprostone in the elderly (>65 years age)
+ LIVAX Solo. Pacific 200ml bot: 230.00 MRP patients remain constant in both young and
Lactulose concentrate oral solution; 1tsf (5ml) + X YLOSE Solo. Delta Pharma older patients.
contains 3.4gm of lactulose USP: syrup. Lactulose concentrate oral solution; 1tsf (5ml) Renal impairment: Lubiprostone has not been
1OOml bot: 140.00 MRP contains 3.35gm of lactulose BP: syrup. studied in patints who have renal impairment.
200ml bot: 250.00 MRP l OOml bot: 120.00 MRP Hepatic impairment: Reduce the dosage in
+ LIVOTON Syp. Kemiko + ZENILAC Soln. Zenith patients with moderate and sever hepatic
Lactulose concentrate oral solution; 1tsf (5ml) Lactulose concentrate oral solution; 1tsf (5ml) impairment.
contains 3.4gm of lactulose USP: syrup. contains 3.35gm of lactulose BP: syrup. Drug inter: There is low likelihood of drug-drug
50ml bot: 70.00 MRP I OOml bot: 120.00 MRP inteactions, because, in vitro studies using human
l OOml bot: 120.00 MRP 200ml bot: 200.00 MRP liver microsomes indicate that cytochrome P450
200ml bot: 230.00 MRP isoenzymes are not involved in the metabolism of
+ LOCTOZ Syp. Amico lubiprostone. Based on the available information,
LUBIPROSTONE138
Lactulose concentrate oral solution; 1tsf (5ml) no protein binding-mediated drug interactions of
contains 3.4gm of lactulose USP: syrup. clinical significance are anticipated.
LUBIPROSTONE: Capsule
l OOml bot: 100.00 MRP
Lubiprostone is a locally acting chloride channel + LUBILAX Cap. Beacon
+ M YLAC Syp. Mystic
activator that enhances a chloride-rich intestinal Lubiprostone INN 8mcg/capsule.
Lactulose concentrate oral solution; 1tsf (5ml)
fluid secretion without altering sodium and 8mcg x 20's pack: 300.00 MRP
contains 3.4gm of lactulose USP: syrup.
potassium concentrations in the serum. It is
l OOml bot: 75.00 MRP
useful in the treatment of chronic idiopathic,
200ml bot: 140.00 MRP
opioid-induced & ms related constipation. POLYETHYLENE GLYCOL26
+ NIPROLAC Soln. NIPRO JMI
Lubiprostone relieves symptoms within 24 hours.
Lactulose concentrate oral solution; 1 tsf (5ml)
It is available as- lubiprostone INN 8mcg/capsule POLYETHYLENE GLYCOL: Powder for
contains 3.35gm of lactulose USP: syrup.
and lubiprostone INN 24mg/capsule. solution
l OOml bot: 100.00 MRP
Mode of action: Lubiprostone acts by specifica­ Polyethylene glycol (also known as macrogol) is
+ ORALAX Syp. Somatec
lly activating CIC-2, which is a normal a synthetic polyglycol having an average
Lactulose concentrate oral solution; 1tsf (5ml)
constituent of the apical membrane of the human molecular weight of 3350. It is an osmotic agent
contains 3.4gm of lactulose USP: syrup.
intestine. By increasing intestinal fluid secretion, and acts as an osmotic laxative. It is presented as
l OOml bot: 120.00 MRP
lubiprostone increases motility in the intestine, a white powder for solution.
+ OSMOLAX Syp. Square.
thereby facilitating the passage of stool & allevi­ Mode of action: As an osmotic agent, polyethy­
Lactulose concentrate oral solution; 1tsf (5ml)
ating symptoms associated with constipa-tion. lene glycol causes water to be retained with the
contains 3 .4gm of lactulose USP: syrup.
After administration, lubiprostone and it's meta­ stool. It appears to have no effect on the active
l OOml bot: 120.00 MRP
bolites are observed only on the apical (luminal) absorption or secretion of glucose or electrolytes.
200ml bot: 230.00 MRP
portion of the gastrointestinal epithelium. Ind: For the treatment of constipation.
+ P-LAC Solo. Pharmadesh
Additionally, activation of CIC-2 by lubiprostone Polyethylence glycol is a prescription only
Lactulose concentrate oral solution; 1tsf (5ml)
recovers mucosa! barrier function via restoration laxative that has been prescribed by the physician
contains 3.35gm of lactulose BP: syrup.
of tight junction protein complexes. to treat constipation. This product should only be
1OOml bot: 93.12 MRP
Ind: Lubiprostone is indicated for the treatment used by the person for whom it is prescribed. •

+ REGULOSE Syp. General

Lactulose concentrate oral solution; 1 tsf (5ml)
contains 3.4gm of lactulose USP: syrup
l OOml bot: 120.00 MRP
+ REWAT Solo. Kumudini
Lactulose concentrate oral solution; 1tsf (5ml)
contains 3.35gm of lactulose BP: syrup.
lOOml bot: 120.00 MRP
+ SERELOSE Solo. Beximco
Lactulose concentrate oral solution; 1tsf (5ml)
of- i. chronic idiopathic constipation in adults;
ii. opioid-induced constipation in adults;
iii. irritable bowel syndrome with constipation in
women of 18 years old and over.
C/I: Patients with known or suspected
mechanical gastrointestinal obstruction.
S/E: Nausea, yomiting, loose stools, dry mouth,
stomach discomfort, headache, dizziness etc.
Precautions: i. Patients taking lubiprostone may
experience nausea. If this occurs, concomitant
Polyethylene glycol solution should be used for 2
weeks or less or as direted by the physician.
C/I: Known or suspected bowel obstruction and
known hypersensitivity to polyethylene glycol.
S/E: Nausea, abdominal bloating, cramping and
flatulence may ·occur. High doses may produce
diarrhea & excessive stool frequency, particularly
in elderly patients. Occasional allergic reaction.
Precautions: Symptoms suggestive of bowel
obstruction (nausea, vomiting, abdominal pain or

....
•
••

•

distention) should be evaluated before initiating
laxative therapy.
Pregnancy & lactation: It is not known whether
polyethylene glycol can cause fetal harm when
administered to a pregnant woman or can affect
reproductive capacity. Polyethylene glycol should
only be administered to a pregnant woman if
clearly needed.
There is no information on the use of polyethylene
glycol while nursing. Consultation with a
. physician is necessary in case of breast-feeding.
Dosage & admin: The usual dose of
polyethylene glycol is 17gm of powder per day
(or as directed by the physician) in a glass of
water, juice, coke, coffee or tea (approx.
240ml). Each bottle of polyethylene glycol is
supplied with a cup that is used t9 measure
17gm or 8.5gm of laxative powder when filled
upto the marked line.
Polyethylene glycol achieves its best results
when used between 1 and 2 weeks. It may be
discontinued after several satisfactory bowel
movements.
Drug inter: No specific drug interaction.
+ AQUALAX Solo. Incepta
Each bottle contains 85gm of polyethylene
glycol: powder for solution.
85gm bot: 120.00 MRP
MILK OF MAGNESIA
MILK OF MAGNESIA: Suspension
Magnesium hydroxide, an antacid laxative.
Preparations: Discussed with antacid group of
drugs.
Bowel cleansing prepns.21
These include: Polyethylene glycol (macrogol),
magnesium citrate, phosphates (oral), sodium
picosulfate with magnesium citrate.
Peripheral opioid-receptor
antllgonists21
•
The only peripherally acting opioid-receptor
antagonist drug licensed for the treatment of
opioid-induced constipation (when response to
other laxatives is inadequate) is:
Methylnaltrexone bromide.
Preparation: Not yet available in our country.
5HT4-receptor agonists21
•
The only 5HT4-receptor agonist drug licensed
for the treatment of chronic constipation in
women (when other laxatives failed) is:
Pruca/opride.
Preparation: This drug in not recommended for
use in the west, because, weaknesses in the
clinical data prevent an assessment of its efficacy
in the target population.
Combined preparadons
I
·, .
QIMP-17 (35)
'
MAGNESIUM HYDROXIDE+
LIQUID PARAFFIN26
MAGNESIUM HYDROXIDE +LIQUID
PARAFFIN: Oral emulsion
This is a combined preparation of magnesium
hydroxide & liquid paraffin, available as oral
emulsion. Each 5ml contains magnesium
hydroxide BP 300mg & liquid paraffin BP l .25ml.
It is recommended for the temporary relief of
constipation.
Mode of action: This preparation has a dual­
relief formulation containing a gentle laxative
ingredient and a lubricant which eases the
discomfort associated with straining and bowel
movement.
Ind: Constipation; hyperacidity with
constipation, anorectal disorder, post-operative
constipation; constipation associated with chronic
cholecystitis; hernia.
C/I: Acute GI conditions like abdominal pain.
S/E: Rectal irritation, potassium loss (thirst,
weakness,nausea and diarrhea).
Precautions: Renal and hepatic impairment.
Maintain adequate fluid intake.
Pregnancy & lactation: Can be given to
pregnant and lactating mother.
Dosage & admin: Adults: 15-30ml before
breakfast or at bedtime.
Children: Over 7 .years, 7.5ml-15ml at
bedtime; 3-7 years, 5;1Oml at bedtime.
The dose may be mixed with milk or half a
glass of water if desired.
Note: Don't take for more than I week unless
under doctor's supervision.
Drug inter: Cimetidine, diuretics, famotidine
and ranitidine may cause irritation of stomach or
bowel.
+ MAGFIN Oral Emulsion Incepta
Each 5ml contains magnesium hydroxide BP
300mg & liquid paraffin BP l .25ml: Oral emulsion
100m1 bot: 95.00 MRP
·
SODIUM DIHYDROGEN
YROSPRATE + DISODIUM
. HYDROGEN PHOSPHATE
DODECAHYDRATE129
SODIUM DIHYDROGEN PHOSPHATE +
DISODIUM HYDROGEN PHOSPHATE
DODECAHYDRATE: Oral Solution
This is an aqueous oral solution of combined
preparation, each 5ml of which contains sodium
dihydrogen phosphate dihydrate BP 2.7l lgm and
disodium hydrogen phosphate dodecahydrate BP
l .2gm.
Ind: This combined oral preparation is used as a
laxative to relief occasional constipation, and as a
bowel cleanser to prepare the patient for surgery
or for preparing the colon for x-ray or endoscopic
ex amination.
C/I: CHF, renal failure or clinically significant
impaired renal function, congenital or acquired
megacolon, bowel/gastrointestinal obstructions,
ascites, perforation of ileus, active inflammatory
bowel disease.
S/E: Gastrointestinal side effects of the tablet
form of sodium biphosphate and sodium
GASTRO-INTESTINAL DRUGS
phosphate have included bloating (31% to 41%)
nausea (26% to 30%), abdominal pain (23% to
25%) and vomiting (4% to 9%). Nervous system
side effects have included dizziness, headache,
and seizures. Renal side effects have included
renal impairment, increased blood urea nitrogen
(BUN), increased creatinine, acute renal failure,
acute phosphate nephropatlzy, nephrocalcinosis,
and renal tubular necrosis. Hypersensitivity
reactions reported have included anaphylaxis,
rash, pruritus, urticaria, throat tightness,
bronchospasm, cyspnea.
Precautions: This combined oral solution should
be used with extreme caution in the elderly, the
frail or debilitated patients with colostomy and
patients on a low salt diet, as they are particularly
at risk. These patients should receive additional
•
fluids by mouth, both prior to, and after adminis­
tration of this oral solution, to ensure that dehy­
dration does not occur. Patients undergoing major
bowel procedures, who are on nil by mouth for·
significant period of time, should have their
electrolytes monitored and receive intravenous
fluids containing potassium and calci11m, prior to
surgery. Use with caution in patients taking
diuretics and in patients using medicines known
to prolong the QT interval. Concurrent adminis­
tration of polyethylene glycol bowel cleansing
preparations and this oral preparation may be
dangerous and is not recommended. Patients
should be advised not to use this combined
solution when nausea, vomiting or abdominal
pain are present, unless directed by a physician.
Use in diabetics: As the liquid diet during the
period of administration and prior to bowel
surgery, x-ray of the colon or colonoscopy may
affect the diabetic patients glucose blood levels,
adjustment of their insulin or oral anti-diabetic
medication may be necessary.
Pregnancy & lactation: Because of potential
harm to the fetus from phosphate absorbed across
the placenta, the use of this product is not recom­
mended in pregnant women unless the probable
clinical benefit outweighs the possible risk.
Bacause of potential harm to the infant from
milk, the use of this
phosphate excreted in breast
product is not recommended in nursing mothers
unless the probable clinical benefit outweighs the
possible risk. .
Dosage & admin: Adults & children 12 years
of age & over: The recommended dosage is
45ml and repeated 10 to 12 hours later. The
intake of clear liquid is an essential part of this
regimen. On the day before the procedure, the
patients should only take clear liquids for
breakfast, lunch and dinner and between
doses. No solid food, milk or milk products
should be taken on the day before the proce­
dure. The patient should not drink anything
colored red or purple. Medical procedure is
intended to be performed at early morning,
mid-morning or later, by two alternative
dosage regimens.
Early morning procedure: The first dose is
taken at 7 a.m on the morning before the
procedure. The second dose is taken at 7 p.m
on the evening before the procedure.
Mid-morning (or later) procedure: The first
dose is taken at 7 p.m on the evening before
the procedure. The second dose is taken at

GASTRO-INTESTINAL DRUGS
7 a.m (or at least 3 hours before leaving for the
appointment) or the morning before the
procedure.
First dose: Mix 15ml (one third of the bottle)
of the solution into a full glass (approximately
250ml) of clear liquids and drink. Repeat two
more times within the next 20 minutes.
Between doses: Between the first and second
doses, the patient should drink at least three
more glasses (approximately 250ml each) of
clear liquids or more if desired to prevent
dehydration and to ensure that the bowel
remains easily examinable for the procedure.
Second dose: Mix 15ml of the solution in a full
glass of clear liquids or drinks. Repeat two
more times within the next 20 minutes.
(List of clear liquids: water, tea, or coffee (no
milk or non-dairy creameer), sweeteners are
acceptable, carbonated or non carbonated soft
drinks (not colored red or purple) fruit
flavored cordials (not colored red or purple)
and strained fruit juices without pulp; do not
drink any alcoholic beverage).
Children under 12 years of age: This combined
preparation is not recommended for the
children under 12 years of age.
Drug inter: Use with caution in patients taking
·calcium chanel blockers, diuretics, angiotensin
converting enzyme inhibitors (ACE-is) angioten­
sin receptor blockers (ARB s), non-steroidal anti­
inflammatory drugs (NSAIDs), and lithium
preparations or other medication that might affect
electrolyte levels, as hyperphosphatemia,
hypocalcemia, hypernatremic dehydration and
acidosis may occur. Concurrent administration of
polyethylene glycol bowel cleansing preparations
and this combined preparation may be dangerous
and is not recommended.
Note: For further information, please see the
manufacturer's literature.
t PHOSPHOPREP Solo. UniMed &
UniHealth
Sodium dihydrogen phosphate dihydrate BP
2.71 l gm and disodium hydrogen phosphate
dodecahydrate BP l .2gm/5ml: oral solution.
45ml bot: 230.00 MRP
Abdominal Gas Adsorbents
ULTRACARBON21,33
ULTRACARBON: Tablet
Activated charcoal tablets; available as
250mg/tablet.
Ind: Infections gastro-intestinal disturbances,
gastritis, gastro-enteritis, dysentery, intestinal gas
generation, food & other inorganic poisonings.
Dose: 1-2 tablets to be taken several times
daily, disintegrated in water stirred before
drinking. In severe cases, a large number of
tablets should be taken (4-6-8 or more at
once).
Preparation: May be available in the market.
8. PREPARATIONS FOR
APHTHOUS ULCER
·
..
QIMP-17 (36)
AMLEXANOX42
AMLEXANOX: Oral paste
Amlexanox oral paste is available as amlexanox
INN 50mg/gm (i.e 5% w/w); 5gm paste in tube.
Mode of action: The mechanism of action by
which amlexanox accelerates healing of aphthous
ulcers is unknown. In vitro studies have demon­
strated amlexanox to be a potent inhibitor of the
formation and release of inflammatory mediators
(histamine and leukotrienes) from mast cells,
neutrophils and mononuclear cells. Given orally
to animals, amlexanox has demonstrated anti­
allergic and anti-inflammatory activities and has
been shown to suppress both immediate and
delayed type hypersensitivity reactions. The
relevance of these activities of amlexanox to its
effects on aphthous ulcers has not been
established. After a single oral application of
lOOmg of paste (5mg amlexanox), maximal
serum levels are observed at 2.4 hours.
Ind: For the treatment of aphthous ulcers.
C/I: Amlexanox oral paste is contraindicated in
patients with known hypersensitivity to
amlexanox or other ingredients in the formulation.
A/E: Adverse reactions reported by 1-2% of
patients were transient pain, stinging and/or
burning at the site of application. Infrequent
(<1%) adverse reactions in the clinical studies
were contact mucositis, nausea, and diarrhea.
Precautions: In the event that a rash or contact
mucositis occurs, discontinue use.
Pregnancy & lactation: Teratology studies were
performed with animals at doses up to two hun­
dred and six hundred times, respectively, the pro­
jected human daily dose. No adverse fetal effects
were observed. There are no adequate and well­
controlled studies in pregnant women. Because
animal reproduction studies are not always
predictive of human response, this drug should
be used during pregnancy only if clearly needed.
Amlexanox was found in the milk· of lactating
rats; therefore, caution should be exercised when
administering amlexanox oral paste to a nursing
woman.
Dosage & admin:
1. Apply the paste as soon as possible after
noticing the symptoms of an aphthous
ulcer. Continue to use the paste four times
daily, preferably following oral hygiene
after breakfast, lunch, dinner, & at
bedtime.
2. Dry the ulcer(s) by gently patting it with a
soft, clean cloth.
3. Wash hands before applying.
4. Moisten the tip of the index finger.
5. Squeeze a dab of paste approximately 1/4
inch (O.Scm) on to a finger tip.
6. Gently dab the paste on to the ulcer. Repeat
the process if more than one ulcer are
present.
7. Wash hands after application.
8. Wash eyes promptly if they would come in
contact with the paste.
9. Use the paste until the ulcer heals. If signifi­
cant healing or pain relief has not occurred
in 10 days� try to fmd the other causes.
Pediatric use: Safety and effectiveness of
amlexanox oral paste in pediatric patients
have not been established.
+ AMLEX Oral Paste ACI
Amlexanox INN 50mg/gm (i.e 5% w/w); 5gm
paste in tube.
5gm tube: 75.00 MRP
+ APSOL Oral Paste Square
Amlexanox INN 50mg/gm (i.e 5% w/w); 5gm
paste in tube.
5gm tube: 75.28 MRP
t SOREX Oral Paste SK+F
Amlexanox INN 50mg/gm (i.e 5% w/w); 5gm
paste in tube.
5gm tube: 75.00 MRP
9. L OCAL PREPARATIONS
FOR ANAL & RECTAL
DISORDERS
9.1 Phlebotonic & vascular protecting prepns.
9.2 Soothing haemorrhoidal prepns.
9.3 Compound haemorrhoidal preparations
with corticosteroids
9.4 Rectal sclerosants.
Phlebotonic & Vascular
protecting prepns.
DIOSMIN + HESPERIDIN42,53
DIOS MIN + HESPERIDIN: Tablet
This combined preparation contains diosmin in
micronised form and hesperidin. This has been
prepared for treating venous circulation disorders
(swollen legs, pain, restless legs) and for treating
symptoms due to acute hemorrhoidal attack. This
preparation is available as tablet containing
500mg- micronized purified flavonoid fraction
corresponding to- diosmin 90% (450mg) &
flavonoids expressed as hesperidin 10% (50mg):
Film-coated tablet.
Mode of action: Diosmin and hesperidin
combination acts as a phlebotonic drug and
vascular protecting agent. It reinforces venous
tone by prolonging the activity of parietal
noradrenaline. It thus decreases venous
capacitance, venous distensibility, and venous
emptying time. It protects the microcirculation by
fighting the microcirculation damaging process.
It combats venous inflammation by decreasing
leukocyte activation, and as a consequence by
inhibiting the release of inflammatory mediators,
principally free redicals and prostaglandin. Thus,
this combined preparation normalizes capillary
permeability and strengthens capillary resistance.
This also acts on the lymphatic system, and
improves lymphatic drainage by increasing
lymph flow and lymph oncotic pressure.
Ind: Acute hemorrhoidal attacks, chronic
hemorrhoidal disease; organic and functional
chronic venous insufficiency (venous circulation
disorders) of the lower limbs with the following
symptoms: swollen or heavy legs, pain, restless
legs; nocturnal cramps.
C/I: Proper data is not available.
S/E: Some cases of routine gastric disorders and
neurovegetative disorders (feeling of discomfort)
have been reported. In these cases discontinu-

ation of treatment is not required.
Precautions: Acute haemorrhoidal attack: If the
haemorrhoid symptoms do not disappear within
15 days, consult your doctor for advice.
Venous circulation disorders: The most effective
I '
-
way of giving this treatment is in combination
with a healthy lifestyle. Avoid exposure to the
sun, heat, excessive standing & being overweight.
Walking and wearing special support stockings
stimulate blood circulation. If there is any doubt,
ask the physician for advice.
Pregnancy & lactation: Experimental studies in
animal have not demonstrated any teratogenic
effect and no harmful effects have been reported
in women to date. Breast feeding is not
recommended during treatment.
Dosage & admin: Each fdm-coated tablet
contains micronised diosmin INN 450mg and
hesperidin INN 50mg.
Acute hemorrhoidal attacks: 3 tablets twice
daily for the first 4 days, then 2 tablets twice
daily for 3 days and if required 1 tablet twice
daily as maintenance dosage.
Chronic hemorrhoids: 1 tablet twice daily.
Chronic venous insufficiency: 1 tablet twice
daily initially for 7 days; duration may be
increased depending on severity. Tablet should
be taken at meal times.
Drug inter: Proper data is not available.
+ AVONOID Tab. UniMed & UniHealth
Micronised diosmin INN 450mg & hesperidin
INN 50mg/tablet (f.c)
30's pack: 240.00 MRP
+ DAFLON Tab. Servier
Micronised diosmin INN 450mg & hesperidin
INN 50mg/tablet (f.c)
30's pack: 364.50 MRP
+ DIOHES Tab. Opsonin
Micronised diosmin INN 450mg & hesperidin
INN 50mg/tablet (f.c)
30's pack: 211.92 MRP
+ DIORIN Tab. Incepta
Micronised diosmin INN 450mg & hesperidin
INN 50mg/tablet (f.c)
30's pack: 240.00 MRP
+ HEMONOR Tab. Apex
Micronised diosmin INN 450mg & hesperidin
INN 50mg/tablet (f.c)
30's pack: 240.00 MRP
+ HEMORAL Tab. Aristopharma
Micronised diosmin INN 450mg & hesperidin
INN 50mg/tablet (f.c)
30's pack: 240.00 MRP
+ HEMORIF Tab. Square
Micronised diosmin INN 450mg & hesperidin
INN 50mg/tablet (f.c)
30's pack: 241.20 MRP
+ NORMANAL Tab. Renata
Micronised diosmin INN 450mg & hesperidin
INN 50mg/tablet (f.c)
30's pack: 240.90 MRP
+ PILESTOP Tab. Acme
Micronised diosmin INN 450mg & hesperidin
INN 50mg/tablet (f.c)
20's pack: 140.20 MRP
+ SANGRIL Tab. Healthcare
Micronised diosmin 450mg & hesperidin
50mg/tablet (f.c)
30's pack: 255.00 MRP
QIMP-17 (37)
Compound steroidal prepns.
BETAMETHASONE + PHENYLE­
PHRINE + LIGNOCAINE 21,47,126
BETAMETHASONE + PHENYLEPHRINE
LIGNOCAINE: Rectal ointment.
This is a compound steroidal preparation
available for ano-rectal use.
Comp: Betamethasone valerate 0.05% w/w,
phenylephrine 0.1 % .w/w & lignocaine
hydrochloride 2.5% w/w: rectal ointment.
Ind: Local anorectal conditions like hemorrhoids
and fissures where, there is inflammation & pain.
C/I: Topical corticosteroids are contraindicated
in: i. Primarily infected skin lesions caused by
viral infections e.g herpes simplex, vaccinia or
varicella (chicken pox}, by bacteria e.g impetigo,
by fungal infections e.g candidiasis, tineasis or
by tuberculous infection of the anal region;
ii. Sensitivity to any components of the product;
iii. Dermatoses in children under 1 year of age.
S/E: As with all topical corticosteroids, its use
for prolonged periods, may cause systemic
absorption, specially in children. Prolonged and
intensive treatment with active corticosteroid
preparations may also cause local atrophic
changes in the skin. There are reports of
pigmentation changes and hypertrichosis with
topical steroids, and in this situation it should be
discontinued.
Some patients may experience burning upon
application, specially if.the mucous membrane is
not intact.
Precautions: Long-term continuous treatment
should be avoided. Discontinue if sensitization .
occurs.
Pregnancy & lactation: The safe use of topical
corticosteroids in human pregnancy has not been
fully established. Topical administration of
corticosteroids to pregnant animals can cause
abnormalities of fetal development including
cleft palate and intrauterine growth retardation.
Therefore, there may be a very small risk of such
effects in the human fetus. So, it should not be
used unnecessarily in large amounts or for
prolonged period.
Use & application: Apply locally 2 or 3 times
daily initially, using the applicator if internal
administration is required. When inflamma­
tion is subsiding once-daily application is
sufficient in most cases.
Drug inter: Not known.
+ METHOVATE Rectal Oint. Gaco
Betamethasone valerate 0.05% w/w, phenyle­
phrine 0.1% w/w & lignocaine hydrochloride
2.5% w/w: rectal ointment.
15gm tube: 30.00 MRP
+ RELITCH Rectal Oint. Drug Inter.
Betamethasone valerate 0.05% w/w, phenyle­
phrine 0.1% w/w & lignocaine hydrochloride
2.5% w/w: rectal ointment.
15gm tube: 30.00 MRP
.
HYDROCORTISONE + AESCULIN +
CINCHOCAINE + FRAMYCETIN/
NEOMYCIN 2 I ,42,46,48
GASTRO-INTESTINAL DRUGS
HYDROCORTISONE + AESCULIN +
CINCHOCAINE + FRAMYCET IN/
NEOMYCIN: Rectal ointment/Suppository
.
This is a compound steroidal preparation of four
components, viz: hydrocortisone, aesculin,
cinchocaine hydrochloride and framycetin or
neomycin sulphate, available for ano-rectal use.
+ Comp: See below under individual product.
Ind: Ointment: Haemorrhoids (internal & exter­
nal), prophylaxis between two attacks to prevent
recurrence and complications, anal fissure,
pruritus, and inflammatory anal conditions.
Suppository: _Short term relief of pain & inflam­
mation of hemorrhoids; post-partum hemorrho­
ids; anal fissures and proctitis; post-hemorrhoide­
ctomy application to relieve pain & discomfort.
C/I; S/E; Precautions: See above under the text
of 'betamethasone compound preparations'.
Pregnancy & lactation: See above under the
text of 'betamethasone compound preparations'.
Use & application: Ointment: Adult & child­
application of ointment on the painful or
pruritic area by using finger, at morning and
night and after defaecation.
Suppository: Use 1 ·suppository in the morn­
ing and one in the evening & after each stool.
Drug inter: Not known.
+ ANOREL Oint. Popular
Aesculin 1 %, cinchocaine HCI 0.5%,
hydrocortisone 0.5%, framycetin sulphate 1% in
•
an ointment preparation.
15gm tube: 80.30 MRP
+ ANUSTAT Oint. Beximco
Aesculin 1 %, cinchocaine HCI 0.5%, hydrocorti­
sone 0.5%, neomycin sulphate 1% in an ointment
preparation.
15gm tube: 70.00 IP
+ ARIPROCT Suppo. Aristopharma
Each suppository contains hydrocortisone BP
5mg, aesculin INN 1Omg, cinchocaine
hydrochloride BP 5mg, framycetin sulphate 1Omg.
1O's pack: 80.00 MRP
+ CINOPLUS Suppo. Acme
Each suppository contains hydrocortisone BP
5mg, aesculin INN 1Omg, cinchocaine
hydrochloride BP 5mg, framycetin sulphate 1Omg.
lO's pack: 52.50 MRP
+ ERIAN Oint. Square
Aesculin 1 %, cinchocaine HCI 0.5%,
hydrocortisone 0.5%, framycetin sulphate 1 % in
an ointment preparation.
15gm tube: 68.00 MRP
+ ERIAN Suppo. Square
Each suppository contains hydrocortisone BP
5mg, aesculin INN 1Omg, cinchocaine
hydrochloride BP 5mg, framycetin sulphate 1Omg.
lO's pack: 80.00 MRP
10. DRUGS AFFECTING
EXOCRINE & INTESTI­
NAL SECRETIONS
10.1 Drugs affecting exocrine secretion:
treatment of dry mouth
10.2 Digestive enzyme: Pancreatin
10.3 Bile acid sequestrants
10.4 Aprotinin
10.5 Antigallstones drugs: bile acids

•
Drugs affecting Exocrine
secretion : Treatment of dry
mouth
PILOCARPINE36
PILOCARPINE: Tablet
Pilocarpine, a cholinergic agonist drug, can be
used as an exocrine stimulant in the treatment of
dry mouth. It is available as- pilocarpine
hydrochloride BP 5mg in tablet.
Mode of action: Pilocarpine exerts a broad
spectrum of pharmacologic effects with
predominant muscarinic action. Pilocarpine, in
appropriate dosage, can increase secretion b)· the
exocrine glands such as sweat, salivary, lacrimal,
gastric, pancreatic, and intestinal glands and the
mucous cells of the respiratory tract. The tone
and motility of urinary tract, gallbladder and
biliary duct, smooth muscle may be enhanced.
Ind: Pilocarpine hydrochloride oral preparation
(tablet) is indicated for-
i. the treatment of symptoms of dry mouth
from salivary gland dysfunction caused by
radiotherapy for cancer of the head & neck;
ii. the treatment of symptoms of dry mouth in
patients with Sjogren's syndrome.
C/I: Pilocarpine is contraindicated in patients
with uncontrolled asthma, cardiovascular disease,
known hypersensitivity to pilocarpine and when
miosis is undesirable, e.g in acute iritis and in
narrow-angle (angle closure) glaucoma.
S/E: Headache, visual disturbance, lacrimatio11,
sweating, respiratory distress, gastrointestinal
spasm, nausea, vomiting, diarrhea, atrioventricu­
lar block, tachycardia, bradycardia, hypotension,
hypertension, shock, mental confusion, cardiac
arrhythmia, tremors etc may occur. Most of the
adverse experiences observed during pilocarpine
treatment were consequences of exaggerated
parasympathetic stimulation. These adverse expe­
riences were dose-dependent and usually mild &
self-limited. However, severe adverse experien­
ces might occasionally occur and therefore
careful monitoring of the patient is recommended.
Precautions: Pilocarpine should be administered
with caution to patients with known or suspected
cholelithiasis or biliary tract disease. If a patient
sweats excessively while taking pilocarpine
hydrochloride and can not drink enough liquid,
the patient should consult a physician.
Pregnancy & lactation: Pregnancy category C.
There are no adequate and well-controlled
studies in pregnant women. Pilocarpine should be
used during pregnancy only if the patient's
benefits justify the potential risk to the fetus.
It is also not known whether the drug is excreted
in human milk. However, decision should be
made whether to discontinue nursing or to
discontinue the drug, taking into account the
importance of the drug to the mother.
Dosage & admin: Head & neck cancer patients:
The recommended initial dose of pilocarpine
QIMP-17 (38)
·'
·,
hydrochloride is 5mg, three times a day.
Dosage should be titrated according to Antigallstones Drugs: Bile
therapeutic response and tolerance. The
acids
maximum daily dose is 30mg daily (not to
exceed 1Omg per dose). T herapy should be
discontinued if no improve-ment is noted after URS ODEOXYCHOLIC ACJD34
2-3 months of therapy.
--
Sjogren 's syndrome: T he recommended dose is
URSODEOXYCHOLIC ACID:
5mg, four times a day. Expected result was
Tablet/Suspension
achieved by 6 weeks of use.
Ursodeoxycholic acid is a bile acid & is available
Pilocarpine tablet should be taken with a glass
as ursodeoxycholic acid BP l 50mg & 300mg
of water during or directly after meals. The
oral tablet & suspension.
last tablet should always be taken in
Ind: Dissolution of cholesterol gallstones;
conj unction with evening meal. T he starting
primary biliary cirrhosis; primary sclerosing
dose in patients with moderate hepatic
cholangitis; morbid obesity.
impairment should be 5mg twice daily
C/I: Non-functioning gallbladder. Calcified and
regardless of the indication, followed by
pigment gallstones. Pregnancy and women may
adjustment based on therapeutic response and
become pregnant. Inflammatory bowel disease.
tolerability. Patients with mild hepatic
S/E: Nausea, vomiting, diarrhea, gallstone
insufficiency do not require dosage reductions.
calcification, pruritus.
Children: Safety and effectiveness in pediatric Precaution: Pregnancy & lactation: The drug is
patients have not been established.
best avoided during pregnancy and lactation as
Drug inter: Pilocarpine should be administered
r10 information of its safety is available.
with caution to patients taking beta adrenergic
Dosage & admin: Dissolution of gallstones: 8-
antagonists because of the possibility of
12mg/kg daily as a single dose at bedtime or in
conduction disturbances. Pilocarpine might
two divided doses for up to 2 years; treatment
antagonize the anticholinergic effects of drugs
is continued for 3-4 months after stones
used concomitantly.
dissolved.
t PILOGEN Tab. Aristopharma Primary biliary cirrhosis: 10-15mg/kg daily in
Pilocarpine hydrochloride BP 5mg/tablet. 2-4 divided doses.
5mg x 30's pack: 300.00 MRP Drug inter: Ursodeoxycholic acid combined
with a mixture of monoterpenes or a low
cholesterol diet may enhance gallstone
Digestive Enzyme dissolution. Any drug that binds with bile acids
in vitro (for example cholestyramine, charcoal,
colestipol and antacids) may interfere with the
PANCREATIN21•33 absorption of ursodeoxycholic acid.
t LICONOR Tab. Opsonin
PANCREATIN: Tablet/Capsule
Ursodeoxycholic acid BP l 50mg & 300mg/tablet
Oral pancreatin preparation is used to compen­
150mg x 30's pack: 291.35 MRP
sate for reduced or absent pancreatin secretion in
300mg x 1O's pack: 176.65 MRP
cystic fibrosis, and following pancreatectomy,
+ LICONOR Susp. Opsonin
total gastrectomy or chronic pancreatitis.
Ursodeoxycholic acid BP 250mg/5ml: suspension
Ind: Digestive disorder due to enzyme
50ml bot: 158.94 MRP
deficiency as in children with cystic fibrosis; in '-
+ OXYCOL Tab. UniMed & UniHealth
adults following pancreatectomy , total
Ursodeoxycholic acid BP l 50mg & 300mg/tablet
gastrectomy, or chronic pancreatitis, dyspepsia.
150mg x 20's pack: 400.00 MRP
S/E: It may irritate the skin surrounding the
300mg x 20's pack: 720.00 MRP
mouth and anus.
+ UDIHEP Tab. Mundipharma
Dosage & admin: Adult: 2 gm of pancreatin
Ursodeoxycholic acid BP 150mg/tablet
BP daily in divided doses according to the
l 50mg x 30's pack: 380.00 MRP
patients need.
+ UDIHEP Forte Tab. Mundipharma
Children: Upto 1 year, 500-750mg with each
Ursodeoxycholic acid BP 300mg/tablet
meal; 1-12 years 0.75- lgm with (or just
300mg x 50's pack: 1175.00 MRP
before) meals.
(As pancreatin is inactivated by gastric acid + ULIV Tab. Acme
Ursodeoxycholic acid BP l 50mg & 300mg/tablet
there/ore pancratin preparations are best taken
l 50mg x 20's pack: 241.00 MRP
with food or immediately before or after food).
300mg x lO's pack: 200.70 MRP
t A-ZYME Tab. Acme
•
t URSOCOL Tab. Sun Pharma
Pancreatin 325mg/tablet (e.c)
Ursodeoxycholic acid BP l 50mg & 300mg/tablet
1 OO's pack: 250.00 MRP
l 50mg x 50's pack: 552.50 MRP
t CREZYME Tab. Opsonin
300mg x 30's pack: 603.00 MRP
Pancreatin 325mg/tablet (e.c)
l OO's pack: 219.92 MRP + URSODIL Tab. General
t SUZYME Tab. Square Ursodeoxycholic acid BP 300mg/tablet
Pancreatin 325mg/tablet (e.c) I O's pack: 200.70 MRP
1 OO's pack: 250.00 MRP t URSOLIC Tab. Drug Inter.
+ ZYMET Tab. Beximco Ursodeoxycholic acid BP l 50mg & 300mg/tablet
Pancreatin 325mg/tablet (e.c) 150mg x 20's pack: 220.00 MRP
I OO's pack: 300.00 IP 300mg x lO's pack: 200.00 MRP

DRUGS USED IN THE
DISEASES OF THE CAR­
DIOVASCULAR SYSTEM
The drugs used in the diseases of the
cardiovascular system are classified in the
following broad groups:
1. Anti-arrhythmic drugs
2. Positive inotropic drugs: Cardiac glycosides
3. Anti-hypertensive drugs
4. Drugs used in angina & ischaemic heart
diseases
5. Peripheral & cerebral vasodilator drugs
6. Sympathomimetics
7. Anticoagulants & Protamine
8. Antiplatelet drugs
9. Fibrinolytic drugs
•
10. Antifibrinolytic & haemostatic drugs
11. Antihaemophilic factor (Factor VIII)
12. Lipid-lowering drugs
13. Local sclerosants
1. ANTI-ARRHYTHMIC
DRUGS
1.1 Drugs for supraventricular arrhythmias
viz. Adenosine, Cardiac glycosides,
Verapamil
1.2 Drugs for supraventricular and
ventricular arrhythmias viz. Amiodarone,
Beta-blockers, Disopyramide, Flecainide,
Procainamide, Propafenone & Quinidine
·
1.3 Drugs for ventricular arrhythmias viz.
Bretylium, Lignocaine, Mexiletine,
Moracizine, Phenytoin & Tocainide
ADENOSINE133
ADENOSINE: Injection
Adenosine BP 6mg/2ml ampoule: i.v injection
Mode of action: Adenosine slows conduction
time through the A- V node, can interrupt the
.
.
reentry pathways through the A- V node, and can
restore normal sinus rhythm in patients with
paroxysmal supraventricular tachycardia.
Ind: Intravenous adenosine is indicated for the
following:
Conversion of paroxysmal supraventricular
tachycardia (PSVT) to sinus rhythm, including
that associated with accessory bypass tracts
(Wolff-Parkinson-White syndrome).
C/I: Adenosine is contraindicated in: 1. Second
or third degree A-V block (except in patients
with a functioning artificial pacemaker). 2. Sinus
node disease, such as sick sinus syndrome or
symptomatic bradycardia (except in patients with
a functioning artificial pacemaker). 3. Known
•
.
..
..
hypersensitivity to adenosine.
S/E: The following reactions were reported with
intravenous adenosine use: Cardiovascular:
Facial flushing, headache, sweating, palpitations,
chest pain, hypertention. Respiratory: Shortness
of breath/ dyspnea, chest pressure, hyperventila­
tion, and head pressure. Central nervous system:
Lightheadedness, dizziness, tingling in arms,
numbness, apprehension, blurred vision, burning
sensation, heaviness in arms, neck & back pain.
Gastrointestinal: Nausea, metallic taste, tightness
in throat, pressure in groin.
In post-market clinical experience with adenosine
use, following reactions have been reported:
Prolonged asystole, ventricular tachycardia,
ventricular fibrillation, transient increase in blood
pressure, bradycardia, hypotension, atrial
fibrillation and bronchospasm.
Precaution: Pregnancy & lactation: Since it is
not known whether adenosine can cause fetal
harm when administered to pregnant women,
adenosine should be used during pregnancy only
if clearly needed.
Dosage & admin: Adult: Initial dose, 6mg
given as rapid i.v bolus (administered over 1-2
seconds period). Repeat dose: If the first dose
does not result in elimination of the supraven­
tricular tachycardia within 1-2 minutes, 12mg
should be given as rapid intravenous bolus;
this 12mg dose may be repeated for second
time if required.
Pediatric patients: The dosages used in
neonates, infants, children & adolescents were
equivalent to those administered to adults on a
weight basis.
Pediatric patients with a body weight <50kg:
Initial dose, 0.05 to O.lmg/kg as a rapid i.v
bolus given either centrally or peripherally. A
saline flush should follow.
Repeat dose: If conversion of PSVT does not
occur within 1-2 minutes, additional bolus
injections of adenosine can be administered at
incrementally higher doses, increasing the
amount given by 0.05 to O.lmg/kg. A saline
flush should follow. This process should
continue until sinus rhythm is established or a
maximum single dose of 0.3mg/kg is used.
Pediatric patients with a body weight >50kg:
The adult dose is recommended. Doses greater
than 12mg are not recommended for adult &
pediatric patients.
Drug inter: Intravenous adenosine injection has
been effectively administered in the presence of
other cardioactive drugs, such as quinidine, beta­
adrenergic blocking agents, calcium channel
blocking agents and angiotensin converting
enzyme inhibitors without any change in the
adverse reaction profile. Digoxin and verapamil
use may be rarely associated with ventricular fib­
rillation when combined with adenosine. Because
.
of the potential for additive or synergistic depres-
sant effects on the SA and AV nodes, however,
adenosine should be used with caution in the
presence of these agents. The use of adenosine in
patients receiving digitalis may be rarely associa­
ted with ventricular fibrillation. The effects of
adenosine are antagonized by methylxanthines,
such as caffeine and theophylline.
Storage: Store in a cool dry place protected from
light. Do not refrigerate as crystallization may
occur. If crystallization has occurred, dissolve
crystals by warming to room temperature. The
solution must be clear at the time of use.
+ ADECARD lnj. Popular
Adenosine BP 6mg/2ml ampoule: i. v injection
6mg (2ml) amp x S's pack: 750.00 MRP
AMIODARONE48
AMIODARONE: Tablet
Amiodaro11e is an antiarrhythmic drug, used to
correct abnormal rhythms of the heart.
Mode of action: Amiodarone is considered as a
'broad spectrum' antiarrh)rthmic drug. Its
important electrical effects are-
i. a delay in the rate at which the heart's electrical
system 'recharges' after the heart contracts
(repolarization); ii. a prolongation in the
electrical phase during which the heart's muscle
cells are electrically stimulated (action potential);
iii. a slowing of the speed of electrical
conduction (how fast each individual impulse is
conducted through the heart's electrical system);
iv. a reduction in the rapidity of firing of the
normal generator of electrical impulses in the
heart (the heart's pacemaker); v. a slowing of
conduction through various specialized electrical
pathways (called accessory pathways) which can
be responsible for arrhythmias. In addition to
being an antiarrhythmic medication, amiodarone
also causes blood vessels to dilate (enlarge), as a
result, there is a drop in blood pressure. Because
of this effect, it also may be of benefit in patients
with congestive heart failure.
Ind: Amiodarone is used for many serious
arrhythmias of the heart including ventricular
fibrillation, ventricular tachycardia, atrial
fibrillation, and atrial flutter.
S/E: The most severe side effects of amiodarone
therapy are related to the lungs. These effects can
be fatal. Patients should report any symptoms of
cough, fever, or painful breathing. Although quite
rare, fatal liver toxicity may occur with amioda­
rone therapy. Reversible corneal microdeposits
(sometimes with night glare), rarely impaired
vision due to optic neuritis; peripheral neuropa­
thy and myopathy (usually reversible on withdra­
wal); bradycardia and conduction disturbances;
phototoxicity and rarely persistent skin discolora­
tion; hypothyroidism, hyperthyroidism; raised
serum trasaminases (may require dose reduction
or withdrawal if accompanied by acute liver
disorders); jaundice, hepatitis and cirrhosis
reported; rarely nausea, vomiting, metallic taste,
tremor, sweating, vertigo, headache, sleepless-
CARDIOVASCULAR DRUGS
ness, fatigue, alopecia, benign raised intracranial
pressure, ataxia, rashes, hypersensitivity
including vasculitis, renal involvement and
thrombocytopenia; haemolytic or aplastic
anaemia. In some cases, dose of amiodarone can
be reduced. In other cases, amiodarone therapy
may need to be stopped.
Pregnancy & lactation: In general, amiodarone
should not be administered during pregnancy
because there have been reports of hypo- or
hyperthyroidism in infants from oral amiodarone
use during pregnancy. If amiodarone use is
considered essential, however, the patient should
be warned of the risk to the fetus. The safe use of
amiodarone in women who are breast-feeding
has not neen established.
Dosage & admin: Amiodarone usually is given
in several daily doses to minimize stomach
upset whcih is seen more frequently with
higher doses. For this same reason, it is also
recommended that amiodarone should be
taken with meals.
Oral dose is 200mg 3 times daily for 1 week,
reduced to 200mg twice daily, or the minimum
dose required to control arrhythmia.
Drug inter: Amiodarone may interact with beta­
blockers such as atenolol, propranolol,
metoprolol, or certain calcium-channel blockers,
such as verapamil or diltiazem, resulting in an
excessively slow heart rate. Amiodarone
increases the blood levels of digoxin when the
two drugs are given together. Flecainide blood
concentrations increase by more than 50% with
amiodarone. Procainamide and quinidine
concentrations increase by 30-50% during the
frrst week of amiodarone therapy. Amiodarone
also can interact with tricyclic antidepressants.
Amiodarone interacts with warfarin and increases
the risk of bleeding. Amiodarone inhibits the
metabolism of dextromethorphan.
t CARDIRON Tab. Drug Inter.
Amiodarone hydrochloride BP 200mg/tablet.
200mg x 30's pack: 210.00 MRP
t PACET Tab. Beximco
Amiodarone hydrochloride BP 1 OOmg &
200mg/tablet.
l OOmg x 30's pack: 150.60 IP
200mg x 30's pack: 301.20 IP
DISOPYRA MIDE 21•26
DISOPYRAMIDE: Capsule
Disopyramide phosphate is a type 1 anti­
arrhythmic drug.
Mode of action: In animal studies disopyramide
decreases the rate of diastolic depolarization in
cells with augmented automaticity, decreases the
upstroke velocity and increases the action poten­
tial duration of normal cardiac cells, decreases
the disparity of refractoriness between infarcted
and adjacent normally perfused myocardium and
has no effect on alpha and beta adrenergic
receptors. As a result it reduces heartbeat.
Ind: Ventricular arrhythmias particularly follow­
ing myocrdial infarction; also effective in supra­
ventricular & paroxysmal supraventricular tachy­
cardia and in wolf-parkinson-white syndrome.
C/I: Disopyramide is contraindicated in the pre­
existing A-V heart block, shock, glaucoma, uri-
QIMP-17 (40) ·'
nary retention & known hypersensitivity to the
drug.
Precautions: Disopyramide should not be
administered to patients with cardiomyopathy &
associated congestive heart failure unless the
patient is digitalized and adequately
compensated. Disopyramide should be used with
caution in the presence of digitalis intoxication.
S/E: Usually disopyramide is well tolerated but
occasionally in some cases dry mouth, nose &
eye; nausea, vomiting, diarrhea, bloating; blurred
vision, urinary problems, headache, skin rash,
dizziness, nervousness & impotence (1-3%) may
occur.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women,
so disopyramide should be used during
pregnancy only if the potential benefit justifies
the potential risk to the fefus. As the nursing
infants are potentially in the risk of serious
adverse reactio-ns, a decision should be made
whether to dicon-tinue nursing or to discontinue
the drug, taking into account the importance of
the drug to the mother.
Dosage & admin: The recommended initial
dose is 400mg daily in 4 divided doses i.e
lOOmg 6 hourly, then 150mg 6 hourly,
adjusting to maintenance, 400-800mg daily in
divided doses. Patients in whom rapid control
of ventricular arrhythmia is essential, an
initial loading dose of 300mg disopyramide is
recommended, followed by the appropriate
maintenance dosage.
In patients with renal insufficiency, dosage
schedule should be made according to the
creatinine clearance rate. If clearance rate is
40-30ml/min, give lOOmg 8 hourly; if 30-15ml/
min, lOOmg 12 hourly; if >15ml/min, lOOmg in
24 hours.
Child: Not recommended.
Drug inter: Drug interactions may occur if
disopyramide is used along with beta­
adrenoceptor blockers or verapamil, lignocaine,
phenytoin, procainamide or erythromycin.
t NORBIT Cap. Incepta
Disopyramide phosphate 1OOmg/capsule
30's pack: 240.00 MRP
LIGNOCAINE 21
LIGNOCAINE HCI: Injection
Lignocaine hydrochloride 2% solution in 50ml
bottle.
Ind: Ventricular arrhythmias especially after
myocardial infarction
C/I: Complete heart block, supraventricular
tachycardia, Sino-atrial disorder.
· S/E: Confusion, convulsion
Caution: Hepatic or Renal insufficiency, CCF.
Adult: 50 -lOOmg i.v. followed by continuous
i. v. infusion of usually 0.2 °/o solo. (i.e. by
diluting 2o/o soln. with. 5°/o dextrose soln.) at
2-4mg/min. rate.
Child: Not recommended
Prepns: May not be available.
PRO·PAfENONE 129
PROPAFENONE HCI: Tablet
Propafenone is an antiarrhythmic drug. It has
some structural similarities to beta-adrenergic
blockers. It is available as propafenone
hydrochloride BP 150mg/tablet (film-coated)
Mode of action Propafenone works by slowing
the influx of sodium ions into the cardiac muscle
cells, causing a decrease in excitability of the
..
cells. Propafenone is more selective for cells with
a high rate, but also blocks normal cells more
than class la or lb. Propafenone differs from the
prototypical class le antiarrhythmic in that it has
additional activity as a beta-adrenergic blocker
which can cause bradycardia and bronchospasm.
Ind: Propafenone is indicated for the treatment
of paroxysmal atrial fibrillation/flutter (PAF),
paroxysmal supraventricular tachycardia (PSVT).
Propafenone is also indicated for the treatment of
documented ventricular arrhythmias.
C/I: Propafenone is contraindicated in the
presence of uncontrolled congestive heart failure,
cardiogenic shock, sinoatrial, atrioventricular and
intraventricular disorders of impulse generation
and/or conduction (e.g sick sinus node syndrome�
atrioventricular block) in the absence of an
artificial pacemaker, bradycardia, marked
hypotension, bronchospastic disorders, manifest
electrolyte imbalance and known hypersensitivity
to the drug
AIR: Adverse reactions associated with
propafenone occur most frequently in the
gastrointestinal, cardiovascular and. central •
nervous systems. Change in taste, constipation,
diarrhea, dizziness, drowsiness, dry mouth, gas,
headache, light-headedness, nausea, tiredness etc.
may happen. Occasional severe allergic reactions
also reported with propafenone.
Precautions: Hepatic dysfu.nction: Propafenone
is highly metabolized by the liver and should
therefore, be administered cautiously to patients
with impaired hepatic function. As a result, the
dose of propafenone given to patients with
impaired hepatic function should be
approximately 20 to 30% of the dose given to
patients with normal hepatic function.
Renal dysfanction: A considerable percentage of
propafenone metabolites (18.5% to 38o/o of the
-
dose/48 hours) are excreted in the urine. Until
further data are available, propafenone should be
administered cautiously to patients with impaired
renal function.
Neuromuscular dysfunction: Exacerbation of
myasthenia gravis has been reported during
propafenone therapy.
Pregnancy & lactation: Pregnancy category C
(by FDA). There are no controlled data on human
pregnancy. Limited data indicate that
propafenone has been administered during the
third trimester of pregnancy without adverse
maternal or fetal effects. Propafenone should be
given during pregnancy only when benefit
outweighs risk.
It is not known whether this drug is excreted in
human milk. Because many drugs are excreted in
human milk and because of the potential for
serious adverse reactions in nursing infants from
propafenone, a decision should be made whether
to discontinue nursing or to discontinue the drug,
taking into account the importance of the drug to
the mother.
Dosage & admin: The dose of propafenone
•

must be individually adjusted on the basis of
response and tolerance. The recommended
initial dose of propafenone is 150mg to be
given every eight hours (i.e 450mg/day).
Dosage may be increased at a minimum of 3 to
4 day intervals to 225mg every 8 hours (i.e
675mg/day) and if necessary, to 300mg every 8
hours (i.e 900mg/day). The usefulness & safety
of dosages exceeding 900mg per day have not
been established.
Pediatric use: The safety and effectiveness of
propafenone in pediatric patients have not
been established.
Drug inter: Propafenone is metabolized by
CYP2D6 (major pathway) and CYPIA2 and
CYP3A4. Drugs that inhibit CYP2D6 (such as
desipramine, paroxetine, ritonavir, sertraline),
CYPIA2 (such as amiodarone) and CYP3A4
(such as ketoconazole, ritonavir, saquinavir,
erythromycin and grapefruit juice) can be
expected to cause increased plasma levels of
propafenone. In addition, propafenone is an
inhibitor of CYP2D6. Co-administration of
propafenone with drugs metabolized by CYP2D6
(such as desipramine, imipramine, haloperidol,
venlafaxine) might lead to increase plasma
concentration of these drugs.
+ RYT HMOSIN Tab. UniMed & UniHealth
Propafenone hydrochloride BP 150mg/tablet
(film-coated)
30's pack: 450.00 MRP
SOTALOL: BETA-BLOCKER129
SOTALOL HCI: Tablet
Sotalol is an anti-arrhythmic drug with class-II
(beta-adrenoreceptor blocking) and class-III
(cardiac action potential duration prolongation)
properties. It is available as sotalol hydrochloride
USP 80mg tablet.
Ind: Treatment of life-threatening arrhythmias
including ventricular tachyarrhythmias,
symptomatic non-sustained ventricular
tachyarrhythmias. Prophylaxis of paroxysmal
atrial tachycardia or fibrillation, paroxysmal AV
re-entrant tachycardias (both nodal and involving
accessory pathways), paroxysmal
supraventricular tachycardia after cardiac
surgery, maintenance of sinus rhythm following
cardioversion of atrial fibrillation or flutter.
•
C/I: Sotalol should not be given to patients with
sinus bradycardia, sick sinus syndrome or
second or third degree AV block (unless a
functional pacemaker is present); congenital or
acquired long QT syndromes, torsades de
pointes, uncontrolled congestive heart failure,
cardiogenic shock; anaesthesia that produces
myocardial depression, hypotension (except due
to arrhythmia), severe peripheral circulatory
disturbances; chronic obstructive airway disease
or bronchial asthma; renal failure (ceratinine
clearance <40ml/min) and previous evidence of
hypersensitivity to sotalol. Sotalol should not be
given to patients suffering from diabetic keto­
acidosis or metabolic acidosis; therapy with
sotalol can be recommenced or resumed when
the metabolic condition has been corrected.
S/E: The most significant adverse effects are
those which are typical of its class-I and
QIMP-17 (41)
class-II (cardiac action potential duration prolon­
gation) effects.
Precaution & warnings: Sotalol is not for
everyone with irregular heartbeats (atrial fibrill­
ation). Sotalol is not indicated for those patients
who have serious kidney problems or are on
kidney dialysis, lung disease causing shortness of
breath (such as asthma, chronic bronchitis or
emphysema), symptoms of heart failure (such as
shortness of breath when in exercise or physical­
ly active and swelling of the ankles or legs), very
slow heart beat and do not have an implanted
.
artificial pacemaker.
Pregnancy & lactation: Its use throughout
pregnancy should be avoided unless it is
absolutely necessary as it crosses the placenta
and may cause foetal bardycardia. Infants should
not be fed with breast milk from mothers being
treated with sotalol.
Dosage & admin: Initially 80mg daily in single
or 2 divided doses. After ECG monitoring and
measurement of corrected QT interval,
arrhythmias, dose is increased gradually at
intervals of 2-3 days to usual dose of 160-
320mg daily in 2 divided doses; higher doses
of 480-640mg daily for life-threatening ventri­
cular arrhythmias should be given under
specialist supervision. The dosage should be
reduced in renal impair-ment. If creatinine
clearance is >60ml/min, recommended dose is
160mg twice daily; if creatinine clearance
between 40 and 60mJ/min, the dose is 160mg
once daily. In patients with creatinine
clearance less than 40ml/min, sotalol is
contraindicated.
Drug inter: In combined therapy, clonidine
should not be discontinued until several days
after withdrawal of sotalol. Use with great cau­
tion with drugs that also prolong QT interval, e.g
disopyramide, amiodarone, class-I antiarrhythmic
agents, calcium antagonists of the verapamil type
or tricyclic antidepressants. Interactions also
occur with phenothiazines, terfenadine, astemi­
zole and diltiazem. Concomitant use of reserpine,
guanethidine, or alpha methyldopa requires close
monitoring for evidence of hypotension and/or
marked bradycardia, syncope. Hypoglycemia
may occur and the dosage of insulin or
antidiabetic drugs may require adjustment.
+ SOTALEX-80 Tab. UniMed & UniHealth
Sotalol hydrochloride USP 80mg/tablet .
30's pack: 300.00 MRP
OTHER BETA-BLOCKERS- As anti-arrhyth­
mic drug, see under antihypertensive drugs (later).
OTHER PREPNS.
CARDIAC GLYCOSIDES- As anti-arrhyth­
mic drugs, see under cardiac glycosides.
V ERAPAMIL: Tablet
See under calcium channel blocker.
2. POSITIVE INOTROPIC
DRUGS
2.1 Cardiac glycosides
2.2 Phosphodiesterase inhibitors
CARDIOVASCULAR DRUGS
Cardiac glycosides
DIGOXIN21,33
DIGOXIN: Tablet/Capsule/Injection
Ind: Heart failure, supraventricular arrhythmias.
(Particularly atrial fibrillation).
C/I: Ventricular tachycardia. AV block. Sinus
bradycardia. Elective electroconversion.
Hypercalcaemia.
S/E: Nausea, vomiting, heart block, arrhythmias,
rash.
·
Caution: Recent acute infarction,
hypothyroidism, severe pulm. or hepatic disease,
renal failure & elderly age. Cation imbalance.
Dosage & admin: Adult: Slow digitalization,
0.25-0. 75mg daily; maintenance 0.25-0.5mg
daily. Rapid digitalization, 0.75-1.Smg follo­
wed by 0.25mg. 6 hourly until ventricular rate
70-80/min.
Child: Under 10 years, digitalization
10-20mcg/kg body-wt. 6 hourly; maintenance,
ususally 10-20 mcg/kg body-wt. daily in single
or divided doses.
+ AGOXIN Tab. Aristopharma
Digoxin 0.25mg/tablet.
1OO's pack: 109.00 MRP
+ CENTOXIN Tab. Opsonin
Digoxin 0.25mg/tablet.
50's pack: 47.95 MRP
+ CENTOXIN Elixir Opsonin
Digoxin 0.25mg/5ml: syrup.
60ml bot: 62.22 MRP
+ DIGOXEN Soft Cap. Drug Inter.
Digoxin USP O. l mg & 0.2mg/capsule (soft).
O.lmg x l OO's pack: 94.00 MRP
0.2mg x 50's pack: 67.00 MRP
3. ANTIHYPERTENSIVE
DRUGS
3.1 Centrally acting antihypertensive drugs
3.2 Ganglion (sympathetic) blocking drugs
3.3 Adrenergic neurone blocking drugs
3.4 Beta adrenoceptor blocking drugs
3.5 Alpha adrenoceptor blocking drugs
3.6 Drugs affecting the renin-angiotensin
system
3. 7 Vasodilator antihypertensive drugs
3.8 Drugs acting on blood volume: diuretics
3.9 Drugs for pulmonary arterial
hypertansion (PAH)
3.10 Misc preparations:
i. Non-classified preparations
ii. Combined antihypertensive
preparations
Centrally acting
antihypertensive dr11:gs
Centrally acting antihypertensive drugs
include: Clonidine, Methyldopa, Moxonidine.
 CARDIOVASCULAR DRUGS
CLONIDINE78
+ CATAPRES Tab. Navana
Clonidinedrochloride USP O.lmg and
0.3mg/tablet.
Mode of action: Clonidine hydrochloride
stimulates alpha-adrenoreceptors in the barin
stem. This action results in reduced sympathetic
outflow from the central nervous system and in
decreased in peripheral resistance, renal vascular
resistance, heart rate, and blood pressure.
Ind: Clonidine is indicated in multiple uses: i.
Hypertensive urgencies, resistant hypertension
and atrial fibrillation; ii. For the treatment of
attention deficit hyperactivity disorder- ADHD
(is characterized by behavioral and learning
disorder); iii. Autism, (a development
disturbance, characterized by an abnormal or
impaired development in social communications
and interaction skills and significantly restricted
range of activities and interests); iv. Tourette's
syndrome, (a neurological disorder in which the
major symptom is tics which are sudden, brief,
involuntary movements or sounds); v. For growth
retardation, (clonidine has been reported to be a
stimulant of growth hormone release, presumably
as a result of central alpha adrenergic
stimulation); vi. Menopausal hot flash; and vii.
Opioid detoxification.
C/I: Any hypersensitivity to clonidine.
S/E: Most adverse effects are mild and tend to
diminish with continued therapy. The most
frequent adverse effects (which appear to be dose
related) are dry mouth, drowsiness, dizziness,
constipation and sedation. Less frequent adverse
effects are headache, with-drawal syndrome,
tachycardia, bradycardia, depressibn,
nervousness, anxiety, restlessness, urticaria, urine
retention etc.
Pregnancy & lactation: No adequate, well con­
trolled stuides have been conducted in pregnant
women. So, it should be used during pregnancy
only if clearly needed. As clonidine is excreted in
human milk, caution should be exercised when it
is administered to nursing mother.
Dosage & admin: i. Hypertensive urgencies,
O.lmg twice daily to manage the hypertensive
crisis than tailing off the therapy; resistant
hypertension, O.lmg twice daily; atrial
fibrillation, 0.075mg once or twice daily alone
or with digoxin; ii. For the treatment of
attention deficit hyperactivity disorder
(ADHD), 5mcg/kg/day. iii. Autism, 0.15mg to
0.2mg/day. iv. Tourette's syndrome, 150-
200mcg/day. v. For growth retardation, 37.5-
150mcg/m2/day. vi. Menopausal hot flash,
O.lmg to 0.4mg daily for up to 2 weeks.
Drug inter: Clonidine may potentiate CNS
depressive effect of alcohol, barbiturates or other
sedative drugs. Hypotensive effect may be
reduced if a patient receives clonidine and
tricyclic anti-depressant, where increased dose of
clonidine is required. Due to a potential for
additive effects (such as bradycarida & A.V
block) caution is warranted in patients receiving
clonidine concomitantly with agents (e.g
digitalis, calcium channel blockers & ? -blockers)
known to affect sinus node function or A.V nodal
conduction.
O.lmg x SO's pack: 301.00 MRP
I
QIMP-17 (42)
METHYLDOPA2t,33
MET HYLDOPA: Tablet/ Capsule/ Injection.
Ind: All grades of hypertension, inconjunction
with a diuretic; hypertensive crisis.
C/I: History of depression, active liver disease,
phaeochromocytoma. Renal impairment.
Anaesthesia.
S/E: Sedation, headache, asthenia, depression,
bradycardia, nasal congestion, dry mouth, G 1
upset. Positive coombs test, jaundice, haemolytic
anaemia.
•
Dose: Adult, initially, 250 mg 2 or 3 times
daily increased to max. 3gm daily adjust at
two day intervals. Child, initially 1 Omg/kg
body-wt. daily in 2-4 divided doses.
+ DOPAMET Tab. Opsonin
Methyldopa (anhydrous) 250mg/tablet.
50's pack: 135.47 MRP
+ DOPEGYT Tab. Ambee
Methyldopa 250mg/tabl((t.
l OO's pack: 309.00 MRP
+ SARDOPA Tab. Incepta
Methyldopa 250mg/tablet.
50's pack: 154.00 MRP
Ganglion (sympathetic)
blocking drugs21
In this group the only drug used to reduce
hypertension was Trimetaphan.
Now a day, it is not used therapeutically.
Adrenergic neurone
blocking drugs21
The only member of adrenergic neurone
blocking (i.e inhibiting the release of
noradrenaline from postganglionic adrenergic
neurones) agents that used as antihypertensive
drug is Guanethidine.
But, due to some limitations and adverse effects
such as, failure to control supine blood pressure
and causing postural hypotension, its use has
become very much restricted.
Beta-adrenoceptor blocking
drugs
Beta-adrenoceptor blocking drugs (beta-blockers)
are effectively used in the treatment of
hypertension. They act by blocking the beta­
adenoc�ptors in the heart, peripheral vasculature,
bronchi, pancreas, and liver. These drugs include:
Propranolol, Acebutolol, Atenolol, Bisoprolol,
Carvedilol, Celiprolol, Esmolol, Labetalol,
Metoprolol, Nadolol, Nebivolol, Oxprenolol,
Pindolol, Sotalol & Timolol.
PROPRANOLOL 2t,4s,s2
PROPRANOLOL HCI: Tablet/Capsule/
Injection.
Propranolol hydrochloride is a selective p 1-
blocker.
Mode of action: Propranolol, as a selective P1-
blocker, it blocks the effects of adrenergic stimu­
lation mediated through these receptors. The
cardio-selectivity is dose-related. Propranolol
causes a reduction in blood pressure by lowering •
cardiac output, decreasing the plasma renin
activity and sympathetic outflow from CNS.
Propranolol also causes a reduction in myocar­
dial oxygen demand by virtue of its negative
inotropic and negative chronotropic effects.
Ind: Propranolol is indicated in- i. the control of
essential and renal hypertension, ii. the manage­
ment of angina pectoris, iii. the long term pro­
phylaxis after recovery from acute myocardial
infarction, iv. the control of most forms of car­
diac arhythmia, v. the prophylaxis of migraine,
vi. the management of essential tremor, vii. the
control of anxiety and anxiety tachycardia, viii.
the adjunctive management of thyrotoxicosis and
thyrotoxic crisis, ix. manage-ment of hypertrophic
obstructive cardiomyo-pathy, x. management of
phaeochromocytoma (with an alpha blocker).
C/I: Propranolol should not be used in the pres­
ence of- i. second or third degree heart block, ii.
cardiogenic shock, iii. history of bronchos-pasm,
iv. after prolonged fasting, v. metabolic acidosis
(e.g in some diabetics), vi. several peripheral vas­
cular disease (including intermittent claudica­
tion), vii. sick sinus syndrome, viii. uncon­
trolled heart failure, ix. hypotension, x. untreated
phaeocromocytoma, xi. Prinz1netal's angina.
S/E: Pronounced fatigue and cold extremities
have been observed in 10-20% of the treated
subjects. Complaints about bradycardia, dizziness
and gastrointestinal symptoms are less frequent.
Despite its relative selectivity, atenolol can cause
bronchospasms in asthma patients. Rarely
observed side-effects are sleep disturbances,
depression, paresthesiae, impotence, exanthema,
psoriasis exacebations and arthropathies.
Clinically relevant changes in the blood sugar
have hardly occurred. There is no clarity as to the
practical significance of the above mentioned
changes in the lipid metabolism.
Precautions & warnings: Special care should be
taken with patients whose cardiac reserve is poor.
P-adrenoceptor blocking drugs should be avoided
in overt heart failure. However, they may be used
in patients whose signs of failure have been con­
trolled. Heart failure due to thyrotoxicosis often
responds to propranolol alone, but if other
adverse factors co-exist myocardial contractility
must be maintained and signs of failure contro­
lled with digitalis and diuretics.
One of the pharmacological actions of propra­
nolol is to reduce heart rate. In the rare instance
when symptoms may be attributable to the slow
heart rate, the dose may be reduced.
Propranolol modifies the tachycardia, of hypo­
glycaemia. Caution should be exercised in the
concurrent use of propranolol and hypoglycaemic
therapy in diabetic patients. Propranolol may
prolong the hypoglycaemic response to insulin.
In patients suffering from ischaemic heart dis­
ease, as with other p-blocking agents, treatment
should not be discontinued abruptly. Either the
equivalent dosage of another b-blocker may be
substituted or the withdrawal of propranolol

should be gradual. Care should be taken in the
parenteral administration of preparations
containing adrenaline to patients taking J3-
blocking drugs as, in rare cases, vasoconstriction,
hypertension and bradycardia may result.
Caution should be exercised when transferring
patients from clonidine to J3-blocker. If J3-
blockers and clonidine are given concurrently,
clonidine should not be discontinued until several
.
days after withdrawal of the J3-blocker (see also
prescribing information on clonidine ).
Care should be taken in prescribing a J3-blocker
with class 1 antidysrhythmic agents such as
disopyramide. J3-blockers should be used with
caution in combination with verapamil in patients
with impaired ventricular function. The ,
combination should not be given to patients with
conduction abnormalities. Neither drug should be
administered intravenously within 48 hours of
discontinuing the other.
Anaesthesia: It is not advisable to withdraw J3-
blockers prior to surgery in the majority of
patients.
However, care should be taken when using
anaesthetic agents such as ether, cyclopropane
and trichloroethylene. Vagal dominance, if it
occurs, may be corrected with atropine ( l -2mg i.v).
.
Pregnancy & lactation: As with all other drugs,
it should not be given in pregnancy unless its use
is essential. There is no evidence of
teratogenicity with propranolol.
Dosage & admin: By mouth: Adult­
Hypertension, initially 80mg twice daily
increasing if necessary at weekly intervals to
160-320 mg daily. Anxiety, 40mg 2-3 times
daily increasing if necessary at weekly interval
upto 120-140mg/ day.
Phaeochromocytoma, 60mg daily with an
alpha-blocker for 3 days preoperatively or
30mg daily in inoperable case.
Arrythmias, hypertrophic obstructive
cardiomyopathy, anxiety tachycardia and
thyrotoxicosis- 10-40�g 3-4 times daily.
Anxiety with symptoms such as palpitations,
sweating, tremor etc., 40mg 2-3 times daily.
Child: 0.25-0'Smg/kg 3 or 4 times daily.
By intravenous injection: lmg over 1 minute,
preceded by atropine sulphate 1-2 mg; if
necessary, repeat at 2 minutes intervals;
maximum lOmg (5mg in anaesthesia).
Prophylaxis after infarction- 40mg 4 times
daily for 2-3 days then 80mg thrice daily,
begining 5-21 days after infarction.
Migraine prophylaxis- initially 40mg 2-3 times
daily; maintenance 80-160mg daily.
t ADLOCK Tab. Sonear
Propranolol hydrochloride 1Omg, 40mg &
80mg/tablet.
lOmg x lOO's pack: 50.00 MRP
40mg x lOO's pack: 150.00 MRP
t BETACAP T R Tab. Sun Pharma
Propranolol hydrochloride 40mg/tablet (extended
release).
50's pack: 125.00 MRP
t INDEVER Tab. ACI
Propranolol hydrochloride 1Omg & 40mg/tablet.
lOmg x lOO's pack: 51.00 MRP
40mg x lOO's pack: 150.00 MRP
t PROPRANOL Tab. Opsonin
Propranolol hydrochloride 1Omg, 40mg/tablet.
QIMP-17 (43)
1Omg x 200's pack: 89.73 �1RP
40mg x lOO's pack: 131.95 MRP
ATENOLOL21,42,4s,s2
ATENOLOL: Tablet/Injection
Atenolol, chemically a phenylacetamide, and
functionally a selective J31-blocker.
Mode of action: Atenolol as a beta-blocker, it
has an effect on the heart by blocking the action
of noradrenaline and adrenaline on J3-receptor
and controls its rate and rhythm of beating. By
reducing the heart rate and the force of muscle
contraction, atenolol reduces the need of heart
muscle for oxygen (demanad). Because angina
occurs when oxygen demand of the heart exceeds
supply, atenolol is also helpful in treating angina.
Ind: Hypertension, angina, arrhythmias.
C/I: Atenolol is contraindicated with a known
hypersensitivity to atenolol, severe bradycardia,
second or third degree heart block, uncontrolled
heart failure, hypotension, severe peripheral
vascular disease (including intermittent
claudication), sick sinus syndrome, cardiogenic
shock, phaeocromocytoma (without a
concomitant alpha blocker), metabolic acidosis.
S/E: Pronounced fatigue and cold extremities
have been observed in 10-20o/o of the treated
subjects. Complaints about bradycardia, dizziness
and gastrointestinal symptoms are less frequent.
Despite its relative selectivity, atenolol can cause
bronchospasms in asthma patients. Rarely
observed side-effects are sleep disturbances,
depression, paresthesiae, impotence, exanthema,
psoriasis exacebatiops and arthropathies.
Clinically relevant changes in the blood sugar
have hardly occurred. There is no clarity as to
the practical significance of the above mentioned
changes in the lipid metabolism.
Precautions: Poor cardiac reserve. Avoid in
overt heart failure, anaesthesia and chronic
obstructive airway disease or asthma. Withdrawal
of beta-bl�cking drugs should be gradual in
patients with ischaemic heart disease. Withdrawal
of clonidine. Co-administration with verapamil or
class 1 antidysrhythmic agents modifies the
tachycardia of hypoglycaemia. If symptoms
attributable to slow heart rate reduce dose. In
renal disese reduce dose.
Pregnancy & lactation: Atenolol crosses the
placenta. So it should not be given in pregnancy
and lactation.
Dosage & admin: By mouth: Hypertension,
50mg daily (higher doses no longer considered
necessay).
Angina, 1 OOmg daily in 1 or 2 doses
Arrhythmias, 50-1OOmg daily.
By intravenous injection: Arrhythmias, 1.5 mg
at a rate of lmg/min, repeated at 5-minute
intervals to a maximum of lOmg.
By intravenous infusion: Arrhythmias,
150mcg/kg over 20 minutes, repeated every 12
hours if required.
Early intervention within 12 hours of
infarction, 5-l Omg by slow i.v injection, then
by mouth 50mg after 15 minutes, 50mg after
12 hours, then· 1oomg daily.
Note: Excessive bradycardia can be countered
with intravenous injection of atropine sulphate
0.6-2.4mg in divided doses of 0.6mg.
CARDIOVASCULAR DRUGS
Drug inter: The effects of other myocardial
depressant agents, including anti-arrhythmics
such as quinidine, procainamide, or lignocaine,
phenytoin, and medicines which interfere with
calcium transport, such as verapamil, may be
enhanced by atenolol. The effects of atenolol are
diminished by J3-adrenoceptor stimulating agents
such as isoprenaline; the hypotensive effects of
atenolol may be dangerously reversed and the
peripheral vasoconstrictor effects enhaced by a­
adrenoceptor stimulating agents such as nora­
drenaline or those with mixed a- and J3-adreno­
ceptor stimulating properties such as adrenaline;
bradycardia may also occur. The effects of
atenolol may be enhanced by adrenergic neuron
blocking agents such as guanethidine or bethani­
dine, or catecholamine-depleting agents such as
reserpine and the hypotensive effects by diure­
tics. Atenolol may enhance some of the cardiac
effects of digitalis and diminish others. It has
been suggested that clonidine withdrawal symp­
toms may be exacerbated in patients who are
concurrently taking a J3-blocker.
(For more information, see under the text of
propranolol).
+ ANOL Tab. Modern
Atenolol BP SO mg/tablet
50mg x lOO's pack: 77.00 MRP
t ANOL-50 Tab. Medicon
Atenolol BP 50mg/tablet
50mg x lOO's pack: 76.00 MRP
+ ANOLOL Tab. Euro Pharma
Atenolol BP 50mg & 1OO mg/tablet
50mg x lOO's pack: 77.00 MRP
lOOmg x lOO's pack: 138.00 MRP
t APICARD Tab. APC Pharma
Atenolol BP SO mg/tablet
50mg x lOO's pack: 75.00 MRP
t ATEBIT Tab. Asiatic
Atenolol BP SOmg & 1OO mg/tablet
50mg x IOO's pack: 77.00 MRP
lOOmg x lOO's pack: 138.00 MRP
t ATENOL Tab. Pharmadesh
Atenolol BP SO mg/tablet
50mg x 1OO's pack: 80.00 MRP
t ATEZEN Tab. Z enith
Atenolol BP SOmg & 1OO mg/tablet
50mg x lOO's pack: 77.00 MRP
lOOmg x lOO's pack: 137.00 MRP
+ ATIN Tab. Jayson
Atenolol BR SO mg/tablet
50mg x 1OO's pack: 76.00 MRP
t ATOL Tab. Mystic
Atenolol BP 50mg/tablet
50mg x lOO's pack: 75.00 MRP
t B-CARD-50 Tab. Nipa
Atenolol BP 50mg/tablet
50mg x lOO's pack: 77.00 MRP
+ BETANOL Tab. Sanofi-aventis
Atenolol BP 25mg, 50mg & 1OO mg/tablet
25mg x 200's pack: 90.00 MRP
50mg x 200's pack: 154.00 MRP
lOOmg x lOO's pack: 136.99 MRP
t BETASEC Tab. Opsonin
Atenolol BP 50mg/tablet
50mg x lOO's pack: 67.73 MRP
t CARDILOCK Tab. Alco Pharma
Atenolol BP 50mg/tablet
50mg x lOO's pack: 77.00 MRP

CARDIOVASCULAR DRUGS
+ CARDIPRO Tab. Square
Atenolol BP 50mg & 1 OOmg/tablet
SOmg x l OO's pack: 77.00 MRP
l OOmg x l OO's pack: 143.00 MRP
+ CARSEC Tab. Medimet
Atenolol BP 50mg & 1 OOmg/tablet
50mg x 140's pack: 105.00 MRP
l OOmg x 140's pack: 189.00 MRP
+ ENOL Tab. Edruc
Atenolol BP 50mg/tablet.
50mg x l OO's pack: 77.00 MRP
+ ETNOL Tab. B iopharma
Atenolol BP 50mg & 1OOmg/tablet
50mg x 1 OO's pack: 77.00 MRP
l OOmg x l OO's pack: 138.00 MRP
+ LONET Tab. B eximco
Atenolol BP 50mg & 1 OOmg/tablet
SOmg x 1OO's pack: 77.00 MRP
l OOmg x l OO's pack: 137.00 MRP
+ LOPRES Tab. Orion Pharma
Atenolol BP 50mg/tablet.
50mg x 1 OO's pack: 70.00 MRP
+ NORMATEN Tab. Navana
Atenolol BP 50mg/tablet.
50mg x l OO's pack: 76.00 MRP
+ NORPRESS Tab. Kemiko
Atenolol BP 50mg/tablet.
50mg x l OO's pack: 75.00 MRP
+ PRECINOL Tab. Doctor's
Atenolol BP 50mg/tablet
1OO's pack: 73.00 MRP
+ TENOC ARD Tab. Aristopharma
Atenolol BP SOmg/tablet
50mg x lOO's pack: 75.00 MRP
t TENOLOC Tab. Acme
Atenolol BP 50mg & 1 OOmg/tablet.
50mg x l OO's pack: 77.00 MRP
l OOmg x l OO's pack: 137.00 MRP
+ TENOMIN Tab. Pacific
Atenolol BP 50mg/tablet
SOmg x 1 OO's pack: 77.00 MRP
+ TENOREN Tab. ACI
Atenolol BP 25mg, SOmg & 1 OOmg/tablet.
25mg x 50's pack: 22.50 MRP
50mg x 150's pack: 115.50 MRP
l OOmg x l OO's pack: 138.00 MRP
+ TENOVIR Tab. Virgo
Atenolol BP SOmg/tablet.
50mg x l OO's pack: 75.00 MRP
BISOPROLOL45,130
BISOPROLOL HEMIFUMARATE: Tablet
Bisoprolol hemifumarate is a highly BI selective
(cardio-selective) B-blocker. It is almost com­
pletely (>90%) absorbed from the gastrointestinal
tract. The high absorption rate and the small first­
pass effect (<10%) lead to an absolute bioavai­
lability (88%) of bisoprolol. Concomitant food
intake does not affect the absorption. Bisoprolol
is available as- bisoprolol hemifumarate 2.Smg,
5mg & l Omg/tablet (film-coated).
Mode of action: Most of the desirable therapeu­
tic actions of B-blockers result from blocking the
Bl-receptors. Beta-blockers with high Bl selectiv­
ity have substantial clinical advantages over non­
selective agents. Avoiding the inhibition of B2-
receptor-mediated actions (only show very low
affinity) helps to avoid undesirable side-effects
on lung function, peripheral circulation, serum
.
"
QIMP-17 (44)
lipids and carbohydrate metabolism. The B 1 sele­
ctivity of bisoprolol extends beyond the therape­
utic dose range. The beneficial effects of antihy­
pertensive therapy with Bl selective B-blockers in
non-diabetic and diabetic patients became
evident in various clinical studies in patients with
CAD and hypertension. Bisoprolol is devoid of
intrinsic sympathomimetic activity (ISA),
without relevant membrane stabilising activity
and has no pronounced negative inotropic effect.
Ind: Hypertension, angina pectoris & stable
chronic moderate to severe heart failure (in
addition to ACE inhibitors & diuretics).
C/I: Untreated cardiac failure, cardiogenic shock,
sinoatrial block, second or third degree AV block,
marked bradycardia (heart rate less than 60 beat
per minute) or extreme hypotension.
S/E: Bisoprolol is well tolerated. Those reported
are due to its pharmacological actions- lassitude,
dizziness, mild headache, perspiration, aggrava­
tion of intermittent claudication or Raynaud's dis­
ease & paresthesia observed. Sleep disturbances
only rarely reported.
Precaution: Use with care in patients with
prolonged PR interval, poor cardiac reserve &
peripheral circulatory disturbances, such as­
Raynaud's phenomenon, chronic obstructive
airways disease and diabetes. In patients with .
ischaemic heart disease, treatment should not be
withdrawn abruptly.
Pregnancy & lactation: Pregnancy category C.
Like other P-blockers, use in pregnancy only if
the potential benefit justifies the risk to the fetus.
Bisoprolol fumarate has not been studied in
nursing mothers, but, small amounts of bisoprolol
fumarate have been detected in the milk of
lactating rats. Because of the potential for serious
adverse reactions in nursing infants, a decision
should be made whether to discontinue nursing
or to discontinue the drug, taking into account
the importance of the drug to the mother.
Dosage: Hypertension & angina: Usually 5mg
once daily; recommended range Smg-1 Omg
daily. Chronic heart failure: The treatment
should be started with a small dose; the dose
should be slowly & progressively up-titrated
according to tolerance up to the maximum
recommended dose of 1 Omg (if needed, please
see detailed prescribing information in the
text). In patients with fmal stage renal or liver
disease, dose should not exceed to 1 Omg
bisoprolol once daily. No dose adjustment
required for the elderly.
Child: Not recommended for children.
Drug inter: May potentiate the effects of other
cardiovascular agents, insulin or other oral
hypoglycemic drugs. Rifampicin can reduce the
half-life of bisoprolol.
+ ANCOR Tab. Aristopharma
Bisoprolol hemifumarate 2.5mg, 5mg &
1 Omg/tablet
2.5mg x 30's pack: 180.00 MRP
5mg x 30's pack: 300.00 MRP
lOmg x lO's pack: 160.00 MRP
+ BETABIS Tab. Acme
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
Smg x 30's pack: 300.00 MRP
+ BISLOL Tab. Opsonin
Bisoprolol hemifumarate 2.5mg, 5mg &
•
1 Omg/tablet
2.5mg x 30's pack: 158.87 MRP
5mg x 30's pack: 264.97 MRP
lOmg x 30's pack: 423.84 MRP
+ BISOCOR Tab. Square
Bisoprolol hemifumarate 2.5mg, 5mg &
•
1Omg/tablet
2.5mg x 30's pack: 180.60 MRP
5mg x 30's pack: 301.20 MRP
l Omg x l O's pack: 160.60 MRP
+ BISOLOC Tab. Orion Pharma
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
5mg x 30's pack: 300.00 MRP
+ BISOPRESS Tab. NIPRO JMI
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
5mg x 30's pack: 300.00 MRP
+ BISOPRO Tab. Incepta
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
5mg x 30's pack: 300.00 MRP
+ BISOREN Tab. Renata
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
5mg x 30's pack: 300.00 MRP
+ BISU Tab. Popular
Bisoprolol hemifumarate 2.Smg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
5mg x 30's pack: 300.00 MRP
+ B-PROLOL Tab. Sharif
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.Smg x 30's pack: 180.00 MRP
5mg x 30's pack: 300.00 MRP
+ CARDICOR Tab. UniMed & UniHealth
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
5mg x 30's pack: 300.00 MRP
+ CARDINOR Tab. Labaid Pharma
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
5mg x 30's pack: 300.00 MRP
+ CONBIS Tab. RAK Pharma
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
Smg x 30's pack: 300.00 MRP
+ CONCOR Tab. Popular
Bisoprolol hemifumarate 1 Omg/tablet •
1 Omg x 30's pack: 780.00 MRP
+ MYOCOR Tab. B iopharma
Bisoprolol hemifumarate 2.5mg/tablet
2.5mg x 30's pack: 180.00 MRP
+ PROBIS Tab. ACI
Bisoprolol hemifumarate 2.Smg & 5mg/tablet
2.5mg x 30's pack: 180.00 MRP
Smg x 30's pack: 300.00 MRP
t TENOBIS Tab. Drug Inter.
Bisoprolol hemifumarate 2.5mg & 5mg/tablet
2.5mg x SO's pack: 300.00 MRP
5mg x 30's pack: 300.00 MRP
CARVEDILOL21,26,42
CARVEDILOL: Tablet/ Capsule
Carvedilol is a racemic mixture in which nonse­
lective P-adrenoreceptor blocking activity is
present in the S(-) enantiomer and a-adrenergic
blocking activity is present in both R(+) and S(-)
enantiomers at equal potency. Carvedilol has no
intrinsic sympathomimetic activity.
 I
I
Carvedilol is used in the treatment of
hypertension, angina pectoris and congestive
heart failure. It is available as- carvedilol INN
6.25mg, 12.5mg & 25mg/tablet (film-coated); &
carvedilol phosphate INN I Omg & 20mg/capsule
(controlled release).
Mode of action: See at the beginning under the
text of beta blockers. Besides, carvedilol has an
additional peripheral arteriolar vasodilator action
by diverse mechanisms, and thus lower
peripheral resitance. It also has antiproliferative
properties and is a scavenger of reactive free
oxidant radicals.
Ind: Congestive heart failure: Carvedilol is
indicated for the treatment of mild or moderate
heart failure to reduce the progression of disease
as evidenced by cardiovascular death,
cardiovascular hospitalization, or the need to
adjust other heart failure medications. Carvedilol
may be used in patients unable to tolerate an
ACE inhibitor. Carvedilol may be used in
patients who are or are not receiving digitalis,
hydralazine or nitrate therapy.
Hypertension: Carveditol can be used alone or in
combination with other antihypertensive agents
especially with thiazide type diuretics.
Myocardial infarction: Carvedilol is indicated to
reduce cardiovascular mortality in clinically
stable patients who have survived the acute phase
of a myocardial infarction and have a left
ventricular ejection fraction of 40%.
C/I: Carvedilol is contraindicated in patients
with NYHA class IV (New York Heart
A ssociation class IV) decompensated cardiac
failure requiring intravenous inotropic therapy;
bronchial asthma or related bronchospastic
conditions; second or third-degree AV block, sick
sinus syndrome (unless a permanent pacemaker
is placed); cardiogenic shock or severe
bradycardia. Therapy is not to be initiated in
severe heart failure.
S/E: Postural hypotension, dizziness, headache,
fatigue, gastrointestinal disturbances,
bradycardia; occasionally diminished peripheral
circulation, peripheral oedema and painful
extremities, dry mouth, dry eyes, eye irritation
or disturbed vision, impotence, disturbances of
micturition, influenz.ae-like symptoms, rarely
angina, AV block, exacerbation of intermittent
claudication or Raynaud's phenomenon, allergic
skin reactions, exacerbation of psoriasis, nasal
stuffiness, wheezing, depressed mood, sleep
disturbances, paresthesia, heart failure, changes
in liver enzymes, thrombocytopenia, leukopenia
are also reported.
Cautions: Take caution in hepatic impairment,
and in heart failure, monitor clinical status for 2-
3 hours after initiation and after increasing each
dose. Before increasing dose ensure that the renal
function and heart failure are not deteriorating.
Pregnancy & lactation: Carvedilol should not
be used during pregnancy & breast- feeding,
since no studies have been performed in pregnant
& lactating women; animal studies have shown
that carvedilol crosses the placental barrier &
also excreted in breast milk. Safety and efficacy
of carvedilol in neonates & children have not
been established.
Dosage & admin: Tablet preparation (f.c):
In hypertension- treatment should be started
I
QIMP-17 (45)
with 12.Smg once daily, then increased to
25mg daily after 2 days; the dose may further
be increased to max. 50mg daily in single or
divided doses, at intervals of at least 2 weeks,
if necessary. In elderly patients, the initial
dose of 12.Smg daily may be sufficient for
adequate control.
In angina- initially 12.Smg twice daily, then
increased to 25mg twice daily after 2 days.
In heartfailure- carvedilol may be given
initially 3.125mg twice daily with food; dose
may be increased at intervals of at least 2
weeks to 6.25mg twice daily, then to 12.Smg
twice daily, then to 25mg twice daily. The dose
may be increased to highest dose tolerated, in
patients less than 85kg body-weight, max.
25mg twice daily and in patients over 85kg,
max. 50mg twice daily.
Capsule preparation (c.r):
Heart failure: The recommended starting dose
of carvedilol phosphate is 1Omg once daily for
2 weeks. Patients who tolerate a dose of 1Omg
once daily may have their dose increased to
20mg, 40mg, & 80mg over successive intervals
of at least 2 weeks. Patients should be
maintained on lower doses if higher doses are
not tolerated.
Myocardial infarction: It is recommended that
carvedilol phosphate be started at 20mg once
daily and increased after 3-10 days, based on
tolerability to 40mg once daily, then again to
the target dose of 80mg once daily.
Hypertension: The recommended starting dose
of carvedilol phosphate is 20mg once daily, the
dose should be maintained for 7-14 days and
then increased to 40mg once daily if needed.
This dose should also be maintained for 7-14
days and can then be adjusted upward to
80mg once daily if tolerated and needed.
Drug inter: Digoxin- in normal healthy
volunteers a single dose of carvedilol taken
together with a single dose of digoxin resulted in
significantly increased levels of digoxin 24-hour
later. Patients with congestive heart failure
stabilized on digoxin have been given carvedilol
concomitantly without any adverse effects.
Increased monitoring of digoxin is recommended
when initiating, adjusting, or discontinuing the
dose of carvedilol. Rifampin- pretreatment with
rifampin resulted in a 60% decrease in Cmax and
AUC. Clonidine- b-receptor antagonists
potentiate the pressor reaction which may follow
sudden withdrawal of treatment with clonidine
although, in theory, the a-blocking action of
carvedilol should modify the pressure rise.
t ARILOL Tab. Pacific
Carvedilol INN 6.25mg 12.Smg & 25mg/tablet
6.25mg x 30's pack: 90.00 MRP
12.5mg x 30's pack: 150.00 MRP
25mg x 30's pack: 240.00 MRP
t AVIDOL Tab. Ad-din
Carvedilol INN 6.25mg/tablet
6.25mg x 60's pack: 180.00 MRP
t CARDEX Tab. Opsonin
Carvedilol INN 3.125mg, 6.25mg & 12.Smg/
tablet
3.125mg x lOO's pack: 132.83 MRP
6.25mg x 50's pack: 132.40 MRP
12.5mg x 30's pack: 132.48 MRP
t CARD I VAS Tab. Sun Pharma
-
...
CARDIOVASCULAR DRUGS
Carvedilol INN 6.25mg & 12.5mg/tablet
6.25mg x 50's pack: 227.50 MRP
12.5mg x 30's pack: 196.50 MRP
t CARVED Tab. Biopharma
Carvedilol INN 6.25mg, 12.5mg & 25mg/tablet
6.25mg x 30's pack: 135.00 MRP
12.5mg x 30's pack: 195.00 MRP
25mg x 30's pack: 240.90 MRP
t CARVIS TA Tab. lncepta
Carvedilol INN 6.25mg, l 2.5mg & 25mg/tablet
6.25mg x l OO's pack: 300.00 MRP
12.5mg x 50's pack: 250.00 MRP
25mg x 30's pack: 240.00 MRP
t CARVIPRESS Tab. Acme
Carvedilol INN 6.25mg & l 2.5mg/tablet
6.25mg x 30's pack: 90.00 MRP
12.50mg x 30's pack: 150.30 MRP
t CAVELON Tab. Drug Inter.
Carvedilol INN 6.25mg & l 2.5mg/tablet
6.25mg x 50's pack: 150.00 MRP
12.5mg x 50's pack: 300.00 MRP
t DILAPRESS Tab. Beximco
Carvedilol INN 6.25mg, 12.5mg & 25mg/tablet
6.25mg x 30's pack: 90.00 IP
12.50mg x 30's pack: 150.00 IP
25mg x 30's pack: 240.00 IP
t DILATREND Tab. Roche/Radiant
Carvedilol INN 6.25mg/tablet
6.25mg x 30's pack: 330.00 MRP
+DILGARD Tab. General
Carvedilol INN 6.25mg, 12.5mg & 25mg/tablet
6.25mg x 30's pack: 90.30 MRP
l 2.5mg x 30's pack: 150.60 MRP
25mg x 30's pack: 240.90 MRP
t DILOCARD Tab. White Horse
Carvedilol INN 6.25mg & 12.5mg/tablet
6.25mg x 50's pack: 150.00 MRP
12.5mg x 30's pack: 150.00 MRP •
t DILOL Tab. Mystic
Carvedilol INN 6.25mg & 12.5mg/tablet
6.25mg x 1OO's pack: 300.00 MRP
12.5mg x 50's pack: 250.00 MRP
t DIOLA Tab. Sandoz
Carvedilol INN 6.25mg & 12.5mg/tablet
6.25mg x 30's pack: 187.50 MRP
12.5mg x 30's pack: 285.00 MRP
t DUROL Tab. Square
Carvedilol INN 6.25mg & 12.5mg/tablet
6.25mg x 30's pack: 90.30 MRP
12.50mg x 30's pack: 150.30 MRP
t DUROL CR Cap. Square
Carvedilol phosphate INN 1 Omg & 20mg/capsule
(controlled release)
lOmg x 30's pack: 270.00 MRP
20mg x 30's pack: 450.00 MRP
t KOREG Tab. Silva
Carvedilol INN 6.25mg, 12.5mg & 25mg/tablet
6.25mg x 30's pack: 90.00 MRP
12.5mg x 30's pack: 150.00 MRP
25mg x 30's pack: 240.00 MRP
t REVODIL Tab. Ibo Sina
Carvedilol INN 6.25mg/tablet
6.25mg x 40's pack: 120.00 IP
t R O V EDILOL Tab. Healthcare
Carvedilol INN 6.25mg & 12.5mg/tablet
6.25mg x 30's pack: 120.00 MRP
12.5mg x 30's pack: 210.00 MRP
+ UCARD OL Tab. Unimed & unihealth
Carvedilol INN 6.25mg, 12.5mg & 25mg/tablet
6.25mg x 30's pack: 90.00 MRP
CARDIOVASCULA.R DRUGS
12.Smg x 30's pack: 150.00 MRP
25mg x 30's pack: 270.00 MRP
t VESODIL Tab. Rangs Pharma
Carvedilol INN 6.25mg, 12.5mg & 25mg/tablet
6.25mg x 30's pack: 90.00 MRP
12.Smg x 30's pack: 150.00 MRP
25mg x 30's pack: 240.00 MRP
CELIPROLOL65
CELIPROLOL HCI: Tablet
Celiprolol is a selective beta1-adrenoreceptor
blocking agent. It is available as celiprolol
hydrochloride BP 200mg & 400mg tablet.
Mode of action: Celiprolol is a beta1-selective
(cardioselective), beta-adrenoreceptor blocking
agent, which possesses mild beta2 agonist activi­
ty and weak alpha2-blocking activity, but does
not exhibit quinidine-like membrane stabilizing
properties. These and other receptor modulating
effects may account for its absence of cardiode­
pressant effect, lack of adverse effects on serum
lipids, decrease in peripheral vascular resistance
as well as a reduced risk of adverse bronchopul­
monary effects compared with other beta­
adrenoreceptor blocking agents.
Ind: Celiprolol is indicated for the treatment of
hypertension and effort-induced angina pectoris.
C/I: All beta blockers contraindicated in
are
bronchial asthma or other obstructive lung disor­
ders, uncontrolled heart failure, cardiogenic
shock, sick-sinus syndrome, grade 2 and 3 A-V
block, intranodal A-V block and severe bradycar­
dia and also avoid in severe renal impairment.
S/E: Adverse effects are transient and mild. The
most frequently observed are headache,
dizziness, fatigue, abdominal discomfort,
weakness, rash, bradycardia, oedema, palpitation
and muscle cramps; depression and pneumonitis
reported rarely.
Precautions: Avoid abrupt withdrawal specially
in angina; first-degree AV block; reduce oral dose
of celiprolol in liver disease; renal impairment;
diabetes; history of obstructive airways disease.
Celiprolol therapy must be reported to the
anaesthetist prior to general anaesthesia.
Pregnancy & lactation: Celiprolol in not terato­
genic in experimental animals but is embryotoxic
in rabbits and rats at 54 to 60 times the highest
recommended human oral dose. It crosses the
placenta in animals but is not known to what
extent it crosses the placenta in humans. So, it
should not be given in pregnancy unless its use is
considered to be essential. The extent to which
celiprolol is excreted in breast milk has not been
established therefore, breast-feeding should not
be continued by mothers receiving this product.
Dosage & admin: Hypertension: The recom­
mended initial dose is 200mg once daily. The
effect will be fully established after one to two
weeks. The dose may be increased to 400mg
once daily if necessary at 2 to 4 week intervals.
Angina pectoris: It is indicated for the long­
term management of patients with angina
pectoris. The usual dose is 200mg once daily;
dosage may be increased to 400mg or 600mg
once daily after 2 to 4 weeks intervals until
optimum clinical response obtained. If
treatment is to discontinue, reduce the dosage
gradually over a period of 1 to 2 weeks.
•
QIMP-17 (46)
Celiprolol should be taken at least one hour
before or two hours after meals.
Drug inter: Verapamil and celiprolol both slow
A-V conduction and depress myocardial contrac­
tility through different mechanisms. Therefore,
clinical signs and ECG should be carefully
monitored during the treatment with this combi­
nation particularly when initiating therapy. The
bioavailability of celiprolol has been shown to be
reduced by the concomitant administration of
chlorthalidone, hydrochlorothiazide or theophy­
lline. While no effect on the efficacy of
celiprolol has been demonstrated, patients
response should be monitored after dosage
adjustments involving these medications.
t CELIPRESS Tab. SK+F
Celiprolol hydrochloride 200mg/tablet
200mg x 20's pack: 160.00 MRP
LABETALOL48•133
LABETALOL: Tablet/Injection
Labetalol is an adrenergic receptor blocking
agent possessing both alpha- I (post-synaptic)
and beta-receptor blocking activity. It is available
as labetalol hydrochloride USP 1OOmg & 200mg
tablet & 50mg in I Oml ampoule (i.e 5mg/ml) for
intravenous (i.v) injection.
Mode of action: Labetalol lowers blood pressure
by blocking peripheral arteriolar a-adrenoceptors,
thus reducing peripheral resistance, and by con­
current �-blockade, protects the heart from reflex
sympathetic drive that would otherwise occur.
Cardiac output is not significantly reduced at rest
or after moderate exercise. Increases in systolic
blood pressure during exercise are reduced but
corresponding changes in diastolic pressure are
essentially normal. All these effects would be
expected to benefit hypertensive patients.
Ind: Labetalol is indicated for hypertension
(including hypertension in pregnancy, hyperten­
sion with angina, and hypertension following
acute myocardial infarction). Parenteral therapy
is specially indicated in severe hypertension
when rapid control of blood pressure is essential;
controlled hypotension in anaesthesia.
C/I: Labetalol is contraindicated in second or
third degree heart block, cardiogenic shock and
other conditions associated with severe and
prolonged hypotension or severe bradycardia.
When peripheral vasoconstriction suggests low
cardiac output, the use of injection to control
hypertensive episodes following acute
myocardial infarction is contraindicated.
S/E: Adverse effects reported are postural
hypotension (avoid upright position during and
for 3 hours after i.v administration), tiredness,
weakness, headache, rashes, scalp tingling,
difficulty in micturition, epigastric pain, nausea,
vomiting, liver damage.
Precautions: There have been rare reports of
severe hepatocellular injury with labetalol
therapy. The hepatic injury is usually reversible
and has occurred after both short and long term
treatment. Appropriate laboratory testing should
be done at the first sign or symptom of liver
dysfunction. If there is laboratory evidence of
liver injury or the patient is jaundiced, labetalol
therapy should be stopped and not re-started .
Labetalol does not adversely affect renal function
and is particularly suitable for use in hyperten­
sive patients with renal disease.
Pregnancy & lactation: Although no teratogenic
effects have been demonstrated in animals,
labetalol should only be used during the first
trimester of pregnancy if the potential benefit
outweighs the potential risk. Adverse events of
unknown causality have been reported very
rarely in breast-fe.d neonates. Caution should be
exercised when labetalol is administered to breast
feeding women.
Dosage & admin: By mouth: The recommend­
ed initial dose is 1 OOmg twice daily with food,
increased at intervals of 14 days to usual dose
of 200mg twice daily, upto 800mg daily in 2
'
divided doses. Maximum 2.4gm daily in
divided doses. The usual maintenance dose is
200 to 400mg twice daily. Optimal doses are
usually lower in patients also receiving a
diuretic since an additive antihypertensive
effect can be expected.
By i. v injection: SOmg over at least 1 minute,
repeated after 5 minutes if necessary;
maximum total dose 200mg.
By i. v infusion: 2mg/minute until satisfactory
response then discontinue; usual total dose 50-
200mg. Hypertension of pregnancy:
20mg/hour, doubled every 30 minutes; usual
maximum 160mg/hour. Hypertension follow­
ing myocardial infarction: 15mg/hour, gradu­
ally increased .to maximum 120mg/hour.
Dilution fluid can be used: Labetalol injection
is compatible with 5�o dextrose BP, 0.18°/o
sodium chloride and 4°/o dextrose BP, 0.3°/o
potassium chloride and 5°/o dextrose BP, com­
pound sodium lactate BP i.v infusion fluids.
Drug inter: Labetalol may enhance the
hypotensive effects of halothane. Care should be
taken if labetalol is used concomitantly with
either class I antiarrhythmic agents or calcium
antagonists of the verapamil type. The
hypotensive effect of labetalol may be reduced
when used in combination with prostaglandin
synthetase inhibitors (NSAIDs ). Dosage
adjustments may therefore be necessary.
t LABECARD I.V·Inj. Popular
Labetalol hydrochloride USP 50mg in 1Oml
ampoule (i.e 5mg/ml): i.v injection.
IOrhl (50mg) amp. x l 's pack: 100.00 MRP
t LABETA Tab. Beximco
Labetalol hydrochloride USP I OOmg &
200mg/tablet.
IOOmg x 60's pack: 361.20 IP
200mg x 30's pack: 301.20 IP
METOPROLOL21,33 ,52
METOPROLOL: Tablet/Injection
Metoprolol tartrate is a �1 selective
(cardioselective) adrenoreceptor blocking agent.
Mode of action: By blocking �1 receptors,
metoprolol causes reduction in heart rate and
cardiac output at rest and upon exercise,
reduction of systolic blood pressure upon
exercise, inhibition of isoproterenol-induced
tachycardia, and reduction of reflex orthostatic
tachycardia. By reducing the heart rate and the
force of muscle contraction, it also reduces heart
muscle oxygen demand. .

I Ind: Hypertension, arrhythmias, angina,
migraine prophylaxis, thyrotoxicosis.
C/I; S/E; Cautions: See under propranolol
hydrochloride; reduce dose in hepatic and renal
impairment.
Dosage & admin: By mouth:
Hypertension, the usual initial dosage is 25 to
1 OOmg daily in a single dose, whether used
I alone or added to a diuretic; maintenance 100-
200mg daily in 1-2 doses.
Angina, 50-1 OOmg 2-3 times daily.
Arrhythmias, usually 50mg 2-3 times daily; up
to 300mg daily in divided doses if necessary
Migraine prophylaxis, 100-200mg daily in
divided doses
T hyrotoxicosis (adjunct), 50mg 4 times daily.
By intravenous injection:
Arrhythmias, up to 5mg at a rate 1- 2mg/min,
repeated after 5 minutes if necessary, total
dose 10-15mg.
In surgery, 2-4mg by slow i.v injection at
induction or to control arrhythmias
developing during anaesthesia; 2mg doses may
be repeated to a maximum of lOmg.
Note: Excessive bradycardia can be countered
with i.v injection of atropine sulphate 0.6-2.4mg
in divided doses of 0.6mg.
+ ANGILAT Tab. ACI
Metoprolol tartrate 25mg & 50mg/tablet
25mg x lOO's pack: 150.00 MRP
50mg x lOO's pack: 200.00 MRP
+ BETACARD Tab. Aristopharma
Metoprolol tartrate 50mg/tablet
50mg x lOO's pack: 200.00 MRP
+ BETALOC Tab. Drug Inter.
Metoprolol tartrate 25mg & 50mg/tablet
25mg x lOO's pack: 150.00 MRP
50mg x 1OO's pack: 200.00 MRP
+ BETALOC-XR Tab. Drug Inter.
Metoprolol succinate 47.Smg equivalent to
metoprolol tartrate 50mg/tablet & metoprolol
succinate 95mg equivalent to metoprolol tartrate
1OO mg/tablet (extended release).
50mg x IOO's pack: 400.00 MRP
lOOmg x 50's pack: 300.00 MRP
+ BETAONE 50 Tab. Acme
Metoprolol tartrate 50mg/tablet
50mg x 1OO's pack: 200.00 MRP
+ LOPRESOR Tab. Bristol
Metoprolol tartrate SO mg/tablet
IOO's pack: 131.00 MRP
+ METALOC Tab. Renata
Metoprolol tartrate 50mg & 1OO mg/tablet
50mg x lOO's pack: 132.00 MRP
lOOmg x SO's pack: 125.50 MRP
+ METOCARD I.V Inj. Popular
Metoprolol tartrate 5mg/5ml ampoule: injection.
S m g (5ml) amp x S's pack: 602.25 MRP
+ METOPROL XL Tab. Beximco
Metoprolol tartrate 50mg & 1OO mg/tablet
(extended release)
50mg x SO's pack: 150.00 MRP
1OOmg x SO's pack: 250.00 MRP
+ M-LOC 50 Tab. Sharif
Metoprolol tartrate 50mg/tablet
50mg x 50's pack: 100.00 MRP
+ PRELOC Tab. Opsonin
Metoprolol tartrate 50mg/tablet
50mg x 50's pack: 8 7.97 MRP
+ PRESONIL Tab. Incepta
I
QIMP-17 (47) ·:'
Metoprolol tartrate 50mg/tablet
IOO's pack: 130.00 MRP
+ SELOMET Tab. Unimed & unihealth
Metoprolol tartrate 25mg & 50mg/tablet
25mg x 30's pack: 45.00 MRP
50mg x 30's pack: 60.00 MRP
+ SELOMET-SR Tab. Unimed & unihealth
Metoprolol succinate USP 47.5mg equivalent to
metoprolol tartrate USP 50mg/tablet (sustained
release).
Dosage & admin: Dosages are same as other
normal tablet preparations - see above under
the text.
50mg x 30's pack: 120.00 MRP
+ T OPRESS Tab. SK+F
Metoprolol tartrate 50mg/tablet
1OO's pack: 200.00 MRP
NEBIVOLOL s2
NEBIVOLOL: Tablet
Nebivolol is a competitive and selective beta1-
receptor antagonist with mild vasodilatirig
properties. Nebivolol reduces heart rate & blood
pressure at rest & during exercise. It is available
as 2.Smg & 5mg film coated tablet.
Mode of action: See description above.
Ind: Nebivolol is indicated in: i. mild to moder­
ate essential hypertension; ii. mild to moderate
hypertension, with coronary artery diseases
(CAD), with hyperlipidemia, in elderly, with
diabetes mellitus; iii. chronic heart failure (CHF).
C/I: Known hypersensitivity to nebivolol, car­
diogenic shock, untreated phaeochromocytoma,
sick sinus syndrome, 2nd & 3rd degree heart
block, liver insufficiency or liver function
impairment, pregnancy and lactation, bradycardia
(heart rate< 50/m), metabolic acidosis, bronchial
asthma, history of bronchospasm.
S/E: The most common side effects are­
headache, dizziness, tiredness, paraesthesia, diar­
rhea, constipation, nausea, dyspnoea, and edema.
Other side effects include bradycardia, slowed
AV conduction/AV block, hypotension, heart
failure, intermittent claudication, impaired vision,
impotence, depression, nightmares, dyspepsia,
flatulence, vomiting, bronchospasm, rash.
Precautions: P1- receptor antagonist should not
be used in ischemic heart disease, circulatory
disorders, first degree heart block, anesthesia,
diabetes, hype�hyroidism, chronic obstructive
pulmonary disorders, and allergen sensitivity.
Pregnancy & lactation: Nebivolol is
contraindicated in pregnancy and lactation.
Dosage & admin: Hypertension: Adults: Smg
(ltablet) daily, preferable at the same time of
the day. Elderly (patients over 65 years): The
recommended starting dose is 2.Smg (half­
tablet) daily. The dose may be increased to
Smg (1tablet) daily if needed. Due to limited
experience lo patients above 75 years, caution
must be exercised and these patients to be
monitored closely. Patient with renal
insufficiency: The recommended starting dose
is 2.5mg (half- tablet) daily. The daily dose
may be increased to 5mg (!tablet) if needed.
Nebivolol Smg if given in combination with
12.5-25mg hydrochlorothiazide, an additional
antihypertensive effect has been observed.
Chronic heart failure: The initial uptitration
-
CARDIOVASCULAR DRUGS
in case of chronic heart failure patients should
be done according to the following steps at 1-2
weekly intervals based on patient tolerability:
1.25mg daily, to be increased to 2.Smg once
daily, then to Smg once daily and then to 1 Omg
once daily. The ma.ximum recommended dose
is lOmg daily.
Children: In children safety and efficacy of
nebivolol has not been demonstrated.
Drug inter: Nebivolol interacts with calcium
channel antagonists (e.g. verapamil, diltiazem),
class 1 antiarrythmic drugs and amiodarone.
+ BIPINOR.Tab. ACI
Nebivolol 2.5mg & 5mg/tablet (film-coated)
2.5mg x 30's pack: 150.60 MRP
5mg x 30's pack: 240.90 MRP
+ NEBICARD Tab. UniMed & UniHealth
Nebivolol 2.5mg & 5mg/tablet (film-coated)
2.5mg x 28's pack: 196.00 MRP
5mg x 28's pack: 336.00 MRP
Alpha adrenoceptor
blocking drugs
The useful alpha-adrenoceptor blocking drugs
include:Prazosin, Doxazosin, Indoramin &
Terazosin.
Mode of action: Alpha-adrenoceptor blocking
drugs have post synaptic alpha-blocking effect,
results in vasodilatation. These drugs however,
cause a rapid reduction in blood pressure after
the frrst dose and should be introduced with
caution. Alpha-blockers may be used with other
antihypertensive drugs in the treatment of
hypertension.
Note: For furhter infomation, see below under
the text of individual products.
PRAZOS1N21,33
PRAZOSIN HCl: Tablet
Prazosin hydrochloride is available as 1mg &
2mg tablet.
Ind: Hypertension, congestive cardiac failure.
S/E: Postural hypotension, drowsiness,
weakness, headache, vertig, asthma.
Cautions: First dose may cause collapse due to
hypotension; reduce initial dose in renal failure.
Dosage & admin: Adult: 0.5 mg on first
evening, then 0.5 mg 2 or 3 times daily for 3-
7 days followed by 1 mg 2 or 3 times daily for
3-7 days; there after, increase gradually as
required. Max. 20mg daily.
Child: Not recommended.
+ ALPHAPRESS Tab. Renata
Prazosin hydrochloride 1mg & 2mg/tablet.
lmg x lOO's pack: 400.00 MRP
2mg x lOO's pack: 600.00 MRP
+ PRAZOPRESS Tab. UniMed & UniHealth
Prazosin hydrochloride lmg & 2mg/tablet.
lmg x 30's pack: 120.00 MRP
2mg x 30's pack: 18 0.00 MRP
TERAZOSIN21,26,49
T ERAZOSIN HCI: Tablet
Terazosin hydrochloride is a selective
CARDIOVASCULAR DRUGS
a.-1 adrenoceptor competitive blocking agent
with a longer duration of action. It is a
quinazoline derivative. When it is taken orally, it
is absorbed very rapidly & action started within
15 minutes of ingestion.
Mode of action: See above under the text of
alpha adrenoceptor blocking drugs.
Ind: Mild to moderate hypertension. In benign
prostatic hyperplasia, single therapy is useful to
relieve signs and symptoms.
C/I: Known to be hypersensitive to terazosin or
its analogues.
S/E: Dizziness, lack of energy, peripheral oede­
ma; urinary frequency and priapism reported.
Cautions: First dose may cause collapse due to
hypote11sion (within 30-90 minutes, therefore
should be taken on retiring to bed), may also
occur with rapid dose increase. Caution should
also be observed when terazosin is administered
with other antihypertensive agents, avoid the
possibility of significant hypotension. When
adding terazosin to a diuretic or other antihyper­
tensive agent, dosage reduction and adjustment
may be necessary. In case of initiation of
terazosin therapy patients should be cautioned to
avoid driving & hazardous tasks, where injury
could result due to syncope.
Pregnancy & lactation: Terazosin is not
recommended during pregnancy unless the
potential benefit overweighs the potential risk to
mother & foetus. As terazosin is.excreted in the
breast milk, caution should also be exercised
when administered in nursing mother.
Dosage & admin: Hypertension, initial dose­
lmg at bedtime (compliance with bedtime
·dose important, see cautions); dose can be
increased or doubled after 7 days if necessary;
usual maintenance dose- 2-1Omg once daily;
more than 20mg daily rarely improves efficacy.
Benign prostatic hyperplasia, initial dose-
1mg at bedtime is starting dose of all patients
and this dose should not be exceeded;
subsequent dose- the dose slowly increases to
achieve the desired response, the usual recom­
mended dose range is 5-lOmg once daily.
t PROSTOL Tab. Drug Inter.
Terazosin hydrochloride lmg & 2mg/tablet.
lmg x 50's pack: 150.00 MRP
2mg x 50's pack: 250.00 MRP
t TERAZON Tab. Incepta
Terazosin hydrochloride 2mg & 5mg/tablet.
2mg x 50's pack: 250.00 MRP
Smg x 30's Pack: 240.00 MRP
Drugs affecting the renin-
ang1otens1n system
• •
1. Angiotensin-converting enzyme (ACE)
inhibitors
2. Angiotensin-Il receptor antagonists or
blocker
3. Renin inhibitors
ACE Inhibitors21,22,23
Angiotensin converting enzyme (ACE) inhibitors
include: Captopril, Cilazapril, Enalapril,
QIMP-17 (48)
•
••>
Fosinopril, Imidapril, Lisinopril, Moexipril,
Perindopril, Quinapril, Ramipril &
TrandolapriL
Mode of action: Angiotensin converting enzyme
or ACE inhibitors inhibit the conversion of
angiotensin I to angiotension II. They are
effective and generally well tolerated.
Indications:
Hypertension: ACE inhibitors are usually
considered in hypertension when thiazides and
betablockers are contra-indicated, not tolerated,
or failed to control blood pressure; they are
particularly indicated for hypertension in insulin
dependent diabetics with nephropathy.
Heart failure: ACE inhitiotrs have a valuable
role in all grades of heart failure, combined when
appropriate with diuretic and digoxin treatment.
Myocardial infarction: ACE inhibotors are used
in the immediate and long term management of
patients who have had a myocardial infarction.
Diabetic nephropathy: It is recommended that
all diabetic patients with nephropathy causing
albuminuria and all insulin-dependent diabetic
patients with established microalbuminuria
should be treated with an ACE inhibitor even if
the blood pressure is normal .
C/I: Hypersensitivity to ACE inhibitors; known
or suspected renovascular disease (unless the
blood pressure cannot be controlled by other
drugs); aortic stenosis; pregnancy; porphyria.
S/E: Hypotension, dizziness, headache, fatigue,
asthenia, nausea (or occasionally vomiting),
diarrhoea, muscle cramps, persistent dry cough,
throat discomfort, voice changes, taste alteration,
stomatitis, dyspepsia, abdo�nal pain, renal
impairment, hyperkalaemia, angioedema,
urticaria, rashes and hypersensitivity reactions;
blood disorders (e.g agranulocytosis, neutrope­
nia); other side-effects reported include upper
respiratory symptoms, hyponatraemia, tachycar­
dia, palpitations, arrhythmias, myocardial infarc­
tion and CVD, back pain, flushing, jaundice,
pancreatitis, sleep disturbances, nervousness,
mood changes, paraesthesia, impotence, alopecia.
Cautions: Renal function and electrolytes
should be checked before starting ACE inhibitors
and monitored during treatment. Caution with
diuretics as the first dose may cause hypotension,
because ACE inhibitors can cause rapid fall of
blood pressure in volume depleted patients,
therefore if possible, any diuretic should be
discontinued or the dose reduced significantly
2-3 days before initiation of an ACE inhibitor.
Diuretic therapy may be resumed if necessary
after a few weeks.
Patients with renal impairment, S.L.E & other
autoimmune collagen disorders & during concur­
rent use of immunosuppressant or leukopenic
drugs monitor WBC counts & urinary protein
before & during therapy. Lactation. Anaesthesia.
Dosage: See under the text of the individual
preparation.
CAPTOPRIL2t,33
CAPTOPRIL: Tablet.
Ind: In mild to moderate hypertension alone or
with thiazide diuretics; severe hypertension
resistant to other treatment; adjunct to diuretics
& digitalis in severe refractory congestive car-
diac failure; following.:myocardial infarction; dia­
betic nephropathy in insulin-dependent diabetes.
C/I; S/E; Caution: See above under the text of
ACE inhibitor.
Dosage & admin: Mild to moderate hyperten­
sion: Initially 12.5mg twice daily with a thia­
zide diuretic. Maintenance, 25mg twice daily '
increasing gradually at 2-4 weeks inter-val if
necessary to maximum 50mg twice daily.
Severe hypertension: 25mg twice daily increa­
sing if necessary to 50mg three times daily.
Heart failure: As adjunct initially 6.25-12.5mg
under close medical supervision; usual
maintenance dose 25mg 2-3 times daily, and
maximum 150mg daily.
Diabetic nephropathy: 75-lOOmg daily in divid­
ed doses; if further blood pressure reduction
required, other antihypertensives may be used
in conjuction with captopril; in severe renal
impairment, initially 12.Smg twice daily.
+ ACETOR Tab. Drug Inter.
Captopril 25mg/tablet.
IOO's pack: 300.00 MRP
+ ANGITEN Tab. Ibo Sina
Captopril 25mg/tablet.
lOO's pack: 325.00 IP
+ CAPOTRIL Tab. Alco Pharma
Captopril 25mg/tablet.
40's pack: 120.00 MRP
+ CATOPIL Tab. Zenith
Captopril USP 25mg/tablet.
25mg x IOO's pack: 300.00 MRP
+ CARDOPRIL Tab. Beximco
Captopril 25mg & 50mg/tablet.
25mg x lOO's pack: 301.00 IP
50mg x lOO's pack: 602.00 IP
ENALAPRIL2t,33
ENALAPRIL MALEATE: Tablet
Ind: All grades of hypertension; treatment of
congestive heart failure as adjunct; prevention of
symptomatic heart failure and prevention of
coronary ischaemic events in patients with left
ventricular dysfunction.
C/I; S/E; Caution: See above under the text of
ACE inhibitor.
Dosage & admin: Hypertension, used alone,
initially 5mg once daily; if used in addition to
diuretic, in elderly patients or in renal impair­
ment, initially 2.5mg daily; usual maintenace
dose 10-20mg once daily; in severe hyperten­
sion may be increased to maximum 40mg once
daily.
Heart failure- in asymptomatic left ventricular
dysfunction, as an adjunct, initially 2.5mg
daily under close medical supervision; usual
maintenance 20mg daily in 1-2 divided doses.
+ ANAPRIL Tab. SK+F
Enalapril maleate 5mg & 1O mg/tablet.
Smg x IOO's: 151.00 MRP
1Omg x 1OO's: 270.00 MRP
+ ENARIL Tab. Beximco
Enalapril maleate Smg/tablet.
Smg x lOO's: 100.00 IP
+ MINIPRIL Tab. Renata
Enalapril maleate 5mg & 1Omg/tablet.
5mg x lOO's: 202.00 MRP
lOmg x lOO's: 202.00 MRP

+ VASOPRIL Tab. Square
Enalapril maleate 5mg & 1Omg/tablet.
5mg x lOO's: 125.00 MRP
lOmg x 50's: 113.00 MRP
LISINOPRIL21,s2
LISINOPRIL: Tablet
Ind: All grades of essential hypertension and
renovascular hypertension where standard therapy
ineffective or inappropriate.
Congestive heart failure in conjunction with
diuretics and/or digitalis.
C/I: Pregnancy, aortic stenosis, cor pulmonale.
S/E: Hypotension, renal failure, angioedema,
rash, dizziness, headache, diarrhoea, cough,
fatigue, palpitations, chest pain, asthenia.
Cautions: Renal impairment; monitor renal
function before & during treatment; lactation.
Dosage & admin: Adults: Initially, 2.Smg once
daily increasing gradually over 2-4 weeks to
·
maintenance of 10-20mg once daily.
Therapy to be initiated in hospital only.
In hypertension, if any diuretic is given
concurrently, reduce the dose or discontinue
the diuretic for 2-3 days beforehand and
resume later if required.
Child: Not recommended.
Drug inter: K+ sparing diuretics, K+ supple­
ments and indomethacin (should be avoided).
+ ACEPRIL Tab. Drug Inter.
Lisinopril 5mg & 1Omg/tablet
5mg x 50's pack: 200.00 MRP
lOmg x 30's pack: 210.00 MRP
+ LIPRIL Tab. Acme
Lisinopril 5mg & 1Omg/tablet
5mg x 50's pack: 150.00 MRP
lOmg x 30's pack: 165.00 MRP
+ LISPRIL Tab. Medimet
Lisinopril 5mg/tablet
5mg x 50's pack: 112.50 MRP
+ NEOPRIL Tab. Beximco
Lisinopril 5mg/tablet
. 5mg x 1OO's pack: 301.00 IP
+ NOP Tab. Ambee
Lisinopril 1Omg/tablet
5mg x 50's pack: 177.50 MRP
+ STRIL Tab. ACI
Lisinopril 5mg/tablet
5mg x 28's pack: 84.28 MRP
PERINDOPRIL21·53
PE RINDOPRIL ERBUMINE : Tablet.
Perindopril erbumine is an angiotensin-conver­
ting enzyme (ACE) inhibitor. It is available as
2mg, 4mg & 8mg tablet.
I
j Ind: Essential hypertension; congestive heart
failure (as adjunct).
C/I; Caution: See above under the text of ACE
inhibitor.
S/E: See notes above under the text of ACE
inhibitor; asthenia, flushing, mood & sleep
disturbances.
Dosage & Admi.n: Hypertension- 4mg once a
day in the morning, if necessary, the dose may
be increased to 8mg after 1 month of
treatment; it should be taken before food.
Congestive heart failure- perindopril should
QIMP-17 (49)
be started under close medical supervision at
a starting dose of 2mg in the morning, this
may be increased to 4mg once blood pressure
acceptability bas been demonstrated. Elderly
patients, start treatment with 2mg daily.
+ CADNYL 4 Tab. Square
Perindopril erbumine INN 4mg/tablet.
4mg x 30's pack: 361.50 MRP
+ COVERSYL Tab. Servier
Perindopril erbumine 4mg & 8mg/tablet.
4mg x 30's pack: 495.00 MRP
8mg x 30's pack: 750.00 MRP
+ PENDORIL Tab. Renata
Perindopril erbumine 2mg, 4mg & 8mg/tablet.
2mg x 20's pack: 180.00 MRP
4mg x lO's pack: 140.00 MRP
4mg x 20's pack: 280.00 MRP
8mg x lO's pack: 240.90 MRP
+ PERICARD Tab. Asiatic
Perindopril erbumine BP 2mg & 4mg/tablet.
2mg x lO's pack: 70.00 MRP
4mg x lO's pack: 120.00 MRP
+ PERIPRIL Tab. lncepta
Perindopril erbumine 2mg, 4mg & 8mg/tablet.
2mg x 20's pack: 140.00 MRP
4mg x 20's pack: 240.00 MRP
8mg x 20's pack: 480.00 MRP
+ VERSIL Tab. Acme
Perindopril erbumine 4mg/tablet.
4mg x 30's pack: 361.50 MRP
RAMIPRIL26,48
RAMIPRIL: Tablet/Capsule
Ramipril is an angiotensin converting enzyme
(ACE) inhibitor, useful in the treatment of
hypertension and congestive heart failure. It is
available as- Ramipril BP 1.25mg, 2.5mg, 5mg &
1Omg tablet and capsule.
Mode of action: Ramipril in the "body, after
hydrolysis to ramiprilat, blocks the conversion of
angiotensin I to the vasoconstrictor substance,
angiotensin II. So, inhibition of ACE by ramipril
results in decreased plasma angiotensin II, which
leads to decreased vasopressor activity and
decreased aldosterone secretion. Thus, ramipril
exerts its antihypertensive activity. It is long
acting & well tolerated; so, can be used in long
term therapy.
Ind: i. Mild to severe hypertension, where it may
be used alone or in combination with thiazide
diuretics. ii. Congestive heart failure.
iii. To reduce the risk of stroke, myocardial
infarction and death from cardiovascular events
in patients with a history of cardiovascular
disease. iv. Proteinuric non-diabetic nephropathy.
C/I; S/E; Caution: See above under the text of
ACE inhibitor.
Dosage & admin: Dosage of Ramipril must be
adjusted according to the patient tolerance
and response.
Hypertension- For the management of
hypertension in adults not receiving a diuretic,
the usual initial dose is 1.25-2.Smg once daily.
Dosage generally is adjusted no more rapidly
than at 2-week intervals. The usual maintena­
nce dosage in adults is 2.5-20mg daily given as
a single dose or in 2 divided doses daily. If BP
is not controlled with Ramipril alone, a
. . .,
ACME
diuretic may be added.
Congestive heart failure after myocardial
infarction- In this case, Ramipril therapy may
be initiated as early as 2 days after myocardial
infarction. An initial dose of 2.Smg twice daily
is recommended, but if hypotension occurs,
dose should be reduced to 1.25mg twice daily.
T herapy is then adju�ted to a target daily dose
of Smg twice daily.
Prevention of major cardiovascular.events- In
this case, the recommended dose is 2.Smg
twice daily for the t)rst week of therapy and
Smg once daily for the following 3 weeks;
dosage then may be increased, as tolerated to
a maintenance dosage of lOmg once daily.
Dosage in renal impairment- For the patients
with hypertension and renal impairment, the
recommended initial dose is 1.25mg once
daily. Subsequent dosage should be adjusted
according to individual tolerance and BP
response, up to a maximum of Smg daily. For
the patients with heart failure and renal
impairment, the recommended dose is 1.25mg
once daily. The dose may be increased to
1.25mg twice daily and up to a maximum dose
of 2.Smg twice daily depending upon clinical
response and tolerability.
Overdosage: Limited data on human overdosage
are available. The most likely clinical manifesta­
tions would be symptoms attributable to hypoten­
sion. Because the hypotensive effect of Ramipril
is achieved through vasodilation and effective
hypovolemia, it is reasonable to treat Ramipril
overdosage by infusion of normal saline solution.
Drug inter: Concomitant administration with
diuretics may lead to serious hypotension and in
addition dangerous hyperkalemia with potassium
sparing diuretics. Concomitant therapy with
lithium may increase the serum lithium
concentration. Reduction in BP may affect the
ability to drive and operate machinery and this
may be exacerbated by alcohol. NSAIDs may
reduce the antihypertensive effect of Ramipril
and cause deterioration of renal function.
+ ACECARD Tab. Healthcare
Ramipril BP 1.25mg, 2.5mg & 5mg/tablet
l .25mg x 30's pack: 90.00 MRP
2.5mg x 30's pack: 150.00 MRP
5mg x 30's pack: 240.00 MRP
+ CARTACE Tab. Ad-din
Ramipril BP 2.5mg/tablet
2.5mg x 40's pack: 184.00 MRP
+ GEPRIL Tab. Globe
Ramipril BP 5mg/tablet
5mg x 30's pack: 240.00 MRP
+ G-RAMIPRIL Tab. Gonosbas
Ramipril BP 2.5mg & Smg/tablet
2.5mg x 30's pack: 75.00 MRP
5mg x 30's pack: 120.00 MRP
+ HYPACE 5 Tab. Tecbno Drugs
Ramipril BP 5mg/tablet
5mg x 30's pack: 240.00 MRP
+ NUVACE Tab. Orion Pharma
Ramipril BP 2.5mg & 5mg/tablet
2.5mg x 30's pack: 150.00 MRP

ACME
5mg x 30's pack: 240.00 MRP
+ PIRAMIL Tab. Sandoz
Ramipril BP 2.5mg & 5mg/tablet
2.5mg x 30's pack: 210.00 MRP
5mg x 30's pack: 300.00 MRP
+ PRICARD Tab. White Horse
Ramipril BP 2.5mg/tablet
2.5mg x 50's pack: 200.00 MRP
+ PRIMACE Cap. Beximco
Ramipril BP 1.25mg, 2.5mg & 5mg/capsule
1.25mg x 30's pack: 75.00 IP
2.5mg x 30's pack: 150.00 IP
5mg x 30's pack: 240.00 IP
+ PRIMACE Tab. Beximco
Ramipril BP 2.5mg, 5mg & 1Omg/tablet
2.5mg x 30's pack: 150.00 IP
5mg x 30's pack: 240.00 IP
lOmg x l's pack: 12.00 IP
+ PROTACE Tab. Unimed & unihealth
Ramipril BP 2.5mg & 5mg/tablet
2.5mg x 30's pack: 150.00 MRP
5mg x 30's pack: 240.00 MRP
+ RACARD Tab. Pacific
Ramipril BP I .25mg, 2.5mg & 5mg/tablet
l .25mg x 30's pack: 75.00 MRP
2.5mg x 30's pack: 138.00 MRP
5mg x 30's pack: 240.00 MRP
+ RAMACE Tab. Opsonin
Ramipril BP l .25mg, 2.5mg & 5mg/tablet
l .25mg x 50's pack: 110.40 MRP
2.5mg x 30's pack: 132.48 MRP
5mg x 30's pack: 211.92 MRP
+ RAMICARD Tab. Drug Inter.
•
Ramipril BP 1.25mg, 2.5mg & 5mg/tablet
1.25mg x 50's pack: 125.00 MRP
2.5mg x 50's pack: 250.00 MRP
5mg x 50's pack: 400.00 MRP
+ RAMIL Tab. Popular
Ramipril B P 1.25mg, 2.5mg, & 5mg/tablet
1.25mg x 50's pack: 125.00 MRP
2.5mg x 30's pack: 251.00 MRP
5mg x 50's pack: 401.51 MRP
+ RAMILOK Tab. Aristopharma
Ramipril BP 2.5mg & 5mg/tablet
2.5mg x 50's pack: 250.00 MRP
5mg x 30's pack: 240.00 MRP
+ RAMILON Tab. Virgo
Ramipril BP 2.5mg & 5mg/tablet
2.5mg x 30's pack: 120.00 MRP
5mg x 30's pack:180.00 MRP
+ RAMIPRESS Tab. Silva
Ramipril BP I .25mg, 2.5mg & 5mg/tablet
l .25mg x 30's pack: 75.00 MRP
2.5mg x 30's pack: 150.00 MRP
5mg x 30's pack: 240.00 MRP
+ RAMIPRO Tab. General
Ramipril BP 2.5mg & 5mg/tablet
2.5mg x 50's pack: 151.00 MRP
5mg x 30's pack: 240.90 MRP
+ RAM ORIL Tab. Incepta
Ramipril BP 1.25mg, 2.5mg, 5mg & IOmg/tablet
l .25mg x 50's pack: 125.00 MRP
2.5mg x 50's pack: 250.00 MRP
5mg x 50's pack: 400.00 MRP
1Omg x 30's pack: 360.00 MRP
..'
QIMP-17 (SO)
+ RAMPRIL Tab. Rangs Pharma
Ramipril BP 2.5mg & 5mg/tablet
2.5mg x 30's pack: 120.00 MRP
5mg x 30's pack: 180.00 MRP
+ RIPRiL Tab. Square
Ramipril BP l .25mg, 2.5mg & 5mg/capsule
l .25mg x 30's pack: 75.30 MRP
2.5mg x 30's pack: 150.30 MRP
5mg x 30's pack: 241.20 MRP
+ R-PIL Tab. Biopharma
Ramipril BP l .25mg, 2.5mg & 5mg/capsule
l .25mg x 30's pack: 90.30 MRP
2.5mg x 30's pack: 150.60 MRP
5mg x 30's pack: 240.90 MRP
+ TRITACE Tab. Sanofi-aventis
Ramipril BP 2.5mg, 5mg/tablet
2.5mg x 28's pack: 266.00 MRP
5mg x 28's pack: 392.00 MRP
+ UNIPRIL Tab. Acme
Ramipril BP 2.5mg & 5mg/tablet
2.5mg x 30's pack: 150.30 MRP
5mg x 30's pack: 241.20 MRP
Angiotensin-11 receptor
blocker (ARB ) 21•26•54
Introduction: The angiotensin-II receptor
blockers are newer antihypertensive drugs, act by
blocking the action of angiotensin-II on the heart,
peripheral vasculature and kidney. They are also
useful in the management of heart failure.
The angiotensin-II receptor blockers recently
available are A zilsartan, Candesartan,
- Psychiatric disorders: Anxiety, depression,
Eprosartan, Irbesartan, Losartan, Olmesartan,
Telmisartan & Valsartan.
Mode of action: Angiotensin-II is a potent
vasoconstrictor, the primary vasoactive hormone
of the renin-angiotensin system and an important
component in the pathophysiology of
hypertension. The angiotensin-II receptor
blockers block the vasoconstrictor and
aldosterone secreting effects of angiotensin-II by
selectively blocking the binding of angiotensin­
II. They have many properties & effects similar
to those of the ACE inhibitors; but their merit
over ACE inhibitors that they do not inhibit the
breakdown of bradykinin and other kinins, thus
they do not cause persistent dry cough as
happens with ACE inhibitors.
Ind: Hypertension; congestive heart-failure &
renal arterial stenosis.
C/I: Hypersensitivity to any of the components
of angiotensin-II receptor blocking preparations,
e.g losartan, valsartan etc. Contra-indicated in
pregnancy & lactation, if pregnancy is detected
during therapy should be discontinued as soon as
possible.
S/E: The side-effe.cts that experienced with
angiotensin-II blockers are mild and rare. For
specific side-effects see below under individual
preparation.
Precautions & warnings: Sodium-depleted
and/or volume-depleted patients, such as, those
receiving high doses of diuretics, symptomatic
hypotension may occur in rare cases after
initiation of therapy. Sodium and/or volume
depletion should be corrected before starting
treatment with angiotensin-II receptor blockers
for example, by reducing the diuretic dose. If
hypotension occurs, the patient should be placed
in the supine position and, if necessary, given an
i.v infusion of normal saline. Treatment can be
continued once the blood pressure has stablised.
Dosage: See below under individual
preparation.
CANDESARTAN42
CANDESARTAN: Tablet
Candesartan cilexetil is a newer angiotensin-II
receptor blocker. It is rapidly and completely
bioactivated by ester hydrolysis during
absorption from the gastrointestinal tract to
candesartan, a selective AT 1 subtype angiotensin
II receptor antagonist.
Mode of action: See above under the text of
'angiotensin-11 receptor blocker'.
Ind: It is indicated for the treatment of
hypertension. It may be used alone or in
combination with other antihypertensive agents.
C/I: Pregnancy. Known hypersensitivity to any
component of this product.
S/E: Body as a whole: Asthenia, fever.
Central & peripheral nervous system:
Paresthesia, vertigo. Gastrointestinal system:
Dyspepsia, gastroenteritis.
Cardiovascular system: Tachycardia, palpitation.
Metabolic & nutritional: Creatine phosphokinase
increased, hyperglycaemia, hypertriglyceridemia,
hyperuricemia.
Musculoskeletal system: Myalgia.
Platelet/bleeding-clotting_ disorders: Epistaxis.
somnolence.
Skin & appendages: Rash, sweating increased.
Urinary system: Hematuria.
Precautions & Warmings: See above wider the
text of 'angiotensin-II receptor blocker'.
Pregnancy & lactation: When pregnancy is
detected candesartan should be discontinued as
soon as possible.
It is not known whether candesartan is excreted
in human milk, but has been shown to be present
in rat milk. Therefore, a decision should be made
whether to discontinue nursing or discontinue the
drug, taking into account the importance of the
drug to the mother.
Dosage & admin: Dosage must be
individualized. Blood pressure response is dose
related over the range of 2mg to 32mg. The
usual recommended starting dose is 16mg
once daily when it is used as monotherapy in
patients who are not volume depleted.
Candesartan can be administered once or
twice daily with total daily dosage ranging
from 8mg to 32mg. Larger doses do not
appear to have a greater effect, and there is
relatively little experience with such doses.
Most of the antihypertensive effect is present
within 2 weeks, and maximal blood pressure
reduction is generally obtained within 4 to 6
weeks of treatment with candesartan.
No initial dosage adjustment is necessary for
elderly patients, for patients with mildly
impaired renal function, or for patients with
mildly impaired hepatic function. For patients
with possible depletion of intravascular volu­
me (e.g patients treated with diuretics, parti­
cularly those with impaired renal function),

candesartan should be initiated under close
medical supervision and consideration should
be given to administration of a lower dose.
Candesartan may be administered with or
without food. If blood pressure is not contro­
lled by candesartan alone, a diuretic can be
added. Candesartan may be administered with
other antihyper-tensive agents.
Paediatric patients: Safety and effectiveness in
pediatric patients have not been established.
Drug inter: No significant interactions have
been reported with other drugs such as glyburide,
nifedipme, digoxin, warfarin, hydrochlorothiazide
and oral contraceptives in healthy volunteers.
Because candesartan is not metabolised by the
cytochrome P 450 system and has no effect on P
450 enzymes, interactions with drugs that inhibit,
or are metabolised by, those enzymes could not
be expected.
+ GIRAN Tab. Aristopharma
Candesartan cilexetil INN 8mg & l 6mg/tablet
8mg x 30's pack: 180.00 MRP
l 6mg x 30's pack: 330.00 MRP
+ V ESOTAN Tab. Rangs Pharma
Candesartan cilexetil INN 8mg & 16mg/tablet
8mg x 30's pack: 1 80.00 MRP
16mg x 30's pack: 330.00 MRP
IRBESARTAN63
IRBESARTAN: Tablet
lrbesartan is an angiotensin-II receptor antago­
nist, introduced very recently for the treatment of
hypertension. It is available as irbesartan INN
75mg, 150mg & 300mg/tablet.
Mode of action: See above under the text of
'angiotensin-11 receptor blocker'.
Ind: lrbesartan is indicated for the treatment of
hypertension.
S/E: Adverse events in patients receiving
irbesartan are generally mild and transient with
no relationship to dose:
Cardiovascular: Uncommon- subjective rhythm
disturbance, flushing, ECG abnormality, cardiac
murmur, cardiac rhythm disturbance, orthostatic
hypotension, atrial rhythm disturbance, bradycar­
dia, hypotension. Rare- syncope, conduction
disorder, myocardial infarction.
Dermatologic: Uncommon- pruritus, facial
erythema. Rare- dermatitis, acne, scalp-hair
abnormality.
Endocrine/Metabolic/Electrolyte imbalance:
Uncommon- sexual dysfunction, libido change.
Rare- breast disorder, gout, hot flashes.
Gastrointestinal: Uncommon- constipation,
flatulance, dry mouth, abdomen distention. Rare­
abnormal stool, decreased or increased appetite,
oral lesion, dysphagia, oesophagitis.
General: Uncommon- weakness, hyperhydrosis,
malaise, weight gain. Rare- cold sensation,
warmth sensation, pain.
Haematopoietic: Rare- anaemia.
Musculoskeletal/connective tissue: Uncommon­
muscle cramp, swelling extremity. Rare- arthri tis,
muscleache, myalgia, extremity weakness,
stiffness of lower extremity.
Nervous system: Uncommon- orthostatic dizzi­
ness, numbness, sleep disturbance, depression,
emotion labile/disturbance, somnolence, vertigo,
paresthesia. Rare- stress related disorder, tremor
•
QIMP-17 (51)
..'
coordination disturbance, disturbing dreams.
RenaVGenitourinary: Uncommon- urination
abnormality. Respiratory: Uncommon- epistaxis,
dyspnea. Special senses: Uncommon- vision dis­
turbance, hearing abnormality. Rare- eye distur­
bance, eyelid abnormality, visual field abnormal­
ity, medication bad taste, taste disturbance.
Others: As with other angiotensin-II receptor
antagonists, rare cases of hypersensitivity reac­
tions (urticaria, angioedema) have been reported
since the marketing of irbesartan. The following
have been reported very rarely during post-mar­
keting surveillance: arthralgia, asthenia, hyper­
kalemia, myalgia, tinnitus jaundice, elevated liver
function tests & impaired renal function including
isolated cases of renal failure in patients at risk.
C/I; Precautions & Warnings: See above
under the text. The safety of irbesartan in the
presence of heart failure has not been fully
defined. Sudden death has occurred in some
studies of patients with heart failure, and
although such deaths may have reflected the
natural history of the underlying heart failure,
caution is recommended when treating such
patients with irbesartan. At this time, experience
is limited with irbesartan in the treatment of
patients with ventricular dysfunction or cardiac
arrythmias; caution is advised.
Pregnancy & lactation: Drugs that act directly
on the renin-angiotensin system can cause fetal
and neonatal morbidity and death when
administered to pregnant women. lrbesartan is
excreted in the milk of lactating rats, but not
known whether irbesartan or its metabolites are
excreted in human milk. So, a decision should be
made whether to discontinue breast-feeding or to
discontinue the drug, taking into account the
importance of irbesartan in the therapy of the
mother and the potential risk to the infant.
Dosage & admin: Irbesartan may be used
either alone or in combination with other anti­
hypertensive agents ( e.g thiazide diuretic,
beta-adrenergic blocking agent, long-acting
calcium-channel blocking agent). The usual
initial and maintenance dose of irbesartan is
150mg once daily. It may be administered
with or without food. T herapy should be
adjusted according to blood pressure response.
Patients requiring further reduction in blood
pressure, dose may be increased to 300mg
once daily. If blood pressure is not adequately
controlled with irbesartan alone, a diuretic
(e.g hydrochlorothiazide 12.5mg daily) or
another antihypertensive drug ( e.g beta­
adrenergic blocking agent, long-acting calcium
channel blocking agent) may be added.
Patients with intravascular volume depletion:
Volume and/or sodium-depletion should be
corrected before initiating therapy with irbe­
sartan or a lower starting dose (e.g 75mg)
should be considered. Patients undergoing
haemodialysis should receive a starting dose
of 75mg, and the dose should be adjusted
according to B.P response. If the blood
pressure is not adequately controlled, the dose
can be increased.
Paediatric use: Safety and effectiveness in
paediatric patients have not been established.
Elderly and patients with renal or hepatic
impairment: No dosage reductions is generally
-
CARDIOVASCULAR DRUGS
necessary in the elderly or in patients with
impaired hepatic function (mild to moderate
,_
.
degree) or impaired renal function (regardle�
of degree), unless accompanied by uncorrected
volume depletion.
lrbesartan is contra-indicated in those
patients who are hypersensitive to irbesrtan.
Drug inter: No interactions would be expected
to occur with drugs whose metabolism is depend­
ent upon cytochrome P450 isoenzymes.
Irbesartan is primarily metabolized by CYP2C9,
however, during clinical studies, no significant
drug interactions were observed when irbesartan
was co-administered with warfarin (a drug
metabolized by CYP2C9). lrbesartan does not
affect the pharmacokinetics of digoxin. The phar­
macokinetics of irbesartan is not affected by co­
administration with nifedipine or hydrochloroth­
iazide. Based on experience with the use of
other drugs that affect the renin-angiotensin
system, concomitant use of potassium sparing
diuretics, potassium supplements, or salt
substitutes containing potassium may lead to
increase in serum potassium. Reversible
increases in lithium concentra-tions have been
very rarely reported with irbesartan. Therefore, if
co-administration of irbesartan and lithium
proves necessary, careful monitoring of serum
lithium is necessary.
+ ARBITAN Tab. Opsonin
Irbesartan INN 75mg & l 50mg/tablet.
75mg x 30's pack: 158.87 MRP
150mg x 30's pack: 318.01 MRP .
+ CAVAPRO Tab. Unimed & unihealth
Irbesartan INN 75mg, 150mg & 300mg/tablet.
75mg x 30's pack: 180.00 MRP
150mg x 30's pack: 360.00 MRP
300mg x lO's pack: 240.00 MRP
+ IRBES Tab. SK+F
lrbesartan INN 75mg & 150mg/tablet.
75mg x 50's pack: 250.00 MRP
150mg x 30's pack: 270.00 MRP
LOSARTAN POTASSIUM21,26
LOSARTAN POTASSIUM: Tablet
It is an angiotensin-11 receptor (type AT l )
antagonist, & now regarded as the frrst-line
therapy option for treating high blood pressure.
Mode of action: See above under the text of
'angiotensin-11 receptor blocker'.
Ind: All grades of hypertension, congestive
heart-failure & renal arterial stenosis. It may be
used alone or in combination with other antihy­
pertensive agents. It is an effective alternative for
patients who have to discontinue an ACE
inhibitor because of persistent dry cough.
S/E: The side-effects that experienced with losar­
tan are usually mild and occasional. Symptomatic
hypotension may occur, particularly in patients
with intravascular volume depletion (e.g those
treating with diureics). Hyperkalaemia may occur
occasionally. Other side-effects may include­
diarrhoea, dizziness, myalgia, migraine, urticaria,
pruritus, taste disturbance, upper respiratory
infection, leg pain & altered liver function tests.
C/I & Precautions: See above under the text.
Dosage & Admin: The usual starting dose is
50mg once daily; but, in patients with possible
 ."
osar
QIMP-17 (52)
Losartan Potassium 25 mg & SO mg Tablet
Losartan potassium INN 25mg & 50mg/tablet.
The brand of Losartan you can rely 25mg x 50's pack: 225.00 MRP
® 50mg x 30's pack: 240.00 MRP
Apex
f't � , !r r l i ,l
+ ARATEN-50 Tab. Unimed & unihealth
Losartan potassium INN 50mg/tablet.
depletion of intravascular volume (e.g patients 50mg x 30's pack: 240.00 MRP
treated with diuretics), patients with a history t ARBIUM Tab. Asiatic
of hepatic or renal impairment & in case of Losartan potassium USP 25mg, 50mg &
very elderly patients (over 75 years) should be 1 OOmg/tablet.
started with 25mg once daily. It can be 25mg x 50's pack: 175.00 MRP
administered once or twice daily with total 50mg x 50's pack: 300.00 MRP
daily doses ranging from 25mg to increasing lOOmg x 30's pack: 300.00 MRP
upto 1 OOmg after several weeks, if necessary. t CARD ISAN Tab. Beacon
If blood pressure is not controlled by losartan Losartan potassium INN 50mg/tablet.
alone, a diuretic may be added at a low dose. 50mg x 30's pack: 240.00 MRP
Losartan may be administered with or without t CARD ON Tab. SK+F
food. Losartan potassium INN 25mg & 50mg/tablet.
Children- not recommended. 25mg x 30's pack: 1 35.00 MRP
Drug inter: Losartan potassium, as with other 50mg x 40's pack: 320.00 MRP
drugs that block angiotensin II or its effects, t COZARIL-50 Tab. Hallmark
concomitant use of potassium-sparing diuretics Losartan potassium INN 50mg/tablet.
(e.g spironolactone, triamterene, amiloride), 50mg x 30's pack: 120.60 MRP
potassium supplements, or salt substitutes t G-LOSARTAN Tab. Gonoshas
containing potassium may lead to increases in Losartan potassium INN 25mg & 50mg/tablet.
serum potassium. 25mg x 30's pack: 90.00 MRP
Besides, no significant drug interactions have 50mg x 30's pack: 150.00 MRP
. . . ' .
. .
Losartan Potassium 25 & 50 mg tablet
�are lS on for managing Hypertension
been identified by clinical trials with
+ LARB Tab. Opsonin
hydrochlorothiazide, digoxin, warfarin,
Losartan potassium INN 25mg, 50mg &
cimetidine, ketoconazole and phenobarbital.
1 OOmg/tablet.
25mg x 30's pack: 1 1 8.76 MRP
50mg x 30's pack: 2 1 1 .13 MRP
l OOmg x 30's pack: 3 1 6.69 MRP
RDIL + LK Tab. Pacific
Losartan potassium INN 25mg & 50mg/tablet.
Losartan Potassium USP 25mg, 50mg & 1 OOmg Tablet
25mg x 30's pack: 1 35.00 MRP
50mg x 30's pack: 240.00 MRP
((l') DRUG INTERNATIONAL LTD.
9) TONGMWIPUR t LOK-50 Tab. Globe
Losartan potassium INN 50mg/tablet.
50n1g x 30's pack: 1 80.00 MRP
t ACUSAN 50 Tab. Concord
t LOPASS Tab. Sandoz
Losartan potassi11m 50mg/tablet.
Losartan potassium BP 25mg & 50mg/tablet.
50mg x 30's pack: 240.00 MRP
25mg x 28's pack: 1 68.00 MRP
t ANGILOCK Tab. Square
50mg x 28's pack: 280.00 MRP
Losartan potassium INN 25mg, 50mg &
1 OOmg/tablet. + LOPO Tab. Biopharma
25mg x 50's pack: 225.00 MRP Losartan potassium INN 25mg & 50mg/tablet.
50mg x 50's pack: 400.00 MRP 25mg x 30's pack: 135.00 MRP
l OOmg x 30's pack: 360.00 MRP 50mg x 30's pack: 240.00 MRP
+ ANIN Tab. Delta Pharma t LOPOS Tab. Zenith
Losartan potassium INN 50mg/tablet. Losartan potassi11m INN 25mg & 50mg/tablet.
50mg x 30's pack: 150.00 MRP 25mg x 1 OO's pack: 351:00 MRP
+ ANREB Tab. General 50mg x 30's pack: 1 80:60 MRP
50mg x 1 OO's pack: 602:00 MRP
t LOPOTEN Tab. Euro Pharma
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 30's pack: 1 05.00 MRP
50mg x 30's pack: 180.00 MRP
+ LOSA-25 Tab. Alco Pharma
Losartan potassium INN 25mg/tablet.
25mg x 30's pack: 1 05.00 MRP
+ LOSA-50 Tab. Alco Pharma
Losartan potassium INN 50mg/tablet.
50mg x 30's pack: 1 80.00 MRP
+ LOSACARD Tab. Novo Healthcare
Losartan potassium USP 25mg & 50mg/tablet.
25mg x 30's pack: 135.00 MRP
50mg x 30's pack: 240.00 MRP
t LOSACOR Tab. Healthcare
Losartan potassium INN 50mg/tablet.
50mg x 30's pack: 240.00 MRP
+ LOSAN Tab. Orion Pharma
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 30's pack: 1 35.00 MRP •
50mg x 30's pack: 240.00 MRP
+ LOSAP Tab. Doctor's
Losartan potassium INN 50mg/tablet.
50mg x 30's pack: 1 50.00 MRP
t LOSAR Tab. Nipa
Losartan potassium INN 50mg/tablet.
50mg x 30's pack: 240.00 MRP
t LOSARCAR Tab. Medimet
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 50's pack: 175.00 MRP
50mg x 30's pack: 180.00 MRP
t LOSARDIL Tab. Drug Inter.
Losartan potassium USP 25mg, 50mg &
1 OOmg/tablet.
25mg x 50's pack: 175.00 MRP
50mg x 30's pack: 1 80.00 MRP
l OOmg x 20's pack: 200.00 MRP
t LOSARON Tab. Amico
Losartan potassium INN 50mg/tablet.
'
50mg x 30's pack: 1 50.00 MRP
t LOSARPEX Tab. Apex
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 30's pack: 1 05.00 MRP
50mg x 30's pack: 180.00 MRP
t LOSART Tab. Acme
Losartan potassium INN 25mg, 50mg &
1 OOmg/tablet.
25mg x 30's pack: 135.00 MRP
50mg x 30's pack: 240.00 MRP
1 OOmg x 30's pack: 360.00 MRP

+ IJOSATAN Tab. Popular
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 30's pack: 135.00 MRP
50mg x 30's pack: 240.00 MRP
+ LOSIUM Tab. Ibo Sina
Losartan potassium INN 25mg & 50mg/tablet.
..
25mg x 30's pack: 105.00 IP
50mg x 30's pack: 180.00 IP
+ LOSPIL Tab. White Horse
Losartan potassium INN 50mg/tablet.
50mg x 50's pack: 400.00 MRP
+ LOSPRE Tab. Kumudini
Losartan potassium INN 50mg/tablet.
50mg x 30's pack: 180.00 MRP ·
+ LOTAS Tab. Ambee
Losartan potassium INN 50mg/tablet.
50mg x 30's pack: 170. 70 MRP
+ OSARTAN Tab. Aristopharma
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 50's pack: 225.00 MRP
50mg x 30's pack: 240.00 MRP
+ OSARTEK Tab. Pharmadesh
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 50's pack: 175.00 MRP
50mg x 30's pack: 240.00 MRP
+ OSARTIL Tab. Incepta
Losartan potassium INN 25mg, 50mg &
1 OOmg/tablet.
25mg x 50's pack: 175.00 MRP
50mg x 50's pack: 300.00 MRP
1 OOmg x 30's pack: 300.00 MRP
+ OSTAN Tab. Renata
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 30's pack: 135.00 MRP
50mg x 30's pack: 300.00 MRP
+ PARTEN Tab. Jayson
Los artan potassium INN 25mg & 50mg/tablet.
25mg x 30's pack: 90.60 IP
50mg x 30's pack: 150.60 IP
+ PROSAN Tab. Beximco
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 50's pack: 225.00 IP
50mg x 50's pack: 400.00 IP
+ RAKLOK Tab. RAK Pharma
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 30's pack: 105.00 MRP
Losartan Potassium 25
'
".
QIMP-17 (53)
50mg x 30's pack: 180.00 MRP
+ REPACE Tab. Sun Pharma
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 50's pack: 225.00 MRP
50mg x 50's pack: 400.00 MRP
+ ROSATAN Tab. ACI
Losartan potassium INN 50mg/tablet.
50mg x 30's pack: 180.60 MRP
+ TARAN Tab. Kemiko
Losartan potassium INN 25mg & 50mg/tablet.
25mg x 50's pack: 225.00 MRP
50mg x 50's pack: 400.00 MRP
+ XELOTAN Tab. Pharmasia
Losartan potassium INN 50mg/tablet.
50mg x 30's pack: 180.00 MRP
OLMESARTAN52
OLMESARTAN MEDOXOMIL: Tablet
Olmes artan medoxomil is a selective angiotensin
II receptor (subtype AT 1) antagonist. It is
available as olmesartan medoxomil INN 20mg &
40mg tablet.
Mode of action: Olmesartan medoximil blocks
the vasoconstrictor effects of angiotensin II by
selectively blocking the binding of angiotensin II
to the AT 1 receptor in vascular smooth muscle.
Its action is, therefore, independent of the
pathways for angiotensin II synthesis.
Ind: Olmesartan is indicated for the treatment of
hypertension. It may be used alone or in
.
.
combination with other antihypertensive agents.
C/I: Hypersensitivity to any of its ingredients.
S/E: In general, the side-effects are mild & in a
small number undesired events have been
reported, such as- dizziness, vertigo, hypotension
(rare), tachycardia, abdominal pain, diarrhea,
dyspepsia, gastroenteritis, nausea, bronchitis,
cough (rare), pharyngitis, rhinitis, rash, angio­
oedema (rare), arthritis (arthralgia), back pain,
myalgia, haematuria, urinary tract infection,
hyperlipidemia, hyperuricaemia, hyperkalaemia
(rare), chest pain, fatigue, influenza-like
symptoms and peripheral oedema.
Precautions: Angiotensin II receptor antagonist
The preferred antihypertensive worldwide
mg & 50 mg Tablet
•
Losartan potassium
( olmeartan medoximil) should be used with
caution in patients with impaired renal function
and renal artery stenosis; patients with aortic or
mitral valve stenosis and obstructive hypertrophic
cardiomyopathy. The use of olmesartan is not
recommended in patients with hepatic
impairment, since there is limited experience in
this patient group.
Pregnancy & lactation: There is no experience
with the use of olmes artan medoxomil in
pregnant women. But, drugs that act directly on
the renin-angiotensin system administered during
the second and third trimesters of pregnancy
have been reported to cause foetal and neonatal
injury and even death to the fetus. So it is
probably best to avoid using the drug when
pregnancy is detected. Olmesartan is excreted in
the milk of lactating rats but it is not known
whether olmesartan is excreted in human milk.
However, mothers must not breast-feed if they
are taking olmesartan medoxomil.
25 mg & 50 mg Tablet
&
Dosage & admin: Dosage must be
individualized. The usual initial dose is 1 Omg
once daily. In patients whose blood pressure is
not adequately controlled at this dose, the dose
may be increased to 20mg once daily as the
optimal dose. For patients requiring further
reduction in blood pressure after 2 weeks of
therapy, the dose of olmesartan may be
increased to 40mg. Doses above 40mg do not
appear to have greater effect.
Elderly & renal impairment: The maximum
dose in elderly and patients with mild to
moderate renal impairment is 20mg once daily.
Children & adolescents: The safety and
efficacy have not been established in children
and adolescents up to 18 years of age.
•
Drug inter: No significant drug interactions
were reported when olmesartan was co­
administered with digoxin or warfarin. The blood
pressure lowering effect of olmesartan can be
Apex
J>h,11111c1

increased by concomitant use of other antihyper­
tensive medications. Use of potassium-sparing
diuretics, potassium supplements, and salt
substitutes containing potassium or other drugs
that may increase serum potassium levels (e.g
heparin) may lead to increases in serum
potassium, such concomitant use is therefore not
recommended.
+ ABETIS Tab. ACI
Olmesartan medoxomil INN lOmg, 20mg &
40mg/tablet (film-coated).
1Omg x 30's pack: 150.60 MRP
20mg x 30's pack: 240.90 MRP
40mg x 30's pack: 451.80 MRP
+ OLMECAR Tab. Square
Olmesartan medoxomil INN 20mg &
40mg/tablet (film-coated).
20mg x 30's pack: 240.00 MRP
40mg x 30's pack: 450.00 MRP
+ OLMESAN Tab. Beximco
Olmesartan medoxomil INN 20mg &
40mg/tablet (film-coated).
20mg x 30's pack: 240.00 MRP
40mg x 30's pack: 450.00 MRP
+ OLMESART Tab. Sharif
Olmesartan medoxomil INN 20mg &
40mg/tablet (film-coated).
20mg x 30's pack: 240.00 MRP
40mg x 20's pack: 300.00 MRP
+ OLMETIC Tab. Drug Inter.
Olmesartan medoxomil INN 20mg/tablet (f.c).
20mg x 30's pack: 240.00 MRP
+ OLMEZEST Tab. Sun Pharma
Olmesartan medoxomil INN 1Omg, 20mg &
40mg/tablet (film-coated).
lOmg x 30's pack: 150.00 MRP
20mg x 30's pack: 241.50 MRP
40mg x 30's pack: 450.00 MRP
+ OLSART Tab. Opsonin
Olmesartan medoxomil 20mg & 40mg/tablet
20mg x 30's pack: 211.13 MRP
40mg x 20's pack: 263. 90 MRP
+ XYOTIL Tab. Incepta
Olmesartan medoxomil INN 20mg &
40mg/tablet (film-coated).
20mg x 30's pack: 240.00 MRP
40mg x 30's pack: 450.00 MRP
TELMISARTAN87•146
•
TELMISARTAN: Tablet
Telmisartan is a nonpeptide angiotensin II
receptor (type A T l ) antagonist. It is available as
telmisartan INN 40mg/tablet (film-coated).
Mode of action: See above under the text of
'angiotensin-II receptor blocker'.
Ind: Telmisartan is indicated for the treatment of
hypertension and heart failure.
'
C/I: Telmisartan is contraindicated in patients
who are hypersensitive to any component of the
durg.
S/E: Dyspepsia, myalgia, abdominal pain,
headache and fatigue.
Precaution: Impaired hepatic function: As the
majority of the drug is eliminated by biliary
QIMP-17 (54)
•.
excretion, caution should be taken for these
patients. Renal impairment: Caution should be
taken for the patients with renal impairment.
Pregnancy & lactation: Telmisartan should not
be given in pregnancy and lactation.
Dosage & admin: The usual starting dose of
telmisartan is 40mg once daily. The dose may -
be increased up to 80mg if required.
For management of Telmisartan tablet can be administered with
or without food.
new patient with hypertension Children: Safety and effectiveness in
pediatric patients has not been established.
Drug inter: When telmisartan was .
coadministered with digoxin, median increases in
• digoxin peak plasma concentration (49%) and in
®
trough concentration (20%) were observed. It is,
therefore, recommended that digoxin levels be
monitored when initiating, adjusting, and
Olmesartan 1 O mg, 20 mg & 40 mg tablet
discontinuing telmisartan to avoid possible over­ •
or under-digitalization.
Coadministration of telmisartan did not result in
The best antihypertensive a clinically significant interaction with
amlodipine, acetaminophen, glibenclamide,
simvastatin, hydrochlorothiazide or ibuprofen.
to start with Telmisartan is not metabolized by the
cytochrome P450 system and had no effects in
vitro on cytochrome P450 enzymes, except for
some inhibition of CYP2Cl 9
+ MITOSAN Tab. Sandoz
Telmisartan INN 40mg & 80mg/tablet.
40mg x 30's pack: 390.00 MRP
80mg x 30's pack: 630.00 MRP
+ TELCARDIS Tab. UniMed & UniHealth
Telmisartan USP 40mg & 80mg/tablet.
40mg x 14's pack: 175.00 MRP
80mg x 14's pack: 280.00 MRP
VALSARTAN21•54
VALSARTAN: Capsuleffablet
Ind: Treatment of hypertension.
C/I: Hypersensitivity to any of the components
of valsartan. Pregnancy & lactation.
S/E: The adverse effects that experienced in a
few percentage of people are- headache,
dizziness, viral infection, upper respir'!tory tract
infection, coughing, diarrhoea, fatigue, rhinitis,
sinusitis, back pain, abdominal pain, nausea,
pharyngitis, arthralgia. Other adverse experiences
with a frequency below I% included- oedema,
®
asthenia, insomnia, rash, decreased libido &
vertigo. There are some changes found during
OlrMSartan 20mg + Hydrochlorolhiuide 1 2.Smg tablet
laboratory study, such as, decrease in
haemoglobin & haematocrit, neutropenia.
Occasional elevations of liver function values.
For Hypertension &
Precautions & warnings: Sodium and/or
Isolated Systolic Hypertension volume depleted patients, such as, those
receiving high doses of diuretics, symptomatic
hypotension may occur in rare cases after
initiation of therapy. Sodium and/or volume
depletion should be corrected before starting
treatment with valsartan; (for example, by
reducing the diuretic dose). If hypotension
occurs, the patient should be placed in the supine
position and, if necessary, given an i. v infusion
of normal saline. Treatment can be continued
•
once the blood pressure has stablised .
Renal artery stenosis: No significant chailge·.has
been found with short-term administration, yet
monitoring is recommended as a safety measure.

Effects on ability to drive and use machines: As
with other antihypertensive agents, it is advisable
to exercise caution when driving or operating
machinery.
Pregnancy & lactation: Valsartan should not be
given during pregnancy & lactation; if pregnancy
is detected during therapy, should be discontin­
ued as soon as possible.
Dosage & admin: The recommended dose is
80mg once daily, irrespective of race, age, or
gender. In patients whose blood pressure is not
adequately controlled, the daily dose may be
increased to 160mg, or a diuretic may be
added. No dosage adjustment is required for
patients with renal impairment or for patients
with hepatic insufficiency of nonbiliary origin
and without cholestasis. Valsartan may also be
administered with other antihypertensive
agents.
Child: The safety and efficacy of valsartan
.
.
have not been established in children.
Drug inter: No clinically significant interactions
were observed when valsartan was coadminis­
tered with amlodipine, atenolol, cimetidine,
digoxin, frusemide, glyburide, hydrochloroth­
iazide or indomethacin.
+ AROVAN-80 Cap. Aristopharma
Valsartan 80mg/capsule.
80mg x 30's pack: 300.00 MRP
+ CARDIVAL Cap. Drug Inter.
Valsartan INN 80mg/capsule.
80mg x 30's pack: 300.00 MRP
+ DIOVAN Tab. Novartis
Valsartan 40mg, 80mg & 160mg/tablet.
40mg x 28's pack: 952.00 MRP
80mg x 28's pack: 1344.00 MRP
160mg x 28's pack: 1848.00 MRP
+ DISYS Tab. Healthcare
Valsartan 80mg & 160mg/tablet.
80mg x 30's pack: 300.00 MRP
160mg x 30's pack: 540.00 MRP
+ VALPRESS 80 Cap. Silva
Valsartan INN 80mg/capsule.
80mg x 30's pack: 240.00 MRP
+ VALSAN 80 Cap. Mystic
Valsartan INN 80mg/capsule.
80mg x 20's pack: 500.00 (?) MRP
+ VALSARTIL Tab. Incepta
Valsartan 40mg, 80mg & 160mg/tablet.
40mg x 30's pack: 150.00 MRP
80mg x 30's pack: 270.00 MRP
l 60mg x 30's pack: 480.00 MRP
+ VALSET 80 Cap. Orion Pharma
Valsartan INN 80mg/capsule.
80mg x 30's pack: 180.60 MRP
Vasodilator antihypertensive
drugs
Commonly used vasodilator antihypertensive
drugs include- Diazoxide, Hydralazine,
Minoxidil, Sodium nitroprusside etc.
Preparations: Currently not available.
Diuretics
1. Thiazides and related diuretics
I
QIMP-17 (SS)
. .
2. Loop diuretics
3. Potassium sparing diuretics
4. Aldosterone antagonists
5. Osmotic diuretics
6. Mercurial diuretics
7. Carbonic anhydrase inhibitors.
8. Diuretics with potassium
Thiazides & related diuretics21
T hiazide & related diuretics include­
Bendroflumethiazide (Bendrofluazide),
Benzthiazide, Chlortalidone (Chlorthalidone),
Cyclopenthiazide, Hydrochlorothiazide,
Clopamide, Hydroflumethiazide, Indapamide,
·
Mefruside and Polythiazide.
But, benzthiazide, clopamide,
cyclopenthiazide, and hydrochlorothiazide do
not offer any significant advantage over
bendroflumethiazide or chlortalidone.
Some newer thiazide related diuretics are
available, found more potent and effective
than the olders, which include- Jndapamide,
Metolazone, Xipamide.
Thiazide group of drugs
HYDROCHLOROTHIAZIDE2I,33,52
HYDROCHLOR O T HIAZIDE: Tablet.
Hydrochlorothiazide is a thiazide diuretic. It is
available as hydrochlorothiazide BP 25mg &
50mg/tablet.
Mode of action: Thiazides affect the renal tubu­
lar mechanisms of electrolyte reabsorption,
directly increasing excretion of sodium & chlo­
ride in approximately equivalent amounts.
Indirectly, the diuretic action of hydrochloroth­
iazide reduces plasma volume, with consequent
increases in plasma renin activity, increases in
aldosterone secretion, increases in urinary
potassium loss, & decreases in serum potassium.
Ind: Oedema, hypertension.
C/I: Anuria, lactation, severe renal failure.
S/E: Rashes, thrombocytopenia.
Cautions: May cause hypokalemia; aggravates
diabetes and gout; renal and hepatic impairment
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women.
Hydrochlorothiazide should be used during
pregnancy only if the potential benefit justifies
the risk to the fetus.
Thiazides are excreted in human breast milk.
Because of the potential for serious adverse
reactions in nursing infants, a decision should be
made whether to discontinue nursing or to
discontinue the drug, taking into account the
importance of the drug to the mother. ·
Dosage & admin: Adult: Diuresis, 50-lOOmg
once or twice daily or intermittently.
Hypertension, initially 50-1OOmg daily as a
single or divided doses, max. 200mg daily.
Child: Under 6 months upto 3.5mg/kg body­
wt. daily; 6 months to 2 years 12.5-37.5mg
daily; 2-12 years 37.5-lOOmg daily. All in two
divided doses.
Drug inter: Hydrochlorothiazide, when adminis­
tered concurrently the following drugs may inter-
CARDIOVASCULAR DRUGS
.
act with thiazide diuretics, such as alcohol, barbi­
turates, or narcotics; these may cause potentiation
of orthostatic hypotension.
Antidiabetic drugs (oral agents and insulin)­
dosage adjustment of the antidiabetic drug may
be required.
Other antihypertensive drugs-additive effect or
potentiation.
Cholestyramine and colestipol resins- absorption
of hydrochlorothiazide is impaired in the
presence of anionic exchange resins.
Corticosteroids, ACTH- intensified electrolyte
depletion, particularly hypokalemia.
Skeletal muscle relaxants, tubocurarine- possible
increased responsiveness to the muscle relaxant.
Lithium- diuretic agents reduce the renal
clearance of lithium and add a high risk of
lithium toxicity.
NSAID can reduce the diuretic, natriuretic, and
antihypertensive effects of loop,
potassiumsparing and thiazide duretics.
+ ACUREN Tab. Incepta
Hydrochlorothiazide 25mg & 50mg/tablet.
25mg x l OO's pack: 70.00 MRP
50mg x l OO's pack: 100.00 MRP
+ HTZ Tab. U nimed & unihealth
Hydrochlorothiazide 25mg/tablet.
25mg x lOO's,pack: 70.00 MRP
+ HYPEZIDE Tab. Pacific
Hydrochlorothiazide 50mg/tablet.
50mg x 1OO's pack: 100.00 MRP
Thiazide related diuretics
CHLORTHALIDONE48, 133
CHLORT HALIDONE: Tablet
Chlorthalidone is a thiazide related diuretic.
Chemically it is a monosulfamyl diuretic (a
racemic mixture of 2-chloro-5-( 1-hydroxy-3-oxo-
1-isoindolinyl) benzenesulfonamide), which dif­
fers from thiazide group in that a double-ring
system is incorporated in its structure.
Chlorthalidone is a long acting diuretic with low
toxicity. Its diuretic effect occurs in approximate­
ly 2.6 hours and continues for up to 48-72 hours.
It is available as chlorthalidone USP 25mg tablet.
Ind: 1. Essential hypertension- as a single drug
or in combination with other antihypertensive
drugs. 2. Ascites due to cirrhosis in stable
patients. 3. Edema due to nephrotic syndrome. 4.
Mild to moderate chronic heart failure.
C/I: Patients with anuria, diabetes mellitus, gout
and/or hyperuricemia, hyperlipidemia and known
hypersensitivity to chlorthalidone or other
sulfonamide drugs.
S/E: Dry mouth, thirst, nausea, vomiting, storma­
ch pain, loss of appetite, diarrhea, constipation,
feeling weak, drowsy, restless, dizziness,
headache, or light-headed, fast or uneven
heartheat, orthostatic hypotension, muscle pain or
weakness, low fever, urinating less than usual or
not at all, easy bruising or bleeding, red or purple
spots on skin, purpura, dark urine, clay-colored
stools, unusual weakness, numbness or tingly
feeling, photosensitivity, rash urticaria.
Precautions: Renal impairment: Chlorthalidone
dosage should be reduced in moderate renal fail-
 CARDIOVASCULAR DRUGS
ure - every 24 or 48 hours - and should not be
used in advanced renal failure.
Liver disease: There is a risk of precipitating
hepatic encephalopathy in patients with liver
cirrhosis and ascites.
Pregnancy & lactation: It is better to avoid
chlorthalidone in pregnancy as it crosses the
placenta. Significant amount of chlorthalidone
enter breast milk; like other long-acting thiazides,
it can suppress lactation. Chlorthalidone should
not be prescribed for lactating mother.
Dosage & admin: Hypertension: Therapy, in
most patients, should be initiated with 25mg
single daily dose. If the response is insufficient
after a suitable trial, the dosage may be
increased to a single daily dose of 50mg. If
additional control is required, the dosage of
chlorthalidone may be increased to 1 OOmg
once daily.
Edema: Adults, initially 50 to 1 OOmg daily, or
1OOmg on alternate days. Some patients may
require 150 to 200mg at these intervals or up
to 200mg daily. Dosages above this level, how­
ever, do not usually produce a greater
response.
In the elderly, this is a suitable drug for treat­
ing hypertension, in particular systolic hyper­
tension. Dose of 50mg daily, or less, should be
used to avoid hypovolemia & hypokalemia.
Drug inter: Chlorthalidone may add to or
potentiate the action of other antihypertensive
drugs. Potentiation occurs with ganglionic
peripheral adrenergic blocking drugs.
+ THALIDON Tab. Popular
Chlorthalidone USP 25mg/tablet.
30's pack: 150.60 MRP
+ THALIN Tab. Beximco
Chlorthalidone USP i5mg/tablet.
60's pack: 300.00 MRP
INDAPAMIDE21,s3
INDAPAMIDE: Tablet
lndapamide is a thiazide related diuretic,
chemically related to chlorthalidone.
•
Ind: Treatment of essential hypertension.
C/I: This drug must not be taken in the following
situations- known allergy to this drug or to sul­
phonamides; renal failure; serious liver disease;
hypokalaemia.
S/E: Feeling of tiredness (fatigue). Allergic
manifestations, rare cases of skin rash. Feelings
of vertigo when changing f rom lying to standing
position. Increased risk of dehydration in the
elderly and heart failure patients.
Variations in certain blood parameters may occur,
in particular excessive loss of potassium, particu­
larly in the elderly or malnourished individuals.
Warnings: Administration of this drug must be
stopped in case of liver disease.
Precautions: Use indapamide cautiously in the
following situations- disturbed water/electrolyte
balance, diabetes, gout, kidney disease.
Pregnancy & lactation: In case of pregnancy,
breast-feeding or desiring pregnancy consult
physician before taking indapamide.
Dosage: 2.Smg tablet (or 1.5mg SR tablet)
daily in single dose, preferably in the morning.
Duration of treatment as per physician's
advice. In case of missing dose do not take a
I
QIMP-17 (56)
·.
double dose on the following day.
Drug inter: To avoid possible interactions
between several drugs, and in particular lithium
and certain drugs used for cardiac arrhythmia,
consult physician before taking any other
medication.
+DIBERT SR Tab. Sandoz
Indapamide 1.5mg/tablet (sustained release).
28's pack: 224.00 MRP.
+HYPEN SR Tab. Opsonin
Indapamide 1.5mg/tablet (sustained release).
30's pack: 132.48 MRP
+IDATIX SR Tab. Incepta
Indapamide 1.5mg/tablet (sustained release).
50's pack: 250.00 MRP
+INDAMID SR Tab. Sharif
Indapamide 1.5mg/tablet (sustained release).
30's pack: 150.00 MRP
+INDAPA-SR Tab. Drug Inter.
Indapamide l .5mg/tablet·(sustained release).
50's pack: 250.00 MRP
+INDIMIDE SR Tab. Healthcare
Indapamide 1.5mg/tablet (sustained release).
30's pack: 195.00 MRP
+IPIDE-SR Tab. Renata
Indapamide 1.5mg/tablet (sustained release).
30's pack: 150.00 MRP
+NAT RILIX SR Tab. Servier
Indapamide l .5mg/tablet (sustained release).
30's pack: 264.90 MRP
+NATRI-SR Tab. Renata
Indapamide l .5mg/tablet (sustained release).
30's pack: 150.00 MRP
+ REPRES SR Tab. Square
Indapamide l .5mg/tablet (sustained release).
30's pack: 150.30 MRP
+ T RILIX SR Tab. Silva
Indapamide 1.5mg/tablet (sustained release).
20's pack: 100.00 MRP
+XELIX SR Tab. Aristopharma
Indapamide 1.5mg/tablet (sustained release).
30's pack: 150.00 MRP
Loop diuretics21,26,1os
There are four diuretic agents, which are playing
their major role on the ascending limb of the
loop of Henle, known as loop diuretics. These
are- Bumetanide, Frusemide, Torasemide &
Ethacrynic acid
Loop diuretics are the most effective drugs &
are more useful in emergency manegment of
acute edematous conditions, such as acute
pulmonary edema.
Mode of action: Loop diuretics act on the lumen
of thick ascending limb of loop of Henle, inhibit
the Na+/K+/Cl- cotransport & thus decreasing
reabsorption of Na+, K+, & Cl-. This leads to
remove excess water from the body. It does not
significantly alter glomerular filtration rate, renal
plasma flow, or acid-base balance. Loop diuretics
also increase the CaI I content of urine, while
thiazide diuretics decrease.
BUMETANJDE 26,78
BUMETANIDE: Tablet/Injection
Bumetanide is a loop diuretic with a rapid onset
and short duration of action. Pharmacological
and clinical studies have shown that 1 mg
bumetanide has a diuretic potency equivalent to
approximately 40mg frusemide. Bumetanide is
available as bumetanide BP 1 mg & 5mg tablet &
2mg in 4ml injection.
Mode of action: The major site of bumetanide <
action is the ascending limb of the loop of henle,
as shown by marked reduction of free-water
clearance (CH2 0) during hydration and tubular
free-water reabsorption (TCH2 0) during
hydropenia. Reabsorption of chloride in the
ascending limb is also blocked by bumetanide,
and bumetanide is some what more chloruretic
than natriuretic.
Ind: Bumetanide is indicated for the treatment of
edema associated with congestive heart failure,
hepatic and renal disease, including nephrotic
syndrome.
C/I: Bumetanide is contraindicated in anuria.
Although bumetanide can be used to induce
diuresis in renal insufficiency, any marked
increase in blood urea nitrogen or creatinine, or
the development of oliguria during therapy of .
patients with progressive renal disease, is an
indication for discontinuation of treatment with
bumetanide. Bumetanide is also contraindicated
in patients in hepatic coma or in states of severe
electrolyte depletion until the condition is
improved or corrected. Bumetanide is cotraindi­
cated in patients hypersensitive to this drug.
S/E: Frequently observed side effects are­
muscle cramps, dizziness, hypotension,
headache, nausea, & encephalopathy (in patients
with preexisting liver disease). Less frequent side
effects are- impaired hearing, pruritus,
electrocardiogram changes, weakness, hives,
abdominal pain, arthritic pain, musculoskeletal
pain, rash & vomiting.
Precautions: Serum potassium should be meas­
ured periodically and potassium supplements or
potassium-sparing diuretics can be added if
necessary. Periodic determinations of other
electrolytes are advised in patients treated with
high dosage or for prolonged periods, particularly
in those on low salt diets. Hyperuricemia may
occur; it has been asymptomatic in cases reported
to date. Reversible elevations of the BUN and
creatinine may also occur specially in association
with dehydration and particularly in patients with •
renal insufficiency. Bumetanide may increase
urinary calcium excretion with resultant
hypocalcemia. Diuretics have been shown to
increase the urinary excretion of magnesuim; this
may result in hypomagnesemia.
Warning: Water volume and electrolyte deple­ •
tion: The dose of bumetanide should be adjusted
•
to the patient's need: Excessive doses or too fre-
quent administration can lead to profound water •
loss, electrolyte depletion, dehydration, reduction
in blood volume and circulatory collapse with the -
possibility of vascular thrombosis and embolism,
particularly in elderly patients. Hypokalemia:
Hypokalemia can occur as a consequece of
bumetanide administration. Prevention of
hypokalemia requires particular attention in the
following conditions- patients receiving digitalis
and diuretic for congestive heart failure,. hepatic
cirrhosis and ascites, states of aldosterone excess
with normal renal function, potassium-losing

nephropathy, certain diarrheal states. Allergy to
sulfonamides: Patients allergic to sulfonamides
may show hypersensitivity to bumetanide.
Thrombocytopenia: Patients should be observed
regularly for possible occurrence of thrombocy­
topenia.
Pregnancy & lactation: Pregnancy category-C.
Bumetanide is neither teratogenic nor embryoci­
dal in mice when given in doses up to 3400 times
the maximum human therapeutic dose.
Dosage & admin: The usual total daily dosage
is O.Smg to 2mg and in most patients given as
single dose. If the diuretic response to an
initial dose of bumetanide is not adequate, in
view of its rapid onset and short duration of
action, a second or third dose may be given at
4 to 5-hour intervals up to a maximum daily
dose of 1 Omg.
Drug inter: May increase digitalis and lithium
toxicity. Hypokalemia may cause with digitalis,
diuretics in CHF. Alcohol & CNS depressants
may increase orthostatic hypotension. Avoid
probenecid and indomethacin. Ototoxicity may
be potentiated with aminoglycosides.
t BUMECARD Tab. Incepta
Bumetanide BP l mg & 5mg/tablet.
l m g x 30's pack: 150.00 MRP
5mg x 30's pack: 540.00 MRP
t BUMECARD Inj. Incepta
Bumetanide BP 2mg/4ml ampoule: i.m/i.v injectin.
2mg (4ml) amp x S's pack: 150.00 MRP
t CONART Tab. ACI
Bumetanide BP 1mg/tablet.
lmg x 30's pack: 60.30 MRP
t URINIDE Tab. Navana
Bumetanide BP 1mg/tablet.
lmg x 20's pack: 200.80 MRP
FRUSEMIDE 21,26,46,129
FRUSEMIDE: Tablet/Syrup/Injection.
Frusemide is a short-acting loop diuretic of
sulfonamide group. It is available as- frusemide
BP 40mg & 250mg oral tablet, 20mg/5ml syrup
and 20mg/2ml ampoule for i.m or i.v injection.
Mode of action: Frusemide inhibits the
Na+/K.+/2Cl- co-transport in the ascending limb
of loop of Henle, as well as in both proximal and
distal tubules, and blocks the reabsorption of
electrolytes (Na+, K+ and Cl- ions) and water.
Ind: Oedema of cardiac, hepatic or renal origin
(e.g oliguria in acute or chronic renal failure,
nephrotic syndrome etc.). Toxaemia of pregnan­
cy. Mild, moderate or severe hypertension.
C/I: Precomatose state associated with liver
cirrhosis.
S/E: Rashes; tinnitus and deafness in impaired
renal function.
Cautions: Causes hypokalaemia & hyponatra­
emia; aggravates diabetes and gout, liver failure,
prostatism.
Dosage & admin: By mouth: Adult: Initially
20-80mg once or twice daily, then adjusted
according to response. In patients with chro­
nic renal insufficiency- initial daily dose of
2S0mg; if a satisfactory diur�sis is not pro­
duced- dose may be increased in steps of
250mg at 4-6 hourly intervals up to a maxi­
mum daily dose of l.Sgm in 24 hours, and in
QIMP-17 (57)
exceptional cases up to 2gm in 24 hours in
severe oliguria may be given.
By i.m or slow i.v injection: 20-40mg; by i.v
infusion in oliguria 0.25-lgm at a rate not
exceeding 4mg/min.
t FRUDEMA Tab. Pacific
Frusemide 40mg/tablet
l OO's pack: 53.00 MRP
t FRUNEP 250 Tab. UniMed & Uni.Health
Frusemide BP 250mg/tablet
250mg x 50's pack: 160.00 MRP
t FRUSIN Tab. Opsonin
Frusemide 40mg/tablet
1 OO's pack: 46.62 MRP
t FRUSIN Syp. Opsonin
Frusemide 20mg/5ml: syrup
60ml bot: 75. 06 MRP ·
t FRUSIN Inj. Opsonin
Frusemide 20mg/2ml ampoule: injection
25's pack: 77.63 MRP
t FUSID Tab. Square
Frusemide 40mg/tablet.
200's pack: 128.00 MRP
t FUSID lnj. Square
Frusemide 20mg/ampoule: injection
10 amps pack: 80.00 MRP
t G-FRUSEMIDE Tab. Gonoshas.
Frusemide 40mg/tablet
1OO's pack: 50.00 MRP
t G-FRUSEMIDE Inj. Gonoshas.
Frusemide 20mg/2ml ampoule: injection
2ml amp x 25's pack: 75.00 MRP
t LASIX Tab. Sanofi-aventis
Frusemide 40mg/tablet
l OO's pack: 64.00 MRP
t LASIX lnj. Sanofi-aventis
Frusemide 20mg/2ml ampoule: injection
2ml amp x 25's pack: 200.00 MRP
t T ROFURIT Tab. Ambee
Frusemide 40mg/tablet
l OO's pack: 53.00 MRP
t T ROFURIT Inj. Ambee
Frusemide 20mg/2ml ampoule: injection
10 amps pack: 35.30 MRP
TORASEMIDE 26
TORASEMIDE: Tablet
Torasemide is also a loop diuretic of sulfonamide
group.
Mode of action: See above under the loop
diuretics.
Ind: Management of edmea of cardiac, renal and
hepatic origin. Management of hypertens�on, as a
sole therapeutic agent or in combination with
other classes of antihypertensive agents.
C/I: Known hypersensitivity to torasemide and
other sulfonyl ureas. It is also contraindicated in
patients with anuria.
S/E: Usually torasemide is well tolerated.
However, a few side effects like dry mouth,
dizziness, tiredness, skin rash, diarrhea,
constipation, nausea, vomiting, orthostatic
hypotension and muscle cramp may occur. All
side effects are usually mild and transient.
Precautions: Precautions should be taken while
torasemide is advised in patients with diabetes,
gout, hypotension and liver failure.
Pregnancy & Lactation: As there are no ade-
CARDIOVASCULAR DRUGS
quate and well-controlled stddies of torasemide
have been carried out in pregnant & nursing
mother, & animal reproduction studies are not
always predictive of human response, torasemide
can only be used during pregnancy if it is clearly
needed, & caution should be exercised when
administering to a nursing mother.
Dosage & admin: Edema- usual oral dose is
Smg once daily, preferably in the morning. If
necessary, the dose can be increased stepwise
up to 20mg once daily. The usual maximum
dose is 40mg daily. Dosage can be taken
without regard to meal.
Essential hypertension- an oral low dose of
2.Smg once daily is recommended. If necessa­
ry, the dose can be increased to Smg once daily.
Children: Safety and efficacy of torasemide in
children have not been established.
Drug inter: ACE inhibitors- potentiation of
hypotension may occur. Aminoglycosides­
torasemide may increase the ototoxicity of
aminoglycosides.
Corticosteroids- increment of risk of
hypokalemia.
t DILAST 20 Tab. Incepta
Torasemide INN 20mg/tablet
20mg x 30's pack: 240.00 MRP
t DYTOR Tab. UniMed & UniHealth
Torasemide 2.5mg & 5mg/tablet
2.5mg x 28's pack: 168.00 MRP
5mg x 28's pack: 308.00 MRP
t LURETIC Tab. Drug Inter.
Torasemide INN 2.5mg & 5mg/tablet
2.5mg x 50's pack: 100.00 MRP
5mg x 50's pack: 175.00 MRP
Potassium-sparing diuretics &
Aldosteroneantagonua
Potassium-sparing diuretics include- Amiloride
& Triamterene. These two diuretics are weak in
action, but, as they cause retention of potassium,
they are used in combination with thiazide or
loop diuretics as a more effective alternative to
potassium supplements. For details- see below
with combined preparatios.
Aldosterone antagonists include- Eplerenone
& Spironolactone.
EPLERENONE 21,26
EPLERENONE: Tablet
Eplerenone is a selective aldosterone antagonist
and used as an adjunct in left ventricular dys­
function with evidence of heart failure following
a myocardial infarction. It is available as
eplerenone INN 25mg tablet.
Mode of action: Eplerenone is a selective block­
er of aldosterone binding at the mineralocorticoid
receptor. Eplerenone binds to the mineralocorti­
coid receptor & blocks the binding of aldosterone,
a component of the renin-angiotensin­
aldosterone-system (RAAS). Aldosterone
synthesis, which occurs primarily in the adrenal
gland, is modulated by multiple factors,
including angiotensin II and other mediators such
as adrenocorticotropic hormone and potassium.
Aldosterone binds to mineralocorticoid receptors

CARDIOVASCULAR DRUGS
in both epithelial (e.g. kidney) and nonepithelial
(e.g. heart, blood vessels, and brain) tissues and
increases blood pressure through induction of
sodium reabsorption and possibly by other
mechanisms. Eplerenone has been shown to
produce sustained increases in plasma renin and
serum aldosterone, consistent with inhibition of
the negative regulatory feedback of aldosterone
on renin secretion. The resulting increased
plasma renin activity and aldosterone cjrculating
levels do not overcome the effects of Eplerenone.
Ind: Congestive heart failure after an acute
myocardial infarction. Hypertension.
C/I: Eplerenone is contraindicated in- hyper­
kalaemia, severe renal impairment (creatinine
clearance less than 30ml/min), severe hepatic
impairment. Concomitant use with potent
CYP3A4 inhibitors like Ketoconazole, ltracona­
zole, Nefazodone, Troleandomycin, Clarithromy­
cin, Ritonavir, and Nelfinavir or other potassium­
sparing diuretics are also contraindicated.
S/E: Headache, dizziness, diarrhea, stomach
pain, nausea, cough or flu-like symptoms may
occur. Symptoms of a serious allergic reaction
like rash, itching, swelling, severe dizziness,
trouble breathing can occur.
Precautions: Eplerenone should be used with
caution in hyperkalemia, severe kidney disease,
diabetic patients with congestive heart failure
after an acute myocardial infarction including
those with proteinuria.
Potassium supplements must not be given with
aldosterone antagonists.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women.
Eplerenone should be used during pregnancy
only if the potential benefit justifies the potential
risk to the fetus. _The concentration of Eplerenone
in human breast milk after oral administration is
unknown. Because many drugs are excreted in
human milk and because of the unknown poten­
tial for adverse effects on the nursing infant, a
decision should be made whether to discontinue
nursing or discontinue the drug, taking into
account the importance of the drug to the mother.
Dosage & admin: Congestive heart failure
after an acute myocardial infarction:
Eplerenone 50mg once daily. Treatment
should be initiated at 25mg once daily and
titrated to the target dose of 50mg once daily
preferably within 4 weeks as tolerated by the
patient. Eplerenone may be administered with
or without food.
Hypertension: Eplerenone may be used alone
or in combination with other antihypertensive
agents. The recommended starting dose of
Eplerenone is 50mg administered once daily.
For patients with an inadequate blood pres­
sure response to SOmg once daily, the dosage
of Eplerenone should be increased to 50mg
twice daily. Higher dosages of Eplerenone are
not recommended either because they have no
greater effect on blood pressure than 1 OOmg
or because they are associated with an
increased risk of hyperkalemia. Pediatric use:
The safety and effectiveness of eplerenone has
not been established in pediatric patients.
+ ALDONIST Tab. UniMed & UniHealth
Eplerenone INN 25mg & 50mg/tablet
25mg x 28's pack: 1260.00 MRP
QIMP-17 (58)
50mg x 14's pack: 1190.00 MRP
+ EPLERON 25 Tab. Incepta
Eplerenone INN 25mg/tablet
25mg x 20's pack: 900.00 MRP
SPIRONOLACTONE21,26,46
SPIRONOLACTONE: Tablet/Capsule
Spironolactone is a long-acting aldosterone
antagonist, potassium-sparing diuretic.
Mode of action: Spironolactone inhibits the
reabsorption of sodium and excretion of
potassium at the distal tubule by blocking the
action of aldosterone.
.
Ind: Congestive heart failure; hypertension;
hepatic cirrhosis; idiopathic oedema; nephrotic
syndrome; Conn's syndrome; potentiation of
thiazide & loop diuretics.
C/I: Hyperkalaemia, renal & hepatic impairment.
S/E: Hyperkalaemia, gastro-intestinal
disturbances, gyneacomastia.
Precautions: Potassium supplements must not be
given with potassium-sparing diuretics.
Administration of a potassium-sparing diuretic to
a patient receiving an ACE inhibitor or an
angiotensin-11 receptor antagonist can also cause
severe hyperkalaemia.
Dosage & Admin: Congestive heart failure,
1 OOmg daily, increasing if necessary to 400mg
daily; maintenance 75-200mg daily
•
Hypertension, 50-1 OOmg daily increasing if
necessary at two weekly intervals upto 200mg
daily.
Children: Initially 3mg/kg body-wt. daily in
divided doses.
+ INOSPIRON Tab. Incepta
Spironolactone 25mg/tablet
25mg x 1OO's pack: 500.00 MRP
+ SPIRETIC Tab. Drug Inter.
Spironolactone USP 25mg/tablet
25mg x 30's pack: 150.00 MRP
+ SPIROCARD Tab. Popular
Spironolactone USP 25mg & 1OOmg/tablet
25mg x l OO's pack: 502.00 MRP
1OOmg x 30's pack: 542.10 MRP
+ VEROSPIRON Tab. Ambee
Spironolactone 25mg/tablet
, Frusemide 20mg & spironolactone 50mg/tablet.
25mg x 1OO's pack: 501.00 MRP
Potassium-sparing diuretics
with other diuretics
FRUSEMIDE+
SPIRONOLACTONE
26,46
FRUSEMIDE + SPIRONOLACTONE: Tablet
This is a combination of two diuretics, viz:
Frusemide, a short-acting loop-diuretic & spiro­
nolactone, a long-acting aldosterone antagonist,
potassium-sparing diuretic. This combination
produces synergistic or additive diuretic effects.
Mode of action: Frusemide inhibits the
Na+/K+/2Cl- co-transport in the ascending limb
of loop of henle and blocks the reabsorption of
electrolytes (Na+, K+ and Cl- ions) and water.
Spironolactone inhibits the reabsorption of
sodium and excretion of potassium at the distal
r
tubule by blocking the action of aldosterone. So
the excretion of sodium is increased and the
excess loss of potassium, induced by the
frusemide is decreased.
Ind: i. Essential hypertension, ii. Chronic conge­
stive heart failure, iii. Ascites of liver cirrhosis,
iv. Edema (swelling due to excess fluid retention),
v. Hyperaldosteronism, and vi. Resistant oedema
associated with secondary hyperaldosteronism.
C/I: This combination is contraindicated in
patients with acute renal failure, renal
insufficiency (creatinine clearance <30ml/min),
anuric states, hyperkalemia, hyponatremia,
Addison's disease; patients with hypersensitivity
to frusemide, spironolactone or sulphonamide.
S/E: Generally, this combined preparation is well
tolerated. However, a few side effects like
fatigue, nausea, vomiting, malaise or gastric
upset, abdominal pain, diarrhea, constipation,
headache, hypotension, skin rash may be seen
which disappears after withdrawal of the drug.
Besides these, irregular menstrual cycle,
impotence, gynecomastia rarely may occur.
Precautions: Caution should be taken in patients
liable to electrolyte deficiency. This preparation
should also be used with caution in diabetes,
enlarged prostate, hypotension and in
hypovolemia.
Pregnancy & lactation: Frusemide is safe in
pregnancy but spironolactone may cross the
placental barrier. So, it should be used in
pregnancy only if strictly indicated & for short­
term treatment and if expected benefits to the
mother is greater than the possible risk to the fetus.
This combined preparation is excreted into the
breast milk, so it is contraindicated in lactating
mother.
Dosage & admin: 1 to 4 tablets daily
according to the patients response or as
directed by the physician.
Children: Not recommended.
Drug inter: Precautions should be taken while
co-administration with the following drugs: ACE
inhibitors, nephrotoxic & ototoxic antibiotics,
corticosteroids, NSAIDs, carbenoxolone and
sucralfate.
+ DIRETIC Tab. Drug Inter.
..
50's pack: 300.00 MRP
+ DIRETIC-DS Tab. Drug Inter.
Frusemide 40mg & spironolactone 50mg/tablet.
50's pack: 400.00 MRP
+ DIRUCOM Tab. Popular
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 180.60 MRP
+ EDELOSS Tab. Incepta
Frusemide 20mg & spironolactone 50mg/tablet.
50's pack: 300.00 MRP
+ EDELOSS Plus Tab. Incepta
Frusemide 40mg & spironolactone 50mg/tablet.
50's pack: 400.00 MRP
+ EDEMIDE 20 Tab. Acme
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 240.00 MRP
+ EDEMIDE 40 Tab. Acme
Frusemide 40mg & spironolactone 50mg/tablet.
30's pack: 300.00 MRP
+ EDENIL 20 Tab. SK+F
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 180.00 MRP

+ EDENIL 40 Tab. SK+F
Frusemide 40mg & spironolactone SOmg/tablet.
30's pack: 240.00 MRP
+ FRULAC Tab. Orion Pharma
Frusemide 20mg & spironolactone SOmg/tablet.
SO's pack: 400.00 MRP
+ FRULAC 40 Tab. Orion Pharma
Frusemide 40mg & spironolactone SOmg/tablet.
30's pack: 300.00 MRP
+ FRUSELAC Tab. Aristopharma
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 180.00 MRP
+ FRUSELAC Plus Tab. Aristopharma
Frusemide 40mg & spironolactone SOmg/tablet.
30's pack: 240.00 MRP
+ FRUSIN 20 Plus Tab. Opsonin
Frusemide 20mg & spironolactone SOmg/tablet.
30's pack: 158.87 MRP
+ FRUSIN 40 Plus Tab. Opsonin
Frusemide 40mg & spironolactone 50mg/tablet.
30's pack: 211.92 MRP
+ FRUSITON-20 Tab. Globe
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 180.00 MRP
+ FRUSITON-40 Tab. Globe
Frusemide 40mg & spironolactone SOmg/tablet.
30's pack: 240.00 MRP
+ FRUSON-20 Tab. Ibo Sina
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 180.00 IP
+ FRUSPA Tab. Zenith
Frusemide BP 20mg & spironolactone PB
50mg/tablet.
30's pack: 180.00 MRP
+ FURO Plus Tab. Beacon
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 180.00 MRP
+ FUROTONE Tab. Novo Healthcare
Frusemide USP 20mg & spironolactone USP
SOmg/tablet.
30's pack: 180.00 MRP
+ FUSID Plus Tab. Square
Frusemide 20mg & spironolactone SOmg/tablet.
40's pack: 320.00 MRP
+ FUSID 40 Plus Tab. Square
Frusemide 40mg & spironolactone 50mg/tablet.
40's pack: 400.00 MRP
+ LACITONE Tab. General
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 180.60 MRP
+ LASILACTONE Tab. Sanofi-aventis
Frusemide 20mg & spironolactone 50mg/tablet.
50's pack: 301.00 MRP
+ LAXICON Tab. White Horse
Frusemide 20mg & spironolactone SOmg/tablet.
30's pack: 180.00 MRP
+ LAXUR Tab. Healthcare
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 240.00 MRP
+ REDEMA 20 Tab. Rangs Pharma
Frusemide 20mg & spironolactone 50mg/tablet.
30's pack: 180.00 MRP
+ REDEMA 40 Tab. Raogs Pharma
Frusemide 40mg & spironolactone SOmg/tablet.
30's pack: 240.00 MRP
+ RESITONE Tab. Beximco
Frusemide 20mg & spironolactone SOmg/tablet.
30's pack: 180.60 IP
+ RESITONE Plus Tab. Beximco
Frusemide 40mg & spironolactone 50mg/tablet.
•
QIMP-17 (59) CARDIOVASCULAR DRUGS
30's pack: 240.90 MRP water secreted with it, resulting in a fall in the
+ SPIROCARD Plus Tab. Popular intra-ocular pressure, hence it is used mostly by
Frusemide 20mg & spironolactone 25mg ? the ophthalmologist in the treatment of glaucoma.
/tablet. It also may be used in some other conditions.
30's pack: 180.60 MRP Ind: Glaucoma, oedema, congestive cardiac fail­
+ TONEMIDE Tab. Pacific ure, toxaemia of pregnancy, premenstrual tension.
Frusemide 20mg & spironolactone SOmg/tablet. C/I: Renal hyperchloraemic acidosis, adrenal
30's pack: 180.00 MRP insufficiency; severe renal or hepatic failure;
+ URITONE 20 Tab. Renata chronic closed angle glaucoma.
Frusemide 20mg & spironolactone 50mg/tablet. Caution: Gout, diabetes, pregnancy.
30's pack: 180.00 MRP D osage & admio: Initially 250-375mg once
+ URITONE 40 Tab. Renata daily in the morning or on alternate days.
Frusemide 40mg & spironolactone 50mg/tablet. Premenstrual tension,125-375 mg as a single
.
30's pack: 240.00 MRP daily dose beginning 5-10 days before
+ UROSPIN Tab. Biopharma menstruation. Glaucoma, initially 500mg,
Frusemide 20mg & spironolactone 50mg/tablet. subsequent doses 250mg every 6 hours.
30's pack: 180.60 MRP
+ ACEMOX Tab. Acme
+ VEROSPIRON Plus Tab. Ambee
Acetazolamide 250mg/tablet.
Frusemide 20mg & spironolactone 50mg/tablet.
1 OO's pack: 200.00 MRP
30's pack: 150.60 MRP
+ REMOX Tab. Reman
Acetazolamide 250mg/tablet.
21,5 7
THIAZIDE + AMILORIDE lOO's pack: 200.00 MRP
THIAZIDE + AMILORIDE: Tablet
Ind: Congestive heart failure, hepatic cirrhosis Osmotic diuretics
with ascites; hypertension.
C/I: Hyperkalaemia, severe renal failure,
MANNITOL 21,56
pregnancy, lactation.
D osage & admio: Adult: 1-2 tabs. daily in
MANNITOL: 10% & 20oo/ l.V Infusion
single or divided doses, increasing if necessary
Mannitol, a hyperosmolar solution, used as
to max. 4 tabs.
dehydrating agent or to promote polyuria. It is
Child: Not recommended.
availalbe as 10% & 20% solution for i.v infusion.
Ind: Cerebral oedema; forced diuresis (as in to
+ AMIZIDE Tab. Sanofi-aventis
prevent acute renal insufficiency of shock, in
Hydrochlorothiazide 50mg + amiloride
decreased renal perfusion, in exogenic &
hydrochloride 5mg/tablet.
endogenic toxicoses, in oedemas of nephrotic,
200's pack: 144.01 MRP
cardiac & hepatic origin).
+ KALTIDE Tab. ACI
C/I: Congestive cardiac failure, pulmonary
Hydrochlorothiazide SOmg + amiloride
oedema, acute tubular necrosis, severe cardiac
hydrochloride Smg/tablet.
decomposition.
l OO's pack: 201.00 MRP
S/E: Chills, fever.
Cautions: extravasation may cause inflammation
TIDAZIDE + TRIAMTERINE 21,33 & thrombophlebitis.
•
Dose: By i.v infusion 50-200gm over 24 hours,
TmAZIDE + TRIAMTERINE:Tablet preceded by a test dose of 200mg/litre by slow
Ind: Oedema; mild to moderate hypertension. i.v injection. Maximum 1000ml (litre) per day.
Adult: Oedema, initially 1 tab. twice daily
+ MANISOL 20°/o Inj. Orion Infusion
after meals, reducing to usually 1 daily or 2 on
Mannitol 200gm (20%)/litre: i.v infusion.
alternate days. Max. 4 daily. Hypertension,
500ml bot: 155.00 MRP
initially 1 daily.
+ MANNITOL 20°/o lnj. Opso Saline
Child: Not recommended.
Mannitol 200gm (20%)/litre: i.v infusion.
500ml bot with set: 155.00 MRP
+ DEZIDE Tab. SK+F
Hydrochlorothiazide 25mg + Triamterine
+ OSMOSOL 20°/o Inj. Beximco
Mannitol 200gm (20%)/litre: i.v infusion.
50mg/tablet.
500ml bot with set: 155.00 IP
1OO's pack: 100.00 MRP
+ G-THIAZIDE T Tab. Gonoshasthaya
Hydrochlorothiazide 25mg + Triamterine
50mg/tablet.
Drugs for Pulmonary
1OO's pack: 50.00 MRP Arterial Hypertansion (PAH)
Carbonic anhydrase inhibitors D �D;M!"fJ
Da'L'-D:BIL :.t.l"JIH
�. Dlfi !'.'�! 129
BOSENTAN: Tablet
ACETAZOLAMIDE 21,33 Bosentan is a dual endothelin receptor antagonist
(ERA) with affinity for both endothelin A anW
ACETAZOLAMIDE: Tablet •
•
(ETA and ETB) receptors, and found effective iu
..
.
.
·A cetazolamide is a carbonic anhydrase inhibitor. the treatment of pulmonary arterial hypertension �..
It reduces bicarbonate in aqueous humour and (PAH). It is available as bosentan monohydtate · ·
CARDIOVASCULAR DRUGS
INN equivalent to bosentan 62.Smg/tablet (film
coated).
Mode of action: Bosentan decreases both
pulmonary and systemic vascular resistance
resulting in increased cardiac output without
increasing heart rate.
The neurohormone endothelin-1 (ET-1) is one of
the most potent vasoconstrictors known and can
also promote fibrosis, cell proliferation, cardiac
hypertrophy and remodelling, and is pro­
inflammatory. These effects are mediated by
endothelin binding to ETA and ETB receptors
located in the endothelium and vascular smooth
muscle cells. ET-1 concentrations in tissues and
plasma are increased in several cardiovascular
disorders and connective tissue diseases,
including pulmonary arterial hypertension,
scleroderma, acute and chronic heart failure,
myocardial ischemia, systemic hypertension and
atherosclerosis, suggesting a pathogenic role of
ET- I in these diseases. In pulmonary arterial
hypertension and heart failure, in the absence of
endothelin receptor antagonism, elevated ET- I
concentrations are strongly correlated with the
severity and prognosis of these diseases.
Ind: Treatment of pulmonary arterial hyperten­
sion (PAH) to improve exercise capacity and
symptoms in patients with WHO functional class
Ill; some improvements have also been shown in
patients with PAH WHO functional class II.
C/I: Hypersensitivity to the active ingredient or
to any of the excipients; moderate to severe
hepatic impairment, i.e Child-Pugh class B or C;
baseline values of liver aminotransferases i.e,
aspartate aminotransferases (AST) and/or alanine
aminotransferases (ALT), greater than 2 times the
upper limit of normal; concomitant use of
cyclosporine A; pregnancy.
S/E: Treatment with bosentan has been associa­
ted with dose-dependent elevations in liver
aminotransferases and decrease in hemoglobin
concentration. Other side effects include­
thrombocytopenia, neutropenia, leucopenia,
hypersensitivity reactions, headache, syncope,
palpitations, flushing, hypotension, gastro­
esophageal reflux disease, aminotransferase
elevations associated with hepatitis and/or
jaundice, liver cirrhosis, liver failure (rarely),
erythema, diarrhea, edema, fluid retention.
Precautions: Liver aminotransferase levels must
be measured prior to initiation of treatment and
subsequently at monthly intervals for the duration
of treatment with bosentan. In addition, liver
aminotransferase levels must be measured 2
weeks after any dose increase.
Recommendations in case of ALT/AST eleva­
tions: Please see the manufacturer's literature.
In the case of associated clinical symptorms of
liver injury, i.e nausea, vomiting, fever,
abdominal pain, jaundice, unusual lethargy or
fatigue, flu-like syndrome (arthralgia, myalgia,
fever), treatment must be stopped and re­
introduction of bosentan is not to be considered.
Hemoglobin concentration: Treatment with
bosentan has been associated with dose-related
Amlodlpine 5 mg+ Atenolol 50 mg film coated bi·layer Tablet
QIMP-17 (60)
decrease in hemoglobin concentration.
Women of child-bearing potential: Bosentan
treatment must not be initiated in women of
child-bearing potential unless they practise
reliable contraception.
Pulmonary arterial hypertension patients with
concomitant left ventricular failure: No specific
study has been performed in patients with
pulmonary hypertension and concomitant left
ventricular dyspunction.
Effects on ability to drive & use machines:
Bosentan may cause dizziness, which could
affect the ability to drive or use machines.
Pregnancy & lactation: Bosentan is
contraindicated in pregnancy. It is not known
whether bosentan is excreted in human breast
milk. How ever, breast-feeding is not
recommended during treatment with bosentan.
Dosage & admin: Adults: Tablets are to be
taken orally at morning and evening with or
without food.
Bosentan treatment should be initiated at a
dose of 62.Smg twice daily for 4 weeks and
then increased to the maintenance dose of
12Smg twice daily.
For pediatric patients aged 2 years or older,
the optimal maintenance dose has not been
defmed in well-controlled studies. However,
pediatric pharmacokinetic data have shown
that bosentan plasma concentrations in
children were on average lower than in adult
patients and were not increased by increasing
the dose of bosentan above 2mg/kg body
weight twice daily.
Discontinuation oftreatment: If the decision to
withdraw bosentan is taken, it should be done
gradually while an alternative therapy is
introduced.
Dosage in hepatic impairment: No dose
adjustment is needed in patients with mild
hepatic impairment (i.e Child-Pugh class A).
Bosentan is contraindicated in patients with
noderate to severe liver dysfunction.
Dosage in renal impairment: No dose
adjustment is required in patients with renal
impairment. No dose adjustment is required in
patients undergoing dialysis.
Dosage in elderly patients: No dose adjustment
is required in patients over the age of 65 years.
Drug inter: Please see the manufacturer's
literature.
Note: For further information, please see the
manufacturer's literature.
t PULMOTEN Tab. UniMed & UniBealth
Bosentan monohydrate INN equivalent to
bosentan 62.Smg/tablet (film coated).
62.Smg x 7's pack: 1050.00 MRP
Combined antihypertensive
preparations
•
ATENOLOL + AMLODIPINE48, 52
Most wiclPly usPd con1binat1on antihypertensivp
ATENOLOL + AMLODIPINE: Tablet
A fixed-dose combinations of atenolol and
amlodipine are available for the treatment of
hypertension alone or in co-existance with
ischemic heart dease. The ftxed-dose
combinations are: i. atenolol 25mg + amlodipine •
5mg and ii. atenolol 50mg + amlodipine 5mg.
Amlodipine besilate is a dihydropyridine calcium
channel blocker and atenolol is a
phenylacetamide, a selective beta1 blocker.
Mode of action: Given under the text of atenolol
and amlodipine separately.
Ind: i. Hyp�rtension not controlled by
monitherapy, ii. angina pectoris & hypertension
as co-existing diseases, iii. post-MI patients, iv.
refractory angina pectoris where nitrate has failed.
S/E: Given under the text of atenolol &
amlodipine separately. •
C/I: Amlodipine is contraindicated in patients
with a known sensitivity to dihydropyridines. It
should not be used in cardiogenic shock,
clinically significant aortic stenosis, unstable
angina (excluding Prinzmetal's angina).
Atenolol is contraindicated with a known
hypersensitivity to atenolol, severe bradycardia,
second or third degree heart block, uncontrolled
heart failure, hypotension, severe peripheral
vascular disease (including intermittent
claudication), sick sinus syndrome, cardiogenic
shock, phaeocromocytoma (without a
concomitant alpha blocker), metabolic acidosis.
Precaution: Renal impairment: The combination
can be used in patients with renal impairment.
However, caution may be necessary if the
creatinine clearance is less than 30ml/min
because of possible reduction in the excretion of
unchanged atenolol.
Hepatic impairment: Caution may be necessary
in the use of the combination in patients with
severe liver damage because of prolongation of
the elimination halflife of amlodipine.
Bronchospasm: The combination should be used
with caution in patients with airway obstruction.
Drug withdrawal: Since coronary heart disease
may exist without being recognised, patients
should be warned against stopping the drug
suddenly. Any discontinuation should be gradual
and under observation.
Pregnancy & lactation:
Atenolol crosses the placenta. On the other hand,
the use of amlodipine in pregnancy and lactation
has yet not been established. So, the combination
is contraindicated in pregnancy and lactation.
Dosage & admin: The recommended dosage is
one tablet of amlodipine Smg and atenolol
2Smg or SOmg daily. Depending upon the
therapeutic response, titration of the dosage is
recommended. If necessary, the dosage may
I
be doubled to two tablets daily. In elderly
•
patients, it is advisable to initiate the therapy
with lower dosage, such as, amlodipine 2.Smg
and atenolol 2Smg daily.
Drug inter: Given under the text of atenolol and
amlodipine separately.
in
Apex
bi-layer l'
, .
tablet form
� � '
. .
i ..... '

+ ALOTEN Tab. Kemiko
Atenolol BP 25mg & amlodipine BP 5mg/tablet.
50's pack: 212.00 MRP
+ ALOTEN Forte Tab. Kemiko
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
50's pack: 225.00 MRP
+ AMDIN Plus Tab. Alco Pharma
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
50's pack: 225.00 MRP
+ AMDOCAL Plus 25 Tab. Beximco
Atenolol BP 25mg & amlodipine BP 5mg/tablet.
30's pack: 157.50 IP
+ AMDOCAL Plus 50 Tab. Beximco
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
60's pack: 360.00 IP
+ AMLOBET Tab. Sun Pharma
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
-
..
50's pack: 300.00 MRP
,
+ AMLOCARD Plus-25 Tab. Drug Inter.
Atenolol BP 25mg & amlodipine BP 5mg/tablet.
50's pack: 250.00 MRP
+ AMLOCARD Plus-50 Tab. Drug Inter.
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
50's pack: 300.00 MRP
+ AMLOCOM Tab. B eacon
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
Amlodipine & Atenolol (5/25 mg & 5/50 mg) tablet
Takes BP towards
50's pack: 225.00 MRP
+ AMLOSIN Plus Tab. Doctor's
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 120.00 MRP
+ AMLOTEN 25 Tab. Acme
Atenolol BP 25mg & amlodipine BP 5mg/tablet.
30's pack: 157.50 MRP
+ AMLOTEN 50 Tab. Acme
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 180.00 MRP
+ AMLOVAS AT Tab. Popular
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
50's pack: 201.00 MRP
+ AMOCAL-AT Tab. Opsonin
-
• •
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 158.35 MRP
+ AMPIL Plus Tab. White Horse
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
50's pack: 300.00 MRP
+ AMPRE-Plus Tab. Kumudini
I
-
. , ..
QIMP-17 (61)
Amlodipine S mg + Atenolol 50 mg film coated bi-layer Tablet
. .
. .
Atenolol BP 50mg & amlodipine BP 5mg/tablet. fl\11'.t wirl,·ly U�f·d combination untihyp£:rten�1v1!
30's pack: 180.00 MRP
+ AMTINOL Plus Tab. Euro Pharma
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 135.00 MRP
+ ANGICAL-50 Tab. Apex 50's pack: 300.00 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + CARDOSIA Plus Tab. Pharmasia
30's pack: 180.00 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ ATEPINE Tab. Pharmadesh 20's pack: 220.80 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + COMBICARD Tab. Healthcare
30's pack: 165.00 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ ATEZEN Plus Tab. Z enith 30's pack: 180.00 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + CV NOR A Tab. Navana
50's pack: 180.00 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ BETACAL Tab. Orion Pharma 30's pack: 150.00 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + DIPLOR Plus-25 Tab. Ibn Sina
50's pack: 300.00 MRP Atenolol BP 25mg & amlodipine BP 5mg/tablet.
+ BETANOL-A 25 Tab. Sanofi-aventis 30's pack: 120.00 IP
+
Atenolol BP 25mg & amlodipine BP 5mg/tablet. DIPLOR Plus-50 Tab. Ibn Sina
50's pack: 262.50 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ BETANOL-A 50 Tab. Sanofi-aventis 30's pack: 150.00 IP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + EMLON Plus Tab. Biopharma
50's pack: 300.00 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ BPNOL-Plus Tab. Delta Pharma 30's pack: 180.00 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + FIXOCARD 25 Tab. Incepta
30's pack: 120.00 MRP Atenolol BP 25mg & amlodipine BP 5mg/tablet.
• • •
+ CALBETA Tab. Unimed & unihealth 50's pack: 212.50 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + FIXOCARD 50 Tab. Incepta
30's pack: 180.00 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ CALCHEK Plus Tab. General 50's pack: 225.00 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + HIPRE Plus Tab. Pacific
30's pack: 180.00 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ CALOCK Plus 50 Tab. Medimet 30's pack: 180.00 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + IMPED Plus-25 Tab. Rephco
42's pack: 210.00 MRP Atenolol BP 25mg & amlodipine BP 5mg/tablet.
+ CALPIN Plus 50 Tab. Globe lOO's pack: 400.00 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + IMPED Plus-50 Tab. Rephco
30's pack: 135.00 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ CAMLODIN Plus 25 Tab. Square · lOO's pack: 500.00 MRP
Atenolol BP 25mg & amlodipine BP 5mg/tablet. + LOCARD Plus Tab. Jayson
30's pack: 150.00 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ CAMLODIN Plus Tab. Square 30's pack: 90.60 IP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + LODICAL Plus 50 Tab. Somatec
50's pack: 300.00 MRP Atenolol BP 50mg & amlodipine BP 5mg/tablet.
+ CARDIPIN Plus Tab. Renata 30's pack: 180.00 MRP
Atenolol BP 50mg & amlodipine BP 5mg/tablet. + LODICARD Tab. Aristopharma
.9'- ;,P.f� •••
1A"1 !�!��L. •••
� •AllGLAD/£$H
LTD. www.squarepharma.com.bd •••
NUAll•

Atenolol BP 50mg & amlodipine BP 5mg/tablet.
50's pack: 300.00 MRP
+ LOPIN Plus Tab. Edruc
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 135.00 MRP
+ PRISTIN-OL Tab. Novo Healthcare
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 150.00 MRP
+ SIDOPLUS 25 Tab. SK+F
Atenolol BP 25mg & amlodipine BP 5mg/tablet.
40's pack: 210.00 MRP
+ SIDOPLUS 50 Tab. SK+F
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
40's pack: 240.00 MRP
+ TENOCAB 25 Tab. ACI
Atenolol BP 25mg & amlodipine BP 5mg/tablet.
50's pack: 262.50 MRP
+ TENOCAB 50 Tab. ACI
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
50's pack: 300.00 MRP
+ TENODIN 25/5 Tab. Asiatic
Atenolol BP 25mg & amlodipine BP 5mg/tablet.
30's pack: 126.00 MRP
+ TENODIN 50/5 Tab. Asiatic
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 135.00 MRP
+ TENOPIN Tab. Sharif
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 135.00 MRP
+ VASOPIN Plus Tab. Silva
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 135.00 MRP
+ VESOCAL Plus Tab. Rangs Pharma
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 180.00 MRP
+ VIRLON Plus Tab. Virgo
Atenolol BP 50mg & amlodipine BP 5mg/tablet.
30's pack: 135.00 MRP
ATENOLOL + CHLORTHALIDONE 52
ATENOLOL + CHLORTHALIDONE: Tablet
This is a combination preparation of atenolol and
chlorthalidone. Atenolol is a selective (cardiose­
lective) beta-adrenergic receptor blocking agent.
Chlorthalidone is a thiazide-type oral diuretic
with prolonged action. The combination of
atenolol & chlorthalidone offers complementary
mechanisms of action with additive or S)1Ilergistic
effects and better tolerability.
This combination is available in two fixe.d pre­
sentations, viz: i. tablet containing atenolol BP
50mg and chlorthalidone USP 25mg, ii. tablet
containing atenolol BP I OOmg and chlorthalidone
USP 25mg.
Mode of action: Atenolol is a cardioselective 1-
adrenergic receptor blocker. In the heart atenolol
binds with the 1 receptors and antagonizes epine­
phrine/norepinephrine, thus it blocks the adrener­
gic stimulation of heart muscles and decreases
c.ardiac output. The diuretic action of chlorthali­
done occurs within 2 hours of an oral dose. It
produces diuresis by increasing excretion of sodi­
um and chloride, plus inhibiting reabsorption of
sodium and water in the tubules. In this way, the
QIMP-17 (62)
action of chlorthalidone also results in decrease
in cardiac output. The antihypertensive effects of
these two agents are additive or synergistic.
Ind: This combination is indicated in the
treatment of hypertension.
C/I: This combination is contraindicated in
hypersensitivity to this product or to sulfona­
mide-derived drugs. It is also contraindicated in
patients with sinus bradycardia, heart block
greater than first degree, cardiogenic shock, overt
cardiac failure & anuria.
S/E: Atenolol and chlorthalidone combination is
usually well tolerated. Most adverse effects have
been mild and transient. However dizziness,
fatigue, vertigo, nausea, diarrhea and bradycardia
have been reported rarely.
Precautions & warnings: Atenolol and
chlorthalidone combination should be given with
caution to patients with severe renal impairment,
uncontrolled heart failure, impaired hepatic
function or liver disease. In patients receiving
thiazides, sensitivity reactions may occur with or
without a history of allergy or bronchial asthma.
The possible exacerbation or activation of
systemic lupus erythematosus has been reported.
The antihypertensive effects of thiazides may be
enhanced in the postsympathectomy patient.
Use in elderly: Clinical studies of atenolol &
cholrthalidone combination did not include
su.fficient mumbers of sunjects aged 65 and over
to determine whether they respond differently
from younger subjects.
Pregnancy & lactation: Atenolol & hlorthali­
done combination can cause harm to the develo­
ping fetus and may appear in breast milk. So, it
should not be given during pregnancy & lactation.
Dosage & admin: Dosage of this combination
must be individualized.
The initial dose should be one tablet (atenolol
SOmg + chlorthalidone 25mg) given once a day.
Drug inter: Atenolol and chlorthalidone
combination may potentiate the action of other
antihypertensives, such as clonidine, diltiazem.
Prostaglandin synthetase inhibiting drugs e.g
indomethacin may decrease the hypotensive
effects of beta-blockers. This combination should
not be given with lithium due to high risk of
lithium toxicity.
+ ATECHLOR 50 Tab. Silva
Atenolol BP 50mg & chlorthalidone 25mg/tablet.
50's pack: 125.00 MRP
+ ATECHLOR 100 Tab. Silva
Atenolol BP 1 OOmg & chlorthalidone
25mg/tablet.
50's pack: 150.00 MRP
+ CARDIPRO 50 Plus Tab. Square
Atenolol BP 50mg & chlorthalidone 25mg/tablet.
30's pack: 82.80 MRP
+ TENOREN Plus Tab. ACI
Atenolol BP 50mg & chlorthalidone 25mg/tablet.
50's pack: 150.50 MRP
ATENOLOL + NIF'EDIPINE 42
ATENOLOL + NIFEDIPINE: Capsule
A fixed�dose combination of atenolol and
nifedipine is available for the treatment of hyper.:.
tension alone or in co-existance with ischemic
heart <lease. The fixed-dose combination is
atenolol USP 50mg + nifedipine USP 20mg
presented as sustained release capsule.
In this combination, atenolol is a selective p 1
blocker & nifedipine is a cacium-channel blocker.
Mode of action: See under the text of atenolol
and nifedipine separately.
Ind: Management of hypertension where therapy
with either a P-blocking drug or a calcium
channel blocker proves inadequate.
Management of chronic stable angina pectoris
where therapy with calcium channel blocker or a
P-adrenoceptor blocking drug proves inadequate.
C/I: This combination should not be used in
patients with any of the following conditions:
Known hypersensitivity to either active
component, or any other excipient or other
dihydropyridines; bradycardia; cardiogenic
shock; hypotension; metabolic acidosis; severe
peripheral arterial circulatory disturbances;
second or third degree heart block; sick sinus
syndrome; untreated phaeochromocytoma;
uncontrolled heart failure; women capable of
childbearing or during pregnancy or during
lactation; patients with clinically significant
aortic stenosis; patients with marked renal
impairment. This combination should not be used
for secondary prevention of myocardial infarction.
S/E: The following undesired events have been
reportd: Cardiovascular: Flushing, edema; CNS:
dizziness, headache; Gastrointestinal:
gastrointestinal disturbance; Haematological:
purpura; Reproductive: inpotence; Others: fatigue.
Precautions: Due to its beta-blocker component
this combination may increase the number and
duration of angina attacks in patients with
Prinzmetal's angina due to unopposed alpha
receptor mediated coronary artery
vasoconstriction. Due to its negative effect on
conduction time, caution must be exercised if it
is given to patients with first degree heart block.
Pregnancy & lactation: This combination is
•
contraindicated in women capable of childbearing
or during pregnancy or during lactation.
Dosage & admin: Adult: Hypertension: One
capsule daily swallowed with water. If
necessary, the dosage may be increased to 1
capsule every 12 hours.
Angina: One capsule every 12 hours swallowed
with water. Where additional efficacy is
necessary, prophylactic nitrate therapy or
additional nifedipine may be of benefit.
Elderly: Dosage should not exceed 1 capsule
daily in hypertension or 1 capsule twice daily
angma.
• •
10
Drug inter: This combination must not be used
in conjunction with calcium channel blocker with
negative inotropic effects e.g verapamil, diltia­
zem. Concomitant therapy with additional dihy­
dropyridines, e.g nifedipine, may increase the •.
risk of hypotension, and cardiac failure may
occur in patients with latent cardiac insufficiency.
In this combination, atenolol and nifedipine has
little effect on the pharmacokinetics of either. In
the elderly, the systemic bioavailability & elimi­
nation half-life of both components are increased.
+ NIDIPRO Cap. Square
Atenolol USP 50mg & nifedipine USP
20mg/capsule (sustained release).
50's pack: 135.00 MRP

BENAZEPRIL + AMLODIPINE26
BENAZEPRIL + AMLODIPINE: Capsule
This is a fixed combination preparation of
benazepril and amlodipine. The products are
available as capsules in three presentations: i.
capsule contaning benazepril hydrochloride USP
1Omg and amlodipine besylate BP equivalent to
amlodipine 2.5mg; ii. capsule contaning
benazepril hydrochloride USP 1Omg and
amlodipine besylate BP equivalent to amlodipine
5mg; iii. capsule contaning benazepril
hydrochloride USP 20mg and amlodipine
besylate BP equivalent to amlodipine 5mg.
Mode of action: Benazepril inhibits angiotensin­
converting enzyme (ACE). This ACE is a
peptidyl dipeptidase that catalyzes the conversion
of angiotensin I to the vasoconstrictor substance
angitensin II. Angiotensin II also stimulates
aldosterone secretion by the adrenal cortex.
Inhibition of ACE results in decreased plasma
angiotensin II, which leads to decreased
vasopressor activity and aldosterone secretion.
Mechanism through which benazepril lowers
blood pressure is belived to be primarily
suppression of the renin-angiotensin-aldosterone
system. Benazepril has an antihypertensive effect
even in patients with low-renin hypertension.
Amlodipine is a dihydropyridine calcium
antagonist which inhibits the transmembrane
influx of calcium ions into vascular smooth
muscle and cardiac muscle. It has greater effect
on vascular smooth muscle cells than on cardiac
muscle cells. Amlodipine causes a preipheral
arterial vasodilatation that leads to reduction in
peripheral vascular resistance and reduction in
blood pressure. Serum calcium concentration is
not affected by amlodipine.
Ind: This combination product is indicated for
the treatment of hypertension, where
monotherapy is not sufficient.
C/I: Known hypersensitivity to benazepril, to
any other ACE inhibitor, or to amlodipine.
S/E: Cough, headache, dizziness, and edema;
persistent nonproductive cough has been reported
with all ACE inhibitors, and always resolving
after discontinuation of therapy. Other side
effects considered possibly or probably related to
the drugs are- angioedema, asthenia and fatigue,
insomnia, nervousness, anxiety, tremor; dry
mouth, nausea, abdominal pain, constipation,
diarrhea, dyspepsia, and esophagitis;
hypokalemia, back pain, musculoskeletal pain,
cramps; polyuria, decreased libido, impotence etc.
Precautions: Impaired renal function: When the
renin-angiotensin-aldosterone system is inhibited
by benazepril, changes in renal function may be
anticipated in severe renal disease. Treatment
with benazepril was associated with increases in
�
blood urea and serum creatinine in hypertensive
I
patients with unilateral or bilateral renal artery
•
stenosis.
Hyperkalemia: Risk factors for the develop­
ment of hyperkalemia include renal insufficiency,
diabetes mellitus, and the concomitant use of
potassium-sparing diuretics, potassium supple­
ments, &/or potassium-containing salt substitutes.
Patients with congestive heart failure: In general,
all calciun channel blockers should be used with
caution in patients with heart failure. In patients
. ..
QIMP-17 (63)
.
with severe congestive heart failure, whese renal
function may depend on the activity of the renin­
angiotensin-aldosterone system, treatment with
ACE inhibitors (including benazepril) may be
associated with oliguria and/or progressive
azotemia and (rarely) with acute renal failure.
Patitnts with hepatic failure: Since amlodipine is
extensively metabolized by the liver, caution
should be exercised when administering
amlodipine and benazepril to patients with severe
hepatic impairment.
Pregnancy & lactation: Caution should be
exercised in frrst trimester of pregnancy
categories C and in second and third trimesters of
pregnancy categories D.
Although it is not known whether amlodipine is
excreted in human, but, minimal amounts of
unchanged benazepril is excreted into the breast
milk of lactating mothers, so, it is recommended
that nursing should be discontinued while
amlodipine and benazepril combined
preparations are administered.
Dosage & admin: Amlodipine and benazepril
combination therapy to be given once daily.
Usual dose: In this combination therapy
amlodipine doses range from 2.5mg to 1Omg
and benazepril doses :'"ange from 1Omg to
20mg; the physician can initiate the therapy
with any fixed combination as preferred; the
antihypertensive effect can be increased by
increasing and adjusting the doses of
amlodipine and/or benazepril in all patient
groups. From this combination therapy all
patients are benefited from the reduction in
amlodipine-induced edema.
Children: Safety and effectiveness in
paediatric patients have not been established.
Drug inter: Diuretics: patients on diuretics may
occasionally experience an excessive reduction
of blood pressure after initiation of therapy with
amlodipine and benazepril. Potassium-sparing
diuretics ( e.g spironolactone) or potassium
supplement can increase the risk of hyperkalemia.
Lithium: Increased serum lithium level and
symptoms of lithium toxicity have been reported
in patients receiving ACE inhibitors during
therapy with lithium.
t AMDOPRIL 10/2.5 Cap. Beximco
Benazepril 1 Omg & amlodipine 2.5mg/capsule.
60's pack: 240.00 IP
t AMDOPRIL 10/5 Cap. Beximco
Benazepril 1Omg & amlodipine 5mg/capsule.
60's pack: 360.00 IP
t AMDOPRIL 20/10 Cap. Beximco
Benazepril 20mg & amlodipine lOmg/capsule.
30's pack: 300.00 IP
t AMLOZEP 10 Cap. Beacon
Benazepril 1Omg & amlodipine 5mg/capsule.
30's pack: 180.00 MRP
t individual product.
AMOCAL-BZ 10/2.5 Cap. Opsonin
Benazepril 1Omg & amlodipine 2.5mg/capsule.
30's pack: 106.09 MRP
t AMOCAL-BZ 10/5 Cap. Opsonin
Benazepril 1Omg & amlodipine 5mg/capsule.
30's pack: 158.87 MRP
t BENADIP 10/2.5 Cap. Incepta
Benazepril 1Omg & amlodipine 2.5mg/capsule.
20's. pack: 80.00 MRP
t BENADIP 10/5 Cap. Incepta
• The combination may be substituted for the
Benazepril 1Omg & amlodipine 5mg/capsule.
CARDIOVASCULAR DRUGS
28's pack: 168.00 MRP
t BENADIP 20/5 Cap. Incepta '
Benazepril 20mg & amlodipine 5mg/capsule.
20's pack: 160.00 MRP
t BENADIP 20/10 Cap. lncepta
Benazepril 20mg & amlodipine 1 Omg/capsule.
28's pack: 280.00 MRP
t CAMLOPRIL 10/5 Cap. Square
Benazepril 1Omg & amlodipine 5mg/capsule.
30's pack: 180.60 MRP
t CAMLOPRIL 20/5 Cap. Square
Benazepril 20mg & amlodipine 5mg/capsule.
30's pack: 241.20 MRP
BISOPROLOL + HYDROCHLOROTH-
IAZIDE 42
BISOPROLOL +
HYDROCHLOROTHIAZIDE: Tablet (f.c)
This is a fixed combination preparation of biso­
prolol and hydrochlorothiazide. The products are
available as film coated tablets in three presenta­
tions: i. tablets contaning bisoprolol fumarate/
hemifumarate USP 2.5mg & hydrochlorothiazide
BP 6.25mg; ii. tablets contaning bisoprolol
fumarate/hemifumarate USP 5mg and
hydrochlorothiazide BP 6.25mg; & iii. tablets
contaning bisoprolol fumarate/hemifumarate USP
1Omg and hydrochlorothiazide BP 6.25mg.
Mode of action: Bisoprolol fumarate/hemifuma­
rate and hydrochlorothiazide have been used
individually and in combination for the treatment
of hypertension. The antihypertensive effects of
these agents are additive; hydrochlorothiazide
6.25mg significantly increases the antihyperten­
sive effect of bisoprolol fumarate/hemifumarate.
The incidence of hypokalemia with the bisopro­
lol fumarate/hemifumarate & hydrochlorothia­
zide 6.25mg combination is significantly lower
than with hydrochlorothiazide 25mg.
For specific mode of action: See under individual
product.
Ind: Management of hypertension.
C/I: It is contraindicated in'patients in cardio­
genic shock, overt cardiac failure, second or third
degree AV block, marked sinus bradycardia,
anuria and hypersensitivity to either component
of this product or to other sulfonamide drugs.
S/E: Generally well tolerated. Most side effects
have been mild and transient. Side effects which
may occur: fatigue, dizziness, headache,
bradycardia, arrhythmia, peripheral ischemia,
chest pain, palpitations, rhythm disturbances,
cold extremities, claudication, orthostatic
hypotension, diarrhoea, constipation, nausea,
dyspepsia, rhinitis, pharyngitis etc.
Precaution: See under individual product.
Pregnancy & lactation: See under the text of
Dosage & admin: Antihypertensive therapy
may be initiated with the lowest dose of
bisoprolol/hydrochlorothiazide, one 2.5mg/
6.25mg tablet once daily. Subsequent titration
(14 day intervals) may be carried out with
bisoprolol/hydrochlorothiazide tablets up to
the maximum recommended dose 20mg/
12.5mg once daily, as appropriate.
titrated individual components.

CARDIOVASCULAR DRUGS
Drug inter: See under the text of individual
product.
t ANCOR Plus-2.5 Tab. Aristopharma
Bisoprolol fumarate USP 2.5mg and
hydrochlorothiazide BP 6.25mg/tablet (f.c).
30's pack: 180.00 MRP
t ANCOR Plus-5 Tab. Aristopharma
Bisoprolol fumarate USP 5mg and
hydrochlorothiazide BP 6.25mg/tablet (f.c).
30's pack: 300.00 MRP
t BISLOL Plus 2.5 Tab. Opsonin
Bisoprolol hemifumarate USP 2.5mg and
hydrochlorothiazide BP 6.25mg/tablet (f.c).
30's pack: 158.35 MRP
t BISLOL Plus 5 Tab. Opsonin
Bisoprolol hemifumarate USP 5mg and
hydrochlorothiazide BP 6.25mg/tablet (f.c).
30's pack: 263.90 MRP
t BISLOL Plus 10 Tab. Opsonin
Bisoprolol hemifumarate USP 1Omg and
hydrochlorothiazide BP 6.25mg/tablet (f.c).
30's pack: 281.50 MRP
t BISOCOR Plus 2.5/6.25 Tab. Square
Bisoprolol fumarate USP 2.5mg and
hydrochlorothiazide BP 6.25mg/tablet (f.c).
30's pack: 180.00 MRP
t BISOCOR Plus 5/6.25 Tab. Square
Bisoprolol fumarate USP 5mg and
hydrochlorothiazide BP 6.25mg/tablet (f.c).
30's pack: 300.00 MRP
t PROBIS Plus 2.5/6.25 Tab. ACI
Bisoprolol fumarate USP 2.5mg and
hydrochlorothiazide BP 6.25mg/tablet (f.c).
30's pack: 180.00 MRP
t PROBIS Plus 5/6.25 Tab. ACI
Bisoprolol fumarate USP 5mg and
hydrochlorothiazide BP 6.25mg/tablet (f.c).
30's pack: 300.00 MRP
INDAPAMIDE + PERINDOPRIL 33
INDAPAMIDE + PERIND OPRIL: Tablet
This is a fixed combination of indapamide and
perindopril; preparations are available in two
presentations, viz: i. tablet containing indapamide
0.625mg and perindopril erbumine 2mg, and ii.
tablet containing indapamide l .25mg &
perindopril erbumine 4mg.
In this combination perindopril is an ACE
inhibitor and indapamide is a thiazide-like
diuretic, both of these lead to additive synergy
of the antihypertensive effects of the product.
Mode of action: The pharmacological actions of
these two components are derived from those of
each of the components taken separately. In
addition to those due to the additive synergistic
action of the two constituents, when combined, it
shows beneficial effets on vascular endothelium,
arteriolocapillary microcirculation, and the target
organs of hypertension.
Ind: Essential hypertension.
C/I: Absolute: Known allergy to perindopril
erbumine, indapamide, or sulfonamides; history
of Quincke's edema linked to previous ACE
inhibitor therapy; severe renal failure; serious liver
disorder; hypokalemia; pregnancy & lactation.
Relative: Combination therapy with lithium,
potassium salts, potassium-sparing diuretics, and
certain medicines which can cause heart rhythm
disorders.
'
QIMP-17 (64)
. ...
S/E: Asthenia, dizziness, headache, mood swings
and/or sleep disturbances, cramps, hypotension,
allergic reactions, skin rashes, gastrointestinal
disorders, dry cough, dry mouth, risk of
dehydration in the elderly and in patients
suffering from heart failure; changes in blood test
results may occur.
Precautions: Disorders of electrolyte balance,
diabetes, gout, hypotension, or strict sodium-free
diets, heart or renal failure, atherosclerosis, renal
artery stenosis, elderly.
Pregnancy & lactation: This combination is
absolutely contraindicated in pregnancy and
lactation.
Dosage & admin: One tablet daily (strength as
advised by the physician), preferably to be
taken in the morning and before a meal.
Elderly patients: Normal dosage.
Renal failure: Creatinine clearance (CrCI)
>30ml/min: No dosage modification. CrCl
<30ml/min: treatment contraindicated.
Drug inter: Not recommended: combinations
with lithium, potassium-sparing diuretics,
potassium (salts), antiarrhythmic drugs which
cause torsade de pointes, anesthetic drugs,
cytostatic or immunosuppressive agents.
t COVERSYL Plus Tab. Servier
lndapamide l .25mg and perindopril erbumine
4mg/tablet
30's pack: 630.00 MRP
t INDAPRIL 2 Tab. lncepta
Indapamide 0.625mg and perindopril erbumine
2mg/tablet
30's pack: 210.00 MRP
t INDAPRIL 4 Tab. Incepta
Indapamide l .25mg and perindopril erbumine
4mg/tablet
20's pack: 240.00 MRP
t PENDORIL Plus 2 Tab. Renata
Indapamide 0.625mg and perindopril erbumine
2mg/tablet
20's pack: 200.00 MRP
t PENDORIL Plus 4 Tab. Renata
Indapamide l .25mg and perindopril erbumine
4mg/tablet
20's pack: 300.00 MRP
t PERICARD Plus 2 Tab. Asiatic
Indapamide BP 0.625mg and perindopril
erbumine BP 2mg/tablet
30's pack: 210.00 MRP
t PERICARD Plus 4 Tab. Asiatic
Indapamide 1.25mg and perindopril erbumine
4mg/tablet
lO's pack: 120.00 MRP
t PERINDAL 2 Plus Tab. Opsonin
Indapamide 0.625mg and perindopril erbumine
2mg/tablet
30's pack: 185.53 MRP
t PERINDAL 4 Plus Tab. Opsonin
Indapamide l .25mg and perindopril erbumine
4mg/tablet
20's pack: 212.00 MRP
t REPRES Plus 2 Tab. Square
Indapamide 0.625mg and perindopril erbumine
2mg/tablet
30's pack: 210.60 MRP
t REPRES Plus 4 Tab. Square
Indapamide l .25mg and perindopril erbumine
4mg/tablet
20's pack: 241.00 MRP
-
C ANDESARTAN + HY­
DROCHLOROTHIAZIDE 36,48,52
CANDESARTAN +
HYDROCHLOROT HIAZIDE: Tablet
Combination preparation of candesartan and
hydrochlorothiazide is available as candesartan
cilexetil INN 8mg & hydrochlorothiazide BP
l 2.5mg/tablet.
Mode of action: See under the text of individual
product.
Ind: These combined preparations are indicated
for the treatment of hypertension. These fixed
dose combinations are not indicated for initial
therapy of hypertension, except when the
hypertension is severe enough that the value of
achieving prompt blood pressure control exceeds
the risk of initiating combination therapy in these
patients.
C/I: This combination is contraindicated in
patients- i. who are hypersensitive to any
component of this product; ii. hydrochlorothiazide
is particularly contraindicated in patients with
•
anuria or hypersensitivity to other sulfonamide
group of drugs; iii. pregnancy & lactation.
S/E: Adverse effects are generally mild and
transient in nature. The overall incidence of
adverse events reported with this combination
occurring in greater than 2% of patients are­
respiratory tract infection (3.6%), back pain
(3.3%), influenza-like symptoms (2.5%),
dizziness (2.9%}, and headache (2.9%).
Precautions: In clinical trials of various doses of
candesartan cilexetil and hydrochlorothiazide, the
incidence of hypertensive patients who
developed hypokalemia (serum potassium
<3.5mEq/L) was 2.5% versus 2.1% for placebo;
the incidence of hyperkalemia (serum potassium
>5.7mEq/L) was 0.4% versus 1.0% for placebo.
No patient receiving this combination 16-
12.5mg had to discontinue the drug due to
increases or decreases in serum potassium.
Overall, the combination of candesartan cilexetil
and hydrochlorothiazide had no clinically
significant effect on serum potassium.
Pregnancy & lactation: When pregnancy is
detected, this drug should be discontinued as
soon as possible. It should not be used in
lactation also.
Dosage & admin: Initially 4mg (2mg in
hepatic and renal impairment) once daily
adjusted according to response; usual
maintenance dose is 8mg once daily;
maximum 32mg once daily. Doses larger than
32mg do not appear to have a greater blood
pressure lowering effect. Hydorchlorothiazide
is effective in doses of 12.5 to 50mg once daily.
Drug inter: See above under the text of
'candesartan cilexetil' and 'hydrochlorothiazide'
separately.
t
t GIRAN-H Tab. Aristopharma
Candesartan cilexetil INN 8mg &
hydrochlorothiazide BP 12.5mg/tablet.
30's pack: 180.00 MRP
IRBESARTAN + HYDROCHLOROTH­
IAZIDE
81

IRBESARTAN +
HYDROCHI.OROT HIAZIDE: Tablet
Combination preparations of irbesartan and
hydrochlorothiazide are available in three fixed­
dose presentations, viz: i. Irbesartan INN 150mg
+ Hydrochlorothiazide BP l 2.5mg/tablet, ii.
Irbesartan INN 300mg + Hydrochlorothiazide BP
12.5mg/tablet, and iii. Irbesartan INN 300mg +
Hydrochlorothiazide BP 25mg}tablet.
Mode of action: See above under the text of
'Candesartan+ Hydrochlorothiazide' preparation.
Ind: This combination is indicated for the
treatment of hypertension for patients in whom
combination therapy is appropriate.
C/I: See above under the text of 'Candes artan +
Hydrochlorothiazide' preparation.
S/E; Precautions & warnings: See above under
the text of 'Candesartan + Hydrochlorothiazide'.
Pregnancy & lactation: When pregnancy is
detected, this drug should be discontinued as
soon as possible. It should not be used in
lactation also.
Dosage & admin: A patient whose blood
pressure is inadequately controlled by
irbesartan or hydrochlorothiazide alone may
be switched to this combination product once
daily to minimize dose independent side
effects. Recommended doses of this product,
in order of increasing mean effect, are
(irbesartan/hydrochlorothiazide)
150mg/12.5mg, 300mg/12.5mg, and
300mg/25mg. The largest incremental effect
will likely be in the transition from
monotherapy to 150mg/12.5mg. It takes 2-4
weeks for the blood pressure to stabilize after
a change in the dose of this combination
product. The usual dose of product is one
tablet (150mg/12.5mg) once daily. More than
two tablets once daily is not recommended.
The maximal antihypertensive effect is attained
about 2-4 weeks after initiation of therapy.
Use in patients with renal impairment: The
usual regimens of therapy with this product
may be followed as long as the patient's
I or oral hypoglycemic agents may be required.
creatinine clearance is 30ml/min.
Patients with hepatic impairment: No dosage
adjustment is necessary in patients with
hepatic impairment.
Drug inter: See above under the text of
• Impaired hepatic functions: This combination is
•
'irbesartan' and 'hydrochlorothiazide' separately.
+ ARB ITAN Plus 75 Tab. Opsonin
lrbesartan INN 75mg & hydrochlorothiazide
l 2.5mg/tablet.
30's pack: 159.14 MRP
t ARB ITAN Plus 150 Tab. Opsonin
Irbesartan INN l 50mg & hydrochlorothiazide
12.5mg/tablet.
30's pack: 318.01 MRP
t CAVAZIDE-75 Tab. UniMed & Unffiealth
lrbesartan INN 75mg & hydrochlorothiazide
t
I
•
12.5mg/tablet.
30's pack: 180.00 MRP
t CAVAZIDE-150 Tab. UniMed & UniHealth
lrbe sartan INN 150mg & hydrochlorothiazide
12.5mg/tablet.
I
30's pack: 360.00 MRP
t CAVAZIDE-300 Tab. UniMed & Unffiealth
lrbesartan INN 300mg & hydrochlorothiazide
l 2.5mg/tablet.
IO's pack: 240.00 MRP
•
I
•
QIMP-17 (65) CARDIOVASCULAR DRUGS
twice-a-day regimen at the same total daily
LOSARTAN+
dose or an increase in dose may give a more
HYDROCHLOROTHIAZIDE48,52 satisfactory reporse.
Hydrochlorothiazide is effective in doses of
LOSARTAN+ 12.5mg to 50mg once daily and can be given at
HYDROCHLOROTHIAZIDE: Tablet doses of 12.Smg to 25mg.
Combination preparations of losartan potassium To minimize dose-dependent side effects, it is
and hydrochlorothiazide are available in two usually appropriate to begin combination
fixed strengths, viz: i. Losartan potassium INN therapy only after a patient has failed to
25mg + Hydrochlorothiazide BP 12.5mg, and ii. achieve the desired effect with monotherapy.
Losartan potassi11m INN 50mg+ T hese combinations may also be administered
Hydrochlorothiazide BP 12.5mg. with other antihypertensive agents if required.
Mode of action: See above under the text of Paediatric use: Safety and effectiveness in
'Candesartan + Hydrochlorothiazide' preparation. .
paediatric patients have not been established.
Ind: These combined preparations are indicated Drug inter: See above under the text of 'losartan
for the treatment of hypertension. These fixe.d potassium' and 'hydrochlorothiazide' separately.
dose combinations are not indicated for initial
t ACUSAN Plus Tab. Concord
therapy of hypertension, except when the
Losartan potassium 50mg & hydrochlorothiazide
hypertension is severe enough that the value of
l 2.5mg/tablet.
achieving prompt blood pressure control exceeds
30's pack: 240.00 MRP
the risk of initiating combination therapy in these
t ANGILOCK Plus Tab. Square
patients.
Losartan potassium 50mg & hydrochlorothiazide
C/I: This combination is contraindicated in
.' . \
l 2.5mg/tablet.
patients who are hypersensitive to any compoq��
50's pack: 400.00 MRP
ent of this product. Hydrochlorothiazide is
+ ANGILOCK Plus 100/12.5 Tab. Square
particularly contraindicated in patients with
Losartan potassium 1 OOmg &
anuria or hypersensitivity to other sulfonamide
hydrochlorothiazide l 2.5mg/tablet.
group of drugs.
30's pack: 330.00 MRP
S/E: Generally this combination is well tolerated.
t ANGILOCK Plus 100/25 Tab. Square
However, few side-effects including abdominal
Losartan potassium 1OOmg &
pain, swelling, back pain, dizziness, rash and
hydrochlorothiazide 25mg/tablet.
cough may occur in rare cases.
30's pack: 360.00 MRP
Precautions & warnings: In patients treated
+ ANIN 50 Plus Tab. Delta Pharma
with various doses of losartan and
Lo sartan potassium 50mg & hydrochlorothiazide
hydrochlorothiazide, there was a dose-related
l 2.5mg/tablet.
decrease in the hypokalemic response to
20's pack: 120.00 MRP
hydrochlorothiazide as the dose of losartan was
+ ANREB Plus 50 Tab. General
increased, as well as a dose-related decrease in
Losartan potassi11m 50mg & hydrochlorothiazide
serum uric acid with increasing doses of losartan.
l 2.5mg/tablet.
Periodic determination of serum electrolytes to
30's pack: 240.00 MRP
detect possible electrolyte imbalance should be
+ ANREB Plus 100 Tab. General
performed at appropriate intervals.
Losartan potassium 1OOmg &
In diabetic patients dosage adjustments of insulin
hydrochlorothiazide l 2.5mg/tablet.
20's pack: 240.00 MRP
Hypotension: In patients who are intravascularly
t ARATEN Plus-50 Tab. UniMed &
volume-depleted (e.g those treated with
UniBealth
diuretics), symptomatic hypotension may occur
Losartan potassium 50mg & hydrochlorothiazide
after initiation of this combined therapy.
l 2.5mg/tablet.
30's pack: 240.00 MRP
not recommended for patients with hepatic
+ ARBIUM Plus 50/12.5 Tab. Asiatic
impairment who require titration with losartan.
Losartan potassium USP 50mg &
The lower starting dose of losartan recommended
hydrochlorothiazide BP 12.5mg/tablet.
for that patients.
50's pack: 300.00 MRP
Patients with renal impairment: In patients with
more severe renal impairment this is not
+ ARB IUM Plus 100/12.5 Tab. Asiatic
Losartan potassium USP 1OOmg &
recommended.
hydrochlorothiazide BP l 2.5mgltablet.
Pregnancy & lactation: When pregnancy is 30's pack: 300.00 MRP
detected, this drug should be discontinued as
+ ARBIUM Plus 100/25 Tab. Asiatic
soon as possible. It should not be used in
Losartan potassium USP l OOmg &
lactation also.
hydrochlorothiazide BP 25mg/tablet.
Dosage & admin: Dosing must be individuali­ 30's pack: 300.00 MRP
zed. + CARDISAN Plus Tab. Beacon
The usual starting dose of losartan is 50mg Losartan potassium 50mg & hydrochlorothiazide
once daily; 2Smg is recommended for patients l 2.5mg/tablet.
with intravascular volume depletion and 30's pack: 240.00 MRP
patients with a history of hepatic impairment. t CARDOPLUS 50 Tab. SK+F
Losartan can be administered once or twice Losartan potassium 50mg & hydrochlorothiazide
daily at total daily doses of 25mg to 1OOmg. If 12.Smg/tablet.
the antihypertensive effect measured at trough 20's pack: 160.00 MRP
using once-a-day dosing is inadequate, a + LARD 50 Plus Tab. Opsonin
CARDIOVASCULAR DRUGS Q�-17(66)

Losartan potassium 50mg & hydrochlorothiazide 30's pack: 240.00 MRP

12.5mg/tablet. t LOSIUM Plus-50 Tab. Ibo Sina OLMESARTAN + AMLODIPINE52
30's pack: 211.13 MRP Losartan potassium 50Qlg & hydrochlorothiazide
+ L ARB 100 Plus Tab. Opsonin 12.5mg/tablet. OLMESARTAN + AMLODIPINE: Tablet
Losartan potassium I OOmg & 30's pack: 195.00 IP This is a combination preparation of olmesartan
hydrochlorothiazide l 2.5mg/tablet. + LOSPIL Plus Tab. White Horse medoxomil and amlodipine, where olmesartan is
30's pack: 316.69 MRP Losartan potassium 50mg & hydrochlorothiazide an angiotensin II receptor blocker (ATl subtype),
+ L K Plus Tab. Pacific l 2.5mg/tablet. & amlodipine is a dihydropyridine, calcium
Losartan potassium 50mg & hydrochlorothiazide 50's pack: 400.00 MRP channel blocker. This preparation is available as
l 2.5mg/tablet. t LOTAS Plus Tab. Ambee a fixed combination of olmesartan medoxomil
30's pack: 240.00 MRP Losartan potassium 50mg & hydrochlorothiazide INN 20mg and amlodipine besylate BP
t LOK-50 Plus Tab. Globe 12.5mg/tablet. equivalent to amlodipine 5mg in tablet form.
Losartan potassium 50mg & hydrochlorothiazide 30's pack: 150.60 MRP Mode of action: See under the text of
l 2.5mg/tablet. t OSARTAN-HZ Tab. Aristopharma olmesartan & amlodipine separately.
30's pack: 180.00 MRP Losartan potassium 50mg & hydrochlorothiazide Ind: This combined preparation is indicated for
+ LOPO Plus Tab. Biopharma 12.5mg/tablet. the treatment of hypertension, in patients who are
Losartan potassium 50mg & hydrochlorothiazide 30's pack: 240.00 MRP likely to need multiple antihyperterisive agents to •

12.5mg/tablet.
30's pack: 240.00 MRP
t LOPASS Plus Tab. Sandoz
Losartan potassium BP 50mg &
hydrochlorothiazide l 2.5mg/tablet.
28's pack: 280.00 MRP
t LOPOS Plus Tab. Zenith
Losartan potassium 50mg & hydrochlorothiazide
l 2.5mg/tablet.
50's pack: 500.00 MRP
t LOSACARD-HZ Tab. Novo Healthcare
Losartan potassium USP 50mg &
hydrochlorothiazide USP 12.5mg/tablet.
30's pack: 240.00 MRP
t LOSACOR Plus Tab. Healthcare
Losartan potassium 50mg & hydrochlorothiazide
l 2.5mg/tablet.
30's pack: 240.00 MRP
t LOSAN D Tab. Orion Pharma
Losartan potassium 50mg & hydrochlorothiazide
l 2.5mg/tablet.
30's pack: 240.00 MRP
t LOSARDIL 25 Tab. Drug Inter.
Losartan potassium INN 25mg &
hydrochlorothiazide BP 12.5mg/tablet.
50's pack: 250.00 MRP
t LOSARDIL 50 Tab. Drug Inter.
Losartan potassium INN 50mg &
hydrochlorothiazide BP 12.5mg/tablet.
50's pack: 300.00 MRP
t LOSARDIL 100/12.5 Tab. Drug Inter.
Losartan potassium USP 1 OOmg &
hydrochlorothiazide USP l 2.5mg/tablet.
20's pack: 180.00 MRP
t LOSARDIL 100/25 Tab. Drug Inter.
Losartan potassium USP 1 OOmg &
hydrochlorothiazide USP 25mg/tablet.
20's pack: 200.00 MRP
t LOSART Plus 50/12.5 Tab. Acme
Losartan potassium 50mg & hydrochlorothiazide
12.5mg/tablet.
30's pack: 240.00 MRP
t LOSART Plus 100/12.5 Tab. Acme
t OSARTIL 50 Plus Tab. Incepta
Losartan potassium 50mg & hydrochlorothi<lZide
l 2.5mg/tablet.
50's pack: 300.00 MRP
t OSARTIL 100 Plus Tab. Incepta
Losartan potassium l OOmg &
hydrochlorothiazide l 2.5mg/tablet.
30's pack: 300.00 MRP
t OSCARD Tab. Sharif
Losartan potassium 50mg & hydrochlorothiazide
l 2.5mg/tablet.
30's pack: 180.00 MRP
+ OSTAN Plus Tab. Renata
Losartan potassium 50mg & hydrochlorothiazide
12.5mg/tablet.
30's pack: 240.00 MRP
+ OSTAN 100 Plus Tab. Renata
Losartan potassium 1OOmg &
hydrochlorothiazide l 2.5mg/tablet.
·
30's pack: 300.00 MRP
t PARTEN Plus Tab. Jayson
Losartan potassium 50mg & hydrochlorothiazide
l 2.5mg/tablet.
30's pack: 180.60 MRP
t PER'I'ILOS Plus Tab. Navana
Losartan potassium 50mg & hydrochlorothiazide
l 2.5mg/tablet.
30's pack: 240.00 MRP
t PRESLO-H Tab. Labaid Pharma
Losartan potassium 50mg & hydrochlorothiazide
12.5mg/tablet.
30's pack: 240.00 MRP
t PROSAN HZ 50/12.5 Tab. Beximco
Losartan potassium 50mg & hydrochlorothiazide
l 2.5mg/tablet.
30's pack: 180.00 IP
t PROSAN HZ 100/12.5 Tab. Beximco
Losartan potassium 1OOmg &
hydrochlorothiazide l 2.5mg/tablet.
30's pack: 270.00 IP
t PROSAN HZ 100/25 Tab. Beximco
Losartan potassium 1 OOmg &
achieve their blood pressure goals; chronic stable
angina and vasospastic angina. This preparation
may be administered with other antihypertensive
agents.
C/I� Patients who are hypersensitive to any com­
ponent of this product or to any of its ingredients.
S/E: The common side effects include edema,
hypotension, orthostatic hypotension, rash, pruri­
tus, palpitation, urinary frequency, and nocturia.
Precautions: Caution should be exercised in
patients with volume or salt depletion, severe
aortic stenosis, severe obstructive coronary artery
disease, congestive. heart failure, impaired renal
function, and hepatic impairment. No initial
dosage adjustment is recommended for patients
with moderate to marked renal impairment
(Creatinine clearance <40 mL/min). Combination
of amlodipine & olmesartan is not recommended
below creatinine clearance <20 ml/min.
Pregnancy & lactation: Olmesartan medoxomil:
Pregnancy categories C (frrst trimester) and D
(second and third trimesters).
Amlodipine: There are no adequate and well­
controlled studies in pregnant women.
Amlodipine should be used during pregnancy
only if the potential benefit justifies the potential
risk to the fetus. When pregnancy is detected,
discontinue this combination as soon as possible.
It is not known whether the amlodipine or
olmesartan is excreted in human milk.
Dosage & admin: Initial therapy: The usual
starting dose of this combined preparation is
one tablet (20mg/Smg) once daily. Depending
on the blood pressure response, the dose may
be titrated at intervals of 1-2 weeks to
maximum 2 tablets (i.e 40mg/1Omg) once
daily. Maximum antihy-pertensive effects are
attained within 2 weeks.
This combined preparation may be taken with
or without food.
Replacement therapy: This preparation may be
substituted for its individually titrated
•

components. When substituting for individual

Losartan potassium 1 OOmg &
hydrochlorothiazide 12.5mg/tablet.
30's pack: 360.00 MRP
t LOSART Plus 100/25 Tab. Acme
Losartan potassium 1 OOmg &
hydrochlorothiazide 25mg/tablet.
30's pack: 360.00 MRP
t LOSATAN HZ Tab. Popular
Losartan potassium 50mg & hydrochlorothiazide
l 2.5mg/tablet.
hydrochlorothiazide 25mg/tablet.
components, the dose of one or both of the
30's pack: 300.00 IP
components can be increased if blood pressure
t REPACE H Tab. Sun Pharma control has not been satisfactory.
Losartan potassium 50mg & hydrochlorothiazide Add-on therapy: This preparation may be used
l 2.5mg/tablet. to provide additional blood pressure lowering
50's pack: 400.00 MRP for patients not adequately controlled with
+ XELOTAN Plus Tab. Pharmasia amlodipine (or another dihydropyridine
Losartan potassium 50mg & hydrochlorothiazide calcium channel blocker) alone or with
l 2.5mg/tablet. olmesartan medoxomil (or another angiotensin
30's pack: 180.00 MRP receptor blocker) alone.

•

Elderly patients: No dosage adjustment is
necessary in elderly patients � 65 years age.
Patients with hepatic impairment: Initial
therapy with this preparation is not
recommended in patient's �75 years and in
patients with hepatic impairment.
Children: Not recommended.
Drug int�r: In vitro data indicate that
amlodipine has no effect on the human plasma
protein binding of digoxin, phenytoin, warfarin,
•
and indomethacin. No significant drug
interactions were reported when olmesartan was
co-administered with digoxin or warfarin.
t ABECAB 20/S Tab. ACI
Olmesartan medoxomil INN 20mg + amlodipine
besylate BP equivalent to amlodipine 5mg/tablet.
30's pack: 240.90 MRP
t ABECAB 40/S Tab. ACI
Olmesartan medoxomil INN 40mg + amlodipine
besylate BP equivalent to amlodipine 5mg/tablet.
30's pack: 450.00 MRP
t BIZORAN 20/S Tab. Beximco
Olmesartan medoxomil INN 20mg + amlodipine
besylate BP equivalent to amlodipine 5mg/tablet.
30's pack: 240.00 IP
t CAMLOSART 20/5 Tab. Square
Olmesartan medoxomil INN 20mg + amlodipine
besylate BP equivalent to amlodipine 5mg/tablet.
30's pack: 240.00 MRP
t CAMLOSART 40/5 Tab. Square
Olmesartan medoxomil INN 40mg + amlodipine
besylate BP equivalent to amlodipine 5mg/tablet.
20's pack: 300.00 MRP
t DISARTAN 20/S Tab. Drug Inter.
Olmesartan medoxomil INN 20mg + amlodipine
besylate BP equivalent to amlodipine 5mg/tablet.
30's pack: 240.00 MRP
t OLMEZEST AM 40/S Tab. Sun Pharma
Olmesartan medoxomil INN 40mg + amlodipine
besylate BP equivalent to amlodipine 5mg/tablet.
30's pack: 255.00 MRP
t OLSART Plus 20 Tab. Opsonin
Olmesartan medoxomil INN 20mg + amlodipine
besylate BP equivalent to amlodipine 5mg/tablet.
30's pack: 211.13 MRP
OLMESARTAN +
HYDROCHLOROTHIAZIDE52
OLMESARTAN +
HYDROCHLOROT HIAZIDE: Tablet
This is a combination preparation of olmesartan
medoxomil and hydrochlorothiazide, where
olmesartan is an angiotensin II receptor blocker
(ATI subtype), & hydrochlorothiazide is a
thiazide diuretic. This preparation is available as
a fixed combination of olmesartan medoxomil
INN 20mg and hydrochlorothiazide BP 12.5mg
in tablet form.
Mode of action: See under the text of
olmesartan & hydrochlorothiazide separately.
Ind: This combination is indicated for the
treatment of hypertension, particularly in patients
I
QIMP-17 (67)
whose blood pressure is not controlled adequate­
ly on olmesartan alone. It is not indicated for
initial therapy.
C/I: Patients who are hypersensitive to any of the
compnents, or excipients or other sulfonamide­
derived substances (since hydrochlorothiazide is
a sulfonamide-derived medicinal product).
S/E: Treatment with olmesartan-hydrochlorothia­
zide is well tolerated. Adverse events are
generally mild, transient and have no relationship
to the dosages, such as- vertigo, coughing, back
pain, rash, weakness, transient blurred vision,
diarrhea, headache, and urinary tract infection.
Precautions: See under the text of olmesartan &
hydrochlorothiazide separately.
Pregnancy & lactation: Pregnancy categories C
(first trimester) & D (second & third trimesters).
It is not known whether olmesartan is excreted in
human milk, but olmesartan was excreted in the
milk of lactating rats. Thiazides appear in human
milk. Because of the potential for adverse effects
on the nursing infant, a decision should be made
whether to discontinue nursing or discontinue the
drug, taking into account the importance of the
drug to the mother.
Dosage & admin: The treatment with this
combination & its dosage must be
individualized.
Adults: The usual recommended starting dose
is one tablet (20mg/12.Smg) once daily.
Depending on the blood pressure response, the
dose may be titrated at intervals of 2-4 weeks
to 2 tablets (40mg/2Smg) once daily.
T his preparation can be taken with or without
food.
Elderly: In elderly, no dosage adjustment is
required.
Renal impairment: No dosage adjustment is
necessary in mild to moderate renal
impairment (Creatinine clearance, 30ml/min
to <60ml/min). In patients with more severe
renal impairment, loop diuretics are preferred
to thiazides, so this combination is not
recommended.
Children & adolescents: T his combined
preparation is not recommended for use in
children below 18 years due to a lack of data
on safety & efficacy.
Drug inter: See under the text of olmesartan &
hydrochlorothiazide separately.
t ABETIS Plus 20 Tab. ACI
Olmesartan medoxomil INN 20mg +
hydrochlorothiazide BP 12.5mg/tablet (f.c ).
30's pack: 240.90 MRP
t OLMECAR Plus Tab. Square
Olmesartan medoxomil INN 20mg +
hydrochlorothiazide BP l 2.5mg/tablet (f.c).
30's pack: 240.00 MRP
+ OLMESAN Plus Tab. Beximco
Olmesartan medoxomil INN 20mg +
hydrochlorothiazide BP 12.5mg/tablet (f.c).
30's pack: 240.00 MRP
t OLMETIC Plus Tab. Drug Inter.
Olmesartan medoxomil INN 20mg +
.9'-qn
I�I ;�_;;�AU
Amlodipine 5 mg + Olmesartan 20 mg tablet
Amlodipine 5 mg + Olmesartan 40 mg tablet
hydrochlorothiazide BP 12.5mg/tablet (f.c).
30's pack: 240.00 MRP
t OLMEZEST H 20 Tab. Sun Pharma
Olmesartan medoxomil INN 20mg +
hydrochlorothiazide BP 12.5mg/tablet (f.c).
30's pack: 255.00 MRP
t OLSART HZ 20 Tab. Opsonin
Olmesartan medoxomil 20mg +
hydrochlorothiazide l 2.5mg/tablet.
30's pack: 211.13 MRP
t OLSART HZ 40 Tab. Opsonin
Olmesartan medoxomil 40mg + hydrochloroth
iazide l 2.5mg/tablet.
30's pack: 397 .45 MRP
t XYOTIL 20 Plus Tab. Incepta
Olmesartan medoxomil INN 20mg +
hydrochlorothiazide BP 12.5mg/tablet (f.c).
30's pack: 240.00 MRP
RAMIPRIL+
HYDROCHLOROTHIAZIDFJ6
RAMIPRIL + HYDROCHLOROT HIAZIDE:
Tablet
This is a fixed combination of ramipril and
hydrochlorothiazide; preparations are available in
,
two presentations, viz: i. tablet containing
ramipril BP 2.5mg and hydrochlorothiazide BP
12.5mg, and ii. tablet containing ramipril BP 5mg
and hydrochlorothiazide BP 25mg.
. Ind: This combined preparation is indicated for
'
the treatment of hypertension.
C/I; S/E; Precautions: See under the text of
ramipril & hydrochlorothiazide separately.
Pregnancy & lactation: Not recommended in
pregnancy & lactation.
Dosage & admin: A patient whose blood
pressure is not adequately controlled with
ramipril (or another ACE inhibitor) alone or
with hydrochlorothiazide (or another thiazide
diuretic) alone, may be switched to any of the
combination therapy. The usual starting dose
of this combination is either one tablet of
2.5mg/12�5mg or 5mg/25mg once daily. If
necessary, the dose may be increased up to two
tablets of Smg/2Smg once daily.
Dosage in renal ilpairment: I.n patients with a
creatinine clearance between 60 & 30ml/min,
treatment should be initiated with ramipril
1.25mg monotherapy. If blood pressure is not
adequately controlled, the dose of ramipril
may be increased to 2.5mg. If blood pressure
is still not controlled, patient may be switched
to one tablet of this combination 2.5mg/12.Smg
once daily. Dosage may be titrated upward to
Smg/25mg until blood pressure is controlled.
Drug inter: See under the text of ramipril &
hydrochlorothiazide separately.
•••
•••
LTJJ.
www.squarepharma.com.bd •••
MUAlllE
 •

. ,.
... .. .. .
.
CARDIOVASCULAR DRUGS
.
' QIMP-17 (68)
'

.
'
' •

t PIRAMIL 2.S Plus Tab. Sandoz in patients who are hypersensitive to any of the component of this product; patients with anuria

. .
�pril. BP
' .'.
2.5mg
.. .
� .hydrochlorothiazide BP components. or hypersensitivity to other sulfonamide derived

-
:.l. 2.5mg/tablet.
- '·
S/E: The combination of amlodipine and drugs.
2-8's pack; 210.00 MRP . - · •

telmisartan is well tolerated. Rare side effects
+ PIRAMIL 5 Plus Tab. Sandoz may include headache, palpitations, flushing,
Ramipril BP 5mg & hydrochlorothiazide BP edema, depression, dizziness, dyspepsia,
25mg/tablet. dyspnoea, muscle cramps, fatigue, cold
28's pack: 300.00 MRP extremities and bradycardia.
t PROTACE-H 2.S Tab. UniMed & Precaution: See under the text of telmisartan &
UniHealth amlodipine separately.
Ramipril BP 2.5mg & hydrochlorothiazide BP
Pregnancy & lactation: This combination
12.5mg/tablet.
should not be given during pregnancy & lactation.
30's pack: 150.00 MRP
Dosage & admin: The recommended dosage of
t RAMICARD-2.S Plus Tab. Drug Inter.
this formulation (telmisartan BP 40mg +
Ramipril BP 2.5mg & hydrochlorothiazide BP
amlodipine Smg) is one tablet daily. If neces-
12.Smg/tablet. �
S/E: Most side effects are mild in intensity &
transient in nature & did not require
discontinuation of therapy. Common side effects
are diarrhea, nausea, dizziness, cough & fatigue.
Precautions: Impaired hepatic functions: As the
majority, telmisartan is eliminated by biliary
excretion, patients with biliary obstructive
disorders or hepatic insufficiency can be
expected to have reduced clearance. Telmisartan
should be used with caution in these patients.
Impaired renal function: As a consequence of
inhibiting the renin- angiotensin- aldosterone
system, changes in renal function may be

anticipated in susceptible individuals. Caution

sary, the dosage may be increased to 2 tablets
•

50's pack: 150.00 MRP should be taken for these patients.

daily. The dosage however should be individu­
t RAMICARD-S Plus Tab. Drug Inter. alized. It ••Y be given with or without food. Pregnancy & lactation: When pregnancy is
Ramipril BP 5mg & hydrochlorothiazide BP Drug withdrawal: Since coronary heart disease detected, this drug should be discontinued as
25mg/tablet. may exist without being recognized, patients soon as possible. It should not be used in
I
30's pack: 150.00 MRP should be warned against stopping the drug lactation also.

+ RAMORIL 2.S Plus Tab. Incepta suddenly. Any discontinuation should be Dosage & admin: The usual starting dose of
Ramipril BP 2.5mg & hydrochlorothiazide BP gradual and under observation. this combination preparation is telmisartan
12.5mg/tablet. Drug inter: See under the text of telmisartan & 40mg once daily; blood pressure response is
30's pack: 150.00 MRP amlodipine separately. dose related over the range of 40-80mg.

v-· 10 mg Tablet
..; -�o mg Tablet
Tablet
Amlodipine 5 mg & Telmisartan 40 mg

pharmasia A SONY //hRA '.'< ;'-; Enterprise

+ RAMORIL 5 Plus Tab. Incepta
Ramipril BP 5mg & hydrochlorothiazide BP
25m�tablet.
30's pack: 240.00 MRP
+ TRITAZIDE 10/25 Tab. Sanofi-aventis
Ramipril BP 1Omg & hydrochlorothiazide BP
25mg/tablet.
28's pack: 561.96 MRP
TELMISARTAN + AMLODIPINE
TELMISARTAN + AMLODIPINE: Tablet
This combination preparation is available as­
Telmisartan BP 40mg + Amlodipine
equivalent to Smg amlodipine in tablet form.
Telmisartan is a nonpeptide Angiotensin
Receptor Blocker (ARB) and Amlodipine is a
dihydropyridine calcium antagonist.
Mode of action: See under the text of telmisar­
t CARDOTEL Tab. Pharmasia Hydrochlorothiazide is effective in doses of
Telmisartan BP 40mg + Amlodipine besylate BP 12.Smg to 50mg once daily and can be given at
equivalent to amlodipine 5mg/tablet. doses of 12.Smg to 2Smg.
30's pack: 240.00 MRP It is usually appropriate to begin combination
therapy only after aiJatient has failed to
achieve the desired effect with monotherapy.
TELMISARTAN + Telmisartan combination therapy may be
HYDROCHLOROTHIAZIDE 82 administered with other antihypertensive
drugs & it also may be administered with or
TELMISARTAN + without food.
87,146 HYDROCHLOROTHIAZIDE: Tablet Drug inter: Digoxin levels be monitored when
The combined preparations of telmisartan & initiating, adjusting & discontinuing telmisartan.
hydrochlorothiazide are available in two fixed­ Alcohol, barbiturates, anti-diabetic drugs may
dose presentations, viz: i. Telmisartan INN 40mg interact with thiazide diuretics.
+ Hydrochlorothiazide BP 12.5mg/tablet; ii.
besylate BP + MITOSAN 40 Plus Tab. Sandoz
Telmisartan INN 80mg + Hydrochlorothiazide
Telmisartan INN 40mg & hydrochlorothiazide
BP 12:smg/tablet.
BP l 2.5mg/tablet.
Mode of action: See above under the text of
20's pack: 260.00 MRP
'Candesartan + Hydrochlorothiazide' preparation.
t MITOSAN 80 Plus Tab. Sandoz
Ind: These combined preparations are indicated
Telmisartan INN 80mg & hydrochlorothiazide "
..

for the treatment of hypertension. These fixed

tan & amlodipine separately. BP 12.5mg/tablet.
dose combinations are not indicated fot initial
Ind: This combined preparation is indicated for 20's pack: 420.00 MRP
therapy .of hypertension.
·

the treatment of hypertension, chronic stable + TELCARDIS Plus 40 Tab. UniMed &
angina and vasospastic angina. C/I: This combined preparation is contraindicat­ UniHealth
C/I: This combined preparation is contraindicated ed in patients who are hypersensitive to any Telmisartan INN 40mg & hydrochlorothiazide

•

BP 12.5mg/tablet.
14's pack: 175.00 IP
t TELCARDIS Plus 80 Tab. UniMed &
UniHealth
Telmisartan INN 80mg & hydrochlorothiazide
BP 12.5mg/tablet.
l 4's pack: 280.00 IP
VALSARTAN+ AMLODIPINE62 •133
VALSARTAN + AMLODIPINE: Tablet
The combined preparations of valsartan &
amlodipine are available in three fixed-dose
presentations, viz: i. Valsartan 80mg +
Amlodipine BP 5mg/tablet; ii. Valsartan l 60mg +
v
- Amlodipine BP 5mg/tablet; & Valsartan 160mg +
Amlodipine BP IOmg/tablet.
Mode of action: See above under the text of
valsartan & amlodipine given separately.
Ind: Amlodipine and valsartan combination is
indicated for the treatment of hyertension. This
fixed combination preparations are not indicated
for the initial therapy of hypertension.
C/I: Known hypersensitivity to any component
of the preparations.
S/E: Adverse experiences have generally been
mild and transient in nature and have only
infrequently required discontinuation of therapy.
Precautions: Impaired hepatic function, beta­
blocker withdrawal. Renal insufficiency: There is
no apparent correlation between renal function
(measured by creatinine clearance) and exposure
(measured by AUC) to valsartan in patients with
different degrees of renal impairment.
Pregnancy & lactation: Preparations containing
valsartan should not be given during pregnancy
& lactation; if pregnancy is detected during
therapy, should be discontinued as soon as .
possible. It should not be used in lactation also.
Dosage & admin: Amlodipine is an effective
treatment of hypertension in once daily doses
of 2.5mg-1Omg while valsartan is effective in
doses of 80mg to 320mg. In clinical trials with
amlodipine and valsartan combination using
amlodipine doses of 5mg-10mg and valsartan
doses of 160mg-320mg, the antihypertensive
effects increased with increasing doses.
Pediatric use: Safety and effectiveness of
amlodipine and valsartan combination in
pediatric patients have not been established.
Drug inter: See under the text of 'valsartan' and
'amlodipine' separately.
t AMLOSARTAN 80/5 Tab. Incepta
Valsartan INN USP 80mg + Amlodipine BP
5mg/tablet (f.c).
30's pack: 270.00 MRP
t AMLOSARTAN 160/5 Tab. Incepta
Valsartan INN USP l 60mg + Am1odipine BP
-
...
5mg/tablet (f.c).
30's pack: 480.00 MRP
t AMLOSARTAN 160/10 Tab. Incepta
Valsartan INN USP l 60mg + Amlodipine BP
lOmg/tablet (f.c).
30's pack: 480.00 MRP
t AMLOVAS V S 80/S Tab. Popular
Valsartan INN USP 80mg + Amlodipine BP
5mg/tablet (f.c).
30's pack: 270.90 MRP
t AMLOVAS V S 160/5 Tab. Popular
I
-
QIMP-17 (69) CARDIOVASCULAR DRUGS
Valsartan INN USP l 60mg + Amlodipine BP Ind: These combined preparations are indicated
5mg/tablet (f.c). for the treatment of hypertension. These fixed
30's pack: 481.80 MRP dose combinations are not indicated for initial
t AML OVAS V S 160/10 Tab. Popular therapy of hypertension.
Valsartan INN USP l 60mg + Amlodipine BP C/I: Hypersensitive to any component of this
lOmg/tablet (f.c). product; particularly hydrochlorothiazide
30's pack: 481.80 MRP component is contraindicated in patients with
+ AV -5 Tab. Drug Inter. anuria or hypersensitivity to other sulfonamide­
Vals artan INN USP 160mg + Amlodipine BP derived drugs. Pregnancy & lactation.
5mg/tablet (f.c). S/E: Allergic reaction, anaphylaxis, asthenia and
20's pack: 160.00 MRP dependent edema. Palpitations, syncope, and
+ AV-10 Tab. Drug Inter. tachycardia. Flushing, rash, sunburn and
Valsartan INN USP l 60mg + Amlodipine BP increased sweating. Increased appetite, constipa­
lOmg/tablet (f.c). tion, dyspepsia, flatulence, dry mouth, dehydra­
20's pack: 200.00 MRP tion, nausea, abdominal pain, and vomiting.
t AV ODIL VL 10/320 Tab. Opsonin Arthralgia, gout, muscle cramps, muscle
Valsartan INN USP 320mg + Amlodipine BP weakness, arm pain, and leg pain etc. .
lOmg/tablet (f.c). Precautions: Impaired hepatic function, beta­
20's pack: 563.00 MRP blocker withdrawal. Renal insufficiency: There is
t CAMOVAL 80/5 Tab. Square no apparent correlation between renal function
Valsartan INN USP .80mg + Amlodipine BP (measured by creatinine clearance) and exposure
5mg/tablet (f.c). ···
(measured by AUC) to valsartan in patients with
30's pack: 270.90 MRP different degrees of renal impairment.
t CAMOVAL 160/5 Tab. Square Pregnancy & lactation: When pregnancy is
Valsartan INN USP l 60mg + Amlodipine BP detected, this drug should be discontinued as
5mg/tablet (f.c). soon as possible. It should not be used in
20's pack: 321.20 MRP lactation also.
t CO-DISYS 80/5 Tab. Healthcare Dosage & admin: The recommended starting
Valsartan INN USP 80mg + Amlodipine BP dose of valsartan is 80mg or 160mg once daily
5mg/tablet (f.c). when used as monotherapy in patients who
30's pack: 300.00 MRP are n�t volume depleted. Patients requiring
t CO-DISYS 160/5 Tab. Healthcare greater reductions may be started at a higher
Valsartan INN USP l 60mg + Amlodipine BP dose. Valsartan may be used over a dose range
5mg/tablet (f.c). of 80mg to 320mg daily, administered once-a­
30's pack: 540.00 MRP day. A patient whose blood pressure is not
t CO-DISYS 160/10 Tab. Healthcare adequately controlled with valsartan
Valsartan INN USP l 60mg + Amlodipine BP monotherapy, patient may be switched over to
lOmg/tablet (f.c). valsartan combination formula with
30's pack: 570.00 MRP hydrochlorothiazide. Hydrochlorothiazide is
t EXFORGE 5/80 Tab. Novartis effective in doses of 12.5 to 50mg daily, and
Amlodipine BP 5mg + Valsartan INN USP can be given at doses of 12.5mg to 25mg in
80mg/tablet (f.c). combination with valsartan (valsartan 80mg/
28's pack: 1409.80 MRP hydrochlorothiazide 12.5mg or valsartan
t EXFORGE 5/160 Tab. Novartis 160mg/ hydrochlorothiazide 12.5mg) once
Amlodipine BP 5mg + Valsartan INN USP daily. H blood pressure remains uncontrolled
160mg/tablet (f.c). after about 3-4 weeks of treatment, either
28's pack: 1975.05 MRP valsartan or both components m·ay.be
t EXFORGE 10/160 Tab. Novartis increased depending on clinical response.
Amlodipine BP IOmg + Valsartan INN USP Children: The efficacy and effectiveness of this
160mg/tablet (f.c). combination preparation have not been
28's pack: 2207.80 MRP established in patients <18 years of age.
t REOVAN A 80/5 Tab. RAK Pharma Drug inter: See above under the text of
Valsartan INN USP 80mg + Amlodipine BP 'valsartan' and 'hydrochlorothiazide' separately.
5mg/tablet (f.c). •
30's pack: 270.00 MRP
t CARDIVAL Plus-80 Tab. Drug Inter.
Valsartan INN USP 80mg + hydrochlorothiazide
•
BP 12.5mg/tablet (f.c).
VALSARTAN+ 20's pack: 160.00 MRP
HYDROCHLOROTHIAZIDE62 t CARDIVAL Plus-160 Tab. Drug Inter.
Valsartan INN USP 160mg +
VALSARTAN+ hydrochlorothiazide BP 12.5mg/tablet (f.c).
HYDROCHLOROT HIAZIDE: Tablet 1O's pack: 160.00 MRP
Combination preparations of valsartan and t CO-DIOVAN 80/12.5 Tab. Novartis
hydrochlorothiazide are available in two fixed Valsartan INN USP 80mg + hydrochlorothiazide
presentations, viz: i. valsartan INN USP 80mg + BP 12.5mg/tablet (f.c).
hydrochlorothiazide BP 12.5mg, and ii. valsartan 28's pack: 1344.00 MRP
INN USP l 60mg + hydrochlorothiazide BP t CO-DIOVAN 160/12.5 Tab. Novartis
12.5mg. Valsartan INN USP 160mg +
Mode of action: See above under the text of hydrochlorothiazide BP 12.5mg/tablet (f.c).
'candesartan + hydrochlorothiazide' combined 28's pack: 1848.00 MRP
preparation. + DISYS Plus Tab. Healthcare
CARDIOVASCULAR DRUGS
Valsartan INN USP 80mg + hydrochlorothiazide
BP 12.Smg/tablet (f.c).
30's pack: 300.00 MRP
t VALSARTIL 80 Plus Tab. Incepta
Valsartan INN USP 80mg + hydrochlorothiazide
BP 12.Smg/tablet (f.c).
30's pack: 270.00 MRP
t VALSARTIL 160/12.5 Tab. Incepta
Valsartan INN USP 160mg +
hydrochlorothiazide BP 12.Smg/tablet (f.c).
30's pack: 480.00 MRP
t VALSARI'IL 160 Plus Tab. Incepta
Valsartan INN USP 160mg +
hydrochlorothiazide BP 25mg/tablet (f.c).
30's pack: 480.00 MRP
t VALZIDE 80/12.5 Tab. Renata
Valsartan INN USP 80mg + hydrochlorothiazide
BP 12.Smg/tablet (f.c).
20's pack: 220.00 MRP
t VALZIDE 160/12.5 Tab. Renata
Vals artan INN USP 160mg +
hydrochlorothiazide BP 12.Smg/tablet (f.c).
20's pack: 400.00 MRP
Renin inhibitors2.21
Introduction: Renin is a renal enzyme, released
into the circulation, which acts on the peptide
substrate angiotensinogen (manufactured in the
liver) and producing angiotensin I in the
circulation. This in turn is converted in to
angiotensin II by angiotensin-converting enzyme
(ACE), largely in the pulmonary capilary bed.
Angiotensin II is then plays the major role in
renin-angiotensin-aldosterone (RAA) system for
controlling renal sodium excretion.
Renin inhibitors inhibit the action of renin
directly at the initial phase of this system.
Combination treatment with an ACE inhibitor or
an angioten-sin II receptor antagonist is contra­
indicated in patients with diabetes mellitus, and
also not recommended in all other patients. The
.
only renin inhibitor available for use is aliskiren.
AL.lSKlltEN54
ALISKIREN: Tablet (f.c)
Aliskiren is a renin inhibitor, useful in the
treatment of hypertension. It is available as­
aliskiren 150mg & 300mg/tablet (film-coated).
Mode of action: See above, introduction on
·
renin inhibitors.
Ind: Treatment of hypertension.
C/I: Hypersensitivity to aliskiren or to any of the
excipients; concomitant use with ACE inhibitors
or angiotensin II receptor antagonists with type 2
diabetes mellitus; pregnancy & lactation.
S/E: Common: Diarrhea, hyperkalemia.
Uncommon: Rash.
Laboratory values: Decrease in hemoglobin and
hematocrit, increase in serum potassium.
Frequency unknown: Anaphylactic reactions
including angioedema, hypersensitivity, urticaria;
dizziness; peripheral edema; hypotension; liver
diosorder; severe cutaneous adverse reactions
including toxic epidermal necrolysis/Stevens
Johnson's syndrome, pruritus, erythema; renal
failure, renal impairment, serum creatinine
increased; hepatic enzymes increased.
•
QIMP-17 (70)
Precautions & warnings: Rare cases of
hypotension after initiation of treatment. Close
medical supervision in patientS with an activated
renin-angiotensin system is required (e.g volume
and/or salt-depleted patients). Not recommended
in patients with severe renal dysfunction. Caution
in patients with renal artery stenosis, a history of
dialysis, nephrotic syndrome, or renovascular
hypertension (specially in combination with
NSAIDs or other RAAS agents treatment).
Monitoring of serum electrolyte levels advised.
Discontinue in case of anaphylactic reaction or
angioedema and ensure appropriate therapy and
monitoring measures are initiated.
Pregnancy & lactation: Aliskiren is contra­
indicated during pregnancy. Discontinue as soon
as pregnancy is detected. Discontinue nursing or
discontinue with aliskiren, taking into account the
importance of the treatment to the mother.
Dosage & admin: 150mg-300mg once daily,
alone or in combination with other
antihypertensive drugs, (but not with ACE
inhibitors or angiotensin II receptor
•
antagonists).
Children: Not recommended in children.
Elderly patients: No initial dosage adjustment
is required for elderly patients.
Renal impairment: No initial dose adjustment
is required for patients with mild to moderate
renal impairment. Aliskiren should be avoided
in patients with severe renal impairment (GFR
< 30 ml/min).
Hepatic impairment: No initial dosage
adjustment is required for patients with mild
to severe hepatic impairment.
Drug inter: Monitoring when used concomitant­
ly with frusemide. Interactions with ciclosporin,
itraconazole, ketoconazole, atorvastatin, verapa­
mil. Concomitant treatment with drugs that may
increase serum potassil1m levels. Concomitant
treatment with NSAIDs including Cox-2
inhibitors may decrease antihypertensive effects.
Note: For further information, please consult
manufacturer's literature.
t RASILEZ Tab. Novartis
Aliskiren l 50mg & 300mg/tablet (film-coated).
150mg x 28's pack: 1750.00 MRP
300mg x 28's pack: 2184.00 MRP
ALISKIREN+
HYDROCHLOROTHIAZIDE36,54
ALISKIRE N+
HYDROCHLOROTHIAZIDE: Tablet
Combination preparation of aliskiren and
hydrochlorothiazide is available as aliskiren
l 50mg & hydrochlorothiazide BP 12.Smg/tablet.
Mode of action: See under the text of individual
product.
Ind: This combined preparation is indicated for
the treatment of hypertension. This fixed dose
combination is not indicated for initial therapy of
hypertension, except when the hypertension is
severe enough that the value of achieving prompt
blood pressure control exceeds the risk of
initiating combination therapy in these patients.
C/I: This combination is contraindicated in
patients- i. who are hypersensitive to any compo­
nent of this product; ii. concomitant use with
ACE inhibitors or angiotensin II receptor antago­
nists with type 2 diabetes mellitus iii. hydrochlo­
rothiazide is particularly contraindicated in
patients with anuria or hypersensitivity to other
sulfonamide group of drugs; iv. pregnancy &
lactation.
S/E;Precautions: See under the text of
individual product.
Pregnancy & lactation: This combination is
contraindicated during pregnancy. When pregnan­
cy is detected, it must be discontinued as soon as
possible. It should not be used in lactation also.
Dosage & �dmin: 150mg/12.5mg one tablet
once daily.
Children: Not recommended in children.
Drug inter: See above under the text of
'aliskiren' and 'hydrochlorothiazide' separately. ..
Note: For further information, please consult
manufacturer's literature.
t RASILEZ HCT 150/12.5 Tab. Novartis
Aliskiren 150mg & hydrochlorothiazide BP
12.S rnptablet.
28's pack: 1750.00 MRP
4. DRUGS USED IN ANGINA
& ISCHAEMIC HEART
DISEASES
Drugs used in angina & ischaemic heart
diseases can further be divided in the
following groups:
4.1 Nitrates: Coronary vasodilators
4.2 Calcium-channel blockers
4.3 Potassium-channel activators
4.4 Misc. Antianginal & anti-ischaemic drugs
Nitrates: Coronary vasodilators
Nitrate coronary vasodilator drugs available
for therapeutic use are:
Glyceryl trinitrate, Isosorbide dinitrate,
Isosorbide mononitrate.
GLYCERYL TRINITRATE2t,42,64
GLYCERYL TRINITRATE: Tablet/Injection/
Ointment/Inhalation or Spray.
Glyceryl trinitrate or nitroglycerin is a coronary
vasodilator drug, used in the treatment of angina
& ischemic heart diseases. It is available as
sublingual tablet & ointment, oral capsule &
tablet, injection & inhalation or spray.
Mode of action: The principal pharmacological
action of nitroglycerin is relaxation of vascular
•
smooth muscle and consequent dilatation of
peripheral arteries and veins. Dilatation of the
veins promotes peripheral pooling of blood and
decreases venous return to the heart, thereby
reducing left ventricular end-diastolic pressure &
pulmonary capillary wedge pressure (preload).
Arteriolar relaxation reduces systemic vascular
resistance, systolic arterial pressure, and mean
arterial pressure (after load). Dilatation of the
coronary arteries also occurs.
 QIMP-17 (71) CARDIOVASCULAR DRUGS

Ind: Nitroglycerin preparations are indicated for t ANRIL SR Tab. Square

prophylaxis and treatment of angina pectoris Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet
including variant angina, left ventricular failure.· (sustained release).
Nitroglycerin injection is particularly indicated 30's pack: 200.50 MRP
for the treatment of peri-operative hypertension; t ANRIL S pray Square
for controlling of congestive heart failure in the Glyceryl trinitrate (nitroglycerine)
setting of acute myocardial infarction; for 400mcg/metered dose: aerosol spray.
treatment of angina pectoris in patients who have 200 doses unit: 215.80 MRP
not responded to sublingual nitroglycerin and t ANRIL Inj. Square
�-blockers and for induction of intraoperative Glyceryl trinitrate (nitroglycerine) USP 5mg/ml;
hypotension. lOml ampoule: injection for i.v infusion.
C/I: Marked anemia, head trauma, cerebral lOml amp x 4's pack: 301.12 MRP
haemorrhage, closed angle glaucoma. t GTN 2.6 Tab. SK+F
S/E: Throbbing headache, flushing, dizziness, Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet
tachycardia, postural hypotension. 50's pack: 200.00 MRP
Cautions: Hypotensive condition, development t NIDOCARD Retard Tab. Drug Inter.
of tolerance. Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet

Pregnancy & lactation: Pregnancy category C. (sustained release).

It is not known whether nitroglycerin is excreted 50's pack: 200.00 MRP

in human milk. Because many drugs are excreted t NIDOCARD Retard-6.4 Tab. Drug Inter.

in human milk, caution should be exercised Glyceryl trinitrate (nitroglycerine) 6.4mg/tablet

when nitroglycerin injection is..al:hninistered to a (sustained release).

nursing mother. 50's pack: 350.00 MRP

t NIDOCARD Spray Drug Inter.
Dosage & admin: Sublingually: 0.5-lmg,
Glyceryl trinitrate (nitroglycerine)
repeat as requird.
400mcg/metered dose: aerosol spray.
By mouth: 2.6-6.4mg as sustained release
200 doses unit: 250.00 MRP
capsule or tablets, 2-3 times daily.
t NIDOCARD Inj. D�ug Inter.
By i.v infusion: 10-200mcg/min.
Glyceryl trinitrate (nitroglycerine) USP 5mg/ml;
Nitroglycerin injection is a concentrated, -.�
.
.•
_ _ · .
41',.,
-<e._

lOml (50mg) ampoule: injection for i.v infusion.

potent drug which must be diluted in dextrose
lOml amp x l's pack: 100.00 MRP
(50/o) injection or normal saline (0.90/o)
t NITRIN SR Cap. Healthcare
·

injection prior to its infusion. Nitroglycerin

Glyceryl trinitrate (nitroglycerine) 2.6mg/capsule
injection should not be mixed with other drugs.
(sustained release).
Initial diluti.on: Initially nitroglycerin should
60's pack: 279.00 MRP
be diluted aseptically into a glass bottle of
t NITRIN SR Tab. Healthcare
either dextrose (50/o) or normal saline
Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet.
injection (0.9%) that makes the dilution a
(sustained release).
concentration of 1OOmcg/ml.
60's pack: 300.00 MRP
Maintenance dilution: It is important to t NITROCAP Cap. Orion Pharma
consider the fluid requirements of the patient Glyceryl trinitrate (nitroglycerine) 2.6mg/capsule
· as well as the expected duration of infusion in (sustained release pellets).
selecting the appropriate dilution of 30's pack: 150.60 MRP
nitroglycerin injection. After the initial dosage
t NITROCARD Tab. Aristopharma
titration, the concentration of the solution may Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet.
be increased, if necessary, to limit fluids given 50's pack: 200.00 MRP
to the patient. The nitroglycerin concentration
t NITROCONTIN 2.6 CR Tab. Mundipharma
should not exceed 400mcg/ml.

By spray: Treatment or prophylaxis of angina,

aeroso Glyceryl trinitrate (nitroglycerine) USP
2.6mg/tablet (controlled release).
spray 1-2 doses under tongue and then-close 25's pack: 134.00 MRP
mouth. NITROCONTIN 6.4 CR Tab. Mundipharma
The 180 times life saver Glyceryl trinitrate (nitroglycerine) 6.4mg/tablet
(controlled release).
25's pack: 200.00 MRP
t NITROMINT Retard Tab. Egis/City
Overseas
Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet
N itrog lyceri n sustained release tablet
(controlled release).
30's pack: 147.00 TP
SK+f Budapest Hungary
t NITROMINT S pray Egis/City Overseas
-

Glyceryl trinitrate (nitroglycerine)

t ANGICARD Tab. Drug Inter.
400mcg/metered dose: aerosol spray.
Glyceryl trinitrate 0.5mg/tablet.
180 doses unit: 215.00 TP
lOO's pack: 300.00 MRP
For Details : t NITROSOL S pray Beximco
t ANGIS T SR Tab. Acme
Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet
City Overseas Ltd. Glyceryl trinitrate (nitroglycerine) 400mcg/
Yakub South Center (4th Floor) metered dose: aerosol spray.
(sustained release).
67/D Dhanmondi, 156 Lake Circus 200 doses unit: 225.00 IP
30's pack: 120.30 MRP
Kalabagan, Mirpur Road, Dhaka-1205
t ANRIL Tab. Square t NITRO-SR Tab. UniMed & UniHealth
Glyceryl trinitrate (nitroglycerine) 0.5mg/tablet. Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet
30's pack: 90.30 MRP (sustained release).
 •

CARDIOVASCULAR DRUGS QIMP-17 (72)

30's pack: 120.00 MRP Felodipine, lsradipine, Lacidipine,

ISOSORBIDE MONONITRATEit,33
t NITROVAS SR Tab. Popular Lercanidipine, Nicardipine, Nifedipine,
Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet Nimodipine, Nisoldipine, VerapamiL
ISOSORBIDE MONONITRATE: Tablet
(sustained release).
Ind: Prophylaxis and treatment of angina;
50's pack: 201.00 MRP
adjunct in congestive heart failure. AMLODIPINE2 l ,48,52
t NI'I'ROVAS Oint. Popular
C/I; S/E; Cautions: See under 'glyceryl trinitrate'.
Glyceryl trinitrate (nitroglycerine) 0.4%' (i.e
Dose: Initially 20mg 2-3 times daily- or 40mg AMLODIPINE BESYLATE: Tablet
4mg/gm): ointment (sublingual application).
twice daily (1Omg twice daily in those who Amlodipine besilate is a dihydropyridine calcium
30gm pack: 130.49 MRP
have not previously received nitrates); up to channel blocker.
t PACTORIN Retard Tab. ACI 120mg daily in divided doses if required. Mode of action: As calcium antagonist amlodi­
Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet
t A-CARD Tab. Acme pine besilate inhibits the transmembrane influx of
(retard).
Isosorbide mononitrate 20mg/tablet calcium ions into vascular smooth muscle and
50's pack: 201.00 MRP
1 OO's pack: 142.00 MRP cardiac muscle. The contractile process of
t RECTOCARE Oint. Square cardiac muscle & vascular smooth muscle is
t ANGIFIX 20 Tab. Incepta
Glyceryl trinitrate (nitroglycerine) 0.4% (i.e dependent upon the movement of extracellular
Isosorbide-5-mononitrate 20mg/tablet
4mg/gm): ointment (sublingual application). calcium ions into these cells through specific jon
50's pack: 71.00 MRP
15gm pack: 65.25 MRP channels. Amlodipine inhibits calcium ion influx
t ESMO Tab. Square
+ REPANE Oint. lncepta Isosorbide mononitrate 20mg/tablet across cell membranes selectively, with a greater
Glyceryl trinitrate (nitroglycerine) 0.4% (i.e 1OO's pack: 142.00 MRP effect on vascular smooth muscle cells than on
4mg/gm): ointment (sublingual application). cardiac muscle cells. It acts directly on vascular
t ESMO LA Cap. Square
30gm pack: 200.00 MRP Isosorbide mononitrate 50mg/capsule (long acting) smooth muscle to cause a reduction in peripheral

30's pac.k: 210.60 MRP vascular resistance & reduction in blood pressure.
t TROCER 2.6 SR Cap. Incepta
Glyceryl trinitrate (nitroglycerine) 2.6mg/capsule t ISM Tab. Aristopharm2' .. Ind: Essential hypertension, angina pectoris,
(sustained release). Isosorbide mononitrate 20mg/tabl�t. vasospastic angina.
30's pack: 120.00 MRP 1 OO's pack: 140.00 MRP . . C/I: Amlodipine is contraindicated in patients
.. ..
.
· · . ..

.'- ., .
,.
.:�·�
:�: .�. �.'/..
. ·"
·
.
_:.i�:
�z:: �.
·:
'' ·
�:
:·: ·
� ''

. . ' : ' '"

;";!-;'.
-·.�·· ', . ·•,
. ' , ;_ · : ·

Nitroglycerin sustained rel�ase tablet

t 'I'ROCER 2.6 SR Tab. Incepta t MONATE Tab. Beximco with a known sensitivity to dihydropyridines. It
Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet Isosorbide mononitrate 20mg/tablet should not be used in cardiogenic shock,
(sustained release). l OO's pack: 142.00 MRP clinically significant aortic stenosis, unstable
30's pack: 120.00 MRP t MONITEN Tab. ACI angina (excluding Prinzmetal's angina). It is also

t XYNOCARD SR Tab. White Hone Isosorbide mononitrate 20mg/tablet contraindicated in pregnant woman.
Glyceryl trinitrate (nitroglycerine) 2.6mg/tablet. l OO's pack: 142.00 MRP S/E: The most common side-effects are associat­

(sustained release). t MONOCARD Tab. Drug Inter. ed with vasodilator action, such as, dizziness,
SO's pack: 150.00 MRP Isosorbide mononitrate 20mg/tablet flushing, headache, hypotension and peripheral
l OO's pack: 150.00 MRP oedema. Gastrointestinal disturbances, increased
t MONOCARD SR Cap. Drug Inter. frequency of micturition, lethargy, eye pain and
ISOSORBIDE DINITRATEit,33
Isosorbide mononitrate 50mg/capsule (sustained mental depression may also occur. A paradoxical
release) increase in ischaemic chest pain may occur at the
ISOSORBIDE DINITRATE: Tablet/
40's pack: 280.00 MRP start of the treatment and in a few patients exces­
Capsule/Injection.
t MONOTRATE 20 Tab. Sun Pharma sive fall in blood pressure may lead to cerebral or
Ind: Prophylaxis and treatment of angina; left
Isosorbide-5-mononitrate 20mg/tablet myocardial ischaemia or transient blindness.
ventricular failure.
50's pack: 71.00 MRP Gum hyperplasia, erythema multiforme also
CII,S/E, Cautions: Same as glyceryl trinitrate.
reported.
Dosage & admin: Acute attack, 5-lOmg t MONOTRATE OD Tab. Sun Pharma
Cautions: Caution should be taken in patients
sublingually. Isosorbide-5-mononitrate 50mg/tablet
with hepatic impairment, during pregnancy and
By mouth, prophylaxis, angina 30-120mg daily 30's pack: 123.90 MRP
breast-feeding.
in 3 or 4 divided doses; left ventricular failure,
Pregnancy & lactation: Use of amlodipine in
40-160mg upto 240mg daily if required, in
divided doses.
Calcium-channel blockeri• pregnancy & lactation has yet not been established.

By i.v infusion, 2-1Omg/hour, higher Dosage & Admin: Hypertension- usual dose is
doses upto 20mg/hour may be required. Calcium-channel blockers currently available Smg once daily; maximum dose is 1 Omg once
Preparations: Presently not available. for therapeutic use are: Amlodipine, Diltiazem, daily; elderly patients with hepatic insufficiency

I
 .

QIMP-17 (73) CARDIOVASCULAR DRUGS

- - .

may be started with 2.5mg once daily. In hy­ Amlodipine BP 5mg & 1Omg/tablet. Amlodipine BP 5mg/tablet.
-­

pertension it may be used alone or in com-bi­ 5mg x 50's pack: 200.00 MRP 5rr1g x 30's pack: 150.00 MRP
.

- -··­
...
__ .

nation with other antihypertensive therapy.
Angina- 5-lOmg once daily; using the lower
dose in the elderly and in patients with hepatic
insufficiency. Most patients require IOmg.
Amlodipine may be taken without regard to
meals.
•
1Omg x 50's pack: 187.50 MRP
+ CALPIN Tab. Globe
Amlodipine BP 5mg/tablet.
5mg x 50's pack: l 75.00 MRP
+ CALPRESS Tab. Asiatic
Amlodipine BP besilate 5mg & 1Omg/tablet.
+ LODIPIN-5 Tab. Aristopharma
Amlodipine BP Smg/tablet.
5mg x 50's pack: 250.00 MRP
+ LOPIN Tab. Edruc
Amlodipine BP 5mg/tablet.
5n1g x 30's pack: 90.00 MRP

Drug inter: No significant drug interaction. 5mg x 50's pack: 200.00 MRP + M-CARD Tab. Zenith
IOmg x 30's pack: 180.00 MRP Amlodipine B P 5mg/tablet.
+ AMDIN Tab. Alco Pharma
\ + CALVASC Tab. UniMed & UniHealth 5mg x 50's pack: 200.50 MRP
Amlodipine BP 5mg & 1Omg/tablet.
Amlodipine BP 5mg & 1Orng/tablet. + NELOD 'fab. Kemiko
5mg x 50's pack: 200.00 MRP
5mg x 30's pack: 150.00 MRP Amlodipine B P 5mg & 1Omg/tablet.
1Omg x 30's pack: 180.00 MRP
1Omg x 30's pack: 240.00 MRP 5mg x 50's pack: 250.00 MRP
+ AMDOCAL Tab. Beximco 1Omg x 50's pack: 400.00 MRP
t CAMLODIN Tab. Square
Amlodipine BP 5mg & 1Omg/tablet.
Amlodipine BP 5mg & lOmg/tablet. + NOPIDIN Tab. Ad-din
5mg x lOO's pack: 500.00 IP
5mg x 60's pack: 300.00 MRP Amlodipine BP 5mg/tablet.
I01ng x 60's pack: 420.00 IP
,

_ .._,_
.
- .
lOmg x 30's pack: 180.60 MRP 5mg x 50's pack: 150.00 MRP
+ AMDOPER Tab. Hallmark
+ CARDIPIN Tab. Renata + PRISTIN Tab. Novo Healthcare
Amlodipine BP 5mg/tablet.
Amlodipine BP 5mg/tablet. Amlodipine BP 5mg/tablet.
5mg x 30's pack: 90.30 MRP
5mg x 50's pack: 250.00 MRP 5mg x 30's pack: 135.00 MRP
+ AMDOPIN Tab. Ziska
+ CARDOLAB 5 Tab. Labaid Pharma + RAKLOPIN lab. RAK Pharma
Amlodipine BP 5mg/tablet.
. ·

Amlodipine BP 5mg/tablet. Amlodipine BP 5mg & 1Omg/tablet.

5mg x 50's pack: 175.00 MRP
5mg x 50's pack: 250.00 MRP 5mg x 50's pack: 200.00 MRP
t AMLO Tab. Pharmadesh
..

'
+ CARDOSIA Tab. Pharmasia 10n1g x 30's pack: 180.00 MRP
Amlodipine BP 5mg/tablet.
Amlodipine BP 5mg/tablet. + SIDOPIN Tab. SK+i. ...

5mg x 50's pack: 175.00 MRP

5mg x 30's pack: 120.60 MRP i\.mlodipine BP 5mg/tablet.
+ AMLOCARD Tab. Drug Inter. 5mg x 50's pack: 250.00 MRP
+ CCB-5 Tab. Orion Pharma
Amlodipine BP 5mg & 1Omg/tablet.
Amlodipine BP 5mg/tablet. + VASOPIN Tab. Silva
'
5mg x 1OO's pack: 450.00 MRP
Amlodipine BP 5mg & 1Omg/tablet.
- '

5mg x 50's pack: 150.50 MRP

. -
- .

1Omg x 50's pack: 350.00 MRP

+ CORDIL Tab. Techno Drugs 5mg x 30's pack: 120.00 MRP
- .
+ AMLOPIN Tab. Acme lOmg x 30's pack: 150.00 MRP
Amlodipine BP 5mg/tablet.
Amlt)dipine BP 5mg & 1Omg/tablet.
5mg x 30's pack: 90.00 MRP t VESOCAL Tab. Rangs Pharma
5mg x 30's pack: 150.00 MRP
t CVNOR 5 Tab. Navana Amlodipine BP 5mg & 1Omg/tablet.
1Omg x 30's pack: 210.00 MRP
Amlodipine BP 5mg/tablet. 5mg x 50's pack: 250.00 MRP
+ AMLOSIN-5 Tab. Doctor's
.
.
.
5mg x 30's pack: 120.60 MRP lOmg x 30's pack: 240.00 MRP
Amlodipine BP 5mg/tablet.
. .
.,
.

+ CVNOR 10 Tab. Navana + VIRLON Tab. Virgo

.

5mg x 30's pack: l 02.30 MRP

Amlodipine BP IOmg/tablet. Amlodipine BP 5mg/tablet.
+ AMLOSUN Tab. Sun Pharma
. . '
,....

lOmg x 30's pack: 180.60 MRP 5mg x 30's pack: 120.00 MRP
,.
,.
. .
- .

Amlodipine BP 5mg/tablet.
. __,
...

t DIPINE Tab. Bristol + XELCARD Tab. Healthcare

-··

5mg x 50's pack: 250.00 MRP

Amlodipine BP 5mg/tablet. Amlodipine BP 5mg/tablet.
+ AMLOTAB Tab. Incepta
5mg x 50's pack: 200.00 MRP 5mg x 30's pack: 150.00 MRP
Amlodipine BP 5mg/tablet.
+ DIPLOR Tab. Ibo Sina
5mg x 50's pack: 200.00 .MRP
Amlodipine BP 5mg & 1Omg/tablet.
.. -..

DILTIAZEM21J3
.,,

+ AMLOVAS Tab. Popular

.
- .

5mg x 30's pack: 127.50 IP

. - ":
- �..

••'c< ·'\

Amlodipine BP 5mg/tablet.
• >
. .
.

lOmg x 30's pack: 210.60 JP

-- �'
....,
.
. -
. '
... _,.·

5mg x 50's pack: 175.50 MRP DILTIAZEM HCI: Tablet/Capsule

.

+ DOPIN Tab. Medicon

+ AMLOWIDE Tab. Beacon Ind: Prophylaxis and treatment of angina; hyper­
..,,.
.
__

Amlodipine BP 5mg/tablet.
Amlodipine BP 5mg/tablet. tension.
5mg x 30's pack: 120.00 MRP
-
5mg x 50's pack: 150.00 MRP C/l: Severe bradycardia, left ventricular failure,
. '
+ EMLON Tab. Biopharma
t AMOCAL Tab. Opsonin second- or third-degree AV block (unless pace­
Amlodipine BP 5mg & 1Omg/tablet.
Amlodipine BP 5mg/tablet. maker fitted), sick sinus syndrome; pregnancy
5mg x 50's pack: 250.00 MRP
5mg x 30's pack: 128.29 MRP (toxicity in animal studies); porphyria.
lOmg x 30's pack: 210.00 MRP
1Omg x 30's pack: 158.97 MRP S/E: Bradycardia, sino-atrial block, atrioventricu­
+ G-AML0-5 Tab. Gonoshasthaya
+ AMPIL Tab. White Horse lar block, hypotension, malaise, headache, hot
.
-
-
. Amlodipine BP 5mg/tablet.
Amlodipine BP 5mg/tablet. flushes, gastro-intestinal disturbances, ankle
- . .-.
5mg x 30's pack: 75.00 MRP
Smg x SO's pack: 250.00 MRP oedema; rarely rashes (erythema multiforme re­
+ G-AML0-10 Tab. Gonoshasthaya
t AMPRE Tab. Kumudini ported); altered liver function tests; hepatitis and
•

Amlodipine BP 1Omg/tablet.
Amlodipine BP Smg/tablet. depression reported.
lOmg x 30's pack: 120.00 MRP
5mg x 30's pack: 150.00 MRP Cautions: Reduce dose in hepatic and renal im­
+ HIPRE Tab. Pacific
+ AMTINOL Tab. Euro Pharma pairment� heart failure or significantly impaired
Amlodipine B P 5mg & 1Omg/tablet.
Amlodipine BP 5mg/tablet. left ventricular function, mild bradycardia (avoid
5mg x 50's pack: 250.00 MRP
5mg x 30's pack: 120.00 MRP if severe), first degree AV block, or prolonged P R
lOmg x 30's pack: 210.00 MRP
+ CAB Tab. ACI interval.
+ HYPOTEN Tab. Cosmic
Amlodipine BP 5mg/tablet. Dose: Angina, 60mg 3 times daily ( ederly ini­
Amlodipine BP 5mg/tablet.
5mg x 30's pack: 120.00 MRP tially twice daily); increased if necessary to
5mg x 30's pack: 108.00 MRP
·-
. .
5mg x 50's pack: 250.00 MRP 360mg daily (max. 480mg daily).
+ CALCHEK Tab. General + LOCARD Tab. Jayson SR (sustained reliease) preparations- angina
Amlodipine BP 5mg/tablet.
Amlodipine BP 5mg/tablet. and mild to moderate hypertension, initially
5mg x 50's pack: 152.50 IP
51ng x 50's pack: 250.00 MRP 90mg twice daily (elderly and in hepatic and
+ CALOCK Tab. Medimet + LODICAL 5 Tab. Somatec renal impairment, dose form not appropriate

,

•
CARDIOVASCULAR DRUGS
for initial dose titration); increased if neces­
sary to 120mg or 180mg twice daily.
+ CARDIL Tab. Ibo Sina
Diltiazem hydrochloride 30mg & 60mg/tablet
30mg x l OO's pack: 225.00 IP
60mg x 1OO's pack: 400.00 IP
+ CARDIZEM Tab. Drug Inter.
Diltiazem hydrochloride 30mg & 60mg/tablet
30mg x 1OO's pack: 300.00 MRP
60mg x IOO's pack: 500.00 MRP.
+ CARDIZEM-SR Cap. Drug Inter.
Diltiazem hydrochloride 90mg & 120mg/capsule
(sustained release)
90mg x 50's pack: 300.00 MRP
120mg x 50's pack: 400.00 MRP
+ DIAL Tab. Nipa
Diltiazem hydrochlor. 60mg/tablet
60mg x 1OO's pack: 380.00 MRP
+ DILTIZEM-SR Tab. Square
Diltiazem hydrochloride 90mg/tablet (sustained
release)
90mg x 40's pack: 224.40 MRP
+ EVASCON Tab. Renata
Diltiazem hydrochloride 30mg & 60mg/tablet
30mg x IOO's pack: 202.00 MRP
60mg x IOO's pack: 385.00 MRP.
+ LITIZEM Tab. Incepta
Diltiazem hydrochloride 30mg & 60mg/tablet
30mg x 50's pack: 100.00 MRP
60mg x 30's pack: 114.00 MRP
LERCANIDIPINE 26
LERCANIDIPINE HCl: Tablet
Lercanidipine is an antihypertensive drug. It is a
selective calcium channel blocker of the dihy­
dropyridine group.
Mode of action: Lercanidipine acts by selective
inhibition of the transmembrane influx of calcium
into smooth muscle. Its antihypertensive action is
due to a direct relaxant effect on vascular smooth
muscle, thus lowering total peripheral resistance.
Lercanidipine is endowed with a prolonged anti­
hypertensive activity because of its high mem­
brane partition coefficient, and is devoid of
negative inotropic effects due to its high vascular
selectivity.
Ind: Mild to moderate essential hypertension.
C/I: Lercanidipine is contraindicated in patients
with left ventricular outflow tract obstruction, un­
treated congestive cardiac failure, unstable angina
pectoris, within 1 month of a myocardial infarc­
tion and known hypersensitivity to any dihy­
dropyridine. Lercanidipine should not be taken
with grapefruit juice.
S/E: Treatment with lercanidipine is generally
well tolerated. The most common side effects are
related to the vasodilator properties of lercanidip­
ine such as flushing, peripheral edema, headache,
dizziness and asthenia. Other side effects, which
occurred in less than 1% of patients include fa­
tigue; g.i disturbances such as dyspepsia, nausea,
vomiting, epigastric pain and diarrhea, polyurea,
rash, somnolence & myalgia.
Precaution: Special care should be exercised
when lercanidipine is used in patients with sick
sinus syndrome, left ventricular dysfunction and
ischaemic heart disease.
Pregnancy & lactation: Since there is no clinical
•
QIMP-17 (74)
data with lercanidipine in pregnancy, it should
not be administered during pregnancy or to
woman with child bearing potential unless effec­
tive contraception is used.
Lercanidipine is highly lipophilic and distribution
in milk may be expected. Therefore, it should not
be administered to nursing mother.
Dosage & admin: Adult: lOmg orally once
daily at least 15 minutes before meals; the dose
may be increased to 20mg depending on the in­
dividual patient's response. It may take about
2 weeks before the maximal antihypertensive
effect is apparent.
Some individuals, not adequately controlled on
a single antihypertensive agent, may benefit
from the addition of lercanidipine to therapy
with a beta-adrenoceptor blocking drug
(atenolol), a diuretic (hydrochlorothiazide) or an
ACE inhibitor (ramipril).
Use in children: Use in children under the age
of 18 years is not currently recommended.
Use in renal or hepatic dysfunction: Special
care should be exercised in patients with mild
to moderate renal or hepatic dysfunction.
Dosage above 20mg daily must be approached
with caution. Lercanidipine is not recom­
mended for use in patients with severe hepatic
or renal dysfunction.
Drug inter: Concomitant treatment of lercanidip­
ine with cyclosporin, phenytoin, carbamazepine,
rifampicin, ketoconazole, itraconazole, ritonavir,
erythromycin, troleandomycin, and midazolam
should be avoided. Caution should be exercised
when lercanidipine is co-prescribed with astemi­
zole, amiodarone, quinidine, cimetidine, metopro­
lol and simvastatin.
+ LARCADIP Tab. lncepta
Lercanidipine hydrochloride INN 1Omg/tablet.
30's pack: 150.00 MRP
+ LOTENSYL Tab. Sun Pharma
Lercanidipine hydrochloride INN 1Omg/tablet.
50's pack: 277 .50 MRP
LACIDIPINE36
LACIDIPINE: Tablet
Lacidipine is a lipophilic calcium-channel block­
er. It belongs to dihydropyridine class and is used
in the treatment of hypertension. It is available as
lacidipine BP 2mg & 4mg film-coated tablet.
Mode of action: Lacidipine inhibits the influx of
calcium into smooth muscle cells by the competi­
tive inhibition of voltage-dependent calcium 'L'
channels. But it is more vasoselective than other
calcium channel blockers, i.e it works more on
blood vessels than on heart muscle. Hence, in ad­
diton to controlling blood pressure it seems suit­
able for heart failure patients as well. Moreover, it
works as an antioxidant and thereby reduces the
progression of atherosclerosis. It also increases
insulin sensitivity in diabetic patients.
Ind: Treatment of hypertension, either alone or in
combination with other antihypertensive agents
such as beta-blockers and diuretics. In different
studies it has found suitable for congestive heart
failure patients who remain symptomatic despite
'
receiving long-term therapy with ACE inhibitors,
digoxin and diuretics.
C/I: Hypersensitivity to dihydropyridine deriva­
tives. Cardiogenic shock, aortic stenosis, avoid
-
r-
within 1 month of myocardial infarction, preg­
nancy and breast-feeding.
S/E: Flushing, palpitation, headache, dizziness,
rarely gastro-intestinal disturbances, gum hyper­
plasia, mood disturbances, asthenia, polyuria,
muscle cramps, skin rash (including pruritus and
erythema).
Precaution: Cardiac conduction abnormalities,
poor cardiac reserve, hepatic impairment, with­
draw if ischemic pain occurs shortly after initiat­
ing treatment or if cardiogenic shock develops,
avoid grapefruit juice.
Pregnancy "- lactation: Although no teratogenic
effects of lacidipine have been established in ani­
mals there are no data on the safety of lacidipine
in human pregnancy & therefore, it is contraindi­
cated. Milk transfer studies in animals have
shown that lacidipine is excreted into breast milk
and therefore, lacidipine should not be used
during lactation.
Dosage & admin: Initially 2mg once daily
preferably in the morning; increased if neces­
sary to 4mg daily after 3-4 weeks, then if nec­
essary to 6mg daily.
Elderly: The efficacy and tolerability of
lacidipine in elderly hypertensive patients is
comparable with that in younger patients.
T herefore, dosage adjustment is not required.
Children: Treatment with lacidipine has not
been evaluated in children.
Drug inter: Cimetidine increases the concentra­
tion of lacidipine. Lacidipine increases the con­
centration of digoxin & propranolol, but
propranolol derceases the maxim11m concentra­
tion & AUC of lacidipine.
+ LACICARD-2 Tab. Aristopharma
Lacidipine hydrochloride BP 2mg/tablet (f.c).
2mg x 50's pack: 200.00 MRP
+ LACICARD-4 Tab. Aristopharma
Lacidipine hydrochloride BP 4mg/tablet (f.c ).
4mg x 30's pack: 180.00 MRP
+ LACITAB-2 Tab. Acme
Lacidipine hydrochloride BP 2mg/tablet (f.c).
2mg x 50's pack: 200.50 MRP
+ LACITAB-4 Tab. Acme •
Lacidipine hydrochloride BP 4mg/tablet (f.c).
4mg x 30's pack: 180.60 MRP
+ LACITEN 2 Tab. Square
Lacidipine hydrochloride BP 2mg/tablet (f.c ).
2mg x 28's pack: 112.00 MRP
+ LACITEN 4 Tab. Square
Lacidipine hydrochloride BP 4mg/tablet (f.c).
4mg x 28's pack: 168.00 MRP
+ L-CARDIN-2 Tab. Drug Inter.
Lacidipine hydrochloride BP 2mg/tablet (f.c).
2mg x 50's pack: 150.00 MRP
+ L-CARDIN-4 Tab. Drug Inter.
Lacidipine hydrochloride BP 4mg/tablet (f.c).
4mg x 30's pack: 150.00 MRP
'
NIFEDIPINE21•33•42
NIFEDIPINE: Tablet/Capsule/Injection
Nifedipine is a cacium-channel blocker. It is
available as tablet, capsule & injection.
Mode of action: Nifedipine as a cacium-channel
blocker, it blocks the transport of calcium, via
holes called channels, into the smooth muscle
cells lining the coronary blood vessels and other

peripheral blood vessels of the body. Blocking
calcium transport relaxes the muscles of the
blood vessels and makes them wider. Unlike ver­
apamil it has no anti-arrhythmic activity.
Ind: Prophylaxis and treatment of angina,
hypertension, raynauds phenomenon.
C/I: Women of child bearing age.
S/E & Cautions: See under amlodipine.
Dosage & admin: Adults: S-20mg 3 times daily
with or after meals. If immediate effect re­
quired, bite capsule & allow liquid to retain in
the mouth. Children: Not recommended.
+ NIDIPINE SR Tab. Square
Nifedipine 20mg/tablet (sustained release)
l OO's pack: 64.00 MRP
+ NIFECAP Cap. Drug Inter.
Nifedipine 1Omg in soft capsule.
l Omg x 30's pack: 63.00 MRP
+ NIFIN Tab. Acme
Nifedipine 1Omg/tablet
l OO's pack: 34.00 MRP
NIMODIPINE42
NIMODIPINE: Tablet (ftlm-coated)
Nimodipine is a calcium channel blocker. It is
available as nimodipine BP 30mg tablet (f.c).
Mode of action: The contractile process of
smooth muscle cells are dependent upon calcium
ions, which enter these cells during depolarization
as slow ionic transmembrane currents. Nimodip­
ine inhibits calcium ion transfer into these cells
and thus inhibits contractions of vascular smooth
muscle. Nimodipine had a greater effect on cere­
bral arteries than on arteries elsewhere in the
body perhaps because it is highly lipophilic, al­
lowing it to cross the blood-brain barrier. It is
therefore preferable in treating subarachnoid
hemorrhage (SAH) patients.
Ind: For the improvement of neurological out­
come by reducing the incidence and severity of
ischemic deficits in patients with subarachnoid
hemorrhage from ruptured intracranial berry
aneurysms regardless of their post-ictus neurolog­
ical condition.
C/I: Not known.
S/E: Although side effects from nimodipine are
not common, the following can occur, such as:
headache, dizziness or light-headedness, flushing
(feeling of warmth), heartburn, fast heartbeat,
slow heartbeat, upset stomach, stomach pain,
constipation, depression, feeling low, or the
'blues' unusual bruising or bleeding.
Precautions: Blood pressure: Blood pressure
should be carefully monitored during treatment
with nimodipine based on its known pharmacolo­
gy and the known effects of calcium channel
blockers.
Hepatic disease: In patients with impaired he­
patic function, the metabolism of nimodipine is
decreased. In these patients nimodipine should
be given in a lower dose; blood pressure & pulse
rate of the patients should be monitored closely.
Pregnancy & lactation: Large doses of nimodip­
ine have been shown to cause birth defects· in ani­
mals. Human studies have not been done.
However, in pregnancy it should not be given.
Nimodipine may pass into breast milk but has not
been reported to cause problems; caution is ad-
•
QIMP-17 (75)
vised.
Dosage & admin: Initial dose is 60mg (2
tablets) every four hours for 21 consecutive
days, preferably not less than one hour before
or two hours after meals. Oral nimodipine
therapy should be commencing within 96
hours of the subarachnoid hemorrhage.
+ NIMOCAL Tab. Square
Nimodipine BP 30mg/tablet (f.c).
30's pack: 150.30 MRP
+ NIMODI Tab. SK+F
Nimodipine BP 30mg/tablet (f.c).
30's pack: 150.00 MRP
VERAPAMil.J1.33
VERAPAMIL HCI: Tablet.
It is a calcium channel blocker & acts by inter­
fering with the slow inward depolarising calcium
flow particularly in the S.A and A.V nodal cells.
Ind: Supraventricular arrhythmias, paroxysmal
ventricular tachyarrythmias, angina, hypertension.
C/I: Hypotension, bradycardia, second and third
degree heart block, sick sinus syndrome, cardio­
genic shock, sino-atrial block, uncompensated
heart failure, atrial flutter or fibrillation compli­
cating Wolff-parkinson white (WPW) syndrome.
S/E: Constipation, less commonly nausia, vomit­
ing, flushing, headache, dizziness, fatigue, ankle
oedema. After intravenous administration, hy­
potension, bradycardia, heart block, ventricular
fibrillation and asystole.
Dosage & admin: By mouth: Supraventricular
arrhythmias, 40-120mg t.d.s. Angina, 80-
120mg t.d.s. daily. Hypertension, 240-480mg
daily in 2-3 divided doses.
By slow i.v injection: Over 2 minutes S-lOmg
(preferably with E.C.G. monitoring); in parox­
ysmal tachyarrhythmias a further Smg after
S-10 minutes if required.
Note: Verapamil should not be injected into pa­
tients recently treated with beta-blockers because
of the risk of hypotension and asystole. It is
sugg-ested an interval of 30 minutes before giv­
ing beta-blocker is sufficient but this too is open
to doubt.
+ ANGIMIL Tab. Medimet
Verapamil hydrochloride 40mg & 80mg/tablet.
40mg x l OO's pack: 225.00 MRP
80mg x l OO's pack: 425.00 MRP
+ ANGIMIL SR Tab. Medimet
Verapamil hydrochloride 240mg/tablet (s.r).
240mg x 15's pack: 105.00 MRP
+ VERACAL Tab. lncepta
Verapamil hydrochloride 40mg & 80mg/tablet.
40mg x 50's pack: 112.50 MRP
80mg x 50's pack: 150.00 MRP
+ VERACAL SR 180 Tab. Incepta
Verapamil hydrochloride l 80mg/tablet (sustained
release).
180mg x 30's pack: 180.00 MRP
+ VERACAL SR Tab. Incepta
Verapamil hydrochloride 240mg/tablet (sustained
release).
240mg x 30's pack:· 210.00 MRP
+ VERACAL Inj. Incepta
Verapamil hydrochloride 2.5mg/ml; 2ml am­
poule: injection.
2ml amp (5mg) x S's pack: 150.00 MRP
CARDIOVASCULAR DRUGS
+ VERAMIL Tab. Rangs Pharma
Verapamil hydrochloride 80mg/tablet.
50's pack: 150.00 MRP
+ VERAMIL SR Tab. Rangs Pharma
Verapamil hydrochloride 240mg/tablet (sustained
release).
240mg x 30's pack: 210.00 MRP
Potassium-channel Activators
Drug currently available as potassium-channel
activator: Nicorandil
NICORANDIIJ1.34
NICORANDIL: Tablet
Nicorandil INN 5mg & 1 Omg/tablet.
Mode of action: It is a potassium-channel activa­
tor, and causes both arterial and venous vasodila­
tion.
Ind: Prevention and long-term treatment of
chronic stable angina pectoris.
C/I: Cardiogenic shock. Left ventricular failure
with low filling pressure. Hypotension.
S/E: Headache; cutaneous vasodilatation with
flushing; nausea, vomiting; dizziness, weakness
also reported; rarely oral ulceration and myalgia;
at high dosage reduction in blood pressure and/or
increase in heart rate; angioedema, hepatic dys­
function also reported.
Precautions: It should be used with caution in
patients with hypovolaemia, low systolic pres­
sure, acute pulmonary oedema, acute myocardial
infarction with acute left ventricular failure and
low filling pressure.
Pregnancy & lactation: It should not be given to
pregnant women as well as lactating mothers, as
there is no evidence of safety profile for these
cases.
Dosage & admin: Initially 1 Omg twice daily (if
susceptible to headache 5mg twice daily);
usual dose is 10-20mg twice daily, up to 30mg
twice daily may be used.
Drug inter: Nicorandil does not have any phar­
macokinetic interaction with commonly pre­
scribed drugs.
+ CORANGI-10 Tab. UniMed & UniHealth
Nicorandil INN 1 Omg/tablet.
l Omg x 30's pack: 180.00 MRP
Misc. Antianginal & Anti-is­
chaemic drugs
;,.'yn.,0
HT D A. ft(l�J
A. ,D� '.1,�E",.,6,42
• •• • o •• M • •• • • ••• •• • • .- • • ••
IVABRADINE HCI: Tablet/Syrup
Ivabradine is a new class of selective heart rate
lowering agent, and is useful in the symptomatic
treatment of chronic stable angina pectoris in pa­
tients with normal sinus rhythm. It is available as­
Ivabradine hydrochloride INN equivalent to
ivabradine 5mg & 7 .5mg in filin-coated tablet.
Mode of action: lvabradine is a new class of pure
heart rate lowering agent. It acts by selective and
specific inhibition of cardiac pacemaker ..ifchan­
nel, in the sinus node. lvabradine decreases

CARDIOVASCULAR DRUGS
the slope of the diastolic depolarization potential,
prolonging the time to action potential firing.
This action results in a reduction of heart rate at
rest and during exercise, with little or no effects
on mean arterial blood pressure or left ventricular
pressure. By decrea- sing heart rate, i"·abradine
decreases the cardiac workload and tberefore
oxygen consumption. Concomitantly, ivabradine
prolongs diastole allowing increased perfusion of
coronary arteries and increased oxygen supply to
the heart. The cardiac effects are specific to the
sinus node with no effect on intra-atrial, atrioven­
tricular or intraventricular conduction times, nor
on myo-cardial contractility or ventricular repo­
larization.
Ind: Symptomatic treatment of chronic stable
angina pectoris in patients with normal sinus
rhythm, who has contraindications or intolerance
with beta-blockers.
C/I: History of hypersensitivity to ivabradine;
resting heart rate below 60 before treatment; car­
diogenic shock; acute MI; severe hypotension; se­
vere hepatic insufficiency; unstable angina. S/E:
Visual symptoms (Luminous Phenomena),
blurred vision, bradycardia, 1st degree AV-block,
ventricular extra systole, dizziness etc.
Precautions: Mild heart failure, mild to moderate
hypotension, atrial fibrillation, prolong QT syn­
drome, moderate hepatic insufficiency, severe
renal insufficiency.
Pregnancy & lactation: Contraindicated.
Dosage & admin: Usual recommended starting
dose is 5mg twice daily w·hich may be in­
creased after 3-4 weeks to 7.5mg twice daily,
depending on therapeutic response. It may be
adj. usted to 2.5mg twice daily as necessary.
Doses are usually given in the morning and in
the evening during meal.
Drug inter: QT prolonging medicinal products.
+ CORABID Tab. UniMed & UniHealth
Ivabradine hydrochloride 5mg & 7.5mg/tablet
(film-coated).
5mg x 14's pack: 490.00 MRP
7.5mg x 14's pack: 700.00 MRP
+ IVANOR Tab. Square
Ivabradine hydrochloride INN equivalent to
ivabradi11e 5mg & 7.5mg/tablet (film-coated).
5mg x lO's pack: 250.00 MRP
7.5mg x IO's pack: 350.00 MRP
+ IVAPREX Tab. Incepta
Ivabradine hydrochloride INN equivalent to
ivabradine 5mg & 7.5mg/tablet (film-coated).
5mg x 1O's pack: �00.00 MRP
7.5mg x IO's pack: 450.00 MRP
+ IVATEN Tab. Drug Inter.
Ivabradine hydrochloride INN equivalent to
ivabradine 5mg & 7.5mg/tablet (film-coated).
5mg x lO's pack: 250.00 MRP
7.5mg x IO's pack: 350.00 MRP
RANOLAZINE26•34
RANOLAZINE: Tablet (f.c)
Ranolazine is a11 anti-anginal and anti-ischaemic
QIMP-17 (76)
agent of miscellaneous group. It is available as­
Ranolazine INN 500mg in film-coated, extended
or sustained release (SR) tablet.
Mode of action: Ranolazine is a specific in­
hibitor of late sodium current at therapeutic lev­
els. During ischemic episodes excess sodium can
flow into cardiac cells through sodium channels.
This excess sodiurn can trigger a subsequent
overload of calcium that can lead to problems
with proper contraction and relaxation of the
heart. Inhibition of late sodium current (IN a)
causes a decrease in influx of Ca++ through Na+­
CaII- channel. Thus, administration of ranolazine
inhibits Ca t+ overload and decreases oxygen
consumption of heart and improves mechanical
and electrical dysfunctions of cardiac cells under
these circumstances.
Ranolazine's anti-angina and anti-ischemic ef­
fects do not depend upon reduction in heart rate
or blood pressure. It does not affect the rate-pres­
sure product, a measure of myocardial work, at
maximal exercise.
Ind: Ranolazine is indicated in the treatment of
chronic angina. It may be used with �-blockers,
nitrates, calcium channel blockers, anti-platelet
therapy, lipid-lowering therapy, ACE inhibitors
and angiotensin receptor blockers.
C/I: Taking strong inhibitors of CYP3A (e.g ke­
toconazole, clarithromycin, nelfinavir).
Taking inducers of CYP3A (e.g phenobarbital, ri­
fampicin).
Significant hepatic impairment
S/E: Cardiac disorders- bradycardia, palpitations;
Gastrointestinal disorders- abdominal pain, dry
mouth, vomiting;
Respiratory disorders- dyspnea;
Vascular disorders- hypotension, orthostatic hy­
potension
· Labyrinth disorders- tinnitus, vertigo;
General disorders- peripheral edema;
Precautions: Heart rhythm problems (e.g brady­
cardia, QT prolongation, ventricular tachycardia),
liver problems, certain uncorrected mineral im­
balances (low potassium/magnesium levels), se­
vere kidney problems.
Co-administration of ranolazine and digoxin in­
creases the plasma concentrations of digoxin by
approximately 1.5-fold and the dose of digoxin
may have to be reduced accordingly. The dose of
other P-gp substrates may have to be reduced as
well as ranolazine is co-administered.
Ranolazine can inhibit the activity of CYP2D6
and thus the metabolism of drugs that are mainly
metabolized by this enzyme, the dose of such
drugs may have to be reduced when ranolazine is
co-administered.
Pregnancy & lactation: Pregnancy category C.
Lactation- undetermined.
Dosage & admin: Ranolazine dosing should be
initiated at 500mg twice daily and can be in­
creased to lOOOmg twice daily, if needed, based
on clinical symptoms. Take ranolazine with or
without meals. Swallow ranolazine tablets
whole; do not crush, break or chew. The maxi­
mum recommended daily dose is lOOOmg twice
sa-�.Ps#
C&l
� !��!'!�
lt..HGl.ADESH
.. LS tn>.
-
daily. If a dose of ranolazine is missed, take the
prescribed dose at the next scheduled time; do
not double the next dose.
Drug inter: Inhibitors of CYP3A (e.g ketocona­
zole� clarithromycin, nelfinavir);
Inducers of CYP3A4 (e.g phenobarbital, ri­
fampicin);
P-gp inhibitors (e.g cyclosporine);
Dn1g transported by P-gp or metabolized by
CYP2D6 (e.g digoxin, TCA etc.);
CYP450 2D6 substrates;
QT interval prolonging drugs;
Paroxetine; Simvastatin.
+ RALOZINE 500 SR Tab. Incepta
Ranolazine INN 500mg/tablet (sustained release).
500n1g x 20's pack: 500.00 MRP
+ RA..t�OLIN XR 500 Tab. Square
Ranolazine INN 500mg/tablet (extended release).
500mg x 20's pack: 320.00 MRP
+ RANOLIN XR lgm Tab. Square
Ranolazine INN l gm/tablet (extended release).
l g m x l O's pack: 250.00 MRP
+ RENOLAER Tab. General
Ranolazine INN 500mg/tablet (extended release).
500mg x 20's pack: 320.00 MRP
TRIMETAZIDINE26,87
TRIME TAZIDINE: Tablet
Trimetazidine is an antianginal & anti-ischernic
agent that display anti-ischemic effects without
inducing hemodynamic changes and improves the
status of the ischemic myocardium.
It is available as trimetazidine hydrochloride/ di­
hydrochloride BP 20mg/tablet (f.c) and
35mg/tablet (modified release).
Mode of action: By preserving the energy metab­
olism in cells exposed to hypoxi_a or ischemia,
trimetazidine prevents a decrease in intracellular
ATP levels, thereby ensuring the proper function­
ing of ionic pumps and trans-membranous
sodium-potassium flow while maintaining cellt1-
lar homeostasis. The distur-bances of tissue oxy­
gen supply during ischemia decrease
mitochondrial ATP production and increase the
generation of free radicals (02-, OH). By dimin­
ishing the bioavailability of free radicals,
trimetazidine lessens all their toxic effects.
Trimetazidine acts on the inactivation of enzy­
matic membrane proteins; it antagonizes free rad­
ical-induced stimulations of phospholipase A2
and thromboxane synthetase.
Ind: Trimetazidine is indicated in- i. prophylactic
treatment of episodes of angina pectoris and se­
quelae of infarction 'heart failure'; ii. adjuvant
symptomatic treatment of vertigo and tinnitus; iii.
adjuvant treatment of the decline of visual acuity
and visual field disturbances, presumably of vas­
cular origin.
C/I: Hypersensitivity to trimetazidine.
S/E: Rare cases of gastrointestinal disorders, nau­
sea, headache and vertigo. The side effects are
mild and non-spcific.
Precautions: Not recommended in pregnancy
•••
•••
www.squarepharma.com.bd •••
SOUAM
•
 -

QIMP-17 (77)

and nursing mother. + T RIMET MR Tab. Drug Inter.

Pregnancy & lactation: Studies in a.nimals have
not demonstrated any teratogenic effect. How­
e\1er, in the absence of clinical data and for safety
reasons, prescription should be avoided during
pregnancy.
There is no information on the secretion of
trimetazidine into breast milk. So, in the absence
of data, breastfeeding is not recommended during
treatment.
Dosage & admin: 20mg tablet preparations: 1
tablet 3 times dailv after meals.
�
35mg tablet preparations: 1 tablet at meal­
times in the morning and evening.
No dosage adjustments are required in patients
with impaired renal and hepatic function.
Child: Not recommended.
+ANGIMET Tab. Orion Pharma
Trimetazidine dihydrochloride INN 20mg/tablet
(film-coated).
20mg 50's pack: 150.50 MRP
x
+ANGIMET MR Tab. Orion Pharma
Trimetazidine dihydrochloride INN 35mg/tablet
(modified release).
35mg x 30's pack: 150.60 MRP
+ANGINOX Tab. General
Trin1etazidine dihydrochloride INN 20mg/tablet
(film-coated).
20mg x 30's pack: 90.00 MRP
+ANGIRID MR Tab. Acme
Trimetazidine dihydrochloride INN 35mg/tablet
(modified release).
35mg x 30's pack: 150.30 MRP
+ANGIV ENT M R Tab. Square
Trimetazidine dihydrochloride INN 35mg/tablet
(modified release).
35mg x 30's pack: 150.30 MRP
+ANTORIS MR Tab. Opsonin
Trimetazidine dihydrochloride INN 35mg/tablet
(modified release).
35mg x 30's pack: 158.35 MRP
+ FEELNOR Tab. lncepta
Trimetazidine dihydrochloride INN 20mg/tablet
(film-coated).
20mg x 50's pack: 90.00 MRP
j
+ FEELNOR MR Tab. lncepta
Trimetazidi11e dihydrochloride INN 351ng/tablet
(modified release).
35mg x 30's pack: 150.00 MRP
+METACARD M R Tab. Aristopharma
Trimetazidine dihydrochloride INN 35mg/tablet
(modified release).
35mg x 50's pack: 300.00 MRP
+METAVAS MR Tab. NIPRO JMI
Trimetazidine dihydrochloride INN 35mg/tablet
(modified release).
35mg x 30's pack: 150.00 MRP
+METAZINE MR Tab. Beximco
Tritnetazidine dihydrochloride INN 35mg/tablet
(modified re] ease).
35mg x 30's pack: 180.00 IP
+ TRIMET Tab. Drug Inter.
Trimetazidine dihydrochloride BP 20mg/tablet (f.c)
20mg x 50's pack: 150.00 MRP
Trimetazidine dihydrochloride INN 35mg/tablet
(modified release).
35mg x 30's pack: 150.00 MRP
+VASTADIN MR Tab. Sharif
Trimetazidine hydrochloride BP 35mg/tablet
(modified release).
35mg x 30's pack: 150.00 MRP
+VASTAREL MR Tab. Servier
Trimetazidine dihydrochloride INN 35mg/tablet
(modified release).
35mg x 30's pack: 250.20 MRP
+V ESTAR MR Tab. Healthcare
Trimetazidine hydrochloride BP 35mg/tablet
(modified release).
35mg x 30's pack: 180.00 MRP
Combined preparations of
Anti-angina/ & Lipid-lowering
drugs.
AMLODIPINE + ATORVASTATIN26
AMLODIPINE + ATORVASTATIN: Tablet
In this combination formula of above two drugs­
amlodipine is a dihydropyridine calcium antago­
nist (antihypertensive/antianginal agent) and ator­
vastatin is a HMG-CoA reductase inhibitor
(cholesterol lowering agent).
These two drugs are found in a fixed-dose combi­
nation, viz: atnlodipine besylate BP equivalent to
amlodipine 5mg and atorvastatin calcium trihy­
drate INN equivalent to atorvastatin 1Omg as
film-coated tablet.
Mode of action: Given under the text of amlodi­
pine and atorvastatin separately.
Ind: This co1nbination product is indicated in pa­
tients for whom treatment with both amlodipine
and atorvastatin is appropriate. For detail, please
see under the text of amlodipine and atorvastatin
separately.
C/I: Combination of amlodipine and atorvastatin
is contraindicated in patients with known hyper­
sensitivity to any component of this medication.
Atorvastatin is particularly contraindicated in pa­
tients with active liver disease which may include
unexplained persistent elevations of serum
transaminases.
S/E: I n general, treatment with. amlodipine and
atorvastatin combination is well tolerated. Some
common side effects include headache, dizziness,
tiredness, sleepiness, stomach pain, nausea,
stomach upset, diarrhea, edema, flushing, ar­
rhythmia, palpitation, muscle & joint pain etc.
Precaution: Before instituting therapy with ator­
vastatin, an attempt should be made to control hy­
percholesterolemia with appropriate diet,
exercise, and weight reduction in obese patients,
and to treat other underlying medical problems.
Information.for patients: Patients should be ad­
vised to report promptly unexplained muscle
pain, tenderness, or weakness, particularly if
accompanied by malaise or fever. Care should be
taken in patients with renal failure, impaired he­
patic function, and heart failure as amlodipine
may deteriorate the conditions.
Pregnancy & lactation: Pregnancy category X.
This means the risks of this product involved its
use in pregnant women clearly outweighs poten­
tial benefits.
The combination wl1ich includes atorvastatin,
should be a.c\ministered to women of childbearing
age only when such patients are highly unlikely
to conceive and have been informed of the poten­
tial hazards.
Adequate human data are not available in case of
lactation.
Dosage & admin: This combination product
may be substituted for its individually titrated
components, or may be given as additional
therapy in patients who are on treatment with
one of its components. As initial therapy for
one indication and continuation of treatment
of the other, the recommended starting dose
should be selected based on the continuation
of the component being used & the recommen­
ded starting dose for the added monotherapy.
This combination product may be used to ini­
tiate treatment in patients with h}-perlipide­
mia and either hypertension or angina. The
recommended starting dose should be based
on the appropriate combination of recommen­
dations for the monotherapies.
The maximum dose of the amlodipine compo­
nent is lOmg once daily. The maximum dose of
the atorvastatin component is 80mg once daily.
Drug inter: Please see under the text of amlodip­
ine and atorvastatin give11 separately.
+ADV...\ST Tab. Alco Pharma
Atnlodipine 5mg + Atorvastatin lOmg/tablet (f.c).
30's pack: 300.00 MRP
+AMDOVA Tab. Beximco
Amlodipine 5mg + Atorvastatin lOmg/tablet (f.c).
30's pack: 330.00 MRP
+ATV Plus Tab. Delta Pharma
Amlodipine 5mg + Atorvastatin lOmg/tablet (f.c).
IO's pack: 80.00 MRP
+CAMLOTOR Tab. Square
Amlodipine 5mg + Atorvastatin I Omg/tablet (f.c).
30's pack: 331.20 MRP
+DIVASTIN PLUS Tab. Drug Inter.
Amlodipine BP 5mg + Atorvastatin IN"N
lOmg/tablet ( f.c).
30's pack: 330.00 MRP
+ LIPICHEK Tab. General
Amlodipine 5mg + Atorvastatin I Omg/tablet (f.c).
20's pack: 220.00 MRP
t LIPIGENT Plus Tab. Pacific
Amlodipine 5mg + Atorvastatin I 01ng/tablet (f.c).
30's pack: 330.00 MRP
+RAKLOPIN-AT Tab. RAK Pharma

An ideal antianginal agent for

round-the-clock metabolic cardioprotection
Trimetazidine HCI BP 35 mg .A..CJVIE:

•
 CARDIOVASCULAR DRUGS QIMP-17 (78)

Amlodipine 5mg + Atorvastatin lOmg/tablet (f.c).

30's pack: 300.00 MRP

+ SYNCARD Plus Tab. Incepta

Amlodipine 5mg + Atorvastatin lOmg/tablet (f.c). ALBASINE
30's pack: 330.00 MRP Almitrine Bismesylate INN & Raubasine INN Tablet

5. PERIPHERAL & CERE­

BRAL VASODILATOR & 30's pack: 360.00 MRP
+ T RUXIL Tab. Square
NEUROSENSORY OXY­ Almitrine bismesylate 30mg + raubasine
GENATOR DRUGS lOmg/tablet (f.c).
30's pack: 300.00 MRP

5.1 Cerebral vasodilator & Neurosensory oxy­

genator drugs VINPOCETINEz•.ss
5.2 Peripheral vasodilator drugs
S.3 Drugs for Muscular energy metabolism VINPOCET INE: Tablet/Injection.
Ind: Mental and neurological symptoms of re­
versible cerebrovascular disturbances, viz. amne­
Cerebral vasodilator & Neu­ sia, aphasi� apraxia, locomotor disorders,

rosensory oxygenator drugs vertigo, headache. Hypertensive encephalopathy,

intermittent cerebrovascular insufficiency, cere­
bral endarteritis etc.
ALMITRINE + RAUBASINE53 C/I: Pregnancy
S/E: Slight fall in blood pressure, occasional
tachycardia.
ALMIT RINE + RAUBASINE: Tablet .

.
.
.
·-....
Dose: initially 1-2 tabs. 3 times daily; mainte­
This is a combination formula of two compo­
. ·.

nance, 1 tab. 3 times daily.

nents, available as- almitrine bismesylate 30mg &
raubasine 1Omg in tablet form. + AVINTOL Tab. ACI
Mode of action: This combined product acts as a Vinpocetine (apovincaminic ethylester) INN
neurosensory oxygenator drug and effective in 5mg/tablet.
the treatment of cerebral insufficiency. 50's pack: 200.00 MRP
Ind: Minor, age-related neurological disorders + CAMITON Tab. Drug Inter.
(such as disorders of memory, concentration etc); Vinpocetine (apovincaminic ethylester) INN
some visual disorders & disorders of the inner ear 5mg/tablet.
(such as hearing loss, dizziness, buzzing sounds lOO's pack: 400.00 MRP
in the ear) related to the ischaemic circulation.
+ CAVINTON Tab. Gedeon Richter/City
C/I: Known allergy to the drug. Severe liver dis­ Overseas
ease. Don't give with MAOis. Vinpocetine (apovincaminic ethylester)
A/E: Mild gastrointestinal disorders, nausea, sen­ Smg/tablet.
sations of heaviness and burning in the stomach, 50's pack: 440.00 TP
diarrhea, or constipation. Insomnia, drowsiness, + CAVINTON Inj. Gedeon Richter/ City
agitation, anxiety, dizziness. Palpitations, During Overseas
long-term treatment (1 year or more), rarely, sen­ Vmpocetine 1Omg/2ml ampoule: injection
sation of 'pins and needles', stinging, or numbness Dose: In acute case, lOmg slow i.v or in infu­
in the lower limbs, or weight loss and usually sion, daily 2 to 3 times, then followed by oral
disappear after discontinuation of the treatment. dose, 1-2 tabs t.i.d.
Cautions: Do not exceed the recommended dose. 10 amps pack: 502.00 TP
During long-term treatment, if abnormal sensa­
+ CAVITON Tab. Opsonin
tion in the lower limbs, or weight loss occurs, dis­ Vinpocetine (apovincaminic ethylester) INN
continue treatment and consult physician. Avoid 5mg/tablet.
concomitant use of other drugs containing 50's pack: 132.40 MRP
almitrine.
+ CERENIN Tab. Ambee
Pregnancy & lactation: It is not recommended Vinpocetine (apovincaminic ethylester) INN
in women during pregnancy & lactation unless the 5mg/tablet.
therapeutic benefits outweigh any potential risk. 50's pack: 177.50 MRP
Dosage: 1 tablet once or twice daily (one in the
+ CERETON Tab. General
morning & one in the evening). In case of miss­ Vinpocetine (apovincaminic ethylester) INN
ing dose, take the next dose at the normal Smg/tablet.
time; do not take a double dose. SO's pack: 201.00 MRP
Overdosage: In case of massive overdosage with
+ CERETON I.Mil. V Inj. General
cardio-respiratory signs gastric lavage and symp­ Vinpocetine 1Omg/2ml ampoule: i.m/i. v injection
tomatic supportive measures should be applied Dose: In acute case, 1 Omg slow i. v or in infu­
under close cardiorespiratory observation with re­ sion, daily 2 to 3 times, then followed by oral
peated monitoring of blood gases. dose, 1-2 tablet(s) 3 times daily.

+ ALBASINE Tab. Drug Inter.

Almitrine bismesylate 30mg + raubasine
lOmg/tablet (f.c).

I

5 amps pack: 200.00 MRP
t CEREVAS Tab. Square
Vmpocetine (apovincaminic ethylester) INN
5mg/tablet.
50's pack: 200.50 MRP
+ CERIVIN Tab. Beximco
..
Vinpocetine (apovincaminic ethylester) INN
5mg/tablet.
l OO's pack: 402.00 IP
t VINCET Tab. SK+F
Vinpocetine (apovincaminic ethylester) INN
5mg/tablet.
50's pack: 200.00 MRP
t VINSETINE Tab. Incepta
Vinpocetine (apovincaminic ethylester) INN
5mg/tablet.
l OO's pack: 400.00 MRP
+ VINTON Tab. Aristopharma
Vmpocetine (apovincaminic ethylester) INN
5mg/tablet.
IOO's pack: 400.00 MRP
Peripheral Vasodilator drugs:
Intermitent Claudication
CILOSTAZOL48
CILOSTAZOL: Tablet
Cilostazol is a quinolinone derivative.
It is available as cilostazol USP 50mg & l OOmg
tablet.
Mode of action: Cilostazol acts by specific inhi­
bition of cellular phosphodiesterase III (PDE III)
and suppreses cAMP degradation with a resultant
·
increase in cAMP and decrease in intracellular
calcium ion in platelets and blood vessels, lead­
ing to inhibition of platelet aggregation and va­
sodilation.
Ind: It is indicated for the reduction of symp­
toms of intermittent claudication, as indicated by
an increased walking distance.
C/I: Congestive heart failure of any severity;
--
known or suspected hypersensitivity to any of its
components.
-
S/E: Cilostazol is well tolerated with some most
common side effects such as headache, diarrhoea,
vomiting, rash etc. A few less frequent side ef­
fects also been reported such as anorexia, face
oedema etc.
Precautions: As grapefruit juice inhibits
CYP3A4, avoid concurrent use with cilostazol.
Renal impairment- the total activity of cilostazol
and its metabolites is similar in subjects with mild
to moderate renal impairment and in healthy sub­
jects.
Pregnancy & lactation: There are no adequate
and well controlled studies in pregnant women,
so use during pregnancy only if the potential
benefit justifies the potential risk to the fefus. As
cilostazol is secreted into the milk of experimen­
tal animals, there is potential risk for the nursing
infants, so a decision should be made to discon­
tinue nursing or to discontinue cilostazol.
• •
I An id.eal antianginal agent for
Trimetazidine HCI BP 35 mg
I
QIMP-17 (79)
Dosage & admin: The recommended dosage is
1OOmg orally twice daily, taken at least half an
hour before or two hours after breakfast and
di.oner. A dose of 50mg b.i.d should be consid­
ered during coadministration of inhibitors of
CYP3A4 (e.g ketoconazole, itraconazole,
erythromycin and diltiazem) and during coad­
ministration of inhibitors of CYP2C19 (e.g
omeprazole). Patients may respond as early as
2 to 4 weeks after the initiation of therapy but
treatment for up to 12 weeks may be needed
before a beneficial effect is experienced.
Pediatric use: The safety and effectiveness of
cilostazol in pediatric patients have not been
established.
Overdosage: Information on acute overdosage
with cilostazol in humans is limited. The signs
and symptoms of an acute overdose are severe
headache, diarrhea, hypotension, tachycardia, and
possibly cardiac arrhythmias. The patient should
be carefully observed and given supportive treat­
ment.
Drug inter: Pharmacokinetic studies have
demonstrated that omeprazole and erythromycin
significantly increase the systemic exposure of
cilostazol and/or its major metabolites. Patients
concurrently treated with diltiazem may cause
higher concentrations of cilostazol. There is no
information with respect to the efficacy or safety
of the concurrent use of cilostazol and clopido­
grel. Short-term coadministration of aspirin with
cilostazol showed an increase in inhibition of
ADP-induced platelet aggregation; effects on
long-term coadministration are unknown. Cilosta­
zol did not inhibit the metabolism or the phanna­
cologic effects of warfari n following a single
dose; effect of concomitant multiple dosing of
warfarin or cilostazol on either drug is unknown.
t CILOSTA Tab. Square
Cilostazol USP IOOmg/tablet
l OOmg x 30's pack: 361.50 MRP
t INCLAUD Tab. ACI
Cilostazol USP 1 OOmg/tablet
lOOmg x 20's pack: 240.00 MRP
t VASOCIL Tab. Ibo Sina
Cilostazol USP 50mg & 1OOmg/tablet
50mg x 30's pack: 210.00 IP
l OOmg x 20's pack: 240.00 IP
t ZOCIL Tab. Beximco
Cilostazol USP 50mg & 1OOmg/tablet
50mg x 30's pack: 210.00 MRP
l OOmg x 20's pack: 240.00 MRP
OXPENTIFYLLINE21.s9
Or
PENTOXIFYLLINE
PENTOXIFYLLINE (OXPENT IFYLLINE):
Tablet
Ind: Peripheral vascular disease.
C/I: Acute myocardial infarction, profuse bleed­
ing, brain haemorrhage.
S/E: G.I disturbances (nausea, vomiting, stomach
round-the-clock metabolic cardioprotection
CARDIOVASCULAR DRUGS
pain), tension, dizziness, headache, rarely flush­
ing tachycardia; ralely pruritus and urticaria.
Caution: Hypotension, coronary artery disease,
porphyria.
Dose: Initial dose is 200mg 3 times daily (dur­
ing the first week); the dose should be lowered
to 1OOmg 3 times daily in the case of excessive
blood pressure reduction, as well as in
longterm treatment.
In slow release form 400mg tab. 2-3 times daily
may be given. All dosages usually after meal.
t OXIFYL CR Tab. Square
Pentoxifylline 400mg/tablet (controlled release)
30's pack: 210.60 MRP
+ TRENTAL Dragee Tab. Sanofi-aventis
Pentoxiphylline 400mg/tablet
30's pack: 451.79 MRP
Drugs for muscular energy
metabolism
LEVOCARNITINE26,4s
LEVOC ARNITINE: Tablet/Syrup
Levocamitine is a naturally occurring substance
required in mammalian energy metabolism. It is
available in tablet & syrup form: i. levocarnitine
USP 330mg/tablet, & ii. levocarnitine USP
l OOmg/ml of syrup.
Mode of action: Levocarnitine plays role as car­
rier molecule in mammalian energy metabolism.
It facilitates long-chain fatty acid transport &
entry into cellular mitochondria, thereby deliver­
ing substrate for oxidation and subsequent energy
production. Fatty acids are utilized as energy sub­
strate in all tissues except the brain. I11 skeletal
and cardiac muscles, fatty acids are the main sub­
strate for energy production.
Ind: Chronic fatigue syndrome, heart disease,
congestive heart failure, high cholesterol, inter­
mittent claudication, kidney disease, dementia
and memory impairment, Down syndrome, male
infertility, hyperthyroidism.
C/I: Not known.
S/E: Generally levocamitine is well tolerated.
However, few side effects including transient
nausea and vomiting, abdominal cramps, and di­
arrhoea may occur.
Precautions: The safety and efficacy of oral lev­
ocamitine has not been evaluated in patients with
renal insufficiency. Chronic administration of
high doses of oral levocarnitine in patients with
severely compromised renal function or in ESRD
patients on dialysis may result in accumulation
of potentially toxic metabolites, trimethylamine
(TMA) and trimethylamine-N-oxide (TMAO),
since these metabolites are normally excreted in
the urine.
Pregnancy & lactation: There is no adequate
.A..CJVIi3:
CARDIOVASCULAR DRUGS
and well controlled studies in pregnant wo1nen.
This drug should be used during pregnancy only
if clearly needed.
Levocamitine supplementation in nursing 1noth­
ers has not been specifically studied. In nursing
mothers receiving levocamitine, any risks to the
child of excess camitine intake need to be
weighed against the benefits of levocamitine sup­
plementation to the mother. Consideration may be
given to discontinuation of nursing or of levocar­
nitine treatment.
Dosage & admin: Adults: 300mg 2 or 3 times
daily, depending on clinical response.
Infants & children: 50-lOOmg/kg/day in di­
vided doses, with a maximum of 3gm/day.
Dosage should begin at 50mg/kg/day. The
exact dosage will depend on clinical response.
Drug inter: Not known.
+ CARNITAB Tab. Bexin1co
Levocamitine USP 330mg/tablet
30's pack: 150.60 IP
+ CARNITEN Tab. Drug Inter.
Levocamitine USP 330mg/tablet
49's pack: 245.00 MRP
+ CARTINE Tab. ACI
Levocamitine USP 330mg/tablet
30's pack: 150.60 MRP
+ CARTINE Solo. ACI
Levocamitine USP 500mg/5rnl: syrup
lOOml bot: 100.00 MRP
+ ENVITOR Tab. Opsonin
1 dose be reduced.
Levocamitine USP 330mg/tablet
30's pack: 132.48 MRP
+ L-CARNI Tab. General
Levocamitine USP 330mg/tablet
30's pack: 150.60 MRP
+ LEVOCAR Tab. Square
Levocamitine USP 330mg/tablet
30's pack: 150.30 MRP
+ LEVOCAR Syp. Square
Levocamitine USP 500mg/5ml: syrup
lOOml bot: 100.38 MRP
+ OCARNIX Tab. Incepta
Levocamitine USP 330mg/tablet
20's pack: 100.00 MRP
6. SYMPATHOMIMETICS
6.1 lnotropic sympathomimetics
6.2 Vasoconstrictor sympathomimetics
Inotropic sympathomimetics 21
Commonly used inotropic sympathomimetics in­
clude- Dobutamine, Dopamine, Dopexamine, Iso­
prenaline, Xamoterol.
DOBUTAMINE49·121
DOBUTAMINE HCI: Injection
Introduction & mode of action: Dobutamine
hydrochloride injection is an inotropic agent
whose primary activity results from stimulation
of the receptors of tl1e heart while producing
comparatively mild chronotropic, hypertensive,
arrhythmogenic and vasodilative effects. The
drug is believed to be a direct agonist which, in
•
Qll\lP-17 (80)
animal studies, produces less increase in heart
rate and less decrease in peripheral vascular re­
sistance for a given inotropic effect than does iso­
prenaline.
Facilitation of atrioventricular conduction has
been observed in human electrophysiologic stud­
ies in normal subjects and in patients with atrial
fibrillation. Systematic vascular resistance is usu­
ally decreased with administration of dobuta­
mine. Occasionally, minimal vasoconstriction has
been observed.
The onset of action is within one to two minutes;
however, as n1t1ch as ten minutes may be required
to obtain the peak effect of' a particular infusion
rate.
Ind: Dobutamine hydrochloride injection is indi­
cated in adults who require short-term treat­
ment of cardiac failure secondary to acute
myocardial infarctior1, or cardiac surgery.
C/l: Dobutamine hydrochloride injection is con­
traindicated in patients with idiopathic hypcr­
trophic subaortic stenosis and previous
hypersensitivity to dobutamine.
S/E: Many of the side-effects of dobutamine are
a quantitative extension of the pharmacological
actions. The following adverse effects have been
reported. Increased heart rate, blood pressure, and
ventricular ectopic activity. Approximately 5% of
patients have had increase premature ventricular
beats during infusions. These effects are dose re­
lated and their occurrence may require that the
lvfisc. uncommon effects: The following adverse
effects have been reported in 1-3% of patients-:
nausea, headache, angina! pain, nonspecific chest
pain, palpitations and shortness of breath.
Hypersensitivity reactio11s including rash, fever,
eosinophilia and bronchospasm. As with other
catechola1nines, decreases in serum potassium
concentrations have occurred, rarely to hy­
pokalaemic values.
Warnings: Increase in heart rate or blood pres­
sure- dobutamine may cause a marked increase in
heart rate or blood pressure, especially systolic
pressure. Reduction of dosage usually reserves
these effects pro1nptly. Because dobutamine facil­
itates atrioventricular conduction, patients with
atrial fibrillation are at risk of developing rapid
ventricular response. patients with preexist-ing
hyperten-sion appear to face an increased risk of
developing an exaggerated pressor response.
Ectopic activity: Dobutamine may precipitate or
exacerbate ventricular ectopic activity, but it
rarely has caused ventricular tachycardia.
Anaesthetics: The myocardium may be sensitised
to the effect of dobutamine b y cyclopropane or
halogenated hydrocarbon anaesthetics, and these
should be avoided.
Dobutamine hydrochloride injection solution con­
tains sodium metabisulfite, whcih may cause al­
lergic-type reactions, including anaphylactic
sy1nptoms and life-threatening or less severe asth­
matic episodes in susceptible people.
Precautions: During the administration of dobut­
amine, as with any adrenergic agent, ECG and
blood pressure shuold be continuously monitored.
In addition, pulmonary wedge pressure and car­
diac output should be monitored whenever possi­
ble to aid in the safe and effective infusion of
dobutamine.
Hypovolaemia should be corrected with suitable
volume expanders before treatment with dobuta­
mine is i11stituted.
In patients who have atrial fibrillation with rapid
ventricular response, a. digitalis preparation
should be used prior to instituting therapy with
dobutamine.
Animal studies indicate that dobutamine may be
ineffective if the patient has recently received a
beta-blocking drug. In such case, the peripheral
vascular resistance may increase.
No improvement may be observed in the pres­
ence of mark.ed mechanical obstruction, such as
severe valvular aortic stenosis.
Pregnancy & lactation: Since there are no ade­
quate and well-controlled studies in pregnant
women, dobutatnine hydrochloride should not be
used during pregnancy t1nless the potential bene­
fits outweigh the potential risk to the fetus.
As it is not known if dobt1tamine is secreted into
the breast milk, the use of dobutami11e in lactating
wo1nen should take into account the potential
harmful effects to tl1e infant.
Dosage & adµtln: Adults: The rate of infusion
needed to increase cardiac output usually
ranges from 2.5-15mcg/kg/min. On rare occa­
sions, infusion rates up to 40mcg/kg/min have
been required to obtain the desired effect.
Dobutamine causes a dose related improve­
ment in the cardiac output in patients with
congestive heart failure. However, the possi­
bility of intensifying myocardial. ischaemia
should be borne in mind and the lowest effec­
tive dose infused.
Use in children: The safety and efficacy of
dobutamine for use in children have not been
studied.
Dilution for i. v infusion: Dobutamine hy­
drochloride injection must be diluted at the
time of administration to at least 50ml solu­
tion, such as in 5o/o or 10°/o Dextrose injection,
5°/o Dextrose & 0.45°/o or 0.9°/o Sodium chlo­
ride injection, or 0.9°/o Sodium chloride injec­
tion, Lactated Ringer's injection & Sodium
lactate injection. Although chemically stable
for 24 hours, prepared solutions should be
used immediately after dilution.
Rates of infusion for concentrations oj.250, 500
& 1,000mg/l:
1. 250mg per litre of diluent
2. 500mg per litre or 250mg per 500ml of diluent
3. 1 OOOmg per litre or 250mg per 250ml ofdiluent
The rate of administration and the duration of
therapy should be adjusted according to the
patient's response, as determined by heart
rate, presence of ectopic activity, blood pres­
sure, urine flow, and whenever possible, meas­
ure-ment of central venous or pulmonary
wedge pressure and cardiac output.
Concentrations up to 5000mcg/ml have been •
administered to humans (250mg/50ml). The
final volume administered should be deter­
mined by the fluid requirements of the patient.
Note: Do not add dobutamine hydrochloride in­
jection to 5% sodium bicarbonate injection or
any other strongly alkaline solutions. Dobutamine
hydrochloride should not be used in conjunction
with other agents or diluents containing sodium
·
bisulfite. ·

Overdosage: Overdoses of dobutamine have
been reported rarely. The following is provided
to serve as a guide if such an overdose is
encountered.
Signs & symptoms: Toxicity from dobutamine
hydrochloride is usually due to excessive cardiac
receptor stimulation. The symptoms of toxicity
may include anorexia, nausea, vomiting, tremor,
anxiety, palpitations, headache, shortness of
breath and angina! and nonspecific chest pain.
The positive inotropic and chronotropic effects of
dobutamine on the myocardium may cause
hypertension, tachyarrhythmias, myocardial
ischaemia, and ventricular fibrillation.
Hypotension may result from vasodilation.
Treatment: Because the duration of action of
dobutamine is short, reducing the rate of admin­
istration or temporarily discontinuing dobutamine
therapy until the patients condition stabilises is
usually adequate. However, in managing
overdosage, consider the posibility of multiple
dl1rg overdoses, interaction among drugs, and
unusual drug kinetics in the patient's body.
The initial actions to be taken in a dobutamine
hydrochloride overdose are- discontinuing
administration, establishing an airway, and
ensuring oxygenation and ventilation.
Resuscitative measures should be initiated
promptly. Severe ventricular tachyarrhythmias
may be successfully treated with propranolol or
lignocaine. Hypertension usually responds to a
reduction in dose or discontinuation of therapy.
Protect the patient's airway and support
ventilation and perfusion. If needed, meticulously
monitor and maintain the patient's vital signs,
blood gases, serum electrolytes etc. (within
acceptable limits).
+ DOBUMIN lnj. ACI
Dobutamine hydrochloride 250mg/20ml ampoule
(i.e 1.25%): injection for i.v infusion.
250mg (20ml) amp: 250.94 MRP
+ .DOBUTAMINE Inj. Panpharma/City
Overseas
Dobutamine hydrochloride 250mg/20ml vial:
injection for i.v infusion.
250mg (20ml) vial: 285.00 TP
+ DOBUTIN lnj. Incepta
Dobutamine hydrochloride 250mg/20ml ampoule
(i.e 1.25%): injection for i.v infusion.
250mg (20ml) amp: 250.00 MRP
DOPAMINE21,33
DOPAMINE HYDROCHLORIDE : Injection
Ind: Cardiogenic shock in infarction or cardiac
surgery.
C/I: Tachyarrhythmia, phaeochromo-cytqma
S/E: Nausea and vomiting, peripheral vasocon­
striction, hypotension, hypertension, tachycardia
Cautions: Correct hypovolaemia; low dose in
shock due to acute myocardial infarction.
Dose: By i.v infusion, 2-5mcg/kg/min. initially.
Not: Dosage of dopamine is critical, since
although low doses induce vasodilatation and
increase renal perfusion, higher doses (more than
5mcg/kg/min) lead to vasoconstriction and may
exacerbate heart failure, so the dosage regimen
should be carefully maintained.
•
QIMP-17 (81)
+ CARDOPA I.V Inj. ACI
Dopamine hydrochloride 200mg/5ml ampoule:
i. v injection
5ml amp x S's pack: 225.85 MRP
+ D-DOPA MINE I.V lnj. Drug Inter.
Dopamine hydrochloride USP 200mg/5ml
ampoule: i. v injection
5ml amp x 3's pack: 135.00 MRP
+ DOPAMINE-ROTEX Inj. Rotex Medical
City Overseas
Dopamine hydrochloride 200mg/5ml ampoule:
i.v injection
5ml amp x lO's pack: 600.00 TP
+ MYOMINE I.V Inj. Incepta
Dopamine hydrochloride 200mg/5ml ampoule:
i. v injection
5ml amp x S's pack: 225.00 MRP
Vasoconstrictor/Venotonics3
DIOSMIN + HESPERIDIN42,53
DIOSMIN + HESPERIDIN: Tablet
.
This combined preparation contains diosmin in
micronised form and hesperidin. This has been
prepared for treating venous circulation disorders
(swollen legs, pain, restless legs) and for treating
symptoms due to acute hemorrhoidal attack. This
preparation is available as tablet containing
500mg- micronized purified flavonoid fraction
corresponding to- diosmine 90% (450mg) &
flavonoids expressed as hesperidin 10% (50mg):
coated tablet.
Mode of action: See before, under phlebotonic
& vascular protecting preparations in the chapter
of gastrointestinal drugs.
Ind: This combined preparation is recommended
for treating venous circulation disorders (swollen
legs, pain, restless legs) & for treating symptoms
due to acute hemorrhoidal attack.
C/l; S/E; Precautions: See before, under
phlebotonic & vascular protecting preparations
Pregnancy & lactation: See before, under
phlebotonic & vascular protecting preparations
Dosage & admin: The tablets should be taken
at meal times.
Venous insufficiency: 2 tablets daily, one at
midday and one in the evening.
Acute haemorrhoidal attack: A 4-day .course of
6 tablets daily, followed by 4 tablets daily over
the next 3 days.
Drug Inter: See before, under phlebotonic &
vascular protecting preparations
Preparations: See before, under phlebotonic &
vascular protecting preparations in the chapter of
gastrointestinal preparations.
7. ANTICOAGULANTS
7 .1 Parenteral anticoagulants
a) Standard or unfractionated Heparin
b) Low molecular weight heparins
.
7.2 Oral anticoagulants
Parenteral Anticoagulants
CARDIOVASCULAR DRUGS
Standard or unfractionated
Heparin
HEP.ARIN2 1 3 3,
HEPARIN: Injection
Heparin sodium 1000 units, 5000 units & 25000
units per 1 ml ampoule.
Ind: Treatment & prophylaxis against deep-vein
thrombosis & pulmonary embolism; disseminated
intravascular coagulation (DIC); prevention of
post operative thrombosis; unstable angina &
acute peripheral arterial occlusion; myocardial
infarction.
C/I: Hemophilia and other hemorrhagic condi­
tions, thrombocytopenia, peptic ulcer, recent
cerebral hemorrhage, severe hypertension, severe
liver disease (including oesophageal varices),
renal failure, after major trauma or recent surgery;
hypersensitivity to heparin.
S/E: Hemorrhage, skin necrosis, thrombocyto­
penia, hypersensitivity reactions (including
urticaria, angioedema, & anaphylaxis);
osteoporosis after prolonged use & rarely alopecia.
Cautions: Concurrent admn. of oral anticoagu­
lants, dextran inj. or drugs affecting platelet
function; pregnancy; thrombocytopenia- usually
develops after 6 to 10 days of heparin use, so
incase of pat�ents receiving heparin for longer
than 5 days, if any develops thrombocytopenia­
stop heparin immediately. In these cases
alternative therapy with low molecular weight
heparin or oral anticoagulant may be given.
Dosage: Treatment of deep-vein thrombosis
and pulmonary embolism: adult, by i.v injec­
tion, loading dose of 5000 units (10,000 units
in severe pulmonary embolism) .followed by
continuous infusion of 1000-2000 units/ hour,
or by subcutaneous injection of 15,000 units
every 12 hourly under laboratory monitoring.
Prophylaxis of deep vein thrombosis: 5000
units 2 hour before surgery then every 8-12
hours until patient is ambulant; in pregnancy,
10,000 units every 12 hourly (with monitoring).
Child: lower loading dose, then 15-25 units/kg/
hour by i.v infusion or 250 units/kg every 12
hours by s.c injection.
Unstable angina & acute peripheral arterial
occlusion: Intravenous treatment regimen as
for deep-vein thrombosis and pulmonary
embolism (above).
Prophylaxis in general surgery: By s.c injection
5000 units 2 hours before surgery, then every
8-12 hours for 7 days or until patient is
anbulant (monitoring not needed); during
pregnancy (with monitoring), 5000-10,000
units every 12 hours.
Myocardial infarction: For the prevention of
coronary re-occlusion after thrombolysis,
heparin is used in a variety of regimens
according to- locally agreed protocols.
Prevention of mural thrombosis: Heparin is
considered effective when given by s.c inj. of
12,500 units every 12 hours for at least 10 days.
+ HEPARIN LEO lnj. Leo Pharma/Kapricorn
Heparin sodium 5000 i.u/ml: injection
5ml vial x 1 's pack: 704.00 MRP
+ HEPARIN-ROTEX Inj. Rotex Medica/City

CARDIOVASCULAR DRUGS
Overseas
Heparin sodium 5000 i.u/ml: injection
5ml vial x l's pack: 350.00 TP
Low molecular weight Heparins
Common low molecular weight heparins are:
Certoparin, Dalteparin, Enoxaparin, and
nnzaparin.
DALTEPARIN21,60
+ FRAGMIN Inj. Pharmacia-Pfizer/Janata
Dalteparin sodium 5000 i.u & 7,500 i.u in
prefilled syringe for subcutaneous injection.
Ind: Prophylaxis & treatment of deep-vein
thrombosis; prevention of clotting in
extracorporeal circuits.
C/l;S/E;Cautions: See under Heparin.
Dosage & admin: Prophylaxis of deep vein
thrombosis, by s.c injection, moderate risk,
2500 units 1-2 hours before surgery, then 2500
units every 24 hours for 5 days; high risk,
2500 units 1-2 hours before surgery, then 2500
units 12 hours later, then 5000 units every 24
hours for 5 days.
Treatment of deep-vein thrombosis, by s.c inj.
200 units/kg as a single daily dose (max.
18,000 units daily); patients with increased
risk of haemorrhage, 100 units/kg twice daily.
Prevention of clotting in e:xtracorporeal cir­
cuit, please consult manufacturer's literature.
5000 i.u prefilled syringe x IO's pack: 3375.00
MRP
7,500 i.u prefilled syringe x IO's pack: 6314.80
MRP
ENOXAPARIN21,35
ENOXAPARIN: Injection
Enoxaperin is a low molecular weight heparin,
available as enoxaparin sodium 20mg (2000
IU)/0.2ml, 40mg (4000 IU)/0.4ml, 60mg (6000
IU)/0.6ml & 80mg (8000 JU)/0.8ml contained in
ampoule or ready-to-use prefilled syringe: for s.c
injection.
Ind: i. Prophylaxis of venous thromboembolic
diseases (prevention of blood clot formation in
the veins) in particular after certain procedures,
ii. prevention of thrombus formation in the extra
corporal circulation during haemodialysis.
C/I; S/E; Cautions: See under heparin. Do not
inject intramuscularly.
Dosage & Admin: Prophylaxis of deep vein
thrombosis, by s.c injection (in the subcuta­
neous celluler tissue of the anterolateral or
posterolateral abdominal wall, alternatively
between the left and right sides), moderate
risk, 20mg 1-2 hours before surgery then
20mg every 24 hours for 7-10 days; high risk,
40mg 12 hours before surgery then 40mg
every 24 hours for 7-10 days.
In general surgery, the first injection should
be given 2 hours before the surgical
procedure; in orthopaedic surgery, the first
injection is to be given 12 hours preoperatively.
Enoxaparin therapy is usually prescribed for
an average period of 7 to 10 days; longer
treat mdt duration may be appropriate in
•
QIMP-17 (82)
certain cases and the treatment should be
continued for as long as there is a risk of
venous thrombo-embolism and until the
patient is ambulatory.
Prevention ofextra corporeal thrombus during
haemodialysis: The recommended dose is
lmg/kg. Enoxaparin should be introduced in
the arterial line of the circuit at the beginning
of the dialysis session. The effect of this dose is
usually sufficient for a 4-hour session; in the
event, if fibrin rings are found, a further dose
of 0.5-lmg/kg may be given.
Treatment of established deep vein thrombosis:
A dose of lmg/kg should be given s.c every 12
hours. The duration of treatment should not
exceed a period of 10 days.
Treatment of unstable angina & non-Q-wave
myocardial infarction: a dose of lmg/kg should
be given s.c every 12 hours. The recommended
treatment should be prescribed for a period of
2 to 8 days, until clinical stabilization of the
patient. Enoxaparin should be administered
concurrently with aspirin (100 to 325mg daily
per oral route).
Elderly: No dosage adjustment is necessary in
preventive therapy; in curative therapy mea­
surement of anti-Xa activity is recommended.
Children: Enoxaparin in not recommended in
children.
Renal impairment: No dosage adjustment is
necessary at prophylactic doses, whereas
dosage adjustment is necessary and the
monitoring of anti-Xa activity is recommended
at curative doses.
Patients under 40kg and over 1 OOkg weight:
particular clinical surveillence is necessary in
order to adjust dosage if necessary.
Management of overdose: accidental
overdosage after s.c injection of massive doses
of enoxaparin could lead to bleeding
complications. Neutralization can be obtained
by slow i.v injection of protamine (lmg
protamine can be used to neutralize the
anticoagulant effect of lmg of enoxaparin).
Drug inter: In order to avoid possible
interactions not recommended combinations
(substances increasing the risk of haemorrhage)­
acetylsalicylic acid (and derivatives) at analgesic
and antipyretic doses, NSAIDs (general route),
ticlopidine, dextran 40 (parenteral use).
Combinations to be used with caution- oral
anticoagulant, thrombolytic drugs, acetylsalicylic
acid at anticoagulant platelet doses (in the treat­
ment of unstable angina & non-Q-wave myocar­
dial infarction}, glucocorticoids (general route).
t CARDINEX Inj. Drug Inter
Enoxaperin sodium 40mg (4000 IU)/ampoule,
60mg (6000 JU)/ampoule & 80mg (8000
IU)/ampoule: for s.c injection.
40mg (or 4000 IU) ampoule: 350.00 MRP
60mg (or 6000 IU) ampoule: 525.00 MRP
80mg (or 8000 JU) ampoule: 575.00 MRP
+ CLAXO Inj. General
Enoxaperin sodium 40mg (4000 IU)/0.4ml &
60mg (6000 IU)/0.6ml contained in ready-to-use
pre-filled syringe. It is a low molecular weight
heparin.
40mg (or 4000 IU) in 0.4ml pre-filled syringe:
325.00 MRP
60mg (or 6000 IU) in 0.6ml pre-filled syringe:
-
475.00 MRP
t CLEV EN Inj. Beximco
Enoxaperin sodium 20mg (2000 IU)/0.2ml, 40mg
(4000 IU)/0.4ml, 60mg (6000 IU)/0.6ml & 80mg
(8000 IU)/0.8ml contained in ready-to-use pre­
filled syringe. It is a low molecular weight
heparin.
20mg (or 2000 IU) in 0.2ml pre-filled syringe:
200.00 MRP
40mg (or 4000 IU) in 0.4ml pre-filled syringe:
350.00 MRP
60mg (or 6000 IU) in 0.6ml pre-filled syringe:
500.00 MRP
80mg (or 8000 IU) in 0.8ml pre-filled syringe:
550.00 MRP
+ CLEXANE Inj. Sanofi-aventis
Enoxaperin sodium 20mg (2000 IU)/0.2ml, 40mg
(4000 IU)/0.4ml, 60mg (6000 IU)/0.6ml & 80mg
(8000 IU)/0.8ml contained in ready-to-use
prefilled syringe. It is a low molecular weight
heparin.
20mg (or 2000 JU) in 0.2ml prefilled syringe:
425.06 MRP
40mg (or 4000 IU) in 0.4ml prefilled syringe:
743.06 MRP
60mg (or 6000 IU) in 0.6ml prefilled syringe:
1049.52 MRP
80mg (or 8000 IU) in 0.8ml prefilled syringe:
1343.38 MRP
t CLOTINEX Inj. Square
Enoxaperin sodium 40mg (4000 IU)/prefilled
syringe, 60mg (6000 IU)/prefilled syringe &
80mg (8000 IU)/prefilled syringe: s.c injection.
40mg (or 4000 IU) prefilled injection: 450.00 MRP
60mg (or 6000 IU) prefilled injection: 575.00 MRP
80mg (or 8000 IU) prefilled injection: 650.00 MRP
t ENOPARIN Inj. Popular
Enoxaperin sodium 40mg (4000 IU)/prefilled
syringe, 60mg (6000 IU)/prefilled syringe &
80mg (8000 IU)/prefilled syringe: s.c injection.
40mg (or 4000 IU) prefilled injection: 450.00 MRP
60mg (or 6000 IU) prefilled injection: 500.00 MRP
80mg (or 8000 IU) prefilled injection: 550.00 MRP
+ EPARIN Inj. Beacon
Enoxaperin sodium 60mg (6000 IU)/prefilled
syringe: s.c injection.
60mg (or 6000 IU) prefilled injection: 575.00 MRP
t INTRAVAS Inj. Aristopharma
Enoxaperin sodium 40mg (4000 IU)/0.4ml
ampoule, 60mg (6000 IU)/0.6ml ampoule &
80mg (8000 JU)/0.8ml ampoule: s.c injection.
40mg (or 4000 JU) in 0.4ml amp: 350.00 MRP
60mg (or 6000 IU) in 0.6ml amp: 525.00 MRP
80mg (or 8000 IU) in 0.8ml amp: 550.00 MRP
+ PARINOX Inj. Incepta
Enoxaperin sodium 20mg (2000 IU)/ampoule,
40mg (4000 IU)/ampoule & 60mg (6000
IU)/ampoule & 80mg (8000IU)/ampoule: for s.c
injection.
20mg (or 2000 JU) ampoule: 175.00 MRP
40mg (or 4000 IU) ampoule: 325.00 MRP
60mg (or 6000 IU) ampoule: 475.00 MRP
80mg (or 8000 IU) ampoule: 525.00 MRP
Oral Anticoagulants
WARFARJN21,26
WARFARIN: Tablet

Warfarin sodit1m is an anticoagulant that acts by
inhibiting the synthesis of vitamin K dependent
cloting factors, viz. Factors II, VII, IX and X .
Anticoagulant effect generally occurs within 24
hours after drug administration. This reaches a
maximum in 36-48 hours and is maintained for
48 hours or more after administration is stopped.
Warfarin sodium is widely used than others due
to less allergic side-effects.
Ind: Prophylaxis of embolisation in rheumatic
heart disease and atrial fibrillation; prophylaxis
after insertion of prosthetic heart valve;
prophylaxis & treatment of venous thrombosis &
pulmonary embolism; transient ischaemic attacks.
C/I: Actual or potential haemorrhagic conditions
e.g peptic ulcer; severe hypertension; severe
hepatic or renal disease; pregnancy; known
hypersensitivity to warfarin; bacterial endocardi­
tis. Its use within 24 hours following surgery or
labour should be undertaken with caution, it at all.
S/E: Haemorrhage is the principal adverse effect
of oral anticoagulants. Other adverse reactions
include nausea, vomiting, diarrhoea, hypersen­
sitivity, rash, alopecia, and unexplained drop in
I
haematocrit, 'pwple toes', skin necrosis, jaundice,
and hepatic dysfunction.
Cautions & Warnings: Hepatic or renal disease,
recent surgery.
Periodic determination of prothrombin time
(PT)/intemational normalized ratio (INR) or
other suitable coagulation test is essential. It is
generally good practice to monitor the patient's
response with additional PT/INR determination
in the period immediately after discharge from
the hospital and whenever other medications are
initiated, discontinued or taken irregularly.
Careful additional laboratory control is necessary
if the patient is to be changed from one
formulation to another. Reversal of warfarin
anticoagulation by vitamin K takes several days.
In emergency situations fresh frozen plasma
should be given.
Pregnancy & lactation: Warfarin is contraindi­
cated in the frrst trimester of pregnancy because
of the risk of teratogenicity. It should not be used
in women who are or may become pregnant
because the drug passes through the placental
barrier and may cause fatal haemorrhage to the
foetus. Warfarin appears in the milk of nursing
mothers in an inactive form. Infants nursed by
mothers treated with warfarin had no change in
prothrombin times. Effects in premature infants
have not been evaluated.
Dosage & Admin: The base-line prothrombin
time should be deter1nined before the initial
dose of warfarin is given, whenever is possible.
The usual adult induction dose of warfarin is
1 Omg daily for 2 days. The initial dose should
be reduced if base-line prothrombin time is
prolonged, the liver-function tests are
abnormal or if the patient is in cardiac failure,
is on parenteral feeding less than average
body weight, or over 80 years of age.
The subsequent maintenance dose must
depend upon the prothrombin time and is
usually 3-9mg daily and should be taken at the
same time each day. The mainte-nance dose is
omitted if the prothrombin time is excessively
prolonged. Once the maintenance dose is
established in the therapeutic range, it is
•
QIMP-17 (83)
rarely necessary to alter. In emergencies,
anticoagulant therapy should be initiated with
heparin and warfarin together. Where there is
less urgency, as in patients disposed to or at
special risk of thromboembolism, anticoagu­
lant therapy may be initiated with warfarin
alone. Control tests must be made at regular
intervals and maintenance dosage should be
adjusted every time according to the results
obtained.
Use in children: Safety and efficacy in child­
ren <18 years old have not been established.
However, there is evidence of use and the
initial dose in usually O.lmg/kg/day adjusted
subsequently to aim for an INR (international
normalized ratio) range the same as in adults.
Drug Inger: Oral anticoagulants have a greater
potential for clinically significant drug interac­
tions. Warn all patients about potential hazards
and instruct against taking any drug, including
non-prescription products, without the advice of
a physician.
Overdosage: If haemorrhage occurs or a poten­
tial bleeding state arises, excessive depression of
the coagulation activity can be corrected by
temporary withdrawal of warfarin accompanied,
if necessary, by infusion of fresh-frozen plasma
or whole blood. Vitamin K, 5 to 1 Omg orally or
intravenously, may be required to supplement
specific treatment with factor concentrates .
t FARE VAN Tab. Gaco
Warfarin sodium 5mg/tablet
lOO's pack: 304.00 MRP
+ WARIN Tab. lncepta
Warfarin sodium 5mg/tablet
1OO's pack: 300.00 MRP
8. ANTIPLATELET DRUGS
Antiplatelet drugs, that act by decreasing platelet
aggregation and thus inhibiting thrombus
formation on the arterial side of the blood
circulation. These include- Aspirin, Clopidogrel,
Dipyridamole, 1iclopidine. 21
.
ASPIRIN42,s2
ASPIRIN: Tablet
Aspirin (or acetyl salicylic acid) is a potent
analgesic, antipyretic & anti-inflammatory drug
belonging to the NSAID group. It also has got
antiplatelet & antithrombotic action & hence
used in the treatment of coronary & cerebro­
vascular diseases. For vascular disorder, it is
available as 75mg & lOOmg enteric-coated tablet.
Mode of action: The antithrombotic action of
aspirin is mediated through inhibition of platelet
activation. Aspirin acts by causing irreversible
inhibition of the cyclooxygenase (COX-I)
enzyme, which is responsible for the formation
of thromboxane A2 from arachidonic acid and
this thromboxane A2 is ultimately
responsible for platelet aggregation through a
series of reactions.
Ind: Prophylaxis of cerebrovascular disease or
myocardial infarction; to reduce the risk of
myocardial infarction in patients who have had a
previous attack or in patients with t1nstable
CARDIOVASCULAR DRUGS
angina. Prevention of graft occlusion following
aortocoronary by-pass surgery.
C/I: Children under 12 years (unless specially
indicated) and in breast feeding mother, active
peptic ulceration, haemophilia and other bleeding
disorders. Aspirin should not be given to patients
with asthma.
S/E: Side-effects are mild for usual dosage of
aspirin. These are nausea, dyspepsia,
gastrointestinal ulceration & bronchospasm.
Aspirin may induce gastric irritation and
gastrointestinal haemorrtage. There may be skin
reactions in hypersensitive patients. Prolonged
administration may give rise to hearing
disturbances·, such as tinnitus.
Precautios: Aspirin should be administered
cautiously in uncontrolled blood pressure & in
patients with history of brochospasm or asthma
(if clearly needed); impaired renal or hepatic
function; dyspepsia & dehydration.
It should be given with caution to patients with
nasal polyps and nasal allergy.
Pregnancy & lactation: It is evident that aspirin
is safe in pregnancy, but it may prolong labour
and contribute to maternal and neonatal bleeding
and is best avoided in the last trimester of
pregnancy unless recommended by the
physician. Aspirin is excreted in low
concentration in breast milk, but is 11nlikely to
cause adverse effect to the breast-fed infant.
Dosage & Admin: Thrombotic cerebrovascular
or cardiovascular disease: 7Smg tablet 1 to 4
daily.
Myocardial infarction: 7Smg tablet 1 to 2 daily.
Followig by-pass surgery: 7Smg tablet daily or
as directed by the physician.
Children: Not to be given to children under 12
years, unless the expected benefits outweigh
the possible risks.
Drug Inter: Aspirin may enhance the effects of
anticoagulants, oral hypoglycaemics and
methotrexate and decreases the action of
uricosuric drugs.
+ ANGIN Tab. Pharmadesh
Aspirin 75mg/tablet
1OO's pack: 50.00 MRP
t. ASORIN-75 Tab. Kemiko
Aspirin 75mg/tablet (e.c)
1OO's pack: 50.00 MRP
+ CAID Tab. Jayson
Aspirin 75mg/tablet (enteric coated)
75mg x 1OO's pack: 50.00 MRP
+ CARVA Tab. Square
Acetylsalicylic acid 75mg/tablet (enteric coated)
200's pack: 114.00 MRP
t ECOSPRIN Tab. Acme
Aspirin 75mg/tablet (enteric coated)
75mg x lOO's pack: 58.00 MRP
t ENCOPRIN L.D Tab. Medimet
Aspirin 75mg/tablet (low dose).
70's pack: 35.00 MRP
t ERAS-75 Tab. UniMed & UniHealth
Aspirin 75mg/tablet (e.c)
75mg x lOO's pack: 57.00 MRP
+ G-ASPIRIN Tab. Gonoshas.
Aspirin 1OOmg & 300mg/tablet (e.c)
1OOmg x 1OO's pack: 30.00 MRP
300mg x 1OO's pack: 20.00 MRP
t MYSPRIN Tab. Pacific
Aspirin 75mg/tablet (e.c)
CARDIOVASCULAR DRUGS

lOO's pack: 50.00 MRP clopidogrel 75mg/tablet Clopidogrel bisulphate INN equivalent to
+SOLRIN Tab. Opsonin 30's pack: 300.00 MRP clopidogrel 75mg/tablet
Aspirin 75mg/tablet +ANPLAT Tab. RAK Pharma 20'.s pack: 200.00 MRP
75mg x lOO's pack: 43.98 MRP Clopidogrel bisulphate INN equivalent to +LIREL 75 Tab. Silva
clopidogrel 75mg/tablet Clopidogrel bisulphate INN equivalent to
30's pack: 300.00 MRP clopidogrel 75mg/tablet
CLOPIDOGREL 87
+ANTIPLET Tab. Rangs Pharma 20's pack: 200.00 MRP • • ;
. '•
,

Clopidogrel bisulphate INN equivalent to +LIVOCARD Tab. White Horse

CLOPIDOGREL: Tablet
clopidogrel 75mg/tablet Clopidogrel bisulphate INN equivalent to
Clopidogrel is a thienopyridine derivative, and is
30's pack: 300.00 MRP clopidogrel 75mg/tablet
effective as an antiplatelet agent. It is available as
+APT 75 Tab. Sharif 30's pack: 360.00 MRP
tablet of clopidogrel bisulphate INN 97 .88mg
Clopidogrel bisulphate INN equivalent to +LOPIREL Tab. Incepta
equivalent to clopidogrel 7 5mg.
clopidogrel 75mg/tablet Clopidogrel bisulphate INN equivalent to
Mode of action: Clopidogrel is an inhibitor of
20's pack: 200.00 MRP clopidogrel 75mg/tablet
platelet aggregation. It acts by interfering with
+C ARDOGREL Tab. Pharmasia 30's pack: 300.00 MRP
the platelet activation cascade. It blocks the acti­
Clopidogrel bisulphate INN equivalent to +NOCLOG Tab. SK+F
vation of platelets by adenosine diphosphate
clopidogrel 75mg/tablet Clopidogrel bisulphate INN equivalent to
(ADP) receptor selectively and irreversibly
20's pack: 200.00 MRP clopidogrel 75mg/tablet
inhibiting the binding of the glycoprotein GP llb­
+CLA\'IX Tab. Techno Drugs 20's pack: 240.00 MRP
Illa complex, the major receptor for fibrinogen
Clopidogrel bisulphate INN equivalent to +ODREL Tab. Beximco
present in the platelet surface. Clopidogrel may
clopidogrel 75mg/tablet Clopidogrel bisulphate INN equivalent to
antagonize the ADP induced inhibition of adeny­
30's pack: 300.00 MRP clopidogrel 75mg/tablet •

late cyclase possibly resulting in an elevated

+ CLOGNIL Tab. Orion Pharma 1O's pack: 120.00 IP
platelet cyclic adenosine monophosphate level
Clopidogrel bisulphate INN equivalent to 30's pack: 360.00 IP
after stimulation by an appropriate agonist.
clopidogrel 75mg/tablet +PLADEX Tab. UniMed & UniHealth
Ind: Clopidogrel is used for the reduction of ath­
30's pack: 330.00 MRP Clopidogrel bisulphate INN equivalent to
erosclerotic events in patients with atherosclero­
+CLOGREL Tab. Ad-din clopidogrel 75mg/tablet
sis documented by recent stroke, recent myocar­
Clopidogrel bisulphate 75mg/tablet 30's pack: 360.00 MRP
dial infarction or with established peripheral
45's pack: 405.00 MRP +PLAGRIN Tab. Renata
arterial disease. The major indications are­
+CLONT Tab. Opsonin Clopidogrel bisulphate INN equivalent to
stroke, myocardial infarction, peripheral vascular
Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet (film coated).
diseases.
clopidogrel 75mg/tablet 20's pack: 200.80 MRP
C/I: Known case of hypersensitivity to the drug;
30's pack: 316.69 MRP t PLATREL Tab. Sandoz
active pathological bleeding such as peptic ulcer
+CLOPID Tab. Drug Inter. Clopidogrel bisulphate INN equivalent to
or intracranial haemorrhage.
Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet (film coated).
S/E: Very rarely hypersensitivity reactions, such
clopidogrel 75mg/tablet 30's pack: 375.00 MRP
as- angioedema, bronchospasm and anaphylactic
30's pack: 360.00 MRP +PLAVIX Tab. Navana
reactions. The clinical adverse reactions are as
+ CLOPIDOL Tab. Alco Pharma Clopidogrel bisulphate INN equivalent to
gastro-intestinal haemorrhage, agranulocytosis,
Clopidogrel bisulphate equivalent to clopidogrel clopidogrel 75mg/tablet (film coated).
dyspepsia, gastritis, diarrhoea, rash, palpitation
75mg/tablet 30's pack: 301.20 IP
and vomiting.
30's pack: 300.00 MRP +PRECLOT Tab. Popular
Precautions: Clopidogrel should be used with
+ CLOPIGEL Tab. Pacific Clopidogrel bisulphate INN equivalent to
caution in patients who may be at risk of
Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet (film coated).
increased bleeding from trauma, surgery or other
clopidogrel 75mg/tablet 30's pack: 360.00 MRP
pathological onditions.
30's pack: 273.00 MRP +REPLET Tab. Healthcare
Pregnancy & lactation: No adequate and well­
+CLOPILET Tab. Sun Pharma Clopidogrel bisulphate INN equivalent to
controlled studies have been done in pregnant &
Clopidogrel bisulphate INN equivalent to clopidogrel 75mg/tablet (film coated).
lactating women. Hence, during pregnancy,
clopidogrel 75mg/tablet 30's pack: 300.00 MRP
clopidogrel is only used if it is clearly needed &
50's pack: 552.50 MRP
in lactation, usually not recommended. •

+CLOPIREL Tab. Novo Healthcare

Dosage & admin: 75mg once daily with or
without food. No dosage administra-tion
adjustment is necessary for elderly patients or
patients with renal disease.
Children: Not recommended.
Drug inter: Aspirin does not modify the
clopidogrel mediated inhibition of ADP-induced
platelet aggregation. Concomitant administration
of clopidogrel with NSAIDs such as naproxen is
associated with gastro-intestinal blood loss. No
clinically significant interactions have been
observed when clopidogrel is co-administered
with atenolol, nifedipine or both atenolol and
nifedipine.
PRASUGREL 26 •52
Clopidogrel bisulphate INN equivalent to
clopidogrel USP 75mg/tablet
PRASUGREL: Tablet
30's pack: 300.00 MRP
Prasugrel hydrochloride is a thienopyridine class
+CLOREL Tab. ACI
of product, which is an antiplatelet agent. It is
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg/tablet available as prasugrel hydrochloride INN equiva­
30's pack: 301.20 MRP lent to prasugrel 5mg & 1Omg in tablet form.
Mode of action: Prasugrel is an inhibitor of
+DCLOT Tab. Acme
Clopidogrel bisulphate INN equivalent to platelet activation and aggregation through the
clopidogrel 75mg/tablet irreversible binding of its active metabolite to the
30's pack: 301.20 MRP P2Y12 class of adenosine diphosphate ( ADP)
receptors on platelets.
+DOGREL Tab. Astra
Clopidogrel bisulphate INN equivalent to Ind: Prasugrel is indicated to reduce the rate of
clopidogrel 75mg/tablet thrombotic cardiovascular (CV) events (including

I O's pack: 100.00 MRP stent thrombosis) in patients with acute coronary
+ANCLOG Tab. Square syndrome (ACS) who are to be managed with
Clopidogrel bisulphate INN equivalent to +DOREL Tab. General
percutaneous coronary intervention (PCI) as
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg/tablet following:
clopidogrel 75mg/tablet
30's pack: 360.00 MRP i. Patients with unstable angina (UA) or non­
30's pack: 301.20 MRP
+ANLET-75 Tab. Globe ST-elevation myocardial infarction (NSTEMI).
Clopidogrel bisulphate INN equivalent to +FREE Tab. Nipa ii. Patients with ST-elevation myocardial

infarction (STEMI) when managed with
primary or delayed PCI.
C/I: Active pathological bleeding, such as- peptic
ulcer or intracranial hamorrhage. Patient with a
history of prior transient ischemic attack or stroke
S/E: Bleeding; thrombotic thrombocytopenic
purpura. Other side effects include- headache,
back pain, dyspn.ea, nausea, hypertension,
bradycardia, rash etc.
�recaution: CABG-related bleeding: Risk
increases in patie11ts receiving prasugrel who
undergo CABG .
Discontinuation of prasugrel: Premature
discontinuation increases risk of stent
thrombosis, Ml, and death.
Pregnancy & lactation: Pregnancy category B.
-
,,.
There are no adequate and well-controlled
studies of prasugrel use in pregnant women.
Reproductive and developmental toxicology
studies in rats and rabbits at doses of up to 30
times the recommended therapeutic exposures in
humans revealed no evidence of fetal hann;
however, ani1nal studies are not always
predictive of a human response.
I
It is not known whether prasugrel is excreted in
human milk. Because many drugs are excreted in
human milk, prasugrel should be used during
nursing only if the potential benefit to the mother
justifies the potential risk to the nursing infant.
Dosage & admin: Treatment should be
initiated with a single 60mg oral loading dose.
Continue at lOmg once daily with or without
food. Consider Smg once daily for patients < prasugrel 5mg & 1Omg/tablet.
60kg. Patients should also take aspirin (75mg
to 325mg) daily.
Geriatric use: Patients'> 75 years of age who
received prasugrel had an increased risk of
fatal bleeding events (1.0°/o) compared to
patients who received clopidogrel (0.1°/o ).
Hepatic & Renal impairment: No dosage
adjustment is necessary for patients with mild
to moderate hepatic & renal impairment.
There is limited experience in patients with
end-stage renal disease.
Drug inter: Coadministration of prasugrel and
warfarin increases the risk of bleeding.
Coadministration of prasugrel and NSAIDs (used
chronically) may increase the risk of bleeding.
Prasugrel can be administered with drugs that are
inducers or inhibitors of cytochrome P450
enzy1nes. Prasugrel ca.n be administered with
aspirin (75mg to 325mg per day), heparin,
GPllb/IIla inhibitors, statins, digoxin, and drugs
that elevate gastric pH, including proton pump
inhibitors and H2 blockers.
Note: For further information, please contact
manufacturer's literature.
t ASUREL Tab. Navana
Prasugrel hydrochloride 5mg & 1Omg/tablet.
5mg x 30's pack: 360.00 MRP
IOmg x 20's pack: 400.00 MRP
t APAGREL Tab. Healthcare
Prasugrel hydrochloride 5mg & l Omg/tablet.
5mg x 30's pack: 360.00 MRP
lOmg x 30's pack: 600.00 MRP
t EFIGREL Tab. Square
Prasugrel hydrochloride TNN equivalent to
prasugrel 5mg & lOmg/tablet.
5mg x 20's pack: 240.00 MRP
lOmg x 20's pack: 400.00 MRP
•
QIMP-17 (85)
t EFIREL Tab. Opsonin
Prasugrel hydrochloride INN equivalent to
prasugrel 5mg & 1Omg/tablet.
5mg x 20's pack: 211. l 3 MRP
lOmg x 10's pack: 175.94 MRP
t HEMAGREL Tab. ACI
Prasugrel hydrochloride INN equivalent to
prasugrel 5mg & 1 Omg/tablet.
5mg x 30's pack: 360.00 MRP
lOmg x 20's pack: 400.00 MRP
t OPAGREL Tab. Orion Pharma
Prasugrel hydrochloride INN equivalent to
prasugrel 5mg & l Omg/tablet.
5mg x 30's pack: 240.00 MRP
IOmg x 30's pack: 450.00 MRP
t PRAPID Tab. Drug Inter.
Prasugrel hydrochloride INN equivale11t to
prasugrel 5mg & 1Omg/tablet.
5mg x 20's pack: 240.00 MRP
l 01ng x 1O's pack: 200.00 MRP
t PRASULET Tab. Beacon
Prasugrel hydrochloride INN . equivale11t to
prasugrel 5mg & 1 Orng/tablet.
5mg x 30's pack: 358.64 MRP
lOmg x 30's pack: 598.58 MRP
t PRASUREL Tab. Incepta
Prasugrel hydrochloride INN equivalent to
prasugrel 5mg & 1Omg/tabJet.
5mg x 30's pack: 360.00 MRP
lOmg x 20's pack: 400.00 MRP
t PRASUVA Tab. Beximco
Prasugrel hydrochloride INN equivalent to
5mg x 30's pack: 360.00 MRP
1Omg x 20's pack: 400.00 MRP
CLOPIDOGREL + ASPIRIN26
CLOPIDOGREL +ASPIRIN: Tablet
This is a fixed-dose combination formula
comprising clopidogrel and aspirin; both are
acting as antiplatelet agent. The preparation is
available as film-coated tablet, each containing
clopidogrel bisulphate TNN 97.88mg equivalent
to clopidogrel 75mg and aspirin BP 75mg
Mode of action: See under the text of
clopidogrel and aspirin separately.
Ind: This combined preparation is indicated for
the reduction of thrombotic events as in: i.
Recent MI, recent stroke or established
peripheral arterial disease; ii. Acute coronary
syndro1ne (unstable angina/non-Q-wave Ml).
C/I: Hypersensitivity to clopidogrel or aspirin or
any NSAID. Recent history of gastrointes-tinal
bleeding. Active pathological bleeding such as
peptic ulcer or intracranial hemorrhage, or
bleeding disorders like hemophilia.
S/E: The drug is generally well tolerated. Side
effects that have been reported are- abdominal
pain, dyspepsia, gastritis, dia11·hea, nausea,
vomiti11g, constipation, gastrointestinal
hemorrhage, ulceration, neutropenia, rash,
palpitation, syncope, drowsiness, asthenia,
neuralgia, paresthesia and vertigo.
Precautions: General: As with other anti-platelet
agents, this combination drug should be used
with caution in patients who may be at risk of
increased bleeding from trauma, surgery, or other
pathological conditions. If patient is to undergo
elective surgery and an anti-platelet effect is not
CARDIOVASCULAR DRUGS
desired, this drug should be discontinued 7 days
prior to surge1y.
GI bleeding: The combination of clopidogrel and
aspirin prolongs the bleeding time. So, it should
be used with caution in patients who have lesions
with a propensity to bleed (such as ulcers).
Thrombotic th.rombocytopenic purpura (TTP):
TTP has been reportedrarely following use of
clopidogrel.
Re.ve'j' syndrome: Reye's syndrome may develop
in individuals who have chicke11 pox, influenza
or flu symptoms. This co1nbination is not
recommended for use in patients with chicken
pox, influenza or tlu symptoms.
Nasal polyps or nasal allergies: The
combination drug of clopidogrel and aspirin
should be administered with caution in patients
with nasa] polyps or nasal allergies.
Hepatic or rerial impairment: This should be
avoided in patients with impaired hepatic and
renal function. Aspirin causes sodium and water
retention in patients with rena] impairment and
increases the risk of gastrointestinal bleeding.
Pregnancy & lactation: Asdverse effects are
increased in the mother a.nd the fetus following
chronic ingestion of aspirin. Because of possible
adverse effects on the neonate and the potential
for increased maternal blood loss, this
combination should be avoided during the last
three months of pregnancy. This product should
also be avoided in nursing mothers because of
the possible risk of developing Reye's syndrome.
Regular use of high doses of aspirin could impair
platelet function & produce hypoprothrombinemia
in infants if neonatal vitamin K levels are low.
Dosage & admin: Recent Ml, recent stroke, or
established peripheral arterial disease: The
recommended daily dose of this combined
preparation (75mg + 75mg) is one tablet daily.
Acute coronary syndrome: In acute coronary
syndrome (unstable angina/non-Q-wave Ml),
the dose should be initiated with a 4 tablet stat
loading dose and then continued at one tablet
daily.
Pediatric use: Not recommended.
Drug inter: Given under the text of aspirin and
clopidogrel separately.
t ANCLOG Plus Tab. Square
Clopidogrel bisulphate INN equivalent to clopi­
dogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 360.00 MRP
t ASCLOP Tab. Biopharma
Clopidogrel bisulphate INN equivalent to clopi­
dogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 375.00 MRP
+ ASPIN Plus Tab. Aristopharma
Clopidogrel bisulphate INN equivalent to clopi­
clogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 330.00 MRP
t C ARDOGREL Plus Tab. Pharmasia
Clopidogrel bisulphate INN equivalent to clopi­
dogrel 7.5mg & aspirin BP 75mg/tablet (f.c)
20's pack: 220.00 MRP
+ CLAS Tab. Delta Pharma
Clopidogrel bisulphate INN equivalent to clopi­
dogrel 75mg & aspirin BP 75mg/tablet (film­
coated).
20's pack: 160.00 MRP
t CLOGNIL Plus Tab. Orion Pharma
Clopidogrel bisulphate INN equivalent to clopi-

CARDIOVASCULAR DRUGS
dogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 360.00 MRP
t CLONTAS Tab. Opsonin
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 290.15 MRP
t CLOPID-As Tab. Drug Inter.
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 360.00 MRP
t CLOPIDOL Plus Tab. Alco Pharma
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
20's pack: 240.00 MRP
t CLOPIGEL Plus Tab. Pacific
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 300.00 MRP
t CLOPILET A Tab. Sun Pharma
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 330.00 MRP
t CLOREL-A Tab. ACI
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 331.20 MRP
Clopidogrel 75 mg & Aspirin 75 mg tablet
it
t DOGREL Plus Tab. Astra
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
lO's pack: 110.00 MRP
t DOREL Plus Tab. General
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
20's pack: 220.80 MRP
t ECOSPRIN Plus Tab. Acme
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 331.20 MRP
t LIREL Plus Tab. Silva
Clopidogrel bisulphate INN equivalent to
•
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 331.00 MRP
t LIVOCARD Plus Tab. White Horse
Clopidogrel bisulphate INN equivalent to clopi
dogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 360.00 MRP
t LOPIREL Plus Tab. Incepta
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 360.00 MRP
t LOPLATE Plus Tab. Kemiko
QIMP-17 (86)
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 330.00 MRP
t NOCLOG Plus Tab. SK+F
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
20's pack: 240.00 MRP
t ODREL Plus Tab. Beximco
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 360.00 IP
t PLADEX-A Tab. UniMed & UniHealtb
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 375.00 MRP
t PLAGRIN Plus Tab. Renata
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
20's pack: 220.80 MRP
t PLAVIX Plus Tab. Navana
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 361.50 MRP
t PRECLOT AS Tab. Popular
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 360.00 MRP
t REPLET PLUS Tab. Healthcare
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 330.00 MRP
t ZESPRIN Tab. Zenith
Clopidogrel bisulphate INN equivalent to
clopidogrel 75mg & aspirin BP 75mg/tablet (f.c)
30's pack: 330.00 MRP
9. FIBRINOLYTIC DRUGS
STREPTOKINASE21,60
STREPTOKINASE: Injection
Ind: Deep-vein thrombosis, pulmonary
embolism, acute arterial thromboem-bolism,
thrombosed arteriovenous shunts; acute myocar­
dial infarction.
C/I: Recent haemorrhage, trauma, or surgery
(including dental extraction), coagulation defects,
bleeding diatheses, history of cerebrovascular
disease specially recent events or with any resid­
ual disability, recent symptoms of possible peptic
•
I'"
ulceration, heavy vaginal bleeding, severe
hypertension, pulmonary disease with cavitation,
acute pancreatitis, diabetic retinopathy, severe
liver disease, oesophageal varices. In the case of
streptokinase previous allergic reactions to drug,
or therapy with the drug from 5 days to 12
months previously.
S/E: Side-effects are mainly mausea and
vomiting and bleeding. Back pain has been
reported. Bleeding is usually limited to the site of
infection, but intracerebral haemorrhage or
bleeding from other sites may occur. Serious
bleeding ca
. lls for discontinuation of the drug
and may require administration of coagulation
factors and antifibrinolytic drugs (aprotinin or
tranexamic acid). Streptokinase may cause
allergic reactions & anaphylaxis has been reported.
Cautions: risk of bleeding from venepuncture or
invasive procedures, any external chest
compression, pregnancy, possibility of pre­
existing thrombus as in abdominal aneurysm or
enlarged left atrium with atrial fibrillation (risk of
dissolution of clot and subsequent embolisation),
recent or concurrent anticoagulant therapy.
Dosage & admin: B y intravenous infusion,
rotection
250,000 units over 30 minutes, then 100,000
units ever y hour for up to 24-72 hours
according to condition. M yocardial infarction,
1500,000 units over 60 minutes followed by
aspirin 150mg daily by mouth for at least 4
weeks.
t DURAKINASE lnj. Dong Kook/Hyeimpex
Streptokinase powder (for reconstitution),
1.5 million unit/vial: injection.
1.5 million unit vial: 3252.95 MRP
t STREPTASE lnj. Sanofi-aventis
Streptokinase powder (for reconstitution),
1.5 million unit/vial: injection.
1.5 million unit vial: 3757.01 MRP
(_
t S-KINASE Inj. Popular
Streptokinase powder (for reconstitution),
1.5 million unit/vial: injection.
1.5 million unit vial: 3400.00 MRP
10. ANTIFIBRINOLYTIC/
C OAGULANT/
HAEMOSTATIC DRUGS

ADRENOCHROME
MONOSEMICARBAZONE21,40
t ANAROXYL Tab. Nuvista
Adrenochrome monosemicarbazone 2.5mg/tablet
Ind: Haemorrhagic disorder.
Dose: Orally, 1-2 tablets 3 times daily.
30's pack: 590.70 MRP
t ANAROXYL Inj. Nuvista
Adrenochrome monosemicarbazone 5mg/ lml
ampoule: injection.
Ind: Haemorrhagic disorder.
Dose: By i.m. injection 1 amp. once to thrice
daily, for medical haemorrhage.
5 amps.pack: 333.50 MRP
AMINOCAPROIC AC1D21,31
AMINOCAPROIC ACID: Injection
It is an effective antifibrinolytic haemostatic
agent.
Ind: All haemorrhagic syndromes due to
enhanced fibrinolysis; post-partum & other
obstetric haemorrhages with hyperfibrinolytic
pathogenesis; haemorrhages after prostate,
cardiac, pulmonary & other surgical procedures
& haemophilia & dental extraction.
C/I: Thromboembolic diseases, arterial & venous
thrombosis; early pregnancy.
S/E: Fatigue, conjunctiva} occlusion, pruritus,
skin rashes. After oral adrii in.- nausea,
diarrhoea, dizziness; if hypersen-sitization., avoid
or stop treatment..
Cautions: Renal impairment; it is advisable to
avoid in pregnancy (as
transplacental transit occurs) particularly in frrst
& 2nd trimester.
Dose: Usual dose is 4-Sgm initially i.v. (or
orally) followed by 1.2Sgm/hour until bleeding
is controlled. The total dose should not exceed
30gm in 24 hours. The average dose is 8-16gm
a day & is to be given as 1-2 amps. 6 hourly.
Rapid i.v. admin. should be avoided to prevent
hypotension, bradycardia & other
arrhythmias.
t CAPROLEX Inj. Techno Drugs
Aminocaproic acid 1gm in Sml & 2gm in 1Om1
ampoule: injection
5ml ( l gm) amp x 5's pack: 125.00 MRP
1Oml (2gm) amp x S's pack: 175.00 MRP
t E-CAPRO Inj. Edruc
Aminocaproic acid 2gm in 1Oml ampoule: injection
lOml (2gm) amp x 6's pack: 210.00 MRP
t HEMOSIN Inj. Chemist
Aminocaproic acid 1gm in 5ml ampoule: injection
10 amps pack: 151.70 MRP
•
PHYTOMENAD IONE 21·26, 50
(Natural Vit.-K)
PHYTOMENADIONE: Injection
Phytomenadione is a natural vitamin Kl . It is
I
QIMP-17 (87)
available in injection form for oral, intramuscular
and intravenous use.
Mode of action: Phytomenadione (Vitamin Kl )
is a procoagulant factor. As a component of a
hepatic carboxylase system, Vitamin Kl is
involved in the post-translational carboxylation
of clotting factors II (Prothrombin), VII, IX and
X and the clotting inhibitors protein C and
protein S. Coumarins inhibit the reduction of
Vitamin Kl (quinone form) to Vitamin Kl
(hydroquinone) and also prevent the Vitamin K1
epoxide arising after carboxylation from being
reduced to the quinone form.
Vitamin Kl is an antagonist of coumarin-type
anticoagulants, e.g. Phenprocoumon. It does not,
however, neutralise the activity of Heparin;
Protamine is the antagonist of Heparin.
Vitamin Kl is ineffective in hereditary hypopro­
thrombinemia or hypoprothrombinemia induced
by severe hepatic failure.
Lack of Vitamin K1 leads to an increased tenden­
cy to haemorrhagic disease in the newborn.
Vitamin Kl administration, which promotes syn­
thesis of the above-mentioned coagulation factors
by the liver, can reverse an abnormal coagulation
status and bleeding due to vitamin Kl deficiency.
Ind: I . Haemorrhage or risk of haemorrhage as a
result of severe 'hypoprothrombinemia' (i.e. defi­
ciency of clotting factors II, VII, IX and X) of
various etiologies, including overdosage of cour­
marin-type anticoagulants, their combination
with Phenylbutazone, and other forms of hypovi­
taminosis K (e.g in obstructive jaundice as well
as liver and intestinal disorders, and after pro­
longed treatment with antibiotics, sulphonamides
or salicylates).
2. Prophylaxis & treatment of haemorrhagic
diseases of the newborn (synthetic analogues of
vita-k, should be avoided in newborn because of
the risk of kemicterus).
Caution: Anaphylactoid reactions may occur
with parenteral administration.
Dosage & admin: By mouth: Adults, 10-20mg,
max. 40mg in 24 hours. Children: Neonates,
lmg; over 3 months, S-lOmg.
By injection: Adults, 10-20mg i.m or slow i.v,
maximum 40mg in 24 hours.
Children: Neonates, lmg i.m; over 3 months,
S-lOmg.
t BABYKION Oral/IM/IV lnj. Chemist
Phytomenadione 2mg/0.2ml ampoule: injection
2mg amp x 5's pack: 100.00 MRP
t DINAKION-10 Oral/IM/IV lnj. Drug Inter.
Phytomenadione lOmg/lml ampoule: injection
IOmg amp x 5's pack: 225.00 MRP
t DINAKION-MM Pediatric Oral/IM/IV lnj.
Drug Inter.
Phytomenadione 2mg/0.2ml ampoule: injection
2mg amp x 5's pack: 99.45 MRP
+ K MM Oral/IM/IV lnj. Incepta
Phytomenadione IOmg/lml ampoule: injection
IOmg amp x 5's pack: 229.30 MRP
+ K MM Pediatric Oral/IM/IV lnj. Incepta
Phytomenadione 2mg/0.2ml ampoule: injection
.9'-nN
���;���At�
-
ACME
2mg amp x 5's pack: 99.45 MRP
t KONAKION Inj. Roche/Radiant
Phytomenadione 2mg/0.2 ml ampoule & I Omg
per 1ml ampoule: injection
2mg amp (0.2ml) x 5's pack: 490.00 TP
lOmg amp ( l ml) x S's pack: 511.00 TP
+ K-ONE MM Inj. Square
Phytomenadione 2mg/ 0.2ml ampoule: injection
2mg (0.2ml) amp x 3's pack: 59.67 MRP
TRANEXAMIC ACID 21,33
TRANEXAMIC ACID: Tablet/Capsule/
Injection
Mode of action: It acts by inhibiting plasminogen
activation & fibrinolysis.
Ind: Tranexamic acid is useful in haemorrhage in
prostatectomy, dental extraction in haemophiliacs
or menorrhagia; also used in hereditary
angioedema & in streptokinase overdose.
C/I: Thromboembolic disease.
S/E: Nausea, vomiting, diarrhoea (reduce dose);
giddiness on rapid intravenous injection.
Cautions: Reduce dose in renal impairment;
·
massive haematuria (avoid if risk of ureteric
obstruction); regular eye examination and liver
function tests in long-term treatment of
hereditary angioedema.
Dose: Orally, 1-1.Sgm 2-4 times daily. By slow
intravenous injection, O.S-lgm 3 times daily.
t ANAXYL Tab. ACI
Tranexamic acid 500mg/tablet
500mg x 20's pack: 400.00 MRP
t ANAXYL Inj. ACI
Tranexamic acid 500mg/5ml ampoule: slow i.v
injection
500mg x 5 amps pack: 250.95 MRP
t BIONEX Cap. Biopharma
Tranexamic acid 500mg/capsule
500mg x 20's pack: 320.00 MRP
t ENCLOT Cap. Opsonin
Tranexamic acid 500mg/capsule
500mg x 20's pack: 264.97 MRP
t ENCLOT Inj. Opsonin
Tranexamic acid 500mg/5ml ampoule: slow i.v
injection
500mg x 5 amps pack: 220.76 MRP
t FIBRINO Cap. SK+F
Tranexamic acid 500mg/capsule
500mg x l 8's pack: 270.00 MRP
t FIBRINO Inj. SK+F
Tranexamic acid 500mg/5ml ampoule: slow i.v
injection
500mg x 5 amps pack: 250.00 MRP
t FIBROSTAT Cap. Globe
Tranexamic acid 500mg/capsule
500mg x 20's pack: 300.00 MRP
t FIBROSTAT lnj. Globe
•••
•••
l�D www.squarepharmacom.bd •••
...,..

ACME
Tranexamic acid 500mg/5ml ampoule: slow i.v
injection
500mg x 5 amps pack: 225.00 MRP
+ FRABEX Cap. Square
Tranexamic acid 500mg/capsule
500mg x 20's pack: 241.00 MRP
+ FRABEX lnj. Square
Tranexamic acid 500mg/5ml ampoule: slow i.v
1nJect1on
• • •
500mg x 6 amps pack: 240.90 MRP
+ HEMOSTAT Cap. Aristopharma
Tranexamic acid 500mg/capsule
500mg x 20's pack: 300.00 MRP
+ HEMOSTAT Inj. Aristopharma
Tranexamic acid 250mg/5ml ampoule: injection
250mg x 5 amps pack: 150.00 MRP
+ HEMOSTOP Cap. Apex
Tranexamic acid 500mg/capsule
500mg x 20's pack: 240.00 MRP
+ INT RAX Cap. Incepta
Tranexamic acid 500mg/capsule
500mg x 20's pack: 320.00 MRP
+ INTRAX Jnj. Incepta
Tranexamic acid 500mg/5ml amp: i.rn/i.v injection
500mg x 5 amps pack: 250.00 MRP
+ ORANEX Cap. O rion Pharma
Tranexamic acid 500mg/capsule
500mg x 20's pack: 300.00 MRP
+ TRACID Tab. Acme
Tranexamic acid 500mg/tablet.
•
500mg x 20's pack: 120.30 MRP
+ TRACID lnj. Acme
Tranexamic acid 500mg/5ml ampoule: slow i. v
injection
500mg x 3 arnps pack: 150.55 MRP
+ T RAMIC Cap. Pacific
Tranexamic acid 500mg/capsule.
500mg x 30's pack: 570.00 MRP
+ TRANEXIL IV Inj. Beximco
Tranexamic acid 500mg/5ml ampoule: slow i. v
injection
500mg x 5 amps pack: 250.00 IP
+ T RAXY L Cap. Nuvista
Tranexamic acid 500mg/capsule.
500mg x 20's pack: 447.40 MRP
+ TRAXYL Inj. Nuvista
Tranexamic acid 250mg/5ml ampoule: injection
250mg x 5 amps pack: 234.00 MRP
+ TREXAM Tab. Healthcare
Tranexamic acid 500mg/tablet.
500mg x 30's pack: 450.00 MRP
+ TREXAM Inj. Healthcare
Tranexamic acid 250mg/5ml ampoule: injection
250mg x 5 amps pack: 200.00 MRP
+ XAMTC Cap. Renata
Tranexamic acid 500mg/capsule.
500mg x 20's pack: 301.00 MRP
+ XAMIC Inj. Renata .
Tranexamic acid 500mg/5ml amp: i.rn/i.v injection
500mg x 5 amps pack: 400.00 MRP
ANTIHAEMOPHILIC FACTOR
Factor V III 21·61
( )
•
QIMP-17 (88)
HUMA.1'l ANT IHAEMOPHILIC FAC'fOR
(Factor VIII): Injection
I-Iuman antihaemophilic factor (Factor VIII) is a
sterile, lyophilized concentrate preparation,
collected from pooled plasma from suitable
human donors.
It is supplied as a single dose for intravenous
administration.
Ind: Control of haemorrhage in Haemophilia A;
or acquired factor VIII deficiency.
S/E: Allergic reactions including chills, fever;
hyperfibrinogenaemia occurred after massive
'
doses \Vith earlier products but less likely since
fibrinogen content has now been substantially
reduced.
Cautions: Intravascular haemolysis after large or
frequently repeated doses in patients with blood
groups A, B or AB
Dosage & Admin: This should be administered
i.v within three hours after reconstitution
with the diluent supplied. It may be
administered by injection (plastic syringe
only) or drip infusion. Administer at room
temperature, do not refrigerate after
reconstitution & discard any unused contents.
Dose calculation: The following formula
provides a guide for dosage calculation-
Body wt. (in kg) x 0.40 IU/kg x percent of
desired factor VIII increase (%) =required units
of antihaemophilic factor.
In paediatric patients, a factor of 0.5 TU/kg can
be calculated.
Mild to moderate haemorrhages can usually be
treated with a single administration sufficient to
raise the plasma Factor VIII level to 20-30%. In
the event of more serious haemorrhage, the
patient's plasma Factor VIII level should be
raised to 30-50%. Infusions are generally
required at twice daily intervals over several days.
Surgery in patients with Factor VIII deficiency
requires that postoperati-vely, the Factor VIII
level be raised to 50-80�� and maintained at or
above 30%, for approximately two weeks. For
dental extractions the Factor VIII levei should be
raised to 50% immediately prior to the
procedure; further antihaemophilic Factor
preparation may be given if bleeding occurs.
In patients with se\iere Factor VIII deficiency
who experience frequent l1aemorrhages, the
antihaemophilic Factor preparation may be
administered prophylactically on a daily or every
other day schedule to raise the Factor VIII level
to approximately l 5o/o. Factor VIII levels should
be monitored periodically to evaluate individual
patient response to the dosage regime.
Preparations: As per information, no product is
available now in our market, from any registered
company.
+ ALPHANATE 250 IU lnj. Grifols/Shuvro
Ltd.
Human antihaemophilic factor or Factor Villi
\'WF (Von Willebrand factor) complex
concentrate; double inactivated & highly
purified: i.v injection.
Factor VIII & VWF naturally go together in the
· human blood,. VWF is the natural carrier mole­
cule of factor VIII. The survival of factor VIII
depends on VWF by which it is protected in the
plas1na; the presence of VWF prevents factor
VIII degeneration & creates a prolonged antigen
presentation, which could be beneficial in terms
of immune tolerance induction.
Ind; S/E; Cautions: See above under the text.
Dosage & admin: See above under the text.
250 I.U vial: 9500.00 MRP
12. LIPID-REGULATING
DRUGS21,26
The lipid (cholesterol) content of the liver and
blood circulation is derived predominantly from
three sources. The liver can synthesize choles­
terol, take up cholesterol from the circulating
lipoproteins, or take up cholesterol absorbed by
the small intestine. Intestinal cholesterol is
derived primarily from cl1olesterol secreted in
the bile and from dietary cholesterol. Therefore,
the drugs that are usi11g in lipid-regulation work
on any of the lipid sources of the human body
system.
Lipid-regulating drugs that are available,
classified as:
1. Anion-exchange resins: Such as,
Cholestyramine, Colestipol.
These are used in the management of
hypercholesterolaemia.
2. Ezetimibe
Ezetimibe is a different class of lipid-lowering
compounds that selectively inhibits the
intestinal absorption of cholesterol and related
phytosterols. It can be used alone or in
combination with a statin (if appropriate)
3. Fibrates & lspaghula: Such as, Bezafibrate,
Ciprofibrate, Clofibrate, Fenofibrate,
Gemfibrozil.
These are considered as broad-spectrum lipid­
regulating agents, they mainly decrease serum
triglycerides & also tend to reduce LDL­
cholesterol and raise HDL- cholesterol.
Ispaghula husk
It is a soluble fiber & is used as an adjunct to
a lipid-lowering diet.
4. Statins: Such as, Atorvastatin, Cerivastatin,
Fluvastatin, Pitavastatin, Pravastatin,
Rosuvastatin, Simvastatin.
Statins are drugs of first choice for treating
hypercholesterolaemia & also used in the
treatment of mixed hyperlipidaemia.
5. Nicotinic acid group: Acipimox, Nicotinic
acid, lnQsitol nicotinate.
Nicotinic acid and its ester inositol nicotinate
are also lipid-lowering agents but their use is
limited due to their side-effects specially
vasodilatation.
Ezetimibe
EZETIMIBE26•48
EZETIMIBE: Tablet
Ezetimibe INN 1 Omg/tablet.
Mode of action: Ezetimibe belongs to a class of r
lipid-lowering compounds that selectively
inhibits the intestinal absorption of cholesterol
and related phytosterols. Ezeti1nibe redt1ces total­
C, LDL-C, Apo-B and TG, and increases HDL-C
in patients with hypercholesterolemia. Ezetimibe

inhibits intestinal cholesterol absorption by about
54%, compared with placebo. Ezetimibe has a
mechanism of action different from others. It
does not inhibit cholesterol synthesis in the liver,
or increase bile acid excretion. Instead, ezetimibe
localizes and appears to act at the brush border of
.
the small intestine and inhibits the absorption of
'
cholesterol, leading to a decrease in the delivery
of intestinal cholesterol to the blood circulation
and liver. This causes a reduction of hepatic
cholesterol stores and an increase in clearance of
cholesterol from the circulation. This distinct
mechanism is complementary to that of HMG­
CoA reductase inhibitors (viz, statins). As a
result, administration of ezetimibe with an HMG­
CoA reductase inhibitor is effective in improving
serum total-C, LDL-C, Apo-B, TG and HDL-C
beyond either treatment alone.
Ind: Primary hypercholesterolemia (viz: i.
Primary heterozygous familial and non-familial
hypercholesterolemia, ii. Homozygous familial
hypercholesterolemia (HoFH), iii. Homozygous
familial sitosterolemia (phytosterolemia)).
C/I: Hypersensitivity to any component of this
medication. The combination of ezetimibe with
an HMG-CoA reductase inhibitor (statin) is
contraindicated in patients with active liver
disease or unexplained persistent elevations in
serum transaminases.
S/E: In clinical trials ezetimibe was found
generally well tolerated. The rare side effects
include fatigue, abdominal pain, diarrhea, viral
infection, pharyngitis, sinusitis, arthralgia, back
pain, coughing.
Precautions: Concurrent administration of
ezetimibe with a specific HMG-CoA reductase
inhibitor (statin) should be in accordance with
the product labeling for that HMG-CoA
reductase inhibitor. When ezetimibe is co­
administered with an HMG-CoA reductase
inhibitor, liver function tests should be performed
at initiation of therapy and according to the
recommendations of the HMG-CoA reductase
inhibitor therapy. Hepatic insufficiency- due to
the unknown effects of the increased exposure to
ezetimibe in patients with moderate or severe
hepatic insufficiency, ezetimibe is not
recommended in these patients.
Pregnancy & lactation: There are no adequate
and well-controlled studies of ezetimibe in
pregnant women. Therefore, ezetimibe should be
used during pregnancy only if the potential
benefit justifies the risk to the fetus.
Dosage & admin: Before starting treatment
with ezetimibe, the patient should be placed
on a standard cholesterol-lowering diet and
should be continued on this diet during
treatment with the drug. The recommended
dose of ezetimibe is 1Omg once daily. It can be
administered with or without food.
Treatment with ezetimibe in children (<10
years) is not recommended.
Primary (heterozygous familial and non­
familial) hypercholesterolemia:
Ezetimibe monotherapy:
Ezetimibe administered alone, is indicated as
adjunct therapy to diet for the reduction of
elevated total-C, LDL-C, and Apo-B in
patients with primary (heterozygous familial
and non-familial) hypercholesterolemia.
II
I.
�
I
QIMP-17 (89)
Ezetimibe combination therapy with HMG­
CoA reductase inhibitors: Ezetimibe,
administered in combination with an HMG­
CoA reductase inhibitor, is also indicated as
adjunct therapy to diet for the reduction of
elevated total-C, LDL-C, and Apo-B in
patients with primary (heterozygous familial
and non-familial) hypercholesterolemia. In
case of combination therapy, the daily dose of
ezetimibe may be taken at the same time
schedule as for the HMG-CoA reductase
inhibitor therapy.
Homozygous familial hypercholesterolemia
(HoFH):
Ezetimibe combination therapy with HMG­
CoA reductase inhibitors: The combination of
ezetimibe and atorvastatin or simvastatin, is
indicated for the reduction of elevated total-C
and LDL-C levels in patients with HoFH, as
an adjunt to other lipid-lowering treatments
(e.g LDL apheresis) or if such treatments are
unavailable. In case of combination therapy,
the daily dose of ezetimibe may be taken at
the same time schedule as for the HMG-CoA
reductase inhibitor therapy.
Homozygous familial sitosterolemia
(phytosterolemia):
Monotherapy: Ezetimibe is indicated as
adjunctive therapy to diet for the reduction of
elevated sitosterol and campesterol levels in
patients with homozygous familial
sitosterolemia.
•
Patients with hepatic and renal insufficiency:
No dosage adjustment is necessary in patients
with mild hepatic and renal insufficiency.
Elderly patients: No dosage adjustment is
necessary in geriatric patients.
Co-administration with bile acid sequestrants:
Dosing of ezetimibe should occur either 2
hours before or 4 hours after administration
of a bile acid sequestrant.
Drug inter: Ezetimbe has no significant effect
on a series of porobe drugs (caffeine, dextro­
methorphan, tolbutamide, and i.v midazolam).
This indicates that ezetimibe is neither an
inhibitor nor an inducer of these cytochrome
P450 isozymes, and it is unlikely that ezetimibe
will affect the metabolism of drugs that are
metabolized by these enzymes. Concomitant
administration of ezetimibe (lOmg once daily)
had no significant effect on warfarin, digoxin,
oral contraceptives, and cimetidine.
HMG-CoA reductase inhibitors: Concomitant
administration of ezetimibe ( lOmg one� daily)
had no significant effect on the bioavailability of
either atorastatin, lovastatin, simvastatin,
pravastatin, or fluvastatin.
Fenofibrate: Fenofibrate (200mg once daily)
administration increased the mean Cmax and
AUC values of total ezetimibe approximately
64% and 48%, respectively. Pharmacokinetics of
fenofibrate was not significantly affected by
ezetimibe ( lOmg once daily).
Cholestyramine: In a study of forty healthy
hypercholesterolemic (LDL-C> 130mg/dl) adult
subjects, concomitant cholestyramine (4gm twice
daily) administration decreased the mean AUC
values of total ezetimibe and ezetimibe
approximately 55% and 80%, respectively.
CARDIOVASCULAR DRUGS
t EZETA Tab. Beximco
Ezetimibe INN IOmg/tablet.
20's pack: 200.80 IP
t EZETIM Tab. Incepta
Ezetimibe INN IOmg/tablet.
30's pack: 300.00 MRP
t EZETROL Tab. UniMed & UniHealth
Ezetimibe INN 1Omg/tablet.
30's pack: 300.00 MRP
Fibrates
FENOFIBRATE26•87
FENOFIBRATE: Capsuleffablet
Fenofibrate is a fibric acid derivative approved
for the treatment of hyperlipidemia.
Mode of action: Fenofibrate is rapidly
hydrolyzed after oral ingestion to its
pharmacologically active form, fenofibric acid.
Fenofibric acid causes reductions in total
cholesterol, LDL cholesterol, apolipoprotein B,
total triglycerides and VLDL. In addition,
treatment with fenofibrate results in increase in
HDL and apo-proteins apoAI apoAII.
Fenofibrate also reduces serum uric acid levels in
hyperuricemic and normal individuals by
increasing the urinary excretion of uric acid.
Ind: Fenofibrate is indicated for hyperlipidemias
of typ� Ila, lib, III, IV & V in patients who have
not responded adequately to diet & other
appropriate measures.
C/I: Fenofibrate is contraindicated in patients
with known hypersensitivity to the drug, severe
renal impairment, existing gall bladder disease,
hepatic dysfunction including biliary cirrhosis,
pregnant women and breast feeding mothers,.
photosensitivity to ketoprofen. . .
-
S/E: Nausea, anorexia, gastric pain; pruritus,
urticaria; impotence; headache, dizzmess; .
.
vertigo, fatigue, hair loss; myotoxicity.
.
Precautions: Special care needed in patients
with renal disease, as progressive increases in
serum creatinine concentration or failure to
follow dosage guidelines may result in serum
creatinine concentration or failure to follow
dosage guidelines may result in myotoxicity;
discontinue if myotoxicity suspected or
creatinine kinase concentration increases
significantly. Liver function tests recommended
every 3 months for first year.
•
Pregnancy: Fenofibrate is not recommended for
pregnant women.
Dosage & admin: Adult: F enofibrate 200mg
one capsule onee daily or 67mg 3 capsules
daily in divided doses is recommended as the
dose for the treatment of primary
hypercholesterolemia, hypertriglyceridemia or
mixed hyperlipidemia.
Children: 67mg 1 capsule/20kg body-weight
daily.
Absorption of fenofibrate is increased by appr­
oximately 350/o when administered with food.
Drug inter: Fenofibrate potentiates ··the anticoag­
ulant effects of warfarin. When administered
with antidiabetic drug it may improve glucose
tolerance and have additive effect. Fenofibrate
may also increase the nephrotoxicity of
cyclosporine. Due to a potential increase in the
 CARDIOVASCULAR DRUGS
risk of rhabdomyolysis, cautions should be taken
against the use of fenofibrate with HMG-CoA
reductase inhibitors. However, the use of low­
dose statins with fenofibrate appears to be well
tolerated.
t FENATROL 145 Tab. Drug Inter.
Fenofibrate USP 145mg/tablet (film-coated).
145mg x 30's pack: 240.00 MRP
t FENATROL Cap. Drug Inter.
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.00 MRP
·
t FENOCAP Cap. Orion Pharma
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.90 MRP
t FENOCOL Cap. Peoples
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.00 MRP
t FENOLID Cap. General
Fenofibrate BP 200mg/capsule.
200mg x 40's pack: 281.20 MRP
t FENORAT Cap. Pacific
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.00 MRP
t FIBRE 200 Cap. White Horse
Fenofibrate BP 200mg/capsule (micronized).
•
Fenofibrate BP 200 mg Capsuie
An ISO 9001: 2008 Certified Company
200mg x 50's pack: 350.00 MRP
t LIPIDOF Cap. Acme
Fenofibrate BP 200mg/capsule (micronized).
200mg x 20's pack: 140.40 MRP
t LIPIRED 160 Tab. Square
Fenofibrate BP l 60mg/tablet.
160mg x 30's pack: 150.00 MRP
•
t LIPIRED 200 Cap. Square
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.60 MRP
t LOFAT Cap. Beximco
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.00 IP
t NOFIATE Cap. Incepta
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.00 MRP
t NOFICON Cap. SK+F
Fenofibrate BP 200mg/capsule (micronized).
200mg x 40's pack: 280.00 MRP
t TIGICON Cap. Aristopharma
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.00 MRP
t TIGIRATE Cap. Opsonin
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 185.79 MRP
•
QIMP-17 (90)
t T IZABET Cap. ACI
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.00 MRP
t TRIGENT Cap. UniMed & UniHealth
Fenofibrate BP 200mg/capsule (micronized).
200mg x 30's pack: 210.00 MRP
GEMFIBROZJL21,33
GEMFIBROZIL: Capsule
Ind: Hyperlipidaemias of types Ila, Ilb, ill, IV
and V in patients who have not responded
adequately to diet and other appropriate
measures; primary prevention of coronary heart
disease in men aged 40-55 years with
hyperlipidaemias that have not responded to diet
and other appropriate measures.
C/I: Alcoholism, hepatic impairment, gallstones;
pregnancy.
S/E: Gastro-intestinal disturbances; pruritus,
urticaria, rash, headache, dizziness, blurred
vision, painful extremities; rarely myalgia;
impotence reported.
Cautions: Lipid profile, blood counts & liver­
function tests before initiating long-term treat-
ment; renal impairment; annual eye examina­
tions.
Dose: l.2gm daily, usually in 2 divi ded doses;
range 0.9-1.Sgm daily.
t D ELIPID Cap. Square
Gemfibrozil 300mg/capsule
30's pack: 210.30 MRP
Stati.ns
ATORVASTATIN 42• 65
ATORVASTATIN: Tablet
Atorvastatin, a synthetic lipid-lowering agent.
Available as film coated tablet.
Mode of action: It is a selective, competitive
inhibitor of 3-hydroxy-3-methylglutaryl­
coenzyme A (HMG-CoA) reductase. This
enzyme catalyses the conversion of HMG-CoA
to mevalonate, an early and rate-limiting step in
cholesterol biosynthesis particularly in the liver.
The drug lowers elevated total cholesterol (c),
low-density lipoprotein (LDL) cholesterol,
apolipoprotein B (apo B), and triglyceride (TG)
in patients with primary hypercholesterolaemia
and with mixed dyslipidaemia.
Ind: Atorvastatin is indicated as an adjunct to
diet to reduce elevated total-C, LDL-C, apo-B,
and TG levels in patients with primary
hypercholesterolaemia (heterozygous familial
and non-familial) and mixed hyperlipidaemia.
Atorvastatin is also indicated to reduce total-C
and LDL-C in patients with homozygous familial
hypercholesterolaemia as an adjunct to other
lipid lowering treatments (eg. LDL apheresis) or
if such treatments are unavailable. C/I: The
absolute contra-indications to the administration
of atorvastatin include active liver disease or
unexplained persistent elevations of serum
transaminases and hypersensitivity to any
component of this medication.
Adverse reactions: Atorvastatin is well
tolerated. Adverse reactions have usually been
mild and transient. Less than 2% of patients
were discontinued from clinical trials due to side­
effects attributed to atorvastatin. The adverse
effects that are rarely observed are constipation,
flatulence, dyspepsia, abdominal pain, headacle,
nausea, myalgia, asthenia, diarrhoea and
•
•
•
•
Better Qu ality Always
www.whitehorsepharma.com
insomnia. Atorvastatin can cause elevation in
ALT/AST, alkaline phosphatase, GGT, bilirubin
and creatine phosphokinse.
Precautions & warnings: Liver function tests
should be performed before the initiation of
treatment and periodically thereafter. Patients
who develop increased transaminase levels
should be monitored until the abnormalities
resolve. An increase in ALT or AST > 3 times the
upper limit of normal, is recommended to reduce
the dose or withdraw atorva8tatin therapy.
Prior to initiating therapy with atorvastatin, seco­
ndary causes for hypercholesterol-aemia (eg.
PQ<}f!Y controlled diabetes mellitus, hyothy­
roidism, nephrotic syndrome, dysproteinaemia,
obstructive liver disease, other drug therapy, and
alcoholism) should be identified and treated.
Atorvastatin should be used with caution in
patients who consume sustained quantities of
alcohol and/or have a history of liver disease.
Atorvastatin therapy should be temporarily with­
held or discontinued in any patient with an acute,
serious condition suggestive of a myopathy or
having a risk factor predisposing to the develop­
ment of renal failure secondary to rhabdomyoly-
 To prevent stroke & heart attack
QIMP-17 (91) •

sis, eg. severe acute infection, hypotension, major Drug inter: Caution should be exercised when
Atorvastatin 1 O mg Tablet
surgery, tra11ma, severe metabolic, endocrine and atorvastatin is administ-ered with· inhibitors of
For patients wilh more than 1 risk factor
electrolyte disorders, & uncontrolled seizures. cytochrome P450 3A4 (eg. cyclosporin,
· even with normal lipid profile
Pregnancy & lactation: Cholesterol and other macrolide antibiotics including erythromycin and
products of cholesterol biosynthesis are essential azole antifungals or niacin). Co- administration of
for foetal development (including synthesis of an oral antacid suspension containing magnesium 20mg x 20's pack: 360.00 MRP
steroids and cell membranes). Since HMG-CoA and aluminium hydroxide with atorvastatin, t ATOSTIN Tab. Somatec
reductase inhibitors decrease cholesterol decreases atorvastatin plasma concentrations Atorvastatin lOmg & 20mg/tablet (f.c)
synthesis and possibly the synthesis of other approximately 35%, however, LDL-C reduction 1Omg x 30's pack: 300.00 MRP
biologically active substances derived from usually not altered. Plasma concentration of 20mg x lO's pack: 180.00 MRP
cholesterol, they may cause foetal harm when atorvastatin lowers (approximately 25%) when t ATOVA Tab. Beximco
administered to pregnant women. Therefore, cholestyramine is co-administered than when Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
HMG-CoA reductase inhibitors are either drug is given alone. lOmg x 30's pack: 300.00 IP
contraindicated during pregnancy and in nursing Co-administration of multiple doses of 20mg x 20's · pack: 360.00 IP
mothers. Atorvastatin should be administered to atorvastatin and digoxin increased steady-state 40mg x 20's pack: 480.00 IP
women of child-bearing age only when such plasma digoxin concentrations by approximately t ATOVEX Tab. RAK Pharma
patients are highly unlikely to conceive and have 20%. Patients taking digoxin should be Atorvastatin 1Omg & 20mg/tablet (f.c)
been informed of the potential hazards. If the monitored appropriately. 1Omg x 30's pack: 300.00 MRP
patient becomes pregnant while taking this drug, 20mg x 20's pack: 320.00 MRP
therapy should be discontinued and the patient
t A NZITOR Tab. Square + ATOVIN Tab. Alco Pharma
appraised of the potential hazard to the foetus. Atorvastatin lOmg, 20mg & 40mg/tablet (f.c) Atorvastatin lOmg & 20mg/tablet (f.c)
Dosage & Admin: Atorvastatin can be lOmg x 50's pack: 502.00 MRP lOmg x lO's pack: 100.00 MRP
administered within the dosage range of 10-80 20mg x 30's pack: 541.80 MRP 20mg x lO's pack: 150.00 MRP
mg/day as a single daily dose, and can be 40mg x lO's pack: 240.90 MRP t AT ROVAST Tab. Nuvista
taken at any time of the day, with or without + ASTER Tab. Euro Pharma Atorvastatin 1Omg & 20mg/tablet (f.c)
food. Therapy should be individualized Atorvastatin lOmg & 20mg/tablet (f.c) 1Omg x 30's pack: 360.00 MRP

•
.. .,..
-­
.
•
- • _ <(;
,., ...
- .:.. .
- · .;_
. .
•
.
•
•
· '

:�
� -

• '.. . .
•
.

.
·-
:': :: · --. . .
.
.
. .'-
. . .
..
. ; ..

.-
•
. -
:

.
•

•
• .
•

•
® '.

..

·-•
•

Atorvastati'n 10 mg & 20 mg tablet

,

according to the target lipid levels, the recom­ 1Omg x 30's pack: 240.00 MRP 20mg x 20's pack: 360.00 MRP
mended goal of therapy, and the patient's 20mg x 30's pack: 450.00 MRP + ATV Tab. Delta Pharma
response. Primary hypercholesterolaemia and + ASTIN Tab. Jayson Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
combined byperlipidaemia, usually lOmg once Atorvastatin lOmg & 20mg/tablet (f.c) MRP
lOmg x 30's pack: 150.00
daily. Familial hypercholesterol-aemia, 1Omg x 30's pack: 241.20 IP 20mg x 30's pack: 300.00 MRP
initially 1Omg daily, increased at intervals of 4 20mg x lO's pack: 150.50 IP 40mg x lO's pack: 150.00 MRP
weeks to 40mg once daily; if necessary, t ATASIN Tab. A C I t AVAS Tab. Opsonin
further increased to max, 80mg once daily (or Atorvastatin 1Omg, 20mg, 40mg & 80mg/tablet Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
combined with anion-exchange resin in (f.c) MRP
lOmg x 30's pack: 264.97
heterozygous familial hypercholesterolaemia). 1Omg x 30's pack: 301.20 MRP 20mg x 1O's pack: 158.96 MRP
R enal disease has no influence on the plasma 20mg x lO's pack: 180.70 MRP 40mg x lO's pack: 211.92 MRP
concentrations or on the LDL-C reduction of 20mg x 20's pack: 361.40 MRP t AVASTATIN Tab. Edruc
atorvastatin; thus, no adjustment of the dose 40mg x 1O's pack: 240.90 MRP Atorvastatin lOmg/tablet (f.c)
is re quired. 80mg x 12's pack: 480.00 MRP lOmg x lO's pack: 80.00 MRP
Plasma concentrations of atorvastatin are t ATOLIP Tab. Ziska t AVATOR Tab. NIPRO JMI
markedly increased in patients with chronic Atorvastatin lOmg/tablet (f.c) Atorvastatin 1Omg & 20mg/tablet (f.c)
alcoholic liver disease (Childs-Pugh B). The 1Omg x 30's pack: 240.00 MRP 1Omg x 30's pack: 300.00 MRP
benefits of therapy should be weighed against t ATONOR Tab. Asiatic 20mg x 20's pack: 360.00 MRP
the risks when atorvastatin is to be given to Atorvastatin lOmg & 20mg/tablet (f.c) t AVOC ARD Tab. White Horse
patients with hepatic insufficiency. 1Omg x 30's pack: 300.00 MRP Atorvastatin USP lOmg & 20mg/tablet (f.c)

.9'-�N •••
� ��L����A S lTD www.squarepharmacom.bd
•••
•••
.......

I
 •• • QIMP-17 (92)
.
Atorvastatin
1Omg x 30's pack: 300.00 MRP
20mg x 30's pack: 480.00 MRP
+AZTOR Tab.Sun Pharma
Atorvastatin USP lOmg, 20mg & 40mg/tablet (f.c)
l Omg x 50's pack: 502.50 MRP
20mg x 30's pack: 543.00 MRP
40mg x 30's pack: 720.00 MRP
+CLOLES-10 Tab. Doctor's
Atorvastatin lOmg/tablet (f.c)
lOmg x 30's pack: 240.00 MRP
+COLOSTAT Tab. lbn Sina
Atorvastatin lOmg & 20mg/tablet (f.c)
lOmg x 30's pack: 300.00 IP
20mg x 30's pack: 451.80 IP
+CORD Tab. Hallmark
Atorvastatin lOmg/tablet (f.c)
lOmg x lO's pack: 80.30 MRP
+DIVAS'I'IN Tab. Drug Inter.
Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
lOmg x 30's pack: 300.00 MRP
20mg x 20's pack: 360.00 MRP
40mg x 20's pack: 480.00 MRP
+G-ATROVAST Tab. Gonoshas.
Atorvastatin lOmg & 20mg/tablet (f.c)
lOmg x 30's pack: 210.00 MRP
20mg x 30's pack: 375.00 MRP
+LIPEX-10 Tab.Orion Pharma
Atorvastatin lOmg & 20mg/tablet (f.c)
1Omg x 30's pack: 270.90 MRP
20mg x 20's pack: 301.20 MRP
+LIPICON Tab.SK+F
Atorvastatin lOmg & 20mg/tablet (f.c)
1Omg x 40's pack: 400.00 MRP
20mg x 20's pack: 360.00 MRP
+LIPICUT Tab. Rangs Pharma
Atorvastatin lOmg & 20mg/tablet (f.c)
1Omg x 30's pack: 300.00 MRP
20mg x 20's pack: 360.00 MRP
+LIPIGENT Tab. P acific
Atorvastatin lOmg & 20mg/tablet (f.c)
1Omg x 30's pack: 300.00 MRP
Atorvastatin 10
•
20mg x 20's pack: 360.00 MRP
+LIPILES Tab. Pharmasia
Atorvastatin lOmg & 20mg/tablet (f.c)
lOmg x 20's pack: 200.00 MRP
20mg x 1O's pack: 180.00 MRP
+LIPITIN Tab. General
Atorvastatin lOmg & 20mg/tablet (f.c)
1Omg x 30's pack: 301.20 MRP
20mg x 20's pack: 361.40 MRP
40mg x lO's pack: 240,00 MRP
+LIPLO Tab. Globe
Atorvastatin lOmg & 20mg/tablet (f.c)
lOmg x lO's pack: 100.00 MRP
20mg x 1O's pack: 150.00 MRP
+LIPOBI Tab. Nipa
Atorvastatin lOmg/tablet (f.c)
1Omg x 30's pack: 300.00 MRP
+LIPOSTAT Tab. Navana
Atorvastatin lOmg & 20mg/tablet (f.c)
1Omg x 30's pack: 300.00 MRP
20mg x 30's pack: 450.00 MRP
+LIPOVAST Tab. Sharif
Atorvastatin lOmg & 20mg/tablet (f.c)
lOmg x 30's pack: 300.00 MRP
20mg x 20's pack: 300.00 MRP
+LIPTOR Tab.Acme
Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
1Omg x 30's pack: 301.20 MRP
20mg x 20's pack: 361.20 MRP
40mg x lO's pack: 240.90 MRP
+LIVAS Tab. Techno Drugs
Atorvastatin lOmg & 20mg/tablet (f.c)
1Omg x 30's pack: 300.00 MRP
20mg x 20's pack: 360.00 MRP
+LOCOL Tab. Popular
Atorvastatin IOmg, 20mg & 40mg/tablet (f.c)
1Omg x 30's pack: 301.21 MRP
20mg x 20's pack: 361.40 MRP
40mg x 20's pack: 481.00 MRP
+ORVA Tab. Sanofi-aventis
Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
1Omg x 30's pack: 301.20 MRP
20mg x 30's pack: 542. l 0 MRP
40mg x 30's pack: 750.00 MRP
+ORVATIN Tab. Kemiko
Atorvastatin lOmg & 20mg/tablet (f.c)
. . .. . .. . . .
1 0r ... for uncompromised chol�sterol control
mg & 20 mg Tablet
lOmg x 20's pack: 200.00 M.RP
20mg x 20's pack: 360.00 MRP
+STACOR Tab. UniMed & UniHealth
Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
IOmg x 30's pack: 300.00 MRP
20mg x 20's pack: 360.00 MRP
40mg x lO's pack: 240.00 MRP
+TAVEN Tab. Renata
Atorvastatin lOmg & tablet (f.c)
1Omg x 30's pack: 301.20 MRP
20mg x 30's pack: 541.80 MRP
40mg x 30's pack: 720.00 MRP
+TCL-R Tab. Aris topharma
Atorvastatin 1Omg & 20mg/tablet (f.c)
IOmg x 30's pack: 300.00 MRP
20mg x lO's pack: 180.00 MRP
+TIGINOR Tab. Incepta
Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
1Omg x 30's pack: 300.00 MRP
20mg x 20's pack: 360.00 MRP
40mg x 20's pack: 480.00 MRP
+TORVAS Tab. Kumudini
Atorvastatin 1Omg/tablet (f.c)
lOmg x 30's pack: 270.00 MRP
+TROVA Tab. Biopharma
Atorvastatin lOmg & 20mg/tablet (f.c)
1 Omg x 30's pack: 300.00 MRP
20mg x lO's pack: 180.00 MRP
+VASS Tab.Sandoz
Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
lOmg x 30's pack: 360.00 MRP
20mg x 20's pack: 400.00 MRP
40mg x 1O's pack: 250.00 MRP
+VASTIN Tab. Pharmadesh
Atorvastatin 1Omg/tablet (f.c)
lOmg x 20's pack: 160.60 MRP
+XELITOR Tab. Novo Healthcare
Atorvastatin INN lOmg & 20mg/tablet (f.c)
1Omg x 30's pack: 300.00 MRP
20mg x 30's pack: 540.00 MRP
+XELPID Tab. Healthcare
Atorvastatin lOmg, 20mg & 40mg/tablet (f.c)
IOmg x 30's pack: 300.00 MRP
20mg x 1O's pack: 180.00 MRP
40mg x lO's pack: 240.00 MRP
+XEROVA Tab. Beacon
.-. � .
Apex
!l!l
' 1''11.l

Atorvastatin lOmg & 20mg/tablet (f.c)
1Omg x 30's pack: 300.00 MRP
20mg x 20's pack: 360.00 MRP
t ZAPITOR Tab. Apex
Atorvastatin lOmg & 20mg/tablet (f.c)
1Omg x 30's pack: 300.00 MRP
20mg x 20's pack: 360.00 MRP
FLUVASTATIN54
FLUVASTATIN: Tablet
Ind: Primary hypercholesterolaemia & mixed
dyslipidaemia (Fredrickson types lla/llb) as an
adjunct to diet. To slow the progression of coro
nary atherosclerosis in patients with primary
hypercholesterolae-mia, including mild forms,
and coronary heart disease.
C/I: Hypersensitivity to the drug. Active liver
disease or unexplained, persistent elevations in
serum transaminases. Pregnancy, lactation,
women of childbearing potential unless they are
taking adequate contraceptive precautions.
AIR: Dyspepsia, nausea, abdominal pain & other
minor gastrointestinal symptoms; insomnia,
headache. Elevation of transaminase levels. Rare
I hazards. If the patient becomes pregnant while
cases of hypersensitivity reactions, mainly rashes
and urticaria, but very rarely also other skin
reactions, thrombocytopenia, angioedema,
vasculitis, and lupus erythematosus-like reactions
have been reported.
Precautions & Warnings: Caution is required in
patients with a history of liver disease or heavy
alcohol consumption, with unexplained diffuse
myalgias, muscle tenderness or weakness, and
marked elevation of creatine phosphokinase
values, or with severe renal insufficiency.
Dosage: Prior to initiating fluvastatin, the
patient should be placed on a standard choles­
terol-lowering diet; dietary therapy should be
continued during treatment. The recommend­
ed starting dose is 40mg (one 40mg capsule)
once daily in the evening. In mild cases 20mg
may be adequate. At very high cholesterol
levels, the dosage may be increased to 80mg
daily (one 40mg capsule twice daily or one
80mg XL tablet once daily in the evening).
Interactions: Bile acid-sequestering agents;
cimetidine, ranitidine, omeprazole; rifampicin.
Note: For further information, please see
manufacturer's literature.
t FLUVAS 20 Cap. Silva
Fluvastatin 20mg/capsule
20mg x 12's pack: 144.00 MRP
t LESCOL Cap. Novartis
Fluvastatin 20mg & 40mg/capsule
20mg x 28's pack: 1050.00 MRP
40mg x 28's pack: 1596.00 MRP
t LESCOL XL Tab. Novartis
Fluvastatin 80mg/tablet (prolonged release)
80mg x 28's pack: 1638.00 MRP
t LESTEROL Cap. Opsonin
Fluvastatin 20mg/capsule
20mg x lO's pack: 106.00 MRP
PITAVASTATIN36
PITAVASTATIN: Tablet
Pitavastatin, a synthetic lipid-lowering agent,
available as- Pitavastatin calcium INN equivalent
•
QIMP-17 (93)
to pitavastatin 2mg in film-coated tablet.
Mode of action: Pitavastatin completely inhibits
HMG CoA reductase, the rate-determining
enzyme in hepatic cholesterol synthesis.
Consequently, LDL-C receptors in the liver are
increased, thereby increasing the removal of
LDL-C from the blood.
Ind: Pitavastatin is indicated as an adjunctive
therapy to diet to reduce elevated total
cholesterol (TC), low-density lipoprotein
cholesterol (LDL-C), apolipoprotein B (Apo B),
triglycerides (TG), and to increase HDL-C in
adult patients with primary hyperlipidemia or
mixed dyslipidemia.
C/I: Patients with a known hypersensitivity to
any component of this product. Pitavastatin is
contraindicated in patients with active liver
disease, which may include unexplained persis­
tent elevations of hepatic transaminase levels.
S/E: Pitavastatin is generally well tolerated. The
common side effects are headache, myalgia,
asthenia, constipation, dizziness and abdominal
pain. It may rarely cause rhabdomyolysis and
hypersensitivity reaction, such as- rash, pruritus,
and urticaria.
Pregnancy & lactation: The safety and efficacy
of pitavastatin in pregnancy have not been
established. It is not known whether pitavastatin
is excreted in human milk
Dosage & admin: The dose is 1- 4mg orally
once daily at any time of the day with or
without food. The recommended starting dose
is 2mg and the maximum dose is 4mg. The
starting and maintenance doses should be
individualized.
Children: Safety and effectiveness of
pitavastatin in pediatric patients have not
•
been established.
Renal impairment: Patients with moderate
renal impairment (glomerular ftltration rate
30 to 60 ml/min/l.73 m2) and end-stage
< aggressive lipid targets, a 20mg starti.ng dose
renal disease receiving hemodialysis should
receive a starting dose of pitavastatin lmg
once daily and a maximum dose of
pitavastatin 2mg once daily.
Hepatic impairment: Pitavastatin is contra­
indicated in patients with active liver disease,
which may include unexplained persistent
elevations of hepatic transaminase levels.
Drug inter: Pitavastatin is metabolized primarily
by glucuronidation and minimally by the cyto­
chrome P450 system via CYP2C9 & CYP2C8,
which may result in drug interactions with other
medications metabolized via the same route.
t LIPLOSS Tab. Drug Inter.
Pitavastatin calcium INN equivalent to
pitavastatin 2mg/tablet (film-coated).
2mg x 20's pack: 200.00 MRP
t PAVIGARD Tab. Acme
Pitavastatin calcium INN equivalent to
pitavastatin 2mg/tablet (film-coated).
2mg x 20's pack: 200.00 MRP
t PITAVAS Tab. Aristopharma
Pitavastatin calcium INN equivalent to
pitavastatin 2mg/tablet (film-coated).
2mg x 30's pack: 300.00 MRP
t PI VALO 2 Tab. Square
Pitavastatin calcium INN equivalent to
pitavastatin 2mg/tablet (film-coated).
2mg x 30's pack: 300.00 MRP
-
CARDIOVASCULAR DRUGS
ROSUVASTATIN42
ROSUVASTATIN: Tablet
Rosuvastatin is a synthetic lipid-lowering agent.
It is available as rosuvastatin INN 1Omg film­
coated tablet.
Ind: Heterozygous hypercholesterolemia
(familial and nonfamilial), homozygous
hypercholesterolemia (familial), mixed
dyslipidemia (Fredrickson type Ila and lib).
C/I: Rosuvastatin is contraindicated in patients
with a known hypersensitivity to any component
of this produc
_ t. Rosuvastatin is contraindicated in
patients with active liver disease or with
unexplained persistent elevations of serum
transaminases.
S/E: Rosuvastatin is generally well tolerated. The
most frequent adverse events thought to be
related to rosuvastatin were myalgia, constipation
asthenia, abdominal pain, and nausea.
Pregnancy & lactation: Rosuvastatin should be
administered to women of childbearing age only
when such patients are highly unlikely to
conceive and have been informed of the potential
taking this drug, therapy should be discontinued
immediately and the patient apprised of the
potential hazard to the fetus. It is not known
whether rosuvastatin is excreted in human milk.
Dosage & admin: Heterozygous hypercholes­
terolemia (familial and nonfamilial) and mixed
dyslipidemia (Fredrickson type Ila and lib):
The usual recommended starting dose of rosu­
vastatin is 1Omg once daily. Initiation of thera­
py with 5mg once daily may be considered for
patients requiring less aggressive LDL-C
reductions or who have predisposing factors
for myopathy. For patients with marked
hypercholesterolemia (LDL-C >190mg/dl) and
may be considered. A 40mg dose of rosuvas­
tatin should be reserved for those patients who
have not achieved goal LDL-C at 20mg. After
initiation and/or upon titration of rosuvas­
tatin, lipid levels should be analyzed within 2
to 4 weeks and dosage adjusted accordingly.
Homozygous hypercholesterolemia (familial):
The recommended starting dose of rosuvasta­
tin is 20mg once daily. The maximum recom­
mended daily dose is 40mg. Rosuvastatin
should be used in these patients as an adjunct
to other lipid-lowering treatments (e.g LDL
apheresis) or if such treatments are unavail­
able.
Dosage in patients with renal insufficiency: No
modification of dosage is necessary for
patients with mild to moderate renal
insufficiency. For patients with severe renal
impairment (CLcr < 30ml/min/1.73 m2) not on
hemodialysis, dosing of rosuvastatin should be
started at 5mg once daily and not to exceed
1Omg once daily.
Pediatric patients: The safety and effectiveness
in pediatric patients have not been
established.
t CORESTIN Tab. UniMed & UniHealth
Rosuvastatin INN 5mg & lOmg/tablet (f.c)
5mg x 28's pack: 350.00 MRP
1Omg x 14's pack: 350.00 MRP

t C R ESTON Tab. SK+F
Rosuvastatin INN lOmg/tablet (f.c)
1Omg x 20's pack: 400.00 MRP
t N ESTOR Tab. Navana
Rosuvastatin INN 5mg & lOmg/tablet (f.c)
5mg x 30's pack: 300.00 MRP
1Omg x 20's pack: 400.00 MRP
t ROCOVAS 10 Tab. Incepta
Rosuvastatin INN lOmg/tablet (f.c)
lOmg x IO's pack: 200.00 MRP
t ROPITOR Tab. Opsonin
Rosuvastatin INN 5mg, lOmg & 20mg/tablet (f.c)
5mg x 30's pack: 263.90 MRP
lOmg x 20's pack: 351.88 MRP
20mg x IO's pack: 263.90 MRP
t ROSE TOR Tab. ACI
Rosuvastatin INN 5mg & lOmg/tablet (f.c)
5mg x 30's pack: 300.00 MRP
lOmg x 20's pack: 360.00 MRP
t ROSTAB Tab. Acme
Rosuvastatin INN 1Omg & 20mg/tablet (f.c)
Rosuvastatin 1 O mg film coated tablet
I
1Omg x 20's pack: 300.00 MRP
20mg x 1O's pack: 250.00 MRP
t ROSTATIN Tab. Drug Inter.
Rosuvastatin INN 5mg, lOmg & 20mg/tablet (f.c)
5mg x 20's pack: 160.00 MRP
1Omg x 20's pack: 300.00 MRP
20mg x 1O's pack: 250.00 MRP
t ROSU Tab. Popular
Rosuvastatin 5mg, 1Omg & 20mg/tablet (f.c)
Smg x 30's pack: 300.00 MRP
1Omg x 20's pack: 360.00 MRP
20mg x lO's pack: 300.00 MRP
t ROSUGEN Tab. General
Rosuvastatin INN 5mg & lOmg/tablet (f.c)
5mg x 30's pack: 300.00 MRP
1Omg x 20's pack: 400.00 MRP
t ROSUTIN Tab. Beximco
Rosuvastatin INN 5mg & lOmg/tablet (f.c)
5mg x 30's pack: 300.00 MRP
lOmg x 20's pack: 400.00 MRP
t ROSUVA Tab. Square
. 500mg and 750mg tablet.
Rosuvastatin INN 5mg, lOmg & 20mg/tablet (f.c)
5mg x 30's pack: 300.00 MRP
IOmg x 30's pack: 602.10 MRP
20mg x 1O's pack: 300.00 MRP
•
QIMP-17 (94)
t ROZAVEL 10 Tab. Sun Pharma
Rosuvastatin calcium INN lOmg/tablet (f.c)
1Omg x 30's pack: 750.00 MRP
t R UVASTIN Tab. Aristopharma
Rosuvastatin INN 5mg & lOmg/tablet (f.c)
5mg x 30's pack: 300.00 MRP
1Omg x 20's pack: 400.00 MRP
SIMVASTATJN21,33
SIM VASTATIN: Tablet
Ind: Hypercholesterolaemia- patients with
primary hypercholesterolaemia, in home response
to diet & other non-pharmacological measures
has been inadequate.
Coronary heart disease- in patients with a plasma
cholesterol level 5.5mmol/l or greater.
Concomitant therapy with immunosupp-ressives.
C /I: Hypersensitivity to this product; active liver
disease or persistant elevation of serum
transaminase; porphyria; pregnancy, lactation.
Women of child bearing potential unless
adequately protected by non-hormonal methods.
S/E: Headache, fatigue, insomnia, nausea,
constipation or diarrhoea, flatulence, dyspepisa,
• •
c':.;"!f
.
._.,
abdominal cramps, myalgia, myositis, myopathy;
rhabdomyolysis (rare) with acute renal failure
secondary to myoglobinuria; hepatitis,
pancreatitis; rash, angioedema.
Caution: Monitor liver function before and
during treament; minor asymptomatic transient
rises in serum transaminase may occur soon after
initiation of therapy with simvastatin which do
not require the drug to be discontinued; if the
transaminase levels rise to three times the upper
limit of normal & are persistent, the drug should
be discontinued. History of liver disease. High
alcohol intake. Advise patients to report muscle
pain. Discontinue treatment if markedly elevated
CPK levels occur or if myopathy is diagnosed.
Dosage & admin: The patient should be
placed on a standard cholesterol-lowering diet
before receiving simvastatin and should
continue on this diet during treatment with
simvastatin.
Hypercholesterolaemia- initially lOmg once
daily at night; d. ose range 10-40mg/day. (A
marked response to simvastatin is seen within
two weeks and the maximum therapeutic
response occurs within four to six weeks. The
response is maintained during continuation of
therapy. When therapy with simvastatin is
stopped, total cholesterol has been shown to
return to pretreatment levels.) Adjustment of
dosage, if required, should be made at inter­
vals of not less than four weeks, depending on
the patient's individual response.
-
(If LDL-cholesterol level falls below 1.94
mmol/I or total serum cholesterol level falls
below 3.6 mmol/I, consider-ation should be
given to reduce the dose of simvastatin.)
CHD- initially 20mg/day once daily at night.
(Adjustment of dosage, if required, should be
made as specified above for 'hypercholestero­
laemia').
Concomitant therapy with immunosu-ppres­
sives- maximum lOmg/day.
Drug inter: digoxin, coumarin derivatives.
t AVASTIN Tab. Beximco
Simvastatin 1Omg/tablet.
30's pack: 451.00 IP
t NO VAS'l'IN Tab. Drug Inter.
Simvastatin 1Omg/tablet.
30's pack: 330.00 MRP
t SIMVA'I'IN Tab. Acme
-tatin
Simvastatin 1Omg/tablet.
IOmg x 20's pack: 220.80 MRP
t VASTOCOR Tab. lncepta
Simvastatin 1Omg/tablet.
30's pack: 360.00 MRP
t ZOSTIN Tab. Renata
Simvastatin 1Omg/tablet.
30's pack: 424.80 MRP
Nicotinic acid group
INOSITOL NICOTINATE26
INOSITOL NICO'I'IN ATE : Tablet
Inositol nicotinate is the hexanicotinic acid ester
of meso-inositol, also called inositol
hexaniacinate (IHN) or inositol hexanicotinate or
inositol nicotinate. The compound consists of six
molecules of nicotinic acid and one molecule of
inositol. It is available as inositol nicotinate BP
Mode of action: Pharmacokinetic studies have
indicated that inositol nicotinate ester is absorbed
intact and hydrolyzed in the body with release of

free niacin and inositol. It has been proven effec­
tive at lowering VLDL, LDL and total choles­
terol and triglyceride levels while raising HDL
levels. Niacin is vital for cellular metabolism.
Due to its vasodilatory effects, niacin has been
prescribed for the treatment of cardiovascular
disease, particularly the hyperlipidemias.
Ind: Inositol nicotinate has a fairly broad range
of therapeutic applications. The most well
researched conditions include the hyperlipi­
demias, Raynaud's disease and intermittent
claudication. Promising applications, which bear
further investigation, include its use for stasis
ulcers, dysmenorrhea, dermatitis herpetiformis,
alcoholism, diabetes, cancer prevention and
hypertension.
C/I: Inositol nicotinate is contraindicated to
children, early stage of stroke & people who
have recently had a heart attack. It should not be
used if any one is allergic to one or any of its
ingredients.
S/E: The most common side effects are
headache, rash, paraesthesia, dizziness, nausea
and vomiting, flushing, excessive fluid retention
in the body tissues, postural hypotension, fainting.
Precautions: Cautions should be exercised in
patients with angina not well controlled by
medical treatment and decreased blood supply
through the vessels of the brain (cerebrovascular
insufficiency).
Pregnancy & lactation: There is no information
available about the safety of this medicine during
pregnancy, therefore it is not recommended for
use during pregnancy, unless considered essential
by the physician.
There is no information available regarding the
safety of this medicine during breast-feeding.
Dosage & admin: Recommended dosage for
lipid-lowering and improving conditions
related to peripheral vascular insufficiency
ranges from 1500mg to 4 gms daily in 2 to 3
divided dosages.
Drug inter: There are no significant interactions
reported with this medicine.
•
+ NIAPID Tab. Drug Inter.
Inositol nicotinate (niacin) BP 500mg/tablet
500mg x 30's pack: 180.00 MRP
+ NICOSIT Tab. Incepta
Inositol nicotinate BP 500mg & 750mg/tablet
500mg x 20's pack: 100.00 MRP
750mg x 20's pack: 140.00 MRP
+ RIDEL ER Tab. lncepta
Inositol nicotinate (niacin) BP 500mg/tablet
(extended release).
500mg x 20's pack: 160.00 MRP
DRUGS USED IN
RESPIRATORY
DISEASES
I
QIMP-17 (95)
OMEGA-3-ACID ETHYL ESTERS86
OMEGA-3-ACID ETHYL ESTERS: Capsule
Omega-3-acid ethyl esters contain the ethyl
esters of omega-3-fatty acids. These are
predominantly a combination of ethyl esters of
Eicosape-ntaenoic acid (EPA) &
Docosahexaenoic acid (DHA). In traditional
formula, in l OOOmg of Omega-3-acid ethyl
esters, the quantity of EPA is 300mg (30o/o) and
DHA is 200mg (20%), which are most important
nutritionally & therapeutically. The remaining
500mg (50%) are various unsaturated fatty acids,
which are not therapeutically important.
In another higher strength formula, in l OOOmg of
Omega-3-acid ethyl esters, the quantity of EPA is
330mg (33%) and DHA is 220mg (22%). The
remaining 450mg (45%) are non-important
various unsaturated fatty acids.
Omega-3-fatty acids are essential because they
are not synthesized by the body and must be
obtained through diet or supplementation.
Mode of action: The mechanism of action of
Omega-3-acid ethyl esters is not completely
understood. Potential mechanisms of action
include inhibition of acyl CoA: 1, 2-diacylgly­
cerol acyltransferase, increased mitochondrial
and peroxisomal �-oxidation in the liver,
decreased lipogenesis in the liver, and increased
plasma lipoprotein lipase activity. Omega-3-acid
ethyl esters may reduce the synthesis of
triglycerides (TGs) in the liver because EPA and
DHA are poor substrates for the enzymes
responsible for TG synthesis, and EPA and DHA
inhibit esterfication of other fatty acids.
Ind: �ry high triglycerides: Omega-3-acid ethyl
esters are indicated as an adjunct to diet to
reduce triglyceride (TG) levels in adult patients
with very high (>500mg/dl) triglyceride levels;
adjunct in secondary prevention after myocardial
infarction.
C/I: Hypersensitivity to any of the component of
this medication.
S/E: Anorexia, constipation, dry mouth,
gastrointestinal disorders, increased appetite,
myalgia, dizziness etc. are rarely reported.
Precaution: Every attempt should be made to
control serum TG levels with appropriate diet,
exercise, weight reduction in overweight patients
and control of any medical problems (such as
diabetes mellitus and hypothyroidism) that may
be contributing to the patients TG abnormalities.
Omega-3-acid ethyl esters should be used with
caution in patients with known sensitivity or
allergy to fish.
Respiratory drugs are discussed in the
following groups:21
1. Bronchodilators
2. Prophylactics of asthma:
i. Cromoglycate & related drugs
ii. Leukotriene receptor antagonists
®
Rosuvastatin
Pregnancy & lactation: Omega-3-aqid ethyl
esters should be used during pregnancy only if
the potential benefit justifies the potential risk to
the fetus. It is not known whether Omega-3-acid
ethyl esters are excreted in human milk. Caution
should be exercised when Omega-3-acid ethyl
esters are administered to a lactating mother.
Dosage & admi.n: Patients should be placed on
an appropriate lipid-lowering diet before
receiving Omega-3-acid ethyl esters, and
should include this diet during treatment with
Omega-3- acid ethyl esters. In clinical studies,
Omega-3- acid ethyl esters were administered
with meals. The initial dose of Omeega-3-acid
ethyl esters� lOOOmg (1 capsule)3;times a day.
As maintenance, the dose may be 2 capsules a
day in divided doses. The maximum dose is 4
capsules a day in divided d�ses. ·
,
It is advisable to swallow the capsule
immediately after ingestion of food or after
snacks. Since Omega-3 capsule contains
refined marine fish oil, there remains the
chance of feeling the smell of fish oil if it is
taken in empty stomach and belching may
occur due to this or any other reason.
T herefore, it is suggested to take the capsule
as per above recommendation.
Drug inter: Medication known to exacerbate
high triglycerides (such as beta blockers, thiazide
and estrogens) should be discontinued or
changed, if possible before considering TG­
lowering drug therapy.
+ OMESOFT SG Cap. Pacific
Each soft gelatin capsule contains Omega-3-acid
ethyl esters BP 1OOOmg. These are predominantly
a combination of ethyl esters of Eicosapentaenoic
acid (EPA) & Docosahexaenoic acid (DHA). In...
1OOOmg of Omega-3-acid ethyl esters, the
quantity of EPA is 330mg (33o/o) and DHA is
220mg (22%), (higher strength formula).
1 OOOmg x 30's pack: 300.00 MRP
1 OOOmg x 50's pack: 500.00 MRP
+ OMG-3 Cap. Drug Inter.
Each soft gelatin capsule contains Omega-3-acid
ethyl esters BP 1 OOOmg. These are predominantly
a combination of ethyl esters of Eicosapentaenoic
acid (EPA) & Docosahexaenoic acid (DHA). In
1OOOmg of Omega-3-acid ethyl esters, the quanti­
ty of EPA is 300mg (30%) & DHA is 200mg (20%)
lOOOmg x 30's pack: 180.00 MRP
3. Respiratory corticosteroids
4. Antihistamines, antiallergics, antiinflam­
matory & hyposensitisation drugs
5. Cough preparations; mucolytics
6. Respiratory stimulants & pulmonary sur­
factants
RESPIRATORY DRUGS
7. Aromatic inhalations
8. Oxygen
9. Systemic nasal decongestants.
1. BRONCHODILATORS21
1.1 Adrenoceptor stimulants
a. Selective beta2-adrenoceptor stimulants
i. Short-acting beta2 agonists (stimulants)
ii. Long-acting beta2 agonists (stimulants)
b. Other adrenoceptor stimulants
1.2 Antimuscarinic bronchodilators
1.3 T heophylline & related drugs
1.4 Compound bronchodilator prepns.
Adrenoceptor Sdmulants
(Sympathomimetics)
Selective P2-adrenoceptor
stimulants21
The selective Jii-adrenoceptor stimulants
include:
1. Short-acting- such as Salbutamol,
Terbutaline (widely available formulations),
Bambuterol (a pro-drug of terbutaline),
TulobuteroL
2. Long-acting- such as Formoterol (Eformote­
rol), Salmeterol & Fenoterol, Reproterol
(these are administered by inhalation & not
indicated for the relief of an acute attack;
they are usually added to existing
corticosteroid therapy and not replace it).
Indacaterol (another long-acting �2-
adrenoceptor agonist (stimulant) licensed for
chronic obstructive pulmonary disease).
Short-acting selective
beta2-adrenoceptor stimulants
A LB U T AM O L2 1 •42•63
S 400mcg for persistent symptoms up to 3-4
SALBUTAMOL: Tablet/Syrup/Injection
SALBUTAMOL: Inhaler (DPl/MDI)
SALBUTAMOL HFA: Inhaler (MDI)
SALBUTAMOL HFA: Evohaler (MDI)
Salbutamol is a short-acting, selective beta2-
adrenoceptor stimulant (agonist), used in the
treatment of asthma and other forms of diffuse
reversible ainways obstructive diseases. It is
available as tablet, syrup, injection & inhaler/
HFA inhaler.
Tablet - 2mg & 4mg tablet.
Syrup - 2mg/5ml; 60ml & 1 OOml bottle.
Injection - 50mcg/ml; 20ml vial.
Inhaler (DP/) - Dry powder inhaler (DPI).
Inhaler (MDI) - Metered dose inhaler (MDI),
using CFC (chlorofluorocarbon) propellant.
Inhaler HFA (MDI) - Metered dose inhaler
(MDI), using HFA (hydrotluoroalkane) propellant.
Evohaler HFA (MDI)- Evohaler HFA is a
metered dose inhalation device and is used by
aerosol inhalation only, using HFA
(hydrofluoroalkane) as propellant.
•
QIMP-17 (96)
CFC (Chlorofluorocarbon): CFC- using as MDI
propellant is safe for human, but, as it emits CFC
to the environment, it harms the planet by
depleting ozone layer.
HFA (Hydrojluoroalkane): Recently an advanced
HFA (Hydrofluoroalkane) technology has
developed as MDI propellant replacing CFC
propellant. HFA is an ozone-benign, environment
.friendly, CFC-free MDI propellant.
Mode of action: The primary pharmacological
action of -adrenoceptor stimulant drug is to
stimulate adenyl cyclase, the enzyme which
catalyzes the formation of cyclic AMP (cyclic 3,
4 adenosine-mono-phosphate) from adenosine­
tri-phosphate (ATP). The cyclic AMP thus
formed mediates the cellular response that results
in bronchodilation.
Ind: Salbutamol is indicated for the treatment
and prophylaxis of bronchial asthma and for the
treatment of reversible airways obstruction
associated with bronchitis and emphysema; status
asthmaticus; prophylactic therapy before exertion
or to prevent exercise-induced asthma.
C/I: Although intravenous salbutamol, and
occasionally oral preparations are used in the
management of premature labour (not
complicated by any conditions such as placenta
praevia, ante-partum haemorrhage or toxaemia of
pregnancy), salbutamol inhaler preparations are
not appropriate for managing premature labour.
Salbutamol preparation should not be used for
threatened abortion during the frrst or second
trimester of pregnancy. Salbuatmol is
contraindicated in patients with a history of
hypersensitivity to any of its components.
S/E: Salbutamol is generally well tolerated and
serious toxic effects are a few.
Salbutamol may cause fine tremor of skeletal
muscles (particularly of the hands), palpitations,
and muscle cramps. Tachycardia, tenseness,
headache, peripheral vasodilatation and
hypokalaemia have been reported after large
dose. They usually disappear with continued
treatment. Hypersensitive reactions including
angioedema, urticaria, reflex bronchospasm,
hypotension and collapse have been reported
very rarely. In case of inhalation therapy, the
potential for paradoxical bronchospasm should
be kept in mind, if it occurs, therapy should be
discontinued immediately and alternative
medication should be instituted.
Precautions: Salbutamol and other 2 agonists
should be given with caution in hyperthyroidism,
myocardial insufficiency, arrhythmias,
susceptibility to QT-interval prolongation,
hypertension, and diabetes mellitus. In severe
asthma, particular cautionis also required to
avoid inducing hypokalaemia as this effect may
be potentiated by hypoxia or by concomitant
administration of other anti-asthmatic drugs; 2
agonists such as salbutamol are not appropriate
for use alone in the treatment of severe asthma.
Salbutamol and non-selective blockers such as
propranolol should not be prescribed together. In
the event of a previously effective dose of
salbutamol inhaler, failing to give relief for at
least 3 hours, the patients should be advised to
seek medical advice in order that any necessary
additional steps may be taken.
Inhaled salbutamol preparations are not appropri-
ate for managing premature labor and also should
not be used for threatened abortion during the
frrst or second trimester of pregnancy.
Pregnancy & lactation: Although there is no
evidence that salbutamol is teratogenic, it should
be used in the first trimester only if absolutely
essential. Inhalation has particular advantage as a
mean of administration of 2 agonists during
pregnancy as the therapeutic action can be
achieved without the requirement for such
plasma concentration liable to have a
pharmacological effect on the fetus.
Salbutamol probably enters breast milk, but the
concentration is unknown. However, no adverse
effect have been reported in the breast-fed babies
of mothers taking the drug by inhalation.
Dosage & admin: By mouth: Adult- 2 to 4mg
3 or 4 times daily. Child- under 2 yrs. not
recommended; 2-6 yrs. 1-2mg. 6-12 yrs. 2mg.
Both 3 or 4 times daily. Or, 0.1 mg/kg/dose, 3
or 4 times daily.
By injection: 500mcg i.m or s.c injection, may
be repeated every 4 hours if necessary. Or,
By slow i.v injection: 250mcg, repeated if
necessary.
By i. v infusion: Initially Smcg/min, adjusted
according to response & heart-rate usually in
range 3-20mcg/min, or more if necessary.
Child: Not recommended.
By metered dose aerosol inhalation (MDI):
Adults: For the relief of acute bronchospasm
and for managing intermittent episodes of
asthma, 1 or 2 puffs (100 or 200mcg) as a
single dose; for chronic maintenance therapy,
2 puffs 3 or 4 times daily; for prevention of
exercise-induced bronchospasm, 2 puffs
before exertion.
Prophylaxis, 2 puffs 3 or 4 times daily.
Children: For relief of acute bronchospasm,
management of episodic asthma and for
prevention of exercise induced bronchospasm,
1 puff; for routine maintenance & prophylaxis,
1 puff 3 or 4 times daily, increasing if necessary
to 2 puffs 3 or 4 times daily.
Elderly- the dosage is the same as that for
adults.
By dry powder inhalation (DPI): Adult: 200-
times daily; Child 200mcg.
Prophylaxis in exercise-induced bronchospasm
400mcg; Child, 200mcg.
DPI or Dry powder inhalation is for oral
inhalation only. An inhalation device (such as,
Acuhaler, Cozyhaler, Cyclohaler, Rotahaler) is '
used for dry powder inhalation.
Rinsing the mouth after dry powder
inhalation is used.
By inhalation of nebulised solution: Chronic
bronchospasm unresponsive to conventional
therapy and severe acute asthma, adult and •
child over 18 months 2.Smg, repeated up to 4
times daily; may be increased to Smg if
necessary, but medical assessment should be
considered since alternative therapy may be
indicated; child under 18 months, clinical
efficacy uncertain (transient hypoxaemia may
occur- consider supplemental oxygen).
t ACTOLIN Tab. Globe
Salbutamol 4mg/tablet
4mg x l OO's pack: 34.00 MRP

+ ACTOLIN Syp. Globe
Salbutamol 2mg/5ml: syrup.
1OOml bot: 21.00 MRP
+ ALVOLEX Syp. Silva
Salbutamol 2mg/5.ml: syrup.
1 OOml bot: 16.00 MRP
+ ASMALIN HFA Inhaler (MDI)
Aristopharma
Salbutamol 1 OOmcg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant.
Dosage & admin: See above under the text.
200 doses unit: 195.00 MRP
+ ASMALIN HFA Inhaler (Refill Can)
•
Aristopharma
Salbutamol 1 OOmcg/puff or actuation; each
canister contains 200 metered doses: inhalation
aerosol. (MDI), using HFA (hydrofluoroalkane)
as propellant.
Dosage & admin: See above under the text.
200 doses canister: 155.00 MRP
+ ASMATOL Syp. Rephco
Salbutamol 2mg/5ml: syrup.
60ml bot: 14.45 MRP
t ASMOLEX Syp. Aristopharma
Salbutamol 2mg/5ml: syrup.
l OOml bot: 22.92 MRP
t ASNIL Syp. Ziska
Salbutamol 2mg/5ml: syrup
l OOml bot: 16.00 MRP
/
+ ASTHMOLIN Tab. Pharmadesh
Salbutamol 2mg/tablet.
2mg x 1OO's pack� 28.00 MRP
+ ASTHMOLIN Syp. Pharmadesh
Salbutamol 2mg/5ml: syrup
60ml bot: 11.38 MRP
IOOml bot: 21. 08 MRP
t ASUL Tab. Asiatic
Salbutamol sulphate 4mg/tablet
4mg x lOO's pack: 34.00 MRP
+ ASUL Syp. Asiatic
Salbutamol 2mg/5ml: syrup.
I OOml bot: 22. 92 MRP
+ AZMARE L Tab. Euro Pharma
Salbutamol 2mg & 4mg/tablet
2mg x 1 OO's pack: 26.00 MRP
4mg x 1OO's pack: 34.00 MRP
I
•
!
+ AZMA.REL Syp. Euro Pharma
Salbutamol 2mg/5ml: syrup.
lOOml bot: 22.00 MRP
t AZMASOL Tab. Beximco
Salbutamol 2mg & 4mg/tablet
2mg x 500's pack: 130.00 MRP
4mg x 500's pack: 200.00 MRP
+ AZMASOL Inhaler (MDI) Beximco
Salbutamol 1OOmcg/puff or actuation: metered
dose inhalation (MDI).
Dosage & admin: See above under the text.
200 doses unit: 180.00 MRP
'
•
+ AZMASOL Inhaler (Refill Can) Beximco
Salbutamol 1OOmcg/puff or actuation; each
canister contains 200 metered doses: inhalation
aerosol. (MDI)
Dosage & admin: See above under the text.
200 doses canister: 150.00 MRP
t AZMASOL HFA Inhaler (MDI) Beximco
Salbutamol 1OOmcg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant.
Dosage & ad min: See above under the text.
I
•
QIMP-17 (97) RESPIRATORY DRUGS
200 doses unit: 195.00 IP + BRONDYL Syp. Millat
300 doses unit: 260.00 IP Salbutamol 2mg/5ml: syrup.
+ AZMASOL HFA Inhaler (Refill Can) 1 OOml bot: 22.80 MRP
Beximco + BRONIL-S Syp. Seema
Salbutamol 1OOmcg/puff or actuation; each Salbutamol 2mg/5ml: syrup.
canister contains 200 metered doses: inhalation l OOml bot: 23.00 MRP
aerosol. (MDI), using HFA (hydrofluoroalkane)
+ BRONKOLAX Syp. Beximco
as propellant.
Salbutamol 2mg/5ml: syrup
Dosage & admin: See above under the text.
IOOml bot: 22.93 MRP
200 doses canister: 170.00 IP
t D-BUTAMOL Syp. Doctor's
+ AZMASOL Bexicap Inhaler (DPI) Beximco
Salbutamol 2mg/5ml: syrup
Salbutamol 200mcg/bexicap; dry powder
1OOml bot: 22.80 MRP
inhalation (DPI).
+ DECABUTAMOL Syp. Decent Pharma
Azmasol bexicap inhaler (DPI) is administered
Salbutamol 2mg/5ml: syrup
by special inhaler device through oral inhalation
60ml bot: 12.00 MRP
route.
IOOml bot: 21.83 MRP
Dosage: See above under the text.
+ DILATOL Syp. Kemiko
200mcg x 30 caps pack: 75.00 MRP
Salbutamol 2mg/5ml: syrup
+ AZMASOL Respirator Soln. Beximco
l OOml bot: 22.84 MRP
Salbutamol sulphate 5mg/ml (i.e 0.5%) for use
t ETOL Syp. Edruc
with a nebuliser or ventilator.
Salbutamol 2mg/5ml: syrup
Dose: See above under the text.
1OOml bot: 23.00 MRP
20ml pack: 120.00 IP
+ G-SALBUTAMOL Tab. Gonoshastha
+ AZMET Syp. Medicon
Salbutamol 4mg/tablet.
Salbutamol 2mg/5ml: syrup.
1 OO's pack: 34.00 MRP.
60ml bot: 15.00 MRP
+ G:.SALBUTAMOL Syp. Gonoshastha
l OOml bot: 22.00 MRP
Salbutamol 2mg/5ml.: Syrup
+ BROAD Syp. Nipa
1 OOml bot: 18.00 MRP
Salbutamol 2mg/5ml: syrup
+ G-SALBUTAMOL Inj. Gonoshastha.
IOOml bot: 15.00 MRP
Salbutamol 50mcg/ml; 20ml vial: injection
+ BRODIL Tab. ACI
Dosage & Admin: See above under the text.
Salbutamol 2mg & 4mg/tablet.
20ml vial x l ' s pack: 100.00 MRP
2mg x 500's pack: 130.00 MRP
+ H-SELAX Tab. Hudson
4mg x IOO's pack: 34.00 MRP
Salbutamol 4mg/tablet
4mg x 500's pack: 200.00 MRP
1OO's pack: 34.00 MRP
+ BRODIL Syp. ACI
+ H-SELAX Syp."Hudson
Salbutamol 2mg/5ml: syrup.
Salbutamol 2mg/5ml: syrup
IOOml bot: 22.93 MRP
60ml bot: 10.80 MRP
+ BRODIL Acucap Inhaler (DPI) ACI
l OOml bot: 15.00 MRP
Salbutamol 200mcg/acucap; dry powder
+ ORSAL Syp. Orion Pharma
inhalation (DPI).
Sulbutamol 2mg/5ml: syrup
Brodil acucap inhaler (DPI) is administered by
IOOml bot: 22.85 MRP
acuhaler device through oral inhalation route.
+ PULMOLIN Tab. Opsonin
Rinsing the mouth after dry powder inhalation is
Salbutamol 4mg/tablet
used.
4mg x l OO's pack: 29.91 MRP
200mcg x 32 caps pack: 43.20 MRP
+ PULMOLIN Syp. Opsonin
+ BRODIL HFA Inhaler (MDI) ACI
Sulbutamol 2mg/5ml: syrup
Salbutamol 1 OOmcg/puff or actuation: metered
60ml bot: 9.19 MRP
dose inhaler (MDI), using HFA
l OOml bot: 20.17 MRP
(hydrofluoroalkane) as propellant.
+ RESDIL Tab. Cosmo Pharma
Dosage & admin: See above under the text.
Salbutamol 4mg/tablet
200 doses unit: 195.00 MRP
200's pack: 66.00 MRP
+ BRODIL HFA Inhaler (Refill Can) ACI + RESPOLIN Tab. Jayson
Salbutamol 1 OOmcg/puff or actuation; each Salbutamol 4mg/tablet
canister contains 200 metered doses: inhalation lOO's pack: 33.00 MRP
aerosol (MDI), using HFA (hydrofluoroalkane) as + RESPOLIN Syp. Jayson
propellant. Salbutamol 2mg/5ml: syrup
Dosage & admin: See above under the text. l OOml bot: 22.92 MRP
200 doses canister: 170.00 MRP + SABUL Nebuliser Solo. Chemist
Salbutamol sulphate 5mg/ml (i.e 0.5%) for use
+ BRODIL Respiratory Solo. ACI
Salbutamol sulphate 5mg/ml (i.e 0.5%) for use with a nebuliser or ventilator.
with a nebuliser or ventilator. Dose: See above under the text.
Dose: See above under the text. 20ml bot: 110.00 MRP
20ml pack: 120.00 MRP + SALBU Tab. Biopharma
Salbutamol 2mg & 4mg/tablet
+ BRONCOTROL 4 Tab. Pacific
Salbutamol 4mg/tablet 2mg x 1 OO's pack: 26.00 MRP
200's pack: 68.00 MRP 4mg x 1OO's pack: 34.00 MRP
+ BRONCOTROL Syp. Pacific + SALBU Syp. Biopharma
Salbutamol 2mg/5ml: syrup. . Salbutamol 2mg/5ml: syrup
lOOml bot: 22.00 MRP 60ml bot: 11.04 MRP
 •

RESPIRATORY DRUGS QIMP-17 (98)

l OOml bot: 22.93 MRP + SULTOLIN-SR Tab. Square 2mg x 500's pack: 131.67 MRP
+ SALBUT Syp. General Salbutamol 8mg/tablet (sustained release) 4mg x 500's pack: 200.00 MRP
Salbutamol 2mg/5ml: syrup 200's pack: 184.00 MRP + VENTOLIN Syp. GlaxoSmithKline
l OOml bot: 22.90 MRP + SULTOLIN Syp. Square Salbutamol sulph. 2mg/5ml: syrup
+ SALBUTAL Tab. Sanofi-aventis Salbutamol sulph. 2mg/5ml: syrup l OOml bot: 22.93 MRP
Salbutamol 2mg & 4mg/tablet IOOml bot: 22.93 MRP + VENTOLIN UFA Evohaler (MDI)
2mg x 500's pack: 130.01 MRP + SULTOLIN Inhaler (MDI) Square GlaxoSmithKline
4mg x 500's pack: 169.97 MRP Salbutamol 1OOmcg/puff or actuation; metered Salbutamol 1 OOmcg/puff or actuation: metered
+ SALBUTAL Syp. Sanofi-aventis dose inhalation (MDI). dose inhaler (MDI), using HFA
Salbutamol 2mg/5ml: syrup 200 dose unit: 180.68 MRP (hydrofluoroalkane) as propellant.
l OOml bot: 22.89 MRP + SULTOLIN HFA Inhaler (MDI) Square 200 doses unit: 200.00 MRP
+ SALBUTAMOL Syp. Amico Salbutamol I OOmcg/puff or actuation; metered + VENTOLIN Nebules GlaxoSmithKline
Salbutamol 2mg/5ml: syrup dose inhaler (MDI), using HFA (hydrofluoro­ Salbutam9l sulphate 2.5mg/2.5ml (i.e 0.1%) for
l OOml bot: 21.75 MRP alkane) as propellant. use with a nebuliser.
+ SALBUTAMOL Tab. Bristol 200 doses unit: 195.00 MRP Ind. & Dose: See above; (content of each
Salbutamol 2mg & 4mg/tablet + SULTOLIN HFA Reftll (MDI) Square nebule may be diluted with sterile sodium
2mg x 500's pack: 130.00 MRP Salbutamol I OOmcg/puff or actuation: refill for chloride solution 0.9°/o if administration time
4mg x 500's pack: 170.00 MRP metered dose inhalation (MDI), using HFA in excess of 10 minutes is required).
+ SALIX-4 Tab. M odern (hydrofluoroalkane) as propellant. 2.5mg (2.5ml) x 30's pack: 803.40 MRP
Salbutamol 4mg/tablet 200 doses unit: 170.00 MRP + VENTOLIN Respirator Solo.
1 OO's pack: 34.00 MRP + SULTOLIN Cozycap Inhaler (DPI) Square GlaxoSmithKline
+ SALIX Syp. Modern Salbutamol 200mcg/cozycap; dry powder Salbutamol sulphate 5mg/ml (i.e 0.5%) for use
Salbutamol 2mg/5ml: syrup inhalation (DPI). with a nebuliser or ventilator.
60ml bot: 14.47 MRP Sultolin cozycap inhaler (DPI) is administered by 20ml pack: 172.90 MRP
l OOml bot: 22.90 MRP cozyhaler device through oral inhalation route. t VENTOSOL Syp. Ad-din
Rinsing the mouth after dry powder inhalation is
.

+ SALMOL Tab. Medimet Salbutamol sulph. 2mg/5ml: syrup

Salbutamol 4mg/tablet used. 1OOml bot: 20.00 MRP
l OO's pack: 40.00 MRP 200mcg x 30 caps pack: 45.00 MRP + WINDEL Tab. Incepta
+ SALMOL Syp. Medimet + SULTOLIN Nebuliser Soln. Square Salbutamol 2mg & 4mg/tablet.
Salbutamol 2mg/5ml: syrup Salbutamol sulphate 2.5mg/2.5ml (i.e 0.1%) for 2mg x 200's pack: 52.00 MRP
60ml bot: 13.00 MRP use with a nebuliser. 4mg x 200's pack: 68.00 MRP
l OOml bot: 22.00 MRP Ind. & Dose: See above; ( content of each + WINDEL Syp. Incepta
+ SALMOLIN Tab. Acme nebule may be diluted with sterile sodium Salbutamol sulph. 2mg/5ml: syrup
.
Salbutamol (as sulphate) 4mg/tablet chloride solution 0.9o/o if administration time l OOml bot: 22.90 MRP
l OO's pack: 40.00 MRP in excess of 10 minutes is required). + WINDEL Convicap Inhaler (DPI) lncepta
+ SALMOLIN Syp. Acme 2.5mg (2.5ml) x IO's pack: 140.00 MRP Salbutamol 200mcg/convicap; dry powder
Salbutamol (as sulphate) 2mg/5ml: syrup inhalation (DPI).
+ SULTOLIN Respirator Solo. Square
60ml bot: 10.83 MRP Windel convicap inhaler (DPI) is administered by
Salbutamol sulphate 5mg/ml (i.e 0.5%) for use
l OOml bot: 22.93 MRP convihaler device through oral inhalation route.
with a nebuliser or ventilator.
+ SALMOLIN 200 Inhaler (DPI) Acme 200mcg x 30 convicaps pack: 75.00 MRP
20ml pack: 120.46 MRP
Salbutamol (as sulphate) 200mcg/rotacap (or
+ TOLIN Tab. M ystic + WINDEL Respiratory Soln. lncepta
puff), dry powder inhalation (DPI).
Salbutamol 4mg/tablet Salbutamol sulphate 5mg/ml (i.e 0.5%) for use
Salmolin inhaler (DPI) is administered by
I OO's pack: 34.00 MRP with a nebuliser or ventilator.
'rotahaler' device through oral inhalation route.
+ TOLIN Syp. M ystic 20ml pack: 120.00 MRP
Dose: See above under the text.
Salbutamol 2mg/5ml: syrup
30 caps pack: 45.00 MRP + ZENTOLIN Syp. Zenith
l OOml bot: 15.00 MRP
+ SALMOLIN (HFA) Inhaler (MDI) Acme Salbutamol sulph. 2mg/5ml: syrup
+ VENLET Syp. Apollo 60ml bot: 14.46 MRP
Salbutamol (as sulphate) l OOmcg/puff or
Salbutamol 2mg/5ml: syrup •

actuation; metered dose inhaler (MDI), using l OOml bot: 21.78 MRP
1 OOml bot: 22.7 5 MRP
HFA (hydrofluoroalkane) as propellant.
+ VENOL Syp. Gaco
Dose: See above under the text.
Salbutamol 2mg/5ml: syrup LEVOSALBUTAMOL26,48
200 doses unit: 195.00 MRP
60ml bot: 10.75 MRP
+ SALMOLIN Respiratory Solo. Acme
+ VENTISAL Tab. Ibo Sina LEVOSALBUTAMOL: Tablet/Syrup/Inhaler
Salbutamol sulphate 5mg/ml (i.e 0.5%) for use
Salbutamol 4mg/tablet Levosalbutamol is a single isomer beta-2 agonist
with a nebuliser or ventilator.
IOO's pack: 34.00 MRP that differs from racemic sulbutamol by
20ml pack: 120.00 MRP
+ VENTISAL Syp. Ibn Sina elimination of (S)-salbutamol. It is available as
+ SALOL Syp. Cosmic Salbutamol 2mg/5ml: syrup levosalbutamol sulphate INN equivalent to
Salbutamol sulph. 2mg/5ml: syrup IOOml bot: 22.92 MRP levosalbutamol l mg & 2mg/tablet, l mg/5ml of
l OOml bot: 22.00 MRP + VENTOL Syp. CPL syrup & 50mcg/puff (inhalation).
+ SALOMAX 100 Inhaler (MDI) SK+F Salbutamol 2mg/5ml: syrup Mode of action: Levosalbutamol is an effective
Salbutamol IOOmcg/puff or actuation; metered 60ml bot: 10.50 MRP bronchodilator whose primary mechanism of
dose inhalation (MDI). IOOml bot: 15.00 MRP action is unimpeded by (S)-salbutamol. Thus,
Dose: See above under the text. + VENTOLEX-4 Tab. Desh Pharma when compared with racemic salbutamol,
200 dose unit: 160.00 MRP Salbutamol 4mg/tablet clinically comparable bronchodilatation can be
+ SULBION Syp. Kumudini 500's pack: 170.00 IP achieved with doses that substantially lessen
Salbutamol sulph. 2mg/5ml: syrup + VENTOLEX Syp. Desh beta-mediated side effects. Levosalbutamol
l OOml bot: 20.00 MRP Salbutamol 2mg/5ml: syrup produces bronchodilatation through stimulation
+ SULTOLIN Tab. Square IOOml bot: 20.00 IP of beta-2-adrenergic receptors in bronchial
Salbutamol 4mg/tablet + VENTOLIN Tab. GlaxoSmithKline smooth muscle, thereby causing relaxation of
200's x 4mg: 80.00 MRP Salbutamol 2mg & 4mg/tablet. bronchial muscle fibres.
 -

QIMP-17 (99) RESPIRATORY DRUGS

Ind: Levosalbutamol is indicated for the treat­ t ASMOLEX-L Syp. Aristopharma + LETOL Syp. Globe
ment & prevention of bronchospasm in adults, Levosalbutamol sulphate INN equivalent to Levosalbutamol sulphate l mg/5ml: syrup. _

adolescents, & children 6 yrs of age & older with l mg/5ml: syrup. lOOml bot: 35.00 MRP
reversible obstructive airway disease. 1OOml bot: 35.00 MRP t LEVAIR Tab. General
C/I: History of hypersensitivity to levosalbuta­ t BRIZY Tab. SK+F Levosalbutamol sulphate INN equivalent to 1mg
mol or any of its components. Levosalbutamol sulphate INN equivalent to lmg & 2mg/tablet
S/E: Hypocalcaemia, palpitation, fine tremors of & 2mg/tablet l mg x lOO's pack: 90.00 MRP
the skeletal muscle & muscle cramps may occur. lmg x 50's pack: 50.00 MRP 2mg x 50's pack: 85.50 MRP
The other likely side effects are nausea, vomiting, 2mg x 50's pack: 100.00 MRP + LEVAIR Syp. General
burning substemal or epigastric pain & diarrhea. + BRIZY Syp. SK+F Levosalbutamol sulphate INN equivalent to
Precaution: Particular caution is advised in Levosalbutamol sulphate INN equivalent to 1mg/5ml: syrup.
acute severe asthma as this effect may be 1mg/5ml: syrup. lOOml bot: 35.13 MRP
potentiated by hypoxia & by concomitant 60ml bot: 32.00 MRP + LEVENlA Syp. Novo Healthcare
treatment with xanthine derivatives, steroids & t BRODIL LEVO Tab. ACI Levosalbutamol sulphate INN equivalent to
diuretics. Serum potassium levels should be Levosalbutamol sulphate INN equivalent to 1mg l mg/5ml: syrup.
monitored in such situations. & 2mg/tablet lOOml bot: 35.00 MRP
Pregnancy & lactation: The drug should be l mg x lOO's pack: 110.00 MRP t LEVOSTAR Tab. Square
used during pregnancy only if the potential 2mg x lOO's pa�k: 190.00 MRP Levosalbutamol sulpbate INN equivalent to l mg
benefit justifies the potential risk of the fetus. It t BRODIL LEVO Syp. ACI & 2mg/tablet
is not known whether levosalbutamol is excreted Levosalbutamol sulphate INN equivalent to l mg x lOO's pack: 91.00 MRP
in human milk. So, caution should be exercised l mg/5ml: syrup. 2mg x 50's pack: 85.00 MRP
when oral levosalbutamol is administered to a 50ml bot: 28.00 MRP t LEVOSTAR Syp. Square
nursmg woman. 1OOml bot: 42.00 MRP Levosalbutamol sulphate INN equivalent to
•

Dosage & admin: Oral therapy: Adults & t BROMOL Syp. Somatec l mg/5ml: syrup.
adolescents above 12 years: lmg to 2mg, 3 Levosalbutamol sulphate INN equivalent to 50ml bot: 25.10 MRP
times daily. 1mg/5ml: syrup. 1OOml bot: 38.15 MRP
Children (6-llyrs)- lmg (Sml) 3 times daily. lOOml bot: 38.00 IP t LEVOSTAR Inhaler Square
By inhalation: Adults & children above the t COMFIL-2 Tab. Pharmasia Levosalbutamol sulphate INN equivalent to
age of 4 years: For the relief of acute episodes Levosalbutamol sulphate INN equivalent to 50mcg/puff or dose: metered dose inhalation
of bronchospasm- 1 or 2 puffs as necessary; to 2mg/tablet (MDI).
prevent allergen or exercise induced 2mg x 50's pack: 85.50 MRP 200 doses unit: 200.75 MRP
bronchospasm- 2 puffs 15 minutes prior to t COMFIL Syp. Pharmasia + LIVODEL Syp. Popular
exercise or exposure to allergen. The Levosalbutamol sulphate INN equivalent to Levosalbutamol sulphate INN equivalent to
maximum dose is 8 puffs in 24 hours. l mg/5ml: syrup. 1mg/5ml: syrup.
Drug inter: Other short-acting sympathomimetic 1OOml bot: 38.00 MRP lOOml bot: 35.13 MRP
bronchodilators or epinephrine should be used t ISOSAL Syp. NIPRO JMI t PURILIN Tab. Opsonin
with caution with levosalbutamol. If additional Levosalbutamol sulphate INN equivalent to Levosalbutamol sulphate INN equivalent to 1mg
adrenergic drug �re to be administered by any 1 mg/5ml: syrup. & 2mg/tablet
route, they should be used with cautoin to avoid 1OOml bot: 42.00 MRP lmg x lOO's pack: 79.13 MRP
deleterious cardiovascular effects. t LEBROD Tab. Alco Pharma 2mg x lOO's pack: 149.74 MRP
Levosalbutamol sulphate INN equivalent to l mg t P URILIN Syp. Opsonin
t ACTISAL Tab. Silva & 2mg/tablet Levosalbutamol sulphate INN equivalent to
Levosalbutamol sulphate INN equivalent to 1mg l mg x lOO's pack: 75.00 MRP 1mg/5ml: syrup.
& 2mg/tablet 2mg x lOO's pack: 140.00 MRP 50ml bot: 22.07 MRP
lmg x lOO's pack: 90.00 MRP t LEBROD Syp. Alco Pharma lOOml bot: 30.90 MRP
2mg x 1OO's pack: 171. 00 MRP Levosalbutamol sulphate INN equivalent to t P URISAL Tab. lncepta
+ ACTISAL Syp. Silva l mg/5ml: syrup. Levosalbutamol sulphate INN equivalent to 1mg
Levosalbutamol sulphate INN equivalent to 1OOml bot: 45.00 MRP & 2mg/tablet
1mg/5ml: syrup. t LEBUTAL Tab. Pacific l mg x lOO's pack: 90.00 MRP
50ml bot: 25.00 MRP Levosalbutamol sulphate INN equivalent to 1mg 2mg x lOO's pack: 170.00 MRP
lOOml bot: 35.00 MRP & 2mg/tablet + PURISAL Syp. Incepta
+ AIRE Tab. Delta Pharma l mg x IOO's pack: 100.00 MRP Levosalbutamol sulphate INN equivalent to
Levosalbutamol sulphate INN equivalent to 1mg 2mg x IOO's pack: 190.00 MRP l mg/5ml: syrup.
& 2mg/tablet t LEBUTAL Syp. Pacific 50ml bot: 25.00 MRP
lmg x 50's pack: 45.00 MRP Levosalbutamol sulphate INN equivalent to 1OOml bot: 38.00 MRP
2mg x 50's pack: 85.00 MRP l mg/5ml: syrup. + PURISAL Nebuliser Solo. Incepta
t AROLAX Tab. Navana IOOml bot: 40.00 MRP Levosalbutamol sulphate 0.3 l mg/3ml ampoule,
.

Levosalbutamol sulphate INN equivalent to 0.63mg/3ml ampoule, & l .25mg/3ml ampoule;

t LESAL Tab. Apex
l mg/tablet for use with a nebuliser or ventilator.
Levosalbutamol sulphate INN equivalent to l mg
lmg x lOO's pack: 100.00 MRP 0.3lmg (3ml amp) x lO's pack: 100.00 MRP
& 2mg/tablet
0.63mg (3ml amp) x 1O's pack: 150.00 MRP
+ AROLAX Syp. Navana lmg x 50's pack: 45.00 MRP
l .25mg (3ml amp) x lO's pack: 200.00 MRP
Levosalbutamol sulphate INN equivalent to 2mg x 50's pack: 75.00 MRP
l mg/5ml: syrup. + RESPIRA Tab. Beximco
t LESAL Syp. Apex
60ml bot: 25.00 MRP Levosalbutamol sulphate INN equivalent to 1mg
Levosalbutamol sulphate INN equivalent to
lOOml bot: 38.00 MRP & 2mg/tablet
l mg/5ml: syrup.
lmg x lOO's pack: 90.00 IP
+ ASMOLEX-L Tab. Aristopharma 60ml bot: 28.00 MRP
2mg x 1OO's pack: 170.00 IP
.

Levosalbutamol sulphate INN equivalent to 1mg lOOml bot: 38.00 MRP

& 2mg/tablet + LETOL Tab. Globe + RESPIRA Syp. Beximco
l mg x lOO's pack: 80.00 MRP Levosalbutamol sulphate 2mg/tablet Levosalbutamol sulphate equivalent to l mg/5ml:
2mg x 50's pack: 75.00 MRP 2mg x 1OO's pack: 170.00 MRP syrup.

'

I
RESPIRATORY DRUGS
IOOml bot: 38.00 MRP
+ RESPIRA Inhaler Beximco
Levosalbutamol sulphate INN equivalent to
50mcg/puff or dose: metered dose inhalation
(MDI).
200 doses unit: 200.00 IP
+ SALMOLIN-L Tab. Acme
Levosalbutamol sulphate INN equivalent to lmg
& 2mg/tablet
l mg x lOO's pack: 90.00 MRP
2mg x lOO's pack: 170.00 MRP
+ SALMOLIN-L Syp. Acme
Levosalbutamol sulphate INN equivalent to
1mg/5ml: syrup.
60ml bot: 25.00 MRP
lOOml bot: 38.15 MRP
t SANLE V Tab. Sandoz
Levosalbutamol sulphate INN equivalent to
I mg/tablet
ln1g x lOO's pack: 150.00 MRP
+ TRULAX Syp. Renata
Levosalbutamol sulphate INN equivalent to
1mg/5ml: syrup.
lOOml bot: 45.00 MRP
+ VENTISAL-L Tab. Ibo Sina
Levosalbutamol sulphate INN equivalent to
.
2mg/tablet
2mg x lOO's pack: 200.00 IP
+ VENTISAL-L Syp. Ibo Sina
Levosalbutamol sulphate INN equivalent to
l mg/5ml: syrup.
50ml bot: 30.00 IP
lOOml bot: 40.00 IP
TERBUTALINE21,63
TERBUTALINE: Tablet/Syrup
Introduction & mode of action: Terbutaline is a
direct-acting sympathomimetic with predominan­
tly P-adrenergic activity and is a selective P2-
adrenergic receptor agonist used as bronchodilator.
Ind: Bronchospasm in br. asthma, chronic
bronchitis, status asthmaticus, emphysema.
S/E & Cautions: See above under sulbutamol;
premature labour.
Dosage & admin: Use in bronchospasm:
Adults- during the first 1-2 weeks 2.5mg 3
times daily is recommended. The dose may
then be increased to 5mg 3 times daily to
achieve adequate bronchodi-latation. Elderly­
dosage as for adults. Children 7 to 15 years­
the usual starting dose is 2.5mg 2 times daily;
in some patients, the dose may need to be
increased to 2.5mg 3 times daily.
t TARBULIN Tab. Ibo Sina
Terbutaline sulphate BP 2.5mg/tablet
lOO's pack: 100.00 IP
t TERBULIN Syp. Ibo Sina
Terbutaline sulphate BP 1.5mg/5ml: syrup
1OOml bot: 35.14 IP
t TERVENT Tab. UniMed & UniHealth
Terbutaline sulphate BP 2.5mg/tablet
1OO's pack: 50.00 MRP
+ TERVENT Syp. UniMed & UniHealth
Terbutaline sulphate BP l .5mg/5ml: syrup
lOOml bot: 25.00 MRP
BAMBUTEROL6 5
•
QIMP-17 (100)
BAMBUTEROL HCl: Tablet/Syrup
Bambuterol is an oral long-acting b2-agonist,
used to treat symptoms of chronic bronchial asth­
ma, particularly in patients who are unable to use
inhaled products such as children and the elderly.
Bambuterol is available as tablet and syrup.
Mode of action: Bambuterol is a long-acting P2-
agonist. It is a pro-drug of terbutaline that is
slowly converted in the body to the active form,
thus providing a prolonged action.
Ind: Chronic bronchial asthma, specially for
prevention of nocturnal symptoms; bronchospasn
(breathing difficulties due to a narrowing of the
airways); chronic obstructive airway disease.
Bambuterol is not intended to treat acute asthma
attacks.
C/I: Cirrhosis and severe hepatic impairment.
Hypersensitivity to bambuterol or any of its
component. Avoid in children due to limited
clinical data in this age group.
S/E: Fine tremor, nervous tension, headache,
peripheral vasodilatation, palpitations,
tachycardia, rarely muscle cramps;
hypersensitivity reactions including paradoxical
bronchospasm, urticaria, angioedema reported.
Precautions & warnings: Reduce the dose in
renal impairment. Care should be taken with
patients suffering from myocardial insufficiency
or thyrotoxicosis. Due to the hyperglycaemic
effects of b2-stimulants, additional blood glucose
measurements are recommended initially when
bambuterol therapy is commenced in diabetic
patients. Due to positive inotropic effects of b2-
agonists, these drugs should not be used in
patients with hypotrophic cardiomyopathy.
Pregnancy & lactation: There is no defmite
evidence of ill consequence during pregnancy.
Nevertheless, the drug should not be used during
the first trimester of pregnancy, unless the
expected benefit is thought to outweigh any
possible risk to the foetus. It is excreted in the
breast milk, so patients taking this drug should
not breast-feed.
Dosage & admin: Adult- 20mg once daily at
bedtime is effective if the patient has been
• previously tolerated with b2- agonists
stimulants; other patients, initially lOmg once
daily at bedtime, increased if necessary after
1-2 weeks to 20mg once daily.
In elderly, dose adjustment is not required.
In significant hepatic dysfunction, not
recommen_ded because of unpredictable
conversion to terbutaline.
Drug inter: Bambuterol inhibits plasma
cholinesterases and can prolong the action of
drugs such as suxamethonium that is inactivated
by these enzymes. Bambuterol may partly or
totally inhibit the effect of b-blockers.
Bambuterol tablet & oral solution
. . ...
�---••••p'f
or,.lo.
SK•F
+ AERODYL Tab. Silva
Bambuterol hydrochloride 1Omg & 20mg/tablet
lOmg x lOO's pack: 150.00 MRP
20mg x lOO's pack: 301.00 MRP
t AERODYL Syp. Silva
Bambuterol hydrochloride 5mg/5ml: syrup.
60ml bot: 20.00 MRP
t BAMBELOR Tab. Inecpta
Bambuterol hydrochloride 1Omg & 20mg/tablet
lOmg x lOO's pack: 150.00 MRP
20mg x lOO's pack: 300.00 MRP
+ BAMBELOR Syp. Inecpta
Bambuterol hydrochloride 5mg/5ml: syrup.
60ml bot: 25.00 MRP
t DILATOR Tab. SK+F
Bambutero� hydrochloride 1Omg & 20mg/tablet
lOmg x lOO's pack: 300.00 MRP
20mg x 1OO's pack: 400.00 MRP
+ DILATOR Syp. SK+F
Bambuterol hydrochloride 5mg/5ml: syrup.
60ml bot: 30.00 MRP
+ VENTEROL Tab. Ibo Sina
Bambuterol hydrochloride 1Omg & 20mg/tablet
lOmg x lOO's pack: 150.00 IP
20mg x 50's pack: 150.50 IP
+ VENTEROL Syp. Ibo Sina
Bambuterol hydrochloride 5mg/5ml: syrup.
60ml bot: 35.14 IP
TULOBUTEROL2l,63
TULOBUTEROL HCI: Tablet/Syrup
Tulobuterol, due to its highly selective action on
the B2 adrenoceptors, relaxes the bronchial
smooth muscles and has been shown to be
clinically effective in the symptomatic treatment
of reversible obstructive airway disease (ROAD),
such as bronchial asthma and also in bronchitis
and emphysema.
Ind: Indicated in reversible airways obstruction
& used in prophylaxis and control of broncho­
spasm in bronchial asthma, chronic bronchitis,
asthmatic bronchitis, pulmonary emphysema,
bronchiectasis, tracheo-bronchitis with broncho­
constriction, other bronchospastic disorders and
conditions characterized by bronchoconstriction.
Routine maintenance therapy in chronic asthma
and bronchitis
S/E: Like other sympathomimetic agents
tulobuterol can cause less frequent adverse
reactions, such as hypertension, palpitation,
angina, vomiting, vertigo, central nervous system
stimulation, insomnia and headache.
Cautions: Tulobuterol should be used with
caution in patients with diabetes mellitus,
hypertension and hyperthyroi-dism. Caution
should· be taken in cardiac patients, especially
those with arrythmia and coronary insufficiency.
Pregnancy & Lactation: Safety of tulobuterol
during pregnancy �nd lactation has not been
established yet . It is not known whether
tulobuterol is excreted in breast milk and or has a
harmful effect to the new born. Therefore,
prescription in such cases should be done
considering the risk benefit ratio.
Dosage & Admin: Adult, a convenient starting
dose for adults and children of 12 years and
over, is 1 mg twice daily. After 7-10 days of
treatment, the dose should be increased to
2mg twice daily to achieve greater effect.
Some patients however may require dosage
adjustment and the adult dose may be
increased upto 6mg daily when needed.

Children, 6-10 years 0.5-1 mg twice daily; over
10 years 1-2mg twice daily. (Who are suppo­
sed to take syrup- 1-6years, 1/4- 1/2 tsf twice
daily; 6-12 years, 1/2-1 tsf twice daily).
The above recommended dosage may have to
be modified depending upon the patient
response.
t BRETON Tab. Drug Inter.
Tulobuterol hydrochloride 2mg/tablet
1 OO's pack: 250.00 MRP
+ BRETON Syp. Drug Inter.
Tulobuterol hydrochloride l mg/5ml: syrup
60ml bot: 35.00 MRP·
Long-acting Selective {32-
adrenoceptor Stimulants
SALMETEROL21,33,48
SALMETEROL XINAFOATE: Metered Dose
Inhalation (MDI)/Dry Powder Inhalation (DPI)
It is a long-acting adrenoceptor stimulant. It is
usually not used for the relief of an acute attack,
but added to existing corticosteroid and/or
sodium cromoglycate therapy and not replace it.
Ind: Reversible airways obstruction (including
nocturnal asthma and prevention of exercise­
induced bronchospasm) in patients requiring
long-term regular bronchodilator therapy, who
should normally also be receiving regular and
adequate doses of inhaled anti-inflammatory
drugs (e.g corticosteroids and/or in children,
sodium cromoglycate) or oral corticosteroids.
S/E: Cautions: See under salbutamol; important:
significant incidence of paradoxical
bronchospasm, which may be clinically
important in severe or deteriorating asthma.
Dosage & admin: Metered dose inhalation
(25mcg/puff or dose): By inhalation, 50mcg (2
puffs) twice daily; up to 100 mcg (4 puffs)
twice daily in more severe airways obstruc-
.
tion. Children: Under 4 years, not recommen-
ded, over 4 years, 50mcg (2 puffs) twice daily.
Dry powder inhalation (50mcg/puff or dose):
By inhalation, 50mcg (1 puft) twice daily; up
to lOOmcg (2 puffs) twice daily in more severe
airways obstruction.
Children: Under 4 years, not recommended,
over 4 years, 50mcg (1 puff) twice daily.
t AROBID HFA Inhaler (MDI) A ristopharma
Salmeterol xinafoate 25mcg/puff or dose:
metered dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant
200 inhalations unit: 210.00 MRP
t BEXITROL Inhaler (MDI) Beximco
Salmeterol xinafoate 25mcg/puff or dose:
.
•
metered dose inhalation (MDI).
200 inhalations u.nit: 190.00 IP
+ SALMATE Inhaler (MDI) Square
Salmeterol xinafoate 25mcg/puff or dose:
metered dose inhalation (MDI).
200 doses unit: 190.72 MRP
t SALMATE HFA Inhaler (MDI) Square
Salmeterol xinafoate 25mcg/puff or dose:
metered dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant
200 inhalations unit: 210.00 MRP
•
QIMP-17 (101)
INDACATEROL21,54
INDACATEROL MALEATE: Dry Powder
Inhalation (DPI) Capsule
Indacaterol is a long-acting beta2 agonist (stimu­
lant), used for long-term bronchodilator treatment
of chronic obstructive pulmonary disease (COPD),
and not used for the relief of acute bronchospasm.
It is available�as- dry powder inhalation (DPI)
capsules containing indacaterol maleate equiva­
lent to indacaterol INN 150mcg and 300mcg.
Ind: Indacaterol is indicated for long-term,
maintenance bronchodilator treatment of airflow
obstruction in patients with chronic obstructive
pulmonary disease (COPD).
C/1: None.
S/E: Common (1 to 10%): Nasopharyngitis,
upper respiratory tract infection, cough, muscle
spasm, oropharyngeal pain, sinusitis, myalgia,
peripheral edema, ischemic heart disease,
diabetes mellitus and hyperglycemia, dry mouth,
rhinorrhea, musculoskeletal pain, chest pain.
Uncommon (0.1 to 1 %): Atrial fibrillation, chest
discomfort, vertigo, paresthesia.
•
Precautions & warnings: Asthma: Should not
be used in asthama.
Paradoxical bronchospasm: As with other
inhalation therapy, administration may result in
parado-xical bronchospasm that may be life­
threatening. If paradoxical bronchospasm occurs,
indacaterol should be discontinued immediately
and alternative therapy instituted.
Deterioration of disease: In case of deterioration
of COPD whilst on treatment, a reevaluation of
the patients and COPD treatment regimen should
be undertaken.
Systemic effects: As with other beta2 adrenergic
agonists, it should be used with caution in
patients with cardiovascular disorders (coronary
artery disease, acute myocardial infarction,
cardiac arrhythmias, hypertension); in patietns
with convulsive disorders or thyrotoxicosis; in
patients who are unusually responsive to beta2-
adrenergic agonists.
Cardiovascular effects: Like other beta2-
adrenergic agonists, may produce a clinically
significant cardiovascular effect in some patients
as measured by increases in pulse rate, blood
pressure, and/or symptoms, ECG changes.
Hypokalemia: Beta2-adrenergic agonists may
produce. significant hypokalemia in some patients,
which has the potential to produce adverse
cardiovascular effects. In patients with severe
COPD, hypo�alemia may be potentiated by
hypoxia and concomitant treatment which may
increase the susceptibility to cardiac arrhythmias.
Hyperglycaemia: Clinically notable changes in
blood glucose &/or serum potassium are generally
more frequent by 1 to 2% during clinical studies
at the recommended doses than on placebo.
lndacaterol should not be used in conjunction
with other long-acting beta2-adrenergic agonists
or medications containing long-acting beta2-
adrenergic agonists.
Pregnancy & lactation: Indacaterol should be
used during pregnancy and lactation only if the
expected benefit justifies the potential risk to the
fetus or the nursing infant.
Reproduction studies or other data in animals did
not reveal a problem or potential problem
RESPIRATORY DRUGS
concerning fertility in either males or females.
Dosage & admin: Adults: lndacaterol is
recommended as once-daily inhalation of the
content of one 150mcg capsule using the
indacaterol inhaler. The dosage should only be
increased on medical advice. Once-daily
inhalation of the content of one 300mcg
capsule using the indacaterol inhaler, has been
shown to provide additional clinical benefit to
some patients, e.g with regard to
breathlessness, particularly for patients with
severe COPD. The maximum dose is 300mcg
once-daily.
Children(< 18 years): Should not be used in
patients under'18 years of age.
Special patients population: No dosage
adjustment is required for geriatric patients,
patients with mild and moderate hepatic
impairment, or renally impaired patients; no
data is available for subjects with severe
hepatic impairment.
Mode of admin: Indacaterol dry powder
inhalation capsules must be administered only
by the oral inhalation route and only using the
indacaterol inhaler. Capsules must not be
swallowed. lndacaterol should be administered
�t the same time of each day. If a dose is
missed, the next dose should be taken at the
usual time on the next day. Capsules must
always be stored in the blister, & only removed
immediately before use.
·Rinsing the mouth after dry powder inhalation
is complete.
Drug inter: Indacaterol should be administered
with caution to patients being treated with
monoamine oxidase inhibitors, tricyclic
antidepressants, or drugs known to prolong the
QT interval; concomitant administration of other
sympathomimetic agents may potentiate the
undesirable effects; concomitant treatment with
methylxanthine derivatives, steroids, or
nonpotassium sparing diuretics may potentiate the
possible hypokalemic effect of beta2-adrenergic
agonists; should not be given together with
beta2-adrenergic blockers (including eye drops)
unless there are compelling reasons for their use;
inhibition of the key contributors of indacaterol
clearance, CYP3A4 and P-gp, has no impact on
safety of therapeutic doses.
Note: For further information, please consult
manufacturer's literature.
t ONBREZ BREEZHALER Inhaler (DPI)
Cap. Novartis
lndacaterol dry powder inhalation (DPI) capsules
containing indacaterol maleate equivalent to
indacaterol INN 150mcg and 300�cg/capsule.
Dosage & admin: See above under the text.
Onbrez Breezhaler (indacaterol) dry powder
inhalation capsules rnust be administered only
by the oral inhalation route and only using the
Onbrez Breezhaler inhaler. Rinsing the mouth
after dry powder inhalation is complete.
l 50mcg cap. x 30 pack: 2796.00 MRP
'
300mcg cap. x 30 pack: 3795.00 MRP
Other Adrenoceptor stimulants
The drugs discussed under this group are­
Adrenaline, Ephedrine, Orciprenaline etc •
RESPIRATORY DRUGS
ADRENALINE21,33
ADRENALINE: Injection/Inhaler
Ind: Bronchospasm, chronic bronchitis; emerge­
ncy treatment of acute anaphylaxis.
C/I: Hyperthyroidism, hypertension, coronary
disease
S/E: Anxiety, tremor, tachycardia, cardiac
arrhythmias.
Cardiac disease; diabetes; should not be used
within 2 wks. of MAO inhiitors. Not to be given
intravenously because of increased risk of
cardiac irregularities.
Dose: Bronchospasm, as a single dose by s.c. or
i.m or by oral inhalation of nebulised solution,
200-500mcg by aerosol inhalation, 280-560mcg.
(1-2 puffs) upto 3-4 times daily. Acute
ana phylaxis, by s.c or i.m injection, 0.5-1mg.
+ ADRENALINE Inj. Techno Drugs
Adrenaline 1 mg in 1ml ( 1:1000) ampoule:
injection
lml amp x 1O's pack: 250.00 MRP
+ ADRINE lnj. Gaco
Adrenaline lmg in l ml (1: 1000) ampoule:
injection
1 ampoule: 25.00 MRP
+ ADRINOR lnj. lncepta
Adrenaline 1mg in 1ml (1: 1000) ampoule:
injection
l ml ampe x 5's pack: 125.00 MRP
EPHEDRINE21,33
EPHEDRINE HCI: Tablet/Syrup/
Drop/Injection.
Ind: Bronchospasm, nasal congestion.
C/I: Hyperthyroidism, hypertension, coronary
disease, renal impairment.
S/E: Tremor, tachycardia, insomnia, urinary
retention, dry moulh cold extremities.
Caution: Cardiac diseases, diabetes. Should not
be given within 2 wks. of MAO inhibitors.
Adult: By mouth, 15-60mg 3 times daily
Child: Upto 1 year, 7.5 mg; 1-5years, 15mg; 6-
12years 30mg; all 3 times daily.
+ EPHIDIN Inj. Popular
Ephedrine hydrochloride 25mg/5ml ampoule:
injection
10 amps pack: 120.50 MRP
+ EPIDRON Inj. Renata
Ephedrine hydrochloride 25mg/5ml ampoule:
injection
5 amps pack: 60.25 MRP
+ FEDRIN Inj. Jayson
Ephedrine hydrochloride 25mg/5ml ampoule:
injection
10 amps pack: 120.50 IP
+ G-EPHEDRINE Inj. Gonoshasthaya
Ephedrin.e hydrochloride 5mg/5ml ampoule:
injection
5 amps pack: 60.00 MRP , Other common adverse reactions reported are­
Antimuscarinic
Bronchodilators21
Antimuscarinic bronchodilators are more effec-
•
QIMP-17 (102)
tive in chronic obstructive pulmonary disease
rather than in relieving asthma.
Ipratropium & oxitropium may be used by
inhalation in the management of chronic asthma
in patients who already require high-dose inhaled
corticosterodis. Ipratropium by nebulisation may
be added to other standard treatment in life
threatening asthma or where acute asthma fails to
improve with standard therapy.
Tiotropium is a long-acting, antimuscarinic
agent, which is often referred to as an anticholin­
ergic. It has similar affmity to the subtypes of
muscarinic receptors. It is indicated for the long­
term, once-daily approach to manage and mainte­
nance treatment of bronchospasm associated with
chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and emphysema.
IPRATROPIUM26 ,42
IPRATROPIUM BROMIDE: Oral inhalation/
Nasal spray I N ebulisation
Ipratropium bromide is a synthetic quaternary
anti-cholinergic parasympatholytic ammonium
compound, chemically related to atropine.
Ipratropium bromide is available as oral inhaler,
nasal spray or nebuliser solution.
Mode of action: lpratropium appears to inhibit
vagally mediated reflexes by antagonizing the
action of acetylcholine- the neurotransmitter
released by the vagus nerve. It is a competitive
antagonist at the muscarinic acetylcholine
receptors. Anti-cholinergics prevent the increases
in intracellular concentration of cyclic GMP
which are caused by interaction of acetylcholine
with the muscarinic receptors on bronchial
smooth muscle. The bronchodilation following
oral inhalation or nasal spray or nebulisation of
ipratropium bromide is primarily a local, site­
specific effect, not a systemic one.
Ind & uses: As bronchodilator in treatment of
chronic reversible airway obstruction as in
asthma and chronic obstructive pulmonary
disease (COPD) including chronic bronchitis
and emphysema.
Treatment of acute reversible airways obstruction.
Ipratropium bromide inhalation aerosol or nasal
spray is not indicated for the initial treatment of
acute episodes of bronchospasm where rapid
response is required.
C/I: Konwn hypersensitivity to ipratropium
bromide, atropine or its derivative. Also
contraindicated in patients with a history of
hypersensitivity to soya lecithin or related food
products such as soybean, lecithin and peanut.
S/E: Idiosyncratic reactions to ipratropium bro­
mide are rare. Severe adverse effects due to inhi­
bition of muscarinic receptors and ganglion
blockade are theoretically possible but unlikely
with the metered-dose aerosol.
Regular use of ipratropium can lead to a dry
mouth through inhibition of salivary flow.
dryness of the mouth & oropharynx, nausea,
dizziness, blurred vision/difficulty in accommo­
dation & drying of secretions.
Less frequently reported adverse reactions
include tachycardia, nervousness, paresthesia,
drowsiness, co-ordination difficulty, itching,
hives, flushing, alopecia, constipation, tremor &
mucosa! ulceration.
Case of precipitation or worsening of narrow­
angle glaucoma, acute eye pain & hypotension
also have been reported.
Allergic-type reactions such as skin rash, angio­
oedema of tongue, lips & face, urticaria (includ­
ing giant urticaria), laryngospasm and anaphylac­
tic reaction have also been reported; with
positive rechallenge in some cases. Ipratropium
bromide does not produce adverse effects on
mucocilliary clearance, in contrast to atropine
and other muscarinic antagonists. There is no
evidence �hat in the therapeutic dose range
ipratropium bromide has any adverse effect on
bronchial secretion.
Precaution: Patients should be advised that tem­
porary blurring of vision, precipitation or wors­
ening of narrow angle glaucoma or eye pain may
result if the aerosol is sprayed into the eyes.
If recommended dosage does not provide relief
or symptoms become worse, patients should
seek immediate medical attention. While taking
ipratropium bormide inhalation aerosol, other
inhaled drugs should not be used unless
prescribed.
Immediate hypersensitivity reactions may occur
after administration of ipratropium bromide, as
demonstrated by rare cases of urticaria,
angiooedema, rash, bronchospasm and
oropharyngeal oedema.
Pregnancy & lactation: The safety of ipratropi­
um bromide during human pregnancy has not
been established. It is also not known whether
ipratropium is excreted into the breast milk.
Therefore, the benefit of using ipratropium during
pregnancy and lactation must be weighed against
possible hazards to the fetus or neoborn child.
•
Dosage & admin: For oral inhalation/nasal
spray: Adults: The usual dose is 1-2 puffs/spray
3 or 4 times daily. Single dose up to 80mcg (4
puffs or spray of 20mcg/puff or 2 puffs of
40mcg/puff) may be required to obtain maxi­
mum benefit during early treatment. Patients
may take additional inhalations as required;
however, the total number of oral inhalations
or nasal spray should not exceed 12 puffs
(20mcg/puff) or 6 puffs ( 40mcg/puff) in 24 hrs.
Children: 6 to 12 years- usually 1-2 puffs or
spray (20mcg/puff) 2 to 3 times daily. Below 6
years- the usual dose is 1 puff or spray
(20mcg) 3 times daily. In order to ensure that
the inhaler is used correctly, administration
should be supervised by an adult.
For nebulisation: Children over 3 years- the
usual dose is 0.4-2.0ml ipratropium bromide
solution (100-500mcg) up to three times daily.
Adults (including elderly and adolescents)
over 12 years of age- the usual dose is 0.4-
2.0ml (100-500mcg) up to four times daily.
On clinical trials, no specific information &
adverse reactions on the use of the product in
the elderly is available.
Drug inter: Ipratropium bromide has been used
concomitantly with other drugs, including sym­
pathomimetic bronchodilators, methylxanthines,
steroids and cromolyn sodium, commonoy used
in treatment of COPD, without any adverse drug
reactions.
+ G-IPRA Respirator Solo. Gonoshasthaya
Ipratropium bromide 250mcg/ml: Respirator

(nebuliser) solution for inhalation.
20ml vial: 60.00 MRP
+ IPRAM ID Inhalar Beximco
Ipratropium bromide 20mcg/puff (spray): oral
inhalar.
Each canister of Ipramid inhaler contains 4mg of
I AMINOPHYLLINE21,48
' ipratropium bromide BP.
I
200 puffs inhalar: 200.00 IP
+ IPRATOP Nebuliser Soln. Incepta
Ipratropium bromide BP 250mcg/ml: solution for
nebulisation.
20ml bot: 130.00 MRP
+ IPREX Inhalar Square
Ipratropium bromide 20mcg/puff (spray): oral
,
inhalar.
Each canister of Iprex inhaler contains 4mg of
-
• ipratropium bromide BP.
200 puffs inhalar: 200.75 MRP
+ IPREX Nebuliser Solo. Square
Ipratropium bromide BP 500mcg/2ml ampoule:
solution for nebulisation.
2ml amp x lO's pack: 140.00 MRP
+ IPREX Respirator Soln. Square
Ipratropium bromide 250mcg/ml: Respirator
(nebuliser) solution for inhalation.
20ml pack: 130.49 MRP
t RINASE Respirator Solo. ACI
Ipratropium bromide 250mcg/ml: Respirator
(nebuliser) solution for inhalation.
20ml vial: 130.00 MRP
TIOTROPIUM42
TIOTROPIUM BROMIDE: DPl/MDI
Tiotropium is a long-acting antimuscarinic bron­
chodilator. It is available as dry powder inhalation
(DPI) & metered dose aerosol inhalation (MDI).
DP!: Tiotropium bromide monohydrate INN
l 8mcg/Rotacap. Dry powder inhalation is for
oral inhalation only.
MDI: Tiotropium bromide monohydrate INN
9mcg/puff; Metered dose aerosol inhalation (MDI).
Mode of action: Tiotropium is a long-acting,
antimuscarinic agent, which is often referred to
as an anticholinergic. It has similar affi11ity to the
subtypes of muscarinic receptors, M 1 to M5. In
the airways, it exhibits it's effects through
inhibition of M3-receptors at the smooth muscle
leading to bronchodilation. The bronchodilation
following inhalation of tiotropium is
predominantly a site-specific effect.
Ind: Tiotropium bromide is indicated for the
long-term, maintenance treatment of
bronchospasm associated with chronic
obstructive pulmonary disease (COPD),
including chronic bronchitis and emphysema.
C/I: Tiotropium is contraindicated in patients
with a history of hypersensitivity to atropine or
•
its derivatives, including ipratropium, or to any
component of the product.
-
-
S/E: The most commonly reported adverse
reaction was dry mouth; it was usually mild and
often resolved during continued treatment. Other
reactions reported include constipation, increased
heart rate, blurred vision, glaucoma, urinary
difficulty, and urinary retention.
Precaution: As an anticholinergic drug, tiotropi­
um may potentially worsen symptoms and signs
associated with narrow-angle glaucoma, prostatic
hyperplasia or bladder neck obstruction and
I
QIMP-17 (103)
should be used with caution in patients with any
of these conditions. As a predominantly renally
excreted drug, patients with moderate to severe
renal impairment treated with tiotropium· should
be monitored closely. Eye pain or discomfort,
blurred vision, visual halos or colored images in
congestion and corneal edema may be signs of
acute narrow angle glaucoma. Should any of
these signs and symptoms develop, consult a
physician immediately. Miotic eye drops alone
are not considered to be effe.ctive treatment.
Pregnancy & lactation: Tiotropium should be
used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.
The safety & effectiveness of tiotropium has not
been studied during labor and delivery. Clinical
data from nursing women exposed to tiotropium
are not also available, so, caution should be
exercised if tiotropium is administered to a
nursing mother.
Dosage & admin: Metered dose inhalation
(MDI):
Adults and adolescents 12 years & older: The
recommended dosage of tiotropium bromide is
the inhalation of 2 puffs (9mcg/puft) once
daily for the maintenance treatment of
bronchospasm associated with COPD. No
adjustment of tiotropium dosage in geriatric
patients is warranted.
Children below 12 years: Not recommended.
MDI or Metered dose inhaler is to be used by
aerosol inhalation only.
Dry powder inhalation (DPI):
Adults and adolescents 12 years & older: The
recommended dosage of tiotropium bromide is
the inhalation of 1 Rotacap (18mcg/Rotacap)
once daily for the maintenance treatment of
bronchospasm associated with COPD. No
adjustment of tiotropium dosage in geriatric
patients is warranted.
Children below 12 years: Not recommended.
DPI or Dry powder inhalation is for oral
inhalation only. Rotahaler device is used for
dry powder inhalation.
Rinsing the mouth after dry powder
inhalation is complete.
Drug inter: Tiotropium has been used
concomitantly with other drugs commonly used
in COPD without increases in adverse drug
reactions. These include sympathomimetic
bronchodilators, methylxanthines, and oral and
inhaled steroids. However, the co-administration
of tiotropium with other anticholinergic­
containing drugs ( e.g ipratropium) has not been
studied and is therefore not recommended.
+ TRIOMID Inhaler (MDI) Beximco
Tiotropium bromide monohydrate INN
9mcg/puff: Metered dose inhalation (MDI).
120 puffs unit: 350.00 IP
Theophylline & related drugs 21
.
Theophylline is a methylxanthine derivative,
used as bronchodilator to treat moderate to
severe reversible broncho-spasm that occurs in
asthma or chronic obstructive pulmonary disease
(COPD).
Theophylline is given by injection in its salt
form as aminophylline, a mixture of theophylline
RESPIRATORY DRUGS
with ethylenediamine, which is about 20 times
more soluble than theophylline alone, but have
no major therapeutic advantage. Aminophylline
thus contains about 85% theophylline.
AMINOPHYLLINE: Tablet/Injection/
Suppos.
Aminophylline BP is a stable mixture or combi­
nation of theophylline and ethylenediamine.
Ethylenediamine confers greater solubility in
water.
Ind: It is indicated for the treatment and
prophylaxis of bronchospasm associated with
asthma, emphysema and chronic bronchitis. Also
indicated in adults for the treatment of cardiac
asthma and left ventricular or congestive cardiac
failure.
C/I: Aminophylline should not be administered
to patients with hypersensitivity to xanthines or
ethylenediamine. It should not be administered to
patients with active peptic ulcer, since it may inc­
rease the volume & acidity of gastric secretions.
S/E: The most common adverse effects are
gastric irritation, nausea, vomiting, epigastric
pain and tremor. These are usually early signs of
toxicity; however, with high doses, ventricular
arrhythmias or seizures may be the first signs to
appear. Adverse reactions include:
Gastrointestinal symptoms- such as nausea, vom­
iting, epigastric pain, hematemesis, diarrhoea,
anorexia, intestinal bleeding and reactivation of
peptic ulcer; CNS symptoms- headache, irritabili­
ty, restlessness, insomnia, twitching, convulsion
& reflex hyperexcitability; Cardiovascular
symptoms- palpitation, tachycardia, hypotension,
circulatory failure, ventricular arrhythmias, and
flushing; Renal symptoms- albuminuria, diuresis
and hematuria; Others- hyperglycemia,
tachypnea and inappropriate ADH syndrome.
Precautions: Aminophylline should be given
with caution to patients with peptic ulceration,
hyperthyroidism, hypertension, cardiac
arrhythmias or other cardiovascular diseases, or
epilepsy, as these conditions may be exacerbated.
It should also be given with caution to patients
with heart failure, hepatic dysfunction, chronic
alcoholism, acute febrile illness, and to neonates
and the elderly, since in all of these circumstan
ces theophylline clearance may be decreased,
resulting in increases in serumtheophylline
concentrations and serum half-life.
Pregnancy & lactation: Theophylline crosses
the placental barrier and also passes freely into
breast milk, where concentrations are similar to
plasma levels. Safe use in pregnancy has not
been established relative to possible adverse
effects on fetal development. Therefore, use of
aminophylline in pregnant women should be
weighed against the risk of uncontrolled disease.
Dosage: By mouth: Adult, initially
100-200mg 2-3 times daily for one week, then
maintenance 200-600mg twice daily. Child,
under 1 year not recommended; over 1 year
12mg/kg body-wt. twice daily.
Special tablet preparations (LA/Rtd tablet): See
below under individul product.
Note: Tablets should be swallowed whole and
not chewed because of the structure of the
 RESPIRATORY DRUGS QIMP-17 (104)

tablet. bronchitis and emphysema. t CONTIFIL 400 SR Tab. Square

By injections: Adult, 125-250mg by slow (over C/I: Known hypersensitivity to its components; Theophylline sodium glycinate 400mg/tablet.
patients with active peptic ulcer disease.
·-
10-15 mins) i.v injection, usually given in 5°/o (sustained release). .
.

.
�
dextrose in aqua or normal saline. (rapid S/E: The following side effects have been 30's pack: 89.40 MRP �

injection may result in cardiac arrest). observed: Nausea, vomiting, epigastric pain and + CONTINE Tab. Aristopharma "
'V
Children, 2-3mg/kg 2-3 times daily by very diarrhoea; Headache, irritability, restlessness, Theophylline sodium glycinate 200mg &
•
•
•

slow i.v injection. insomnia, muscles twitching; Palpitation, 300mg/tablet.

By rectum in suppositories: Adult, 360mg once
or twice daily. Child, once or twice daily, upto
1 yr. 12.5-25mg; 1-5 yrs. 50-l OOmg; 6-12 yrs.
100-200mg.
Drug inter: Beta-blockers (e.g propranolol) may
oppose the effects of aminophylline.
Barbiturates, phenytoin & smoking may decrease
theophylline l�vels in blood or circulation.
•
+ AMINOPHYLLINE Tab. Ambee
Aminophylline 1OOmg/tablet
500's pack: 190.00 MRP
+ AMINOPHYLLINE Inj. Ambee
Aminophylline l 25mg/5ml ampoule: injection
5 amps pack: 27.30 MRP
+ AMINOPHYLLINE Tab. Bristol
Aminophylline 1 OOmg/tablet
200's pack: 190.00 MRP
+ FILIN Tab. Opsonin
Aminophylline 1 OOmg/tablet
1OO's pack: 34.30 MRP
+ FILIN lnj. Opsonin
Aminophylline 125mg/5ml ampoule: injection
10 amps pack: 47.95 MRP
+ L ARNOX-LA Tab. Beximco
Aminophylline BP 350mg/tablet (sustained
release-long acting).
Dosage & admin: The recommended initial
dose is 1 tablet (350mg) every 12 hours. The
dosage may be gradually increased to a
maximum of 2 tablets (700mg) twice a day
depending on the patient?s response.
350mg x 50's pack: 111.00 IP
+ MINOMAL R Tab. Pacific
Aminophylline 175 & 350mg/tablet (retard)
Dosage & admin: The recommended initial
dose is 1 tablet (350mg) every 12 horns. The
dosage may be gradually increased to a
maximum of 2 tablets (700mg) twice a-day
depending on the patients response.
175mg x l OO's pack: 123.00 MRP
350mg x 50's pack: 110.00 MRP
+ MINOMAL-R SR Tab. P acific
Aminophylline dihydrate 600mg/tablet
(sustained release ).
Dosage: 1/2 -1 tablet every 12 hours, unless
otherwise directed by the doctor.
Administration on a full stomach is advised.
20's pack: 72.00 MRP
THEOPHYLLINE Sodium Glycinate21,36
THEOPHYLLINE Sodium Glycinate:
Tablet/Capsule/Syrup
Structurally theophylline is a xanthine derivative.
It is available in tablet, capsule & syrup form.
Mode of action: Theophylline is a
bronchodilator. It directly relaxes the smooth
muscle of the bronchial airways, pulmonary
airways and pulmonary blood vessels.
tachycardia, hypotension, circulatory failure;
Tachypnoea; Potentiation of diuresis. Others:
Alopecia, hyperglycemia, rash etc.
P recautions: Theophylline should not be admin­
istered concurrently with other xanthine. Use with
caution in patients with hypoxemia, hypertension,
or those with history of peptic ulcer. Do not
attempt to maintain any dose that is not tolerated.
P regnancy & lactation: It is also not known
whether theophylline can cause fetal harm when
administered to a pregnant woman or can affect
reproduction capacity. Xanthine should be given
to a pregnant woman only if clearly needed.
Theophylline is excreted into breast milk and
may cause irritability or other signs of toxicity in
nursing infants. So, it should be given to nursing
mother only if clearly needed.
Dosage & admin: Dosages are adjusted to
maintain serum theophylline concentrations
that provide optimal relief of symptoms with
minimal side effects. The recommended
dosages for achieving serum theophylline
concentrations within the accepted therapeutic
range are as following:
Adult: 125-250mg 3-4 times daily.
Children: 1-6 months, lOmg/kg/day; 6 months-
1 year 15mg/kg/day; 1-9 years, 24mg/kg/day;
10-16 years, 18mg/kg/day, in 3-4 divided doses.
Drug inter: Allopurinol, cimetidine,
ciprofloxacin, erythromycin, lithium carbonate,
oral contraceptive, propranolol increases serum
theophylline level when administered
concomitantly and rifampicin decreases serum
theophylline level.
N.B: 2gm of theophylline sodium glycinate is
approximately equivalent to 1.1gm theophylline
anhydrous.
+ AROFIL 300 SR Tab. lncepta
Theophylline sodium glycinate 300mg/tablet.
(sustained release).
50's pack: 117.50 MRP
+ AROFIL 400 SR Tab. Incepta
Theophylline sodium glycinate 400mg/tablet.
(sustained release).
50's pack: 149.00 MRP
+ ASMAIN Syp. Edruc
Theophylline sodium glycinate 120mg/5ml: syrup
l OOml bot: 25.00 MRP
+ ASMALOC 300 SR Tab. Sharif
Theophylline sodium glycinate 300mg/tablet.
(sustained release).
50's pack: 118.00 MRP
+ ASMALOC 400 SR Tab. Sharif
Theophylline sodium glycinate 400mg/tablet.
(sustained release).
50's pack: 149.00 MRP
+ ASMALOC Syp. Sharif
Theophylline sodium glycinate 120mg/5ml: syrup
. lOO's pack: 331.00 MRP
lOOml bot: 30.00 MRP
+ CONTIFIL 300 SR Tab. Square
•
200mg x l OO's pack: 160.00 MRP
300mg x l OO's pack: 235.00 MRP
+ CONTINE Syp. Aristopharma
Theophylline sodium glycinate 120mg equivalent
to theophylline 55mg/5ml: syrup
1OOml bot: 30.95 MRP
+ JASOPHYLIN Ta1'. Jayson
Theophylline sodium glycinate 300mg/tablet
1OO's pack: 131.00 MRP
+ JASOPHYLIN Syp. Jayson
Theophylline sodium glycinate 120mg/5ml: syrup
1OOml bot: 25.10 MRP
+ NEULYN Tab. Orion Pharma
Theophylline sodium glycinate 400mg/tablet.
(sustained release).
1OO's pack: 251.00 MRP
+ TEOLEX 200 SR Tab. ACI
Theophylline sodium glycinate 200mg/tablet.
(sustained release).
200mg x l OO's pack: 149.00 MRP
+ TEOLEX 300 SR Tab. ACI
Theophylline sodium glycinate 300mg/tablet.
(sustained release).
300mg x 1OO's pack: 200.00 MRP
+ TEOLEX 400 SR Tab. ACI
Theophylline sodium glycinate 400mg/tablet.
(sustained release).
400mg x IOO's pack: 267.00 MRP
+ THENGLATE SR Tab. Acme
Theophylline sodium glycinate 250mg &
400mg/tablet (sustained release).
250mg x 50's pack: 87.50 MRP
400mg x 50's pack: 133.50 MRP
+ THENGLATE Syp. Acme
Theophylline sodium glycinate 120mg/5ml: syrup
1OOml bot: 30.95 MRP
+ THEONATE Tab. Doctor's
Theophylline sodium glycinate 300mg/tablet.
1OO's pack: 131.00 MRP
+ THEONATE Syp. Doctor's
Theophylline sodium glycinate l 20mg/5ml: syrup
50ml bot: 15.20 MRP
l OOml bot: 25.00 MRP
+ THEOVENT-SR Tab. Drug Inter.
Theophylline sodiu.m glycinate USP 200mg &
300mg/tablet (sustained release).
Theophylline sodium glycinate BP 400mg/tablet.
(sustained release).
200mg x l OO's pack: 159.00 MRP
300mg x 1OO's pack: 200.00 MRP
400mg x 50's pack: 134.00 MRP
+ THEOVENT SR Cap. Drug Inter.
Theophylline sodiun glycinate 300mg/capsule
(sustained release granules).
1 OO's pack: 292.00 MRP
t UNICONTIN 200 CR Tab. Mundipharma
Theophylline sodium glycinate 200mg/tablet.
(controlled release).
+ UNICONTIN 400 CR Tab. M undipharma

Ind: Theophylline is indicated for relief and/or Theophylline sodium glycinate 300mg/tablet. Theophylline sodium glycinate 400mg/tablet.
prevention of symptoms from asthma and (sustained release). (controlled release).
reversible bronchospasm associated with chronic l OO's pack: 235.41 MRP I OO's pack: 630.00 MRP

I

t UNIKON SR Tab. Ibo Sina
Theophylline sodium glycinate 400mg/tablet.
(sustained release).
l OO's pack: 268.00 MRP
t UNIKON Syp. Ibo Sina
Theophylline sodium glycinate 120mg/5ml: syrup
l OOml bot: 26.00 MRP
t UNILIN Syp. Opsonin
Theophylline sodium glycinate 120mg/5ml: syrup
50ml bot: 13.28 MRP
1OOml bot: 23.28 MRP
THEOPHYLLINE AnhydrouSll,36
THEOPHYLLINE ANHYDROUS:
Tablet/Capsule
Ind: Bronchospasm associated with asthma, ch.
bronchitis, emphysema.
C/I; S/E; Cautions: See above under the text of
'theophylline sodium glycinate'.
Pregnancy & lactation: See above under the text
of 'theophylline sodium glycinate'.
Dosage: Adult, over SOkg 2S0-300mg (1 tablet)
twice daily in the morning & evening. Adults
with low body weight & adolescents, half the
adult dose (112 tablet) 2-3 times daily.
l Children: 10-lSmg/kg given in 2 divided doses
I at 12 hours intervals. It is better taken after
I meals with a little water. It is suitable for
longterm administration.
Drug inter: See above under the text of
'theophylline sodium glycinate'.
I t ASMACON SR Tab. Pacific
Theophylline anhydrous 400mg/tablet (sustained
release).
50's pack: 133.50 MRP
+ CONTINE-400 Tab. Aristopharma
Theophylline anhydrous 400mg/tablet (in
continuous controlled release system).
Dose: See above under the text; but instead of
two times, give once daily.
l OO's pack: 298.00 MRP
t OD PHYLLINE Tab. Sun Pharma
Theophylline anhydrous 400mg/tablet (controlled
release).
Dose: See above under the text; but instead of
two times, give once daily.
400mg x 50's pack: 133.50 MRP
t UNILIN CR 200 Tab. Opsonin
Theophylline anhydrous 200mg/tablet (controlled
release).
200mg x IOO's pack: 131.07 MRP
t UNILIN CR 300 Tab. Opsonin
Theophylline anhydrous 300mg/tablet (controlled
release).
300mg x l OO's pack: 184.73 MRP
t UNILIN CR 400 Tab. Opsonin
Theophylline anhydrous 400mg/tablet (controlled
release).
Dose: See above under the text; but instead of
two times, give once daily.
400mg x 1OO's pack: 240 .15 MRP
Compound bronchodilator
prepns.
SALBUTAMOL + IPRATROPJUM42,48
•
QIMP-17 (105)
SALBUTAMOL + IPRATROPIUM BRO­
MIDE: Metered dose inhaler(MDI)/ Nebuliser
This is a combined formulation of two
components- salbutamol, a short-acting, selective
beta2-adrenergic bronchodilator and ipratropium
•
bromide, an anti-cholinergic bronchodilator.
This preparation is available as- i. metered dose
inhalation aerosol, which delivers 1OOmcg of
salbutamol BP & 20mcg of ipratropium bromide
BP per actuation; ii. nebuliser solution in ampoule,
which contains 2.5ml isotonic, solution for
inhalation of salbutamol sulphate BP equivalent
to salbutamol 2.5mg and ipratropium bromide BP
equivalent to ipratropium 0.5mg per ampoule.
Ind: This combined formulation (metered dose
aerosol and nebuliser solution) is indicated for
use in patients with chronic obstructive
pulmonary disease (COPD) on a regular aerosol
bronchodilator who continue to have evidence of
bronchospasm and who require a second
bronchodilator.
C/I: See above under the text of 'salbutamol' &
'ipratropium bromide' separately.
S/E; Precautions: See above under the text of
'salbutamol' & 'ipratropium bromide' separately.
Pregnancy & lactation: There are no adequate
and well-controlled studies of salbutamol &
ipratropium bromide combination inhalation
aerosol in pregnant women. So, the use of this
combination aerosol product for the tre atmnt of
COPD during pregnancy and labor should be
restricted to those patients in whom the benefits
clearly outweigh the risk to the fetus.
It is not known whether the components of
salbutamol & ipratropium bromide combination
inhalation aerosol are excreted in human milk.
However, because many drugs are excreted in
human milk, caution should be exercised when
this combination inhalation aerosol is
administered to a nursing mother.
Dosage: Adults & chidren over 12 years:
Metered dose inhalation: The dose of
inhalation aerosol is 2 puffs 4 times a day.
Patients may take additional inhalations as
required; however, the total number of
inhalations should not exceed 12 in 24 hours.
Nebuliser solution: Nebuliser solution in
ampoule may be administered from a suitable
nebuliser or an intermittent positive pressure
ventilator. Adults & chidren over 12 years, 1
ampoule as required for the relief of symptoms
or as directed, up to 3 or 4 ampoules daily.
Patients should be advised to consult a doctor
or the nearest hospital immediately in the case
of acute or rapidly worsening dyspnoea if
additional inhalations do not produce an
adequate improvement.
Children (below 12 years): Not recommended.
t COMBAIR HFA Inhaler (MDI) ACI
Each single actuation or puff of this aerosol
inhaler delivers I OOmcg of salbutamol BP &
20mcg of ipratropium bromide BP; metered dose
inhaler (MDI), using HFA (hydrofluoroalkane) as
propellant.
200 puffs unit: 250.00 MRP
t COMBAIR Respiratory Solo. ACI
Each ml of respiratory (nebuliser) solution
contains salbutamol sulphate BP equivalent to
salbutamol 2.5mg and ipratropium bromide BP
equivalent to ipratropium 0.5mg (500mcg).
RESPIRATORY DRUGS
20ml solution: 225.JO MRP
t IPRALIN HFA Inhaler (MDI)
Aristopharma
Each single actuation or puff of this aerosol
inhaler delivers 1 OOmcg of salbutamol BP &
20mcg of ipratropium bromide BP; metered dose
inhaler (MDD, using HFA (hydrofluoroalkane) as
propellant.
200 puffs unit: 250.00 MRP
+ IPRASOL Inhaler (MDI) Beximco
Each single actuation or puff of this aerosol
inhaler delivers 1OOmcg of salbutamol BP &
20mcg of ipratropium bromide BP; metered dose
inhaler (MDI).
200 puffs unit: 230.00 IP
t SALPIUM HFA Inhaler (MDI) Acme
Each single actuation or puff of this aerosol
inhaler delivers 1OOmcg of salbutamol BP &
20mcg of ipratropium bromide BP; metered dose
inhaler (MDI), using HFA (hydrofluoroalkane) as
propellant.
200 puffs unit: 250.00 MRP
+ SULPREX Inhaler (MDI) Square
Each single actuation or puff of this aerosol
inhaler delivers 1OOmcg of salbutamol BP &
20mcg of ipratropium bromide BP; metered dose
inhaler (MD n.
200 puffs unit: 230.86 MRP
t SULPREX HFA Inhaler (MDI) Square
Each single actuation or puff of this aerosol
inhaler delivers 1 OOmcg of salbutamol BP &
20mcg of ipratropium bromide BP; metered dose
inhaler (MDI), using HFA (hydrofluoroalkane) as
propellant.
200 puffs unit: 250.00 MRP
+ SULPREX Nebuliser Solo. Square
Each ampoule of nebuliser solution contains
2.5ml isotonic solution for inhalation of
salbutamol sulphate BP equivalent to salbutamol
2.5mg and ipratropium bromide BP equivalent to
ipratropium 0.5mg (500mcg) per ampoule.
2.5ml amp x IO's pack: 150.00 MRP
t SULPREX HFA Refill Square
Each single actuation or puff of this refill aerosol
delivers 1OOmcg of salbutamol BP & 20mcg of
ipratropium bromide BP; metered dose inhalation
(MDI) refill, using HFA (hydrofluoroalkane) as
propellant.
200 puffs HFA refill: 230.00 MRP
+ WIND EL Plus Nebuliser Solo. Incepta
Each ampoule of nebuliser solution contains
2.5ml isotonic solution for inhalation of
salbutamol sulphate BP equivalent to salbutamol
2.5mg and ipratropium bromide BP equivalent to
ipratropium 0.5mg per ampoule.
2.5ml amp x 1 O's pack: 150.00 MRP
2. PROPHYLACTICS OF
ASTHMA21
2.1 Cromoglycate & related drugs: such as,
Sodium cromoglycate, Nedocromil sodium
& related drug such as, ketotifen.
2.2 Leukotriene receptor antagonists: such as,
Montelukast, Zafirlukast.
Cromoglycate & Related drugs
 RESPIRATORY DRUGS
SODIUM CROMOGLYCATE 21,33,42
SODIUM CROMOGLYCATE: Aerosol Spray
Introduction & mode of action: Sodium cromo­
glycate is an antiasthmatic, antiallergic and mast
cell stabilizer. It has no intrinsic bronchodilator,
antihistaminic, vasoconstrictor or anti-inflamma­
tory activity. It prevents release of the mediators
of type- I allergic reactions, including histamine
and slow reacting substance of anaphylaxis
(SRS-A) from sensitized mast cells after the anti­
gen-antibody reaction has taken place. The drug
does not inhibit the binding of IgE to mast cells,
nor the interaction between cell bound IgE and
the specific antigen; inst� sodium cromogly­
cate suppresses the release of substances (e.g his­
tamine, SRS-A) in response to this reaction. The
drug also inhibits type-ID (late allergic, arthus)
reactions to a lesser extent. The action of sodium
cromoglycate on the mast cell is not restricted
to antigen-evoked secretion, since the drug has
also been shown to inhibit secretion induced by
other mast cell secretagogues (e.g the polyamine
48/80). Bronchial asthma induced by the
inhalation of antigens can be inhibited to varying
degrees by sodium cromoglycate pre-treatment.
Sodium cromoglycate acts locally on the lungs to
which it is directly applied by inhalation.
Ind: Prophylaxis of bronchial asthma; prevention
of exercise-induced asthma. Children seem to
response better than adults.
·
It has no value in the treatment of acute attack
of asthma.
C/I: Patients who have shown hypersensitivity to
sodium cromoglycate or to any of its compo­
nents. It is not indicated as the primary treatment
of status asthmaticus or other acute episodes of
asthma where intensive measures are required.
S/E: Coughing, transient bronchospasm & throat
irritation due to inhalation of powder.
Precautions: The recommended dosage should
be decreased in patients with renal or hepatic
dysfunction.
Where a concomitant bronchodilator is pres­
cribed, it is recommended that this be adminis­
tered prior to the sodium cromoglycate inhalation.
In patients currently treated with steroids, the
addition of sodium cromoglycate inhalation to
the regimen may make it possible to reduce the
I times daily; when control achieved may be
main tenance dose or to discontinue steroid com­
pletely. The patient must be carefully supervised
while the steroid dose is reduced; a rate of reduc­
tion of l 0% weekly is suggested. If reduction of
steroid dosage is possible, sodium cromoglycate
inhalation should not be withdrawn until steroid
cover has been re-instituted.
Since the therapy is prophylactic, it is important
to continue therapy in those patients who get
benefit. If it is necessary to withdraw this
treatment, it should be done gradually over a
period of one week.
Pregnancy & lactation: As with all medication,
caution should be exercised specially during the
first trimester of pregnancy. Cumulative experi­
ence with sodium cromoglycate suggests that it
has no adverse effects on foetal development.
However, it should only be used in pregnancy
where there is a clear need.
It is not known whether sodium cromoglycate is
excreted in the breast milk, there is also no evi-
•
QIMP-17 (106)
dence that the use of sodium cromoglycate has Adult: l -2mg twice daily with food.
any undesirable effects on the breast-fed baby. Child: Under 2 years, not recommended; over
Dose: By aerosol inhalation, adults & chil­ 2 years lmg twice daily with food.
dren- 1 Omg (or 2 puffs) 4 times daily initially
at regular intervals in spinhaler, increasing in
severe cases or duringperiods of risk to 6-8 •®
times daily. Before exercise, additional doses
may be taken. Maintenance, Smg(l puff) 4
times daily. Therapy should be continuous. Ketotifen fumerate tablet & syrup
By inhalation of powder, adults & children-
20mg 4 times daily, increased in severe cases
SK•F
to 8 times daily.
By inhalation of nebulised solution, adults &
+ AEROFEN Tab. Silva
children- 20mg 4 times daily, increased in
Ketotifen fumerate Img/tablet.
severe cases to 6 times daily.
50's pack: 75.00 MRP
+ INTAL 5 Inhaler Sanofi-aventis + AEROFEN Syp. Silva
I
Sodium cromoglycate 5mg/inhalation; 112 Ketotifen fi1merate l mg/5ml: syrup.
inhalations tinit: spin inhaler. l OOml bot: 45.00 MRP
112 inhalations unit: 515.00 MRP + ALARID Tab. Square
Ketotifen fumerate Img/tablet.
IOO's pack: 150.00 MRP
NEDOCROMIL SODJUM2 1,33
+ ALARID Syp. Square
Ketotiten fumerate l mg/5ml: syrup.
NEDOCROMIL SODIUM: Aerosol Inhalation
lOOml bot: 40.15 MRP
Nedocromil sodit1m has a pharmacological action
+ ALLERKIT Syp. MonicoPharma
similar to that of sodium cromoglycate.
Ketotifen fi1merate l .38mg/5ml: syrup.
Ind: Prophylaxis of asthma; management of
l OOml bot: 40.00 MRP
reversible obstructive airway diseases (ROAD) in
+ ASMAFEN Tab. Globe
patients of a wide age range. It is intended for
Ketotifen fumerate I mg/tablet.
regular prophylactic treatment & not for sympto­
I OO's pack: 150.00 MRP
matic relief. (Other than bronchial asthma, ROAD
+ ASMAFEN Syp. Globe
includes asthmatic bronchitis, late onset asthma,
Ketotifen fi1merate l mg/5ml: syrup.
exercise induced asthma, & bronchospasm
IOOml bot: 40.00 MRP
provoked by a variety of stimuli such as cold air,
+ BROKET Tab. Orion Pharma
inhaled allergens, atmospheric pollutants and
Ketotifen fumerate l mg/tablet.
other irritants).
1OO's pack: 151.00 MRP
C/I: There are no specific contra-indications.
+ BROKET Syp. Orion Pharma
S/E; Cautions: See under sodium cromoglycate;
Ketotifen fumerate l mg/5ml: syrup.
also headache, nausea, vomiting, dyspepsia,
l OOml bot: 40.15 MRP
abdominal pain (mild and transient); bitter taste.
+ FENAT Tab. Drug Inter.
Pregnancy & lactation: Studies in pregnant and
Ketotifen fumerate I mg/tablet.
lactating animals have failed to reveal any
IOO's pack: 200.00 MRP
hazard; however, as with all new medicines
+ FENAT Syp. Drug Inter.
caution should be exercised, especially during the
Ketotifen fumerate l mg/5ml: syrup.
frrst trimester of pregnancy.
I OOml bot: 45.00 MRP
Dosage & Admin: Adults (including the
+ KEFfON Syp. Zenith
elderly) and children over 6 years of age, in
Ketotifen fumerate l mg/5ml: syrup.
initial and maintenance therapy 4mg (2 puffs)
l OOml bot: 40.00 MRP
twice daily; if necessary may be increased to 4
+ KETIFEN Tab. Acme
Ketotifen fi.unerate l mg/tablet.
possible to reduce to 2 times daily. R egular
l OO's pack: 200.00 MRP
use 1s necessary.
•
+ KETIFEN Syp. Acme
Children below 6 years, not recommended.
Ketotifen fumerate l mg/5ml: syrup.
l OOml bot: 45.00 MRP
+ T ILADE 2 Inhaler Sanofi-aventis
+ KETODIL Cap. Techno Drugs
Nedocromil sodium 2mg/actuation or puff;
Ketotifen fumerate l mg/capsule.
metered dose aerosol inhalation.
50's pack: I 00.00 MRP
112 actuations unit: 900.00 MRP
+ KETODIL Syp. Techno Drugs
Ketotifen fumerate l mg/5m1: syrup. •
KETOTIFEN2 1,33 l OOml bot: 45.00 MRP
+ KETOF Tab. Ibo Sina
KETOTIFEN: Tablet/Syrup Ketotifen fumerate l mg/tablet.
Ind: Prophylaxis of bronchial asthma; symptom­ l OO's pack: 160.00 IP
atic relief of allergy such as hay fever, urticaria. + KETOF Syp. Ibo Sina
C/I: Concurrent admin. of oral hypoglycaemics. Ketotifen fumerate l mg/5ml: syrup.
S/E: Dry mouth, sedation. 1 OOml bot: 50.00 IP
Cautions: Alertness may be impaired; avoid + KETOMAR Tab. Incepta
alcohol; previous anti-asthmatic treatment should Ketotifen fumerate l mg/tablet.
be continued for a minimum of 2 weeks after IOO's pack: 150.00 MRP
initiation of ketotifen treatment. + KETOMAR Syp. Incepta

Ketotifen fi1merate l mg/5ml: syrup.
1OOml bot: 40.00 MRP
t KETOPAC Tab. Pacific
Ketotifen fumerate l mg/tablet.
l OO's pack: 200.00 MRP
t KETOPAC Syp. Pacific
Ketotifen fi1merate l mg/5ml: syrup.
l OOml bot: 40.00 MRP
+ KETORIF Tab. Biopharma
Ketotifen fumerate l mg/tablet.
l OO's pack: 150.00 MRP
t KETORIF Syp. Biopharma
Ketotifen fi1merate l m g/5ml: syrup.
1OOml bot: 40.00 MRP
t KETOTIF Tab. Delta Pharma
Ketotifen fumerate l mg/tablet.
l OO's pack: 150.00 MRP
t KOFEN Tab. Opsonin
Ketotifen fumerate l mg/tablet.
l OO's pack: 175.94 MRP
t KOFEN Syp. Opsonin
Ketotifen fumerate l mg/5ml: syrup.
l OOml bot: 39.58 MRP
+ MINIA Syp. Novo Healthcare
Ketotifen fumerate l mg/5ml: syrup.
l OOml bot: 45.00 MRP
t PROSMA Tab. ACI
Ketotifen fumerate 1mg/tablet.
l OO's pack: 200.00 MRP
t PROSMA Syp. ACI
Ketotifen fumerate l mg/5ml: syrup.
l OOml bot: 45.00 MRP
t SAN.KETO Tab. Sandoz
Ketotifen fumerate !mg/tablet.
l OO's pack: 250.00 MRP
t S-KIT Tab. Sharif
Ketotifen fi1merate l mg/tablet.
50's pack: 100.00 MRP
t S-KIT Syp. Sharif
Ketotifen fumerate l mg/5ml: syrup.
lOOml bot: 45.00 MRP
t STAFEN Tab. Aristopharma
Ketotifen fumerate !mg/tablet.
l OO's pack: 160.00 MRP
t STAFEN Syp. Aristopharma
Ketotifen fumerate l mg/5ml: syrup.
1 OOml bot: 42.00 MRP
+ TIFEN Tab. Somatec
Ketotifen fumerate l mg/tablet.
1OO's pack: 200.00 MRP
t TIFEN Syp. Somatec
Ketotifen fumerate l mg/5ml: syrup.
l OOml bot: 45.00 MRP
t TOFEN Tab. Beximco
Ketotifen fumerate !mg/tablet.
l OO's pack: 200.00 IP
200's pack: 400.00 IP
t TOFEN Syp. Beximco
Ketotifen fumerate l mg/5ml: syrup.
l OOml bot: 50.00 IP
+ TOMA Tab. Navana
•
Ketotifen fumerate !mg/tablet.
1OO's pack: 200.00 IP
+ TOMA Syp. Navana
Ketotifen fumerate l mg/5ml: syrup.
I
QIMP-17 (107)
50ml bot: 25.00 IP
lOOml bot: 45.00 IP
t TOTI Tab. SK+F
Ketotifen fumerate 1mg/tablet.
lOO's pack: 150.00 MRP
t TOTI Syp. SK+F
Ketotifen fi1merate l mg/5ml: syrup.
IOOml bot: 45.00 MRP
t TOTIFEN Tab. Renata
Ketotifen fumerate l mg/tablet.
l OO's pack: 150.00 MRP
t TOTIFEN Syp. Renata
Ketotifen fumerate l mg/5ml: syrup.
l OOml bot: 40.00 MRP
t ZADIFEN Tab. UniMed & UniHealth
Ketotifen fumerate l mg/tablet.
50's pack: 75.00 MRP
t ZADIFEN Syp. UniMed & UniHealth
Ketotifen fumerate l mg/5ml: syrup.
l OOml bot: 35.00 MRP
t ZADIT Tab. Popular
Ketotifen fumerate l mg/tablet.
1 OO's pack: 151.00 MRP
t ZADIT Syp. Popular
Ketotifen fumerate l mg/5ml: syrup.
IOOml bot: 40.00 MRP
t ZITEN Tab. Pharmadesh
Ketotifen fumerate !mg/tablet.
I OO's pack: 200.00 MRP
t ZITEN Syp. Pharmadesh
Ketotifen fi1merate l mg/5ml: syrup.
IOOml bot: 40.00 MRP
Leukotriene receptor
antagonists
•
MONTELUKAS'f26,46
MONTELUKAST : Tablet/Chewable tablet/
Oral granules
Montelukast is a selective and orally active
leukotriene receptor antagonist, synthesized
chemically. It is used as prophylactic and also in
the management of chronic asthma. It is available
as- Montelukast sodium INN 4mg, 5mg & 1Omg
oral, orodispersible & chewable tablet.
Mode of action: Montelukast is a selective &
competitive leukotriene receptor antagonist, that
inhibits the cysteinyl leukotriene CysLTl to
occupy the receptors. The occupation of
leukotriene receptors by the cysteinyl leukotriene
(CysLT l ) has been correlated with the patho­
physiology of asthma. Montelukast demonstrates
virtually no affinity for adrenergic, histamine,
serotonin, muscarinic or prostanoid receptors.
Ind: Montelukast is indicated for the prophylaxis
and treatment of chronic asthma in adults and
paediatric patients 2 years of age and older.
C /I: History of hypersensitivity to any compo­
nent of the product.
S/E: Montelukast is usually well-tolerated.
However, there may be some side- effects, which
RESPIRATORY DRUGS
include dizziness, headache, diarrhoea, restless­
ness, abdominal pain, cough, fever, asthenia, rash
and upper respiratory tract infection.
Precautions: Montelukast is not indicated for
use in the reversal of bronchospasm in acute
asthma attacks (in case of status asthmaticus).
In rare cases, patients on therapy with
Montelukast may present with systemic
eosinophilia, sometimes presenting with clinical
I features of vasculitis consistent with churg­
strauss syndrome- a condition which is often
treated with systemic corticosteroid therapy .
Physician �hould be alert to eosinophilia,
vasculitic rash, worsening pulmonary symptoms,
cardiac complications, and/or neuropathy
presenting in their patients. A causal association
between Montelukast and these underlying
conditions has not been established.
Pregnancy & lactation: There are no adequate
and well-controlled studies of Montelukast in
pregnant women, so it should be used during
pregnancy only if clearly needed.
It is also not known whether Montelukast is
excreted in human mi� so caution should be
exercised when Montelukast is given to a nursing
mother.
Dosage & admin: Adults (15 years & over)­
lOmg daily to be taken in the evening.
C hildren, 6.14 years- 5mg daily to be taken in
the evening; 2-5 years- 4mg daily to be taken
in the evening. Paediatric patients younger
than 2 years of age- not recommended.
Drug Inter: Montelukast has been administered
with other therapies routinely used in the pro­
phylaxis and treatment of chronic asthma with no
appropriate increase in adverse reactions.
Cytochrome P-450 inducers: Although pheno­
barbital induces hepatic metabolism, no dosage
adjustment for montelttlcast is recommended. It is
reasonable to employ appropriate clinical
monitoring when potent cytochrome P-450
enzyme inducers, such as phenobarbital or
rifampin, are co-administered with montelukast.
+ AERON Ff 4 Tab. Healthcare
Montelukast sodium INN 4mg/tablet (flash or
orally dispersible tablet)
4mg x 30's pack: 180.00 MRP
+ AERON Ff 5 Tab. Healthcare
Montelukast sodium INN 5mg/tablet (flash or
orally dispersible tablet)
Smg x 30's pack: 240.00 MRP
+ AERON Tab. Healthcare
Montelt1kast sodium INN I Omg/tablet
IOmg x 30's pack: 450.00 MRP
+ AMEKAST Tab. Beacon
Montelukast sodit1m INN 4mg, 5mg &
1 Omg/tablet
4mg x 30's pack: 180.00 MRP
Smg x 30's pack: 240.00 MRP
I Omg x 20's pack: 300.00 MRP
t AROKAST Tab. Navana
Montelukast sodit1m INN 4mg, 5mg &
1 Omg/tablet
4mg x 30's pack: 150.00 MRP
. ,. . .-.
:.'
'
 ® QIMP-17 (108) •

Montelukast t LUMONA4 Granules SK+F oral suspension.

5mg x 30's pack: 210.00 MRP
1Omg x 30's pack: 300.00 MRP
Montelukast sodium INN 4mg granules in packet: 4mg sachet x 30's pack: 240.00 MRP
oral suspension. t MONOVAS Tab. White Horse
4mg packet x 30's pack: 180.00 MRP Montelukast sodium USP 1Omg/tablet
+ MAXAIR Tab. RAK Pharma lOmg x 30's pack: 360.00 MRP
Montelukast sodium INN 5mg & 1Omg/tablet t MONPROX 10 Tab. Rangs Pharma
5mg x 30's pack: 240.00 MRP Montelukast sodium INN 1Omg/tablet
'

t AROVENT Tab. Orion Pharma
Montelukast sodi11m INN 5mg & 1Omg/tablet
5mg x 20's pack: 160.00 MRP
1Oi'ng x 20's pack: 300.00 MRP
t ASMONT Tab. Somatec
Montelukast sodium INN 4mg, 5mg &
1Omg x 20's pack: 300.00 MRP lOmg x lO's pack: 150.00 MRP
t M-KAST Tab. Drug Inter. t MONTAIR Tab. Incepta
Montelukast sodium INN 4mg, 5mg & 1Omg/tablet Montelukast sodi11m INN 4mg, 5mg &
4mg x 30's pack: 150.00 MRP lOmg/tablet
5mg x 30's pack: 210.00 MRP 4mg x 30's pack: 180.00 MRP
lOmg x 20's pack: 240.00 MRP 5mg x 30's pack: 240.00 MRP "

1Omg/tablet t M-LUKAS Tab. Popular lOmg x 20's pack: 300.00 MRP

'

4mg x 20's pack: 120.00 MRP Montelukast sodium INN 4mg, 5mg & 1Omg/tablet 1Omg x 30's pack: 450.00 MRP
5mg x 1O's pack: 70.00 MRP 4mg x 30's pack: 180.00 MRP t MONTECAST 10 Tab. Pacific
•

lOmg x lO's pack: 100.00 MRP
+ CROMA Tab. Sharif
Montelukast sodium INN 4mg, 5mg &
5mg x 30's pack: 240.00 MRP Montelukast sodium INN 1Omg/tablet
1Omg x 30's pack: 450.00 MRP 1Omg x 20's. pack: 300.00 MRP
+ MOKAST Tab. Alco Pharma t MONTEK Tab. Sun Pharma
• ••
.

1Omg/tablet
4mg x 30's pack: 180.00 MRP
5mg x 20's pack: 160.00 MRP
1Omg x 30's pack: 450.00 MRP
Montelukast sodium INN 4mg & 1Omg/tablet Montelukast sodium INN 4mg & 1Omg/tablet
4mg x 20's pack: 120.00 MRP 4mg x 30's pack: 180.00 MRP
lOmg x lO's pack: 100.00 MRP lOmg x 30's pack: 450.00 MRP
t MOLUKAT Tab. Kemiko t MONTELA 5 Chew. Tab. Delta Pharma
..

t EDRON 10 Tab. Edruc Montel11kast sodi11m INN 4mg, 5mg & 1Omg/tablet Montelukast sodium INN 5mg/tablet (chewable)
Montelukast sodium INN 1Omg/tablet
•

4mg x 20's pack: 120.00 MRP 5mg x 20's pack: 120.00 MRP
lOmg x lO's pack: 150.00 MRP 5mg x 20's pack: 160.00 MRP t MONTELA 10 Tab. Delta Pharma

"
----�
'"'"""·�" -�
�_ ,..,_
_ ,,,...,._
�

I
. .
• I

..
,.
. .
.. ·. '
. -' ·" 2;
.
.
.
-
- -
-

'°

-:;:.,;:;: , · 'Cilfl. ly, 11·q1;1-s.,t;#.�tlv�Y,�tl·-lstamlne

.:
.
V.: :
..=:� ·/?;/, · ·
. .
�
:-� : -
\�:1 ··.
<': �.:
; -

·.·
.
, , _.-

.·· /
.: ._;:->

.- .
-�

"'
:. -. �

.·.. ! brug of .choice for ctllergic,conditions

• •.
t
.

! .Safe f'* �ard�c pai�nts -�,,

:
• • ••

.-_
. .- - _. .:: _
.
': .· - ;. .
.
1•
•
.

..

· �I
t FREEGEST Tab. Biopharma 1Omg x 20's pack: 240.00 MRP Montelukast sodium INN 1Omg/tablet • .
J

Montelukast sodi11m INN 4mg, 5mg & 1Omg/tablet t MONARK-10 Tab. Hallmark 1Omg x 30's pack: 300.00 MRP ;..� •

4mg x 30's pack: 180.00 MRP Montelukast sodium INN 1Omg/tablet t MONTELON Tab. Apex '
•

5mg x 30's pack: 240.00 MRP
1Omg x 20's pack: 300.00 MRP
t LIAM 10 Tab. Asiatic
Montelukast sodium INN 1Omg/tablet
lOmg x lO's pack: 150.00 MRP
t LUMENTA Chew. Tab. Sandoz
1Omg x 20's pack: 281.20 MRP Montelukast sodi11m INN IOmg/tablet
t MONAS Tab. Acme 1Omg x 20's pack: 300.00 MRP
Montelukast sodium INN 4mg, 5mg & 1Omg/tablet t MONTELUK Tab. Astra
4mg x 30's pack: 180.60 MRP Montelukast sodi11m INN 5mg & 1Omg/tablet
5mg x 30's pack: 241.20 MRP 5mg x 1O's pack: 80.00 MRP
lOmg x 15's pack: 225.75 MRP lOmg x lO's pack: 150.00 MRP •

Montelukast sodium INN 5mg/tablet (chewable)
5mg x 20's pack: 180.00 MRP
t LUMENTA 10 Tab. Sandoz
Montelukast sodium INN 1Omg/tablet
1Omg x 28's pack: 448.00 MRP
t LUMONA 5 Tab. SK+F
Montelukast sodium INN 5mg/tablet
5mg x 30's pack: 180.00 MRP
t LUMONA 10 Tab. SK+F
Montelukast sodi11m INN 1Omg/tablet
lOmg x 30's pack: 360.00 MRP
t MONKAST Tab. Pharmasia t MONTENE Chew. Tab. Square
Montelukast sodi11m INN 5mg & 1Omg/tablet Montel11kast sodium INN 4mg & 5mg/tablet
5mg x 20's pack: 150.00 MRP (chewable)
lOmg x lO's pack: 145.00 MRP 4mg x 20's pack: 120.00 MRP
t MONOCAST Tab. Beximco 5mg x 20's pack: 160.00 MRP
Montelukast sodium INN 4mg, 5mg & 1Omg/tablet t MONTENE 10 Tab. Square
4mg x 20's pack: 110.00 MRP Montelukast sodium INN 1Omg/tablet
5mg x 20's pack: 150.00 MRP 1Omg x 30's pack: 301.00 MRP
lOmg x lO's pack: 140.00 MRP t MONTEX Tab. Ibo Sina
t MONOCAST 4 Sachet Beximco Montelukast sodi11m INN 5mg & 1Omg/tablet
Montelukast sodium INN 4mg granules in sachet: 5mg x 20's pack: 160.00 IP

Apex
JJhdtl)),)
Monte I ukast 10 mg Tablet

•
 -

• ®

I
QIMP-17 (109)

Montelukast 1 Omg tab, 4mg & Smg ODT

lOmg x lO's pack: 160.00 IP
+ MONTIFAST 4 Chew. Tab. Globe
Montelukast sodi\1m INN 4mg/tablet (chewable)
4mg x 20's pack: 140.00 MRP
+ MONTIFAST 5 Tab. Globe
Montelukast sodium INN 5mg/tablet
5mg x 20's pack: 150.00 MRP
+ MONTIFAST 10 Tab. Globe
Montelukast sodium INN 1Omg/tablet
1Omg x 20's pack: 300.00 MRP
+ MONTILAB 10 Tab. L abaid Pharma
Montelukast sodium INN 1Omg/tablet
lOmg x 20's pack: 300.00 MRP
+ MONTILET Tab. Amulet
Montelukast sodium INN 1Omg/tablet
lOmg x lO's pack: 150.00 MRP
+ MONTIVA 10 Tab. NIPRO JMI
Montelukast sodium INN 1Omg/tablet
1Omg x 20's pack: 200.00 MRP
+ MONTRIL-4 Oroflash Tab. Aristopharma
Montelukast sodium INN 4mg/tablet (oroflash)
4mg x 30's pack: 210.00 MRP
+ MONTRIL-5 Chew. Tab. Aristopharma
Montelukast sodium INN 5mg/tablet (chewable)
5mg x 30's pack: 240.00 MRP
+ REVERSAIR OD
Montelukast sodium INN 4mg & 5mg/tablet
(orodispersible)
4mg x 20's pack: 140.60 MRP
5mg x 20's pack: 160.60 MRP
+ REVERSAIR 10 Tab. A CI
Montelukast sodium INN 1Omg/tablet
lOmg x lO's pack: 200.00 MRP
lOmg x 20's pack: 301.20 MRP
+ TELUKAST Tab. General
Montelukast sodium INN 4mg, 5mg &
1Omg/tablet
4mg x 30's pack: 165.00 MRP
5mg x 20's pack: 150.60 MRP
lOmg x 20's pack: 200.00 MRP
+ TRILOCK Tab. Opsonin
Montelukast sodi\1m INN 4mg, 5mg &
1Omg/tablet
4mg x 30's pack: 158.87 MRP
5mg x 30's pack: 211.92 MRP
lOmg x 30's pack: 397.45 MRP
+ TRILOCK 4 Granules Opsonin
Montelukast sodium INN 4mg granules for oral
suspension.
•
Tab. ACI
cirhosis. Zafirlukast is also contraindicated in
children under 12 years of age until safety
information is available.
Adverse effects: Zafrrlukast may be associated
with headache or gastrointes-tinal disturbance,
these symptoms are usually mild and do not
necessitate withdrawal from therapy.
Hypersensitivity reactions, includ.ing urticaria
and angioedema have been reported; rashes,
including blistering, have also been reported.
Infrequently, elevated serum transaminase levels
have been observed, but rarely this transaminase
profile has been consistent with drug-induced
hepatitis which resolved following cessation of
zafrrlukast therapy.
Warnings & Precautions: Zafrrlukast should be
taken regularly to achieve benefit, even during
symptom free periods; zafrrlukast therapy should
normally be continued during acute
exacerbations of asthma. Zafrrlukast does not

+ MONTRIL-10 Tab. Aristopharma 4mg granules packet x IO's pack: 70.64 MRP allow a reduction in existing steroid treatment.

. ;:; . -f :
. ... : .: .;_ . :
,_,_ . .
· ..
. .

.
·
.

'
.

the only USP Montelukast

® ®

Montelukast USP Bambuterol 10 mg, 20 mg tablet & 60 ml oral solution

Truly once daily oral bronchodllator

'
Montelukast sodium INN 1Omg/tablet
IOmg x 20's pack: 300.00 MRP
+ MOTILUK Tab. Rephco
Montelukast sodium INN 4mg, 5mg & 1Omg/tablet
4mg x 20's pack: 120.00 MRP
5mg x 20's pack: 160.00 MRP
lOmg x lO's pack: 150.00 MRP
+ ODMON Tab. Renata
Montelukast sodium INN 5mg & 1Omg/tablet
5mg x 1O's pack: 80.00 MRP
lOmg x lO's pack: 150.00 MRP
lOmg x 20's pack: 300.00 MRP
+ PROVAIR Chew. Tab. UniMed &
UniHealth
Montelukast sodium INN 4mg & 5mg/tablet
4mg x 30's pack: 180.00 MRP
5mg x 30's pack: 240.00 MRP
+ PROVAIR-10 Tab. UniMed & UniHealth
Montelukast sodium INN 1Omg/tablet
1Omg x 30's pack: 450.00 MRP
As with inhaled steroids and cromones (disodium
ZAFIRLUKAST46•95 cromoglycate, nedocromil sodium), zafrrlukast is
not indicated for use in the reversal of
ZAFIRLUKAST: Tablet bronchospasm in acute asthma attacks.
Zafrrlukast is a leukotriene receptor antagonist, Elderly- clinical experience with zafirlukast in
synthesized chemically. It is used as prophylactic the elderly (over 65 years) is limited & caution
and in the management of chronic asthma. is recommended until furher information is
Mode of action: Zafirlukast is a selective, available.
competitive antagonist of cysteinyl leukotrienes Renal impaiment- no dosage adjustment is
(LTC4, LTD4 & LTE4) at the cysteinyl necessary in patients with mild renal impairment.
leukotriene receptor (currently designated as Zafrrlukast has not been evaluated in the
CysLTl ). Zafirlukast demonstrates virtually no treatment of labile (brittle) or unstable asthma.
affinity for adrenergic, histamine, serotonin, Elevations in serum transaminases can occur
muscarinic or prostanoid receptors. during treatment with zafrrlukast. These are
I nd: Zafrrlukast is indicated for the prophylaxis usually asymp-tomatic and transient but could
and the management of chronic asthma in adults represent early evidence of hepatotoxicity.
and children aged 12 years and over. If clinical symptoms or signs suggestive of liver
C/I: History of hypersensitivity to the product or dysfunction occur (e.g nausea, vomiting, right
any of its ingredients; history of moderate or upper quadrant pain, fatigue, lethargy, flu-like
severe renal impairment; hepatic impairment or symptoms, enlarged liver, pruritus and jaundice),

.9'-�n
•••
SQUARE
l'HAIWACEUTIC41.S �TD
•ANOLADESH
www .squareph arma.com.bd •••
•••
'
-.,.,
- ...,.,.
-· - - '.. ...
.�--· - � - . .-
· .
,.
. -
·- ··
.
..
.··
·· - ..
. . . . · - · --·. - . -. .· .
. . .

. _,,_ :.- . - _
...,
..,,.
...,
.
.

r
RESPIRATORY DRUGS
the serum transaminases, in particular serum
ALT, should be measured and the patient
managed accordingly. A decision to discontinue
zafrrlukast should be individuailsed to the
patient's conditon, weighing the risk of hepatic
dysfunction against the clinical benefit of
zafrrlukast to the patient.
Pregnancy & Latation: The safety of zafirlttlcast
in human pregnancy has not been established,
therefore, zafrrl1ikast should be used during
pregnancy only if clearly needed. Zafirlukast is
excreted in human breast milk, so, zafirlukast
should not be administered to mothers who are
breast-feeding.
Dosage & Admin: Adults & children over 12
years of age- 20mg twice daily; it should be
taken at least 1 hour before or 2 hours after
meals, or as directed by the physician.
Drug inter: Please see the manufacturer's
literature.
+ ZAFT Tab. Renata
Za.firlukast INN 20mg/tablet
l O's pack: 260.00 MRP
3. RESPIRATORY
GLUCOCORTICOIDS:
CORTICOSTEROIDS21
Glucocorticoid steroid preparations are found
effective in asthma; they reduce bronchial
mucosal inflama
m tion by reducing oedema &
secretion of mucus into the airway. Chronic
obstructive pulmonary diseases usually show lit­
tle or no response to corticosteroids. Whether
inhaled corticosteroids improve the lung function
in COPD yet not been established; but, corticos­
teroid inhalations are recommended for prophy­
lactic treatment of asthma when patients are
using a beta2-stimulant (agonist) 3 times a week
or more or if symptoms disturb sleep more than
once a week or if the patient has suffered exacer­
bations in the last 2 years requiring a systemic
corticosteroid or a nebulised bronchodilator.21
Commonly used respiratory corticosteroids are­
Beclomethasone dipropionate, Budesonide,
Ciclesonide, Fluticasone propionate,
Mometasonefuroate, Triamcinolone etc.
Mode of action: The precise mechanism of glu­
cocorticoid action in asthma is unknown.
Glucocorticoids have been shown to inhibit mul­
tiple cell types (e.g mast cells, eosinophils,
basophils, lymphocytes, macrophages, and neu­
trophils) and mediator production and secretion
(e.g histamine, eicosanoids, leukotrienes, and
cytokines) involved in the asthmatic response.
These anti-inflammatory actions of glucocorti­
coids may contribute to their efficacy in asthma.
Ind; C/I: See below under the individual
preparation.
S/E: Inhaled corticosteroids have considerably
fewer systemic side-effects than oral corticos­
teroids, but high-dose inhalations are sometimes
•
QIMP-17 (110)
associated with some adrenal suppression and
effects on bone metabolism; also hoarseness of
voice and candidiasis of mouth or throat (usually
only with large doses); rearly rash.
Precautions: Active or quiescent tuberculosis;
may need to reinstate systemic therapy during
periods of stress or when airways obstruction or
mucus prevent drug access to smaller airways.
During withdrawal from oral corticosteroids,
some patients may experience symptoms of
systemically active corticosteroid withdrawal, e.g
joint and/or muscular pain, lassitude and
depression, despite maintenance or even
improvement of respiratory functions. If there is
paradoxical bronchospasm, steroid inhalation
should be discontinued and alternative therapy
should be given; or, transfer from an aerosol
inhalation to a dry powder inhalation.
Because of the possibility of systemic absorption
of inhaled corticosteroids, patients treated with
these drugs should be observed carefully for any
evidence of systemic corticosteroid effets.
Particular care should be taken in observing
patients post operatively or during periods of
stress for evidence of inadequate adrenal respone.
Dosage & admin: See below under the
individul preparation.
BECLOMETHASONE46,47,48
BECLOMETHASONE DIPROPIONATE:
Inhaler (DPl/MDI)
Beclomethasone dipropionate is a commonly
used synthetic halogenated respiratory
corticosteroid with potent anti-inflammatory
activity. It is available as dry powder inhaler
(DPI) & metered dose aerosol inhaler (MDI).
Inhaler (DP/): Beclomethasone dipropionate,
available as 1OOmcg, 200mcg, & 400mcg/capsule
(cyclocap): Dry powder inhaler (DPI), for oral
inhalation only.
Inhaler (MDI): Beclomethasone dipropionate,
available as 50mcg, 1OOmcg, & 250mcg/puff or
actuation: Metered dose inhaler (MDI), using
CFC (chlorofluorocarbon) as propellant.
Inhaler HFA (MDI): Beclomethasone
dipropionate, available as 50mcg & 1OOmcg/puff
or actuation: Metered dose inhaler (MDI), using
HFA (hydrofluoroalkane) as propellant.
CFC (Chlorofluorocarbon): CFC- using as MDI
propellant is safe for human, but, as it emits CFC
to the environment, it harms the planet by
depleting ozone layer.
HFA (Hydrojluoroalkane): Recently an
advanced HFA (Hydrofluoroalkane) technology
has developed as MDI propellant replacing CFC
propellant. HFA is an ozone-benign, environment
friendly, CFC-free MDI propellant.
Mode of action: See above under the text of
respiratory corticosteroids.
Ind: Prophylaxis and maintenance treatment of
asthma specially if not fully controlled by
bronchodilators or cromoglycate.
S/E; Cautions: See above under the text of
respiratory corticosteroids.
Dosage & admin:
By inhalation (DP/): Adults & adolescents:
Recommended starting dose is 200mcg twice
daily or 1 OOmcg 3-4 times daily; in more
severe cases initially 600-800mcg may be given
daily. ,
Children (5-11 yrs): 50-lOOmcg 2-4 times daily.
Dry powder inhaler (DPI) is administered by a
device (such as Cozyhaler, Cyclohaler,
Rotahaler) through oral inhalation route only.
Rinsing the mouth after inhalation is advised.
By inhalation (MDI): Adults & adolescents:
Recommended starting dose- 500mcg
(250mcg/puft) twice daily or 250mcg
(250mcg/puff) four times daily; if necessary
may be increased to 500mcg (250mcg/puff) 3-4
times daily in severe condition. High doses
upto 2000mcg in a day may control asthmatics
not adequately controlled wi�h more conven­
tional doses. The usual recommended mainte­
nance dose is 100-250mcg given 3 or 4 times a
day. Or, alternatively 200-SOOmcg given twice
daily has been found effective in some patients.
Children (5-11 yrs): The usual starting dose is
1 OOmcg twice daily. Some patients may
require lOOmcg 3 to 4 times daily or 200mcg
twice daily. Total dose for children should not
exceed 500mcg daily.
By inhalation HFA (MDI): The recommended
dosage of HF A based inhalation aerosol rela­
tive to traditional CFC based inhalation is
lower due to differences in delivery character­
istics between the products.
Adults & adolescents: Recommended starting
dosage- in patients previously treated with
bronchodilators alone, is 50-1 OOmcg twice
daily, may be increased upto 400mcg twice
daily; dosage in patients previously treated
with inhaled corticosteroid, is 50-200mcg twice
daily, may be increased upto 400mcg twice
daily.
Children (5-11 yrs): Recommended starting
dosage- in patients previously treated with
'
bronchodilators alone, is 50-lOOmcg twice
daily, may be increased and maintained upto (
1 OOmcg twice daily; dosage in patients
previously treated with inhaled corticosteroid,
is 50-200mcg twice daily, may be maintained
upto lOOmcg twice daily.48
+ ASCON HFA Inhaler (MDI) Acme
Ascon 100: Beclomethasone dipropionate
1OOmcg/ puff or actuation: metered dose inhaler
(MDI), using HFA (hydrofluoroalkane) as
propellant.
Ascon 250: Beclomethasone dipropionate
250mcg/pu.ff or actuation: metered dose inhaler
(MDI), using HFA (hydrofluoroalkane) as
propellant. •
Ind: Bronchial asthma
Dosage & admin: See above under the text
(Dosage of inhaler MDI).
Ascon 100 (HFA) x 200 doses \1nit: 270.00 MRP
Ascon 250 (HFA) x 200 doses unit: 320.00 MRP

t ASCON 250 (CFC) Inhaler (MDI) Acme
Ascon 250 (CFC): Beclomethasone dipropionate
250mcg/puff or actuation: metered dose inhaler
(MDI), using CFC (chlorofluorocarbon) as
propellant.
Ind: Bronchial asthma
I
Dosage & admin: See above under the text
(Dosage of inhaler MDI).
Ascon 250 (CFC) x 200 doses unit: 250.94 MRP
t BECLOCORT HFA Inhaler (MDI)
Aristopharma
Beclocort-50 HFA inhaler: Beclomethasone
dipropionate 50mcg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant.
Beclocort-100 HFA inhaler: Beclomethasone
dipropionate 1OOmcg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant.
Beclocort-250 HFA inhaler: Beclomethasone
dipropionate 250mcg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant.
Ind: Bronchial asthma.
Dosage & admin: See above under the text
(Dosage of inhaler HFA (MDI)).
Beclocort-50 HFA x 200 doses unit: 220.00 MRP
Beclocort-100 HFA x 200 doses unit: 270.00 MRP
Beclocort-250 HFA x 200 doses unit: 350.00 MRP
t BECLOMIN HFA Inhaler (MDI) Square
Beclomin 50 HFA inhaler: Beclomethasone
dipropionate 50mcg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propella11t.
Beclomin 100 HFA inhaler: Beclomethasone
dipropionate 1OOmcg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant.
Beclomin 250 HFA inhaler: Beclomethasone
dipropionate 250mcg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant.
Ind: Bronchial asthma.
Dosage & admin: See above under the text
•
(Dosage of inhaler HF A (MDI)).
Beclomin 50 HFA x 200 doses unit: 220.84 MRP
Beclomin 100 HFA x 200 doses 11nit: 270.00 MRP
Beclomin 250 HFA x 200 doses unit: 320.00 MRP
t DECOMIT Inhaler (MDI) Beximco
Decomit 100: Beclomethasone dipropionate
1OOmcg/ puff or actuation: metered dose inhaler.
Decomit 250: Beclomethasone dipropionate
250mcg/puff or actuation: metered dose inhaler.
Ind: Bronchial asthma.
Dosage & admin: See above under the text
(Dosage of inhaler MDI).
Decomit l 00 x 200 doses unit: 200.00 IP
Decomit 250 x 200 doses unit: 250.00 IP
!
•
t DECOMIT HFA Inhaler (MDI) Beximco
Decomit 50 HFA: Beclomethasone d�propionate
50mcg/puff or actuation: metered dose inhaler
(MDI), using HFA (hydrofluoroalkane) as
propellant.
I Decomit 100 HFA: Beclomethasone dipropionate
1OOmcg/puff or actuation: metered dose inhaler
(MDI), using HFA (hydrofluoroalkane) as
propellant.
Ind: Bronchial asthma.
Dosage & admin: See above under the text
I
QIMP-17 (111)
(Dosage of inhaler HFA (MDI)).
Decomit 50 HFA x 200 doses unit: 220.00 IP
Decomit 100 HFA x 200 doses unit: 270.00 IP
t STERADIN HFA Inhaler (MDI) ACI
Steradin HFA 100 inhaler: Beclomethasone
dipropionate 1OOtncg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant.
Steradin HFA 250 inhaler: Beclomethasone
dipropionate 250mcg/puff or actuation: metered
dose inhaler (MDI), using HFA
(hydrofluoroalkane) as propellant.
Ind: Bronchial asthma.
Dosage & admin: See above under the text
(Dosage of inhaler HFA (MDI)).
Steradin HFA 100 x 200 doses unit: 271.02 MRP
Steradin HFA 250 x 200 doses unit: 351.32 MRP
BUDESONIDE42
BUDESONIDE: Inhaler
Budesonide is a synthetic corticosteroid having
potent glucocorticoid activity and weak
mineralocorticoid activity. It has approximately a
200-fold higher affinity for the glucocorticoid
receptors. Budesonide is used as inhaler, or used
with a nebuliser or ventilator, recommended
mainly for prophylactic treatment of asthma.
Mode of action: See above under the text of
respiratory corticosteroids.
Ind: Budesonide inhaler or nebuliser suspension
is indicated for the maintenance treatment of
asthma as prophylactic therapy in adult and
pediatric patients 6 years of age and older. It is
also indicated for patients requiring oral
corticosteroid therapy for asthma. It is not
indicated for the relief of acute bronchospasm.
C/I: Budesonide is contraindicated in the
primary treatment of status asthmaticus or other
acute episodes of asthma where intensive
measures are required.
Hypersensitivity to any of the ingredients of this
preparation contraindicates its use.
S/E: Sneezing, headache, sore throat, dry mouth,
nausea etc. have been reported as the common
side effects.
Precautions: Budesonide inhaler or nebuliser
suspension should be used with caution in
patients with active or quiescent tuberculous
infection, untreated fungal, bacterial, or systemic
viral infections, or ocular herpes simplex
infection.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women.
Budesonide inhaler or nebuliser suspension, like
other corticosteroids, should be used during
pregnancy only if the potential benefit justifies
the potential risk to the fetus.
It is not known whether budesonide is excreted
in human milk. Because other corticosteroids are
excreted in human milk, caution should be
exercised when budesonide inhaler or nebuliser
suspension is administered to nursing women.
Dosage & admin: The recommended starting
dose and the highest recommended dose of
this drug, based on prior asthma therapy, are
given as below:
Adults & Adolescents: Patient treated previous­
ly with bronchodilators alone: Recommended
•
RESPIRATORY DRUGS
starting dose is 200-400mcg twice daily; high­
est recommended dose is 400mcg twice daily.
Patient treated previously with inhaled
corticosteroids: Recommended starting dose is
200-400mcg twice daily; highest recommended
dose is 800mcg twice daily.
Patient treated previously with oral
corticosteroids: Recommended starting dose is
400-800mcg twice daily; highest recommended
dose is 800mcg twice daily.
Children 6 to 11 Years: Patient treated
previously with bronchodilators alone:
Recommended starting dose is 200mcg twice
daily; highest recommended dose is 400mcg
twice daily.
Patient treated previously with inhaled
corticosteroids: Recommended starting dose is
200mcg twice daily; highest recommended
dose is 400mcg twice daily.
In patients with mild to moderate asthma who
are well-controlled on inhaled corticosteroids,
dosing with the drug 200mcg or 400mcg may
be considered. This can be administered once
daily either in the morning or in the evening.
Rinsing the mouth after each inhalation is
used.
Dosage of budesonide nebuliser: See below
under individual preparation.
Drug inter: In clinical studies, concurrent
administration of budesonide and other drugs
commonly used in the treatment of asthma has
not resulted in an increased frequency of adverse
effects. Ketoconazole, a potent inhibitor of
cytochrome p450 3A, may increase plasma levels
of budesonide during concomitant dosing. The
clinical signifcance of concomitant
administration of ketoconazole with this drug is
not known, but caution may be warranted.
+ AERONID Inhaler (MDI) Beximco
Budesonide BP 200mcg per metered dose or
actuation (puff): metered-dose aerosol inhalation
(MDI).
Dosage & admin: See above under the text of
Budesonide.
Aeronid inhaler is administered by a metered­
dose aerosol inhalation (MDI) device.
200mcg x 120 doses (puffs): 400.00 IP
t BUDESON-200 Inhaler (DPI) Acme
Budesonide BP 200mcg/Rotacap: dry powder
inhalation (DPI).
Burleson inhaler is a DPI (dry powder inhalation)
system and administered by Rotahaler device
through oral inhalation route.
Rotahaler, a dry powder inhalation (DPI) device.
Dosage & admin: See above under the text of
Budesonide.
Budeson inhaler is administered by Rotahaler
through oral inhalation route.
Rinsing the mouth after inhalation is advised.
200mcg x 30 doses (puffs): 90.00 MRP
+ BUDICORT 0.5 Nebuliser Solo. Incepta
Budesonide BP 0.5mg/2ml ampoule for use with
a nebuliser or ventilator.
Dosage guideline: Starting dose (in case of
severe asthma & while reducing or
discontinuing oral corticosteroids): Children 3
months to 12 years of age, 0.5-lmg twice
daily; Adults and elderly, 1-2mg twice daily.
Maintenance dose: Usually half of the above
RESPIRATORY DRUGS
doses.
2ml amp (0.5mg) x S's pack: 200.00 MRP
CICLESONIDE48
CICLESONIDE: Inhaler (MDI)
Ciclesonide is a new generation inhaled
corticosteroid for asthma control. It is available
as metered dose inhalation (MDI) aerosol, in two
strengths- 80mcg/actuation or dose &
l 60mcg/actuation or dose. Each canister contains
120 metered doses for both concentrations.
Mode of action: Ciclesonide is an ester prodrug,
which is hydrolysed by endogenous esterases in
the lung to form its active metabolite. The
activated ciclesonide has an approximately 100-
fold greater affinity for glucocorticoid receptors
compared with the parent compound.
Ind: For the treatment to control persistent
asthma in adults (18 years and older).
C/I: Patients with known hypersensitivity to any
of the ingredients of the product.
S/E; Cautions: See above under the text of
respiratory corticosteroids.
Pregnancy & lactation: If the potential benefit
to the mother justifies the potential risk to the
mother, foetus or child, the lowest effective dose
of ciclesonide needed to maintain adequate
asthma control should be used.
Dosage & admin: Starting dose of ciclesoni(le
is 160mcg once daily, which is usual and also
the maximum dose. Dose reduction to 80mcg
once daily may be an effective maintenance
dose for some patients. Ciclesonide should
preferably be administered in the evening.
Although morning dosing of ciclesonide has
also been shown to be effective.
Drug inter: Co-administration with a potent
inhibitor of the cytochrome P450 3A4 system
(e.g ketoconazole, itraconazole and ritonavir or
nelfmavir) should be considered with caution.
The risk of clinical adverse effect (e.g cushingoid
syndrome) cannot be excluded.
Storage: The inhaler should be stored below
30°C, protected from direct sunlight and heat.
The canister should not be broken, punctured or
burnt, even when apparently empty. Keep away
from eyes.
+ CESONIDE 80 Inhaler (MDI) Beximco
Ciclesonide 80mcg/actuation or metered dose (or
pufl): metered dose aerosol inhalation (MDI).
Dosage & admin: See above under the text of
ciclesonide.
80mcg x 120 doses unit: 250.00 IP
+ CESONIDE 160 Inhaler (MDI) Beximco
Ciclesonide 160mcg/actuation or metered dose
(or pufl): metered dose aerosol inhalation (MDI).
Dosage & admin: See above under the text of
ciclesonide.
160mcg x 120 doses unit: 350.00 IP
MOMETASONE FUROATE35
� . . ,. . .
MOMETASONE FUROATE: Dry Powder
Capsule Inhalation (DPI)
Mometasone furoate is a respiratory corticos­
teroid with anti-inflammatory properties. It is
available as- mometasone furoate BP 220mcg
powder inhalation capsule (DPI- e.g convicap ). It
QIMP-17 (112)
is used by dry powder inhaler (e.g convihaler)
through oral inhalation route only.
Mode of action: See above under the text of
respiratory corticosteroids.
Ind: Mometasone furoate is indicated for the
maintenance treatment of asthma as prophylactic
therapy in patients 4 years of age and older. It is
not indicated for the relief of acute
bronchospasm. It is not indicated in children less
than 4 years of age.
C/I: Hypersensitivity to any of the ingredients of
this preparation contraindicates its use.
Mometasone furoate therapy is contraindicated in
the primary treatment of status asthmaticus or
other acute episodes of asthma where intensive
measures are required.
S/E; Cautions: See above under the text of
respiratory corticosteroids.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women.
Mometasone furoate, like other corticosteroids
should be used during pregnancy only if the
potential benefits justify the potential risk to the
fetus. It is also not known if mometasone furoate
is excreted in human milk. Since other
corticosteroids are excreted in human milk,
caution should be exercised when mometasone
furoate is administered to nursing women.
Dosage & admin: Recommended dosages in
patients 4 years of age and older:
1. Previous therapy: Patients � 12 years who
received bronchodilators alone:
Recommended starting dose- 220mcg once
daily in the evening; highest recommended
daily dose- 220mcg twice daily or as 440mcg
once daily.
2. Previous therapy: Patients � 12 years who
received inhaled corticosteroids:
Recommended starting dose- 220mcg once
daily; highest recommended daily dose-
440mcg once or twice daily.
3. Previous therapy: Patients � 12 years who
received oral corticosteroids:
Recommended starting dose- 440mcg once
daily; highest recommended daily dose-
440mcg once or twice daily.
As, dry powder inhaler (e.g convihaler) is used
through oral inhalation route only, so, rinsing
the mouth after each inhalation.
Drug inter: Ketoconazole, a strong inhibitor of
cytochrome P4503A4 may increase plasma levels
of mometasone (uroate during concomitant
dosing.
Note: For further information, please see
manufacturer's literature.
+ MOMESON Convicap (DPI) Incepta
Each convicap contains mometasone furoate BP
220mcg: dry powder inhalation capsule (DPI).
'Convicap capsule' is a pre-metered single dose
medication for inhalation, specially to be used
with 'convihaler'.
220mcg convicap x 30's pack: 300.00 MRP
TRIAMCINOLONE ACETONIDE35
+ AZMACORT Oral Inhaler Sanofi-aventis
Triamcinolone acetonide 200mcg/actuation (of
dry which approximately 1OOmcg are delivered from
the unit in-vitro testing); 240 inhalations-unit:
oral inhaler
Ind: Triamcinolone oral inhaler is indicated only
for patients who require chronic treatment with
corticosteroids for the control of the symptoms of
bronchial astham. Such patients would include
those already receiving systemic corticosteroids
and selected patients who are inadequately •
controlled on a non-steroid regimen and in whom
steroid therapy has been withheld because of
concern over potential adverse effects.
Triamcinolone oral inhaler is not indicated: i. for
relief of asthma which can be controlled by
bronchodilators & other non-steroid medications;
ii. in patients who require systemic corticosteroid
treatment infrequently; iii. in the treatment of
non-asthmatic bronchitis.
C/I: It is contraindicated in the primary treatment
of status asthmaticus or other acute episodes of
asthma where intensive measures are required.
Hypersensitivity to any of the ingredients of this
preparation. Localized infections with candida
albicans have occurred infrequently in the mouth
and pharynx.
S/E; Cautions; Warnings: See above under
beclomethasone aerosol inhaler.
Dosage & admin: All patients should be
instructed that the triamcinolone oral inhaler
must be used on a regular daily basis. Reliable
dosage delivery can not be assured after 240
actuations and patients should be cautioned
against longer use of individual canisters.
Good oral hygiene including rinsing of the
mouth after inhalation is recommended.
Adults: The usual dosage is 2 puffs (approxi­
mately 200mcg) given 3 to 4 times a day. The
maximal daily intake should not exceed 16
puffs (l600mcg) in adults. Higher initial doses
(12 to 16 puffs per day) may be advisable in
patients with more asthma, the dosage then
being adjusted down-ward according to the
response of the patient. In some patients main­
tenance can be accomplished when the total
daily dose is given on a twice a day schedule.
Children: 6 to 12 years of age, the usual dosage
is 1 or 2 puffs (lOOmcg or 200mcg) given 3 to 4
times a day according to the response of the -
patient.
The maximal daily intake should not exceed
12 puffs (1200mcg) in children of 6-12 years.
Insufficient clinical data exist with respect to
the administration of triamcinolone oral
inhaler in children below the age of 6 years.
The long-term effects of inhaled steroids on
growth are still under evaluation.
Patients receiving bronchodilators by inhala­
tion should be advised to use the bronchodila­
tor before triamcinolone oral inhaler in order
to enhance penetration of the drug into the
bronchial tree. After use of an aerosol
bronchodilator, several minutes should elapse
before use of the triamcinolone oral inhaler to
reduce the potential toxicity from the inhaled
fluorocarbon propellants in the two aerosols.
Note: For further information, please see
manufacturer's literature.
240 inhalations unit (60mg): 498.00 MRP
Gucocorticoid & /32-adrenoceptor
Agonist Combined preparations
•
 . , .
BUDESONIDE + FORMOTEROL26,42,48
•
•
BUDESONIDE + FORMOTEROL: Dry Pow­
der Capsule Inhalation (DPI) & Metered Dose
Inhalation (MDI)
This is a combined inhalation preparation of
budesonide BP & formoterol fumarate dihydrate
BP. Budesonide is a potent glucocorticoid that
binds with high affinity to the glucocorticoid
receptor, and when inhaled has a rapid (within
hours) and dose dependent anti-inflammatory
action in the airways, resulting in reduced
symptoms and fewer asthma exacerbations. ·
Formoterol fumarate dihydrate is a v�ry potent,
long-acting P2- adrenoceptor agonist with a high
intrinsic activity & a rapid onset of action.
Budesonide and formoterol have different mode
of action and show additive effects in terms of
reduction of asthma exacerbations. The specific
properties of budesonide and formoterol allow
the combination to be used both as maintenance
and reliever therapy, and as maintenance
treatment for asthma.
The combined inhaler preparations of budesonide
BP & formoterol fumarate dihydrate BP are
available as- Dry Powder Inhalation (DPI- e.g
bexihaler, convihaler & cozyhaler) & Metered
Dose Inhalation (MDI). The DPI (dry powder
inhalation) devices are used through oral inhala­
tion route only and MDI (metered dose inhala­
tion) device is used by aerosol inhalation only.
The DPI capsule preparations are available in 3
presentations:
i. Capsules contaning budesonide BP 1 OOmcg &
formoterol fumarate dihydrate BP 6mcg;
ii. Capsules contaning budesonide BP 200mcg
and formoterol fumarate dihydrate BP 6mcg; &
iii. Capsules contaning budesonide BP 400mcg
-
' .
and formoterol fumarate dihydrate BP l 2mcg.
Metered dose inhalation (MDI): Metered dose
inhalation (MDI) device uses two types of pro­
pellant, viz- traditional CFC (Chlorofluoro-car­
bon) or recently introduced HFA (hydrofluro­
alkane).
CFC (Chlorofluorocarbon): CFC- using as MDI
propellant is safe for human, but, as it emits CFC
to the environment, it harms the planet by
depleting ozone layer.
HFA (Hydrojluoroalkane): Recently an
advanced HFA (Hydrofluoroalkane) technology
has developed as MDI propellant replacing CFC
propellant. HFA is an ozone-benign, environment
friendly, CFC-free MDI propellant.
The MDI HFA Inhaler preparations are
available in 2 presentations:
i. 60 & 120 metered doses unit or canister-
each actuation delivers formoterol fumarate dihy­
drate BP 4.5mcg and budesonide BP 80mcg.
ii. 60 & 120 metered doses unit or canister-
each actuation delivers formoterol fumarate dihy­
drate BP 4.5mcg and budesonide BP 160mcg.
Mode of action: The mode of action described
below for the individual components.
Budesonide BP: See under the text of budesonide
and corticosteroids.
Formoterol fumarate dihydrate BP: It is a long­
acting, selective �1-adrenergic agonist with a
rapid onset of action. Inhaled formoterol fumarate
dihydrate BP acts locally in the lungs as a
•
- -
" •
..,
.
QIMP-17 (113)
bronchodilator. The pharmacological effects of
P2-adrenoceptor agonist dfugs ar� attributable to
the stimulation of intracellular adenyl cyclase,
the enzyme that catalyses the conversion of
adenosine triphosphate ( ATP) to cyclic AMP .
Increased cyclic AMP levels cause relaxation of
bronchial smooth muscle and inhibit the release
of mediators of immediate hypersensitivity from
the cells, specially from mast cells.
Ind: Asthma: Budesonide and formoterol
combination is indicated in the regular treatment
of asthma where use of a combination (inhaled
corticosteroid and long acting �2-agonist) is
appropriate. This includes: i. patients who are not
adequately controlled with inhaled corticosteroid
therapy and as needed inhaled short-acting �2-
adrenoceptor agonists; ii. patients who are
already adequately controlled on regular separate
long-acting P2-agonist and inhaled corticosteroid
therapies.
Formoterol/budesonide combination is not indi­
cated for the relief of acute bronchospasm.
Chronic obstroctive pulmonary disease (COPD):
Budesonide and formoterol combination is indi­
cated in the regular treatment of adult patients
with moderate to severe chronic obstructive
pulmonary disease (COPD), with a history of
repeated symptoms or exacerbations despite
regular therapy with long-acting bronchodilators.
C/I: Patients with a history of hypersensitivity to
any of the components of the drug product (viz,
budesonide, formoterol & lactose).
S/E: Budesonide: Hoarseness, and candidiasis
(thrush) of the mouth and throat can occur in
some patients. Cutaneous hypersensitivity
reactions have been reported.
Formoterol fumarate dihydrate: Tremor,
palpitations, and headache have been reported.
Cardiac arrhythmias, muscle cramps, and
hypersensitivity reactions, including rash, edema,
and angio-edema, may occur in some patients.
Precautions: Budesonide and formoterol capsule
should be administered with caution in patients
with severe cardiovascular disorders, including
heart rhythm abnormalities, diabetes mellitus
untreated hypokalemia or thyrotoxicosis.
Paradoxical bronchospasm may occur. In such
cases, budesonide & formoterol fumarate dihyd­
rate capsule should be discontinued immediately.
Treatment with this combination should not be
initiated to treat a severe exacerbation or if
patients have significantly worsening or acutely
deteriorating asthma.
Pregnancy & lactation: Administration of this
combined product in pregnant women and
lactating mother should only be considered if the
expected benefit to the mother is greater than any
possible risk to the fetus and infants.
Dosage & admin: The combined inhaler
preparations of budesonide & formoterol
fumarate are available as- DPI (Dry Powder
Inhaler e.g Bexihaler, Convihaler &
Cozyhaler), & MDI (Metered Dose Inhaler e.g
aerosol inhalation).
There are two treatment approaches:
A. Maintenance therapy.
B. Single maintenance & reliever therapy.
Dosare ruide-lineforDeyPowderInhaler
(])Pl):
Bronchial asthma: Dosage is individual and
•
RESPIRATORY DRUGS
should be adjusted accordlng to disease severi­
ty. When control has been achieved, the dose
should be titrated to the lowest effective dose.
A. Maintenance therapy: Patients taking
formoterol/budesonide combination as regular
malntenance treatment with a separate rapid
acting bronchodilator as rescue, should be
advised to have their separate rapid acting
bronchodilator available for rescue use at all
times.
Adults (18 years and older): Combination of
100mcg/6mcg & 200mcg/6mcg capsule-1-2
capsules (i.e 1-2 inhalations) twice daily, max.
dose is 4 capsules (i.e 4 inhalations) twice daily;
Combination of 400mcg/12mcg capsule- 1
capsule twice daily, max. dose is 2 capsules
twice daily.
Adolescents (12-17 years): Combi.nation of
100mcg/6mcg & 200mcg/6mcg capsule- 1-2
capsules twice daily;
Combination of 400mcg/12mcg capsule- 1 ·
capsule twice daily.
Children (6-11 years): Combination of
100mcg/6mcg capsule- 2 capsules, twice daily;
Or, 200mcg/6mcg capsule- 1 capsule, twice
daily.
B. Single maintenance & reliever therapy:
Combination of 100mcg/6mcg & 200mcg/6mcg
capsule only.
Patients should take a daily maintenance dose
of this combination and in addition take this
product as needed in response to symptoms.
Patients should be advised to always have this
combined product available for use.
Adults (18 years and older): The recommended
maintenance dosage is 2 capsules (i.e 2
inhalations) per day as maintenance therapy
(either 1 capsule twice daily, or 2 capsules
once daily in either the morning or the
evening), although some patients may require
2 capsules twice daily.
Patients should take 1 additional capsule as
needed in response to symptoms.
If symptoms persist after a few mlnutes, an
'
additional capsule (inhalation) should be
taken. Not more than 6 capsules should be
taken on any single occasion.
A total daily dose of more than 8 capsules is
not normally needed; however, a total daily
dose of up to 12 capsules could be used for a
limited period.
Patients using more than 8 capsules daily
should be strongly recommended to seek
medical advice.
COPD (Chronic Obstructive Pulmonary
Disease): Combination of 200mcg/6mcg
capsule: 2 capsules, twice daily.
How to use: Capsules are used by DPI (dry
powder inhalation) device through oral
inhalation route only. Insert the capsule in the
DPI device just prior to use (as capsule
exposed to moisture may not tear easily).
Rinsing the mouth after inhalation is used.
Capsules must not be swallowed.
Dosqreruide-line/ocMDIHFAInhaler;
Bronchial asthma: Dosage is individual and
should be adjusted according to disease severi­
ty. When control has been achieved, the dose
should be titrated to the lowest effective dose.
A. Maintenance therapy: Patients taking for-
 RESPIRATORY DRUGS
moterol/budesonide combination as regular
maintenance treatment with a separate rapid
acting bronchodilator as rescue, should be
advised to have their separate rapid acting
bronchodilator available for rescue use at all
times.
Adults (18years & older): Formoterol/Budeso­
nide 4.5/80 HFA inhaler or
Formoterol/Budeso-nide 4.5/160 HFA inhaler:
1 2 inhalations, twice daily.
Adolescents(12 17 years): Formoterol/Budeso­
nide 4.5/160 HFA inhaler:l 2 inhalations,
twice daily.
Children (6 11 years): Formoterol/Budesonide
4.5/160 HFA Inhaler: 1 inhalation, twice daily.
The maximum recommended dosage is two
inhalations of 4.5mg formoterol fumarate
dihydrate and 160mg budesonide twice daily.
For all patients it is desirable to titrate to the
lowest effe-ctive dose after adequate asthma
stability is achi-eved. Improvement in asthma
control following inhaled administration of
formoterol/budesonide HFA inhaler can occur
within 15 minutes of beginning treatment,
although maximum benefit may not be
achieved for 2 weeks or longer after beginning
treatment. Individual patients will experience
a variable time to onset and degree of
symptom relief.
B. Single maintena'!-ce & reliever therapy:
Patients taking formoterol/budesonide
combination as regular maintenance and as
needed in response to symptoms- should take
a daily maintenance dose of
I formoterol/budesonide HFA inhaler and in
combination take formoterol/bude-
. BP 4.5µg & budesonide BP 160µg per actuation.
sonide HFA inhaler as needed in response to
.
symptoms. Patients should be advised to
always have formoterol/budesonide HFA
. .
inhaler available for use.
Adults.(18years & older): The recommended
maintenance dosage is 2 inhalations per day as
maintenance therapy (either one inhalation
twice daily, or ·two inhalations in either the
morning or the evening), although some
patients may require two inhalations twice
daily. Patients should take 1 additional
inhalation as needed in response to symptoms.
If symptoms persist after a few minutes, an
·
additional inhalation should be taken.
Not more than 6 inhalations should be taken
on any single occasion.
COPD (Chronic Obstructive Pulmonary
Disease): Formoterol/budesonide 4.5/160HFA
Inhaler: 2 inhalations, twice daily.
Drug inter: Concomitant treatment with
ritonavir, itraconazole, ketoconazole or other
potent CYP3A4 inhibitors should be avoided.
t BUDEMET 100 Convicap (DPI) Incepta
Each convicap contains budesonide BP 1OOmcg
& formoterol fumarate dihydrate BP 6mcg.
100 cozycap x 30's pack: 210.00 MRP ·
+ BUDEMET 200.Convicap (DPI) Incepta
Each convicap contains budesonide BP 200mcg
& formoterol fumarate dihydrate BP 6mcg.
200 cozycap x 30's pack: 270.00 MRP
t BUDEMET 400 Convicap (DPI) Incepta
Each convicap contains budesonide BP 400mcg
& formoterol fumarate dihydrate BP 12mcg.
400 cozycap x 30's pack: 420.00 MRP
QIMP-17 (114)
t BUDISON F-80 HFA Inhaler (MDI)
Aristopharma ·
·
HFA(Hydrofluoroalkane) based metered dose
inhaler containing budesonide BP 80µg & formo­
terol fumarate dihydrate BP 4.5µg per actuation.
Price: Burlison F-80 HFA Inhaler x 60 doses
unit: 400.00 MRP
t BUDISON F-160 HFA Inhaler (MDI)
Aristopharma
HFA(Hydrofluoroalkane) based metered dose
inhaler containing budesonide BP 160µg & form­
oterol fumarate dihydrate BP 4.5µg per actuation.
Price: Burlison F-160 HFA Inhaler x 60 doses
unit: 500.00 MRP .
t BUFOCORT 100 Cozycap (DPI) Square
Each cozycap contains budesonide BP 1OOmcg &
formoterol fumarate dihydrate BP 6mcg.
100 cozycap x 30's pack: 210.00 MRP
t BUFOCORT 200 Cozycap (DPI) Square
'Each cozycap contains budesonide BP 200mcg &
formoterol fumarate dihydrate BP 6mcg.
200 cozycap x 30's pack: 270.00 MRP
t BUFOCORT 400 Cozycap (DPI) Square
Each cozycap contains budesonide BP 400mcg &
formoterol fumarate dihydrate BP 12mcg.
400 cozycap x 30's pack: 420.00 MRP
t OXYCORT 4.5/80 HFA Inhaler (MDI) ACI
HFA(Hydrofluoroalkane) based metered dose.
inhaler containing formoterol fumarate dihydrate
BP 4.5µg & budesonide BP 80µg per actuation.
Price: Oxycort 4.5/80 HFA Inhaler x 120 doses
unit: 600.00 MRP
t OXYCORT 4.5/160 HFA Inhaler (MDI) ACI
HFA(Hydrofluoroalkane) based metered dose
inhaler containing formoterol fumarate dihydrate
Price: Oxycort 4.5/160 HFA Inhaler x 120 doses
unit: 800.00 MRP
t SYMBION 6/100 Bexicap (DPI) Beximco
Each bexicap contains formoterol fumarate
dihydrate BP 6mcg & budesonide BP 1OOmcg.
6/100 bexicap x 30's pack: 210.00 MRP
t SYMBION 6/200 Bexicap (DPI) Beximco
Each bexicap contains formoterol fumarate
dihydrate BP 6mcg & budesonide BP 200mcg.
61200 bexicap x 30's pack: 270.00 MRP
t SYMBION 4.5/80 HFA Inhaler (MDI)
Beximco
HFA(Hydrofluoroalkane) based metered dose
inhaler containing formoterol fumarate dihydrate
BP 4.5µg & budesonide BP 80µg per actuation.
Price: Symbion 4.5/80 HFA Inhaler x 120 doses
canister: 625.00 MRP
t SYMBION 4.5/160 HFA Inhaler (MDI)
Beximco
HFA(Hydrofluoroalkane) based metered dose
inhaler containing formoterol fumarate dihydrate
BP 4.5mcg & budesonide BP 160mcg per
actuation.
Price: Symbion 4.5/160 HFA Inhaler x 120 doses
canister: 980.00 MRP
SALMETEROL +
FLUTICASONE 21,42,47,48
SALMETEROL + FLUTICASONE: DPI/MDI
The combined inhalation preparations of salme­
terol xinafoate BP and fluticasone propionate BP
are available as- i. Dry Powder Inhalation, such
as- Acuhaler, Convihaler, Cozyhaler, Cyclohaler
•
and Rotahaler and ii. Metered dose inhalation,
such as- Evohaler.
Dry Powder Inhalation (DPI): Dry Powder
Inhalation, such as- Accuhaler, Convihaler,
Cozyhaler, Cyclohaler & Rotahalar devices are
used by oral inhalation only. So that, rinsing the
mouth after each inhalation.
Metered dose inhalation (MDI): Metered dose
inhalation- such as Evohaler device is used by
aerosol inhalation only. Metered dose inhalation
devic_e uses two types of propellant, viz­
traditional CFC (Chlorofluorocarbon) or recently
introduced HFA(Hydrofluoroalkane).
CFC (Chlorofluorocarbon): CFC- using as MDI
propellant is safe for human, but, as it emits CFC
to the environment, it harms the planet by
depleting ozone layer.
HFA (Hydrojluoroalkane): Recently an
advanced HFA(Hydrofluoroalkane) technology
has developed as MDI propellant replacing CFC
propellant. HFA is an ozone-benign, environment
friendly, CFC-free MDI propellant.
Mode of action: Salmeterol xinafoate is a
selective, long acting beta-2 agonist used in the
treatment of asthma and other forms of diffuse
'
airways obstruction. Fluticasone propionate is a
corticosteroid with mainly glucocorticoid
activity. Fluticasone propionate is stated to exert
a topical effect on the lungs without systemic
effects at usual dose.
Ind: Treatment of asthma: Fluticasone propi­
onate & salmeterol xinafoate combination is indi­
cated for the regular treatment of asthma in chil­
dren (aged 4 years and older) and adults patients.
It is indicated for patients not adequately con­
trolled on a long-term asthma control medication,
such as an inhaled corticosteroid or whose
disease severity clearly warrants initiation of
treatment with both an inhaled corticosteroid and
LABA. Once asthma control is achieved and
maintained, assess the patient at regular intervals
and step down therapy if possible without loss of
asthma control and maintain the patient on a
long-term asthma control medication, such as an
inhaled corticosteroid. It is not indicated for the
relief of acute bronchospasm.
Maintenance treatment of chronic obstructive
pulmonary disease (COPD): Fluticasone
propionate & salmeterol xinafoate combination is
also indicated for the maintenance treatment of
airflow obstruction and to reduce exacerbations
in patients with chronic obstructive pulmonary
disease, including chronic bronchitis and/or
emphysema.
C/I: This combination is contraindicated in the
following conditions:
Primary treatment of status asthmaticus or other
acute episodes of asthma or COPD where
intensive measures are required.
Severe hypersensitivity to any of the ingredients
and milk proteins.
A/E: The type and severity of adverse reactions
associated with each of the compounds may be.
expected. There is no incidence of additional
adverse events following concurrent administra­
tion of the two compounds. Therefore, adverse
events which have been associated with salme­
terol or fluticasone propionate (steroid) are
almost same as with the individual preparation.
(Please see above, under the preparations of sal-
 QIMP-17 (115)
meterol & for fluticasone, under any steroid
preparation such as beclomethasone inhaler).
Precautions & Warnings:
This combined preparation is not for relief of
acute symptoms, so, it should not be initiated in
patients during rapidly deteriorating or
potentially life-threatening episodes of asthma or
chronic obstructive pulmonary disease.
In this situation, a fast and short-acting
bronchodilator (e.g salbutamol) is required to
initiate the therapy. Patients should be advised to
have their relief medication available at all times.
Increasing use of short-acting bronchodilators to
relieve asthma symptoms indicates deterioration
of asthma control. Sudden and progressive
deterioration in control of asthma is potentially
life threatening and the patient should be
reviewed by a physician. Consideration should be
given to increasing corticosteroid therapy. Also,
where the current dosage has failed to give
adequate cotrol of reversible obstructive airway
disease, the patient should be reviewed by a
physician. This combination should not be used
for the relief of acute bronchospasm.
Consideration should be given to additional
corticosteroid therapies, and include
administration of antibiotics if an infection is
present. Treatment with this preparation should
not be stopped abruptly.
As with all inhaled medication containing corti­
costeroids, it should be administered with caution
in patients with active or quiescent pulmonary
tuberculosis, infe.ctions of the respiratory tract;
untreated systemic fungal, bacterial, viral, or
parasitic infections; or ocular herpes simplex.
These drugs should be administered with caution
in patients with thyrotoxicosis. Rare instances of
glaucoma and increased intra-ocular pressure
have been reported following administration of
inhaled corticosteroids. Care should be taken
when transferring patients to this combined
therapy, particularly if there is any reason to
suppose that adrenal function is impaired from
previous systemic steroid therapy.
Pregnancy & lactation: Pregnancy category C.
This combination should be used during
pregnancy only if the potential benefit justifies
the potential risk to the fetus; and the women
who are breastfeeding should only be considered
if the expected benefit to the mother is greater
than any possible risk to the child.
Dosage & admin: The combined inhaler
preparations of salmeterol and Outicasone are
available as Accuhaler (dry powder for inhala­
tion), Convihaler (dry powder for inhalation),
Cozyhaler (dry powder for inhalation),
Cyclohaler (dry powder for inhalation),
Evohaler (aerosol inhalation), ·Metered dose
inhaler (MDI- aerosol inhalation) and
Rotahaler (dry powder inhalation).
Accuhaler, Convihaler, Cozyhaler, Cyclohaler
and Rotahaler- all are 'dry powder inhalation
( DPI)' devices and are used by oral inhalation
route only.
Evohaler is a MDI (metered dose inhalation)
device and is used by aerosol inhalation only.
Individual patients will experience a variable
time of onset and degree of symptom relief.
Generally, preparation containing Outicasone
propionate inhalation has a relatively rapid
I
RESPIRATORY DRUGS
onset of action for an inhaled corticosteroid.
Improvement in asthma control following
inhaled administration of fluticasone
propionate can occur within 24 hours of
beginning the treatment, although maximum
benefit may not be achieved for 1 to 2 weeks
or longer after starting the treatment.
Patients should be made aware that the
inhaler must be used regularly for optimum
benefit. Patients should be regularly
reassessed by a physician, so that the strength
of inhaler they are receiving remains optimal
and is only changed on medical advice. The
dose should be adjusted to the lowest dose at
which effective control of symptoms is
maintained. Patients should be given the
strength of inhaler containing the appropriate
Outicasone propionate dosage for the severity
of their disease.
Recomm endeddosueraimensqf
D aPowderInhalation fDPJ);
'Dry powder inhaler' is used by oral inhala­
tion route only. So, rinsing the mouth after
each inhalation.
Treatment ofAsthma;
Adults & adolescents (12 years & older):
1 puff of the dry powder inhaler containing
Outicasone 1OOmcg in mild to moderate,
250mcg in moderate to severe and 500mcg in
severe asthma twice daily (morning and
evening, approximately 12 hours apart).
The maximum recommended dosage is flutica­
sone 500mcg twice daily.
Children 4-11 years: 1 puff of the dry powder·
inhaler containing fluticasone 1 OOmcg twice
daily (morning and evening, approximately 12
hours apart). The dose can be reduced to 1
puff once daily if control maintained.
Chronic obstructive pulmonary disease (COPD):
Dry powder inhaler containing fluticasone
250mcg 1 puff twice daily (morning and
evening, approximately 12 hours apart).
Recommendeddosa.reraimensgf
MeteredDoseInhalerfMDD;
Metered dose inhaler is to be used by aerosol
inhalation only.
Adults & adolescents (12 years & older): 2 puffs
of metered dose inhaler containing fluticasone
50mcg in mild to moderate, 125mcg in moder­
ate to severe and 250mcg in severe asthma
twice daily (morning and evening, approxi­
mately 12 hours apart).
Children 4-11 years: 2 puffs of metered dose
inhaler containing fluticasone 50mcg twice
daily (morning and evening, approximately 12
hours apart). The dose can be reduced to 2
puffs once daily if control mai.ntained.
Metered dose inhaler containing fluticasone
125mcg and 250mcg is not applicable in cases
of children.
Special patients groups: There is no need to
adjust the dose in elderly patients or in those
with renal impairment. There are no data .
available for use of inhaler in patients with
hepatic impairment.
Drug inter: The use of strong CYP3A4
inhibitors (e.g., ritonavir, atazanavir, clari­
thromycin, indinavir, itraconazole, nefazodone,

RESPIRATORY DRUGS
nelfmavir, saquinavir, ketoconazole, telithromy­
cin) with fluticasone propionate & salmeterol
xinafoate combination is contraindicated because
increased systemic corticosteroid and increased
cardiovascular adverse effects may occur.
Ketoconazole, beta-adrenergic receptor blocking
agents and nonpotassium-sparing diuretics are
also contraindicated.
Note: For further information, please consult
manufacturer's literature.
roti
®
I
I
I e Inhaler
I Sameterol 25mcg+�125mcg
I Samet9"d 25mcg + �250mcg
Sl<•F
t AROFLO UFA Inhaler (MDI)
Aristopharma
Aroflo-50 HFA Inhaler (MDI): HFA (Hydroflu­
oroalkane) based metered dose inhaler containing
25mcg of salmeterol xinafoate BP and 50mcg of
fluticasone propionate BP per actuation.
Aroflo-125 HFA Inhaler (MDI): HFA (Hydrofl­
uoroalkane) based metered dose inhaler contain­
ing 25mcg of salmeterol xinafoate BP & 125mcg
of fluticasone propionate per BP actuation.
Arojlo-250 HFA Inhaler (MDI): HFA (Hydrofl­
uoroalkane) based metered dose inhaler contain­
ing 25mcg of salmeterol xinafoate BP & 250mcg
of fluticasone propionate per BP actuation.
Prices:
Aroflo-50 Inhaler x 120 doses 11nit: 520.00 MRP
Aroflo-125 Inhaler x 120 doses 11nit: 595.00 MRP
Aroflo-250 Inhaler x 120 doses unit: 795.00 MRP
Aroflo-250 Inhaler x 60 doses unit: 430.00 MRP
t AROTIDE Inhaler (MDI)SK+F
Arotide 251125 Inhaler: Metered dose inhaler
containing 25mcg of salmeterol xinafoate BP and
125mcg of fluticasone propionate BP (delivered
from the inhaler) per actuation.
Arotide 251250 Inhaler: Metered dose inhaler
containing 25mcg of salmeterol xinafoate BP and
250mcg of fluticasone propionate BP (delivered
from the inhaler) per actuation.
Prices:
Arotide 25/125 Inhaler (120 doses unit) x l's:
575.00 MRP
Arotide 25/250 Inhaler (120 doses unit) x l's:
750.00 MRP
t BEXITROL F Inhaler (MDI)Beximco
Bexitrol F Inhaler 25150: Metered dose inhaler
containing 25mcg of salmeterol xinafoate BP and
50mcg of fluticasone propionate BP (delivered
from the inhaler) per actuation.
Bexitrol F Inhaler 251125: Metered dose inhaler
containing 25mcg of salmeterol xinafoate BP and
125mcg of fluticasone propionate BP (delivered
from the inhaler) per actuation.
Bexitrol F Inhaler 251250: Metered dose inhaler
containing 25mcg of salmeterol xinafoate BP and
250mcg of fluticasone propionate BP (delivered
from the inhaler) per actuation.
Prices:
Bexitrol F 25/50 (120 doses unit) xi's: 520.00 IP
Bexitrol F 25/125 (120 doses unit) xi's: 595.00 IP
Bexitrol F 25/250 (120 doses unit) xi's: 795.00 IP
•
QIMP-17 (116)
t BEXITROL F 25/250 HFA Inhaler (MDI)
Beximco
Bexitrol F 251250 HFA Inhaler (MDI): HFA
(Hydrofluoroalkane) based metered dose inhaler
containing 25mcg of salmeterol xinafoate BP and
250mcg of fluticasone propionate BP per
actuation.
Price:
Bexitrol F 251250 HFA Inhaler x 120 doses unit:
895.00 MRP
t BEXITROL F Bexicap (DPI)Beximco
Bexitrol F 501100 Bexicap (DPI): Each bexicap
capsule contains salmeterol zinafoate BP 50mcg
& fluticasone propionate BP 1OOmcg: dry
powder inhalation.
Bexitrol F 501250 Bexicap (DPI): Each bexicap
capsule contains salmeterol zinafoate BP 50mcg
& fluticasone propionate BP 250mcg: dry
powder inhalation.
Bexitrol F 501500 Bexicap (DPI): Each bexicap
capsule contains salmeterol zinafoate BP 50mcg
& fluticasone propionate BP 500mcg: dry
powder inhalation.
'Bexicap capsule' is a pre-metered single dose
medication ·for inhalation, specially to be used
with 'bexihaler'.
Bexicap capsule contains an admixture of
micronised drug (<5 ) with a carrier, lactose.
'Bexihaler'- a dry powder inhalation (DPI)
device, using bexicap capsule for inhalation.
Prices:
Bexitrol F 100 Bexicap x 30's pack: 145.50 MRP
Bexitrol F 250 Bexicap x 30's pack: 276.00 MRP
Bexitrol F 500 Bexicap x 30's pack: 450.00 MRP
t FLUTISAL Convicap (DPI)Incepta
Flutisal 100 Convicap (DPI): Each capsule
contains- fluticasone propionate BP 1 OOmcg and
salmeterol xinafoate BP equivalent to saJmeterol
50mcg: dry powder inhalation.
Flutisal 250 Convicap (DPI): Each capsule
contains- fluticasone propionate BP 250mcg and
salmeterol xinafoate BP equivalent to salmeterol
50mcg: dry powder inhalation.
Flutisal 500 Convicap (DPI): Each capsule
contains- fluticasone propionate BP 500mcg and
salmeterol xinafoate BP equivalent to salmeterol
50mcg: dry powder inhalation.
'Convicap capsule' is a pre-metered single dose
medication for inhalation, specially to be used
with 'convihaler'.
Convicap capsule contains an admixture of
micronised drug (<5) with a carrier, lactose.
Convihaler- a dry powder inhalation (DPI)
device, using convicap capsule for inhalation.
Prices:
Flutisal 100 Convicap x 30's pack: 150.00 MRP
Flutisal 250 Convicap x 30's pack: 300.00 MRP
Flutisal 500 Convicap x 30's pack: 450.00 MRP
t SALFLU Rotacap (DPl)Acme
Salflu 100 Rolllcap (DPI): Each capsule
contains- fluticasone propionate BP 1 OOmcg and
salmeterol xinafoate BP equivalent to salmeterol
50mcg: dry powder inhalation.
Salflu 250 Rolllcap (DPI): Each capsule
contains- fluticasone propionate BP 250mcg and
salmeterol xinafoate BP equivalent to salmeterol
50mcg: dry powder inhalation.
Salflu 500 Rolllcap (DPI): Each capsule
contains- fluticasone propionate BP 500mcg and
salmeterol xinafoate BP equivalent to salmeterol
•
50mcg: dry powder inhalation.
'Rotacap capsule' is a pre-metered single dose
medication for inhalation, specially to be used
with 'Rotahaler'.
Rotacap capsule contains an admixture of
micronised drug (<5) with a carrier, lactose.
Salflu inhaler is a DPI (dry powder inhalation)
system and administered by Rotahaler device
through oral inhalation route.
Rotahaler- a dry powder inhalation (DPI) device,
using rotacap capsule for inhalation
Prices:
Salflu 100 Rotacap x 30's pack: 142.80 MRP
Salflu 250 R· otacap x 30's pack: 271.20 MRP
Salflu 500 Rotacap x 30's pack: 451.50 MRP
+ SERETIDE Accuhaler/Evohaler
GlaxoSmithKline
Seretide 100 Accuhaler (DPI): Moulded plastic
device containing a foil strip with 60 blisters,
each containing 50mcg of salmeterol xinafoate
and 1OOmcg of fluticasone propionate; dry
powder inhalation (DPI).
Seretide 250 Accuhaler (DPI): Moulded plastic
device containing a foil strip with 60 blisters,
each containing 50mcg of salmeterol xinafoate
and 250mcg of fluticasone propionate; dry
powder inhalation (DPI).
Seretide 500 Accuhaler (DPI): Moulded plastic
device containing a foil strip with 60 blisters,
each containing 50mcg of salmeterol xinafoate
and 500mcg of fluticasone propionate; dry
powder inhalation (DPI).
Prices:
Seretide 100 Accuhaler x 60 doses unit:
1086.51 MRP
Seretide 250 Accuhaler x 60 doses unit:
1238.12 MRP
Seretide 500 Accuhaler x 60 doses unit:
1440.26 MRP
+ SERETIDE Evohaler GlaxoSmithKline
Seretide 50 Evohaler (MDI): CFC free metered
dose inhaler containing 25mcg of salmeterol
xinafoate and SOmcg of fluticasone propionate
(delivered from the valve) per actuation; 120
doses unit.
Seretide 125 Evohaler (MDI): CFC free metered
dose inhaler containing 25mcg of salmeterol
xinafoate and l 25mcg of fluticasone propionate
(delivered from the valve) per actuation; 120
doses 11nit.
Seretide 250 Evohaler (MDI): CFC free metered
dose inhaler containing 25mcg of salmeterol
xinafoate and 250mcg of fluticasone propionate
(delivered from the valve) per actuation; 120
doses unit.
Prices:
Seretide 50 Evohaler x 120 doses unit:
750.00 MRP .
Seretide 125 Evohaler x 120 doses unit:
•
1074.69 MRP
Seretide 250 Evohaler x 120 doses unit:
1250.00 MRP
t SEROXYN HFA Inhaler (MDI)ACI
Seroxyn HFA 251125 Inhaler: HFA (Hydrofluo­
roalkane) based metered dose inhaler containing
25mcg of salmeterol xinafoate BP and 125mcg of
fluticasone propionate BP (delivered from the
inhaler) per actuation.
Seroxyn HFA 251250 Inhaler: HFA (Hydrofluo­
roalkane) based metered dose inhaler containing

25mcg of salmeterol xinafoate BP and 250mcg of
fluticasone propionate BP (delivered from the
inhaler) per actuation.
Prices:
Seroxyn HFA 25/125 (120 doses unit) x l 's pack:
595.00 MRP
Seroxyn HFA 25/250 (120 doses unit) x l's pack:
795.00 MRP
t SEROXYN Acucap (DPI) ACI
Seroxyn 501100 Acucap (DPI): Each acucap
capsule contains salnieterol zinafoate BP 50mcg
& fluticasone propionate BP 1OOmcg; dry
powder inhalation.
Seroxyn 501250 Acucap (DPI): Each acucap
capsule contains salmeterol zinafoate BP 50mcg
& fluticasone propionate BP 250mcg; dry
-
powder inhalation.
.>
Seroxyn 501500 Acucap (DPI): Each acucap
capsule contains salmeterol zinafoate BP 50mcg
& fluticasone propionate BP 500mcg; dry
powder inhalation.
'Acucap capsule' is a pre-metered single dose
medication for inhalation, specially to be used
with 'acuhaler'.
Acucap capsule contains an admixture of
micronised drug (<5 ) with a carrier, lactose.
Acuhaler- a dry powder inhalation (DPI) device,
using acucap capsule for inhalation.
Prices:
Seroxyn 100 Acucap x 32's pack: 155.20 MRP
Seroxyn 250 Acucap x 32's pack: 294.40 MRP
Seroxyn 500 Acucap x 32's pack: 480.00 MRP
t TICAMET Inhaler (MDI) Square
1icamet 50 Inhaler (MDI): Each actuation or
dose contains salmeterol xinafoate BP 25mcg and
fluticasone propionate BP 50mcg; metered dose
i inhalation.
1icamet 250 Inhaler (MDI): Each actuation or
dose contains salmeterol xinafoate BP 25mcg and
fluticasone propionate BP 250mcg; metered dose
inhalation.
Prices:
Ticamet 50 (120 doses unit) x l's pack: 526.99
MRP
Ticamet 250 (120 doses unit) x l's pack: 752.83
MRP
t TICAMET HFA Inhaler (MDI) Square
1icamet HFA 251125 Inhaler: HFA (Hydrofluo­
roalkane) based metered dose inhaler containing
25mcg of salmeterol xinafoate BP and 125mcg of
fluticasone propionate BP (delivered from the
inhaler) per actuation.
1icamet HFA 251250 Inhaler: HFA (Hydrofluo­
roalkane) based metered dose inhaler containing
25mcg of salmeterol xinafoate BP and 250mcg of
fluticasone propionate BP (delivered from the
inhaler) per actuation.
Prices:
-
Ticamet HFA 25/125 (120 doses unit) x l's pack:
'
595.00 MRP
Ticamet HFA 25/250 (120 doses 11nit) x l's pack:
795.00 MRP
t TICAMET Cozycap (DPI) Square
1icamet 100 Cozycap (DPI): Each cozycap con-
I
QIMP-17 (117)
tains salmeterol zinafoate BP SOmcg &
fluticasone propionate BP 1OOmcg; dry powder
inhalation.
1icamet 250 Cozycap (DPI): Each cozycap
contains salmeterol zinafoate BP 50mcg &
fluticasone propionate BP 250mcg; dry powder
inhalation.
'Cozycap' is a pre-metered single dose
medication for inhalation, specially to be used
with 'cozyhaler'.
Cozycap contains an admixture of micronised
drug (<5 ) with a carrier, lactose.
Cozyhaler- a dry powder inhalation (DPD device,
using cozycap for inhalation.
Prices:
Ticamet 100 Cozycap x 30's pack: 145.50 MRP
Ticamet 250 Cozycap x 30's pack: 276.30 MRP
Device for Dry Powder
Inhalation (DP/)
t CYCLOHALER Inhalation device
Pharmachemie/City Overseas
'Cyclohaler' is an inhalation device, used for dry
powder inhalation (DPD by mouth only.
Rinsing the mouth after dry powder inhalation is
used.
l's pack: 125.00 TP
4. ANTIHISTAMINES,
ANTI-ALLERGICS,
ANTIINFLAMMATORY &
HYPO SENSITISATION
DRUGS
•
OMALI
t XOLAIR Inj. Novartis
Omalizumab 150mg powder in vial and solvent
for solution. Reconstituted xolair contains
125mg/ml of omalizumab (150mg in l .2ml):
injection.
Omalizumab is a ht1manized monoclonal antibody
manufactured from a mammalian cell line.
Ind: Adults & children (6 years & above) with
moderate to severe persistent allergic asthma
whose symptoms are inadequately controlled
with inhaled corticosteroids.
C/I: Hypersensitivity to omalizumab or to any of
the excipients.
AIR: Serious/rare adverse reactions include:
Angioedema, anaphylactic reactions and other
allergic conditions, allergic bronchospasm.
Serious additional undesirable effects reported
during post marketing observations are: Allergic
granulomatous angiitis, idiopatic severe thrombo­
cytopenia. Very common undesirable effect is:
Pyrexia (in children). Most common undesirable
effects are: Headache (very common in children},
� ��!ALS
RESPIRATORY DRUGS
injection site pain, swelling, erythema, pruritus,
upper abdominal pain (in children). Uncommon
undesirable effects are: Dizziness, ·somnolence,
parasthesia, syncope, postural hypotension, flush­
ing, pharyngitis, coughing, nausea, diarrhea, dys­
peptic signs and symptoms, urticaria, rash, photo­
sensitivity, weight increase, fatigue, swelling
arms, influenza-like illness. Rare undesirable
effects are: Parasitic infections, laryngoedema.
Other additional undesirable effects reported
during post marketing observations are: Alopecia,
arthralgia, myalgia, joint swelling.
Precautions & warnings: Not indicated for the
treatment of acute asthma exacerbations, acute
bronchospasm or status asthmaticus; no abrupt
discontinuation of corticosteroids; caution in use
with renal or hepatic impaired patients; patients
with autoimmune diseases and immune complex­
mediated conditions; patients with high risk of
parasitic infections; occurrence of local or sys­
temic allergic reactions, including anaphylaxis;
pregnancy; lactation; patients with diabetes mel­
litus, the glucose-galactose malabsorption syn­
drome, fructose intolerance or sucrose-isomaltase
deficiency should be warned that one l 50mg
xolair powder and solvent dose contains 108mg
of sucrose. Among the different xolair presenta­
tions, only xolair powder vial contains sucrose.
Dosage & admin: One to three injections (i.e
1S0-4S0mg) s.c. every two to four weeks
according to body weight and baseline serum
total IgE level.
Drug inter: None known.
Note: Before prescribing, please read full
prescribing information.
l 50mg vial x l's pack: 33654.00 MRP
ROFL UMILAST: Tablet
Roflumilast is an anti-inflammatory medicine
called selective phosphodiesterase 4 inhibitor. It
is available as- roflumilast INN 500mcg/tablet
(film coated).
Mode of action: Roflumilast reduces the activity
of phosphodiesterase 4, a protein occurring natu­
rally in body cells. When the activity of this pro­
tein is reduced, there is less inflammation in the
lungs. This helps to stop narrowing of airways
occurring in chronic obstructive pulmonary dis­
ease (COPD). Thus Roflumilast eases breathing.
Ind: Rofl11milast is used to treat severe COPD in
adults. COPD is a chronic disease of the lungs
that results in tightening of the airways
(obstruction), swelling and irritation of the walls
of the small air passages (inflammation) leading
to symptoms such as- coughing, wheezing, chest
tightness or difficulty in breathing. Roflumilast is
to be used in addition to bronchodilators in
COPD patients.
C/I: Roflumilast is contra�dicated to patients
with a history of hypersensitivity to roflumilast
or any of other ingredients of the tablet and if a
patient has moderate to severe liver impairment.
••••
LTI>. www.squarepharmacom-.bd ·
•••
•••
11u•w
 QIMP-17 (118)

Dextromethorphan HBr, Psoudoephedrine HCI & C/I: Contra-indication or special precaution in

Triprolidine HCI Syrup BUTAMIRATE CITRATE54 hepatic dysfunction
S/E: Constipation; may occasionally cause
BUTAMIRATE CITRATE: Tablet drowsiness, excitation, dizziness, mental
Butamirate citrate is a non-sedative cough sup­ confusion & g.i. disturbances. Large doses may
S/E: Normally, roflumilast is well tolerated. pressant preparation. It is available as butamirate cause respiratory depression.
Common side-effects are weight loss, decreased citrate BP 50mg tablet in sustained release form. Cautions: Asthma; as cough suppressant may
appetite, sleeplessness, headache, diarrhoea, Mode of action: Butamirate citrate is a centrally cause sputum retention, this may be harmful in
nausea, stomach ache etc. acting cough suppressant which is neither patients with ch. bronchitis & bronchiectasis.
chemically nor pharmacologically related to Though commonly used in acute bronchitis &
Precautions: Roflumilast is not a bronchodilator
opium alkaloids. In addition to its antitussive pneumonia, they are usually ·unnecessary & such
and should not be used for the treatment of a
effect, butamirate also decreases the airway conditions are best treated by prompt
sudden attack of breathlessness. Patients treated
resistance and thereby facilitates respiration of administration of antibacterial drugs.
with this drug should have their weight moni­
asthma patient. Adult: 5Dll (ltsf) 3 or 4 times daily
tored regularly. If unexplained or clinically sig­
Ind: Butamirate citrate is indicated in acute dry Child: Under 1 year, not recommended; 1-5
nificant weight loss occurs, this should be evalu­
cough, pre- and post-operative cough sedation for yrs, 1/4 th adult dose; 6-12 yrs, 1/2 adult dose.
ated, and discontinuation of roflumilast should be
surgical procedures & bronchoscopy. Butamirate
considered. Roflumilast should be given with
is also widely prescribed in productive cough t BROFEX Syp. Square
caution in patients with severe immunological
along with antibiotic or chemotherapeutic agent Dextromethorphan 1Omg/5ml: syrup.
diseases (HIV infection, multiple sclerosis, lupus 1 OOml bot: 35.00 MRP
for faster cough suppression.
erythematosus, progressive multifocal leukoen­
P regnancy & lactation: Butamirate citrate only t COLDFLU Syp. Amico
cephalopathy and others), severe acute infectious
can be given in pregnancy if the benefits Dextromethorphan 1Omg/5ml: syrup.
diseases (tuberculosis or acute hepatitis), cancer
overweigh the potential risks. l OOml bot: 23.00 MRP
(except basal-cell carcinoma), severe impairment
Dosage & admin: Children of 5-10 years, 1-2 t D-COUGH Syp. Opsonin
of the heart function.
tablets daily; Children over 10 years·& adults, Dextromethorphan I Omg/5ml: syrup.
P regnancy & lactation: Roflumilast is pregnan­
2-3 tablets daily irrespective of food intake. l OOml bot: 30.79 MRP
cy category C drug. There are no adequate and
Usual duration 5-7 days. However, butamirate t DEXSOL Syp. Gaco
well controlled studies of it in pregnant women citrate can be prescribed up to 2 months in Dextromethorphan I Omg/5ml: syrup.
and lactating mothers. Roflumilast should be chronic diseases. l OOml bot: 35.00 MRP
used during pregnancy only if the potential Butamirate citrate is safe in extremes of ages. t DEXTROMETHORP HAN Syp. Beximco
benefit justifies the potential risk to the fetus and Note: For further information, please consult Dextromethorphan 1Omg/5ml: syrup.
should not be used by women who are nursing. manufacturer's literature. 1OOml bot: 35.00 MRP
Dosage & admin: In adults (above 18 years of t DEXTROMETHORP HAN Syp. Ambee
age), the recommended dose of Roflumilast is t BUCOD 50 SR Tab. Sharif Dextromethorphan I Omg/5ml: syrup
one 500mcg tablet per day, with or without Butamirate citrate BP 50mg/tablet (sustained I OOm1 bot: 24.37 MRP
food. As there are lack of safety information of release). t EXOP HAN Syp. Apollo
this drug in children so, it should be avoided 30's pack: 240.0� MRP Dextromethorphan 1Omg/5ml: syrup.
in children & adolescent under 18 years of • BUKOF Tab. Beacon 1 OOml bot: 24.00 IP
age. Butamirate citrate BP 50mg/tablet (sustained t TOMEPHEN Syp. Incepta
release). Dextromethorphan 1Omg/5ml: syrup.
·

Drug inter: Roflumilast may be taken with med­

icines used in the treatment of COPD such as­
30's pack: 299.99 MRP I OOml bot: 30.00 MRP

inhaled or oral corticosteroids or bronchodilators.

t DECONIL Tab. Orion Pharma
Butamirate citrate BP 50mg/tablet (sustained
But it shows drug interactions with- rifampicin,
phenobarbital, carbamazepine, phenytoin,
release). Combined cough
30's pack: 301.20 MRP
erythromycin, ketoconazole, fluvoxamine, suppressants45•65•66
enoxacin, cimetidine and ethinyl estradiol. t KOFNIX SR Tab. ACI
Butamirate citrate BP 50mg/tablet (sustained

t DILAROF Tab. UniMed & UniHealth release). DEXTROMETHORPHAN+

MRP
•

Roflumilast INN 500mcg (0.5mg)/tablet (f.c). 30's pack: 300.00 P SEUDOEPHEDRINE+ TRIPROLIDINE:

500mcg x 20's pack: 400.00 MRP t MIRAKOF SR Tab. Square Or,

t LUMAST Tab. Square Butamirate citrate BP 50mg/tablet (sustained DEXTROMETHORP HAN+ P SEU­

Roflumilast INN 500mcg (0.5mg)/tablet (f.c). release). DOEPHED RINE + GUAIPHENESIN: Syrup

500mcg x 30's pack: 450.00 MRP 30's pack: 301.20 MRP This is a combination of dextromethorphan, an

t ROFLAST Tab. Beacon t SINAKOF Tab. lbn Sina antitussive, pseudoeph edrine, a decongestant and

Roflumilast INN 500mcg (0.5mg)/tablet (f.c). Butamirate citrate BP 50mg/tablet (sustained triprolidine, an antihistamine preparation.

500mcg x 30's pack: 450.00 MRP release). Comp: Each 5ml syrup contains

t ROXAIR Tab. Incepta 30'� pack: 300.00 IP dextromethorphan hydrobromide �p I Omg,

Roflumilast INN 500mcg (0.5mg)/tablet (f.c). t SINECOD SR Tab. Sandoz pseudoephedrine hydrochloride BP 30mg and

500mcg x 30's pack: 450.00 MRP Butamirate citrate BP 50mg/tablet (sustained triprolidine hydrochloride BP l .25mg or
release). guaiphenesin BP 1OOmg
50's pack: 600.00 MRP Mode of action: Dextromethorphan is a cough
suppressant, which has a central action on the
5. COUGH PREPARATIONS21
cough centre in the medulla. Pseudoephedrine is
DEXTROMETHORPHAN21,33 an effective decongestant, which produces its
5.1 Cough suppressants decongestant effect in the upper respiratory tract.
5.2 Combined cough suppressants DEXTROMETHORPHN Triprolidine binds competitively with histamine
5 3 Cough' expectoran.ts & mucolytics
.•
·
. : · HYDROBROMIDE: Syrup HI receptor and provides symptomatic relief of
s.1· -'Co�bined cough_ expectorants
.
.
. .
, . . .

Ind: Non-narcotic �titussive agent, used in dry allergic rhinitis and common cold .
. .

. ·.

"
.

_ ·
.. , .
.

or painful cough: Benefits of treatm�nt is only .

. .
.
Ind: Symptomatic relief of allergic r.hinitis &
'

. _ ,,,: .
.
. ,

. .)
. "' '•
. . ·

occa.sionally, such as if sleep is disturbed by a Upp.er resp. tract disorders accompttnied by

Cough suppressants
· . .

dry cough. . -
'" . . :
'
unproductive cough. .
. . .· .,

. .-•
. .

•

C/I: Severe hypertension or severe coronary
artery disease, MAOls therapy within the
preceeding 2 wks.
S/E: Dizziness, gastro-intestinal disturbances,
fear, anxiety, restlessness, tremor, insomnia, con
fusion, irritability, sedation.
Caution: Severe renal & hepatic impairment,
persistent cough.
Dosage & admin: Adults & children over 12
years - 2 tsf 3 times daily.
Children 2-5 years - 1/2 tsf 3 times daily; 6-12
years 1 tsf 3 times daily.
t A-COF Syp. Acme
Dextromethorphan hydrobromide 1Omg,
pseudoephedrine hydrochloride 30mg &
,,. triprolidine hydrochloride l .25mg/5ml: syrup.
IOOml bot: 60.00 MRP
t ANKOF Syp. General
Dextromethorphan hydrobromide 1Omg,
I
pseudoephedrine hydrochloride 30mg &
'
triprolidine hydrochloride 1.25mg/5ml: syrup.
1 OOml bot: 60.00 MRP
t CASICA Syp. Pharmadesh
'
Dextromethorphan hydrobromide 1Omg,
pseudoephedrine hydrochloride 30mg &
I .
Dextromethorphan+Psoudoephedrine+Triprolidine Syrup
I
THE TOTAL COUGH REMEDY
triprolidine hydrochloride l .25mg/5ml: syrup.
l OOml bot: 65.00 MRP
+ COFNO Syp. Alco Pharma
Dextromethorphan hydrobromide 1 Omg,
pseudoephedrine hydrochloride 30mg &
triprolidine hydrochloride l .25mg/5ml: syrup.
1OOml bot: 70.00 MRP
t COPRIN Syp. Doctor's
Dextromethorphan hydrobromide 1 Omg,
pseudoephedrine hydrochloride 30mg &
triprolidine hydrochloride l .25mg/5ml: syrup.
IOOml bot: 55.00 MRP
t DECOFF Syp. Hudson
Dextromethorphan hydrobromide 1Omg,
pseudoephedrine hydrochloride 30mg &
triprolidine hydrochloride l .25mg/5ml: syrup.
IOOml bot: 50.00 MRP
t DEXDIN Syp. Somatec
Dextromethorphan hydrobromide 1 Omg,
pseudoephedrine hydrochloride 30mg & ·
triprolidine hydrochloride l .25mg/5ml: syrup.
1OOml bot: 60.00 MRP
+ DEXITRA Syp. Novo Healthcare
Dextromethorphan hydrobromide 1Omg,
pseudoephedrine hydrochloride 30mg &
triprolidine hydrochloride l .25mg/5ml: syrup.
I
-
QIMP-17 (119) RESPIRATORY DRUGS
lOOml bot: 55.00 MRP IOOml bot: 50.00 IP
t DEXPOTEN Syp. SK+F t TEXCO Syp. Globe
Dextromethorphan hydrobromide 1 Omg, pseu Dextromethorphan hydrobromide' 1Omg,
doephedrine hydrochloride 30mg & triprolidine pseudoephedrine hydrochloride 30mg &
hydrochloride l .25mg/5ml: syrup. triprolidine hydrochloride 1.25mg/5ml: syrup.
l OOml bot: 70.00 MRP l OOml bot: 50.00 MRP
t DEXTROP Syp. Edruc t TUSIVA Syp. Opsonin
Dextromethorphan hydrobromide 1Omg, Dextromethorphan hydrobromide 1 Omg,
pseudoephedrine hydrochloride 30mg & pseudoephedrine hydrochloride 30mg &
triprolidine hydrochloride l .25mg/5ml: syrup. triprolidine hydrochloride 1.25mg/5ml: syrup.
l OOml bot: 55.00 MRP IOOml bot: 52.78 MRP
t DIXXAR Syp. ACI
Dextromethorphan hydrobromide 1Omg,
pseudoephedrine hydrochloride 30mg & Cough expectorants &
triprolidine hydrochloride l .25mg/5ml: syrup.
lOOml bot: 70.00 MRP
Mucolytics
t EXORDIN Syp. Millat
Dextromethorphan hydro bromide 1 Omg, AMBROXOL42
pseudoephedrine hydrochloride 30mg &
triprolidine hydrochloride l .25mg/5ml: syrup. AMBROXOL HCI: Drop/Syrup/Capsule
1OOml bot: 60.00 MRP Ambroxol is the active metabolite of bromhexine
t FREECOF Syp. Aristopharma and it has been proven that this metabolite
Dextromethorphan hydrobromide 1Omg, possesses a greater bronchosecretolytic effect
pseudoephedrine hydrochloride 30mg & than bromhexine. It is available as ambroxol
triprolidine hydrochloride l .25mg/5ml: syrup . hydrochloride BP 6mg/1ml drop, 15mg/5ml
..
•
•
Guaifensin+Pseudoephedrine+Triprolidine syrup
•
Effective relief from
congestive cough & cold
IOOml bot: 70.00 MRP syrup and 75mg/capsule (sustained release).
t KOFTEX-D Syp. Amico
Mode of action: Ambroxol hydrochloride
improves sputum rheology by hydrating
Dextromethorphan hydrobromide 1 Omg,
mechanism leading to liquefaction of mucus in
guaiphenesin BP 1 OOmg & pseudoephedrine
the lumen of respiratory tract, thus facilitating
hydrochloride 30mog/ 5ml: syrup.
expectoration of mucus and reducing dyspnea. It
1OOml bot: 50.00 MRP
t NILKOF Syp. Ambee
stimulates production of phospholipids of
Dextromethorphan hydrobromide 1 Omg,
surfactant by alveolar cells, thus contributing to
the lowering of superficial tension in the alveoli.
pseudoephedrine hydrochloride 30mg &
.
It also reduces bronchial hyper-reactivity.
triprolidine hydrochloride l .25mg/5ml: syrup.
Ambroxol has anti-inflammatory properties
lOOml bot: 50.19 MRP
owing to the inhibitory effect on the production
t OFKOF Syp. Square of cellular cytokines and arachidonic acid
Dextromethorphan hydrobromide 1Omg,
metabolites. In patients with COPD it
pseudoephedrine hydrochloride 30mg & traditionally improves airway patency.
triprolidine hydrochloride l .25mg/5ml: syrup. Ind: i. Productive cough. ii. Acute and chronic
lOOml bot: 70.00 MRP
inflammatory disorders of upper and lower
t PRUDEX Syp. Beximco respiratory tracts associated with viscid mucus
Dextromethorphan hydrobromide 1Omg, including acute and chronic bronchitis. iii.
pseudoephedrine hydrochloride 30mg & Laryngitis, pharyngitis, sinusitis and rhinitis
triprolidine hydrochloride l .25mg/5ml: syrup. associated with viscid mucus. iv. Asthmatic
1OOml bot: 70.00 IP bronchitis, bronchial asthma with thick expectora­
tion. v. Bronchiectasis. vi. Chronic pneumonia.
t SUDOCOF Syp. Incepta
Dextromethorphan hydrobromide 1Omg, C/I: Known hypersensitivity to ambroxol or
pseudoephedrine hydrochloride 30mg & bromhexine.
triprolidine hydrochloride l .25mg/5ml: syrup. S/E: Epigastric pain, stomach overfill feeling
RESPIRATORY DRUGS QIMP-17 (120)

may occur occasionally. Rarely allergic responses t AMBORAL Drop Pharmadesh Ambroxol hydrochloride BP l5mg/5ml: syrup
such as eruption, urticaria or angioneurotic Ambroxol hydrochloride BP 6mg/ml: drop lOOml bot: 45 .00 MRP
edema has been reported. 15ml bot: 25 .00 MRP t AROXOL Drop Healthcare
Precautions: Ambroxol should be given t AMBOSIL Syp. Silva Ambroxol hydrochloride BP 6mg/ml: drop
cautiously to patients with peptic ulceration or Ambroxol hydrochloride BP 15mg/5ml: syrup 15ml bot: 35 .00 MRP
.
convulsive disorders. Caution should be taken in lOOml bot: 40.00 MRP t BILCO Syp. Doctor's
patients with hepatic and renal insufficiency. t AMBOSIL Drop Silva Ambroxol hydrochloride BP 15mg/5ml: syrup

Pregnancy & lactation: Teratogenic and fetal Ambroxol hydrochloride BP 6mg/ml: drop lOOml bot: 30.00 MRP

toxicity studies have shown no harmful effect of 15ml bot: 20.00 MRP t BILCO Drop Doctor's
ambroxol. However, it is advised not to lise in t AMBOTEN Syp. SK+F Ambroxol hydrochloride BP 6mg/ml: drop

pregnancy, specially during the 1 st trimester. Ambroxol hydrochloride BP 15mg/5ml: syrup l5ml bot: 20.00 MRP

Safety during lactation has not been established 1OOml bot: 40.01 MRP t BOXOL Syp. Opsonin
yet. . t AMBOTEN Drop SK+F Ambrox�l hydrochloride BP 15mg/5ml: syrup
.
Dosage & admin: Average daily. dose Ambroxol hydrochloride BP 6mg/ml: drop 1OOml bot: 35 .19 MRP

(preferably after meal). · ·

15ml bot: 30.00 MRP t BOXOL Drop Opsonin
Pediatric drops: 0-6 months old- O.Sml 2 times t AMBOXOL Syp. Kumudini Ambroxol hydrochloride BP 6mg/ml: drop

a day; 6-12 months old- lml 2 times a day; 1-2 Ambroxol hydrochloride BP 15mg/5ml: syrup 15ml bot: 17.67 MRP

years old- 1.2Sml 2 times a day. 1OOml bot: 40.00 MRP t BROCULYT Syp. NIPRO .;rMI
t AMBOXOL Drop Kumudini
·

Syrup preparation: 2-S years old- 2.S ml (1/2 Ambroxol hydrochloride BP l5mg/5ml: syrup

tsf) 2-3 times a day; S-10 years old- Sml (1 tsf) Ambroxol hydrochloride BP 6mg/ml: drop l OOml bot: 40.00 MRP

2-3 times a day; 10 years old & adults- lOml 15ml bot: 20.00 MRP t BRONCHOSIL Syp. Apollo
(2 tsf) 3 times a day. t AMBOZIN-SR Cap. Rephco Ambroxol hydrochloride BP 15mg/5ml: syrup

Tablet preparation (30mg): Adults & children Ambroxol hydrochloride BP 75mg/capsule 1OOml bot: 38.00 MRP

over 10 years- 1 tablet (30mg) 3 times a day. (sustained release) t BROX Syp. Navana
Capsule preparation (7Smg SR): Adults and 30's pack: 150.00 MRP Ambroxol hydrochloride BP l5mg/5ml: syrup

children over 12 years- 1 capsule once daily. t AMBOZIN Syp. Rephco 1OOml bot: 40.00 MRP
Drug inter: Ambroxol should not be taken Ambroxol hydrochloride BP 15mg/5ml: syrup t BROXIDIL Syp. Ziska
simultaneously with antitussives ( e.g codeine) 1OOml bot: 40.00 MRP Ambroxol hydrochloride BP 15mg/5ml: syrup
because phlegm, which has been liquefied by t AMBRONIL Syp. Orion Pharma l OOml bot: 30.00 MRP
ambroxol might not be expectorated. Ambroxol hydrochloride BP 15mg/5ml: syrup t BROXOLIN Syp. Jayson .
..
1OOm1 bot: 40.00 MRP Ambroxo. l hydrochlof.ide BP l5mg/5ml: syrup
t AMBRONIL Drop Orion Pharma .

1 OOml bot:. 33.00 IP ,.;,�

.
_'
·
�
· · .
.

.
.

sylJ�· Pacific
'

Ambroxol hydrochloride BP 6m$1'ml: drop • BROXOLIT ..

.

.
·

. ,
:

®
15ml bot: 25 .00 MRP Ambroxol hydrochloride BP l5mg/5ml: syrup
t AMBROSOL Syp. Popular lOOml bot: 40.00 MRP
.
.

Ambroxol hydrochloride BP 15mg/5ml: syrup t BROXOLIT Drop Pacific

Ambroxol syrup and paediatric drops
lOOml bot: 30.11 MRP Ambroxol hydrochloride BP 6mg/ml: drop
t AMBROTIL Syp. Amico 15ml bot: 19.00 MRP
SK•F Ambroxol hydrochloride BP 15mg/5ml: syrup
t DILYT Syp. Novo Healthcare
1OOml bot: 40.00 MRP
Ambroxol hydrochloride BP 15mg/5ml: syrup
t ACOREX Syp. Apex t AMBROTON Syp. Organic Health 1 OOml bot: 40.00 MRP
Ambroxol hydrochloride BP 15mg/5ml: syrup Ambroxol hydrochloride BP 15mg/5ml: syrup
t FEMEX Syp. Globe
l OOml bot: 40.00 MRP l OOml bot: 40.00 MRP
Ambroxol hydrochloride BP 15mg/5ml: syrup
t ACTICOL Syp. GlaxoSmithKline t AMBROX 75 SR Cap. Square lOOml bot: 40.00 MRP
Ambroxol hydrochloride BP l5mg/5ml: syrup Ambroxol hydrochloride BP 75mg/capsule
t HYBROX Syp. Kemiko
lOOml bot� 40.00 MRP (sustained release)
Ambroxol hydrochloride BP 15mg/5ml: syrup
30's pack: 150.30 MRP
t AMBIX Syp. Modern 1OOml bot: 40.00 MRP .
Ambroxol hydrochloride BP 15mg/5ml: syrup t AMBROX Syp. Square t HYBROX Drop Kemiko
l OOml bot: 40.00 MRP Ambroxol hydrochloride BP 15mg/5ml: syrup
Ambroxol hydrochloride BP 6mg/ml: drop
1 OOml bot: 40.00 MRP
t AMBOKOF Syp. Novelta 15ml bot: 30.00 MRP
Ambroxol hydrochloride BP l5mg/5ml: syrup t AMBROX Drop Square t KUFFLIN Syp. Desh Pharma
lOOml bot: 40.00 MRP Ambroxol hydrochloride BP 6mg/ml: drop
Ambroxol hydrochloride BP 15mg/5ml: syrup
•

15ml bot: 30.00 MRP

t AMBOKOF Drop Novelta l OOml bot: 30.00 IP
Ambroxol hydrochloride BP 6mg/ml: drop t AMBROXOL SR Cap. Biopharma t LYTEX-SR Cap. Ibn Sina
Ambroxol hydrochloride BP 75mg/ capsule
.

l5ml bot: 30.00 MRP Ambroxol hydrochloride BP 75mg/capsule

•

(sustained release)
t AMBOLIN Syp. Virgo (sustained release)
Ambroxol hydrochloride BP l5mg/5ml: syrup 30's pack: 150.00 MRP 30's pack: 165 ..00 IP
lOOml bot: 40.00 MRP t AMBROXOL Syp. Biopharma t LYTEX Syp. lbn Sina
Ambroxol hydrochloride BP l5mg/5ml: syrup
t AMBOLIN Drop Virgo Ambroxol hydrochloride BP l5mg/5ml: syrup
Ambroxol hydrochloride BP 6mg/ml: drop lOOml bot: 40.00 MRP
lOOml bot: 40.00 IP
15ml bot: 25 .00 MRP t AMBRYL Syp. RAK Pharma t LYTEX Drop Ibn Sina
Ambroxol hydrochloride BP 15mg/5ml: syrup
t AMBOLYT Syp. Incepta Ambroxol hydrochloride BP 6mg/ml: drop
Ambroxol hydrochloride BP l5mg/5ml: syrup lOOml bot: 40.00 MRP
l5ml bot: 30.00 IP
1OOml bot: 40.00 MRP t AMBRYL Drop RAK Pharma t MAXOF Syp. CPL
Ambroxol hydrochloride BP 6mg/ml: drop
t AMBOLYT Drop Incepta Ambroxol hydrochloride BP l 5mg/5ml: syrup
Ambroxol hydrochloride BP 6mg/ml: drop 15ml bot: 30.00 MRP
lOOml bot: 40.00 MRP
l5ml bot: 20.00 MRP t AMSIV Syp. Delta Pharma t M BOSS Syp. CPL
Ambroxol hydrochloride BP l5mg/5ml: syrup Ambroxol hydrochloride BP 15mg/5ml: syrup
t AMBORAL Syp. Pharmadesh
Ambroxol hydrochloride BP l5mg/5ml: syrup lOOml bot: 40.00 MRP lOOml bot: 40.00 MRP

l OOml bot: 38.00 MRP t AROXOL Syp. Healthcare t MUBROX Syp. Hallmark
 QIMP-17 (121) RESPIRATORY DRUGS

Ambroxol hydrochloride BP 15mg/5ml: syrup l OOml bot: 30.00 MRP

l OOml bot: 35.00 MRP BROMHEXINE26,63 + BROSTIN DS Tab. Rephco
+ MUBROX Drop Hallmark Bromhexine hydrochloride 8mg/tablet (double
Ambroxol hydrochloride BP 6mg/ml: drop BROMHEXINE: Tablet/Syrup strength).
15ml bot: 20.70 MRP Brom.hexine hydrochloride is a highly effective 8mg x l OO's pack: 200.00 MRP
+ MUCOBROX Syp. Somatec mucolytic expectorant syrup. It is used in the + BROSTIN Syp. Rephco
Ambroxol hydrochloride BP l 5mg/5ml: syrup treatment of respiratory disorders associated with Bromhexine hydrochloride BP 4mg/5ml:syrup
l OOml bot: 40.00 MRP productive cough. l OOml bot: 30.00 MRP
+ MUCOBROX Drop Somatec Mode of action: Bromhexine alters the structure + BROXINE Syp. General
Ambroxol hydrochloride BP 6mg/ml: drop of mucus to decrease its visco-sity and therefore Bromhexine hydrochloride BP 4mg/5ml:syrup
15ml bot: 20.08 MRP facilitate its removal by ciliary action or expecto­ I OOml bot: 30.11 MRP
+ MUCOSOL Syp. Beximco ration. + COFLYT Syp. Asiatic
Ambroxol hydrochloride BP 15mg/5ml: syrup Ind: Respiratory diseases associated with Bromhexine hydrochloride BP 4mg/5ml: syrup
IOOml bot: 40.00 IP productive cough. 1 OOml bot: 30.00 MRP
+ MUCOSOL Drop Beximco C/I: Patients sensitive to bromhexine hydrochlor. + EXPECTO Syp. Aristopharma
Ambroxol hydrochloride BP 6mg/ml: drop S/E: Gastrointestinal side-effects may occur Bromhexine hydrochloride BP 4mg/5ml: syrup
15ml bot: 30.00 IP occasionally with bromhexine and a transient rise 1OOml bot: 40.00 MRP
+ MUCOVAN Syp. Ad-din in serum aminotransferase values has been + MEXILYT Syp. Pharmadesh
Ambroxol hydrochloride BP 15mg/5ml: syrup reported. Other adverse effects may include­ Bromhexine hydrochloride BP 4mg/5ml: syrup
l OOml bot: 30.00 MRP headache, dizziness, sweating and skin rash. 60ml bot: 18.06 MRP
+ MYROX Syp. ACI Cautions: Since mucolytics may disrupt the gas­ I OOml bot: 25.09 MRP
Ambroxol hydrochloride BP 15mg/5ml: syrup tric mucosa, so bromhexine should be used with + MUCODIL Syp. NIPRO JMI
l OOml bot: 40.00 MRP care in patients with a history of peptic ulcera­ Bromhexine hydrochloride BP 4mg/5ml: syrup
+ MYROX Drop ACI tion. Care is also advisable in asthmatic patients. 1OOml bot: 40.00 MRP
Ambroxol hydrochloride BP 6mg/lml: drop Dosage & Admin: Adult: The recommended + MUCOLA Syp. Amico
l 5ml bot: 30.00 MRP daily dose is 8-16mg (10-20ml) 3-4 times daily. Bromhexine hydrochloride BP 4mg/5ml: syrup
+ NEOBROX Syp. Concord Children: Suggested dosage for children aged 1OOml bot: 25.00 MRP
Ambroxol hydrochloride BP 15mg/5ml: syrup 5-10 years, 4mg (Sml) 4 times daily; under 5 + MUCOLYT 8 Tab. Incepta
IOOml bot: 40.00 MRP years, 4mg (Sml) twice daily. Bromhexine hydrochloride BP 8mg/tablet.
+ NEXOL Syp. Aristopharma l OO's pack: 200.00 MRP
Ambroxol hydrochloride BP 15mg/5ml: syrup + A-COLD Syp. Acme + MUCOLYT Syp. Incepta
Bromhexine hydrochloride BP 4mg/5ml: syrup
l OOml bot: 40.00 MRP Bromhexine hydrochloride BP 4mg/5ml: syrup
1OOml bot: 40.00 MRP
+ NEXOL Drop Aristopharma 1OOml bot: 30.00 MRP
Ambroxol hydrochloride BP 6mg/lml: drop + BROHEXIN 8 Tab. Millat + MUCONIL Syp. Ziska
Bromhexine hydrochloride BP 8mg/tablet. Bromhexine hydrochloride BP 4mg/5ml: syrup
l 5ml bot: 30.00 MRP
lOO's pack: 200.00 MRP
+ PROKOF Syp. Everest l OOml bot: 30.00 MRP
Ambroxol hydrochloride BP l 5mg/5ml: syrup + BROHEXIN Syp. Millat + MUCOPRONT Syp. Cosmic
Bromhexine hydrochloride BP 4mg/5ml: syrup
IOOml bot: 40.15 MRP Bromhexine hydrochloride BP 4mg/5ml: syrup
IOOml bot: 30.00 MRP
+ RECOF Syp. Renata IOOml bot: 31.00 MRP
Ambroxol hydrochloride BP 15mg/5ml: syrup + BROLYT Tab. Alco Pharma + MUCOSPEL 8 Tab. Square
Bromhexine hydrochloride BP 4mg &
IOOml bot: 40.00 MRP Bromhexine hydrochloride BP 8mg/tablet.
8mg/tablet. IOO's pack: 201.00 MRP
+ REMAP Syp. MonicoPharma
4mg x 50's pack: 35.00 MRP
Ambroxol hydrochloride BP 15mg/5ml: syrup + MUCOSPEL Syp. Square
8mg x 50's pack: 50.00 MRP Bromhexine hydrochloride BP 4mg/5ml: syrup
l OOml bot: 30.00 MRP
+ BROLYT Syp. Alco Pharma 50ml bot: 28.00 MRP
+ RESOL Syp. Sharif Bromhexine hydrochloride BP 4mg/5ml: syrup l OOml bot: 40.00 MRP
Ambroxol hydrochloride BP l 5mg/5ml: syrup l OOml bot: 27.00 MRP
+ MUCUT Syp. Biopharma
IOOml bot: 40.00 MRP + BROMEX Tab. Somatec Bromhexine hydrochloride BP 4mg/5ml: syrup
+ RIXOL Syp. Medicon Bromhexine hydrochloride BP 8mg/tablet. l OOml bot: 40.00 MRP
Ambroxol hydrochloride BP l 5mg/5ml: syrup 1OO's pack: 200.00 IP
+ MULYT Syp. Gaco
l OOml bot: 40.00 MRP + BROMEX Syp. Somatec Bromhexine hydrochloride BP 4mg/5ml: syrup
Bromhexine hydrochloride BP 4mg/5ml: syrup
+ ROXAL Syp. Edruc 1OOml bot: 40.00 MRP
l OOml bot: 40.00 IP
Ambroxol hydrochloride BP 15mg/5ml: syrup + MUNIL Syp. Opsonin
+ BROMOLIT Syp. Peoples Bromhexine hydrochloride BP 4mg/5ml: syrup
1OOml bot: 40.00 IP
Bromhexine hydrochloride BP 4mg/5ml: syrup l OOml bot: 35.19 MRP
+ ROXAL Drop Edruc l OOml bot: 30.00 MRP
+ NAXCEL Syp. Kumudini
Ambroxol hydrochloride BP 6mg/ lml: drop
+ BROMOTEX Syp. Ibo Sina Bromhexine hydrochloride BP 4mg/5ml: syrup
15ml bot: 20.00 IP Bromhexine hydrochloride BP 4mg/5ml: syrup
1OOml bot: 40.00 MRP
+ SEEBROX Syp. Seema l OOml bot: 40.00 IP
+ N-HEXIN Syp. Nipa
Ambroxol hydrochloride BP l 5mg/5ml: syrup + BROMOXOL Syp. Healthcare Bromhexine hydrochloride BP 4mg/5ml: syrup
l OOml bot: 40.00 MRP Bromhexine hydrochloride BP 4mg/5ml: syrup
I OOml bot: 30.00 MRP
l OOml bot: 45.00 MRP
+ X-COLD Syp. Acme + SPULYT Syp. Beximco
Ambroxol hydrochloride BP l 5mg/5ml: syrup + BROMOXOL DS Syp. Healthcare Bromhexine hydrochloride BP 4mg/5ml: syrup
Bromhexine hydrochloride BP 8mg/5ml: syrup
IOOml bot: 40.00 MRP 1OOml bot: 40.00 IP
(double strength)
+ X-COLD Drop Acme + SPUTEN Syp. Silva
l OOml bot: 65.00 MRP
Ambroxol hydrochloride BP 6mg/ lml: drop Bromhexine hydrochloride BP 4mg/5ml: syrup
+ BRONCHODEX Syp. Organic Health
15ml bot: 30.00 MRP l OOml bot: 30.00 MRP
Bromhexine hydrochloride BP 4mg/5ml: syrup
+ XEROKOF Syp. Pharmasia l OOml bot: 40.00 MRP + TOPSIL Tab. Zenith
Ambroxol hydrochloride BP l 5mg/5ml: syrup + BRONCOMET Syp. Drug Inter. Bromhexine hydrochloride BP 4mg/tablet.
1OOml bot: 40.00 MRP Bromhexine hydrochloride BP 4mg/5ml: syrup 4mg x l OO's pack: 70.00 MRP

I
 RESPIRATORY DRUGS
•
t TOPSIL Syp. Zenith
Bromhexine hydrochloride BP 4mg/5ml: syrup
1OOml bot: 30.00 MRP
t X-PECTORAN 8 Tab. Rangs Pharma
Bromhexine hydrochloride BP 8mg/tablet.
50's pack: 100.00 MRP
t X-PECTORAN Syp. Rangs Pharma
Bromhexine hydrochloride BP 4mg/5ml: syrup
1OOml bot: 40.00 MRP
CARBOCISTEINE34,65
CARBOCISTEINE: Capsule/Syrup
Carbocisteine is a mucolytic expectorant preparn.
It is available as- carbocisteine BP 375mg/cap­
sule; 125mg/5ml & 250mg/5ml syrup.
Mode of action: It reduces the viscosity of non­
infected secretions from mucus cells in the
respiratory tract. The mucolytic action is due to
two mechanisms. It breaks the disulphide bonds
which cross-link certain glycoprotein molecules
present in the mucus and also alters local ionic
charges, both of which factors affect the
viscosity of mucus. There is also evidence that it
alters the composition of mucin secreted by the
respiratory mucosa, decreasing the proportion of
neutral glycopeptides and increasing the
sialoglycopeptides.
Ind: 1. Expectoration in the following diseases:
upper respiratory tract inflammation (pharyngitis,
laryngitis), acute bronchitis, bronchial asthma,
chronic bronchitis, bronchiectasis, pulmonary
tuberculosis. 2. Drainage in chronic sinusitis. 3.
Drainage in otitis media (glue-ear) with effusion
specially in children.
C/I: Contraindicated in active peptic ulceration
and in patients with hypersensitivity to the drug.
S/E: Gastrointestinal discomfort, nausea,
diarrhoea, gastrointestinal bleeding, headache
and skin rash may occur.
Precautions: No specific precaution is
recommended, but carbocisteine should be used
with a ca�tion in patients with a recent history of
peptic ulcer & recurrent gastrointestinal bleeding.
Pregnancy & lactation: Although there are no
reports of teratogenic effects with carbocisteine,
the drug is not recommen-ded in the frrst
trimester of pregnancy. No information available
on the use of carboc isteine during lactation.
Dosage & admin: Adults (includintg elderly):
Dosage is based upon an initial dose of
2250mg daily in divided doses (750mg 3 times
daily), reduced to 1500mg daily in divided
doses (375mg 4. times daily), when a satisfac­
tory response has been obtained.
Children: Normal daily dose is 20mg/kg body
weight in divided doses. The following dosage
schedule is recommended: 2-5 years, 62.5-
125mg 4 times daily; 6-12 years, 250mg 3
times daily.
Infants: Not recommended.
Drug inter: Neither hazardous nor therapeutically
significant interactions have been reported.
t CARBOLIN Syp. SK+F
Carbocisteine BP 125mg/5ml: syrup
lOOml bot: 30.00 MRP
t CARBOLIN DS Syp. SK+F
Carbocisteine BP 250mg/5ml: syrup (double
strength)
•
. '
�
.,.
$·.
' , . .
• f
QIMP-17 (122)
1OOm1 bot: 40.00 MRP
t CARBOTEN DS Syp. Amico
Carbocisteine BP 250mg/5ml: syrup (double
strength)
1OOml bot: 40.00 MRP
t FLEGNIL Syp. Orion Pharma
Carboc isteine BP 125mg/5ml: syrup
1 OOml bot: 30.11 MRP
t FLEGNIL DS Syp. Orion Pharma
Carbocisteine BP 250mg/5ml: syrup
(double strength)
1OOml bot: 40.15 MRP
t NOKOF Syp. Beximco
Carbocisteine BP 125mg/5ml: syrup
1OOm1 bot: 30.00 IP
t NOKOF DS Syp. Beximco
Carbocisteine BP 250mg/5ml: syrup (double
strength)
1OOml bot: 40.00 IP
t TULSI Syp. Euro Pharma
Carbocisteine BP 125mg/5ml: syrup
l OOml bot: 40.00 MRP
GLYCEROL PREPN.65
GLYCEROL+ LIQUID SUCROSE: Oral Solo.
This combined oral product of glycerol and
liquid sucrose is prepared & used for relieving
dry coughs and sore throats.
Mode of action: Glycerol acts by blocking
sensory cough receptors within the respiratory
tract. Glycerol also has demulcent properties
(soothing effect).
Ind: This combined product is indicated for relief
of irritating, tickling dry coughs and sore throats.
S/E: No side effect would be anticipated.
Precaution: Diabetic patients should take note of
the carbohydrate content of this product.
Pregnancy & lactation: There is no sufficient
data to establish the safety of the glycerol
preparation in pregnancy and lactation.
Nevertheless, glycerol or any other medication
should be used during pregnancy or lactation
only if clearly needed.
Dosage & admin: Oral administration only.
Adults & children over 5 years: lOml or 2 tsf;
Children 1 to 5 years: Sml or 1 tsf; Children 3
months to 1 year: Sml or 1 tsf. The dose may
be repeated 3-4 times a day.
Elderly: No need for dosage reduction in the
elderly.
Overdose: Over dosage would not be expected
to cause any problems and treatment would be
merely symptomatic and supportive.
. t CODYL Syp. Medimet
Drug inter: No significant interaction is known.
t HONYCOL Lictus Renata
Each 5ml liquid contains glycerol 0. 75ml and
liquid sucrose l .93ml: oral solution.
1OOml bot: 40.00 MRP
200ml bot: 55.21 MRP
t BUNNY Oral Solo. SK+F
Each 5ml liquid contains glycerol 0.75ml and
liquid sucrose l .93ml: oral solution.
1OOml bot: 40.00 MRP
+ NECTAR Oral Solo. Square
Each 5ml liquid contains glycerol 0.75ml and
liquid sucrose l .93ml: oral solution.
1OOml bot: 40.15 MRP
POTASSIUM GUAIACOUI,33
.
POTASSIUM GUAIACOL: Syrup
Ind: Potassium guaiacol sulphonate is a
stimulant cough expectorant. It liquifies thick
viscid bronchial secretion & thereby facilitates its
expulsion from the chest. It also helps in repair in
chronic inflamma-tory conditions of the
respiratory tract.
S/E: It produces mild irritation of the bronchial
mucous membrane during their excretion.
Use & Dose: 1-2 tsf 2-4 times daily is the
usual dosage.
t N.P.G Syp. Nipa
Potassium guaiacol sulphonate 125mg USP/5ml:
syrup.
1OOml bot: 20.23 MRP
t POTASSIUM GUAIACOL Syp. Drug Inter.
Potassium guaiacol sulphonate 125mg USP/5ml:
syrup.
l OOml bot: 18.40 MRP
Combind cough expectorantsi1.33
PSEUDOEPHEDRINE +
GUAIPHENESIN + TIUPROLIDINE
PSEUDOEPHED RINE + GUAIPHENESIN +
TRIPROLIDINE: Syrup
This combined preparation is available as­
pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP l .25mg/5ml: syrup.
Ind: Cough expectorant & decongestant.
Dose: 2 tsf 3 to 4 times daily.
t ABEX Syp. Ibo Sina
Pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP l .25mg/5ml: syrup.
1OOml bot: 50.00 IP
t ANTUSS Syp. Gaco
Pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP l .25mg/5ml: syrup.
1OOml bot: 60.00 MRP
t AQUAPHEN Syp. Incepta
Pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP 1.25mg/5ml: syrup.
l OOml bot: 42.00 MRP
t CODEX Syp. Ambee
Pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 50.00 MRP
Pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP 1.25mg/5ml: syrup.
1OOml bot: 50.00 MRP
t COFDIL Syp. CPL
Pseudoephedrine BP 30mg, guaiphenesin BP
l OOmg & triprolidine BP 1.25mg/5ml: syrup.
1OOml bot: 50.00 MRP
t COFNIL Syp. General
Pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP l .25mg/5ml: syrup.
1OOml bot: 50.00 MRP
t COFRID Syp. Acme
Pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP l .25mg/5ml: syrup.
lOOml bot: 55.00 MRP

t COFSON Syp. Hudson
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 50.00 MRP
t COLDEX Syp. Millat
Pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 55.00 MRP
t COPHILEX Syp. Opsonin
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP 1.25mg/5ml: syrup.
l OOml bot: 48.38 MRP
t COPHYL Syp. Pharmadesh
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 53.00 MRP
t E-COF Syp. Edruc
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 50.00 MRP
+ EXITRA Syp. Novo Healthcare
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5 ml: syrup.
l OOml bot: 40.00 MRP
t EXPOTEN Syp. SK+F
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5 ml: syrup.
l OOml bot: 55.00 MRP
t GPT Syp. Kumudini
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5 ml: syrup.
1OOml bot: 50.00 MRP
t KOFED Syp. Biopharma
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP 1.25mg/5ml: syrup.
l OOml bot: 55.00 MRP
t KOFTEX Syp. Amico
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 50.00 MRP
t LUREX Syp. Kemiko
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 55.00 MRP
t PHENDYL Syp. Sharif
Pseudoephedrine hydrochloride BP 30mg,
guaiphenesin BP 1 OOmg & triprolidine
hydrochloride BP l .25mg/5ml: syrup.
l OOml bot: 55.00 MRP
t SMILE Syp. Nipa
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 35.00 MRP
t TOPEX Syp. Renata
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
1 OOml bot: 30.34 MRP
t TRIDEX Syp. Navana
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
1 OOml bot: 50.19 MRP
t TRIEX Syp. Supreme
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 50.00 MRP
t TRINIL Syp. Medicon
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 55.00 MRP
I
QIMP-17 (123)
t TRIPEC Syp. Beximco
Pseudoephedrine BP 30mg, guaiphenesin BP
l OOmg & triprolidine BP l .25mg/5ml: syrup.
l OOml bot: 55.00 IP
t TRIPHEN Syp. Doctor's
Pseudoephedrine BP 30mg, guaiphenesin BP
1OOmg & triprolidine BP l .25mg/5ml: syrup.
1OOml bot: 50.00 MRP
t TUSCA Syp. Square
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
lOOml bot: 55.00 MRP
t TUSSIN Syp. Orion Pharma
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syp.
l OOml bot: 55.00 MRP
t TYREX Syp. ACI
Pseudoephedrine BP 30mg, guaiphenesin BP
1 OOmg & triprolidine BP l .25mg/5ml: syrup.
1 OOml bot: 55.00 MRP
6. ANTIHISTAMINICS
Uses of Antihistaminics as Respiratory anti­
allergens and decongestants: See in the section of
Allergic disorders.
7. RESPIRATORY STIMU­
L ANTS & PULMONARY
SURFACTANTS21
7.1 Respiratory stimulants: analeptics
7.2 Pulmonary surfactants
7 .3 Morphine & other narcotic analgesic
antagonists
Respiratory Stimulants:
Analeptics21,33
ADRENALINE
ADRENALINE: Injection.
Adrenaline lmg in l ml ampoule: injection
Ind: Bronchospasm, chronic bronchitis;
emergency treatment of acute anaphylaxis.
C/I; S/E; Cautions: See under bronchodilators
Dose: 1 amp. (lml) to be injected s.c, i.m, i.v
or direct intracardiac injection. May be
repeated, if necessary.
Prepns: See under bronchodilators
AMINOPHYLLlNE
AMINOPHYLLINE: Injection.
Aminophylline 250mg in 1 Oml ampoule for slow
i.v injection.
Ind: It is indicated in the treatment and prophy­
laxis of bronchospasm associated with asthma,
emphysema and chronic bronchitis. Also indica­
ted in the treatment of cardiac asthma and left
ventricular or congestive cardiac failure in adult
patients.
RESPIRATORY DRUGS
Caution: Rapid injection may result in cardiac
arrest.
·
Dosage & admin: 250-500mg given over 10-15
minutes.
Prepns: See under bronchodilators.
NIKETHAMIDE
t NIKE THAMIDE Inj. Jayson
Nikethamide 25% injection in 2ml amp: injection
Ind: Acute respiratory failure
C/I: Respiratory failure due to neurological
disease or drug overdose.
S/E: Vomiting, restlessness, convulsions.
Dose: 2 to 1 Oml by slow i. v injection of the
usual 25°/o solution every 20 to 30 mins. if
necessary.
10 amps pack: 120.00 IP
Pulmonary Surfactants
PHOSPH0'LIPID49
(Pulmonary Surfactants)
+ SURVANTA Intratracheal Suspn.
AbboWUniMed & UniHealth
Each lml of survanta contains 25mg of total
phospholipids (beractant): Intratracheal suspension.
Ind: Treatment and prevention of neonatal
respiratory distress syndrome (RDS).
S/E: Transient bradycardia has occurred.
Precautions: The specified dosing procedure for
survanta should be followed carefully as errors
could result in hyperinflation or obstruction of
separate areas of the lungs. Close monitoring of
arterial blood gases, the fraction of inspired
oxygen, and ventilatory pressures is mandatory.
Dosage & admin: The recommended dose of
survanta is lOOmg phospholipid/kg body
·
weight administered intratracheally in a vol­
ume not exceeding 4ml/kg. It is recommended
that survanta should be administered in two
half-doses (or four quarter-doses) through a
neonatal suction valve, with the infant in dif­
ferent positions to ensure homogenous distri­
bution. Treatment should be administered
early in the course of RDS, i.e preferably in
babies less than 8 hours of age. For treatment
and prophylaxis of RDS in high risk infants,
up to four doses of survanta may be adminis­
tered within 48 hours. The first dose is given
at 15 minutes postpartum, with up to three
additional doses at intervals of at least six
hours. Unopened, unused vials of survanta
that have been warmed to room temperature,
may be returned to the refrigerator within 8
hours of warming, and stored for future use.
Survanta should not be warmed and re-refrig­
erated more than once. Used vials containing
residual medicine should be discarded.
Note: For full prescribing information, please
consult manufacturer's literature.
4ml vial: 20726.73 MRP
8ml vial: 24254.05 MRP
RESPIRATORY DRUGS QIMP-17 (124)

menthol, eucalyptus oil- known as aromatic

Morphine & other narcotic inhalations, are traditionally used in respiratory LEVOMENTHOL + THVMOL +
discomfort as in bronchitis for deliberate inspira­ CHLOROBUTANOL +
analgesic antagonists21 tion & also used for the relief of nasal obstruc­
TERPINEOL, 62·158
tion (congestion) in acute rhinitis or sinusitis.

NALOXONE
NALOXONE: Injection
Naloxone hydrochloride is a respiratory stimulant,
which antagonises the respiratory depression
action of morphine & other narcotic analgesics.
Ind: Reversal of narcotic-induced respiratory
depression, including that due to pentazocine &
dextropropoxyphen. Overdosage with morphine
like compounds. Diagnosis of acute opioid
overdosage.
Caution: Pregnancy (except in labour); opioid
dependence. Keep patient under observation as
repeat doses may be needed.
Dosage & admin: Adult: 0.4-2mg by i.v, i. m,
or s.c inj. every 2-3 min. as required or by i.v
infusion to a maximum of 1Omg if respiratory
function does not improve. By continuous i.v.
21·39
BENZOIN TINCTURE
BENZOIN TINCT URE : Inhalation
Benzoin tincture containing balsamic acids
approx. 4.5% BP: volatile compound.
Ind: Respiratory discomfort as in bronchitis,
nasal congestion in acute rhinitis or sinusitis.
Dosage & admin: add one teaspoonful to a
pint of hot, (not boiling), water and inhale the
vapour.
Children- the use of strong aromatic
decongestants is not advised for infants under
the age of 3 months.
Preparations: May be available in the market.
+ ESPIRAR Breathe Easy Inhalation Cap.
Pumava/ Renata
'Espirar' breathe easy inhalation capsule contains
4 principal components- levomenthol, thymol,
chlorobutanol & terpineol. It also contains pine
oil & cinnamon oil. The capsule is presented as
soft gel capsule for inhalation.
Ind & action: A head cold can hamper sleep,
making for restless nights. Espirar's combination
of natural vapours from levomenthol, thymol,
chlorobutanol & terpineol work gently to help
adult patients or children breathe more easily.
Precautions: Not to be taken internally; avoid
direct contact with eyes or skin; if ingested, seek
medical advice immediately.
Dosage & use: Snip the top of the capsule

infusion, 2mg diluted in 500ml i.v. infusion MENTHOL & EUCALYPTUS OJL21 carefully, pointing the top downwards and

solution at a rate adjusted according to the away from the face.

response. Post operative- 0.1-0.2mg i.v.
repeated as required.
Child: Neonates, see below; Others, lOmcg/kg
by i.v, i.m or s.c inj. repeated as required or by
i.v infusion.
Prepns: May be available in the medicine market.
8.AROMATIC
21
INHALATIONS
Aromatic inhalations: Inhalations containing
volatile substances such as benzoin tincture,
MENTHOL & EUCALYPTUS OIL:
Inhalation
Racementhol or levomenthol 2gm, eucalyptus oil
1Oml, light magnesium carbonate 7gm, water to
lOOml: inhalation
Ind: Respiratory discomfort as in bronchitis,
nasal congestion in acute rhinitis or sinusitis.
Use: Add one teaspoonful to a pint of hot, (not
boiling), water and inhale the vapour.
Children- the use of strong aromatic
decongestants is not advised for infants under
the age of 3 months.
Preparations: May be available in the market.
For babies over 3 months & young children:
Squeeze the capsule contents onto a
handkerchief secured nearby, but out of the
reach of the child. Not to be used for children
under 3 months.
For older children & adults:
Squeeze the capsule contents onto bedding or
a handkerchief nearby.
Or, Squeeze the capsule contents into 375ml of
hot water and inhale the vapour freely. Take
care when using hot water.
10 caps pack: 55.00 MRP

Relative efficacy equivalence:21

21
1. HYPNOTICS Considering the diazepam as standard, the

DRUGS ACTING ON relative efficacy of different benzodiazepines are

Hypnotic: A drug that induces sleep. Hypnotics given as below:
THE NERVOUS act as a sedative when given in low doses.
Diazepam 5mg equals to-
The commonly used hypnotics can be divided as
SYSTEM21 following:
- Chlordiazepoxide 15mg
- Loprazolam 0.5-lmg
1.1 Benzodiazepines - Lorazepam 0.5mg
Drugs acting on the nervous system are classified - Lormetazepam 0.5-lmg
1.2 Barbiturates
in the following groups: - Nitrazepam 5mg
1.3 Chloral hydrate & its derivatives
1.4 Paraldehyde. - Oxazepam 15mg
1. Hypnotics •

1.5 Miscellaneous hypnotics - Temazepam lOmg

2. Sedative & tranquillisers: anxiolytics
3. Anti-psychotic and related drugs a. Zolpidem & Zopiclone
4. Antidepressant drugs b. Chlormethiazole DIAZEPAM
5. Drugs used in nausea, vomiting & vertigo c. Antihistamines (such as
6. Antiepileptics/ Anticonvulsants diphenhydramine, promethazine)
See under the group of anxiolytic drugs.
7. Drugs used in parkinsonism & related
disorders
8. Central nervous system stimulant Benzodiazepines21 FLURAZEPAM 21,36
9. Appetite suppressants
10. Drugs for dementia Benzodiazepines, that are used as hypnotics FL URAZEPAM: Capsule
11. Analgesics include- Diazepam, Flurazepam, Nitrazepam, Ind: Short-term treatment of insomnia where day
12. Drugs used in substance dependence Loprazolam, Lormetazepam & Temazepam. time sedation is acceptable.

C/I: Acute pulmonary insufficiency, respiratory
depression, chronic psychosis.
S/E: Hangover on the following day with
drowsiness, dizziness, ataxia (particularly in
elderly), confusion, dry mouth; GI. disturbances;
hypersensitivity reactions; visual disturbances;
skin rashes; urinary retention; change in libido.
Risk of dependence increases the higher the dose
and the longer term treatment.
Caution: Chronic pulmonary insuffi-ciency,
chronic renal or hepatic disease, the elderly,
pregnancy, labour and lactation. Avoid long term
use; withdraw gradually.
Dosage & admin: Adult: Elderly,15 mg at bed
time & Others, 15-30mg at bedtime.
Child: Not recommended.
+ ALUCTIN Cap. Ambee
Flurazepam hydrochloride 30mg/capsule.
1OO's pack: 600.00 MRP
+ SLIPAM Cap. General
Flurazepam hydrochloride l 5mg &
30mg/capsule.
15mg x 30's pack: 175.50 MRP
30mg x 30's pack: 180.60 MRP
est u(
MIDAZOLAM2 l ,34,50
MIDAZOLAM: Tablet/Injection
It is a water soluble benzodiazepine which is
often used in preference to diazepam. Recovery
is faster than with diazepam. It is available as­
midazolam 7.5mg & 15mg/tablet; midazolam
5mg/ l ml ampoule, 5mg/5ml ampoule &
15mg/3ml ampoule for i.m/i.v injection.
Ind: Disturbance of sleep rhythm & all forms of
insomina particularly difficulty in falling asleep
either initially or after premature awakening.
Sedation in premedication & induction of
anaesthesia (local & general) before surgical and
diagnostic procedure.
C/I; S/E; Caution: See above under Flurazepam.
Important- profound sedation reported with oral
midazolam.
Dosage & Admin: By mouth: T he usual adult
dose is 7.5-lSmg daily. In elderly & debilitated
patient the recommended dose is 7.Smg. This
dose is also applied to the patient with
impaired liver & kidney function. For premed­
ication of adult 15mg of midazolam should be
given orally 30-60 minutes before the opera-
QIMP-17 (125)
tion unless the parenteral route is preferred.
Byinjection: Sedation, by i.v injection- over 30
seconds, 2mg (elderly 1-1.Smg) followed after
2 minutes by increments of 0.5-lmg if sedation
not adequate; usual range 2.5-7.Smg (about
70mcg/kg), elderly 1-2mg.
Premedication, by i.m injection, 70-lOOmcg/kg
30-60 minutes before surgery; usual dose Smg
(2.Smg in elderly).
Induction, by slow i.v injection, 200-300mcg/kg
(elderly 100-200mcg/kg).
Sedation ofpatients receiving intensive care,
by i.v infusion, initially 30-300mcg/kg given
over S minutes, then 30-200mcg/kg/hour;
reduce dose (or omit initial dose) in hypovo­
lemia, vasoconstriction, or hypothermia; low
doses may be adequate if opioid analgesic also
used; avoid abrupt withdrawal after
prolonged administration (safety after more
than 14 days not established).
Drug inter: Plasma concentration increased by
erythromycin, diltiazem and verapamil.
t ANQUIL Tab. General
Midazolam maleate 7.5mg & 15mg/tablet.
7.5mg x 30's pack: 240.90 MRP
Midazolam 7.5 mg, 15 mg tablet & 15 mg/3 ml IM/IV injection
ftts, e resfted
15mg x lO's pack: 150.60 MRP
+ BENQUIL Tab. Biopharma
Midazolam maleate 7.5mg/tablet.
7.5mg x 30's pack: 240.00 MRP
+ DORMAX Tab. Aristopharma
Midazolam maleate 7.5mg/tablet.
7.5mg x 30's pack: 240.00 MRP
+ DORMAX Inj. Aristopharma
Midazolam hydrochloride l 5mg/3ml ampoule:
i.m/i.v injection
15mg (3ml) amp x l 's pack: 150.00 MRP
+ DORMICUM Inj. Roche/Radiant Pharma
Midazolam hydrochloride 5mg/5ml ampoule &
l 5mg/3ml ampoule: i.m/i.v injection
5mg (5ml) amp x lO's pack: 1511.10 TP
15mg (3ml) amp x 5's pack: 1020.00 TP
+ DORMICUM Tab. Roche/Radiant Pharma
Midazolam maleate 7.5mg/tablet.
7.5mg x 30's pack: 585.00 MRP
t DORMILAT Inj. ACI
Midazolam hydrochloride 5mg/5ml ampoule &
15mg/3ml ampoule: i.m/i.v injection
5mg (5ml) amp x 5's pack: 275.00 MRP
15mg (3ml) amp x 5's pack: 375.00 MRP
+ DORMITOL Tab. Square
Midazolam maleate 7.5mg/tablet.
CNS DRUGS
7.5mg x 30's pack: 241.20 MRP
t DORMITOL lnj. Square ·
Midazolam hydrochloride l 5mg/3ml ampoule:
i.m/i.v injection
15mg (3ml) amp x l 's pack: 75.00 MRP
+ HYPNOCUM Tab. Healthcare
Midazolam maleate 7.5mg/tablet.
7.5mg x 30's pack: 300.00 MRP
t HYPNOFAST Tab. Incepta
Midazolam maleate 7.5mg & 15mg/tablet.
7.5mg x 30's pack: 240.00 MRP
15mg x lO's pack: 150.00 MRP
+ MIDABEN Tab. Amico
Midazolam maleate 7.5mg/tablet.
7.5mg x 30's pack: 240.00 MRP
t MIDOLAM Tab. Opsonin
Midazolam maleate 7.5mg & l 5mg/tablet.
7.5mg x 30's pack: 211.92 MRP
l 5mg x 20's pack: 264.97 MRP
+ MIDOLAM Inj. Opsonin
Midazolam hydrochloride 5mg/ l ml ampoule &
15mg/3ml ampoule: i.m/i. v injection
5mg (lml) amp x l's pack: 44.16 MRP
15mg (3ml) amp x 1's pack: 66.22 MRP
15mg (3ml) amp x 5's pack: 329.72 MRP
s
t MILAM Tab. SK+F
Midazolam maleate 7.5mg & l 5mg/tablet.
•
7.5mg x 40's pack: 400.00 MRP
15mg x 20's pack: 400.00 MRP
+ MILAM Inj. SK+F
Midazolam hydrochloride l 5mg/3ml ampoule:
i.m/i.v injection
15mg (3ml) amp x l 's pack: 100.00 MRP
t MIZOLAM Tab. Acme
Midazolam maleate 7.5mg/tablet.
7.5mg x 30's pack: 241.20 MRP
+ SEDAQUIL Tab. Rangs Pharma
Midazolam maleate 7.5mg/tablet.
7.5mg x 30's pack: 240.00 MRP
NITRAZEPAM21,33
NITRAZEPAM: Tablet/Capsule t
Ind: Short-term treatment of insomnia
where day time sedation is acceptable; insomnia
with early morning wakening.
C/I: Acute pulmonary insufficiency, respiratory
depression, chronic psychosis.
S/E: Hangover on the following day with •
drowsiness, dizziness, ataxia (p'a�icularly in eld-
.
T
"
•

. •
. -'...��
. . -
-
.
�
.
'' .
Midazolam
erly), confusion, dry mouth; Gl. disturbances;
hypersensitivity reactions; visual disturbances;
skin rashes; urinary retention; change in libido.
Risk of dependence increases the higher the dose
and the longer term treatment.
Caution: Chronic pulmonary insufficiency, ch.
renal or hepatic disease, the elderly, pregnancy,
labour and lactation. Avoid long term use;
withdraw gradually.
Dosage: Adult: Elderly, 2.5-5mg at bedtime;
others, 5-lOmg at bedtime.
Child: Not recommended.
t EPAM Tab. Opsonin
Nitrazepam 5mg/tablet.
200's pack: 131.95 MRP
t NOCTIN Tab. Ambee
Nitrazepam 5mg/tablet.
IOO's pack: 69.00 MRP
Barbiturates •
PHENOBARBITONE21
PHENOBARBITONE: Tablet/Elixir/
Injection.
Phenobarbitone (Phenobarbital), a barbiturate,
nonselective, central nervous system depressant
which is primarily used as a sedative hypnotic &
also as an anticonvulsant in subhypnotic doses.
Ind: It is indicated for the following conditions:
1. As sedatives. 2. Hypnotics for the short-term
treatment of insomnia. 3. Long-term (oral)
anticonvulsants for the treatment of generalized
tonic-clonic and cortical local seizures. And,
parenteral preparations are used in the emergency
control of certain acute convulsive episodes
(those associated with status epilepticus,
eclampsia, meningitis, tetanus, and toxic
reactions to strychnine or local anesthetics).
4. Pre-anesthetics.
C/I; S/E; Caution: See under anti-epileptic drugs.
Dosage & admin: Adult: 15-30mg 2 or 3 times
daily. Maximum, 600mg in 24 hours.
Child: Up to 1 year, 15-30mg daily; 1-12 years,
30-60mg daily, in divided doses.
Preparations: See under anti-epileptic drugs.
Trichloroethanol derivatives
CHLORAL HYDRATE21
CHI,ORAL HYDRATE: Capsule/
Elixir/Mixture
Chloral hydrate (as mixture) 500mg/5ml,
200mg/5ml in paediatric elixir & 500mg./capsule.
Ind: Insomnia, sedation in children and elderly;
pre-operative sedative; adjunct to opiates and
analgesics, and in first stage of labour (it induces
sleep in about half an hour lasting 6-8 hours).
C/I: Severe hepatic, renal or cardiac disease;
Gastritis.
-·
. .
QIMP-17 (126)
S/E: Gastro-intestinal distrubances, skin rashes
may occur, little hangover on the following day
with drowsiness, dizziness, ataxia, headache,
excitement & delirium; ketonuria.
Caution: Little hangover may affect patient's
ability to drive or operate machinery judgement
and dexterity may be impaired, patients should be
warned of these effects. Doses are taken well
diluted to minimise g.i. disturbances. Contact
with skin and mucous membrane should be
avoided.
Dosage & admin: Adult: Insomnia, 500mg­
l gm taken with water 15-30 mins. before.
bedtime or 1-2 hours before surgery.
Maximum, 2gm daily. Sedation, 250mg 3 times
daily with water.
Child: 30-50mg/Kg upto a max. single dose of
lgm.
Preparations: May not be available.
Misc. Hypnotics
PROME'I'HAZINE21,33
PROMETHAZINE HCI : Tablet/Elixir/
Injection.
Ind: Sedation in children and adults, nasal
allergy, urticaria and other allergic disorders.
S/E: Drowsiness, dryness of mouth, g.i.
disturbances.
Caution: As patient is affected with sedation and
drowsiness, should not drive or operate
machinery requiring alertness. Alcohol and other
CNS depressants can potentiate the sedative
effect of antihistaminics and patient should be
warned of these effects.
Dosage & admin: Adult: By mouth, 10-20mg,
2 or 3 times daily. By injection 25-50mg. by
deep i.m. or slow i.v. inj. after dilution.
Child: By mouth, under 6 months, not
recommended; 6 months-1 year, 5-lOmg, 1-5
yrs. 5 to 15mg; over 5yrs. 10-25mg. If two
doses in 24 hours are reqd. use lower amount
stated. By injection, under 5 years not
recommended; over 5 yrs. 6.25-12.50mg by
deep i.m. injection.
Prepns.: See in the section of anti-allergic drugs.
ZOLPIDEM44
ZOLPIDEM: Tablet (f.c)
Zolpidem tartrate is a non-benzodiazepine
miscellaneous hypnotic of the imidazopyridine
class. It is available as- Zolpidem tartrate 5mg
and 1Omg film-coated tablets for oral
administration. Zolpidem has both a rapid
absorption and onset of hypnotic action.
Mode of action: Zolpidem, an imidazopyridine,
is structurally unrelated to other hypnotic agents.
It binds selectively to the omega- I receptor sub­
type (also known as the benzodiazepine-1 sub­
type) which constitutes the alpha-unit of the
GABA-A receptor complex. Whereas benzodi­
azepines non-selectively bind to all three omega
receptor subtypes, zolpidem binds to the omega- I
receptor preferentially. The modulation of the
chloride anion channel via this receptor subtype
leads to the specific sedative effects demonstrated
•
by zolpidem. These effects of zolpidem are
reversed by the benzodiazepine antagonist
flumazenil.
Objective assessments (polysomnography) of
patients receiving zolpidem showed decreased
sleep onset latency, improved sleep efficiency
'
and increased total sleep time. There were no
effects on the number of awakenings or sleep
architecture compared to placebo.
Ind: Zolpidem is indicated for the short-term
treatment of insomnia.
C/I: Patients with obstructive sleep apnoea,
myasthenia_ gravis, severe hepatic insufficiency,
acute pulmonary insufficiency or respiratory
depression. ·
Patients with psychotic illness.
Hypersensitivity to zolpidem.
S/E: There is evidence of a dose-relationship for
adverse effects associated with zolpidem use,
particularly for certain CNS and gastrointestinal
events. These occur most frequently in elderly
patients.
In clinical trials �ide effects observed during
treatment at doses up to l Omg included drowsi­
ness, dizziness, diarrhoea, headache, nausea and
vertigo. Daytime drowsiness, dizziness,
headache, asthenia, nausea and vomiting occa­
sionally led to withdrawal of treatment in clinical
trials of zolpidem.
Memory disturbance (anterograde amnesia),
nightmares, nocturnal restlessness depressive
syndrome, episodes of confusion, perceptual
disturbances or diplopia, tremor, unsteady gait
and falls have been observed very rarely in long
term clinical trials.
Precautions & warnings: The cause of insomnia
should be identified wherever possible and the
underlying factors treated before a hypnotic is
prescribed. The failure of insomnia to remit after
a 7-14 day course of treatment may indicate the
presence of a primary psychiatric or physical
disorder which should be evaluated.
Although, vehicle driving remains unaffected
with zolpidem medication, drivers and machine
operators should be warned ihat, as with other
hypnotics, there may be a possible risk of
drowsiness, the morning after therapy.
As with other sedative/hypnotic drugs, zolpidem
should be administered with caution in patients
exhibiting symptoms of depression. Suicidal
tendencies may be present therefore the lowest
dose of drug that is effective should be supplied
to these patients because of the possibility of
intentional overdosage by the patient.
Extreme caution should be exercised when
prescribing for patients with a history of drug or
alcohol abuse. These patients should be under
careful surveillance when receiving zolpidem or
any other hypnotic, since they are at risk of
habituation and psychological dependence.
General precautions with hypnotics: General
information relating to effects seen following
administration of benzodiazepines and other
hypnotic agents which should be taken into
account by the prescribing physician, such as:
i. Tolerance: Development of tolerance after
repeated use for a few weeks.
ii. Dependence: Development of physical & psy­
chological dependence of these products, which
increases with dose and duration of treatment.

iii. Rebound insomnia- usually may occur on
abrupt withdrawal of hypnotic treatment, which
may be accompanied by other reactions including
mood changes, anxiety and restlessness. It is
therefore, recommended that the dosage is
decreased gradually where clinically appropriate.
iv. Amnesia: Benzodiazepines or bezodiazepine­
•
like agents may induce anterograde amnesia; the
condition occurs most often several hours after
ingesting the product and therefore to reduce the
risk patients should ensure that they will be able
to have an uninterrupted sleep of 7-8 hours.
v. Psychiatric and 'paradoxical' reactions:
Reactions like restlessness, agitation, irritability,
aggressiveness, delusion, rages, nightmares,
hallucinations, psychoses, inappropriate behavior
and other adverse behavioral effects are known to
occur when using benzodiazepines or
benzodiazepine-like agents. If any of these occur,
the product should be discontinued.
Pregnancy & lactation: Safety in human
pregnancy has not been established. As with all
drugs zolpidem should be avoided in pregnancy
particularly during the first trimester.
Infants born to mothers who took
benzodiazepines or benzodiazepine-like agents
chronically during the later stages of pregnancy
may have developed physical dependence and
may be at some risk of developing withdrawal
symptoms in the postnatal period.
Small quantities of zolpidem appear in breast
milk. Therefore, the use of zolpidem in nursing
mothers is not recommended.
, If the product is prescribed to a woman of child
bearing potential, she should be warned to
contact her physician about stopping the product
if she intends to become or suspects that she is
pregnant.
Dosage & admin: Adults: The recommended
daily dose for adults is 1 Omg.
I is not recommended.
Elderly or debilitated patients: This group of
pati-ents may be specially sensitive to the
effects of zolpidem, therefore a 5mg dose is
recommended. In patients under 65 years, the
dosage may be increased to 1Omg only where
I
the clinical response is inadequate & the drug
is well tolera-ted. The total dose should not
exceed 1Omg.
Hepatic impairment: As clearance and metabo­
lism of zolpidem is reduced in hepatic impair­
ment dosage should begin at 5mg with partic­
ular caution being exercised in elderly patients.
Zolpidem should be taken immediately before
retiring to bed.
Children: Not recommended for use in
children.
Overdosage: In reports of overdose with zolpi­
dem alone, impairment of consciousness has
ranged from somnolence to light coma.
'
Individuals have fully recovered from zolpidem
overdoses upto 400mg, 40 times the recommen­
ded dose.
General symptomatic and supportive measures
should be used, along with immediate gastric
lavage where appropriate; intravenous fluids
should be administered as needed. If there is no
advantage in emptying the stomach, activated
charcoal should be given to reduce absorption.
Sedating drugs should be withheld even if excita­
tion occurs. Zolpidem has been shown to be non-
I
-
QIMP-17 (127) CNS DRUGS
dialysable. Use of flumazenil may be considered
where serious symptoms are observed. ESZOPICLONE46
Drug inter: Concomitant intake of zolpidem
ESZOPICLONE: Tablet
with alcohol is not recommended. The sedative
Eszopiclone is a nonbenzodiazepine hypnotic, a
effect may be enhanced when the product is used
pyrrolopyrazine derivative of the cyclopyrrolone
in combination with alcohol. This affects the
class with a chemical structure unrelated to
ability to drive or operate machines .
pyrazolopyrimidines, imidazopyridines,
Enhancement of the central depressive effect may
benzodiazepines, barbiturates, or other drugs with
occur in cases of concomitant use with antipsy­
known hypnotic properties.
chotics (neuroleptics), hypnotics, anxiolytics/
It is available as eszopiclone INN 1 mg & 2mg
sedatives, anti-depressant agents, narcotic anal­
film-coated tablet.
gesics, antiepileptic drugs, anaesthetics and
Mode of action: The precise mechanism of
sedative antihistamines.
action of eszopiclone as a hypnotic is unknown,
In the case of narcotic analgesics enhancement of
but its effect is believed to result from its
the euphoria may also occur leading to an
interaction with GABA-receptor complexes at
increase in psychological dependence.
binding domains located close to or allosterically
Compounds which inhibit certain hepatic
coupled to benzodiazepine receptors.
enzymes (particularly cytochrome P450) may
Ind: Eszopiclone is used for the treatment of
enhance the activity of benzodiazepines and
insomnia (chronic insomnia, transient insomnia)
benzodiazepine-like agents.
characterized by difficulty falling asleep and/or
+ NITREST Tab. Sun Pharma difficulty maintaining sleep during the night and
Zolpidem tartrate lOmg/tablet (film-coated) early morning.
lOmg x 30's pack: 148.50 MRP C/I: Known case of hypersensitivity to
eszopiclone.
S/E: The most common side effects are:
ZOPICLONEit,35,52 drowsiness, dizziness, lightheadedness, difficulty
with coordination.
ZOPICLONE: Tablet Precautions: No need of specific precaution to
Zopiclone is a cyclopyrrolone product. be exercised.
Mode of action: Zopiclone exhibits anticonvul­
Pregnancy & lactation: There are no adequate
sant, muscle relaxant and hypnosedative
and well-controlled studies of eszopiclone in
properties in animals. It recognizes specifically,
pregnant women. So, it should be used during
and with high affinity, binding sites that belong
pregnancy only if the potential benefit justifies
to the GABAA - benzodiazepine chloride channel
the potential risk to the fetus.
macromolecular receptor complex and increases
It is not known whether eszopiclone is excreted
the chloride ion secretion.
in human milk. So, caution should be exercised
Ind: Short-term use for the treatment of insomnia
when eszopiclone is administered to a nursing
(no longer than four weeks duration). As with
woman.
other hypnotics, long-term continuous treatment
Dosage & admin: The recommended starting
dose of eszopiclone for most non-elderly adults
C/I: Sse in pregnancy should be avoided if a
safer alternative is known. Zopiclone is excreted is 2mg immediately before bedtime. Dosing
·
can be initiated at or raised to 3mg if clinically
in breast milk, so use in nursing mother must be
avoided. indicated. The recommended starting dose of
eszopiclone for elderly patients whose primary
Caution: Hepatic impairment; pregnancy and
complaint is difficulty falling asleep is lmg
breast-feeding; elderly; history of drug abuse,
immediately before bedtime. In these patients,
psychiatric illness; avoid prolonged use (and
the dose may be increased to 2mg if clinically
abrupt withdrawal thereafter).
indicated. For elderly patients whose primary
Driving- drowsiness may persist the next day and
complaint is difficulty staying asleep, the
affect performance of skilled tasks (e.g. driving);
recommended dose is 2mg immediately before
effects of alcohol enhanced.
bedtime. Or, as directed by the physician.
S/E: Bitter or metallic taste; gastro-intestinal dis­
Drug inter: Alcohol (which causes sedation) and
turbances including nausea and vomiting; irri­
drugs that have sedating effects should not be
tability, confusion, depressed mood; drowsiness,
used with eszopiclone since their sedating effects,
dizziness, lightheadedness, and incoordination on
when added to those of eszopiclone, may cause
next day; dependence; rarely urticaria and rashes;
excessive sedation.
hallucinations, amnesia, and behavioural
disturbances (including aggression) reported.
+ S-CLON Tab. Beximco
Dose: 7.5mg at bedtime increased to 15mg in Eszopiclone INN lmg & 2mg/tablet (f.c).
severe insomnia; Elderly, initially 3. 75mg at l mg x 50's pack: 120.60 IP
bedtime; Child not recommended. 2mg x 30's pack: 90.30 IP
+ SLEEPON Tab. Silva
Drug Inter: Patients should be cautioned against
the simultaneous ingestion of zopiclone and Eszopiclone INN lmg & 2mg/tablet (f.c).
lmg x 50's pack: 100.00 MRP
alcohol or other CNS depressant drugs because
2mg x 50's pack: 150.00 MRP
of possible additive effects.
+ SLEEPWEL Tab. Popular
+ IMOVANE Tab. Sanofi-aventis Eszopiclone INN lmg & 2mg/tablet (f.c).
Zopiclone 7.5mg/tablet. lmg x 30's pack: 60.30 MRP
30's pack: 228.60 MRP 2mg x 30's pack: 90.30 MRP ·
• •
• ?
CNS DRUGS
+ SONO Tab. Acme
Eszopiclone INN lmg & 2mg/tablet (f.c).
1mg x 30's pack: 60.30 MRP
2mg x 30's pack: 90.00 MRP
2. SEDATIVE & TRANQUIL­
21 23
LISERS: ANXIOLYTICS '
Sedative: A drug (or dose of a drug) that calms
or soothes without inducing sleep though it may
cause sleepiness: a small dose of a hypnotic or
tranquilliser often suffices for this.
Tranquilliser: A drug that will quieten a patient
without notably impairing consciousness. The
ideal tranquilliser would allay pathological
anxiety and nervous tension without altering any
other cerebral functions; specially it would not
cause sleepiness.
In fact there is no clear distinction between
tranquillisers and sedatives.
The commonly used sedative & tranquillisers
may be grouped as:
2.1 Benzodiazepines
2.2 Phenothiazines
2.3 Misc. anxiolytics
Benzodiazepines
Benzodiazepines that are used as anxiolytics
include- Diazepam, Alprazolam, Bromazepam,
Chlordiazepoxide, Clorazepate, Lorazepam,
Oxazepam.
DIAZEPAM21,33
DIAZEPAM: Tablet/Syrup/Injection/
Suppository.
Ind: Anxiety, insomnia, night terrors in children;
adjunctive treatement of acute alcohol withdrawal;
epilepsy & other convulsions.
C/I: Acute palmonary insufficiency, respiratory
depression.
S/E: Drowsiness, dizziness, ataxia (particularly in
elderly), occasionally confusion, dry mouth; resp.
depression on i.v injection. Pain &
thrombophlebitis.
Caution: Neuromuscular disorders, closed angle
glaucoma, resp. disease, late pregnancy, nursing
mothers; reduce dosages in elderly & debiliated
patients, liver disease, renal impairment;
patient's ability to avoid alcohol & other CNS
depressants; avoid abrupt withdrawal.
Dosage & admin: By mouth: Anxiety, 2mg, 3
times daily, increased in severe anxiety to 15-
30mg. daily in divided doses. Child, 1-5mg.
daily in divided doses. Insomnia, 5-30 mg at
bedtime.
By i.m. or slow i.v. injection: For severe anxiety,
control of acute panic attack and acute alcoholic
withdrawal, lOmg (at a rate of not more than
5mg/min.) repeat if necessary 4 hourly. In
QIMP-17 (128)
epilepsy- see under anticonvulsant drugs. Alprazolam 0.25mg, 0.5mg, lmg & 2mg tablet
By rectum as suppositories: When oral route (normal & extended release) . .
not appropriate, apply lOmg suppository 1 ty
Ind: Alprazolam has antianxiety properties,
3 times daily.
effective in treatment of generalized anxiety
disorders, panic anxiety, agoraphobia, situational
+ AZEPAM Tab. Acme
Diazepam 5mg/tablet. anxiety, anxiety depression syndrome, cardiac
200's pack: 136.00 MRP neurosis & anxiety associated with medical
conditions & depressive disorders.
+ DIAZEMET Tab. Medimet
Diazepam 5mg/tablet. C/I: Sensitivity to the drug; acute narrow angle
1OO's pack: 50.00 MRP glaucoma; pregnancy & lactation.
+ D-PAM Tab. General Warning: Patients should avoid- driving &
Diazepam 5mg/tablet. operation machinery or doing jobs requiring
lOO's pack: 68.00 MRP complete mental alertness, simultaneous
+ EASIUM Tab. Opsonin ingestion of alcohol & other CNS depressant
drugs like psychotropics, anticonvulsants etc.
Diazepam 5mg/tablet.
200's pack: 121.40 MRP P recautions: The dosage of alprazolam tablets
+ EASIUM Inj. Opsonin should be withdrawn gradually, since withdrawal
Diazepam 1Omg in 2ml ampoule: injection seizures have been reported upon abrupt
25 amps pack: 81.15 MRP withdrawal. Addiction-prone individuals should
+ EASIUM Suppo. Opsonin be under careful surveillance.
Diazepam 1O mg/suppository
S/E: Side effects are generally observed at the
1O's pack: 26.48 MRP
beginning of therapy & usually disappear with
+ EVALIN Tab. Aristopharma
continued medication
Diazepam 5mg/tablet
In usual course, the common side effects are an
500's pack: 340.00 MRP
extension of the pharmacological activity e.g
+ G-DIAZEPAM Tab. Gonoshasthaya
drowsiness, light headedness & dry mouth, nau­
Diazepam 5mg/tablet.
sea, vomiting, allergy, tachycardia. Paradoxical
1OO's strip: 22.00 MRP
reactions such as agitation may rarely occur.
+ G-DIAZEPAM Inj. Gonoshasthaya
Diazepam 1O mg in 2ml ampoule: injection Dosage & admin: For anxiety- 0.25-0.Smg 3
10 amps pack: 30.00 MRP times daily (maximum dose 4mg daily).
+ P '.AM Tab. Pharmadesh For panic disorder of agoraphobia- 0.5mg 3
Diazepam 5mg/tablet times daily after meals for 2 days and then the
250's pack: 62.50 MRP dose may be increased by adding 0.5mg to lmg
of the existing dose every 2-3 days until 2mg
+ RELAXEN Tab. Sonear
Diazepam 5mg/tablet thrice daily is given; usual dose 3-6mg daily.
Dosage equivalence- 0.5mg of alprazolam is
lOO's pack: 68.00 MRP
equivalent to 5mg of diazepam
+ ROZAM Tab. Navana
Diazepam BP 5mg/tablet
+ ALPAM Tab. Asiatic
200's pack: 42.00 MRP
Alprazolam 0.25mg & 0.5mg/tablet.
+ SEDAPAN Tab. Amico
0.25mg x IOO's pack: 100.00 MRP
Diazepam 5mg/tabl�t.
0.5mg x 50's pack: 100.00 MRP
1OO's pack: 21.00 MRP
+ ALP RAX Tab. Opsonin
+ SEDATAB Tab. Supreme
Alprazolam 0.25mg & 0.5mg/tablet.
Diazepam 5mg/tablet.
0.25mg x 50's pack: 43.97 MRP
lOO's pack: 68.00 MRP
0.5mg x 50's pack: 88.41 MRP '
+ SEDIL Tab. Square
+ ALP RAX XR Tab. Opsonin
Diazepam 5mg/tablet
Alprazolam lmg & 2mg/tablet (extended release).
SOO's pack: 345.00 MRP
l mg x 30's pack: 106.09 MRP
+ SEDIL lnj. Square
2mg x 30's pack: 211.92 MRP
Diazepam 1Omg in 2ml ampoule: injection
+ ALZOLAM Tab. Sun Pharma
10 amps pack: 30.50 MRP
Alprazolam 0.25mg & O .S mg/tablet.
+ SEDUXEN Tab. Ambee
0.25mg x IOO's pack: 112.00 MRP
Diazepam 5mg/tablet
0.5mg x lOO's pack: 203.00 MRP
200's pack: 46.00 MRP
+ ALZOLAM SR Tab. Sun Pharma
+ SEDUXEN lnj. Ambee
Alprazolam l m g/tablet (sustained release).
Diazepam 1Omg in 2ml ampoule: injection
l mg x lOO's pack: 400.00 MRP
10 amps pack: 36.00 MRP
+ NIXALO Tab. Square
Alprazolam 0.5mg/tablet.
ALPRAZOLAM44 0.5mg x lOO's pack: 200.00 MRP
+ SERELAM Tab. General
ALP RAZOLAM: Tablet Alprazolam 0.25mg & 0.5mg/tablet.
Alprazolam is a drug of benzodiazepine group, 0.25mg x IOO's pack: 100.00 MRP
used as an anxiolytic. It is available as- 0.5mg x lOO's pack: 201.00 MRP

+ XAN AX Tab. Navana
Alprazolam 0.25mg & 0.5mg/tablet.
0.25mg x 1OO's pack: I 00.00 IP
0.5mg x 50's pack: 125.00 IP
t XIOTIC Tab. Globe
Alprazolam 0.5mg/tablet.
•
0.5mg x lOO's pack: 175.00 MRP
+ XOLAM XR Tab. Aristopharma
Alprazolam 0.5mg & lmg/tablet (ext. release).
0.5mg x 50's pack: 125.00 MRP
lmg x 50's pack: 200.00 MRP
t ZOLAX Tab. Beximco
Alprazolam 0.25mg & 0.5mg/tablet.
0.25mg x 1OO's pack: I 00.00 IP
0.5mg x 1 OO's pack: 200.00 IP
t Z OLIUM Tab. lncepta
Alprazolam 0.25mg & 0.5mg/tablet.
0.25mg x IOO's pack: 150.00 MRP
0.5mg x lOO's pack: 300.00 MRP
BROMAZEPAM21•50
BROMAZEPAM: Tablet
Ind: Anxiety (short-term use).
C/I; S/E; Caution: See under diazepam.
Dosage & admin: Adult: 3-18mg daily in
divided doses; elderly (or debilitated) half adult
dose; max. (in exceptional circumstances in
hospital patients) 60mg daily in divided doses.
Child, not recommended.
Bromazepam tablet
SK•F
+ ANCOTIL Tab. Rangs Pharma
Bromazepam BP 3mg/tablet
50's pack: 200.00 MRP
+ ANXIO Tab. UniMed & UniHealth
Bromazepam BP 3mg/tablet
30's pack: 135.00 MRP
I
QIMP-17 (129)
t ANXIONIL Tab. NIPRO JMI
Bromazepam BP 3mg/tablet
50's pack: 250.00 MRP
+ ANXIRE L Tab. Novo Healthcare
Bromazepam BP 3mg/tablet
30's pack: 120.00 MRP
t ANXOPAM Tab. Popular
Bromazepam 3mg/tablet
30's pack: 120.00 MRP
t BOMAZ Tab. Sharif
Bromazepam 3mg/tablet
.
50's pack: 200.00 MRP
t BOPAM Tab. Opsonin
Bromazepam 3mg/tablet
50's pack: 197.83 MRP
t BROMAZEP Tab. Orion Pharma
Bromazepam 3mg/tablet
50's pack: 200.00 MRP
t BRONIUM Tab. Doctor's
Bromazepam 3mg/tablet
50's pack: 150.00 MRP
t DROZE Tab. Biopharma
Bromazepam 3mg/tablet
50's pack: 250.00 MRP
t BROZEP Tab. Alco Pharma
Bromazepam 3mg/tablet
IOO's pack: 400.00 MRP
+ FRETEN Tab. Delta Pharma
Bromazepam 3mg/tablet
30's pack: 150.00 MRP
+ KPAM Tab. Kemiko
® Bromazepam 3mg/tablet
50's pack: 200.00 MRP
t LATEN Tab. Supreme
Bromazepam 3mg/tablet
30's pack: 90.00 MRP
t LAXONIL Tab. Rephco
. Bromazepam 3mg/tablet
50's pack: 150.00 MRP
+ LAXYL Tab. Square
Bromazepam 3mg/tablet
50's pack: 250.00 MRP
t LEXNIL Tab. Asiatic
Bromazepam 3mg/tablet
CNS DRUGS
50's pack: 200.00 MRP
t LEXOPIL Tab. Healthcare
Bromazepam 3mg/tablet
50's pack: 250.00 MRP
t LEXOTANIL Tab. Roche/Radiant
Bromazepam 3mg/tablet
70's pack: 490.00 MRP
+ MAPEZ Tab. Kumudini
Bromazepam 3mg/tablet
50's pack: 200.00 MRP
t NIGHTUS Tab. Beximco
Bromazepam 3mg/tablet
lOO's pack:·300.00 IP
t NORRY Tab. Renata
Bromazepam 3mg/tablet
50's pack: 250.00 MRP
+ NOTENS Tab. Aristopharma
Bromazepam 3mg/tablet
50's pack: 250.00 MRP
t RELAXIUM Tab. Amico
Bromazepam 3mg/tablet
30's pack: 75.00 MRP
+ REM Tab. Ambee
Bromazepam 3mg/tablet
30's pack: 90.00 MRP
t RESTOL Tab. SK+F
Bromazepam 3mg/tablet
30's pack: 150.00 MRP
t SIESTA Tab. Incepta
Bromazepam 3mg/tablet
30's pack: 90.00 MRP
t TENAPAM Tab. General
Bromazepam 3mg/tablet
30's pack: 150.00 MRP
t TENIL Tab. Acme
Bromazepam 3mg/tablet
lOO's pack: 500.00 MRP
t XIONIL Tab. Sandoz
Bromazepam 3mg/tablet
50's pack: 250.00 MRP
t ZEPAM Tab. ACI
Bromazepam 3mg/tablet
50's pack: 250.00 MRP
. .. � · .- -�.
-
·'"' '
- -- --.
- %
. :
.. - "
-•i .
- .

CNS DRUGS QIMP-17 (130)
drug belonging to benzodiazepine group. It is
CLOBAZAM2I ,33 available as lmg tablet & 4mg in lml ampoule
for i.m/i.v injection.
CLOBAZAM: Tablet/Capsule Mode of action: Lorazepam interacts with the y­
Ind: Anxiety�nsion, agitation. aminobutyric acid (GABA)-benzodiazepine
C/I; S/E; Caution: See under Diazepam. receptor complex, which is widespread in the
Adult: Elderly, 20mg; others, 20-30mg. Both brain of humans as well as other species. This
daily in divided doses or as a single dose at interaction is presumed to be responsible for
night. Maximum 60mg daily. lorazepam's mechanism of action. Lorazepam
Child: Under 3 years, not rcommended; 3-12 exhibits relatively high and specific affinity for
years, upto half adult dose. its recognition site but does not displace GABA.
Attachment to the specific binding site enhances
+ CALM Tab. Biopharma
the affinity of GABA for its receptor site on the
Clobazam 1Omg/tablet
same receptor complex. The pharmacodynamic
1OO's pack: 276.00 MRP
consequences of benzodiazepine agonist actions
+ CLOB Tab. Opsonin
include antianxiety effects, sedation, and
Clobazam 1Omg/tablet
reduction of seizure activity. The intensity of
1OO's pack: 242.80 MRP
action is directly related to the degree of
+ CLOBAM Tab. Square
benzodiazepine receptor occupancy.
Clob azam 1Omg/tablet
Ind: Lorazepam is used for the treatment of
1OO's pack: 400.00 MRP
anxiety states, including anxiety associated with
+ CLOBID Tab. Medimet
phobic & obsessional states, psychosomatic,
Clob azam 1Omg/tablet
organic or psychotic illness, insomnia associated
1OO's pack: 300.00 MRP
with anxiety, nervousness, restlessness, nausea
+ CLOZAM Tab. Navana
and vomiting related to chemotherapy and
Clobazam 1Omg/tablet
anticonvulsants, and as a premedicant before
l OO's pack: 285.00 IP
dental or general surgery or prior to investigative
+ COLAX Tab. Pharmadesh
procedures where there may be discomfort.
Clobazam 1Omg/tablet
Lorazepam injection is specially indicated in
50's pack: 137.50 MRP
��
r •
adult patients for preanesthetic medication,
+ COSIUM Tab. Acme
producing sedation (sleepiness or drowsiness),
Clobazam 1Omg/tablet
relief of anxiety, and a decreased ability to recall
1OO's pack: 350.00 MRP
events related to the day of surgery. It is most
+ EBAZAM Tab. Edruc
useful in those patients who are anxious about
Clob azam 1Omg/tablet
their surgical procedure an·d who would prefer to
1OO's pack: 300.00 MRP
have diminished recall of the events of the day of
+ EPSON Tab. Zenith
surgery.
Clobazam BP 1Omg/tablet
Lorazepam injection is also effective in the
1OO's pack: 281.00 MRP
treatment of status epilepticus, acute panic
+ FRISIUM Tab. Sanofi-aventis
attacks & sedation with amnesia.
Clobazam 1Omg/tablet
C/I; S/E; Caution: See under diazepam.
l OO's pack: 500.00 MRP
Dosage & admin: For optimal result dose,
+ KEOLAX Tab. Beximco ·
frequency of administration and duration of
Clobazam 1Omg/tablet.
therapy should be individualized according to
l OO's pack: 277.00 IP
patient's response.
+ NEBIUM Tab. Globe
Clobazam 1Omg/tablet. By mouth: The usual range of dosage is 2-
l OO's pack: 255.00 MRP 7mg/day given in divided doses; the largest
+ PREZIUM Tab. Nipa dose being taken before bedtime, but the
Clobazam 1Omg/tablet. largest dosage may vary from 1 to lOmg/day.
1OO's pack: 250.00 MRP For anxiety, most patients require an initial
+ T ENSNIL Tab. Alco Pharma dose of 2-3mg/day given b.i.d. or t.i.d.
Clobazam 1Omg/tablet. For elderly or debilitated patients, an initial
1OO's pack: 400.00 MRP dosage of l-2mg/day in divided doses is
recommended, to be adjusted as needed and
+ TRANQUIL Tab. Ibn Sina
tolerated. For insomnia l-2mg before bedtime
Clobazam 1Omg/tablet.
and as premedicant 1-2mg the night before
1OO's pack: 400.00 IP
surgery and 1 to 2 hour before surgery.
+ VENIUM Tab. Hudson
Lorazepam is not recommended in anxiety
Clobazam 1Omg/tablet.
1OO's pack: 270.00 MRP states in children but may be used as
premedicant before surgery at a dose of
0.05mg/kg in children aged 5 to 13 years.
CLONAZEPAM
When needed, the dosage of lorazepam should
be increased gradually to avoid adverse effects.
I Please see under the anticonvulsant/antiepileptic
When higher dosage is indicated, the evening
drugs.
dose should be increased before the daytime.
By injection:
LORAZEPAM2I,26 Preanesthetic medication:
Intramu_scular injection: For the designated
LORAZ�PAM: _ Tablet/Injection indications as a premedicant, the usual recom­
Loraiepimi is a ·short-acting tranqulizer anxiolytic mended dose of lorazepam for i.m injection is
•
0.05 mg/kg up to a maximum of 4 mg. As with
all premedicant drugs, the dose should be
individualized. For optimum effect, measured
as lack of recall, i.m lorazepam should be
administered at least two hours before the
anticipated operative procedure.
Intravenous injection: For the primary
purpose of sedation and relief of anxiety, the
usual recommended initial do!e of lorazepam
for i.v injection is 2mg total, or 0.02mg/lb
(0.044 mg/kg), whichever is smaller. This dose
will suffice for sedating most adult patients
and should. not ordinarily be exceeded in
patients over 50 years of age. In those patients
in whom a greater likelihood of lack of recall
for perioperative events would be beneficial,
larger doses as high as 0.05mg/kg up to a total
of 4mg may be administered. For optimum
effect, measured as lack of recall, i. v lorazepam
should be administered 15 to 20 minutes
before the anticipated operative procedure.
There are insufficient data to support efficacy
or make dosage recommendations for i.m/ i. v
lorazepam in patients less than 18 years of
age; therefore, such use is not recommended.
Status epilepticus:
Intramuscular injection: I.M loraz.epam is _not ..
preferr�d in �he treatment of status epileptic1is
,·beea1'se therap�utic lorazepam level$ may no.! ·
·be reached as quickly as with i.v ·.J
� :,.
·
administration. However, when an i.v p.ort i� :
not available, the i.m route may pf9ve· useflil. '-�
Intravenous injection: For the treatment of· ·�?."
status epilepticus, the usual recomme.. ded .. ) :
. . . . �
.
dose of lorazepam injection is 4mg given : '_:·;_.1:
slowly (2mg/ min) for patients 18 years and
..
.
,.'
older. H seizures cease, no additional ·
, .#
lorazepam injection is required. If seizures ' ·. ·.
..
•
continue or recur after a 10 to 15 minutes
observation period, an additional 4 mg
intravenous dose may be slowly administered.
Infants & children - O.lmg/kg slow i.v over 2-5
� .
minutes; do not exceed 4 mg/single dose; may
repeat second dose of 0.05mg/kg slow i.v. in
10-15 minutes if needed.
Adolescents- 0.07mg/kg slow i. v over 2-5
minutes; maximum: 4 mg/dose; may repeat in
10-15 minutes.
I
Acute panic attacks:
I.M or slow i.v injection (into a large vein): 25-
30mcg/kg (usual range l.5-2.5mg), repeated
every 6 hours if necessary.
Child- not recommended.
Sedation with amnesia & premedication:
Slow i.v injection, preferably diluted with an
equal volume of sodium chloride i. v infusion
0.9°/o or water for injections. 50mcg/kg, 30-40
minutes before operation. Intramuscular
injection: Diluted as above, SOmcg/kg, 60-90
·
minutes before operation.
+ LORAPAM Inj. Popular
Lorazepam USP 4mg/ l ml ampoule: i.m/i.v
injection.
4mg ( l ml) amp x 5's pack: 376.40 MRP
+ LOZICUM Tab. Incepta
Lorazepam USP l m g/tablet.
l mg x l OO's pack: 200.00 MRP . -
+ TRAPEX Tab. Sun. Pharma
Lorazepam BP l mg/tablet.
l mg x 50's pack: 100.00 MRP

OXAZEPAM42
OXAZEPAM: Tablet
Oxazepam is an anxiolytic drug belonging to
benzodiazepine group. It is available as­
Oxazepam BP 1Omg tablet.
Mode of action: Oxazepam acts on the brain and
nerves (central nervous system) to produce a
calming effect. It works by enhancing the effect
of a natural chemical in the brain GABA.
Ind: Oxazepam is used in the treatment of anxiety
disorders, including anxiety associated with
depression. This drug seems to be particularly
effective for anxiety, tension� agitation and
irritability in older people. It is also prescribed to
relieve symptoms of acute alcohol withdrawal.
C/I: Allergic reaction to oxazepam or other
benzodiazepines such as diazepam. Oxazepam
should not be prescribed if any patient is being
treated for mental disorders which are more
serious than anxiety.
S/E: More common side effect includes drowsi­
ness. Less common or rare side effects include:
Blood disorders, change in libido, dizziness,
excitement, fainting, headache, liver problems,
loss or lack of muscle control, nausea, skin rash­
es or eruptions, sluggishness or unresponsive­
ness, slurred speech, swelling due to fluid reten­
tion, tremors, vertigo, yellowed eyes and skin.
Side effects due to rapid decrease or abrupt
withdrawalfrom oxazepam: Abdominal & muscle
cramps, convulsions, depressed mood, inability to
fall or stay asleep, sweating, tremors, vomiting.
Side effects cannot be anticipated. If any develop
or change in intensity, doctor should be informed
immediately. Doctor will determine if it is safe
for a patient to continue taking oxazepam.
Precautions: This drug may make dizzy, drowsy
or cause blurred vision; caution should be taken
while engaging in activities requiring alertness
such as driving or using machinery. Limit should
be maintained while taking alcoholic beverages.
Caution is advised when using this drug in the
elderly because they may be more sensitive to the
effects of the drug, specially the drowsiness
effect.
Pregnancy & lactation: This medication is not
recommended for use during pregnancy due to
the potential possible fetal harm. This drug may
pass into breast milk and may have undesirable
effects on a nursing infant. Therefore, breast­
feeding while using this medication is not
recommended.
Dosage & admin: Adult: Mild to moderate
anxiety with tension, irritability and agitation:
The usual dose is 10-15mg 3 or 4 times per
day. Severe anxiety, depression with anxiety,
or alcohol withdrawal: The usual dose is 15-
30mg 3 or 4 times per day.
Children: Safety and effectiveness have not
been established for children less than 6 years
of age, nor have dosage guidelines been
established for children 6 to 12 years. Doctor
will adjust the dosage to fit the child's needs.
Older adults: The usual starting dose is 1 Omg
3 times a day. Doctor may increase the dose to
15mg 3 or 4 times a day, if needed.
Overdose: An overdose of oxazepam can be
fatal. Symptoms of mild oxazepam overdose may
include: Confusion, drowsiness, lethargy.
QIMP-17 (131)
Symptoms of more serious overdose may
include: Coma, hypnotic state, lack of co-ordina­
tion, limp muscles and low blood pressure.
Drug inter: Oxazepam may intensify the effects
of alcohol. It may be best to avoid alcohol while
taking this medication. If oxazepam is taken with
certain other drugs, the effects of either could be
increased, decreased, or altered.
It is specially important to check with a doctor
before combining oxazepam with the following:
Antihistamines such as diphenhydramine, narcot­
ic painkillers such as oxycodone and pethidine
sedatives such as secobarbital and triazolam
tranquilizers such as diazepam and alprazolam.
+ ANOXA Tab. Square
Oxazepam BP 1 Omg/tablet
lOmg x 30's pack: 105.30 MRP
3. ANTIPSYCHOTIC &
RELATED DRUGS21
3.1 Antipsychotic drugs
3.2 Atypical antipsychotic drugs
3.3 A.ntimanic drugs
Antipsychotic drugs21
Generally anti-psychotic drugs tranqui-llise
without impairing consciousness and without
causing paradoxical excitement, but they should
not be regarded merely as tranquillisers.
In the short-term they are used to quieten
disturbed patients whatever the underlying
psychopathology and to alleviate severe anxiety.
The commonly used anti-psychotics are:
1. Phenothiazines
2. T hiozanthenes
3. Butyrophenone
4. Dihydroindolone
5. Dibenzoxazepine
Phenothiazine derivatives
CHLORPROMAZINE HCI 21,33
CHLORPROMAZINE HCI: Tablet/
Syrup/Injection/Suppository.
Ind: Schizophrenia and related psychoses,
tranquillization and emergency control in
behavioral disturbances, psychoneuroses;
induction of hypothermia; emesis & intractable
hiccup; adjunctive treatment of alcohol or drug
withdrawal or terminal disease.
C/I: Comatose state; poisoning caused by CNS
depressants; bone-marrow depression.
· S/E: Extrapyramidal symptoms (which can be
reversed by dose reduction or anticholinergic
agents) and on, prolonged administration,
occasionally tardive dyskinesia; hypothermia,
drowsiness, apathy, pallor, nightmares, insomnia,
depression and more rarely agitation;
anticholinergic symptoms e.g. dry mouth,
constipation, difficulty with micturition and
blurred vision; hypotension, cardiac arrhythmias.
Cautions: Liver and renal dysfunction; cardio-
CNS DRUGS
vascular disease; parkinsonj.siµ, epilepsy;
pregnancy, lactation; concurrent admn. of CNS
depressants & ·guanethi-dine; past history .of
jaundice; leucopenia. ,.
Dosage & admin: Adult, initially 25mg 3 tinies
.
-
daily increasing if necessary by 25mg daily.
Maintenance, usually 75-300mg daily. Child,
upto 5 years 5-lOmg 3 times daily; 5-12 yrs.
third to half adult dose.
Injection: Adult, 25-SOmg i.m. as a single dose
or repeated if necessary 6 to 8 hourly. Follow
as soon as possibl� by oral therapy. Child,
severe cases only, use equv. oral dose by i.m.
injection..
t LARGACTIL Tab. Sanofi-aventis
Chlorpromazine hydrochloride 25mg, 50mg &
1OOmg/tablet.
25mg x 500's pack: 205.00 MRP
50mg x l OO's pack: 60.00 MRP
l OOmg x lOO's pack: 101.00 MRP
+ LARGAC TIL Inj. Sanofi-aventis
Chlorpromazine hydrochloride 50mg in 2ml
ampoule: injection
10 amps pack: 41.20 MRP
t OPSONIL Tab. Opsonin
Chlorpromazine hydrochloride 50mg &
1OOmg/tablet.
50mg x 1 OO's pack: 52. 78 MRP
lOOmg x l OO's pack: 88.85 MRP
t OPSONIL Inj. Opsonin
Chlorpromazine hydrochloride 50mg in 2ml
ampoule: injection
25 amps pack: 88.41 MRP
FLUPHENAZINE21 ,33
FLUPHENAZINE DECANOATE: Injection
Ind: Maintenance treatement of psychotic
disorders particularly schizophrenia.
C/I: Phaeochromocytoma; marked cerebral
atherosclerosis; renal or hepatic failure; cardiac
insufficiency; anxiety & tension states or geriatric
confusion and agitation.
S/E; Extrapyram.idal symptoms occur more. fre""'
quently (particularly in elderly females) usually a
few hours after dose has been adminstered and
continued for 2 days. See also under clopenthixol.
Cautions: Hepatic, respiratory and cardiac
diseases, cardiac arrhythmias, thyrotoxicosis,
epilepsy, glaucoma, hypothyroidism, myasthenia
gravis, prostatic hypertrophy, pregnancy lactation.
Dosage & admin: Adult: Initially 12.5mg
(6.25mg elderly) by deep i.m. inj. into gluteal
region to test susceptibility to extrapyramidal
reactions, then adjust dose according to
response. Usual dosage range, 12.5mg-100mg
every 2-5 weeks, starting 4 to 7 days after test.
Child: Not recommended.
t FENAZINE Inj. Incepta
Fluphenazine decanoate 25mg/lml ampoule:
injection.
lml amp x S's pack: 350.00 MRP
t FLUPHENAZINE DECANOATE-Rotex Inj.
Rotex Medica/City Overseas
Fluphenazine decanoate 25mg/ml; 1ml ampoule
& 1 Oml vial: injection.
lml amp x 1 O's pack: 1100.00 TP
1Oml vial x l's pack: 700.00 TP

TRIFLUOPERAZINE21,65
TRIFLUOPERAZINE: Tablet/Syrup/Injection
Ind: Schizophrenia, psychoses due to organic
brain damage, behavioral disorder and toxic
psychoses. Anxiety, depressive symptoms
secondary to anxiety. Senile agitation and
confusion. Nausea & vomiting.
C/I; S/E; Caution: See under haloperidol.
Dosage & admin: By mouth: Adult, Psychoses­
initially lOmg daily in single or divided doses
increasing after 7 days to 15mg daily. If reqd.
increase further by 5mg at 3 day intervals,
then reduce to maintenance dose lOmg daily.
Anxiety (Psychoneuroses)- 2 to 6mg daily in
divided or single doses. Child, Psychoses­
under 12 yrs. upto 5mg in divided doses, then
adjust according to tlie response. Anxiety­
under 3 yrs. not recommended; 3-5 yrs. 1 mg
daily in divided doses ( as syp.); 6-12 yrs. upto
4mg daily (as syp.) in divided doses.
By Injection: Adult, 1-3mg daily by i.m. inj.
max. 6mg daily. Child, lmg/20kg body-wt.
,
daily by i.m. inj. in divided doses.
t SIZONIL Tab. Healthcare
Trifluoperazine dihydrochlor. 1mg & 5mg/tablet
lmg x lOO's pack: 200.00 MRP
5mg x 1OO's pack: 350.00 MRP
t STELA Tab. Delta Pharma
Trifluoperazine dihydrochlor 1mg & 5mg/tablet
lmg x 50's pack: 75.00 MRP
5mg x 50's pack: 125.00 MRP
t T ELAZINE Tab. SK+F
Trifluoperazine dihydrochlor. l m g & 5mg/tablet
l mg x l OO's pack: 200.00 MRP
5mg x 1OO's pack: 300.00 MRP
Phenothiazine related drugs
CLOZAPINE21,33
CLOZAPINE: Tablet
Ind: Schizophrenia in patients unresponsive to,
or intolerant of, conventional antipsychotic drugs.
C/I: Severe cardiac disease; history of drug­
induced neutropenia/ agranulocy-tosis; bone
marrow disorders; alcoholic and toxic psychoses;
history of circulatory collapse or paralytic ileus;
drug intoxication; coma or severe CNS
depression; uncontrolled epilepsy; pregnancy and
breast-feeding.
S/E: See under chlorpromazine hydrochloride
but less sedating and high incidence of antimus­
carinic symptoms; extrapyramidal symptoms may
occur less frequently; neutropenia and potentially
fatal agranulocytosis, fever (evaluate to rule out
underlying infection or agranulocytosis),
headache and dizziness, hypersalivation, urinary
incontinence, priapism, pericarditis and myocar­
ditis; and deliruim; hypotension- rarely circula­
tory collapse with cardiac and respiratory arrest
(but hypertension also reported), also nausea and
QIMP-17 (132)
vomiting; hyperglycaemia reported.
Cautions: See under chlorpromzine hydrochlo­
ride; initiation must be in hospital in-patients,
and leucocyte and differential blood counts must
be normal before treatment and must be moni­
tored weekly for first 18 weeks then at least fort­
nightly- patients who have received clozapine for
a year or more and have stable blood counts may
have their blood monitoring reduced to every 4
weeks; avoid drugs which depress leucopoiesis
such as co-trimoxazole and carbamaze-pine (and
taper off conventional neuroleptic before start­
ing); withdraw treatment if leucocyte count falls
below 3000/mm3; patients should report any
infections.
Withdrawal: On planned withdrawal reduce dose
gradually over 1-2 weeks to avoid risk of
rebound psychosis. If abrupt withdrawal
necessary observe patient carefully.
Dosage & admin: (Close medical supervision
on initiation- risk of collapse due to hypoten­
sion) 12.Smg once or twice on first day then
25-50mg on second day, then slowly increased
(if well tolerated) in steps of 25-50mg over 14-
21 days to 300mg daily in divided doses
(larger dose at night, up to 200mg daily may
be taken as a single dose at bed time); if
necessary may be further increased in steps of
50-lOOmg once (preferably) or twice weekly;
usual antipsychotic dose 200-450mg daily
(max. 900mg daily); subsequent adjustment to
usual maintenance of 150-300mg.
Child: Not recommended.
Elderly and special risk groups: In elderly,
12.Smg once on first day- subsequent
adjustments restricted to 25mg daily; in
·
cardiovascular disease, hepatic or renal
impairment or if history of epilepsy, 12.Smg on
first day-subsequent adjustments slowly and
in small steps (if epileptic seizures- suspend
for 24 hours and resume at lower dose);
restarting after interval of more than 2 days,
12.Smg once or twice on first day (but may be
feasible to increase more quickly than on
initiation)- unless previous respiratory or
cardiac arrest with initial dosing in which case
extreme caution.
t SENSIPIN Tab. Beximco
Clozapine 25mg/tablet.
25mg x 30's pack: 115.20 IP
t SIZOPIN Tab. Sun Pharma
Clozapine 25mg & 1OOmg/tablet.
25mg x 50's pack: 127.50 MRP
lOOmg x 50's pack: 477.50 MRP
t ZAPENIA Tab. Incepta
Clozapine 25mg & 1OOmg/tablet.
25mg x 50's pack: 125.00 MRP
lOOmg x 30's pack: 270.00 MRP
FLUPENTHIXOL21,26,67
FLUPENTHIXOL: Tablet/Injection
Flupenthixol- a neuroleptic with anxiolytic and
antidepressant properties of its own when given
in small doses.
Ind: Psychoses, schizophrenia except manic
phase & psychomotor hyperactivity; maintenance
in schizophrenia & related psychoses. Depression.
C/I: Intolerance to neuroleptic drugs; excitable or
over active patient; parkinsonism; severe
atherosclerosis; senile confusional state;
advanced renal, hepatic or cardiovascular disease.
S/E: Extrapyramidal symptoms occur frequently
(1-3 days after administration & continue for 5
days). Aggregation or agitation may appear (in
this stage, should be replaced by another drug). •
Also see under chlorpromazine.
Caution: Renal & hepatic impairment;
atherosclerosis; pregnancy.
Dosage & admin: Flupenthixol decanoate: By
i.m injection- initially use test does 20mg; then
100-200mg by deep i.m injection (better glu­
teal muscle) after 5 to 10 days; repeat usually
every 2-4 weeks maximum 400mg weekly.
Child: Not recommended.
Flupenthixol dihydrochloride: Adult, 3-9mg
twice daily; maximum 18mg daily.
Child: Not recommended.
t FLUANXOL Tab. Lundbeck/Lilac
Flupenthixol dihydrochloride 0.5mg &
l m g/tablet.
0.5mg x l OO's pack: 1096.00 MRP
lmg x 50's pack: 839.50 MRP
t FLUANXOL Depot Inj. Lundbeck/ Lilac
Flupenthixol decanoate 20mg/ml & 40mg/2ml
ampoule: injection
l ml (20mg) amp x lO's pack: 3491.50 MRP
2ml (40mg) amp x IO's pack: 6614.00 MRP
t SENTIX Tab. SK+F
Flupenthixol dihydrochloride 0.5mg &
1 mg/tablet.
0.5mg x 50's pack: 150.00 MRP
lmg x 30's pack: 150.00 MRP
FLUPENTHIXOL +
MELITRACEN21,26,67
FLUPENTHIXOL+ MELITRACEN: Tablet
Flupenthixol- a neuroleptic with anxiolytic and
antidepressant properties of its own when given
in small doses, and melitracen- a bipolar thymo­
leptic with activating properties in low doses.
In combination the compounds render a
preparation with antidepressant, anxiolytic and
activating properties, but does not seem to
influence the pharmacokinetic properties of the
individual compounds.
Ind: Psychoses, schizophrenia except manic
phase and psychomotor hyperactivity.
Maintenance in schizophrenia & related
psychoses.
C/I; S/E; Caution: See above under the text of
'flupenthixol'.
Dosage & admin: Flupenthixol + melitracen:
Adult, usually 2 tablets daily divided in
morning and evening doses. In severe cases,
morning dose may be increased to 2 tablets.
Elderly, 1 tablet in the morning; maintenance,
usually 1 tablet in the morning.
Child: Not recommended.
t ADELAX Tab. ACI
Flupenthixol dihydrochloride 0.5mg & melitracen
hydrochloride 1Omg melitracen/tablet.
80's pack: 320.00 MRP
t AMILAX Tab. Amico
Flupenthixol dihydrochloride 0.5mg & melitracen
hydrochloride INN 1Omg melitracen/tablet.
50's pack: 160.00 MRP
 QIMP-17 (133)

Flupentixol BP 0.5 mg

+ ANFREE Tab. Aristopharma 50's pack: 200.00 MRP Mel itracen BP 10 mg

Flupenthixol dihydrochloride 0.5mg & melitracen + EXUTEN Tab. Pharmadesh

hydrochloride 1Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen

1 OO's pack: 400.00 MRP hydrochloride 1Omg/tablet.

t ANGENTA Tab. Healthcare 30's pack: 105.30 MRP

Flupenthixol dihydrochloride 0.5mg & melitracen t FEMANOL Tab. Kemiko hydrochloride 1Omg/tablet.

hydrochloride 1Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen 50's pack: 200.00 MRP
1 OO's pack: 500.00 MRP hydrochloride 1 Omg/tablet. t MELIXOL Tab. Square
I 50's pack: 200.00 MRP Flupenthixol dihydrochloride 0.5mg & melitracen
t ANTISON Tab. Asiatic
Flupenthixol dihydrochloride 0.5mg & melitracen + FEMIXIT Tab. MonicoPharma hydrochloride 1Omg/tablet.
Flupenthixol dihydrochloride 0.5mg & melitracen 50's pack: 200.00 MRP
hydrochloride 1Omg/tablet.
1 OO's pack: 400.00 MRP hydrochloride 1 Omg/tablet. t MELI'IX Tab. Navana
50's pack: 175.00 MRP Flupenthixol dihydrochloride 0.5mg & melitracen
t ANZET Tab. Popular
Flupenthixol dihydrochloride 0.5mg & melitracen t FLUMETRA Tab. Virgo hydrochloride· 1Omg/tablet.
Flupenthixol dihydrochloride BP 0.5mg & 50's pack: 400.00 MRP
hydrochloride 1Omg/tablet.
1OO's pack: 400.00 IP
melitracen hydrochloride 1 Omg/tablet. t MELXIT Tab. Ziska
30's pack: 120.00 MRP Flupenthixol dihydrochloride 0.5mg & melitracen
t BENZIT Tab. Biopharma
Flupenthixol dihydrochloride 0.5mg & melitracen
t FLUXIT Tab. Opsonin hydrochloride 1Omg/tablet.
Flupenthixol dihydrochloride 0.5mg & melitracen 50's pack: 175.00 MRP
hydrochloride 1Omg/tablet.
l OO's pack: 351.00 MRP hydrochloride 1Omg/tablet. t MOOT Tab. Apex
50's pack: 175.94 MRP Flupenthixol dihydrochloride 0.5mg & melitracen
t BP-XIT Tab. Bristol
hydrochloride 1Omg/tablet.
Flupenthixol dihydrochloride 0.5mg & melitracen + FMR Tab. RAK Pharma
hydrochloride 1 Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen
50's pack: 175.00 MRP
1 OO's pack: 350.00 MRP hydrochloride 1Omg/tablet. + NEOXIT Tab. Novo Healthcare
t DELETA Tab. General 50's pack: 200.00 MRP Flupenthixol dihydrochloride 0.5mg & melitracen

Flupentixol BP & Melitracen INN tablet

6uarant_ pp1nes
•

Flupenthixol dihydrochloride 0.5mg & melitracen t FRAXIT Tab. Pharmasia hydrochloride 1Omg/tablet.
hydrochloride 1 Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen 30's pack: 120.00 MRP
50's pack: 200.00 MRP hydrochloride 1Omg/tablet. t PENTIXOL Tab. Techno Drugs
t DEPRESIL Tab. Rangs Pharma SO's pack: 200.00 MRP Flupenthixol dihydrochloride 0.5mg & melitracen
Flupenthixol dihydrochloride 0.5mg & melitracen t FRENXIT Tab. Beximco hydrochloride 1Omg/tablet.
hydrochloride 1Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen 30's pack: 90.00 MRP
50's pack: 200.00 MRP hydrochloride 1Omg/tablet. t PENXIT Tab. Peoples
t DEXIT Tab. UniMed & UniHealth 150's pack: 750.00 IP Flupenthixol dihydrochloride 0.5mg & melitracen
Flupenthixol dihydrochloride 0.5mg & melitracen t HENXIT Tab. Hudson hydrochloride 1Omg/tablet.
hydrochloride 1 Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen 50's pack: 150.00 MRP
50's pack: 200.00 MRP hydrochloride 1Omg/tablet. t RADEX Tab. Globe
t DICONTEN Tab. Drug Inter. l OO's pack: 350.00 MRP Flupenthixol dihydrochloride 0.5mg & melitracen
Flupenthixol dihydrochloride 0.5mg & melitracen t INSPRA Tab. Medicon hydrochloride 1Omg/tablet.
hydrochloride 1 Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen 30's pack: 120.00 MRP
50's pack: 200.00 MRP hydrochloride 1Omg/tablet. t RELUX Tab. Rephco
+ Flupenthixol dihydrochloride O.Smg & melitracen
-
' DINXI Tab. Chemist 50's pack: 200.00 MRP
Flupenthixol dihydrochloride 0.5mg & melitracen t LEANXIT Tab. Acme hydrochloride 1Omg/tablet.
hydrochloride 1Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen lOO's pack: 300.00 MRP
50's pack: 150.00 MRP hydrochloride 1 Omg/tablet. t REMOOD Tab. Ibo Sina
+ DORMIR Tab. Somatec 1OO's pack: 400.00 MRP Flupenthixol dihydrochloride 0.5mg & melitracen
Flupenthixol dihydrochloride 0.5mg & melitracen t LUMEXIT Tab. Kumudini hydrochloride 1Omg/tablet.
hydrochloride 1Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen 50's pack: 200.00 IP •

50's pack: 175.50 MRP hydrochloride 1Omg/tablet.

t RENXIT Tab. Renata
t EXD,OR Tab. Sun Pharma 50's pack: 200.00 MRP Flupenthixol dihydrochloride 0.5mg & melitracen
Flupenthixol dihydrochloride O.Smg & melitracen + MELANXIT Tab. Organic Health hydrochloride 1Omg/tablet.
hydrochloride 1 Omg/tablet. Flupenthixol dihydrochloride 0.5mg & melitracen l OO's pack: 400.00 MRP

l
 QIMP-17 (134)
®

the gluteal muscle, test dose lOOmg, then after x. Alcohol withdrawlal syndrome & delirium
7-28 days 100-200mg or more, followed by tremens.
Flupentixol + Melitracen
.
•

200-400mg repeated at intervals of 2-4 weeks, xi. Pre-anaesthetic medication.

t SENSIT Tab. SK+F
Flupenthixol dihydrochloride 0.5mg & melitracen
adjusted according to the response; max.
Children (oral administration only):
600mg weekly. i. Childhood behavioral disorders especially
Child: Not recommended.
when associated with hyperactivity and
lml amp x lO's pack: 4967.60 MRP aggression.
•

hydrochloride 1Omg/tablet. ii. Gilles de la Tourette syndrome.

t CLOPIXOL ACUPHASE Inj.
50's pack: 200.00 MRP iii. Childhood schizophrenia.
Lundbeck/Lilac
t STIMO Tab. Delta Pharma Zuclopenthixol acetate 50mg/ lml & 100mg/2ml C/I: Comatose states, CNS depression,
Flupenthixol dihydrochloride 0.5mg & melitracen
ampoule: injection. Parkinson's disease, known hypersensitivity to
hydrochloride 1Omg/tablet.
C/I; S/E; Caution: See under Chlorpromazine haloperidol, lesions of the basal ganglia.
50's pack: 175.00 MRP
dihydrochlor. & f'lupenthixol; avoid in children
t TENAXIT Tab. Incepta S/E: Extrapyramidal symptoms, acute dystonia,
and in porphyria; treatment duration should not
Flupenthixol dihydrochloride 0.5mg & melitracen parkinsonian rigidity, tremor, oculogyric crises
exceed 2 weeks.
hydrochloride 1Omg/tablet. and laryngeal dystonia, confusional states or
Dosage & admin: By deep i.m. injection, 50-
50's pack: 175.00 MRP epileptic fits, depression, sedation, agitation, \

150mg (elderly 50-1OOmg), if necessary

drowsiness, insomnia, headache, vertigo and
t TENSA Tab. SAPL repeated after 2-3 days (1 additional dose may
Flupenthixol dihydrochloride 0.5mg & melitracen apparent exacerbation of psychotic symptoms,
be needed 1-2 days after the first injection);
hydrochloride IOmg/tablet. nausea, loss of appetite, constipation and
max. cumulative dose 400mg per course and
50's pack: 175.00 MRP dyspepsia, dry mouth as well as excessive
max. 4 injections; if maintenance treatment
salivation, blurred vision, urinary retention have
t TENSICON Tab. White H orse necessary change to an oral antipsychotic 2-3
Flupenthixol dihydrochloride 0.5mg & melitracen been reported.
days after last injection, or to a longer acting
hydrochloride 1Omg/tablet. Cautions: Caution is advised in patients with
antipsychotic depot injection given
50's pack: 175.00 MRP liver disease, renal failure, epilepsy and condi­
concomitantly with last injection of
·

tions predisposing to epilepsy (e.g alcohol with­

t THENXET Tab. Pacific zuclopenthixol acetate.
Flupenthixol dihydrochloride 0.5mg & melitracen drawal and brain damag�) or convulsions.
lml amp (50mg) x S's pack: 2763.05 MRP
hydrochloride 1Omg/tablet. Haloperidol should only be used with great cau­
2ml amp (lOOmg) x S's pack·: 3684.10 MRP
lOO's pack: 400.00 MRP tion in patients with disturbed thyroid function.
Liver and renal failure, epilepsy, thyrotoxicosis,
t THIXTRA Tab. NIPRO JMI
Flupenthixol dihydrochloride 0.5mg & melitracen parkinsonism, pregnancy, severe cardiovascular
Butyrophenone: Haloperidol disease.
hydrochloride 1Omg/tablet. .
30's pack: 105.00 MRP
: Dosage & admin: Dosage fo� all indications
-should be individually determined and is best
t TIXOCIN Tab. Sharif HALOPERIDOL42
Flupenthixol dihydrochloride 0.5mg & melitracen ·.
•
initiated a�d titrated under close clinical
.

·hydrochloride 1Omg/tablet. supervision. To _determine the initial dose con-

HALOPERIDOL: Tablet/ Liquid/Injection. sideration should be given to the patients age,
30's pack: 120.00 MRP
Haloperidol is a highly effective neuroleptic
severity of symptoms and previous response to
t TIXOL Tab. Alco Pharma butyropbenone drug with a wide range of actions.
Flupenthixol dihydrochloride 0.5mg & melitracen other neuroleptics. The normal starting dose
Haloperidol is rapidly absorbed after oral or
should be halved, followed by a gradual
hydrochloride 1Omg/tablet.
parenteral administration, it is then crosses the
50's pack: 200.00 MRP titration to achieve an optimal response.
blood brain barrier. It's µalf life is approximately
Oral administration: Adults: Schizophrenia,
t U4 Tab. Orion Pharma 20 hours. It is available as- haloperidol BP 5mg/
Flupenthixol dihydrochloride 0.5mg & melitracen psychoses, mania and hypomania, mental or
tablet; 2.5mg/Sml syrup; 5mg/lml ampoule: i.m
hydrochloride 1Omg/tablet. behavioral problems, psychomotor agitation,
injection.
50's pack: 200.00 MRP excitement, violent or dange-rously impulsive
Mode of action: After administration, Although
behavior, organic brain damage:
t XIT Tab. Everest the complex mechanism is not clearly established
Flupenthixol dihydrochloride 0.5mg & melitracen Initial dosage- moderate symptomatology
haloperidol is known to produce a selective effect
hydrochloride 1Omg/tablet. l.5mg-3mg twice or 3 times daily;
on the central nervous system by competitive
50's pack: 175.00 MRP Severe symptomatology/resistant patients-
blockade of dopamine receptors and increased
3mg-5mg twice or 3 times daily;
t XOLITRA Tab. Beacon turnover of brain dopamine. There is some
The same starting doses may be employed in
Flupenthixol dihydrochloride 0.5mg & melitracen
blockade of alpha-adrenergic receptors of the
adolescents, but in certain cases, this may
hydrochloride 1Omg/tablet.
autonomic nervous system.
require up to 30mg or exceptionally up to
50's pack: 200.00 MRP
Ind: Adults: Haloperidol is indicated in the 60mg/day;
t ZENXIT Tab. Z enith
following cases: In resistant schizophrenics daily dosages up to
Flupenthixol dihydrochloride 0.5mg & melitracen
i. Schizophrenia: Treatment of symptoms and lOOmg (or rarely up to 120mg) may be
hydrochloride 1Omg/tablet.
prevention of relapse. necessary to achieve an optimal response.
lOO's pack: 325.00 MRP
ii. Other psychoses- especially paranoid, mania Maintenance dosage: Once satisfactory control
and hypomania. of symptoms has been achieved, dosage should
ZUCLOPENTHIXOL 21• 67 iv. Mental or behavioural problems such as­ be gradually reduced to the lowest
aggression, hyperactivity and self-mutilations
I

maintenance dose, often as low as Smg/ day.

t CLOPIXOL Depot Inj. Lundbeck/Lilac
Zuclopenthixol decanoate 200mg/l ml ampoule:
oily injection.
Ind: Psychoses, especially schizophrenia with
agitation or aggression.
C/I; S/E; Caution: See under chlorpromazine
hydrochloride & flupenthixol; should not be used
in apathetic or withdrawal states; avoid in
children and in porphyria.
Dosage & admin: By deep i.m injection into
in the mentally retarded and in patients with
organic brain damage.
v. As an adjunct to short-term management of
moderate to severe psychomotor agitation,
excitement, violent or dangerously impulsive
behavior.
vi. Intractable hiccup.
vii. Restlessness and agitation in the elderly.
viii.Gilles de la Tourette syndrome & severe tics.
ix. Nausea and vomiting.
Too rapid a dose reduction should be avoided.
Restlessness or agitation in elderly: Initial dose-
1.5mg-3mg twice or 3 times daily, titrated to
attain an effective maintenance dose (1.5-Smg
daily).
Gilles de la Tourette syndrome/Severe tics/
Intractable hiccup: Starting dose l.Smg 3 times
daily adjusted according to response. A daily
maintenance dose of 1Omg may be required in
Gilles de la Tourette syndrome.

For control of acutely agitated patients with
moderate symptoms: 2-1Omg.
LMinjecdon: (Haloperidol can also be admin­
istered by i.v route) Nausea & vomiting 1-2mg.
Children: By mouth:
Childhood behavioural disorder/schizophrenia:
Total daily maintenance dose of 0.025-0.0Smg/
kg/day, half the total dose should be given in
the morning and the other half in the evening,
up to a maximum of 1Omg daily.
By injection: Not recommended for parenteral
use in children.
Drug inter: Potentially hazardous interactions:
Lithium: The combination of haloperidol with
lithium may predispose to the neuroleptic malig­
nant syndrome, but this should not be a problem
unless very high dose of lithium is given.
Dopamine antagonists: Co-administration of
antidopaminergic antiemetics increases the risk of
extrapyramidal adverse effects.
Other CNS depressants: An additive depressant
effect occurs.
Indomethacin: An idiosyncratic reaction of
haloperidol and indomethacin to produce severe
drowsiness has been reported.
t G- HALOPERIDOL Tab. Gonoshas
Haloperidol 5mg/tablet.
5mg x 1OO's pack: 40.00 MRP
t HALOP Tab. Opsonin
Haloperidol 5mg/tablet.
5mg x IOO's pack: 43.94 MRP
t HALOPID Tab. Incepta
Haloperidol 5mg/tablet.
5mg x IOO's pack: 100.00 MRP
+ HALOPID lnj. lncepta
Haloperidol 5mg/ lml ampoule: i.m injection.
10 amps pack: 108.00 MRP
t PERIDOL Tab. Square
Haloperidol 5mg/tablet.
5mg x IOO's pack: 100.00 MRP
t PERIGEN Tab. General
Haloperidol 5mg/tablet.
5mg x lOO's pack: 100.00 MRP
t PERIGEN I.M lnj. General
Haloperidol 5mg/1ml ampoule: i.m injection.
10 amps pack: 120.00 MRP
t PEROL Tab. Ambee
Haloperidol 5mg/tablet.
5mg x IOO's pack: 51.00 MRP
t PEROL lnj. Ambee
Haloperidol 5mg/l ml ampoule: injection.
10 amps pack: 100.40 MRP
Atypical Antipsychodcs21
The 'atypical antipsychotics' include­
Amisulpride, Aripiprazole, Clozapine,
Olanzapine, Quetiapine, Risperidone,
Sertindole, Ziprasidone & Zotepine.
ARIPIPRAZOLE34
ARIPIPRAZOLE: Tablet
Aripiprazole is an 'atypical antipsychotic drug'.
It is available as aripiprazole INN 5mg, IOmg &
l 5mg film-coated tablet.
Ind: Schizophrenia; acute manic & mixed
episodes associated with bipolar disorder.
I
QIMP-17 (135)
C/I: Aripiprazole is contraindicated in patients
with a known hypersensitivity to the product;
child, adolescent & breast feeding mothers.
S/E: Headache, asthenia, fever, nausea, vomiting,
constipation, anxiety, insomnia, lightheadedness,
somnolence, akathisia, tremor, rhinitis, coughing,
rash, postural hypotension, dyspepsia and blurred
vision. Neuroleptic malignant syndrome, tardive
dyskinesia, hyperglycemia and diabetes mellitus
have been rarely seen during aripiprazole therapy.
Cautions: Aripiprazole should be used
cautiously in patients at risk of orthostatic
hypotension, seizure, patients of cognitive and
motor impairment, dysphagia, suicide, patients
with concomitant illness, elderly, pregnancy.
Pregnancy & lactation: Aripiprazole should be
used in pregnancy only if the potential benefits
outweigh the potential risk to the fetus and it is
recommended that women receiving aripiprazole
should not breast-feed
Dosage & admin: Schizophrenia: Usual
recommended starting and target· dose for
aripiprazole is lOmg to 15mg/day
administered on a once-a-day schedule without
regard to meals. Aripiprazole has been shown
to be effective in a dose range of 1Omg to
30mg/day. Maximum dosage increase should
not be made before 2 weeks.
Acute manic & mixed episodes associated with
bipolar disorder: Usual recommended starting
dose is 30mg given once a day. Dose may be
decreased to 15mg based on assessment of
tolerability. Dosage adjustments are not
routinely indicated on the basis of age, gender,
race or renal or hepatic impairment status.
Drug inter: Ketoconazole and quinidine· increase
the AUC of aripiprazole; so, dose should be
reduced by half when co-administered with these
drugs. Carbamazepine decreases the AUC of
aripiprazole; so dose should be doubled while
carbamazepine is co-administered.
t ARIPEN Tab. Opsonin
Aripiprazole INN 1Omg & 15mg/tablet
1Omg x 30's pack: 132.48 MRP
l 5mg x 20's pack: 123.68 MRP
+ ARIPRA Tab. Incepta
Aripiprazole INN 1 Omg & l 5mg/tablet
1Omg x 50's pack: 250.00 MRP
15mg x 50's pack: 350.00 MRP
t ARIPRAZOLE Tab. General
Aripiprazole INN 5mg & IOmg/tablet
5mg x 50's pack: 175.50 MRP
lOmg x 30's pack: 150.60 MRP
t SIZOPRA Tab. Acme
Aripiprazole INN lOmg & 15mg/tablet
lOmg x 30's pack: 150.00 MRP
15mg x 20's pack: 140.40 MRP
OLANZAPJNE52
OLANZAPINE: Tablet
01anzapine is a thienobenzodiazepine atypical
antipsychotic drug.
Mode of action: Olanzapine is a thienobenzodi­
azepine atypical antipsychotic drug. It is a com­
petitive antagonist of dopamine, acting by bin­
ding to the dopamine receptors (D1, D2 & D4) in
the mesolimbic system of brain. It also has affini­
ty for histamine (HI), serotonin (5-HT2),
CNS DRUGS
muscarinic (M1) & adrenergic (a1) receptors.
Ind: Olanzapine is indicated for· the management
of schizophrenia and other psychotic disorders. It
is as effe.ctive as haloperidol against positive
symptoms & more effective against negative
symptoms in short-term & possibly in the long­
term.
Olanzapine is also indicated for the short-term
treatment of acute manic or mixed episodes of
manic depression. It is associated with a
relatively low incidence of extrapyramidal
disorders and is therefore being used in the
treatment of drug-induced psychosis in patients
with Parkinson's disease.
C/I: i. Patients with a known hypersensitivity to
the drug ii. Nursing mother iii. Patients with pre­
existing CNS depression or coma. iv. Narrow­
angle glaucoma v. Paediatric patients (under 18
years of age) vi. Patients with prolactin­
dependent tumors.
S/E: Frequent (>10%)- somnolence & weight
gain. Occasional (1-10% )- dizziness, increased
appetite, peripheral oedema, orthostatic hypoten­
sion, mild & transient anticholinergic effects like
constipation & dry mouth, elevated creatine
phosphokinase & hepatic transaminse concentra­
tion. Other features are tachycardia, hypertension.
Lower incidence- Parkinsonism, akathisia, dysto­
nia. Rare (<1%)- photosensitivity, hyper-prolacti­
naemia, back pain, articular impairment, fever.
Warnings: Development of neuroleptic
malignant syndrome (NMS)- immediate
discontinuation of the drug should be considered
& development of Tardive Dyskinesia due to
long-term use- drug discon-tinuation or dose
reduction should be done.
Precautions: Patients with known cardiovascular
disease (history of myocardial infarction,
ischemia, heart failure, conduction abnormali­
ties). Patients with a history of seizure. Patients
with hepatic impairment & who are being treated
with potentially hepatotoxic drug or in case of
elevation of hepatic transaminase. Patients
receiving concomitant medication with anti­
cholinergic drugs, being subject to dehydration
or exposure to extreme heat. Patients with low
leucocyte (neutrophil) count or hypereosinophilic
condition. Patient with bone marrow depres­
sion/toxicity due to drug, chemotherapy, radiation
or illness. Patient with clinically significant pro­
static hypertrophy, history of paralytic ileus, dia­
betes mellitus, hypotension, myasthenia gravis.
Patients with impaired kidney function. Elderly
patients with dementia.
Patient receiving Olanzapine therapy should be
cautious about operating hazardous machinery &
motor vehicles.
Pregnancy & lactation: When potential benefit
justifies the potential risk to the foetus. Patients
should notify their physician if they become
pregnant or intend to become pregnant during
the therapy (since there is no report to show
teratogenicity).
Dosage & Admin: Initial dose: 1Omg once
daily regardless of meal. Daily dosage may
subsequently be adjusted on the basis of indi­
vidual clinical status within the range of 5-
20mg once daily. Doses of 15mg or more daily
should be given only after appropriate clinical
reassessment.
CNS DRUGS
Metabolism rate of Olanzapine is slower in
Female, elderly (over 65 years of age) & non­
smokers. So, a lower initial & a more gradual
dose schedule should be considered.
Patients with renal impairment- starting dose
is Smg once daily.
Patients with hepatic impairment- starting
dose is Smg once daily & only increased with
caution.
Drug Inter: Drugs which inhibit or act as a
substrate to Cytochrome P450 isoenzymes or
glucoronyl transferase enzymes (omeprazole,
rifampicin, fluvoxamine), Dopamine agonists,
antihypertensives & antiarrhythmics (methyl
dopa, guanethidine, procainamide, quinidine),
tricyclic antidepressants (fluvoxamine.
fluoxetine), antiepileptics (phenobarbitone,
carbamazepine, phenytoin), Terfenadine.
t DEPREX Tab. Square
Olanzapine INN 5mg & 1 Omg/tablet
5mg x l OO's pack: 250.00 MRP
1Omg x l OO's pack: 450.00 MRP
t LOPEZ Tab. General
Olanzapine INN 5mg & 1 Omg/tablet
5mg x 50's pack: 125.00 MRP
1Omg x 50's pack: 200.00 MRP
t OLANAP Tab. Incepta
Olanzapine INN 5mg & lOmg/tablet
5mg x 50's pack: 125.00 MRP
lOmg x 50's pack: 225.00 MRP
t OLANZA Tab. Rephco
Olanzapine INN 5mg & l Omg/tablet
5mg x 20's pack: 30.00 MRP
1Omg x 20's pack: 50.00 MRP
t OLEANZ Tab. Sun Pharma
Olanzapine INN 5mg & 1 Omg/tablet
5mg x 50's pack: 127.50 MRP
1Omg x 50's pack: 227.50 MRP
t PERICAM Tab. Beximco
Olanzapine INN 5mg & 1 Omg/tablet
5mg x lOO's pack: 150.00 IP
1Omg x 1OO's pack: 251.00 IP
t XYTREX Tab. ACI
Olanzapine INN 5mg & 1 Omg/tablet
5mg x 50's pack: 125.50 MRP
l Omg x 50's pack: 225.00 MRP
QUETIAPINE26
QUETIAPINE FUMARATE: Tablet
'
Quetiapine is an atypical psychotropic agent
belonging to a chemical class, the dibenzothia­
zepine derivatives. It is available as quetiapine
fumarate INN equivalent to quetiapine 25mg &
l OOmg/tablet (film-coated).
Mode of action: Quetiapine is an antagonist at
multiple neurotransmitter receptors in the brain,
such as- serotonin 5HT1A and 5HT2, dopamine
D l and D2, histamine H l , and adrenergic 1 & 2
receptors. Quetiapine has no appreciable affinity
at cholinergic muscarinic and benzodiazepine
receptors. The actual mechanism of action of
quetiapine is unknown. However, it has been pro­
posed that this drug's efficacy in schizophrenia is
mediated through a combination of dopamine D2
and serotonin 5HT2 antagonism. Quetiapine's
antagonism of histamine H 1 receptors may
explain the somnolence and that of adrenergic
a1 receptors may explain the orthostatic
QIMP-17 (136)
hypotension observed with this drug.
Ind: Bipolar mania: Quetiapine is indicated for
the treatment of acute manic episodes associated
with bipolar I disorder, as either monotherapy or
adjunct therapy to lithium or divalproex.
Schizophrenia: Quetiapine is indicated for the
treatment of schizophrenia.
C/I: Known hypersensitivity to this medication
or any of its ingredients.
S/E: Somnolence, dizziness, dry mouth, constipa­
tion, dyspesia, postural hypotension, elevated
ALT (SGPT) levels, weight gain.
Precautions: Neuroleptic malignant syndrome,
tardive dyskinesia. Hypotension and syncope,
specially during the initial dose titration period.
Conduct eye examinations prior to or shortly
after starting quetiapine and at 6-month intervals
thereafter; doscontinue the drug if clinically
significant lens changes are observed. History of
seizures. Hypothyroidism. Hyperprolactinemia.
Antiemetic effect. Suicide. Use with great caution
in moderate or severe hepatic impairments. Renal
impairment. Cardiovascular disease. Disruption
of body temperature regulation. Hyperglycemia.
Lactation (avoid breast-feeding).
Pregnancy & lactation: Quetiapine should be
used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.
Nursing mothers receiving quetiapine should not
breast feed.
Dosage & admin: Bipolar mania: As mono­
therapy or as adjunct therapy with other anti­
psychotic drugs: 1st day- 50mg twice daily;
2nd day- lOOmg twice daily; 3rd day- 150mg
twice daily; 4th day- 200mg twice daily; 5th
day- 300mg twice daily; 6th day- 400mg twice
daily.
Data indicates that the majority of patients
responded between 400mg to 800mg/day. The
safety of doses above 800mg/day has not been
evaluated in clinical trials.
Schizophrenia: Usual dose: Quetiapine should
generally be administered with an initial dose
of 25mg twice daily, with increments of 25-
50mg twice daily or thrice daily on the second
and third day, as tolerated, to a target dose
range of 300mg to 400mg daily by the 4th day,
given twice daily or thrice daily. Further
dosage adjustments- if indicated, should gen­
erally occur at intervals of not less than 2
days, as steady-state for quetiapine would not
be achieved for approximately 1-2 days in the
typical patient. When dosage adjustments are
necessary, dose increments/decrements of 25-
50mg twice daily are recommended. Most effi­
cacy data with quetiapine were obtained using
thrice daµy regimens, but in one controlled
trial 225mg twice daily was also effective.
Physician who elects to use quetiapine for
extended periods should periodically re­
evaluate the long-term usefulness of the drug
for the individual patient.
Pediatric use: The safety and effectiveness of
quetiapine in pediatric patients less than 18
years have not been established.
Drug inter: May enhance the effects of other
centrally acting drugs, certain antihypertensive
agents; may antagonize the effects of dopamine
agonists ans levodopa. Increased clearance of
quetiapine by phenytoin, barbiturates, rifampicin,
carbamazepine. Increased concentrations of
quetiapine with azole antifungals and macrolide
antibiotics.
t QMAX Tab. ACI
Quetiapine fumarate INN equivalent to
quetiapine 25mg & l OOmg/tablet (film-coated).
25mg x 30's pack: 90.00 MRP
1 OOmg x 30's pack: 300.00 MRP
+ QPINE Tab. Sanofi-aventis
Quetiapine fumarate INN equivalent to
quetiapine 25mg & l OOmg/tablet (film-coated).
25mg x l OO's pack: 301.01 MRP
1 OOmg x 30's pack: 301.20 MRP
+ QUIET Tab. Incepta
Quetiapine fumarate INN equivalent to
quetiapine 25mg & lOOmg/tablet (film-coated). I
25mg x 50's pack: 150.00 MRP
1 OOmg x 50's pack: 500.00 MRP
+ QUTIPIN Tab. Sun Pharma
Quetiapine fumarate equivalent to quetiapine
25mg & 1OOmg/tablet (film-coated).
25mg x 50's pack: 150.00 MRP
1 OOmg x 50's pack: 502.50 MRP
t T IAPINE Tab. General
Quetiapine fumarate INN equivalent to
quetiapine 25mg & 1OOmg/tablet (film-coated).
25mg x 50's pack: 150.00 MRP
1 OOmg x 30's pack: 301.20 MRP
RISPERIDONE106
RISPERIDONE: Tablet/Injection
Risperidone is an atypical antipsychotic drug. It
is available as- l mg, 2mg & 4mg oral tablet;
25mg, 37.5mg & 50mg long acting injection.
Ind: Risperidone is indicated for any patient with
schizophrenia including affective symptoms, who
requires long-term antipsychotic therapy.
Risperidone is also indicated in other psychotic
conditions where positive and/or negative symp­
toms are prominent. Also, behavioural disturba­
nces in patients with dementia where aggressive
symptoms (verbal outbursts, physical violence),
activity disturbances (agitation, wandering) or
psychotic symptoms are prominent.
C/I: Hypersensitivity to the drug.
S/E: Generally well tolerated. Commonly­
insomnia, agitation, anxiety, headache. Less com­
monly- somnolence, fatigue, dizziness, impaired
concentration, constipation, dyspepsia, nau­
sea/vomiting, abdominal pain, blurred vision, pri­
apism, erectile/ejaculatory dysfunction, orgasmic
dysfunction, urinary incontinence, rhinitis, rash,
allergic reactions. EPS are usually mild nad
reversible. Rarely- neuroleptic malignant syn­
drome. Occasionally- orthostatic dizziness,
hypotension (including orthostatic), tachycardia
(including reflex) and hypertension observed..
Raised plasma prolactin with associated galactor­
rhoea, gynaecomastia and menstrual cycle distur­
bances. Edema and increased hepatic enzyme
levels. A mild fall in neutrophil and/or thrombo­
cyte count has been reported. Rarely- water
intoxication with hyponatremia, tardive dyskine­
sia, body tempe rature dysregulation and seizures.
Precautions: Orthostatic hypotension.
Cardiovascular disease. Reduce dose if hypoten­
sion. If tardive dyskinesia, consider stopping all
antipsychotic durgs. Parkinson's disease.

Epilepsy. Advise of potential for weight gain.
Advise not to drive or operate machinery if
alertness affected.
Pregnancy & lactation: In pregnancy only if
benefits outweigh the risks. In lactation, avoid
the drug.
Dosage & admin: By mouth:
Adults: Start with 2mg daily in single or two
divided doses; may be increased to 4mg/day on
the second day. Some patients slower in initia­
tion. Maintain unchanged, or adjust if needed.
Most patients benefit from doses of 4-6mg/day,
but an optimal response may be obtained at
lower doses. Above lOmg/day may increase
extrapyramidal symptoms risk, consider risks
vs benefits. Maximum dose 16mg/day.
Elderly, renal & liver disease: Start with 0.5mg
twice daily; adjust by 0.5mg twice daily to1-
2mg thrice daily.
Behavioural disturbances in patients with
dementia: Start with 0.25mg twice daily;
adjust by 0.25mg twice daily every other day.
Optimum- 0.5mg twice daily; some may
benefit from lmg twice daily. Once target is
achieved, consider once daily dosing. Review
regularly, discontinue if no benefit seen or
intolerance occurs. Well tolerated in elderly.
By injection:
Recommended starting dise:
If the patient previously on <4mg/day of oral
risperidone, start with risperidone injection
25mg i.m by every 2 weeks interval.
If the patient previously on 2:,4mg/day of oral
risperidone, start with risperidone injection
37.5mg i.m by every 2 weeks interval.
Risperidone injection ensures long-acting
efficacy and tolerability with continuous
administration of the drug.
Caution in renal and liver diseases.
Children: Not recommended.
Drug inter: Caution with centrally acting drugs.
May antagonise effects of dopamine agonists. If
starting or stopping hepatic enzyme-inducing
drugs, re-evaluate dose.
Phenothiazines, tricyclic antidepressants and
some beta-blockers may increase the plasma
concentration of risperidone but not those of the
antipsychotic fraction. Fluoxetine may increase
the plasma concentration of risperidone but less
so of the antipsychotic fraction.
+ FRENIA Tab. Incepta
Risperidone INN 1 mg, 2mg & 4mgltablet.
l m g x 50's pack: 100.00 MRP
2mg x 50's pack: 150.00 MRP
4mg x 30's pack: 165.00 MRP
+ RESCO Tab. Drug Inter.
Risperidone INN 1 mg & 2mg/tablet.
lmg x 50's pack: 75.00 MRP
2mg x 50's pack: 100.00 MRP
+ RISCORD Tab. General
Risperidone INN lmg, 2mg & 4mg/tablet.
l m g x 50's pack: 100.00 MRP
2mg x 30's pack: 90.00 MRP
4mg x 30's pack: 165.00 MRP
+ RISDON Tab. UniMed & UniHealth
Risperidone INN l mg, 2mg & 4mg/tablet.
l m g x 30's pack: 90.00 MRP
2mg x 30's pack: 150.00 MRP
4mg x 30's pack: 270.00 MRP
QIMP-17 (137)
+ RISPA Tab. Orion Pharma
Risperidone INN l m g & 2mg/tablet.
l m g x 50's pack: 150.00 MRP
2mg x 50's pack: 250.00 MRP
+ RISPERDAL CONSTA Inj. Janssen­
Cilag/UniHealth
Risperidone 25mg, 37.5mg & 50mg/vial: long
acting injection.
25mg vial x l 's pack: 9413.42 MRP
37.5mg vial x 1 's pack: 12521.23 MRP
50mg vial x l's pack: 18826.82 lv!RP
+ RISPERDEX Tab. Opsonin
Risperidone INN lmg & 2mg/tablet.
1mg x 50's pack: 66.42 MRP
2mg x 50's pack: 88.41 MRP
+ RISPOLUX Tab. Sandoz
Risperidone INN lmg, 2mg & 4mg/tablet.
lmg x l OO's pack: 310.00 MRP
2mg x 1 OO's pack: 510.00 MRP
4mg x 30's pack: 273.00 MRP
+ SIZODON Tab. Sun Pharma
Risperidone INN 1mg, 2mg & 4mgltablet.
l mg x 50's pack: 150.00 MRP
2mg x 1 OO's pack: 600.00 MRP
4mg x 50's pack: 450.00 MRP
+ SPERID Tab. Renata
Risperidone INN l m g & 2mg/tablet.
lmg x 50's pack: 75.00 MRP
2mg x 50's pack: 100.00 MRP
ZIPRASIDONE130
ZIPRASIDONE: Capsule
Ziprasidone INN 20mg & 40mg/capsule.
Ziprasidone is well absorbed after oral
administration; the absorption is increased upto
two-fold in the presence of food. Elimination of
ziprasidone is mainly via hepatic metabolism.
Ind: Ziprasidone is indicated for the treatment of
schizophrenia.
C/I: Ziprasidone is contraindicated in patients
with a known history of QT prolongation, with
recent acute myocardial infarction, or with
uncompensated heart failure.
S/E: The most common side effects are rash,
asthenia, postural hypotension, anorexia, dry
mouth, increased salivation, arthralgia, anxiety,
dizziness, dystonia, hypertonia, somnolence,
tremor, rhinitis and abnormal vision.
Precautions: Ziprasidone should be used with
caution in patients with known cardiovascular
disease including those associated with
prolongation of QT interval.
Pregnancy & lactation: It should be used with
caution during pregnancy and only if the
expected benefit to the mother is greater than the
possible risk to the fetus. It is excreted into breast
milk; so, mothers should avoid using ziprasidone
while breast-feeding.
Dosage & admin: Ziprasidone should be
administered at an initial dose of 20mg twice
daily with food. In some patients, daily dosage
may subsequently be adjusted on the basis of
individual clinical status up to 80mg twice
daily; Or, as directed by the physician.
Drug inter: Ziprasidone may enhance the effects
of certain antihypertensive agents, may antago­
nize the effects of levodopa & dopamine agonists.
CNS DRUGS
+ ZIPRADON Cap. Drug In�er.
Ziprasidone INN 20mg & 40mg/capsule.
20mg x 50's pack: 250.00 MRP
40mg x 30's pack: 300.00 MRP
Antimanic drugs: Lithium salt
LITHIUM CARBONAT E21,68
LITIDUM CARBONATE: Tablet.
Ind: Acute ·mania; prevention of manic
depressive illness (prophylaxis of recurrent
effective disorders).
C/I: Pregnancy, lactation. Addison's disease.
Hypothyroidism, renal or cardiac disease.
Conditions disturbing sodium balance.
S/E: Mild gastro-intestinal disturbances, fine
tremor, polyuria, polydipsia; also weight gain and
oedema.
Toxicity: Signs of Lithium intoxications are
blurred vision, increasing g.i disturbances
(anorexia, vomiting, diarrhoea), increasing CNS
disturbances (mild drowsiness & sluggishness
increasing to giddiness with ataxia, coarse ,
tremor, lack of co-ordination, disarthria). Require
withdrawal of treatment .
With severe overdosage (blood level 2mmol/L ),
hyperreflexia and hyper extension of limbs, fits,
toxic psychoses, syncope, oliguria, circulatroy
failure, coma and occasionlally death.
Cautions: Treatment should be initiated in
hospital. Concurrent admin. of diuretics .
Maintain adequate salt and fluid intake . Monitor
thyroid function.
Dosage & admin: Adult: Acute mania, 0.25-
2gm daily in divided doses, adjust the dose by
daily blood tests to maintain a serum lithium
level in range 0.6-1.2 mmol/L12 hours after
last dose for 5 to 7 days. Prophylaxis, 0.25-1.2
gm daily in divided doses, adjust the dose to
minatiain a serum level in range 0.5-1 mmol/L
for first 7 days.
Elderly, usually 0.5-lgm/day given in divided
doses.
Child: Not recommended.
Overdosage: No specific antidote. Elimination
of lithium can be facilitated by infusion of sodi­
bicarbnonate, acetazolamide, urea or mannitol.
Continuous peritoneal dialysis may be effective.
+ LITHOSUN SR Tab. Sun Pharma
Lithium carbonate 400mg/tablet. (sust. release).
50's pack: 252.50 MRP
+ LIT IAM ER Tab. ACI
Lithium carbonate 400mg/tablet. (ext. release).
40's pack: 200.00 MRP
4. ANTIDEPRESSANT
DRUGS21
Antidepressants are the drugs effective in the
treatment of moderate to severe depression
associated with psychomotor and physiological
changes such as loss of appetite and sleep.
Normally mild depression is not advised to
treat with any antidepressant, initial psycho­
therapy may suffice it.

CNS DRUGS
The major classes of antidepressant drugs
include:
4.1 Tricyclic & related antidepressant drugs
a. Tertiary amines
b. Secondary amines
c. Piperazine
d. Triazolepyridine
4.2 Monoamine-oxidase inhibitors (MAOls)­
such as Phenelzine, lsocarboxazid,
Tranylcypromine.
Reversible MAOis- such as Moclobemide.
4.3 Selective serotonin re-uptake inhibitors­
such as Citalopram, Fluoxetine,
Fluvoxamine, Paroxetine, Sertraline etc.
4.4 Other Antidepressants- such as
Agomelatine, Bupropion, Duloxetine,
Flupenthixol, Mirtazapine, Tryptophan,
Trazodone, Venlafaxine.
Tricyclic & related
Antidepressants
Tricyclic antidepressants: These drugs include­
,Amitriptyline, Clomipramine, Dosulepin,
Doxepin, Imipramine, Lofepramine,
Nortriptyline, Trimipramine.
Related antidepressants: These include­
Maprotiline, Mianserin, Trazodone.
AMITRIPTYLJNE2I,33
AMITRIPTYLINE HCI : Tablet/Capsule/
Syrup/Injection.
Amitriptyline is a tricyclic antidepressant drug,
used in the treatment of depressive illness particu­
larly with anxiety. It is available as- amitriptylline
hydrochloride USP 1Omg & 25mg/tablet; also
available as capsule, syrup & injection.
Ind: Depressive illness particularly with anxiety
(where sedation is required), nocturnal enuresis
in children.
C/I: Acute myocardial infarction; heart block;
mania; pregnancy, severe liver disease.
S/E: Dry mouth, blurred vision, constipation,
difficulty in micturition; sedation; postural
hypotension, tachycardia, syncope partricularly
with high doses. Sweating, tremor, rashes;
behavioral disturbances (particularly in children);
interference with sexual function etc.
Cautions: Cardiovascular disease, liver
disorders, hyperthyroidism, epilepsy, diabetes;
psychoses, patients with suicidal tendencies.
Alertness may be impaired. Reduce doses for the
elderly; extreme caution in glaucoma.
Dosage & admin: By mouth: Adult, initially
75mg (elderly 10-50mg) daily in divided doses
or as a single dose at night, increasing if reqd.
to max. 200mg daily. Usual maintenance, 50-
1OOmg at night.
Nocturnal enuresis-child 7-10 years 10-20mg,
11-16 years 25-50mg at night for maximum
3 months.
By injection: By i.m. or i.v. injection 20-30mg 4
times daily.
+AMILIN Tab. Opsonin
Amitriptylline hydrochloride 1Omg & 25mg/tablet.
lOmg x l OO's pack: 43.97 MRP
25mg x 1 OO's pack: 70.34 MRP
QIMP-17 (138)
+AMIT Tab. General
Amitriptylline hydrochloride 1 Omg & 25mg/tablet.
1 Omg x 1OO's pack: 56.00 MRP
25mg x l OO's pack: 100.00 MRP
+AMITRIPTYLINE Tab. GlaxoSmithKline
Amitriptylline hydrochloride 25mg/tablet.
25mg x 500's bot: 400.99 MRP
+AMTYLIN Tab. Edruc
Amitriptylline hydrochloride USP 1 Omg &
25mg/tablet.
lOmg x l OO's pack: 50.00 MRP
25mg x l OO's pack: 80.00 MRP
+TRIP 10 Tab. Medicon
Amitryptyline 1Omg/tablet
lOmg x l OO's pack: 50.00 MRP
+TRYPTIN Tab. Square
Amitryptyline 1Omg & 25mg/tablet
lOmg x 200's pack: 110.00 MRP
25mg x 200's pack: 200.00 MRP
CLOMIPRAMINE21
CLOMIPRAMINE: Tablet/Capsule/Syrup/
Injection.
Ind: Depression, obsessive compulsive disorder,
phobic & obsessional states; adjunctive treatment
of cataplexy associated with narcolepsy.
C/I; S/E; Caution: See under amitriptyline.
Dosage & admin: By mouth, initially lOmg
daily, increased gradually as necessary to 30-
1 SOmg daily in divided doses or as a single
dose at bedtime; max. 250mg daily; usual
maintenance 30-50mg daily; Elderly initially
I Omg daily, increased to 30-50mg daily; Child
not recommended.
Phobic and obsessional states, initially 25mg
daily (elderly lOmg daily) increased over 2
weeks to 100-150mg daily; Child not
recommended.
Adjunctive treatment of cataplexy associated
with narcolepsy, initially lOmg daily, gradually
increased until satisfactory response (range
10-50mg daily).
By i.m injection, initially 25-50mg daily,
increased by 25mg daily to 100-150mg daily;
Child not recommended.
By i.v infusion (careful monitoring see cau­
tion), initially to assess tolerance, 25-50mg,
then increase by 25mg daily to usual dose of
lOOmg daily for 7-10 days; Child not recom­
mended.
+ ANAFRANIL Tab. Novartis
Clomipramine hydrochloride 25mg/tablet.
50's pack: 325.00 MRP
+CLOFRANIL Tab. Sun Pharma
Clomipramine hydrochloride 25mg/tablet.
50's pack: 275.00 MRP
+TIMEX Tab. Orion Pharma
Clomipramine hydrochloride 25mg/tablet.
30's pack: 150.00 MRP
DOXEPIN141
DOXEPIN HYDROCHLORIDE: Capsule
Doxepin hydrochloride is one of a class of psy­
chotherapeutic agents known as dibenzoxepin tri­
cyclic compounds. Chemically, doxepin hydroch­
loride is a dibenzoxepin derivative and is the first
•
of a family of tricyclic psychotherapeutic agents.
It i s available as doxepin hydrochloride USP
equivalent to 75mg of doxepin in capsule.
Ind: Doxepin hydrochloride is recommended for
the treatment of: 1. Psychoneurotic patients with
depression and/or anxiety; 2 . Depression and/or
anxiety associated with alcoholism (not to be
taken concomitantly with alcohol); 3. Depression
and/or anxiety associated with organic disease
(the possibility of drug interaction should be
considered if the patient is receiving other drugs
concomitantly); 4. Psychotic depressive disorders
with associated anxiety including involutional
depression and manic-depressive disorders.
C/I: Doxepin is contraindicated in individuals
who have shown hypersensitivity to the drug.
Possibility of cross sensitivity with other
dibenzoxepines should be kept in mind.
Doxepin is contraindicated in patients with
glaucoma or a tendency to urinary retention.
These disorders should be ruled out, particularly
in older patients.
S/E: Nausea, vomiting, indigestion, taste distur­
bances, diarrhea, anorexia, dry mouth, blurred
vision, constipation, drowsiness, confusion, dis­
orientation, hallucinations, numbness, paresthe­
sias, ataxia, extrapyramidal symptoms, seizures,
tremor and urinary retention have been reported.
Cardiovascular effects including hypotension,
hypertension, and tachycardia have been reported
occasionally. Skin rash, edema, photosensiti74-
tion, and pruritus have occasionally occurred.
Eosinophilia has been reported in a few patients.
There have been occasional reports of bone mar­
row depression manifesting as agranulocytosis,
leukopenia, thrombocytopenia, and purpura.
Raised or lowered libido, testicular swelling,
gynecomastia in males, enlargement of breasts
and galactorrhea in the female, raising or lower­
ing of blood sugar levels and syndrome of inap­
propriate antidiuretic hormone secretion have
been reported with tricyclic administration.
Dizziness, tinnitus, weight gain, sweating, chills,
fatigue, weakness, flushing, jaundice, alopecia,
headache, exacerbation of asthma & hyperpyrex­
ia (in association with chlorpromazine) have been
occasionally observed as adverse effects.
Precautions: Patients, their families and their
attendents should be encouraged to be alert to the
emergence of anxiety, agitation, panic attacks,
insomnia, irritability, hostility, aggressiveness,
impulsivity, akathisia (psychomotor restlessness),
hypomania, mania, other unusual changes in
behavior, worsening of depression, and suicidal
ideation, specially early during antidepressant
treatment and when the dose is adjusted up or
down. Families and caregivers of patients should
be advised to look for the emergence of such
symptoms on a day to day basis, since changes
may be abrupt. Such symptoms should be •
reported to the patient's doctor specially if they
are severe, abrupt in onset, or were not part of the
patient's presenting symptoms. Symptoms such
as these may be associated with an increased risk
for suicidal thinking and behavior and indicate a
need for very close monitoring and possibly
changes in the medication.
Pregnancy & lactation: In animal studies, there
was no evidence of harm to the animal fetus. The
relevance to humans is not known. Since there is

no experience in pregnant women who have
received this drug, safety in pregnancy has not
been established. There has been a report of
apnea and drowsiness occurring in a nursing
infant whose mother was talcing doxepin.
Dosage & admin: Mild to moderate illness, a
starting daily dose of 75mg is recommended.
Dosage may subsequently be increased or
decreased at appropriate intervals and accord­
ing to individual response. The usual optimum
dose range is 75mg/day to 150mg/day.
In more severe illness, higher doses may be
required with subsequent gradual increase to
300mg/day if necessary. Additional therapeutic
effect is rarely to be obtained by exceeding a
dose of 300mg/day.
In patients with very mild symptomatology or
emotional symptoms accompanying organic
disease, lower doses may suffice. Some of these
patients have been controlled on doses as low
as 25mg to 50mg/day.
The total daily dosage of doxepin (as
hydrochloride) may be given on a divided or
once a day dosage schedule. If the once a day
schedule is employed the maximum recom­
mended dose is 150mg/day. This dose may be
given at bedtime. The 150mg capsule strength
is intended for maintenance therapy only & is
not recom1nended for initiation of treatment.
Children: Not recommended.
t ADNOR Cap. Apex
Doxepin hydrochloride USP equivalent to 75mg
of doxepin/capsule.
28's pack: 140.00 MRP
IMIPRAMINE2t,33
IMIPRAMINE: Tablet/ Syrup/ Injection.
Ind: Depression; adjunct in chronic rheumatic
pain. Nocturnal enuresis in children.
C/I; S/E; Cautions: See under Amitriptyline, but
less sedative & s/e occurs more frequently.
By mouth: Adult, 25mg 3 times daily for 3
days, increasing to 50mg 3 or 4 times daily.
Elderly, initially lOmg at night increasing to
10-25mg 3 times daily.
Children: Under 6 yrs. not recommended; 6-7
yrs. 25mg; 8-11 yrs. 25-SOmg ; over 11 yrs. 50-
75mg. All at bedtime for 6-8 wks. then
gradually withdraw therapy.
+ DEPRAM Tab. Square
Imipramine hydrochloride 25mg/tablet.
50's pack: 200.00 MRP
+ PINOR Tab. Aristopharma
Imipramine hydrochloride 25mg/tablet.
lOO's pack: 400.00 MRP
+ PRAMIN Tab. Incepta
Imipramine hydrochloride 25mg/tablet.
•
50's pack: 100.00 MRP
+ TOFRANIL Tab. Sandoz
Imipramine hydrochloride 25mg/tablet
1OO's pack: 550.00 MRP
33
NORTRIPTYLINE 21,
NORTRIPTYLINE: Tablet/Capsule/Syrup.
Ind: Depressive illness, nocturnal enuresis in
children.
QIMP-17 (139)
C/I; S/E; Cautions: Same as Imipramine.
Adult: 20-40mg daily in divided doses
increasing if necessary to lOOmg daily. Usual
maintenance. 30-75mg daily.
Elderly: Initially 1 Omg 3 times daily.
Child: Enuresis, under 6 yrs. not recommended;
over 6 yrs.10-35 mg 30mins. before bedtime.
+ NORTIN Cap. Navana
Nortriptyline 1Omg & 25mg/capsule.
l Omg x lOO's pack: 63.00 MRP
25mg x lOO's pack: 85.00 MRP
Related Antidepressant
MAPROTILINE2 l ,33
MAPROTILINE:Tablet
Ind: All forms of depression particularly with
anxiety.
C/I; S/E; Caution: See under a.mitriptylline but
less sedating & anticholinergic effects occur less
frequently. Rashes commonly occur & there is an
increased risk of convulsions at higher dosage.
Dosage & admin: Adults: Initially 25-75mg
daily in one dose (usually at night) or 3
divided doses, adjusting after 1-2 weeks as
necessary. Maximum 150mg daily.
Elderly: Initially 30mg at night or lOmg 3
times dialy.
Child: Not recommended.
+ LUDIOMIL Tab. Sandoz
Maprotiline hydrochloride 25mg/tablet
50's pack: 325.00 MRP
MIANSERIN
MIANSERIN HCl: Tablet
Prepn: May not be available.
M onoamine-oxidase inhibitors
(MAOIs)
Monoamine-oxidase inhibitors (MAOis):
These include-
Phenelzine, Isocarboxazid, Tranylcypromine.
Reversible MAOis : Such as- Moclobemide.
Note: Prep�rations not yet available in our
country.
Selective serotonin re-uptake
inhibitors (SSRls)
Selective serotonin re-uptake inhibitors
(SSRis) include- Citalopram, Escitalopram,
Fluoxetine, Fluvoxamine, Paroxetine,
Sertraline etc.
CITALOPRAM26
CITALOPRAM: Tablet
Citalopram is an orally administered selective
serotonin reuptake inhibitor (SSRI) with a
CNS DRUGS
chemical structure unrelated to that of other
SSRis, tricyclic, tetracyclic or _other available
antidepre-ssant agents.
Mode of action: The mechanism of action of
citalopram as an antidepressant is presumed to be
linked to potentiation of serotonergic activity in
central nervous system resulting from its inhibition
of CNS neuronal reuptake of serotonin (5-HT).
Ind: Citalopram is indicated for depressive
illness and panic disorder. It is also indicated in
substance abuse disorders and alcohol
dependence. Citalopram has also been given in
variety of anxiety disorders including obsessive­
compulsive disorder and social phobia. It is also
effective in generalized anxiety disorder, post­
traumatic stress disorder, premenstrual syndrome,
idiopathic Parkinson's disease and eating disorder.
C/I: Citalopram should not be used if the patient
enters a manic phase. Patients taking MAO
inhibitors. Hypersensitivity to the drug or any of
its ingredients.
S/E: SSRis are less sedating and have fewer
antimuscarinic and cardiotoxic effects than tri­
cyclic antidepressants. However, side-effects may
be seen, include gastro-intestinal effects, such as
nausea, vomiting, dyspepsia, abdominal pain,
diarrhea, constipation; anorexia with weight loss,
palpitations, tachycardia, postural hypotension,
cough, confusion, impaired concentration,
amnesia, urinary retention, sweating, movement
disorders, urticaria, anaphylaxis, arthralgia,
myalgia and photosensitivity.
Precaution: Caution should be taken in patients
with epilepsy, concurrent electroconvulsive
therapy, history of mania, cardiac disease,
diabetes mellitus, angle-closure glaucoma,
history of bleeding disorders, hepatic and renal
impairment. Abrupt withdrawal of citalopram
should be avoided.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women,
therefore, citalopram should be used during preg­
nancy only if the potential benefit justifies the
potential risk to the fetus. Citalopram is excreted
in human breast milk, so, a decision should be
made whether to discontinue nursing or to dis­
continue citalopram therapy, taking into account
the importance of the treatment for the mother.
Dosage & admin: Depressive illness- 20mg
daily as a single dose in the morning or
evening; increased if necessary to maximum
60mg daily (elderly, maximum 40mg daily).
Panic disorder- initially lOmg daily, increased
to 20mg after 7 days; usual dose 20-30mg
daily; maximum 60mg daily (elderly,
maximum 40mg daily).
Drug inter: Ketoconazole, itraconazole or
macrolide antibiotics and citalopram co­
administration decreases the metabolism of the
later. Co-administration with omeprazole might
decrease the clearance of citalopram.
+ ARPOLAX Tab. Incepta
Citalopram hydrobromide INN equivalent to
citalopram 20mg/tablet.
20mg x 30's pack: 240.00 MRP
t CITAPRAM Tab. General
Citalopram hydrobromide INN equivalent to
citalopram 1 Omg & 20mg/tablet.
I Omg x 50's pack: 251.00 MRP
20mg x 30's pack: 240.9J> MRP

CNS DRUGS
ESCITALOPRAM42
ESCITALOPRAM: Tablet
Escitalopram oxalate INN lOmg/tablet (film­
coated tablet).
Escitalopram oxalate is an orally administered
selective serotonin reuptake inhibitor (SSRl). It
is the pure s-enantiomer of the recemic bicyclic
phthalane derivative of citalopram.
Mode of action: The mechanism of
antidepressant action of escitalopram is presumed
to be linked to potentiation of serotonergic
activity in the central nervous system resulting
from its inhibition of CNS neuronal reuptake of
serotonin (5HT). Escitalopram is highly selective
serotonin reuptake inhibitor (SSRl) with minimal
effects on norepinephrine and dopamine neuronal
reuptake. It is at least 100 times more potent than
the R-enantiomar with respect to inhibtion of 5-
HT reuptake and inhibition of 5-HT neuronal
firing rate. Escitalopram has no or very low
affinity for serotonergic (5-HT 1-7) or other
receptors including alpha- and beta-adrenergic,
dopamine (Dl-5), histamine ( H l -3), muscarinic
(Ml-5) and benzodiazepine receptors.
Ind: Escitalopram oxalate is indicated for the
treatment of major depressive disorder and main­
tenance therapy to prevent people with depres­
sion from suffering a relapse. A major depressive
episode implies a prominent and relatively per­
sistent (nearly every day for at least 2 weeks)
depressed or dysphoric mood that usually inter­
feres with daily functioning, and includes at least
five of the following nine symptoms: depressed
mood, loss of interest in usual activities, signifi­
cant change in weight and/or appetite, insomnia
or hypersomnia, psychomotor retard.ation or agi­
tation, increased fatigue, feelings of guilt or
worthlessness, slowed thinking or impaired con­
centration, a suicide attempt or suicidal ideation.
C/I: Concomitant use in patients taking MAO
inhibitor is contraindicated. This is contraindicat­
ed in patients with known hypersensitivity to
escitalopram oxalate or citalopram. If a patient
enters a manic phase, escitalopram oxalate should
be discontinued. As with all drugs effective in the
treatment of major depressive disorder, escitalo­
pram should be used cautiously in patients with a
history of mania. Escitalopram oxalate should be
used with caution in patients with a history of
seizure disorder. Rarely, the occurrence of
serotonin syndrome has been reported in patients
receiving SSRls. A combination of symptoms,
possibly including agitation, confusion, tremor,
myoclonus and hyperthermia, may indicate the
development of this condition. The use of
citalopram in hepatically impaired patients
should be approved with caution and a lower
maximum dosage ( lOmg/day) is recommended.
Clinical experience with escitalopram in patients
with concomitant systemic illness is limited.
Escitalopram should be used with caution in dia­
betic patients on insulin or other antidiabetic
drugs.
S/E: The following adverse reactions have been
reported: agitation or restlessness, blurred vision,
diarrhea, indigestion, nausea, increased or
decreased appetite, increased sweating, sexual
difficulties (decreased sexual ability or desire,
ejaculatory delay), taste alterations, tremor
QIMP-17 (140)
(shaking), weight changes.
Pregnancy & lactation: The safety of
escitalopram during pregnancy and lactation has
not been established. Therefore, escitalopram
should not be used during pregnancy, unless, in
the opinion of the concerned physician, the
expected benefits to the patient markedly
outweigh the possible hazards to the fetus.
Escitalopram is excreted in human milk, so, it
should not be administered to nursing mothers
unless, in the opinion of the treating physician,
that the expected benefits to the patient markedly
outweigh the possible hazards to the child.
Dosage & admin: Adults: The initial dose of
escitalopram oxalate is lOmg once daily. (A
fixed dose trial of escitalopram oxalate
demonstrated the effectiveness of both lOmg
and 20mg of escitalopram, but failed to
demonstrate a greater benefit of 20mg over
lOmg). If the dose is increased to 20mg, this
should occur after a minimum of one week.
Elderly: A single oral dose of lOmg/day is the
recommended dose for most elderly patients.
No significant differences in safety or
effectiveness between the elderly group (age
65 and over) and the younger subjects ware
observed, but greater sensitivity of some
elderly individuals could not be ruled out.
Administering in excess of recommended dose
has not been yet established.
Children: Safety and effectiveness in children
below the age of 18 years have not been
established.
Drug inter: Concomitant use in patients taking
MAO inhibitor is contraindicated. Escitalopram
should be used with caution in diabetic patients
on insulin or other antidiabetic drugs.
+ CITALEX Tab. Opsonin
Escitalopram oxalate INN equivalent to
escitalopram lOmg/tablet (film-coated).
1Omg x 20's pack: 141.28 MRP
+ CITALON Tab. Popular
Escitalopram oxalate INN equivalent to
escitalopram 1Omg/tablet (film-coated).
lOmg x 30's pack: 240.90 MRP
+ ESIPRAM Tab. Incepta
Escitalopram oxalate INN equivalent to
escitalopram 5mg & IOmg/tablet (film-coated).
5mg x 30's pack: 165.00 MRP
IOmg x 30's pack: 300.00 MRP
+ ESITA Tab. Healthcare
Escitalopram oxalate INN equivalent to
escitalopram 5n1g & 1Omg/tablet (film-coated).
5mg x 20's pack: 140.00 MRP
1Omg x 30's pack: 360.00 MRP
+ LOSITA Tab. SK+F
Escitalopram oxalate INN equivalent to
escitalopram 5mg & lOmg/tablet (film-coated).
5mg x 40's pack: 240.00 MRP
lOmg x 20's pack: 200.00 MRP
+ MELIVA Tab. Jayson
Escitalopram oxalate INN equivalent to
escitalopram lOmg/tablet (film-coated).
lOmg x 30's pack: 240.90 IP
+ NEXCITAL Tab. UniMed & UniHealth
Escitalopram oxalate INN equivalent to
escitalopram 5mg & 1Omg/tablet (film-coated).
5mg x 30's pack: 165.00 MRP
1Omg x 30's pack: 300.00 MRP
+ NEXITO Tab. Sun Pharma
,.....
Escitalopram oxalate INN equivalent to
escitalopram 5mg & 1Omg/tabl�t (film-coated).
5mg x 50's pack: 275.00 MRP
lOmg x 30's pack: 300.00 MRP
+ OXAPRO Tab. Square
Escitalopram oxalate INN equivalent to
escitalopram 5mg & 1Omg/tablet (film-coated).
5mg x 30's pack: 165.60 MRP
1Omg x 30's pack: 300.00 MRP
+ S-CITAPRAM Tab. General
Escitalopram oxalate INN equivalent to
escitalopram Smg & lOmg/tablet (film-coated).
5mg· x 30's pack: 210.00 MRP
lOmg x 20's·pack: 200.80 MRP
+ SEROPAM Tab. Beximco
Escitalopram oxalate equivalent to escitalopram
5mg & lOmg/tablet (film-coated).
5mg x 30's pack: 165.00 I P
1Omg x 30's pack: 240.00 IP
+ TALOPRAM Tab. Navana
Escitalopram oxalate Smg & IOmg/tablet (film­
coated).
5mg x 30's pack: 150.00 MRP
lOmg x 30's pack: 240.00 MRP
FLUOXETINE2 l ,33
FLUOXETINE: Capsule/Tablet
Fluoxetine is a selective serotonin re-uptake
inhibitor (SSRl). It is available as- fluoxetine
hydrochloride 20mg capsule & tablet.
Mode of action: It acts by selectively inhibiting
the re-uptake of serotonin (5-
hydroxytryptamine), and considered to be an
effective antidepressant preparation.
Ind: Depressive ilness, bulimia nervosa,
obsessive-compulsive disorder.
C/I: SSRI preparations should not be giv�n in the
patients entering a manic phase.
S/E: Gastro-intestinal (fairly common- include
nausea, vomiting, dyspepsia, abdominal pain,
diarrhoea, constipation, anorexia with weight loss
and possible changes in blood sugar); hypersensi­
tivity reactions (important: see also below); also
dry mouth, nervousness, anxiety, headache,
insomnia, palpitations, tremor, confusion, dizzi­
ness, hypotension, hypomania or mania, drowsi­
ness, asthenia, convulsions, fever, sexual dysfun­
ction, sweating; movement disorders and dyski­
nesias, neuroleptic malignant sydrome-like event;
hyponatraemia (may be due to inappropriate
antidiuretic hormone secretion-SIADH), abnor­
mal liver function tests reported; also reported
(no causal relationship established)- aplastic
anaemia, cerebrovascular accident, ecchymoses,
eosinophilic pneumonia, gastro-intestinal hemor­
rhage, hyperprolactinaemia, hemolytic anemia,
pancreatitis, pancytopenia, suicidal ideation,
thrombocytopenia, thrombocytopenic purpura,
vaginal bleeding on withdrawal, violent beha­
viour; hair loss also reported.
Hypersensitivity- angioedema, urticaria, pruritus,
and other allergic reactions including anaphylaxis
have been reported (discontinue if rash occurs,
may be warning of impending serious systemic
reaction, possibly associated with vasculitis);
pharyngitis and rarely pulmonary inflammation
or fibrosis (with dyspnoea only warning sign)
also reported; possible hypersensitivity signs
associated with other SSRis include arthralgia,

myalgia.
SSRl preparations should not be given in the
patients enter a manic phase.
Precautions: SSRl preparations should be used
with caution in patients with cardiac disease,
epilepsy (avoid if poorly controlled, discontinue
- I
if convulsions develop), concurrent
electroconvulsive therapy (prolonged seizures
reported), history of mania, hepatic and renal
impairment, pregnancy and breast-feeding, avoid
abrupt withdrawal.
Driving- may impair performance of skilled
tasks (e.g. driving)
Pregnancy & lactation: Although no teratogenic
effects have been observed SSRI preparations
should be used during pregnancy or lactation
with caution.
Dosage & admin: Depressive illness, 20mg
daily; child, not recommended.
Bulimia nervosa, 60mg daily; child, not
recommended.
Obsessive-compulsive disorder, initially 20mg
daily, dose increase may be considered if no
response after several weeks, but may be
increased potential for side-effects; max. 60mg
daily; child, not recommended.
Long duration of action- account should be
taken of the long half-life of fluoxetine when
adjusting dosage (or in overdosage).
Drug inter: Monoamine oxidase inhibitors- it is
prudent to avoid their combined use, experience
suggests that the combination may produce a
potentially lethal serotonin syndrome.Oral
anticoagulants - prothrombin time should be
carefully monitored when fluoxetine therapy is
initiated or stopped in patients on oral coagulants.
CNS-active drugs- hypertension and CNS
excitation may occur if used with dopaminergic
drugs. Cemetidine- plasma concentration of
fluoxetine increased by cemetidine.
t MODIPRAN Cap. Beximco
Fluoxetine hydrochloride 20mg/capsule
1OO's pack 289 .00 IP
t NODEP Tab. General
I Fluoxetine hydrochloride 20mg/tablet
50's pack: 140.00 MRP
t NODEPRESS Cap. Kemiko
Fluoxetine hydrochloride 20mg/capsule
50's pack: 130.00 MRP
t OXETIN Cap. Decent
Fluoxetine hydrochloride 20mg/capsule
50's pack: 144.00 MRP
t PRODEP Cap. Sun Pharma
Fluoxetine hydrochloride 20mg/capsule
50's pack: 150.00 MRP
t PROLERT Cap. Square
Fluoxetine hydrochloride 20mg/capsule
50's pack: 150.00 MRP
t SEREN Cap. Sonear
Fluoxetine hydrochloride 20mg/capsule
30's pack 86.10 MRP
FLUVOXAMJNE34
FLUVOXAMINE: Tablet
Fluvoxamine is a selective serotonin reuptake
inhibitor (SSRI). It is available as fluvoxamine
maleate BP 50mg tablet.
Ind: Obsessive-compulsive disorder, depressive
QIMP-17 (141)
illness. It is also indicated in panic disorder,
eating disorders, chronic tension headache.
C/I: Fluvoxamine maleate should not be used if
the patient enters a manic phase.
S/E: Gastro-intestinal side effects are- anorexia
with weight loss (increased appetite and weight
gain also reported), hypersensitivity reactions
with rash, urticaria, angioedema, arthralgia,
myalgia and photosensitivity. Other side effects
include dry mouth, nervousness, anxiety,
headache, insomnia and sexual dysfunction,
palpitation, tachycardia (may also cause
bradycardia), rarely postural hypotension,
confusion, ataxia, abnormal liver function tests.
Precautions: Fluvoxamine maleate should be
used vith caution in patients with a history of
mania, seizures, suicide, concurrent ECT therapy,
cardiac disease, diabetes mellitus, angle-closure
glaucoma, history of bleeding disorders (specially
gastro-intestinal bleeding), hepatic and renal
impairment. Fluvoxamine maleate may also
impair preformance of skilled tasks (driving).
Pregnancy & lactation: Fluvoxamine maleate
should be avoided in pregnancy and lactation
Dosage & admin: Obsessive-compulsive
disorder: Initially 50mg in the evening for 3-4
days, increasing if necessary to 300mg daily
(over 150mg in divided doses). Child- over 8
years, initially 25mg daily, increased if
necessary in steps of 25mg every 3-4 days to
maximum 200mg daily in divided doses.
Depression: Initially 50-lOOmg daily in the
evening, increased if necessary to 300mg daily
(over 150mg in divided doses). Usual
maintenance dose 1 OOmg daily. Child- not
recommended.
Drug inter: Fluvoxamine maleate should not be
used concurrently with monoamine oxidase
inhibitors, warfarin, benzodiazepines,
theophylline, aminophylline, tricyclic
antidepressants and alcohol.
t RELAFIN Tab. General
Fluvoxamine maleate BP 50mg/tablet
30's pack: 451.80 MRP
PAROXETINE48
PAROXETINE HCI: Tablet.
Paroxetine is a potent selective serotonin re­
uptake inhibitor (SSRI). It is available as paroxe­
tine hydrochloride 20mg tablet.
Mode of action: Paroxetine selectively inhibits
neuronal re-uptake of serotonin (5-Hydroxy
tryptamine, 5-HT), which potentiates serotonergic
activity in the central nervous system, which
appears to be associated with antidepressant
activity. Studies have demonstrated that paroxe­
tine blocks the uptake of serotonin into human
platelets. In vitro studies in animals also suggest
that paroxetine has only very weak effects on
norepinephrine and dopamine neuronal reuptake.
Ind: Major depressive disorder, Obsessive
compulsive disorder, Panic disorder, Social
anxiety disorder, Generalized anxiety disorder &
Post-traumatic stress disorder.
C/I: Known hypersensitivity to paroxetine.
Concomitant use in patients taking either
monoamine oxidase inhibitors (MAOls), or
thioridazine.
CNS DRUGS
S/E: Asthenia, sweating, nausea, decreased
appetite, somnolence, dizziness, insomnia,
tremor, nervousness, ejaculatory disturbance and
other male genital disorders.
Precautions: Caution is advised when treating
patients with cardiac conditions, patients with
epilepsy (avoid if poorly controlled, discontinue
if convulsions develop). Paroxetine should be
discontinued in any patients who develops
seizures ECT, (incidence of seizures in patients
treated with paroxetine is <0.1%). Caution is
advised when treating patients with history of
mania. Paroxetine may impair performance of
skilled tasks (e.g driving).
Pregnancy & lactation: This drug should be
used during pregnancy only if the potential
benefit justifies the potential risk to the fetus. The
effect of paroxetine on labor and delivery in
humans is unknown. Like many other drugs
paroxetine is secreted in human milk and caution
should be exercised when administered in a
nursing mother.
Dosage & admin: Major depressive disorder:
Usual initial dose is paroxetine 20mg as a sin­
gle daily dose with or without food, preferably
in the morning. Some patients not responding
to 20mg dose may benefit from dose increases
in lOmg/day increments up to a maximum of
50mg/day. Dose changes should occur at inter­
vals of at least 1 week. Maintenance therapy:
Efficacy of paroxetine hydrochloride is
maintained for periods of up to 1 year with
doses that averaged about 30mg.
Obsessive compulsive disorder (OCD): Patients
should be started on 20mg/day and the dose
can be increased weekly in 1 Omg/day
increments. Maintenance therapy: Efficacy of
paroxetine hydrochloride is maintained for
periods of up to 1 year with doses that
averaged about 30mg.
Panic disorder: Usual initial dose is paroxetine
20mg as a single daily dose with or without
food, preferably in the morning. The target
dose in the treatment of panic disorder is
40mg/day. Dose changes should occur in
lOmg/day increments at intervals of at least 1
week. The maximum dosage should not exceed
60mg/day. Maintenance therapy- dosage
adjustments should be made to maintain the
patient on the lowest effective dosage and
patients should be periodically reassessed to
determine the need for continued treatment.
Social anxiety disorder (SAD): Usual initial
dose is paroxetine 20mg as a single daily dose
with or without food, preferably in the
morning. Dose may be increased after 2 weeks
if necessary with an increments of lOmg at
weekly intervals to a maximum of 50mg daily.
Generalized anxiety disorder (GAD): The
recommended starting dosage and the
established effective dosage is 20mg/day.
Post-traumatic stress disorder (PTSD): The
recomn,ended starting dosage and the estab­
lished effective dosage is 20mg/day. Dose
changes, if indicated, should occur in lOmg/day
increments at intervals of at least 1 week.
Dosage for Elderly or Debilitated and Patients
with Severe Renal or Hepatic impairment: The
recommended initial dose is 10mg/day for eld­
erly patients, debilitated patients and/or
•
CNS DRUGS
patients with severe renal or hepatic impair­
ment. Increases may be made if indicated.
Dosage should not exceed 40mg/day.
Drug inter: Tryptophan: An interaction between
paroxetine and tryptophan may occur, resulting
in a serotonin syndrome suggested by develop­
ment of agitation, restlessness and gastrointesti­
nal symptoms including diarrhoea. Drug metabo­
lizing enzyme inducers/inhibitors: The metabo­
lism and pharmacokinetics of paroxetine may be
affected by drugs, which induce or inhibit hepatic
drug metabolizing enzymes. When paroxetine is
to be co-administered with a known drug metab­
olizing inhibitor, consideration should be given to
using doses at the lower end of the range.
Alcohol: Although paroxetine does not increase
the impairment of mental and motor skill caused
by alcohol, the concomitant use of paroxetine and
alcohol in depressed patients is not advised.
Haloperidol/Amylobarbitone/Oxazepam:
Paroxetine does not increase the sedation and
drowsiness associated with haloperidol, amylo­
barbitone or oxazepam when given in combina-
tion. MAOis: An interaction between paroxetine
and monoamine oxidase (MAO) inhibitors may
occur. Treatment with paroxetine should not be
started until 2 weeks after stopping an MAO!.
Lithium: The concurrent administration of
paroxetine and lithium should be undertaken with
caution. Lithium levels should be monitored.
Phenytoin/Anticonvulsants: Co-administration of
paroxetine and phenytoin is associated with an
increased incidence of adverse experiences.
Warfarin: Preliminary data suggest that there may
be a pharmacodynamic, interaction between
paroxetine and warfarin, which may result in
increased bleeding in the presence of unaltered
prothrombin times. Paroxetine should therefore
be administered with great caution to patients
receiving oral anticoagulants.
t MELEY 20 Tab. Beximco
Paroxetine hydrochloride 20mg/tablet
20mg x 30's pack 286.20 MRP
+ OXAT 20 Tab. Square
Paroxetine hydrochloride 20mg/tablet
20mg x 30's pack 360.00 MRP
t PAROTIN Tab. ACI
Paroxetine hydrochloride 1Omg & 20mg/tablet
lOmg x 30's pack 180.60 MRP
20mg x 30's pack 301.20 MRP
t PAROXET-20 Tab. Jayson
Paroxetine hydrochloride 20mg/tablet
20mg x 30's pack 270.90 MRP
SERTRALINE21,34
SERTRALINE : Tablet
Sertraline is a selective serotonin re-uptake
inhibitor (SSRI). Therefore, it acts by selectively
inhibiting the re-uptake of serotonin (5-
bydroxytryptamine), and considered to be an
effective antidepressant preparation. , 50mg x 50's pack: 301.00 MRP
Ind: Depressive illness; management of
obsessive-compulsive disorder; panic disorder.
C/I; S/E; Cautions: See notes above under
fluoxetine.
Pregnancy & lactation: See notes above under
fluoxetine.
Dosage & A dmin: Depression- initially 50mg
QIMP-17 (142)
daily, increased if necessary by 50mg over sev­
eral weeks to max. 200mg daily; then reduced
to usual maintenance dose 50mg daily.
Obsessive-compulsive disorder- initially 50mg
daily, increased if necessary by 50mg over sev­
eral weeks; usual dose range 50-200mg daily.
Panic disorder- 25mg once daily; after one
week the dose should be increased to 50mg
once daily.
Child: Not recommended.
Drug inter: See notes above under fluoxetine.
+ ANDEP Tab. Healthcare
Sertraline hydrochloride INN 50mg/tablet
50mg x 50's pack: 275.00 MRP
t AT RALIN Tab. Beximco
Sertraline hydrochloride INN 50mg/tablet
50mg x 50's pack: 250.00 IP
t CHEAR Tab. ACI
Sertraline hydrochloride INN 25mg, 50mg &
1OOmg/tablet
25mg x l OO's pack: 301.00 MRP
50mg x 50's pack: 301.00 MRP
.
1OOmg x 30's pack: 301.20 MRP
t MUDIRAL Tab. Opsonin ..
Sertraline hydrochloride INN 25mg, 50mg &
1 OOmg/tablet
25mg x 50's pack: 132.40 MRP
50mg x 50's pack: 264.79 MRP
1OOmg x 30's pack: 238.31 MRP
t REPOSE Tab. Incepta
Sertraline hydrochloride INN 25mg, 50mg &
1OOmg/tablet
25mg x 50's pack: 150.00 MRP
50mg x 50's pack: 300.00 MRP
l OOmg x 30's pack: 285.00 MRP
t SARTRA Tab. Pacific
Sertraline hydrochloride INN 50mg/tablet
50mg x 50's pack: 300.00 MRP
+ SELOTIN Tab. White Horse
Sertraline hydrochloride INN 50mg/tablet
50mg x 30's pack: 150.00 MRP
t SERA Tab. Ambee
Sertraline hydrochloride INN 25mg/tablet
25mg x 50's pack: 201.00 MRP
t SERLIN Tab. Ibo Sina
Sertraline hydrochloride INN 25mg & 50mg I
tablet
25mg x 1OO's pack: 300.00 IP
50mg x 30's pack: 180.00 IP
t SEROLUX Tab. Sandoz
Sertraline hydrochloride INN 25mg, 50mg &
1 OOmg/tablet
25mg x 50's pack: 200.00 MRP
50mg x 50's pack: 350.00 MRP
l OOmg x 30's pack:- 333.00 MRP
t SERTAL Tab. Drug Inter.
Sertraline hydrochloride INN 50mg/tablet
50mg x 50's pack: 250.00 MRP
+ SETRA Tab. General
Sertraline hydrochloride INN 25mg, 50mg &
1 OOmg/tablet
25mg x 50's pack: 150.50 MRP
1 OOmg x 30's pack: 301.20 MRP
" t TRALIN Tab. Silva
Sertraline hydrochloride INN 25mg, 50mg &
1 OOmg/tablet
25mg x 1OO's pack: 250.00 MRP
50mg x 50's pack: 200.00 MRP
1OOmg x 50's pack: 351.00 MRP
t ZOSERT Tab. Sun Pharma
Sertraline hydrochloride INN 25mg, 50mg &
1 OOmg/tablet
25mg x 50's pack: 150.00 MRP
50mg x 50's pack: 300.00 MRP
l OOmg x 30's pack: 300.00 MRP
Other antidepressant drugs21
Other antidepressants include: Agomelatine,
Bupropion, Duloxetine, Flupenthixol,
Milnacipran, Mirtaza-pine, Reboxetine,
Tryptophan, Venlafaxine.
AGOMELATINE 21,138
AGOMELATINE: Tablet
Agomelatine is a melatonin agonist and a
selective serotonin receptor antagonist, i.e it does
not affect the uptake of serotonin, noradrenaline
& dopamine. It is available as- agomelatine INN
25mg/tablet.
Ind: Major depressive disorder; generalized
anxiety disorder; bipolar depression; sleep
disturbances; seasonal affective disorder;
migraine and cluster headaches.
C/l: Hypersensitivity to the active substances or
any of the excipients; hepatic impairment (i.e
cirrhosis or active liver disease); concomitant use
of potent CYP IA inhibitors (e.g fluvoxamine).
S/E: The commonly reported adverse effects are
headache, nausea and diarrhea.
Precautions: Agomelatine is not recommended
in the treatment of depression in patients under
18 years of age.
Pregnancy & lactation: The specific data on
safety for its use in pregnancy and lactating
mother is not available, but animal studies have
not shown any risk. Therefore, caution should be
exercised when prescribing to pregnant women.
Dosage & admin: The effective dose of
agomelatine is 25mg/day given once at bed
time. If no improvement is noticed after two
weeks, the dosage can be increased to
50mg/day. Night time dosing is recommended
because agomelatine improves the quality of
sleep without day time sedation. It can be
given with or without food.
Children & adolescents: A gomelatine is not
recommended in the treatment of depression
in patients under 18 years since safety and
efficacy of agomelatine have not been
established in this age group. In certain cases
can only be given on medical advice.
Elderly patients: E fficacy has not been clearly
demonstrated in the elderly� 65 years)
patient. Therefore, caution should be exercised
when prescribing agomelatine to these groups.
Drug inter: Agomelatine is metabolised mainly
by cytochrome P450 1A2 (CYP1A2) (90%) and
by CYP2C9 (10%). Medicinal products that
interact with these isoenzymes may decrease or
increase the bioavailability of agomelatine.
Fluvoxamine, a potent CYP1A2 and moderate
CYP2C9 inhibitor markedly inhibits the
metabolism of agomelatine resulting in a 60-fold
(range 12-412) increase of agomelatine exposure.
Consequently, co-administration of agomelatine

with potent CYP1A2 inhibitors (e.g fluvoxamine)
is contraindicated.
+ AGOTIN Tab. Beacon
Agomelatine INN 25mg/tablet.
25mg x lO's pack: 500.00 MRP
-
'
BUPROPION48
BUPROPION HCl: Tablet
Bupropion hydrochloride is an antidepressant of
the aminoketone class, chemically unrelated to
tricyclic, tetracyclic, or other known antidepre­
ssants. Its structure closely resembles that of
diethylpropion; it is related to phenylethylamines.
Mode of action: Bupropion inhibits reuptake of
dopamine, noradrenaline, and serotonin in the
central nervous system, is a non-competitive
nicotine receptor antagonist.
Ind: Bupropion hydrochloride is indicated in the
treatment of depression. It is also indicated in
smoking cessation.
C/I: Bupropion hydrochloride is contraindicated
in patients with a seizure disorder, such as,
patients with epilepsy. Bupropion hydrochloride
is contraindicated in patients treated with other
medications that contain bupropion because the
incidence of seizure is dose-dependent. It is also
contraindicated in patients with a current or prior
diagnosis of bulimia or anorexia nervosa because
of a higher incidence of seizures noted in such
patients treated for bulimia with bupropion
hydrochloride. The concurrent administration of
bupropion hydrochloride and a monoamine oxi­
dase (MAO) inhibitors is contraindicated. At least
14 days should elapse between discontinuation of
an MAO inhibitor and initiation of treatment with
bupropion hydrochloride. Bupropion hydrochlo­
ride is contraindicated in patients who have
shown an allergic response to bupropion or other
ingredients of the preparation.
S/E: Agitation, anxiety, and insomnia often occur
during the initial stages of bupropion therapy.
Other relatively common side effects reported
are- fever, dry mouth, headache or migraine,
dizziness, nausea and vomiting, constipation,
tremor, sweating, and skin rashes.
Hypersensitivity reactions, ranging from pruritus
& urticaria, less commonly angioedema, dyspnea,
and anaphylactoid reactions have occurred.
Precautions: As bupropion is contraindicated in
patients with a history of seizure disorders, it
should be used with extreme caution in patient
with other predisposing factors for seizures, such
as severe hepatic cirrhosis or CNS tumour, and in
those undergoing abrupt withdrawal from alcohol
or benzodiazepines. The use of bupropion in
patients with other risk factors for seizures (e.g
alcohol abuse, a history of head trauma, diabetes,
and drugs known to lower the seizure threshold)
should only be under taken when there are com­
pelling clinical reasons. Bupropion should be
used with caution in patients with bipolar depres­
sion or psychoses and in patients with a recent
history of myocardial infarction or unstable heart
diesease and in hepatic or renal impairment.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women.
This drug should be used during pregnancy only
if clearly needed. Like many other drugs, bupro-
QIMP-17 (143)
pion and its metabolites are secreted in human
milk, because of the potential for serious adverse
reactions in nursing infants from bupropion, a
decision should be made whether to discontinue
nursing or to discontinue the drug, taking into
account the importance of the drug to the mother.
Dosage & admin: Depression: The usual adult
target dose for bupropion is 300mg/day, given
as 150mg twice daily. Treatment should begin
at 150mg/day given as a single daily dose in
the morning. If the 150mg initial dose is
adequately tolerated, an increase to the
300mg/day target dose, given as 150mg twiee
daily, may be made as early as fourth day of
therapy. T here should be an interval of at least
8 hours between successive doses. Increasing
the dosage above 300mg/day: As with other
antidepressants, the full antidepressant effect
of bupropion hydrochloride may not be
evident until 4 weeks of treatment or longer.
An increase in dosage to the maximum of
400mg/day, given as 200mg twice daily, may
be considered for patients in whom no clinical
improvement is noted after several weeks of
treatment at 300mg/day. Bupropion hydro­
chloride should be discontinued in patients
who do not demonstrate an adequate response
after an appropriate period of treatment at
450mg/day. Maintenance: The lowest dose
that maintains remission is recommended.
Although it is not known how long the patients
should remain on bupropion hydro-chloride,
it is generally recognized that acute episodes of
depression require several months or longer of
anti-depressant drug treatment.
Child & adolescent under 18 years: Not
recommended.
Drug inter: Bupropion should not be given
concurrently with or within 14 days of stopping
an MAO inhibitor. The use of alcohol should be
minimised or avoided completely because it may
alter the seizure threshold. Similarly, other drugs
that lower the seizure threshold, such as other
antidepressants, antimalarials, antipsychotics,
sedating antihistamines, quinolones, tramadol,
theophylline, or systemic corticosteroids, should
be used with extreme caution together with
bupropion. Carbamazepine, phenobarbital, or
phenytoin may induce the metabolism of bupro­
pion while other drugs such as cimetidine or
ritonavir may inhibit its metabolism. Interaction
may occur between bupropion and orphenadrine,
cyclophosphamide, and ifosfamide. Caution
should be exercised when it is given with drugs
such as some antidepressants, antipsychotics,
beta-blockers, and type 1 C antiarrhythmics.
+ DEPNOX SR Tab. Jayson
Bupropion hydrochloride USP l 50mg/tablet
(sustained release)
150mg x 30's pack: 300.90 IP
+ ZYBEX SR Tab. Beximco
Bupropion hydrochloride USP l 50mg/tablet
(sustained release)
150mg x 30's pack: 300.00 IP
DULOXETINE26
DULOXETINE HCl: Tablet
Duloxetine hydrochloride is a selective serotonin
CNS DRUGS
and norepinephrine reuptake inhibitor (SSNRl). It
is available as duloxetine hydrochloride INN
equivalent to duloxetine 20mg and 30mg/tablet
(enteric-coated).
Mode of action: Duloxetine hydrochloride is a
selective serotonin and norepinephrine reuptake
inhibitor (SSNRI). It is a less potent inhibitor of
dopamine reuptake. It has no significant affinity
for dopaminergic, adrenergic, cholinergic, hista­
minergic, opioid, glutamate, and GABA receptors
in vitro. Duloxetine dose not inhibit monoamine
oxidase (MAO). Orally administered duloxetine
hydrochlorid� is well absorbed. Elimination of
duloxetine is mainly through hepatic metabolism.
Ind: 1. Treatment of major depressive disorder
(MDD) which is associated with the following
symptoms: i. depressed mood, ii. loss of interest
in usual activities, iii. significant change in
weight and/or appetite, iv. insomnia or hypersom­
nia, v. psychomotor agitation or retardation, vi.
increased fatigue, vii. feelings of guilt or worth­
lessness, viii. slowed thinking or impaired conc­
entration, ix. suicide attempt or suicidal ideation.
2. Management of neuropathic pain associated
with diabetic peripheral neuropathy.
C/I: Duloxetine is contraindicated in patients
with a known hypersensitivity to this drug or any
of the inactive ingredients. Concomitant use in
patients taking monoamine oxidase inhibitors
(MAOls) is contraindicated. It should be avoided
in patinets with uncontrolled narrow-angle
glaucoma.
S/E: The most commonly observed abverse
events are- nausea, dizziness, dry mouth,
constipation, decreased appetite, fatigue,
somnolence, increased sweating, hyperhidrosis
& asthenia. It may slightly increase blood
pressure. No clinically significant differences were
observed for QT, PR, & QRS intervals between
duloxetine-treated and placebo-treated patients.
Precautions: Blood pressure should be measured
prior to initiating treatment with duloxetine
hydrochloride and preiodically measured
throughout treatment. It should be used cautious­
ly in patients with a history of mania, seizure
disorder and controlled narrow-angle glaucoma.
Duloxetine hydrochloride should ordinarily not
be prescribed to patients with substantial alcohol
use.
Pregnancy & lactation: Duloxetine should be
used during pregnancy and labor only if the
potential benefit justifies the potential risk to the
fetus.
It is not known whether duloxetine and/or it's
metabolites are excreted into human milk,
however, breast feeding is not recommended
when the mother is on duloxetine therapy.
Dosage & admin: Major depressive disorder
(MDD): 20-30mg twice daily or 60mg once
daily.
Diabetic peripheral neuropathy: A total dose of
60mg given once a day.
Duloxetine hydrochloride can be taken
regardless of meals.
Children: Safety and efficacy in pediatric
patients have not been established.
Drug inter: Both CYP1A2 and CYP2D6
isozymes are responsible for duloxetine metabo­
lism. When duloxetine was co-administered with
tluvoxamine, a potent CYP 1A2 inhibitor, the
CNS DRUGS
AUC, Cmax and t l /2 of duloxetine was
increased. Other durgs that inhibit CYP 1A2
metabolism include cimetidine and quinolone
antimicrobials such as ciprofloxacin and
enoxacin would be expected to have similar
effects and these combinations should be avoid­
ed. Because CYP2D6 is involved in duloxetine
metabolism, concomitant use of duloxetine with
potent inhibitors of CYP2D6 may result in higher
concentrations of duloxetine.
+ DILINER DR Cap. Square
Duloxetine hydrochloride INN equivalent to
duloxetine 30mg & 60mg/capsule (delayed
release).
30mg x 18's pack: 180.72 MRP
60mg x l 8's pack: 289.08 MRP
+ DULOX Tab. Acme
Duloxetine hydrochloride INN equivalent to
duloxetine 20mg & 30mg/tablet (enteric-coated).
20mg x 1O's pack: 70.20 MRP
30mg x lO's pack: 100.00 MRP
+ DULOXEN Tab. Incepta
Duloxetine hydrochloride INN equivalent to
duloxetine 20mg & 30mg/tablet (enteric-coated).
20mg x 30's pack: 210.00 MRP
30mg x 30's pack: 300.00 MRP
+ DUZELA 20 Cap. Sun Pharma
Duloxetine hydrochloride INN equivalent to
duloxetine 20mg/capsule.
20mg x 25's pack: 352.50 MRP
+ STRESIN 20 Cap. UniMed & UniHealth
Duloxetine hydrochloride INN equivalent to
duloxetine 20mg/capsule.
20mg x 30's pack: 240.00 MRP
+ XINOLAX DR Cap. Opsonin
Duloxetine hydrochloride INN equivalent to
duloxetine 20mg, 30mg & 60mg/capsule
(delayed release).
20mg x 30's pack: 184.73 MRP
30mg x 20's pack: 175.94 MRP
60mg x 20's pack: 281.50 MRP
FLUPENTHIXOL &
FLUPENTHIXOL +
MELITRACJN 21,26,67
FLUPENTHIXOL + MELIT RACIN: Tablet/
Injection
Mode of action: Flupenthixol- a neuroleptic with
anxiolytic and antidepressant properties of its
own when given in small doses, and melitracen­
a bipolar thymoleptic with activating properties
in low doses.
In combination the compounds render a
preparation with antidepressant, anxiolytic and
activating properties, but does not seem to
influence the pharmacokinetic properties of the
individual compounds.
Ind: Depressive illness with anxiety, masked
depression, asthenia & long lasting myogenic
headache, migraine; psychosomatic affections
with anxiety & asthenia. Dysphoria & depression
in alcoholic and drug addicts.
C/I: Intolerance to neuroleptic drugs; excitable or
over active patient; parkinsonism; severe
atherosclerosis; senile confusional state;
advanced renal, hepatic or cardiovascular disease.
S/E: Extrapyramidal symptoms occur frequently
(1-3 days after admn. & continue for 5 days).
QIMP-17 (144)
Aggregation or agitation may appear (in this
stage, should be replaced by another drug). Also
see under chlorpromazine.
Caution: Renal & hepatic impairment; athero­
sclerosis; pregnancy.
Dosage & admin: Flupenthixol decanoate: See
below under the individual preparation.
Flupenthixol dihydrochloride: See below
under the individual preparation.
Flupenthixol + melitracen: Adult, usually 2
tablets daily divided in morning and evening
doses. In severe cases, morning dose may be
increased to 2 tablets. Elderly, 1 tablet in the
morning; maintenance, usually 1 tablet in the
morning.
•
Child: Not recommended.
Prepns: See above under antipsychotic drugs.
MILNACIPRAN138
MILNACIPRAN: Tablet (f.c)
Milnacipran is a potent inhibitor of neuronal
norepinephrine and serotonin reuptake in
approximately 1:3 ratio respectively. These
actions simultaneously works synergistically to
treat both depression and fibromyalgia and also
improve multiple fibromyalgia symptoms such as
peripheral and central pain, depressiveness, sleep
and quality of life. It is well absorbed after oral
administration & bioavailability is approximately
85%-90%. Milnacipran and its metabolites are
eliminated primarily by renal excretion.
Following oral administration, approximately
55% of the drug dose is excreted in urine as
unchanged milnacipran. Terminal half-life of
milnacipran is approximately 6 to 8 hours.
Milnacipran is available as- milnacipran hydro­
chloride INN 50mg/tablet (film-coated).
Ind: Milnacipran is indicated for the treatment
of- i. major depressive disorder, and ii. fibro­
myalgia.
C/I: Milnacipran is contraindicated to
concomitant use with MAOls or within 14 days
of discontinuing treatment with an MAOI &
uncontrolled narrow angle glaucoma.
S/E: Generally nausea, headache, constipation,
dizziness, hot flush, vomiting, palpitations, and
dry mouth.
Precaution: After extended use, the dose should
be tapered and not abruptly dicontinued.
Withdrawal symptoms have been reported in
patients when discontinuing treatment with
milnacipran. A gradual dose reduction is
recommended.
At least 14 days should elapse between
discontinuation of an MAOI and initiation of
therapy with milnacipran. In addition, allow at
least 5 days after stopping milnacipran before
starting an MAOI.
Pregnancy & lactation: Milnacipran belongs to
pregnancy category C. It has not been adequately
studied in pregnant women. It may be given to a
pregnant woman only if the benefit to the woman
outweigh any possible risk to the fetas. There are
no data on the excretion of milnacipran into
human milk.
Dosage & admin: The recommended dose of
milnacipran hydrochoride is 50mg twice daily.
Maximum dosage is 1 OOmg twice daily.
Based on efficacy and tolerability, dosing may
be titrated according to the following
schedule:
Day 1 : 12.Smg once;
Day 2-3 : 12.5mg twice daily (25mg/day);
Day 4-7: 25mg twice daily (50mg/day);
After day 7: 50mg twice daily ( lOOmg/day).
The recommended dose for depression is
1 OOmg/day (given as 50mg twice daily), with a
starting period of 4 days on 25mg/day.
After successful treatment of the acute
depressive episode patients shoud be
maintained on milnacipran for several months
(normally 9 months) in order to prevent
relapse of depression.
Children: It is not approved for use in pedia­
tric patients due to insufficient clinical data.
Drug inter: In vitro and in vivo studies showed
that milnacipran is unlikely to be involved in
clinically significant pharmacokinetic drug
interactions with MAOis, 5HTt receptor
antagonists, epinephrine, nor-epinephrine,
clonidine, digitalis etc.
+ MILRAN Tab. Beacon
Milnacipran hydrochloride INN 50mg/tablet (f.c).
50mg x 20's pack: 300.00 MRP
+ NEOCIPRAN Tab. lbn Sina
Milnacipran hydrochloride INN 50mg/tablet (f.c).
50mg x 30's pack: 450.00 IP
MIRTAZAPJNE34
MIRTAZAPINE: Tablet
Mirtazapine is an antidepressant drug, belonging
to miscellaneous group.
Ind: Mirtazapine is indicated for the treatment of
depression.
C/I: Known hypersensitivity to mirtazapine.
S/E: Increased appetite and weight gain, seda­
tion; less commonly oedema, dizziness,
headache, rarely postural hypotension, abnormal
dreams, mania, convulsions, tremor, myoclonus,
paraesthesia, arthralgia, myalgia, restless legs,
exanthema, reversible agranulocytosis.
(_
Precautions: Epilepsy, hepatic or renal impair­
ment, cardiac disorders, hypotension, history of
urinary retention, angle-closure glaucoma, dia­
betes mellitus, psychoses (may aggravate psy­
chotic symptoms), history of bipolar depression;
avoid abrupt withdrawal.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women
and lactating mother. So, it should not be used in
pregnancy and nursing mother.
Dosage & admin: Adults: Initially 15mg daily
at bedtime. The dosage may need to be
increased to obtain an optimal clinical response.
The effective daily dose is usually between 15
and 45mg as a single or 2 divided doses.
Children: Not recommended.
Overdose: Depression of the central nervous
system with disorientation and prolong
sedation, together with tachycardia and mild
hyper- or hypotension have been reported
with mirtazapine overdose. T hese patients
should be treated by gastric lavage with appro­
priate symptomatic & supportive therapy.
Drug inter: Mirtazapine should not be used con­
comitantly with or within two weeks of discon­
tinuing an MAOls; at least two weeks should
•
 QIMP-17 (145) CNS DRUGS

elapse between discontinuation of an MAOls and
initiation of mirtazapine therapy. Administration
of mirtazapine concurrently with alcohol, anxi­
olytic or hypnotics may potentiate sedation
effect.
t MITAPREX Tab. Incepta
Mirtazapine USP 15mg & 30mg/tablet.
15mg x 30's pack: 240.00 MRP
30mg x 30's pack: 450.00 MRP
t MIRTAZ Tab. Sun Pharma
Mirtazapine USP 15mg & 30mg/tablet.
l 5mg x 50's pack: 402.50 MRP
30mg x 50's pack: 750.00 MRP
t MITRAZINE Tab. General
t VENIZ XR 75 Tab. Sun Pharma
Venlafaxine hydrochloride ·INN 84.90mg
equivalent to venlafaxine 75mg per tablet
(extended release).
75mg x 30's pack: 300.00 MRP
+ VENLAX Tab. General
Venlafaxine hydrochloride INN 42.45mg &
84.90mg equivalent to venlafaxine 37.5mg &
75mg per tablet respectively.
37.5mg x 30's pack: 165.60 MRP
75mg x 20's pack: 200.80 MRP
Combined antidepressant
preparations.
•
• t ATEVAL Tab. Ziska
_
Fluphenazine hydrochloride O.Smg +
. nortriptyline hydrochloride 1Omg/tablet.
l OO's pack: 100.00 MRP
t EUPHOR Tab. Biopharma
Fluphenazine hydrochloride 0.5mg +
nortriptyline hydrochloride 1 Omg/tablet.
1OO's pack: 80.00 MRP
t FLUTRIP Tab. General
Fluphenazine hydrochloride 0.5mg +
nortriptyline hydrochloride 1Omg/tablet.
IOO's pack: 71.00 MRP
t FRESH '.fab. Nipa
Fluphenazine hydrochloride 0.5mg +
nortriptyline hydrochloride 1Omg/tablet.

Mirtazapine INN 15mg/tablet.

l OO's pack: 80.00 MRP
15mg x 30's pack: 240.90 MRP
t MOODON Tab. Ibn Sina
FLUPHENAZINE + Fluphenazine hydrochloride 0.5mg +

nortriptyline hydrochloride 1Omg/tablet.

VENLAFAXINE2 l ,34
VENLAFAXINE HCI: Tablet
Venlafaxine hydrochloride is an antidepressant
drug belonging to miscellaneous group.
Mode of action: Venlafaxine is a 'serotonin and
noradrenaline reuptake inhibitor (SNRI)' having
antidepressant effect, but it lacks of sedative and
antimuscarinic action of typical tricyclic
antidepressants.
Ind: It is indicated in depressive illness &
generalised anxiety disorder.
C/I: Venlafaxine is contraindicated in severe
hepatic or renal impairment, & during pregnancy
and breast feeding.
S/E: Most frequently reported side-effects
include nausea, headache insomnia, dry mouth,
dizziness, constipation, sweating, nervousness,
asthenia. Other side-effects reported include
anorexia, dyspepsia, abdominal pain, anxiety,
sexual dysfunction, visual disturbances, vasodi­
latation, vomiting, tremor, chills, palpitations,
sgitation, rashes, convulsion, hypertension. Ortho­
static hypotension has been seen occasionally.
Precautions: Patient should be treated very
cautiously in case of history of myocardial
infarction or unstable heart disease, blood
pressure monitoring advisable if dose exceeds
200mg daily; history of epilepsy, mania, hepatic
or renal impairment. Avoid abrupt withdrawal (if
taken for more than 1 week, withdraw over at
least 1 week). Glaucoma.
Dosage & admin: Depression- initially 75mg
(1 tablet) in 2 divided doses, and can be
increased if necessary after several weeks to
150mg daily in 2 divided doses.
Severely depressed or hospitalized patients­
initially 150mg daily in 2 divided doses, and
NORTRIPTYLINE2 l ,33
200's pack: 170.00 MRP
t NORFLU Tab. Acme
FLUPHENAZINE + NORTRIPTYLINE: Fluphenazine hydrochloride 0.5mg +
Tablet. nortriptyline hydrochloride 1Omg/tablet.
Fluphenazine hydrochloride & Nortriptyline I OO's pack: 80.00 MRP
hydrochloride combination has been found as an
+ NORZIN Tab. Airstopharma
effective preparation for the patients suffering
Fluphenazine hydrochloride 0.5mg +
from 'anxiety' or 'depression' or both.
nortriptyline hydrochloride 1Omg/tablet.
Fluphenazine is a potent phenothiazine deriva­
250's pack: 200.00 MRP
tive. Nortriptyline is a tricyclic antidepressant
t PERMIVAL Tab. Opsonin
having less sedative action. This combination
Fluphenazine hydrochloride 0.5mg +
helps to restore functional ability without
nortriptyline hydrochloride 1 Omg/tablet.
developing any drug dependence. 200's pack: 131.89 MRP
Ind: Mild to moderate mixed anxiety/depression,
+ SANIT Tab. Square
emotional disturbance, sleep disorder, gastric
Fluphenazine hydrochloride 0.5mg +
problems. nortriptyline hydrochloride 1Omg/tablet.
C/I: History of grandma! epilepsy or organic
IOO's pack: 80.00 MRP
brain damage, blood dyscrasias, severe cardiac
insufficiency, renal or liver damage, MAO
inhibitors, younger children. 5. C.N.S STIMULANT
S/E: Dryness of mouth, drowsiness, constipation,
tachycardia, nasal congestion, blurred vision and DRUGS21
excitement.
Caution: Concurrent admin. of CNS depressants. CNS stimulants can be classified as:
Patients with glaucoma, prostate enlargement, 1 Weak central nervous stimulants, e.g
cardiac failure and myocardial infarction. The Caffeine.
drug may impair alertness and abilities to drive a 2 Amphetamines & related drugs, e.g
car or operating machinery. Safety in human Dexamphetamine, Methylphenidate,
pregnancy has not yet been established. Breast Atomoxetine, ModafiniL
feeding is not recommended. 3 Analeptics, e.g Adrenaline, Aminophylline,
Dosage & admin: Adult: 1 tablet (tluphenazine Nikethamide (Note: Analeptics are discussed
hydrochlor. 0.5mg + nortriptyline hydrochlor. under respiratory drugs).
lOmg per tablet.) 2 to 3 times daily for max. 3 4 Drugs used for attention deficit
months. hyperactivity disorder (ADHD): These also
Child: Not recommended. include- Atomoxetine, Dexamphetamine,
Methylphenidate.
t AMIVAL Tab. Amico
Fluphenazine hydrochloride 0.5mg +

can be increased if necessary in steps of up to nortriptyline hydrochloride 1Omg/tablet. ATOMOXETINE42

IOO's pack: 80.00 MRP
75mg every 2-3 days to max. 375mg daily then
.
7 •
•
•

t AMIVAL-F Tab. Amico

•
'
. .
.

gradually reduced. Generalised anxiety ATOMOXETINE: Capsule �

.
Fluphenazine hydrochloride l .5mg
.
.

disorder- 75mg daily as a single dose.
Drug inter: Venlafaxine should not be used
concomitantly with MAOis. Cimetidine inhibits
the hepatic metabolism of venlafaxine.
+ VENAX Tab. Renata
Venlafaxine hydrochloride INN 42.45mg &
84.90mg equivalent to venlafaxine 37.5mg &
75mg per tablet respectively.
37.5mg x 20's pack: 80.00 MRP
50mg x 20's pack: 120.00 MRP
+
Atomoxetine is a selective norepinephrine' reup­
nortriptyline hydrochloride 30mg/tablet.
take inhibitor. It is primarily licensed for the
IOO's pack: 201.00 MRP
management of 'attention deficit hyperactivity
+ ANFLU Tab. Alco Pharma disorder (ADHD)' in children. Atomoxetine is
Fluphenazine hydrochloride 0.5mg +
well-absorbed after oral administration and is mini­
nortriptyline hydrochloride 1Omg/tablet.
mally affected by food. Maximal plasma concen­
IOO's pack: 75.00 MRP
trations (Cmax) are reached approximately 1 to 2
t APRESIN Tab. Beximco hours after dosing. Atomoxetine has a half-life of
Fluphenazine hydrochloride 0.5mg + about 5 hours. It is eliminated primarily by oxida­
nortriptyline hydrochloride 1Omg/tablet. tive metabolism through the cytochrome P450 2D6
IOO's pack: 105.00 MRP (CYP2D6) enzymatic pathway. It is available as-
CNS DRUGS
atomoxetine hydrochloride INN 1 Omg/capsule.
Mode of action: The precise mechanism by which
atomoxetine produces its therapeutic effects in
'attention deficit hyperactivity disorder (ADHD)'
is unknown. But, it is thought to be related to
selective inhibition of the pre-synaptic nor­
epinephrine transporter.
Ind: Attention deficit hyperactivity disorder
(ADHD).
C/I: Patients known to be hypersensitive to
atomoxetine.
Precautions: Effects on blood pressure and heart
rate should be monitored; caution should be
exercised in case of severe liver injury.
Pregnancy & lactation: Not applicable.
Dosage & admin: Initial treatment:
Children & adolescents up to 70kg body weight:
Initiated at a total daily dose of approximately
O.Smg/kg and increased after a minimum of 3
days to a target total daily dose of approximate­
ly 1.2mg/kg administered either as a single daily
dose in the morning or as evenly divided doses
in the morning & late afternoon/early evening.
The total daily dose in children and adolescents
should not exceed 1.4mg/kg or total 100mg,
whichever is less.
Children & adolescents over 70kg body weight &
adults: Initiated at a total daily dose of 40mg
and increased after a minimum of 3 days to a
target total daily dose of approximately 80mg
administered either as a single daily dose in the
morning or as evenly divided doses in the morn­
ing and late afternoon/early evening. After 2 to
4 additional weeks, the dose may be increased
to a maximum of lOOmg in patients who have
not achieved an optimal response. There are no
data that support increased effectiveness at
higher doses. Maintenance treatment: There is
no evidence available from controlled trials to
indicate how long the patient with ADHD
should be treated with atomoxetine. It is gener­
ally agreed, however, that pharmacological
treatment of ADHD may be needed for
extended periods. The physicians who choose to
use atomoxetine for extended periods should
periodically re-evaluate the long-term
usefulness of the drug for the individual patient.
Drug inter: Albuterol, CYP2D6 inhibitors,
antihypertensive agents & monoamine oxidase
inhibitors (MAOis) may interact with atomoxetine.
Note: For further information, please consult
manufacturer's literature.
+ SUEV 10 Cap. Square
Atomoxetine hydrochloride INN 1 Omg/capsule.
1Omg x 30's pack: 240.00 MRP
6. DRUGS USED IN NAUSEA,
VOMITING & VERTIGCf 1
Drugs used in different types of nausea &
vomiting:
1 Drugs used in vestibular disorders
including Meniere's disease
2 Drugs used in nausea in pregnancy
3 Symtomatic relief of nausea from
underlying diseases
4. Drugs used in nausea & vomiting induced
by cytostatic chemotherapy & radiotherapy.
QIMP-17 (146)
or other CNS centres.
Drugs used in vestibular
.
Ind: Prevention and treatment of nausea,
vomiting, dizziness, motion sickness, radiation
disorders sickness and vertigo associated with diseases of
the vestibular system (e.g Meniere's syndrome,
labyrinthitis and other vestibular disturbances). &
CINNARIZINE21,33
morning sickness duri.ng pregnancy.
C/I: Known hypersensitivity to meclizine.
CINNARIZINE: Tablet
S/E: Drowsiness, dry mouth, and on rare
Cinnarizine is a vestibular sedative. It is available
occasions, blurred vision have been reported.
as cinnarizine BP 15mg in tablet form.
Precautions: As meclizine may impair mental
Mode of action: Cinnarizine acts mainly as a
alertness or physical coordination, patients should
vestibular sedative through inhibition of the
be warned regarding operating machinery,
calcium influx into the vestibular sensory cells.
driving a motor vehicle, and other haz:ardous
Cinnarizine thus acts predominantly on the .
activities. Patients should avoid alcoholic
peripheral vestibular system.
beverages while taking this drug. Due to its
Ind: Nausea, vertigo, labyrinthine disorders,
potential anticholinergic action, this drug should
motion sickness, Meniere's disease, peripheral
be used with caution in patients with asthma,
vascular disease, Raynaud's syndrome.
glaucoma, or enlargement of the prostate gland.
S/E; Cautions: See under the peripheral
Pregnancy & lactation: Based on available data,
vasodilator drugs.
meclizine found as an antiemetic with lowest
Dosage & admin: Adult: Nausea, 1S-30mg 3
risk of teratogenicity and is the drug of first
times daily. Vestibular disorder, 2S- 30 mg
choice in treating nausea and vomiting during
3 times daily. Motion sickness, 30mg 2 hours
pregnancy. Meclizine may excrete into the milk;
before, then 15mg 8 hourly during journey.
although it causes no harm to the nursing babies,
Child: Under S years, not recommended; S-12
safety of meclizine has not been established
years half adult dose.
during breast feeding.
t CINARIN Tab. Nipa Dosage & admin: Meclizine is administered
Cinnarizine 15mg/tablet orally.
lOO's pack: 100.00 MRP Adult & children, 12 years & over: Nausea
t CINARON Tab. Square and vomiting: 2S-S0mg daily or as directed by
Cinnarizine 15mg/tablet the physician. Motion sickness: Take an initial
200's pack: 200.00 MRP dose of 2S-SOmg, 1 hour prior to travel; may
t CINARYL Tab. Opsonin repeat the dose every 24 hours for the
Cinnarizine 15mg/tablet duration of the journey.
l OO's pack: 87.92 MRP Radiation sickness: SOmg administered 2-12
t CINARZ.IN Tab. Ibo Sina hours prior to radiation treatment. Vertigo:
Cinnarizine l 5mg/tablet 25-1OOmg daily in divided doses.
l OO's pack: 100.00 IP Emergency contraception: 2S-S0mg, 1 hour
t CINAZIN Tab. Acme before first ECP dose; repeat if needed in 24
Cinnarizine 15mg/tablet hours.
1OO's pack: 70.00 MRP The safety and efficacy for use in children less
t CINNARIZINE Tab. Bristol than 12 years of age have not been established.
Cinnarizine 15mg/tablet Drug inter: The CNS depressant effects of
200's pack: 200.00 MRP meclizine can be potentiated by concurrent use of
t CINOMYST Tab. Mystic ethanol or other CNS depressant agents such as
Cinnarizine l 5mg/tablet benzodiazepines, barbiturates, tricyclic
l OO's pack: 70.00 MRP antidepressants, opiate agonists, skeletal muscle
+ INARZIN Tab. Beximco relaxants, and antihistamines. Concurrent use of I
Cinnarizine 15mg/tablet other anticholinergics can potentiate the
1OO's pack: 90.00 IP anticholinergic effects of meclizine. Meclizine
t SUZARON Tab. Rephco can also increase the absorption of digoxin by
Cinnarizine l 5mg/tablet decreasing gastrointestinal motility.
l OO's pack: 100.00 MRP Overdosage: Overdosage of the drug is demon­
+ ZINCIN Tab. Aristopharma strated by symptoms, such as extreme excitabili­
Cinnarizine 15mg/tablet ty, seizures, drowsiness and hallucinations. This
250's pack: 250.00 MRP can be combated by appropriate supportive and
symptomatic treatment. Dialysis may be
considered.
MECUl�INE26
+ ACLIZ Tab. Aristopharma
MECLIZINE HCl: Tablet Meclizine hydrochloride 50mg/tablet (f.c).
Meclizine is a piperazine-derivative antihista­ 1OO's pack: 250.00 MRP
mine, used mainly as an antiemetic. It has t ANOSEA Tab. Ibo Sina
antiemetic, anticholinergic, and antihistaminic Meclizine hydrochloride 50mg/tablet (f.c).
properties. 50's pack: 130.00 IP
Mode of action: Meclizine reduces the sensitivi­ t AVERT Tab. Biopharma
ty of the labyrinthine apparatus. The action may Meclizine hydrochloride 50mg/tablet (f.c).
be mediated through nerve pathways to the vomi­ 50's pack: 125.50 MRP
ting centre (VC) from the chemoreceptor trigger t CLIZIN Tab. Peoples
zone (CTZ), peripheral nerve pathways, the VC, Meclizine hydrochloride 50mg/tablet (f.c).

lOO's pack: 250.00 MRP
•EMEGO Tab. Opsonin
Meclizine hydrochloride 50mg/tablet (f.c).
50's pack: 110.40 MRP
•EMENIL Tab. Incepta
Meclizine hydrochloride 50mg/tablet (f.c).
lOO's pack: 250.00 MRP
•EMEZIN Tab. SK+F
Meclizine hydrochloride 50mg/tablet (f.c).
50's pack: 125.00 MRP
•MECZIN Tab. Ad-din
Meclizine hydrochloride 50mg/tablet (f.c).
50's pack: 125.00 MRP
•MELIZIN Tab. Pacific
Meclizine hydrochloride lO mg/tablet (f.c).
50's pack: 125.00 MRP
•NOMOSIC Tab. Drug Inter.
Meclizine hydrochloride 50mg/tablet (f.c).
50's pack: 125.00 MRP
• VOMEC Tab. Belimco
Meclizine hydrochloride 50mg/tablet (f.c).
50's pack: 125.00 IP
CJNNARIZJNE +
DIMENHYDRINATE 26
CINNARIZINE + DIMENHYDRINATE:
Tablet
This is a combination preparation of cinnarizine
& dimenhydrinate. Dimenhydrinate is the chloro­
theophylline salt of diphenhydramine, which acts
as an antihistamine with anticholinergic
properties. Cinnarizine is a vestibular sedative.
This combination is available as cinnarizine BP
20mg & dimenhydrinate BP 40mg in tablet form.
Mode of action: Dimenhydrinate exhibits anti­
emetic and antivertiginous effects through
influencing the chemoreceptor trigger zone in the
region of the 4th ventricle. Cinnarizine acts
mainly as a vestibular sedative through inhibition
of the calcium influx into the vestibular sensory
cells. Cinnarizine thus acts predominantly on the
peripheral vestibular system. The combination
product is more effective than the individual
compounds.
Ind: This combined preparation is indicated for
the treatment of vertigo symptoms of various
ongms.
• •
C/I: Diphenhydramine is completely excreted
renally, so this product should not be used by
patients with severe renal impairment. Since both
active components of the combined product are
extensively metabolised by hepatic cytochrome
P450 enzymes. So this product should not be
used by patients with severe hepatic impairment.
This product is contra-indicated in patients with
known hypersensitivity to the active substances,
diphenhydramine or other antihistamines of
similar structure or to any of the excipients.
S/E: The most frequently occurring side-effects
are somnolence and dry mouth. These reactions
are usually mild and disappear within a few days
even if treatment is continued. In addition the
following adverse reactions are associated with
dimenhydrinate and cinnarizine:
Dimenhydrinate: Paradoxical excitability (spe­
cially in chil<jren), worsening of an existing
angle-closure glaucoma and reversible agranulo­
cytosis.
QIMP-17 (147)
Cinnarizine: Constipation, weight gain, tightness
of the chest, cholestatic jaundice, extrapyramidal
symptoms, lupus-like skin reactions, lichen
planus.
Precautions: This combined product does not
reduce blood pressure significantly, however, it
should be used with caution in hypotensive
patients. This should also be taken after meals to
minimize any gastric irritation.
Pregnancy & lactation: The safety of this
combined product in human pregnancy has not
been established.
Dimenhydrinate and cinnarizine both are
excreted in human breast milk, so, these should
not be taken by women who are breast feeding.
Dosage & admin: Adult & elderly: 1 tablet 3
times daily, to be taken with liquid after meals.
Children and adolescents under the age of 18
years: It is not recommended because there
are no data available on the use of this
combination product in this age group.
In general, the duration of treatment should
not exceed four weeks. The physician shall
decide whether longer treatment is required.
Drug inter: The anticholinergic and sedative
effects of the components of this combined
preparation may be potentiated by monoamine
oxidase inhibitors. In common with other antihis­
tamines, these may potentiate the sedative effects
of CNS depressants including alcohol, barbitu­
rates, narcotic analgesics and tranquillisers. These
may also enhance the effects of antihyperten­
sives, ephedrine and anticholinergics such as
atropine and tricyclic antidepressants.
•CINARON Plus Tab. Square
Cinnarizine BP 20mg + dimenhydrinate BP
40mg/tablet .
lOO's pack: 200.00 MRP
•CINARYL Plus Tab. Opsonin
Cinnarizine BP 20mg + dimenhydrinate BP
40mg/tablet.
lOO's pack: 175.94 MRP
•CINARZIN Plus Tab. Ibo Sina
Cinnarizine BP 20mg + dimenhydrinate BP
40mg/tablet .
lOO's pack: 150.00 IP
•CINAZIN Plus Tab. Acme
Cinnarizine BP 20mg + dimenhydrinate BP
40mg/tablet .
50's pack: 75.00 MRP
•REVERT Tab. Incepta
Cinnarizine BP 20mg dimenhydrinate BP
+ Meclizine hydrochloride USP 25mg
40mg/tablet .
50's pack: 100.00 MRP
MECLIZINE + PYRIDOXINE26,139
MECLIZINE + PYRIDOXINE: Tablet
This is a combination preparation of meclizine &
pyridoxine. Meclizine is a piperazine-derivative
antihistamine, used as an antiemetic. Pyridoxine
(B6) is a vitamin B component having some
antiemetic property.
This combination is available as a film coated
tablet containing meclizine hydrochloride BP
25mg & pyridoxine hydrochloride BP 50mg.
Mode of action: Meclizine: See above under the
text of meclizine.
Pyridoxine (B6), either alone or in combination
CNS DRUGS
has been used to prevent nausea & vomiting due
to its antiemetic property;..
Ind: For prophylaxis and symptomatic relief of
nausea, vomiting, dizziness, motion sickness,
radiation sickness and vertigo associated with
diseases of vestibular system ( e.g Meniere's syn­
drome, labyrinthitis & other vestibular distur­
bances) & morning sickness during pregnancy.
C/I: Known hypersensitivity to meclizine &/or
pyridoxine.
S/E; Precautions: See above under the text of
meclizine preparation.
Pregn ancy. & lactation: Meclizine: Large scale
human studies have not demonstrated adverse
fetal effects. Based on available data, it has been
suggested that, meclizine presents the lowest risk
of teratogenicity and is the drug of frrst choice in
treating nausea and vomiting during pregnancy.
Pyrioxine: Pyridoxine itself is considered safe
during pregnancy, and has been used in pregnant
women without any evidence of fetal harm.
Dosage & admin: The fixed dose combination
(FDC) is recommended for oral administration.
Nausea &: vomiting (including morning sickness
in pregnancy): One tablet 1-2 times daily or as
required.
Motion sickness: The initial dose is one or two
tablets daily, it should be taken one hour prior
to journey for protection against motion
sickness. Therfore, the dose may be repeated
every 24 hours as indicated for the duration of
the journey.
Vertigo: One tablet two times daily or as
required.
Labyrinthine and vestibular disturbances: The
optimal dosage of meclizine is usually 25-
1OOmg daily in divided doses, depending on
the clinical response.
Radiation sickness: SOmg (meclizine) adminis­
tered 2-12 hours prior to radiation treatment.
Dosage in pregnancy: Meclizine: Dosage varies
from 25-50mg/day in pregnancy or as •
required. Not recommended in last 2 weeks of
pregnancy due to retrolental fibroplasia risk._
Pyridoxine: 7Smg/day is FDA-approved for
use in pregnancy. Pregnant and breast feeding
women should not take more than lOOmg/day
without a doctor's supervision.
Drug inter: See above under the text of meclizine.
•ACLIZ Plus Tab. Aristopharma
+ pyridoxine
hydrochloride BP 50mg/tablet (film coated).
lOO's pack: 300.00 MRP
•ANCLIZ Tab. MonicoPharma
'·
Meclizine hydrochloride USP 25mg + pyridoxine
hydrochloride BP 50mg/tablet (film coated).
50's pack: 150.00 MRP
• ANOSEA Plus Tab. Ibo Sina
Meclizine hydrochloride USP 25mg + pyridoxine
hydrochloride BP 50mg/tablet (film coated).
50's pack: 150.00 IP
•AN'I'INOS Tab. Pharmasia
Meclizine hydrochloride USP 25mg + pyridoxine
hydrochloride BP 50mg/tablet (film coated).
50's pack: 175.00 MRP
•AVERT PLUS Tab. Biophar1na
Meclizine hydrochloride USP 25mg + pyridoxine
hydrochloride BP 50mg/tablet (film coated).
50's pack: 150.00 MRP
 CNS DRUGS QIMP-17 (148)

+ AVONEX Tab. Novo Healthcare promethazine hydrochloride). lOO's pack: 27.83 MRP
Meclizine hydrochloride USP 25mg + pyridoxine C/I: Sensitivity to phenothiazine derivatives. t MELATIL Inj. Gaco
hydrochloride BP 50mg/tablet (film coated). S/E: Drowsiness, headache, dry mouth, gastro­ Prochlorperazine mesilate 12.5mg/ml: injection
30's pack: 75.00 MRP intestinal disturbances, blurred vision. 1 ampoule: 3.54 MRP
t DE VOMIT Tab. Silva Caution: Hepatic disease, impairment in driving t PROMTIL Tab. Square
Meclizine hydrochloride BP 25mg + pyridoxine machinery; alcohol increases CNS depression. Prochlorperazine maleate 5 mg/tablet.
hydrochloride BP 50mg/tablet (film coated). Dosage & admin: Adult: 25-7Smg daily. For 300's pack: 138.00 MRP
t

50's pack: 150.00 MRP severe nausea & vomiting in pregnancy, 25mg t PROMTIL Inj. Square
+ EMEGO Plus Tab. Opsonin at bedtime, incre-ased if necessary to a Prochlorperazine mesilate l 2.5mg/ml: injection
Meclizine hydrochloride USP 25mg + pyridoxine maximum of 1OOmg daily. l ml amp x lO's pack: 50.00 MRP
hydrochloride BP 50mg/tablet (film coated). Child: 5-10 years. 12.S-37.5mg daily. + STEMETIL Tab. Sanofi-aventis
50's pack: 131.89 MRP Prochlorperazine maleate 5mg/tablet.
t EMENIL Plus Tab. Incepta
t AVOMINE Tab. Sanofi-aventis 500's pack: 230.02 MRP
Promethazine theoclate 25mg/tablet.
Meclizine hydrochloride USP 25mg + pyridoxine t STEMETIL Inj. Sanofi-aventis
500's pack: 285.00 MRP
hydrochloride BP 50mg/tablet (film coated). Prochlorperazine mesilate 12.5mg/ml: injection
lOO's pack: 300.00 MRP • • •
lml amp x lO's pack: 50.00 MRP
• • • • • •

t t
• • •

EMEZIN Plus Tab. SK+F VERGON Tab. Opsonin

Meclizine hydrochloride USP 25mg + pyridoxine Prochlorperazine maleate 5mg/tablet.
PROMETHAZINE HCI: Tablet/ Syrup/
hydrochloride BP 50mg/tablet (film coated). 408's pack: 165.10 MRP
Injection.
50's pack: 150.00 MRP
Ind: Nausea, vomiting, vertigo, labyrinthine
t VERGON Syp. Opsonin
t MACLIXINE Tab. General
disorders, motion sickness, (and acts as anti­
Prochlorperazine mesilate 5mg/5ml: syrup
Meclizine hydrochloride BP 25mg + pyridoxine
histaminic ).
50ml bot: 35.19 MRP
hydrochloride BP 50mg/tablet (film coated).
C/I; S/E; Caution: See above i.e as P. theoclate.
t VERGON Inj. Opsonin
50's pack: 150.50 MRP Prochlorperazine mesilate 12.5mg/ml: injection
Dosage & admin: By mouth: Adult, 2S-50mg
t MECPY Tab. Medicon
daily in single or divided doses; Child, daily,
lml amp x 50's pack: 219.81 MRP
Meclizine hydrochloride USP 25mg + pyridoxine
upto 1 year S-10mg; 1-S yrs. 10-15 mg; 6-12
t VERTIGAN Tab. Pharmadesh
hydrochloride BP 50mg/tablet (film coated). Prochlorperazine maleate 5mg/tablet.
yrs. 15- 25mg.
50's pack: 150.00 MRP 500's pack: 200.00 MRP
By injection: Deep i.m injection, half oral dose.
t NOMESIS Tab. Healthcare
Prepns: See in the section of antihistaminics.
Meclizine hydrochloride BP 25mg + pyridoxine
hydrochloride BP 50mg/tablet (film coated). Drugs/or Meniere's disease
50's pack: 175.00 MRP PROCID,ORPERAZINE 21,33
+ NVP Tab. Acme
Meclizine hydrochloride BP 25mg + pyridoxine PROCHI.ORPERAZINE MALEA'I'E/
BETAHISTINE26,42
hydrochloride BP 50mg/tablet (film coated). MESILATE: Tablet/ Syrup/Injection.
50's pack: 150.00 MRP BETABISTINE: Tablet
Ind: Nausea, vomiting, vertigo, labyrinth ine
t OPT IMIN Tab. Cosmic Betahistine is a histamine analog that was
disorders, migraine, minor mental and emotional
Meclizine hydrochloride BP 25mg + pyridoxine developed following successful parenteral use of
disturbances, acute and chronic psychoses
hydrochloride BP 50mg/tablet (film coated). histamine in patients with Meniere's syndrome.
specially schizophrenia.
50's pack: 155.00 MRP Betahistine is available as betahistine
C/I: Comatose state; hone marrow depression;
t PYRIMAC Tab. ACI dihydrochloride & mesylate.
liver damage.
Meclizine hydrochloride BP 25mg pyridoxine Mode of action: Betahistine relieves dizziness &
+ S/E: Dry mouth, drowsiness. With high doses
hydrochloride BP 50mg/tablet (film coated). vertigo symptoms by improving circulation in the
extrapyramidal symptoms may occur, particularly
50's pack: 150.50 MRP microvasculature of the inner ear which leads to a
in children, elderly and debilitated patients.
t PYRIZIN Tab. Amulet pressure reduction on the membranous labyrinth
Caution: Undiagnosed and prolonged vomiting.
Meclizine hydrochloride BP 25mg pyridoxine and relives the symptoms of Meniere's disease.
+ Cardiovascular disease. Pregnancy. Concurrent
hydrochloride BP 50mg/tablet (film coated). Ind: Meniere's disease and Meniere's-like
amin. of CNS depressants. Alertness may be
50's pack: 150.00 MRP syndromes characterized by attacks of dizziness
impaired.
t S-VOM Tab. Sharif and feeling of dizziness, vertigo, tinnitus and/or
Dosage & admin: By month: Adult- minor
Meclizine hydrochloride BP 25mg pyridoxine progressive loss of hearing, usually accompanied
+ mental disturbances, S-20 mg daily in divided
hydrochloride BP 50mg/tablet (film coated). also by nausea and vomiting.
doses increasing to max. 40mg daily.
50's pack: 150.00 MRP C/I: Betahistine is contraindicated in
Schizophrenia, 75-1OOmg daily.
t VERTINA Plus Tab. Square Pheochromocytoma.
Nausea & vomiting, initially 20mg then 10mg
Meclizine hydrochloride BP 25mg pyridoxine S/E: Betahistine is generally well tolerated and
+ after 2 hours if reqd. vertigo- 15 mg daily in
hydrochloride BP 50mg/tablet (film coated). there is no known serious adverse effects. In
divided (3) doses, max. 30mg daily. Child, (use
50's pack: 150.50 MRP some circumstances gastrointestinal disturbances
syrup) 1-5 yrs. 2.5mg twice daily; 6-12 yrs.
(nausea/vomiting), headache, rashes and pruritus
+ V-NIL Tab. Alco Pharma 5mg 2 or 3 times daily.
Meclizine hydrochloride BP 25mg + pyridoxine have been reported.
By inj: Adult, 12.5 mg by deep i.m injection .
hydrochloride BP 50mg/tablet (film coated). Precautions: Caution should be exercised in
Child, use syrup.
50's pack: 150.00 MRP patients with- i. bronchial asthma (since

+ VOMEC Plus Tab. Beximco

+ AME TIL Tab. Aristopharma betahistine has a histamin-like action, it may
Prochlorperazine maleate 5mg/tablet. cause respiratory tract contraction through the
Me·clizine hydrochloride BP 25mg + pyridoxine
500's pack: 230.00 MRP intervention of HI-receptors), ii. and peptic
hydrochloride BP 50mg/tablet (film coated).
50's pack: 150.00 MRP
·

t AVOTIL Tab. Rephco ulceration (since betahistine has a histamin-like

PROMF:'J'HAZINE 21,33
PROMET HAZINE THEOCLATE: Tablet
Ind: Nausea, vertigo, labyrinthine disorders,
motion sickness (acts longer than the
Prochlorperazine maleate 5mg/tablet. action, it may enhance gastric acid secretion
200's pack: 60.00 MRP through the intervention of H2-receptors ).
t EMITAB Tab. Sonear Pregnancy & lactation: The safety of
Prochlorperazine maleate 5mg/tablet Betahistine in human pregnancy has not been
lOO's pack: 46.00 MRP completely established, although there is no
t MELATIL Tab. Gaco known teratogenic effects in animals. A careful
Prochlorperazine maleate 5mg/tablet assessment of potential benefit should be made

I

before prescribing Betahistine in pregnancy.
Betahistine is excreted in the breast milk of
mursing mother in concentrations similar to those
found in plasma. But, toxicity to the neonate at
these concentrations is not known.
Dosage & admin: See below under the
individual preparation.
Drug inter: There are no proven cases of
hazardous interactions. Yet there may be a chance
of antagonism between Betahistine and
antihistamines on a theoretical basis, but no such
interactions have heen reported.
+ MENARIL Tab. Incepta
Betahistine dihydrochloride INN 8mg/tablet
Ind; C/I; S/E; Cautions: See above under the
text.
Dosage & admin: The usual initial dose is 8mg
to 16mg 3 times daily taken preferably with
meals; maintenance dosage up to 48mg daily
have been recommended.
Children: Not recommended for children.
8mg x l OO's pack: 200.00 MRP
+ MERISON Tab. Square
Betahistine mesylate INN 6mg/tablet
Ind; C/I; S/E; Cautions: See above under the
text.
Dosage & admin: The usual initial dose is 6mg
to 12mg 3 times daily taken preferably after
meals. The dosage may be adjusted depending
on the patient's age and symptoms.
Maintenance dosage may be given up to 36mg
daily.
Children: Not recommended for children.
6mg x l OO's pack: 201.00 MRP
+ TINIRIL Tab. Opsonin
Betahistine dihydrochloride INN 8mg/tablet
Ind; C/I; S/E; Cautions: See above under the
text.
Dosage & admin: The usual initial dose is 8mg
to 16mg 3 times daily taken preferably with
meals; maintenance dosage up to 48mg daily
have been recommended.
Children: Not recommended for children.
8mg x 1 OO's pack: 176.82 MRP
+ VESERC Tab. UniMed & UniHealth
Betahistine dihydrochloride BP 8mg &
16mg/tablet
Ind; C/I; S/E; Cautions: See above under the
text.
Dosage & admin: The usual initial dose is 8mg
to 16mg 3 times daily taken preferably with
meals; maintenance dosage up to 48mg daily
have been recommended.
Children: Not recommended for children.
8mg x 50's pack: 150.00 MRP
16mg x 50's pack: 250.00 MRP
Drugs used in nausea &
vomiting in pregnancy21
Nausea & vomiting in the frrst trimester of
pregnancy usually does not require drug therapy.
If vomiting is severe, an antihistamine or a
phenothiazine (e.g. promethazine) may be given.
If not controlled within 24 to 48 hours, a
specialist advice may be required.
Preparation: See above.
I
•
QIMP-17 (149) CNS DRUGS
+ MOTILON Tab. Sanofi-aventis
Symptomatic relief of nausea Metoclopramide hydrochloride I Omg/tablet
500's pack: 169.97 MRP
& vomiting from underlying
+ MOTILON Syp. Sanofi-aventis
diseases Metoclopramide hydrochloride 5mg/5ml: syrup
l OOml bot: 15.83 MRP
+ MOTILON Drop Sanofi-aventis
CHLORPROMAZINE121 Metoclopramide hydrochloride l mg/l ml: drop
15ml bot: 9.80 MRP
CHLORPROMAZINE HCI: Tablet/ Syrup/ + MOTILON Inj. Sanofi-aventis
Injection. Metoclopramide hydrochloride 1Omg/2ml
Ind: Nausea, vomiting, intractable hiccup. Other ampoule: injection
indications, see under antipsychotic drugs. l 0 amps pack: 37 .64 MRP
C/I; S/E; Caution: see under antipsychotic
drugs.
By mouth: Adult, 25-50mg 3 times daily. Drugs used in nausea &
Child, upto 5 yrs. 5-1Omg 3 times daily; 5-12
yrs. 3/4 to 1/2 adult dose vomiting induced by
By inj: By s.c or i.m injection 12.5 -50mg 3
Chemotherapy & Radiotherapy
times daily.
Preparations: See in the section of antipsychotic
drugs. DOMPERIDONE21,26
METOCLOPRAMIDE21,33 DOMPERIDONE: Tablet/Suspension/
Suppositories
Domperidone is a dopamine antagonist. It is
METOCLOPRAMIDE HCI: Tablet/ Syrup/
available as tablet, suspension & suppositories.
Drop/Injection.
Preparations: The text literature and available
Ind: Nausea & vomiting particularly due to
preparations are being discussed in the chapter- I
gastro-intestinal disorders; Migraine, intolerence
under 'gastro-intestinal drugs'..
to drugs (i.e. vomiting); Congestive heart failure;
Post-operative conditions; Deep X-ray or cobalt
therapy.
GRANISETRON42
S/E: Drowsiness, constipation, extra pyra-midal
effects ( spcecially in children.)
GRANISETRON HCl: Tablet/Injection
Cautions: Parkinsonism; Children; Concurrent
Granisetron is a selective 5-hydroxytryptamine 3
ad.min. of anti cholinergics, phenothiazines or
(5-HT3) receptor antagonist with little or no
butyrophenones.
affinity for other serotonin receptors. It is
Adult: 15 to 20 years 5-lOmg; others, lOmg.
available as tablet and injection form. Each tablet
Both 3 times daily.
contains granisetron l mg as granisetron
Child: Under 1 yr, 1 mg twice daily; 1-3 yrs.
hydrochloride INN Each injection ampoule
.
lmg 2 or 3 times daily ; 3-5 yrs. 2mg 2 or 3
contains granisetron 1mg in 1ml as granisetron
times daily; 5-14 yrs
hydrochloride INN .
2.5-5mg 3 times daily. All orally, i.m or i. v.
Mode of action: Granisetron is a selective 5-
Usual max. doses, all ages O.Smg/kg body-wt.
hydroxytryptamine 3 (5-HT3) receptor antagonist
daily.
with little or no affinity for other serotonin
+ MAXIL Tab. Nipa receptors, including 5-TH l , SHTlA, 5-HTIB/C,
Metoclopramide hydrochlor. 1Omg/tablet. 5-HT4; for alpha!, alpha2, or beta adrenoceptors;
lOO's pack: 34.00 MRP for dopamine D2; or for histamine H1;
+ MAXIL Syp. Nipa benzodiazepine; picrotoxin; or opioid receptors.
Metoclopramide 5mg/5ml: syrup Ind: Granisetron injection is indicated for the
l OOml bot: 14.11 MRP prevention of nausea and vomiting associated
+ MAXOCOL Tab. Medimet with initial and repeat courses of emetogenic
Metoclopramide hydrochlor. 1 Omg/tablet. cancer chemotherapy including high dose
lOO's pack: 34.00 MRP cisplatin; the prevention and treatment of
+ MAXOCOL Syp. Medimet postoperative nausea and vomiting.
Metoclopramide hydrochloride 5mg/5ml: syrup. Tablet preparation is also indicated for nausea
1 OOml bot: 15.77 MRP and vomiting associated with initial and repeat
+ MECLID Tab. Jayson courses of emetogenic cancer chemotherapy,
Metoclopramide hydrochloride l Omg/tablet. including high dose cisplatin; nausea & vomiting
MRP associated with radiation, including total body
lOO's pack: 32.00
+ MECLID lnj. Jayson irradiation and fractionated abdominal radiation.
Metoclopramide hydrochloride 1Omg/2ml C/I: Granisetron is contraindicated in patients
ampoule: injection with known hypersensitivity to this drug.
10 amps pack: 35.50 MRP S/E: Headache, constipation, asthenia, diarrhea,
+ METOCOL Syp. Opsonin abdominal pain, dyspepsia, nausea and vomiting,
Metoclopramide hydrochloride 5mg/5ml: syrup dizziness, insomnia, anxiety.
l OOml bot.: 13.92 MRP Pregnancy & lactation: No evidence of
+ METOCOL Drop Opsonin impaired fertility or harm to the animal fetus
Metoclopramide hydrochloride l mg/l ml: drop have been found. However, this drug may be
15ml bot: 9.37 MRP used in pregnancy only if clearly needed. It is
CNS DRUGS
also not known whether granisetron is excreted
in ht1man milk, so, caution shoud be exercised
when granisetron is administered to a nursing
mother.
Dosage & admin: By Injection:
Prevention of chemotherapy induced nausea
and vomiting: Adults- the recommended
dosage is 1 Omcg/kg administered i. v within 30
minutes before initiation of chemotherapy, and
only on the day(s) chemotherapy is given;
injection may be administered i.v either
undiluted over 30 seconds, or diluted with
0.9o/e sodium chloride or So/e dextrose and
infused over S minutes. Paediatric patients­
the recommended dose in paediatric patients
2-16 years of age is lOmcg/kg; uses of this
drug under 2 years of age have not been
studied. Geriatric patients, renal failure
patients Ot;' hepatically impaired patients- no
dosage adjustment is required.
Prevention & treatment of postoperative nausea
& vomiting: Adults- the recommended dosage
for prevention of postoperative nausea and
vomiting is, a single dose of lmg (lml) of
injection should be diluted to Sml and admini­
stered as a slow i.v injection (over 30 seconds);
administration should be completed prior to
induction of anesthesia. For the treatment of
established post-operative nausea and vomi­
ting in adults, a single dose of lmg (lml) of
injection should be diluted to Sml & adminis­
tered by slow i.v injection (over 30 seconds).
The recommended dosage for the treatment of
nausea and/or vomiting after surgery is lmg
(lml) of injection undiluted, administered i.v
over 30 seconds. Paediatric patients- safety
and effectiveness of parenteral injection have
not been established. Geriatric patients, renal
failure patients or hepatically impaired
patients- no dosage adjustment is required.
Tablet preparation:
Einetogenic chemotherapy: The recommended
adult dosage of oral granisetron is 2mg once
daily or lmg twice daily. In the 2mg once-daily
regimen, two lmg tablets are given up to one
hour before chemotherapy; in the lmg twice­
daily regimen, the first 1 mg tablet is given up
to one hour before chemotherapy, and the
second tablet 12 hours after the frist; either
regimen is administered only on the day(s)
chemotherapy is given. Use in the elderly,
renal failure patients or hepatically impaired
patients- no dosage adjustment is required.
Radiation (either total body i"adiation or frac
tionate abdominal radiation): The
recommended adult dosage of oral granisetron
is 2mg once daily; two lmg tablets are taken
within one hour of irradiation. Paediatric use­
there is no experience with oral granisetron in
the prevention of radiation induced nausea
and vomiting in paediatric patients.
Drug inter: Granisetron does not induce or
inhibit the cytochrome P450 drug-metabolizing
enzyme system. Because granisetron is metabo­
lized by hepatic cytochrome P450 drug metabo­
lizing enzymes inducers or inhibitors of these
enzymes may change the clearance and, h�nce,
the half-life of granisetron.
+ NAURIF Tab. Square
Granisetron hydrochloride INN equivalent to
QIMP-17 (150)
granisetron I mg/tablet.
l mg x 20's pack: 562.00 MRP
+ NAURIF lnj� Square
Granisetron hydrochloride INN equivalent to
granisetron lmg/lml ampoule: injection
l mg ( l ml amp) x 5's pack: 240.95 MRP
ONDANSETRON50,58
ONDANSETRON: Tablet/Syrup/Injection/
Suppository
Ondansetron hydrochloride dihydrate is a potent,
highly selective 5-HT3 (serotonin) receptor
antagonist. It is available as- i. Ondansetron hyd­
rochloride dihydrate BP/USP equivalent to
ondansetron 4mg & 8mg/tablet (f.c ); ii. Ondan­
setron hydrochloride BP 4mg/5ml syrup; iii.
Ondansetron hydrochloride dihydrate BP/USP
2.49mg/ml equivalent to ondansetron 2mg/ml,
4ml (8mg) ampoule for i.m/i.v injection; iv.
Ondansetron hydrochloride BP/USP equivalent to
ondansetron 16mg/suppository.
Mode of action: Ondansetron is a selective
5HT3 receptor antagonist. While its mechanism
of action has not been fully characterized, ondan­
setron is not a dopamine-receptor antagonist.
Cytostatic chemotherapeutic agents & radiothera­
py may cause increase in serotonin level by stim­
ulating the mucous membrane of the stomach &
the small intestine. Serotonin receptors of the 5-
HT3 type are present both peripherally on vagal
nerve terminals and centrally in the chemorecep­
tor trigger zone of the area postrema located on
the floor of the fourth ventricle. Serotonin, by the
activation of peripheral vagal afferent fibres con­
taining 5-HT3 receptors initiates vomiting reflex,
and also promotes emesis by stimulating 5-HT3
receptors present in the central chemoreceptor
trigger zone of the area postrema. Ondansetron
due to antagonism of 5-HT3 receptors on neurons
located both in the central & peripheral nervous
system, inhibits the triggering of vomiting reflex.
Ind: Prevention and treatment of nausea and
vomiting induced by cytostatic chemotherapy and
radiotherapy. Prevention of post operative nausea
and vomiting
C/I: Hypersensitivity of any component of the
preparation; pregnancy and lactation.
S/E: Headache, sensation of warmth or flushing;
occasional alterations in liver enzymes;
constipation; on rare occasions hypersensitivity
reactions (including anaphylaxis); transient visual
disturbance and dizziness (after rapid i.v
administra-tion), pain, arrhythmias, bradycardia,
hypotension, hiccup.
Pregnancy & lactation: Pregnancy category B.
Reproduction studies at daily oral dose up to I 0
and 30mg/kg/day have been performed in ani­
mals and have revealed no evidence of impaired
fertility or harm to the fetus due to ondansetron.
There are, however, no adequate and well­
controlled studies in pregnant women. So the
drug should be used in pregnancy only if clearly
needed. Ondansetron excretes in milk of lactating
animals. Caution should be exercised when
ondansetron is administered to nursing mother.
Dosage & admin: /lymouthltablet&urHJI.);
A. In case of moderately emetogenic chemo­
therapy:
Adult: 8mg orally 1 to 2 hours before
treatment, then followed by 8mg every 12
hours for up to 5 days (or up to 1 to 2 days
after completion of chemotherapy).
Children (4 to 11 years age): The dosage is
4mg given 8 or 12 hourly 2 or 3 times a day
for up to S days.
B. Severely (highly) emeto genie chemo­
therapy:
Adult: The recommended adult oral dosage is
24mg (3 tablets) to be administered 30 minutes
before the start of single-day highly
emetogenic chemotherapy, including cisplatin
? SOmgtm2.
Then followed by 8mg orally every 12 hours
for up to S days.
For geriatric patients, same as the general
population.
The efficacy of ondansetron in highly
emetogenic chemotherapy may be enhanced
by addition of a single dose of 20mg
dexamethasone sodium phosphate by i. v
injection administered prior to chemotherapy.
Children (4 to 11 years age): The dosage is
4mg given 8 or 12 hourly 2 or 3 times a day
for up to S days.
C. Radiotherapy induced nausea and vomiting:
The recommended oral dosage is one 8mg
tablet given 3 times a day.
i. For total body irradiation, one 8mg tablet
should be administered 1 to 2 hours before
each fraction of radiotherapy administered
each day.
ii. For single high-dose fraction radiotherapy
to the abdomen, one 8mg tablet should be
administered 1 to 2 hours before radiotherapy,
with subsequent doses every 8 hours after the
first dose for 1 to 2 days after completion of
radiotherapy.
iii. For daily fractionated radiotherapy to the
abdomen, one 8mg tablet should be
administered 1 to 2 hours before radiotherapy,
with subsequent doses every 8 hours after the
first dose for each day radiotherapy is given.
D. Prevention of postoperative nausea and
vomiting:
• •
Adult- 16mg orally 1 hour before anaesthesia
or 8mg 1 hour before anaesthesia followed by
8mg at intervals of 8 hours for 2 further doses.
niection;
Bv
�ia
A. Moderately emetogenic chemotherapy or
radiotherapy: By i.m or slow i.v injection 8mg
immediately before treatment.
B. Severely emetogenic chemotherapy: By i.m
or slow i.v njection 8mg immediately before
treatment, when necessary followed by 8mg at
intervals of 2-4 hours for further 2 doses.
Children: By slow i.v injection Smglm2
immediately before chemotherapy.
C. Prevention and treatment of postoperative
nausea and vomiting: By i.m or solw i. v \.
injection 4mg at induction of anaesthesia.
Children (over 2 years): By slow i.v injection,
lOOmcg/kg (maximum 4mg before, during or
after induction of anaesthesia.
B_vsHJIJIOSitOC)'j
A. Prevention of chemotherapy induced nausea
& vomiting (CINV): Adult: The recommended
adult dose is one 16mg suppository 1-2 hours
before treatment. Ondansetron should be con­
tinued for upto S days after a course of treat-

ment. The recommended dose is one
suppository daily.
Pediatric patients: Not recommended.
B. Radiotherapy induced nausea & vomiting:
Adult: The recommended adult dose is one
16mg suppository 1-2 hours before treatment.
Ondansetron should be continued for upto 5
days after a course of treatment. The
recommended dose is one suppository daily.
Pediatric patients: Not recommended.
C. Dosage adjustment for patients with impaired
hepatic function: Not recommended.
In a son
Ondansetron USP
I
i
I
t ANSET Tab. Opsonin
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 4mg & 8mg/tablet (f.c).
4mg x 30's pack: 119.28 MRP
8mg x 30's pack: 264.97 MRP
Your trusted therapy in vomiting condition
+ ANSET Solo. Opsonin
Ondansetron hydrochloride BP 4mg/Sml: syrup.
50ml bot: 39.S8 MRP
+ ANSET lnj. Opsonin
Ondansetron hydrochloride dihydrate BP
equivalent to ondansetron 2mg/ml; 4ml (8mg)
ampoule: i.v injection.
4ml amp (8mg) x S's pack: 110.35 MRP
+ ANSET Suppo. Opsonin
Ondansetron hydrochloride BP equivalent to
ondansetron 16mg/suppository.
l 6mg x 1O's pack: 13 l .9S MRP
t AVONA 4 FT Tab. Popular
Ondansetron hydrochloride dihydrate BP
equivalent to ondansetron 4mg/tablet (flash or
orally dispersible tablet).
4mg (FT tab) x 30's pack: 120.00 MRP
t AVONA 8 Tab. Popular
Ondansetron hydrochloride dihydrate BP equiva­
. lent to ondansetron 8mg/tablet (film-coated).
.
8mg x 30's pack: 300.00 MRP
t AVONA lnj. Popular
Ondansetron hydrochloride dihydrate BP
equivalent to ondansetron 2mg/ml; 4ml (8mg)
ampoule: i.m/i. v injection.
'
I
QIMP-17 (lSl)
8mg (4ml) amp x 5's pack: 150.00 MRP
t AVONA Oral Solo. Popular
Ondansetron hydrochloride BP 4mg/5ml: syrup.
50ml bot: 35.00 MRP
t EMEREN Tab. Renata
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 4mg & 8mg/tablet (f.c).
4mg x 30's pack: 180.00 MRP
8mg x 30's pack: 300.00 MRP
t EMEREN Inj. Renata
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i.m/i.v injection.
8mg (4ml) amp x S's pack: 150.00 MRP
t EMISTAT FT Tab. Healthcare
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 4mg/tablet (flash or orally
dispersible tablet).
4mg (FT tab) x 30's pack: 180.00 MRP
t EMISTAT 8 Tab. Healthcare
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 300.00 MRP
t EMISTAT lnj. Healthcare
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
Ondansetron orally dispersible tablet,
Oral solution & IM/IV injection
i.v injection.
4ml amp (8mg) x 1O's pack: 300.00 MRP
t EMISTAT Syp. Healthcare
Ondansetron hydrochloride BP 4mg/Sml: syrup.
50ml bot: 45.00 MRP
t EMISTON-8 Tab. Ibo Sina
Ondansetron hydrochloride dihydrate USP equiv­
alent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 300.00 IP
t EMISTON Inj. Ibo Sina
Ondansetron hydrochloride dihydrate USP equiv­
alent to ondansetron 2mg/ml; 4ml (8mg)
ampoule: i.m/i.v injection.
4ml amp (8mg) x S's pack: 125.00 IP
+ OFRAN Tab. Square
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 301.02 MRP
+ OFRAN Oral Solo. Square
Ondansetron hydrochloride BP 4mg/5ml: syrup.
50ml bot: 40.00 MRP
+ OFRAN Inj. Square
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i.v injection.
-
CNS DRUGS
4ml amp (8mg) x 6's pack: 180.00 MRP
+ OFRAN Suppo. Square
Ondansetron hydrochloride BP equivalent to .
ondansetron l 6mg/suppository.
16mg x l O s pack: 200.00 MRP
'
t ONASERON Tab. Incepta
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 300.00 MRP
t ONASERON Oral Solo. Incepta
Ondansetron (as hydrochloride) BP 4mg/5ml:
syrup.
SOml bot: 30.00 MRP
.
t ONASERON Inj. Incepta
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i. v injection.
4ml amp (8mg) x 5's pack: 125.00 MRP
+ ONASIA Tab. Orion Pharma
Ondansetron hydrochloride dihydrate BP equiva­
•
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: l S0.00 MRP
+ ONASIA Oral Solo. Orion Pharma
Ondansetron hydrochloride BP 4mg/Sml: syrup.
50ml bot: 30.00 MRP
+ ONASIA lnj. Orion Pharma
®
•
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i.v injection.
4ml amp (8mg) x S's pack: 125.00 MRP
t ONAT RON 8 Tab. Novelta
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 300.00 MRP
t ONAT RON Oral Solo. Novelta
Ondansetron hydrochloride BP 4mg/5ml: syrup.
50ml bot: 45.00 MRP
t ONCODEX-4 Tab. Jayson
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 4mg/tablet (film-coated).
4mg x 30's pack: 135.60 IP
t ONCODEX-8 Tab. Jayson
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg .x 30's pack: 240.90 IP
t ONCODEX-8 Inj. Jayson
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i.v injection.
4ml amp (8mg) x 5's pack: 125.50 IP

®
Ondansetron
+ ONDASON-8 Tab. Drug Inter.
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 300.00 MRP
+ ONDASON Syp. Drug Inter.
Ondansetron hydrochloride BP 4mg/5ml: syrup.
50ml bot: 40.00 MRP
+ ONDASON Inj. Drug Inter.
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i.v injection.
4ml amp (8mg) x 3's pack: 90.00 MRP
+ ONSAT 8 Tab. Beximco
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (f.c).
8mg x 30's pack: 300.00 IP
+ ONSAT Inj. Beximco
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i.v injection.
4ml amp (8mg) x 5's pack: 125.00 IP
+ OSETRON Tab. ACI
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x lO's pack: 100.40 MRP
8mg x 30's pack: 301.20 MRP
+ OSETRON Syp. ACI
Ondansetron hydrochloride BP 4mg/5ml: syrup.
- tablet for oral medication.
50ml bot: 30.11 MRP
+ OSETRON lnj. ACI
.
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i.v injection.
4ml amp (8mg) x 5's pack: 125.45 MRP
+ PERISET Syp. Acme
Ondansetron hydrochloride BP 4mg/5ml: syrup.
50ml bot: 40.00 MRP
+ PREMESIS Tab. Globe
On�ansetron hydrochloride dihydfate BP equivale­
nt to ondansetron 4mg & 8mg/tahlet (film-coated).
4mg x 30's pack: 135.00 MRP
8mg x 30's pack: 240.00 MRP
+ PREMESIS Oral Soln. Globe
Ondansetron hydrochloride BP 4mg/5ml: syrup.
50ml bot: 30.00 MRP
+ PREMESIS lnj. Globe
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i.v injection.
4ml amp (8mg) x 5's pack: 125.00 MRP
+ SETON 8 Tab. Delta Pharma
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 240.00 MRP
+ SETRONAX 8 Tab. MonicoPharma
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 300.00 MRP
+ VOMISET Tab. RAK Pharma
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 300.00 MRP
+ VOMISET Oral Solo. RAK Pharma
Ondansetron hydrochloride BP 4mg/5ml: syrup.
50ml bot: 30.00 MRP
•
QIMP-17 (152)
+ ZOFER MD 4 Tab. Sun Pharma
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 4mg/tablet (film-coated).
4mg x 30's pack: 165.00 MRP
+ ZOFRA ODT 4 Tab. SK+F
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 4mg/tablet (film-coated).
4mg x 30's pack: 150.00 MRP
+ ZOFRA ODT 8 Tab. SK+F
Ondansetron hydrochloride dihydrate BP equiva­
lent to ondansetron 8mg/tablet (film-coated).
8mg x 30's pack: 300.00 MRP
+ ZOFR A Syp. SK+F
Ondansetron (as hydrochloride) BP 4mg/5ml:
syrup.
50ml bot: 35.00 MRP
+ ZOFRA Inj. SK+F
Ondansetron hydrochloride d.ihydrate BP equiva­
lent to ondansetron 2mg/ml; 4ml (8mg) ampoule:
i.v injection.
4ml amp (8mg) x S's pack: 150.00 MRP
PALONOSETRON138,148
PALONOSETRON: Injectionffablet
Palonose�on is a highly potent, selective, second
generation serotonin sub-type 3 (5-HT3) receptor
antagonist with a 5-HT3 receptor binding affinity
that is 100 fold higher than other 5-HT3
antagonists. It is available as- palonosetron . ,
hydrochloride INN 0.25mg in 5ml vial and. ··
0.075mg in 1:5ml vial for injectioif & 0.50mg
.•
Mode of action: It is thought that chemothera­
peutic agents produce nausea and vomiting by
releasing serotonin from the enterochromaffm
cells of the small intestine and that the released
serotonin then activates 5-HT3 receptors that are
located on the nerve terminals of the vagus in the
periphery and centrally in the chemoreceptor
trigger zone of the area postrema, to initiate the
vomiting reflex.
Palonosetron works by blocking the actions of
serotonin, associated with nausea and vomiting,
at 5-HT3 receptor. It is likely that palonosetron
works in the small intestine but it may also work
in the brain.
Ind: i. Chemotherapy-induced nausea & vomit­
ing (CINV): Acute CINV resulting in on the day
of treatment with certain types of chemotherapy;
delayed CINV resulting in on days later with
certain types of chemotherapy.
ii. Radiotherapy-induced nausea & vomiting
(RINV).
iii. Post-operative & post-discharge nausea and
vomiting (PONV & PDNV).
C/I: In patients known to have hypersensitivity
to the drug or any of its components.
S/E: The most common adverse reactions in CINV
(incidence- 5%) are headache & constipation.
The most common adverse reactions in PONV
(incidence- 2%) are QT prolongation,
bradycardia, headache and constipation.
Cautions: Hypersensitivity reactions may occur
in patients who have exhibited hypersensitivity to
other 5-HT3 receptor antagonists & patients with
intestinal obstruction or ileus. Rapid injection
may lead to temporary visual changes e.g blurred
VlSIOn.
• •
Palonosetron should be administered with caution
in patients who have or may develop prolongation
of cardiac conduction intervals, particularly QTc.
These include patients with hypokalemia or
hypomagnesemia, p�tients taking diuretics with
potential for inducing electrolyte abnormalities,
patients with congenital QT prolongation.
Pregnancy & lactation: Pregnancy category 'B'.
There are, however, no adequate and well­
controlled studies in pregnant women.
Palonosetron should be used during pregnancy
only if clearly needed.
It is not known whether palonosetron is excreted
in breast milk.
Dosage & admin: Byj.vjgjectioni
Chemotherapy-induced nausea & vomiting: A
..
single i.v dose of 0.25mg palonosetron should
be administered over 30 seconds approxi­
mately 30 minutes before the start of
chemotherapy.
Radiotherapy-induced nausea & vomiting: A
single i.v dose of 0.25mg palonosetron should
be administered over 30 seconds approximately
30 minutes before each week of radiation
fraction.
Post-operative nausea & vomiting: A single i.v
_ setron should be
dose of 0.075mg palono
administered over 10 seconds immediately
before induction of anesthesia. Repeated dos­
ing of palonosetron within a seven day interval
1s not recommended because the safety &
•
efficacy of frequent (consecutive or alternate
day) dosing in patients has not been evaluated.
Bymouthi Adult: 0.5mg tablet once daily
d�si.og..
__
., Elderly patients: No dosage adjustment is reco­
. mu,ended in elderly patients 65 years of age.
.CJ,ildren: Not recommended in patients below
J8 years of age.
·
Impaired renal & hepatic function: No dosage
adjustment is recommended.
Drug inter: In controlled clinical trials, palonos­
etron injection has been safely administered with
corticosteroids, antiemetics1antinauseants, analge­
sics, a�tispasmodics & anticholinergic agents.
Palonosetron did not inhibit the antitumor activity
of cisplatin, cyclophosphamide, cytarabine, doxo­
rubicin & mitomycin C in murine tumor models.
Concomitant administration of palonosetron and
metoclopramide has no significant pharmacoki­
netic interactions.
Palonosetron may have additive effect on
prolonging QT with drugs e.g moxifloxacin,
erythromycin, antipsychotics and TCAs.
+ PALORON Inj. Ziska
Palonosetron hydrochloride INN 0.075mg/l .5ml
vial & 0.25mg/5ml vial: i.v injection.
0.075mg (1.5ml) vial x 4's pack: 300.00 MRP
0.25mg (5ml) vial x 4's pack: 400.00 MRP
+ PALORON Tab. Ziska
Palonosetron hydrochloride INN 0.50mg/tablet.
0.50mg x 20's pack: 200.00 MRP
+ PALOXI Tab. Beacon
Palonosetron hydrochloride INN 0.50mg/tablet.
0.50mg x 20's pack: 400.00 MRP
+ PALOXI lnj. Beacon
Palonosetron hydrochloride INN 0.075mg/l .5ml
vial & 0.25mg/5ml vial: i.v injection.
0.075mg (l .5ml) vial x l 's pack: 75.00 MRP
0.25mg (5ml) vial x l 's pack: 100.00 MRP

7. ANTICONVULSANT/
ANTIEPILEPTIC
DRUGS1,2,3,21
Drugs commonly used in the treatment of
epilepsies & seizures are:
A. Generalised seizures:
1. Drugs used in major or tonic-clonic
seizures (grand mal):
Drugs of choice- Carbamazepine,
Lamotrigine, Sodium valproate,
Topiramate
Second-line drugs- Clobazam,
Levetiracetam, & Oxcarbazapine
Third-line drugs- Phenytoin,
Gabapentin, Primidone, Phenobarbitone,
1igabine or Acetazolamide
2. Drugs used in minor or absence seizures
(petitmal):
Drugs of choice- Ethosuximide
Second-line drugs- Sodium valproate
Third-line drugs- Lamotrigine,
Clonazepam, or Acetazolamide
3. Drugs used in myoclonus or myoclonic
seizures:
•
Drugs of choice- Sodium valproate
Second-line drugs- Clonazepam
Third-line drugs- Lamotrigine,
Phenobarbitone, or Piracetam ·
4. Drugs used in atypical absence,atonic,
& tonic seizures:
Drugs of choice- Clonazepam,
Lamotrigine & Sodium valproate
Second-line drugs- Clobazam,
·
Ethosuximide,·Levetiracetam, &
Topiramate
5. Drugs used in status epilepticus:
Drug of choice- Start with parenteral
'
Diazepam (or lorazepam if fits are not
controlled)
Followed by anticonvulsant drug­
Phenytoin or Sodium valproate or
Carbamazepine
B. Partial (or focal) seizures with or without
secondary generalisation:
1. Drugs used in partial (focal) seizures:
Drugs of choice- Carbamazepine,
Lamotrigine, Oxcarbazapine, Sodium
valproate & Topiramate
Second-line drugs- Clobazam,
Gabapentin, Levetiracetam, Pregabalin,
1iagabine & Zonisamide.
Third-line drugs: Clobazam, Phenytoin,
Prinmidone, Phenobarbitone,
Oxcarbazepine, Levetiracetam, Vigabatrin
or Acetazolamide
CARBAMAZEPINE21,54
CARBAMAZEPINE: Tablet/Syrup
Carbamazepine is an anti-convulsant (anti-epilep­
tic) drug, with neurotropic and psychotropic
properties. It is effective in partial and general­
ized convulsion as well as in mixed types but not
in petit mal seizures. It reduces or abolishes pain
in trigeminal & glossopharyngeal neuralgia.
It is available as ordinary and controlled release
QIMP-17 (153)
tablet and also in suspension form.
Ind: Grandma! and temporal lobe epilepsy,
trigeminal neuralgia, prophylaxis in manic
depressive illness.
C/I: Hypersensitivity to carbamazepine, patients
on MAO inhibitors or within 2 weeks of MAOI
therapy.
S/E: Dizziness, drowsiness, visual and g.i
disturbances; generalised erythematous rash
(3%); leucopenia rarely.
Cautions: Renal or hepatic impairment. Blood
dyscrasias. Pregnancy . Lactation.
Concurrent admin. of doxycycline, oral
anticoagulants and oral contraceptives. Blood
count regularly.
Dosage & admin: Adult: Initially 100-200mg
once or twice daily increasing slowly to
optimum dosage,usually 800mg to 1.2gm
daily; maximum 1.6gm daily.
Child: Upto 1 year,100-200 mg; 1-5 years 200-
400mg; 5-10 years, 400-600mg; 10-15 years
600mg-1gm. All daily in divided doess.
t ANLEPTIC Tab. Square
Carbamazepine 200mg/tablet
50's pack: 175.50 MRP
t ANLEPTIC CR Tab. Square
Carbamazepine 200mg/tablet (controlled release)
50's pack: 226.00 MRP
t ANLEPTIC Syp. Square
Carbamazepine 100mg/5ml: syrup
l OOml bot: 250.94 MRP
t CABRETOL Tab. Renata
Carbamazepine 200mg/tablet
50's pack: 195.50 MRP
t CABRETOL CR Tab. Renata
Carbamazepine 200mg/tablet (controlled release)
50's pack: 195.00 MRP
t CABRETOL Syp. Renata
Carbamazepitie 100mg/5ml: syrup
l OOml bot: 301.13 MRP
t
CARBAZIN Tab. SK+F
Carbamazepine BP 200mg/tablet
50's pack: 200.00 MRP
t CARBAZIN CR Tab. SK+F
Carbamazepine BP 200mg/tablet (cont. release)
50's pack: 225.00 MRP
t CARMAPINE Tab. Incepta
Carbamazepine BP 200mg/tablet
50's pack: 200.00 MRP
t CARMAPINE CR Tab. Incepta
Carbamazepine 200mg/tablet (controlled release)
50's pack: 250.00 MRP
+ CARMAPINE Susp. lncepta
Carbamazepine 100mg/5ml: suspension
l OOml bot: 250.00 MRP
t CAZEP Tab. Opsonin
Carbamazepine BP 200mg/tablet
50's pack: 176.82 MRP
t EPILEP Tab. Beximco
Carbamazepine BP 200mg/tablet
50's pack: 175.50 IP
t EPILEP CR Tab. Beximco
Carbamazepine BP 200mg/tablet (cont. release)
50's pack: 226.00 IP
t T EGRETOL Tab. Novartis
Carbamazepine BP 200mg/tablet
50's pack: 400.00 MRP
t TEGRETOL CR Tab. Novartis
Carbamazepine BP 200mg/tablet (cont. release)
50's pack: 425.00 MRP
t T EGRETOL Syp. Novartis
Carbamazepine BP 100mg/5ml: syrup
lOOml bot: 379.00 MRP
t ZEPTOL Tab. Sun Pharma
Carbamazepine BP 200mg/tablet
1OO's pack: 550.00 MRP
t ZEPTOL CR Tab. Sun Pharma
Carbamazepine BP 200mg & 400mg/tablet
(controlled release)
200mg x 1OO's pack: 600.00 MRP
400mg x 50's pack: 425.00 MRP
CLONAZEPAM21
CLONAZEPAM: Tablet/Drop/Injection
Ind: All forms of epilepsy; myoclonus; status
epilepticus.
C/I: Respiratory depression; acute pulmonary
insufficiency.
S/E: Drowsiness, fatigue, dizziness, muscle
hypotonia, coordination disturbances; hypersali­
vation in infants, paradoxical. aggression,
irritability and �ental changes; rarely blood
.
disorders, abnormal liver-function tests.
Cautio�s: Respiratory disease, hepatic and renal
impairment, elderly and debilitated; pregnancy
·
and breast..: feeding; avoid sudden withdrawal;
porphyria.
Driving: Drowsiness may affect the performance
.
of driving and other skilled tasks.
Dosage & admin: Adult: lmg (elderly,
500mcg), initially at night for 4 nights,
increased over 2-4 weeks to a usual mainte­
nance dose of 4-8mg daily in divided doses.
Child,up to 1 year 250mcg increased as above
to 0.5-lmg,1-5 years 250mcg increased to 1-
3mg, 5-12 years 500mcg increased to 3-6mg.
Overdosage: See treatment of poisoning.
Clonazepam USP tablet
SK+f
+ AROTRIL Tab. Aristopharma
Clonazepam 0.5mg, lmg & 2mg/tablet.
0.5mg x 1OO's pack: 400.00 MRP
lmg x 50's pack: 250.00 MRP
2mg x 30's pack: 180.00 MRP
+ CLOMA Tab. Biopharma
Clonazepam 0.5mg & 2mg/tablet.
0.5mg x 50's pack: 150.00 MRP
2mg x 30's pack: 150.00 MRP
t CLON Tab. Globe
Clonazepam 0.5mg/tablet.
0.5mg x 1OO's pack: 200.00 MRP
t CLONAPIN Tab. Popular
Clonazepam 0.5mg & 2mg/tablet.
0.5mg x 30's pack: 90.00 MRP
2mg x 30's pack: 150.00 MRP
 •,

.
For managing Arix�ty
' .. I
& SI�
-> disorder�
·
.
.
•,
.
..
.
,
·
- .

..
.

QIMP-17 (154)
.

+ EPNIL Tab. Sandoz 0.5mg x IOO's pack: 300.00 IP

IP
.

, •··J
-
Clonazepam 0.5mg & 2mg/tablet. 2mg x 50's pack: 250.00
Available as
! .
0.5mg x 50's pack: 275.00MRP
Clonium• 0.5 • Cto·nium• 1. • Cfonium• 2
2mg x 30's pack: 240.00 MRP
•

. .. \•

DIAZEPAM21
- '

+ ESYPAN Tab. Silva

+ CLONATRIL Tab. Healthcare Clonazepam 0.5mg & 2mg/tablet.
Clonazepam 0.5mg, lmg & 2mg/tablet. 0.5mg x 50's pack: 100.00MRP DIAZEP�'1\1: Injection/Suppositories.
0.5mg x 50's pack: 250.00 MRP 2mg x 50's pack: 201.00 MRP Ind: Status epilepticus; febrile and other
lmg x 30's pack: 180.00 MRP + LEPTIC Tab. Acme convulsions where rapid effect is reqd.
2mg x 30's pack: 210.00 MRP Clonazepam 0.5mg & 2mg/tablet. C/I; S/E; Cautions: See under Anxiolytic
+ CLONIUM Tab. ACI MRP
0.5mg x 1OO's pack: 300.00 drugs.
Clonazepam 0.5mg, l mg & 2mg/tablet. 2mg x 50's pack: 250.00 MRP Adult: 10-20mg i.m or i. v at a rate of 2-5
0.5mg x 1OO's pack: 300.00 MRP + LONAPAM Tab. Delta Pharma mg/30 sec. repeated after 30-60 mins. if
lmg x 50's pack: 175.94 MRP Clonazepam 0.5mg & 2mg/tablet. necessary. Then upto 3mg/ kg body-wt. by i. v
2mg x 50's pack: 250.00 MRP 0.5mg x 30's pack: 60.00 MRP inj. over 24 hours.
+ CLOPAM Tab. Sharif 2mg x 30's pack: 120.00 MRP Child: 0.2-0.3 mg/kg.
Clonazepam 0.5mg & 2mg/tablet. + LONAZEP Tab. Sun Pharma Diazepam preprs: See under Sedatives &
0.5mg x 50's pack: 150.00MRP Clonazepam 0.5mg & 2mg/tablet. Anxiolytics.
2mg x 30's pack: 150.00 MRP 0.5mg x l OO's pack: 400.00 MRP
+ CLORON Tab. SK+F 2mg x 50's pack: 300.00 MRP
ETHOSUXIMIDE52
Clonazepam 0.5mg & 2mg/tablet. + MYOTRIL Tab. Ibo Sina
0.5mg x 1OO's pack: 300.00 MRP Clonazepam 0.5mg & 2mg/tablet.
2mg· x 50's pack: 250.00 MRP 0.5mg x 50's pack: 125.00 IP ETHOSUXIMIDE: Syrup

+ COZINIL Tab. Rephco 2mg x 30's pack: 135.00 IP Ethosuximide, an anticonvulsant agent- the drug

Clonazepam 0.5mg & 2mg/tablet. + PASE Tab. Opsonin of choice in the treatment of minor or absence

0.5mg x 50's pack: 150.00 MRP Clonazepam 0.5mg, l mg & 2mg/tablet. seizures (petitmal). It is available as-

. .

.tr:•l'-. ..;$ � ...

, "' • .. •
• ,.., •&·�

lpnl*2
Oil!
n11
1
1
rn.111'1 D
... ..
K1' ,
� ......
:fr
. _.,�-�-� ; ·,· :·�·;- .
',;,.,.,.._ �.:;...,;-;.� ·�'r. ·�
.,..
): :
... .
� --�·«' � -
� .:ii;
� 4-
,...
•

.... """"'� .,
.� -··

� �$. .... �-. �< :b: •.;:W.'<el-""' ..... 6"'

0.
1.,,.
.. ..
...... ··•·•

2mg x 20's pack: 120.00 MRP 0.5mg x 50's pack: 131.95MRP Ethosuximide USP 250mg in 5ml of syrup.

+ DENIXIL Tab. Renata lmg x 30's pack: 105.57 MRP Mode of action: Ethosuximide suppresses the

Clonazepam 0.5mg & 2mg/tablet. 2mg x 30's pack: 131.95 MRP paroxysmal spike and wave pattern common to

0.5mg x 50's pack: 200.00 MRP + PASE Drop Opsonin absence seizures. The frequency of epileptifonn

2mg x 30's pack: 180.00 MRP Clonazepam 1.25mg/ml: drop. attacks is reduced apparently by depression of the

+ DEPANIL Tab. Rangs Pharma IOml drop: 70.64 MRP motor cortex and elevation of the threshold of the

Clonazepam 0.5mg & 2mg/tablet. central nervous system to convulsive stimuli.

+ RIVO Tab. Orion Pharma
0.5mg x SO's pack: 150.00 MRP Compared with other succinimide anticonvulsants,
Clonazepam 0.5mg & 2mg/tablet.
2mg x 30's pack: 150.00 MRP ethosuximide is more specific for pure absence
0.5mg x 50's pack: 150.00 MRP
seizures.
•

+ DISOPAN Tab. Incepta 2mg x 30's pack: 150.00 MRP

Clonazepam 0.5mg & 2mg/tablet. Ind: Ethosuximide is indicated for the control of

MRP
0.5mg x 1 OO's pack: 300.00
+ RIVOTRIL Tab. Roche/Radiant absence seizures.
Clonazepam 0.5mg & 2mg/tablet. C/I: Ethosuximide should not be used in patients
2mg x 50's pack: 250.00 MRP
0.5mg x 50's pack: 350.00 MRP with hypersensitivity to succinimides (e.g.
+ EPICLON Tab. General
2mg x 50's pack: 600.00 MRP methosuximide, phenosuximide) & known
Clonazepam 0.5mg & 2mg/tablet.
hypersensitivity to the active substance or to any
..

0.5mg x 50's pack: 150.00MRP + XETRIL Tab. Beximco

2mg x 30's pack: 150.00 MRP Clonazepam 0.5mg & 2mg/tablet. of the excipients.
S/E: The common side effects are- gastro-intes­
+ EPITRA Tab. Square
tinal disturbances including nausea, vomiting,
Clonazepam 0.5mg, lmg & 2mg/tablet.
diarrhoea, abdominal pain, anorexia, weight loss.
0.5mg x 1OO's pack: 300.00 MRP ®
The less frequent side effects are- headache,
lmg x 60's pack: 240.00 MRP
fatigue, drow�iness, dizziness, hiccup, ataxia,
2mg x 60's pack: 300.00 MRP
mild euphoria, irritability, aggression, impaired
Clonazepam USP tablet
+ EPITRA Drop Square concentration; rarely tongue swelling, sleep dis­
Clonazepam 2.5mg/ml: drop. turbances, night terrors, depression, psychosis,
1 Oml drop: 80.30 MRP
SK•F photophobia, dyskinesia, increased libido, vaginal

bleeding, myopia, gingival hypertrophy, and rash;
hyperactivity, increase in seizure frequency;
blood disorders such as leucopenia, agranulocyto­
sis, pancytopenia, and aplastic anaemia; systemic
lupus erythematosus, and Stevens-Johnson
syndrome.
Precautions: Ethosuximide should be used with
caution in hepatic or renal impairment.
Ethosuximide may impair the mental and/or
physical abilities required for the performance of
potentially hazardous tasks such as driving or
other such activities requiring alertness.
Therefore, the patient should be cautioned
accordingly. Abrupt withdrawal should be
avoided. Patients should be monitored for signs
of suicidal ideation & behaviors and appropriate
treatment should be considered.
Pregnancy & lactation: Ethosuximide crosses
the placenta. Risk-benefit ratio should be
weighed in treating or counseling epileptic
women of childbearing potential.
Ethosuximide is excreted in breast milk. It should
be used in nursing mothers only if the benefits
clearly outweigh the risks. Breast feeding is best
avoided.
Dosage & admin: Pediatric patients:
���r!2�'mF�?��t ��rzi 1tvR�1 ;�:�1•l ·.��· r t.-
··
. . ·. · . : . .. . . . . . . · . .· ... . . . .
- �.
The light protected clonazepam
in Bangladesh
Children 3-6 years of age: Initially 250mg
(5ml) daily in a single dose.
Children � years of age: Initially 500mg
(1Oml) daily in a single dose or divided doses.
Dosage should be increased by small
increments, by 250mg (5ml) every 4-7 days
until seizure control is achieved with minimal
adverse effects. Dosage usually should not be
>1.5gm (30ml) daily, given in divided doses. If
dosage is > 1.5gm daily, clinician must closely
supervise patient.
Usual maintenance dosage- 20mg/kg or
1.2gm/m2 daily
Adults: Initially 500mg (1 Oml) daily in a single
dose or divided doses. Dosage should be
increased by small increments, by 250mg
(5ml) every 4-7 days until seizure control is
achieved with minimal adverse effects. Dosage
usually should not be >1.5gm (30ml), given in
divided doses. Usual maintenance dosage-
20mg/kg or 1.2gm/m2 daily.
Drug inter: The plasma concentrations of
ethosuximide may be reduced by carbamazepine,
primidone, phenobarbitone and lamotrigine and
increased by isoniazid. No consistent changes in
QIMP-17 (155)
levels of ethosuximide occur when used in
combination with phenytoin or sodium valproate.
Phenytoin levels however are increased by
concomitant ethosuximide.
+ SERONTIN Syp. ACI
Ethosuximide USP 250mg/5ml: syrup
70ml bot: 100.00 MRP
FOSPHENYTOIN 133
FOSPHENYTOIN: IM/IV Injection
Fosphenytoin sodium is a pro-drug intended for
•
parenteral administration and its active metabo-
lite is phenytoin. It is available as fosphenytoin
· Phenytoin & other hydantoins are contraindicated
sodium USP 150mg equivalent to 1OOmg
phenytoin sodium in 2ml ampoule as a ready­
mixed solution in water for i.m/i.v injection.
Ind: Fosphenytoin is indicated for short-term
parenteral administration when other means of
phenytoin administration are unavailable,
inappropriate or deemed less advantageous.
F osphenytoin can be used for the control of
generalized con.vulsive status epilepticus and
prevention and treatment of seizures occurring
during neurosurgery or head injury. It can also be
. .
.... . .
·
o· .��11;1�"\�f;!
.
.. .. . - . . .:.· .·t·-;:· . :. . ..'·.. ;:. · · · ·
. . .
: : .
. ... -.
Once daily
.
Clonazepam
••• promises depression and anxiety free life
substituted, short-term, for oral phenytoin. The
safety and effectiveness of fosphenytoin in this
use has not been systematically evaluated for
more than 5 days.
C/I: Fosphenytoin is contraindicated in patients
who have demonstrated hypersensitivity to fos­
phenytoin or its ingredients, or to phenytoin or
other hydantoins. Fosphenytoin is also contra­
indicated in patients with sinus bradycardia, sino­
atrial block, second and third degree A-V block,
and Adams-Stokes syndrome.
S/E: The more important adverse clinical events
caused by the i.v use of fosphenytoin or pheny­
toin are cardiovascular collapse and/or central
nervous system depression. Hypotension can
occur when either drug is administered rapidly by
the i.v route. The rate of administration should
not exceed 150mg PE/min. The adverse clinical
events most commonly observed were nystag­
mus, dizziness, pruritus, paresthesia, headache,
somnolence, and ataxia. General safety advice:
I.V infusion of fosphenytoin has been associated
with severe cardiovascular reactions including
asystole, ventricular fibrillation, and cardiac
arrest. Hypotension, bradycardia, and heart block
CNS DRUGS
have also been reported. The safety advices: 1.
Monitor heart rate, blood pressure, and respirato­
ry function for duration of infusion. 2. Observe
patient for at least 30 minutes after infusion. 3. If
hypotension occurs, reduce infusion rate or
discontinue. 4. Reduce dose or infusion rate in
elderly, and in renal or hepatic impairment
Precautions: Phosphate load: The phosphate
load provided by fosphenytoin (0.0037 mmol
phosphate/mg PE fosphenytoin) should be
considered when treating patients who require
phosphate restriction, such as those with severe
renal impairment.
General: Fosphenytoin is not indicated for the
treatment of absence seizures.
in patients who have experienced phenytoin
hypersensitivity. Phenytoin has been infrequently
associated with the exacerbation of porphyria.
Phenytoin may also raise the serum glucose
concentrations in diabetic patients.
Warnings: Doses of fosphenytoin are expressed
as their phenytoin sodium equivalents in this
labeling (PE=Phenytoin sodium Equivalent). Do
not, therefore, make any adjustment in the rec­
ommended doses when substituting fosphenytoin
. ..
. -�.
Escitalopram tablet
for phenytoin sodium or vice versa. Fosphenytoin
sodium should always be prescribed & dispensed
in phenytoin sodium equivalent units (PE). The
following warnings are based on experience with
fosphenytoin or phenytoin. Status epilepticus
dosing regime: Do not administer fosphenytoin at
a rate greater than 150mg PE/min.
The dose of i.v fosphenytoin ( 15 to 20mg PE/kg)
that is used to treat status epilepticus is adminis­
tered at a maximum rate of 150mg PE/min. The
typical fosphenytoin infusion administered to a
50kg patient would take between 5 and 7 min­
utes. If rapid phenytoin loading is a primary goal,
i. v administration of fosphenytoin is preferred.
Withdrawal precipitated seizure, status epilepti­
cus: Antiepileptic drugs should not be abruptly
discontinued because of the possibility of
increased seizure frequency, including status
epilepticus. When the need for dosage reduction,
discontinuation, or substitution of alternative
antiepileptic medication arises, this should be
done gradually. However, in the event of an aller­
gic or hypersensitivity reaction, rapid substitution
of alternative therapy may be necessary.
Cardiovascular depression: Fosphenytoin should
CNS DRUGS
be used with caution in patients with hypotension
and severe myocardial insufficiency. Rash:
Fosphenytoin should be discontinued if a skin
rash appears. Hepatic injury: Cases of acute
hepatotoxicity, including infrequent cases of
acute hepatic failure, have been reported with
phenytoin. In these patients with acute hepatotox­
icity, fosphenytoin should be immediately discon­
tinued and not read.ministered. Hemopoietic sys­
tem: Hemopoietic complications, some fatal,
have occasionally been reported in association
with administration of phenytoin. These have
included thrombocytopenia, leukopenia, granulo­
cytopenia, agranulocytosis, and pancytopenia
with or without bone marrow suppression.
Alcohol use: Acute alcohol intake may increase
plasma phenytoin concentrations while chronic
alcohol use may decrease plasma concentrations.
Pregnancy & lactation: Fosphenytoin is contra­
indicated during pregnancy. Because prenatal
exposure to phenytoin may increase the risks for
congenital malformations and other adverse
developmental outcomes. Breast-feeding is not
recommended for women receiving fosphenytoin.
Dosage & admin: The dose, concentration in
dosing solutions, and infusion rate of i.v fos­
phenytoin is expressed as phenytoin sodium
equivalents; (fosphenytoin sodium 1.Smg
equivalent to phenytoin sodium lmg) to avoid
the need to perform molecular weight-based
adjustments when converting between fos­
phenytoin and phenytoin sodium doses.
Products with particulate matter or discolo­
ration should not be used. Prior to i.v infusion,
dilute fosphenytoin in So/o dextrose or 0.9°/o
•
saline solution for injection to a concentration
ranging from l.Smg to 25mg PE/ml..
Status epilepticus: By i.v infusion (at a rate of
100mg-150mg (PE)/minute), initially 15mg
(PE)/kg then by i.m injection or by i.v infusion
(at a rate of 50mg-100mg (PE)/minute), 4-Smg
(PE)/kg daily in 1-2 divided doses; dose
adjusted according to response and through
plasma-phenytoin concentration.
Child 5 yean and over: By i.v infusion (at a
rate of 2-3mg (PE)/kg/minute), initially 15mg
(PE)/kg then by intravenous infusion (at a rate
of 1-2mg (PE)/kg/minute), 4-Smg (PE)/kg daily
in 1-4 divided doses; dose adjusted according
to response and through plasma-phenytoin
concentration.
Prophylaxis or treatment of seizures associated
with neurosurgery or head injury: By i.m
injection or by i.v infusion (at a rate of 50-
lOOmg (PE)/minute, initially 10-15mg (PE)/kg
then by i.m injection or by i.v infusion (at a
rate of 50-lOOmg (PE)/minute), 4-Smg (PE)/kg
daily (in 1-2 divided doses), dose adjusted
according to response and through plasma­
phenytoin concentration.
Child 5 yean and over: By i.v infusion (at a
rate of 1-2mg (PE)/kg/minute), initially 10-15
mg (PE)/kg then 4-Smg (PE)/kg daily in 1-4
divided doses; dose adjusted according to
response and through plasma-phenytoin
concentration.
Temporary substitution for oral phenytoin: By
i.m injection or by i.v infusion (at a rate of 50-
1OOmg (PE)/minute); same dose and dosing
frequency as oral phenytoin therapy.
QIMP-17 (156)
Child 5 yean and over: By i.v infusion (at a
rate of l-2mg (PE)/kg/minute), same dose and
dosing frequency as oral phenytoin therapy.
Dosing in special populations: Patients with
renal or hepatic disease: After i. v fosphenytoin
administration to patients with renal and/or
hepatic disease, or in those with hypoalbu­
minemia, fosphenytoin clearance to phenytoin
may be increased without a similar increase in
phenytoin clearance. This has the potential to
increase the frequency and severity of adverse
events. Elderly: Age does not have a signifi­
cant impact on the pharmacokinetics of fosph­
enyton following fospbenyton admin.istration.
Phenyton clearance is decreased slightly in
elderly patients and lower or less frequent
dosing may be required.
Overdosage: Nausea, vomiting, lethargy, tachy­
cardia, bradycardia, asystole, cardiac arrest,
hypotension, syncope, hypocalcemia, metabolic
acidosis, and death have been reported in cases of
overdosage with fosphenytoin. Initial symptoms
of acute phenytoin toxicity are nystagmus, ataxia,
and dys arthria. Treatment is nonspecific since
there is no known antidote to fosphenytoin or
phenytoin overdosage. The adequacy of the respi­
ratory and circulatory systems should be careful­
ly observed, and appropriate supportive measures
employed. Hemodialysis can be considered since
phenytoin is not completely bound to plasma
proteins. Total exchange transfusion has been
used in the treatment of severe intoxication in
children. In acute overdosage the possibility of
other CNS depressants, including alcohol, should
be borne in mind.
Drug inter: No drugs are known to interfere
with the conversion of fosphenytoin to phenytoin.
Drugs that may increase plasma phenytoin con­
centrations include: Acute alcohol intake, amio­
darone, chloramphenicol, chlordiazepoxide,
cimetidine, diazepam, dicumarol, disulfrram,
estrogens, ethosuximide, fluoxetine, Hi-antago­
nists, halothane, isoniazid, methylphenidate, phe­
nothiazines, phenylbutazone, salicylates, succin­
imides, sulfonamides, tolbutamide, trazodone.
Drugs that may decrease plasma phenytoin con­
centrations include: Carbamazepine, chronic
alcohol abuse, reserpine. Drugs that may either
increase or decrease plasma phenytoin concentra­
tions include: Phenobarbital, valproic acid, and
sodium valproate. Similarly, the effects of pheny­
toin on phenobarbital, valproic acid and sodium
plasma valproate concentrations are
unpredictable.
t FOSFEN IM/IV Inj. Popular
Fosphenytoin sodium USP l 50mg (equivalent to
lOOmg phenytoin sodium) in 2ml ampoule as a
ready-mixed solution in water for i.m/i.v
injection.
2ml (150mg) amp x S's pack: 351.30 MRP
GABAPENTIN26
GABAPENTIN: Tablet/Capsule/Syrup
Gabapentin is an anti-convulsant drug. It is a
structural analog of gamma-amino-butyric-acid
(GABA). It is available as- gabapentin USP
1 OOmg, 300mg & 600mg film-coated tablet/cap­
sule & 250mg/5ml syrup.
Mode of action: Pharmacological actions of
gabapentin are due to the activity of its parent
compound. It increases brain GABA levels, binds
to alpha-2-delta subunit of voltage-gated L-type
calcium channel, and. inhibit branched chain
amino acid transferase and probably inhibits neu­
rotransmitter release of excitatory amino acids.
Ind: 1. Neuralgia: (a) pain from diabetic neu­
ropathy, (b) post herpetic neuralgia.
2. Partial seizures: Gabapentin is indicated as
adjunctive therapy in the treatment of partial
seizures with & with-out secondary generaliza­
tion in patients over 12 yrs. of age with epilepsy.
3. Sleep disturbances and mood disorders.
C/I: Known hypersensitivity to the drug.
S/E: Generally gabapentin is well tolerated but a
few side effects like fatigue, dizziness, ataxia,
weight gain, peripheral edema, dry mouth and
somnolence may occur. Rarely, it may cause
fulminant hepatic failure, or aplastic anemia.
Precautions: Patients should be instructed to
take gabapentin only as prescribed.
While using gabapentin patients should be
instructed either not to drive a car or to operate
other complex machinery until they have gained
sufficinet experiences about gabapentin whether
or not it affects their mental and/or motor
performance adversely.
Pregnancy & lactation: Gabapentin is a
pregnancy category-c drug; it should be used
during pregnancy only if the potential benefit
justifies the potential risk to the fetus.
Gabapentin may be secreted through the breast
milk like many other drugs, so it should be used
in women who are nursing, only if the benefits
clearly outweigh the risks.
Dosage & admin: Neuralgia: The effective
dose of gabapentin is 300-1800mg daily in
three divided doses; maximum dose is 3600mg
daily in 3 divided doses. Seizure: The effective
dose of gabapentin is 900-1800mg daily in
three divided doses. The starting dose is
300mg three times a day. Doses of 3600mg/day
have also been administered to a small
number of patients for a relatively short
duration, and have been found well tolerated.
The maximum time between doses should not
exceed 12 boon.
In sleep disorder or mood disorder: 900mg
daily in divided doses found effective.
Children: Safety and effectiveness in pediatric
patients below the age of 12 years have not
been established.
In case of renal impairment gabapentin doses
must be reduced:
Creatinine clearance >60ml/min: max. dose
1200mg daily orally in 3 divided doses.
Creatinine clearance 30-60ml/min: max. dose
600mg daily orally in 2 divided doses.
Creatinine clearance 15-30ml/min: max. dose
'
300mg daily orally in single dose.
Creatinine clearance <15ml/min: max. dose
150mg daily orally in single dose or 300mg
every alternate day.
For patients on hemodialysis: max. 300mg
dose only after each dialysis session.
Gabapentin can be taken orally with or
without food.
Drug inter: Antacids may reduce the bioavail­
ability of gabapentin by up to 20%. Cimetidine
•
 QIMP-17 (157) CNS DRUGS

may alter its renal excretion. Gabapentin does not
interact with other antiepileptic agent or with oral
contraceptive preparation.
Overdosage: Overdosage of up to 30gm has
been reported. The symptoms consist of drwsi­
ness, dizziness, slurred speech and mild diarrhea.
Gabapentin can be removed by hemodialysis .
•
like symptoms, drowsiness; rarely hepatic
dysfunction, lymphadeno-pathy, leucopenia, and
thrombocytopenia reported in conjuction with
rash; angioedema, Stevens-Johnson syndrome,
toxic epidermal necrolysis and photosensitivity
also reported; diplopia, blurred vision, dizziness
drowsiness insomnia, headache, ataxia, tiredness,
500mg/5ml syrup; and levetiracetam USP
500mg/5ml ampoule for i.v infusion.
Mode of action: The exact mechanism of action
is unknown but does not involve inhibitory and
excitatory neurotransmission. Stereo-selective
binding of levetiracetam was confined to synaptic
plasma membranes in the central nervous system

gastro-intestinal disturbances, irriability, with nobinding occurring in peripheral tissues.

+ EPIPEN Tab. Beximco aggression, tremor, agitation, confusion; Ind: Levetiracetam is indicated- i. as adjunctive
Gabapentin USP 300mg/tablet. headache, nausea dizziness, diplopia and ataxia therapy in the treatment of partial onset seizures
300mg x 30's pack: 541.80 IP in patients also taking carbamazepine usually in adults and children 4 years of age and older
+ GABA Tab. Renata resolve when dose of either drug reduced. with epilepsy; ii. as adjunctive therapy in the
Gabapentin USP 300mg & 600mg/tablet. Cautions: Closely monitor (including hepatic, treatment of myoclonic seizures in adults and
300mg x 30's pack: 482.10 MRP renal and clotting parameters) and consider adolescents 12 years of age and older with juve­
600mg x 18's pack: 541.98 MRP withdrawal if rash, fever, influenza-like nile myoclonic epilepsy; iii. as adjunctive therapy
+ GABAMAX Tab. Beacon symptoms, drowsiness, or worsening of seizure in the treatment of primary generalized tonic­
Gabapentin USP 300mg/tablet. control develops, specially in the frrst month of clonic seizures in adults and children 6 years of
300mg x 20's pack: 320.00 MRP treatment. {It is found that lamotrigine given age & older with idiopathic generalized epilepsy.
+ GABAPEN Tab. Incepta with other antiepileptics has been associated with C/I: Hypersensitivity to levetiracetam or any of
Gabapentin USP 1OOmg, 300mg & 600mg/tablet. rapidly P!ogressive illness with status epilepticus, the inactive ingredients in levetiracetam tablets.
l OOmg x 30's pack: 180.00 MRP multi-organ dysfunction, disseminated S/E: Nausea, vomiting, dyspepsia, diarrhoea,
300mg x 30's pack: 480.00 MRP intravascular coagulation & death). Avoid abrupt abdominal pain, anorexia, weight changes; couh;
600mg x 20's pack: 600.00 MRP withdrawal (taper off over 2 weeks or longer). drowsiness, asthenia, amnesia, ataxia, seizures,
+ GABANTIN Cap. Sun Pharma Renal impairment. Pregnancy & breast-feeding. dizziness, headache, tremor, hyperkinesia,
Gabapentin USP 1OOmg & 300mg/capsule Dosage & admin: Don't confuse the different depression, emotional lability, insomnia, anxiety,
1OOmg x 50's pack: 300.00 MRP combinations: impaired attention, aggerssion, irritability;
300mg x 30's pack: 480.00 MRP Monotherapy: thrombocytopenia; myalgia; visual disturbances;
+ GABASTAR Tab. Square Adult: Initially 25mg daily for 14 days then pruritus, rash; also reported pancreatitis, hepatic
Gabapentin USP 1OOmg, 300mg & 600mg/tablet. SOmg daily for further 14 days; usual dysfunction, confusion, psychosis, hallucinations,
1OOmg x 30's pack: 180.60 MRP maintenance as monotherapy, 100-200mg daily suicidal ideation, paraesthesia, leucopenia,
300mg x 30's pack: 481.80 MRP in 1-2 divided doses (up to SOOmg daily has pancytopenia, and alopecia.
600mg x lO's pack: 301.10 MRP been required). Elderly not recommended. Precautions: Patients should be advised that
+ GABASTAR Syp. Square Adjunctive therapy with valproate: levetiracetam may cause dizziness and
Gabapentin USP 250mg/5ml: syrup Adult: Initially 25mg every other day for 14 somnolence. Accordingly, patients should be
50ml bot: 100.00 MRP days then 25mg daily for further 14 days; advised not to drive or operate machinery or
+ GABATIN-300 Tab. UniMed & UniHealth usual maintenance with valproate 100-200mg engage in other hazardous activities until they
Gabapentin USP 300mg/tablet. daily in 1-2 divided doses. Elderly: not have gained sufficient experience on
300mg x 20's pack: 300.00 MRP recommended. levetiracetam to gauge whether it adversely
+ GABON Tab. Acme Children (2-12 years): Adjunctive therapy affects their performance of these activities.
Gabapentin USP 300mg/tablet. with valproate, initially _200mcg/kg daily for 14 Patients should be advised that levetiracetam may
300mg x 30's pack: 480.00 MRP days then SOOmcg/kg daily for further 14 days cause changes in behavior (e.g aggression,
+ GABOTON Tab. Sandoz (those weighing less than 25kg may receive agitation, anger, anxiety, apathy, depression,
Gabapentin USP 300mg/tablet. Smg on alternate days for frrst 14 days); usual hostility, and irritability) and in rare cases
300mg x 30's pack: 483.00 MRP maintenance with valproate 1-Smg/kg daily in patients may experience psychotic symptoms
+ GPENTIN Tab. Opsonin 1-2 divided doses. and/or suicidal ideation.
-

. .. Gabapentin USP 300mg/tablet. Adjunctive therapy without valproate: Pregnancy & lactation: There are no adequate
300mg x 30's pack: 423.84 MRP Adult: Initially SOmg daily for 14 days t�en data from the use of levetiracetam in pregnant
+ GPENTIN Syp. Opsonin SOmg twice daily for further 14 days; usual women. Levetiracetam should not be used during
Gabapentin USP 250mg/5ml: syrup maintenance without valproate 200-400mg pregnancy unless clearly necessary.
l OOml bot: 131.95 MRP daily in 2 divided doses; Discontinuation of antiepileptic treatments may
+ NEPSYTab. SK+F Elderly not recommended. result in exacerbation of the disease which could
Gabapentin USP 300mg/tablet. Children (2-12 years): Adjunctive therapy be harmful to the mother and the foetus.
300mg x 20's pack: 320.00 MRP without valproate, initially 2mg/kg daily in 2 Levetiraetam is excreted in human breast milk.
+ NEUROPEN Tab. Drug Inter. dividd doses for 14 days then Smg/kg daily in Therefore, breast-feeding is not recommended.
Gabapentin USP 300mg/tablet. 2 divided doses for further 14 days; usual Dosage & admin: By mouth:
300mg x 30's pack: 480.00 MRP maintenance without valproate 5-lSmg/kg
Monotherapy:
+ NEUROTIN Tab. Silva daily in 2 divided doses.
Gabapentin USP 300mg & 600mg/tablet. 1. Adults & adolescents from 16 years of age:
300mg x 30's pack: 451.00 MRP + LAMITRIN Tab. ACI The recommended starting dose is 250mg
600mg x 20's pack: 562.00 MRP Lamotrigine 25mg & 50mg/tablet twice daily which should be increased to an
25mg x 30's pack: 300.00 MRP initial therapeutic dose of SOOmg twice daily
50mg x 30's pack: 540.00 MRP after two weeks. The dose can be further
LAMOTRIGINE47 increased by 250mg twice daily every two
weeks depending upon the clinical response.
LEVETIR ACETAM42,54 The maximum dose is lSOOmg twice daily.
LAMOTRIGINE: Tablet
Ind: Monotherapy of partial seizures and primary 2. Adults & adolescentrs (12-17 years) weighing
and secondarily generalised tonic-clonic seizures; LEVETIRACETAM: Tablet/Syrup/Injection 50kg or more: The initial therapeutic doses is
adjunctive treat-ment of partial seizure and Levetiracetam is an antiepileptic drug chemically SOOmg twice daily. This dose can be started on
secondarily generalised tonic-clonic seizures. unrelated to existing antiepileptic drugs {AEDs). the first day of treatment. Depending upon the
C/I: Hepatic impairment. It is available as- levetiracetam USP 250mg & clinical response & tolerability, th,e daily dose
S/E: Commonly rashes, fever, malaise, influenza- 500mg/tablet (film coated); levetiracetam USP can be increased up to 1,SOOmg twice daily.
CNS DRUGS
Dose changes can be made in 500mg twice
daly increases or decreases every 2 to 4 weeks.
3. Elderly (65 years and older): Adjustment of
the dose is recommended in elderly patients
with compromised renal function.
4. Children aged 4 to 11 years & adolescents (12
to 17 years) weighing less than 50kg: The initial
therapeutic dose is lOmg/kg twice daily.
Depending upon the clinical response and tol­
erability, the dose can be increased up to
30mg/kg twice daily. Dose changes should not
exceed increases or decreases of 1Omg/kg twice
daily every two weeks. Dosage in children
50kg or greater is the same as in adults.
5. Infants & children less than 4 years:
1 month to< 6 months 7mg/kg twice daily,
may be increased upto 2lmg/kg twice daily;*
6 months to< 4 years lOmg/kg twice daily,
may be increased upto 25mg/kg twice daily.*
*(The daily dose should be increased every 2
weeks).
6. Patients with renal & hepatic impairment:
The daily dose must be individualised
according to renal function. No dose
adjustment is needed in patients with mild to
moderate hepatic impairment. In patients with
severe hepatic impairment, the creatinine
clearance may underestimate the renal
insufficiency. T herefore a 50°/o reduction of
the daily maintenance dose is recommended
when the creatinine clearance is< 70ml/min.
niectig n;
�ia
Bv
Levetiracetam injection is for intravenous use
only & must be diluted prior to administration.
Levetiracetam injection (500mg/5ml ampoule)
should be diluted in 1 OOml of compatible dilu­
ents and administered intravenously as a 15-
minute i. v infusion. Product with particulate
matter or discoloration should not be used.
Dosing instructions:
i. 500mg in 5ml (1 amp.) to be diluted in
1OOml of compatible diluents and adminis­
tered intravenously as a 15-min. i.v infusion.
ii. lOOOmg in lOml (2 amps.) to be diluted in
1OOml of compatible diluents and adminis­
tered intravenously as a 15-minute i.v infusion.
iii. 1500mg in 15ml (3 amps.) to be diluted in
1OOml of compatible diluents and adminis­
tered intravenously as a 15-minute i.v infusion.
(Compatible diluents- i. Sodium chloride 0.9°/o
injection USP, ii. Lactated Ringer's injection,
iii. Dextrose 5o/o injection USP).
Adult patients with impaired renal function:
Levetiracetam dosing must be individualized
according to the patient's renal function
status. Recommended doses and adjustment:
i. When renal function in normal, (creatinine
clearance >80ml/min), normal dosage schedule
(500-1500mg 12 hourly) can be maintained;
ii. When renal function in mildly impaired
(creatinine clearance 50-80ml/min), dosage
should be adjusted as 500-lOOOmg 12 hourly;
iii. When renal function in moderately
impaired, (creatinine clearance 30-50ml/min),
dosage should be adjusted as 250-750mg 12
hourly;
iv. When renal function in severely impaired,
(creatinine clearance< 30ml/min), dosage
should be adjusted as 250-500mg 12 hourly;
v. If the patient is under dialysis, dosage
QIMP-17 (158)
should be adjusted as 500-lOOOmg daily.
Over dosage: The highest known dose of leve­
tiracetam received in the clinical development
program was 6000mg/day. Other than drowsi­
ness, there were no adverse events in the few
known cases of overdose in clinical trials. Cases
of somnolence, agitation, aggression, depressed
level of consciousness, respiratory depression and
coma were observed with levetiracetam overdos­
es in postmarketing use. If indicated, elimination
of unabsorbed drug should be attempted by
emesis or gastric lavage; usual precautions
should be observed to maintain airway.
Drug inter: Phenytoin: Levetiracetam (3000mg
daily) had no effect on the pharmacokinetic
disposition of phenytoin in patients with refractory
epilepsy. Pharmacokinetics of levetiracetam were
also not affected by phenytoin.
Valproate: Levetiracetam (1500mg twice daily)
did not alter the pharmacokinetics of valproate in
healthy volunteers. Valproate 500mg twice daily
did not modify the rate or extent of levetiracetam
absorption or its plasma clearance or urinary
excretion.
Potential drug interactions between levetiracetam
and other AEDs (carbamazepine, gabapentin,
lamotrigine, phenobarbital, phenytoin, primidone
and valproate) were also assessed by evaluating
the serum concentrations of levetiracetam and
these AEDs during placebo-controlled clinical
studies. These data indicate that levetiracetam
does not influence the plasma concentration of
other AEDs and that these AEDs do not influence
the pharmacokinetics of levetiracetam.
Note: For further information, please consult
manufacturer's literature.
+ CITAZAR Tab. ACI
Levetiracetam USP 250mg & 500mg/tablet (f.c).
250mg x 20's pack: 301.20 MRP
500mg x 1 O's pack: 250.90 MRP
+ ELETAM Tab. UoiMed & UniHealth
Levetiracetam USP 250mg & 500mg/tablet (f.c).
250mg x 20's pack: 240.00 MRP
500mg x 20's pack: 480.00 MRP
+ ELETAM Oral Solo. UniMed & UniHealth
Levetiracetam USP 1 OOmg/ml: syrup.
IOOml bot: 400.00 MRP
+ ERATA Tab. Sandoz
Levetiracetam USP 250mg & 500mg/tablet (f.c).
250mg x 30's pack: 483.00 MRP
500mg x 30's pack: 906.00 MRP
+ IRACET Tab. Square
Levetiracetam USP 250mg & 500mg/tablet (f.c).
250mg x 20's pack: 300.00 MRP
500mg x lO's pack: 250.00 MRP
+ IRACET Oral Soln. Square
Levetiracetam USP 500mg/5ml: syrup.
50ml bot: 200.00 MRP
+ IRACET I.V Inf. Square
Levetiracetam USP 500mg/5ml ampoule for i.v
infusion.
500mg (5ml amp) x 6's pack: 240.00 MRP
OXCARBAMAZEPINE54
OXCARBAMAZEPINE: Tablet/Suspension
Oxcarbamazepine 300mg and 600mg/tablet (f.c).
Ind: Epilepsy- partial seizures or generalised
tonic-clonic seizures.
C/I: Hypersensitivity to oxcarbamazepine or any
other component of the formulation.
S/E: Very common- fatigue, dizziness, headache,
somnolence, nausea, vomiting, diplopia.
Common- asthenia, agitation, amnesia, apathy,
ataxia, impaired concentration, confusion, depres­
sion, emotional !ability, nys�gmus, tremor, con­
stipation, diarrhoea, abdominal pain, asympto­
matic hyponatraemia, acne, alopecia, rash, verti­
go, vision disorders. Uncommon- leucopenia,
increase of liver enzymes, urticaria. Very rare­
angioedema, multiqrgan hypersensitivity disor­
ders, arrhythmia, thrombocytopenia, hepatitis,
symptomatic hyponatraemia, Stevens-Johnson
syndrome, systemic lupus erythematosus.
Precautions & warnings: Hypersensitivity to
carbamazepine. Pregnancy and lactation.
Impaired renal function (creatinine clearance-
>30ml/min). Hyponatraemia (specially in patients
on sodium-lowering comedication). Patients with
pre-existing cardiac insufficiency and secondary
heart failure. Hepatitis. Abrupt discontinuation of
treatment. Road and machinery users. Alcohol.
Dosage & admin: Adults: 600-2400mg/day.
Children: 2 years of age and above 8-46mg/kg/
day. Administration in two divided doses.
Drug inter: Felodipine, oral contraceptives.
Antiepileptics (e.g carbamazepine, phenobarbital,
phenytoin).
Note: For further information consult full
prescribing information.
+ OXAZEP Tab. Incepta
Oxcarbamazepine INN 300mg & 600mg/tablet
(f.c).
300mg x 30's pack: 360.00 MRP
600mg x 20's pack: 400.00 MRP
+ OXAZEP Susp. lncepta
Oxcarbamazepine INN 300mg/5ml: suspension.
1 OOml bot: 250.00 MRP
+ OXETOL Tab. Sun Pharma
Oxcarbamazepine 150mg & 300mg/tablet (f.c).
150mg x 50's pack: 350.00 MRP
300mg x 50's pack: 590.00 MRP
+ T RILEPTAL Tab. Novartis
Oxcarbamazepine 300mg and 600mg/tablet (f .c).
300mg x 50's pack: 1000.00 MRP
600mg x 50's pack: 1750.00 MRP
+ T RILEPTAL Susp. Novartis
Oxcarbamazepine INN 300mg/5ml: suspension.
l OOml bot: 934.00 MRP
PHENOBARBITONE 21,26,33
PHENOBARBITONE:Tabletllnjection
Phenobarbitone (Phenobarbital), a barbiturate,
nonselective, central nervous system depressant
which is primarily used as a sedative hypnotic &
also as an anticonvulsant in subhypnotic doses. It
is available as- phenobarbitone BP 30mg &
60mg/tablet; phenobarbitone BP 20mg/5ml
syrup; & phenobarbital sodium BP 200mg/l ml
ampoule for injection.
Ind: It is indicated for the following conditions:
1. As sedatives. 2. Hypnotics for the short-term
treatment of insomnia. 3. Long-term (oral) anti­
convulsants for the treatment of generalized
tonic-clonic and cortical local seizures. And, par­
enteral preparations are used in the emergency
control of certain acute convulsive episodes (those

associated with status epilepticus, eclampsia,
meningitis, tetanus, & toxic reactions to strychnine
or local anesthetics). 4. Pre-anesthetics.
C/I: Patients with a history of alcohol or drug
abuse, acute intermittent porphyria.
..
S/E: Drowsiness, lethargy, ataxia and allergic
skin reacitons; paradoxical excitement,
restlessness and confusion in the elderly &
hyperkinesia in children, megaloblastic anaemia.
Cautions: Liver disorder, renal impairment,
severe pulmonary insufficiency, the elderly &
debilited, pregnancy, lactation. Tolerence and
dependence may develop.
Dosage & admin: By mouth: Adults: Daytime
sedative, 30mg to 120mg daily in 2 to 3 divided
doses; At night, 60mg to 3 20mg. Children: As
anticonvulsant 1-6mg/kg daily (febrile
convulsion, 3-4mg/kg daily); Preoperative,
lmg to 3mg/kg.
By i.m or i.v injection: Adults: 50- 200mg as a
single dose, repeat after 6 hours if necessary,
maximum 600mg daily. Children: By i.m or i.v
injection, upto 1year 30- 60mg; 1-5 years
90mg; 6-1 2 years 120mg, or 3- 5mg /kg i.m.
(For i.v. administration, dilute injection 1in 10
I with water before administration).
. + BARBir Tab. Incepta
. ·central neuropathic pain, generalised anxiety
fhenobarbital BP 30mg 8i 60mg/tablet
·
30mg x 100.'s pack: 78.00 MRP
60mg x l OO's pack: 114.00 MRP
+ BARBIT Elixir Incepta
Phenobarbital BP 20mg/5ml: syrup
50ml bot: 29.06 MRP
l OOml bot: 57.00 MRP
+ BARBIT lnj. lncepta
..
Phenobarbital sodium BP 200mg/ml; 1ml
ampoule: injection.
l ml amp: x 5's pack: 80.00 MRP
+ BERDINAL Tab. Gaco
Phenobarbitone BP 50mg/tablet
50mg x l OO's pack: 78.00 MRP
+ BERDINAL Inj. Gaco
Phenobarbital sodium BP 200mg/ml; l ml
ampoule: injection. . be lowered (rickets and osteomalacia).
lml amp: x l's pack: 15.99 MRP
+ EMER Tab. Opsonin
Phenobarbital BP l 5mg, 30mg & 60mg/tablet
15mg x l OO's pack: S0.60 MRP
30mg x 1OO's pack: 68.62 MRP
60mg x l OO's pack: 100.28 MRP
+ EMER Elixir Opsonin
Phenobarbital BP 20mg/Sml: syrup
l OOml bot: 50.43 MRP
+ EMER Inj. Opsonin
Phenobarbital sodium BP 200mg/ml; 1 ml
ampoule: injection.
lml amp: x S's pack: 70.60 MRP
+ EPINAL Tab. Square
Phenobarbital BP 30mg & 60mg/tablet
30mg x 1OO's pack: 78.00 MRP
'
60mg x 1 OO's pack: 11S.00 MRP
+ EPINAL Elixir Square
Phenobarbital BP 20mg/5ml: syrup
1OOm1 bot: S6.2 l MRP
+ EPINAL Inj. Square
Phenobarbital sodium BP 200mg/ml; 1 ml
ampoule: injection.
l ml amp: x S's pack: 80.00 MRP
+ G-PHENOBARBITONE Tab. Gonoshas
Phenobarbitone BP 30mg/tablet
I
QIMP-17 (159)
30mg x 30's pack: 21.00 MRP
+ G-PHENOBARBITONE Inj. Gonoshas
Phenobarbital sodium BP 200mg/ml; 1 ml
ampoule: injection.
l ml amp: x S's pack: 6S.OO MRP
+ PHENO Tab. Delta Pharma
Phenobarbital BP 30mg & 60mg/tablet
30mg x 1OO's pack: 78.00 MRP
60mg x 1OO's pack: 114.00 MRP
+ PHENOBA Tab. Biopharma
Phenobarbital BP 30mg & 60mg/tablet
30mg x 1 OO's pack: 78.00 MRP
60mg x l OO's pack: 114.00 MRP
+ PHENOSON Tab. Jayson
Phenobarbital BP 30mg/tablet
30mg x 1OO's pack: 78.00 MRP
PHENYTOIN21,33
PHE.NYTOIN: Tablet/Capsule/Syrup
Phenytoin is an anticonvulsant/antiepileptic drug.
It is available as- phenytoin sodium USP 1OOmg
tablet or capsule and 60mg/Sml suspension.
Ind: Grandmal & temporal lobe epilepsy,
trigeminal neuralgia, migraine.
C/I: Avoid i. v injection in patients with
bradycardia or �eart block.
·
S/E: Nausea, vomiting, mental confusion, dizzi­
ness, headache, tremor, transient nervousness,
insomnia occur commonly; rarely dyskinesias,
peripheral neuropathy; ataxia, slurred speech,
nystagmus and blurred vision are signs of over­
dosage; rashes (discontinue, if mild re-introduce
cautiqusly but discontinue immediately if recur­
rence), coarse facies, acne and hirsutisri1, fever.
and hepatitis; lupus erythematosus, erythema .'
multiforme (Stevens- Johnson syndrome), toxic
epidermal necrolysis, polyarteritis nodosa; lym­
phadenopathy; gingival hypertrophy and tender­
ness; rarely haematological effects, including
megaloblastic anaemia may be treated with folic
acid), leucopenia, thrombocytopenia, agranulocy­
tosis, and aplastic anaemia; plasma calcium may
Cautions: Liver dysfunction, pregnancy (reduce
dose), lactation. Withdraw drug slowly.
Concurrent admin. of coumarin anticoagulants,
isoniazid, chloramphenicol, sulthiame and oral
contraceptives.
Dosage & admin: Adult: 200mg daily
increased to 400mg daily (max. 600mg/day) in
divided doses ( 2-4 times) according to patients
response or 3-4 mg/kg daily in divided doses.
Child: Upto 1year 2 5 mg, 1-5 years 2 5- SOmg
increasing to 75mg, 6-12 years 50-lOOmg
increasing to 150mg. All twice daily, or 5-
8mg/kg daily in divided doses.
+ DIPHEDAN Tab. Ambee
Phenytoin 1OOmg/tablet.
l OO's pack: 201.00 MRP
+ DIPHEDAN Susp. Ambee
Phenytoin 60mg/Sml: suspension.
1 OOml bot: 30.46 MRP
+ D-TOIN Tab. Drug Inter.
Phenytoin USP 1OOmg/tablet.
1 OO's pack: 200.00 MRP
+ XENTOIN Tab. Beacon
Phenytoin sodium 1OOmg/tablet.
50's pack: 200.00 MRP
CNS DRUGS
PIRACETAM42
PIRACETAM: Table�Syrup/lnjection
Piracetam is indicated & may be used in epileptic
patients who are suffering from myoclonus of
cortical origin.
Piracetam is mainly a 'nootrope' psychotropic
agent, which acts directly on the brain to
improve the efficacy of the telencephalon in both
normal subjects and those suffering from some
functional deficits. This drug has been discussed
in this chapter under the 'antiparkinson's drugs'.
PREGABALIN21·26
PREGABALIN: Capsule
Pregabalin is used as a second-line drug for the
treatment of partial (or focal) seizures with or
without secondary generalisation. It is also useful
in the treatment of neuropathic pain &
generalised anxiety disorder. It is available as­
pregabalin INN 50mg, 7Smg, lOOmg & 150mg
capsule.
Ind: Treatment of partial (or focal) seizures with
or without secondary generalisation, peripheral &
disorder & post herpetic_ neuralgia.
C/I: Known hypersensitivity to pregabalin.
S/E: Pregabalin is well tolerated but a few side
effects like dizziness, somnolence and blurred
v1s1on may occur.
• •
Precautions:. Abrupt or .rapid discontinuation of
· , pregabalin may produce some symptoms
including insomnia, nausea, headache and
, . ..diarrhoea. So, pregabalin should be tapered
gradu�lly over a minimum of I week rather than
discontinuirig abruptly.
Pregnancy & lactation: Pregabalin should be
used during pregnancy & lactation only if the
potential benefit justifies the potential risk to the
fetUs & infants.
Dosa.ge & admin: Neuropathic pain: Initially
150mg daily in 2 divided doses, increased if
necessary after 3-7 days to 300mg daily in 2
divided doses, increased further if necessary
after 7 days to maximum 600mg daily in 2
divided doses.
Epilepsy: Initially 150mg daily in 2 divided
doses, increased if necessary after 7 days to
300mg in 2 divided doses, increased further if
necessary after 7days to maximum 600mg
daily in 2 divided doses.
Post herpetic neuralgia: The recommended
dose of pregabalin is 75 to 150mg twice daily.
Dosing should begin at 75mg two times a day
and may be increased to 300mg daily within 1
week based on efficacy and tolerability.
Children: The safety & efficacy of pregabalin
in pediatric patients have not been established.
+ GABA-P Cap. Renata
Pregabalin BP 50mg & 7Smg/capsule.
SOmg x 30's pack: 360.00 MRP
75mg x 30's pack: 482.10 MRP
+ GABAROL Cap. ACI ..
Pregabalin 25mg, Soing, 75mg, IOOmg &
l SOmg/capsule.
2Smg x 20's pack: 160.00 MRP
25mg x 30's pack: 240.00 MRP
 ® QIMP-17 (160)

1OOmg/capsule. 150mg x 20's pack: 600.00 MRP

Pregabalin
50mg x MRP
20's pack: 240.00
50mg x 30's pack: 360.00 MRP
75mg x 30's pack: 481.80 MRP
1OOmg x 20's pack: 441.60 MRP
l 50mg x 20's pack: 602.20 MRP
+ LIRICA Cap. Biopharma
Pregabalin BP 75mg/capsule.
75mg x 30's pack: 480.00 MRP
+ LYRIC Cap. Healthcare
Pregabalin BP 25mg, 50mg, 75mg &
l 50mg/capsule.
25mg x MRP
20's pack: 160.00
50mg x 30's pack: 420.00 MRP
75mg x 30's pack: 540.00 MRP
l 50mg x 24's pack: 720.00 MRP
+ MYRICA Cap. UniMed & UniHealth
Pregabalin INN 50mg, 75mg & 1OOmg/capsule.
50mg x 28's pack: 336.00 MRP
75mg x 28's pack: 448.00 MRP
1 OOmg x 28's pack: 560.00 MRP
+ NERFID Cap. White Horse
25mg x 20's pack: 160.00 IP
50mg x 20's pack: 260.00 IP
75mg x 20's pack: 340.00 IP
1 OOmg x 12's pack: 264.00 IP
+ NEUROLIN Cap. Square
PregabalinINN 50mg, 75mg & 150mg/capsule.
50mg x 30's pack: 360.00 MRP
75mg x 30's pack: 480.00 MRP
150mg x IO's pack: 301.10 MRP
+ NEUROVAN Cap. Aristopharma
Pregabalin INN 50mg, 75mg & 150mg/capsule.
50mg x 30's pack: 360.00 MRP
75mg x 30's pack: 480.00 MRP
l50mg x 20's pack: 600.00 MRP
+ PEGALIN Cap. Popular
Pregabalin INN 25mg, 50mg, 75mg, lOOmg &
150mg/capsule.
25mg x MRP
30's pack: 240.00
50mg x 30's pack: 360.00 MRP
75mg x 30's pack: 481.80 MRP
1OOmg x 30's pack: 662.40 MRP
l 50mg x 20's pack: 602.20 MRP
+ PEGARON Cap. RAK Pharma
Pregabalin INN 50mg & 75mg/capsule.
50mg x 30's pack: 360.00 MRP
+ PREGADEL Cap. Delta Pharma
Pregabalin INN 50mg & 75mg/capsule.
50mg x 24's pack: 240.00 MRP
75mg x 16's pack: 240.00 MRP
+ PREGALEX Cap. Sharif
Pregabalin INN 75mg & 150mg/capsule.
75mg x 30's pack: 480.00 MRP
l 50mg x 20's pack: 600.00 MRP
+ PREGAN Cap. Navana
Pregabalin INN 50mg & 75mg/capsule.
50mg x 30's pack: 330.00 MRP
75mg x 30's pack: 480.00 MRP
+ PRELICA Cap. Radiant
Pregabalin INN 50mg, 75mg & 150mg/capsule.
50mg x 30's pack: 435.00 MRP
75mg x 30's pack: 570.00 MRP
150mg x 18's pack: 630.00 MRP
+ PRELIN Cap. Drug Inter.
Pregabalin INN 50mg, 75mg & 150mg/capsule.
50mg x 20's pack: 220.00 MRP
75mg x 20's pack: 320.00 MRP
150mg x lO's pack: 300.00 MRP
+ PRIGA 75 Cap. MonicoPharma
Pregabalin INN 75mg/capsule.
75mg x 30's pack: 480.00 MRP

Pregabalin 25mg, 50mg, 75mg, 100mg & 150mg capsule

-
. _.
. ': :.: ; ·

Pregabalin BP 50mg & 75mg/capsule. 75mg x 30's pack: 480.00 MRP + PYRICA 75 Cap. Pharmasia
50mg x 30's pack: 360.00 MRP + PG Cap. SK+F PregabalinINN 75mg/capsule.
75mg x 30's pack: 480.00 MRP Pregabalin INN 50mg, 75mg & l 50mg/capsule. 75mg x 30's pack: 480.00 MRP
+ NERVALIN Cap. Beximco 50mg x 30's pack: 330.00 MRP
+ REGAB Cap. Beacon
Pregabalin BP 50mg & 75mg/capsule. 75mg x 30's pack: 480.00 MRP
PregabalinINN 25mg, 50mg & 75mg/capsule.
50mg x 30's pack: 330.00 MRP 150mg x 12's pack: 360.00 MRP
25mg x 20's pack: 160.00 MRP
75mg x 30's pack: 480.00 MRP + PREBALIN Cap. General
50mg x 20's pack: 240.00 MRP
+ NEUGABA Cap. Sun Pharma Pregabalin INN 50mg, 75mg & 150mg/capsule.
75mg x 20's pack: 320.00 MRP
Pregabalin INN 50mg, 75mg & 150mg/capsule. 50mg x 30's pack: 360.00 MRP
50mg x 30's pack: 300.00 MRP 75mg x 30's pack: 481.80 MRP + XABLIN Cap. Sandoz
75mg x 30's pack: 480.00 MRP l 50mg x 20's pack: 602.20 MRP PregabalinINN 75mg/capsule. •

150mg x 30's pack: 900.00 MRP + PREGABA Cap. Opsonin 75mg x 30's pack: 513.00 MRP

+ NEUGALIN Cap. Acme Pregabalin INN 50mg, 75mg & 150mg/ capsule. + XIL Cap. Orion Pharma
Pregabalin INN 50mg, 75mg & 150mg/capsule. 50mg x 30's pack: 318.01 MRP Pregabalin INN 50mg & 75mg/capsule.
50mg x 30's pack: 330.00 IP 75mg x 30's pack: 423.84 MRP 50mg x 30's pack: 240.00 MRP
l50mg x 30's pack: 794.63 MRP 75mg x 30's pack: 301.20 MRP
•

75mg x 30's pack: 480.00 IP

150mg x lO's pack: 300.00 IP + PREGABEN Cap. Incepta
150mg x 30's pack: 900.00 IP Pregabalin INN 50mg, 75mg & 150mg/capsule.
+ NEUREGA Cap. Ibo Sina 50mg x 30's pack: 360.00 MRP SODIUM VALPROATENALPROIC
Pregabalin INN 25mg, 50mg, 75mg & 75mg x 30's pack: 480.00 MRP ACID21,63

,

SODIUM VALPROATE NALPROIC ACID:
Tablet/Injection
Sodium valproate & valproic acid preparations
are available as individual component or in
combination. Different presentations available,
given as below: i. Sodium valproate 200mg/tablet
(e.c); ii. Sodium valproate 200mg/5ml of syrup;
iii. Sodium valproate BP 133.2mg + valproic acid
BP 58mg equivalent to sodium valproate 200mg;
iv. Sodium valproate BP l 99.8mg valproic acid .
+ parameters); over 20kg initially 400mg daily
BP 87mg equivalent to sodium valproate 300mg;
v. Sodium valproate BP 333mg + valproic acid
BP 145mg equivalent to sodium valproate 500mg.
Tablet preparations are available as- enteric
coated and controlled release tablets.
Ind: All forms of epilepsy.
CII: Active liver disease, family history of severe
hepatic dysfunction, porphyria.
S/E: Gastric irritation, nausea, ataxia and tremor;
hyperammonaemia, increased appetite and weight
gain; transient hair loss (regrowth may be curly),
oedema, thrombocytopenia, and inhibition of
platelet aggregation; impaired hepatic function
leading rarely to fatal hepatic failure withdraw
treatment immediately if vomiting, anorexia,
jaundice, drowsiness, or loss of seizure control
occurs); rashes; sedation reported (rarely lethargy
and confusion associated with too high an initial
dose) and also increased alertness (occasionally
aggression, hyperactivity and behavioral distur­
bances); rarely pancreatitis (measure plasma
amylase in acute abdominal pain), leucopenia,
pancytopenia, red cell hypoplasia, fibrinogen
reduction; irregular periods, amenorrhoea,
gynaec.omastia, hearing loss, Fanconi's syndrome,
dementia, toxic epidermal necrolysis, Stevens­
Johnson syndrome, and vasculitis also reported.
Cautions: Monitor liver function before therapy
and during frrst 6 months especially in patients
most at risk, ensure no undue potential for bleed­
ing before starting and before major surgery;
renal impairment; pregnancy; breast-feeding;
systemic lupus erythematosus; false-positive
urine tests for ketones; avoid sudden withdrawal.
Liver toxicity: Liver dysfunction (including fatal
hepatic failure) has occurred in association with
valproate (specially in children under 3 years of
age and those with metabolic or degenerative
disorders, organic brain disease or severe seizure
disorders associated with mental retardation)
usually in the frrst 6 months of therapy and
usually involving multiple antiepileptic therapy
(monotherapy preferred). Raised liver enzymes
are not uncommon during valproate treatment
and are usually transient but patients should be
reassessed clinically and liver function (including
prothrombin time) monitored until return to
normal-an abnormally prolonged prothrombin
time (particularly in association with other
relevant abnormalities) requires discontinuation
of treatment. Any concomitant use of salicylates
should be stopped.
Pregnancy & lactation: Caution should also be
exercised in pregnancy & lactation.
Dosage & admin: By mouth- adult, initially,
QIMP-17 (161) CNS DRUGS
600mg daily given in 2 divided doses, t PROVAL Syp. General
preferably after food, increasing by 200mg/day Valproic acid sodi11m valproate 200mg/5ml: syrup
at 3-day intervals to a maximum of 2.5gm l OOml bot: 75.28 MRP
daily in divided doses, usual maintenance 1- t SODIVAL Tab. ACI
2gm daily (20-30 mg/kg daily); Sodium valproate 20Gmg/tablet.
Child- up to 20 kg, initially 20mg/kg daily in 50's pack: 125.50 MRP
divided doses, may be increased provided t SODIVAL Syp. ACI
plasma concentrations monitored, (also Valproic acid as sodium valproate 200mg/5ml:
monitor clinical chemistry and haematological syrup
1OOml bot: 80.00 MRP
in divided doses increased until control + V ALEX Tab. Incepta
(usually in range of 20-30mg/kg daily); max. Sodium valproate 200mg/tablet.
35mg/kg daily. 50's pack: 125.00 MRP
t VALEX. CR Tab. Incepta
t CONVULES CR Tab. Opsonin Valex CR 200 tablet: Contains sodium valproate
Convules CR 200 tablet: contains sodi11m
BP 133.2mg & valproic acid BP 58mg equivalent
valproate BP 133.2mg & valproic acid BP 58mg
to sodium valproate 200mg.
equivalent to sodium valproate 200mg.
Valex CR 300 tablet: Contains sodium valproate
Convules CR 300 tablet: contains sodium
BP 199.8mg & valproic acid BP 87mg equivalent
valproate BP 199.8mg & valproic acid BP 87mg
to sodium valproate 300mg.
equivalent to sodium valproate 300mg.
Valex CR 500 tablet: Contains sodium valproate
Convules CR 500 tablet: contains sodium BP 333mg & valproic acid BP 145mg equivalent
valproate BP 333mg & valproic acid BP 145mg
to sodium valproate 500mg. (All are controlled
equivalent to sodium valproate 500mg. (All are
release tablet)
controlled release tablet)
Dosage & admin: Valex CR is a prolonged
Dosage & admin: Convules CR is a prolonged
release formulation of sodium valproate, thus
release formulation of sodium valproate, thus
Valex CR may be given once or twice daily.
Convules CR may be given once or twice daily.
For dosage- see under the text (above).
For dosage- see under the text (above).
200mg (CR tablet) x 50's pack: 200.00 MRP
200mg (CR tablet) x 50's pack: 176.82 MRP
300mg (CR tablet) x 50's pack: 300.00 MRP
300mg (CR tablet) x 30's pack: 158.87 MRP
500mg (CR tablet) x 28's pack: 280.00 MRP
500mg (CR tablet) x 20's pack: 176.65 MRP
t VALEX Syp. Incepta
t CONVULES Syp. Opsonin Valproic acid as sodium valproate 200mg/5ml:
Sodium valproate 200mg/5ml: syrup syrup
l OOml bot: 66.22 MRP 1OOml bot: 75.00 MRP
t ENCORATE Tab. Sun Pharma
t VALOATE CR Tab. Square
Sodium valproate 200mg/tablet (enteric coated).
Valoate CR 200 tablet: contains sodi11m valproate
50's pack: 150.00 MRP
BP 133.2mg & valproic acid BP 58mg equivalent
+ ENCORATE Chrono 200 Tab. Sun Pharma
to sodium valproate 200mg.
Sodium valproate + Valproic acid 200mg/tablet.
Valoate CR 300 tablet: contains sodium valp1oate
50's pack: 200.00 MRP
BP 199.8mg & valproic acid BP 87mg equivalent
t ENCORATE Chrono 300 Tab. Sun Pharma
to sodium valproate 300mg.
Sodium valproate + Valproic acid 300mg/tablet.
Valoate CR 500 tablet: contains sodium valproate
50's pack: 302.50 MRP
BP 333mg & valproic acid BP l 45mg equivalent
+ ENCORATE Chrono 500 Tab. Sun Pharma
to sodium valproate 500mg.
Sodium valproate + Valproic acid 500mg/tablet.
(All are controlled release tablet)
30's pack: 301.50 MRP
Dosage & admin: Valoate CR is a prolonged
+ EPILIM Chrono 200 Tab. Sanofi-aventis
release formulation of sodium valproate, thus
Sodium valproate BP 133.2mg + Valproic acid
Valoate CR may be given once or twice daily.
BP 58mg/tablet.
For dosage- see under the text (above).
50's pack: 200.50 MRP
200mg (CR tablet) x 50's pack: 200.50 MRP
+ EPILIM Chrono 300 Tab. Sanofi-aventis
300mg (CR tablet) x 50's pack: 301.00 MRP
Sodium valproate BP 199.8mg + valproic acid
500mg (CR tablet) x 30's pack: 301.20 MRP
BP 87mg/tablet.
50's pack: 301.00 MRP t VALOATE Syp. Square
+ EPILIM Chrono 500 Tab. Sanofi-aventis Valproic acid as sodium valproate 200mg/5ml:
Sodium valproate BP 333mg + valproic acid BP syrup
l 45mg/ tablet. l OOml bot: 75.28 MRP
30's pack: 301.20 MRP t VALPRO Tab. Somatec
+ EPILIM Syp. Sanofi-aventis Sodium valproate 200mg/tablet.
Sodium valproate 200mg/5ml: syrup 50's pack: 125.50 MRP
l OOml bot: 80.30 MRP t VALPRO Syp. Somatec
t PROVAL Tab. General Valproic acid as sodium valproate 200mg/5ml:
Sodium valproate 200mg/tablet. syrup
50's pack: 125.49 MRP l OOml bot: 75.28 MRP
.9'-dM ·
•••
•••
rai �!!�!!� www.squarepharma.com.bd •••.
� llANIJl.A.Df!SH
..l!l lTD.
...,...
 CNS DRUGS
TOPIRAMATE106
TOPIRAMATE: Tablet
Topiramate 25mg & 50mg/tablet.
Ind: Topiramate is indicated as monotherapy or
adjunctive therapy for adults and children (2
years and above) with partial onset seizures or
generalized tonic-clonic seizures in epilepsy. It is
also indicated as adjunctive therapy for the treat­
ment of seizures associated with Lennox-Gastaut
syndrome.
C/I: History of hypersensitivity to any
component of this product.
Adverse effects:
Monotherapy: In a double-blind clinical trial,
adverse events that occurred at a frequency
greater than or equal to I 0% in either treatment
group, are- paraesthesia, headache, dizziness,
fatigue, somnolence, weight decrease, nausea,
and diarrhea. These adverse events with
monotherapy were consistent with, but generally
less frequent than the adverse events with
adjunctive therapy.
Adjunctive therapy: Adults: In double-blind tri­
als, adverse events that occurred with a frequency
greater than or equal to 5% and with a higher
incidence in the topiramate-treated adult patients
than in the placebo group. These include- somno­
lence, dizziness, nervousness, ataxia, fatigue,
1 speech disorders/related speech problems,
psychomotor slowing, abnormal vision, difficulty
with memory (not otherwise specified),
confusion, paraesthesia, diplopia, anorexia,
nystagmus, nausea, weight decrease, language
problems, difficulty with concentration/attention,
depression, abdominal pain, asthenia, and mood
problems. Adverse events that occurred more
frequently with adjunctive therapy than with
monotherapy included somnolence, dizziness,
difficulty with memory, psychomotor slowing,
confusion, nervousness, ataxia, vision abnormal,
diplopia, speech disorders and related speech
problems, and nystagmus.
Pediatric padents: In double-blind clinical trials,
adverse events that occurred at a frequency
greater than or equal to 5% and with a higher
•
incidence in the topiramate-treated pediatric
patients than in the placebo group. These include­
somnolence, anorexia, fatigue, nervousness, per­
sonality disorder, difficulty with concentration/
attention, aggressive reaction, weight decrease,
abnormal gait, mood problems, ataxia, salivation,
nausea, difficulty with memory (not otherwise
specified), hyperkinesia, dizziness, speech disor­
ders/related speech problems, and paraesthesia.
Precautions & warnings: Antiepileptic drugs,
including topiramate, should' be withdrawn
gradually to minimize the potential ·of increased
seizure frequency. In clinical trials, dosages were
decreased by lOO mg/day at weekly intervals. In
some patients withdrawal was accelerated
without complications.
The major route of elimination of unchanged top­
I iramate and its metabolites is the kidney. Renal
QIMP-17 (162)
elimination is dependent on renal function and is
independent for age. Patients with moderate or
severe renal impairment may take 10 to 15 days
to reach steady-state plasma concentrations as
compared to 4 to 8 days in patients with normal
renal function.
In all patients, the titration schedule should be
guided by clinical outcome (i.e seizure control,
avoidance of side-effects) with the knowledge
that subjects with known renal impairment may
require a longer time to reach steady-state at
each dose.
Some patients, specially those with a history of
prior stone formation, or family history of
nephrolithiasis or hypercalci-uria, are at increased
risk for renal stone formation with topiramate
therapy. Adequate hydration is recommended to
reduce this risk.
In addition, patients taking other medica-tions
associated with nephrolithiasis or on a ketogenic
diet may be at increased risk. Therefore, while
using topiramate, patient should avoid ketogenic
diet.
In hepatic impaired patients, topiramate should
be administered with caution as the cleamce of
topiramate may be decreased.
A dietary supplement or increased food intake
may be considered if the patient is losing weight
while on this medication.
Effects on ability to drive and use machines: As
with all AEDs, patient taking topiramate is
potentially in danger while driving a vehicle or
operating machinery, particulary until such time
as the individual patient's experience with the
drug is established.
Pregnancy & lactation: There are no studies
using topiramate in pregnant women. But, as
with other AEDs, topiramate was found
teratogenic in mice, rats and rabbits. Therefore,
topiramate should only be used during pregnancy,
if the potential benefit outweighs the potential
risk to the fetus. In lactating women, it is not
known whether topiramate is excreted in breast
milk. But, as topiramate is excreted in the milk of
lactating rats, and as many drugs are excreted in
human milk, a decision should be made whether
to discontinue nursing or to discontinue the drug,
taking into account the importance of the drug to
the mother.
In marketing experience, cases of hypospadias
have been reported in male infants exposed in
utero to topiramate, with or without other
anticonvulsants; however, a causal relationship
with topiramate has not been established.
Dosage & admin: For optimal seizure control
in both adults and children, it is recommended
that therapy should be initiated at a low dose
followed by titration to an effective dose.
. Because of the bitter taste, tablets should not
be broken.
Monotherapy: When concomitant anti-epilep­
tic drugs (AEDs) are withdrawn to achieve
monotherapy with topiramate, consideration
should be given to the effects of this drug,
that may have on seizure control. Unless safety
.
.9"-nn
ral
� !��!�!A�$
JIAHOL.ADIESH
concern, an abrupt withdrawal of the con­
comitant AED is not advised, rather a gradual
discontinuation at the rate of approximately
one third of the concomitant AED dose every 2
weeks is recommended. When enzyme­
inducing drugs are withdrawn, topiramate
levels will increase. A decrease in topiramate J
I
dosage may be required if clinically indicated.
Adults: Titration should begin at 2Smg nightly
for 1 week. The dosage should then be incre­
ased at 1- or 2-week intervals by increments of
2Smg or SOmg/day, administered in two
divided doses. If the patient is unable to
tolerate the titration regimen, smaller incre­
ments or longer intervals between increments
can be considered. Dose & titration rate should
be guided by clinical outcome.
The recommended initial target dose range for
topiramate monotherapy in adults is 1OOmg to
200mg/day and the maximum recommended
daily dose is SOOmg. Some patients with
refractory forms of epilepsy have tolerated
topiramate monotherapy at doses of
1OOOmg/day. These dosing recommendations
can be applied to all adults including the eld­
erly in the absence of underlying renal disease.
Children: Treatment of children (2 years &
above) should begin at lmg to 3mg/kg nightly
for the first week. The dosage should then be
increased at 1- or 2-week intervals by incre­
ments of lmg to 3mg/kg/day, administered in
two d.ivided doses. If the child is unable to tol­
erate the titration regimen, smaller increments
or longer intervals between dose increments
can be considered. Dose and titration rate
should be guided by clinical outcome.
Adjunctive therepy:
Adults: Titration should begin at 2Smg
nightly for 1 week. Subsequently, at weekly or
biweekly intervals, the dose should be
increased by 2Smg/day and given in two
divided doses. Dose titration should be guided
by clinical outcome. Some patients may
achieve efficacy with once-a-day dosing.
The usual total daily dose of topiramate as
adjunctive therapy is 200mg to 400mg/day in
two divided doses. Individual patients have
received dosages as high as 1600mg/day.
•
Because topiramate is removed from plasma
by hemodialysis, a supplemental dose of
topiramate equal to approximately one-half
the daily dose should be administered in
divided doses at the beginning and completion
of the hemodialysis procedure. This
supplemental dose may vary based on the
characteristics of the dialysis equipment used.
These dosing recommendations can be applied
to all adults, including the elderly, in the
absence of underlying renal disease.
Children: The recommended total daily dose
of topiramate as adjunctive therapy for
seizures in children is approximately Smg to
9mg/kg/day in 2 divided doses. Titration
should begin at lSmg to 25mg (or less based
on a range of lmg to 3mg/kg/day) nightly for
. •••
•••
LTD. -·
· www.squarepharma.com.bd •••
IOUAa

the first week. To achieve optimal clinical res­
ponse, the dosage should then be increased at
1- or 2-week intervals by increments of lmg to
3mg/kg/day (administered in 2 divided doses).
Dose titration should be guided by clinical
outcome. Daily doses up to 30mg/kg/day have
been studied and were generally well tolerated.
Drug inter: Effects of topiramate on other
antiepileptic drugs: The addition of topiramate to
other AEDs (phenytoin, carbamazepine, valproic
acid, primidone, phenobarbitone) has no effect on
their steady-state plasma concentrations, except
in the occasiounal patient, where the addition of
topiramate to phenytoin may result in an increase
in plsma concentrations of phenytoin.
Consequently, any patient on phenytoin showing
clinical signs or symptoms of toxicity should
have phenytoin levels monitored.
Effects of other antiepileptit drugs on
topiramate: Phenytoin and carbamazepine
decrease the plasma concentration of topiramate.
The addition or withdrawal of phenytoin or
cabamazepine to topiramate therapy may require
an adjustment in dosage of the latter. This should
be done by titrating to clinical effect. The
addition or withdrawal of valproic acid does not
produce clinically significant changes in plasma
concentrations of topiramate and, therefore, does
not warrant dose adjustment of topiramate.
Other drug interactions: When topiramate is
added or withdrawn in patients on digoxin
therapy, careful attention should be given to the
routine monitoring of serum digoxin levels.
Topiramate is not recommended to use concomi­
tantly with alcohol or other CNS depressant
drugs. Patients taking topiramate concomitantly
witli oral contraceptives should be asked to report
any change in their bleeding patterns.
• E T OPIRA Tab. UniMed & UniHealth
Topirarnate INN 25mg & 50mg/tablet.
25mg x 30's pack: 150.00 MRP
50mg x 30's pack: 300.00 MRP
• PIRAMED Tab. Square
Topiramate INN 25mg & 200mg/tablet.
25mg x 50's pack: 150.50 MRP
200mg x 20's pack: 301.00 MRP
• TOPMATE Tab. Renata
Topiramate INN 25mg & 50mg/tablet.
25mg x 50's pack: 200.00 MRP
50mg x 50's pack: 300.00 MRP
• TOPIRVA Tab. Incepta
Topiramate INN 25mg & 50mg/tablet.
25mg x 50's pack: 150.00 MRP
50mg x 50's pack: 250.00 MRP
8. DRUGS USED IN
P SONISM&
2
RELATED DISORDERS 1
The drugs used in parkinsonism & related
disorders are classified as:
1 Dopaminergic drugs used in Parkinson's
disease.
2 Antimuscarinic drugs (anticholinergic
drugs) used in parkinsonism
3. Drugs used in essential tremor, chorea, tics
& related disorders
I
QIMP-17 (163)
Dopaminergic drugs21
Dopaminergic drugs include:
1. Dopamine precursor: Levodopa and some
combined preparations, viz: Co-beneldopa,
Co-care/dopa.
2. Dopamine receptor agonists, viz:
i. Non-ergot-derived dopamine-receptor
agonists: Apomorphine, Pramipexole,
Ropinirole & Rotigotine.
ii. Ergot-derived dopamine-receptor
agonists: Bromocriptine, Cabergoline &
Pergolide.
iii. Monoamine-oxidase-B inhibitors:
Rasagiline, Selegiline.
iv. Catechol-0-methyltransferase
inhibitors: Entacapone & Tolcapone.
v. Amantadine: Amantadine hydrochloride.
Dopamine precursors
LEVODOPA21,33
LEVODOPA: Tablet/ Capsule.
Levodopa, the amino acid precursor of dopamine,
acts mainly by replenishing depleted striatal
dopamine. It improves bradykinesia and rigidity
more than tremor. It is generally administered in
conjuction with an extracerebral dopa­
decarboxylase inhibitor (please see below).
.
Ind: Parkinsonism (idiopathic, post-encephalitic
or arteriosclerotic, but not drug-induced
extrapyramidal symptoms).
C/I: Severe psychoses, closed or narrow angle
glaucoma, history of malignant melanoma. With
or within 2 weeks of MAO inhibitors.
S/E: Anorexia, nausea; insomnia, agitation; pos­
tural hypotension, dizziness, tachycardia, cardiac
arrhythmias; polyuria, incontinence, difficulty
with micturition, discoloration of urine and other
body fluids; rarely hypersensitivity; abdominal
pain; abnormal involuntary movements and
psychiatric symptoms may be dose-limiting.
Cautions: Cardiovascular, hepatic, renal,
pulmonary or endocrine diseases. Peptic
ulceration, wide angle glaucoma. Pregnancy.
Monitor blood values and hepatic, renal &
cardiovascular functions.
Dosage & admin: Adult: Initially 250mg. daily
in divided doses (two) after meals, increasing
by 125mg every 3 or 4 days or weekly
intervals. Until optimum response obtained,
maintenance usually 2.5 -8gm daily. The total
daily dose being given in 4 or 5 divided doses
after food. As the patient ages, the
maintenance dose may need to be reduced.
Child: Not recommended.
Preparations: May not be available.
CO-CARELDOP A21,33, 44
CO-CARELDOPA: Tablet
The combined preparation of carbidopa & levo­
dopa is termed as co-careldopa. This combination
is because, levodopa is generally administered in
conjuction with an extracerebral dopadecarbo-
CNS DRUGS
xylase inhibitor, viz. carbidopa (& benserazide)
which prevents the peripheral degradation of
levodopa to dopamine but, unlike levodopa, it
does not cross the blood-brain barrier. So,
•
effective brain concentration of dopamine can be
achieved with lower doses of levodopa. The
proportion of combination in the co-careldopa is
either 1Omg of carbidopa for each 1OOmg of
levodopa, or 25mg of carbidopa for each 1OOmg
of levodopa, or 25mg of carbidopa for each
250mg of levodopa.
Therefore, the available fixed combinations are:
i. Co-careldopa 11Omg (levodopa 1OOmg +
carbidopa l Omg)/tablet; ii. Co-careldopa 125mg
(levodopa 1 OOmg + carbidopa 25mg)/tablet. iii.
Co-careldopa 275mg (levodopa 250mg +
carbidopa 25mg)/tablet.
Ind: Parkinsonism (idiopathic, post-encephalitic
or arteriosclerotic, but not drug-induced
extrapyramidal symptoms).
C/I; S/E; Caution: See above under the text of
levodopa.
Dosage & admin: Dosage of Co-care/dopa 110
(levodopa 1OOmg + carbidopa 1Omg)ltablet:
Adult: Patients not receiving levodopa, initi­
ally 1 tablet 3 times daily increasing in small
increments to maximum 8 tablets daily.
Usual maintenance dose is 2 tablets 3 or 4
times daily after food. As the patient ages, the
maintenance dose may need to be reduced.
Child: Not recommended.
Dosage of Co-care/dopa 275 (levodopa 250mg +
carbidopa 25mg)ltablet:
T his preparation is for the patients already
receiving plain levodopa. First discontinue
levodopa atleast 12 hours before starting the
therapy with this combination. The dose
should be approximately 25°/o of the previous
daily dosage of levodopa. When daily levo­
dopa intake is greater than 1500mg, start with
this co-careldopa 275 one tablet 3-4 times daily
after food.
Maintenance therapy: This should be
individualised and adjusted gradually; the
patient must be maintained on the optimal
therapeutic dosage. When the levodopa
requirement is very high, the total dosage
may be given as co-careldopa 275mg tablets in
3 or 4 doses. As the patient ages, the
maintenance dose may need to be reduced.
Child: Not recommended.
• CO-DOPA 110 Tab. UniMed & UniHealth
Levodopa 1 OOmg + carbidopa 1Omg/tablet
30's pack: 210.00 MRP
• CO-DOPA 275 Tab. UniMed & UniHealth
Levodopa 250mg + carbidopa 25mg/tablet
30's pack: 300.00 MRP
• D-DOPA 110 Tab. Drug Inter.
Levodopa I OOmg + carbidopa 1 Omg/tablet
30's pack: 150.00 MRP
• D-DOPA Plus Tab. Drug Inter.
Levodopa 250mg + carbidopa 25mg/tablet
50's pack: 300.00 MRP
• LEVOPA 110 Tab. Acme
Levodopa 1 OOmg + carbidopa 1 Omg/tablet
30's pack: 120.00 MRP
• LEVOPA 275 Tab. Acme
Levodopa 250mg + carbidopa 25mg/tablet
30's pack: 225.00 MRP
• SYNDOPA 110 Tab. Sun Pharma
CNS DRUGS QIMP-17 (164)

Levodopa l OOmg + carbidopa l Omg/tablet + CRIPTINE Tab. Renata drug or to any of the excipients.
SO's pack: 350.00 MRP Bromocriptine mesylate 2.Smg/tablet. S/E: The common side effects are dizziness,
+ SYNDOPA 275 Tab. Sun Pharma 30's pack: 360.00 MRP dyskinesia, nausea, hypotension, abnormal
Levodopa 250mg + carbidopa 25mg/tablet dreams, confusion, co.nstipation, delusion,
lOO's pack: 1000.00 MRP hallucinations, headache, hyperkinesia, increased
ENTACAPONE54
eating (binge eating, hyperphagia), insomnia,
libido disorders, nausea, peripheral oedema,
Dopamine Receptor Agonists + COMTAN Tab. Novartis paranoia, pathological gambling, hypersexuality
Entacapone 200mg/tablet (f.c). and other abnormal behaviour, somnolence,

BROMOCRIPTINE 21,58 It is a catechol-o-methyl transferase inhibitor. weight increase, sudden onset of sleep, pruritus
Ind: Adjunct to levodopa/benserazide or and rash and other hypersensitivity.
levodopa/carbidopa treatment in patients with Precautions: Caution should be taken in patients
BROMOCRIPTINE: Tablet
Parkinson's disease and end-of dose motor with psychotic disorder, ophthalmologic
Ind: i. Parkinsonism (but not drug induced
fluctuations, who cannot be stabilised on those monitoring is recommended at regular intervals,
extrapyramidal symptoms). ii. Endocrine disor­
combinations. severe cardiovascular disease & renal impairment.
ders (Bromocriptine is used for the suppression
C/I: Known hypersensitivity to entacapone or Pregnancy & lactation: The effect of
of lactation when simpler measures fail, for the
any of the excipients. Pregnancy and breast­ pramipexole on pregnancy and lactation has not
treatment of galactorrhoea and cyclical benign
feeding. Liver impairment. Phaeochromocytoma. been investigated in humans, so it should be used
breast disease, for the treatment of prolactinomas
Concomitant use with nonselective monoamine during pregnancy only if the potential benefit
and treatment of acromegaly but success rate is
oxidase inhibitors (MAO-A and MAO-B). justifies the potential risk to the foetus.
much lower than with prolactinomas).
Concomitant use with a selective MAO-A plus a Pramipexole inhibits secretion of prolactin in
C/l;S/E; Cautions: See under levodopa; perform
selective MAO-B inhibitor. History of humans. The excretion of pramipexole into breast
annual gynaecological assessment for women
neuroleptic malignant syndrome (NMS) and/or milk has not been studied in women, so it should
(post-menopausal, every 6 month). Monitor for
nontraumatic rhabdomyolysis. not be used during breast-feeding. However, if its
pituitary enlargement, particularly during
AIR: Dyskinesia; gastrointestinal symp-toms (e.g use is unavoidable then breast-feeding should be
pregnancy & for peptic ulceration in acromegalic
nausea, vomiting, abdominal pain, constipation, discontinued.
patients
diarrhoea, dry mouth); discoloration of urine; Dosage & admin: Parkinson's disease: Initially
Dosage & admin: Adult: Parkinsonism: first
fatigue, insomnia, paroniria, confusion, hallucina­ 88mcg 3 times daily; dose doubled every 5--7
week, 1-1.25mg at night, second week, 2-2.5mg
tions; dizziness, postural hypotension, vertigo, days if tolerated to 350mcg 3 times daily;
at night, third week, 2.5mg twice daily, then 3
headache; leg cramps, hyperkinesia, tremor, further increased if necessary by 180mcg 3
times daily increasing by 2.5mg every 3-14
increased sweating; slight decrease in hemoglo­ times daily at weekly intervals; maximum
days according to response to a usual range of
bin, erythrocyte count, and haematocrit. Increases dose, 3.3mg daily in 3 divided doses
10-40mg daily; taken with food.
in liver enzymes have been reported rarely. During pramipexole dose titration and
Prevention/suppression of lactation for medical
Precautions & warnings: Dosage of levodopa maintenance levodopa dose should be reduced.
reasons, 2.5 mg on 1st day (prevention) or daily
and other antiparkinsonian medications (e.g Restless legs syndrome: Initially 88mcg once
for 2-3 days (suppression); then 2.5mg twice
dopamine agonists) may need to be adjusted daily 2-3 hours bffore bedtime; dose doubled
daily for 14 days.
when entacapone treatment is initiated. every 4-7 days if necessary to 350mcg daily;­
Hypogonadism/galactorrhoea/infertility, initi­
Levodopa-induced orthostatic hypotension may maximum dose, 540mcg daily.
ally 1-1.25mg at bedtime, increased gradually;
be aggravated. Effects of medicinal products Children: Not recommended for children .
usual dose 7.5mg daily in divided doses,
metabolised by catechol-o-methyl transferase below 18 years of age.
increased if necessary to a max. of 30 mg daily.
Usual dose in infertility without hyperprolacti­ may be potentiated. Caution when discontinuing Drug inter: Pramipexole is the only dopamine
naemia, 2.5 mg twice daily. entacapone treatment (see full prescribing agonist not appreciably metabolized by the P450
Cyclical benign breast disease and cyclical information). system which minimizes about possible drug­
menstrual disorders (particularly breast pain), Dosage: 200mg with each levodopa/ drug interactions. Cimetidine and amantadine
l-l.25mg at bedtime, increased gradually; dopadecarboxylase inhibitor dose. Maximum may reduce the renal clearance of pramipexole.
usual dose �.5mg twice daily. recommended daily dose is 2000mg. Sedating medicinal products or alcohol in
Acromegaly- initially l-l.25mg at bedtime Drug inter: Entacapone and iron preparations combination with pramipexole may cause
increase gradually to 5mg every 6 hours. should be taken at least 2-3 hours apart. additive effects.
i

Prolactinoma- initially 1-l.25mg at bedtime; 30's pack: 2474.40 MRP

increased gradually to 5mg every 6 hours Note: For further information consult full + PARIXOL 88 Tab. ACI
(occasional patients may require up to 30mg prescribing information. Pramipexole 88mcg as hydrochloride/tablet.

daily). 88mcg x 30's pack: 60.30 MRP

All doses should be taken during meals. + PARIXOL 180 Tab. ACI
PRAMIPEXOLV2
Child: not recommended. Pramipexole 180mcg as hydrochloride/tablet.
l 80mcg x 30's pack: 180.60 MRP
+ BROMERGON Tab. Sandoz PRAMIPEXOLE: Tablet
Bromocriptine mesylate 2.Smg/tablet. Pramipexole is a non-ergot dopamine receptor
30's pack: 420.00 MRP ROPINIROLE42
agonist, which is used in the treatment of
+ BROMOCRIPTINE RICTER Tab. Gedeon Parkinson's disease. It is available as oral tablet,
Richter/City Overseas pramipexole 88mcg & l 80mcg as hydrochloride. ROPINIROLE: Tablet
Bromocriptine mesylate 2.Smg/tablet. Mode of action: Pramipexole has high affinity Ropinirole is an antiparkinson's drug. It is
30's pack: 636.00 TP for dopamine D 2-like receptors with highest available as ropinirole hydrochloride INN
+ BROMODEL Tab. Opsonin affinity at dopamine D3 and D 2 receptors. 0.25mg & 2mg film-coated tablets. ·

Bromocriptine mesylate 2.Smg/tablet. Pramipexole's affinity to D 3 receptors might be Ind: 1 . Parkinson's disease. 2. Restless legs
30's pack: 264.97 MRP responsible for its antidepressant activity. syndrome (RLS).
+ BROMOLAC Tab. Square Ind: Pramipexole is indicated for the treatment S/E: Nausea, somnolence, leg edema, abdominal
Bromocriptine mesylate 2.Smg/tablet. of- i. Parkinson's disease, used alone or as an pain, vomiting, & syncope.
30's pack: 360.00 MRP adjunct to levodopa with dopa-decarboxylase Pragnancy & lactation: Ropinirole should not
+ BROMOTINE Tab. Nuvista inhibitor; ii. Moderate to severe restless legs be used during pregnancy. It should also not be
Bromocriptine mesylate 2.Smg/tablet. syndrome used in nursing mothers as it may inhibit lactating.
30's pack: 330.00 MRP C/I: Patients with known hypersensitivity to the Dosage & admin: Parkinson's disease: In all

clinical studies, dosage was initiated at a
subtherapeutic level & gradually titrated to
therapeutic response. The dosage should be
increased to achieve a maximum therapeutic
effect, balanced against the principal side
effects of nausea, dizziness, somnolence, &
dyskinesia.
Ascending-dose schedule of ropinirole for
Parkinson's disease:
The recommended starting dose for
Parkinson's disease is 0.25mg 3 times daily.
Based on individual response, dosage should
then be titrated with weekly increments as
described below:
After week 4, if necessary, daily dosage may be
increased by 1.Smg/day on a weekly basis up
to a dose of 9mg/day, & then by up to a total
dose of 24mg/day. Doses greater than 24mg/day
have not been tested in clinical trials.
When ropinirole is administered as adjunct
therapy to L-dopa, the concurrent dose of L­
dopa may be decreased gradually as tolerated.
L-dopa dosage reduction was allowed during
the advanced Parkinson's disease (with L­
dopa) study if dyskinesias or other
dopaminergic effects occurred.
Ropinirole for Parkinson's disease patients
should be discontinued gradually over a 7-day
period. The frequency of administration
should be reduced from 3 times daily to twice
daily for 4 days; for the rest 3 days, the
frequency should be reduced to once daily up
to complete withdrawal of ropinirole.
Restless legs syndrome: The recommended
adult starting dosage for RLS is 0.25mg once
daily, 1 to 3 hours before bedtime. After 2
days, the dosage can be increased to O.Smg
once daily & to lmg once daily at the end of
the first week of dosing, then increased as
needed to achieve efficacy. For RLS, the safety
& effectiveness of doses greater than 4mg once
daily have not been established.
In clinical trials of patients being treated for
•
RLS with. doses up to 4mg once daily,
ropinirole can be discontinued without a taper.
Note: For further information please consult
manufacturer's literature.
+ PERKIROL Tab. Square
Ropinirole hydrochloride INN 0.25mg &
2mg/tablet (film-coated).
0.25mg x SO's pack: 100.50 MRP
2mg x 30's pack: 180.60 MRP
+ REPITOL Tab. Beximco
Ropinirole hydrochloride INN 0.25mg &
2mg/tablet (film-coated).
0.25mg x 30's pack: 60.30 IP
2mg x 30's pack: 301.20 IP
+ ROPINOL Tab. lncepta
Ropinirole hydrochloride INN 0.25mg, lmg &
2mg/tablet (film-coated).
0.25mg x 50's pack: 100.00 MRP
l m g x 30's pack: 120.00 MRP
2mg x 30's pack: 180.00 MRP
Combined Preparations
LEVODOPA + CARBIDOPA +
ENTACAPONE52,54
I
QIMP-17 (165)
LEVODOPA + CARBIDOPA +
ENTACAPONE: Tablet
This is a combined preparation of 2 dopamine
precursors- levodopa & carbidopa & one dopa­
mine receptor antagonist- entcapone for the
treatment of P arkinson's disease. This combined
formulation is available in variable presentations­
i. levodopa SOmg + carbidopa 12.Smg + malabsorption or sucrase-isomaltase insufficiency.
entcapone 200mg/tablet; ii. levodopa 75mg + Caution when driving or operating machines;
carbidopa 18.75mg + entcapone 200mg/tablet; iii.
levodopa 1OOmg + carbidopa 25mg + entcapone
200mg/tablet; iv. levodopa l 25mg + carbidopa
3 l .25mg + entcapone 200mg/tablet; v. levodopa
150mg + carbidopa 37.Smg + entcapone
•
200mg/tablet; vi. levodopa 200mg + carbidopa
SOmg + entcapone 200mg/tablet.
Mode of action: Levodopa is the metabolic
precursor of dopamine, it crosses the bloodbrain
barrier and is converted to dopamine in the brain.
Carbidopa is a dopa decarboxylase (DDC)
inhibitor which reduces the peripheral
metabolism of levodopa to dopamine, and thus,
more levodopa is available to the brain.
Entacapone is a selective inhibitor of catecholo­
methyltransferase. Given concurrently,
entacapone results in greater and more sustained
plasma levels of levodopa, leading to greater
control of Parkinsonism symptoms.
Ind: Treatment of patients with Parkinson's
disease when end-of-dose motor fluctuations are
not stabilised on levodopa/dopa decarboxylase
(DDC) inhibitor treatment.
C/I: Known hypersensitivity to the active substa­
nces or to any of the excipients; severe hepatic
impairment; narrow-angle glaucoma; pheochro­
mocytoma; concomitant use with a non-selective
monoamine oxidase (MAO-A and MAO-B)
inhibitor, concomitant use with a selective MAO­
A inhibitor and MAO-B inhibitor; a history of
neuroleptic malignant syndrome (NMS) and/or
non-traumatic rhabdomyolysis.
S/E: Common side effects include dyskinesia,
nausea, hyperkinesia, change in urine color, diar­
rhea and stomach pain. Other side effects may
include- hemolytic anemia, neuroleptic malignant
syndrome, rhabdomyolysis, agranulocytosis, hep­
atitis with mainly cholestatic features, malignant
melanoma, sudden sleep onset episodes, mental
changes including paranoid ideation and psycho­
tic episodes, depression with or without suicidal
tendencies. Parkinsonism agravated, dizziness,
dystonia, insomnia, hallucinations, confusion,
paroniria, duodenal ulcer, gastrointestinal bleed­
ing, discoloration of skin, hair, beard and nails,
fatigue, increased sweating, fall, colitis, patholog­
ical gambling, increased libido & hypersexuality.
Precautions & warinings: Not recommended for
the treatment of drug-indcued extrapyramidal
symptoms. Caution is recommended when this
preparation is administered to patients with
severe cardiovascular or pulmonary disease,
bronchial asthma, renal, hepatic or endocrine
disease, chronic wide-angle glaucoma; history of
peptic ulcer disease or convulsions or myocardial
infarction or of ventricular arrhythmias, past or
current psychosis, in the event of general anaes­
thesia, extended therapy or when discontinuing
treatment. Development of mental changes,
depression with suicidal tendencies, and other
serious antisocial behaviour should be monitored
-
CNS DRUGS
carefully. Follow-up of weight recommended in
patients experiencing diarrhoea. General medical
evaluation including live function in case of
progressive anorexia, asthenia & weight decrease
within a relatively short period of time.
Caution in patients with rare hereditary problems
of fructose intolerance, glucose-galactose
patients presenting somnolence and/or sudden
sleep onset episodes must refrain from driving
and operating machinery. Not recommended in
patients under 18 years of age.
. .
Pregnancy & lactation: Pregnancy category C.
The combination of leodopa/carbidopa/entaca­
pone should not be 1:1sed during pregnancy unless
the potential benefit justifies the potential risk to
the fetus. The safety of this combination in the
infant is not known. Women should not breast­
feed during treatment with this combination.
Dosage & admin: Adults: The optimum daily
dose must be determined by careful titration
of levodopa in each patient. Patients should be
instructed to take only 1 combined tablet per
dose administration. The maximum recom­
mended daily dose of entacapone is 2,000mg &
therefore the maximum dose is 10 tablets/day
for combination of So+12.5+ 200mg, 75+18.75
+ 200mg, loo+25+ 200mg, 125+31.25+ 200mg,
& 15o+37.5+200mg; and 7 tablets/day of
combination of 200+5o+ 200mg. Usually this
combination formula is to be used in patients
who are currently treated with corresponding
doses of standard release levodopa/carbidopa
and entacapone.
Method of administration: Each tablet is to be
taken orally either with or without food. One
tablet contains one treatment dose and the
tablet may only be administered as whole
tablet.
How to transfer patients taking levodopa/DDC
inhibitor (carbidopa or benserazide) prepara­
tions & entacapone tablets to this combined
formula: i. Patients who are currently treated
with entacapone and with standard release
levodopa/carbidopa in doses equal to this
triple combination tablet strengths can be
directly transferred to corresponding strength
tablets. For example, a patient taking one
tablet of 100mg/25mg of levodopa/carbidopa
with one tablet of entacapone 200mg 4 times
daily can take one combined tablet of
100+2S+200mg 4 times daily in place of their
usual levodopa/carbidopa and entacapone
doses. ii. When initiating combination therapy
for patients currently treated with entacapone
and levodopa/carbidopa in doses not equal to
available combination formula, the dosing
should be carefully titrated for optimal clinical
response. At the initiation, the combination
formula should be adjusted to correspond as
closely as possible to the total daily dose of lev­
odopa currently used. c. When initiating com­
bination therapy in patients currently treated
with entacapone and levodopa/benserazide in
a standard release formulation, the dosing of
levodopa/benserazide should be discontinued
in the previous night, and combination thera­
py should be started in the next morning. The
starting dose of combination formula should

For .f> PARKINSON ·s DISEASE {Pl))
• •
��.
�1·so r
.....
....
...... ..
......
,..
Ihe True Levodopa
provide either the same amount of levodopa or
slightly (5-lOo/o) more.
How to transfer patients not currently treated
with entacapone to combination therapy:
Initiation of combination formula may be
considered at corresponding doses to current
treatment in some patients with Parkinson's
disease and end-of-dose motor fluctuations,
who are not stabilized on their current
standard release levodopa/DDC inhibitor
treatment. However, a direct switch from
levodopa/ DDC inhibitor to this combination
therapy is not recommended for patients who
have dyskinesias or whose daily levodopa dose
is above 800 mg. In such patients it is
advisable to introduce entacapone treatment
as a separate treatment (entacapone tablets)
and adjust the levodopa dose if necessary,
before switching to this triple combination.
Entacapone enhances the effects of levodopa.
It may therefore be necessary, particularly in
patients with dyskinesia, to reduce levodopa
dose by 10-300/o within the first days to first
weeks after initiating combination therapy.
The daily dose of levodopa can be reduced by
extending the dosing intervals and/or by redu­
cing the amount of levodopa per dose, accor­
ding to the clinical condition· of the patient.
Dose adjustment during the course of the
treatment: When more levodopa is required,
an increase in the frequency of doses and/or
the use of an alternative strength of triple
combination should be considered, within the
dose recommendations. When less levodopa is
required, the total daily dose of triple
combination should be reduced either by
decreasing the frequency of administration by
extending the time between doses, or by
decreasing the strength of triple combination
at an administration. H other levodopa
products are used concomitantly with a triple
combination tablet, the maximum dose
recommendations should be followed.
Discontinuation of triple combination therapy:
If triple combination therapy (leodopa/carbi­
dopa/entacapone) is discontinued and the
patient is transferred to levodopa/DDC
inhibitor therapy without entacapone, it is
necessary to adjust the dosing of other
antiparkinsonian treatments, specially levo­
dopa, to achieve a sufficient level of control of
the Parkinsonian symptoms.
Children: Safety and effectiveness in pediatric
patients have not been established.
Elderly: No dose adjustment is required for
elderly patients.
Hepatic impaired patients: Should be
administered cautiously to patients with mild
to moderate hepatic impairment. Dose
reduction may be needed.
Renally impaired patients: Should be
administered cautiously to patients in severe
renal impairment including those receiving
dialysis therapy.
Overdose: The acute symptoms and signs of
overdose include agitation, confusio11al state,
QIMP-17 (166)
coma, bradycardia, ventricular tachycardia,
'
'. ' I
Cheyne-Stokes respiration, discolorations of skin,
tongue and conjunctiva, and chroJDaturia.
Management of acute overdose with levodopa/
carbidopa/entacapone combination is similar to
acute overdose with levodopa.
Pyridoxine, however, is not effective in reversing
the actions of levodopa/carbidopa/entacapone
combination. Hospitalization is advised and
general supportive measures should be employed
with immediate gastric lavage and repeated doses
of charcoal over time.
Drug inter: Symptomatic postural hypotension
may occur when levodopa is added to the treat­
ment of patients already receiving antihyperten­
sive. Dose adjustment of the antih�rtensive
agent may be required. Caution should be exer­
cised when MAO-A inhibitors, tricyclic antide­
pressants or noradrenaline reuptake inhibitors are
used concomitantly. This combination can be
used with selegiline (a selective MAO-B
inhibitor) but the daily dose of selegiline should
not exceed 1 Omg. The combination therapy
should be carefully observed for loss of
therapeutic response when co-administered with
dop amine receptor antagonists (e.g some
antipsychotics and antiemetics), phenytoin and
papaverine. A control of INR is recommended
when combination therapy is initiated for patients
receiving warfarin. Combination therapy and iron
preparations should be. taken at least 2 to 3 hours
apart. Absorption of combination products may
be impaired in patients on high protein diet.
Note: For further information, please consult
manufacturer's literature.
+ STALEVO 75 Tab. Novartis
This is a triple combination formula of levodopa
75mg & carbidopa 18.75mg & entacapone
200mg/tablet (film-coated).
Price: 30's pack: 2355.00 MRP
+ STALEVO 125 Tab. Novartis
This is a triple combination formula of levodopa
l 25mg & carbidopa 31.25mg & entacapone
200mg/tablet (film-coated).
Price: 30's pack: 2355.00 MRP
+ STALEVO 200 Tab. Novartis
This is a triple combination formula of levodopa
200mg & carbidopa 50mg & entacapone
200mg/tablet (film-coated).
Price: 30's pack: 2355.00 MRP
+ TRIDOPA 50 Tab. ACI
This is a triple combination formula of levodopa
50mg & carbidopa 12.5mg & entacapone
200mg/tablet (film coated).
Price: 20's pack: 300.00 MRP
+ TRIDOPA 100 Tab. ACI
This is a triple combination formula of levodopa
1OOmg & carbidopa 25mg & entacapone
200mg/tablet (film coated).
Price: 20's pack: 500.00 MRP
+ 'I'RIDOPA 150 Tab. ACI
This is a triple combination formula of levodopa
150mg & carbidopa 37.5mg & entacapone
200mg/tablet (film coated).
Price: 20's pack: 600.00 MRP
+ TRIDOPA 200 Tab. ACI
This is a triple combination formula of levodopa
200mg & carbidopa 50mg & entacapone
200mg/tablet (film coated).
Price: 20's pack: 800.00 MRP
,....
Antimuscarinic drugs21
Antimuscarinic (anticholinergic) drugs used in
Parkinsonism include: Orphenadrine hydrochl­
oride, Procyclidine hydrochloride & Trihexyph­
enidyl hydrochloride (Benzhexol hydrochloride).
PROCYCLIDJNE21,33
PROCYCLIDINE HCI: Tablet/ Injection
Ind: Parkin.sonism; drug-induced extrapyramidal
symptoms (but not tardive dyskinesia).
S/E: Dry mouth, g.i disturbances, dizziness,
blurred vision; less commonly urinary retention,
tachycardia, hypersensitivity, nervousness and
with high doses in susceptible patients, mental
confusion, excitement and psychiatric
disturbances which may necessitate
discontinuation of treatment.
Cautions: Urinary retention, closed-angle
glaucoma, cardiovascular disease,
hepatic or renal impairment; gastro-intestinal
obstruction; avoid abrupt discontinuation of
treatment; drugs of this type liable to abuse.
May affect performance of skilled tasks
Dosage & admin: Adult: Initially 2.5-Smg 3
times daily increasing at intervals of 2 or 3
days by 2.5-5mg daily; usual max. 30mg daily.
Parenteral dose, Adult- 10-20mg daily by i. m
or i. v injection.
Acute dystonia- by i.m injection, 5-1Omg
repeated if necessary after 20 minutes; max.
20mg daily; by i.v. injection 5mg (usually
effective within 5 minutes); an occasional
patient may need lOmg or more and may·
require up to half an hour to obtain relief.
Child: Not recommended.
+ CYCLID S Tab. lncepta
Procyclidine hydrochloride 5mg/tablet.
l OO's pack: 100.00 MRP
+ CYCLID Inj. lncepta
Procyclidine hydrochloride USP 1Omg/2ml
ampoule: i.m/i.v injection.
1 amp pack: 30.00 MRP
+ EXTRANIL Tab. General
Procyclidine hydrochloride 5mg/tablet.
1OO's pack: 76.00 MRP
+ EXT RANIL Inj. General
Procyclidine hydrochloride USP 1 Omg/2ml
ampoule: i.m/i. v injection.
l amp pack: 30.00 MRP
+ KDRIN Tab. Opsonin
Procyclidine hydrochloride 5mgltablet.
1 OO's pack: 36.93 MRP
+ KDRIN Inj. Opsonin
Procyclidine hydrochloride USP 1 Omg/2ml
ampoule: i.m/i. v injection.
5 amps pack: 132.44 MRP
+ KEMADRIN Tab. GlaxoSmithKline
Procyclidine hydrochloride 5mg/tablet.
1OO's pack: 186.20 MRP
+ PE RKINIL Tab. Square
Procyclidine hydrochloride 5mg/tablet
200's pack: 152.00 MRP
+ PERKINIL Inj. Square
Procyclidine hydrochloride USP 1Omg/2ml
ampoule: i.m/i.v injection.
1 amp pack: 30.11 MRP

TRIHEXYPHENIDYL HCI13&
T RIHEXYPHENIDYL HCI: Tablet
Trihexyphenidyl (also known as benzhexol) is a
synthetic antimuscarinic (anticholinergic) drug. It
is effective as an adjunct in the treatment of all
forms of parkinsonism. This is available as­
trihexyphenidyl hydrochloride USP 2mg/tablet.
Mode of action: Trihexyphenidyl hydrochloride
is the substituted piperidine salt, which exerts an
inhibitory effect upon the parasympathetic
nervous system, and a direct relaxing effect on
smooth musculature. It's therapeutic properties
are similar to those of atropien, although
.., undesirable side effects are ordinarily less
frequent and severe than with the latter.
Ind: Trihexyphenidyl hydrochloride is indicated
as an adjunct in the treatment of all forms of
parkinsonism (post-encephalitic, arteriosclerotic,
and idiopathic). It is often useful as adjuvant
therapy when treating these forms of
parkinsonism with levodopa. Additionally, it is
indicated for the control of extrapyramidal
disorders caused by central nervous system drugs
such as- dibenzoxazepines, phenothiazines,
thioxanthenes, and butyrophenones.
C/I: Trihexyphenidyl hydrochloride is
contraindicated in patients with hypers�nsitivity
to trihexyphenidyl hydrochloride or to any of the
tablet ingredients. Trihexyphenidyl hydrochloride
is also contraindicated in patients with narrow
angle glaucoma. Blindness a.fter long-term use
due to narrow angle glaucoma has been reported.
S/E: Minor side effects, such as dryness of the
mouth, blurred vision, dizziness, mild nausea or
nervousness will be experienced by 30-50
percent of all patitnts. Such reactions tend to
become less pronounced, and even to disappear,
as treatment continues. Isolated instances of
dryness of the mouth, skin rashes, dilatation of
the colon, paralytic ileus, and certain psychiatric
manifestations such as delusions, hallucinations,
and paranoia, all of which may occur with any of
the atropine-like drugs, have been reproted rarely
with trihexyphenidyl hydrochloride.
Potential side effects are cognitive dysfunctions,
confusion and memory impairment; constipation,
drowsiness, urinary hesitancy or retention,
tachycardia, dilation of the pupil, increased
intraocular pressure, choreiform movements,
weakness, vomiting, and headache.
Adverse events reported in pediatric patients:
Hyperkinesia, psychosis, forgetfulness, weight
loss, restlessness, cfiorea, and sleep alterations.
Cautions: Sensitivity to the actions of parasym­
patholytic drugs may increase with age, particu­
larly over the age of 60, therefore, elderly patie­
nts generally should be started on low doses of
trihexyphenidyl hydrochloride & observed closely.
Pregnancy & lactation: Teratogenic effect
pregnancy category C. It is not known whether
I trihexyphenidyl hydrochloride can cause fetal
I Haloperidol, Piracetam, Riluzole &
harm when administered to a pregnant woman or
can affect reproduction capacity.
It is also not known whether this drug is excreted
in human milk. Because many drugs are excreted
in human milk, caution should be exercised when
trihexyphenidyl hydrochloride is administered to
a nursing woman.
•
Dosage & admin: Dosage should be
I
QIMP-17 (167)
individualized. The initial dose should be low
and then increased gradually, spec.ially in
patients over 60 years of age.
In idiopathic parkinsonism: As initial therapy
for parkinsonism, lmg may be administered
on the first day. The dose may then be increa­
sed by 2mg increments at intervals of 3 to 5
days, until a total of 6 to 1 Omg is given daily.
_Drug-induced parkinsonism: The total daily
dosage usually ranges between 5 and 15mg,
although, in some cases, these reactions have
been satisfactorily controlled on as little as
lmg daily. It may be advisable to commence
therapy with a single 1 mg dose. If the
extrapyramidal manifestations· are not
controlled in a Jew hours, the subsequent
doses may be progressively increased ·until
satisfactory control is achieved.
Concomitant use with levodopa: When
. trihexyphenidyl hydrochloride is used
concomitantly with levodopa, the usual dose of
each �ay ·need to be reduced. Careful
adjustment is necessary, depending on side
effects and degree of symptQm control
Trihexyphenidyl hydrochloride -dosage of 3 to
'
6mg daily in divided doses is usually adequate.
Concomitant use with other parasympathetic
inhibitors: The total daily intake of trihexyph­
enidyl hydrochloride tablet is tolerated best if
divided into 3 doses and taken at mealtimes.
High doses (>lOmg daily) may be divided into
4 parts, with 3 doses administered at meal
times and the fourth at bedtime.
Pediatric use: Safety and effectiveness in
pediatric patients have not been established.
Drug inter: Cannabinoids, barbiturates, opiates,
and alcohol may have additive effects with tri­
hexyphenidyl hydrochloride and thus, an abuse
potential exists. Concurrent use of alcohol or
other CNS depressants with trihexyphenidyl
hydrochloride may cause increased sedative
effects. Monoamine oxidase inhibitors & tricyclic
antidepressants possessing significant anticho­
linergic activity may intensify the anticholinergic
effects of antidyskinetic agents because of the
secondary anticholinergic activities of these
medications. Prophylactic administration of
anticholinergic agents, such as trihexyphenidyl,
as a prevention of drug induced parkinsonism
during neuroleptic therapy is not recommended.
+ HEXINOR Tab. Beacon
Trihexyphenidyl hydrochloride USP 2mg/tablet.
2mg x 50's pack: 250.00 MRP
Drugs used in essential
Tremor, Chorea, Tics &
related disordersi1
The drugs discussed in this group include:
Tetrabenazine.
HALOPERIDOL42
HALOPERIDOL: Tablet/Liquid/Injection.
Haloperidol is a highly effective neuroleptic
butyrophenone drug with a wide range of actions.
CNS DRUGS
Haloperidol is rapidly absorbed after oral or
parenteral administration, it is then crosses the
blood brain barrier. It's half life is approximately
20 hours. It is available as- haloperidol BP 5mg/
tablet; 2.5mg/5ml syriip; 5mg/l ml ampoule: i.m
injection.
Note: For further information & preparations, see
under antipsychotic drugs.
PIRACETAM42
PIRACETAM: Tablet/Syrup/Injection
Piracetam is a 'nootrope', psychotropic agent.
Mode of action: Piracetam as a psychotropic
agent, acts directly on the brain to improve the
efficacy of the telencephalon in both normal
subjects and those suffering from some functional
deficits. This area of the brain is involved in
cognition and also has a role to play in learning
and memory, in alertness and in consciousness.
Piracetam does not cause sedation or stimulation.
It acts on the central nervous system in different
ways. It can modify neurotransmission within the
brain, and can help to improve the metabolic
environment essential for good neuronal function.
It is also a haemorrheological agent and can
improve microcirculation without producing
vasodilation. When given as acute or long-term
treatment for patients, suffering from a functional
CNS deficit, it enhances alertness and increases
cognitive function. Piracetam also protects and
restores cognitive functional capacity 'for cerebral
trauma, e.g hypoxia or intoxication, and after
electroshock therapy. Piracetam may be given
alone or in combination with other drugs when
treating myoclonia due to anoxia. It reduces the
duration of vestibular nystagmus. Piracetam also
improves regional oxygen and glucose uptake in
the brain in patients suffering from dementia
�ubequent to multiple infarcts, or in those with
cerebral ischaemia. Piracetam inhibits the
increased aggregation of activated platelets and,
in conditions where there is abnormal rigidity of
the RBC, it can restore deformability and the
ability to pass through the microvasculature.
Ind: 1. Cerebral vascular accidents and cerebral
insufficiencies- ischaemic or even haemorrhagic
acute accidents, stroke, chronic manifestations of
the above accidents of cerebral atherosclerosis.
2. Mental retardation in children- ease of
resuming individual contact, sociability &
learning, improved intellectual performances and
school results.
3. Behaviour and psychotic problems in old age­
memory deficits, particularly with regard to
fixation and evocation asthenia adoption
disorders, disturbed psychomotor reactions.
4. Patients suffering from myoclonus of cortical
ongm.
• •
S/E: The side effects reported include- nervous­
ness, agitation, irritability, anxiety and sleep
disturbances. The incidence of these during
clinical trials was approximately 5% and they
were more often noted in the older patients
taking >2.4gm daily. In the majority cases, a dose
reduction causes disappearance of the symptoms.
Some patients may complain very rarely of
fatigue or drowsiness, gastrointestinal problems
e.g nausea, vomiting, diarrhoea and stomach
pain. Other symptoms e.g vertigo, headache,

CNS DRUGS
trembling and sexual stimulation have
occasionally been reported.
C/I & Precaution: Piracetam is contra-indicated
in patients with severe renal insufficiency
(creatinine clearance<20ml/min), hepatic
impairment. As the principal route of elimination
for piracetam is :via the kidney, special care must
be taken when treating patients suffering from
renal insufficiency. Monitoring of renal function
is recommended in such cases. This is also true
for the older patients in whom creatinine
clearance is dependent on age.
When the creatinine clearance is <60mVmin, or
serum creatinine is > l .25mg/l OOml, the dosage
should be given half of the normal dose;
accordingly when the creatinine clearance is
<40mVmin, or serum creatinine is
>1.70mg/1OOml; the dosage should be given
quarter of the normal dose.
Pregnancy & lactation: Piracetam should not be
prescribed during pregnancy or when breast
feeding, except under exceptional circumstances.
Piracetam crosses the placental barrier.
Dosage & Admin: Adults, in cerebro-cortical
insufficiency disoders, usual dose is 800mg 3
times a day. In myoclonic seizures, a dose of
7.2gm daily, increasing by 4.8gm per day
every 3 to 4 days up to maximum of 20gm
daily, given in 2 or 3 divided doses.
Children, SOmg/kg of body weight in 3
divided doses. Once the desired results has
been obtained, reduce the initial dose by half.
+ JUVAIN Tab. Opsonin
Piracetam INN 800mg/tablet
800mg x 50's pack: 264.79 MRP
+ JUVAIN Syp. Opsonin
Piracetam INN 500mg/5ml: syrup
lOOml bot: 132.46 MRP
+ LUCETAM Tab. Egis/City Overseas
Piracetam 1200mg/tablet (f.c)
1200mg x 20's pack: 315.00 TP
+ MEMOPIL Tab. ACI
Piracetam INN 800mg/tablet
800mg x 50's pack: 301.00 MRP
+ MEMOPIL Syp. ACI
Piracetam INN 500mg/5ml: syrup
l OOml bot: 150.57 MRP
+ NEUROLEP Tab. Square
Piracetam INN 800mg/tablet
800mg x 40's pack: 240.80 MRP
+ NEUROLEP Syp. Square
Piracetam INN 500mg/5ml: syrup
l OOml bot: 150.57 MRP
+ PIRAMAX Tab. Aristopharma
Piracetam INN 800mg/tablet
800mg x 30's pack: 180.00 MRP
+ PIRATAM Tab. General
Piracetam INN 800mg/tablet
800mg x 40's pack: 240.80 MRP
+ PIRATAM Syp. General
Piracetam INN 500mg/5ml: syrup
l OOml bot: 150.57 MRP
9. APPETITE SUPPRESSANTS/
ANTIOBESITY DRUGS2t
Appetite suppressants can be classified as:
1. Anti-obesity drugs acting on the g.i tract-
•
-
QIMP-17 (168)
a. Bulle forming drugs- (discussed unde
gastrointestinal preparations)
b. Pancreatic lipase inhibitor e.g Orlistat
2. Centrally acting appetite suppressant viz:
Sibutramine-
Pancreatic lipase inhibitor
ORLISTAT50
ORLISTAT: Capsule
Orlistat is an anti-obesity drug acting on the
gastrointestinal tract. It is available as orlistat
INN 60mg & l 20mg capsule.
(
Mode of action: It is a pancreatic lipase inhibitor,
which reduces the absorption of dietary fat.
Ind: For long-term management of obese
and overweight patients, including patients with
risk factors e.g hypercholesterolaemia, noninsulin
dependent diabetes mellitus (NIDDM), impaired
glucose tolerance, hyperinsulinaemia,
hypertension associated with obesity and in a
reduction of visceral fat.
C/I: Chronic malabsorption syndrome; patients
with known hypersensitivity to orlistat or any of
the other components contained in the preparation.
AIR: Adverse reactions are largely gastrointesti­
nal in nature. Commonly observed events are
oily spotting, flatus with discharge, faecal
urgency, fatty or oily stool, oily evacuation,
increased defaecation and faecal incontinence.
These are generally mild and transient.
Cautions: The possibility of experiencing
gastrointestinal events may increase when orlistat
is taken with a diet high in fat.
Pregnancy & Lactation: The safety of orlistat
has not been established in pregnant women.
Orlistat should not be taken by breast-feeding
women, unless the potential benefit outweighs
the potential risk.
Dosage & Admin: Adults, 120mg with each
main meal; if a meal is missed or contains no
fat, the dose of orlistat may be omitted for
that meal. In case of hepatic and renal
impairment, dose adjustment is not required.
Children, below the age of 18 years not
recommended.
Drug inter: There are no evidences of intera­
ctions with commonly prescribed medications.
However, orlistat enhances the bioavailability
and lipid lowering effect of pravastin.
+ ADIPONIL Cap. Incepta
Orlistat INN 120mg/capsule
lO's packs: 400.00 MRP
+ DIETIL Cap. SK+F
Orlistat INN 120mg/capsule
lO's packs: 400.00 MRP
+ SLIMFAST Cap. Helathcare
Orlistat INN l 20mg/capsule
24's packs: 1200.00 MRP
+ SLIMI Cap. UniMed & UniHealth
Orlistat INN 60mg/capsule
2l's packs: 630.00 MRP
+ XENEKAL Cap. Radiant
Orlistat 120mg/capsule
21's packs: 1260.00 MRP
+ XENICAL Cap. Roche/Radiant
Orlistat 120mg/capsule
'
84's packs: 5800.00 MRP

Centrally acting appetite •
suppressants
Centrally acting appetite suppressant, currently
available for medical use- Sibutramine.
SIBUTRAMINE42,52
SIBUTRAMINE: Capsule
Sibutramine is an effective anti-obesity drug. It
works against obesity- i. by supporting the
natural weight-control fimctions in the body by
inhibition of re-uptake of monoamine neurotrans­
miters & ii. by stimulating metabolic activity.
Mode of action: Sibutramine produces its
•
therapeutic effect by inhibition of re-uptake of
neural messenger substances viz. norepinephrine,
serotonin and dopamine (neurotransmiters) in the
brain. Sibutramine and its major phannacolo­
gically active metabolites (Ml and M2) do not
•
act via release of monoamines. Sibutrami ne
exerts its phamacological actions predominantly
by its secondary (M l ) and primary (M2) amine
metaboliltes. However, prevention of resorption
of the aforesaid neurotransmiters in the brain,
allowing them to act at higher concentration on
the nerve cells. Thus increases the feeling of
fullness of stomach. Sibutramine also stimulates
thermogenesis (metabolic activity) indirectly by
activating the 3-system in brown aolipose tissue.
Ind: Sibutramine is used in the management of
obesity, including weight loss and management
of weight loss when used in conjunction with a
reduced caloric diet. Sibutramine is recom­
mended for obese patients with an initial body
mass index (BMI) ? 30kg/m2 or ? 27kg/m2 in the
presence of other risk factors (e.g hypertension,
diabetes, dyslipidaemia).
(BMI is calculated by taking the patient's weight
in kg and dividing by the patient's height, in
meters, squared. Metric conversions are as
follows: Pounds 2.2=kg; inches x 0.0254-ineters.)
C/I: Patients receiving monoamine oxidase
inhibitors (MAOIs); hypersensitivity to sibutra­
mine or any of the active ingredients of sibutram­
ine; patients with anorexia nervosa; patients
taking other centrally acting appetite-suppressant
drugs.
S/E: Commonly reported side-effects of
sibutramine are dry mouth, headache, insomnia
and constipation; diarrhoea, dizziess, drowsiness
and rhinitis have also occured. Less frequently
reported side-effects include dysmenorrhoea,
oedema, influenza-like symptoms, and
depression. Abnormal bleeding, acute interstitial
nephritis, emotional lability, migraine, seizures
and skin rashes have been reported rarely.
Clinically significant increase in heart rate and
blood pressure may occur. Sibu tramine may
decrease salivary flow and therefore increase the
risk of dental caries, periodontal disease, or other
oral disorders. It may also produce mydriasis.
Increases in liver enzyme have been reported.
Cautions: Give with caution to those patients
with a history of hypertension and do not give to
patients with uncontrolled or poorly controlled
hypertension. Use with caution when prescribing
sibutramine with other agents that may raise
QIMP-17 (169)
blood pressure or heart rate including certain
decongestant, cough, cold & allergy medications
that contain agents such as phenylpropanolamine,
ephedrine or pseudoephedrine.
Pregnancy & lactation: The use of sibutramine
is not recommended during pregnancy, and in
nursing mothers.
Dosage & admin: The recommended starting
dose is lOmg once daily with or without food.
If there is inadequate weight loss, the dose
may be increased after 4 weeks to a total of
15mg once daily. The Smg dose should be
reserved for patients who do not tolerate 1Omg
dose. Blood pressure and heart rate changes
should be taken into account when making
decisions regarding dose titration. Analysis of
numerous variables has indicated that 60°/o of
patients who lose at least 4 lbs in the first 4
weeks of treatment with a given dose of
sibutramine in combination with a reduced­
calorie diet lose at least 5°/o of their initial
body weight by the end fo 6 months to 1 year
of treatment on that dose. Conversely, 80°/o of
patients who do not lose at least 4 lbs in the
first 4 weeks of treatment with a given dose,
do not lose at least 5°/o of their initial body
weight by the end of 6 months to 1 year of
treatment on that dose. If a patient has not
lost at least 4 lbs in the first 4 weeks of
treatment, consider re-evaluation of therapy
which may include increasing the dose or
discontinuing sibutramine. The safety and
efficacy of sibutramine have not been
determined beyond 1 year at this time.
Drug inter: Sibutramine should not be given
concurrently with, or within at least two weeks of
stopping an MAOI; at least two weeks should
elapse between discontinuation of sibutramine
and starting therapy with an MAOI. There is a
risk of the serotonin syndrome developing if
sibutramine is administered together with other
serotonergic drug such as selective serotonin
reuptake inhibitors (SSRis), sumatriptan, lithium,
pethidine, fentanyl, dextromethorphan and penta­
zocine. Sibutramine should not be used with
other drugs that may increase heart rate or blood
pressure such as ephedrine, phenylpropanola­
mine, and pseudoephedrine (which may be
ingredients of some cough and cold remedies).
Alcohol should be avoided. Inhibitors of the
cytochrome P450 isoenzyme CYP3A4, such as
ketoconazole and erythromycin, may increase
plasma concentrations of sibutramine.
+ SIBULIN Cap. Beximco
Sibutramine hydrochloride monohydrate INN
equivalent to 5mg sibutramine hydrochloride
INN/capsule.
60's pack: 301.20 IP
10. DRUGS USED IN STROKE
Drugs used in cerebrovascular bleeding
disorder (stroke) cab be classified under the
following subgroups:
1. Antihypertensive drugs- discussed in the
cardiovascular system.
.
2. Cerebral vasodilator drugs- discussed in the
cardiovascular system.
3. Antiplatelet drugs- discussed in the
CNS DRUGS
cardiovascular system.
4. Neurosensory oxygenator drugs- discussed
in the cardiovascular system.
5. Drugs for biosynthesis of the structural
phospholipids of �euronal cell membranes:
such as- Citicoline.
CITICOLINE48
CITICOLINE: I.V/I.M Injectionffablet
Citicoline, a naturally occurring endogenous
nucleoside, is an intermediate compound in the
major pathway for the biosynthesis of the struc­
tural phospholipids of cell membranes, including
neurons. It is available as- citicoline l 25mg/ml;
500mg in 4ml ampoule for i.v or i.m injection.
Mode of action: When citicoline is injected i. v
or i.m, or administered orally, it is absorbed
almost completely in humans. Once absorbed, it
is rapidly hydrolyzed to choline & cytidine,
which then disperse widely throughout the body,
cross the blood brain barrier, and reach the
central nervous system (CNS), where they are
incorporated into the phospholipids fraction of
the cellular membrane and microsomes. Thus,
citicoline activates the bio-synthesis of structural
phospholipids in the neuronal membrane,
increases cerebral metabolism and increases the
level of various neurotransmitters, including
acetylcholine and dopamine.
·
Citicoline has shown neuro protective effects in
situations of hypoxia and ischaemia, as well as
improved learning and memory performance in
animal models for the brain aging. Further more,
it has been demonstrated that citicoline
restoresthe activity of mitochondrial ATPase and
of membranal Na+/K+ATPase, inhibits the
activation of phospholipase A2 and accelerates
the re absorption of cerebral edema in various
experimental models.
Ind: i. Cerebrovascular diseases e.g from
ischemia due to stroke, where citicoline
accelerates the recovery of consciousness &
overcoming motor deficit. Treatment of citicoline
within the frrst 24 hours after onset in patients
with moderate to severe stroke increases the
probability of complete recovery in 3 months.
ii. Head trauma of varying severity: in a clinical
trial, citicoline accelerated the recovery from
post-traumatic coma and the recuperation of
walking ability, achieved a better final fimctional
result and reduced hospital stay.
iii. Cognitive disorders of diverse aetiology e.g
senile cognitive impairment which is secondary
to degenerative diseases (e.g Alzheimer's disease)
& to chronic cerebral vascular disease. Citicoline
improves scores on cognitive evaluation scales &
slowed the progression of Alzheimer's disease.
iv. Parkinson's disease citicoline has also been
shown to be effective as co therapy for
Parkinson's disease.
v. Other effects: a. Affects of citicoline on CNS
dopaminergic system has been experimentally
evidenced. b. After treatment with citicoline,
regeneration of cells in rats with substantina
nigra lesions has been demonstrated.
c. Citicoline increases striatal dopamine &
tyrosine hydroxylase synthesis.
C/I: Must not be administered to patients with
hypertonic of the parasympathetic.

CNS DRUGS
S/E: Occasionally, citicoline may exert a stimu­
lating action of the parasympathetic system, as
well as a fleeting and discrete hypotensive effect.
Precautions: This drug must not be administered
in conjunction with medication containing
meclofenoxate (also known as clophenoxate).
Pregnancy & lactation: There is inadequate
evidence of safe use of citicoline in human
pregnancy. Citicoline should be used in
pregnancy and lactation only if the potential
benefits justify the potential risks.
Dosage & admin: Clinical studies indicate the
most effective oral dosage for citicoline ranges
from 500 2,000mg daily. i.v and i.m adminis­
trations have also used similar dosages.
B•v mouth:
For decline in thinking skills due to age:
2000mg/day.
Citicoline 1000
As tablet: 1OOOmg daily in divided doses with
or between meals.
For ongoing disease of the blood vessels that
serve the brain (chronic cerebrovascular
disease): Citicoline 600mg/day.
For immediate treatment of stroke due to a clot
(ischemic stroke): 500 2000mg of citicoline
per day starting within 24 hours of stroke.
v iniection:
B� ._
Disturbance of consciousness due to head
injury or brain surgery: 100 500mg 1 2 times
daily by i.v drip infusion or i.v injection.
Psychological or neurologic disorder:
Disturbance of consciousness in the acute
stage of cerebral infarction: lOOOmg once a
day by i.v injection for 2 consecutive weeks.
Hemiplegia after cerebral apoplexy: lOOOmg i.v
once a day for 4 consecutive weeks & if a
trend towards improvement is observed,
continue the administration for an additional
4 weeks.
Dosage may be adjusted based on the
seriousness of the disease. It can be
administered by i.m or i.v (3 to 5 minute)
injection and in i.v drip (mixing with i.v fluid
at 40 60 drops/minute). Citicoline is
compatible with all intravenous
isotonic solutions. It can also be mixed with
hypertonic glucose serum.
Drug inter: This drug may potentiate the effects
ofL dopa.
Note: For further information, please consult
manufacturer's literature.
+ CIT ICOL I.V/I.M inj. Beximco
Citicoline 125mg/ml; 500mg in 4ml ampoule for
i.v or i.m injection.
500mg (4ml amp) x S's pack: 700.00 MRP
11. DRUGS FOR DEMENTIA
Currently available drugs that are used in
the treatment of dementia of Alzheimer's type
include:
1. Anticholinesterase agents, such as­
Donepetil, Galantamine, Rivastigmine.
2. NMDA (N-methyl-D-aspartate) receptor
antagonist, such as- Memantine.
DONEPEZIL26,54
QIMP-17 (170)
DONEPEZIL: Tablet
Donepezil hydrochloride is a centrally acting &
reversible anticholinesterase agent. It is available
as- Donepezil hydrochloride INN 5mg film-coated
tablet.
Mode of action: Donepezil hydrochloride binds
reversibly & selectively with acetylcholinesterase
and inactivates it, thus inhibiting hydrolysis of
acetylcholine.
As a result the concentration of acetylcholine
increases at cholinergic synapses in the brain.
Ind: Symptomatic treatment of mild to moderate
dementia· of Alzheimer's type.
C/I: Known hypersensitivity to donepezil
hydrochloried or to piperidine derivatives.
S/E: Generally well tolerated but some patients
may experience nausea, vomiting & diarrhoea.
These adverse events are of mild intensity and
transient, resolving during continued treatment
without the need for dose modification.Less
frequent side effeccts are insomnia, fatigue,
anorexia, muscle cramps, generalized seizure etc.
Precautions: Caution should be taken in sick
sinus syndrome or other supraventricular
conduction abnormalities, patients at risk of
developing peptic ulcers, asthma, obstructive
airway disease and during anaesthetic procedure.
Pregnancy & lactation: There are no adequate
and well controlled studies in pregnant woman.
Donepezil should be used durng pregnancy only
if the potential benefit justifies the potential risk
to the fetus. Nursing mother- it is not known
whether Donepezil hydrochloride is secreted in
human breast milk or not, so it is not advised in
nursing mother.
Dosage & admin: 5mg once daily orally at bed
time, for at least one month, in order to allow
the earliest clinical response to treatment to
be assessed and to allow steady-state concen­
trations of donepezil hydrochloride to be
achieved. Following a one-month clinical
assessment of treatment, the dose can be
increased to lOmg/day (once-a-day dosing).
Since food does not affect the rate or extent of
absorption of donepezil, it can be administered
with or without food.
In case .of renal & hepatic impairment- a simi­
lar dose schedule can be followed for patients
with renal or mild to moderate hepatic impair­
ment as clearance of donepezil hydrochloride
is not affected by these conditions.
In case of children- Donepezil is not
recommended for use in children.
Drug inter: Drugs with anticholinergic proper­
ties & which cross into the brain, such as
atropine, benztropine produce the opposite effects
of Donepezil and should be avoided during
therapy with donepezil. Medication with
carbamazepine, dexamethasone, phenobarbital,
phenytoin may reduce the effect of donepezil,
whereas ketoconazole, quinidine, cimetidine may
increase the effects.
+ AMELOSS Tab. Incepta
Donepezil hydrochloride INN 5mg/tablet (f.c ).
5mg x 30's pack: 300.00 MRP
+ ELZER Tab. Square
Donepezil hydrochloride INN 5mg/tablet (f.c).
5mg x 30's pack: 301.20 MRP
-
GALANTAMINE52
GALANTAMINE HCI: Tablet
Galantamine is a choJinomimetic agent. It is
available as- Galantamine hydrobromide USP
equivalent to 4mg, 8mg & 12mg in tablet form.
Mode of action: Galantamine is a cholinomi­
metic agent. It is a competitive and reversible
inhibitor of the enzyme acetylcholinesterase. In
addition, galantamine enhances the intrinsic
action of acetylcholine on nicotinic receptors. As
a result, an increased activity in the cholinergic
system associated with improved cognitive
function can be achieved in patients with
dementia of the Alzheimer's type.
Ind: Galantamine is indicated in the treatment of
mild to moderate dementia of the Alzheimer's
•
•
type.
C/I: Galantamine is contraindicated in patients
with renal impairment; breast feeding and known
hypersensitivity to the active substance or to any
of the excipients. •
S/E: Common side effects are nausea, vomiting,
diarrhoea, abdominal pain, dyspepsia; syncope;
rhinitis; sleep disturbances, dizziness, confusion,
depression, headache, fatigue, anorexia, tremor;
fever; weight loss; less commonly arrhythmias,
palpitation, myocardial infarction,
cerebrovascular disease, paraesthesia, tinnitus,
and leg cramps.
Precautions: Caution should be taken in patients
with cardiac disease; electrolyte disturbances;
susceptibility to peptic ulcers; asthma, chronic
obstructive pulmonary disease, pulmonary
infection. Galantamine should be avoided in
urinary retention & gastro-intestinal obstruction.
Pregnancy & lactation: Galantamine is in
pregnancy category B. Galantamine should be
used during pregnancy only if the potential
benefit justifies the potential risk to the fetus. It
should not be used during breast-feeding.
However, if its use is unavoidable, then breast­
feeding should be discontinued.
Dosage & admin: Adults: The recommended
starting dose of galantamine is 4mg twice daily
(8mg/day). The dose should be increased to the
initial maintenance dose of 8mg twice daily
(16mg/day) after a minimum of 4 weeks.
A further increase to 12mg twice daily (24mg/
day) should be attempted after a minimum of
4 weeks at 8mg twice daily (16mg/day). Gala­
ntamine should be administered twice daily,
preferably with morning and evening meals.
Children: Galantamine is not recommended in
children.
Hepatic impairment: In patients with modera­
tely impaired hepatic function, the total daily
dose should generally not exceed 16mg/day.
The use of galantamine in patients with severe
hepatic impairment is not recommended.
Renal impairment: For patients with moderate
renal impairment the dose should generally
not exceed 16mg/day. In patients with severe
renal impairment ( creatinine clearance <9ml/
min), the use of galantamine is not recom­
mended.
Drug inter: Galantamine should not be given
concomitantly with other cholinomimetics and
drugs that significantly reduce the heart rate (e.g
digoxin and beta blockers). It can also exaggerate

succinylcholine-type muscle relaxation during
anesthesia. During initiation of treatment with
potent inhibitors of CYP2D6 ( e.g quinidine,
paroxetine, fluoxetine or fluvoxamine) or
CYP3A4 ( e.g ketoconazole), patients may
experience an increased incidence of cholinergic
side effects, predominantly nausea and vomiting.
+ANTIAL Tab. ACI
·
Galantamine hydrobromide USP equivalent to
4mg & 8mg/tablet.
4mg x 20's pack: 241.00 MRP
8mg x 1O's pack: 200.80 MRP
MEMANTINE52
MEMANTINE HCl: Tablet
Memantine is an antidementia drug with low to
moderate affinity to voltage-dependent NMDA
(N-methyl-D-aspartate) receptor antagonist. It is
available as- memantine hydrochloride INN
equivalent to memantine 1Omg in tablet form.
Mode of action: As memantine is a drug with
low to moderate affinity to voltage-dependent
NMDA (N-methyl-D-aspartate) receptor antago­
nist, it selectively blocks the excitoto�c effects
associated with abnormal transmission of gluta­
mate, while allowing for the physiological trans­
mission associated with normal cell functioning.
Ind: Memantine is indicated for the treatment of
moderate to severe dementia in Alzheimer's
disease.
C/I: Patients with a known hypersensitivity to
memantine or any of the excipients.
S/E: The most common side effects are
headache, dizziness, drowsiness, constipation,
dyspnea, hypertension; less common side effects
are vomiting, confusion, fatigue, hallucination,
abnormal gait, thrombosis, heart failure; very rare
side effects are seizures, pancreatitis, psychosis,
depression and suicidal ideation.
Precautions: Mamantine should be used with
caution in patients with epilepsy, former history
of convulsions or patients with predisposing
factors for epilepsy. Some factors that may raise
urine pH may necessitate careful monitoring of
the patient. These factors include drastic changes
in diet, e.g from a carnivore to a vegetarian diet,
or a massive ingestion of alkalizing gastric
buffets. Urine pH may also be elevated by states
of renal tubular acidosis (RTA) or severe infec­
tion of the urinary tracts with proteus bacteria.
Pregnancy & lactation: No clinical data on
exposed pregnancies are available. Animal
studies indicate a potential for reducing intrau­
terine growth at exposure levels that are identical
or slightly higher than at h\1man exposure. The
potential risk of humans is unknown. Mem�tine
should not be used during pregnancy unless
clearly needed.
It is also not known whether memantine is
excreted in human breast milk, however, women
taking memantine should not breast-feed.
Dosage & admin: Initial dose: The recommen­
ded initial dose isSmg once daily, which is
stepwise increased over the first 4 weeks & the
recommended maximum daily dose is 20mg.
Maintenance dose: The recommended
maintenance dose is 20mg daily.
Renal impairment: In patients with moderate
I
QIMP-17 (171) CNS DRUGS
renal impairment (creatinine clearance 30-49 C/I: Known hypersensitivity to rivastigmine,
ml/min) daily dose should be lOmg. If tolera­ other carbamate derivatives, or excipients of the
ted well after at least 7 days of treatment, the formulation.
dose could be increased up to 20mg/day S/E: Nausea, vomiting,.diarrhoea, abdominal pain,
according to standard titration scheme. In loss of appetite, dyspepsia, dizziness, headache.
patients with severe renal impairment
Precautions/warnings: Sick sinus syndrome,
(creatinine clearance 5-29ml/min) daily dose
severe cardiac arrhythmia5, ga.Stroduodenal
should be lOmg per day.
ulcerative conditions in predisposed patients,
Hepatic impairment: In patients with mild to
respiratory disease, urinary obstruction, seizure,
moderately impaired hepatic function, no
pregnancy and lactation.
dosage adjustment is needed. Administration
of memantine is not recommended in patients Dosage & admin: 1.5mg twice daily is the
with severe hepatic impairment. recommend� starting dose. H well tolerated,
Children: Memantine is not recommended for it may be increased after a minimum of 2
children below 18 years due to lack of data on weeks of treatment to 3mg twice daily,
subsequently to 4.Smg twice daily, up to a
safety and efficacy.
maximum of 6mg twice daily. Adverse effects
Drug inter: The pharmacological effects and
may respond to omitting one or more doses. If
mechanism of action of memantine suggest that
they persist, the daily dose should be reduced
the effects of L-dopa, dopaminergic agonists, and
to the previous well tolerated dose.
anticholinergics may be enhanced by concomitant
Rivastigmine patch: See below under
treatment with NMDA-antagonists such as
individual preparation.
memantine. The effects of barbiturates and neu­
Drug inter: Cholinomimetic drugs, anticholiner­
roleptics may be reduced. Concomitant adminis­
gic medications.
tration of mematine with the antispasmodic
agents, dantrolene or baclofen, can modify their Note: For further information please consult
effects and a dosage adjustment may be manufacturer's literature.
necessary. Memantine should not be used with
amantadine, ketamine, dextromethorphan, +EXELON Cap. Novartis
phenytoin, cimetidine, ramtidine, procainamide, Rivastig1nine (hydrogen tartrate) l .5mg, 3mg,
quinidine, quinine & nicotine. 4.5mg & 6mg/capsule
1.5mg x 60's pack: 6420.00 MRP
3.0mg x 60's pack: 6420.00 MRP
+ABIXA 10 Tab. ACI
4.5mg x 60's pack: 6420.00 MRP
Memantine hydrochloride INN equivalent to
6.0mg x 60's pack: 6420.00 MRP
memantine 1Omg/tablet.
1Omg x 20's pack: 200.00 MRP
+EXELON Patch Scm/lOcm Novartis
+DEMENTAS Tab. Ziska
'Exelon patch 5cm' (i.e 5cm patch) contains
Memantine hydrochloride INN equivalent to
rivastigmine INN 9mg, the release rate is
memantine 5mg/tablet.
4.6mg/24 hour.
5mg x 30's pack: 300.00 MRP
'Exelon patch lOcm' (i.e lOcm patch) contains
+MEMOGEN Tab. Orion Pharma
rivastigi11ine INN 18mg; the release rate is
Memantine hydrochloride INN equivalent to
9.Smg/24 hour.
memantine 5mg/tablet.
Dosage & admin: Initiation and re-initiation of
5mg x 30's pack: 300.00 MRP
therapy should start with one 'Exelon patch
5cm' each day. If well tolerated, it may be
RIVASTIGMINE26,54 increased after a minimum of 4 weeks of treat­
ment to one 'Exelon patch 1Ocm' each day
which is the recommended maintenance dose.
RIVASTIGMINE: Capsule/Patch
Patients treated by Exelon capsules or oral
Rivastigniine is a centrally acting, reversible non­
suspension with a maintenance dose of 6mg to
competitive acetylcholinesterase inhibitor,
12mg may be switched to 'Exelon patch lOcm'.
introduced as the specific drug therapy for
'Exelon patch 5cm' x 30's pack: 6720.00 MRP
Alzheimer's patients to improve their functional
'Exelon patch lOcm' x 30's pack: 6720.00 MRP
ability & preserve cognitive performance. It is
available as- Rivastimine (as hydrogen tartrate +DEMELON Cap. UniMed & UniHealth
salt) 1.5mg, 3mg, 4.5mg & 6mg in capsule form. Rivastigr11ine (hydrogen tartrate) l.5mg &
It is also available as- Rivastigmine patch 5 3mg/capsule
containing rivastigmine INN 9mg, the release 1.5mg x 28's pack: 560.00 MRP
rate is 4.6mg/24h. & Rivastigmine patch 10 3mg x l 4's pack: 560.00 MRP
containing rivastigmine INN l 8mg; the release
+RIVAMER Cap. Sun Pharma
rate is 9.5mg/24h.
Rivastig1nine (hydrogen tartrate) l .5mg &
Mode of action: Rivastign1ine binds reversibly
4.5mg/capsule
& selectively with acetylcholinesterase and
l .5mg x 30's pack: 600.00 MRP
inactivates it, thus inhibiting hydrolysis of
4.5mg x 30's pack: 1200.00 MRP
acetylcholine.
As a result the concentration of acetylcholine
increases at cholinergic synapses in the brain at
12. ANALGESICS
selectivity region.
Ind: Mild to moderately severe dementia
associated with Alzheimer's disease or Analgesics are discussed with antipyretic drugs
Parkinson's disease. in the chapter-9.
 - c

CNS DRUGS QIMP-17 (172)

thereafter. alertness and ability to perform hazardous tasks.

13. DRUGS USED IN SUB­
STANCE DEPENDENCE
Alcohol & Opioid dependence
NALTREXONE HCI: Tablet
Naltrexone hydrochloride is an opioid antagonist
and is effective in the treatment of opioid
dependence and alcoholism. It is available as
naltrexone hydrochloride USP 25mg & 50mg
film-coated tablet.
Mode of action: As an opioid antagonist, naltre­
xone blocks the effects of opioids by competitive
binding (i.e analogous to competitive inhibition
of enzymes) at opioid receptors. Naltrexone when
co-administered with morphine on a regular
basis, it blocks the physical dependence to
morphine, heroin and other opioids. In subjects
physically dependent on opioid, naltrexone
precipitates withdrawal symptoms. Naltrexone
markedly attenuates or completely blocks,
reversibly, the subjective effects of intravenously
administered opioids; 50mg of naltrexone will
block the pharmacologic effects of 25mg of
intravenously administered heroin for periods as
long as 24 hours, doubling the dose of naltrexone
provides blockade for 48 hours, and tripling the
dose provides blockade for about 72 hours.
The mechanism of action of naltrexone in alco­
holism is not understood; however, naltrexone
has been shown to reduce alcohol consumption in
clinical studies.
Naltrexone produces some pupillary constriction,
by an unknown mechanism.
Ind: Naltrexone is indicated in the treatment of
opioid dependence and alcoholism. It has not
been shown to provide any therapeutic benefit
except as part of an appropriate plan of
management for the addictions.
C/I: Naltrexone is contraindicated in patients
receiving opioid analgesics, patients currently
dependent on opioids, patients in acute opioid
withdrawal, any individual who has failed the
naloxone challenge test or who has a positive
urine screen for opioids, any individual with a
history of sensitivity to naltrexone or there is any
cross-sensitivity with naloxone or the
phenanthrene containing opioids, any individual
with acute hepatitis or liver failure.
S/E; Precautions & warnings: Please see
manufacturer's literature.
Dosage & admin: A patient is candidate for
treatment with naltrexone if- i. the patient is
willing to take a medicine, ii. the patient is opi­
oid free for 7-10 days, iii. the patient dose not
have severe or active liver or kidney problems,
iv. the patient is not allergic to naltrexone and
no other contraindications a� present.
.
. . .'
'
In alcoholism, a dose of SOmg once daily (up to
12 weeks) is recommended for most patients.
If there is any question of occult opioid
dependence, perform a naloxone challenge test
and do not initiate naltrexone therapy until
the naloxone challenge is negative.
Alternative dosing schedules: Once the patient
has been started on naltrexone, SOmg every
other day, or 150mg every
third day. The degree of blockade produced by
naltrexone may be reduced by these extended
dosing intervals.
Drug inter: Caution is advised if the
concomitant administration of naltrexone and
other drugs is required. The safety & efficacy of
concomitant use of two potentially hepatotoxic
medications is not ordinarily recsuommended
..
unless the probable benefits outweigh the known
risks. Lethargy and somnolence have been
reported following doses of naltrexone and
thioridazine. Patients taking naltrexone may not
be benefited from opioid containing medications
such as cough and cold preparations,
antidiarrhoeal preparations and opioid analgesics.
Note: For further information, please consult
manufacturer's literature.
+ NALTRAX-50' Tab. Navana
Naltrexone hydrochloride USP 50mg/tablet (film­
coated).
50mg x lO's pack: 1405.30 MRP
Drugs for cessation of
Smoking
VARENICLINE: Tablet
Varenicline is a drug, found effective in cessation
of smoking. It is available as- varenicline tartrate
INN equivalent to varenicline 0.5mg/tablet (film
coated).
Mode of action: Varenicline binds with high
affinity and selectivity at alpha-4 beta-2 neuronal
nicotinic acetylcholine receptors. The efficacy of
varenicline in smoking cessation is believed to be
the result of varenicline's activity at alpha-4 bata-
2 sub-type of the nicotinic receptor where its
binding produces agonist activity, while
simultaneously preventing nicotine binding to
these receptors.
Ind: Varenicline is indicated as an aid to smoking
cessation treatment.
C/I: Nonsmokers.
S/E: The most common adverse events associa­
ted with varenicline (>5% and twice the rate seen
in placebo-treated patients) were nausea, sleep
disturbance, constipation, flatulence & vomiting.
Precautions: May cause nausea, possibility of
serious neuropsychiatric disorder, including
changes in mood (depression and mania),
May increase risk of cardiovascular events in
patients with underlying cardiovascular disease.
Pregnancy & lactation: Varenicline pregnancy
category C. Varenicline was not teratogenic in
rats and rabbits at oral doses up to 15 and
30mg/kg/day respectively (36 and 50-times the
maximum recommended human daily exposure
based on AUC at l mg b.i.d respectively).
Dosage & admin: Usual dosage for adults:
Smoking cessation therapies are more likely to
succeed fo� patients who are motivated to stop
smoking and who are provided additional
advice and support. Patients should be provi.:.
ded with appropriate educational materials
and counseling to support the quit attempt.
The patient should set a date to stop smoking.
Varenicline dosing should start one week
before this date.
Varenicline should be taken after eating and
with a full glass of water.
The recommended dose of varenicline is lmg
twice daily following a 1-week titration as
follows:
Days 1-3: O.Smg once daily;
Days 4-7: O.Smg twice daily;
Day 8 to end of the treatment: lmg twice daily.
Duration of treatment: Patients who cannot
tolerate adverse effects of varenicline may
have the dose lowered temporarily or
permanently. Patients should be treated with
varenicline for 12 weeks. For patients who
have successfully stopped smoking at the end
of 12 weeks, an additional course of 12 weeks
treatment.with varenicline is recommended to
further increase the likelihood of long-term
abstinence.
Patients who do not succeed in stopping
smoking during 12 weeks of initial therapy, or
who relapse after treatment, should be
encouraged to make another attempt once
factors contributing to the failed attempt have
been identified and addressed.
Children: Because the safety and effectiveness
of varenicline in pediatric patients have not
been established, it is not recommended for
use in patients under 18 years of age.
Drug inter: Based on varenicline characteristics
and clinical experience to date- varenicline has
no clinically meaningful pharmacokinetic durg
interactions.
Note: For further information, please consult
manufacturer's literature.
+ VARNI Tab. Monicopharma
Varenicline tartrate INN equivalent to varenicline
0.5mg/tablet (film coated).
0.5mg x 20's pack: 300.00 MRP
• • •

In opioid dependence, treatment should be psychosis, hallucinations, paranoia, delusions,

initiated carefully with an initial dose of 2Smg homicidal ideation, hostility, agitation, anxiety,
of naltrexone; if no withdrawal signs occur, abnormal dreams, and panic, as well as suicidal
the patient may be started with SOmg a day ideation, suicide attempt, and suicide. May affect
 ;
DRUGS USED IN
ENDOCRINE DISEASES
Drugs & hormones used in the different
endocrine diseases are discussed under the
following sections:
1. Drugs & hormones used in diabetes
2. Thyroid & antithyroid drugs & hormones
3. Corticosteroid drugs & hormones
4. Sex hormones & drugs
5. Hypothalamic & pituitary hormones &
anti-oestrogens
6. Drugs affecting bon.e metabolism
7. Other endocrine drugs
DRUGS USED IN
DIABETES 21
Two groups of drugs are used in the treatment
of diabetes:
1.1 Insulin & its preparations
1.2 Oral hypoglycaemic drugs.
1.3 Parenteral hypoglycaemic drugs.
1.4 Drugs for diabetic peripheral neuropathy.
Insulin prepns.21
Insulin is a polypeptide hormone of complex
structure. It is usually extracted from beef or pork
pancreas and purified by crystallization; it
can also be made biosynthetically or
,...
semisynthetically as human insulin. The basic
.,
structure of insulin is common to all mammalian
species but there are minor species differences
which result in the development of antibodies in
all patients treated with animal insulins.
Sources of insulin: Three main sources of
insulin with their minor differences are given as
below:
* Bovine insulin- differs from human insulin
by· 3 amino acids and is more antigenic to man
than else one.
* Porcine insulin- which differs from human
type by only one ( 1) amino acid.
* Human insulin- is made either by enzyme
modification of porcine insulin, or by using
recombinant DNA to synthesise the proinsulin,
precursor molecule for insulin. This is done by
artificially introducing the DNA into either E.coli
or yeast. These 3 forms of insulin have the same
amino acid sequence, but are separately
designated as - insulin emp (enzyme modified
porcine), insulin prb (proinsulin recombinant in
bacteria) and insulin pyr (precursor insulin yeast
recombinant).
There is no systematic difference in activity in
human and animal insulin.
I
Types of Insulin! There are three main types of
· 0.5 to 1 i.u per kg body wt. per day.
·
insulin preparations: ,
. • .
1. Short acting: Rapid .onset of action, soluble
. .
forms of insulin.
2. Intermediate acting: Isophane insulin &
insulin zinc suspension.
3. Long acting: Slower in onset and lasts for
long periods e.g. human ultratard.
INSULfN21,26,33,35,122,133,145
INSULIN: Injection
Insulin is a polypeptide hormone of complex
structure. It is usually extracted from beef or pork
pancreas and purified by crystallization. Now a
day, insulin is produced biosynthetically ot
semisynthetically as human insulin by
recombinant DNA method.
Mode of action: Insulins lower blood glucose by
stimulating peripheral glucose uptake by skeletal
muscle and fat following binding of insulin to
the receptors on them, and by inhibiting hepatic
glucose production. Insulins inhibit lipolysis and
proteolysis, and enhance protein synthesis.
Ind: 1. In all cases of Insulin dependent diabetes
mellitus (IDDM)
2. In Non-Insulin dependent diabetes mellitus
(NIDDM) whenever good control with diet & oral
hypoglycemic agent is no longer attainable (e.g.
secondary failure with sulphonylurea therapy).
3. In malnutrition related diabetes mellitus
(MRDM)
4. In NIDDM subjects whenever special
metabolic stresses arise in consequence of
operations, febrile illness or accidents (the
need of insulin therapy is temporary)
5. During diabetic emergencies such as
ketoacidosis, serious breakdown of control.
6. Pregnant diabetic women when diet alone fails
to maintain therapeutic goal.
C/I: Hypoglycaemia. Hypersensitivity to the
active substances or to any of the excipients.
S/E: Local reactions and lipo-atrophy at the site
of injection; overdose causes hypoglycaemia
(signs are vomiting specially in children,
palpitation, trembling, sweating, tingling in the
hands or lip, pallor, impaired visioin, listlessness,
confusion and dizziness); lipodystrophy,_ insulin
resistance & hypersensitivity are rarely reported
with human insulin.
Cautions: Dosages require proper adjustment
druing infections, pregnancy, _emotional distress,
change in species of origin, type or purity of
insulin. Besides insulin requirements may .
increase during concomitant therapy with
·
thyroxine, corticosteroids & MAOI's may effect
. ·
·
insulin requirement. ·
Dosage & admin: Adult & Child: By s�c, i.m
or i� v injection. Dosage according to individual
requirmeots & initially be determined by the
. t ANSULIN R (40 IU/ml) Inj. Square
.
physician. There is no f1Xed rules for insulin
. .
dosage, adjustment in. dosages is needed to
achieve and maintain desired blood glucos� . . .
level. The average insulin requirement is
between
Duration: Soluble or short acting insulin approx.
7-8 hours; intermediate acting insulin, approx.
18-24 hours; long acting insulin approx. 24-36
hours.
For dosage, also see in the treatment section.
Overdose: Insulins have no specific overdose
definitions. However, hypoglycemia may develop
sequential stages:
Mild hypoglycemic episodes can be treated by
oral administration of glucose or sugery products.
Severe hypoglycemic episodes, where the patient
has become unconscious, can be treated by
glucagon (0.5 to 1 mg) ·given intramuscularly or
subcutaneously by a trained person or glucose
given intravenously by a medical professional.
Glucose must also be given intravenously, if the
patient does not respond to glucagon within I 0 to
15 minutes.
Upon regaining consciousness administration of
oral carbohydrate is recommended for the patient
in order to prevent relapse. Adjustments in drug
dosage, meal patterns, or exercise may be needed.
Drug inter: A number of drugs affect glucose
metabolism and may require dose adjustment. .
The following substances may reduce the Insulin
requirements: Oral anti-diabetic products,
angiotensin converting enzyme (ACE) inhibitors,
disopyramide, fibrates, fluoxetine, monoamine
oxidase inhibitors, propoxyphene, pentoxifylline,
salicylates and sulfonamide antibiotics.
The following substances may increase the
Insulin requirements: Thiazides, glucocorticoids,
thyroid hormones, beta-sympathomimetics,
growth hormone and danazol.
�-blockers, clonidine, lithium salts, and alcohol
may either potentiate or weaken the blood­
glucose-lowering effect of insulin glargine.
Beta-adrenergic blockers may mask the
symptoms of hypoglycemia in some patients.
Pharmaceutical precautions: .
Unopened insulin vials should be stored in a
refrigerator (2°C - 8°C). Insulin should not be
stored in the freezer and it should not be allowed
to freeze. Discard vial if frozen. Opened vials,
whether or not refrigerated, must be used within
28 days. They must be discarded if not used
within 28 days. If refrigeration is not possible,
the open vial in use can be kept unrefrigerated for
up to 28 days away from direct heat and light, as
long as the temperature is not greater than 25°C.
Short Acting Insulin
·
. Regular or soluble human insulin (rDNA) BP
40 i.u/ml: s.c injection
40 i.u x IOml vial: 195.00 MRP

t ANSULIN R (100 IU/ml) Inj. Square
Regular or soluble human insulin (rDNA) BP
100 i.u/ml: s.c injection
100 i.u x lOml vial: 415.00 MRP
t ANSULIN R (100 IU/ml) Pen Cartridge Inj.
Square
Regular or soluble human insulin USP (rDNA)
100 i.u/ml in 3ml pen cartridge: s.c injection
100 i.u x 3ml cartridge x 1 's pack: 220.00
t DIASULIN R (40 IU/ml) Inj. ACI
Regular or soluble human insulin (rDNA) USP
40 i.u/ml: s.c injection
40 i.u x lOml vial: 195.00 MRP
t DIASULIN R (100 IU/ml) Inj. ACI
. Regular or soluble human insulin (rDNA) USP
100 i.u/ml: s.c injection
100 i.u x lOml vial: 415.00 MRP
t HUMULIN R lnj. Eli Lilly/Int. Agencies (BD)
Regular or soluble human insulin (rDNA) BP
100 i.u/ml: s.c injection
100 i.u x 4ml vial: 310.00 MRP
100 i.u x lOml vial: 680.00 MRP
t HUMULIN R (lOOIU/ml) Cartridge lnj. Eli
Lilly/Int. Agencies (BD)
Regular or soluble human insulin USP (rDNA)
100 i.u/ml in 3ml cartridge: s.c injection
100 i.u x 3ml cartridge x 5's pack: 2210.00
t INSUL R (40 IU/ml) Inj. Popular
Regular or soluble human insulin (rDNA) BP
40 i.u/ml: s.c injection
40 i.u x lOml vial: 195.00 MRP
t INSUL R (100 IU/ml) lnj. Popular
Regular or soluble human insulin (rDNA) BP
100 i.u/ml: s.c injection
100 i.u x lOml vial: 415.00 MRP
t INSUL R (100 IU/ml) Cartridge Inj. Popular
Regular or soluble human insulin USP (rDNA)
100 i.u/ml in 3ml cartridge: s.c injection
100 i.u x 3ml cartridge x 5's pack: 1100.00
t INSULET R (100 IU/ml) Inj. Aristopharma
Regular or soluble human insulin (rDNA) BP
100 i.u/ml: s.c injection
100 i.u x 4ml vial: 169.70 MRP
100 i.u x lOml vial: 415.00 MRP
t ACTRAPID (40 IU/ml) Inj. Novo Nordisk
Neutral insulin human (rDNA) 40 i.u/ml: for s.c
or i.v injection
40 i.u x lOml vial: 195.00 MRP
t ACTRAP ID (100 IU/ml) Inj. Novo Nordisk
Neutral insulin human (rDNA) 100 i.u/ml: for s.c
or i.v injection
100 i.u x lOml vial: 415.00 MRP
t ACTRAPID (100 IU/ml) Penftll Novo
Nordisk
Neutral insulin h11man (rDNA) 100 i.u/ml with
penfill cartridge: for s.c or i.v injection
3ml cartridge x 5's pack: 1855.00 MRP
t MAXSULIN R lnj. Incepta
Regular or 'soluble human insulin (rDNA) BP
40 i,u/ml & 100 i.u/ml: s.c injection
40 i.u x lOml vial: 195.00 MRP
100 i.u x lOml vial: 415.00 MRP
I'NSULJN ASPARTt22,145
'
-
QIMP-17 (174)
INSULIN ASPART: S.C injection/ Continuous
s.c infusion/ I.V infusion
Insulin aspart is a recombinant (rDNA) rapid-act­
ing insulin analog. It differs from natural human
insulin in that the suostitution of amino acid pro­
line with aspartic acid at position B28 reduces
• the tendency to form hexamers as observed with
'
-
®
soluble human insulin. Insulin aspart is therefore
more rapidly absorbed from the subcutaneous
layer compared to soluble human insulin. The
time to maxim11m concentration is, on average,
Insulin Human (rDNA)
half of that for soluble human insulin. The
glucose lowering capability of insulin aspart and
MRP regular human insulin are equipotent when
•
administered by the intravenous route. After
subcutaneous administration, the effect of insulin
aspart is more rapid in onset and shorter in
duration compared to regular human insulin.
Insulin Glargine (rDNA)
Insulin aspart is available as- 100 units/1ml
solution, in lOml vial, for subcutaneous injection .
Mode of action: The blood glucose lowering
effect of insulin aspart is due to the facilitated
uptake of glucose following binding of insulin to
receptors on muscle and fat cells and to the
simultaneous inhibition of glucose output from
the liver.
Insulin aspart produces a more rapid onset of
action compared to soluble human insulin,
together with a lower glucose concentration, as
Dlasulin® R (401u & 1oo1u)
assessed within the first four hours after a meal.
Insulin aspart has a shorter duration of action
MRP compared to soluble human insulin after
Dlasulin® N (401u & 1oo1u) subcutaneous injection.
Ind: Treatment of diabetes mellitus in adults and
adolescents and children aged 2-17 years.
C/I; S/E; Precautions & Warnings: See under
01111110® 31/71 (4o1u & 1001u) the text of insulin.
Pregnancy & lactation: Insulin aspart can be
used in pregnancy. Intensified blood glucose
control and monitoring of pregnant women with
Dllllllne 51/51 (401u & 100 IU) diabetes (type l diabetes, type 2 diabetes or
gestational diabetes) are recommended
throughout pregnancy and when contemplating
MRP
& pregnancy. Insulin requirements usually fall in
the frrst trimester and increase subsequently
during the second and third trimester. After
GIARINE® (100 IU) delivery, insulin requirements normally return
rapidly to pre-pregnancy values.
There are no restrictions on treatment with
insulin aspart during breast-feeding. Insulin
treatment of the nursing mother presents no risk
to the baby. However, the insulin aspart dosage
may need to be adjusted.
Dosage & admin: Insulin aspart has a faster
onset and a shorter duration of action than
soluble human insulin. When injected
subcutaneously into the abdominal wall, the
onset of action will occur within 10-20 minutes
•
of injection. The maximum effect is exerted
between 1 and 3 hours after the injection. The
duration of action is 3 to 5 hours.
Due to the faster onset of action, insulin aspart
should generally be given immediately before
a meal. When necessary insulin aspart can be
given soon after a meal. The faster onset of
action compared to soluble human insulin is
maintained regardless of injection site.
The dose of insulin aspart is individual and
determined in accordance with the needs of ·
the patient. It should normally be used in com-

bination with intermediate-acting or long­
acting insulin gjven at least once a day. Blood
glucose monitoring and insulin dose
adjustments are recommended to achieve
optimal glycemic control.
The individual insulin requirement in adults
and children is usually between 0.5 & 1.0
unit/kg/day. In a basal-bolus treatment
regjmen so.:.70°/o of this requirement may be
provided by insulin aspart and the remainder
by intermediate-acting or long-acting insulin.
Adjustment of dosage may be necessary if
patients undertake increased physical activity,
change their usual diet or during concomitant
illness.
Special population: As wi�h all insulin produ­
cts, in elderly patients and patients with renal
or hepatic impairment, glucose monitoring
should be intensified and insulin aspart dosage
adjusted on an individual basis.
Paediatric use: No studies have been perfor­
med in children below the age of 2 years.
Insulin aspart should only be used in this age
group under careful medical supervision.
Insulin aspart can be used in children in
preference to soluble human insulin when a
rapid onset of action might be beneficial. For
example, in the timing of the injections in
relation to meals.
Transfer from other insulin products: When
transferring from other insulin products,
adjustment of the insulin aspart dose and the
dose of the basal insulin may be necessary.
Method of administration:
1. Administration with a syringe: Insulin aspart
is administered subcutaneously by injection in
the abdominal wall, the thigh, the upper arm,
the deltoid region or the gluteal region.
Injection sites should therefore always be
rotated within the same region. As with all
insulin products, subcutaneous injection in the
abdominal wall ensures a faster absorption
than other injection sites. The duration of
action will vary according to the dose,
injection site, blood flow, temperature and
level of physical activity.
2. Continuous Subcutaneous Insulin Infusion
(CSII): Insulin aspart may be used for conti­
nuous subcutaneous insuli.n infusion (Csm in
pump systems suitable for insulin infusion.
CSII should be administered in the abdominal
wall. Infusion sites should be rotated.
When used with an insulin infusion pump,
insulin aspart should not be mixed with any
other insulin products.
Patients using CSII should be comprehensi­
vely instructed in the use of the pump system
and use the correct reservoir and tubing for
the pump. The infusion set (tubing and
cannula) should be.changed in accordance
with the instructions in the product
information supplied with the infusion set.
Patients administering insulin aspart by CSII
must have alternative insulin available in case
of pump system failure.
3. Intravenous use: If necessary, insulin aspart
can be administered intravenously which
should be carried out by health care profess­
ionals. For i.v use, infusion systems with
insulin aspart 100 units/ml at concentrations
QIMP-17 (175)
from 0.05 units/ml to 1.0 units/ml insulin
aspart in the infusion fluids 0.9% sodium
chloride, 5o/o dextrose or 1Oo/o dextrose
inclusive 40mmol/l potassium chloride using
polypro-pylene infusion bags are stable at
room temperature for 24 hours.
Although stable over time, a certain amount of
insulin will be initially adsorbed to the materi­
al of the infusion bag. Monitoring of blood
glucose is necessary during insulin infusion.
Overdose: See under the text of insulin.
Drug inter: Combination of insulin aspart with
pioglitazone: Cases of cardiac failure have been
reported when pioglitazone was used in combina­
tion with insulin, specially in patients with risk
factors for development of cardiac heart failure.
This should be kept in mind if treatment with the
combination of pioglitazone and insulin aspart is
considered. If the S combination is used, patients
should be observed for signs and symptoms of
heart failure, weight gain and oedema.
Pioglitazone should be discontinued if any
deterioration in cardiac symptoms occurs.
Interaction with other medicinal products: See
under the text of insulin.
Special precautions for storage: Store in a
refrigerator (2°C - 8°C). Keep away from the
cooling element. Do not freeze. Keep the vial in
the outer carton in order to protect from light.
After frrst opening or carried as a spare: Do not
refrigerate. Store below 30°C.
Insulin aspart must be protected from excessive
heat and light.
Note: For further information please consult
manufacturer's literature.
+ NOVORAPID FlexPen Inj. Novo Nordisk
Insulin aspart, a recombinant (rDNA) rapid�
acting human insulin analog, 100 11nits/ml
solution; 3ml pre-filled pen for injection.
3ml pre-filled pen x S's pack: 432S.OO MRP
+ NOVORAPID Penfill lnj. Novo Nordisk
Insulin aspart, a recombinant (rDNA) rapid­
acting human insulin analog, 100 t1nits/ml
solution; 3ml cartridge with penfill for injection.
3ml cartridge with penfill x S's pack: 387S.OO
MRP
INSULIN GLULISINE35,145
INSULIN GLULISINE: S.C injection/
Continuous s.c infusion/ I.V infusion
Insulin glulisine is a recombinant (rDNA) rapid­
acting human insulin analog. It differs from
hlunan insulin in that the amino acid asparagine
at position B3 is replaced by lysine and the lysine
in position B29 is replaced by glutamic acid at B­
chain. Chemically, insulin glulisine is 38-lysine-
298-glutamic acid-human insulin.
The glucose lowering capability of insulin gluli­
sine and regular human insulin are equipotent
when administered by the intravenous route.
After subcutaneous administration, the effect of
insulin glulisine is more rapid in onset & shorter
in duration compared to regular human insulin.
Insulin glulisine is available as- 100 units/lml in
3 presentations, viz. i. 1Oml vial; ii. 3ml cartridge
system for use with insulin delivery device; and
iii. 3ml SoloStar prefilled pen.
Mode of action: Regulation of glucose metabo
lism is the primary activity of insulins and insulin
analogs, including insulin glulisine. For more
information, see above under the text of insulin.
Ind: Insulin glulisine is a rapid-acting insulin. It
is indicated to improve glycemic control in adults
with type 2 diabetes or adults and children (4
years and older) with type 1 diabetes.
Insulin glulisine given by subcutaneous injection
is usually \ISed with a longer-acting insulin.
When used as a mealtime insulin, insulin
glulisine should be given within l S minutes
before or within 20 minutes after starting a meal.
C/I; S/E; Precautions: See under the text of
•
insulin.
Pregnancy & lactation: Pregnancy category C:
In different studies in pregnant rats and rabbits it
was found that the effects of insulin glulisine did
not differ from those observed with subcutaneous
regular human insulin at the same doses and were
attributed to secondary effects of maternal hypo­
glycemia. There are no well-controlled clinical
studies of the use of insulin glulisine in pregnant
women. Because animal reproduction studies are
not always predictive of human response.
Therefore, this drug should be used during
pregnancy only if the potential benefit justifies
the potential risk to the fetus. It is essential for
patients with diabetes or a history of gestational
diabetes to maintain good metabolic control
before conception and throughout pregnancy.
It is not known whether insulin glulisine is
excreted in human milk. Because many drugs are
excreted in human milk, caution should be
exercised when insulin glulisine is administered
to a nursing woman.Use of insulin glulisine is
compatible with breastfeeding, but women with
diabetes who are lactating may require
•
adjustments of their insulin doses.
Dosage & admin: The dosage of insulin
glulisine must be individualized. Blood glucose
monitoring is essential in all patients receiving
insulin therapy. The total daily insulin
requirement may vary and is usually between
0.5 to 1 unit/kg/day. Insulin requirements may
be altered during stress, major illness, or with
changes in exercise, meal patterns, or co­
administered drugs.
Subcutaneous administration: Insulin glulisine
should be given within 15 minutes before a
meal or within 20 minutes after starting a
meal. Insulin glulisine gjven by subcutaneous
injection should generally be used in regimens
with an intermediate or long-acting insulin.
Insulin glulisine should be administered by
subcutaneous injection in the abdominal wall,
thigh, or upper arm. Injection sites should be
rotated within the same region (abdomen,
thigh or upper arm) from one injection to the
next to reduce the risk of lipodystrophy.
Continuous s.c infusion (insulin pump):
Insulin glulisine may be administered by con­
tinuous subcutaneous infusion in the abdomi­
nal wall. Do not use diluted or mixed insulins
in external insulin pumps. Infusion sites
should be rotated with.in the same region to
reduce the risk of lipodystrophy.

® QIMP-17 (176)
. 1.,2,3& 4
The initial programming of the external
insulin infusion pump should be based on the
total daily insulin dose of the previous regimen.
Intravenous administration:
Insulin glulisine can be administered
intravenously under medical supervision for
glycemic control with close monitoring of
blood glucose and serum potassium to avoid
hypoglycemia and hypokalemia. For
intravenous use, insulin glulisine hould be
used at concentrations of 0.05 units/ml to 1
unit/ml in infusion systems using polyvinyl
chloride (PVC) bags. Insulin glulisine has been
shown to be stable only in normal saline
solution (0.9% sodium chloride). Do not
administer insulin mixtures intravenously.
Note: For further information please consult
manufacturer's literature.
t APIDRA SoloStar Inj. Sanofi-aventis
Apidra, insulin glulisine (a recombinant rapid act­
ing human insulin analog), 100 units/ml solution.
SoloStar is a disposable prefilled insulin pen
containing 3ml solution.
Price: 3ml SoloStar prefilled pen x S's pack:
4673.00 MRP
INSULIN LISPR013J,l45
INSULIN LISPRO: S.C injection/Continuous
s.c infusion/ I.V infusion
Insulin lispro is a recombinant (rDNA) rapid-act­
ing h11man insulin analog. It differs from natural
human insulin in that the amino acid proline at
position B28 is replaced by lysine and the lysine
in position B29 is. replaced by proline at B-chain
(i.e reverse position). Chemically, insulin lispro is
Lys(B28), Pro(B29) human insulin analog.
The glucose lowering capability of insulin lispro
and regular human insulin are equipotent (i.e one
unit of insulin lispro has the same glucose­
lowering capability as one unit of human regular
insulin), but with more rapid activity. The quicker
glucose-lowering effect of insulin lispro is related
to the more rapid absorption rate from
subcutaneous tissue. After subcutaneous
administration, a faster absorption from the site
with a more rapid onset and shorter duration of
hypoglycemic action is observed than regular
insulin. The effect profile of insulin lispro had
showed peak from 30-70 min after
administration, and the duration of its effect was
shortened compared to regular htiman insulin,
between 2 hours and S hours after the injection.
Insulin lispro is available as- I 00 units/ l ml; 3ml
vial, 3ml prefilled pen & cartridge for subcuta­
neous administration, including use in continuous
subcutaneous infusion pumps. If necessary
insulin lispro may be administered intravenously.
Mode of action: The blood glucose lowering
effect of insulin lispro is due to the facilitated
uptake of glucose following binding of insulin to
receptors on muscle and fat cells and to the
simultaneous inhibition of glucose output from
the liver.
.
Ind: Insulin lisprq is a rapid-acting human t INSUL LISPRO Inj. Popular
insulin analog. It is indicated in the treatment of Insulin lispro USP (rDNA) 100 units/ml solution;
patients with diabetes mellitus for the control of 3ml vial: subcutaneous injection.
hyperglycemia. Insulin lispro has a more rapid Price:
onset and a shorter duration of action than human 3ml vial x 1 's pack:. S00.00 IP
regular insulin. Therefore, in patients with type I 3ml cartridge x 3's pack: l S00.00 IP
diabetes, insulin lispro should be used in regi­
mens that include a longer-acting insulin. In
patients with type 2 diabetes, insulin lispro may INSULIN LISPRO MIXED PREPNS.95(a)
be used without a longer-acting insulin when
used in combination therapy with su\fony\urea
INSULIN LISPRO + INSULIN LISPRO
agents.
PROTAMINE Mixed Prepns.: S.C injection/
C/I; S/E; Precautions & warning: See under
Continuous s.c infusion
the text of insulin. .
This is a mixed preparation of insulin lispro and
Pregnancy & lactation: At present there is no
insulin lispro protamine suspension (rDNA
system research result of pregnancy for this
origin). Insulin lispro is a human insulin analog
product. The blood glucose of diabetic patient
of recombinant DNA origin, that is a rapid acting
with gestation should be carefully monitored to
blood glucose-lowering agent. This mixed
keep good metabolic control in whole pregnancy.
preparations are currently available in two fixed
Insulin dosage may be decreased during the first
proportions- i. Insulin lispro 50% +insulin lispro
trimester of pregnancy, and then it should be usu­
protamine SO%; ii. Insulin lispro 2S% + insulin
ally added during the second and third trimesters.
lispro protamine 7S%: for parenteral administra­
Due to rapid decline insulin dose and diet must
tion.
be adjusted after childbirth and in nursing period
Ind: Insulin lispro mixed preparations (SO%/SO%
to decrease hypoglycemia incidence, and
and 2S%/7S%) are indicated in the treatment of
meanwhile carefully monitor blood glucose.
patients with diabetes mellitus that requires
Dosage & admin: Dosage regimens of insulin
insulin for the maintenance of normal glucose
lispro will vary among patients based on their
homeostasis.
metabolic needs, eating habits and lifestyles.
C/I; S/E; Precautions & warnings: See under
Although, the glucose lowering capability of
the text of insulin.
insulin lispro is equipotent to regular human
Pregnancy & lactation: See under the text of
insulin, but due to more rapid activity, an
insulin lispro.
adjustment of dose or schedule of basal insuli.n
Dosage & admin: The dosage of insulin lispro
may be needed when a patient changes from
is determined by the physician in accordance
other insulins to insulin lispro, particularly to
with the requirements of the patient. It should
prevent pre-meal hyperglycemia.
be given by subcutaneous injection, including
When used as a meal-time insulin, insulin
use in continuous subcutaneous infusion
lispro should be given within 15 minutes
pumps; should not be given intravenously.
before or immediately after a meal.
Drug inter: See under the text of insulin.
Human regular insulin is best given 30-60
minutes before a meal. To achieve optimal Note: For further information please consult
glucose control, the amount of longer-acting manufacturer's literature.
insulin being given may need to be adjusted
when using insulin lispro.
t HUMALOG Mix 50/50 Prefilled KwikPen
Inj. Eli Lilly/Int. Agencies (BD)
Insulin lispro absorbs at a consistently faster
This is a mixed preparation of SO% insulin lispro
rate than human regular insulin when given at
& SO% insulin lispro protamine suspension (rDNA t..
3 usual sites of insulin injection, viz. at abdo­
origin), in concentrations of 100 t1nits/ml solution;
minal, deltoid, or femoral sites. When not
3ml prefilled kwikpen: solution for s.c injection.
mixed with other insulins, insulin lispro
Price: 3ml prefilled pen x S's pack: 4397.20 MRP
maintains its rapid onset of action at any of
the sites compared with human regular + HUMALOG Mix 25/75 Prefilled Kwik.Pen
insulin. After abdominal administration, Inj. Eli Lilly/Int. Agencies (BD)
insulin lispro concentrations are higher than This is a mixed preparation of 2S% insulin lispro
those following deltoid or thigh injections. & 7S% insulin lispro protamine suspension (rDNA
Also, the duration of action of insulin lispro is origin), in concentrations of 100 units/ml solution;
slightly shorter following abdominal injection, 3ml prefilled kwikpen: solution for s.c injection.
compared with deltoid and femoral injections. Price: 3ml prefilled pen x S's pack: 4397.20 MRP
As with all insulin preparations, the time
course of action of insulin lispro may vary
considerably in different individuals or within Medium Acting.Insulin •
the same individual. Patients must be educated
to use proper injection techniques.
Drug inter: See under the text of insulin. NEUTRAL ISOPHANE HUMAN
Note: For further information please consult
INSULIN2 t ,26,3s, t 4s
manufacturer's literature.
t HUMALOG Prefilled Kwik.Pen Inj. Eli + ANSULIN N lnj. Square
Lilly/Int Agencies (BD) Neutral isophane human insulin (rDNA) BP
Insulin lispro USP (rDNA) 100 units/ml solution; 40 i.u/ml & 100 i.u/ml: s.c injection.
3ml prefilled Kwikpen: solution for s.c injection. 40 i.u x l Oml vial: 19S.OO MRP
3ml prefilled pen x S's pack: 4397.20 MRP 100 i.u x lOml vial: 41S.OO MRP

t ANSULIN N (100 IU/ml) Pen Cartridge Inj.
Square
..
Neutral isophane human insulin (rDNA)
100 i.u/ml in 3ml pen cartridge: s.c injection
100 i.u x 3ml cartridge x 1 's pack: 220.00
t DIASULIN N Inj. ACI
Neutral isophane human insulin (rDNA)
40 i.u/ml & 100 i.u/ml: s.c injection.
40 i.u x lOml vial: 195.00 MRP
100 i.u x lOml vial: 415.00 MRP
t HUMULIN N Inj. Eli Lilly/Int. Agencies (BD)
I
I Neutral isophane (NPH) human insulin (rDNA)
100 i.u/ml: injection
100 i.u x 4ml vial: 310.00 MRP
100 i.u x lOml vial: 680.00 MRP
t HUMULIN N (100 IU/ml) Cartridge Inj. Eli
I human insulin (NPH) 70%; 100 i.u/ml: injection
• Lilly/Int. Agencies (BD)
I Neutral isophane human insulin (rDNA)
I
100 i.u/ml in 3ml cartridge: s.c injection
I 100 i.u x 3ml cartridge x 5's pack: 2210.00
t INSUL N Inj. Popular
Neutral isophane human insulin (rDNA) BP
40 i.u/ml & 100 i.u/ml: s.c injection.
MRP
40 i.u x lOml vial: 195.00
100 i.u x lOml vial: 415.00 MRP
t INSUL N (100 IU/ml) Cartridge Inj.
Popular
Neutral isophane human insulin (rDNA)
100 i.u/ml in 3ml cartridge: s.c·injection
'
100 i.u x 3ml cartridge x 5's pack: 1100.00
t INSULET N Inj. Aristopharma
Neutral isophane human insulin (rDNA) BP
I
I 100 i.u/ml: s.c injection.
I 100 i.u x 4ml vial: 169.70 MRP
I 100 i.u x lOml vial: 415.00 MRP
t INSULATARD (40 IU/ml) lnj. Novo
I Nordisk
Neutral isophane insulin human (rDNA)
40 i.u/ml: for s.c injection
I 40 i.u x lOml vial: 195.00 MRP
t INS ULATARD (100 IU/ml) Inj. Novo
Nordisk
Neutral isophane insulin human (rDNA)
100 i.u/ml: for s.c injection.
'
MRP
I 100 i.u x lOml vial: 415.00
t INSULATARD (100 IU/ml) Penfill Inj. Novo
I Nordisk
Neutral isophane insulin h11man (rDNA)
100 i.u/ml with penfi.11 cartridge.
I
100 i.u x 3ml cartridge x 5's pack: 1855.00
+ INSUMAN Basal Inj. Sanofi-aventis
Neutral isophane (NPH) human insulin (rDNA)
100 i.u/ml: injection
Onset of action within 60 minutes (gradual);
maximal effect at 3-4 hours; duration of action
11-20 hours.
100 i.u x 5ml vial: 281.70 MRP
'
t MAXSULIN N Inj. Incepta
I ,,..
-
Neutral isophane human insulin (rDNA) BP
40 i.u/ml & 100 i.u/ml: injection.
40 i.u x lOml vial: 195.00 MRP
100 i.u x lOml vial: 415.00 MRP
BIPHASIC PREMIX INSULIN
(REGULAR+ ISOPHANE)21.26,35,145
+ ANSULIN 30/70 lnj. Square
Biphasic premix human insulin (rDNA), as
soluble (regular) human insulin 30% & isophane
-
QIMP-17 (177)
human insulin (NPH) 70%; 40 i.u/ml & 100
i.u/ml: s.c injection
USP 40 i.u x lOml vial: 195.00 MRP
100 i.u x lOml vial: 415.00 MRP
MRP t ANSULIN 30/70 (100 IU/ml) Pen Cartridge
Inj. Square t INSUL 50/50 (100 IU/ml) Cartridge Inj.
USP Biphasic premix human insulin (rDNA), as Popular
soluble (regular) human insulin 30% & isophane Biphasic premix human insulin (rDNA), as
human insulin (NPH) 70%; 100 i.u/ml in 3ml pen soluble (regular) human insulin SO% & isophane
cartridge: s.c injection human insulin (NPH) SO%; 100 i.u/ml in 3ml
100 i.u x 3ml cartridge x l 's pack: 222.00 MRP cartridge: s.c injection
t ANSULIN 50/50 Inj. Square 100 i.u x 3ml cartridge x 5's ·pack: 1100.00 MRP
Biphasic human insulin (rDNA) USP, as soluble + INSULET 30/70 lnj. Aristopharma
(regular) human insulin 50% & isophane human
Biphasic premix human insulin (rDNA), as
insulin (NPH) 50%; 100 i.u/ml: s.c injection soluble (regular) human insulin 30% & isophane
100 i.u x lOml vial: 415.00 MRP
t ANSULIN 50/50 (100 IU/ml) Pen Cartridge 100 i.u x 4ml vial: 169.70 MRP
USP Inj. Square
100 i.u x lOml vial: 41S.OO MRP
Biphasic premix human insulin (rDNA), as
MRP soluble (regular) h11man insulin 50% & isophane
t INSULET SO/SO Inj. Aristopharma
Biphasic human insulin (rDNA), as soluble
human insulin (NPH) 50%; 100 i.u/ml in 3ml pen
(regular) human insulin 50% & isophane human
cartridge: s.c injection
100 i.u x 3ml cartridge x l 's pack: 222.00 MRP insulin (NPH) 50%; 100 i.u/ml: injection
100 i.u x 4ml vial: 169.70 MRP
t DIASULIN 30/70 Inj. ACI
100 i.u x lOml vial: 41S.OO MRP
Biphasic premix human insulin (rDNA), as
soluble (regular) h11man insulin 30% & isophane + MIXTARD 30 (40 IU/ml) Novo Nordisk
h11man insulin (NPH) 70%; 40 i. u/ml & 100 Biphasic isophane insulin ht1man (rDNA), 30%
USP i.u/ml: injection as soluble insulin & 70% as isophane insulin;
40 i.u x lOml vial: 195.00 MRP 40 i.u/ml: for s.c injection.
MRP 100 i.u x lOml vial: 415.00 MRP 40 i.u x lOml vial: 19S.OO MRP
t DIASULIN 50/50 lnj. ACI + MIXTARD 30 (100 IU/ml) Inj. Novo
Biphasic human insulin (rDNA) USP, as soluble Nordisk
(regular) human insulin 50% & isophane h11man Biphasic isophane insulin human (rDNA), 30%
insulin (NPH) 50%; 40 i.u/ml & 100 i.u/ml: as soluble insulin & 70% as isophane insulin;
injection 100 i.u/ml: for s.c injection.
40 i.u x lOml vial: 19S.OO MRP MRP
100 i.u x lOml vial: 41S.OO MRP
100 i.u x lOml vial: 415.00
+ MIXTARD 30 (100 IU/ml) Penfill Inj. Novo
t HUMULIN 30/70 lnj. Eli Lilly/Int. Agencies
Nordisk
(BD)
Biphasic isophane insulin human (rDNA), 30%
Biphasic premix human insulin (rDNA), as
as soluble insulin & 70% as isophane insulin;
soluble (regular) h11man insulin 30% & isophane
100 i.u/ml with penfill cartridge: for s.c injection.
human insulin (NPH) 70%; 100 i.u/ml: injection
3ml cartridge x S's pack: 18SS.OO MRP
100 i.u x 4ml vial: 310.00 MRP
100 i.u x lOml vial: 680.00 MRP t MIXTARD 50 (100 IU/ml) Penfill lnj. Novo
t Nordisk
HUMULIN 30/70 (100 IU/ml) Cartridge lnj.
Biphasic isophane insulin human (rDNA), 50%
Eli Lilly/Int. Agencies (BD)
Biphasic premix human insulin (rDNA), as as soluble insulin & 50% as isophane insulin;
soluble (regular) human insulin 30% & isophane 100 i.u/ml with penfill cartridge: for s.c injection
human insulin (NPH) 70%; 100 i.u/ml in 3ml pen 3ml cartridge x S's pack: 1855.00 MRP
MRP cartridge: s.c injection + INSUMAN Comb 2S Inj. Sanofi-aventis
100 i.u x 3ml cartridge x S's pack: 2210.00 MRP A combination of short acting and intermediate
t INSUL 30/70 Inj. Popular acting human insulin suspension where 25%
Biphasic premix human insulin (rDNA), as regular (soluble) insulin and 75% isophane
soluble (regular) human insulin 30% & isophane insulin; 100 i.u/ml: injection.
human insulin (NPH) 70%; 40 i.u/ml & 100 Onset of action within 30-60 minutes (gradual);
i.u/ml: injection maximal effect at 2-4 hours; duration of action
40 i.u x lOml vial: 19S.OO MRP 12-19 hours (moderately long).
100 i.u x lOml vial: 41S.OO MRP 100 i.u x Sml vial: 281.70 MRP
t INSUL 30/70 (100 IU/ml) Cartridge Inj. t MAXSULIN 30/70 Inj.
Popular
Incepta
Biphasic human insulin (rDNA), as soluble
Biphasic premix human insulin (rDNA), as (regular) human insulin 30% & isophane human
soluble (regular) human insulin 30% & isophane insulin (NPH) 70%; 40 i.u/ml & 100 i.u/ml:
human insulin (NPH) 70%; 100 i.u/ml in 3ml pen injection
cartridge: s.c injection 40 i.u x lOml vial: 195.00 MRP
100 i.u x 3ml cartridge x S's pack: 1100.00 MRP 100 i.u x lOml vial: 415.00 MRP
t INSUL SO/SO Inj. Popular t MAXSULIN SO/SO Inj. Incepta
Biphasic human insulin (rDNA), as soluble Biphasic human insulin (rDNA), as soluble
(regular) human insulin SO% & isophane human (regular) human insulin 50% & isophane human
insulin (NPH) SO%; 100 i.u/ml: injection insulin (NPH) 50%; 100 i.u/ml: injection
100 i.u x lOml vial: 473.99 MRP 100 i.u x lOml vial: 415.00 MRP

BIPHASIC INSULIN ASPART
(rDNA)I22,145
t NOVOMIX 30 Penfill Inj. Novo Nordisk
Novomix 30 is a biphasic insulin aspart injection
(recombinant human insulin analog), which
contains 30% soluble insulin aspart (rapid-acting)
and 70% protamine-crystallised insulin aspart
(intermediate-acting). Soluble insulin aspart
(30%) has a rapid onset of action, thus allowing
it to be given closer to a meal (within zero to 10
minutes of the meal) when compared to soluble
human insulin; the protamine-crystallised insulin
aspart (70%) crystalline phase- which has an
,
activity profile that is similar to that of human
NPH insulin.
When Novomix 30 is injected subcutaneously,
the onset of action will occur within 10 to 20
minutes of injection. The maximum effect is
exerted between 1 and 4 hours after injection.
The duration of action is u� to 24 hours.
Mode of action: See under the text of insulin
aspart.
Ind: Treatment of diabetes mellitus in adults,
adolescents and children aged 10 to 17 years.
C/I; S/E; Precautions: See under the text of
insulin.
Dosage & admin: Novomix 30 dosing is indi­
vidual and determined in accordance with the
needs of the patient. Blood glucose monitoring
and insulin dose adjustments are recommen­
ded to achieve optimal glycaemic control.
In patients with type 2 diabetes Novomix 30
can be given as monotherapy. Novomix 30 can
also be given in combination with oral antidia­
betic medicinal products if the patient's blood
glucose is inadequately controlled with oral
antidiabetic medicinal products alone. For
patients with type 2 diabetes, the recommend­
ed starting dose of Novomix 30 is 6 units at
breakfast and 6 units at dinner (evening meal).
Novomix 30 can also be initiated once daily
with 12 units at dinner (evening meal). When
using Novomix 30 once daily, it is generally
recommended to move to twice-daily when
reaching 30 units by splitting the dose into
equal breakfast and dinner doses. If twice
daily dosing with Novomix 30 results in
recurrent daytime hypoglycaemic episodes, the
morning dose can be split into morning and
lunchtime doses (thrice daily dose).
The following titration guideline is
recommended for dose adjustments:
Pre-meal blood glucose level- Novomix 30 dose
adjustment
< 4.4mmol/I (< 80 mg/di) - 2 units
4.4 6.lmmol/I (80--llOmg/dl) 0 Pregnancy & lactation: Treatment with insulin
6.2-7.8mmol/I ( lll-140mg/dl) + 2 to 3 units
7.9-lOmmol/I (141-180mg/dl) + 4U
> lOmmol/I (> 180mg/dl) + 6U
The lowest of three previous days' pre-meal
levels should be used. The dose should not be
increased if hypoglycaemia occurred within
these days. Dose adjustments can be made
•
QIMP-17 (178)
once a week until target HbAlc is reached.
Pre-meal blood glucose levels should be used
to evaluate the adequacy of the preceding dose.
The combination of Novomix 30 with pioglita­
zone should only be considered followi.ng clini­
cal evaluation of the patient's risk of develop­
ing signs or symptoms of fluid-related adverse
reactions. The initiation of Novomix 30 should
be undertaken cautiously titrating to the low­
est dose required to achieve glycaemic control.
In patients with type 1 diabetes the individual
insulin requirement is usually between 0.5 and
1.0 units/kg/day. Novomix 30 may fully or
partially meet this requirement. The daily
insulin requirement may be higher in patients
with insulin resistance (e.g due to obesity), and
lower in patients with residual endogenous
insulin production.
Drug inter: See under the text of insulin.
Note: For further information please consult
manufacturer's literature.
3ml penfill cartridge x S's pack: 3875.00 MRP
Long Acting Insulin
INSULIN DETEMJRI22,14s
INSULIN DETEMIR: S.C Injection
Insulin detemir is a recombinant (rDNA) soluble,
long-acting insulin analog with a prolonged dura­
tion of action, used as a basal insulin. The glu­
cose lowering capability of insulin detemir and
natural human insulin are equipotent. It is avail­
able as- Insulin detemir 100 units/l ml solution,
3ml (300 units) prefilled disposable injection
device (flexpen) for subcutaneoun injection only.
Mode of action: The blood glucose lowering
effect of insulin detemir is due to the facilitated
uptake of glucose following binding of insulin to
receptors on muscle and fat cells and to the
simultaneous inhibition of glucose output from
the liver.
The prolonged action of insulin detemir is medi­
ated by the strong self-association of insulin
detemir molecules at the injection site & albumin
binding via the fatty acid side-chain. Insulin
detemir is distributed more slowly to peripheral
target tissues compared to NPH insulin. These
combined mechanisms of protraction provide a
more reproducible absorption and action profile
of insulin detemir compared to NPH insulin.
The time action profile of detemir is statistically
significantly less variable & therefore more
predictable than for NPH (Neutral Protamine
Hagedorn) insulin as seen from the within­
subject.
Ind: Treatment of diabetes mellitus in adults,
adolescents and children aged 2 years and above.
C/I; S/E; Precautions: See under the text of
insulin.
detemir can be considered during pregnancy, but
any potential benefit must be weighed against a
possibly increased risk of an adverse pregnancy
outcome.
In general, intensified blood glucose control and
monitoring of pregnant women with diabetes are
recommended throughout pregnancy and when
contemplating pregnancy. Insulin requirements
usually fall in the frrst trimester and increase
foUbsequently duri.ng the second and third
trimester. After delivery, insulin requirements
normally return rapidly to pre-pregnancy values.
It is unknown whether insulin detemir is excreted
in human milk. No metabolic effects of ingested
insulin detemir on the breast-fed newborn/infant
are anticipated since insulin detemir, as a peptide,
is digested into amino acids in the human
gastrointestinal tract. Breast-feeding women may
require adjustments in insulin dose and diet.
Dosage & admin: Insulin detemir can be used
alone as the basal insulin or in combination
with bolus insulin. It can also be used in
combination with oral antidiabetic medicinal
products or as add-on therapy to liraglutide
treatment. It is recommended to use insulin
detemir once daily, initially at a dose of 10
units or 0.1-0.2 units/kg. The dose of detemir
should be titrated based on individual
patients' needs. The following titration •
guideline is recommended for adult diabetes
patients:
Average pre-breakfast SMPG* detemir dose
adjustment:
> 10.0mmol/I (180mg/dl) + 8 units
9.1-10.0mmol/1 (163-180mg/dl) + 6 units
8.1-9.0mmol/I (145-162mg/dl) + 4 units
7.1-8.0mmol/I (127-144mg/dl) + 2 units
6.1-7.0mmol/I (109-126mg/dl) + 2 units
If one SMPG measurement
3.1-4.0mmol/I (56-72mg/dl) - 2 units
< 3.lmmol/I (< 56mg/dl) - 4 units
(* Self Monitored Plasma Glucose)
When insulin detemir is used as part of a
basal-bolus insulin regimen it should be
administered once or twice daily depending on
patients' needs. Dose of detemir should be
adjusted individually.
Adjustment of dose may be necessary if
patients undertake increased physical activity,
change their usual diet or during concomitant
illness.
Transfer from other insulin medicinal products:
When transferring from other intermediate or
long-acting insulin medicinal products
adjustment of the dose and timing of
administration may be necessary. As with all
insulin medicinal products, close glucose
monitoring is recommended during the
transfer and in the initial weeks thereafter.
Concomitant antidiabetic treatment may need
to be adjusted (dose and/or timing of oral
antidiabetic medicinal products or concurrent
short/rapid-acting insulin medicinal products).
Method of administration: Insulin detemir is
for subcutaneous administration only. It is
administered subcutaneously by injection in
the abdominal wall, the thigh, the upper arm,
the deltoid region or the gluteal region.
Injection sites should always be rotated within
the same region in order to reduce the risk of
lipodystrophy. As with all insulin medicinal
products the duration of action will vary
according to the dos
, e, injection site, blood
flow, temperature and level of physical
activity. The injection can be given at any time
during the day, but at the same time each day.
For patients who require twice daily dosing to
optimise blood glucose control, the evening

dose can be administered in the evening or at
bedtime.
Drug inter: Combination ofinsulin detemir with
pioglitazone: Cases of cardiac failure have been
reported when pioglitazone was used in combina­
tion with insulin, specially in patients with risk
factors for development of cardiac heart failure.
This should be kept in mind if treatment with the
combination of pioglitazone and insulin detemir
is considered. If the combination is used, patients
should be observed for signs and symptoms of
heart failure, weight gain and oedema.
Pioglitazone should be discontinued if any
deterioration in cardiac symptoms occurs.
Interaction with other medicinal products: See
under the text of insulin
Note: For further information please consult
manufacturer's literature.
+ LEVEMIR Flexpen Inj. Novo Nordisk
Insulin detemir, a recombinant (rDNA) soluble,
long-acting insulin analog, 100 units/lml
solution, 3ml (300 units) pre-filled disposable
injection device (flexpen) for subcutaneoun
injection only.
3ml pre-filled flexpen injection x 5's pack:
6525.00 MRP
INSULIN GLARGINE26,35
INSULIN GLARGINE: S.C Injection
Insulin glargine is a recombinant (rDNA) human
insulin analog. It is a long-acting (up to 24-hour
duration of action), parenteral blood-glucose-low­
ering agent, for use as a subcutaneous injection.
Insulin glargine differs from normal human
insulin in that the amino acid asparagine at
position A2 l is replaced by glycine and two
arginines are added to the C-terminus of the B­
chain. But, the potency of insulin glargine is
approximately the same as human insulin.
Mode of action: Regulation of glucose metabo­
lism is the primary activity of insulins and insulin
analogs, including insulin glargine. For more
information, see above under the text of insulin.
Ind: Insulin glargine is indicated to improve
glycemic control in adults and children with type
1 diabetes mellitus and in adults with type 2
diabetes mellitus.
C/I; S/E; Precautions: See under the text of
insulin.
Pregnancy & lactation: Pregnancy category C.
. syringes: s.c injection.
Insulin glargine should be used during pregnancy
only if the potential benefit justifies the potential
risk to the fetus.
It is unknown whether insulin glargine is
excreted in human milk. Because many drugs,
including human insulin, are excreted in human
milk, caution should be exercised when insulin
glargine is administered to a nursing woman.
Lactating women may require adjustments in
insulin dose & diet.
Dosage & admin: Insulin glargine exhibits a
relatively constant glucose-lowering profile
over 24 hours that permits once-daily dosing.
Potency of insulin glargine is approximately
the same as human insulin.
Insulin glargine is recommended for once
I
QIMP-17 (179)
daily subcutaneous administration & may be
administered at any time during the day.
However, once started should be administered
at the same time every day. The dose of insulin
glargine must be individualized based on clini­
cal response. Blood glucose monitoring is
essential in all patients with diabetes. In
patients with type 1 diabetes, insulin glargine
must be used in regimens with short-acting
insulin. Insulin glargine is not recommended
for i.v administration. Intravenous
administration of the usual subcutaneous dose
could result in severe hypoglycemia.
Injection sites should be rotated within the
same region (abdomen, thigh, or deltoid) from
one injection to the next.
Initiation of Insulin glargine therapy:
The recommended starting dose of insulin
glargine in patients with type 1 diabetes
should be approximately one-third of the total
daily insulin requirements. Short-acting,
premeal insulin should be used to satisfy the
remainder of the daily insulin requirements.
The recommended starting dose of insulin
glargine in patients with type 2 diabetes who
are not currently treated with insulin is 10
units (or 0.2 units/kg) once daily, which should
subsequently be adjusted to the patient's
needs.
Converting to Insulin glargine from other
insulin therapies: If changing from a treatment
regimen with intermediate- or long-acting
insulin to a regimen with insulin glargine, the
amount and timing of shorter-acting insulins
and doses of any oral anti-diabetic drugs may
need to be adjusted.
If transferring patients from once-daily NPH
insulin to once-daily insulin glargine, the
recommended initial insulin glargine dose is
the same as the dose of NPH that is being
discontinued
H transferring patients from twice-daily NPH
insulin to once-daily insulin glargine, the
recommended initial insulin glargine dose is
80o/o of the total NPH dose that is being
discontinued
Overdose: See under the text of insulin.
Drug inter: See under the text of insulin.
Note: For further information please consult
manufacturer's literature.
+ GLARINE Inj. ACI
Insulin glargine INN (recombinant human insulin
analogue) 100 units/ml; 3ml vial with disposable
3ml vial (with disposable syringes) x l's pack:
600.00 MRP
+ INSUL GLARGINE Inj. Popular
Insulin glargine INN (recombinant human insulin
analogue) 100 units/ml; 3ml vial with disposable
syringes: s.c injection.
3ml vial (with disposable syringes) x l's pack:
600.00 MRP
+ INSUL GLARGINE Cartridge Inj. Popular
Insulin glargine INN (recombinant human insulin
analogue) I 00 units/ml; 3ml cartridge: s.c
injection.
100 i.u x 3ml cartridge x 3's pack: 18 00.00 MRP
+ INSULET GN Inj. Aristopharma
Insulin glargine INN (recombinant human insulin
•
analogue) 100,units/ml; 3ml vial with disposable
syringes: s.c injection.
·
_ _
3ml vial (with disposable syringes) x l's pack:.
.
600.00 MRP
+ LANTUS SoloStar Inj. Sanofi-aventis
Insulin glargine (recombinant-human insulin
analogue) I 00 units/ml; 3ml Vial with disp�sable
syringes: s.c injection.
3ml vial (with syringes) x 5's pack: 5 587.88 MRP
+ VIBRENTA lnj. lncepta
Insulin glargine (recombinant human insulin
analogue) 100 units/ml; 3ml vial with disposable
syringes: s.c injection.
3ml vial (with 2 syringes) x l's pack: 600.00 MRP
Antidiabetic Drugs21,2 3
1. Oral hypoglycaemic drugs
2. Parenteral hypoglycaemic drugs
Oral hypoglycaemic drugs are used for non­
insulin dependent (type 2) diabetes; they should
not be used until patients have been shown not to
respond adequately to a period of at least three
month's restriction of energy and carbohydrate
intake. They should be used to augment the effect
of diet, and not to replace it.
The oral hypoglycaemic drugs can be classified as:
A. Sulphonylureas:
Frist generation-
i. Acetohexamide
ii. Chlorpropamide,
iii. Tolaz.amide iv. Tolbutamide
Second generation-
i. Glibenclamide,
ii. Gliclazide, iii. Glimepiride,
iv. Glipizide, v. Glyburide,
vi. Glyquidone etc.
B. Biguanides:
i. Metformin (only available
biguanide).
C. Other antidiabetics:
a) a.-Glucosidase inhibitors:
i. Acarbose, ii. Miglitol
b) Dipeptidylpeptidase-4 inhibitors:
i. Linagliptin, ii. Saxagliptin, iii. Sitagliptin
& iv. Vildagliptin.
c) Meglitinide analogs (carbamomethyl
benzoic acid-CMBA derivatives):
i. Nateglinide, ii. Repaglinide
d) Thiazolidinedione group:
i. Pioglitazone
Parenteral hypoglycaemic drugs that are used
for non-insulin dependent (type 2) diabetes:
a) Glucagon-like peptide-l(GLP-1) receptor
agonists (given by s.c injection):
i. Exenatide, ii. Liraglutide.

.. ; '.. .. . : ,!
.. . .
" '.: ", '
'•
·�i�· �;!/"� ' -
.
...... ·-·�' :'�_ ..,·
..
..
Oral Hypoglycaemic
drugs 21,23,1os
Sulfonylureas21,26, 42,s3,s6
The sulf onylureas are the most widely used oral
antidiabetic agents for the treatment of Type 2
diabetes mellitus (Non-insulin-dependent
diabetes mellitus- NIDDM).
Mode of action: The mode of action of the
sulphonylureas include- i. stimulation of insulin
release from the functioning - cells of the
pancreas, ii. increasing sensitivity of peripheral
tissues & receptors to insulin (during long-:term
administration), & iii. reduction of serum
glucagon levels.
Ind: See below under the individual preparation.
C/I: Insulin dependent (Type 1) diabetes melli­
tus; diabetic precoma or coma. Hypersensitivity
to sulfonylureas, and other sulfonamides. Patients
with severe renal or hepatic impairment; ndocrine
disorders; stress, infection; surgical procedure.
Pregnancy & lactation.
S/E: Hypoglycaemic manifestations- such as
sweating, pallor, intense hunger, malaise,
temporary viual impairment. Other side-effects
include gastro- intestinal disturbances, such as
anorexia, nausea, vomiting, epigastric
discomport; others may include weakness,
paraesthesia, sensitivity reactions including fever,
rashes, jaundice, headache. Very rarely blood
disorders, which may include thrombocytopenia,
agranulocytosis, and aplastic anaemia. Patients
on sulfonylurea therapy may develop facial
flushing after alcohol drinking.
Abnormal laboratory results affecting blood and
liver functions.
Precautions: Hepatic & renal insufficiency;
obese patients. Elderly patients should avoid
long-acting sulphonylureas (e.g chlorpropamide),
as it may cause hypoglycaemia.
Warnings: Hypoglycaemia: This medicine is
susceptible to cause episodes of hypoglycaemia
(decrease of blood sugar levels); in the case of
sweating, intense hunger, trembling, pallor,
visual disturbances, feeling of malaise, abnormal
behavior, immediately eat sugar or something
containing sugar and inform your physician.
Hypoglycaemia is favoured by a strict or poorly
balanced diet, by prolonged or strenuous
exercise, by the intake of alcohol or during use of
other hypoglyca-emic drugs (see drug
interactions below).
In consequence, treatment with a hypoglycaemic
sulphonylurea requires: i. a regular diet- it is
important to eat regular meals, including break­
fast, never miss a meal; ii. Precise regularity in
treatment- it is important to take the treatment
regularly.
Pregnancy & lactation: In case of pregnancy
diabetes should be treated with insulin. In case of
suspecting or diagnosing a new pregnancy while
QIMP-17 (180)
taking oral diabetic medication, stop the therapy + DAONIL Tab. Sanofi-aventis
immediately, and prescribe a more suitable Glibenclamide 5mg/tablet
treatment schedule with insulin for the rest period 500's pack: 139.65 MRP
of pregnancy. t DIBENOL Tab. Square
.
'
-
In case of desired pregnancy, a suitable treatment Glibenclamide 5mg/tablet
schedule should be prescribed with insulin 300's pack: 102.00 MRP
Sulphonylureas are also contra-indicated when t DICON Tab. Jayson r
breast-feeding, so, a suitable treatment schedule Glibenclamide 5mg/tablet
should be prescribed with insulin during the 1 OO's pack: 28.00 MRP
nursing period. t GLUCON Tab. Opsonin
Dosage & Amdin: See below under the Glibenclamide 5mg/tablet
individual preparation. l OO's pack: 29.91 MRP
Advices to the patients: Follow as closely as
possible the dietary advice & medicine
prescribed by the doctor. Regularly carry out
GLICLAZIDE 21 ,53,86
the laboratory tests as advised you. Inform
your physician in different conditions, such as­ GLICLAZIDE: Tablet
in the case of surgery, trauma, fever or Ind: Gliclazide is used alone in Type 2 diabetes
infection, difficult eating; in the case of a patients with diet & exercise after an adequate
planned pregnancy; in the case of taking other trial of dietary therapy and exercise that have
drugs, particularly an anti-inflammatory been proved 11nsatisfactory. It can also be used in
agent, beta-blocker, corticosteroid. combination with other oral insulin sensitizing
Overdose: The administration of an excessive drugs like metformin, acarbose & piogliazone,
·
dose of any sulphonylurea results in and with insulin when diet, exercise and the
•
hypoglycaemia (see warnings) whcih should above oral hypoglycemic agents do not result in
be treated immediately by the administration adequate glycemic control.
of sugar (4 to 6 lumps). In severe cases, if there C/I; S/E; Cautions: See above under the text of
is clouding of consciousness, lOo/o-30% sulfonylurea.
hypertonic glucose solution must be Pregnancy & lactation: Sulphonylureas are
administered intravenously without delay and contra-indicated during pregnancy & breast­
the patient should be transferred to the feeding, so, a suitable treatment schedule should
hospital immediately. be prescribed with insulin.
Missing dose: In case of forgotten or missing Dosage & admin: Dosage of 80mg Plain tablet:
one or more doses- do not take a double dose Initially 40-80mg daily, adjusted according to
to compensate or the single dose that is response; up to 160mg as a single dose with
forgotten or missed to take. Take the regular breakfast; higher dose should be given in
dose in regular time. divided doses; max. 320mg may be given daily.
Drug inter: The hypoglycemic effect of sulpho­ Dosage of 30mg MR (modified release)
nylureas may be potentiated by NSAID particu­ tablet/CR (controlled release) capsule: The
larly aspirin, phenylbuta zone, sulphonamides, usual daily dosage is 1 to 4 MR tablets or CR
co11marin derivatives, MAOls,-adrenergic block­ capsules per day as a single dose. It is recom­
ers, H2 antagonists e.g cimetidine, tetracyclines, medned that the drug should be taken at
chloramphenicol, clofibrate, and anti-fungal oral breakfast time. The tablets/capsules must be
agents like miconazole & fluconazole. Ingestion taken whole with half a glass of water just
of alcohol may also increase the hypoglycemic before breakfast.
•
effect of gliclazide. Every administration of tablets/capsules must
Some drugs, on the contrary, may reduce its be followed by a meal.
activity e.g barbiturates, corticosteroids, thiazide Drug Inter: See under the text of sulfonylurea.
diuretics, thyroid hormones, phenytoin, laxatives
and oral contraceptives. + ADMIRA-80 Tab. UniMed & UniHealth
Gliclazide 80mg/tablet
30's pack: 180.00 MRP
GLIBENCLAMIDE 21,33 + ADMIRA MR Tab. UniMed & UniHealth
Glic]azide 30mg/tablet (modified release).
30's pack: 180.00 MRP
GLIBENCLAMIDE: Tablet.
t COMPRID Tab. Square
Ind: Non-insulin dependent (Type 2) diabetes
Gliclazide 80mg/tablet
mellitus.
60's pack: 420.00MRP
C/I; S/E; Cautions: See above under the text of
t COMPRID XR Tab. Square
sulfonylurea.
Gliclazide 30mg/tablet (extended release).
Pregnancy & lactation: Sulphonylureas are
30's pack: 180.60 MRP
contra-indicated during pregnancy & breast­
t CONSUCON Tab. Incepta
feeding, so, a suitable treatment schedule should
Gliclazide 80mg/tablet
be prescribed with insulin.
50's pack: 300.00 MRP
Dosage & admin: Adult: Initially 5mg daily as
•
t CONSUCON MR Tab. lncepta
single dose at breakfast, increasing if Gliclazide 30mg/tablet (modified release).
necessary by 2.S-5mg at weekly intervals to 50's pack: 300.00 MRP
max. 15 mg daily.
t DIAB Tab. Rephco
Child: not recommended. Gliclazide 80mg/tablet
Overdose; Drug inter: See above under the text 50's pack: 300.00 MRP
of sulfonylurea. t DIACON-80 Tab. Millat
 QIMP-17 (181)

Gliclazide 80mg/tablet
50's pack: 300.00 MRP
50's pack: 300.00 MRP
t GL-80 Tab. CPL
Double dosage
t DIAMICRON MR 60 Tab. Servier Gliclazide BP 80mg/tablet Double
Gliclazide 60mg/tablet (modified release). 50's pack: 350.00 MRP
30's pack: 540.00 MRP t GLIBEN Tab. Concord •

+ DIAPRID Tab. Alco Pharma Gliclazide 80mg/tablet 50's pack: 350.00 MRP
Gliclazide 80mg/tablet 50's pack: 350.00 MRP t GLUZIT Tab. Popular
30's pack: 180.00 MRP t GLICA-80 Tab. Modern Gliclazide 80mg/tablet
t DIAPRO Tab. Beximco Gliclazide 80mg/tablet 50's pack: 350.00 MRP
Gliclazide 80mg/tablet 40's pack: 200.00 MRP t GORED Tab. General
50's pack: 350.00 MRP t GLICASll, Tab. Silva Gliclazide 80mg/tablet
t DIAPRO 30 MR Tab. Beximco Gliclazide 80mg/tablet 50's pack: 350.00 MRP
Gliclazide 30mg/tablet (modified release). 50's pack: 251.00 MRP t GORED MR Tab. General
30's pack: 210.00 MRP t GLICLID Tab. Acme Gliclazide 30mg/tablet (modified release).
t DIATROL Tab. Pacific Gliclazide 80mg/tablet 28's pack: 247.24 MRP
Gliclazide 80mg/tablet 50's pack: 350.00 MRP t KEZID Tab. Kemiko
50's pack: 400.00 MRP t GLICRON Tab. Renata Gliclazide 80mg/tablet
lOO's pack: 800.00 MRP Gliclazide 80mg/tablet 50's pack: 400.00 MRP
t DIATROL MR Tab. Pacific 30's pack: 210.00 MRP t LOZIDE Tab. ACI
Gliclazide 30mg/tablet (modified release). t GLICRON CR Cap. Renata Gliclazide 80mg/tablet
50's pack: 400.00 MRP Gliclazide 30mg/capsule ( controlled release). 40's pack: 280.00 MRP
t DIAT ROL Tab. Pacific 30's pack: 180.60 MRP t NORGLIC 80 Tab. MonicoPharma
Gliclazide 80mg/tablet t GLIMICRON Tab. White Horse Gliclazide 80mg/tablet
50's pack: 400.00 MRP Gliclazide 80mg/tablet 30's pack: 180.00 MRP
lOO's pack: 800.00 MRP 50's pack: 350.00 MRP t OCLAZID Tab. Orion Pharma
t DIAZID 80 Tab. NIPRO JMI t GLIMICRON MR Tab. White Horse Gliclazide 80mg/tablet

Gliclazide 80mg/tablet Gliclazide 30mg/tablet (modified release). 50's pack: 350.00 MRP
50's pack: 300.00 MRP 50's pack: 300.00 MRP t OCLAZID M.R Tab. Orion Pharma
t DIMEROL Tab. Drug Inter. t GLITAB Tab. Hudson Gliclazide 30mg/tablet (modified release).
Gliclazide 80mg/tablet Gliclazide 80mg/tabl_et 30's pack: 180.60 MRP
50's pack: 350.00 MRP 1 OO's pack: 450.00 MRP + ORAZID Tab. Somatec
t DIMEROL-MR Tab. Drug Inter. t GLITZ Tab. Sharif Gliclazide BP 80mg/tablet
Gliclazide 30mg/tablet (modified release). Gliclazide 80mg/tablet 30's pack: 210.00 MRP
50's pack: 300.00 MRP 30's pack: 210.00 MRP t SINAZID Tab. Ibo Sina
t EUCRON Tab. Euro Pharma t GLIVIR Tab. Virgo Gliclazide 80mg/tablet
Gliclazide 80mg/tablet Gliclazide BP 80mg/tablet 50's pack: 325.00 IP
50's pack: 300.00 MRP 50's pack: 250.00 MRP t SUCLEER Tab. RAK Pharma
t EZIDE Tab. Edruc + GLIX 80 Tab. Navana Gliclazide 80mg/tablet
Gliclazide 80mg/tablet Gliclazide 80mg/tablet 50's pack: 300.00 MRP
50's pack: 300.00 MRP 30's pack: 180.00 MRP t SUCLEER MR Tab. RAK Pharma
t G-GLICLAZIDE Tab. Gonoshas t GLIZID Tab. Opsonin Gliclazide 30mg/tablet (modified release).
Gliclazide 80mg/tablet Gliclazide 80mg/tablet 30's pack: 180.00 MRP
30's pack: 120.00 MRP 30's pack: 158.87 MRP t SUCOTAB Tab. Globe
t GIDE Tab. Medicon t GLIZID MR Tab. Opsonin Gliclazide 80mg/tablet
Gliclazide 80mg/tablet Gliclazide 30mg/tablet (modified release). 50's pack: 300.00 MRP
50's pack: 300.00 MRP 30's pack: 158.87 MRP
t SUGRED Tab. Ad-din
+ GLAD Tab. Sandoz t GLUCOSTAT Tab. Biopharma Gliclazide 80mg/tablet
Gliclazide 80mg/tablet Gliclazide 80mg/tablet 30's pack: 180.00 MRP
50's pack: 350.00 MRP 50's pack: 350.00 MRP
+ XIDO Tab. Delta Pharma
+ GLAZID Tab. Techno Drugs t GLUCOZID Tab. Aristopharma Gliclazide 80mg/tablet
Gliclazide 80mg/tablet Gliclazide 80mg/tablet 50's pack: 350.00 MRP
 ® QIMP-17 (182)
1,2,3& 4
+ZENZIDE Tab. Zenith
Gliclazide 80mg/tablet
lOO's pack: 600.00 MRP
+ZIDE Tab. Pharmadesh
Gliclazide 80mg/tablet
50's pack: 350.00 MRP
GLIMEPIRIDE21,42,86
GLIMEPIRIDE: Tablet
Glimepiride is a newer long-acting
sulphonylurea. It is available as glimepiride INN
l mg, 2mg & 3mg tablet.
Mode of action: Glimepiride appears to lower
blood glucose level acutely by stimulating the
release of insulin from the functioning pancreatic
beta-cells. In addition, extrapancreatic effects
may also play a role in the activity of sulfony­
lureas, that glimepiride administration can lead to
increased sensitivity of peripheral tissues to
insulin.
Ind: Glimepiride is used alone in type 2 diabetes
patients with diet & exercise after an adequate
trial of dietary therapy and exercise that have
been proved unsatisfactory. It can also be used in
combination with other oral insulin sensitizing
drugs like metformin, acarbose & piogliazone,
and with insulin when diet, exercise and the
above oral hypoglycemic agents do not result in
adequate glycemic control.
C/I: Known hypersensitivity to glimepiride or
any of the ingredients of the product. Diabetic
ketoacidosis, with or without coma, this
condition should be treated with insulin.
S/E: Hypoglycemia: The incidence of
hypoglycemia with glimepiride is documented.
Others: In patients treated with glimepiride,
adverse events, other than hypoglycemia,
considered to be possibly or probably related to
study drug that occurred in more than 1% of
patients included dizziness (1.7%), asthenia
(1.6%), headache (1.5%), and nausea (1.1%);
Allergic skin reactions, e.g., pruritus, erythema,
urticaria, and morbilliform or maculopapular
eruptions, occur in less than 1% of treated
patients, (these may be transient and may
disappear despite continued use of glimepiride).
Precautions: In the initial weeks of treatment,
the risk of hypoglycemia may be increased and
careful monitoring is essential. If such risk is
present it may be necessary to adjust the dosage
of glimepiride. Hypoglycemia can almost always
be promptly controlled by immediate intake of
carbohydrates (glucose or sugar e.g, in the form
of sugar lumps, sugar-sweetened fruit juice or
sugar-sweetened tea). Caution in renal
insufficiency and obese patients.
Pregnancy & lactation: Sulphonylureas are
contra-indicated during pregnancy & breast­
feeding, so, a suitable treatment schedule should
be prescribed with insulin.
Dosage & Admin: The dosage of glimepiride
must be the lowest one, which is sufficient to
achieve the desired metabolic control. The
usual initial dose is lmg once daily. If neces-
sary, the daily dose can be increased. Any
increase should be based on reqular blood
sugar monitoring, and gradual, i.e at intervals
of one to two weeks, and carried out stepwise
as follows- lmg-2mg-3mg-4mg-6mg. In
patients with well controlled diabetes, the
usual dose range is 1 to 4mg daily. Normally,
a single daily dose is sufficient. This should be
taken immediately before a substantial
breakfast or- if none is taken- immediately
before the first main meal, with sufficient
amounts of liquid (approximately half glass). I
tis very important not to skip meals after
taking the drug.
Secondary dosage adjustment- as the contr ol
of diabetes improves, sensitivity to insulin
increases; therefore, glimepiride requirement
may fall as treatment proceeds. To avoid
hypoglycemia, timely dose reduction or
cessation of glimepiride therapy must be
considered. A dose adjustment must also be
considered whenever the patient's weight or
life-style changes, or other factors arise which
cause an increased susceptibility to hypo- or
hyperglycemia.
When substituting glimepiride for other oral
diabetic agents, the initial daily dose is lmg,
•
this applies even in changeover from the
maximum dose of the drug.
Drug inter: Certain drugs tend to produce
hyperglycemia and may lead to loss of control.
These drugs include the thiazides and other
diuretics, corticosteroids, phenothiazines, thyroid
products, estrogens, oral contraceptives,
phenytoin, nicotinic acid, sympathomimetics, and
isoniazid. When these drugs are administered to a
patient receiving glimepiride, the patient should
be closely observed for loss of control. When
these drugs are withdrawn from a patient
receiving glimepiride, the patient should be
observed closely for hypoglycemia. A potential
interaction between oral miconazole and oral
hypoglycemic agents leading to severe
hypoglycemia has been reported. Whether this
interaction also occurs with the intravenous,
topical, or vaginal preparations of miconazole is
not known. Potential interactions of glimepiride
with other drugs metabolized by cytochrome
P450 2C9 also include phenytoin, diclofenac,
ibuprofen, naproxen, and mefenamic acid.
-
®
Glimepiride
Sl<•F
+ ADGLIM Tab. UniMed & UniHealth
Glimepiride USP l mg & 2mg/tablet
l m g x 30's pack: 90.00 MRP
2mg x 30's pack: 150.00 MRP
+AMARYL Tab. Sanofi-aventis
Glimepiride USP lmg, 2mg, 3mg & 4mg/tablet
l m g x 30's pack: 207.00 MRP
2mg x 30's pack: 387.00 MRP
3mg x 30's pack: 495.00 MRP
4mg x 30's pack: 630.00 MRP
+ CONDIA Tab. RAK Pharma
Glimepiride USP lmg, 2mg & 3mg/tablet
l mg x 30's pack: 90.00 MRP
2mg x 30's pack: 150.00 MRP
3mg x 30's pack: 210.00 MRP
+DACTUS Tab. Acme
Glimepiride USP lmg, 2mg & 3mg/tablet
lmg x 50's pack: 150.00 MRP
2mg x 40's pack: 200.40 MRP
3mg x 30's pack: 210.60 MRP
+DIALON Tab. SK+F
Glimepiride USP lmg, 2mg & 4mg/tablet
l m g x 50's pack: 150.00 MRP
2mg x 30'� pack: 150.00 MRP
4mg x 20's pack: 160.00 MRP
+DIARYL Tab. Beximco
Glimepiride USP lmg, 2mg & 3mg/tablet
l mg x 30's pack: 135.00 IP
2mg x 30's pack: 240.00 IP
3mg x 30's pack: 300.00 MRP
+DIAVIR Tab. Virgo
Glimepiride USP l mg & 2mg/tablet
lmg x 50's pack: 150.00 MRP
2mg x 50's pack: 250.00 MRP
+DIETA Tab. Pacific
Glimepiride USP lmg, 2mg, 3mg & 4mg/tablet
lmg x 30's pack: 150.00 MRP
2mg x 30's pack: 240.00 MRP
3mg x 30's pack: 300.00 MRP
4mg x 30's pack: 360.00 MRP
+GIFON Tab. MonicoPharma
Glimepiride 1mg & 2mg/tablet
l mg x 30's pack: 90.00 MRP
2mg x 30's pack: 150.00 MRP
+GIPID Tab. Alco Pharma
Glimepiride USP l m g & 2mg/tablet
I mg x 30's pack: 90.00 MRP
2mg x 30's pack: 150.00 MRP
+GI.IMIRID Tab. ACI
Glimepiride USP l mg, 2mg, 3mg & 4mg/tablet
l mg x 30's pack: 135.00 MRP
2mg x 30's pack: 240.00 MRP
3mg x 30's pack: 300.00 MRP
4mg x 30's pack: 360.00 MRP
+GLIMS Tab. Opsonin
Glimepiride USP l mg & 2mg/tablet
lmg x 30's pack: 79.43 MRP
2mg x 30's pack: 132.48 MRP
+GLIRID Tab. General
Glimepiride USP lmg & 2mg/tablet
l mg x 30's pack: 90.30 MRP
2mg x 30's pack: 150.60 MRP
+GLUCONOR Tab. Aristopharma
Glimepiride USP lmg & 2mg/tablet
lmg x 50's pack: 150.00 MRP
2mg x 30's pack: 150.00 MRP
+GLUCORID Tab. Biopharma
Glimepiride USP l mg & 2mg/tablet
l mg x 30's pack: 90.00 MRP
2mg x 30's pack: 150.00 MRP -
.
+LIMARYL Tab. Popular
Glimepiride USP l mg, 2mg, 3mg & 4mg/tablet
1mg x 30's pack: 90.00 MRP
2mg x 30's pack: 150.00 MRP
3mg x 30's pack: 210.90 MRP
4mg x 30's pack: 240.90 MRP
+LIMEP Tab. Kemiko
Glimepiride USP l m g & 2mg/tablet
lmg x 50's pack: 150.00 MRP
2mg x 50's pack: 250.00 MRP

t L IMPET Tab. Drug Inter.
Glimepiride USP l mg, 2mg, 3mg & 4mg/tablet
l mg x 50's pack: 150.00 MRP
2mg x 50's pack: 250.00 MRP
3mg x 30's pack: 210.00 MRP
4mg x 30's pack: 270.00 MRP
t LOSUCON Tab. Incepta
Glimepiride USP l mg, 2mg, 3mg & 4mg/tablet
l mg x 50's pack: 150.00MRP
2mg x 50's pack: 250.00 MRP
3mg x 30's pack: 210.00 MRP
4mg x 30's pack: 240.00 MRP
t MEPID Tab. R enata
Glimepiride USP l mg, 2mg & 4mg/tablet
l mg x 30's pack: 75.30 MRP
2mg x 30's pack: 120.30 MRP
4mg x 30's pack: 210.60 MRP
+PRIDE Tab. White Horse
Glimepiride USP l mg & 2mg/tablet
l mg x 50's pack: 250.00 MRP
2mg x 50 's pack: 350.00 MRP
t SECRIN Tab. Square
Glimepiride USP l mg, 2mg, 3mg & 4mg/tablet
l mg x 60's pack: 270.00MRP
2mg x 60's pack: 480.00 MRP
I 3mg x 30's pack: 300.00 MRP
4mg x 30's pack: 360.00 MRP
+STIMULIN Tab. Orion Pharma
Glimepiride USP l mg & 2mg/tablet
l mg x 30's pack: 90.30 MRP
2mg x 30's pack: 150.60 MRP
GLIPIZIDE2t,33,s6
GLIPIZIDE: Tablet
Ind: Glipizide is used alone in Type 2 diabetes
patients with diet & exercise after an adequate
trial of dietary therapy and exercise that have
been proved unsatisfactory. It can also be used in
combination with other oral insulin sensitizing
drugs like metformin, acarbose & piogliazone,
and with insulin when diet, exercise and the
above oral hypoglycemic agents do not result in
adequate glycemic control.
C/I; S/E; Cautions: See above under the text of
sulphonylurea.
Pregnancy & lactation: Sulphonylureas are
contraindicated during pregnancy & breast­
feeding, so, a suitable treatment schedule should
be prescribed with insulin.
Dosage & admin: Initially 2.5-Smg daily,
adjusted according to response; maximum
40mg daily; upto 15mg may be given as a single
dose before breakfast; higher doses divided.
For maximum effect in reducing postprandial
hyperglycemia, glipizide should be ingested 30
mins. before breakfast, since rapid absorption
is delayed when the drug is taken with food.
-..
Overdose; Drug inter: See above under the text
of sulfonylurea.
t DIACTIN Tab. Beximco
Glipizide 5mg/tablet
5mg x lOO's pack: 150.00 IP
t DIAPLUS Tab. Pacific
Glipizide 5mg/tablet
5mg x 50's pack: 100.00
-
MRP
t
DIAPLUS XR Tab. Pacific
Glipizide 5mg/tablet (extended release).
5mg x 30's pack: 84.00 MRP
QIMP-17 (183)
c_iJ Bioequivalent:
Ensures better efficacy
(.v COS grade RM:
Ensures better quality
<..tJ Alu-Alu blister:
Ensures more sta bility
c..v Convenient size & shape of tablet:
Ensures patients' compliance
Yt/tce �.958
SQUARE
PHARMACEUTICALS LTD.
•
BANGLADESH
t GL IMEROL Tab. Drug Inter.
Glipizide 5mg/tablet
5mg x lOO's pack: 150.00 MRP
t PIZIDE-5 Tab. Kemiko
Glipizide 5mg/tablet
5mg x lOO's pack: 200.00 MRP
.
Biguanides
METFORMIN21,86
.
METFORMIN HCl: Tablet/Oral solution.
Metformin is a biguanide antihyperglycemic
agent which improves glucose tolerance in type 2
diabetes patients by lowering basal and postpran­
dial plasma glucose.
Mode of action: Metformin inhibits hepatic glu­
cose production (gluconeogenesis ), reduces intes­
tinal absorption of glucose, and improves periph­
eral insulin sensitivity (increases peripheral glu­
cose uptake & utilization). Unlike sulfonylureas,
metformin does not produce hypoglycemia in
either diabetic or non-diabetic subjects.
Metformin helps lower cholesterol level and also
helps obese patient to lose weight.
Ind: In non-insulin dependent (Type 2) diabetes
mellitus- alone, when blood glucose & obesity
are not responding to dietary therapy; in combi­
nation with a sulfonylurea, repaglinide, pioglita­
zone, acarbose, or insulin.
Adjuvant therapy in insulin-dependent (Type I)
diabetes, particularly in the obese.
C/I: Individual hypersensitivity to metformin,
renal impairment, liver disease, predisposition to
lactic acidosis, heart failure, severe infection or
trauma, dehydration and alcohol dependence.
Metformin is not advised during pregnancy &
lactation; and not for pediatric use.
S/E: Normally well tolerated but hypoglycaemic
attack may occur especially in elderly, debilitated
or traumatised cases. Lactic acidosis is a very
rare occurence (0.003%), when the patient taking
metfonnin over the course of a year, the
symptoms are anorexia, nausea, vomiting, fever
increased respiratory rate, malaise, abdominal
pain, diarrhea. It may induce malabsorption of
vitamin B12, folic acid & elevate liver enzymes.
Cautions: Metformin should only be prescribed
when diet and weight reducton has proven inade­
quate. During concomitant therapy with other
oral hypoglycemic drugs, blood sugar should be
monitored carefully because combined therapy
may cause hypoglycemia. Patient must be colsely
monitored in order to identify any factor or con­
dition that may favour the onset of lactic acido­
sis. The risk of lactic acidosis is higher among
the patients over 60. Patients shouldbe instructed
how to recognize the early symptoms of lactic
acidosis (see above inder side-effects). In the
event of severe trauma, injuries, infectious dis­
eases & high fever, and surgery, it may be neces­
sary to �ve insulin to maintain adequate metabo­
lic control. Caution in excess alcohol intake.
Pregnancy & lactation: Metformin is not rec-

ommended during pregnancy and breast-feeding,
so, a suitable treatment schedule should be
prescribed with insulin.
Dosage & admin: Adult: Initially 500mg twice
daily or 850mg daily with meals increasing
gradually if necessary to maximum 3gm daily.
Reduce to maintenance, usually 500mg thrice
or 850mg twice daily.
Child: Not applicable
Dosage of ER, LA, SR or XR preparations: The
usual starting dose of ER, LA, SR or XR
500mg (metformin hydrochloride- long acting
or extended release) is one tablet once daily
with the evening meal. Dosage can be
increased with a rate of 500mg weekly, up to a
maximum of 2000mg once daily with the
evening meal. If glycemic control is not
achieved ER, LA, SR or XR 2000mg once
daily, a trial of ER, LA, SR or XR 1 OOOmg
twice daily should be considered.
Drug Inter: Nifedipine appears to enhance the
absorption of metformin but the latter has
minimal effects on nifedipine. Thiazides,
corticosteroids, phenothiazines, thyroid
hormones, estrogens, oral contraceptives,
phenytoin, nicotinic acid, sympathomimetics,
calcium channel blockers and isoniazid tend to
produce hyperglycemia and may lead to loss of
glycemic control. Metformin may enhance the
effects of anti-coagulants.
t BIGMET Tab. Renata
Metformin hydrochloride BP 500mg &
850mg/tablet
500mg x lOO's pack: 300.00 MRP
850mg x 1OO's pack: 400.00 MRP
t COMET Tab. Square
Metformin hydrochloride BP 500mg, 750mg,
850mg & l gm/tablet
500mg x 1 OO's pack: 300.00 MRP
750mg x 60's pack: 210.00 MRP
850mg x 50's pack: 225.00 MRP
lgm x 30's pack: 150.00 MRP
t COMET XR 500 Tab. Square
Metformin hydrochloride USP 500mg/tablet
(extended release).
500mg x 50's pack: 250.00 MRP
t COMET XR lgm Tab. Square
Metformin hydrochloride USP lgm/tablet
(extended release).
lgm x 30's pack: 210.60 MRP
t DAOMIN Tab. Acme
Metformin hydrochloride BP 500mg &
850mg/tablet
500mg x l OO's pack: 299.00 MRP
850mg x 40's pack: 199.20 MRP
t DAOMIN XR 500 Tab.Acme
Metformin hydrochloride USP 500mg/tablet
(extended release).
500mg x 50's pack: 250.00 MRP
-
QIMP-17 (184)
t DAOMIN XR lgm Tab.Acme 500mg x 50's pack: 150.00 MRP
Metformin hydrochloride USP 1gm/tablet 850mg x 50's pack: 250.00 MRP
(extended release). + GLYMIN Tab. Healthcare
lgm x 30's pack: 210.00 MRP Metformin hydrochloride 500mg & 850mg/tablet
•
t DEFORMIN Tab. Zenith 500mg x 50's pack: 150.00 MRP
Metformin hydrochloride BP 500mg & 850mg x 40's pack: 160.00 MRP
•
850mg/tablet + GLYMIN 500 XR Tab. Healthcare
500mg x 1 OO's pack: 300.00 MRP Metformin hydrochloride 500mg/tablet (extended
850mg x 1OO's pack: 400.00 MRP release).
+ D-FO Tab. Decent 500mg x 50's pack: 250.00 MRP
Metformin hydrochloride 850mg/tablet + G-METFORMIN Tab. Gonoshas.
850mg x 30's pack: 75.00 MRP Metformin hydrochloride 500mg & 850mg/tablet
t DIAFRE Tab. Mystic 500mg x lOO's pack: 160.00 MRP
Metformin hydrochloride 500mg & 850mg/tablet 850mg x 30's pack: 75.00 MRP
500mg x l OO's pack: 150.00 MRP t G-PHASE Tab. Edruc
850mg x 50's pack: 150.00 MRP Metformin hydrochloride 850mg/tablet I
t DIAMIN Tab.Virgo 850mg x 30's pack: 90.00 MRP
Metformin hydrochloride BP 500mg & t GUAMIN Tab. Ad-din
850mg/tablet. Metformin hydrochloride 850mg/tablet
500mg x 50's pack: 125.00 MRP 850mg x 50's pack: 150.00 MRP
850mg x 30's pack: 90.00 MRP t ID-MET Tab. Hudson
t DIOUT 850 Tab.Asiatic Metformin hydrochloride 850mg/tablet
Metformin hydrochloride BP 850mg/tablet 850mg x l OO's pack: 300.00 MRP
850mg x 50's pack: 112.50 MRP t INFO Tab. Bristol
t ETFORM Tab. Sandoz Metformin hydrochloride 500mg & 850mg/tablet
Metformin hydrochloride 500mg & 850mg/tablet 500mg x 50's pack: 100.00 MRP
500mg x 1OO's pack: 320.00 MRP 850mg x 50's pack: 150.00 MRP
850mg x 50's pack: 275.00 MRP t INFORMET Tab. Beximco
t FORMET Tab.Biopharm.a Metformin hydrochloride 500mg & 850mg/tablet
Metformin hydrochloride 500mg & 850mg/tablet 500mg x l OO's pack: 300.00 IP
500mg x 1 OO's pack: 300.00 MRP 850mg x 60's pack: 270.00 IP
850mg x 50's pack: 250.00 MRP t INFORMET LA Tab. Beximco
t GLIMET-850 Tab. Millat Metformin hydrochloride BP 500mg/tablet (long
Metformin hydrochloride 850mg/tablet actin�. .
850mg x 30's pack: 120.00 MRP 500mg x lOO's pack: 500.00 IP
t GLUCOMET Tab. Aristopharma t INSIME T Tab. Ibo Sina
Metformin hydrochloride 500mg & 850mg/tablet Metformin hydrochloride 500mg & 850mg/tablet
500mg x 1 OO's pack: 300.00 MRP 500mg x 1 OO's pack: 300.00 IP
850mg x 50's pack: 300.00 MRP 850mg x 50's pack: 200.00 IP
.
t GLUCOMET 500 XR Tab.Aristopharma + KEMIN Tab. Kemiko
Metformin hydrochloride 500mg/tablet (extended Metformin hydrochloride 500mg & 850mg/tablet
release). 500mg x 50's pack: 125.00 MRP
500mg x 50's pack: 300.00 MRP 850mg x 50's pack: 200.00 MRP
t GLUCOMET 750 XR Tab.Aristopharma t KEMIN-SR Tab. Kemiko
Metformin hydrochloride 750mg/tablet (extended Metformin hydrochloride 500mg/tablet (sustained
release). release).
500mg x 30's pack: 240.00 MRP 500mg x 50's pack: 250.00 MRP
t GLUCOMIN Tab. NIPRO JM1 t MEFOREX Tab.Jayson
Metformin hydrochloride 500mg & 850mg/tablet Metformin hydrochloride 500mg & 850mg/tablet
500mg x 50's pack: 125.00 MRP 500mg x 50's pack: 100.00 IP
850mg x 50's pack: 150.00 MRP
850mg x 30's pack: 90.00 IP
t GLUNOR Tab. SK+F
t MEFO RIN Tab. RAK Pharma
Metformin hydrochloride 500mg & 850mg/tablet
Metformin hydrochloride 500mg & 850mg/tablet
500mg x 50's pack: 150.00 MRP
500mg x 50's pack: 150.00 MRP
850mg x 50's pack: 200.00 MRP
850mg x 50's pack: 250.00 MRP
t GLUNOR XR Tab. SK+F
Metformin hydrochloride 500mg/tablet (extended t MEFORIN XR Tab.RAK Pharma
Metformin hydrochloride ?OOmg/tablet (extended
release).
release).
500mg x 50's pack: 200.00 MRP
500mg x 30's pack: 150.00 MRP
t GLUPHAGE XR Tab. Silva
Metformin hydrochloride 400mg/tablet (extended t MEFORMIN Tab. Organic Health
release). Metformin hydrochloride BP 500mg &
400mg x 50's pack: 185.00 MRP 850mg/tablet
t GLUTEC Tab. Techno Drugs 500mg x lOO's pack: 200.00 MRP
Metformin hydrochloride 500mg & 850mg/tablet 850mg x 50's pack: 150.00 MRP
.
•••
.
•••
rai �!!�AL$ www.squarepharmacom.bd •••
� aAHOl.ADl&llH
tTIJ.
IQUAIS •

+ MEGLU Tab. UniMed & UniHealth
Metformin hydrochloride 500mg & 850mg/tablet
500mg x 30's pack: 90.00 MRP
850mg x 30's pack: 120.00 MRP
+ MEGLU ER-500 Tab. UniMed & UniHealth
Metformin hydrochloride 500mg/tablet
(extended release).
500mg x 30's pack: 150.00 MRP
+ MET Tab. Opsonin
Metformin hydrochloride 500mg & 850mg/tablet
500mg x 30's pack: 79.17 MRP
850mg x 30's pack: 131.95 MRP
+ MET 500 XR Tab. Opsonin
Metformin hydrochloride 500mg/tablet
(extended release).
500mg x 50's pack: 176.82 MRP
+ MET 750 XR Tab. Opsonin
Metformin hydrochloride 750mg/tablet
(extended release). ·
750mg x 30's pack: 158.87 MRP
+ METARIN Tab. Popular
Metformin hydrochloride 500mg & 850mg/tablet
500mg x 30's pack: 75.30 MRP
850mg x 30's pack: 120.60 MRP
+ METFAR Tab. White Horse
Metformin hydrochloride 500mg & 850mg/tablet
Metformin
a. st answer to D;
i> e
Better
www.whitehorsephanna.com
500mg x 50's pack: 200.00 MRP
850mg x 30's pack: 250.00 MRP
+ METFAR SR Tab. White Horse
Metformin hydrochloride 500mg/tablet
(sustained release).
500mg x 30's pack: 120.00 MRP
+ METFEN Tab. Doctor's
Metformin hydrochloride BP 500mg &
850mg/tablet
500mg x 1OO's pack: 250.00 MRP
850mg x 50's pack: 175.00 MRP
+ METFO Tab. Pacific
Metformin hydrochloride BP 500mg &
850mg/tablet
500mg x 50's pack: 200.00 MRP
500mg x 1OO's pack: 400.00 MRP
850mg x 30's pack: 180.00 MRP
850mg x 1OO's pack: 600.00 MRP
+ METFO XR SOO Tab. Pacific
Metformin hydrochloride USP 500mg/tablet
(extended release).
500mg x 50's pack: 350.00 MRP
+ METFORM Tab. ACI
Metformin hydrochloride BP 500mg &
·
850mg/tablet
I
QIMP-17 (185)
500mg x 1OO's pack: 300.00 MRP
850mg x 50's pack: 225.00 MRP
+ METFORM ER 500 Tab. ACI
Metformin hydrochloride 500mg/tablet (extended
release).
•
500mg x 50's pack: 150.00 MRP
500mg x 50's pack: 250.00 MRP
850mg x 50's pack: 200.00 MRP
+ METFORM ER 1000 Tab. ACI
+ NVMET-500 SR Tab. Navana
Metformin hydrochloride 1OOOmg/tablet
Metformin hydrochloride 500mg/tablet
(extended release).
(sustained release).
l OOOmg x 32's pack: 224.96 MRP
500mg x 50's pack: 200.00 MRP
+ ME'I'IN Tab. Supreme
+ OBEMET Tab. Euro Pharma
Metformin hydrochloride 850mg/tablet
Metformin hydrochloride 500mg & 850mg/tablet
850mg x 30's pack: 148.80 MRP
500mg x l OO's pack: 200.00 MRP
+ METLIFE Tab. Silva 850mg x 50's pack: 200.00 MRP
Metformin hydrochloride 500mg & 850mg/tablet
+ OBID Tab. Delta Pharma
500mg x lOO's pack: 301.00 MRP
Metformin hydrochloride 500mg & 850mg/tablet
850mg x 50's pack: 201.00 MRP
500mg x l OO's pack: 300.00 MRP
+ METMIN Tab. Alco Pharma 850mg x 30's pack: 150.00 MRP
Metformin hydrochloride 500mg & 850mg/tablet
500mg x 50's pack: 150.00 MRP + ORAMET Tab. Drug Inter.
Metformin hydrochloride 500mg & 850mg/tablet
850mg x l OO's pack: 400.00 MRP
500mg x 1OO's pack: 300.00 MRP
+ METNIL Tab. Medicon
850mg x l OO's pack: 400.00 MRP
Metformin hydrochloride 500mg/tablet
l OO's pack: 200.00 MRP + ORAMET-SR Tab. Drug Inter.
+ METOMIN Tab. Somatec Metformin hydrochloride 500mg/tablet
Metformin hydrochloride BP 500mg & (sustained release).
HCI BP 500 & 850 mg Tablet
Metformin HCI BP 500 mg Tablet
CJbet
es
MeJJitus & Obe se
UKA S
Qu ality Alw ays
_...
An ISO 9001: 2008 Certified Company
850mg/tablet 500mg x 50's pack: 250.00 MRP
500mg x 1OO's pack: 300.00 MRP
+ ORAMET-SR lgm Tab. Drug Inter.
850mg x 50's pack: 250.00 MRP Metformin hydrochloride lgm/tablet (sustained
+ METSA Tab. Sanofi-aventis release).
Metformin hydrochloride BP 500mg & lgm x 30's pack: 210.00 MRP
850mg/tablet
+ ORMIN Tab. Orion Pharma
500mg x 1OO's pack: 299.99 MRP
Metformin hydrochloride 500mg & 850mg/tablet
850mg x 50's pack: 250.00 MRP
500mg x 50's pack: 150.00 MRP
+ METSA 500 XR Tab. Sanofi-aventis
850mg x 50's pack: 250.00 MRP
Metformin hydrochloride USP 500mg/tablet
(extended release). + P-MIN Tab. Pharmadesh
500mg x 50's pack: 300.00 MRP . Metformin hydrochloride 500mg & 850mg/tablet
+ M-FORM Tab. CPL 500mg x 1 OO's pack: 250.00 MRP
Metformin hydrochloride BP 850mg/tablet 850mg x 30's pack: 105.30 MRP
1OO's pack: 550.00 MRP + RUZMET Tab. Amico
+ M-MIN Tab. Sharif Metformin hydrochloride 500mg/tablet
Metformin hydrochloride 500mg & 850mg/tablet 500mg x 30's pack: 90.00 MRP
500mg x 50's pack: 150.00 MRP
+ SUCOMET Tab. Globe
850mg x 30's pack: 135.00 MRP
Metformin hydrochloride 500mg & 850mg/tablet
+ NOBESIT Tab. lncepta 500mg x l OO's pack: 250.00 MRP
Metformin hydrochloride 500mg & 850mg/tablet
•
850mg x 50's pack: 150.00 MRP •
500mg x 50's pack: 125.00 MRP
+ SUGAMET Tab. General
850mg x 50's pack: 175.00 MRP
Metformin hydrochloride 500mg & 850mg/tablet
+ NVMET Tab. Navana . 500mg x 1OO's pack: 300.00 MRP
Metformin hydrochloride 500mg & 850mg/tablet
850mg x IOO's pack: 450.00 MRP

Other Antidiabetic arents
a -Glucosidase inhibitor
ACARBOSE: Tablet
Acarbose is an oral hypoglycaemic agent. It is an
a-glucosidase inhibitor. It is available as­
acarbose INN 50mg & l OOmg in tablet form.
Mode of acation: It inhibits intestinal -glucosi­
dase enzyme with resultant reduction in carbo­
hydrate digestion and absorption. It slows down
the digestion of carbohydrates & lengthens the
time it takes for carbohydrate to convert to
glucose (i.e convertion of disaccharide into
monosaccharides ), thereby facilitates better blood
glucose control. It mainly influences the level of
blood sugar after eating, and hence flattens post
meal rises in glucose and insulin levels. It is also
believed that acarbose improves insulin
sensitivity & prevents or delays the progressive
Cleterioration in pancreatic -cells that routinely
occurs in patients with Type II Diabetes mellitus.
Ind: Acarbose as monotherapy, is indicated as an
adjunct to diet to lower blood glucose in patients
with type II diabetes mellitus (NIDDM) whose
hyperglycaemia can not be managed on diet
alone. It may also be used in combination with a
sulfonylurea when diet plus either acarbose or a
sulfonylurea do not result an adequate glycaemic
control.
C/I: Known hypersensitivity to the drug. Since
the information on its effects and tolerability in
children and adolescents is still insufficient it
should not be used in patients under 18 years of
age. Chronic inflammatory & other bowel disor­
ders associated with distinct disturbances of
digestion and absorption (e.g. ulcerative colitis,
Crohn's disease). States which may deteriorate as
a result of increased gas formation in the intestine
(e.g. Roemheld's syndrome, major hernias, intes­
tinal obstruction and intestinal ulcers). Acarbose
should not be administered during pregnancy &
lactation, as no information is available on its use
in these conditions in humen. Acarbose should
not be used in patients with severe renal
impairment (creatinine clearance <25ml/min).
S/E: Frequently flatulence and bowel sounds,
occasionally diarrhoea and abdominal distension
and less frequently abdominal pain. These side
effects may be severe and might be confused
with ileus or ileus-like symptoms. If the prescri­
bed diabetic diet is not maintained the intestinal
side effects may be intensified. If strongly
distressing symptoms develop in spite of
maintaining diabetic diet prescribed, the doctor
must be consulted and the dose may temporarily
or permanently be reduced. In individual cases
hypersensitive skin reactions may occur e.g
erythema, exanthema and urticaria. Very rarely,
hepatitis and/or jaundice have been reported.
Warnings & Precautions: Asymptomatic liver
QIMP-17 (18')
enzyme elevations may occur in individual cases
specially at higher dosages. Therefore, appropri­
ate liver enzyme monitoring should be conside­
red during the first 6 to 12 months of treatment.
In evaluable cases these changes were reversible
on discontinuation of the drug.
Pregnancy & lactation: Acarbose is not recom­
mended during pregnancy and breast-feeding, so,
a suitable treatment schedule should be
prescribed with insulin.
Dosage: Starting dosage: 2Smg 3 times daily
with meals. Usual dosage: SO-lOOmg 3 times
daily or as the number of meals, depending on
the patient's weight and tolerance of side­
effects. Some patients may benefit from gra­
dual dose adaptation by initiating treatment at
SOmg once a day for 1 or 2 weeks, then SOmg
twice a day for 1 or 2 weeks followed by SOmg
three times a day. H necessary, dose can be
increased to 1 OOmg three times a day depend­
ing on the clinical response. Acarbose is to be
taken orally, chewed with the first mouthful of
food, or swallowed whole with a little liquid
directly before the meal. Patients should be
encouraged to follow their dietary guidelines
and avoid sucrose. In elderly patients no dosa­
ge adjustment is required. Acarbose shoud not
be interrupted without consulting a physician
as this can lead to a rise in blood glucose.
Drug inter: Sucrose (cane sugar) and foods con­
taining sucrose often cause abdominal discomfort
or even diarrhoea during treatment with acarbose
as a result of in creased carbohydrate fermenta­
tion in the colon. Acarbose has an antihypergly­
caemic effect, but does not itself induce hypogly­
caemia. If acarbose is prescribed in addition to
sulphonylurea or metformin, or in addition to
insulin, a fall of the blood glucose level into the
hypoglycaemic range may necessitate a suitable
decrease in the sulphonylurea, metformin or
insulin dose. If acute hypoglycaemia develops it
should be borne in mind that sucrose (cane sugar)
is broken down into fructose and glucose more
slowly during treatment with acarbose, for this
reason sucrose is unsuitable for a rapid
alleviation of hypoglycaemia & glucose should
be used instead. Simultaneous administration of
choles-tyramine, intestinal adsorbents, and
digestive enzyme products should be avoided as
they may possibly influence the action of
acarbose. Certain other drugs tend to produce
hyperglycaemia and may lead to loss of blood
glucose control, such as, thiazides and other
diuretics, corticosteroids, pheno-thiazines, thyroid
products, estrogens, oral contraceptives,
phenytoin, nicotinic acid, sympathomi-metics,
calcium channel blockers & isoniazides.
+ ACARIL Tab. White Horse
Acarbose BP 50mg/tablet.
50mg x 30's pack: 450.00 MRP
+ SUGATROL Tab. Pacific
Acarbose INN 50mg & I OOmg/tablet.
50mg x 30's pack: 450.00 MRP
I OOmg x 30's pack: 750.00 MRP
MIGL11'0V2
MIGLITOL: Tablet.
Miglitol is a desoxynojirimycin derivative, oral
hypoglycaemic agent. It is an a-glucosidase
inhibitor. It is available as- miglitol INN 25mg &
50mg in tablet form.
Mode of action: The antihyperglycemic action of
miglitol results from a reversible inhibition of
•
membrane bound intestinal a-glucosidases •
enzymes. Membrane-bound intestinal a-glucosi­ •
dases hydrolyze oligosaccharides and disaccha­
rides to glucose and other monosaccharides in the
brush border of the small intestine. In diabetic
patients, this enzyme inhibition results in delayed
glucose absorption and lowering of postprandial
hyperglycemia. As a consequence of plasma
glucose reduction, miglitol reduces levels of
glycosylated hemoglobin.
Ind: Miglitol as monotherapy, are indicated as an
'
adjunct to diet and exercise to improve glycemic
control in patients with Type II diabetes whose
hyperglycemia cannot be managed with diet
alone. Miglitol may also be used in combination
with a sulfonylurea when diet plus either miglitol
or a sulfonylurea alone do not result in adequate
glycemic control.
C/I: Miglitol is contraindicated in patients with
hypersensitivity to the drug or any of its
components. It is also contraindicated in patients
with diabetic ketoacidosis; inflammatory bowel
disease, colonic ulceration, or partial intestinal
obstruction, and in patients predisposed to
intestinal obstruction; chronic intestinal diseases
associated with marked disorders of digestion or
absorption, or with conditions that may
deteriorate as a result of increased gas formation
in the intestine.
S/E: Gastrointestinal symptoms like abdominal
pain, diarrhea, and flatulence may develop in
patients taking mig,litol. Dermatologic symptoms
like skin rashes may develop in patients receiving
miglitol. Abnormal laboratory findings e.g low
serum iron occurred more often in patients
treated with miglitol but did not persist in the
majority of cases and was not associated with
reductions in hemoglobin or changes in other
hematologic indices.
Precautions: Miglitol given in combination with
a sulfonylurea will cause a further lowering of
blood glucose; it may increase the hypoglycemic
•
potential of the sulfonylurea. When diabetic
patients are exposed to stress such as fever,
trauma, infection, or surgery, a temporary loss of
control of blood glucose may occur. At such
times, temporary insulin therapy may be
necessary. Plasma concentrations of miglitol in
renal impaired patients were proportionally
increased relative to the degree of renal dysfunc­
tion. As there are no adequate and well-controlled
studies in diabetic patients with significant renal
dysfunction, therefore, treatment of these patients
with miglitol is not recommended.
Pregnancy & lactation: Miglitol is pregnancy
category B. The safety of miglitol in pregnant
women has not been established. As there are no
adequate and well-controlled studies in pregnant
women, this drug should be used during
pregnancy only if clearly needed. Miglitol has
been shown to be excreted in human milk to a
very small degree. Although the levels of miglitol
reached in human milk are exceedingly low, it is
recommended that miglitol not be administered
to a nursing woman.

Dosage & admin: Dosage of miglitol must be
individualized on the basis of both effective­
ness and tolerance.
Initial dosage: The recommended starting
dosage is 25mg, given orally 3 times daily at
the start of each main meal. However, some
patients may benefit by starting at 2Smg once
daily to minimize gastrointestinal adverse
effects, and gradually increasing the frequency
of administration to 3 times daily.
Maintenance dosage: The usual maintenance
dose of miglitol is SOmg 3 times daily; but,
some patients may benefit from increasing the
dose to 1 OOmg 3 times daily. In order to allow
adaptation to potential gastrointestinal adver­
se effects, it is recommended that miglitol
therapy be initiated at a dosage of 2Smg 3
times daily, the lowest effective dosage, and
then gradually titrated upward to allow adap­
tation. After 4-8 weeks of the 2Smg 3 times
daily regimen, the dosage should be increased
to 50mg 3 times daily for approximately 3
months, following which a glycosylated hemo­
globin level should be measured to assess ther­
apeutic response. If, at that time, the glycosy­
lated hemoglobin level is not satisfactory, the
dosage may be further increased to 1 OOmg 3
time� daily, the maximum recommended
dosage. If no further reduction in postprandial
glucose or glycosylated hemoglobin level is
observed with titration to 1 OOmg 3 times daily,
consideration should be given to lowering the
dose. Once a'! effective and tolerated dosage is
established, it should be maintained.
Children: Not recommended.
Drug inter: The mean Cmax and AUC values
for glyburide & metformin decrease when co­
administered with miglitol. Miglitol may
significantly reduce the bioavailability of
ranitidine and propranolol. Intestinal adsorbents
(e.g charcoal) and digestive enzyme preparations
containing carbohydrate-splitting enzymes (e.g
amylase, pancreatin) may reduce the effect of
miglitol and should not be taken concomitantly.
t DIASET Tab. ACI
Miglitol INN 25mg & 50mg/tablet.
25mg x 30's pack: 301.20 MRP
50mg x 30's pack: 451.80 MRP
Dipeptidyl Peptidase-4
(DPP-4) Inhibitor
LINAGLIPTIN: Tablet (f.c)
Linagliptin, a dipeptidyl peptidase-4 (DPP-4)
inhibitor, indicated as an adjunct or monotherapy
or in multiple therapy in the treatment of type 2
diabetes mellitus. It is available as- linagliptin
INN 5mg/tablet (film-coated).
Mode of action: Linagliptin, as a dipeptidyl
peptidase-4 inhibitor, it exerts its action by
slowing the inactivation of incretin hormones.
lncretin hormones, including 'glucagon-like
peptide-I (GLP-1)' and 'glucose-dependent
insulinotropic polypeptide (GIP)' are released by
the intestine throughout the day and levels are
increased in response to a meal. These hormones
I
QIMP-17 (187)
are rapidly inactivated by the enzyme DPP-4.
The incretins are part of an endogenous system
involved in the physiologic regulation of glucose
homeostasis. When blood glucose concentrations
are normal or elevated, GLP-1 and GIP increase
insulin synthesis and release from pancreatic beta
cells by intracellular signaling pathways
involving cyclic AMP. GLP-1 also lowers
glucagon secretion from pancreatic alpha cells,
leading to reduced hepatic glucose production.
Ind: Linagliptin is indicated in the treatment of
type 2 diabetes mellitus to improve glycemic
control in adults.
As monotherapy- in patients inadequately contro­
lled by diet and exercise alone and for whom
metformin is inappropriate due to intolerance or
contraindicated due to renal impairment.
As combination therapy- in combination with
me tformin when diet & exercise plus metformin
alone do not provide adequate glycemic control;
- in combination with a sulphonylurea and metfo­
rmin when diet and exercise plus dual therapy
with these drugs do not provide adequate glyce­
mic control.
C/I: Hypersensitivity to the active ingredients or
to any of the excipients.
S/E: There may be hypoglycemia,
nasopharyngitis, cough and pancreatitis in
combination with metformin and sulfonylurea.
Precautions: Linagliptin should not be used in .
patients with type I diabetes or for the treatment .
of diabetic ketoacidosis.
Pregnancy & lactation: Avoid use during
pregnancy. A risk to the breast-fed child cannot
be excluded.
Dosage & admin: Usual dose is Smg once
daily. If added to metformin, the dose of met­
forn1in should be maintained and linagliptin
administered concomitantly. When used in
combination with a sulfonylurea, a lower dose
of the sulphonylurea may be considered to
reduce the risk of hypoglycemia.
Patients with renal impairment: No dose
adjustment is required. Linagliptin can be
taken with or without a meal at any time of
the day.
Drug inter: Linagliptin is a weak competitive
and a weak to moderate mechanism-based
inhibitor of CYP isozyme CYP3A4, but does not
inhibit other CYP isozymes. The risk for
clinically meaningful interactions by other
medicinal products on linagliptin is low and in
clinical studies linagliptin had no clinically
relevant effect on the pharmacokinetics of
metformin, glyburide, simvastatin, warfarin,
digoxin or oral contraceptives.
t LIJENTA S Tab. NIPRO JMI
Linagliptin INN 5mg/tablet (film-coated).
5mg x 1 O's pack: 300.00 MRP
t LINAGLIP Tab. Aristopharma
Linagliptin INN 5mg/tablet (film-coated).
5mg x 20's pack: 400.00 MRP
. .�. . .. . ;. .I'. 127
GIL.�D
.
. . ·
• • ·- ¥ • •
• • - •
SAXAGLIPTIN: Tablet (f.c)
Saxagliptin, a dipeptidyl peptidase-4 (DPP-4)
enzyme inhibitor, indicated as an adjunct or
monotherapy or in multiple therapy in the treat
ment of type 2 diabetes mellitus. It is available
as- saxagliptin hydrochloride INN 2.5mg &
5mg/tablet (film-coated).
Mode of action: Saxagliptin, as a competitive
DPP-4 enzyme inhibitor, it slows the inactivation
of the incretin hormones, and thereby increasing
their bloodstream concentrations and reducing
fasting and postprandial glucose concentrations
in a glucose.;.dependent manner i:o patients with
type 2 diabetes mellitus.
Ind: Saxagliptin is indicated as an adjunct to diet
and exercise to improve glycemic control in
adults with type 2 diabetes mellitus.
C/I: Saxagliptin is contraindicated in patients
with known hypersensitivity to this drug.
S/E: Side effects reported in 2:: 5% of patients
treated with saxagliptin are- upper respiratory
tract infection, urinary tract infection, and
headache. Peripheral edema was reported more
commonly in patients treated with the combina­
tion of saxagliptin and a thiazolidinedione (TW).
Hypoglycemia was reported more commonly in
patients treated with the combination of saxagli­
ptin & sulfonylurea. Hypersensitivity-related
events (e.g urticaria, facial edema) were reported
more commonly in patients treated with
saxagliptin. •
Precautions: Use with medications known to
ca�e·hypoglycemia: Insulin secretagogues, such
as sulfonylureas, cause hypoglycemia. Therefore,
a lower dose of the insulin secretagogue tnay be'
required to reduce the risk of hypoglycemia-when
used in combination with saxagliptin.
Macrovascular outcomes: There have been- no
clinical studies establishing conclusive evidence
of macrovascular risk reduction with saxagliptin
or any other antidiabetic drug.
Pregnancy & lactation: Pregnancy category B.
There are no adequate and well-controlled studies
in pregnant women. Saxagliptin, like other
antidiabetic medications, should be used during
pregnancy only if clearly needed.
It is not known whether saxagliptin is secreted in
human milk. Because many drugs are secreted in
human milk, caution should be exercised when
saxagliptin is administered to a nursing woman.
Dosage & admin: The recommended dose is
2.Smg or Smg once daily taken regardless of
meals.
Patients with renal impairment: No dosage
adjustment is recommended for patients with
mild renal impairment (creatinine clearance
:=:: SOml/min). The dose is 2.Smg once daily for
patients with moderate or severe renal impair­
ment, or with end-stage renal disease (ESRD)
requiring hemodialysis (creatinine clearance
� SOml/min). Saxagliptin should be adminis­
tered following hemodialysis. Saxagliptin has
not been studied in patients undergoing
peritoneal dialysis. Because the dose of
saxagliptin should be limited to 2.Smg based
•
upon renal function. Assessment of renal
function is recommended prior to initiation of
saxagliptin and periodically thereafter.
Overdose: In a controlled clinical trial, oce-daily,
orally-administered saxagliptin in healthy sub-

jects at doses up to 400mg daily for 2 weeks (80
times the MRHD) had no dose related clinical
adverse reactions and no clinically meaningful
effect on QTc interval or heart rate.
Drug inter: Dosage adjustment of saxagliptin is
not recommended in case of rifampin, diltiazem,
amprenavir, aprepitant, erythromycin, flucona­
zole, fosamprenavir, grapefruit juice, and
verapamil. The dose of saxagliptin should be
limited to 2.5mg when coadministered with
ketoconazole, atazanavir, clarithromycin,
indinavir, itraconazole, nefazodone, nelfmavir,
ritonavir, saquinavir and telithromycin.
t GLYZA 2.S Tab. lbn Sina
Saxagliptin hydrochloride INN 2.5mg/tablet
(film-coated)
2.5mg x 30's pack: 900.00 MRP
t GLYZA S Tab. lbn Sina
Saxagliptin hydrochloride INN 5mg/tablet
(film-coated)
5mg x 30's pack: 1500.00 MRP
�
-
- Sitagliptin
SITAGLIPTIN26
SITAGLIPTIN: Tablet
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4)
inhibitor, indicated as an adjunct or monotherapy
or in multiple therapy in the treatment of type 2
diabetes mellitus. It is available as sitagliptin
phosphate INN equivalent to sitagliptin 25mg &
l OOmg/tablet.
Mode of action: See above under the text of
linagliptin.
Ind: Sitagliptin is indicated in the treatment of
type 2 diabetes mellitus to improve glycemic
control in adults.
As monotherapy- in patients inadequately contro­
lled by diet and exercise alone and for whom
metformin is inappropriate due to intolerance or
contraindicated due to renal impairment.
As combination therapy- in combination with
QIMP-17 (188)
metformin, sulfonylurea or thiazolidinediones
when diet and exercise plus the single agent does
not result in adequate glycemic control.
C/I: Hypersensitivity reactions such as anaphy­
laxis, angioedema and exfoliative skin conditions
including Stevens-Johnson syndrome can occur.
S/E: Adverse reactions like upper respiratory
tract infection, nasopharyngitis, and headache can
occur. Hypoglycemia occurs in patients treated
with the combination of sitagliptin and
sulfonylurea, with or without metformin.
Precautions: Dosage adjustment is recommen­
ded in patients with moderate or severe renal
insufficiency and in patients with ESRD. When
used with a sulfonylurea a lower dose of
sulfonylurea may be required to reduce the risk
of hypoglycemia
Pregnancy & lactation: Safety in pregnant
women has not been established. Sitagliptin
should be used during pregnancy only if the
potential benefit justifies the potential risk of the
fetus. It is not known whether sitagliptin is
secreted in human milk, so, it should not be
administered to a breast feeding woman.
Dosage & admin: The recommended dose of
sitagliptin is 1 OOmg once daily. Sitagliptin can
be taken with or without food.
For patients with mild renal insufficiency
(creatinine clearance (CrCI) >SOml/min), no
dosage adjustment is required.
For patients with moderate renal insufficiency
(CrCI >30 to <SOml/min women), the dose of
sitagliptin is SOmg once daily.
For patients with severe renal insufficiency
(CrCl <30ml/min) or with end-stage renal
disease (ESRD) requiring hemodialysis or
peritoneal dialysis, the dose of sitagliptin is
2Smg once daily.
Children: Safety and effectiveness of sitagliptin
in pediatric patients under 18 years of age
have not been established.
Drug inter: There was a slight increase in the
area under the curve & mean peak drug concen­
tration of digoxin with the co-administration of
1 OOmg sitagliptin for 10 days.
.9"-nu
� �,;;;;i;"L$
SLIPTI N
Sitagliptin INN 25rilg, 50mg & 100mg Tablet
-
-
•
t GLIPITA Tab. Beximco
Sitagliptin phosphate INN equivalent to
sitagliptin 50mg & 1 OOmg/tablet.
50mg x l O's pack: 240.00 IP
lOOmg x lO's pack: 470.00 IP
t JANVIA Tab. Acme
Sitagliptin phosphate INN equivalent to
sitagliptin 50mg & 1OOmg/tablet.
50mg x lO's pack: 150.00 MRP
l OOmg x l O's pack: 280.00 MRP
t SGN Tab. Pacific
Sitagliptin phosphate INN equivalent to
sitagliptin 50mg & l OOmg/tablet.
50mg x l O's pack: 200.00 MRP
lOOmg x l O's pack: 350.00 MRP
t SIGLITA Tab. Square
Sitagliptin phosphate INN equivalent to
sitagliptin 50mg & 1OOmg/tablet.
50mg x lO's pack: 180.00 MRP
1 OOmg x 1O's pack: 300.00 MRP
t SIG'fIL Tab. White Horse
Sitagliptin phosphate INN equivalent to
sitagliptin 50mg/tablet.
50mg x 20's pack: 300.00 MRP
t SITAGIL Tab. lncepta
Sitagliptin phosphate INN equivalent to
sitagliptin 25mg, 50mg & 1OOmg/tablet.
25mg x 1 O's pack: 80.00 MRP
50mg x l O's pack: 150.00 MRP
l OOmg x lO's pack: 280.00 MRP
t SLIPTIN Tab. Dru� Inter.
Sitagliptin phosphate INN equivalent to
sitagliptin 25mg, 50mg & 1 OOmg/tablet.
25mg x 30's pack: 240.00 MRP
50mg x 20's pack: 300.00 MRP
l OOmg x IO's pack: 280.00 MRP
•••
LT1>. www.squarepharmacom.bd
•••
•••
9QUAM
-

VILDAGLIPTlN 54• 130
VILDAGLIPTIN: Tablet (f.c)
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4)
inhibitor, indicated as an adjunct or monotherapy
or in multiple therapy in the treatment of type 2
diabetes mellitus. It is available as- vildagliptin
INN 50mg/tablet (film-coated).
Mode of action: See above under the text of
linagliptin.
Vildagliptin when given in patients not adequate­
ly controlled on metformin alone, it complements
the efficacy of metformin by addressing both islet
dysfunction and insulin resistance, & causes
further reduction in HbAlc.
Vildagliptin when given in patients not
adequately controlled on a sulfonylurea (SU)
alone, it delivers significant additional efficacy
and safety and significant reduction in HbA1c.
Vildagliptin when given in patients not adequate­
ly controlled on a thiazolidinedione (TZD) alone,
it delivers breakthrough efficacy in reduction of
. '
HbA1 c as add-on at 24 weeks even in patients
with high-baseline A1c.
Vildagliptin when given in patients not adequate­
ly controlled on insulin alone, vildagliptin and
insulin combinedly produce a greater HbA1c
reduction. Hypoglycemic events are significantly
less common and less severe with vildagliptin as
add-on to insulin than insulin alone.
Ind: Vildagliptin is indicated as an adjunct to diet
and exercise to improve glycaemic control in
patients with type 2 diabetes mellitus. It is indi­
cated as monotherapy and in dual combination
with metformin, or a sulphonylurea, or a
thiazolidinedione, or with insulin when diet,
exercise and a single antidiabetic agent do not
result in adequate glycemic control.
C/I: It is contraindicated for patients with diabe­
tic ketoacidosis; hepatic impairment; moderate or
severe renal impairment, or in patients with End
Stage Renal disease on haemodialysis.
Hypersensitivity to vildagliptin or to any of the
excipients.
S/E: Monotherapy: Common- dizziness; uncom­
mon- constipation, headache, peripheral oedema.
Combination with metformin: Common- headache,
tremor, dizziness.
Combination with a su/phonylurea: Common­
headache, tremor, dizziness, asthenia.
Combination with a thiazolidinedion: Common­
weight increase, peripheral oedema; uncommon­
headache.
Combination with insulin: Common- decreased
blood glucose, headache, nausea, flatulence,
gastroesophageal reflux disease.
Post-marketing experience: Urticaria.
Rare cases of angioedema; rare cases of hepatic
dysfunction (including hepatitis).
Precaution: Caution should be excercised for
elderly patients. It should be used with caution in
patients with impaired hepatic function and heart
failure.
Pregnancy & lactation: Vildagliptin should not
I
QIMP-17 (189)
be used unless the potential benefit jusfies the
potential risk to the foetus.
Breast-feeding: Should not be used.
Dosage & admin: Adult over 18 years: The
usual dose of vildagliptin is 50mg once daily or
1 OOmg daily in two divided doses in
monotherapy. In dual combination with
metformia, or a thiazolidinedione, or insulin
50mg twice daily; in combination with a
sulphonylurea, 50mg daily in the morning. Or,
as directed by the physician.
Drug inter: No clinically relevant interactions
with other oral antidiabetics (glibenclamide,
pioglitazone, metformin), amlodipine, digoxin,
ramipril, simvastatin, valsartan or warfarin were
observed after co-administration with vildagliptin.
ialiptin
Vildagliptin INN 50mg Tablet
+DIALIPTIN Tab. Drug Inter.
Vildagliptin INN 50mg/tablet (film-coated).
50mg x 20's pack: 300.00 MRP
+GALET Tab. White Horse
Vildagliptin INN 50mg/tablet (film-coated).
50mg x 20's pack: 300.00 MRP
+GALVAN Tab. Aristopharma
Vildagliptin INN 50mg/tablet (film-coated).
50mg x 20's pack: 400.00 MRP
+GALVUS Tab. Novartis
Vildagliptin INN 50mg/tablet (film-coated).
50mg x 28's pack: 784.00 MRP
+ VIDA 50 Tab. Pacific
Vildagliptin INN 50mg/tablet (film-coated).
50mg x 20's pack: 400.00 MRP
+ VIGLITA SO Tab. Square
Vildagliptin INN 50mg/tablet (film-coated).
50mg x 20's pack: 400.00 MRP
+ VILDAGIL Tab. Sharif
Vildagliptin INN 50mg/tablet (film-coated).
50mg x 20's pack: 360.00 MRP
+VILDUS Tab. Opsonin
Vildagliptin INN 50mg/tablet (film-coated).
50mg x 20's pack: 351.88 MRP
+VIPTIN Tab. General
Vildagliptin INN 50mg/tablet (film-coated).
50mg x 30's pack: 450.00 MRP
Meglitinide Analogues
NATE.GLINIDE54•86
NATEGLINIDE: Tablet
Nateglinide is an oral blood glucose-lowering
drug belonging to a new class of insulinotropic
agents called meglitinide analog (a
carbamomethyl benzoic acid- CMBA derivative).
Ind: Treatment of patients with Type-2 diabetes,
.9"- '-'H
Id] ��c.us
•
whose hyperglycaemia can not be controlled by
diet and physical exercise. Nateglinide can be
used as monotherapy or in combination with
other oral antidiabetic agents with a
complementary mode of action, such as
metformin and troglitazone.
C/I: Hypersensitivity to nateglinide or to any of
the excipients, Type- I diabetes, diabetic
ketoacidosis; pregnancy and lactation.
S/E: Hypoglycaemia; rare cases of elevations in
liver enzymes and hypersensitivity reactions.
Precautions & Warnings: Hypoglycaemia has
been observed in patients with Type-2 diabetes
on diet and exercise, and in those treated with
oral antidiabetic agents. Elderly, malnourished
patients and those with adrenal or pituitary
insufficiency are more susceptible to the glucose
lowering effect of these treatments. The risk of
hypoglycaemia in Type-2 diabetic patients may
be increased by strenuous physical exercise, or
ingestion of alcohol. Combination with other oral
antidiabetic agents may increase the risk of
hypoglycaemia. Hypoglycaemia may be difficult
to recognise in subjects receiving blockers.
Pregnancy & lactation: Nateglinide is not
recommended during pregnancy and lactation, so,
a suitable treatment schedule should be
prescribed with insulin.
Dosage: The usual dose is 120mg before main
meals.
Drug inter: The hypoglycaemic action of oral
antidiabetic agents may be potentiated by certain
drugs, including non-steroidal anti-inflammatory
agents, salicylates, monoamine oxidase inhib­
itors, and non-selective adrenergic- blocking
agents. The hypoglycaemic action of oral
antidiabetic agents may be reduced by certain
drugs, including thiazides, corticosteroids,
thyroid products and sympathomimetics.
Note: Before prescribing, please consult full
prescribing information.
+STARLIX Tab. Novartis
Nateglinide 120mg/tablet.
84's pack: 2352.00 MRP
REPAGLINIDE26•86
REPAGLINIDE: Tablet
Repaglinide is an oral blood glucose-lowering
drug belonging to a new class of insulinotropic
agents (secretagogue) called meglitinide analog
(a carbamomethyl benzoic acid- CMBA
derivative). It is used in the management of Type
2 diabetes mellitus (NIDDM).
Mode of action: In Type 2 diabetes, the charac­
teristic defect is 'failure of mealtime insulin
response, which is usually slow and insufficient'.
When repaglinide is taken prior to meals, it rapi­
dly corrects mealtime insulin secretion abnor-
•••
LTD. www.squarepharma.com.bd •••
•••
.......
 ® QIMP-17 (190)
uretor o.s,1&2
malities in Type 2 diabetes (NIDDM) and causes
disposal of the mealtime glucose load.
Repaglinide, as selectively stimulates insulin
secretion in response to high glucose level in the
prandial phase, which in turn controls blood glu­
cose peaks- called 'prandial glucose regulation
(PGR)'- is a novel concept in NIDDM manage­
ment. Repaglinide does not stimulate insulin
release from the beta cells in the post-prandial
fasting period i.e in the absence of ex�ess glu­
cose. After oral administration, repaglinide is
rapidly and completely absorbed from the gut - as
the serum concentration increases, its rapid onset
and relatively short duration of action on -cells
the plasma insulin level rises immediately and
usually returns to baseline before the next meal­
time. Rapid elimination ensures that post-prandial
insulin levels quickly returns to pre-prandial
levels as the high prandial glucose level subsides.
Repaglinide allows the pancreas of a person with
NIDDM to respond to meal-related increase in
blood glucose level in a similar manner of the
pancreas of a healthy person without diabetes.
Ind: Repaglinide is indicated in Type 2 diabetes
mellitus (NIDDM) as monotherapy with diet and
exercise (whose hyperglycaemia cannot be con­
trolled satisfactorily by diet and exercise alone);
or in combination with metform in overweight
patients (whose hyperglycaemia cannot be
controlled by either repaglinide or metformin
alone even in conjunction with diet & exercise).
C/I: Known hypersensitivity to the drug or its
excipients; Type 1 diabetes mellitus; diabetic
ketoacidosis, with or without coma; severe renal
or hepatic impairment; pregnancy and breast­
feeding.
S/E: Gastrointestinal side-effects include­
abdominal pain, diarrhoea, constipation, nausea
and vomiting. Hypersensitivity reactions include
rashes and urticaria. Other side-effects may
include- elevated liver enzymes, paresthesia,
chest pain, upper respiratory tract infections,
urinary tract infections & tooth disorder.
Precautions & warnings: Use with caution in
impaired hepatic function. Sa.fety and efficacy
have not been established in children. Substitute
insulin during intercurrent illness such as,
myocardial infarction, coma, infection, trauma,
surgical intervention & renal impairment. All oral
blood glucose lowering drugs are capable of
producing hypoglycaemia so, repaglinide should
be administered with meals to lessen the risk of
hypoglycaemia.
Pregnancy & lactation: Repaglinide is not
recommended during pregnancy and lactation, so,
a suitable treatment schedule should be
prescribed with insulin.
Dosage & Admin: Initially O.Smg to lmg
within 30 minutes before main meals, adjusted
according to response at intervals of 1-2
weeks; upto 4mg may be given as a single
dose, maximum 16mg daily. Patients who skip
a meal (or add an extra meal) should be
instructed to skip (or add) a dose for that meal
Drug inter: Repaglinide metabolism may be
inhibited by antifungal agents like ketoconazole
•
& miconazole, and antibacterial agents like
erythromycin, clarithromycin & azithromycin;
may be increased by troglitazone, rifampicin,
barbiturates & carbamazepine. Highly protein­
bound drugs (e.g NSAIDs) may increase the
plasma level of unbound repaglinide & potentiate
its glucose lowering effect. Thus concurrent
administration of these drugs with repaglinide
may increase the risk of hypoglycaemia.
Concomitant administration with salicylates, sul­
fonamides, chloramphenicol, probenecid, monoa­
mine oxidase (MAO) inhibitors, and adrenergic
blockers may increase the risk of hypoglycaemia.
+ GLIME T Tab. Drug Inter.
Repaglinide INN Img/tablet.
l mg x 50's pack: 150.00 MRP
+ GLURE TOR Tab. Pacific
Repaglinide INN 0.5mg, l mg & 2mg/tablet.
0.5mg x 30's pack: 84.00 MRP
l mg x 30's pack: 120.00 MRP
2mg x 30's pack: 180.00 MRP
+ NOMOPIL Tab. Incepta
Repaglinide INN 0.5mg, 1 mg & 2mg/tablet.
0.5mg x IOO's pack: 200.00 MRP
l mg x l OO's pack: 300.00 MRP
2mg x 50's pack: 250.00 MRP
+ PRANDIL-1 Tab. UniMed & UniHealth
Repaglinide INN l m g/tablet.
l mg x 30's pack: 90.00 MRP
+ PRIFID-1 Tab. White Horse
Repaglinide INN l mg/tablet.
l mg x 50's pack: 150.00 MRP
+ PREMIL Tab. Beximco
Repaglinide INN 0.5mg, 1mg & 2mg/tablet.
0.5mg x 30's pack: 60.00 IP
l mg x 30's pack: 90.00 IP
2mg x 30's pack: 150.00 IP
+ REPAGLID Tab. Alco Pharma
Repaglinide INN 1 mg & 2mg/tablet.
l mg x 30's pack: 90.00 MRP
2mg x 30's pack: 150.00 MRP
+ REPANID Ta�. Opsonin
Repaglinide INN 0.5mg, l mg & 2mg/tablet.
0.5mg x 30's pack: 53.05 MRP
I mg x 30's pack: 79.43 MRP
2mg x 30's pack: 132.48 MRP
t SINGLIN Tab. Renata
Repaglinide INN 0.5mg, l mg & 2mg/tablet.
0.5mg x 1OO's pack: 200.00 MRP
l mg x IOO's pack: 300.00 MRP
2mg x 50's pack: 250.00 MRP
Thiazolidinedione Group
•I�IlAZONE21,26,86
PIOGLITAZONE: Tablet
Pioglitazone is a newer oral antidiabetic agent,
belonging to the thiazolidinedione group. It
improves insulin sensitivity by decreasing insulin
resistance in patients with Type 2 diabetes
mellitus. It is available as pioglitazone hydro­
chloride INN 15mg & 30mg tablet.
Mode of action: In Type 2 diabetes mellitus
(NIDDM), where the cause of diabetes is the
development of insulin resistance in the periph­
ery and in the liver- pioglitazone decreases
insulin resistance in the peripheral tissues (skele-
tal muscle & adipose tissue) and in the liver- as it
is a potent and highly selective agonist for 'pero­
xisome proliferator activated receptor gamma
(PPAR )', activation of PPAR nuclear receptors
•
modulates the transcription of a number of insu-
lin responsive genes involved in the control of
glucose and lipid metabolism. Thus, pioglitazone
improves insulin sensitivity in muscles & adipose
tissues and inhibits hepatic gluconeogenesis.
Ind: Pioglitazone is indicated in patients with
Type 2 diabetes mellitus (NIDDM) as an adjunct
to diet & exercise to bring glycaemic control. It
may be used alone or in conjunction with insulin,
metformin (in obese patients), or a sulfonylurea
when diet & exercise plus the single agent does
not bring satisfactory glycaemic control.
C/I: Pioglitazone is contraindicated in liver
disease, heart disease; Type 1 diabetes mellitus
(insulin-dependent diabetes) and diabetic
ketoacidosis. It should not be given to patients
who have a serious infection, illness, injury or
need surgery. Known hypersensitivity to this
product or any of its components.
S/E: The most common adverse experiences with
pioglitazone therapy are upper respiratory tract
infection, injury, and headache. Other adverse
events reported in controlled clinical studies
include- myalgia (5.4%), tooth disorder (5.3%),
diabetes mellitus aggravated (5.1 %) and pharyn
gitis (5.1%), respectively. In other monotherapy
studies, edema was reported for 4.8% (with doses
from 7 .5 mg to 45mg) of patients treated with
pioglitazone.
Warnings & precautions: Use cautiously in
patients with oedema. If a patient misses a dose,
he has to take the missed dose as soon as he
remembers. If he does not remember until the
next day, should skip the dose he missed and take
only his next regularly scheduled dose but should
not take double dose. Follow the diet, medication
and exercise routines very closely. Use carefully
with other drugs and during taking alcohol.
Hyperglycaemia may occur if one does not take
adequate or skip a dose of drug.
Pregnancy & lactation: Pioglitazone is not
recommended during pregnancy and lactation, so,
a suitable treatment schedule should be
prescribed with insulin.
Dosage & admin: The dose of pioglitazone will
be different in different conditions.
Pioglitazone alone: Adults- at frrst, the dose is
15 or 30mg once daily; it may be increased
later up to 4Smg once daily. Children- dose
must be determined by the physician.
Pioglitazone with insulin, metformin or sulfon­
ylurea: Adults & children- dose is a.s same as
pioglitazone alone. Pioglitazone may be taken
with or without food by a full glass of water.
Drug inter: Use of ketoconazole with pioglita­
zone may decrease the effect of pioglitazone. Co­ -
administration of pioglitazone and an oral contra­
ceptive resulted in decrease in ethinyl estradiol
plasma concentrations. There were no significant
changes in norethindrone AUC (0-24h) and
cmax. In other drug-drug interaction studies,
pioglitazone had no significant effect on the
pharmacokinetics of fexofenadine, metformin,
digoxin, warfarin, ranitidine, or theophylline.
•
+ ACTOSE Tab. UniMed & UniHealth
Pioglitazone hydrochloride INN 15mg &

30mg/tablet.
15mg x 30's pack: 240.00 MRP
30mg x 20's pack: 300.00 MRP
+ ADPAS Tab. General
Pioglitazone hydrochlorideINN l 5mg/tablet.
15mg x 30's pack: 240.90 MRP
t DIAGLIT Tab. Beximco
Pioglitazone hydrochloride INN l 5mg &
30mg/tablet.
15mg x 30's pack: 240.00 IP
30mg x 30's pack: 450.00 IP
t DIATAG Tab. ACI
Pioglitazone hydrochloride INN l 5mg, 30mg &
45mg/tablet.
l 5mg x 30's pack: 240.90MRP
30mg x 30's pack: 450.00 MRP
45mg x 30's pack: 540.00 MRP
t DIAT US Tab. Navana
Pioglitazone hydrochloride INN l 5mg &
30mg/tablet.
15mg x 30's pack: 240.00 MRP
30mg x 30's pack: 450.00 MRP
t GLI TAZON Tab. lbn Sina
Pioglitazone hydrochloride INN l 5mg/tablet.
15mg x 30's pack: 240.00 IP
t GLUCOZON Tab. Aristopharma
Pioglitazone hydrochloride INN l 5mg &
30mg/tablet.
15mg x 30's pack: 240.00 MRP
30mg x 20's pack: 300.00 MRP
+ LIT Tab. White Horse
Pioglitazone hydrochloride INN 15mg &
30mg/tablet.
15mg x 30's pack: 240.00 MRP
30mg x 30's pack: 360.00 MRP
t OGLI Tab. Kemiko
Pioglitazone hydrochloride INN l 5mg &
30mg/tablet.
15mg x 30's pack: 240.00 MRP
30mg x 20's pack: 240.00 MRP
t PEEGEE Tab. Jayson
Pioglitazone hydrochloride INN l 5mg &
30mg/tablet.
15mg x 30's pack: 180.60 IP
30mg x 30's pack: 301.20 IP
t PGT-15 Tab. CPL
Pioglitazone hydrochloride l 5mg/tablet.
l 5mg x 30's pack: 240.00 MRP
t PIDUS Tab. Acme
Pioglitazone hy_drochloride INN l 5mg/tablet.
l 5mg x 30's pack: 241.20 MRP
t PIGLIT Tab. Pacific
Pioglitazone hydrochloride INN l 5mg &
30mg/tablet.
15mg x 30's pack: 240.00 MRP
30mg x 30's pack: 360.00 MRP
t PIGZON Tab. Sharif
Pioglitazone hydrochloride l 5mg & 30mg/tablet.
15mg x 30's pack: 240.00 MRP
30mg x 20's pack: 300.00 MRP
t PIODAR Tab. Incepta
Pioglitazone hydrochloride INN 15mg &
30mg/tablet.
15mg x 30's pack: 240.00 MRP
30mg x 30's pack: 450.00 MRP
t PIOGLIN Tab. Renata
Pioglitazone hydrochloride INN l 5mg &
30mg/tablet (film coated).
15mg x 30's pack: 240.90 MRP
30mg x lO's pack: 150.50 MRP
QIMP-17 (191)
t PIOL Tab. Opsonin
Pioglitazone hydrochloride INN 15mg &
30mg/tablet (film coated).
15mg x 30's pack: 211.92 MRP
30mg x 20's pack: 264.97 MRP
t PIOLIT Tab. Alco Pharma
Pioglitazone hydrochloride INN l 5mg/tablet.
15mg x 30's pack: 240.00 MRP
t PIOZENA Tab. Drug Inter.
Pioglitazone hydrochloride INN l 5mg &
30mg/tablet.
15mg x 50's pack: 400.00 MRP
30mg x 30's pack: 390.00 MRP
+ SAGLIT Tab. Sanofi-aventis
Pioglitazone hydrochloride INN 15mg &
30mg/tablet.
15mg x 30's pack: 240.90 MRP
30mg x 20's pack: 301.19 MRP
+ TOS Tab. Square
Pioglitazone hydrochloride INN l 5mg &
30mg/tablet.
15mg x 30's pack: 241.20 MRP
30mg x 30's pack: 450.00 MRP
ROSIGLITAZONE26,42,86
ROSIGLITAZONE: Tablet
Rosiglitazone is a newer oral antidiabetic agent,
belonging to the thiazolidinedione group. It
improves insulin sensitivity by decreasing insulin
resistance in patients with Type 2 diabetes
mellitus. It is available as rosiglitazone maleate
INN 2mg & 4mg tablet.
Mode of action: See above under the text of
pioglitazone.
Ind: 1. Rosiglitazone is indicated as
monotherapy as an adjunct to diet & exercise to
improve glycemic control in type-2 diabates.
2. In combination with a sulfonylurea,
repaglinide, metformin, acarbose, or insulin when
diet, exercise and single agent do not result in
adequate glycemic control.
3. In combination with- i. Sulfonylurea or
repaglinide plus metformin ii. Sulfonylurea or
repaglinide plus acarbose iii. Sulfonylurea or
repaglinide plus insulin, when diet, exercise &
2-drug regimen do not result in adequate
glycemic control.
C/I: See above under the text of pioglitazone.
S/E: Gastrointestinal disturbances, headache,
dizziness, edema, anemia, & weight gain occur
which are usually mild to moderate in severity &
generally do not require discontinuation of
treatment with rosiglitazone.
Precaution: See above under the text of
pioglitazone. Monitoring of liver functions before
treatment should be done in all patients &
periodically thereafter.
Pregnancy & lactation: Rosiglitazone is not
recommended during pregnancy and lactation, so,
a suitable treatment schedule should be
prescribed with insulin.
Dosage & admin: The management of antidia­
betic therapy should be individualized.
Monotherapy: Rosiglitazone may be adminis­
tered either at a starting dose of 4mg as a
single daily dose or divided as 2mg twice daily
in the morning and evening. For patients who
respond inadequately following 8-12 weeks of
treatment, as determined by reduction in fast
.
Vildag·liR!fn Tablet
. .
ing plasma glucose (FPG), the dose may be
increased to maximum of 8mg daily as a single
dose or divided (twice daily) as monotherapy;
or may be given in combination with any other
insulin secretor or sensitizer or insulin, or any
other 2-drug (antidiabetic) regimen.
Rosiglitazone may be taken with or without
food.
Combination therapy: When rosiglitazone is
added to exiting therapy, the current dose of
the agent can be continued upon initiation of
rosiglitazone therapy.
Sulfonylurea: When used in combination with
sulfonylurea, rosiglitazone may be adminis­
tered either at a starting dose of 4mg as a
single daily dose or divided as 2mg twice daily.
While giving with an insulin secretagogue, the
dose of sulfonylurea should be decreased if
patients report hyperglycemia.
Metformin: When used in combination with
metformin, rosiglitazone may be administered
either at a starting dose of 4mg as a single
daily dose or divided as 2mg twice daily. It is
unlikely that the dose of metf ormin will
require adjustment due to hypoglycemia dur­
ing combination therapy with rosiglitazone.
Insulin: Dose of rosiglitazone greater than
4mg daily in combination with insulin are not
currently indicated. It is rcommended that the
insulin dose be decreased by 10-25o/o if the
patients report hypoglycemia or if FPG conce­
ntration decrease to less than lOOmg/dl.
Further adjustments should be individualized
based on glucose-lowering response.
No dosage adjusment is required when
rosiglitazone is used as monotherapy in
patients with renal impairment.
Use in children: The safety & effectiveness of
rosiglitazone in pediatric patients under 18
years have not been established.
Drug inter: A decrease in the dose of rosiglita­
zone may be needed when gemfibrozil is intro­
duced. Dosage adjustment is also required when
administered with rifampicin. It was shown to
have no clinically relevant effect on the pharma­
cokinetics of nifedipine & oral contraceptives.
t ROGLIT 4 Tab. Pacific
Rosiglitazone maleate INN 4mg/tablet (f.c)
4mg x 30's pack: 240.00 MRP
t ROMEROL Tab. Drug Inter.
Rosiglitazone maleate INN 2mg & 4mg/tablet (f.c)
2mg x 50's pack: 250.00 MRP
4mg x 30's pack: 240.00 MRP
t TAZON-4 Tab. Kemiko
Rosiglitazone maleate INN 4mg/tablet (f.c).
4mg x 30's pack: 240.00 MRP
Combination preparations
GLIMEPIRIDE + PIOGLITAZONE: Tablet
This is a combination of two antihyperglycemic

,._,
�-...... - !!Jii!i!;
��
· � i!iii �
� ii �
illo oor.IA ...��
agents, in which glimepiride is a member of
second generation sulfonylurea and pioglitazone
hydrochloride is a member of the
thiazolidinedione group of other antidiabetics.
The combination preparations of glimepiride and
pioglitazone are available in two fixed presenta­
tions viz: i. Glimepiride 2mg + pioglitazone
30mg; ii. Glimepiride 4mg + pioglitazone 30mg.
Mode of action: See above under the text of
glimepiride & pioglitazone given separately.
Ind: This combination is indicated as an adjunct
to diet and exercise to improve glycemic control
in patients with type 2 diabetes who are already
treated with a combination of pioglitazone and
sulfonylurea as separate tablet or who are not
adequately controlled on a sulfonylurea alone or
for those patients who have initially responded to
pioglitazone alone and require additional
glycemic control.
C/I: Known hypersensitivity to any of· the com­
ponents of the combination. Diabetic ketoacido­
sis, with or without coma, this condition should
be treated with insulin.
S/E: See above under the text of glimepiride &
pioglitazone given separately.
Precautions & warnings: General: Due to the
mechanisms of action, pioglitazone is active only
in the presence of endogenous insulin. Therefore,
combination of pioglitazone and glimepiride
should not be used in patients with type 1 dia­
betes or for the treatment of diabetic ketoacido­
sis. Hypoglycemia: All sulfonylurea drugs are
capable of producing severe hypoglycemia.
Proper patient selection, dosage, and instructions
are important to avoid hypoglycemic episodes.
Elderly patients are particularly susceptible to
hypoglycemic action of glucose lowering drugs.
Debilitated or malnourished patients and those
with adrenal, pituitary, renal, or hepatic insuffi­
ciency are particularly susceptible to the hypo­
glycemic action of glucose lowering drugs. Loss
of control ofblood glucose: When a patient stabi
lized on any antidiabetic regimen is exposed to
stress such as fever, trauma, infection, or surgery,
a temporary loss of glycemic control may occur.
At such times, it may be necessary to withhold
combination of pioglitazone and glimepiride and
temporarily administer insulin. Combination of
pioglitazone and glimepiride may be reinstituted
after the acute episode is resolved. Edema:
Combination of pioglitazone and glimepiride
should be used with caution in patients with
edema. Since thiazolidinediones, including
pioglitazone can cause fluid retention, which can
exacerbate or lead to congestive heart failure,
combination of pioglitazone and glimepiride
should be used with caution in patients at risk for
heart failure. Weight gain: Dose-related weight
gain was seen with pioglitazone alone and in
combination with other hypoglycemic agents.
The mechanism of weight gain is unclear but
probably involves a combination of fluid reten­
tion and fat accumulation. Hepatic Effects: Liver
enzymes should be checked prior to the initiation
of therapy with combination of pioglitazone and
glimepiride in all patients and periodically there-
QIMP-17 (192)
after per the clinical judgment of the healthcare
professional. Therapy with combination of piogli­
tazone and glimepiride should not be initiated in
patients with increased baseline liver enzyme lev­
els (ALT >2.5 x upper limit of normal). If at any
time ALT levels increase to >3 x the upper limit
of normal in patients on therapy with combina­
tion of pioglitazone and glimepiride, liver
enzyme levels should be rechecked as soon as
possible. If ALT levels remain >3 x the upper
limit of normal, therapy with combination of
pioglitazone and glimepiride should be disconti­
nued. If any patient develops symptoms
suggesting hepatic dysfunction, which may
include unexplained nausea, vomiting, abdominal
pain, fatigue, and anorexia, and/or dark urine,
liver enzymes should be checked.
Pregnancy & lactation: This combination is not
recommended during pregnancy & lactation, so,
a suitable treatment schedule should be
prescribed with insulin.
Dosage & admin: Selecting the starting dose of
this combination should be based on the
patient's current regimen of pioglitazone
and/or sulfonylurea. T hose patients who may
be more sensitive to antihyperglycemic drugs
should be monitored carefully during dose
adjustment. It is recommended that a single
dose of this combined product can be adminis­
tered once daily with the first main meal.
Starting dose for patients currently on
Glimepiride monotherapy:
Based on the usual starting dose of
pioglitazone (15 mg or 30mg daily), this
combined product may be initiated at
2mg/30mg or 4mg/30mg tablet strengths once
daily, and adjusted after assessing adequacy of
therapeutic response.
Starting dose for patients currendy on
Pioglitazone monotherapy:
Based on the usual starting doses of
Glimepiride (lmg or 2mg once daily), and
pioglitazone 15mg or 30mg, this combined
product may be initiated at 2mg/30mg once
daily, and adjusted after assessing adequacy of
therapeutic response.
Starting dose for patients switching from
combination therapy of glimepiride plus
pioglitazone as separate tablets:
This combined product may be initiated with
2mg/30mg or 4mg/30mg tablet strengths based
on the dose of glimepiride and pioglitazone
already being taken. Patients who are not con­
trolled with 15mg of pioglitazone in combina­
tion with glimepiride should be carefully moni­
tored when switched to this combined product.
Starting dose for patients currently on a
different sulfonylurea monotherapy or
switching from combination therapy of
pioglitazone plus a different sulf onylurea:
No exact dosage relationship exists between
glimepiride and the other sulfonylurea agents.
Therefore, based on the maximum starting
dose of 2mg glimepiride, this combined
product should be limited initially to a starting
dose of 2mg/30mg once daily, & adjusted after
assessing adequacy of therapeutic response.
Pediatric patients: Safety and effectiveness of
this combination in pediatric patients have not
been established.
Drug inter: See above under the text of
glimepiride & pioglitazone given separately.
•
•
+ DIATAG Plus 2 Tab. ACI
Glimepiride INN 2mg + Pioglitazone
hydrochloride INN 30mg/tablet
30's pack: 391.50 MRP
+ DIATAG Plus 4 Tab. ACI
Glimepiride INN 4mg + Pioglitazone
hydrochloride INN 30mg/tablet
30's pack: 451.80 MRP l
,.
+ DIETA Plus 2 Tab. Pacific
Glimepiride INN 2mg + Pioglitazone
hydrochloride INN 30mg/tablet
..
20's pack: 250.00 MRP , .
+ DIETA Plus 4 Tab. Pacific
Glimepiride INN 4mg + Pioglitazone
hydrochloride INN 30mg/tablet
20's pack: 300.00 MRP
+ TOSIRIN 2 Tab. Square
Glimepiride INN 2mg + Pioglitazone
hydrochloride INN 30mg/tablet
l 5's pack: 240.00 MRP
+ TOSIRIN 4 Tab. Square
Glimepiride INN 4mg + Pioglitazone
hydrochloride INN 30mg/tablet
I S's pack: 270.00 MRP
•
•
GLIMEPIRIDE + ROSIGLITAZONE42
GLIMEPIRIDE + ROSIGLITAZONE: Tablet
This is a combination of two antihyperglycemic
agents, in which glimepiride is a member of sec­
ond generation sulfonylurea and rosiglitazone
maleate is a mernber of the thiazolidinedione
•
•
group of other antidiabetics. •
The combination preparations of glimepiride and
rosiglitazone are available in two fixed presenta­
tions viz: i. Glimepiride I mg + rosiglitazone
4mg; ii. Glimepiride 2mg + rosiglitazone 4mg
Mode of action: See above under the text of
glimepiride & rosiglitazone given separately.
Ind: This combination is indicated as an adjunct
to diet and exercise to improve glycemic control
in patients with type 2 diabetes who are already
treated with a combination of rosiglitazone and
sulfonylurea as separate tablet or who are not •
adequately controlled on a sulfonylurea alone or •
for those patients who have initially responded to
rosiglitazone alone and requ.ire additional
glycemic control.
C/I: Known hypersensitivity to glimepiride or
rosiglitazone or any of the components of
combination. Diabetic ketoacidosis, with or
without coma, this condition should be treated
with insulin.
S/E: See above under the text of glimepiride &
rosiglitazone given separately.
Precautions & warnings: See above under the
t
text of glimepiride & pioglitazone combined
product. •
Pregnancy & lactation: This combination is not
recommended during pregnancy & lactation, so,
a suitable treatment schedule should be
prescribed with insulin.
Dogage & admin: This combined preparation
should be given once daily with the first meal
of the day. The dosage of antidiabetic therapy
with this combination should be individualized
on the basis of effectiveness and tolerability.

For patients inadequately controlled on
sulfonylurea monotherapy or who have initially
responded to rosiglitazone alone and require
additional glycemic control: The usual starting
dose of glimepiride and rosiglitazone combina­
tion is l mg/4mg or 2mg/4mg once daily. When
switching from combination therapy of
glimepiride and rosiglitazone as separate
tablets, the usual starting dose is the dose of
glimepiride and rosiglitazone already being
taken. The maximum recommended daily dose
of this combination is 4mg of glimepiride and
8mg of rosiglitazone. Sufficient time should be
given to assess adequacy of therapeutic
response. Fasting glucose should be used to
determine the therapeutic response to this
combination therapy.
For patients previously treated with sulfony­
lurea monotherapy switched to this combina­
tion: It may take 2 weeks to see a reduction in
blood glucose and 2 to 3 months to see the full
effect of the rosiglitazone component. If addi­
tional glycemic control is needed, the dose of
the glimepiride component may be increased.
The dose of the rosiglitazone component
should not exceed 8mg. As with other suHony­
lurea-containing antidiabetic agents, no transi­
tion period is necessary when transferring
patients to this combination therapy. Patients
should be observed carefully (1 to 2 weeks) for
hypoglycemia when being transferred from
longer half-Iif e sulfonylureas (e.g chlorpro­
pamide) to this combination therapy due to
potential overlapping of drug effect. For
patients previously treated with th.iazolidine­
dione monotherapy switched to this combina­
tion therapy, dose titration is recommended if
patients are not adequately controlled after 1
to 2 weeks. If additional glycemic control is
needed, the daily dose of this combination may
be increased by increasing the glimepiride
component in no more than 2mg increments at
1 to 2 weeks intervals up to the maximum
recommended total daily dose of 4mg
glimepiride/8mg rosiglitazone. If hypoglycemia
occurs during up-titration of the dose or while
maintained on therapy, a dosage reduction of
the sulfonylurea component of this combina­
tion may be considered.
Drug inter: See above under the text of
glimepiride & rosiglitazone given separately.
+ GLYROS 2 Tab. Square
Glimepiride 2mg + rosiglitazone 4mg/tablet
30's pack: 331.20 MRP
+ SUGANA 1 Tab. Pacific
Glimepiride l mg + rosiglitazone 4mg/tablet
30's pack: 300.00 MRP
+ SUGANA 2 Tab. Pacific
Glimepiride 2mg + rosiglitazone 4mg/tablet
30's pack: 360.00 MRP
GLIPIZIDE + METFORMIN 86
GLIPIZIDE + METFO RMIN: Tablet
This is a combination of two antihyperglycemic
agents, in which glipizide is a sulfonylurea and
metformin is a biguanide.
The combination preparations of glipizide and
metformin are available in three fixed presenta-
QIMP-17 (193)
tions, viz: i. Glipizide 2.5mg + Metformin
hydrochloride 250mg, ii. Glipizide 2.5mg +
Metformin hydrochloride 500mg & iii. Glipizide
5mg + Metformin hydrochloride 500mg.
Mode of action: See above under the text of
glipizide & metformin given separately.
Ind: This combination is indicated as initial
therapy, as an adjunct to diet and exercise, to
improve glycemic control in patients with type 2
diabetes whose hyperglycemia cannot be
satisfactorily managed with diet and exercise
alone. It is also indicated as second line therapy
when diet, exercise and initial treatment with
glipizide or metformin do not result in adequate
glycemic control in patients with type 2 diabetes.
C/I: Severe hepatic or renal dysfunction;
congestive heart failure requiring pharmacologic
treatment; known hypersensitivity to glipizide or
metformin hydrochloride; acute or chomic
metabolic acidosis, including diabetic acidosis,
with or without coma'...
S/E: The most common side effects of this
combination are normally minor ones such as
diarrhea, nausea, vomiting, dizziness, headache
and abdominal pain which usually occur during
the first few weeks of therapy.
Precautions: In the events of severe trauma,
injuries, infectious diseases, severe renal &
hepatic impairment, myocardial infarction, coma,
high fever & surgery it may be necessary to give
insulin to maintain adequate metabolic control.
Patients receiving continuous therapy should
have an annual estimation of vitamin B 12 level.
Pregnancy & lactation: This combination is not
recommended during pregnancy & lactation, so,
a suitable treatment schedule should be
prescribed with insulin.
Dosage & admin: Initial therapy: For patients
with type 2 diabetes whose hyperglycemia can
not be satisfactorily managed with diet and
exercise alone: the recommended starting dose
of combination is 2.5mg/250mg once daily with
meal. In clinical trials of this combination as
initial therapy, there was no experience with
total daily doses greater than 1 Omg/2000mg
per day. Second line therapy: For patients not
adequately controlled on either glipizide or
metformin alone, the recommended starting
dose of this combination is 2.5mg/500mg or
5mg/500mg twice daily with the morning and
evening meals. The daily dose should be
titrated in increments of no more than
5mg/500mg up to the minimum effective dose
to achieve adequate control of blood glucose or
to a maximum dose of 20mg/2000mg per day.
Drug inter: The hypoglycemic action of glipi­
zide component may be potentiated by aspirin &
phenylbutazone, sulfonamides, chloramphenicol,
coumarins, probenecid, monoamino oxidase
inhibitors, beta-adrenergic blocking agents, H2
antagonists and oral antifungal agents like
miconazole and fluconazole. Metformin may
enhance the effects of anticoagulants, thiazides,
corticosteroids, thyroid hormones, estrogens, oral
contraceptives, phenytoin, nicotinic acid,
sympathomimetics, calcium channel blockers and
isoniazid tend to produce hyperglycemia and may
lead to loss of glycemic control.
+ MEFOGLIP 250 Tab. Incepta
Glipizide 2.5mg + metformin hydrochloride
®
I ureto r o.s,1&2
250mg/tablet (film-coated)
50's pack: 95.00 IP
+ MEFOGLIP 500 Tab. Incepta
Glipizide 2.5mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 84.00 IP
+ MEFOGLIP DS Tab. Incepta
Glipizide 5mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 111.00 MRP
+ METGLIP Tab. Pacific
Glipizide 2.5mg + metformin hydrochloride
250mg/tablet (film-coated)
50's pack: 125.00 MRP
+ METGLIP Plus Tab. Pacific
Glipizide 2.5mg + metfonnin hydrochloride
500mg/tablet (film-coated)
30's pack: 120.00 MRP
+ METGLIP DS Tab. Pacific
Glipizide 5mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 150.00 MRP
PIOGLITAZONE + METFORMJN42
PIOGLITAZONE + METFO RMIN: Tablet
This is a combination of two antihyperglycemic
agents, in which metformin is a biguanide and
pioglitazone is a member of the thiazolidinedione
group of other antidiabetics.
The combination preparations of pioglitazone and
metformin are available as tablet in two fixed
presentations, viz: i. Pioglitazone hydrochloride
15mg + Metformin hydrochloride BP 500mg; ii.
Pioglitazone hydrochloride 15mg + Metformin
hydrochloride BP 850mg.
Mode of action: See above under the text of
pioglitazone and metformin given separately.
Ind: This combination is indicated as an adjunct
to diet and exercise to improve glycemic control
in patients with type 2 diabetes- i. who are
already treated with a combination of pioglita­
zone and metformin as separate tablets, or ii.
whose diabetes is not adequately controlled with
metformin alone, or iii. for those patients who
have initially responded to pioglitazone alone and
require additional glycemic control.
C/I: Combination of pioglitazone and metformin
is contraindicated in patients with: i. Renal
disease or renal dysfunction [e.g, as suggested by
serum creatinine levels >l .5mg/dl (males),>
l .4mg/dl (females), or abnormal creatinine clear­
ance] which may also result from conditions such
as cardiovascular collapse (shock), acute myocar­
dial infarction, and septicemia; ii. Known hyper­
sensitivity to pioglitazone, metformin or any
other component of the combination; iii. Acute or
chronic metabolic acidosis, including diabetic
ketoacidosis, with or without coma. Diabetic
ketoacidosis should be treated with insulin.
Combination of pioglitazone and metformin
should be temoprarily discontinued in patients
undergoing radiologic studies involving intravas­
cular administration of iodinated contrast materi­
als, becaues use of such products may result in

. •
Glimepiride It
·
1'i991itazpne Tablets
.. ""
' """"
e. �·
.. .
;ic
' :· �,-
. .
"'
acute alteration of renal function.
S/E: The most common adverse events were
upper respiratory tract infection, diarrhea,
combined edema/peripheral edema and headache,
respectively. Most clinical adverse events were
similar between groups treated with pioglitazone
in combination with metformin and those treated
with pioglitazone monotherapy.
Precautions: General: Pioglitazone hydrochlo­
ride exerts its antihyperglycemic effect only in
the presence of insulin. Therefore, combination
of pioglitazone and metformin should not be used
in patients with type l diabetes or for the
treatment of diabetic ketoacidosis. Metformin is
known to be substantially excreted by the kidney
and the risk of metformin accumulation and
lactic acidosis increases with the degree of
impairment of renal function. Thus, patients with
serum creatinine levels above the upper limit of
normal for their age should not receive
combination of pioglitazone and metformin.
Cardiovascular: Therapy with pioglitazone,
cases of congestive heart failure has been
reported in patients both with and without
previously known heart disease. Combination of
pioglitazone and metformin should be used with
caution in patients with edema. Since
thiazolidinediones, including pioglitazone can
cause fluid retention, which can exacerbate or
lead to congestive heart failure. So, combination
of pioglitazone and met formin should be used
with caution in patients at risk for heart failure.
Hepatic effects: Serum ALT (alanine
aminotransferase) levels should be evaluated
prior to the initiation of therapy with combination
of pioglitazone and metformin in all patients and
periodically thereafter do the clinical judgment of
the health care professional. Other liver function
tests should also be done for patients if
symptoms suggestive of hepatic dysfunction, e.g
nausea, vomiting, abdominal pain, fatigue,
anorexia, or dark urine. If jaundice is observed,
drug therapy should be discontinued.
Pregnancy & lactation: This combination is not
recommended during pregnancy & lactation, so,
a suitable treatment schedule should be
prescribed with insulin.
Dosage & admin: Selecting the starting dose of
this combination should be based on the
patient's current regimen of pioglitazone
and/or metformin. This combination should be
given in divided daily doses with meals to
reduce the gastrointestinal side effects
associated with metformin.
Starting dose for pa.tients inadequately
controlled on metformin monotherapy: Based
on the usual starting dose of pioglitazone (15-
JOmg daily), this combination may be initiated
at either the lSmg/SOOmg or 15mg/850mg
tablet on.ce or twice daily, and gradually
titrated after assessing adequacy of
therapeutic response.
Starting dose for patients who initially respon­
ded to pioglitazone monotherapy and require
additional glycemic control: Based on the usual
starting doses of metformin (500mg twice
•
-· �������----iiii
QIMP-17 (194)
• ,,
· k::;· _:
�
daily or 850mg daily), this combination may
be initiated at either the 15mg/500mg tablet
- twice daily or 15mg/850mg tablet once daily,
- _ _ _.i;;J.,,fi,..W,�,
and gradually titrated after assessing
adequacy of therapeutic response.
Starting dose for patients switching from combi­
nation therapy of pioglitazone plus metformin
as separate tablets: Either combination
15mg/500mg or combination 15mg/850mg
based on the dosage of pioglitazone and
metformin already being taken.
Maximum recommended dose: The maximum
recommended dose for pioglitazone is 45mg
daily. The maximum recommended daily dose
for metformin is 2550mg in adults.
+ ACTOMEG SOO Tab. UniMed & UniHealth
Pioglitazone hydrochloride 15mg + metformin
hydrochloride 500mg/tablet (film-coated)
20's pack: 180.00 MRP
+ ACTOMEG 850 Tab. UniMed & UniHealth
Pioglitazone hydrochloride l Smg + metformin
hydrochloride 850mg/tablet (film-coated)
20's pack: 200.00 MRP
+ CODIAGLIT 500 Tab. Beximco
Pioglitazone hydrochloride 15mg + metformin
hydrochloride 500mg/tablet (film-coated)
30's pack: 300.00 MRP
+ CODIAGLIT 850 Tab. Beximco
Pioglitazone hydrochloride 15mg + metformin
hydrochloride 850mg/tablet (film-coated)
30's pack: 345.00 MRP
+ COMPIMET 500 Tab. lncepta
Pioglitazone hydrochloride l 5mg + metformin
hydrochloride 500mg/tablet (film-coated)
30's pack: 270.00 MRP
+ COMPIMET 850 Tab. lncepta
Pioglitazone hydrochloride 15mg + metformin
hydrochloride 850mg/tablet (film-coated)
30's pack: 300.00 MRP
+ GLITAMIN 500 Tab. White Horse
Pioglitazone 15mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 270.00 MRP
+ GLITAMIN 850 Tab. White Horse
Pioglitazone 15mg + metformin hydrochloride
850mg/tablet (film-coated)
30's pack: 300.00 MRP
+ PIOBIG 15/500 Tab. Navana
Pioglitazone hydrochloride l Smg + metformin
hydrochloride 500mg/tablet (film-coated)
30's pack: 270.00 MRP
+ PIOBIG 15/850 Tab. Beximco
Pioglitazone hydrochloride 15mg + metformin
hydrochloride 850mg/tablet (film-coated)
30's pack: 300.00 MRP
+ PIOL-M 500 Tab. Opsonin
Pioglitazone 1Smg + metformin hydrochloride
500mg/tablet (film-coated)
20's pack: 158.87 MRP
+ PIOL-M 850 Tab. Opsonin
Pioglitazone 1Smg + metformin hydrochloride
850mg/tablet (film-coated)
20's pack: 176.65 MRP
+ PIOMET 500 Tab. Silva
Pioglitazone l 5mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 271.00 MRP
+ PIOMET 850 Tab. Silva
Pioglitazone 15mg + metformin hydrochloride
850mg/tablet (film-coated)
30's pack: 301.00 MRP
+ PIOMIN 500 Tab. Pacific
Pioglitazone l 5mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 330.00 MRP
+ PIOMIN 850 Tab. Pacific
Pioglitazone l 5mg + metformin hydrochloride
850mg/tablet (film-coated)
30's pack: 375.00 MRP
+ PIOZENA 15/500 Tab. Drug Inter.
Pioglitazone INN 15mg + metformin
hydrochloride USP 500mg/tablet (film-coated)
20's pack: 200.00 MRP
+ PIOZENA 15/850 Tab. Drug Inter.
Pioglitazone INN 15mg + metformin
hydrochloride USP 850mg/tablet (film-coated)
20's pack: 220.00 MRP
+ POLIMET-500 Tab. Rephco
Pioglitazone 15mg + metformin hydrochloride
500mg/tablet (film-coated)
lOO's pack: 800.00 MRP
+ POLIMET-850 Tab. Rephco
Pioglitazone l 5mg + metformin hydrochloride
850mg/tablet (film-coated)
l OO's pack: l 000.00 MRP
+ POLITOR 500 Tab. ACI
Pioglitazone l 5mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 300.00 MRP
+ POLITOR 850 Tab. ACI
Pioglitazone l 5mg + metformin hydrochloride
850mg/tablet (film-coated)
30's pack: 330.00 �
+ REZULIN 500 Tab. Square
Pioglitazone l 5mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 300.00 MRP
+ REZULIN 850 Tab. Square
Pioglitazone l Smg + metformin hydrochloride
850mg/tablet (film-coated)
30's pack: 330.00 MRP
ROSIGLITAZONE + METFORMJN42
ROSIGLITAZONE + METFORMIN : Tablet
This is a combination of two antihyperglycemic
agents, in which metfonnin is a biguanide and
rosiglitazone is a member of the
thiazolidinedione group of other antidiabetics.
The combination preparations of rosiglitazone
and metformin are available as tablet in two fixed
presentations, viz: i. Rosiglitazone 1mg + Metfor­
min hydrochloride BP 500mg; ii. Rosiglitazone
2mg + Metformin hydrochloride BP 500mg.
Mode of action: See above under the text of
rosiglitazone and metformin given separately.
Ind: This combination is indicated as an adjunct
to diet and exercise to improve glycemic control
in patients with type 2 diabetes- i. who are
already treated with a combination of
rosiglitazone and metformin as separate tablets,
or ii. whose diabetes is not adequately controlled
with metformin alone, or iii. for those patients
who have initially responded to rosiglitazone
alone and require additional glycemic control.
C/I; S/E; Precautions: See above under the text
of pioglitazone and metformin combined
preparations.
Pregnancy & lactation: This combination is not
recommended during pregnancy & lactation, so,

a suitable treatment schedule should be
prescribed with insulin.
Dosage & admin: General: The dosage of
antidiabetic therapy with this combination
should be individualized on the basis of the
effectiveness and tolerability of the individual
component of the product. All patients should
start the rosiglitazone component of the
combination at the lowest recommended dose.
Further increases in the dose of rosiglitazone
should be accompanied by careful monitoring
for adverse events related to fluid retention.
This combined preparation is generally given
in divided doses with meals, with gradual dose
escalation. This reduces gastrointestinal side
effects (largely due to metformin) and permits
determination of the minimum effective dose
for the individual patient.
Combination therapy in drug-naive patients:
The recommended starting dose of this
combination is 2mg/500mg administered once
or twice daily. For patients with HbA lc>ll 0/o
or FPG>270mg/dl, a starting dose of
2mg/500mg twice daily may be considered.
The dose of this combination may be
increased in increments of 2mg/500mg per day
to a maximum of 8mg/ 2,000mg per day given
in divided doses if patients are not adequately
controlled after 4 weeks.
Combination therapy in patients inadequately
controlled with rosiglitazone or metformin
monotherapy: The selection of the dose of this
combination in patients treated with
rosiglitazone and/or metformin therapy should
be based on the patient's current doses of
rosiglitazone and/or metformin. After an
increase in metformin dosage, dose titration is
recommended if patients are not adequately
controlled after 1 to 2 weeks. After an increase
in rosiglitazone dosage, dose titration is
recommended if patients are not adequately
controlled after 8 to 12 weeks.
For patients inadequately controlled on
metformin monotherapy, the usual starting
dose of this combination is 4mg rosiglitazone
(total daily dose) plus the dose of metformin
already being taken.
For patients inadequately controlled on
rosiglitazone monotherapy, the usual starting
dose of this combination is lOOOmg metformin
•
(total daily dose) plus the dose of rosiglitazone
already being taken.
When switching from combination therapy of
rosiglitazone plus metformin as separate
tablets, the usual starting dose of this
combination is the dose of rosiglitazone &
metfor111in already being taken.
+ METARIN Plus Tab. Popular
Rosiglitazone 1mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 120.60 MRP
t METIGLIT 1 Tab. General
Rosiglitazone 1mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 120.60 MRP
t METIGLIT 2 Tab. General
Rosiglitazone 2mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 180.60 MRP
+ ORAME T-PLUS Tab. Drug Inter.
I
QIMP-17 (195)
Rosiglitazone 2mg + metformin hydrochloride
500mg/tablet (film-coated)
50's pack: 350.00 MRP
+ ROGMET 2 Tab. Pacific
Rosiglitazone 2mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 180.00 MRP
+ SENSIMET 1 Tab. Square
Rosiglitazone Img + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 120.30 MRP
+ SENSIMET 2 Tab. Square
Rosiglitazone 2mg + metformin hydrochloride
500mg/tablet (film-coated)
30's pack: 180.60 MRP
SITAGLIPTIN + METFORMIN48,86
SITAGLIPTIN + METFORMIN: Tablet
This is a combination of two antihyperglycemic
agents, in which sitagliptin phosphate is an
orally-active, potent, and highly selective
inhibitor of the dipeptidyl peptidase-4 (DPP-4)
enzyme for the treatment of type 2 diabetes;
metformin is a biguanide antihyperglycemic
agent, which improves glucose tolerance in
patients with type 2 diabetes, by lowering both
basal and postprandial plasma glucose.
The combination preparations of sitagliptin and
metformin are available as tablet in two fixed
presentations, viz: i. Sitagliptin 50mg + should be undertaken with care and appropri­
metformin hydrochlor. BP 500mg; ii. Sitagliptin
50mg + metformin hydrochlor. BP 1OOOmg.
Mode of action: See above under the text of
sitagliptin and metformin given separately.
Ind: This combination is indicated as an adjunct
to diet and exercise to improve glycemic control
in adults with type 2 diabetes mellitus when
treatemnt with both sitagliptin and metformin is
appropriate.
C/I: Hypersensitivity reactions to any of the
components of the combination.
Metformin is contraindicated in renal impairment,
liver disease, predisposition to lactic acidosis,
heart failure, severe infection or trauma,
dehydration and alcohol dependence. Metformin
is not advised during pregnancy & lactation; and
not for pediatric use.
S/E: See above under the text of sitagliptin and
metformin given separately.
Precautions: See above under the text of
sitagliptin and metformin given separately.
Pregmancy & lactation: Metformin is not
recommended during pregnancy and breast­
feeding. Therefore, the combination product
containing metformin should not be given in
pregnant & nursing women.
Dosage & admin: The dosage of this combina­
tion should be individualized on the basis of
the patients current regimen, effectiveness and
tolerability while not exceeding the maximum
recommended daily dose of 1OOmg sitaglipitn
and 2000mg metfor111in. Initial combination
therapy or maintenance of combination thera­
py should be individualized as conditions men­
tioned above. This combined preparation
should generally be given twice daily with
meals, with gradual dose escalation, to reduce
the gastro-intestinal side effects due to met­
formin. The starting dose of the combination
should be based on the patients current
regimen. The recommended starting dose in
patients not currently treated with metformin
is sitagliptin 50mg/metformin hydrohloride
500mg twice daily, with gradual dose
escalation recommended to reduce gastrointes­
tinal side effects associated with metformin.
The starting dose in patients already treated
with metformin should give sitagliptin 50mg
twice daily (lOOmg total daily dose) and the
dose of metformin already being taken. For
patients taking metfor111in 850mg twice daily,
the recommended starting dose of this
combination is 50mg sitagliptin/1OOOmg
metfor111in hydrochloride twice daily.
Patients treated with an insulin secretagogue or
insulin: Co-administration of this combination
with an insulin secretagogue (e.g sulfonylurea)
or insulin may require lower doses of the
insulin secretagogue or insulin to reduce the
risk of hypoglycemia. No studies have been
performed specifically examining the safety
and efficacy of this combination in patients
previously treated with other oral anti.hyper­
glycemic agents & switched to this combina­
tion. Any change in therapy of type 2 diabetes
ate monitoring as changes in glycemic control
can occur.
Geriatric use: Because sitagliptin & metformin
are substantially excreted by the kidney, this
combination should be used with caution as
age increases. Care should be taken in dose
selection & regular monitoring of renal
function.
Pediatric use: Safety and effectiveness of this
combined therapy in patients under 18 years
have not been established.
Drug inter: See above under the text of
sitagliptin and metformin given separately.
t GLIPITA M 50/500 Tab. Beximco
Sitagliptin 50mg + metformin hydrochloride BP
500mg/tablet (film-coated).
1O's pack: 250.00 MRP
t GLIPITA M 50/1000 Tab. Beximco
Sitagliptin INN 50mg + metformin hydrochloride
BP l OOOmg/tablet (film-coated).
IO's pack: 270.00 MRP
+ JANMET 50/SOO Tab. Acme
Sitagliptin 50mg + metformin hydrochloride BP
500mg/tablet (film-coated).
6's pack: 96.00 MRP
+ JANME T 50/1000 Tab. Acme
Sitagliptin 50mg + metformin hydrochloride BP
IOOOmg/tablet (film-coated).
6's pack: 108.00 MRP
+ SGN Plus 500 Tab. Pacific
Sitagliptin INN 50mg + metfonnin hydrochloride
BP 500mg/tablet (film-coated).
12's pack: 300.00 MRP
t SIGLIMET 50/500 Tab. Square
Sitagliptin 50mg + metformin hydrochloride BP
500mg/tablet (film-coated).
l O's pack: 200.00 MRP
+ SIGLIME T 50/1000 Tab. Square

Sitagliptin INN 50mg + metformin hydrochloride
BP 1OOOmg/tablet (film-coated).
lO's pack: 220.00 MRP
t SIGTIL-M Tab. White Horse
Sitagliptin INN 50mg + metformin hydrochloride
BP 500mg/tablet (film-coated).
20's pack: 360.00 MRP
t SITAGIL M 50/500 ER Tab. Incepta
Sitagliptin INN 50mg + metformin hydrochloride
BP 500mg/tablet (extended release).
12's pack: 192.00 MRP
t SITAGIL M 50/1000 ER Tab. Incepta
Sitagliptin INN 50mg + metformin hydrochloride
BP 1 OOOmg/tablet (extended release).
12's pack: 216.00 MRP
t S L IPTIN-M-500 Tab. Drug Inter.
Sitagliptin INN 50mg + metformin hydrochloride
BP 500mg/tablet (film-coated).
14's pack: 224.00 MRP
t SLIPTIN-M-1000 Tab. Drug Inter.
Sitagliptin INN 50mg + metformin hydrochloride
BP IOOOmg/tablet (film-coated).
l 4's pack: 252.00 MRP
VILDAGLIPTIN + METFORMJN42
VILDAGLIPTIN + METFORMIN: Tablet (f.c)
This is a combination preparation of two
antihyperglycemic agents- vildagliptin and
metformin, with complementary mechanism of
action to improve glycemic control in patients
with type 2 diabetes. Vildagliptin, a dipeptidyl
peptidase-4 (DPP-4) inhibitor, which is an orally
active antidiabetic agent of miscellaneous groups.
It is effective in the treatment of type 2 diabetes
mellitus for patients not adequately controlled on
a conventional therapy. Metformin is a biguanide
antihyperglycemic agent, which improves
glucose tolerance in patients with type 2 diabetes,
by lowering both basal and postprandial plasma
glucose level.
The combination preparations of vildagliptin and
metformin are available as film coated tablets in
two fixed presentations, viz: i. vildagliptin INN
50mg + metformin hydrochloride BP 500mg; ii.
vildagliptin INN 50mg + metformin
hydrochloride BP 850mg.
Mode of action: See above under the text of
vildagliptin and metformin given separately.
Ind: This combination is indicated in patients
with type 2 diabetes who are unable to achieve
sufficient glycemic control at their maximally
tolerated dose of oral metformin alone or who are
already treated with the combination of
vildagliptin and Metformin as separate tablets.
C/I: Combination (vildagliptin & metformin
hydrochloride) is contraindicated in patients with:
i. Hypersensitivity to the active substance or to
any of the excipients;
ii. Patients with renal impairment: Creatinine
clearance < 60ml/min;
iii. Patients with acute or chronic metabolic
acidosis, including diabetic ketoacidosis, with or
without coma. Diabetic ketoacidosis should be
treated with insulin;
QIMP-17 (196)
iv. Patients with type I diabetes
S/E: The majority of adverse reactions were mild
and transient, not requiring treatment discontinu­
ations. Lactic acidosis can occur due to metfor­
min. Rare cases of hepatic dysfunction. Some
common side effects like tremor, headache, dizzi­
ness, nausea, hypoglycemia, fatigue are seen.
Clinical trials of up to & more than 2 years' dura­
tion did not show any additional safety signals or
unforeseen risks when use this combinatin.
Precautions: Lactic acidosis can occur due to
metformin accumulation. If metabolic acidosis is
suspected, treatment should be discontinued and
the patient should be hospitalized immediately.
Serum creatinine should be monitored atleast
once a year in patients with normal renal function
and 2-4 times a year in patients with serum
creatinine levels at the upper limit of normal and
in elderly patients. Special caution should be
exercised in elderly patients where renal function
may become impaired (e.g when initiating
antihypertensives, diuretics or NSAIDs). It is
recommended that liver function tests (LFTs) are
monitored prior to initiation of this drug, at three­
monthly intervals in the first year & periodically
thereafter. If transaminase levels are increased,
patients should be monitored with a second liver
function evaluation to confirm the finding and be
followed there after with frequent liver function
tests until the abnormality return to normal. If
AST or ALT persist at 3 x ULN, vildagliptin &
metformin tablets should be stopped patients who
develop jaundice or othersigns of liver
dysfunction. Following withdrawal of treatment
with vildagliptin & metfonnin and LFf
normalization, treatment with vildagliptin &
metformin should not be reinitiated. Vildagliptin
& metformin tablets should be discontinued 48
hours before elective surgery with general
anesthesia and should not usually be resumed
earlier than 48 hours afterwards.
Pregnancy & lactation: There are no adequate
data on the use of vildagliptin & metformin in
pregnant women, hence the potential risk for
hl1man is unknown. It is not known whether
vildagliptin is excreted in human milk. Due to
lack of human data, vildagliptin & metformin
should not be used during lactation.
Dosage & admin: Adults: Based on the
patient's current dose of metfor111in, combina­
tion of vildagliptin & metformin may be
initiated at either 50mg/500mg or 50mg/850mg
twice daily, 1 tablet in the morning and the
other in the evening. The recommended daily
dose is lOOmg vildagliptin plus 2000mg
metformin HCl: Patients receiving vildagliptin
and metformin from separate tablets may be
switched to combination of vildagliptin &
metformin containing the same doses of each
component. Doses higher than lOOmg of
vildaglip-tin are not recommended. There is
no clinical experience of vildagliptin and
metfor111i n in triple combination with other
antidiabetic agents. Taking combination of
vildagliptin & metformin with or just after
food may reduce gastrointestinal symptoms
associated with metformin.
Pediatric use: Combination of vildagliptin &
metformin is not recommended in patients 18
years of age.
Geriatric use: T heir renal function monitored
regularly. Combination of vildagliptin &
metf ormin has not been studied in patients
>75 years. Therefore, the use of combination
•
of vildagliptin & metformin is not recommen­
ded in this population.
Drug inter: In pharmacokinetic studies, no inter­
actions were seen with pioglitazone, metfonnin,
glibenclamide, digoxin, warfarin, amlodipine,
ramipril, valsartan or simvastatin. As with other
oral antidiabetic medicinal products, the glucose­
lowering effect of vildagliptin may be reduced by
certain active substances, including thiazides,
corticosteroids, thyroid products & sympathomi­
metics. Close monitoring of glycemic control is
required, when cationic drugs are co-adminis­
tered. Glucocorticoids, beta-2 agonists, diuretics
and ACE inhibitors may alter blood glucose. The
patient should be informed and more frequent
-
blood glucose monitoring performed, specially at
the beginning of treatment. If necessary, the
dosage of vildagliptin & metformin tablets may
need to be adjusted during concomitant therapy
and on its discontinuation.
t DIALIPTIN-M 500 Tab. Drug inter
Vildagliptin INN 50mg + metformin hydrochlo­
ride BP 500mg/tablet (film-coated).
14's pack: 224.00 MRP
t DIALIPTIN-M 850 Tab. Drug inter
Vildagliptin INN 50mg + metformin hydrochlo­
ride BP 850mg/tablet (film-coated).
14's pack: 238.00 MRP
t GAI.ET-M Tab. White Horse
Vildagliptin INN 50mg + metfonnin hydrochlo­
ride BP 500mg/tablet (film-coated).
20's pack: 360.00 MRP
+GALVAN Plus 500 Tab. Aristopharma
Vildagliptin INN 50mg + metformin hydrochlo­
ride BP 500mg/tablet (film-coated).
20's pack: 420.00 MRP
+GALVAN Plus 850 Tab. Aristopharma
Vildagliptin INN 50mg + metformin hydrochlo­
ride BP 850mg/tablet (film-coated).
20's pack: 440.00 MRP
t GALVUSMET 50/500 Tab. Novartis
Vildagliptin INN 50mg + metformin hydrochlo­
ride BP 500mg/tablet (film-coated).
30's pack: 840.00 MRP
t GALVUSMET 50/850 Tab. Novartis
Vildagliptin INN 50mg + metformin hydrochlo­
ride BP 850mg/tablet (film-coated). •
30's pack: 840.00 MRP
+ VIDA Plus 500 Tab. Pacific
Vildagliptin INN 50mg + metfonnin hydrochlo­
ride BP 500mg/tablet (film-coated).
18's pack: 396.00 MRP
+ VIDA Plus 850 Tab. Pacific '
Vildagliptin INN 50mg + metformin hydrochlo­
ride BP 850mg/tablet (film-coated).
•
20's pack: 480.00 MRP
t VIGLIMET S0/500 Tab. Square
Vildagliptin INN 50mg + metformin hydrochlo­
ride BP 500mg/tablet (film-coated).
20's pack: 440.00 MRP
t VIGLIMET 50/850 Tab. Square
Vildagliptin INN 50mg + metformin hydrochlo­
ride BP 850mg/tablet (film-coated).
20's pack: 460.00 MRP
t VILDAGIL-M 500 Tab. Sharif
Vildagliptin INN 50mg + metformin hydrochlo-
�
. . '
:�;
l1
�i .

ride BP 500mg/tablet (film-coated).
20's pack: 400.00 MRP
t \r"ILDAGIL-M 850 Tab. Sharif
Vildagliptin INN 50mg + metfonnin
hydrochloride BP 850mg/tablet (film-coated).
20's pack: 440.00 MRP
Parenteral Hypoglycaemic
drugSJ.1,133,1s4
Parenteral hypoglycaemic drugs that are used
for non-insulin dependent (type 2) diabetes:
Glucagon-like peptide-l(GLP-1) receptor
agonists (given by s.c injection):
i. Exenatide, ii. Liraglutide.
LIRAGLUTIDE122,145
LIRAGLUTIDE: S.C Injection
Liraglutide, a human glucagon-like peptide- I
(GLP-1) analog produced by recombinant DNA
technology in saccharomyces cerevisiae.
Liraglutide is indicated in the treatment of type 2
diabetes mellitus as monotherapy or
incombination with oral antidiabetics to achieve
desired glycaemic control. It is available as­
liraglutide 6mg/lml of solution; 3ml (18mg) pre­
filled pen for subcutaneous administration.
Mode of action: Liraglutide is a GLP-1 analog
with 97% sequence homology to human GLP-1
that binds to and activates the GLP-1 receptor.
The GLP-1 receptor is the target for native GLP-
1, an endogenous incretin hormone that potenti­
ates glucose-dependent insulin secretion from the
pancreatic beta cells.
Unlike native GLP-1, liraglutide has a pharmaco­
kinetic and pharmacodynamic profile in humans
suitable for once daily administration. Following
subcutaneous administration, the protracted
action profile is based on three mechanisms: self­
association, which results in slow absorption;
binding to alb umin; and higher enzymatic
stability towards the dipeptidyl peptidase IV
,...
_.I
(DPP-IV) and neutral endopeptidase (NEP)
enzymes, resulting in a long plasma half-life.
l,iraglutide action is mediated via a specific
interaction with GLP-1 receptors, leading to an
increase in cyclic adenosine monophosphate
( cAMP). Liraglutide stimulates insulin secretion
in a glucose-dependent manner. Simultaneously,
liraglutide lowers inappropriately high glucagon
secretion, also in a glucose-dependent manner.
Thus, when blood glucose is high, insulin
secretion is stimulated and glucagon secretion is
inhibited. Conversely, during hypoglycemia
liraglutide diminishes insulin secretion and does
not impair glucagon secretion. The mechanism of
blood glucose lowering also involves a minor
delay in gastric emptying. Liraglutide reduces
body weight and body fat mass through
mechanisms involving reduced hunger & lowered
energy intake. Liraglutide has 24-hour duration
of action and improves glycaemic control by
lowering fasting and postprandial blood glucose
in patients with type 2 diabetes mellitus.
Ind: Liraglutide is indicated for treatment of
adults with type 2 diabetes mellitus to achieve
glycaemic control:
I
QIMP-17 (197)
In combination with:
- Metformin or a sulphonylurea, in patients with
insufficient glycaemic control despite maximal
tolerated dose of monotherapy with metfonnin or
· sulphonylurea.
In combination with:
- Metformin & a sulphonylurea or metfonnin &
a thiazolidinedione in patients with insufficient
glycaemic control despite dual therapy.
C/I: Hypersensitivity to the active substance or
to any of the excipients.
S/E: Very common: Nausea, diarrhoea.
Common: Hypoglycaemia (cold sweat, cool pale
skin, headache, fast heart beat, feeling sick,
feeling very hungry, changes in vision, feeling
sleepy, feeling weak, nervous, anxious,
confused, difficulty concentrating, shaking
(tremor)), headache, vomiting, indigestion,
inflamed stomach (gastritis), gastro-esophageal
reflux disease (heartburn), painful or swollen
abdomen, abdominal discomfort, viral infection
in stomach, constipation, wind (flatt1lence),
decreased appetite, bronchitis, common cold,
dizziness, fatigue, fever, toothache.
Injection site reactions (such as bruising, pain,
irritation, itching and rash).
Uncommon: Pancreatitis; thyroid events (like
nodules, increased blood calcitonin and goiters).
Rare side effects: Angioedema.
Precautions & warnings: Liraglutide should not
be used in patients with type 1 diabetes mellitus
or for the treatment of diabetic ketoacidosis.
Liraglutide is not a substitute for insulin.
The addition of liraglutide in patients already
treated with insulin has not been evaluated and is
therefore not recommended.
There is limited experience in patients with
congestive heart failure.
There is limited experience in patients with infla­
mmatory bowel disease and diabetic
gastroparesis & liraglutide is therefore not
recommended in these patients. The use of
liraglutide is associated with transient gastroin­
testinal adverse reactions, including nausea,
vomiting and diarrhoea.
Use of GLP-1 analogs has been associated with
the risk of pancreatitis. There have been few
reported events of acute pancreatitis. Patients
should be informed of the characteristic symptom
of acute pancreatitis- persistent, severe abdominal
pain. If pancreatitis is suspected, liraglutide and
other potentially suspect medicinal products
should be discontinued.
Thyroid adverse events, including increased
blood calcitonin, goitre and thyroid neoplasm
have been reported in clinical trials in particular
in patients with pre-existing thyroid disease.
Patients receiving liraglutide in combination with
a sulphonylurea may have an increased risk of
hypoglycaemia. The risk of hypoglycaemia can
be lowered by a reduction in the dose of
sulphonylurea.
Signs and symptoms of dehydration, including
altered renal function have been reported in
patients treated with liraglutide. Patients treated
with liraglutide should be advised of the potential
risk of dehydration in relation to gastrointestinal
side effects and take precautions to avoid fluid
depletion.
Few patients treated with liraglutide reported at
.
Vida® Plus 500 & s5o
least one episode of severe diarrhoea.
Pregnancy & lactation: There are no adequate
data _from the use of liraglutide in pregnant
women. Studies in animals have shown
reproductive toxicity. Therefore, liraglutide
should not be used during pregnancy, and the use
of insulin is recommended instead. If a patient
wishes to become pregnant, or pregnancy occurs,
treatment with liraglutide should be discontinued.
It is not known whether liraglutide is excreted in
human milk. Because of lack of experience, lira­
glutide should not be used during breast-feeding.
Dosage & admin: To improve gastro-intestinal
tolerability, the starting dose is 0.6mg
liraglutide daily. After at least one week, the
dose should be increased to 1.2mg. Some
patients are expected to benefit from an
increase in dose from 1.2mg to 1.8mg and
based on clinical response, after at least one
week the dose can be increased to 1.8mg to
further improve glycaemic control. Daily doses
higher than 1.8mg are not recommended.
Liraglutide can be added to existing
metformin or to a combination of metformin
and thiazolidinedione therapy. The current
dose of metformin and thiazolidinedione can
be continued unchanged.
Liraglutide can be added to existing sulphony­
lurea or to a combination of metformin and
sulphonylurea therapy. When liraglutide is
added to sulphonylurea therapy, a reduction
in the dose of sulphonylurea should be consi­
dered to reduce the risk of hypoglycaemia.
Self-monitoring of blood glucose is not needed
in order to adjust the dose of liraglutide.
However, when initiating treatment with
liraglutide in combination with a sulphony­
lurea, blood glucose self-monitoring may
become necessary to adjust the dose of the
sulphonylurea.
Special populations:
Elderly (>65 years old): No dose adjustment is
required based on age.
Renal impairment: No dose adjustment is
required for patients with mild renal impair­
ment (creatinine clearance 60-90 ml/min).
There is very limited therapeutic experience in
patients with moderate renal impairment
(creatinine clearance of 30-59 ml/min) and no
therapeutic experience in patients with severe
renal impairment (creatinine clearance below
30 ml/min). Liraglutide can currently not be
recommended for use in patients with moder­
ate and severe renal impairment including
patients with end-stage renal disease.
Hepatic impairment: The therapeutic
experience in patients with all degrees of
hepatic impairment is currently too limited to
recommend the use in patients with mild,
moderate or severe hepatic impairment.
Pediatric population: Liraglutide is not recom­
mended for use in children below 18 years of
age due to lack of data on its safety & efficacy.
Liraglutide is administered once daily at any
time, independent of meals, & is injected only

Vida® Plus soo & s5o
subcutaneously in the abdomen, in the thigh
or in the upper arm. The injection site and
timing can be changed without dose adjust­
ment. However, it is preferable that liraglutide
is injected around the same time of the day,
when the most convenient time of the day has
been chosen.
Drug inter: Liraglutide has shown very low
potential to be involved in pharmacokinetic inter­
actions with other active substances related to
cytochrome P450 and plasma protein binding.
The small delay of gastric emptying with liraglu­
tide may influence absorption of concomitantly
administered oral medicinal products.
Interaction studies show that liraglutide may
interfere with the action, absorption and/or
metabolism of various drugs, such as- paraceta­
mol, atorvastatin, griseofulvin, digoxin, lisinopril,
oral contraceptives (ethinyloestradiol and levono­
rgestrel), warfarin and other coumarin derivatives
Storage precautions: Store in a refrigerator (2°C
- 8°C). Do not freeze. Keep away from the
freezer compartment.
Note: For further information please consult
manufacturer's literature.
t VICTOZA Inj. Novo Nordisk
Liraglutide, a recombinant (rDNA) human
glucagon-like peptide-I (GLP-1) analog,
6mg/lml solution; 3ml (18mg) pre-filled pen:
only for subcutaneous injection.
3ml pre-filled pen x 1 's pack: 7880.00 MRP
Drugs for Diabetic Peripheral
Neuropathy
EPALRES.TAT 6s
EPALRES TAT: Tablet
Epalrestat is an aldose reductase inhibitor (ARI),
useful in the treatment of diabetic neuropathy and
safe for long-term use. It is available as- epalrestat
INN 50mg film coated tablet.
Mode of action: In diabetes mellitus, 'nerve fiber
degeneration' and development of 'peripheral
neuropathy' starts by activating 'aldose reductase
pathway'. This pathway is activated by
intracellular hyperglycemia, resulting in
increased sorbitol formation in presence of the
enzyme aldose reductase that causes a
hyperosmotic affects (accumulation of water and
swelling) on the nerves. This, in turn results in
decreased myo-inositol formation, which breaks
the enzyme Na+fK.+-ATPase and ultimately
causes decreased cellular activity (propagation of
impulses and maintenance of nerve conduction
velocity) of Na+fK.+- ATPase. Aldose reductase
inhibitor (ARI), epalrestat inhibits the enzyme
aldose reductase thus inhibits the process of
formation of sorbitol and nerve damage.
Epalrestat, thereby improves subjective
symptoms and nerve dysfunction in patients with
diabetic peripheral neuropathy.
Ind: Epalrestat is indicated for the improvement
I
QIMP-17 (198)
of subjective symptoms (numbness and pain),
abnormality of vibration sense and abnormal
change in heartbeat associated with diabetic
peripheral neuropathy (when high glycohemoglo­
bin value is noted).
C/I: Known hypersensitivity to epalrestat.
AIR: Major adverse reactions are hepatic
function abnormalities and thrombocytopenia. In
cases of hepatic abnormalities drug should be
discontinued immediately and appropriate
measures should be taken. Other reactions may
be malaise, headache, abdominal pain, nausea,
hypersensitivity reaction etc.
Precautions: The administration of epalrestat
should be considered to patients showing high
glycohemoglobin values even after fundamental
therapies for diabetes mellitus, such as- diet ther­
apy, exercise therapy and treatment with an oral
hypoglycemic agent, insulin etc. The efficacy of
this product has not been established in patients
with diabetic peripheral neuropathy with irrever­
sible organic changes. The patient should be
carefully monitored during the admini stration of
this product. When the efficacy of this product is
not observed even after 12 weeks of administra­
tion, other appropriate therapies should be taken.
Pregnancy & lactation: The safety of epalrestat
in pregnant women has not been established. The
drug may be used in pregnant women or in
women who may possibly be pregnant only if
expected therapeutic benefits outweigh the
possible risks associated with the treatment.
Breast-feeding should be avoided during
administration of epalrestat.
Dosage & admin: The usual adult dose is
50mg 3 times daily before each meal. The
dosage may be adjusted according to the
patient's age and symptoms.
t ALDORIN Tab. SK+F
Epalrestat INN 50mg/tablet (film-coated).
24's pack: 192.00 MRP
PREGABALIN21,26
PREGABALIN: Capsule
Pregabalin is used as a second-line drug for the
treatment of partial (or focal) seizures with or
without secondary generalisation. It is also useful
in the treatment of neuropathic pain & generalis­
ed anxiety disorder. It is available as- pregabalin
INN 50mg, 75mg, I OOmg & l 50mg capsule.
Note: For detail and preparations, please see in
the section of CNS drugs.
2. THY.ROID & ANTI­
THYROID DRUGS21
2.1 Thyroid drugs/hormones
2.2 Antithyroid drugs
2.3 Drugs for iodine deficiency goitre
Thyroid drugs & hormones
These include:
1. Thyroxine &
2. Liothyronine.
THYROXINE/LEVOTHYROXINE2I,26
THYROXINE/LEVOTHYROXINE
SODIUM: Tablet .
Thyroxine sodium (levothyroxine sodium) is a
synthetic thyroid hormone, used in the thyroxine
replacement therapy. Thyroxine (T4) is a natural­
ly occurring hormone produced by the thyroid
gland & converted to the more active hormone
tri-iodothyronine (T3) in peripheral tissues. The
thyroid hormones are required for normal growth
and development particularly of the nervous
system. Thyroxine sodium (levothyroxine
sodium) after ingestion is incompletely and
variably absorbed from the gastrointestinal tract.
The half-life of T4 in normal plasma is 6-7 days,
while that of T3 is about 1 day. The plasma half­
lives of T4 & T3 are decreased in hyperthyroi­
dism and increased in hypothyroidism.
Thyroxine sodium (Levothyroxine sodium) is
largely bound to plasma protein, mainly to
thyroxine binding globulin (TBG) but also to
prealbumin and less avidly to alb11min. The
unbound or free fraction, although only about
0.03% of total thyroxine sodium (levothyroxine
sodium), is of course the fraction available for
peripheral action and conversion to the more
active metabolite tri-iodothyronine (T3).
Ind: 1. Congenital hypothyroidism including cre­
tinism 2. Acquired hypothyroidism- primary
thyroid failure, autoimmune, post surgery, post
radioiodine therapy, drug therapy, myxoedema 3.
Hypothyroidism secondary to pituitary/hypothal­
amic diseases 4. Suppression of goiter 5. In
conjunction with antithyroid drugs in treatment
of thyrotoxicosis.
C/I: Thyroxine sodium (levothyroxine sodium)
is contraindicated in patients with thyrotoxicosis,
angina, cardiovascular disorders; hypersensitivity
to thyroid hormone. It is also contraindicated in
the patients with uncorrected adrenal insuffici­
ency.
S/E: Side-effects may include anginal pain,
arrhythmias, palpitation, skeletal muscle cramps,
tachycardia, diarrhoea, vomiting, tremors,
restlessness, excitability, insomnia, headache,
flushing, sweating, fever, heat intolerance,
excessive loss of weight and muscular weakness.
Precautions: Thyroxine sodium (levothyroxine
sodium) should be used with caution in patients
with cardiovascular disorders, including angina,
coronary artery disease, and hypertension, and in
the elderly who have a greater likelihood of
occult cardiac disease. Use of thyroxine sodium
(levothyroxine sodium) in patients with
concomitant diabetes mellitus, diabetes insipidus
or adrenal cortical insufficiency may aggravate
the intensity of their symptoms. Appropriate
adjustments of the various therapeutic measures
directed at these concomitant endocrine diseases
may therefore be required.
Pregnancy & lactation: Women on maintenance
levothyroxine for hypothyroidism who become
pregnant should not need to alter the dose
because of the pregnancy so long as they are con­
firmed to be euthyroid initially, by normal TSH
levels. T4 dose not cross the placental barrier in
the second and third trimester, although it may do
so in early pregnancy. The amount of T4 in breast
milk is variable but not sufficient to affect the
 •

QIMP-17 (199) DRUGS USED IN ENDOCRINE DISEASES

normal infant. and phenytoin may cause a false low total serum
Dosage & Admin: In adult patients without T4 levels. Serum T3 and TSH levels rather than CARBIMAZOLE21,33
cardac problems: initially adult oral dose is T4 should be used to monitor the patient's thyroid
50-1 OOmcg daily, preferably in the fasting status. CARBIMAZOLE: Tablet
state, adjusted in steps of SOmcg every 3-4
.

Carbimazole is available as carbimazole BP

weeks until normal metabolism maintained.
•
The patient's well being and thyroid function
tests are reassessed after 6-8 weeks. The daily
dosage may then require further minor
adjustment so as to ensure clinical and
biochem.ial euthyroidism. It is important to
correct any steroid deficiency first before
initiating thyroxine replacement therapy.
In the elderly and in patients with cardiac
problems: Initially 25mcg daily or SOmcg on
alternate days adjusted in steps of 25mcg
every 4 weeks until euthyroid.
Maintenance therapy: The usual maintenance
dose to relieve hypothyro-idism is 100-200mcg
daily, which can be administered as a single
dose.
Neonates and children: Replacement therapy
should be started as soon as the diagnosis is
made to prevent the mental & physical
retardation that would otherwise occur. The
initial diagnosis and cause can be reappraised
t ELT ROXIN Tab. GlaxoSmithKline 5mg/tablet.
Levothyroxine sodium 50mcg/tablet· Ind: Thyrotoxicosis.
50mcg x lOO's pack: 255.60 MRP C/I: Tracheal obstruction, breast feeding.
t EUTHYCIN Tab. Incepta S/E: Nausea, headache , rashes, arthralgia, rarely
Levothyroxine sodium 50mcg/tablet alopecia, agranulocytosis. Advice patients to
50mcg x lOO's pack: 120.00 MRP inform you of sore throats, mouth ulcer; if so,
+ JAROXIN-50 Tab. Jayson dicontinue drug.
Levothyroxine sodi11m 50mcg/tablet Cautions: Pregnancy.
50mcg x IOO's pack: 120.00 IP
Pregnancy & lactation: Carbimazole is
t LEROXIN-50 Tab. Popular
contraindicated in breast feeding mother. In
Levothyroxine sodium 50mcg/tablet
pregnant woman it can only be given if it is
50mcg x lOO's pack: 120.00 MRP
clearly needed, but caution should be exercised.
t T HYNOR Tab. SK+F
Thyroxine sodium 50mcg/tablet Dosage & admin: Adult: Moderate cases, 30
50mcg x 90's pack: 135.00 MRP mg; severe cases, 40-60mg. All daily in divided
•
+ T HYRIN Tab. Square doses for 4-6 weeks; when the evidence of
Levothyroxine sodium 25mcg & 50mcg/tablet hyperthyroidism has disappeared, reduce to
25mcg x 60's pack: 66.00 MRP min. daily dose of 10-lSmg to maintain control
50mcg x 90's pack: 144.00 MRP (treatment is usually maintained for 18
t T HYROLAR Tab. Acme months).
Thyroxine sodium 50mcg/tablet Child: 15mg daily in divided doses.

Carbimazole BP 5 mg Tablet

\. .,,-;, .
Testal & T1·ustal IJrug M Hypat

The White Ho11e PhcannGcvcutical1 '

UKAS
Better Qu ality Alw ays w=:±n
M
l

www.whitehorsephanna.com
An ISO 9001: 2008 Certified Company

when the infant is 1 year old. 50mcg x 90's pack: 108.00 MRP t CARBIROID Tab. White Horse
t
•

Dosage: At age 0-6 mon, 8-lOmcg/kg/day; THYRONOR Tab. Nuvista Carbimazole BP 5mg/tablet.
6-12mon, 6-8mcg/kg/day; 1-5 yrs; 5-6mcg/kg/ Thyroxine sodium 50mcg/tablet 5mg x 1OO's pack: 480.00 MRP
day; 6-12 yrs; 4-Smcg; 12 years and over 50mcg x 60's pack: 124.20 MRP t CARBIZOL Tab. Square
2mcg/kg/day. 50mcg x 1OO's pack: 227.00 MRP Carbimazole BP 5mg/tablet.
Over dosage: A massive acute overdose is fortu­ t T HYROX Tab. Renata 5mg x 60's pack: 180.60 MRP
nately uncommon, but potentially lethal. If the Thyroxine sodium 50mcg/tablet
patient presents soon after ingestion of an acute 50mcg x 90's pack: 144.00 MRP
overdose then gastric aspiration and lavage are t TYROID Tab. ACI Drugs for Iodine deficiency
indicated. Other treatment includes propranolol & Levothyroxine sodium 50mcg/tablet
goitre
•

supportive measures to maintain the circulation. 50mcg x lOO's pack: 135.00 �

Drug inter: Levothyroxine, when given to
hypothyroid patients who are already on antico­ LUGOLS IODINE SOLN.21
agulants, will potentiate the effect of warfarin Antithyroid drugs
and other dicoumarin anticoagulants necessitating LUGOLS IODINE: Solution
a marked reduction (50%) in warfarin dosage to T hese include: Aqueous iodine solution (iodine 5%, potassium
prevent execessive prolongation of the prothrom­ 1. Carbimazole iodide l 0%, made upto l 00 parts in purified
bin time and partial thrombo-plastin time. 2. Iodine & iodide water), total iodine 130mg/ml.
Cholestyramine may reduce absorption of 3. Propyl thiouracil Ind: Pre-operative treatment of thyrotoxicosis
levothyroxine. Phenylbutazone, carbamazepine 4. Propranolol S/E: Hypersensitivity like reactions, including

' .
. .' .
.
'
/'; '

. , '. , -,. ;
,-
.;,
--
-

A Perfect Solution "' Hypothy1:oidism

.
-
. ;;...; - ,.:. ·- �' ,'
. - ·-. . . - - . � -:
. . . . , '- -
· _ ' :- ��Dl•-E:

l
I
 DRUGS USED IN ENDOCRINE DISEASES
headache, lachrymation, conjunctivitis, pain in
salivary glands, laryngitis, bronchitis, rashes; on
prolonged treatment depression, insomnia,
impotence, myxoedema; goitre in infants of
mothers taking iodides.
Cautions: Pregnancy, children
Dose: 0.1-0.3 ml 3 times daily (well diluted
with milk or water) for about 2 weeks.
Prepa: May be available.
POTASSIUM IODIDE21
' POTASSIUM IODIDE: Tablet
Potassium iodide 60mg/tablet
Ind: Preoperative treatment of thyrotoxicosis.
S/E; Cautions: Same as Lugol's iodine solution
Dose: 30-60mg daily for about 2 weeks.
Prepn: May be available.
3. CORTICOSTEROID
DRUGS/HORMONES21
Adrenal steroids are chiefly used in medicine
for the following purposes:
1. Replacement therapy: In adrenocortical
insufficiency, Addison's disease.
2. Glucocorticoid therapy: Mainly useful for its
anti-inflammatory and immunosuppressive
effects.
BETAMETHASONE21,33,36
BETAMETHASONE: Tabet/Injection
Betamethasone, a synthetic corticosteroid, has
anti-inflammatory, anti-allergic and vasocons­
trictive actions. Systemic betamethasone
preparations are available as- betamethasone oral
tablet and injection; but, currently injection
preparations are not available in the market.
Ind: Severe asthma, hayfever, allergic skin
conditions, rheumatoid arthritis, collagen
diseases, shock and adrenal crisis.
C/I: Tuberculosis, local or systemic infections
unless controlled by chemotheraphy, herpes
simplex keratitis, active peptic ulcer, psychoses,
osteoporosis, renal dysfunctions, diabetes
mellitus, glaucoma, hypertension, cushing's
syndrome, myasthenia gravis, thromboembolic
disorders, congestive heart failure, diverticulitis,
fresh intestinal anastomoses and pregnancy.
S/E: Hypertension, sodium retention, potassium
loss, muscle weakness; diabetes; osteoporosis
(particularly in elderly); mental disturbances;
euphoria is frequently observed; peptic ulceration
which may result in haemorrhage or perforation;
suppression of growth (in children); spread of
infections; adrenal suppression; menstrual
irregularities. Overdoses may cause cushing's
syndrome, with moon face striae, and acne.
Cautions: Systemic corticosteroid therapy
should be avoided in patients with psoriasis, as
subsequent reduction commonly followed by a
severe and persistent exacerbation; growth and
development in infants & children on prolonged
therapy should be observed; withdrawal of corti­
costeroid therapy should be gradually tapered to
avoid symptoms of acute adrenal insufficiency.
QIMP-17 (200)
Dosage & admin: By mouth: Adults:
1.Rheumatoid arthritis & other rheumatic
Conditions: Initially 1-2.5mg daily; mainte­
nance 0.5-1.5mg.
2. Acute rheumatic fever: 6-8mg daily;
maintenance minimum effective dose.
3. Asthmatic attack: initially 3.5-4.5mg,
maintenance, minimum effective dose; chronic
refractory asthma 3.5mg daily, maintenance
0.5-2.5mg daily.
4. Allergic dermatosis: 2.5-4.5mg daily.
5. Inflammatory ocular conditions: 2.5-4.5mg
daily; maintenance minimum effective dose.
Children: Under 1 year, not recommended; 1-
7 years, 1/4 to 1/2 adult dose; 7-12 years 1/2 to
3/4 adult dose.
By injection: (specially in shock, adrenal
crisis & acute conditions).
Adults: 4-20mg i. v repeated 3 or 4 times daily
if required.
Children: Upto 1 year lmg; 1-5 years, 2mg; 6-
12 years 4mg. All by i.v injection.
t BETNELAN Tab. GlaxoSmithKline
Betamethasone 0.5mg/tablet
500's pack: 359.10 MRP
DEXAMETHASONE 21,42,48
DEXAMET HAS ONE: Tablet/Injection
Dexamethasone, a synthetically produced gluco­
corticosteroid with a high anti-inflammatory
property. It also has anti-allergic, anti-toxic, anti­
shock, anti-pyretic and immunosuppressive prop­
erties. It is available in oral & injection form, as­
dexamethasone micronized BP/USP 0.5mg/tablet
& dexamethasone sodium phosphate BP/USP
equivalent to dexamethasone phosphate 4mg/ lml
& 5mg/ lml ampoule for i.m & i.v injection; it
can be given by intra-articular route also.
Mode of action: In the body tissues dexametha­
sone diffuses across the cell membranes and
complexes with specific cytoplasmic receptors.
Dexamethasone decreases inflamm ation by
acting within cells to prevent the release of
certain chemicals that are important in the
immune system. These chemicals are normally
involved in producing immune & allergic
responses. Dexamethasone also decreases the
number of white cells circulating in the blood.
Dexamethasone has only minimum mineralocor­
ticoid activity, which makes it suitable for use in
patients with cardiac failure or hypertension.
Because of the long biological half-life (36-54
hours) dexamethasone is specially suitable in
conditions when continuous glucocorticoid action
is desired.
Ind: Severe asthma, hayfever, allergic skin con­
ditions, rheumatoid. arthritis, collagen diseases,
shock and adrenal crisis. Cerebral oedema.
C/I; S/E; Cautions: See under betamethasone.
Dosage & admin: In general, glucocorticoid
dosage depends on the severity of the
conditions and response of the patients. Under
certain circumstances, for instance in stress,
extra dosage adjustments may be necessary.
Bv
� iniection:
.
Acute life-threatening situations: Adults:
Cerebral oedema: Initial dose 8-16mg i.v fol­
lowed by 5mg i.v or i.m every 6 hours, until a
satisfactory result bas been obtained. In brain
surgery these dosages may be necessary until
several days after the operation. T hereafter,
the dosage bas to be tapered off gradually.
•
Increase of intracranial pressure associated
with brain tumours can be counteracted by
continuous treatment.
Other acute conditions, such as shock, severe
allergic reactions, fuliminating infections &
hepatic coma: 8-40mg by slow i.v injection or
infusion.
Suggested dosage for children (above acute
conditions): Dosage requirements are variable
and may have to be changed according to indi­
vidual needs. Usually 0.25-0.5mg/kg of body
weight daily by slow i. v injection or infusion.
Once the acute coditions of the diseases are
under control the dosage should be reduced or
tapered off to the lowest suitable level under
continuous monitoring and observation of the
patient.
Local intra-articular injection: The following
dosages can be recommended: 1.6-3mg large
joints; 0.6-0.Smg small joints, intrabursally
1.6-3mg; in tendon sheaths 0.3-0.Smg.
The frequency of these injections may vary
from every 3-5 days to every 2-3 weeks.
By rectal drip:
In cases of ulcerative colitis: 4mg diluted in
120ml saline.
Bv mouth:
•
Adult, l.5-3mg daily in divided doses, reducing
by 0.25 or 0.5mg every 3 or 4 days to
maintenance 0.5 -1.5mg daily.
Cerebral oedema, initially 4-8mg daily then
10-20mg daily.
Children, under 1 year, not recommended; 1-7
years 1/4 to 1/2 adult dose; 7-12 years 1/2 to
3/4 adult dose, or 0.010-0.04mg/kg body-wt.
Modeefqdministration;
Dexamethasone injections may be adminis­
tered intravenously, subcutaneously, intramus­
cularly, by local injection or as a rectal drip.
Rapid intravenous injection of massive doses
of glucocorticoids may sometimes cause
cardiovascular collapse; the injection should
•
therefore be given slowly over a period of
several minutes.
Intra-articular injections should be given
under strictly aseptic conditions.
+ AMASON Tab. Ambee
Dexamethasone 0.5mg/tablet
lOO's pack: 100.00 MRP
t D-CORT Tab. Globe
Dexamethasone O .Smg/tablet
lOO's pack: 75.00 MRP
+ D-CORT Inj. Globe
Dexamethasone sodium phosphate 5mg/1ml
ampoule: i.m/i.v injection
5mg amp x lO's pack: 150.00 MRP
•
+ DECAFOS lnj. Techno Drugs
Dexamethasone sodium phosphate 5mg/lml
ampoule: i.m/i. v injection
5mg amp x lO's pack: 200.00 MRP
+ DECASON Tab. Opsonin
Dexamethasone 0.5mg/tablet
200's pack: 175.85 MRP
+ DECASON Inj. Opsonin
Dexamethasone sodium phosphate 5mg/ lml
ampoule: i.m/i. v injection

5mg amp x lO's pack: 194.14 MRP
+ DESON Tab. Zenith
Dexamethasone 0.5mg/tablet
250's pack: 125.00 MRP
+ DEXA Tab. Renata
Dexamethasone 0.5mg/tablet
250's pack: 187.00 MRP
+ DEXA Inj. Renata
Dexamethasone sodium phosphate 5mg/l ml
ampoule: i.m/i.v injection
5mg amp x 1O's pack: 250.00 MRP
+ DEXAM Tab. Medimet
Dexamethasone 0.5mg/tablet.
1OO's pack: 100.00 MRP
+ DEXAM Inj. Medimet
Dexamethasone sodium phosphate 5mg/l ml
ampoule: i.m/i.v injection
5mg amp x lO's pack: 150.00 MRP
+ DEXAMET Tab. Rephco
Dexamethasone 0.5mg/tablet.
200's pack: 140.00 MRP
+ DEXAMET Inj. Rephco
Dexamethasone sodium phosphate 5mg/l ml
ampoule: i.m/i.v injection
5mg amp x IO's pack: 110.00 MRP
+ DEXAMETHASON Tab. Bristol
Dexamethasone 0.5mg/tablet.
IOO's pack: 100.00 MRP
+ DEXAMETHASONE Tab. APC Pharma
Dexamethasone 0.5mg/tablet.
1 OO's pack: 42.00 MRP
+ DEXAMIN Tab. Jayson
Dexamethasone 0.5mg/tablet.
lOO's pack: 55.00 IP
+ DEXAMIN Inj. Jayson
Dexamethasone sodium phosphate 5mg/ lml
ampoule: i.m/i.v injection
5mg amp x 1O's pack: 180.00 IP
+ DEXAN Tab. Chemist
Dexamethasone 0.5 mg/tablet.
250's pack. 105.00 MRP
+ DEXAN Inj. Chemist
Dexamethasone sodium phosphate 5mg/lml
ampoule: i.m/i.v injection
5mg amp x 20's pack: 300.00 MRP
+ DEXASONE Tab. Pharmadesh
Dexamethasone 0.5mg/tablet.
1OO's pack. 55.00 MRP
+ DEXISON Tab. Edruc
Dexamethasone BP 0.5mg/tablet.
1OO's pack. 90.00 MRP
+ DEXON Inj. Ibo Sina
Dexamethasone sodium phosphate 5mg/1ml
ampoule: i.m/i.v injection
5mg amp x lO's pack: 160.00 IP
+ DEXONEX Tab. Square
Dexamethasone 0.5 mg/tablet.
IOO's pack. 89.00 MRP
+ DEXONEX Inj. Square
Dexamethasone sodium phosphate 5mg/1ml
ampoule: i.m/i.v injection
5mg amp x IO's pack: 200.00 MRP
+ DEXTASON Tab. Ziska
Dexamethasone 0.5 mg/tablet.
IOO's pack. 60.00 MRP
+ DEXTASON Inj. Ziska
Dexamethasone sodium phosphate 5mg/ lml
ampoule: i.m/i.v injection
5mg amp x I O's pack: 120.00 MRP
I
QIMP-17 (201)
+ DEXTOR Tab. SK+F
Dexamethasone 0.5 mg/tablet.
200's pack. 200.00 MRP
+ G-DEXAMETHASONE Inj. Gonoshas.
Dexamethasone sodium phosphate 5mg/1ml
ampoule: i.m/i.v injection
5mg amp x lO's pack: 100.00 MRP
+ GLUDEX Tab. Kemiko
Dexamethasone 0.5mg/tablet.
1 OO's pack. 100.00 MRP
+ GLUDEX Inj. Kemiko
Dexamethasone sodium phosphate 5mg/1ml
1
ampoule: i.m/i.v injection
5mg amp x lO's pack: 200.00 MRP
+ MERADEXON Inj. Gaco
Dexamethasone sodium phosphate 5mg/ lml
ampoule: i.m/i.v injection
5mg amp x 1's pack: 9.81 MRP
+ ODESON Inj. Beximco
Dexamethasone sodium phosphate 4mg/ l ml
ampoule: i.m/i.v injection
4mg x 10 amps pack: 150.00 MRP
+ O RADEXON Tab. Nuvista
Dexamethasone 0. 5mg/tab let.
200's pack: 230.00 MRP
500's pack: 575.00 MRP
+ ROXADEX lnj. Nuvista
Dexamethasone sodium phosphate 5mg/1ml
ampoule: i.m/i.v injection
5mg amp x !O's pack: 289.30 MRP
+ SONEXA Inj. Aristopharma
Dexamethasone sodium phosphate 5mg/ lml
ampoule: i.m/i.v injection
5mg amp x lO's pack: 150.00 MRP
+ STEDEX lnj. Navana
Dexamethasone sodium phosphate USP 5mg/l ml
ampoule: i.m/i.v injection
5mg amp x 12's pack: 264.00 MRP
+ STERON Tab. Acme
Dexamethasone 0.5mg/tablet.
1OO's pack: 90.00 MRP
+ STERON Inj. Acme
Dexamethasone sodium phosphate USP 5mg/ lml
ampoule: i.m/i.v injection
5mg amp x lO's pack: 200.00 MRP
45
HYDROCORTISONE2l,33,
HYDROCORTISONE: Tablet/Injection
Hydrocortisone is a naturally occurring corticos­
teroid used principally for its anti-inflammatory
and immunosuppressive actions or as hormone
replacement therapy. It is available as- hydrocor­
tisone USP 1Omg tablet for oral administration
and hydrocortisone sodium succinate USP 1OOmg
in vial for parenteral administration.
Mode of action: Hydrocortisone inhibits
prostaglandin synthesis by inhibiting the enzyme
phospholipidase A2. Hydrocortisone reduces vari­
ous vasoactive agents released during inflamma­
tion. It also controls the rate of protein synthesis.
Ind: Medical emergencies amenable to intensive
corticosteroid therapy e.g acute adrenal crisis,
cardiogenic hemorrhagic anaphylactic or septic
shock, shock due to burn, oveiwhelming
infections (with chemotherapy); hypersensitivity
reactions such as angioedema, status asthmaticus;
Inflammatory bowel disease (Ulcerative colitis);
and rheumatic disease.
C/I; S/E; Cautions: See under 'betamethasone'.
•
DRUGS USED IN ENDOCRINE DISEASES
Pregnancy & lactation: This should be advised
in pregnancy and lactation only if absolutely
required.
Dosage & admin: By injection:
Adult: Shock, 100-SOOmg i.v repeated as
necessary every 2-6 hours; Status asthmaticus,
SOOmg i.v stat, may be repeated 4-6 hours
later or followed by an infusion of SOOmg
every 4 hours; Acute adrenal crisis, 250mg i.v
then approximately 250mg every 12 hours
interval by i.v infusion; Ulcerative colitis,
lOOmg dissolved in 120ml saline and adminis­
tered as rectal drip.
Children: ·By slow i.v injection, usual doses are
6-1Omg/kg body wt. but SOmg/kg body-wt.
may be required if life threatening states. The
dose should not fall below 25mg daily.
By oral administration (tablet):
The initial oral dosage_ may vary from 20mg to
240mg of hydrocortisone per day depending
on the specific disease entity being treated. In
situations of less severity lower doses will gen­
erally suffice while in selected patients higher
initial doses may be required. The initial
dosage should be maintained or adjusted until
a satisfactory response is noted. If after a
reasonable period of time there is a lack of
satisfactory clinical response, hydrocortisone
tablets should be discontinued and the patient
transferred to other appropriate therapy. It
should be emphasized that dosage require­
ments are variable and must be individualized
on the basis of the disease under treatment
and the response of the patient.
After a favorable response is noted, the proper
maintenance dosage should be determined by
decreasing the initial drug dosage in small
decrements at appropriate time intervals until
the lowest dosage which will maintain an
adequate clinical response is reached.
+ ANACORT lnj. Techno Drugs
Hydrocortisone sodium succinate I 00mg/2ml
amp: i.m/i.v injection
lOOmg (2ml) amp x 5's pack: 225.00 MRP
+ CORTAID Inj. Novo Healthcare
Hydrocortisone sodium succinate 100mg/2ml
vial: i.m/i.v injection
1OOmg (2ml) vial: 50.00 MRP
+ CORTEF Inj. Aristopharma
Hydrocortisone sodium succinate 100mg/2ml
vial: i.m/i.v injection
lOOmg (2ml) vial: 50.00 MRP
+ CORTINEX Inj. Ziska
Hydrocortisone sodium succinate 100mg/2ml
vial: i.m/i.v injection
1OOmg (2ml) vial: 50.00 MRP
+ COTSON Tab. Opsonin
Hydrocortisone USP 1O mg/tablet
lOmg x lOO's pack: 219.85 MRP •
+ COTSON Inj. Opsonin
Hydrocortisone sodium succinate I 00mg/2ml
vial: i.m/i.v injection
lOOmg (2ml) vial: 44.16 MRP
+ HISON Inj. ACI
Hydrocortisone sodium succinate 100mg/2ml
vial: i.m/i.v injection
1OOmg (2ml) vial: 50.19 MRP
+ HYCORT Inj. Chemist
Hydrocortisone sodium succinate I 00mg/2ml
vial: i.m/i.v injection
 DRUGS USED IN ENDOCRINE DISEASES
1OOmg (2ml) vial: 50.00 MRP
• HYDROCORTISONE-Rotex lnj. Rotex
Medica/City Overseas
Hydrocortisone sodium succinate I 00mg/2ml
vial: i.m/i.v injection
2ml vial: 72.00 TP
• INFLANIL Inj. Navana
Hydrocortisone sodium succinate USP
100mg/2ml vial: i.m/i.v injection
lOOmg (2ml) vial: 50.00 MRP
+ INTASONE Inj. Incepta
Hydrocortisone sodium succinate 100mg/2ml
vial: i.m/i.v injection
lOOmg (2ml) vial: 50.00 MRP
PREDNISOLONE2 1,33, 40
PREDNISOLONE: Tablet/Oral Soln./lnjection.
Prednisolone is a synthetic glucocorticoid. It has
4 times the anti-inflammatory potency and 0.8
times the salt-retaining potency of the natural
adrenocortical hormone, hydrocortisone. It is
available as prednisolone USP 5mg ordinary &
micronised tablet. Micronised tablets are easily
absorbed from the gastro-intestinal tract due to its
special property.
Ind: Bronchial asthma, allergic disorders,
nephrotic syndrome, rheumatoid arthritis,
rheumatic fever, allergic and inflammatory skin
diseases; shock, pulm. oedema, cerebral oedema,
status asthmaticus (as parenteral preparation).
C/I; S/E; Cautions: See below under the text of
methyl prednisolone.
Pregnancy & lactation: See below under the
text of methyl prednisolone.
Dosage & admin: By mouth: Adult, 10-20mg
daily in divided (2-3) doses reducing by 2.5 or
5mg every 3 or 4 days to maintenance 5-l5mg
daily.
Child, under 1 year, not recommended; 1-7
years 1/4 to half adult dose; 7-12years 1/2 to
3/4 adult dose.
By injection: By i.v or i.m injection, upto
lOOmg (as sodium phosphate); by i.m.
injection, prednisolone acetate 25-1 OOmg.
Parenteral route usually used in acute
conditions. After remission of acute symptoms,
continue for a few days orally as mentioned
above.
•ADAM 33 Micro. Tab. Nuvista
Prednisolone USP 5mg & 20mg/tablet
(micronised).
5mg x 300's pack: 342.00 MRP
20mg x 50's pack: 197.50 MRP
+ CORTAN Tab. lncepta
Prednisolone USP 5mg, 1Omg & 20mg/tablet.
5mg x 200's pack: 230.00 MRP
. IOmg x lOO's pack: 207.00 MRP
20mg x 50's pack: 186.50 MRP
+ CORTAN Oral Soln. Incepta
Prednisolone USP 5mg/5ml: syrup.
50ml bot: 60.00 MRP
lOOml bot: 95.00 MRP
•CORTISOL Tab. Aristopharma
Prednisolone USP 5mg, 1Omg & 20mg/tablet.
5mg x 200's pack: 228.00 MRP
lOmg x lOO's pack: 208.00 MRP
20mg x 50's pack: 187.50 MRP
QIMP-17 (202)
•CORTISOL Oral Soln. Aristopharma
Prednisolone USP 5mg/5ml: syrup.
50ml bot: 65.00 MRP
+ DELTA Tab. Bristol
Prednisolone USP 5mg/tablet.
5mg x 500's pack: 350.00 MRP
•DELTACORT Tab. Desh Pharma
Prednisolone USP 5mg/tablet.
5mg x 500's pack: 310.00 MRP
•DELTAPRED Tab. Ziska
Prednisolone USP 5mg, 1Omg & 20mg/tablet.
5mg x 500's pack: 550.00 MRP
lOmg x lOO's pack: 200.00 MRP
20mg x 40's pack: 148.00 MRP
+ DELTASONE Tab. Renata
Prednisolone USP 1 mg, 5mg, lOmg &
20mg/tablet.
lmg x lOO's pack: 33.00 MRP
5mg x 500's pack: 570.00 MRP
lOmg x lOO's pack: 207.00 MRP
20mg x 50's pack: 186.50 MRP
+ DELTASONE Oral Soln. Renata
Prednisolone sodium phosphate USP 5mg/5ml:
syrup.
50ml bot: 60.00 MRP
1OOml bot: 95.00 MRP
+ EDRUSON Tab. Edruc
Prednisolone USP 5mg/tablet
5mg x lOO's pack: 115.00 MRP
+ G-PREDNISOLONE Tab. Gonoshasthaya
Prednisolone USP 5mg/tablet
5mg x 100's pack: 114.00 MRP
•INFLAGIC Tab. Square
Prednisolone USP 5mg & 20mg/tablet
5mg x lOO's pack: 115.00 MRP
20mg x 50's pack: 199.00 MRP
•P CORT Oral Soln. Globe
Prednisolone sodium phosphate USP 5mg/5ml:
syrup.
50ml bot: 60.00 MRP
+ PEDIPRED Oral Soln. Ziska
Prednisolone sodium phosphate USP 5mg/5ml:
syrup.
50ml bot: 60.00 MRP
lOOml bot: 95.00 MRP
+ PRECODIL Tab. Opsonin
Prednisolone USP 5mg, 1Omg & 20mg/tablet
5mg x 200's pack: 202.33 MRP
IOmg x lOO's pack: 181.10 MRP
20mg x 60's pack: 196.88 MRP
+ PRECODIL 5 Oral Soln. Opsonin
Prednisolone USP 5mg/5ml: syrup
50ml bot: 57.18 MRP
lOOml bot: 83.57 MRP
+ PRECODIL 15 Oral Soln. Opsonin
Prednisolone USP l 5mg/5ml: syrup
50ml bot: 70.64 MRP
lOOml bot: 114.79 MRP
+ PRED Tab. SK+F
Prednisolone USP 5mg, 1Omg & 20mg/tablet
5mg x 200's pack: 228.00 MRP
lOmg x lOO's pack: 200.00 �
20mg x 50's pack: 185.00 MRP
+ PREDNELAN Tab. GlaxoSmithKline
Prednisolone USP Smg & 20mg/tablet
5mg x 500's pack: 571.90 MRP
20mg x 1OO's pack: 250.94 MRP
+ PREDNISOLONE Tab. Ambee
Prednisolone USP 5mg/tablet
5mg x 500's pack: 375.00 MRP
+ ZENILON Tab. Zenith
Prednisolone USP 5mg/tablet
5mg x 250's pack: 185.00 MRP
METHYL PREDNISOLONE34 ,60,12s
.
METHYL PREDNISOLONE: Tablet (f.c)
Methyl prednisolone USP 2mg, 4mg & 16mg in
film-coated tablet.
Ind: Endocrine disorders: Primary or secondary
adrenocortical insufficiency, congenital adrenal
hyperplasia, nonsuppurative thyroiditis,
hypercalcemia associated with cancer.
·Rheumatic disorders: Rheumatoid arthritis,
juvenile rheumatoid arthritis, ankylosing
spondylitis, acute and subacute bursitis, synovitis
of osteoarthritis, acute nonspecific tenosynovitis,
post-traumatic osteoarthritis, psoriatic arthritis,
epicondylitis, acute gouty arthritis.
Collagerz diseases: Systemic lupus
erythematosus, systemic dermatomyositis and
acute rheumatic carditis.
Dermatologic diseases: Bullous dermatitis
herpetiformis, severe erythema multiforme
(Stevens-Johnson syndrome), severe seborrheic
dermatitis, exfoliative dermatitis, mycosis
fungoides, pemphigus, severe psoriasis.
Allergy: Seasonal or perennial allergic rhinitis,
drug hypersensitivity reactions, serum sickness,
contact dermatitis, bronchial asthma and atopic
dermatitis.
Ophthalmic diseases: Allergic corneal ulcers,
herpes zoster ophthalmicus, anterior segment
inflammation, sympathetic ophthalmia, keratitis,
optic neuritis, allergic conjunctivitis,
chorioretinitis, iritis and iridocyclitis.
Respiratory dieseases: Symptomatic sarcoidosis,
Loeffier's syndrome not manageable by other
means, berylliosis, aspiration pneumonitis.
Hematological disorders: Idiopathic thrombocy­
topenic purpura in adults, secondary thrombocy­
topenia in adults, acquired (autoimmune)
hemolytic anemia, erythroblastopenia, congenital
(erythroid) hypoplastic anemia.
Neoplastic diseases: For palliative management
of leukemias and lymphomas in adults, acute
leukemia of childhood.
•
Edematous states: To induce a diuresis or
remission of proteinuria in the nephrotic
syndrome, without uremia, of the idiopathic type
or that due to lupus erythematosus.
Gastrointestinal disease: To tide the patient over
a critical period of the disease in ulcerative colitis
& regional enteritis.
Organ transplantation: Methyl prednisolone is
also indicated in case of organ transplantation.
C/I: Systemic fungal infections and known
hypersensitivity to components.
S/E: Short courses of methyl prednisolone are
usually well-tolerated with a few, mild side
effects.
Long term, high doses of methyl prednisolone
may produce predictable and potentially serious
side effects. Whenever possible, the lowest effec­
tive doses of methyl prednisolone should be used
for the shortest length of time to minimize side
effects. Alternate day dosing also can help reduce
side effects. Side effects of methyl prednisolone
and other corticosteroids range from mild annoy­
ances to serious irreversible bodily damage. Side

effects include fluid retention, weight gain, high
blood pressure, potassium loss, headache, muscle
weakness, hair growth on the face, glaucoma,
cataracts, peptic ulceration, growth retardation in
children, convulsions, and psychic disturbances
including depression, euphoria, insomnia etc.
Prolonged use of methyl prednisolone can
depress the ability of the body's adrenal glands to
produce corticosteroids. Abruptly stopping
methyl prednisolone in these individuals can
cause symptoms of corticosteroid insufficiency,
with accompanying nausea, vomiting, and even
shock. Therefore, withdrawal of methyl
prednisolone usually is accomplished by
gradually lowering the dose.
Precautions: Adrenocortical insufficiency may
persist for months after discontinuation of thera­
py; therefore, in any situation of stress occurring
during that period, hormone therapy should be
reinstituted. Since mineralocorticoid secretion
may be impaired, salt and/or a mineralocorticoid
should be administered concurrently.
There is an enhanced effect of corticosteroids on
patients with hypothyroidism and in those with
cirrhosis. Corticosteroids should be used
cautiously in patients with ocular herpes simplex
because of possible corneal perforation. Aspirin
should be used cautiously in conjunction with
corticosteroicis in hypoprothrombinemia. Growth
and development of infants and children on
prolonged corticosteroid therapy should be
carefully observed.
Pregnancy & Lactation: Pregnancy category C.
There are no adequate & well-controlled studies
in pregnant women. As animal reproduction
studies are not always predictive of human
response, this drug should be used during
pregnancy only if clearly needed. Prednisolone is
excreted in breast milk, it is reasonable to assume
that as all corticosteroids appear in small
amounts in breast milk, methyl prednisolone may
also appear in breast milk, but no specific data in
known for methyl prednisolone. A maternal dose
of prednisolone up to 40mg daily is unlikely to
cause systemic effects in the infants. Therefore,
infants should be monitored for adrenal suppre­
ssion if the mothers are taking a higher doses.
Dosage & admin: T h e initial dosage of methyl­
prednisolone tablet may vary from 2mg to
40mg per day, depending on the specific dis­
ease entity being treated. Clinical situations in
which high dose therapy may be indicated
include multiple sclerosis (200mg/day), cerebral
edema (200-lOOOmg/day) and organ
transplantation (up to 7mg/kg/day).
In situations of less severity lower doses will
generally suffice. The initial dosage should be
maintained or adjusted until a satisfactory
response is noted. If after a reasonable period
of time there is a lack of satisfactory clinical
response, methyl prednisolone should be dis-
,
continued and the patient transferred to other·
appropriate therapy. It should be emphasized
that dosage requirements are variable and
must be individualized on the basis of the dis­
ease under treatment and the response of the
patient. If after long-term therapy the drug is
to be stopped, it is recommended that it should
be withdrawn gradually rather than abruptly.
After a favorable response is noted, the proper
I
QIMP-17 (203)
maintenance dosage should be determined by
decreasing the initial drug dosage in small
decrements at appropriate time intervals until
the lowest dosage which will maintain an ade­
quate clinical response is reached. It should be
kept in mind that constant monitoring is
needed in regard to drug dosage. If after long­
term therapy the drug is to be stopped, it is
recommended that it should be withdrawn
gradually rather than abruptly. As alternate
day therapy, the typical methyl prednisolone
(4mg tablet) can be used to treat and to
control inflammation associated with arthritis
and other allergic conditions as follows:
Day 1: 2 tablets (4mg x 2) before breakfast+ 1
tablet (4mg) after lunch+ 1 tablet (4mg) after
dinner+ 2 tablets (4mg x 2) at bedtime;
Day 2: 1 tablet before breakfast+ 1 tablet
after lunch+ 1 tablet after dinner+ 2 tablets
at bedtime;
Day 3: 1 tablet before breakfast + 1 tablet
after lunch+ 1 tablet after dinner + 1 tablet at
bedtime;
Day 4: 1 tablet before breakfast + 1 tablet
after lunch + 1 tablet at bedtime;
Day 5: 1 tablet before breakfast+ 1 tablet at
bedtime;
Day 6: 1 tablet.
Drug inter: Erythromycin, clarithromycin,
phenobarbital, phenytoin, rifampin and
ketoconazole inhibit the metabolism of methyl
prednisolone. Estrogens, including birth control
pills, can increase the effect of corticosteroids by
50%. Cyclosporin reduces the metabolism of
methyl prednisolone while methyl prednisolone
reduces the metabolism of cyclosporin. methyl
prednisolone may increase or decrease the effect
of blood thinners (e.g. Warfarin). For all these
interactions, the dose of methyl prednisolone may
need to be lowered.
+ MEDROL Tab. Pfizer/Janata
Methyl prednisolone USP 4mg & 1 6mg/tablet (f.c)
4mg x lOO's pack: 752.00 MRP
16mg x 14's pack: 328.30 MRP
+ METIDPRED Tab. General
Methyl prednisolone USP 2mg & 4mg/tablet (f.c)
2mg x 60's pack: 180.00 MRP
4mg x 45's pack: 225.00 MRP
• • •
METHYL PREDNISOLONE ACETATE:
Injection
Methyl pred.nisolone acetate 40mg/ml; lml &
2ml vial: injection
Ind: Rheumatoid arthritis, inflammatory & aller­
gic conditions, osteoarthritis, cerebral oedema.
C/I; S/E; Cautions: See above under the text of
methyl prednisolone.
Pregnancy & lactation: See above under the
text of methyl prednisolone.
Dosage & admin: Rheumatoid &
osteoarthritis: The dosage depends upon the
size of the joint and severity of the conditions;
max. dose may be upto 120 mg. Injection may
be repeated if needed at an interval of 1 to 5
or more weeks depending upon the degree of
relief obtained from initial dose.
Dermatological conditions: 40-1 20mg (1-3ml).
DRUGS USED IN ENDOCRINE DISEASES
Allergic conditions: 80-1 20mg (2-3ml).
Collagen diseases: 40-120mg (l-3ml) repeated
2-3 weekly if required.
Adrenogenital syndrome: 40mg (lml) every 2
weeks.
Note: For further information, please consult
manufacturer's literature.
+ DEPOMED lnj. Drug Inter.
Methyl prednisolone acetate USP 40mg/ml; 1 ml
& 2ml/vial: injection
1 ml (40mg) vial x 3's pack: 225. 00 MRP
2ml (80mg) vial x 3's pack: 300.00 MRP
+ DEPO-MEDROL lnj. Pharmacia-Pfizer/
Janata
•
Methyl prednisolone acetate 40mg/ml; lml &
2ml vial: injection
lml (40mg) vial: 201.22 MRP
2ml (80mg) vial: 232.20 MRP
+ MEDROL lnj. Techno Drugs
Methyl prednisolone acetate 40mg/ml; 1 ml &
2ml vial:·injection
lml (40mg) vial x S's pack: 325.00 MRP
2ml (80mg) vial x l's pack: 90.00 MRP
+ UNI-MEDROL Inj. Chemist
Methyl prednisolone acetate 40mg/ml; 1n1l &
2ml vial: injection
lml (40mg) vial x 2's pack: 1 30.00 MRP
2ml (80mg) vial x 2's pack: 1 80.00 MRP
• • •
METHYL PREDNISOLONE SODIUM
SUCCINATE: Injection .
Methyl prednisolone sodium succinate 40mg,
1 25mg, 500mg & l gm vial: injection
Ind: See below with the dosage.
C/I; S/E; Cautions: See above under the text of
methyl prednisolone.
Pregnancy & lactation: Please see above under
the text of methyl prednisolone acetate.
Indications & Dosage: 1. As adjunctive therapy
in life-threatening conditions:The
recommended dose is 30mg/kg given i. v over a
period of at least 30 minutes; this dose may be
repeated evry 4-6 hours for up to 48 hours.
2. Corticosteroid responsive diseases in
exacerbation and/or unresponsive to standard
therapy- suggestive schedule:
i. Rheumatic disorders- lgm/day for 1, 2, 3 or
4 days i.v or lmg/month for 6 months i.v.
ii. Systemic lupus erythematosus (SLE)­
l gm/day for 3 days i.v. iii. Multiple sclerosis:
l gm/day for 3 days or 5 days i.v.
iv. Oedematous states (e.g glomerulonephritis,
lupus nephritis)- 30mg/kg every other day for
4 days i.v or l g m/day for 3, 5 or 7 days i.v.
3. Mild to moderately emetogenic
chemotherapy: Administer 250mg i.v over at
least 5 minutes 1 hour before chemotherapy,
at the initiations of chemotherapy, & at the
time of discharge. A chlorinated phenothiazine
may also be used with the first dose of methyl
prednisolone sodium succinate injection for
increased effect.
4. Severely emetogenic chemotherapy:
Administer methyl prednisolone sodium succi­
nate 250mg i. v over at least 5 minutes with
appropriate dosage of metoclopramide or a
butyrophenone 1 hour before chemotherapy,
then 250mg i. v at the initiation of chemothera-
DRUGS USED IN ENDOCRINE DISEASES
py & at the time of discharge.
5. In other indications: Initial dosage will vary
from 10 to 500mg depending on the clinical
problem being treated. Larger dosage may be
required for short-term management of
severe, acute conditions. The initial dose, up to
250mg, should be given i. v over a period of at
least 5 minutes; subsequent dosage may be
given i.v or i.m at intervals dictated by the
patients response & clinical conditions.
Corticosteroid therapy is an adjunct to & not
replacement for, conventional therapy. Dosage
may be reduced for infants & children but
should be governed more by severity of the
condition & response of the patient than by
age or size. It should not be less than 0.5mg/kg
every 24 hours.
Methyl prednisolone sodium succinate may be
administered by i.v or i.m injection or by i.v
infusion, the preferred method for initial
emergency use being intravenous injection.
Note: For further information, please consult
manufacturer's literature.
t METHYL PREDNISOLONE SODIUM
SUCCINATE Inj. Rotex/City Overseas
Methyl predni�olone sodium succinate 500mg
vial: injection
500mg vial x l's pack: 760.00 TP
t PRO-MEDROL Inj. Techno Drugs
Methyl prednisolone sodium succinate 500mg &
I gm vial: injection
500mg vial x l's pack: 800.00 MRP
l gm vial x l's pack: 1200.00 MRP
t SOLU-MEDROL lnj. Pharmacia­
Pfizer/Janata
Methyl prednisolone sodium succinate 40mg,
125mg, 500mg & l gm vial: injection
40mg vial x l's pack: 359.26 MRP
125mg vial x l's pack: 598.77 MRP
500mg vial x l 's pack: 1580.24 MRP
l gm vial x l's pack: 1975.65 MRP
+ SOLUPRED Inj. Ziska
Methyl prednisolone sodium succinate 500mg &
1 gm vial: injection
500mg vial x l's pack: 600.00 MRP
l gm vial x l's pack: 1000.00 MRP
. JI
TRIAMCINOLONE21,33
TRIAMCINOLONE: Tablet/Injection
Ind: Allergic disease, dermatoses or generalized
rheumatoid arthritis and other connective tissue
disorders. May also be given by intra-articular or
intra-bursal administration in traumatic arthritis,
synovitis, bursitis and tendinitis.
C/I: Local for systemic viral infections, tubercu­
losis, active peptic ulcer, acute glomerulonephri­
tis. Pregnancy is relative contraindication for
corticosteroid therapy particularly in the first
trimester of pregnancy. Local administration is
contraindicated in presence of active infections.
S/E: Cushingoid syndrome, weakness, bruising
or purpura, masking of infections, activation or
aggravation of peptic ulcer, activation of latent or
aggravation of existing diabetes, altered
menstrual cycle, hirsutism, acnel form eruptions.
There should be gradual termination in dosage.
Dosage & Admin: For children from 6 to 12
years, initial dose is 40mg. Initial systemic
QIMP-17 (204)
dose for adults and children over 12 years is
40 to 80mg. For adults maximum daily dose is
80 to 1OOmg. For local areas, dose for adults is
up to 1Omg for smaller and 40mg for larger
areas.
+ ALFACORT lnj. Ziska
Triamcinolone acetonide 40mg/ml: i.m injection.
lml vial: 60.00 MRP
t CYNOCORT Inj. Techno Drugs
Triamcinolone acetonide 40mg/ml: i.m injection.
lml amp: 60.00 MRP
+ TRECILON Inj. Rephco
Triamcinolone acetonide 40mg/ml: i.m injection.
lml amp x l's pack: 65.00 MRP
+ TRIACIN Inj. Kemiko
Triamcinolone acetonide 40mg/ml: i.m injection.
lml amp x 1 's pack: 60.00 l\1RP
+ T RIALON Inj. Drug Inter.
Triamcinolone acetonide 40mg/n1l: i.m injection.
lml amp x 3's pack: 210.00 MRP
+ TRIMCORT Inj. Chemist
Triamcinolone acetonide 40mg/ml: i.m injection.
lml amp x 4's pack: 240.00 MRP
+ TRIMON Inj. Globe
Triamcinolone acetonide 40mg/ml: i.m injection.
l m l amp x S's pack: 350.00 MRP
4. SEX HORMONES21
Sex hormones are discussed under the
following broad headings:
1 Female sex hormones
2 Male sex hormones
3 Anabolic steroids
4 Oral Contraceptive prepns.
Female Sex hormones
There are two groups of female sex hormones:
1. Estrogens &
2. Progestogens.
ESTROGENS21,33
Estrogen is a female sex hormone produced by
the ovary & also by the placenta during
pregnancy. The most potent natural estrogen is
estradiol-17P .
In terms of estrogenic activity natural estrogens
( estradiol, estrone & estriol) have a more appro­
priate profile for hormone replacement therapy
(HRT) than synthetic estrogens ( ethinylestradiol,
mestranol & stilboestrol); the profile of conjugat­
ed estrogens resembles that of natural estrogens.
Estrogen therapy is given cyclically or
continuously for a number of gynaecological
conditions. If long-term therapy is required a
progestogen should be added to reduce the risk
of cystic hyperplasia of the endometrium and
possible transformation to cancer. This addition
of a progestogen is not necessary if the patient
has had a hysterectomy or in the case of tibolone.
ESTRIOL21,47
ESTRIOL: Tablet/Cream
Estriol is a natural estrogenic hormone. It is
available as estriol BP 1111g/tablet & l mg/gram of
cream.
Ind: See below with dosage and administration.
C/I: Pregnancy; thrombosis; known or suspected
oestrogen-dependent tumours; undiag11osed
vaginal bleeding; a history of manifestation or
deterioration of otosclerosis during pregnancy or
previous use of steroids.
S/E: Breast tension or pain, nausea, spotting,
fluid retention and cervical hypersecretion may
occasionally occur and be indicative of too high a
dosage. Headache, hypertension, leg cramps and
vision disturbances are seldom observed. In
general most of these adverse reactions disappear
after the first treatment week. As estriol cream is
applied to the mucosal surfaces, it may cause
local irritation or itching.
Pregnancy & lactation: This medicine is con­
traindicated during pregnancy. There are insuffi­
cient data on the use of this medicine during
breast-feeding to assess potential harm to the
infant. It is known, however, that estriol is excret­
ed in breast milk & may decrease milk production.
Precautions & warnings:
1. In order to prevent endometrial stimulation,
the daily dose should not exceed 8mg (or 1
application of intravaginal cream- 0.5mg estriol)
nor should this maximum dose be used for longer
than several weeks.
2. During prolonged treatment with oestrogens,
periodic medical examinations are advisable.
3. With vaginal infections, a concomitant specific
treatment is recommended.
4. Patients also should be monitored for the other
adverse effects as with other oestrogens.
Dosage & Admin:
Tablet preparation:
Ind. & Dosage: Atrophy of the lower urogenital
tract related to oestrogen dficiency leading to
dyspareunia, dryness and itching, recurrent
infections of the va gina and lower urinary tract
including mild urinary incontinence: 4-8mg per
day for the first week, followed by a gradual
reduction, based on relief of symptoms, until a
maintenance dosage (e.g. 1-2mg per day) is
reached. In certain cases of urinary
incontinence a higher maintenance dosage will
•
be required.
Pre- & postoperative therapy in post­
menopausal women undergoing vaginal
surgery: 4-8mg per day in the 2 weeks before
surgery; 1-2mg per day in the 2 weeks after
surgery.
Climacteric complaints such as hot flushes and
night sweating: 4-8mg per day during the first
week, followed by a gradual reduction. For
maintenance therapy the first week, followed ..
. ,
. (
.-
.
.
>
.
by a gradual reduction. For maintenance ther-
·-
apy the lowest effective dosage should be used.
A diagnostic aid in case of a doubtful atrophic
cervical smear: 2-4mg per day for 7 days
before taking the next smear.
Infertility due to cervical hostility: In general 1-
2mg per day on days 6-15 of the menstrual
cycle. However, for some patients dosages flS
low as 0.25mg per day are sufficient. Whereas
others inay need up to 8mg per day.
Therefore, the dosage should be increased
each month until an optimal effect on the cer-

vical mucus is obtained.
Administration: Estriol tablets should be taken
orally, preferably with some fluid. It is
important that the total daily dose is taken at
one time.
Cream preparation:
Ind. & Dosage: Atrophy of the lower urogenital
tract related to oestrogen dficiency leading to
dyspareunia, dryness and itching, recurrent
infections of the vagina and lower urinary tract
including mild urinary incontinence:
1 application per day for the first week,
followed by a gradual reduction, based on
relief of symptoms, until a maintenance dosage
(e.g. 1 application twice a week) is reached. In
,
certain cases of urinary incontinence a higher
maintenance dosage will be required.
Pre- & postoperative therapy in post­
menopausal women undergoing vaginal
surgery: 1 application per day in the 2 weeks
before surgery; 1 application twice a week in
the 2 weeks after surgery.
A diagnostic aid in case of a doubtful atrophic
cervical smear: 1 application on alternate days
in the week before taking the smear.
Administration: Estriol cream should be
administered intravaginally by means of a
calibrated applicator before retiring at night. 1
•
application (applicator filled to the ring mark)
contains O.Sgm estriol cream which
corresponds with O.Smg estriol.
+ DEFOGEN Tab. Incepta
Estriol lmg/tablet.
30's pack: 240.00 MRP
+ FEMASTIN Tab. Square
Estriol 1 mg/tablet.
30's pack: 240.00 MRP
+ OVESTIN Tab. Nuvista
Estriol 1mg/tablet.
30's pack: 297.00 MRP
+ OVESTIN Cream Nuvista
Estriol 1 mg/gram: cream.
Ind: See above under the doses.
15gm tube with applicator: 1114.00 MRP
CONJUGATED ESTROGENS62,134
CONJUGATED ESTROGENS: Tablet
Conjugated oestrogens (equine) 0.625mg &
l .25mg/tablct.
Ind: Menopausal & post-menopausal oestrogen
replacement; post-menopausal osteoporosis;
senile vaginitis, functional amenorrhoea, prostatic
carcinoma.
•
C/I: Pregnancy. Uterine myomatosis.
Endometriosis. Uterine or mammary carcinoma.
Severe cardiac, hepatic or renal disease. History
of thromboembolic disease. Undiagnosed vaginal
bleeding.
S/E: Nausea & vomiting, wt. gain, breast
enlargement and tenderness, withdrawal bleeding,
sodium retention with oedema, changes in liver
function, jaundice, rashes and chloasma,
d.effression, headache, endometrial carcinoma in
•
post-menopausal women.
Dosage & admin: Adult-Menopausal, usually
0.625mg or 1.25mg daily for 21 days starting
on 5th day of menstruation then repeat after
7 days. Postmenopausal osteoporosis,cyclically
QIMP-17 (205)
0.625mg or 1.25mg daily. Functional amenor­
rhoea, 0.625mg or 1.25mg daily for 21 days.
For the last 7 days progesteron therapy should
be added.
Child: Not applicable.
+ ESTRACON Tab. Renata
Conjugated estrogens (equine) 0.625mg/tablet (f.c)
0.625 mg x 28's pack: 560.00 MRP
+ PREMICON Tab. Techno Drugs
Conjugated estrogens USP 0.625mg/tablet (film­
coated).
0.625mg x 28's pack: 420.00 MRP
PROGESTERONE21,33,40,70
PROGESTERONE: Tablet/Gel/Injection/
Pessary
Progesterone is a female sex hormone produced
by the corpus luteum, which develops from the
ruptured ovarian follicle immediately after
ovulation i.e the empty follicle that remains when
the ovum emerges at mid-cycle. Synthetic
progestogenic hormone preparations are availble
as- micronised progesterone, allylestrenol,
dydrogesterone, lynestrenol,
medroxyprogesterone & norethisterone, in the
form of tablet, gel, injection & pessary.
Mode of action: Progesterone after production
from ruptured ovarian follicle promotes
transformation of the estrogen-primed
endometrium, as a result, the endometrium is
transformed into an environment that is receptive
to embryo implantation and able to support early
pregnancy. Synchronization between embryo
development and endometrial receptivity begins
with ovulation and production of progesterone by
the corpus luteum. The embryo arrives in the
uterine cavity from the fallopian tube 4 to 5 days
after ovulation-cycle day 18 or 19 at the morula
stage, but does not implant until day 20 or 21 at
the blastocyst stage. At that time, there is peak
activity of the glands of the endometriuni and it
is best prepared to support the embryo. Thus, it is
clear that the establishment of pregnancy depends
not only on successful fertilisation and embryo
quality but on endometrial receptivity to embryo
implantation.
Progesterone is clearly a critical hormone in
achieving and maintaining pregnancy. This
hormone is essential for the preparation of the
endometrium for implantation. It is also essential
for the maintenance of a viable pregnancy. If
progesterone is withdrawn, miscarriage will
occur.
Ind: See below under individual preparation.
C/I: Progesterone should not be used in
individuals with any of the following conditions:
1. Pregnancy or suspected pregnancy.
2. Known sensitivity to progesterone.
3. Undiagnosed vaginal bleeding.
4. Liver dysfunction or disease.
5. Known or suspected malignancy of the breast
or genital organs.
6. Missed abortion.
7. Active thrombophlebitis or thromboembolic
disorders, or a history of hormone-associated
thro�bophlebitis or thromboembolic
disorders.
Adverse effects: Nausea, weight-gain, headache,
-
DRUGS USED IN ENDOCRINE DISEASES
depression, changes in libido, breast enlargement,
altered menstrual cycles, virilisation of foetus,
acne, urticaria.
Also see under the individual preparation.
Warnings: The physician be alert to the earliest
manifestations of thrombotic disorders
(thrombophlebitis, cerebrovascular disorders,
pulmonary embolism, and retinal thrombosis). If
any of these occur or be suspected, the drug
should be discontinued immediately.
Progesterone and progestins have been used to
prevent miscarriage in women with history of
recurrent spontaneous pregnancy losses. But, no
adequate evidence is available to show that they
are effective for this purpose.
Precautions: General:
1. The pretreatment physical examination should
include special reference to breast and pelvic
organs, as well as papanicolaou smear.
2. In cases of breakthrough bleeding, as in all
cases of irregular vaginal bleeding, nonfunctional
causes should be considered; in cases of undiag­
nosed vaginal bleeding, adequate diagnostic
measures should be undertaken.
3. Because progestogens may cause some degree
of fluid retention, conditions which might be
influenced by this factor (e.g epilepsy, migraine,
asthma, cardiac or renal dysfunction) require
careful observation.
4. The pathologist should be advised of
progesterone therapy when relevant specimens
are submitted.
5. Patients who have a history of psychic
depression should be carefully observed and the
drug discontinued if the depression recurs to a
serious degree.
6. A decrease in glucose tolerance has been
observed in a small percentage of patients on
estrogen-progestin combination drugs. The
mechanism of this decreaes is not known. For
this reason, diabetic patients should be carefully
observed while receiving progestin therapy.
7. In case of intravaginal gel preparation or
pessary, the patient should be advised not to use
concurrently with other local intravaginal
therapy. If it is needed to be used concurrently,
there should be at least a 6-hour interval.
Dosage & admin: Please see below under the
individual preparation.
+ CRINONE 8°/o Gel Serono/Janata
Healthcare
Crinone is a bioadhesive vaginal gel preparation,
containing micronized progesterone 8% in an
emulsion system, which is contained in single
use, one piece polyethylene vaginal applicators.
(There is also another preparation with low
strength - Crinone 4%, not available now in our
country).
Ind: i. Assisted reproductive technology -
Crinone 8% (90mg) is indicated for progesterone
supplementation or replacement as part of an
assisted reproductive technology ('ART')
treatment for infertile women with progesterone
deficiency.
ii. Secondary amenorrhea - Crinone 4% is indi­
cated for the treatment of secondary amenorrhea.
Crinone 8% (90mg) is indicated for use in
women who have failed to respond to treatment
with crinone 4%.
C/I: See above under the text of progesterone.
DRUGS USED IN ENDOCRINE DISEASES
Adverse reactions:
Assisted reproductive technology (ART): In a
study of 61 women with ovarian faliure
undergoing a donor oocyte transfer procedure
receiving progesterone 8% (90mg) twice daily,
treatment-emergent adverse events occurring in
5% or more of the women are as follows:
Body as a whole- bloating, cramps, pain;
Central & peripheral nervous system- dizziness,
headache;
Gastrointestinal system- nausea;
Reproductive- breast pain, genital moniliasis,
vaginal discharge; Skin and appendages- genital
pruritus.
In a second study of 139 women using proges­
terone 8% (90mg) once daily for luteal phase
support while undergoing an 'in vitro fertilization'
procedure, treatment-emergent adverse events
reported in 5% or more of the women are as
follows:
Body as a whole- abdominal pain, perinea! pain;
Central & peripheral nervous system- headache;
Gastrointestinal system- constipation, diarrhea,
nausea, vomiting;
Musculoskeletal system- arthralgia;
Psychiatric- depression, libido decreased,
nervousness, somnolence;
Reproductive- breast enlargement, dyspareunia;
Urinary system- nocturia.
Secondary amenorrhea:
In three studies, 127 women with secondary
amenorrhea received estrogen replacement thera­
py and progesterone 4% or 8% every other day
for six doses. Treatment emergent adverse events
during estrogen and progesterone treatment that
occurred in 5% or more of women are as follows:
Body as a whole- abdominal pain, appetite
increased, abnormal crying, allergic reaction,
allergy, asthenia, edema, face edema, fever, hot
flushes, influenza-like symptoms, water retention,
xerophthalmia decreased, asthenia, edema, face
edema, fever, hot flushes, influenza-like
decreased, asthenia, edema, face edema, fever,
hot fiushes, influenaz-like symptoms, water
refention, xerophthalmia, bloating, cramps,
fatigue;
Central & peripheral nervous system- headache;
Gastrointestinal system- nausea;
Musculoskeletal system- back pain, myalgia;
Psychiatric- depression, emotional !ability, sleep
disorder;
Reproductive- vaginal discharge;
Resistance mechanism- upper respiratory tract
infection;
Skin and appendages- genital pruritus.
Additional adverse events reported in women at
a frequency < 5% in progesterone ART and
secondary amenorrhe_a studies include:
Body as a whole- abnormal crying, allergic
reaction, allergy, appetite decreased, asthenia,
edema, face edema, fever, hot flushes, influenza­
like symptoms, water retention, xerophthalmia;
Cardiovascular system- syncope;
Central & peripheral nervous system- migraine,
tremor;
Autonomic nervous system- dry mouth, increased
sweating;
Gastrointestinal- dyspepsia, eructation,
flatulence, gastritis, toothache;
Metabolic & nutritional- thirst;
QIMP-17 (206)
Musculoskeletal system- leg cramps, leg pain,
skeletal pain;
Neoplasm -benign cyst;
Platelet, bleeding & clotting- purpura;
Psychiatric- aggressive reactions, forgetfulness,
. .
1nsomn1a;
RBC- anemia;
Reproductive- dysmenorrhea, premenstrual
tension, vaginal dryness;
Resistance mechanism-infection, pharyngitis,
sinusitis, urinary tract infection;
Respiratory system- asthma, dyspnea,
hyperventilation, rhinitis;
Skin and appendages- acne, pruritis, rash,
seborrhea, skin discoloration, skin disorder,
urticaria; Urinary system- cystitis, dysuria,
micturition frequency;
Vision disorder- conjunctivitis.
Warnings & Cautions: Please see above under
the text of progesterone.
Pregnancy & lactation: Progesterone 8%
(90mg) has been used to support embryo
implantation and maintain pregnancies through
its use as part of ART treatment regimens in two
clinical studies. In the first study, 54 women were
treated with progesterone 8%. Out of them
clinical pregnancies occurred in 26 wqmen
(48%). Among these 26 pregnancies, one woman
had an elective termination of pregnancy at 19
weeks due to congenital malformations
(omphalocele) associated with a chromosomal
abnormality; one woman pregnant with triplets
had an elective termination of her pregnancy;
seven women had spontaneous abortions; and 17
women delivered 25 apparently normal newborns.
In the second study, progesterone 8% (90mg) was
used in the luteal phase support of women
undergoing 'in vitro fertilization (IVF)'
procedures. In this multi-centre, open-label study,
139 women received progesterone 8% (90mg)
once daily beginning within 24 hours of embryo
transfer and continuing through day 30 past­
transfer. Clinical pregnancies assessed at day 90
post-transfer were seen in 36 women (26%). 32
women (23%) delivered newborns & 4 women
(3%) had spontaneous abortions. Of the 47(?)
newborns delivered, one had a teratoma
associated with a cleft plate; one had respiratory
•
distress syndrome; 44 were apparently normal
& one has lost to followup.
Detectable amounts of progestins have been iden­
tified in the milk of mothers receiving them. The
effect of this on the nursing infant has not been
determined. Pregnancy: progesterone 8% (90mg)
Dosage & admin: Assisted reproductive
technology (ART): Progesterone 8°/o (90mg) is
adminis-tered vaginally at dose of 90mg once
daily in women who require progesterone
supplementation. Progesterone 8°/o (90mg) is
adminis-tered vaginally at a dose of 90mg
twice daily in women with partial or complete
ovarian failure who require progesterone
replacement. If pregnancy occurs, treatment
may be continued until placental autonomy is
achieved, up to 10-12 weeks.
Secondary amenorrhea: Progesterone 4°/o is
administered vaginally every other day up to a
total of six doses. For women who fail to
respond, a trial of progesterone 8°/o (90mg)
every other day up to a total of six doses may
be instituted.
It is important to note that a dosage increase
from the 4°/o gel can only be accomplished by
using the 8o/o gel. Increasing the volume of gel
administered dose n{)t increasee the amount of
progesterone absorbed. •
How to use Crinone: Please consult the
manufacturer's insert.
Drug inter: No drug interactions have been
assessed with crinone.
Price:
Crinone 8% single-use prefilled applicator x l 5's
pack: 4564.80 MRP
.
+ MICROGEST Softgel Cap. Renata
Microgest softgel capsule contains micronised
progesterone, which is structurally and
biologically identical to natural endogenous
progesterone. Micronisation increases the •
-
bioavailability of progesterone. It is available as-
progesterone BP I OOmg & 200mg per softgel
capsule for oral & vaginal use.
Ind: 1. Maintenance of pregnancy in cases of
threatened and recurrent abortion.
2. Luteal support during IUI and ART procedures
IVF-ET.
3. Luteal support in cases of proven luteal phase
insufficiency.
4. Along with estrogen in post-menopausal
hormone replacement therapy (HRT) either in
sequential or in continuous regimen.
5. To prevent endometrial hyperplasia where
endogenous estrogen is present.
6. As progesterone challenge test in secondary
amenorrhoea.
7. For cycle control along with estrogen therapy.
8. Dysfunctional uterine bleeding (DUB)
9. Premenstrual tension.
10. Endometriosis.
11. Oocyte donation programme.
12. Benign mastopathy.
C/I: Hypersensitivity, hepatic dysfunction, undi­
agnosed vaginal bleeding, porphyria, cancers of
uterus and genital organs, breast cancers, history
of stroke or blood clots. It should not be used in a
case of miscarriage and tissue left in the uterus.
S/E: Progesterone is devoid of estrogenic, andro­
genic and mineralocorticoid effects. Mild somno­
lence and other CNS side effects like depression,
breast tenderness and bloating are reported. Side
effects are less when vaginal route is used.
Precautions: Severe renal insufficiency, diabetes
mellitus, seizures, migraine, headache, heart
diseases, depression.
Dosage & admin: The usual recommended
dose: Microgest 100mg/200mg 2 to 3 softgel
capsules daily by the oral or vaginal routes in
divided doses. Flexible dosage regimen can be
followed depending on the indication and
requirements of patients.
Maintenance of pregnancy in cases of
threatened I recurrent abortion: Microgest 200
to 400mg per day in divided doses.
In-vitro fertilization and embryo transfer:
Microgest 200mg thrice a day from the day of
embryo transfer till pregnancy is confirmed. If
pregnant, it is continued till 12th week of
pregnancy.
HRT: In sequential regimen: Microgest 200mg
daily for 12 days in last 2 weeks of each thera­
peutic cycle. In continuous regimen: Microgest

100mg daily throughout the month along with
estrogen.
Oocyte donation programme: Microgest 1OOmg
twice daily from the day of transfer till
pregnancy is confirmed. This may be
increased to a maximum of 600mg per day
and continued till 12th week of pregnancy.
Luteal support: Microgest 100mg thrice a day
from the 17th day of the cycle for 10 days in
induced cycle. If pregnant, it is continued till
12th week of pregnancy.
Luteal phase insuf
f iciency: Microgest l OOmg
thrice daily to be continued up to 12 weeks of
pregnancy, increasing the dose by lOOmg/day/
week to a maximum of 600mg/day in divided
-·
doses if required.
I
In secondary amenorrhoea: Microgest 300mg
for 10 days results in withdrawal bleeding in
80°/o of cases.
Premenstrual syndrome: Microgest 100-200mg
daily for 10 days from 17th to 26th day of each
menstrual cycle.
Benign mastopathy: Microgest 200-300mg for
10 days per month, usually from 17th to 26th
day of the monthly cycle.
Drug inter: Ketoconazole inhibits the
metabolism of progesterone.
IOOmg x 30's pack: 450.00 MRP
200mg x 30's pack: 900.00 MRP
ALLYLESTRENOL62
ALLYLESTRENOL: Tablet
Allylestrenol is an orally active progestogen. It is
an effective and safe pregnancy maintaining
preparation. It is available as 5mg tablet for oral
administration.
Mode of action: Allylestrenol has a pronounced
pregnancy maintaining action in castrated ani­
mals without producing hormonal side-effects. In
the human, premature termination of pregnancy
often follows a fall in the levels of placental hor­
mones. Allylestrenol has been shown to stimulate
•
the placental progesterone production in vitro and
to promote the secretion of placental hormones
(human chorionic gonadotrophin, human
placental lactogen, estrogens and progesterone)
and oxytocinase in patients with pregnancy at
risk. In agreement to this the trophoblastic layers
of the placenta show histological signs of
activation. Clinical studies have indicated that
allylestrenol is an effective and safe pregnancy
maintaining preparation. Administration of
allylestrenol in combination with bed rest can
remove or prevent the threat of abortion in early
pregnancy or stop threatened premature labor.
Ind: Threatened abortion, habitual abortion;
threatened premature labor.
C/I: There are no known contra-indications.
.
'
, AIR: Allylestrenol is generally well tolerated.
Serious adverse reactions have neither been
reported in the mother nor in the offspring.
Gastrointestinal complaints (nausea, vomiting)
have been reported occasionally.
Precautions & warnings: No warnings or
precautions are applicable.
Dosage & admin: T hreatened abortion: 5mg
three times daily for 5-7 days. If necessary, the
treatment period may be extended. After dis­
appearance of the symptoms the dosage
QIMP-17 (207)
should be gradually reduced unless symptoms
return.
Habitual abortion: 5-10mg daily as soon as
pregnancy has been diagnosed. The adminis­
tration should be continued until at least one
month after the end of the critical period.
Threatened premature labor: The dosage must
be determined individually. High dosages (up
to 40mg daily) have been used.
+ ALLYGEST Tab. Nuvista
Allylestrenol 5mg/tablet
30's pack: 231.00 MRP
+ ALLYNOLTab. Popular
Allylestrenol 5mg/tablet
45's pack: 360.00 MRP
+ GESTON Tab. Square
Allylestrenol 5mg/tablet
30's pack: 240.00 MRP
+ GESTRENOL Tab. Renata
Allylestrenol 5mg/tablet
30's pack: 240.90 MRP
t NIDAGEST Tab. Chemist
Allylestrenol 5mg/tablet
30's pack: 240.00 MRP
+ PRELAB Tab. ACI
Allylestrenol 5mg/tablet
45's pack: 360.00 MRP
.•
D YDROGESTERONE149
DYDROGESTERONE: Tablet
Dydrogesterone is an orally-active progestogen.
It is available as- dydrogesterone 1Omg film­
coated tablet for oral administration.
Mode of action: Dydrogesterone (progestogen)
produces a complete secretory endometrium in an
oestrogen-primed uterus thereby providing
protection for estrogen induced increased risk for
endometrium hyperplasia and/or carcinogenesis.
It is indicated in all cases of endogenous
progesterone deficiency. Dydrogesterone bas no
estrogenic, no androgenic, no thermogenic, no
anabolic and no corticoid activity.
Ind: Hormone replacement therapy: To counter­
act the effects of unopposed oestrogen on the
endometrium in hormone replacement therapy for
women with disorders due to natural or surgical
induced menopause with an intact uterus.
Progesterone deficiencies: Treatment of proges­
terone deficiencies such as- treatment of dysmen­
orrhoea; treatment of endometriosis; treatment of
secondary amenorrhoea; treatment of irregular
cycles; treatment of dysfunctional uterine
bleeding; treatment of pre-menstrual syndrome;
treatment of threatend & habitual abortion,
associated with proven progesterone deficiency;
treatment of infertility due to luteal insufficiency.
C/I: 1. Hypersensitivity to the active substance or
to any of the excipients. 2. Known or suspected
progestogen dependent neoplasms. 3. Undiagno­
sed vaginal bleeding. 4. If used to prevent endo­
metrial hyperplasia (in women using estrogens):
Contraindications for use of oestrogens in
combination with progestogens, such as
dydrogesterone.
S/E;Precautions & warnings: See above under
the text of progesterone.
Pregnancy & lactation: From spontaneous sur­
veillance system until now, there is no evidence
•
DRUGS USED IN ENDOCRINE DISEASES
that dydrogesterone can not be used during
pregnancy. No other relevant epidemiological
data on dydrogesterone are available. However, a
recent US case-control study suggested that, at
least a twofold increased risk of second/third
degree hypospadias among boys born by mothers
who took progestogens (predominantly
progesterone) shortly prior or during early
pregnancy. The causality is unclear as the
indication for progesterone in pregnancy may be
potential risk factors for hypospadias.
For dydrogesterone, the risk of hypospadias is
unknown.
Dydrogesteione is excreted in the milk of nursing
mothers. A risk to the suckling child cannot be
excluded. Dydrogesterone should not be used
during breastfeeding.
There is no evidence that dydrogesterone
decreases fertility.
Dosage & admin: Hormone replacement
therapy (HRT): 1. In combination with
continuous oestrogen therapy, lOmg (1 tablet)
dydrogesterone daily during 14 consecutive
days per cycle of 28 days. 2. In combination
with cyclical oestrogen therapy, 10mg (1
tablet) dydrogesterone daily during the last
12-14 days of oestrogen therapy.
3. If endometrial biopsies or ultrasound would
reveal inadequate progestational response,
20mg dydrogesterone should be advised.
Dysmenorrhoea: 10mg twice daily from day 5
to 25 of the cycle.
Endometriosis: 10mg 2 or 3 times daily from
day 5 to 25 of the cycle or continuously.
Dysfunctional bleeding: 10mg twice dail for 5
to 7 days (to arrest bleeding).
Dysfunctional bleeding: 1Omg wice daily from
day 11 to 25 of the cycle (to prevent bleeding).
Amenorrhoea: An oestrogen preparation once
daily form day 1 to 25 of the cycle, together
with 1Omg dydrogesterone twice daily from
day 11 to 25 of the cycle.
Pre-menstrual syndrome: 1Omg twice daily
from day 11 to 25 of the cycle.
Irregular cycles: 10mg twice daily from day 11
to 25 of the cycle.
Threatened abortion: 40mg at once, then 1Omg
every eight hours until symptoms remit.
Habitual abortion: l Omg twice daily until the
20th week of pregnancy.
Infertility due to luteal insufficiency: l Omg
daily from day 14 to 25 of the cycle. Treatment
should be maintained for at least 6 consecutive
cycles. It is advisable to continue treatment for
the first few months of pregnancy.
Dydrogesterone is not recommended for use in
children below age 18 due to insufficient data
on safety and efficacy.
Drug inter: No interaction studies have been
performed.
+ DUPHASTON Tab. Abbott Pharma/
Unimed & UniHealth
Dydrogesterone 1Omg/tablet (film-coated)
1Omg x 20's pack: 596.20 MRP
LYNESTRENOL40
LYNESTRENOL: Tablet
Lynestrenol is a progestogenic agent specially

DRUGS USED IN ENDOCRINE DISEASES
effective in correcting different menstrual disor­
ders due to hom1onal imbalance. It is available as
5mg tablet.
Indications & Dosage:
Polymenorrhoea- 1 tab. daily on days 14-25 of
the cycle.
Menorrhagia & Metrorrhagi-a- 2 tabs. daily for
10 days. Usually the bleeding will cease within
a few days after the start of the treatment.
Treatment is repeated during the next 3
menstrual cycles with 1 tab. daily on days 14-
25 of each cycle.
Further diagnostic procedures are necessary·if
the complaints do not disappear during or
after this treatment.
Selected cases of primary and secondary
amenorrhoea and oligomenorrhoea-Treatment
should start with the adminis-tration of an
estrogen, e.g 0.02-0.05mg ethinylestradiol per
day for 25 days. In conjunction with this, 1
tab. daily of Orgametril is administered on
days 14-25.
After cessation of treatment, a with- drawal
bleeding usually occurs within 3 days.
Treatment is resumed (second cycle) starting
on day 5 of this withdrawal bleeding with the
estrogen given on days 5-25 of the cycle and
again with 1 tab. daily of Orgametril on days
14-25.
This treatment should be repeated for at least
another cycle.
-
Premenstrual syndrome- 1 tablet daily on days
14-25 of the cycle.
Endometriosis- 1-2 tablets daily for at least 6
months.
Selected cases of endometrial carcinoma- 6-10
tabs. daily for prolonged periods.
Benign breast disease- l tablet daily on days
14-25 of the cycle or at least 3-4 months.
Suppression of menstruation, ovulation and
ovulation pain; dysmenorrhoea- Treatment
with 1 tab. daily should start preferably on
day 1, but no later than day 5 of the cycle. The
treatment can be continued for many months
(without tablet-free days). If in spite of
treatment, a breakthrough bleeding occurs,
the dosage should be increased to 2 or 3 tabs.
daily for 3-5 days.
Postponement of menstruation- Treatment with
1 tab. daily should start preferably 2 weeks
before the expected onset of menstruaton. If
treatment is started less than 1 week before
the expected onset of menstruation the dosage
should be 2-3 tabs. per day. However, in that
case a delay of more than 1 week is
undesirable.
The risk of breakthrough bleeding increases if
treatment is started later. Therefore, treatment
should not be started later than 3 days before
the expected onset of menstruation.
As an adjunct to estro gen therapy in peri-and
postmenopause, in order to avoid
endometrial hyperplasia- t/2- 1 tablet daily for
12-15 days per month, e.g. for the first 2 week.s
of every calendar month; the estrogen may be
administered daily without tablet free
intervals at the lowest effective dose.
Administration: Orgametril tablet should be
taken orally with some fluid.
Note: Throughout the text, take the frrst day of
•
QIMP-17 (208)
the menstrual bleeding as day 1 of the cycle. developed proliferative endometrium, conven­
C/I: Please see above under the text of tional estrogen therapy may be employed in
progesterone. conjunction with medroxyproges-terone
AIR: During continuous treatment regimens acetae, in doses of 5-1Omg for 10 days.
breakthrough bleeding or spotting will occur fre­ Amenorhoea & Oligomenorrhoea: 5-1 Omg for
quently (over 10%) during the frrst two months. 1 O days starting from the assumed 16th day of •
During cyclic treatment regimens breakthrough the cycle. When indicated, estrogen therapy
bleeding and spotting will be seen occasionally should be given prior to medroxyprogesterone
(1-10%). acetae.
Temporarily increasing the dose will control the Infertility due to inadequate luteal phase: 2.5-
bleeding in most cases. 1Omg daily from day 16 to day 25.
Other adverse effects- almost same as other Endometriosis: 5-20mg daily for 3-6 months.
progestogenic hormones. Child: Not applicable
Cautions & warnings: Please see above under Parenteral injection preparation:
the text of progesterone. Ovulation suppression: The recommended
dose is 150mg of medroxyprogesterone injec­
+ ORGATRIL Tab. Nuvista table suspension every 3 months administered
Lynestrenol 5mg/tablet. by intramuscular injection in the gluteal or
•
30's pack: 346.50 MRP deltoid muscle. The initial injection should be
given during the first 5 days after the onset of
a menstrual period; within the 5 days post
MEDROXYPROGESTERONE73
partum if not breast feeding; or if exclusively
breast-feeding at or after six weeks post-par-
MEDROXYPROGESTERONE: Tablet/
•
tum. Based on limited experience, some inves-
•
Injection
tigators favour the use of a second injection of
Medroxyprogesterone is a synthetic progesta­
medroxyprogesterone before 90 days to con­
genic agent. It is available as- medroxyproges­
trol troublesome bleeding. The third & subse­
terone acetate 5mg & 1Omg tablet for oral admin­ ·
quent injections should be administered at
istration & medroxyprogesterone acetate USP
separate 90 days intervals. If abnormal bleed­
150mg/ml injection for parenteral administration.
ing persists, appropriate investigations should
Medroxyprogesterone has prolonged progesta­
be done to rule out the possibility of organic
tional effects when administered by intramuscular
pathology. Uterine curettage may be required
injection.
on rare occasions.
•
Mode of action: Medroxyprogesterone suppress­
Endometriosis: 50mg weekly intramuscularly
es the secretion of pituitary gonadotropins, which
or lOOmg every 2 weeks intramuscularly for at
in turns, prevents follicular maturation producing
least 6 months.
long-term anovulation in the reproductive aged
Endometrial & renal carcinoma: 500mg to
women. Medroxyprogesterone suppresses the
1OOOmg intramuscularly per week is
leydig cell function in the male, i.e suppresses
recommended initially. It may be possible to
endogenous testosterone production. Parenteral
maintain improvement with 500mg per week
medroxyprogesterone acetate is a long acting
or less. Medroxyprogesterone is not
progestational steroid hormone. The l 50mg/ml
recommended as primary therapy, but as
formulation reaches half its initial concentration
adjunctive & palliative treatment in advanced
in about 27 days. Its long duration of action
inoperable cases including those with
results from its slow absorption from the
•
recurrent or metastatic disease.
injection site.
Breast cancer: 500mg to 1OOOmg per day
Ind: Oral tablet preparation:
intramuscularly for 28 days. Maintenance
Menstrual irregularities and other disorders
dose is 500mg twice weekly as long as she is
caused by inadequate endocrine secretion of the
responding to treatment. Response to hormo­
corpus luteum hormone, such as- i. functional
nal therapy (medroxyprogesterone) for breast
uterine bleeding, ii. amenorrhoea and
cancer may not be evident until 8-10 weeks of
oligomenorrhoea, iii. infertility due to inadequate
therapy. Treatment.w ith medroxyprogesterone
luteal phase, iv. endometriosis.
should be terminated if rapid progression of
Parenteral injection preparation:
disease occurs at any time during therapy.
i. Ovulation suppression
Medroxyprogesterone injectable suspension
ii. The treatment of endometriosis.
should be vigorously shaken just before use to
iii. Adjunctive and/or palliative treatment of
ensure that the dose being administ�red
recurrent and/or metastatic endometrial or renal
• represents a uniform suspension.
carcmoma.
Drug inter: Aminoglutethimide administered
iv. The treatment of hormone-dependant recurrent
concomitantly with high doses of medroxyprog­
breast cancer in post-menopausal women.
esterone acetate may significantly depress the '
C/I; S/E; Cautions & Warnings: Please see
serum concentration of medroxyprogesterone.
above under the text of progesterone.
Pregnancy & lactation: Not recommended.
Dosage & admin: Oral tablet preparation:
Functional uterine bleeding: 5-l Omg daily for
5-10 days commencing on the assumed or cal­
culated 16-21st day of the cycle so as to com­
plete treatment on the 26th day of the cycle.
Treatment should be given for two consecutive
cycles. When bleeding occurs from a poorly
Sl<•F •
•
 QIMP-17 (209)

t MEDORA Tab. Nuvista Norethisterone

Medroxyprogesterone acetate 5mg & 1 Omg/tablet.
5mg x 30's pack: 14 1 .00 MRP
1 Omg x 30's pack: 262.20.00 MRP
t MEDRINA Tab. Beacon
Medroxyprogesterone acetate USP 5mg/tablet. 5mg x 60's pack: 300.00 MRP
5mg x 30's pack: 1 4 1 .00 MRP t REMENS Tab. Popular
t MEDROGEST Tab. Renata Norethisterone 5mg/tablet.
Medroxyprogesterone acetate 5mg & 1 Omg/tablet. 5mg x 60's pack: 300.00 MRP
5mg x 30's pack: 1 6 1 .40 MRP t RON'I'RII, Tab. Nuvista
1 Omg x 30's pack: 300.00 MRP Norethisterone 5mg/tablet.
.
t MEDROXY Tab. Popular 5mg x 50's pack: 250.00 MRP
· Mfdroxyprogesterone acetate 5mg & 1 Omg/tablet. 5mg x 60'� pack: 300.00 MRP
5mg x 60's pack: 322.80 MRP
1 Omg x 30's pack: 301 .20 MRP
•

Drugs for menopausal sym­

•

.t MEDROXY lnj. Popular

�droxyprogesterone acetate USP 1 50mg/ml vial:
ptoms: Hormone replacement
iaj 11on for parenteral administration.
5..W.g x 60's pack: 322.80 MRP therapy (HRT)40,ss,111(B),122
.

l��� x 301s pack: 301 .20 MRP

t MOVERA Tab. ACI
Medroxyprogesterone acetate 5mg & 1 Omg/tablet. ESTRADIOL ONLY 8' ESTRADIOL ...
5mg x 60's pack: 322.80 MRP NORETHJSTERONE
1 Omg x 30's pack: 300.00 MRP PREPN,4o,ss,111(B),122
t PROVENOR Tab. SK+F
Medroxyprogesterone acetate 5mg & 1 Omg/tablet.
EST RADIOL ONLY & ESTRADIOL­
5mg x 30's pack: 150.00 MRP
NORETHISTERONE PREPN: Tablet/Patches
1 Omg x 30's pack: 300.00 MRP
Hormonal drugs for replacement therapy (HRT)
are prepared in three forms:

NORETHISTERONE58 1. For 'estrogen only HRT'- preparations

containing only estradiol in tablets or patches.
2. For 'regular period HRT'- preparations
NORETIDSTERONE: Tablet
containing estradiol only & estradiol­
Norethisterone is a synthetic progesterone
norethisterone combinedly in tablets or patches.
hormone. It is available as 5mg tablet.
3. For 'periodfree HRT'- preparations
Ind: Postponement of menstruation;
containing estradiol-norethisterone combinedly in
dysmenrrhoea, menorrhagia and premenstrual
tablets or patches.
syndrome; metropathia
Mode of action: Estradiol is a naturally occuring
hemorrhagica; Polymenorrhoea;
hormone and norethisterone acetate is a synthetic
endometriosis. ·

derivative of 1 9-nortestosterone. The active hor­

C/I; S/E; Warnings; Cautions: Please see above
mone of replacement therapy is estradiol, the bio­
under the text of progesterone.
logically most potent estrogen produced by the
Dosage & admin: Adult: Postponement of
ovary. Its synthesis in the ovarian follicles is reg­
mens.- 5mg 3 times daily starting 3 days
before expected onset of menstruation. ulated by pituitary hormones. Estradiol is secret­
ed at different rates during the menstrual cycle.
Dysmenorrhoea- 5mg 3 times daily for 20 days
The endometrium is highly sensitive to estradiol,
starting on Sth day of menstruation, then 8
which regulates endometrial proliferation during
tablet-free days. Maintain treatment for 3 or 4
the follicular phase of the cycle and together with
cycles. Menorrhagia and pre-menstrual
progesterone, induces secretory changes during
syndrome. Smg. 2 or 3 times daily from day
the luteal phase. During the menopause estradiol
19-26 of cycle.
secretion becomes irregular and eventually ceases
Child: Not applicable.
altogether. The absence of estradiol is associated
t ETHINOR Tab. SK+F with menopausal symptoms (such as, vasomotor
Norethisterone 5mg/tablet. instability, sleep disturbances, depressive mood,
5mg x 45's pack: 225.00 MRP signs of vulvovaginal and urogenital atrophy and
t MENOGIA Tab. ACI with increased bone loss). In addition, there is
Norethisterone 5mg/tablet. growing evidence for an increased incidence in
5mg x 60's pack: 300.00 MRP cardiovascular disease in the adsence of estrogen.
t MENORAL Tab. Square Estrogen replacement therapy has been found
Norethisterone 5mg/tablet. effective in most postmenopausal women to com­
5mg x 30's pack: 1 50.00 MRP pensate for the endogenous estrogen depletion.
t NORCOLUT Tab. Gedeon Richter/City However, there is substantial evidence that 'the
Overseas only estrogen therapy' is associated with an
Norethisterone 5mg/tablet. increase in endometrial cancer, but an adjunctive
5mg x 20's pack: 1 45.00 TP progestogen treatment protects against estrogen­
t NORMENS Tab. Renata induced endometrial cencer. Therefore, women
Norethisterone 5mg/tablet. with an intact uterus should receive combination
5mg x 60's pack: 301 .20 MRP estrogen-progestogen hormone replacement
t NOTERON Tab. Incepta therapy.
Norethisterone acetate 5mg/tablet. Norethisterone acetate, a progestogen hormone,

when administered prevents estrogen-related
endometrial proliferation and thus endometrial
cancer.
Ind: Estradiol only & estradiol-norethisterone
combined preparations are indicated for the
treatment of estrogen deficiency syndrome
including prevention of bone mineral content loss
as following-
'Estrogen only HRT'- for hysterectomised
women.
'Regular period HRT'- for premenopausal
- .. ,,
.
.
women. · .
' ·
: .
'Period fre� HRT'- for post. �e�opausal �om�n.'
· ·
" .
Contra-indications: Known, su8pected, 9r history
of carcioma of the breast. Known or suspected
estrogen ctependent neoplasia, e.g endometrial
'.
carcinoma. Acute or chronic liver disease, or
history of liver disease, where liver function
tests have failed to return normal. Deep venous
thrombosis, thromboembolic disorders, cerebral
vascular accident, or a history of these
conditions, associated with previous estrogen use.
Abnormal genital bleeding of unknown aetiology.
Known or suspected pregnancy. Porphyria.
Sideeffects:
Hormonal drugs for 'regular period HRT':
Breast tenderness and bleeding irregularities may
occur, specially during the first few months of
treatment. Nausea, headache and oedema occur
rarely. Symptoms are normally transient.
Alopecia, skin reactions and vision abnormalities
have been reported. Missed tablets may lead to
bleeding episodes. Breast and endometrial cancer,
thromboembolic disorders as well as changes in
hepatic function have been reported, but there is
no reason to believe that the incidence is
increased.
Hormonal drugs for 'period free HRT': Main
side effects are irregular bleedings which occur
most frequently during the first few months of
treatment. Women may even bleed from an
atrophic endometrium, the reasons for which are
presently unknown. After the first month of
treatment a gradual decrease in bleeding
frequency is normally seen. Bleedings may
continue in some postmenopausal women; in
these cases consideration should be given to
change to an alternative therapy. Missed tablets
may lead to bleeding episodes. Breast tenderness,
nausea, headache and oedema may occur.
Symptoms are normally transient. Alopecia, skin
reactions and vision abnormalities have been
reported. Breast cancer and thromboembolic
disorders have been reported, but there is no
reason to believe that incidence is increased.
'Estrogen (estradiol) only HRT': During the
first few months of treatment breast tenderness
may occur. Nausea, headache and oedema may
occur rarely. Symptoms are normally transient.
Skin reactions have been reported. Missed tablets
may lead to bleeding in women with an intact
uterus.
Warnings: Treatment with unopposed estrogens
is known to increase the risk of endometrial can­
cer. The risk appears to depend on both duration
QIMP-17 (210)
of treatment and on estrogen dose. Endometrial
hyerplasia (atypical or adenomatous) often pre­
ormone cedes endometrial cancer. Recent prospective
studies suggest that an excess of endometrial
.
hyperplasia can virtually be avoided if the
endometrium is protected by a sufficient dose of
progestogen for at least 10 days. Kliogest- recent
Norethisterone 5mg tablet studies show that an excess of endometrial hyper­
plasia can virtually be avoided since the
Free�om· from Menstrual Problems
endometrium is brought to an atrophic state by
continuous administration of progestogen during
the entire estrogen treatment period. Long term
ea-® use of estrogen replacement therapy in high
doses is associated with an increase in breast
Allytestrenol 5mg tablet
, cancer risk. Use of small doses for short periods
Strengthens Successful Pregnancy
. ...
shows no measurable increase in risk. The effects
�
, of smaller doses of estrogen for long
• periods are not adequately studied, but are not •
ivion®
.
likely to be associated with any substantially
increased risk of breast cancer.
••• Tibolone 2.Smg tablet
. Precautions: A physical examination and
Triple action hormone for complete medical and family history should be
Postmenopausal Women taken prior to initiation of estrogen therapy,
especially- blood pressure, breast and abdominal
examination, and a gynaecological examination.
®
•
ro1
Women with an intact uterus who are or have
previously been treated with unopposed
estrogens, should be examined with special care
LevoChyroxile ScxiJn 50mcg tablet
to investigate possible hyperstimulation of the
A true hypothyroid therapy endometrium before starting therapy. In general,
estrogen should not be prescribed for longer than
one year without performing another physical
·overa®
Medroxyprogesterone acetate 5mg and 1 Omg tablet
and gynaecological examination. And the lowest
dose of HRT which alleviates symptoms should
be prescribed. Women in antihypertensive
treatment or women with epilepsy, migraine,
A True Progesterone
diabetes, asthma or cardiac failure should be
monitored regularly. Thromboembolism has been
reported in connection with estrogen replacement
therapy, but there is no background to believe the
Levonorgestrel 0.15mg+Ethinyl Estradiol 0.03mg overall incidence is increased.
These preparations have no contraceptive effects.
Regular contraceptive tablet Estrogen only HRT I Regular period HRT:
If abnormal or irregular bleedings occur during
or shortly after therapy, diagnostic aspiration
biopsy or curettage should be performed to rule
an®
out possibility of uterine malignancy.
Period free HRT: During the first few months
Levonorgestrel 0.75mg
bleedings or spottings may occur, but are usually
Emergency contraceptive tablet transient and do not require diagp.ostic aspiration
biopsy or curettage; however, if bleedings or
spottings continue or first appear at a later stage
Advancing Women in treatment or shortly after therapy has been
stopped, diagnostic aspiration biopsy or curettage
Advancing Nation should be performed to rule out possibility of
1:1""•:;;,::
uterine malignancy.
Period free HRT I Regular period HRT:
Long term prophylactic treatment of osteoporosis
should be restriceted to women at increased risk
'
of developing fractures. Factors predisposing to
osteoporosis- White/Asian race, female sex, thin
or petite, family history of the disease, pre- or
postmenopausal estrogen deficiency, early
menopause, inadequate calcium nutrition, cigratte
smoking, alcohol abuse, sedentary life-style.
Indications for immediate withdrawal of
therapy:
Deep venous thrombosis, thromboembolic disor­
ders, appearance of jaundice, emergence of
migraine-type headache, sudden visual distur-

bances, significant increase in blood pressure.
Withdrawal of treatment 4-6 weeks prior to major
surgery is advised.
Preparations: Known preparations are not
available in the market at this moment. May be
available later on.
•
TIBOLONE26,40
TIBOLONE: Tablet
Tibolone is a synthetic steroid with tissue specific
estrogenic, progestogenic and androgenic effect.
It is recently introduced for the 'hormone
replacement therapy (HRT)' of the menopausal
symptoms & other associated post-menopausal
conditions.
Mode of action: As tibolone has got a combined
estrogenic and progestogenic activity with weak
androgenic activity; it suppesses the
gonadotrophin levels in postmenopausal women
(and inhibits ovulation in fertile women).
Following oral administration tibolone is rapidly
metabolized into three compounds, which
•
contribute to the p�armac�logical--eftects of .
tibolone. Two of these metabolites (3 alpha­
hydroxide-tibolone and 3 beta-hydroxide­
tibolone) have predominantly estrogenic activity,
a third metabolite (delta 4-isomer of tibolone)
and the parent compound have progestogenic and
androgenic activities.
It is given continuously without cyclical
progestogen.
Ind: 1. Treatment of the climacteric symptoms
(or vasomotor symptoms, such as- hot flushes,
sweating, vaginal dryness & less elasticity, mood
disorders, anxiety etc. )following natural or
surgical menopause, (unsuitable for use within 12
months of the last menstrual period- may cause
irregular bleeding).
2. Prevention of post-menopausal and post­
oophorectomy osteoporosis and improvement of
bone-mineral density in patients with established
post-menopausal osteoporosis.
3. Vaginal atrophy.
4. Prevention of frequent UTI and urinary
incontinence in post-menopausal women.
C/I: Pregnancy & breast-feeding; hormone­
dependent tumours; history of cardiovascular or
cerebrovascular disease; vaginal bleeding of
unknown etiology; severe liver disorders.
S/E: Occasionaly weight changes, pretibial
oedema, dizziness, seborrhoeic dermatosis,
vaginal bleeding, headache, gastro-intestinal
disturbances, increased facial hair, migraine,
visual disturbances, chnange in liver function
tests, rash and pruritus.
Cautions: Renal inpairment, epilepsy, migraine,
diabetes mellitus, hypercholesterolaemia; with­
draw if signs of thrombo-embolic disease, abnor­
mal liver function tests or cholestatic jaundice.
Warnings: To avoid irregular & abnormal
bleeding, tibolone should be started at least 12
months after last natural bleeding.
I
QIMP-17 (211) DRUGS USED IN ENDOCRINE DISEASES
A higer dose than the recommended one may
induce vaginal bleeding; when higher doses are
Male Sex hormones:
used, additional administration of progestogen at
regular intervals is advisable, for instance every Androgens21 .
3 months for 10 days.
If changing from another preparation for
Male sex hormones (androgens) include:
hormone replacement therapy, the endometrium
may already be stimulated, so induction of a 1. Testosterone & esters
withdrawal bleed with a progestogen is advisable. 2. Mesterolone
During prolonged treatment with steroids with 3. Methyltestosterone (not in use)
hormonal activity, periodic medical examination
is advisable.
Tibolone is not intended for contraceptive use.
Dosage & admin: Climacteric or vasomotor TESTOSTERONE & ESTERS: Capsule/Gel/
symptoms following natural or surgical Injection
menopause, & other post-menopausal Testosterone is the male hormone, indicated for
problems: 2.5mg daily preferably at the same replacement therapy in males for conditions
time. Improvement of symptoms generally associated with a deficiency or absence of
occurs within a few weeks, but optimal results endogenous testosterone.
are obtanined when therapy is continued for It is available in capsule, gel and injection
at lwast 3 months. form for oral, transdermal and parenteral
At the recommended dosage, it may be used administration.
uniteruptedly for longer periods. Ind: Testosterone is indicated for replacement
To prevent osteoporosis in post-menopa-usal
therapy in males for conditions associated with a
women or after oophorec-tomy an deficiency or absence of endogenous
uninterrupted long-term (5-10 years) therapy, testosterone:
at a rate of 2.5mg/day is needed. 1. Primary hypogonadism (congenital of
In case of missed pill, if no more than 12 hours acquired): Testicular failure due to
have passed, the pill should be taken cryptorchidism, bilateral torsion, orchitis,
immediately, otherwise the next dose should be vanishing testis syndrome, orchiectomy,
continued as before. Klinefelter's syndrome, chemotherapy, or toxic
Drug inter: Since tibolone may increase blood damage from alcohol or heavy metals. These men
fibrinolytic activity, it may enhance the effect of usually have low serum testosterone levels and
anticoagulants. This effect has been reported gonadotropins (FSH, LH) above the normal range.
with warfarin. Drugs that induce hepatic 2. Hypogonadotropic hypogonadism (congenital
microsomal enzymes or other enzyme inducing or acquired): Idiopathic gonadotropin or
drugs may accelerate the metabolism of tibolone luteinizing hormone-releasing hormone (L HRH)
and thus lower its activity. deficiency or pituitary-hypothalamic injury from
tumors, trauma, or radiation. These men have low
+ L IVIAL Tab. N uvista testosterone serum levels but have gonadotropins
Tibolone 2.5mg/tablet. in the normal or low range.
28's pack: 1100.00 MRP (Symptoms of hypogonadism include: Inpotence,
+ MENOREST Tab. R enata decreased sexual desire, fatigue and loss of
Tibolone 2.5mg/tablet. energy, mood depression, regression of secondary
28's pack: 561.96 MRP sexual characteristics, osteoporosis).
+ RENORMA Tab. Square 3. Inoperable mammary carcinoma.
Tibolone 2.5mg/tablet. C/I: Testosterone is contraindicated in prostatic
30's pack: 602.10 MRP or mammary carcinoma in the male; nephrosis;
hyper�al<;aemi� pregnan�y & br�t-f��g .. '
+ TIBO Tab. Popular
Testosterone is not indicated for use in women
Tibolone 2.5mg/tablet.
and must not be used in women (except in
30's pack: 602.40 MRP
inoperable mammary carcinoma).
+ TIBONE Tab. Techno Drugs
S/E: Sodium retention with oedema; increase in
Tibolone 2.5mg/tablet.
weight; hypercalcaemia, increased bone growth,
30's pack: 450.00 MRP
priapism, precocious sexual development,
+ TIBONOR Tab. SK+F
gynecomastia and premature closure of epiphyses
Tibolone 2.5mg/tablet.
in pre-pubertal males; virilism in women, and
. . MRP..
30's pack: 600.00
'
. .
suppression of spermatogenesis in men.
+ TIVION Tab. ACI Other side-effects include-allergic reaction, acne,
Tibolone 2.5mg/tablet. alopecia, asthenia, depression, headache,
30's pack: 600.00 MRP hypertension, nausea or vomiting, changes in
+ UBILON Tab. Incepta skin color, swelling of the ankles, breathing
Tibolone. INN 2.?mg/tablet. · � . ;" ·
<;
l! disturbances, abdominal pain or discomfort and
3Q's Pa��:
. .600.oo MRP .. fatigue.
. . . .
.,
$ ,
.
..
� '
'
•••
www.squarepharma.com.bd •••
•••
SOUAllE
DRUGS USED IN E DISEASES
Cautions: Cardiac, renal or hepatic impairment,
epilepsy, migraine, hypertension, ischaemic heart
disease; skeletal metastases; pre-pubital boys;
elderly.
Pregnancy & lactation: Testosterone is not
indicated for use in women and must not be used
in women. In women it is only indicated in
inoperable mammary carcinoma, but in that case
it should be avoided during pregnancy & lactation.
Dosage & admin: See below under individual
preparations.
t ANDRIOL TESTOCAPS Cap. Nuvista
Testosterone undecanoate 40mg/capsule
(testocaps).
Dosage & admin: Initially 120-160mg daily for
2-3 weeks is adequate, followed by a
maintenance dosage of 40-120mg daily.
30's pack: 625.00 MRP
t SUSTOGEN Inj. Techno Drugs
Testosterone BP 250mg/ml; l m l ampoule:
injection.
Dosage & admin: Adult: By deep i.m injection
lml every 3 weeks. (In mammary carcinoma
dose or frequency may be increased).
Child: Not applicable.
l m l ampoule: 129.00 MRP
t TESTANON 250 Inj. Nuvista
Testosterone propionate 30mg, testosterone
phenylpropionate 60mg, testosterone isocaproate
60mg, testosterone decanoate 1OOmg/ml; 1ml
ampoule: injection.
Dosage & admin: Adult: By deep i.m injection
lml every 3 weeks. (In mammary carcinoma
dose or frequency may be increased).
Child: Not applicable.
lml ampoule: 161.70 MRP
t TESTOSTERONE-ROTEX lnj. Rotex
Medica/City Overseas
Testosterone enanthate 250mg/ml; 1ml ampoule:
injection.
Dosage & admin: Adult: By deep i.m injection
lml every 3 weeks. (In mammary carcinoma
dose or frequency may be increased).
Child: Not applicable.
lml amp x IO's pack: 1400.00 TP
Anabolic Steroids (Androgen)
NANDROLONE DECANOATE: Injection
Ind: Osteoporosis, debility, convalescence,
during corticosteroid therapy, aplastic anaemia
and anaemia of chronic renal failure or
malignant disease.
C/I: Severe hepatic impairment, prostate cancer,
male breast cancer, pregnancy and breast-feeding,
porphyria.
S/E: Acne, sodium retention with oedema,
virilisation with high doses including voice
changes (sometimes irreversible), amenorrhoea,
inhibition of spermatogenesis, premature
epiphyseal closure; abnormal liver-function tests
reported with high doses; jaundice on prolonged
treatment; liver tumours reported occasionally on
prolonged treatment with anabolic steroids.
Cautions: Cardiac and renal impairment, hepatic
QIMP-17 (212)
impairment, hypertension, diabetes mellius, 1. Hypothalamic & anterior pituitary hormo­
epilepsy, migraine; monitor skeletal maturation in nes and anti-estrogens:
young patients; skeletal metastases (risk of a. Hypothalamic hormones- viz. Gonadorelin
hypercalcaemia). (F ollicle-stimulating hormone-releasing
Dosage & admin: Adult: 25-50mg i.m. every
hormone or GnRH, luteinising-releasing
three weeks.
hormone); Protirelin, Sermorelin.
Anaemia of chronic renal failure, 100-200mg b. Anterior pituitary hormones- viz.
weekly by deep i.m injection; Corticotrophins (ACTS)- tetracosactide or
aplastic anaemia, 50-150mg weekly; tetracosactrin, an analogue of corticotrophin;
anaemia due to cytotoxic therapy, 200mg
•
Gonadotrophins (chorionic gonadotrophin,
weekly starting 2 weeks prior to cytotoxic FSH or Follitrophin alpha & beta, human
therapy and continuing until blood count is
menopausal gonadotrophin, urofollitrophin);
normal. Growth hormone (omatrophin);
Child: Not recommended.· Prolactin.
c. Anti-estrogens- viz. Clomiphene, Tamoxifen.
t DECABOLON Inj. Techno Drugs
Nandrolone decanoate 50mg/lml amp: injection 2. Posterior pituitary hormones & antagonists
l m l ampoule: 112.00 MRP a. Posterior pituitary hormones- viz.
t DECA-D URABOLIN Inj. Nuvista Vasopressin, (synthetic analogue,
Nandrolone decanoate 50mg/lml amp: injection desmopressin and lypressin).
lml ampoule: 217.00 MRP b. Antagonists (antidiuretic hormone
t HYDECAinj. Chemist antagonists)- viz. Demeclocycline
Nandrolone decanoate 50mg/lml amp: injection
lml ampoule: 125.00 MRP
•
t NANDRON 50 lnj. Renata Drugs for Sterility
Nandrolone decanoate 50mg/lml amp: injection
lml ampoule: 160.00 MRP
CHORIONIC GONADOTROPHIN
• • • (CGf l,40,10
NANDROLONE PHENYLPROPIONATE: H UMAN CHORIONIC GONADOTROPHIN
Injection
(hCG): Injection21,40
Ind: Osteoporosis, debility, convalescence,
Human chorionic gonadotrophin (hCG) is a
during corticosteroid therapy, refractory anemias,
glycoprotein fraction secreted by the placenta and
urenua.
•
obtained from the urine of pregnant women
C/I; S/E; Caution: See above under 'Nandrolone
having the actions of the pituitary luteini.zing
decanoate'.
hormone. It is available as- hl1man chorionic
Dosage & admin: Adult: 25-SOmg i.m weekly.
gona-dotrophin (hCG), powder for reconstitution,
Child: Not recommended.
5000 i.u ampoule for i.m injection.
t ANABOLIN Inj. Techno Drugs Mode of action: The principal pharmacodynamic
Nandrolone phenylpropionate 25mg/lml activity in women is oocyte meiosis resumption,
ampoule: injection follicular rupture (ovulation), corpus luteum
5 amps pack: 200.00 MRP formation and production of progesterone and
t DURABOLIN Inj. Nuvista estradiol by the corpus luteum. In women,
Nandrolone phenylpropionate 25mg/lml chorionic gonadotrophin acts as a surrogate LH­
ampoule: injection surge that triggers ovulation. Chorionic
5 amps pack: 434.50 MRP gonadotrophin binds on the ovarian theca (and
t HYBOLIN Inj. Chemist granulosa) cells to a transmembrane receptor
Nandrolone phenylpropionate 25mg/lml shared with the luteinising hormone, the LH/CG
ampoule: injection receptor, then acts to trigger ovulation.
5 amps pack: 210.00 MRP Ind: Chorionic gonadotrophin is indicated in the
t NANDRON 25 Inj. Renata treatment of:
Nandrolone phenylpropionate 25mg/lml
1. Women undergoing superovulation prior to
ampoule: injection
assisted reproductive techniques such as in
5 amps pack: 300.00 MRP
vitro fertilisation (!VF): Chorionic
gonadotrophin is administered to trigger final
Oral Contraceptive prepns. follicular maturation and luteinistion after
stimulation of follicular growth.
•
2. Anovulatory or oligo-ovulatory women: For
See later under contraceptive preparations induction of ovulation & pregnancy­
chorionic gonadotrophin is administered to
trigger ovulation and luteinisation in
5. HYPOTHALAMIC & anovulatory or oligo-ovulatory patients after
PITUITARY HORMONES stimulation of follicular growth.
3. In male: Hypogonadotrophic hypogonadism,
& ANTI ESTROGENs21 delayed puberty associated with insufficient
gonadotrophic pituitary function & cryp­
Hypothalamic and pituitary hormones are torchidism (not due to anatomical obstruction).
classified as follows: C/I: Chorionic gonadotrophin is contraindicated
•

for safety reasons in case of:
- Tumours of the hypothalamus and pituitary
gland.
- Hypersensitivity to the active substance or
to any of the excipients.
- Ovarian enlargement or cyst due to
'
reasons other than polycystic ovarian
disease.
- Gynecological haemorrhages of unknown
aetiology.
- Ovarian, uterine, or mammary carcinoma.
- Extrauterine pregnancy in the previous 3
months.
- Active thrombo-embolic disorders.
Chorionic gonadotrophin must not be used· when
an effective response cannot be obtained, for
example:
- Primary ovarian failure.
- Malformations of sexual organs
incompatible with pregnancy.
- Fibroid tumours of the uterus incompatible
with pregnancy.
- Postmenopausal women.
S/E: Oedema (particularly in males- reduce dose),
headache, tiredness, mood changes, gynaecomas­
tia, local reactions; sexual precocity with high
doses; may aggravate ovarian hyperstimulation.
Cautions: Cardiac or renal impairment, asthma,
epilepsy, migraine. Treatment requires careful
monitoring to avoid the ovarian hyperstimulation
syndrome & multiple pregnancy.
Dosage & admin: In the male: ..
_
. 2
Hypogonadotrophic hypogonadism, �000-2000
i.u 2 to 3 times per week for at least 3 months
before any improvement in spermato-genesis
can be expected. If the case is sterility, addi­
tional doses of an FSH (containing 75 i.u FSH)
are to be given daily or 2 to 3 times a week.
During this treatment testosterone replace­
ment therapy should be suspended. Delayed
puberty, 15000 i.u 2 to 3 times a week for at
least 6 months.
Cryptorchidism: Under 2 years of age 250 i.u
twice weekly for 6 weeks; under 6 years 500-
1000 i.u twice weekly for 6 weeks; over 6
) for 5 cons-ecutive days starting on within
years 1500 i.u twice weekly for 6 weeks. If
necessary this treatment can be repeated.
In female:·
Induction of ovulation and pregnancy: 5000-
10,000 i.u for one time. Luteal phase support,
1000-3000 i.u, may be repeated 2 to 3 times,
each may be given within 9 days following
ovulation or embryo transfer.
Drug inter: No clinically significant drug inter­
actions have been reported during hCG therapy.
Note: For further informatoin, please consult
manufacturer's literature.
+ HCG 5000 Inj. Popular
Human chorionic gonadotrophin (HCG), powder
for reconstitution, 5000 i.u ampoule with solvent
for i.m/sc injection.
5000 i.u amp x l's pack: 1300.00 MRP
+ PREGNYL Inj. Nuvista
Human chorionic gonadotrophin (HCG), powder
for reconstitution, 5000 i.u ampoule with solvent
for i.m injection.
5000 i.u amp x 2's pack: 2050.00 MRP
• • •
QIMP-17 (213)
RECOMBINANT CHORIONIC
GONADOTROPHIN: Injection40,70
Chorionic gonadotrophin produced by
recombinant DNA techniques in chinese hamster
ovary cells is 'choriogonadotrophin alfa'. It
shares the amino acid sequence with urinary
human chorionic gonadotrophin. This
choriogonadotrophin has the pharmacological
actions of the pituitary luteinizing hormone.
The choriogonadotrophin alfa is available as-
250mcg powder in vial for subcutaneous
injection. A dose of 250mcg is equivalent to
approximately 6500 I.U.
Mode of action: The principal pharmacodynamic
activity in women is oocyte meiosis resumption,
follicular rupture (ovulation), corpus luteum
formation and production of progesterone and
estradiol by the corpus luteum. In women,
chorionic gonadotrophin acts as a surrogate LH­
surge that triggers ovulation. Chorionic
gonadotrophin binds on the ovarian theca (and
granulosa) cells to a transmembrane receptor
shared with the luteinising hormone, the LH/CG
receptor, then acts to trigger ovulation.
Ind: Recombinant chorionic gonadotrophin is
indicated in the treatment of:
1 Women undergoing superovulation prior to
assisted reproductive techniques such as in
vitro fertilisation (!VF): Chorionic
gonadotrophin is administered to trigger fmal
follicular maturation and luteinisation after
stimulation of follicular growth.
Anovulatory or oligo-ovulatory women: For
induction of ovulation & pregnancy­
chorionic gonadotrophin is administered to
trigger ovulation and luteinisation in
anovulatory or oligo-ovulatory patients after
stimulation of follicular growth.
But, there is no clinical experience with
recombinant chorionic gonadotrophin in other
indications commonly treated with urine derived
human chorionic gonadotrophin (hCG).
C/I: See above under the text of human chorionic
gonadotrophin (hCG).
S/E; Precautions: See above under the text of
human chorionic gonadotrophin (hCG), and
consult manufacturer's literature.
Dosage & admin: The followig dosing regimen
should be applied:
1. Women undergoing superovulation prior to
assisted reproductive techniques such as in
vitro fertilisation (/VF): 250mcg (1 vial) is
administered 24 to 48 hours after the last
administration of an FSH- or hMG
preparation, i.e when optimal stimulation
of follicular growth is achieved.
2. Anovulatory or oligo-ovulatory women:
250mcg (1 vial) is administered 24 to 48
hours after optimal stimulation of follicular
growth is achieved. The patient is
recommended to have coitus on the day of,
and the day after, gonadotrophin injection.
Recombinant chorionic gonadotrophin is
intended for subcutaneous administration. The
powder should be reconstituted immediately
prior to use with the solvent provided.
Treatment with recombinant chorionic
gonadotrophin should be performed under the
supervision of a physician experienced in the
treatment of fertility problems.
·
DRUGS USED IN ENDOCRINE DISEASES
Drug inter: No clinically significant drug inter­
actions have been reported during hCG therapy.
Following administration, choriogonadotrophin
alfa may interfere for up to ten days with the
immunological determination of serum/urinary
hCG, leading to a false positive pregnancy test.
During choriogonadotrophin alfa therapy, a minor
thyroid stimulation is possible of which the
clinical relevance is unkn own..
Note: For further information, please consult
manufacturer's literature.
+ OVIDREL 250 Inj. Serono/Janata
Healthcare
Ovidrel is a product of choriogonadotrophin alfa
produced by recombinant DNA techniques in
chinese hamster ovary cells. It shares the amino
acid sequence with urinary human chorionic
gonado-trophin. This choriogonadotrophin has
the pharmacological actions of the pituitary
luteinizing hormone.
Ovidrel is available as choriogonadotrophin alfa
250mcg powder in vial with solvent for subcuta­
neous injection, (each vial contains 285mcg to
ensure delivery of 250mcg dose). A dose of
250mcg is equivalent to approximately 6500 I.U.
Price: 250mcg vial x l's pack: 4695.65 MRP
CLOMIPHENE21•33
CLOMIPHENE: Tablet
Ind: Sterility due to ovulatory failure due to
impaired hypothalamic-pituitary function;
oligospermia; secondary amenorrhoea.
C/I: Liver dysfunction; large ovarian cyst;
Endometrial carcinoma, undiagnosed uterine
bleeding.
S/E: Visual disturbances (withdraw), ovarian
hyperstimulation (withdraw), hot flushes, abdom­
inal discomfort, occasion- ally nausea, vomiting,
depression, insomnia, breast tenderness, weight
gain, rashes, dizziness, hair loss.
Caution: Exclude pregnancy, before and during
tratment. Withdraw if visual disturbances occur.
Dosage & admin: Adult: 50mg (1 tab) daily
about 5 days of onset of menstrual cycle
(preparably 2nd day). Or at any time if cycle
has ceased. Ovulation usually occurs 6 to 10
days following the last day of treatment. In
absence of satisfactory result, daily 1OOmg
may be given in the subsequent cycle as a rule
for 3 (not more than 6) cycle.
Oligospermia- 50mg daily for 6 weeks.
Secondary amenorrhoea- 50mg daily for 5
days starting at any time.
Child: Not applicable.
+ COMIPEN Tab. Pacific
Clomiphene citrate 50mg/tablet.
50mg x 30's pack: 150.00 MRP
+ FERMID Tab. Gaco
Clomiphene citrate 50mg/tablet.
50mg x 1O's pack: 100.00 MRP
+ FERTIL Tab. Beximco
.
Clomiphene citrate 50mg/tablet.
50mg x 50's pack: 500.00 IP
+ OVUCLON Tab. Incepta
Clomiphene citrate 50mg & 1 OOtng/tablet.
50mg x 30's pack: 300.00 MRP
1OOtng x 20's pack: 360.00 MRP
DRUGS USED IN ENDOCRINE DISEASES
+ OVUL ET Tab. Renata
Clomiphene citrate 50mg & 1 OOmg/tablet.
50mg x 1 O's pack: 100.00 MRP
l OOmg x 5's pack: 90.30 MRP
+ REOMEN Tab. SK+F
Clomiphene citrate 50mg/tablet.
50mg x 20's pack: 200.00 MRP
FOLLICLE STIMULATING
HORMONE21,40,10
FOLLITROPIN ALFA: Injection70
Follitropin alfa is a recombinant follicle
stimulating hormone (r-hFSH). It is available as a
freeze-dried powder for reconstitution, 75
i.u/ampoule: injection.
Ind: i. Follitropin alfa, followed by chorionic
gonadotrophin (hCG), is recommended for the
stimulation of follicular development and
ovulation in women with hypothalamic-pituitary
dysfunction who present with either
oligomenorrhoea or amenorrhoea. These women
are classified as WHO Group II patients and
usually receive clomiphene citrate as primary
therapy. They have evidence of endogenous
Danazol 100 & 200 mgcapsule
An outstanding hormonal therapy
estrogen production and thus will either
spontaneously menstruate or experience
withdrawal bleeding after progestagen
administration. Polycystic ovarian disease
(PCOD) is part of the WHO II classification and
is present in the majority of these patients.
ii. Follitropin alfa is indicated for stimulation of
multifollicular development in patients
undergoing superovulation for assisted
reproductive technologies (ART) such as in vitro
fertilization (IVF), gamete intra-fallopian transfer
(GIFT and zygote intra-fallopian transfer (ZIFT).
C/I: Follitropin alfa is contraindicated for safety
reasons
•
1n:
- pregnancy & lactation,
- ovarian enlargement or cyst not due to
polycystic ovarian disease,
- gynaecological haemorrhages of unknown
aetiology,
- ovarian, uterine or mammary carcinoma,
- tumours of the hypothalamus and pituitary
gland,
- case of prior hypersensitivity to follitropin
alfa.
Follitropin alfa is contraindicated when an
QIMP-17 (214)
effective response cannot be obtained, such as:
- primary ovarian failure,
- malformation of sexual organs incompatible
with pregnancy,
- fibroid tumors of the uterus incompatible with
pregnancy.
S/E; Warnings & Cautions: Please see below,
under the text of follitropin beta (Puregon
injection).
Dosage & admin: Follitropin alfa is intended
for subcutaneous or intramuscular adminis­
tration. The powder should be reconstituted
immediately prior to use with the diluent pro­
vided. In order to avoid the injection of large
volumes, up to 3 containers of follitropin alfa
75 or 150 may be dissolved in lml of diluent.
Women with hypothalamic-pituitary dysfunc­
tion who present with either oligomenorrhoea
or amenorrhoea (WHO Group II):
The object of follitropin alfa therapy is to
develop a single mature Graafian follicle from
which the ovum will be liberated after the
administration of hCG
Follitropin alfa may be given as a course of
daily injections. In menstruating patients
® ®
Clomiphene citrate 50 mg tablet
A hope for infertile couples
treatment should commence within the first 7
days of the menstrual cycle. Treatment should
be tailored to the individual's response as
assessed by measuring (i) follicle size by
ultrasound and/or (ii) estrogen secretion. A
commonly used regimen commences at 75-150
IU FSH daily and is increased by 37.5 IU (up
to 75 IU) at 7 or 14 day intervals if necessary,
to obtain an adequate, but not excessive,
response. If a patient fails to respond
adequately after 5 wks. of treatment, that
cycle should be abandoned.
When an optimal response is obtained, single
injection of up to 10,000 IU hCG should be
administered 24-48 hours after the last folli­
tropin alfa injection. The patient is recommen­
ded to have coitus on the day of, & the day
following hCG administration.
If an excessive response is obtained, treatment
should be stopped and hCG withheld.
Treatment should recommence in the next
cycle at a dosage lower than that of the
previous cycle.
Women undergoing superovulation for in-vitro
fertilization and other assisted reproductive
technologies:
A regimen for superovulation involves the
administration of 150-225 IU of follitropin alfa
daily, commencing on days 2 or 3 of the cycle.
Treatment is continued until adequate
•
follicular development has been achieved (as
assessed by monitoring of serum estrogen
concentrations and/or ultrasound
examination), with the dose adjusted
according to the patient's response, to usually
not higher than 450 IU daily.
A single injection of up to 10,000 IU hCG is
administered 24-48 hours after the last folli­
tropin alfa injection to induce final follicular
maturation.
Down-regulation with a gonadotrophin­
releasing homone (GnRH) agonist is now
commonly used in order to suppress the
endogenous LB surge and to control tonic
•
levels of LB. In a commonly used protocol,
follitropin alfa is started approxima-tely 2
weeks after the start of agonist treatment, both
being continued until adequate follicular
development is achieved. For example,
following two-weeks treatment with an agonist
225 IU follitropin alfa are administered
(subcutaneous or intramuscularly) for the first
7 days. The dose is then adjusted according to
the ovarian response.
Drug inter: Clinically no significant adverse drug
interactions have been reported during follitropin
alfa therapy.
Concomitant use of follitropin alfa with other
agents used to stimulate ovulation may potentiate
the follicular response, whereas concurrent use
of GnRH agonist-induced pituitary desensitisa­
tion may increase the dosage of follitropin alfa
needed to elicit an adequate ovarian response.
+ GONAL-F Inj. Serono/Janata Healthcare
Follitropin alfa, recombinant follicle stimulating
hormone (r-hFSH) as a freeze-dried powder in
ampoule with solvent, 75 i.u/ampoule: injection.
Price: 75 i.u ampoule with solvent: 1889.13 MRP
• • •
FOLLITROPIN BETA: Injection21,40
•
Follitropin beta is a recombinant follicle
stimulating hormone (r-hFSH). It is available as a
freeze-dried powder in vial for reconstitution; 50
i. u and 100 i. u/vial: injection.
Ind: Follitropin is indicated for the treatment of

female infertility in the following clinical
situations- anovulation (including polycystic
ovarian disease- PCOD), in women who have
been 11nresponsive to treatment with clomiphene
citrate; controlled ovarian hyperstimulation to
induce the developm-ent of multiple follicles in
medically assisted reproduction programs (e.g in
vitro fertilisation/embryo transfer (IVF/ET),
gamete intra-fallopian transfer (GIFT) and
intracytoplasmic sperm injection (ICSI).
C/I: Tumours of ovary, breast, uterus, pituitary or
hypothalamus; pregnancy or lactation; undigno­
sed vaginal bleeding; hypersensitivity to folli­
tropin; primary ovarian failure; ovarian cysts or
enlarged ovaries, not related to polycystic ovarian
disease (PCOD); malformations of the sexual
organs incompatible with pregnancy; fibroid tum­
ours of the uterus incompatible with pregnancy.
S/E: Unwanted ovarian hyperstimulation has
been observed in 5% of subjects. Characteristic
symptoms of this condition- see under
precautions & special warnings. There may be
some local reactions at the site of injection, such
as bruising, pain, redness, swelling and itching,
the majority of which are mild.
Precautions: The presence of uncontrolled
nongonadal endocrinopathies (e.g thyroid,
adrenal or pituitary disorders) should be
excluded. The frrst injection of follitropin should
only be given under direct medical supervision.
Unwanted ovarian hyperstimulation- in the
treatment of female patients ultrasonographic
assessment of follicular development, and
determination of estradiol levels should be
performed prior to treatment & at regular
intervals during treatment.
A slightly increased risk of ectopic pregnancy
and multiple gestations has been seen. In rare
instances, arterio-thromboembolisms may occur
with follitropin/hCG therapy.
Warnings: Early ultrasound confirmation should
be made whether the pregnancy is intrauterine or
ectopic or multiple gestation. Since follicles of
over 14mm may lead to pregnancies, multiple
pre-ovulatory follicles exceeding l 4mm carry the
risk of multiple gestations. In that case hCG
'
should be withheld and pregnacy should be
avoided in order to prevent multiple gestations.
Rates of pregnancy loss in women undergoing
replacement therapy are higher than in the
normal population.
Dosage & admin: Anovulation- a sequential
treatment is recommended, initially a daily
dose of 75 i.u FSH activity, wihich is to be
countinued for at least 7 days; if no ovarian
response the daiy sose is then gradually
increased until follicle growth ano/or plasma
estadiol levels indicate an adequate phrmaco­
dynamic response. The daily dose is then
maintained until prevodulary condition�ar�
fached .. when there is ulti"asonographic
evidence of a dominant follicle of at least 1�
mm in diameter and or when plasma estadiol
.
14 days oftreatmet is suffient to reach this
' ..
.
state. The administration of follitropin is then
discontinued and ovulation canbe induced by
adminusteing human chorionic gonadotropin
(hCG).
t PUREGON Inj. Nuvista
Follitropin beta, recombinant follicle-stimulating
I
QIMP-17 (215)
hormone (r-hFSH) as a freeze-dried powder in
ampoule & vial with solvent, 50 i.u and 100 i.u/
vial: injection.
50 i.u vial (0.5ml): 2300.00 MRP
100 i.u vial (0.5ml): 4600.00 MRP
• • • redness.
UROFOLLITROPIN: lnjection2l,40,l33
Urofollitropin is a human follicle stimulating hor­
mone (FSH) extracted from the urine of post­
menopausal women. Urofollitropin (FSH) con­
sists of two non-covalently linked glycoproteins
designated as the alfa and beta subunits. The alfa
subunit has 92 amino acids of which two are
modified by attachment of carbohydrates. The
beta subunit has 111 amino acids of which two
are modified by attachment of carbohydrates.
The glycoproteins of urofollitropin (FSH) is
acidic and water soluble. It is available as sterile
lyophi-lized powder in vial for reconstitution
with sterile 0.9% sodium chloride solution for
subcutaneous (s.c) or intramuscular (i.m)
injection; each vial contains 50 l.U urofollitropin
(FSH) BP.
Mode of action: Urofollitropin (FSH)
administered for 7 to 12 days produces ovarian
follicular growth in women who do not have
primary ovarian failure. Treatment with
urofollitropin (FSH) in most instances results
only in follicular growth and maturation. When
sufficient follicular maturation has occurred,
HCG must be given to induce ovulation.
Ind: In the•female:
Ovulation induction:
Urofollitropin (FSH) administered i.m or s.c with
HCG in a sequential manner, which is indicated
for ovulation induction in patients who have
previously received pituitary suppression.
Multi-follicular development:
During ART urofollitropin (FSH) administered
i.m in conjunction with HCG is indicated for
multiple follicular developments (controlled
ovarian stimulation) during ART cycles in
patients who have previously received pituitary
suppression.
•
Polycystic ovarian syndrome (PCOS):
Used to treat polycystic ovarian syndrome
(PCOS) related infertility.
In the Male:
Male infertility treatment in combination with
HCG induction of spermatogenesis in men
deficient spermatogenesis due to
hypogonadotrophic-hypogonadism.
C/I: Tumours of the ovary, breast, uterus,
pituitary or hypothalamus; pregnancy or
lactation; undiagnosed vaginal bleeding;
hypersensitivity to the active ingredients or to
any of the excipients; primary ovarian failure;
fibroid tumours of the uterus incompatible with
pregnancy; primary testicular failure.
S/E: Urofollitropin (FSH) sometimes excites the
ovaries too much. This may cause pelvic pain or
breathing problems. It may also cause less urine.
In rare cases, patients with this problem have had
serious lung problems, including fluid in the
lungs, trouble breathing, & worsening of asthma,
blood clots and strokes, severe pelvic pain, chest
pain, or abdominal pain, nausea, vomiting,
sudden weight gain and bloating.
DRUGS USED IN ENDOCRINE DISEASES
Urofollitropin (FSH) may cause twins or multiple
births.
The most common side effects with urofollitropin
(FSH) are headache, yaginal bleeding, nausea,
and hot flashes. Sometimes there is a reaction at
the site of injection, such as bruising, pain, or
Precautions & warnings: Please consult
manufacturer's literature.
Pregnancy & lactation: Category X.
Urofollitropin (FSH) must not be used during
pregnancy and lactation.
Dosage & admin:
Dosage in female: There are great inter- and
intra-individual variations in the response of
the ovaries to exogenous gonadotrophins. This
makes it impossible to set a uniform dosage
schedule. The dosage should, therefore, be
adjusted individually depending on the ovari­
an response. This requires ultrasonography
and monitoring of oestradiol levels. There
should be consideration to minimize the risk
of unwanted ovarian hyperstimulation.
Urofollitropin (FSH) can be given either alone,
or in combination with a GnRH analogue to
prevent premature luteinisation. In the latter
case, specially when using a GnRH agonist, a
higher total treatment dose of urofollitropin
(FSH) may be required to achieve an adequate
follicular response. Clinical experience with
urofollitropin (FSH) is based on up to three
treatment cycles in both indications. Overall
experience with IVF indicates that in general
the treatment success rate remains stable
during the first four attempts and gradually
declines thereafter.
Ovulation induction in women:
Starting daily dose of 50 IU of urof ollitropin
(FSH) is administered s.c or i.m for at least the
first 7 days. The dose is increased by 2S or 50
IU at weekly intervals until follicular growth
and/or serum estradiol levels indicate an
adequate response. When an acceptable pre­
ovulatory state is achieved, final oocyte
maturation is achieved with 5,000 to 10,000 IU
of human chorionic gonadotropin (HCG). The
woman and her partner should have
intercourse daily, beginning on the day prior
to the administration of HCG and until
ovulation becomes apparent.
Assisted reproductive technology (ART):
In women: Starting dose of 150 to 225 IU of
urofollitropin (FSH) is administered i.m for at
least the first 4 days of treatment. Subsequent
doses are adjusted based upon ovarian
response as determined by ultrasound
evaluation of follicular growth and serum
estradiol levels. Final oocyte maturation is
induced with a dose of 5,009 - 10,000 IU of
HCG Oocyte (egg) retrieval is performed 34
to 36 hours later.
Polycystic ovarian hyperstimulation (PCOS):
Urofollitropin (FSH) injections are given each
morning as an i.m injection. It is best to start
with the lowest dose of urofollitropin (FSH)
per day (using 50 IU/day). These doses are
used for 4 to 6 days at a time. The ovarian
response is determined by measuring estrogen
levels in the blood. When the estrogen begins
to rise, the urofollitro-pin (FSH) is successfully
DRUGS USED IN ENDOCRINE DISEASES
growing an egg or eggs. If there is no response
to a dose of urofollitropin (FSH) in 5-6 days of
injections the dose will be increased. The
normal dose increments are 75 units, 112
units, 150 units and 225 units per day. Most
patients respond with 75 to 150 IU per day.
However, it is very important that increments
are only made cautiously.
Dosage in male: Induction of spermatogenesis
in men: Pre-treatment with HCG alone 1500
IU twice weekly is required. If serum testos­
terone levels have not normalized after 8
weeks of HCG treatment, the dose may be
increased to 3000 IU twice a week after nor­
malization of serum testosterone levels, admin­
ister 450 IU per week (225 IU twice weekly or
150 IU three times weekly) of urofollitropin
(FSH) s.c with the same pre-treatment HCG
dose used to normalize testosterone level.
Reconstitution: To prepare the solution, inject
lml of sterile saline for injection into the vial
of 50 IU urofollitropin (FSH). Do not shake,
but gently swirl until the solution is clear.
Generally urofollitropin (FSH) dissolves
immediately. Check the liquid in the container,
if it is not clear or contains particles, do not
use it. For patients requiring a single injection
from multiple vials of urofollitropin (FSH) up
to 6 vials can be reconstituted with lml of
sterile saline for injection. This can be accom­
plished by reconstituting a single vial as desc­
ribed above. Then draw the entire contents of
the first vial into a syringe and inject the
contents into a second vial of Iyophilized
urofollitropin. Gently swirl the second vial,
once again checking to make sure the solution
is clear and free of particles. This step can be
repeated as required for a total up to 6 vials
(300 IU) of 50 IU urofollitropin (FSH).
Method of administration: To prevent painful
injections and minimize leakage from the
illjection site, urofollitropin (FSH) should be
slowly administered i.m or s.c. The
subcutaneous injection site should be
alternated to prevent lipoatrophy. Any unused
solution should be discarded.
Storage: Store at 2°C-8°C (in refrigerator), do
not freeze; or store below 25°C for single period
of not more than 3 months.
Note: For further information, please consult
manufacturer's literature.
+ FHS Inj. Popular
Urofollitropin, a highly purified 'human follicle
stimulating hormone (FSH-HP)' extracted from
the urine of postmenopausal women. It is
presented as a sterile lyophilized and freeze-dried
powder in vial for injection with a sterile sodium
chloride (0.9%) solution ( l ml ampoule) as a
solvent for reconstitution; each vial contains
urofollitropin (FSH) BP 50 I.U for subcutaneous
(s.c) or intramuscular (i.m) injection.
Price: 50 i.u vial with solvent ( l ml): 1375.00 MRP
Drugs for Growth failure
GRO.WTR HORMONE 21
Growth hormone is an anterior pituitary hor­
mone, which has several different functions, but
QIMP-17 (216)
the most physiologic role is to promote protein
synthesis and thus helps in the growth of the
individual.The deficiency of growth hormone
leads to growth failure.
Growth hormone is used in the treatment of
growth hormone deficiency (including short
stature in Turner syndrome); only the human type
is effective since growth hormone is species
specific. The use of growth hormone of human
origin (somatotropin) devoloped a fatal
neurologic disease (Creutzfeldt-Jakob disease) in
several persons. So, it has been replaced by a
synthetic growth hormone of human sequence
(somatropin), produced by using recombinant
DNA technology.
SOMATROPJN2t,33
SOMATROPIN: Injection
It is a biosynthetic human growth hormone
(r-hGH) produced by using recombinant DNA
technology.
Ind: Children:
i) Long term treatment of children who have
growth failure due to endogenous growth hormo­
ne deficiency (GHDp).
ii) Short stature associated with Turner syndrome
(TS).
iii) Short stature associated with chronic renal
insufficiency (CRI).
iv) In short c'hildren/adolescents born small for
gestational age (SGA).
v) With a birth weight and/or length below -2
standard deviation, who failed to show catch-up
growth by 4 years of age or later.
vi) Prader-Willi syndrome (PWS)- for
improvement of growth and body composition.
Adults:
i) Replacement therapy in adults with
pronounced growth hormone deficiency defmed
as known hypothalamic pituitary pathology and
at least one known deficiency of a pituitary
hormone not being prolactin (GHDa).
C/I: Hypersensitivity to somatropin or to any of
the excipients; any evidence of fumour activity
and ongoing anti-tumour therapy; patients with
closed epiphyses (for growth promotion); acute
critical illness suffering complications follwing
open heart surgery, abdominal surgery, multiple
accidental trauma, acute respiratory failure or
similar conditions.
S/E: Antibody formation; local reactions (rotate
subcutaneous injection sites to prevent lipo­
atrophy); in Turner syndrome temporary
exacerbation of lymphoedema reported.
Precautions & warnings: Somatropin may
induce a state of insulin resistance and in some
patients hyperglycemia. Therefore, patients
should be observed for evidence of glucose intol­
erance. In patients with already manifested dia­
betes mellitus, the anti-diabetic therapy might
require adjustment when somatropin is instituted.
Theoretically development of hypothyroidism
and hyperthyroidism are possible. Somatropin
may reduce serum cortisol levels, thus corticos­
teroid replacement therapy should be optimised
before initiation of somatropin therapy. Signs of
any relapse of malignant disease should be
monitored. In patients with endocrine disorders,
slipped epiphyses of the hip may occur. Patients
limping during treatment with somatropin, should
be examined clinically. In cases of severe or
recurrent headache, visual problems, nausea
and/or vomiting, a �ndoscopy for papilloedema
is recommended as some rare cases of benign
intracranial hypertension have been reported and
if appropriate treatment should be discontinued.
In CRI, renal function should be below 50% of
normal before institution of therapy. Conservative
treatment for renal insufficiency should have
been established and be maintained during thera­
py. Discontinue GH after renal transplantation.
Avoid in pregnancy (theoretical risk).
Dosage & admin: See below under individual
products.
t OMNI TROPE 3.3mg/ml Inj. Sandoz
Somatropin 3.3mg/ml solution; l .5ml cartridge
corresponding to 5mg (15 units; produced by
recombinant DNA technology in Escherichia
coli): Cartridge for injection (subcutaneous).
Ind; C/I; S/E; Cautions: See above under the
text of somatropin.
Dosage & admin: Dose should be personalized
for each individual. The subcutaneous
injection site should be varied to prevent
lipoatrophy. Dosages are given as below:
Children;
Growth hormone deficiency (GHD)- 0.025 -
0.035mg/kg/day, higher doses can be used.
Turner syndrome (TS)- 0.045 - 0.050mg/kg/day.
Short stature associated with chronic renal
insufficiency (CRI)- 0.045 - 0.050mg/kg/day;
higher doses may be needed if growth velocity
is too low; a dose correction may be needed
after 6 months of treatment.
Small for gestational age (SGA)- 0.035mg/kg/
day until fmal height is reached.
Prader-Willi syndrome (PWS)- 0.035mg/kg/day;
daily doses of 2.7mg should not be exceeded.
Adults;
Growth hormone deficiency (GHD)- start with
low dose, 0.15 - 0.3mg/day; the dose should be
gradually increased as determined by the IGF-
1 concentration; clinical response and side
effects may guide dose titration; women may
require higher dose than men.
Before administration, dissolve the sterile powder
in the solvent and prepare a solution for
subcutaneous injection.
l.Sml (5mg or 15 units) cartridge x 5's pack:
45000.00 MRP
t OMNI TROPE Pen 5 Sandoz
Omnitrope pen 5 is an injection device for
omnitrope (somatropin) 3.3mg/ml =
5mg/cartridge subcutaneous injection.
Omnitrope pen 5 (injection device) x 1 's pack:
4500.00 MRP
,
Growth Hormone Antagonists:
•
Somatostaan/Somatosman
Analogues
SOMATOSTATJN 21,10
SOMATOSTATIN: Injection for i.v infusion
Somatostatin is a synthetic peptide hormone. It is ,
available as- 3mg injection in ampoule for intra-

venous infusion.
Ind: Severe acute haemorrhage from gastric &
duodenal ulcer; bleeding from acute erosive &
haemorrbagrc gastritis, oesophageal varices;
pancreatic, biliary & g.i fistulae, complications of
postoperative pancreatitis; acute pancreatitis.
C/lz Pregnancy, puerperium & lactation period.
S/E: Nausea, flushing, g.i distress, diarrh oea &
minor fluctuations in blood sugar.
Dosage & admin: Administer at a rate of
250mcg/hour or 6mg (2 amps) in 24 hours in a
continuous infusion until documented
cessation of bleeidng for upto even 5 days.
Duration of infusion: For bleeding, 5-120
hours; prophylaxis, 120-140 hours; fistulae, 5-
15 days. Reports of continuous infusion upto
37 days without complications are available.
+ STILAMIN lnj. Serono/Janata
Somatostatin (a synthetic peptide hormone) 3mg
in ampoule: injection.
3mg amp x l's pack: 5025.86 MRP
OCTREOTIDE54·145
OCT REOTIDE: I.VI S.C Injection
Octreotide acetate, a long-acting octapeptide with
pharmacologic actions similar to the natural hor­
mone somatostatin (i.e somatostatin analogue). It
is available as- octreotide acetate 0.05mg (50mcg)
in l ml ampoule (for subcutaneous injection) and
20mg (20,000mcg) larger dose vial for multiple
dose injection or continuous i.v infusion.
Mode of action: Octreotide acetate (somatostatin
analogue) is an even more potent inhibitor of
growth hormone, glucagon, & insulin than soma­
tostatin. Like somatostatin, it also suppresses LH
response to GnRH, decreases splanchnic blood
flow, and inhibits release of serotonin, gastrin,
vasoactive intestinal peptide, secretin, motilin,
and pancreatic polypeptide.
By virtue of these pharmacological actions,
octreotide acetate has been used to treat the
symptoms associated with metastatic carcinoid
tumors (flushing and diarrhea), and vasoactive
intestinal peptide (VIP) secreting adenomas
(watery diarrhea).
Octreotide acetate substantially reduces growth
hormone and/or IGF-1 (somatomedin C) levels in
patients with acromegaly.
Single doses of octreotide acetate have been
shown to inhibit gallblader contractility and to
decrease bile secretion in normal volunteers. In
controlled clinical trials the incidence of
gallstone or biliary sludge formation was
markedly increased.
Octreotide acetate suppresses secretion of thyroid
stimulating hormone (TSH).
Ind: 1. Emergency management to stop bleeding
and to protect from re-bleeding owing to gastro­
esophageal varices in patients with cirrhosis,
acromegaly, control of symptoms of neuro­
endocrine tumors.
2. Symptomatic control & reduction of growth
hormone in acromegaly.
C/I: Known hypersensitivity to octreotide or to
any component of the formulation.
S/E: Anorexia, nausea, vomiting, crampy abdom­
inal pain, abdominal bloating flatulence, loose
•
stools, diarrhoea, steatorrhoea, hypersensitivity,
QIMP-17 (217)
isolated cases of bradycardia.
Precautions: Please see manufacturer's literature.
Pregnancy & lactation: Experience with
Octreotide acetate in pregnant or nursing women
is limited, and they should therefore be given the
drug only under compelling circumstances.
Dosage & admin: Vasoactive therapy in acute
bleeding from gastro-esophageal varices: 50mcg
i. v bolus followed by 25-50mcg/hour in
continuous i.v infusion (total of 12 ampoules in
1OOOml of normal saline (NS), dextrose in
aqua (DA) or dextrose normal saline (DNS) to
be infused over 24 hours) for 5 days.
Symptomatic control & reduction of growth
hormone in acromegaly: Initially 50-lOOmcg by
s.c injection every 8 or 12 hours. Dosage
adjustment should be based on monthly
assessment of GH and IGF-1 Ievels (target;
GH<2.5ngm/ml; IGF-1 within normal range)
and clinical syptoms, and on tolerability. In
most patients, the optimal daily dose will be
0.3mg (300mcg). A maximum dose of 1.5mg
(1500mcg) per day should not be exceeded.
For patients on a stable dose of octreotide,
assessment of GH should be made every 6
months. If no relevant reduction in GH levels
and no improvement in clinical symptoms
have been achieved within 3 months of
starting treatment with octreotide, therapy
should be discontinued.
The injection should be inspected and brought
to room temperature before administration.
Overdose: Doses of up to 2000mcg octreotide
given as s.c. injection t.i.d. for several months
have been well tolerated. The maximum i.v.
single dose so far given to an adult has been 1mg
by bolus injection. The signs and symptoms
observed were a brief drop in heart rate, facial
flushing, abdominal cramps, diarrhoea, an empty
feeling in the stomach, and nausea, all of which
resolved within 24 hours of drug administration.
Drug inter: Octreotide has been associated with
alterations in nutrient absorption, so it may have
an effect on absorption of orally administred
drugs. Concomitant admnistration of octreotide
with cyclosporine may decrease blood levels of
cyclosporine and result in transplant rejection.
Patients receiving insulin, oral hypoglycemic
agents, beta blockers, calcium chamel blockers,
or agents to control fluid and electrolyte balance,
may require dose adjustments of these
therapeutic agents.
Note: For full information, please consult
manufacturer's literature.
• SANDOSTATIN SC Inj. Novartis
Octreotide acetate 0.05mg (50mcg)/lml ampoule:
s.c injection.
50mcg ampoule x 5 's pack: 6226.00 MRP
+ SANDOSTATIN LAR Inj. Novartis
Octreotide acetate 20mg (larger dose) vial: s.c
injection/i.v injection or infusion.
20mg vial x 1 's pack: 79240.00 MRP
6. PINEAL HORMONE
MELATONIN42
MELATONIN: Tablet
DRUGS USED IN ENDOCRINE DISEASES
r.
'
·
Melatonin is a hormone secreted b y the pineal
gland in the brain. It is available as- Melatonin
INN 3mg tablet.
Action of melatonin: It helps regulate other
hormones & maintains the body's circadian
·
rhythm. Melatonin is involved in photic
regulations of various kinds, including adaptation
to light intensity, daily changes of light and
darkness, and seasonal changes of photoperiod
lengths. Darkness stimulates the production of
melatonin while light suppresses its activity. Jet
lag, shift work, and poor vision can disrupt
melatonin cycles. Melatonin helps control the
timing and release of female reproductive
hormones. Many researchers also believe that
melatonin levels are related to the aging process.
In addition to its hormonal actions, melatonin has
strong antioxidant effects. It also helps strengthen
the immune system.
Mode of action: Melatonin and melatonin
agonists inhibit the release of dopamine from
retina through activation of a site that is
pharmacologically different from a serotonin
receptor. These inhibitory. effects are antagonized
by the melatonin receptor antagonist luzindole,
which suggests that melatonin activates a
presynaptic melatonin receptor.
Ind: Melatonin is used for numerous conditions
but is showing the most promise in short-term
regulation of sleep patterns, including jet lag.
1. Insomnia
Melatonin helps to induce sleep in people
with-
- disrupted circadian rhythms (such as those
suffering from jet lag or poor vision or those
who work the night shift)
- low melatonin levels (such as some elderly
and individuals with schizophrenia)
- children with learning disabilities who suffer
from insomnia.
2. Osteoporosis
Melatonin stimulates cells called osteoblasts
that promote bone growth.
3. Jn Menopause
Melatonin helps peri- or postmenopausal
women to regulate sleep patterns.
. 4. Eating disorders
Melatonin levels may play a role in the
symptoms of anorexia.
5. Sarcoidosis
•
6. Attention Deficit Hyperactivity Disorder
(ADHD)
It may be effective in managing sleep
disturbances in children with this condition.
C/I: Melatonin should not be used by patients
who have autoimmune diseases.
S/E: Possible adverse effects include headache
and depression. Drowsiness may be experienced
within 30 minutes after taking melatonin and
may persist for 1 hour and thus may affect
driving skills.
Precautions: Caffeine and fluvoxamine may
increase'the effects of melatonin, while melatonin
may decrease the antihypertensive effect of
nifedipine.
Pregnancy & lactation: Information regarding
safety and efficacy in pregnancy and lactation is
not available.
Dosage & admin: Adult:
Insomnia: 3-6mg one hour before bedtime
DRUGS USED IN ENDOCRINE DISEASES
Jet lag: 0.50 to 5mg one hour prior to bedtime
at final destination or, 1 to 5mg 1 hour before
bedtime for 2 days prior to departure and for
2 to 3 days upon arrival at final destination.
Eastbound travel- take a preflight early
·
evening treatment followed by treatment at
bedtime for 4 days after arrival.
Westbound travel- take for 4 days at be<ttime
when in the new time zone.
Sarcoidosis: 20mg per day for 4 to 12 months.
Depression: 0.125mg twice in the late
afternoon, each dose 4 hours apart.
Difficulty falling asleep: 5mg 3 to 4 hours
before an imposed sleep period over a 4-weeks
period.
Children (6 months to 14 years of age with sleep
disorders): 0.30mg/day.
Overdose: There is little or no evidence of any
major toxicities with melatonin, even at high
doses.
Drug inter: Antidepressant medications:
Melatonin reduces the antidepressant effects of
desipramine and fluoxetine. In addition,
fluoxetine leads to measurable depletion of
melatonin in people.
Antipsychotic medications: People with schizo­
phrenia and tardive dyskinesia taking antipsy­
chotic medications with melatonin has signifi­
cantly reduced mouth movements compared to
those who did not take the supplements.
Benzodiazepines: The combination of melatonin
and triazolam improves sleep quality. In addition,
there have been a few reports suggesting that
melatonin supplements may help individuals stop
using long-term benzodiazepine therapy.
Blood pressure medications: Melatonin may
reduce the effectiveness of blood pressure
medications like methoxamine and clonidine. In
addition, calcium channel blockers (such as
nifedipine, verapamil, diltiazem, amlodipine,
nimodipine, felodipine, nisoldipine, and bepridil)
may decrease melatonin levels. Use of beta­
blockers (propranolol, acebutolol, atenolol,
labetolol, metoprolol, pindolol, nadolol, sotalol,
and timolol) may reduce melatonin production in
the body.
Blood-thinning medications, anticoagulants:
Melatonin may increase the risk of bleeding
from anticoagulant medications such as warfarin.
Irzterleukin-2: In one study of 80 cancer patients,
use of melatonin in conjunction with interleukin-
2 led to more tumor regression & better survival
rates than treatment with interleukin-2 alone.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs):
NSAIDs such as ibuprofen may reduce the levels
of melatonin in the blood.
Steroids and immunosuppressant medications:
People should not take melatonin with
corticosteroids or other medications used to
suppress the immune system because the
st1pplement may cause them to be ineffective.
• birth, abortion or miscarriage; it can also be used
Tamoxiferz: Preliminary research suggests that
the combination of tamoxifen (a chemotherapy
drug) and melatonin may benefit certain patients
with breast and other cancers.
Other substances: Caffeine, tobacco, and alcohol
can all diminish levels of melatonin in the body
while cocaine and amphetamines may increase
melatonin production.
QIMP-17 (218)
+ FILFRESH Tab. Square
Melatonin INN 3mg tablet.
3mg x 20's pack: 90.30 MRP
7.DRUGS AFFECTING
BONE METABOLISM
1 Calcitonin
2 Bisphosphonates
Note: For detail, please see in the chapter 'drugs
used in bone formation & bone disorders'
8. OTHER ENDOCRINE
DRUGS
1 Bromocriptine & other dopamine receptor
agonists (stimulants)- viz. Bromocriptine,
Cabergoline, Quinagolide
2 Drugs affecting (inhibiting)
gonadotrophins- viz. Cetrorelix, Danazol,
Gestrinone
3 Metyrapone & trilostane- viz. Metyrapone,
Trilostane
Drugs for Milk suppression
BROMOCRIPTINE MESYLATE21,58
BROMOCRIPTINE MESYLATE: Tablet
Ind: i. Endocrine disorders- bromocriptine is
used for the suppression of lactation when
simpler measures fail, for the treatment of
galactorrhoea and cyclical benign breast disease,
for the treatment of prolactinomas and treatment
of acromegaly but success rate is much lower
than with prolactinomas). ii. Parkinsonism (but
not drug induced extrapyramidal symptoms).
Preparations: See under CNS drugs in the
section of 'drugs used in parkinsonism'.
CABERGOLINE133
CABERGOLINE: Tablet
Cabergoline is a dopamine receptor agonist (stim­
ulant). It is useful in the treatment to stop breast
milk production and also in other conditions of
hormonal disturbance where prolactin production
is high (hyperprolactinemia). It is available as­
cabergoline BP O.Smg per tablet.
Mode of action: Cabergoline works by reducing
the amount of prolactin that is released from the
anterior pituitary gland.
Ind: i. Cabergoline is used to stop breast milk
production (lactation) soon after childbirth, still­
if one does not want to continue breast-feeding.
ii. Cabergoline can also be used to treat other
conditions caused by hormonal imbalance which
due to increased production of prolactin (as in
tumours of pituitary gland in both men & women).
C/I: i. History of serious mental disease, particu­
larly psychotic disorders; ii. Liver or kidney dis­
ease; iii. High blood pressure in pregnancy
associated with swelling and protein in the urine
(toxemia of pregnancy); iv. Anti-psychotics or
have a history of mental illness associated with
child-birth (puerperal psychosis); v.
Hypersensitivity (allergy) to cabergoline or other
ergot alkaloids (e.g pergolide, bromocriptine,
lisuride, ergotamine or ergometrine) or other •
ingredients of the preparation.
S/E: No information of any significant side-effect.
Precautions & warnings: i. Pregnancy and
breast-feeding; ii. Treatment with cabergoline for
a long period and have or had fibrotic reactions
(scar tissue) affecting the heart.
Pregnancy & lactation: Pregnant or planning to
be pregnant, discuss with the doctor before
treatment through the pregnancy category B.
Before start treatment with cabergoline check that
patients not pregnant. Pregnant for at least one
month, one should stop taking cabergoline, as
cabergoline will stop producing milk. . If someone
plan to breast-feed should not take cabergoline.
Dosage & admin: The recommended dosage of
cabergoline for initiation of therapy is 0.25mg
twice a week. Dosage may be increased by
0.25mg twice weekly up to a dosage of 1 mg
twice a week according to the patient's serum
prolactin level. Dosage increases should not
occur more rapidly than every 4 weeks, so that
the physician can assess the patient's response
to each dosage level. If the patient does not
respond adequately and no additional benefit
is observed with higher doses, the lowest dose
that achieved maximal response should be
used and other therapeutic approaches
considered. After a normal serum prolactin
level has been maintained for 6 months'
cabergoline may be discontinued with periodic
monitoring of the serum prolactin level to
determine whether or when treatment with
cabergoline should be reinstituted.
To prevent milk production- lmg (two 0.5mg
tablets) on the first day after delivery.
To stop lactation once have started to
breastfeed- 0.25mg (half of cabergoline 0.5mg
tablet) every 12 hours for two days.
To reduce prolactin levels in other conditions­
initially take one 0.5mg tablet dividing in two
halves, spreading out over a week (e.g half a
tablet on monday and the other half of the
tablet on thurseday). Dose will be increased up
to a maximum dose of 4.5mg or until have
responded fully to treatment.
Drug inter: i. Medicines to lower blood pres­
sure; ii. Medicines used to treat mental illness
(e.g anti-psychotic medicines like chlorproma­
zine, haloperidol); iii. Medicines for nausea &
vomiting (e.g domperidone, metoclopramide);
iv. Medicines for severe migraine headaches (e.g
pergolide, bromocriptine, lisuride, ergotamine,
dihydroergotamine, ergometrine or methysergide).
Note: For further information, please consult
manufacturer's literature.
+ CABERGOL Tab. Popular
Cabergoline BP O.Smg/tablet
O.Smg x 6's pack: 480.00 MRP
+ CABOLIN Tab. Renata
Cabergoline BP O.Smg/tablet
O.Smg x 4's pack: 320.00 MRP

Drugs affecting (inhibiting)
gonadotrophins
CETRORELIX70
+ CETROTIDE lnj. Serono/Janata Traders
Cetrorelix acetate 0.26-0.27mg equivalent to
cetrorelix 0.25mg/vial: powder for injection with
one pre-filled syringe containing l ml water as
solvent.
Mode of action: Cetrorelix inhibits the effects of
a natural hormone, called luteinising hormone
releasing hormone (LHRH). LHRH regulates the
secretion of luteinising hormone (LH), which
induces ovulation during the menstrual cycle.
Cetrorelix inhibits premature ovulation which is
undesirable during hormone treatment for ovarian
stimulation as only mature egg cells are suitable
for fertilisation.
Ind: Prevention of premature ovulation in
patients undergoing a controlled ovarian
stimulation, followed by oocyte pick-up and
assisted reproductive techniques.
C/I: Hypersensitivity to cetrorelix acetate,
extrinsic peptide hormones or mannitol;
pregnancy ;11tt..l lactation; postmenopausal women;
patients with moderate and severe renal and
hepatic impairment.
S/E: Mild and transient reactions at the injection
site, e.g erythema, itching and swelling.
Occasionally systemic side effects, e.g nausea
and headache have been reported. In addition, a
single case of pruritus has been reported during
treatment with cetrorelix.
A severe hypersensitivity reaction, associated
with cough, rash and hypotension, was observed
in one patient after 7 months of treatment of
ovarian cancer with cetrorelix ( lOmg/day). The
patient recovered completely within 20 minutes.
A causal relationship could not be excluded.
Occasionally an ovarian hyperstimulation
syndrome (OHSS) can occur which is an intrinsic
risk of the stimulation procedure (see precautions
& warnings for use). Symptoms like abdominal
pain, tension, nausea, vomiting, diarrhoea and
breathing difficulties may indicate an OHSS.
Please inform the concerned doctor immediately,
if the patient feels such symptoms.
If the patient notices any unwanted effect not
mentioned in the list of side-effects or if she is
unsure about the effect of this medicine, please
inform the concerned doctor immediately.
Precautions & warnings: During or following
ovarian stimulation an ovarian hyperstimulation
syndrome can occur. This event must be consid­
ered as an intrinsic risk. of the stimulation proce­
dure with gonadotropins.
An ovarian hyperstimulation syndrome should be
treated symptomatically, e.g with rest, intrave­
nous electrolytes/colloids and heparin therapy.
Luteal phase support should be given according
to the reproductive medical centre's practice.
There is limited experience up to now with the
administration of cetrorelix during a repeated
ovarian stimulation procedure. Therefore,
cetrorelix should be used in repeated cycles only
after a careful risk/benefit evaluation.
QIMP-17 (219)
Pregnancy & lactation: Cetrorelix is not intene­
ded to be used during pregnancy & lactation.
Studies in animals have indicated that cetrorelix
exerts dose related influence on fertility, repro­
ductive performance and pregnancy. No teratoge­
nic effects occured when the drug was adminis­
tered during the sensitive phase of gestation.
Dosage & admin: Cetrorelix 0.25mg should
only be prescribed by a specialist experienced
in this field.
Cetrorelix 0.25mg is for subcutaneous
injection into the lower abdominal wall.
The content of 1 vial (0.25mg cetrorelix) is to
be administered once daily, at 24 hours inter­
vals, either in the morning or in the evening.
Administration in the morning: Treatment with
cetrorelix 0.25mg in the morning should
commence on day 5 or 6 of ovarian
stimulation (approximately 96 to 120 hours
after start of ovarian stimulation) with urinary
or recombinant gonadotropins and is to be
continued throughout the gonadotropin
treatment period including the day of
ovulation induction.
Administration in the evening: Theratment
with cetrorelix 0.25mg in the evening should
commence on day 5 of ovarian stimulation
(approximately 96 to 108 hours after start of
ovarian stimulation) with urinary or
recombinant gonadotropins and is to be
continued throughout the gonadotropin
treatment period until the evening prior to the
day of ovulation induction.
Cetrorelix injection can be administered by
the patient herself after appropriate
instructions by her doctor. (For instructions
for use and handling the injection- see
manufacturer's literature).
Missing a dose: Ideally cetrorelix 0.25mg
should be administered at 24 hours intervals.
But if missed to administer the injection at the
right time it is no problem to administer this
dose at a different time of the same day. If
missed to administer cetrorelix 0.25mg on one
day, please contact the concerned doctor
immediately and ask for advice.
Drug inter: In vitro investigations have shown
that interactions are unlikely with medications
that are metabolised by cytochrome P450 or
glucuronised or conjugated in some other way.
However, the possibility of interactions with
commonly used medicinal products cannot
entirely be excluded.
Price: 250mcg vial with water in pre-filled
syringe x 7's pack: 25130.50 MRP
DANAZOL2l,85,94
DANAZOL: Capsule
Danazol is a synthetic steroid drug derived from
ethisterone. Different studies established that the
drug is neither estrogenic nor progestational but
has some weak androgenic activity, which is dose
related. Danazol inhibits pituitary gonadotrophins
i.e it depresses the output of both follicle­
stimulating hormone (FSH) and luteinizing
hormone (LH).
Ind: Endometriosis; benign (fibrocystic) breast
cysts; gynaecomastia; menorrha-gia; severe
cyclical mastalgia; pre-operative thining of
DRUGS USED IN ENDOCRINE DISEASES
endometrium; hereditary angioedema (of all
types).
C/I: Pregnancy; breast-feeding; undiagnosed
abnormal genital bleeding; markedly impaired
hepatic, renal or cardiac function; thromboem­
bolic diseases; androgen-dependent tumours;
porphyria.
S/E: Nausea, dizziness, skin reactions including
rashes, photosensitivity and exfoliative dermati­
tis, fever, backache, nervousness, mood changes,
anxiety, changes in libido, vertigo, fatigue, epi­
gastric and pleuritic pain, headache, weight gain;
menstrual disturbances, vaginal dryness and
irritation, flushing and reduction in breast size; .
musculo-skeletal spasm, joint pam and swelling,
hair loss; androgenic effects including acne, oily
skin, oedema, hirsutism, voice changes and rarely
clitoral hypertrophy; temporary alteration in lipo­
proteins and other metabolic changes, insulin
resistance; thrombotic events; leucopenia,
thrombocytopenia, eosinophilia, reversible
erythrocytosis or polycythaemia reported;
headache and visual disturb-ances may indicate
benign intracranial hypertension; rarely choles­
tatic jaundice, pancreatitis, peliosis hepatis and
benign hepatic adenomata.
Cautions: Because danazol may cause some
degree of fluid retention, conditions that might
be influenced by this factor, such as epilepsy,
migraine, cardiac or renal function, hypertension
require careful observation. Elderly. Withdraw
treatment if virilisation.
Warnings: As danazol is contra-indicated in
pregnancy, a pregnancy test is recommended
prior to starting therapy. Additionally a non­
hormonal method of contraception should be
used during therapy. If a patient becomes
pregnant while taking danazol, therapy should be
discontinued and the patient should be apprised
of the potential risk of the foetus.
Dosage & admin: Drug treatment usually
given in up to 4 divided doses; in women of
child-bearing potential, treatment should start
during menstruation, preferably on day 1.
Endometriosis: 200-800mg daily in up to 4
divided doses, adjusted to achieve
amenorrhoea, usually for 6 months (up to 9
months in some cases).
Menorrhagia: 200mg daily, usually for 3
months (but in view of its side-effects, treat­
ment with other drugs may be preferable).
Severe cyclical mastalgia: 100-400mg daily
usually for 3-6 months.
Benign breast cysts: 300mg daily usually for
3-6 months.
Gynaecomastia: 400mg daily in up to 4 divided
. doses for 6 months (adolescents 200mg daily,
increased to 400mg daily if no response after 2
months).
Pre-operative thinning of endometrium:
400-800mg daily in up to 4 divided doses for
3-6 weeks.
Hereditary angioedema: start with 200mg 2 or
3 times daily. After favourable initial respone
(is obtained in terms of prevention of episodes
of oedematous attacks) the proper continuing
dosage should be determined by decreasing
the dosage by 50°/o or less at intervals of 1-3
months or longer if frequency of attacks prior
to treatment dictates. If an attack occurs dur-

DRUGS USED IN ENDOCRINE DISEASES
ing therapy the d�ily dosage may be increased
by up to 200mg.
® up to 200 mg/kg/day during organogenesis.
I ana
Oanazol capsule
SK•F
+ DANAMET Cap. SK+F
Danazol 1OOmg & 200mg/capsule.
1OOmg x l 8's pack: 360.00 MRP
200mg x 18's pack: 684.01 MRP
+ DANZOL Cap. Renata
Danazol 1OOmg & 200mg/capsule.
l OOmg x 30's pack: 600.00 MRP
200mg x 20's pack: 760.00 MRP
+ LOZANA Cap. Incepta
Danazol 1OOmg & 200mg/capsule.
l OOmg x 20's pack: 400.00 MRP
200mg x 14's pack: 532.00 MRP
9. NON-HORMONE SEX
STIMULANT DRUGS .
SILDENAFIL CITRATE141
SILDENAFIL CITRATE: Tablet
Sildenafil citrate is a non-hormone sex stimulant,
and particularly useful in the treatment of erectile
dysfunction. It is available as sildenafil citrate
INN equivalent to sildenafil 25mg/tablet,
50mg/tablet and 1 OOmg/tablet (film-coated).
Mode of action: Sildenafil is a selective inhibitor
of cyclic guanosine monophosphate (cGMP)­
specific phosphodiesterase type 5 (PDE5). The
physiologic mechanism of erection of the penis
involves release of nitric oxide in the corpus
cavemosum during sexual stimulation. Nitric
oxide then activates the enzyme guanylate
cyclase, which results in increased levels of
cyclic guanosine monophosphate (cGMP),
producing smooth muscle relaxation in the
corpus cavemosum and allowing inflow of blood.
Sildenafil has no direct relaxant effect on isolated
human corpus cavernosum, but enhances the
effect of nitric oxide by inhibiting phosphodieste­
rase type 5 (PDE5), which is responsible for
degradation of cGMP in the corpus cavemosum.
When sexual stimulation causes local release of
nitric oxide, inhibition of PDE5 by sildenafil
causes increased levels of cGMP in the corpus
cavemosum, resulting in smooth muscle
relaxation and inflow of blood to the corpus
cavemosum. Sildenafil at recommended doses
has no effect in the absence of sexual stimulation.
Ind: Sildenafil is indicated for the treatment of
erectile dysfunction.
C/I: Consistent with its known effects on the
nitric oxide/cGMP pathway, sildenafil was shown
to potentiate the hypotensive effects of nitrates,
and its administration to patients who are using
organic nitrates, either regularly and/or intermit­
tently, in any form is therefore contraindicated.
Pregnancy & Lactation: Pregnancy category B,
QIMP-17 (220)
but there is no adequate and well-controlled stud­
ies of sildenafil in pregnant women. No evidence
of teratogenicity, embryotoxicity or fetotoxicity
was observed in rats and rabbits which received
Dosage & admin: For most patients, the
recommended dose is 50mg taken, as needed,
approximately 1 hour before sexual activity.
However, sildenaftl may be taken anywhere
from 4 hours to half an hour before sexual
activity. Based on effectiveness and toleration,
the dose may be increased to a maximum
recommended dose of 1 OOmg or decreased to
25mg. The maximum recommended dosing
frequency is once per day.
Drug Inter: Sildenafil metabolism is principally
mediated by the cytochrome P450 (CYP) iso­
forms 3A4 (major route) and 2C9 (minor route).
Therefore, inhibitors of these isoenzymes may
reduce sildenafil clearance and inducers of these
isoenzymes may increase sildenafil clearance.
+ ACT IVA Tab. Pacific
Sildenafil citrate INN equivalent to sildenafil
50mg & 1OOmg/tablet (film-coated).
50mg x 4's pack: 100.00 MRP
1OOnig x 4's pack: 160.00 MRP
+ ADEGRA Tab. ACI
Sildenafil citrate INN equivalent to sildenafil
25mg, 50mg & 1OOmg/tablet (film-coated).
25mg x 4's pack: 80.00 MRP
50mg x 4's pack: 120.00 MRP
1OOmg x 4's pack: 200.00 MRP
+ AGGRA Tab. SK+F
Sildenafil citrate INN equivalent to sildenafil
50mg & lOOmg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP.
1 OOmg x 4's pack: 200.00 MRP
•
+ DANAFIL 50 Tab. NIPRO JMI
Sildenafil citrate INN equivalent to sildenafil
50mg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
+ EDEGRA Tab. Sun Pharma
Sildenafil citrate INN equivalent to sildenafil
50mg & 1 OOmg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
I OOmg x 4's pack: 200.00 MRP
+ ENEGRA 50 Tab. Beximco
Sildenafil citrate INN equivalent to sildenafil
50mg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
+ ENJOFIL Tab. Navana
Sildenafil citrate INN equivalent to sildenafil
25mg, 50mg & I OOmg/tablet (film-coated).
25mg x 4's pack: 60.00 MRP
50mg x 4's pack: 120.00 MRP
lOOmg x 4's pack: 200.00 MRP
+ ERECTA Tab. Renata
Sildenafil citrate INN equivalent to sildenafil
50mg & I OOmg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
lOOmg x 4's pack: 200.00 MRP
+ EUROFIL Tab. Novo Healthcare
Sildenafil citrate INN equivalent to sildenafil
50mg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
+ FULFEEL Tab. Orion Pharma
Sildenafil citrate INN equivalent to sildenafil
50mg/tablet (film-coated).
50mg x 8's pack: 240.00 MRP
---------liiii---�
+ IMMENSE Tab. Biopharma
Sildenafil citrate INN equivalent to sildenafil
25mg & 50mg/tablet (film-coated).
25mg x 4's pack: 72.00. MRP
50mg x 4's pack: 100.00 MRP
+ kX-50 Tab. Kemiko
Sildenafil citrate INN equivalent to sildenafil
'
50mg/tablet (film-coated).
50mg x S's pack: 150.00 MRP
+ kX-100 Tab. Kemiko
Sildenafil citrate INN equivalent to sildenafil
1 OOmg/tablet (film-coated).
1OOmg x S's .pack: 250.00 MRP
+ NIAGRA Tab. Delta Pharma
Sildenafil citrate INN equivalent to sildenafil
25mg, 50mg & l OOmg/tablet (film-coated).
25mg x 8's pack: 120.00 MRP
50mg x 8's pack: 200.00 MRP
1OOmg x 8's pack: 320.00 MRP
+ NOVAGRA 50 Tab. Novelta
Sildenafil citrate INN equivalent to sildenafil
50mg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
50mg x 20's pack: 600.00 MRP
+ SILFIL Tab. Organic Health
Sildenafil citrate INN equivalent to sildenafil
50mg & l OOmg/tablet (fiim-coated).
50mg x 20's pack: 600.00 MRP
l OOmg x 20's pack: 1000.00 MRP
+ SINAFIL Tab. Everest
Sildenafil citrate INN equivalent to sildenafil
50mg & I OOmg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
1OOmg x 4's pack: 200.00 MRP
.
+ SUPERGRA-50 Tab. Apex
Sildenafil citrate INN equivalent to sildenafil
50mg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
+ VEAGRA Tab. Astra
Sildenafil citrate INN equivalent to sildenafil
50mg & l OOmg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
I OOmg x 4's pack: 200.00 MRP
+ V-GRA Tab. Aristopharma
Sildenafil citrate INN equivalent to sildenafil
25.mg, 50mg & 1 OOmg/tablet (film-coated).
25mg x lO's pack: 160.00 MRP
50mg x l O's pack: 300.00 MRP
lOOmg x l O's pack: 500.00 MRP
+ VIAMAX Tab. UniMed & UniHealtb
Sildenafil citrate INN equivalent to sildenafil
25mg, 50mg & l OOmg/tablet (film-coated).
25mg x 4's pack: 80.00 MRP
50mg x 4's pack: 120.00 MRP
l OOmg x 4's pack: 200.00 MRP
+ VIARA Tab. Medicon
Sildenafil citrate INN equivalent to sildenafil
50mg & 1 OOmg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
l OOmg x 4's pack: 200.00 MRP
+ VIGOREX Tab. Square
Sildenafil citrate INN equivalent to sildenafil •
25mg, 50mg & l OOmg/tablet (film-coated).
25mg x 4's pack: 80.00 MRP
50mg x 4's pack: 120.00 MRP
I OOmg x 4's pack: 200.00 MRP
+ VISAGRA 50 Tab. Sharif
Sildenafil citrate INN equivalent to sildenafil
50mg/tablet (film-coated).
50mg x 4's pack: 120.00 MRP
.
•
•

+ X-CITE 50 Tab. Alco Pharma
Sildenafil citrate INN equivalent to sildenafil
SOmg/tablet (film-coated).
SOmg x 4's pack: 120.00 MRP
+ YOGRA Tab. W hite Horse
Sildenafil citrate USP SOmg & lOOmg/tablet (f.c).
SOmg x lO's pack: 300.00 MRP
lOOmg x lO's pack: S00.00 MRP
TADALAFIL26
TADALAFIL: Tablet
Tadalafil is also a non-hormone sex stimulant and
is useful in the treatment of erectile dysfunction,
benign prostatic hyperplasia and erectile
dysfunction with benign prostatic hyperplasia.
Chemically, tadalafil is a selective, reversible
inhibitor of cyclic guanosine monophosphate
(cGMP)-speci-fic phosphodiesterase type 5
(PDES). It is available as tadalafil INN lOmg &
20mg film-coated tablet.
Mode of action: Penile erection during sexual
stimulation is caused by increased penile blood
flow resulting from the relaxation of penile arter­
ies and corpus cavernosal smooth muscle. T his
response is mediated by the release of nitric
oxide (NO) from nerve terminals and endothelial
cells, which stimulates the synthesis of cGMP in
smooth muscle cells. Cyclic GMP causes smooth
muscle relaxation and increased blood flow into
the corpus cavemosum. The inhibition of phos­
phodiesterase type S (PDES) enhances erectile
function by increasing the amount of cGMP.
Tadalafil inhibits PDES. Because sexual stimula­
tion is required to initiate the local release of
nitric oxide, the inhibition of PDES by tadalafil
has no effect in the absence of sexual stimulation.
The effect of PDES \nhibition on cGMP
concentration in the corpus cavernosum and
pulmonary arteries is �lso observed in the smooth
muscle of the prostate, the bladder and their
vascular supply. The mechanism for reducing
BPH symptoms has not been established.
Ind: Treatment of erectile dysfunction, benign
prostatic hyperplasia and erectile dysfunction
with benigri prostatic hyperplasia.
C/I: Tadalafil should not be used in patients with
hypersensitivity to tadalafil or to any of the
excipients. In clinical studies, tadalafil was
shown to augment the hypotensive effects of
nitrates. T his is thought to result from the com­
bined effects of nitrates and tadalafil on the nitric
oxide/cGMP pathway. T herefore, administration
of tadalafil to patients who are using any form of
organic nitrate is contra-indicated. Agents for the
treatment of erectile dysfunction, including
tadalafil, should not be used in men witlLcardiac
disease for whom sexual activity is inadvisable.
Physicians should consider the potential cardiac
risk of sexual activity in patients with pre­
existing cardiovascular disease.
The following groups of patients with cardiovas­
cular disease were not included in clinical trials
& the use of tadalafil is therefore contraindicated:
- Patients with myocardial infarction within
the last 90 days.
- Patients with unstable angina or angina
occurring during sexual intercourse.
- Patients with uncontrolled arrhythmias,
hypotension (<90/SO mmHg) or uncontrolled
'
'
\ I
'
I
QIMP-17 (221)
hypertension.
Patients with a stroke within the last 6
months.
S/E: The most commonly reported adverse reac­
tions are headache, dizziness, flushing & dyspep­
sia, nasal congestion, back pain, myalgia, swell­
ing of eyelids is uncommon adverse reactions.
The adverse events reported with tadalafil were
transient, and generally mild or moderate.
Precautions:
• Prior to initiating any treatment for erectile
dysfunction, physicians should consider the
cardiovascular status of their patients, since there
is a degree of cardiac risk associated with sexual
·
activity.
•
Tadalafil has vasodilator properties, resulting
in mild and transient decreases in blood
pressure.
•
There is limited clinical data on the safety of
tadalafil in the following groups; if prescribed,
a careful individual benefit/risk evaluation
should be und�rtaken by the prescribing
physician:
- Patients with severe renal insufficiency
- Patients with severe hepatic insufficiency
•
Tadalafil should not be administered to patients
with hereditary problems of galactose
intolerance.
The safety and efficacy of combinations of
•
tadalafil and other treatments for erectile dys­
function have not been studied. Therefore, the
use of such combinations is not recommended.
•
Caution should be exercised when tadalafil is
administered to patients with anatomical
deformation of the penis.
•
Patients who suffer from problems that
increase the possibility of priapism (sickle-cell
anemia, multiple myeloma, leukemia) should
use this product with caution.
Pregnancy & Lactation: Tadalafil is not
indicated for use by women. There are no studies
of tadalafil in pregnant women.
Dosage & admin: Erectile dysfunction:
The recommended dose is 1 Omg taken prior to
anticipated suual activity and without regard
to food. Those patients in whom tadalaftl
lOmg does not produce an adequate effect,
20mg might be tried. It can be taken from 30
minutes to 12 hours prior to sexual activity.
Efficacy of tadalafil may persist up to 24
hours post-dose. The maximum recommended
dosing frequency is once per day.
Benign prostatic hyperplasia: Smg, taken at
approximately the same time every day. .
Erectile dysfunction with benign prostatic
hyperplasia: Smg, taken at approximately the
same time every day.
Use in elderly men: Dosage adjustments are
not required in elderly patients.
Use in men with impaired renal function: T here
are no available data about the administration
of doses higher than 1 Omg of tadalaftl to
patients with renal impairment.
Use in men with impaired hepatic function:
There are no available data about the
administration of doses higher than lOmg of
tadalafil to patients with hepatic impairment.
Use in men with diabetes: Dosage adjustments
are not required in diabetic patients.
Use in children: Tadalaftl should not be used
-
DRUGS USED IN ENDOCRINE DISEASES
in individuals below 18 years of age, or before
marriage.
•
Overdose: Single doses of up to SOOmg have
been given to healthy subjects, and multiple daily
doses up to lOOmg have.been given to patients.
Adverse events were similar to those seen at
lower doses. In cases of overdose, standard sup­
portive measures should be adopted, as required.
Drug inter: Although specific interactions have
not been studied, some protease inhibitors, such
as ritonavir and saquinavir, and other CYP3A4
inhibitors, such as erythromycin, clarithromycin,
itraconazole a�d grapefruit juice, should be co­
administered with caution as they would be
expected to increase plasma concentrations of
tadalafil. Concomitant administration of other
CYP3A4 inducers, such as rifampicin,
phenobarbital, phenytoin and carbamazepine, will
also decrease plasma concentrations of tadalafil.
Effects of tadalafil on other medicinal products:
Tadalafil was shown to augment the hypotensive
effects of nitrates, therefore, administration of
tadalafil to patients who are using any form of
organic nitrate is contraindicated.
+ ADAFIL Tab. Beximco
Tadalafil INN lOmg & 20mg/tablet (f.c).
1Omg x 4's pack: 140.00 MRP
20mg x 4's pack: 240.00 MRP
+ CELESTE Tab. General
Tadalafil INN lOmg & 20mg/tablet (f.c).
lOmg x 4's pack: 140.00 MRP
20mg x 4's pack: 240.00 MRP
+ CIAFIL Tab. Navana
Tadalafil INN Smg, 1 Omg & 20mg/tablet (f.c ).
5mg x 4's pack: 72.00 MRP
lOmg x 4's pack: 140.00 MRP
20mg x 4's pack: 220.00 MRP
+ CIALIX 10 Tab. NIPRO JMI
Tadalafil INN 1 Omg/tablet ( f.c).
lOmg x 4's pack: 140.00 MRP
+ CIATON Tab. ACI
Tadalafil INN Smg, lOmg & 20mg/tablet (f.c).
Smg x 4's pack: 72.00 MRP
lOmg x 4's pack: 140.00 MRP
20mg x 4's pack: 240.00 MRP
+ EDYSTA Tab. UniMed & UniHealth
Tadalafil INN Smg, 1Omg & 20mg/tablet (f.c).
Smg x lO's pack: 180.00 MRP
lOmg x 4's pack: 140.00 MRP
20mg x 4's pack: 240.00 MRP
+ INTIMATE Tab. Square
Tadalafil INN Smg, lOmg & 20mg/tablet (f.c).
5mg x 4's pack: 72.00 MRP
lOmg x 4's pack: 140.00 MRP
20mg x 4's pack: 240.00 MRP
+ k T X Tab. Kemiko
Tadalafil INN Smg, lOmg & 20mg/tablet (f.c).
Smg x S's pack: 90.00 MRP
I Omg x S's pack: l 7S.OO MRP
20mg x S's pack: 300.00 MRP
+ MEGAFIL Tab. Acme
Tadalafil INN 1Omg & 20mg/tablet (f.c).
lOmg x 4's p·ack: 140.00 MRP
20mg x 4's pack: 240.00 MRP
+ PAWAR Tab. Aristopharma
Tadalafil INN Smg, 1 Omg & 20mg/tablet (f.c).
Smg x lO's pack: 180.00 MRP
lOmg x 1O's pack: 3SO.OO MRP
20mg x 1O's pack: 600.00 MRP

DRUGS USED IN ENDOCRINE DISEASES
t PROLONGA Tab. Pacific
,
Tadalafil INN IOmg & 20mg/tablet (f.c).
lOmg x 4's pack: 100.00 MRP
20mg x 4's pack: 160.00 MRP
t REFEEL Tab. Orion
Tadalafil INN lOmg & 20mg/tablet (f.c).
IOmg x 8's pack: 240.00 MRP
20mg x 8's pack: 400.00 MRP
CONTRACEPTIVE
METHODS
Different physicochemical contraceptive methods
have been discussed in the clinical section of this
book. Only hormonal contraceptive preparations
(oral pills) are discussed hear in this chapter.
Oral contraceptive prepns.
Progestogen-Only-Pill (POP)
DESOGESTREL62
DESOGESTREL: Tablet
Desogestrel is a progestogen- female sex hormone.
A small amount of this hormone is used in the
preparation of contraceptive pills. As this contra­
ceptive pill contains only desogestrel as progesto­
gen and no oestrogen homone, therefore called a
progestogen-only-pill (POP), or a minipill. This
progestogen-only-pill is available as- Desogestrel
BP 75mcg tablet for oral administration.
Mode of acton: Most minipills work primaily by
preventing the sperm cells from entering the
womb but do not always prevent the egg cell
from ripening, which is the primary action of
combined pills. Desogestrel is distinct from other
mini-pills in having a dose that in most cases is
high enough to prevent the egg cell from
ripening. As a result, desogestrel provides high
contraceptive efficacy. In contrast to the
combined pill, desogestrel can be used by women
who do not tolerate estrogens and by women who
are breast-feeding. A disadvantage is that vaginal
bleeding may occur at irregular intervals during
the use of desogestrel and also may not have any
bleeding at all.
Ind: Desogestrel is used to provide contraceptive
efficacy in women who want to prevent
pregnancy. Desogestrel has·proved to be highly
efficacious as a contraceptive pill and is an
alternative for women who have a weak tolerance
levels for the estrogen hormones or who are
lactating or breast feeding.
C/I; S/E; Precautions & warnings: See under
QIMP-17 (222)
t TADAFIL Tab. Astra
Tadalafil INN 5mg & lOmg/tablet (f.c).
5mg x 4's pack: 72.00 MRP
lOmg x 4's pack: 140.00 MRP
t TAFIL 10 Tab. Sharif
Tadalafil INN lOmg/tablet (f.c).
lOmg x 4's pack: 140.00 MRP
t TIAGRA Tab. Ziska
the text of progesterone.
Pregnancy & lactation: Not recommended for
use during pregnancy. Desogestrel does not affect
the production or quality of breast milk. Small
amounts of the metabolite etonogestrel are
excreted with the milk. Long term follow-up data
are not available; however, 7 month data do not
indicate a risk to the nursing infant.
Dosage & admin: One tablet (75mcg) at the
same time each day, taken continuously 28
tablets without a break. Tablets should be
taken within 3 hours of the same time each
day. Woman who takes this pill may have
some bleeding during the use, but must contin­
ue to take the tablets as normal. When a strip
is complete, should start with a new strip of
desogestrel on the next day without interrup­
tion and without waiting for a bleed. One can
stop taking desogestrel whenever she wants.
But, from the day of stopping desogestrel she
is no longer protected from pregnancy.
Starting first strip of desogestrel: If one is not
using hormonal contraception at present (or in
the past month) wait for menstrual period to
begin. On the first day of period take the first
tablet. If one takes the first tablet on days 2 to
5 of the period, use an additional barrier
method of contraception for the first 7 days of
tablet taking.
·
When change from a combined pill: Start deso­
gestrel on the day after the last active tablet of
the combined pill. In this case additional
contraceptive precaution is not necessary.
When change from a mini-pill, injection,
implant or hormonal IUD: Switch on any day
from another mini-pill. Start desogestrel the
day an implant or IUD is removed or the day
of next injection would be due, additional
contraceptive precautions are not necessary.
t BREDICON Tab. Renata
Desogestrel BP 75mcg/tablet.
28 tabs pack: 60.20 MRP
t POP-D Tab. Incepta
Desogestrel BP 75mcg/tablet.
28 tabs pack: 60.20 MRP
NORGESTREL62
NORGESTREL: Tablet
Norgestrel is a progestogen female sex hormone.
A small amount of this hormone is used in the
preparation of contraceptive pills. As this contra-
-
Tadalafil INN 5mg, lOmg & 20mg/tablet (f.c).
5mg x 4's pack: 72.00 MRP
5mg x lO's pack: I 80.00 MRP
lOmg x 4's pack: I 20.00 MRP
20mg x 4's pack: 206.00 MRP
+ VIEV 10 Tab. Alco Pharma
Tadalafil INN 1Omg/tablet (f.c).
IOmg x 4's pack: 140.00 MRP
ceptive pill contains only norgestrel as progesto­
gen and no oestrogen homone, therefore, this is
also a progestogen-only-pill (POP), or a minipill.
This progestogen-only-pill is available as­
Norgestrel BP 75mcg tablet for oral adminis­
tration.
Ind: Norgestrel contraceptive pill is indicated for
fertility control in women and for the control of
cases of dysfunctional uterine bleeding and
symptomatic treatment of primary dysmenor­
rhoea where contraception is also desired.
C/I; S/E; Precautions & warnings: See under
the text of progesterone.
Dosage & admin: See under individual
preparation.
t RENATRIL Tab. Renata
Norgestrel BP 0.075mg/tablet.
Ind; C/I; S/E; Cautions: See note at the
beginning (under the text of norgestrel).
Dosage & admin: Take the first pill on day 1
of menstruation. Take it with food or
immediately after a meal to prevent stomach
upset. Norgestrel should be taken daily at the
same time each day. Use a supplemental form
of birth control during the first two months of
taking norgestrel since it takes a while to be
effective.
Missed dose: Use a back-up method of birth
control for 2 days if one is more than 3 hours
late in taking this pill. If one forgets to take
one dose, should take the dose as soon as she
remembers, and should take the next dose at
her regular time. One should use a back-up
method of birth control until her next
menstrual period. If she forgets to take 2
doses, should take 2 doses when she
remembers, and the dose for that day. Then
she should use a back-up method of birth
control until her next period.
28 tabs pack: 25.00 MRP
Combined Oral Pills
ESTROGEN+
PROGESTER ONE 21,26,40,58,62
ESTROGEN+ PROGESTERONE PREPN:
Tablet (Pill).
This combination formula of estrogen & proges­
terone is used to prepare oral pills for contra­
ceptive purpose. Commonly available synthetic

estrogen preparation is ethinyJestradiol and syn­
thetic progesterone preparations are different,
such as- desogestrel, drospirenone, gestodene,
levonorgestrel, lynestrenol & norgestrel.
Mode of action: The contraceptive effect of the
oral pills containing synthetic oestrogen and
progesterone is based on the interaction of vari­
ous factors. But, the most important of which are
seen as the inhibition of ovulation & the changes
in cervical secretion. When oral pills are taken as
per instruction, the egg cells (normally released
by the ovary each month) are prevented from
maturing to the point where they can be fertilized.
Secondary mechanisms, which may contribute to
the effectiveness of contraceptive pills, include
changes in the cervical mucus, (which remains so
thick that constitutes a barrier to sperm pene­
tration), and changes in the endometrium (which
reduce the likelihood of implantation).
Ind: i. Contraception (prevention of pregnancy)
& ii. Also to regularize menstrual cycle & helps
to reduce discomforts experienced duri11g
menstruation. (The cycle is more regular and the
menstruation is often less painful and bleeding is
lighter).
C/I: Pregnancy. History or presence of
thrombophlebitis, thromboembolic disorders,
cerebrovascular or cardiovascular diseases, sickle
cell anaemia. Acute or ch. liver diseases,
impaired hepatic excretory function; history of
idiopathic jaundice of pregnancy. Herpes of
pregnancy. Hormone-dependent carcinoma.
Persistence of HCG levels after removal of
hydatidiform mole. Abnormal vaginal bleeding.
S/E: Nausea, vomiting, headache, breast tender­
ness, changes in body weight. changes in libido,
depression, chloasma, hypertension, impairment
of liver function, benign hepatic tumours,
reduced menstrual loss, spotting in early cycles,
amenorrhoea; vaginal infection (e.g candidiasis).
Cautions: Diabetes, hypertension, cardiac or
renal disease, migraine, epilepsy, depression,
asthma, multiple sclerosis, wearing of contact
lenses, uterine fibromyomata, lactation.
Risk of arterial thrombosis associated with oral
contraception is increased with age and
aggravated by smoking and obesity.
Examine blood pressure, pelvic organ and
breasts before and regularly during treatment.
Dosage & admin: See under individual
preparation.
• • •
ETHINYLEST RAD IOL + DESOGESTREL:
Tablet
Ethinylestradiol 0.03mg (30mcg) & desogestrel
0.1 Smg (150mcg)/tablet.
Ind; C/I; S/E; Cautions: See note at the
-
beginning.
r
Dosage & admin: 1 tablet daily for 21 days
starting on 5th day of menstruation, then after
an interval of 7 days start the next course.
+ DESOLON Tab. Renata
Ethinylestradiol 0.03mg (30mcg) & desogestrel
0.1 Smg (150mcg)/tablet.
21's strip x l's pack: 85.05 MRP
21's strip x 1O's pack: 600.60 MRP
t MARVELON Tab. Nuvista
Ethinylestradiol 0.03mg (30mcg) & desogestrel
QIMP-17 (223)
0.15mg (150mcg)/tablet.
21 's pack x I's: 97.65 MRP
• • •
EHINYLEST RADIOL + DROSPIRENONE:
Tablet
Each package of this contraceptive preparation
contains either 21 tablets or 28 tablets (21 hor­
monal or active+ 7 placebo or inactive tablets).
Each hormonal or active tablet contains- ehinyl­
estradiol 0.03mg & drospirenone 3mg. Placebo
or inactive tablets are given to maintain the cycle.
Mode of action: See above under the text of
contraceptive pills.
Drospirenone has antimineralocorticoid activity,
counteracting oestrogen related sodium retention.
In combination with ethinylestradiol, drospiren­
one displays a favourable lipid profile with an
increase in high-density lipoprotein HDL.
Drospirenone exerts antiandrogenic activity and
does not counteract the ethinylestradiol-related
sex hormone binding globulin (SHBG) increase
which is useful for binding and inactivating the
endogenous androgens.
Ind; C/I; S/E; Cautions: See notes at the
beginning.
Dosage & admin:
1. When no hormonal contraceptive has been
used in the past month, start taking the oral
pill from the first day of menstrual bleeding.
Take the first tablet from the left corner of the
top row (with arrow mark indicating begin) of
the pack. Continue taking the tablet each day
along the arrow mark. Take it with food or
immediately after a meal to prevent stomach
upset. The pill should be taken daily at the
same time each day for consecutive 21 days.
2. After taking 21 tablets for 21 days- if there
is placebo tablets, continue taking it every day
for next 7 days. If there is no placebo tablets,
don't take any tablet during the next 7 days.
3. A period should begin during these 7 days
(the withdrawal bleed); unusually it may start
on day 2-3 after the last active (hormonal)
tablet. Should not discontinue taking placebo
tablets (if any) if bleeding starts. Start taking
the next pack on the 8th day even if the period
continues. If her menstruation does not start
during this time, check with the doctor to
make sure that she is not pregnant.
4. Once the previous pack is complete, should
continue regularly with a new pack, as
directed. This means that one will always start
new packs on the same day of the week and
also that she will have her withdrawal
bleeding on about the same days each month.
5. Missed dose: If one forgets to take a tablet
one day, should take the missed tablet as soon
as she remembers. This may mean taking two
tablets the very next day. Additionally she
should use some other method of
contraception while she is taking the tablets &
until her next menstruation.
If one forgets to take the tablets for two con­
secutive days, then it is likely that she will no
longer be protected against pregnancy. She
should therefore discontinue taking the tablet
and adopt some other temporary methods
(condom/foam tablet etc.) till her next men-
CONTRACEPTIVE PREPARATIONS
struation. Discard the unfinished pack of
tablets and start taking tablets from the very
first light yellow tablet of the top row from a
fresh pack from the first day of next
menstruation.
Note: For further information please consult
manufacturer's literature.
t NOVELON 21 Tab. Renata
Each Novelon pack contains 21 tablets. On the
pack, each tablet is marked with the day of the
week on which it is to be taken. Each tablet con­
tains Ehinylestradiol BP 0.03mg & Drospirenone
BP 3mg. Ethiilylestradiol is a synthetic oestrogen
and drospirenone is a synthetic progesterone.
Price:
21 tabs strip x 1's pack: 399.00 MRP
21 tabs strip x S's pack: 1995.00 MRP
+ ROSEN 28 Tab. lncepta
Each Rosen pack contains 28 tablets, among
these 21 tablets are light yellow and each
contains Ehinylestradiol 0.030mg &
Drospirenone 3mg. Ethinylestradiol is a synthetic
oestrogen and drospirenone is a synthetic
progesterone. Other 7 tablets are white placebo or
inactive tablets given to maintain the cycle.
Price:
28 tabs pack: 399.00 MRP
• • •
ETHINYLESTRADIOL + GESTODENE:
Tablet
Each package of this contraceptive preparation
contains 28 tablets, among these 21 tablets are
small & white and each contains Ethinylestradiol
BP 0.030mg & Gestodene BP 0.075mg. Other 7
tablets are larger & white at the bottom row of
the pack are placebo or inactive tablets given to
maintain the cycle.
Ind; C/I; S/E; Cautions: See notes at the
beginning.
Dosage & admin:
1. From the first day of menstruation, start
taking the first small white tablet from the left
corner of the top row (with arrow mark
indicating begin) of the pack. Continue taking
one small white tablet each day along the
arrow mark. Take it with food or immediately
after a meal to prevent stomach upset. The
small white tablet should be taken daily at the
same time each day for consecutive 21 days.
2. After taking 21 small white tablets for 21
days, then continue taking the large white
placebo tablet every day from the last row in
the pack for next 7 days.
3. It is most likely that menstruation will start
while taking the large white tablets. Do not
discontinue taking these tablets. Taking of the
white tablets for 7 days will help one keep her
tablet taking routine. If her menstruation does
not start during this time, check with the
doctor to make sure that she is not pregnant.
4. Once the previous pack is complete, should
continue regularty with a new pack, as
directed.
5. Missed dose: If one forgets to take a tablet
one day, should take the missed tablet as soon
as she remembers. T his may mean taking two
tablets the very next day. Additionally she
-. ·':
CONTRACEPTIVE PREPARATIONS
should use some other method of
contraception while she is taking the tablets &
until her next menstruation.
If one forgets to take the tablets for two
continuous days, then it is likely that she will
no longer be protected against pregnancy. She
should therefore discontinue taking the tablet
and adopt some other temporary methods
(condom/foam tablet) till her next menstrua­
tion. Discard the unfinished pack of tablets
and start taking tablets from the very first
white small tablet of the top row from a fresh
pack from the first day of next menstruation.
6. How to delay a period: To delay a period you
should continue with another new pack of the
tablets just after finishing the small white
active tablet of the present pack (that is no
need to take large white placebo tablet of
present pack). The extension can be carried on
for as long as wished until the end of the
second pack. When one wishes her period to
begin, just stop tablet taking. While using the
second pack woman may have some
breakthrough bleeding or spotting. Start with
the next pack after the usual 7 day large white
inactive tablet interval.
+ GESTOP 28 Tab. Incepta
Each Gestop pack contains 28 tablets, among
these 21 tablets are small & white and each con­
tains Gestodene BP 0.075mg & Ehinylestradiol
BP 0.030mg. Ethinylestradiol is a synthetic
version of oestrogen and gestodene is a synthetic
form of progesterone. Other 7 tablets are larger &
white at the bottom row of the pack are placebo
or inactive tablets given to maintain the cycle.
Price: 28 tabs pack: 99.75MRP
• • • menstruation:
ETHINYLESTRADIOL +
LEVONORGESTREL +IRON: Tablet
Each package of this contraceptive preparation
contains 28 pills. Among these 21 pills are white
in color & each contains Ethinylestradiol BP
0.030mg & Levonorgestrel BP 0.150mg. Each of
7 brown pill contains 75mg of ferrous fumarate
BP.
Mode of action: See above under the text of
contraceptive pills.
Ind; C/I; S/E; Cautions: See notes at the
beginning.
Dosage & admin: To achieve maximum
® -
An Emergency Contraceptive Pill
· QIMP-17 (224)
contraceptive effe.ctiveness, the tablets must be
....
taken in the order directed on the package and
at intervals not exceeding 24 hours. Women
should be instructed to take the pills at about
the same time every day, preferably after the
evening meal or at bedtime. One pill is to be
taken daily for 28 consecutive days. Each
subsequent pack is started on the day after the
current pack is completed.
1. If one has decided to take the pill for
contraception, wait for the next menstruation
begins. From the first day of menstruation,
start taking the first white pill from the left
corner of the top row (with arrow mark) of the
pack. Continue taking one white pill each day
along the arrow mark.
2. After taking 21 white pills for 21 days,
continue taking one brown iron pill every day
from the last row in the foil for next 7 days.
3. It is most likely that menstruation may start
while taking the brown pills. In that case
should not discontinue taking the brown pills.
In addition to giving iron supplementation
regular taking of the brown tablets for 7 days
will help the person keep her pill taking
routine. If menstruation does not start during
this time, the patient should check with the
doctor to make sure that she is not pregnant.
4. After completing the seven iron pills, start
taking white pills from another new pack and
continue taking the pill as long as one doesn't
want to be pregnant.
5. Missing dose: If one forgets to take a pill
one day, take the missed pill as soon as she
remembers. This may mean taking two pills
the very next day. Additionally she should use
some other method of contraception while she
is taking the pills & until her next
If she forgets to take the pills for two
continuous days, then it is likely that she will
no longer be protected against pregnancy. She
should therefore discontinue taking the pill
and adopt some other temporary methods
(condom/foam tablet) till her next
menstruation. Discard the unfinished pack of
pills and start taking pills from the very first
white pill of the top row from a fresh pack
from the first day of next menstruation.
+LYTA 28 Tab. Incepta
Each Lyta package contains 28 pills. Among
these 21 pills are white in color & each contains-
ml G�DEON RICHTER LTD
llUJ ,PUDAPEST, HUNGARY
ethinylestradiol BP 0.03mg & levonorgestrel BP
O . l 5mg. Each of 7 brown pill contains 75mg of
ferrous fumarate BP.
Price: 28's pack x 1 's: 23.52 MRP
.
+ MINI 28 Tab. Incepta
Each Mini package contains 28 pills. Among
these 21 pills are white in color & each contains­
ethinylestradiol BP 0.03mg & levonorgestrel BP
O. l 5mg. Each of 7 brown pill contains 75mg of
ferrous fumarate BP.
Price: 28's pack x I O's: 235.20MRP
• • •
ETHINYLESTRADIOL +LY NESTRENOL:
Tablet
This combined contraceptive pill is available in
different strengths, such as- i. Ethinyloestradiol
0.05mg & lynestrenol 2.5mg/tablet; ii.
Ethinyloestradiol USP 0.0375mg + lynestrenol
BP 0.75mg/tablet.
Ind; C/I; S/E; Cautions: See note at the
beginning.
Dosage & admin: 1 tablet daily regularly for
22 days starting on 5th day of menstruation
until 26th day. Then after an interval of 6 days
..
start the next course.
+LYNES Tab. Nuvista
Ethinyloestradiol 0.05mg & lynestrenol
2.5mg/tablet.
22's pack x l's: 115.72MRP
+ OVO STAT Gold Tab. Nuvista
Ethinyloestradiol USP 0.0375mg + lynestrenol
BP 0.75mg/tablet.
22's pack x l's: 65.12MRP
+ REGUMEN Tab. Renata
Ethinyloestradiol 0.05mg & lynestrenol
2.5mg/tablet.
2 1 tabs pack: 75.39 MRP
• • •
ETHINYLEST RADIOL + NORGESTREL +
IRON: Tablet
Each package of this contraceptive preparation
contains 21 white active tablets containing
0.03mg ethinylestradiol USP & 0.3mg norgestrel
USP per tablet, and 7 brown inert tablets
containing 75mg ferrous fumarate each.
Ind; C/I; S/E; Cautions: See notes at the
beginning.
Dosage & admin: 1. Take the first white pill on
For Details :
City Overseas Ltd.
Yakub South Center (4th Floor)
67/D Ohanmondi, 156 Lake Circus
Kalabagan, Mirpur Road, Dhaka-1205
 QIMP-17 (225) CONTRACEPTIVE PREPARATIONS

day 1 of menstruation. Take it with food or
immediately after a meal to prevent stomach
upset. This white pill should be taken daily at
the same time each day for consecutive 21
days.
hormone. It is used as an 'emergency
contraceptive pill'.
Mode of action: Levonorgestrel is a progestogen.
A single dose of 0.75mg levonorgestrel taken
immediately after the sexual intercourse prevents
Postinor again.
Precaution: Consult a gynecologist if necessary.
Dosage & admin: I tablet within 72 hours
after the event of unprotected intercourse and
•

a second one 12 hours after the first. Do not

2. Start taking the brown pills once daily for 7
days after finishing the white pills.
3. Missed dose: If one forgets to take one dose,
should take the dose as soon as she remember,
and take the next dose at regular time.
If one forgets to take 2 doses, should take 2
doses when she remembers and the dose for
conception. It acts by preventing or delaying
delay treatment unnecessarily. As the use of
ovulation, inhibiting fertilization or enhancing
this drug is ineffective & contra-indicated in
implantation depending on which part of the
confirmed pregnancy, but its use does not
female cycle it is used.
interrupt an established pregnancy, and
Ind: Emergency oral contraception, to prevent
remains thereof without effect in these cases.
unwanted pregnancy after unprotected
intercourse (such as, usual intercourse without No more than 4 tablets are allowed to be taken

that day. Then she should use a back-up taking any contraceptive measure, broken per month.

method of birth control until her next period.
4. Once the previous pack is complete, should
continue regularty with a new pack, as
directed.
+ CONRENA-R Tab. Renata
Each package contains 2 1 white active tablets
containing 0.03mg ethinylestradiol USP & 0.3mg
norgestrel USP per tablet, and 7 brown inert
tablets containing 75mg ferrous fumarate each.
. .
condom, dislodged diaphragm, IUD loss or
+ EMCON Tab. Renata
removal, unsuccessful withdrawal). Failure rate
Levonorgestrel 0.75mg/tablet.
is only 2% in women who use it correctly. No
0.75mg x 2's pack: 45.16 MRP
more than 4 tablets can be taken monthly at 2-4
t EMCON I Tab. Renata
occasions. To females having sexual intercourses
Levonorgestrel l .5mg/tablet.
more frequently combined oral contraceptives (or
l .5mg x 1's pack: 60.00 MRP
other contraceptive methods) are recommended.
l.5mg x 5's pack: 300.00 MRP
Lactating mother can use it
+ E-PLAN Tab. ACI
C/I: Confrrmed pregnancy. In case of vaginal
Levonorgestrel 0.75mg/tab let.

bleeding of unknown origin, hepatic and biliary

Price: 0.75mg x lO's pack: 225.00 MRP
·

disease, history of gestational jaundice, breast,

28 tabs pack: 30.00 MRP
Emergency Contraceptive Pill
LEVONORGESTREL58
LEVONORGESTREL: Tablet
Levonorgestrel is a synthetic progestogen
.• t I-PILL Tab. Popular
ovarian or uterine carcinoma, it should be
.. Levonorgestrel 0.75mg/tabl et.
administered after careful consideration of the
2 tabs pack: 45.00 MRP
risk/benefit ratio (unwanted pregnancy/aboriton).
+ NORPILL Tab. Square
S/E: Nausea, break-through or withdrawal Levonorgestrel l .5mg/tablet.
bleeding may occur 2-3 days after taking the 5 tabs pack: 300.00 MRP
tablets which may be reduced by Rutascorbin t POSTINOR-2 Tab. Gedeon Richter/ City
administration. Overseas
In case of more severe bleeding gynae-cological Levonorgestrel 0.75mg/tablet.
examination is recommended before taking 2 tabs pack: 52.00 TP

B. According to mechanism of action: 4. Antiprotozoal drugs

5. Anthelmintics
1. Inhibitors of cell wall synthesis-
6. Parasiticidal drugs (systemic)
ANTIMICROBIAL i. Lactam antibiotics (see above)
ii. Vancomycin
DRUGS iii. Bacitracin 1. ANTIBACTERIAL
2. Inhibitors of protein synthesis­
i. Tetracyclines DRUGS21
Antimicrobial drugs are classified in different
ii. Aminoglycosides
ways: such as, i. according to chemical structure,
iii. Macrolides 1.1 Penicillin group of drugs
ii. mechanism of action, & iii. activity against 1.2 Cephalosporins & other beta-
iv. Chloramphenicol
different organisms.
v. Clindamycin lactam antibiotics
A. According to chemical structure: 3. Inhibitors of metabolism or folate 1.3 Tetracycline group of drugs

1. P-Lactam antibiotics- such as, antagonists- 1.4 Aminoglycosides

i. Penicillins i. Sulphonamides 1.5 Macro/ides

ii. Trimethoprim 1.6 Clindamycin
ii. Cephalosporins
4. Inhibitors of nucleic acid function or 1. 7 Some other antibiotics
iii. Carbapenems
iv. Monobactams synthesis- 1.8 Sulphonamides & trimethoprim

2. Tetracyclines i. Quinolones & Fluoroquinolones 1. 9 4-Quinolones

3. Aminoglycosides ii. Rifampicin 1.10 Antituberculous drugs

4. Macrolides 5. P-Lactamase inhibitors l .I lAntileprotic drugs

5. Clindamycin i. Clavulanic acid 1.12 Metronidazole & tinidazole

6. Chloramphenicol ii. Sulbactam 1.13 Urinary tract anti-infectives.

7. Vancomycin iii. Tazobactam

8.
9.
Bacitracin C. According to activity against different
1.1 Penicillin group of
Rifampicin organisms:
•

10. Sulfonamides & Trimethoprim 1. Antibacterial drugs drugs21,23,1os

11. Quinolones & Fluoroquinolones 2. Antiviral drugs I Anti-AIDS drugs
12. Metronidazole & tinidazole 3. Anti fungal drugs Penicillins are the oldest & most widely used

•
ANTIMICROBIAL DRUGS
antibiotics. Penicillin is an organic acid derived
from cultures of the mold penicillium
chrysogenum. In the pathway of production of
penicillin, the key intermediate product is 6-
aminopenicillanic acid. The newer penicillin
derivatives are synthesized by chemical
substitution of different side chains at the R
position of 6-aminopenicillanic acid.
Structurally penicillins belong to lactam group.
Addition of side chains (at R position) affects the
antimicrobial spectrum, stability to stomach acid,
& susceptibility to bacterial degradative enzymes
(i.e lactamase or penicillinase).
Penicillins are the highly effective but least toxic
drugs among the known antibiotics. The major
adverse reaction of penicillin is hypersensitivity.
Classification:
1. Benzylpenicillin & Phenoxymethyl
penicillins : such as, Benzylpenicillin,
Phenoxymethylpenicillin, Procaine penicillin.
2. Long acting penicillins: such as, Benzathine
penicillin.
3. Penicillinase-resistant penicillins: such as,
Cloxacillin, Dicloxacillin, Flucloxacillin,
Methicillin, Nafcillin, Oxacillin, Temocillin.
4. Broad spectrum penicillins: such as,
Ampicillin, Amoxyillin, Co-amoxiclav, Co­
fluampicil.
5. Antipseudomonal penicillins: such as,
Azlocillin & Mezlocillin, Carbenicillin,
Piperacillin, Ticarcillin.
6. Mecillinams: Such as, Pivmecillinam
hydrochloride.
Mode of action: Penicillins are the bactericidal
drugs that they kill the bacteria by interfering
with synthesis of the cell wall. The bacterial cell
wall consists of strands of a linear peptidoglycan
made up of alternating building blocks of N­
acetylglucosamine and N-acetylmuramic acid.
The synthesis of bacterial cell wall occurs in
three steps, in the first step formation of
nucleotide (UDP-N -acetylmuramic acid­
pentapeptide); in the second step formation of the
linear peptidoglycans; in the third or final step,
there is cross-linking (or transpeptidation) of
these linear strands occur by an enzyme
'transpeptidase'. Penicillins (and cephalosporins)
interfere with this final step of bacterial cell wall
synthesis (transpeptidation or cross-linkage), that
they bind to this enzyme 'transpeptidase' and act
as competitive inhibitors, leading to synthesis a
defective cell membrane, which is osmotically
less stable. In addition, changes in the cellular
shape of bacteria occur after binding of
penicillins to various penicillin-binding proteins
(PBPs) in the cell wall. Finally, cell lysis occurs
after release of murein hydrolases present in the
cell wall, which degrade performed cell wall.
Benzylpenicillin &
Phenoxymethyl penicillin
PENICILLIN G21,33
PENICILLIN G or BENZYL PENICILLIN:
Injection.
Ind: Indicated in tonsillitis, acute & chronic
QIMP-17 (226)
bronchitis, bronchopneumonia, lobar pneumonia; +CYTAPEN-V Tab. Edruc
acute & chronic sinusitis; otitis media; scarlet Phenoxymethyl penicillin 250mg/tablet.
fever, erysipelas, lung abscess, furunculosis, IOO's pack: 230.00 MRP
carbuncle; gonorrhoea and organisms causing gas +CYTAPEN-V Syp. Edruc
gangrene, actinomyces, anthraces and syphilis, Penicillin V 125mg in ·5ml: syrup.
(for elaborate, see pharmocology section). lOOml bot: 28.00 MRP
C/I: Penicillin allergy; renal impairment. +ERACILLIN-K Tab. Gaco
S/E: Sensitivity reaction including urticaria, Phenoxymethyl penicillin 250mg/tablet.
fever, joint pain, angioedema, anaphylactic shock lOO's pack: 148.00 MRP
in hypersensitive patient; diarrhoea after +ERACILLIN-K Syp. Gaco
administration by mouth. Phenoxymethyl penicillin 125mg/5ml: syrup
Dosage & admin: In general infection, 5 to 10 50ml bot: 18.21 MRP
lac. units (300-600mg) slow i.v or i.m 4 times + G-PENICILLIN V Tab. Gonoshas
.
daily. Phenoxymethyl penicillin 250mg/tablet.
In Syphilis, total dose should not be less than IOO's pack: 200.00 MRP
50 lac units. +G-PENICILLIN V Syp. Gonoshas
In Gonorrhoea, 5 lac units 8 or 12 hourly Phenoxymethyl penicillin 125mg/5ml: syrup.
daily. 50 ml bot: 19.76 MRP
Intrathecal injection, 10,000-20,000 units once +OPEN Tab. Opsonin
or twice daily. Phenoxymethyl penicillin 250mg & 500mg/tablet
Meningitis, by slow i.v injection or by infusion 250mg x IOO's pack: 200.57 MRP
4,00,000 units/kg/day in 4 divided doses. 500mg x lOO's pack: 403.74 MRP
Child: upto 12 yrs. 10-20 mg/kg daily; +OPEN Susp. Opsonin
Neonate, 30mg/kg daily in divided doses. Phenoxymethyl penicillin 125mg/5ml: suspension
50ml bot: 16.19 MRP
+COMBIPEN 4 Lac lnj. Acme
+ORACYN-K Tab. Sanofi-aventis
Procaine penicillin 3 lac + benzyl penicillin 1
Phenoxymethyl penicillin 250mg & 500mg/tablet
lac/vial: injection
250mg x 500's pack: 1130.00 MRP
5 vial pack: 70.25 MRP
500mg x 250's pack: 1100.01 MRP
+PEN G Inj. Opsonin
+ORACYN-K Susp. Sanofi-aventis
Benzyl penicillin 5 lac & 10 lac units vial:
Phenoxymethyl penicillin 125mg/5ml: suspension
injection.
50ml bot: 18.41 MRP
5 lac vial x I O's pack: 99.32 MRP
+ORA-K Tab. Desh Pharma
10 lac vial x lO's pack: 147.26 MRP
Phenoxymethyl penicillin BP 250mg/tablet
+PENICILLIN-G SODIUM Inj. Renata 250mg x 500's pack: 850.00 MRP
Benzyl penicillin 5 lac & I 0 lac units vial:
+ORA-K Susp. Desh Pharma
injection.
Phenoxymethyl penicillin 125mg/5ml: suspension
5 lac vial x l's pack: 6.23 MRP
50ml bot: 18.00 MRP
10 lac vial x l's pack: 9.21 MRP
+PACIN-V Tab. Zenith
+PRONAPEN 4 Lac & 8 Lac lnj. Renata
Phenoxymethyl penicillin 250mg/tablet
Procaine penicillin- G 3 lac+ Crystalline
250mg x 80's pack: 172.00 MRP
penicilin- G 1 lac (total 4 lac) in 1 vial: injection.
250mg x lOO's pack: 210.00 MRP
5 vial pack: 70.25 MRP
+PENCIN-V Tab. Nipa
+PRONAPEN 8 Lac Inj. Renata
Phenoxymethyl penicillin 250mg/tablet.
Procaine penicillin 6 lac, Benzyl penicilin 2 lac
lOO's pack: 152.00 MRP
(total 8 lac) in 1 vial: injection.
+PENICILLIN Tab. Bristol
I vial pack: 9.10 MRP
Phenoxymethyl penicillin 250mg/tablet.
IOO's pack: 228.00 MRP
33
PENICILLIN v21, +PENTAB Tab. Sonear
Phenoxymethyl penicillin 250mg/tablet
lOO's pack: 229.00 MRP
PENICILLIN-V Or PHENOXYMETHYL
+ PENVIK Tab. Square
PENICILLIN: Tablet/Syrup
Phenoxymethyl penicillin 250mg/tablet
Ind: Oral penicillin against oropharyngeal
lOO's pack: 229.00 MRP
infections, tonsillitis, bacterial pneumonia,
+PENVIK DS Tab. Square
bronchitis, Otitis media and other penicillin
Phenoxymethyl penicillin 500mg/tablet
sensitive gm+ve infections.
lOO's pack: 443.00 MRP
C/I: History of allergy to any penicillin.
+ PENVIK Syp. Square
S/E: Hypersensitivity reactions.
Phenoxymethyl penicillin 125mg/5ml: syrup.
Dosage & admin: 250-500mg every 6 hours, at
1OOml bot: 28.97 MRP
least 30 minutes before food.
+PENVIK Forte Syp. Square
Child, up to 1 year 62.5mg, 1-5 years 125mg
Phenoxymethyl penicillin 250mg/5ml: syrup
6-12 years 250mg every 6 hours.
(double strength).
1OOml bot: 52.49 MRP
+BIOPEN VK Tab. Biopharma
+P EN Tab. Pharmadesh
Phenoxymethyl penicillin 250mg/tablet.
Phenoxymethyl penicillin 250mg/tablet.
250mg x 1OO's pack: 151.00 MRP
100's pack: 220.00 MRP
+BIOPEN VK Syp. Biopharma
Phenoxymethyl penicillin 125mg/5ml: syrup +PHARMAPEN Syp. Pharmadesh
50ml bot: 18.28 MRP Phenoxymethyl penicillin 125mg/5ml: syrup
lOOml bot: 28.91 MRP 60ml bot: 18.40 MRP
 QIMP-17 (227) ANTIMICROBIAL DRUGS

+ CLOXICAP Cap. Renata positive bacteria, particularly useful against peni­

Long acting penicillin Cloxacillin 500mg/capsule cillinase producing staphylococci.
1OO's pack: 585.00 MRP Flucloxacillin is available as flucloxacillin sodi­
+ CLOXIL Cap. Doctor's um BP in capsule, dry suspention & injection
BENZATHINE PENICILLIN21,33
·

Cloxacillin 500mg/capsule form.

BENZATHINE PENICILLIN: Injection
Ind: Long acting penicillin, specially indicated
in the long term treatment of syphilis &
rheumatic fever.
C/I: History of allergy to any penicillin.
S/E: Hypersensitivity reaction ..
Dose: 1 injection (12 lac) weekly or longer
intervals.
Rheumatic fever, 1 vial (12 lac) deep i.m 4
weekly.
+ BENZAPEN Inj. Square
Benzathine penicillin 12 lac units vial: injection.
12 lac units vial x S's pack: 139.80 MRP
l OO's pack: 594.00 MRP Mode of action: Flucloxacillin is a bactericidal
+ CLOXIMA Cap. Modern antibiotic. It kills bacteria by interfering in the
Cloxacillin 500mg/capsule synthesis of the bacterial cell wall.
50's pack: 253.00 MRP Ind: Infections due to penicillinase-producing
+ CLOXIN Cap. Opsonin staphylococci including otitis extema, adjunct in
Cloxacillin 500mg/capsule pneumonia, impetigo, cellulitis & in
52's pack: 270.35 MRP staphylococcal endocarditis.
+ CLOXIN Syp. Opsonin C/I; S/E; �autions: See under benzyl penicillin.
Cloxacillin 125mg/5ml: syrup Hepatitis & cholestatic jaundice may occur upto
l OOml bot: 39.44 MRP several weeks after treatment with flucloxacillin;
+ CLOXIN Inj. Opsonin in that situation it is advised to stop the drug.
Cloxacillin 500mg/vial: injection Administration for more than 2 weeks & increas­
500mg vial 4's pack: 89.06 MRP ing age are risk factors. Caution in porphyria.
+ CLOXPEN Cap. Drug Inter. Pregnancy & lactation: The use of flucloxacillin
Cloxacillin 500mg/capsule in second and third trimester of pregnancy may '

+ DIAMINE PENICILLIN Inj. Renata 40's pack: 200.00 MRP result in sensitization of the foetus. During lacta-
Benzathine penicillin 12 lac units/vial: injection. + COSCLOX Cap. Cosmo Pharma tion, trace quantities of penicillins can be detect­
12 lac unit vial: 24.21 MRP Cloxacillin 500mg/capsule ed in the breast milk. So, the use of flucloxacillin
40's pack: 218.40 MRP in pregnancy & lactation should be reserved for
+ CYCLOX Cap. Sonear cases considered essential by the clinicians.
Penicillinase-resistant Cloxacillin 500mg/capsule Dosage & admin: By mouth, 250mg every 6
40's pack: 238.40 MRP hours, atleast 30 min. before food.
penicillins By i.m injection, 250mg every 6 hours.
+ FICLOX Cap. Sanofi-aventis
Cloxacillin 500mg/capsule By slow i.v injection or by infusion, 0.25-1 gm

CLOXACILLIN21,33 l OO's pack: 595.84 MRP every 6 hours.

+ FICLOX Syp. Sanofi-aventis Doses may be doubled in severe infections.
Cloxacillin 125mg/5ml: syrup. Child: any route, under 2 yrs. quarter adult
CLOXACILLIN: Capsule/Syrup/
l OOml bot: 44.84 MRP dose; 2-10 yrs. half adult dose.
Injection/Drop.
+ FICLOX Drop Sanofi-aventis Drug inter: The administration of probenecid
Ind: Gram-positive organisms, specially strepto­
Cloxacillin 1OOmg/ lml: drop. with flucloxacillin results in higher serum peak
cocci, pneumococci, and virtually all staphylo­
l 5ml bot: 27.25 MRP concentrations and prolongs the time that thera­
cocci including penicillin resistant strains. Mainly
+ FICLOX Inj. Sanofi-aventis peutic concentrations of fluploxacillin are
used for skin & soft tissue infections.
Cloxacillin 500mg vial: injection achieved in serum. Physical incompatibility
C/I: History of penicillin allergy.
500mg vial x 1 's pack: 25.39 MRP and/or loss of activity of flucloxacillin in solution
S/E: Allergic menifestations.
+ HI-CLOX Cap Hudson have been reported when given with gentamycin
Dose: By mouth, SOOmg 6 hourly, at least 30
Cloxacillin 500mg/capsule. sulphate, streptomycin sulphate, and vitamin
minutes before food; by i.m. inj. 250mg 4-6
40's pack: 200.00 MRP mixture. Physical incompatibility of flucloxa­
hourly; by i.v. inj. 500mg-lgm every 4-6
+ ID-CLOX Syp. Hudson cillin, up to 72 hours at l 5°C and/or 30°C was
hours.
Cloxacillin 125mg/5ml: syrup reported with atropine sulphate, benzylpenicillin.
Children: Any route, 1/4-1/2 adult dose.
l OOml bot: 45.00 MRP chlorpromazine, diazepam, hyoscine butylbro­

+ A-CLOX Cap. Acme + MICLOCIN Cap. Millat mide, isosorbide dinitrate, metoclopramide,

Cloxacillin 500mg/capsule Cloxacillin 500mg/capsule tetracycline, prochlorperazine, promethazine, etc.

1 OO's pack: 596.00 MRP lOO's pack: 595.00 MRP

+ A-FLOX Cap. Acme
+ A-CLOX Dry Syp. Acme + MICLOCIN Syp. Millat
Flucloxacillin 250mg & 500mg/capsule
Cloxacillin BP 125mg/5ml: syrup Cloxacillin 250mg/5ml: syrup
250mg x 48's pack: 270.72 MRP
100 ml bot: 44.83 MRP l OOml bot: 43.00 MRP
500mg x 48's pack: 506.40 MRP
+ A-CLOX Inj. Acme + PENCLOX Cap. CPL
+ A-FLOX Susp. Acme
Cloxacillin 250mg & 500mg/vial: injection. Cloxacillin 500mg/capsule
Flucloxacillin l 25mg/5ml: Suspension
250mg vial x S's pack: 68.55 MRP 1OO's pack: 580.00 MRP
1OOml bot: 61.42 MRP
500mg vial x 5's pack: 121.75 MRP + PENCLOX Syp. CPL
+ A-FLOX lnj. Acme
+ AMBEECLOX Cap. Ambee Cloxacillin 125mg/5ml: syrup.
Flucloxacillin 250mg & 500mg/vial: injection
Cloxacillin 500mg/capsule l OOml bot: 43.00 MRP
250mg vial x 5's pack: 175.70 MRP
1OO's pack: 596.00 MRP + SINACLOX Cap. Ibo Sina
500mg vial x 5's pack: 225.85 MRP
+ BPCLOX Cap. Bristol Cloxacillin 500mg/capsule
+ ANCOC Cap. SAPL
Cloxacillin 500mg/capsule. 48's pack: 276.00 MRP
Flucloxacillin 250mg & 500mg/capsule
1OO's pack: 400.00 MRP + SINACLOX Syp. Ibo Sina
250mg x 30's pack: 165.00 MRP
+ BPCLOX Syp. Bristol Cloxacillin 125mg/5ml: syrup.
500mg x 20's pack: 200.00 MRP
Cloxacillin 125mg/5ml: syrup 1OOml bot: 43.00 MRP
+ ANCOC Susp. SAPL
1 OOml bot: 44.00 MRP
Flucloxacillin 125mg/5ml: suspension
+ CLOBEX Cap. Beximco FLUCLOXACILLIN21,33,45 l OOml bot: 60.00 MRP
Cloxacillin 500mg/capsule. + AUXIL Cap. Doctor's
1OO's pack: 596.00 MRP FLUCLOXACILLIN: Capsule/Suspension/ Flucloxacillin 250mg & 500mg/capsule
+ CLOBEX Syp. Beximco Injection 250mg x 20's pack: 110.00 MRP
Cloxacillin 125mg/5ml: syrup Flucloxacillin is an isoxazolyl penicillin. It is a 500mg x 40's pack: 400.00 MRP
100 ml bot: 43.85 MRP bactericidal antibiotic with activity against gram- + AUXIL Susp. Doctor's

I
 •
® QIMP-17 (228)
Flucloxacillin
Flucloxacillin 125mg/5ml: suspension
1 OOml bot: 60.00 MRP
t BDFLOX Cap. Bengal Drugs
Flucloxacillin 500mg/capsule
500mg x 48's pack: 480.00 MRP
t BDFLOX Susp. Bengal Drugs
Flucloxacillin l 25mg/5ml: suspension
1OOml bot: 60.00 MRP
t CAPFLU Cap. Alco Phar.ma
Flucloxacillin 250mg & 500mg/capsule
250mg x 60's pack: 300.00 MRP
500mg x 28's pack: 280.00 MRP
t CAPFLU DS Susp. Alco Pharma
Flucloxacillin 250mg/5ml: suspension
1OOml bot: 110.00 MRP
t CLOXAFU Cap. Sonear
Flucloxacillin 250mg & 500mg/capsule
250mg x 40's pack: 225.60 MRP
500mg x 20's pack: 205.00 MRP
+ CLOX-F Cap. Asiatic
Flucloxacillin 250mg & 500mg/capsule
250mg x 48's pack: 240.00 MRP
500mg x 48's pack: 480.00 MRP
t CLOX-F Susp. Asiatic
Flucloxacillin l 25mg/5ml: suspension
I OOml bot: 60.00 MRP
+ CLOX-F DS Susp. Asiatic
Flucloxacillin 250mg/5ml: suspension
I OOml bot: 110.00 MRP
+ DOLOPEN Cap. Techno Drugs
Flucloxacillin 500mg/capsule
500mg x 30's pack: 315.00 MRP
t DOLOPEN Susp. Techno Drugs
Flucloxacillin 125mg/5ml: suspension
1OOml bot: 60.00 MRP
+ DOLOPEN Inj. Techno Drugs
Flucloxacillin 500mg/vial: injection
500mg x 7's vial: 315.00 MRP
t E-FLU Cap. Edruc
Flucloxacillin 500mg/capsule
500mg x 20's pack: 222.00 IP
+ E-FLU Susp. Edruc
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 60.70 IP
+ EFLUCIN Cap. Jayson
Flucloxacillin 250mg & 500mg/capsule
250mg x 20's pack: 115.40 IP
500mg x 20's pack: 200.60 IP
+ EFLUCIN Susp. Jayson
Flucloxacillin 125mg/5ml: suspension
1OOml bot: 61.24 IP
+ EFLUCIN Inj. Jayson
Flucloxacillin 250mg & 500mg/vial: injection
250mg x 5 vial (combi pack): 120.45 IP
500mg x 5 vial (combi pack): 175.65 IP
+ ENOCLOX Cap. Modern
Flucloxacillin 500mg/capsule
500mg x 20's pack: 200.80 MRP
t ENOCLOX Susp. Modern
Flucloxacillin 125mg/5ml: suspension
1 OOml bot: 60.00 MRP
+ FAXILIN Cap. Kumudini
Flucloxacillin 250mg & 500mg/capsule
250mg x 28's pack: 154.00 MRP
500mg x 28's pack: 280.00 MRP
t FAXILIN Susp. Kumudini
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 60.00 MRP
+ FCX Cap. Gaco
Flucloxacillin 250mg & 500mg/capsule
250mg x 28's pack: 154.00 MRP
500mg x 20's pack: 200.00 MRP
+ FCX Susp. Gaco
Flucloxacillin l 25mg/5ml: suspension
1 OOml bot: 60.00 MRP
+ FLAC Cap. Bristol
Flucloxacillin 250mg & 500mg/capsule
250mg x 60's pack: 300.00 MRP
500mg x 40's pack: 400.00 MRP
+ FLAC Susp. Bristol
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 50.00 MRP
+ FLONEX-500 Cap. Decent
Flucloxacillin 500mg/capsule
500mg x 32's pack: 320.00 MRP
+ FLORA Cap. Mystic
Flucloxacillin 250mg & 500mg/capsule
250mg x 20's pack: 100.00 MRP
500mg x 20's pack: 200.00 MRP
+ FLORA Susp. Mystic
Flucloxacillin 125mg/5ml: Suspension
lOOml bot: 59.00 MRP
+ FLOX Cap. Hallmark
Flucloxacillin 250mg & 500mg/capsule
250mg x 28's pack: 154.56 N!RP
500mg x 20's pack: 210.00 MRP
+ FLOX Susp. Hallmark
Flucloxacillin 125mg/5ml: suspension
1 OOml bot: 60.22 MRP
+ FLOXAPEN Cap. General
Flucloxacillin 250mg & 500mg/capsule
250mg x 50's pack: 288.50 MRP
500mg x 20's pack: 210.80 MRP
+ FLOXAPEN Susp. General
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 61.23 MRP
·+ FLOXASON Cap. Hudson
Flucloxacillin 250mg/capsule
250mg x 40's pack: 200.00 MRP
t FLOXASON-DS Cap. Hudson
Flucloxacillin 500mg/capsule
500mg x 20's pack: 200.00 MRP
+ FLOXASON Susp. Hudson
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 60.00 MRP
+ FLOXIRAK Cap. RAK Pharma
Flucloxacillin 500mg/capsule
500mg x 32's pack: 320.00 MRP
+ FLUBAC Cap. Popular
Flucloxacillin 250mg & 500mg/capsule
250mg x 52's pack: 300.04 MRP
500mg x 32's pack: 321.28 MRP
+ FLUBAC Susp. Popular
Flucloxacillin 125mg/5ml: Suspension
l OOml bot: 61.23 MRP
+ FLUBAC DS Susp. Popular
Flucloxacillin 250mg/5ml: suspension
1OOml bot: 110.42 MRP
+ FLUBEX Cap. Beximco
Flucloxacillin 250mg & 500mg/capsule
250mg x 50's pack: 275.00 IP
500mg x 30's pack: 315.00 IP
t FLUBEX Susp. Beximco
Flucloxacillin 125mg/5ml: suspension
1OOml bot: 60.00 IP
t FLUBEX DS Susp. Beximco
Flucloxacillin 250mg/5ml: suspension
l OOml bot: 110.00 IP
t FLUBIOTIC Cap. Navana
Flucloxacillin 250mg.& 500mg/capsule
250mg x 20's pack: 110.40 IP
500mg x 30's pack: 301.20 IP
t FLUBIOTIC Susp. Navana
Flucloxacillin 125mg/5ml: Suspension
l OOml bot: 60.23 IP
t FLUC Cap. Astra
Flucloxacillin 500mg/capsule
500mg x 15's pack: 150.0011RP
+ FLUC Susp. Astra
Flucloxacillin 125mg/5ml: suspension
1 OOml bot: 60.00 MRP
+ FLUCIL Cap. Cosmo pharma
Flucloxacillin 250mg & 500mg/capsule
250mg x 50's pack: 273.00 IP
500mg x 20's pack: 200.00 IP
+ FLUCIL Susp. Cosmo pharma
Flucloxacillin 125mg/5ml: suspension
1OOml bot: 60.00 IP
t FLUCILLIN Cap. Medimet
Flucloxacillin 250mg & 500mg/capsule
250mg x 40's pack: 220.00 MRP
500mg x 20's pack: 200.00 MRP
+ FLUCILLIN Susp. Medimet
Flucloxacillin 125mg/5ml: suspension
1OOml bot: 60.00 MRP
t FLUCIN Cap. Millat
Flucloxacillin 250mg & 500mg/capsule
250mg x 48's pack: 276.00 MRP
500mg x 30's pack: 315.00 MRP
+ FLUCIN Susp. Millat
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 61.14 MRP
+ FLUCIN DS Susp. Millat
Flucloxacillin 250mg/5ml: suspension
1 OOml bot: 110.00 MRP
+ FLUCLOX Cap. ACI
Flucloxacillin 250mg & 500mg/capsule
250mg x l OO's pack: 577.00 MRP
500mg x 40's pack: 421.00 MRP
+ FLUCLOX Susp. ACI
Flucloxacillin 125mg/5ml: Suspension
1OOml bot: 61.23 MRP
+ FLUCLOX DS Susp. ACI
Flucloxacillin 250mg/5ml: suspension
60ml bot: 70.00 MRP
l OOml bot: 110.41 MRP
+ FLUCLOX Inj. ACI
Flucloxacillin 250mg & 500mg/vial: injection
250mg vial: 35.13 MRP
500mg vial: 45.14 MRP
+ FLUCLOXI Cap. Desh Pharma
Flucloxacillin 250mg & 500mg/capsule
250mg x 60's pack: 330.00 IP
500mg x 20's pack: 220.00 IP
+ FLUCLOXI Susp. Desh Pharma \
Flucloxacillin 125mg/5ml: Suspension
1 OOml bot: 60.50 IP
+ FLUCLOXIN Cap. SK+F
Flucloxacillin 250mg & 500mg/capsule
250mg x IOO's pack: 556.00 MRP
500mg x 36's pack: 378.00 MRP
+ FLUCLOXIN Susp. SK+F
Flucloxacillin soduim 125mg/5ml: suspension
1 OOml bot: 61.00 MRP
+ FLUCOPEN Cap. Somatec

Flucloxacillin 250mg & 500mg/capsule
250mg x 28's pack: 154.84 MRP
500mg x 20's pack: 200.60 MRP
+ FLUCOPEN Susp. Somatec
Flucloxacillin 125mg/5ml: suspension
\
1OOml bot: 60.23 MRP
+FLU-K Cap. Kemiko
Flucloxacillin 250mg & 500mg/capsule
I 250mg x 60's pack: 337.80 MRP
500mg x 20's pack: 210.00 MRP
•
+FLU-K Susp. Kemiko
Flucloxacillin 125mg/5ml: suspension
1OOml bot: 60.00 MRP
+FLUKIN Cap. Pharmasia
Flucloxacillin 250mg & 500mg/capsule
250mg x 28's pack: 154.56 MRP
500mg x 28's pack: 294.00 MRP
•
• +FLUKIN Susp. Pharmasia
Flucloxacillin l 25mg/5ml: suspension
1 OOml bot: 60.00 MRP
+FLUKIN DS Susp. Pharmasia
Flucloxacillin sodium 250mg/5ml: suspension
(double strength)
l OOml bot: 110.00 MRP
+FLUMARK-500 Cap. Aexim
Flucloxacillin 500mg/capsule
500mg x 20's pack: 200.00 MRP
+FLUMARK Susp. Aexim
Flucloxacillin 125mg/5ml: suspension
100m1 bot: 60.00 MRP
+FLUMED Cap. Medicon
Flucloxacillin 250mg & 500mg/capsule
250mg x 30's pack: 165.00 MRP
500mg x 20's pack: 200.00 MRP
+FLUMED Susp. Medicon
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 60.00 MRP
+FLUPEN Cap. Drug Inter.
Flucloxacillin 250mg & 500mg/capsule
250mg x 70's pack: 350.00 MRP
500mg x 21's pack: 220.50 MRP
+FLUPEN Susp. Drug Inter.
Flucloxacillin 125mg/5ml: suspension
1OOml bot: 60.00 MRP
+ FLURIF 500 Cap. Sharif
Flucloxacillin 500mg/capsule
500mg x 28's pack: 294.00 MRP
+FLUSTAR Cap. Renata
Flucloxacillin 250mg & 500mg/capsule
250mg x 48's pack: 264.00 MRP
500mg x 28's pack: 280.00 MRP
+FLUSYRUP Susp. Alco Pharma
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 60.00 MRP
+FLUTEC-250 Cap. APC Pharma
Flucloxacillin 250mg/capsule
250mg x 40's pack: 230.00 MRP
+FLUTEC-DS Cap. APC Pharma
Flucloxacillin 500mg/capsule
500mg x 40's pack: 400.00 MRP
+FLUTEC Susp. APC Pharma
Flucloxacillin 125mg/5ml: suspension
1OOml bot: 60.00 MRP
+FLUX Cap. Op sonin
Flucloxacillin 250mg & 500mg/capsule
250mg x 28's pack: 142.12 MRP
500mg x 28's pack: 259.61 MRP
+FLUX Susp. Opsonin
Flucloxacillin 125mg/5ml: suspension
I OOml bot: 53.87 MRP
QIMP-17 (229)
+FLUX DS Susp. Opsonin
Flucloxacillin sodium BP 250mg/5ml: suspension
(double strength)
1OOml bot: 97 .13 MRP
+FLUX lnj. Opsonin
Flucloxacillin 500mg/vial: injection
500mg vial x 4's pack: 158.94 MRP
+ FLUXICAP Cap. Ziska
Flucloxacillin 250mg & 500mg/capsule
250mg x 40's pack: 184.00 MRP
500mg x 40's pack: 400.00 MRP
+FLUXI Susp. Ziska
Flucloxacillin soduim 125mg/5ml: suspension
l OOml bot: 60.00 MRP
+FLUXIN Cap. Ambee
Flucloxacillin 250mg & 500mg/capsule
250mg x 60's pack: 335.40 MRP
500mg x 20's pack: 200.80 MRP
+FLUXIN Susp. Ambee
Flucloxacillin soduim 125mg/5ml: suspension
1OOml bot: 58.88 MRP
+FLXZEN Cap. Zenith
Flucloxacillin 250mg & 500mg/capsule
250mg x 60's pack: 301.20 MRP
500mg x 20's pack: 160.60 MRP
+FLXZEN Susp. Zenith
Flucloxacillin 125mg/5ml: suspension
I OOml bot: 60.23 MRP
+ FUCIL Cap. Nipa
Flucloxacillin 250mg & 500mg/capsule
250mg x 60's pack: 330.00 MRP
500mg x 20's pack: 200.00 MRP
+ FUCIL Susp. Nipa
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 60.00 MRP . Flucloxacillin 250mg & 500mg/capsule
+ FULCIN Cap. Supreme
Flt1cloxacillin 250mg & 500mg/capsule
250mg x 30's pack: 165.00 MRP
500mg x 24's pack: 252.00 MRP
+FULCIN Susp. Supreme
Flucloxacillin 125mg/5ml: suspension
1OOml bot: 60.00 MRP
+ G-FLUCLOXACILLIN Cap. Gonoshas.
Flucloxacillin 500mg/ capsule
500mg x 20's pack: 140.00 MRP
+ G-FLUCLOXACILLIN Inj. Gonoshas.
Flucloxa�illin 500mg/vial: injection
500mg vial x l's pack: 25.00 MRP
+ G-FLUCLOXACILLIN Susp. Gonoshas.
Flucloxacillin sodium l 25mg/5ml: suspension
l OOml bot: 56.00 MRP
+HALOPEN Cap. NIPRO JMI
Flucloxacillin 250mg & 500mg/capsule
250mg x 40's pack: 221.20 MRP
500mg x 28's pack: 280.00 MRP
+HALOPEN Susp. NIPRO JMI
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 60.23 MRP
+INCLOX Cap. Incepta
Flucloxacillin 250mg & 500mg/capsule
250mg x 50's pack: 275.00 MRP
500mg x 50's pack: 500.00 MRP
+ISOCLOX Cap. Globe
Flucloxacillin 250mg & 500mg/capsule
250mg x 20's pack: 110.00 MRP
500mg x 24's pack: 240.00 MRP
+ISOCLOX Susp. Globe
Flucloxacillin soduim 125mg/5ml: suspension
lOOml bot: 60.00 MRP
+ISOFLU Cap. CPL
ANTIMICROBIAL DRUGS
Flucloxacillin 500mg/capsule
500mg x 40's pack: 400.00 MRP
+ISOFLU Susp. CPL
Flucloxacillin soduim 125mg/5ml: suspension
l OOml bot: 60.00 MRP
+LUF Cap. Apex
Flucloxacillin 250mg & 500mg/capsule
250mg x 40's pack: 220.00 MRP
500mg x 28's pack: 280.00 MRP
+LUF Susp. Apex
Flucloxacillin soduim l 25mg/5ml: suspension
1OOml bot: 60.00 MRP
+MONACLOX-F Cap. Amico
Flucloxacillin 2501ng & 500mg/capsule
250mg x 30's pack: 165.00 MRP
500mg x 28's pack: 280.00 MRP
+MONACLOX-F Susp. Amico
Flucloxacillin sodium 125mg/5ml: suspension
l OOml bot: 65.00 MRP
+MONACLOX-F DS Susp. Amico
Flucloxacillin sodium 250mg/5ml: suspension
(double strength)
l OOml bot: 100.00 MRP
+ORGAFLU Cap. Organic Health
Flucloxacillin BP 250mg & 500mg/capsule
250mg x 60's pack: 333.60 MRP
500mg x 40's pack: 420.00 MRP
+ORGAFLU Susp. Organic Health
Flucloxacillin sodium BP 125mg/5ml: suspension
IOOml bot: 60.00 MRP
+ OXACOL Cap. Ad-din
Flucloxacillin 500mg/capsule
500mg x 30's pack: 270.00 MRP
+PERPEN Cap. Rangs Pharma
250mg x 40's pack: 220.00 MRP
500mg x 28's pack: 295.12 MRP
+PERPEN Susp. Rangs Pharma
Flucloxacillin sodium 125mg/5ml: suspension
l OOml bot: 60.00 MRP
+PHYLOPEN Cap. Square
Flucloxacillin sodium 250mg/capsule
SO's pack: 276.00 MRP
+PHYLOPEN DS Cap. Square
Flucloxacillin sodium 500mg/capsule
30's pack: 316.20 MRP
+PHYLOPEN Susp. Square
Flucloxacillin sodium l 25mg/5ml: suspension
l OOml bot: 60.22 MRP
+PHYLOPEN Forte Susp. Square
Flucloxacillin sodium 250mg/5ml: suspension
I OOml bot: 110.41 MRP
+PHYLOPEN Inj. Square
Flucloxacillin 500mg/vial: injection
500mg vial x 5's pack: 225.80 MRP
+REVISTAR Cap. Biopharma
Flucloxacillin 250mg & 500mg/capsule
250mg x 28's pack: 154.56 MRP
500mg x 28's pack: 281.12 MRP
+REVISTAR Susp. Biopharma
Flucloxacillin sodium 125mg/5ml: suspension
100m1 bot: 60.23 MRP
+S-FLUCLOX Cap. Seema
Flucloxacillin sodium 250mg & 500mg/capsule
250mg x 40's pack: 280.00 MRP
500mg x 40's pack: 420.00 MRP
+SILOX Cap. Silva
Flucloxacillin sodium 250mg & 500mg/capsule
250mg x 30's pack: 173.00 MRP
500mg x 20's pack: 200.00 MRP
ANTIMICROBIAL DRUGS QIMP-17 (230)

+ SILOX Susp. Silva
Flucloxacillin sodium 125mg/5ml:suspension
l OOml bot: 60.00 MRP
t SINAFLOX Cap. Ibo Sina
Flucloxacillin sodium 250mg & 500mg/capsule
250mg x 32's pack: 179.20. IP
500mg x 28's pack: 294.00 IP
t SIN AFLOX Susp. Ibo Sina
Flucloxacillin sodium 125mg/5ml: suspension
l OOml bot: 65.00 IP
+ SKILOX Cap. Healthcare
Flucloxacillin sodium 250mg & 500mg/capsule
250mg x 50's pack: 275.00 MRP
500mg x 30's pack: 300.00 MRP
+ SKILOX Susp. Healthcare
Flucloxacillin so·dium 125mg/5ml: suspension
l OOml bot: 60.00 MRP
t SOFA Cap. Apollo
AMPICILLIN: Capsule/Suspension/
Injection/Drop.
Ind: Broad spectrum antibiotic therapy- specially
typhoid fever, Urinary tract and Respiratory tract
infections, Gastrointestinal & Gonococcal
infections, meningitis, otitis media.
C/I: Penicillin allergy, infectious mononucleosis.
S/E: Allergic menifestations, diarrhoea, nausia.
Dose: By mouth, 250-500mg 6 hourly, 5-7
days or more ( atleast 30min. before meal).
Gonorrhoea, 2gm as a single dose with
probenecid lgm.
UTI, 500mg every 8 hourly.
By i.m. or i.v. inj. 500mg 4-6 hourly; higher
doses in meningitis
Child, any route 1/2 adult dose.
+ ACMECILIN Cap. Acme
Otitis media, child 3-10 years, 750mg 2 times
daily for 2 days.
By i.m. inj. 500mg every 8 hours; Child, 50-
100 mg/kg daily in divided doses.
By i.v. inj. or infusion (in severe infections), I
gm every 6 hours; Child, 50- lOOmg/kg. daily
in divided doses.
In bacterial endocarditis- single 3 gm dose one
hour before dental procedure from which
bacteraemia may arise; Child, half adult dose.
Repeat 6 hours later if necessary.
t ALMOXII, Cap. Aexim
Amoxycillin 500mg/capsule
500mg x 50's pack: 250.00 MRP.
t ALMOXII, Susp. Aexim
Amoxycillin 125mg/5ml: suspension
l OOml bot: 45.00 MRP
•

Ampicillin 250mg/capsule t AMBEEXIN Cap. Ambee

Flucloxacillin sodium 250mg & 500mg/capsule
250mg x 48's pack: 252.00 IP
500mg x 24'8 pack: 240.00 IP
t SOFA Susp. Apollo
Flucloxacillin sodium 125mg/5ml:suspension
l OOml bot: 60.00 IP
t SOFTAPEN Cap. Rephco
Flucloxacillin sodium 500mg/capsule
500mg x 40's pack: 440.00 MRP
t SOFTAPEN Susp. Rephco
Flucloxacillin sodium 125mg/5ml:suspension
1OOml bot: 70.00 MRP
+ STAFOXIN Cap. Aristopharma
Flucloxacillin sodium 250mg & 500mg/capsule
250mg x 48's pack: 264.00 MRP
500mg x 28's pack: 280.00 MRP
+ STAFOXIN Susp. Aristopharma
Flucloxacillin sodium 125mg/5ml:suspension
1 OOml bot: 60.00 MRP
t STAPHYLOX-500 Cap. Pharmadesh
Flucloxacillin sodium 500mg/capsule
28's pack: 294.00 MRP
t STAPHYLOX Susp. Pharmadesh
Flucloxacillin sodium 125mg/5ml:suspension
l OOml bot: 75.00 MRP
t STAPKIL Cap. Pacific
Flucloxacillin 250mg & 500mg/capsule
250mg x 50's pack: 275.00 MRP
500mg x 30's pack: 300.00 MRP
t STAPKIL Susp. Pacific
Flucloxacillin 125mg/5ml: suspension
l OOml bot: 46.00 MRP
t SURGEFLOX Cap. Cosmic
Flucloxacillin sodium 250mg & 500mg/capsule
250mg x 40's pack: 247.20 MRP
500mg x 20's pack: 205.80 MRP
t SURGEFLOX Susp. Cosmic
Flucloxacillin sodium 125mg/5ml:suspension
l OOml bot: 62.00 MRP
t SYFLU Cap. MST Pharma
Flucloxacillin 500mg/capsule
500mg x 30's pack: 300.00 MRP
t SYFLU Susp. MST Pharma
Flucloxacillin l 25mg/5ml: suspension
l OOml bot: 61.00 MRP
Broad spectrum penicillins
AMPICILLIN2t,33
1OO's pack: 332.00 MRP Amoxycillin 250mg/capsule
t ACMECILIN Inj. Acme l OO's pack: 355.00 MRP
Ampicillin 250mg & 500mg/vial: injection. t AMBEEXIN Susp. Ambee
250mg vial x 5 's pack: 81.2.0 MRP Amoxycillin 125mg/5ml: suspension
500mg vial x 5's pack: 114.25 MRP l OOml bot: 46.55 MRP
t AMPEXIN lnj. Opsonin + AMBEEXIN Drop Ambee
Ampicillin 250mg & 500mg vial: Injection Ampicillin 125mg/1.25ml: drop.
250mg x 4 vial: 63 .27 MRP 15ml bot: 28.42 MRP
500mg x 4 vial: 84.45 MRP t AMOCAP Cap. Sonear
+ AMPIMET Cap. Medimet Amoxycillin 250mg & 500mg/capsule
Ampicillin 250mg/capsule 250mg x l OO's pack: 359.00 MRP
250mg x l OO's pack: 325.00 MRP 500mg x 40's pack: 246.00 MRP
t AMPIMET D/S Susp. Medimet t AMOCIL Cap. MST Pharma
Ampicillin l 25mg/5ml: suspension (double Amoxycillin 500mg/capsule
strength). 500mg x 50's pack: 300.00 MRP
l OOml bot: 43.75 MRP + AMOCIL Susp. MST Pharma
+ AMPIREX Susp. Jayson Amoxycillin 125mg/5ml: suspension
Ampicillin 125mg/5ml: suspension. I OOml bot: 50.00 MRP
1OOml bot: 33.80 MRP t AMOCIN Cap. Pacific
t AMPIREX Inj. Jayson Amoxycillin 250mg & 500mg/capsule
Ampicillin 250mg & 500mg/vial: injection. 250mg x 1OO's pack: 330.00 MRP
250mg x 5 vial (combi pack): 82.00 MRP 500mg x 50's pack: 335.00 MRP
500mg x 5 vial (combi pack): 112.10 MRP + AMOCIN Susp. Pacific
t PEN-A Cap. Renata Amoxycillin 125mg/5ml: suspension
Ampicillin 250mg/capsule l OOml bot: 40.00 MRP
250mg x l OO's pack: 218.00 MRP + AMOTID Cap. Biopharma
t PEN-A Inj. Renata Amoxycillin 250mg & 500mg/capsule
Ampicillin 250mg/vial: i.m/i.v injection 250mg x IOO's pack: 361.00 MRP
250mg vial x 1 's pack: 20.36 MRP 500mg x IOO's pack: 602.00 MRP
+ AMOTID Susp. Biopharma
Amoxycillin 125mg/5ml: suspension
AMOXYCILL1N21,33
IOOml bot: 46.17 MRP
t AMOTID-F Susp. Biopharma
AMOXYCILLIN: Capsule/Syrup/ Injection Amoxycillin 250mg/5ml: suspension (double
Ind: Broad spectrum antibiotics-specially respi­ strength)
ratory tract, ear, nose & throat infections; biliary l OOml bot: 65.25 MRP
tract, urinary tract, soft tissue and skin infections; + AMOTID Drop Biopharma
gonorrhoea and prophylaxis of bacterial endocar­ Amoxycillin 125mg/ l .25ml: paediatric drop
ditis; also typhoid fever and dental prophylaxis. 15ml bot: 30.11 MRP
C/I: Penicillin sensitive patients. + AMOX Cap. Doctor's
S/E: Allergic menifestations, Diarrhoea. Amoxycillin 250mg & 500mg/capsule
Dose: By mouth, 250mg (or 500mg in severe 250mg x lOO's pack: 300.00 MRP
infections) every 8 hours; Child, upto 10 yrs. 500mg x 40's pack: 227.60 MRP
half adult dose, upto 2 yrs. 1/4-1/2 adult dose. + AMOX Susp. Doctor's
Severe and recurrent purulent respiratory Amoxycillin 125mg/5ml: suspension
infection, 3 gm every 12 hourly. l OOml bot: 45.00 MRP
Short course oral therapy- + AMOX Drop Doctor's
Dental abscese, 3 gm stat and repeated after 8 Amoxycillin 125mg/l .25ml: drop
hours; 15ml bot: 26.86 MRP
UTI, 3 gm stat and repeated after 10-12 hours; t AMOXI Inj. Renata
Gonorrhoea, single dose of 3gm with Amoxycillin 500mg/vial: i.m/i. v injection
probenecid lgm; 500mg vial+ water: 25.52 MRP

+ AMOXIC Cap. Cosmo Pharma
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 323.00 MRP
500mg x 1OO's pack: 500.00 MRP
+ AMOXIC Susp. Cosmo Pharma
•
Amoxycillin 125mg/5ml: suspension
1OOml bot: 40.00 MRP
+ AMOXIC Drop Cosmo Pharma
Amoxycillin IOOmg/lml: drop
l 5ml bot: 28.00 MRP
+ AMOXICAP Cap. Renata
Amoxycillin 250mg/capsule
1 OO's pack: 360.00 MRP
+ AMOXICON Cap. Medicon
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 3 50.00 MRP
500mg x 50's pack: 300.00 MRP
+ AMOXICON Susp. Medicon
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.00 MRP
+ AMOXIMA Cap. Modern
Amoxycillin 250mg & 500mg/capsule
250mg x 1OO's pack: 360.00 MRP
500mg x 50's pack: 338.00 MRP
+ AMOXIMA Susp. Modern
Amoxycillin l 25mg/5ml: suspension
1OOml bot: 47.29 MRP
+ AMOXIMA Drop Modern
Amoxycillin 1OOmg/lml: drop
l 5ml bot: 30.20 MRP
+ AMO XIRAK Cap. RAK Pharma
Amoxycillin 500mg/capsule
500mg x 50's pack: 325.00 MRP
+ AMOXIZEN Cap. Zenith
Amoxycillin 250mg/capsule
250mg x lOO's pack: 3 51.00 MRP
+ AMOXIZEN DS Cap. Zenith
Amoxycillin 500mg/capsule
500mg x 50's pack: 304. 50 MRP
+ AMOXIZEN Susp. Zenith
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.69 MRP
+ AMOXON Cap. Jayson
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 361.00 MRP
500mg x 50's pack: 33 8.00 MRP
+ AMOXON Susp. Jayson
Amoxycillin 125 mg/5ml: suspension
lOOml bot: 47.47 MRP
+ AMOXON Drop Jayson
Amoxycillin 1 OOmg/lml: drop
l 5ml bot: 30.19 MRP
+ AMOXON Inj. Jayson
Amoxyllin 250mg & 500mg/vial: injection
250mg x 5 vial (combi pack): 8 7.40 MRP
500mg x 5 vial (combi pack): 122.95 MRP
+ AMX Cap. NIPRO JMI
Amoxycillin 250mg & 500mg/capsule
250mg x IOO's pack: 360.00 MRP
500mg x 50's pack: 33 8.00 MRP
+ AMX Susp. NIPRO JMI
Amoxycillin 125 mg/5ml: suspension
lOOml bot: 47.47 MRP
+ ANTIF Cap. Rangs Pharma
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 361.00 MRP
500mg x 50's pack: 337.50 MRP
+ ANTIF Susp. Rangs Pharma
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.45 MRP
QIMP-17 (231)
+ ANTIF DS Susp. Rangs Pharma
Amoxycillin 250mg/5ml: suspension (double
strength)
1OOml bot: 6 5.00 MRP
+ ANTIF Drop Rangs Pharma
Amoxycillin 1OOmg/lml: drop
15ml bot: 30.00 MRP
+ APIMOX Cap. Apollo
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 345.00 MRP
500mg x 50's pack: 340.00 MRP
+ APIMOX Susp. Apollo
Amoxycillin l 25mg/5ml: suspension
lOOml bot: 45.00 MRP
+ APIMOX Drop Apollo
Amoxycillin 1OOmg/lml: drop
15ml bot: 28.00 MRP
+ APOXY Cap. Apex
Amoxycillin 500mg/capsule
500mg x 50's pack: 275.00 MRP
+ APOXY Susp. 1\pex
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.47 MRP
+ ARISTOMOX Cap. Aristopharma
Amoxycillin 250mg & 500mg/capsule.
250mg x lOO's pack: 3 50.00 MRP
500mg x 50's pack: 300.00 MRP
+ ARISTOMOX Susp. Aristopharma
Amoxycillin 125mg/ml: suspension
1OOml bot: 45.00 MRP
+ AVLOMOX Cap. ACI
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 345.00 MRP
500mg x 40's pack: 244.00 MRP
+ AVLOMOX Susp. ACI
Amoxycillin l 25mg/5ml: suspension
IOOml bot: 46.00 MRP
t AVLOMOX DS Susp. ACI
Amoxycillin 250mg/5ml: suspension (double
strength)
IOOml bot: 6 5.25 MRP
+ AVLOMOX Drop ACI
Amoxycillin 1OOmg/lml: drop
15ml bot: 30.20 MRP
+ AVLOMOX lnj. ACI
Amoxyllin 500mg/vial: injection
500mg vial+ Water: 25.09 MRP
t BACTAMOX Tab. Renata
Amoxycillin 250mg & 500mg/tablet (f.c)
250mg x IOO's pack: 338.00 MRP
500mg x 50's pack: 290.50 MRP
t BACTAMOX Susp. Renata
Amoxycillin l 25mg/5ml: suspension
lOOml bot: 45.52 MRP
+ BACTAMOX Drop Renata
Amoxycillin lOOmg/lml: drop
l 5ml bot: 28.32 MRP
t BACTAMOX Inj. Renata
Amoxyllin 250mg & 500mg/vial: injection
250mg vial+ Water: 1 8.03 MRP
500mg vial+ Water: 25.52 MRP
+ BPMOX Cap. Bristol
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 225.00 MRP
500mg x 50's pack: 300.00 MRP
+ BPMOX Susp. Bristol
Amoxycillin 125mg/5ml: suspension
IOOml bot: 45.00 MRP
+ BPMOX Drop Bristol
Amoxycillin lOOmg/lml: drop
ANTIMICROBIAL DRUGS
15ml bot: 28.40 MRP
+ BRODAMOX Cap. Cosmic
Amoxycillin 250mg/capsule
250mg x 1OO's pack: 360.00 MRP
+ BRODAMOX-DS c·ap. Cosmic
Amoxycillin 500mg/capsule
500mg x 50's pack: 328.00 MRP
+ BRODAMOX Susp. Cosmic
A1noxycillin 125mg/5ml: suspension
lOOml bot: 47.45 MRP
+ CEMOXIN Cap. CPL
Amoxycillin 250mg & 500mg/capsule
250mg x 100'.s pack: 340.00 MRP
500mg x 50's pack: 325.00 MRP
+ CEMOXIN Susp. CPL
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.00 MRP
+ DEMOX Cap. Desh Pharma
Amoxycillin 250mg/capsule
250mg x 1OO's pack: 300.00 MRP
+ DEMOX-500 Cap. Desh Pharma
Amoxycillin 500mg/capsule
500mg x 50's pack: 300.00 MRP
+ DEMOX Susp. Desh Pharma
Amoxycillin 125mg/5ml: suspension
lOOml bot: 44.00 MRP
+ DEMOX Drop Desh Pharma
Amoxycillin lOOmg/lml: drop
I 5ml bot: 28.00 MRP
+ DEMOXJJ, Cap. Drug Inter.
Amoxycillin 250mg & 500mg/capsule
250mg x 50's pack: 1 7 5.00 MRP
500mg x 50's pack: 312. 50 MRP
+ DEMOXIL Susp. Drug Inter.
Amoxycillin 125mg/5ml: suspension
1 OOml bot: 47.00 MRP
+ DEMOXIL DS Susp. Drug Inter.
Amoxycillin 250mg/5ml: suspension (double
strength)
IOOml bot: 6 5.00 MRP
+ DEMOXIL Inj. Drug Inter.
Amoxyllin 250mg, 500mg & l gm/vial: injection
250mg vial+ water: 19.00 MRP
500mg vial+ water: 26.00 MRP
l gm vial+ water: 45.00 MRP
+ DOPEN 500 Cap. Hallmark
Amoxycillin 500mg/capsule
500mg x 50's pack: 33 8.00 MRP
+ DOPEN Susp. Hallmark
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.67 MRP
+ E-MOX Cap. Edruc
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 339.00 MRP
500mg x 50's pack: 303.50 MRP
+ E-MOX Susp. Edruc
Amoxycillin 125mg/5ml: suspension
lOOml bot: 44.00 MRP
+ E-MOX Drop Edruc
Amoxycillin 1OOmg/lml: drop
l 5ml bot: 30.00 MRP
+ FIMOXYL Cap. Sanofi-aventis
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 360.96 MRP
500mg x 50's pack: 33 8.00 MRP
+ FIMOXYL Tab. Sanofi-aventis
Amoxycillin 250mg & 500mg/tablet
250mg x lOO's pack: 347.99 MRP
500mg x 50's pack: 301.00 MRP
+ FIMOXYL Susp. Sanofi-aventis
ANTIMICROBIAL DRUGS QIMP-17 (232)

Amoxycillin 125mg/5ml: suspension Amoxycillin 125mg/l .25ml: drop Amoxycillin 250mg/5ml: suspension (double
IOOml bot: 47.46 MRP l 5ml bot: 28.32 MRP strength)
+ FIMOXYL DS Susp. Sanofi-aventis + KAMOXY Cap. Kemiko 1OOml bot: 65 .25 MRP
Amoxycillin 250mg/5ml: suspension (double Amoxycillin 250mg & 500mg/capsule + MOXACIL Drop. Square
strength) 250mg x 1OO's pack: 300.00 MRP Amoxycillin 125mg/l .25ml: drop.
1OOml bot: 68.26 MRP 500mg x 80's pack: 480.80 MRP l 5ml bot: 30.11 MRP
\

+ FIMOXYL Drop Sanofi-aventis + KAMOXY Susp. Kemiko + MOXACIL Inj. Square

Amoxycillin IOOmg/1ml: drop
15ml bot: 30.20 MRP
+ G-AMOXYCILLIN Cap. Gonoshas
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 27 5 .00 MRP
500mg x 50's pack: 300.00 MRP
+ G-AMOXYCILLIN Susp. Gonosbas
Amoxycillin 125mg/5ml: suspension
lOOml bot: 40.00 MRP
+ G-AMOXYCILLIN Drop Gonoshas
Amoxycillin I OOmg/ I ml: drop
15ml bot: 24.00 MRP
+ G-AMOXYCILLIN Inj. Gonosbas
Amoxyllin 500mg/vial: Injection
500mg vial (+ water) x I's pack: 24.00 MRP
+ GENAMOX Cap. General
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 361.00 MRP
500mg x 50's pack: 33 8.00 MRP
+ GENAMOX Susp. General
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.45 MRP
+ GENAMOX Drop General
Amoxycillin lOOmg/lml: drop
l 5ml bot: 30.11 MRP
+ HECTAMOX Cap. Millat
Amoxycillin 250mg & 500mg/capsule
250mg x 1 OO's pack: 364.00 MRP
500mg x 50's pack: 33 5.00 MRP
+ HECTAMOX Susp. Millat
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.00 MRP
+ HECTAMOX DS Susp. Millat
Amoxycillin 250mg/5ml: suspension (double
strength)
lOOml bot: 65.00 MRP
+ HECTAMOX Drop Millat
Amoxycillin lOOmg/lml: drop
15ml bot: 30.00 MRP
+ HICONCIL Cap. Medimet
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 345.00 MRP
500mg x 50's pack: 300.00 MRP
+ HICONCIL Susp. Medimet
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.00 MRP
+ HI-MOX Cap. Hudson
Amoxycillin 250mg/capsule
1OO's pack: 3 50.00 MRP
+ HI-MOX-DS Cap. Hudson
Amoxycillin 500mg/capsule
50's pack: 300.00 MRP
+ HI-MOX Susp. Hudson
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.00 MRP
+ J-MOX Cap. Ad-din
Amoxycillin 250mg & 500mg/capsule
250mg x 1 OO's pack: 286.00 MRP
500mg x 50's pack: 285.50 MRP
+ J-MOX Susp. Ad-din
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.00 MRP
+ J-MOX Drop Ad-din
Amoxycillin 125mg/5ml: suspension
IOOml bot: 47.46 MRP
+ KAMOXY Drop Kemiko
Amoxycillin 125mg/l .25ml: drop.
15ml bot: 28.00 MRP
+ KUMUMOX Cap. Kumudini
Amoxycillin 250mg & 500mg/capsule
250mg x I OO's pack: 300.00 MRP
500mg x 50's pack: 275.00 MRP
+ KUMUMOX susp. Kumudini
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.00 MRP
+ LOXYL-250 Cap. Asiatic
Amoxycillin 250mg/capsule
1OO's pack: 361.00 MRP
+ LOXYL-500 Cap. Asiatic
Amoxycillin 500mg/capsule
50's pack: 338.00 MRP
+ LOXYL Susp. Asiatic
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.46 MRP
+ MONAMOX Cap. Amico
Amoxycillin 250mg & 500mg/capsule
250mg x IOO's pack: 300.00 MRP
500mg x 50's pack: 300.00 MRP
+ MONAMOX Susp. Amico
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.40 MRP
+ MONAMOX DS Susp. Amico
Amoxycillin 250mg/5ml: suspension (double
strength)
lOOml bot: 60.00 MRP
+ MONAMOX Drop. Amico
Amoxycillin 125mg/l . 25ml: drop.
l 5ml bot: 28.00 MRP
+ MOX Cap. Astra
Amoxycillin trihydrate 500mg/capsule
500mg x 50's pack: 300.00 MRP
+ MOXA Cap. Decent
Amoxycillin 250mg & 500mg/capsule
250mg x 1OO's pack: 350.00 MRP
500mg x 50's pack: 335.00 MRP
+ MOXA Susp. Decent
Amoxycillin I 25mg/5ml: suspension
lOOml bot: 47.00 MRP
+ MOXACIL Cap. Square
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 361.00 MRP
500mg x 50's pack: 338.50 MRP
+ MOXACIL 875 Tab. Square
Amoxycillin 8 7 5mg/tablet
Dosage convenience: The usual dose of
amoxycillin 250mg or 500mg is 6 to 8 hourly;
but, the dosage schedule of amoxycillin 875 is
12 hourly.
8 7 5mg x 30's pack: 30 1.20 MRP
+ MOXACIL DT Tab. Square
Amoxycillin 250mg/tablet (dispersible)
lOO's pack: 349.00 MRP
+ MOXACIL Susp. Square
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.47 MRP
+ MOXACIL Forte Susp. Square
Amoxycillin 500mg/vial: injection.
500mg vial x S's pack: 126.10 MRP
+ MOXAPEN Cap. Nipa
Amoxycillin 250mg & 500mg/capsule
250mg x 1OO's pack: 3 50.00 MRP
500mg x 3_0's pack: 180.00 MRP
+ MOXAPEN Susp. Nipa
Amoxycillin 125mg/5ml: suspension
IOOml bot: 45.52 MRP
+ MOXAPEN Drop. Nipa
Amoxycillin 1OOmg/lml: Drop
15ml bot: 28.33 MRP
+ MOXICO Cap. Supreme
Amoxycillin 250mg & 500mg/capsule
250mg x 1OO's pack: 360.00 MRP
500mg 50's pack: 300.00 MRP
+ MOXICO Susp. Supreme
Amoxycillin l 25mg/5ml: suspension
lOOml bot: 47.00 MRP
+ MOXICO DS Susp. Supreme
Amoxycillin 250mg/5ml: suspension (double
strength)
lOOml bot: 65.00 MRP
+ MOXJl,JN Cap. Acme
Amoxycillin 250mg & 500mg/capsule
250mg x IOO's pack: 362.00 MRP
500mg x 50's pack: 337.50 MRP
+ MOXII,IN Susp. Acme
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47 .46 MRP
+ MOXILIN DS Susp. Acme
Amoxycillin 250mg/5ml: suspension (double
strength)
1OOml bot: 68.25 MRP
+ MOXILIN Drop. Acme
Amoxycillin lOOmg/lml: Drop.
15ml bot: 30.19 MRP
+ MOXII.IN Inj. Acme
Amoxycillin 250mg & 500mg/vial: injection.
,_
250mg x 5 vials: I06.00 MRP
500mg x 5 vials: 125.50 MRP
+ MOXIN Cap. Opsonin
Amoxycillin 500mg/capsule
500mg x 50's pack: 296.45 MRP
+ MOXIN Tab. Opsonin
Amoxycillin 250mg/tablet
250mg x I OO's pack: 306.13 MRP
+ MOXIN 875 Tab. Opsonin
Amoxycillin 8 7 5mg/tablet
Dosage convenience: The usual dose of
amoxycillin 250mg or 500mg is 6 to 8 hourly;
but, the dosage schedule of amoxycillin 875 is
12 hourly.
8 7 5mg x 20's pack: 204. 80 MRP
+ MOXIN Susp. Opsonin
Amoxycillin 125mg/5ml: suspension
lOOml bot: 41. 76 MRP
+ MOXIN DS Susp. Opsonin
Amoxycillin 250mg/5ml: suspension
1OOml bot: 68.53 MRP
+ MOXIN Drop Opsonin
Amoxycillin 125mg/l . 25ml: drop.
15ml bot: 26. 5 7 MRP
 •

• .<i_ ' ' o ""J I V • • • o·. '•• • • ' •

QIMP-17 (233)
. .
.·
.
'

. ..
. .
.
..
.'.. ..;;.
;; - -

·» .
-
. ..
-

_.·Amoxicilli
. .;
·
-
�

- ..
·
. -
-

·
500mg x 40's pack: 220.00 MRP .
. .

+ MOXIN Inj. Opsonin n .

'
..
·
·, _
- .
.
.;
· ·
. · .
·
.
.
. .

..
. . ..

+ REMAMOX Susp. Reman

,.

Amoxycillin 250mg & 500mg/vial: injection.

.
. .
.
-

250mg x 4 vial: 6 7.10 MRP Amoxycillin 125mg/5ml: suspension

500mg x 4 vial: 92.09 MRP
+ MOX-Plus Susp. Hudson
Amoxycillin 250mg/5ml: suspension (double
strength)
lOOml bot: 65.00 MRP
t MUMOX Cap. SAPL
Amoxycillin 250mg & 500mg/capsule
250 x 1 OO's pack: 300.00 MRP
500 x 50's pack: 300.00 MRP
t MUMOX Susp. SAPL .
Amoxycillin 125mg/5ml: suspension
l OOml bot: 45.00 MRP.
t MYM OXCIL Cap. Mystic
Amoxycillin 250mg & 500mg/capsule
250mg x 1OO's pack: 3 50.00 MRP.
500mg x 50's pack: 300.00 MRP.
t MYM OXCIL Susp. Mystic
Amoxycillin 125 mg/5 ml: suspension
lOOml bot: 45.60 MRP
lOOml bot: 45.50 MRP
t REMOXIN Cap. Rephco
Amoxycillin 500mg/capsule Amoxycillin 250mg/5ml: suspension (double
500mg x 50's pack: 325.00 MRP strength)
t REMOXIN Susp. Rephco 1OOml bot: 6 5.00 MRP
Amoxycillin 125mg/5ml: suspension t SK-MOX Drop SK+F
lOOml bot: 46.00 MRP Amoxycillin 125mg/1.25ml: drop
+ SAPOX Cap. Alco Pharma 1 5ml bot: 28.32 MRP
Amoxycillin 250mg/capsule + TYCIL Cap. Beximco
lOO's pack: 344.00 MRP Amoxycillin 250mg & 500mg/capsule
t SAPOX-DS Cap. Alco Pharma 250mg x lOO's pack: 361.00 MRP
Amoxycillin 500mg/capsule 500mg x 50's pack: 338.50 MRP
lOO's pack: 60 7.00 MRP + TYCIL Susp. Beximco
+ SAPOX Susp. Alco Pharma Amoxycillin 125mg/5ml: suspension
Amoxycillin 125mg/5ml: suspension lOOml bot: 46.61 MRP
lOOml bot: 45.0 5 MRP t TYCIL DS Susp. Beximco
+ SAPOX-DS Susp. Alco Pharma Amoxycillin 250mg/5ml: suspension (double
Amoxycillin 250mg/5ml: suspension (double strength)
strength) 1OOml bot: 6 5.25 MRP

t NAVAMOX Cap. Navana
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 3 51.00 MRP
500mg x 50's pack: 326.50 MRP
t NAVAMOX Susp. Navana
Amoxycillin 125 mg/5 ml: suspension
lOOml bot: 47.00 MRP
+ ORGAMOX Cap. Organic Health
Amoxycillin BP 250mg & 500mg/capsule
250mg x lOO's pack: 3 54.00 MRP
500mg x 50's pack: 33 8.00 MRP
t ORGAMOX Susp. Organic Health
I Amoxycillin BP 125 mg/5 ml: suspension
lOOml bot: 47.00 MRP
t PEMOX Cap. APC Pharma
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 300.00 MRP
500mg x 50's pack: 300.00 MRP
t PEMOX Susp. APC Pharma
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.00 MRP
t PEMOX Drop APC Pharma
Amoxycillin 1OOmg/lml: drop.
1 5ml bot: 28.00 MRP
t PENMOX Cap. Techno Drugs
•
Amoxycillin 500mg/capsule
500mg x 50's pack: 33 8.00 MRP
+ PENMOX Susp. Techno Drugs
Amoxycillin 125mg/5ml: suspension
1OOml bot: 5 8.00 MRP
t PENMOX lnj. Techno Drugs
Amoxycillin 250mg/5ml & 500mg/5ml vial:
injection.
250mg (5ml) x 1 vial: 22.00 MRP
500mg (5ml) x 5 vial: 130.00 MRP
I
+ PHARM OXYL Cap. Pharmadesh
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 325.00 MRP
500mg x 50's pack: 293.00 MRP
+ PHARMOXYL Susp. Pharmadesh
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.43 MRP
+ PHARM OXYL Drop Pharmadesh
Amoxycillin lOOmg/lml: drop
15ml bot: 30.11 MRP
t REMAM OX Cap. Reman
Amoxycillin 250mg & 500mg/capsule
lOOml bot: 65.00 MRP
+ SAPOX Drop Alco Pharma
Amoxycillin 125mg/1.25ml: drop.
15ml bot: 28.32 MRP
+ SEEMAXYL Cap. Seema
Amoxycillin 250mg/capsule
250mg x 1OO's pack: 360.00 MRP
+ SEEMAXYL DS Cap. Seema
Amoxycillin 500mg/capsule
500mg x 50's pack: 338.00 MRP
+ SEEMAXYL Susp. Seema
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.00 MRP
t SIMOX Cap. Silva
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 3 51.00 MRP
500mg x 50's pack: 301.00 MRP
t SIMOX Susp. Silva
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.00 MRP
t SIMOX DS Susp. Silva
Amoxycillin 250mg/5ml: suspension (double
strength)
lOOml bot: 6 5.00 MRP
t SIMOX Drop Silva
Amoxycillin lOOmg/lml: drop
1 5ml bot: 27.00 MRP
t SINAMOX Cap. Ibo Sina
Amoxycillin 250mg & 500mg/capsule
250mg x 1 OO's pack: 360.00 MRP
500mg x 80's pack: 540.40 MRP
t SINAMOX Susp. Ibo Sina
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.46 MRP
+SINAMOX DS Susp. Ibo Sina
Amoxycillin 250mg/5ml: suspension
1 OOm1 bot: 6 9.00 MRP
t SINAMOX Drop Ibo Sina
Amoxycillin lOOmg/lml: drop
15ml bot: 30.00 MRP
+SK-MOX Cap. SK+F
Amoxycillin 250mg & 500mg/capsule
250mg x 1OO's pack: 3 54.00 MRP
500mg x 48's pack: 291.36 MRP
+ SK-MOX Susp. SK+F
Amoxycillin 125mg/5ml: suspension
1OOml bot: 46.40 MRP
+ TYCIL Drop. Beximco
Amoxycillin 125mg/1.25ml: drop.
l 5ml bot: 30.20 MRP
+ TYMOX Cap. Somatec
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 341 .00 MRP
500mg x 50's pack: 301.00 MRP
+ TYMOX Susp. Somatec
Amoxycillin 125mg/5ml: suspension
l OOml bot: 44.6 7 MRP
+ TYMOX Drop Somatec
Amoxycillin 125mg/l.25ml: drop
1 5ml bot: 30.11 MRP
t ULT RAM OX Cap. Globe
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 3 50.00 MRP
500mg x 50's pack: 303.50 MRP
t ULT RAMOX Susp. Globe
Amoxycillin 125mg/5ml: suspension
l OOml bot: 45.00 MRP
t UNIMOX Cap. Gaco
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 360.00 MRP
500mg x 20's pack: 134.60 MRP
+ UNIMOX Susp. Gaco
Amoxycillin 125mg/5ml: suspension
lOOml bot: 47.29 MRP
+ UNIMOX Drop Gaco
Amoxycillin 125mg/1.25ml: drop
15ml bot: 28.32 MRP
t XTRAMOX Cap. Bengal Drugs
Amoxycillin BP 250mg & 500mg/capsule
250mg x IOO's pack: 3 50.00 MRP
500mg x 50's pack: 300.00 MRP
+ XTRAMOX Susp. Bengal Drugs
Amoxycillin BP 125mg/5ml: suspension
l OOml bot: 46.00 MRP
+ ZIMOXYL Cap. Ziska
Amoxycillin 250mg & 500mg/capsule
250mg x lOO's pack: 310.00 MRP
500mg x 50's pack: 300.00 MRP
t ZIMOXYL Susp. Ziska
Amoxycillin 125mg/5ml: suspension
lOOml bot: 45.00 MRP
CO-AMOXICLAV21,33

250mg x 1OO's pack: 250.00 MRP + SK-MOX DS Susp. SK+F CO-AMOX ICL AV: Tablet/Syrup

Comp: Co-amoxiclav is a mixture of amoxycillin
and clavulanic acid; proportions of ratio are
expressed in the form x/y respectively; thus the
usual combinations are 250/125 or 500/125 in
milligrams. Calvulanic acid is a beta-lactamase
inhibitor. It itself has no significant antibacterial
role, but by inactivating penicillinases, it makes
the combination active against penicillinase-pro­
ducing bacteria that are resistant to amoxycillin.
These include most staph. aureus, 50% of E. coli
strains, and up to 15% of H. influenzae strains, as
well as many bacteroides and klebisiella spp.
Ind: As amoxycillin + penicillinase-producing
bacteria as mentioned above.
C/I; S/E: Same as amoxycillin.
Caution: hepatic impairment; in renal
impairment dosage frequency should be 12
hourly; patients on anticoagulant therapy.
Warnings: use in pregnancy is not recommended
if not considered essential.
Dosage: By mouth, adults and children over
12 years, the usual dose is amoxycillin 250mg
(or co-amoxiclav 375mg) 8 hourly taken with
or before meals; for severe infections,
amoxycillin 500mg (or co-amoxiclav 625mg)
may be given. For children below 12 years 5ml
to 1Oml of suspension 8 hourly according to
age and severity of infection.
By injection, adult, amoxycillin lgm (or co­
amoxiclav 1.2gm) 8 hourly by i.v injection
over 3-4 minutes or slowly by i.v infusion; in
case of more serious infections, may be given 6
hourly instead of 8 hourly.
Infants to age 3 months, amoxycillin 25mg/kg
8 hourly (or 12 hourly during perinatal period
or in case of premature infants); 3 months to
12 years, 25mg/kg 8 hourly; in case of more
serious infections, may be given 6 hourly
instead of 8 hourly.
In all cases, duration of treatment should be as
that of amoxycillin therapy.
t AMOCLAV 375 Tab. Techno Drugs
Co-amoxiclav 250/125 (amoxycillin trihydrate
250mg + clavulanic acid 125mg as potassium
salt) per tablet.
375mg x 20's pack: 325.00 MRP
t AMOCLAV 625 Tab. Techno Drugs
Co-amoxiclav 500/125 (amoxycillin trihydrate
500mg + clavulanic acid l 25mg as potassium
salt) per tablet.
625mg x l 8's pack: 360.00 MRP
t AMOCLAV lgm Tab. Techno Drugs
Co-amoxiclav 875/125 (amoxycillin trihydrate
875mg + clavulanic acidl 25mg as potassium
salt) per tablet.
Dosage convenience: The usual dose of co­
amoxiclav 375mg or 625mg is 8 hourly; but,
dosage schedule of co-amoxiclav lgm is 12
hourly.
l gm x 6's pack: 138.00 MRP
t AMOCLAV Susp. Techno Drugs
Co-amoxiclav 125/31 (amoxycillin Qi.hydrate
l 25mg + clavulanic acid 3 l .25mg as potassium
salt)/5ml: suspension.
60ml bot: 130.00 MRP
QIMP-17 (234)
1OOml bot: 190.00 MRP
t AMOCLAV Forte Susp. Techno Drugs
Co-amoxiclav 400/57 (amoxycillin trihydrate
400mg + clavulanic acid 57.50mg as potassium
salt)/5ml: suspension.
35ml bot: 90.00 MRP
t AMOCLAV 0.6 I.V Inj. Techno Drugs
Co-amoxiclav 600mg powder for reconstitution,
at a proportion of 500/100 (amoxycillin 500mg
as sodium salt + clavulanic acid 1 OOmg as
potassium salt)/vial: i.v injection
600mg vial x l 's pack: 135.00 MRP
t AMOCLAV 1.2 I.V Inj. Techno Drugs
Co-amoxiclav l 200mg powder for reconstitution,
at a proportion of 1000/200 (amoxycillin 1 OOOmg
as sodium salt + clavulanic acid 200mg as
potassi11m salt)/vial: i.v injection
1200mg vial x l ' s pack: 250.00 MRP
t CLAMOX 375 Tab. Opsoni.n
Co-amoxiclav 250/ 125 (amoxycillin trihydrate
250mg + clavulanic acid l 25mg as potassium
salt) per tablet.
l 8's pack: 262.22 MRP
t CLAMOX 625 Tab. Opsonin
Co-amoxiclav 500/125 (amoxycillin trihydrate
500mg + clavulanic acid125mg as potassium
salt) per tablet.
12's pack: 211.97 MRP
t CLAMOX lgm Tab. Opsonin
Co-amoxiclav 875/125 (amoxycillin trihydrate
875mg + clavulanic acid 125mg as potassium
salt)/tablet.
Dosage convenience: The usual dose of co­
amoxiclav 375mg or 625mg is 8 hourly; but,
dosage schedule of co-amoxiclav lgm is 12
hourly.
12's pack: 264.97 MRP
t CLAMOX Susp. Opsonin
Co-amoxiclav 125/31 (amoxycillin trihydrate
125mg + clavulanic acid 3 lmg as potassium salt)
/5ml: suspension.
l OOml bot: 132.46 MRP
t CLAMOX DS Susp. Opsonin
Co-amoxiclav 400/57 (amoxycillin trihydrate
400mg + clavulanic acid 57.50mg as potassium
salt)/5ml: suspension.
35ml bot: 79.47 MRP
. t CLAMOX 0.6gm I. V Inj. Opsonin
Co-amoxiclav 600mg powder for reconstitution,
at a proportion of 500/100 (amoxycillin 500mg
as sodium salt + clavulanic acid 1OOmg as
potassium salt)/vial: i.v injection
600mg vial x 1 's pack: 123.62 MRP
t CLAMOX 1.2gm I.V Inj. Opsonin
Co-amoxiclav l 200mg powder for reconstitution,
at a proportion of I 000/200 (amoxycillin IOOOmg
as sodium salt + clavulanic acid 200mg as
potassium salt)/vial: i.v injection
l .2gm vial x l 's pack: 242.84 MRP
t DEMOXICLAVE-375 Tab. Drug Inter.
Co-amoxiclav 250/125 (amoxycillin trihydrate
250mg + clavulanic acid125mg as potassium
salt)/tablet.
21 's pack: 336.00 MRP
t DEMOXICLAVE-625 Tab. Drug Inter.
Co-amoxiclav 500/ 125 (amoxycillin trihydrate
500mg + clavulanic acid125mg as potassium
salt) per tablet.
625mg x 21's pack: 504.00 MRP
t DEMOXICLAVE Susp. Drug Inter.
Co-amoxiclav 125/31 (amoxycillin trihydrate
125mg + clavulanic acid 3 l mg as potassium salt)
/5ml: suspension.
IOOml bot: 150.00 MRP
t DEMOXICLAVE FORTE Susp. Drug Inter.
Co-amoxiclav 400/57 (amoxycillin trihydrate '
400mg + clavulanic acid 57.50mg as potassi11m
salt)/5ml: suspension.
35ml bot: 90.00 MRP
t FIMOXYCLAV 375 Tab. Sanofi-aventis
Co-amoxiclav 250/125 (amoxycillin trihydrate
250mg + clavulanic acid 125mg as potassium
salt) per tablet.
375mg x 30's pack: 750.00 MRP
t FIMOXYCLAV 625 Tab. Sanofi-aventis
Co-amoxiclav 500/125 (amoxycillin tri.hydrate
500mg + clavulanic acid 125mg as potassium
salt) per tablet
625mg x 30's pack: 960.00 MRP
t FIMOXYCLAV lgm Tab. Sanofi-aventis
Co-amoxiclav 875/125 ( amoxycillin trihydrate
875mg + clavulanic acid 125mg as potassium
salt) per tablet.
Dosage convenience: The usual dose of co­
amoxiclav 375mg or 625mg is 8 hourly; but,
dosage schedule of co-amoxiclav lgm is 12
hourly.
20's pack: 900.00 MRP
t FIMOXYCLAV Susp. Sanofi-aventis
Co-amoxiclav 125/31 (amoxycillin trihydrate
l 25mg + clavulanic acid 3 l .25mg as potassium
salt)/5ml: suspension.
IOOml bot: 245.00 MRP
t FIMOXYCLAV bid Susp. Sanofi-aventis
Co-amoxiclav 400/57 (amoxycillin trihydrate
400mg + clavulanic acid 57.50mg as potassium
salt)/5ml: suspension.
50ml bot: 245.00 MRP
t FIMOXYCLAV 600 I. V Inj. Sanofi-aventis
Co-amoxiclav 600mg powder for
reconstitution, at a proportion of 500/100
(amoxycillin 500mg as sodi11m salt + clavulanic
acid IOOmg as potassium salt)/vial: i.v injection
600mg x 1 combipack: 150.00 MRP
t FIMOXYCLAV 1200 I.V Inj. Sanofi-aventis
Co-amoxiclav l 200mg powder for reconstitution,
at a proportion of 1000/200 (amoxycillin 1OOOmg
as sodium salt + clavulanic acid 200mg as
potassium salt)/vial: i.v injection
1200mg x 1 combipack: 300.00 MRP
t MOXACLAV 375 Tab. Square
Co-amoxiclav 250/125 (amoxycillin trihydrate
250mg + clavulanic acid 125mg as potassium
salt) per tablet.
24's pack: 480.00 MRP
t MOXACLAV 625 Tab. Square
Co-amoxiclav 500/125 (amoxycillin trihydrate
500mg + clavulanic acid l 25mg as potassium
salt) per tablet.
l 8's pack: 450.00 MRP
t MOXACLAV lgm Tab. Square
Co-amoxiclav 875/125 (amoxycillin trihydrate
875mg clavulanic acid 125mg as potassium
+
salt) per tablet.
Dosage convenience: The usual dose of co­
amoxiclav 375mg or 625mg is 8 hourly; but,
dosage schedule of co-amoxiclav lgm is 12
hourly.
12's pack: 360.00 MRP
t MOXACLAV Susp. Square

Co-amoxiclav 125/31 (amoxycillin trihydrate
125mg + clavulanic acid 31.25mg as potassium
salt)/5ml: suspension.
. 60ml bot: 135.51 MRP
l OOml bot: 175.00 MRP
t MOXACLAV Forte Susp. Square
Co-amoxiclav 400/57 (amoxycillin trihydrate
400mg + clavulanic acid 57.50mg as potassium
salt)/5ml: suspension.
35ml bot: 90.34 MRP
t MOXACLAV 600 I.V Inj. Square
Co-amoxiclav 600mg powder for
reconstitution, at a proportion of 500/l 00
(amoxycillin 500mg as sodium salt + clavulanic
acid lOOmg as potassium salt)/vial: i.v injection
600mg vial x l's pack: 140.00 MRP
t MOXACLAV 1.2gm I.V Inj. Square
Co-amoxiclav l 200mg powder for reconstitution,
at a proportion of 1000/200 (amoxycillin 1OOOmg
as sodium salt + clavulanic acid 200mg as
potassium salt)/vial: i.v injection
l .2gm vial x l's pack: 275.00 MRP
+ TYCLAV 375 Tab. Beximco
Co-amoxiclav 250/125 (amoxycillin trihydrate
250mg + clavulanic acid 125mg as potassium
salt) per tablet.
18's pack: 360.00 MRP
t TYCLAV 625 Tab. Beximco
Co-amoxiclav 500/125 (amoxycillin trihydrate
500mg + clavulanic acid 125mg as potassium
salt) per tablet.
l 8's pack: 450.00 MRP
+ TYCLAV lgm Tab. Beximco
Co-amoxiclav 875/125 (amoxycillin trihydrate
875mg + clavulanic acid 125mg as potassium
salt) per tablet.
Dosage convenience: The usual dose of co­
amoxiclav 375mg or 625mg is 8 hourly; but,
dosage schedule of co-amoxiclav lgm is 12
hourly.
12's pack: 420.00 MRP
Anti.pseudomonal penicillins
PIPERACJUIN + TAZOBAC.'IJ\M 133
PIPERACILLIN + TAZOBACTAM:
I.V Infusion
This is a combined preparation of piperacillin
sodium, a semisynthetic antibiotic of .
antipseudomonal penicillin group & tazobactam
sodium, a lactamase inhibitor. This combination
is produced for the treatment of patients with
moderate to severe infections caused by
piperacillin-resistant, piperacillin/tazobactam
susceptible,-lactamase producing strains of the
designated bacterial microorganisms. . failure. If bleeding manifestations occur,
This combination is available as- Piperacillin
sodium BP equivalent to 4gm piperacillin and
tazobactam sodium INN equivalent to 0.5gm
tazobactam powder in vial for intravenous
administration.
Mode of action: Piperacillin exerts bactericidal
activity by inhibiting septum formation and cell
wall synthesis of susceptible bacteria. In vitro,
piperacillin is active against a variety of gram­
positive and gram-negative aerobic and anaerobic
bacteria. It is also a lactamase inhibitor of the
Richmond-Sykes class III (Bush class 2b & 2b')
I
QIMP-17 (235)
penicillinases and cephalosporinases. It varies in
its ability to inhibit class II and IV (2a & 4)
penicillinases.
Tazobactam does not induce chromosomally­
mediated-lactamases at tazobactam concentrations
achieved with the recommended dosage regimen.
Ind: Piperacillin and tazobactam i.v infusion is
indicated for the following specified conditions:
1. Appendicitis (complicated by rupture or
abscess) and peritonitis caused by
piperacillin-resistant,-lactamase producing
strains of Escherichia coli or different
members of the Bacteroides fragilis group
(viz. B. fragilis, B. ovatus, B.
thetaiotaomicron, or B. vulgatus).
2. Uncomplicated and complicated skin and skin
structure infections, including cellulitis,
cutaneous abscesses and ischemic/diabetic
foot infections caused by piperacillin-resistant
lactamase producing strains of staphylococcus
aureus.
3. Postpartum endometritis or pelvic inflamma­
tory disease caused by piperacillin-resistant,­
lactamase producing strains of Escherichia coli.
4. Community-acquired pneumonia (moderate
severity only) caused by piperacillin­
resistant,-lactamase producing strains of
Haemophilus influenzae.
5. Nosocomial pne11monia (moderate to severe)
caused by piperacillin-resistant,-lactamase
producing strains of Staphylococcus aureus
and by piperacillin/tazobactam-susceptible
Acinetobacter baumanii, Haemophilus
influenzae, Klebsiella pneumoniae, & Pseu­
domonas aeruginosa (Nosocomial pne11monia
caused by P. aeruginosa should be treated in
combination with an aminoglycoside ).
6. Infections caused by piperacillin-susceptible
organisms, for which piperacillin has been
shown to be effective, are also amenable to
this combination treatment due to its
piperacillin content. The tazobactam compo­
nent does not interfare with the activity of the
piperacillin component against piperacillin­
susceptible organisms. Therefore, the treat­
ment of mixed infections caused by
piperacillin-susceptible organisms and
piperacillin-resistant, lactamase producing
organisms susceptible to piperacillin and
tazobactam should not require the addition of
another antibiotic.
7. This combination is also useful as presump­
tive therapy in the indicated conditions prior
to the identification of causative organisms
because of its broad spectrumof bactericidal
activity against gram-positive and gram-nega
tive aerobic and anaerobic organisms.
Piperacillin/tazobactam has been shown to be
active against most strains of the following
microorganisms both in vitro and in clinical
infections.
1. Aerobic andfacultative gram-positive
microorganisms: Staphylococcus aureus
(excluding methicillin and oxacillin-resistant
isolates).
2. Aerobic andfacultative gram-negative
microorganisms: Acinetobacter baumanii,
Escherichia coli, Hemophilus influenzae
(excluding-lactamase negative, ampicillin­
resistant isolates), Klebsiella pneumoniae,
ANTIMICROBIAL DRUGS
Pseudomonas aeruginosa (given in
combination with an aminoglycoside to which
the isolate is susceptible)
3. Gram-negative anaerobes: Bacteroides
fragilis group (B. fragilis, B. ovatus, B.
thetaiotaomicron, and B. vulgatus).
4. Aerobic andfacultative Gram-positive
microorganisms: Enterococcus faecalis
(ampicillin or penicillin-susceptible isolates
only), Staphylococcus epidermidis (excluding
methicillin and oxacillin-resistant isolates),
Streptococcus agalactiae*, Streptococcus
pneumoniae* (penicillin-susceptible isolates
only), Streptococcus pyogenes*, Viridans
group streptococci*.
5. Aerobic andfacultative Gram-negative
microorganisms: Citrobacter koseri,
Moraxella catarrhalis, Morganella morganii,
Neisseria gonorrhoeae, Proteus mirabilis,
Proteus vulgaris, Serratia marcescens,
Providencia stuartii, Providencia rettgeri,
Salmonella enterica
6. Gram-positive anaerobes: Clostridium
perfringens
7. Gram-negative anaerobes: Bacteroides
distasonis, Prevotella melaninogenica
*These are not-lactamase producing bacteria and,
therefore, are susceptible to piperacillin alone.
C/I: Piperacillin and tazobactam is
contraindicated in patients with a history of
allergic reactions to any of the penicillins,
cephalosporins, or --lactamase inhibitors.
S/E: Adverse events primarily involving the skin,
including rash and pruritus; the gastrointestinal
system, including diarrhea, nausea, and vomiting;
and allergic reactions. Adverse local reactions
that were reported, irrespective of relationship to
therapy with piperacillin and tazobactam were
phlebitis, i.v infusion site reaction, pain,
inflammation, thrombophlebitis, and edema.
Gastrointestinal-hepatitis, cholestatic jaundice.
Hematologic- hemolytic anemia, anemia,
thrombocytosis, agranulocytosis, pancytopenia.
Immune-hypersensitivity reactions, anaphylac­
tic/anaphylactoid reactions (including shock).
Infections- candidal superinfections.
Renal-interstitial nephritis, renal failure.
Skin and appendages- erythema multiforme,
Stevens-Johnson syndrome, toxic epidermal
necrolysis.
Precautions: Bleeding manifestations have
occurred in some patients receiving - lactam
antibiotics, including piperacillin. These reactions
have sometimes been associated with abnormali­
ties of coagulation tests such as clotting time,
platelet aggregation and prothrombin time, and
are more likely to occur in patients with renal
piperacillin and tazobactam i. v infusion should be
discontinued and appropriate therapy instituted.
The possibility of the emergence of resistant
organisms that might cause superinfections
should be kept in mind. If this occurs, appropri­
ate measures should be taken. As with other peni­
cillins, patients may experience neuromuscular
excitability or convulsions if higher than recom­
mended doses are given intravenously (particu­
larly in the presence of renal failure). piperacillin
and tazobactam contains a total of 2.79 mEq
(64mg) of Na+ per gram of piperacillin in the

ANTIMICROBIAL DRUGS
combination product. This should be considered
when treating patients requiring restricted salt
intake. Periodic electrolyte determinations should
be performed in patients with low potassium
reserves, and the possibility of hypokalemia
should be kept in mind with patients who have
potentially low potassium reserves and who are
receiving cytotoxic therapy or diuretics. As with
other semisynthetic penicillins, piperacillin thera­
py has been associated with an increased inci­
dence of fever and rash in cystic fibrosis patients.
In patients with creatinine clearance > 40 ml/min
and dialysis patients (hemodialysis and CAPO),
the intravenous dose should be adjusted to the
degree of renal,function impairment.
Pediatric patients: Safety and efficacy in
pediatric patients less than 2 months of age have
not been established. There are no dosage
recommendations for piperacillin and tazobactam
in pediatric patients with impaired renal function.
Geriatric patients: Patients over 65 years are not
at an increased risk of developing adverse effects
solely because of age. However, dosage should
be adjusted in the presence of renal insufficiency.
In general, dose selection for an elderly patient
should be cautious, usually starting at the low
end of the dosing range, reflecting the greater
frequency of decreased hepatic, renal, or cardiac
function, and of concomitant disease or other
drug therapy.
Warnings: Serious anaphylactic/anaphylactoid
reactions (including shock) require immediate
emergency treatment with epinephrine. Oxygen,
intravenous steroids, and airway management,
including intubation, should also be administered
as indicated.
Clostridium difficile associated diarrhea (COAD)
has been reported with use of nearly all antibac­
terial agents, including piperacillin and tazobac­
tam and may range in severity from mild diarrhea
to fatal colitis. Treatment with antibacterial
agents alters the normal flora of the colon leading
to overgrowth of C. difficile. If COAD is
suspected or confmned, ongoing antibiotic use
not directed against C. difficile may need to be
discontinued. Appropriate fluid and electrolyte
management, protein supplementation, antibiotic
treatment of C. difficile, and surgical evaluation
should be instituted as clinically indicated.
Pregnancy & lactation: Pregnancy category B.
Piperacillin and tazobactam cross the placenta in
humans. Piperacillin is excreted in low concen­
trations in human milk; tazobactam concentra­
tions in human milk have not been studied.
Caution should be exercised when piperacillin
and tazobactam i.v infusion is administered to a
pregnant and nursing woman.
Dosage & admin: Piperacillin and tazobactam
should be administered by intravenous ·
infusion over 30 minutes. The usual total daily
dose of Piperacillin and tazobactam for adults
is 3.375gm every 6 hours totaling 13.Sgm
(12.0gm piperacillin/l.Sgm tazobactam).
Nosocomial pneumonia:
Initial presumptive treatment should start
with piperacillin and tazobactam at a dosage
of 4.Sgm every 6 hours plus an
aminoglycoside, totaling 18.0gm (16.0gm
piperacillin/2 .0gm tazobactam). Treatment
with the aminoglycoside should be continued
�������----�
QIMP-17 (236)
in patients from whom Pseudomonas aerugi­
nosa is isolated. H Pseudomonas aeruginosa is
not isolated, the aminoglycoside may be
discontinued at the discretion of the treating
physician. Due to the in vitro inactivation of
the aminoglycoside by beta-lactam antibiotics,
piperacillin & tazobactam & the aminoglyco­
side are recommended for separate adminis­
tration. Piperacillin and tazobactam and the
aminoglycoside should be reconstituted,
diluted, and administered separately when
concomitant therapy with aminoglycosides is
indicated.
Renal Insufficiency:
In patients with renal insufficiency (creatinine
clearance > 40 ml/min), the intravenous dose
of piperacillin and tazobactam i. v infusion
should be adjusted to the degree of actual
renal function i.mpairment. In patients with
nosocomial pneumonia receiving concomitant
aminoglycoside therapy, the aminoglycoside
dosage should be adjusted according to the
recommendations of the manufacturer. The
recommended daily doses of Piperacillin and
tazobactam for patients with renal
insufficiency are as follows:
Renal function All Indications Nosocomial
pneumoma
(creatinine clear- (except noncomi-
•
ance, ml/min) nal pneumonia)
>40 ml/min 3.375gm 6 hourly 4.5gm 6 hourly
20-40 ml/min* 2.25gm 6 hourly 3.375gm 6 hourly
<20 ml/min* 2.25gm 8 hourly 2.250gm 6 hourly
Hemodialysis•• 2.25gm 12 hourly 2.250gm 8 hourly
CAPO 2.25gm 12 hourly 2.250gm 8 hourly
* Creatinine clearance for patients not
receiving hemodialysis
** 0. 75gm should be administered following
each hemodialysis session on hemodialysis
days for patients on hemodialysis, the
maximum dose is 2.2Sgm every twelve
hours for all indications other than
nosocomial pneumonia and 2.2Sgm every
eight hours for nosocomial pneumonia.
Since hemodialysis removes 300/o to 400/o of
the administered dose, an additional dose
of 0.7Sgm piperacillin and tazobactam
should be administered following each
dialysis period on hemodialysis days. No
additional dosage of piperacillin and
tazobactam is necessary for CAPD patients.
Hepatic Insufficiency:
The half-life of piperacillin and of tazobactam
increases by approximately 25°1• and 180/o,
respectively, in patients with hepatic cirrhosis
compared to healthy subjects. However, this
difference does not warrant dosage adjustment
of piperacillin and tazobactam due to hepatic
cirrhosis.
Duration of therapy:
The usual duration of piperacillin and
tazobactam treatment is 7-10 days. However,
the recommended duration of piperacillin and
tazobactam treatment of nosocomial
pneumonia is 7 to 14 days. In all conditions,
the duration of therapy should be guided by
the severity of the infection and the patient's
clinical and bacteriological progress.
Drug inter: Aminoglycosides: The mixing of
beta-lactam antibiotics with aminoglycosides in
vitro can result in substantial inactivation of the
aminoglycoside. The inactivation of aminoglyco­
sides in the presence of penicillin-class drugs has
been recognized. It has been postulated that
penicillin-aminoglycoside complexes form; these
complexes are microbiologically inactive and of
unknown toxicity. Sequential administration of
piperacillin and tazobactam with tobramycin to
patients with normal renal function and mild to
moderate renal impairment has been shown to
modestly decrease serum concentrations of
tobramycin but does not significantly affect
tobramycin ph�acokinetics. When aminoglyco­
sides are administered in combination with
piperacillin to patients with end-stage renal dis­
ease requiring hemodialysis, the concentrations
of the aminoglycosides (specially tobramycin)
may be significantly altered and should be moni­
tored. Since aminoglycosides are not equally sus­
ceptible to inactivation by piperacillin, considera­
tion should be given to the choice of the amino­
glycoside when administered in combination with
piperacillin to these patients.
Note: For further information, consult
manufacturer's literature.
t BRODACTAM 4.Sgm IV Inf. Sanofi-aventis
Each vial contains sterile lyophilized piperacillin
sodi11m BP equivalent to 4gm of piperacillin and
tazobactam sodi11m INN equivalent to 0.5gm of
tazobactam (powder for reconstitution): for i.v
infusion.
4.Sgm combipack: 1000.00 MRP
t MEGAClI,JN 4.Sgm IV W. Popular
Each vial contains sterile lyophilized piperacillin
sodium BP equivalent to 4gm of piperacillin and
tazobactam sodium INN equivalent to 0.5gm of
tazobactam (powder for reconstitution): for i.v
infusion.
4.Sgm combipack: 1003.77 MRP
t TAZOCIL 4.Sgm IV Inf. Square
Each vial contains sterile lyophilized piperacillin
sodium BP equivalent to 4gm of piperacillin and
tazobactam sodiwp. INN equivalent to O.Sgm of
tazobactam (powder for reconstitution): for i.v
infusion.
4.Sgm combipack: 1000.00 MRP
t TAZOPEN 4.Sgm IV Inf. Renata
Each vial contains sterile lyophilized piperacillin
sodi11m BP equivalent to 4gm of piperacillin and
tazobactam sodi11m INN equivalent to O.Sgm of
tazobactam (powder for reconstitution): for i.v
infusion.
4.Sgm combipack: I 000.00 MRP
Mecillinams
PIVMECILLINAM21,33
PIVMECILLINAM HCI: Tablet/ Injection
Ind: Urinary tract infections, acute cystitis;
salmonellosis, shigellosis, enteropathic E. coli
diarrhoea; Gram-negative septicaemia; biliary
infections; yersiniosis.
C/I: Hypersensitivity to penicillins or
cephalosporins.
S/E; Cautions: See under benzyl penicillin; also
monitor liver & kidney functions in long term
use.
I
 QIMP-17 (237) ANTIMICROBIAL DRUGS

Dosage & admin: Adult: U.T.I- Acute cystitis, CEPHALEXIN: Capsule/Suspension

initially 400mg then 200mg 6-8 hourly daily to Cephalexin is the orally active 'first generation'
•

a total of 2gms (i.e 3 days); in complicated cephalosporin with broad-spectrum activity.

UTI usual treatment time is 1-2 weeks.
Recurrent bacteriuria- 400 mg 6-8 hourly.
Salmonellosis-1.2 to 2.4 gm daily for 14 days.
All doses are taken with or immediately after
meal.
Child: UTI- under 40kg, 20-40mg/kg daily in 6
or 8 hourly, divided doses; over 40 kg. same as
adult, usually for 3 days. Salmonellosis- under
40 kg, 30-60 mg/kg daily in 6 or 8 hourly
divided doses; over 40 kg, same as adult. All
for 14 days.
+ ALEXID Tab. Aristopharma
Pivmecillinam hydrochloride 200mg/tablet.
'
> 50's pack: 750.00 MRP
+ BACILEX Tab. Pharmadesh
Pivmecillinam hydrochloride 200mg/tablet.
20's pack: 360.00 MRP
+ EMCIL Tab. Square
Pivmecillinam hydrochloride 200mg/tablet.
30's pack: 361.50 MRP
Mode of action: Cephalosporins have the same
mode of action as the penicillins. They are
bactericidal in action. They interfere with the last
step of bacterial cell wall synthesis
(transpeptidation or cross-linkage). The synthesis
of bacterial cell wall occurs in three steps- i. in
the first step formation of nucleotides (UDP-N -
,.
acetylmuramic acid-pentapeptide); ii. in second
step formation of the linear peptidoglycans; iii. in
the third or final step there is cross-linking (or
transpeptidation) of these linear strands occur by
an enzyme 'transpeptidase'. Penicillins and
cephalosporins bind to this enzyme in the final
step and act as competitive inhibitors, leading to
synthesis a defective cell membrane, which is
osmotically less stable. Finally, cell lysis occurs
after release of murein hydrolases present in .the
cell wall, which degrade performed cell wall.
Ind: Broadspectrum antibiotic, and active against
all common gram+ve cocci- pneurnococci,
:· ',;"; ::. '..
.
.... .......

· staphylococci (including penicillinase producing

:
. ,,

.: .-· �:: :f::1'.H=j:1

"

+ LEXIPEN Tab. Techno Drugs strains), beta-haemolytic strep. cocci & strep.
Pivmecillinam hydrochloride 200mg/tablet. viridens. Gram-ve bacilli such as, E. coli,
.
30's pack: 350.00 MRP Nit
a..zoxiae
.an
... Tablet &
klebsiella & proteus mirabilis are also susceptible.
· •· •

+ PINAM Tab. Kemiko Powder &' SUsper\sion

Thus infection of resp. tract, urinary tract, g. i
Pivmecillinam hydrochloride 200mg/tablet. tract, skin and of soft tissues are best treated.
30's pack: 360.00 MRP For_ dysentery C/I: History of hypersensitivity to cephalosporins
+ PIVICIL Tab. General •

or penicillins; meningitis, rhe\1matic fever

Pivmecillinam hydrochloride 200mg/tablet. prophylaxis, and anaerobic infections.
20's pack: 241.00 MRP •• S/E: Allergic reactions; nausea, vomiting,
+ PIVCILIN Tab. Rangs Pharma abdominal pain, dyspepsia; fever, arthralgia,
Pivmecillinam hydrochloride 200mg/tablet. transient hepatitis, and cholestatic jaundice,
20's pack: 240.00 MRP reversible interstitial nephritis, hyperactivity,
+ RELEXID Tab. Renata nervousness, sleep disturbance, confusion, . . ..
Pivmecillinam hydrochloride 200mg/tablet. . . hypertonia and dizziness.
· ·

·
:�::: ;:
......... ..
.. .....

30's pack: 360.00 MRP Cautions: Penicillin sensitivity; renal

. .'. .
impairment; pregnancy and breast-feeding (but
. ..... ·
--·: - .,
. · - � -
appropriate to use); false positive urinary glucose
1.2 Cephalosporins & and false positive Coomb's test (if done).
Dosage & admin: 250-500mg every 6 hours;
Cephamycins .
.

. .
• Child, 2S-50mg/kg daily in divided doses.

Cephalosporins are the broad-spectrum

1n + ACELEX Cap. Acme
Cephalexin 250mg & 500mg/capsule
antibiotics of lactam group. Most cephalosporins
250mg x 20's pack: 132.60 MRP
are produced semisynthetically by the chemical
500mg x 20's pack: 250.80 MRP
attachment of side chains to 7-aminocephalospo­
ranic acid.
+ ACELEX Susp. Acme
Cephalexin 125mg/5ml: suspension
1OOml bot: 77.29 MRP
Classification:
+ ALEXIN Cap. Renata
1. First generation cephalosporins: Such as, Cephalexin 250mg & 500mg/capsule.
cephalexin, cephradine, cefadroxil, 250mg x SO's pack: 279.00 MRP
cefazoUn. 500mg x 50's pack: 571.00 MRP
2. Second generation cephalosporins: + ALSPORIN Tab. Renata
Such as, cefaclor, cefamandole, cefprozi/, Cephalexin 250mg & 500mg/tablet.
cefoxitin, cefuroxime & cefuroxime axetil. 250mg x lOO's pack: 660.00 MRP
3. Third generation cephalosporins: Such as, 500mg x SO's pack: 609.50 MRP
•

cefdinir, cefetamet, cefixime, cefotaxime, + ALSPORIN Susp. Renata

cefpodoxime, ceftazidime, ceftibuten, Cephalexin 125mg/5ml: suspension
ceftriaxone, moxalactam. 1OOml bot: 82.24 MRP
4. Fourth generation cephalosporins: Such as, + CEFALEX Cap. Drug Inter.
Cefepime, Cefpirome Cephalexin 500mg/capsule
50's pack: 400.00 MRP
+ CEFALEX Susp. Drug Inter.
First generation Cephalexin 125mg/5ml: suspension
1OOml bot: 81.00 MRP
+ CEP HALEN Cap. Beximco
CEPHALEXJN21,33
Cephalexin 250mg & 500mg/capsule
 ANTIMICROBIAL DRUGS
250mg x IOO's pack: 673.00 IP
500mg x 50's pack: 630.00 IP
t CEPHALEN Susp. Beximco
Cephalexin 125mg/5ml: suspension
lOOml bot: 81.81 IP
+ CEPHAXIN Cap. Pharmadesh
Cephalexin 500mg/Capsule
500mg x 20's pack: 210.60 MRP
+ CEPHAXIN Susp. Pharmadesh
Cephalexin 125 mg/5 ml: Suspension
1OOml bot: 72.27 MRP
t CEPORAL Cap. Medimet
Cephalexin 250mg & 500mg/capsule
250mg x 40's pack: 220.00 MRP
500mg x 20's pack: 200.00 MRP
t CEPORAL Susp. Medimet
Cephalexin 125mg/ 5ml: suspension
1 OOml bot: 78.00 MRP
t CEPOREX Cap. GlaxoSmithKline
Cephalexin 250mg & 500mg/Capsule
250mg x 1OO's pack: 688.41 MRP
500mg x 50's pack: 634.54 MRP
t CEPOREX Susp. GlaxoSmithKline
Cephalexin 125mg/5ml: suspension
1OOml bot: 84.27 MRP
t NEOREX Cap. SK+F
Cephalexin 500mg/capsule
500mg x 48's pack: 625.00 MRP
t SUPRALEX Cap. Biopharma
Cephalexin 250mg & 500mg/capsule.
250mg x 30's pack: 195.60 MRP
500mg x 30's pack: 361.50 MRP
t SUPRALEX Susp. Biopharma
Cephalexin 125mg/5ml: suspension.
1OOml bot: 77 .29 MRP
CEFADROXJL21,26
CEFADROXIL: Capsule/Suspension/ Drop
Cefadroxil is an acid-stable semi-synthetic broad­
spectrum oral antibiotic of cephalosporin group.
Mode of action: See above under the text of
'cephalexin'.
Ind: Cefadroxil is indicated in the treatment of
patients with infection caused by susceptible
strains of the designated organisms in the
following diseases:
Upper respiratory tract infections caused by
Streptococcus pyogenes (Group A haemolytic
streptococci) and Streptococcus pneumoniae;
urinary tract infections caused by E. coli, Proteus
mirabilis, and Klebsiella species; skin and soft
tissue infections caused by Staphylococci
(including penicillinase producing strains) and
Streptococci.
C/I: History of hypersensitivity to cephalosporins
or penicillins; meningitis, rheumatic fever
prophylaxis, and anaerobic infections.
S/E: Allergic reactions; nausea, vomiting,
abdominal pain, dyspepsia; fever, arthralgia,
transient hepatitis, and cholestatic jaundice,
reversible interstitial nephritis, hyperactivity,
nervousness, sleep disturbance, confusion,
hypertonia and dizziness.
Cautions: Penicillin sensitivity; renal
impairment; pregnancy and breast-feeding (but
appropriate to use); false positive urinary glucose
and false positive Coomb's test (if done).
Dosage & Admin: Upper respiratory tract
infections: Adults, 1 gm per day in single or
I
QIMP-17 (238)
.
divided doses (b.i.d.) for 10 days; children,
.
30mg/kg/day in a single or in divided doses
every 12 hours for 10 days. Urinary tract
infections: for uncomplicated infections 1 or·
2gm per day in single or divided doses (b.i.d);
for all other UTis 2gm per day in divided
doses (b.i.d); children, 30mg/kg/day in divided
doses every 12 hours. Skin & soft tissue
infections: lgm per day in single or divided
doses (b.i.d); children, 30mg/kg/day in divided
doses every 12 hours.
Effects & absorption of cefadroxil are not
affected by foods, so if it is ad111:inistered with
food, may be helpful in diminishing potential
gastrointestinal complaints associated with
oral cephalosporin therapy.
Patients with renal impairment: The dosage
of Cefadroxil should be adjusted according to
creatinine clearance rates to prevent drug
accumulation. The following schedule is
suggested. In adults, the initial dose is 1OOOmg
and the maintenance dose (based on the
creatinine clearance rate (ml/min/1. 73m2) is
500mg at the time intervals listed bellow:
Creatinine clearance: 0-lOml/min, dosage
interval- 36 hours.
Creatinine clearance: 10-2Sml/min, dosage
interval- 24 hours.
Creatinine clearance: 25-50ml/min, dosage
interval- 12 hours.
Creatinine clearance: >SOml/min, dosage
interval- no adjustment.
Overdosage: If amounts >250mg/kg is
ingested, gastric lavage or inducing vomiting is
appropriate. Cefadroxil monohydrate can be
removed from the body by haemodialysis.
Drug interaction: There is no known clinically
important drug interactions with cefadroxil
t ADOCIL-500 Cap. Kemiko
Cefadroxil monohydrate USP 500mg/capsule
500mg x 20's pack: 240.00 MRP
t ADOCIL Susp. Kemiko
Cefadroxil monohydrate USP l 25mg/5ml:
suspension
•
1OOml bot: 80.00 MRP
+ ADORA Cap. Incepta
Cefadroxil monohydrate USP 500mg/capsule
500mg x 20's pack: 240.00 MRP
+ ADORA Susp. Incepta
Cefadroxil monohydrate l 25mg/5ml: suspension
60ml bot: 50.00 MRP
lOOml bot: 70.00 MRP
+ ADORA Drop Incepta
Cefadro xil monohydrate lOOmg/l ml: drop
15ml bot: 50.00 MRP
t AROCEF Cap. SK+F
Cefadroxil monohydrate USP 500mg/capsule
500mg x 24's pack: 288.00 MRP
t AROCEF Susp. SK+F
Cefadroxil monohydrate 125mg/5ml: suspension
l OOml bot: 70.00 MRP
t BEXAN Cap. NIPRO JMI
Cefadroxil monohydrate USP 500mg/capsule
MRP
500mg x 20's pack: 241.00
t BEXAN Susp. NIPRO JMI
Cefadroxil monohydrate l 25mg/5ml: suspension
l OOml bot: 70.26 MRP
t CEFADOR Cap. Somatec
Cefadroxil monohydrate USP 500mg/capsule
500mg x 20's pack: 241.00 MRP
+ DROXD. 500 Cap. Rangs Pharma
·
Cefadroxil monohydrate USP 500mg/capsule
. 500mg x 20's pack: 240.00 MRP
+ DROXIL Susp. Rangs Pharma
Cefadroxil monohydrate l 25mg/5ml: suspension
1OOml bot: 70.00 MRP
+ DROXIL Drop Rangs Pharma
Cefadroxil monohydrate l OOmg/lml: drop
15ml bot: 50.00 MRP
t SEFADOL Cap. Techno Drugs
Cefadroxil monohydrate USP 500mg/capsule
500mg x 18's pack: 216.00 MRP
+ SEF�OL Susp. Techno Drugs
Cefadroxil monohydrate 125mg/5ml: suspension
l OOml bot: 70.00 MRP
t SEFANID Cap. Drug Inter.
Cefadroxil monohydrate USP 500mg/capsule
500mg x 50's pack: 600.00 MRP
t SEFANID Susp. Drug Inter.
Cefadroxil monohydrate l 25mg/5ml: suspension
1OOml bot: 70.00 MRP
t TRUBID Cap. Opsonin
Cefadroxil monohydrate USP 500mg/capsule
500mg x 24's pack: 254.40 MRP
+ TRUBID Susp. Opsonin
Cefadroxil monohydrate 125mg/5ml: suspension
60ml bot: 44.16 MRP
l OOml bot: 61.81 MRP
t TRUBID DS Susp. Opsonin
Cefadroxil monohydrate 250mg/5ml: suspension
(double strength)
l OOml bot: 105.96 MRP
t TWICEF Cap. Acme
Cefadroxil monohydrate USP 500mg/capsule
500mg x 20's pack: 241.00 MRP
t TWICEF Susp. Acme
Cefadroxil monohydrate 125mg/5ml: suspension
1 OOml bot: 70.26 MRP
CEPHRADJNE21,33
CEPHRADINE: Capsule/Suspension/Drop/
Injection
Ind: Broadspectrum antibiotic, and active against
all common gram+ve cocci- pneumococci,
staphylococci (including penicillinase producing
strains), beta-haemolytic strep. cocci & strep.
viridens. Gram-ve bacilli such as, E. coli,
klebsiella & proteus mirabilis are also susceptible.
Thus infection of resp. tract, urinary tract, g.i
tract, skin and of soft tissues are best treated.
C/I; S/E; Caution: See above under Cefadroxil.
Dose: by mouth, 250-500 mg every 6 hours;
Child, 25-SO mg/kg daily in divided doses .
By i. m or i. v injection, 0.5-1 gm every 6
hours; Child, 50-100 mg/kg daily in 6 hourly
divided doses.
t ABAC-500 Cap. Chemist
Cephradine 500mg/capsule.
500mg x 40's pack: 505.60 MRP
t ABAC Susp. Chemist
Cephradine 125mg/5ml: suspension
1OOml bot: 81.92 MRP
+ ABAC Drop Chemist
Cephradine 1 OOmg/ml: drop
15ml bot: 50.00 MRP
t ACEFRA Cap. Apollo
Cephradine 500mg/capsule.
500mg x 20's pack: 240.00 IP
 QIMP-17 (239) ANTIMICROBIAL DRUGS

+ ACE FRA Susp.Apollo Cephradine 250mg/5ml: suspension (double Cephradine 250mg & 500mg/capsule
Cephradine l 25mg/5ml: suspension strength) 250mg x 50's pack: 350.00 MRP
1 OOml bot: 78.00 IP lOOml bot: 110.00 MRP 500mg x 20's pack: 240.00 MRP
+ ADECEF Cap. Supreme t BELOCEF Drop Amico + CE FRAMED Susp. Medimet
Cephradine 500mg/capsule. Cephradine 1 OOmg/ml: drop Cephradine 125mg/5ml:· suspension
500mg x 24's pack: 300.00 MRP l 5ml bot: 50.00 MRP lOOml bot: 80.00 MRP
t ADECEF Susp. Supreme t BETASEF Cap.Alco Pharma t CEF RAMED Drop Medimet
Cephradine 125mg/5ml: suspension Cephradine 250mg & 500mg/capsule. Cephradine 1OOmg/ml: drop
l OOml bot: 80.25 MRP 250mg x 20's pack: 132.00 MRP 15ml bot: 50.00 MRP
+ ADECEF DS Susp. Supreme 500mg x 20's pack: 253.00 MRP t CEF RAN O V 500 Cap.Novus
Cephradine 250mg/5ml: suspension (double + BETASEF Susp.Alco Pharma Cephradine 500mg/capsule
strength) Cephradine 125mg/5ml: suspension 500mg x 24's pack: 300.00 MRP
lOOml bot: 120.00 MRP l OOml bot: 79.00 MRP + CEFRAN O V Susp. Novus
t ANCEF Cap. UniMed & UniHealth + BETASEF DS Susp. Alco Pharma Cephradine 125mg/5ml: suspension
Cephradine 250mg & 500mg/capsule. Cephradine 250mg/5ml: suspension (double l OOml bot: 80.00 MRP
250mg x 20's pack: 130.00 MRP strength) + CEFRASYN Cap. MST Pharma
500mg x 20's pack: 250.00 MRP 1OOml bot: 120.00 MRP Cephradine 500mg/capsule
+ ANCEF Susp. UniMed & UniHealth + BETASEF Drop Alco Pharma 500mg x 20's pack: 260.00 MRP
Cephradine 125mg/5ml: suspension Cephradine 1OOmg/ml: drop + CEFRASYN Susp. MST Pharma
lOOml bot: 85.00 MRP 15ml bot: 51.00 MRP Cephradine 125mg/5ml : suspension
t ANCEF Forte Susp. UniMed & UniHealth + BRACE Cap. Hallmark l OOml bot: 80.00 MRP
Cephradine 250mg/5ml: suspension (double Cephradine 250mg & 500mg/capsule + CEODIN Susp. CPL
strength) 250mg x 28's pack: 182.84 MRP Cephradine 125mg/5ml: suspension
lOOml bot: 120.00 MRP 500mg x 20's pack: 250.00 MRP l OOml bot: 80.00 MRP
+ ANCEF Drop UniMed & UniHealth + BRACE Susp. Hallmark + CEPHID Cap. Zenith
Cephradine 1OOmg/ml: drop Cephradine 125mg/5ml: suspension Cephradine 250mg & 500mg/capsule
l 5ml bot: 50.00 MRP 1OOml bot: 80.00 MRP 250mg x 30's pack: 195.60 MRP
+ APHRIN Cap. Apex + CEFAD Cap. Mystic 500mg x 20's pack: 251.00 MRP
Cephradine 500mg/capsule. Cephradine 500mg/capsule t CEPHII> Susp. Zenith
I 500mg x 20's pack: 240.00 MRP 500mg x 20's pack: 235.00 MRP Cephradine 125mg/5ml: suspension
+ APHRIN Susp. Apex + CEFAD Susp. Mystic 1OOml bot: 80.00 MRP
Cephradine 125mg/5ml: suspension Cephradine 125mg/5ml: suspension t CEPHRACAP Cap. Euro Pharma
1OOml bot: 80.00 MRP 1OOml bot: 86.00 MRP Cephradine 500mg/capsule
t APHRIN Drop Apex + CEFADIN SOO Cap. Ziska 500mg x 20's pack: 250.00 MRP
Cephradine 1OOmg/ml: drop Cephradine 500mg/capsule + CEPHRACAP Susp. Euro Pharma
l5ml bot: 50.00 MRP 500mg x 28's pack: 336.00 MRP Cephradine 125mg/5ml: suspension
t AVLOSEF Cap.ACI + CEFADIN Susp. Ziska IOOml bot: 80.00 MRP
Cephradine 250mg & 500mg/capsule. Cephradine 125mg/5ml: suspension + CEPHRADEX-500 Cap. SAPL
250mg x 20's pack: 130.40 MRP lOOml bot: 80.00 MRP Cephradine 500mg/capsule
250mg x 32's pack: 208.64 MRP + CEFADIN Inj. Ziska 500mg x 20's pack: 250.00 MRP
500mg x 32's pack: 401.60 MRP Cephradine 500mg & 1gm/vial: i.m/i.v injection. t CEPHRADEX Susp. SAPL
+ AVLOSEF Susp.ACI 500mg vial x l's pack: 50.00 MRP Cephradine 125mg/5ml: suspension
Cephradine l 25mg/5ml: suspension lgm vial x l's pack: 80.00 MRP l OOml bot: 85.00 MRP
1OOml bot: 82.31 MRP t CEFASIA Cap. Pharma.sia + CEPHRAN Cap. Opsonin
+ AVLOSEF DS Susp.ACI Cephradine 500mg/capsule Cephradine 500mg/capsule
Cephradine 250mg/5ml: suspension (double 500mg x 20's pack: 260.00 MRP 500mg x 30's pack: 331.20 MRP
strength) + CEFASIA Susp. Pharmasia + CEPHRAN Susp. Opsonin
100ml bot: 120.45 MRP Cephradine 125mg/5ml: suspension Cephradine 125mg/5ml: suspension
+ AVLOSEF Drop ACI lOOml bot: 80.31 MRP l OOml bot: 70.64 MRP
Cephradine 1 OOmg/ml: drop + CEFASIA DS Susp. Pharmasia + CEPHRAN DS Susp. Opsonin
15ml bot: 50.19 MRP Cephradine 250mg/5ml: suspension (double Cephradine 250mg/5ml: suspension
+ AVLOSEF Inj.ACI strength) l OOml bot: 105.96 MRP
Cephradine 500mg & lgm/vial: i.m/i.v injection. lOOml bot: 140.00 MRP + CEPHRAN Drop Opsonin
500mg vial x l 's pack: 56.21 MRP + CEFLIN Cap. Nipa Cephradine 1OOmg/ml: drop
l gm vial x l's pack: 80.30 MRP Cephradine 500mg/capsule 15ml bot: 44.16 MRP
+ BACTOKIL Cap. Virgo 500mg x 20's pack: 253.20 MRP + CEPHRAN Inj. Opsonin
Cephradine USP 250mg & 500mg/capsule. t CEFLIN Susp. Nipa Cephradine 500mg, l gm/vial: i.m/i.v injection.
250mg x 24's pack: 156.00 MRP Cephradine 125mg/5ml: suspension 500mg vial x 4's pack: 190.72 MRP
500mg x 24's pack: 300.00 MRP lOOml bot: 80.00 MRP lgm vial x l 's pack: 70.64 MRP
+ BACTOKII. Susp. Virgo + CEFLIN Drop Nipa + CEPRO VAL Cap. Peoples
•

Cephradine USP 125mg/5ml: suspension Cephradine 1OOmg/ml: drop Cephradine BP 500mg/capsule

l OOml bot: 80.00 MRP 15ml bot: 50.00 MRP 500mg x 20's pack: 250.00 MRP
+ BELOCEF Cap. Amico t CEFRACEF Cap. NIPRO JMI t CEPRO VAL Susp. Peoples
Cephradine 250mg & 500mg/capsule. Cephradine 250mg & 500mg/capsule Cephradine BP 125mg/5ml: suspension
250mg x 20's pack: 130.00 MRP 250mg x 30's pack: 195.90 MRP lOOml bot: 85.00 MRP
500mg x 20's pack: 250.00 MRP 500mg x 24's pack: 301.20 MRP
+ COSCEF Cap. Cosmo Pharma
t BELOCEF Susp.Amico t CEFRACEF Susp.NIPRO JMI Cephradine 500mg/capsule
Cephradine 125mg/5ml: suspension Cephradine 125mg/5ml: suspension 500mg x 20's pack: 240.00 IP
1OOml bot: 80.00 MRP 1OOml bot: 80.31 MRP
+ COSCEF Susp. Cosmo Pharma
t BELOCEF DS Susp.Amico + CEF RAMED Cap. Medimet Cephradine 125mg/5ml: suspension

I
 ANTIMICROBIAL DRUGS
lOOml bot: 80.00 IP
t CUSEF Cap. Delta Pharma
Cephradine 250mg & 500mg/capsule
250mg x 20's pack: 130.00 MRP
500mg x 24's pack: 300.00 MRP
t CUSEF Susp. Delta Pharma
Cephradine 12Smg/Sml: suspension
l OOml bot: 80.00 MRP
t DICEF Cap. Drug Inter.
•
Cephradine 2SOmg & SOOmg/capsule
2SOmg x SO's pack: 3SO.OO MRP
SOOmg x 30's pack: 390.00 MRP
t DICEF Susp. Drug In�er.
Cephradine 12Smg/Sml : suspension
1OOml bot: 81.00 MRP
+ DICEF Forte Susp. Drug Inter.
Cephradine 2SOmg/Sml: suspension (double
strength)
lOOml bot: 120.00 MRP
t DICEF Drop Drug Inter.
Cephradine lOOmg/ml : drop
lSml bot: S0.00 MRP
t DICEF Inj. Drug Inter. '
Cephradine 2S0mg, SOOmg & lgm/vial: i.m/i.v
injection.
2S0mg vialx l's pack: 30.00 MRP
SOOmg vialx l's pack: 45.00 MRP
lgrn vialx l 's pack: 8S.OO MRP
t DOLOCEF Cap. Techno Drugs
Cephradine 2SOmg & SOOmg/capsule
2SOmg x 18's pack: 117.00 MRP
500mgx 18's pack: 225.00 MRP
t DOLOCEF Susp. Techno Drugs
Cephradine 125mg/Sml: suspension
.
lOOml bot: 86.00 MRP
+ DOLOCEF Inj. Techno Drugs
Cephradine SOOmg & lgm/vial: i.m/i.v injection.
SOOmg vialx l's pack: 50.00 MRP
lgm vialx l 's pack: 80.00 MRP
t EDIN Cap. Millat
Cephradine 2S0mg & SOOmg/capsule
250mg x 30's pack: l9S.OO MRP
SOOmgx 20's pack: 2SO.OO MRP
t EDIN Susp. Millat
Cephradine 12Smg/Sml: suspension
lOOml bot: 86.00 MRP
t EDIN DS Susp. Millat
Cephradine 250mg/Sml: suspension (double
strength)
l OOml bot: 120.00 MRP
t EDIN Drop Millat
Cephradine 1OOmg/ml : drop
l Sml bot: 50.00 MRP
t EFRAD Cap. Edruc
Cephradine BP 2S0mg & 500mg/capsule
2SOmgx 20's pack: 130.00 IP
SOOmg x 20's pack: 250.00 IP
+ EFRAD Susp. Edruc
Cephradine BP 12Smg/Sml: suspension
lOOml bot: 82.00 IP
t EUSEF Cap. Globe
Cephradine 500mg/capsule
.5oomgx 30's pack: 360.00 MRP
t EUSEF Susp. Globe
Cephradine 12Smg/Sml : suspension
lOOml bot: 80.00 MRP
t EUSEF DS Susp. Globe
Cephradine 250mg/5ml: suspension
l OOml bot: 120.00 MRP
t EUSEF Drop Globe
QIMP-17 (240)
Cephradine lOOmg/ml : pediatric drop
lSml bot: 50.00 MRP
t EUSEF Inj Globe
Cephradine SOOmg & lgm/vial: i.m/i.v injection.
SOOmg amp x l's pack: S0.00 MRP
lgm ampx l's pack: 80.00 MRP
t EVECEF Cap. Everest
Cephradine 500mg/capsule
SOOmg x 30's pack: 300.00 MRP
+ EVECEF Susp. Everest
Cephradine 12Smg/Sml: suspension
lOOml bot: 70.00 MRP
t EVECEF Drop Everest
Cephradine 1OOmg/ml : pediatric drop
l Sml bot: 50.00 MRP
t EXTRACEF Cap. Aristopharma
Cephradine 2S0mg & SOOmg/capsule.
250mg x 30's pack: 19S.OO MRP
500mg x 28's pack: 3S0.00 MRP
t EXTRACEF Susp. Aristopharma
Cephradine 125mg/5ml: suspension
lOOml bot: 82.00 MRP
t EXTRACEF DS Susp. Aristopharma
Cephradine 2S0mg/5ml: suspension (double
strength)
lOOml bot: 125.00 MRP
t EXTRACEF Drop Aristopharma
Cephradine lOOmg/ml : pediatric drop
15ml bot: S0.00 MRP
t EXTRACEF Inj. Aristopharma
Cephradine SOOmg & l gm/vial: i.m/i.v injection.
500mg vialx S's pack: 250.00 MRP
lgm vial x l's pack: 80.00 MRP
t G-CEFRADINE Cap. Gonoshas
Cephradine 500mg/capsule
500mgx 20's pack: 210.00 MRP
+ G-CEFRADINE Susp. Gonoshas
Cephradine 125mg/5ml: suspension
lOOml bot: 6S.OO MRP
+ G-CEFRADINE Drop Gonoshas
Cephradine lOOmg/ml : drop
lSml bot: 40.00 MRP
+ G-CEFRADINE lnj. Gonoshas
Cephradine 500mg/vial: i.m/i.v injection.
500mg vialx l's pack: 40.00 MRP
t GIGACEF Cap. Pacific
Cephradine 500mg/capsule
500mg x 20's pack: 254.00 MRP
t GIGACEF Susp. Pacific
Cephradine 125mg/5ml : suspension
lOOml bot: 64.00 MRP
t GIGACEF Drop Pacific
Cephradine 1OOmg/ml : drop
lSml bot: 46.00 MRP
t INTRACEF Cap. Beximco
Cephradine 250mg & SOOmg/capsule
2SOmg x 48's pack: 312.00 MRP
2SOmg x 50's pack: 325.00 IP
500mg x 40's pack: S00.00 IP
t INTRACEF Susp. Beximco
Cephradine l 2Smg/5ml : suspension
lOOml bot: 80.00 IP
t INTRACEF DS Susp. Beximco
Cephradine 250mg/5ml: suspension (double
strength)
lOOml bot: 120.00 IP
t INTRACEF Drop Beximco
Cephradine 1OOmg/ml: drop
1Sml bot: 50.00 IP
t INTRACEF Inj. Beximco
Cephradine 2S0mg & SOOmg/vial: i.m/i.v
injection.
2SOmgx IO vials : 351.40 IP
SOOmg x 10 vials :. 501.90 IP
t JEDINE Cap. Ad-din
Cephradine 500mg/capsule •
SOOmg x 30's pack: 375.00 MRP
t JEDINE Susp. Ad-din
Cephradine 12Smg/5ml: suspension
1OOml bot: 80.00 MRP
t JEDINE Drop Ad--din
Cephradine 1OOmg/ml: drop
15ml bot: 50.00 MRP
+ KEFDRIN Cap. GlaxoSmithKline
Cephradine SOOmg/capsule
SOOmg x 20's pack: 272.12 MRP
+ KEFDRIN Susp. GlaxoSmithKline
Cephradine 12Smg/5ml: suspension
1OOml bot: 86.30 MRP
+ KEPRAD Cap. Sonear
Cephradine 2SOmg & 500mg/capsule.
2SOmg x 40's pack: 328.00 MRP
SOOmg x 20's pack: 307.60 MRP
t LEBAC Cap. Square
Cephradine 250mg & SOOmg/capsule
250mg x l 8's pack: 117.S4 MRP
500mg x 18's pack: 376.20 MRP
t LEBAC Susp. Square
Cephradine 12Smg/Sml : suspension
l OOml bot: 80.30 MRP
+ LEBAC Forte Susp. Square
Cephradine 250mg/5ml: suspension
l OOml bot: 120.46 MRP
t LEBAC Drop Square
Cephradine l OOmg/ml: drop
l Sml bot: S0.20 MRP
t LEBAC Inj. Square
Cephradine 500mg & lgm/vial : i.m/i.v injection.
500mg vial x l's pack: 50.20 MRP
lgm vialx 1's pack: 80.30 MRP
+ LINDEX Cap. Rangs Pharma
Cephradine 250mg & 500mg/capsule
2SOmgx 20's pack: 130.00 MRP
SOOmgx 20's pack: 2SO.OO MRP
+ LINDEX Susp. Rangs Pharma
Cephradine 12Smg/5ml: suspension
1OOml bot: 80.00 MRP
t LINDEX DS Susp. Rangs Pharma
I
Cephradine 250mg/5ml: suspension (double
strength)
lOOml bot: 120.00 MRP
+ LINDEX Drop Rangs Pharma
Cephradine 1OOmg/ml: drop
lSml bot: S0.00 MRP
+ LINDEX Inj. Rangs Pharma
Cephradine SOOmg & lgm/vial: i.m/i.v injection.
SOOmg vial x S's pack: 2SO.OO MRP
lgm vialx l's pack: 80.00 MRP
t MEDICEF Cap. Medicon
Cephradine 500mg/capsule
SOOmg x 20's pack: 2SO.OO MRP
t MEDICEF Susp. Medicon
Cephradine 125mg/5ml: Suspension
l OOml bot: 80.00 MRP
+ MEFRAD Cap. Modern
Cephradine 500mg/capsule
500mg x 40's pack: 251.00 MRP
+ MEFRAD Susp. Modem
Cephradine 125mg/5ml: Suspension
l OOml bot: 100.00 MRP
 .

QIMP-17 (241) ANTIMICROBIAL DRUGS

•

+ MEFRAD Drop Modem t POLYCEF Inj. Renata

Cephradine I OOmg/ml: drop Cephradine 250mg, 500mg & lgm/vi al: injection.
15ml bot: 50.00 MRP 250mg vial+ water: 38.10 MRP
t MEGA-CEF Cap. Hudson · 500mg vi a l+ water: 65.00 MRP
Cephradine 500mg/capsule lgm vial+ water: 90:00 MRP
500mg x 30's pack: 357.00 MRP t PROCEF Cap. Incepta
t MEGA-CEF Susp. Hudson Cephradine 250mg & 500mg/capsule.
Cephradine 125mg/5ml: suspension 250mg x 24's pack: 156.00 MRP
lOOml bot: 81.00 MRP 500mg x 20's pack: 250.00 MRP
t MULTICEF Cap. Desh Pharma t PROCEF Susp. Incepta
Cephradine 250mg & 500mg/capsule Cephradine 125mg/5ml: suspension
250mg x 30's pack: 210.00 MRP lOOml bot: 80.00 MRP
500mg x 20's pack: 260.00 MRP t PROC�F Fort Susp. Incepta
t MULTICEF Susp. Desh Pharma Cephradine 250mg/5ml: suspension
Cephradine 125mg/5ml: suspension lOOml bot: 120.00 MRP
lOOml bot: 75.00 MRP t PROCEF Drop Incepta
t MULTICEF Drop Desh Pharma Cephradine 1 OOmg/ml: drop
Cephradine I OOmg/ml: drop 15ml bot: 50.00 MRP
15ml bot: 55.00 MRP t PROCEF lnj. Incepta
t MYCEF Cap. Ambee Cephradine 250mg, 500mg & lgm/vi al: injection.
Cephradine 500mg/capsule 250mg vi a l x 4's pack: 120.00 MRP
500mg x 20's pack: 250.80 MRP 500mg vi a l x 4's pack: 200.00 MRP
t MYCEF Susp. Ambee l gm vi a l x l's pack: 80.00 MRP
Cephradine 125mg/5ml: suspension + RAD-500 Cap. Decent
lOOml bot: 80.31 MRP Cephradine 500mg/capsule
t MYCEF-DS Susp. Ambee ® 500mg x 32's pack: 408.00 MRP
Cephradine 250mg/5ml: suspension + RAD Susp. Decent
lOOml bot: 120.00 MRP Cephradine l25mg/5ml: suspension
t MYCEF Drop Ambee 1OOml bot: 80.00 MRP
Cephradine I OOmg/ml: drop t RECEPR A 500 Cap. Reliance
Cephradine BP
l5ml bot: 50.19 MRP Cephradine 500mg/capsule
t NOVADIN Cap. Aexim 500mg x 20's pack: 250.00 MRP
Cephradine 500mg/capsule + RECEPR A Susp. Reliance
Cephradine 125mg/5ml: suspension
Stay
500mg x 20's pack: 240.00 MRP
-

I
t NOVADIN Susp. Aexim lOOml bot: 75.00 MRP
I
Cephradine 125mg/5ml: suspension t REOCEF-500 Cap. Rephco
lOOml bot: 80.00 MRP �:: �:J appy Cephradine 500mg/capsule
t ORGACEF Cap. Organic Health 500mg x 40's pack: 600.00 MRP
Cephradine BP 250mg & 500mg/capsule. t REOCEF Susp. Rephco
250mg x 30's pack: 195.00 MRP Cephradine 125mg/5ml: suspension
500mg x 20's pack: 250.00 MRP lOOml bot: 87.00 MRP
t ORGACEF Susp. Organic Health
Cephradine BP 125mg/5ml: suspension
Available as:, + REVOC Cap. Novo Healthcare
Cephradine 500mg/capsule
1OOml bot: 80.00 MRP 500mg x 24's pack: 288.00 MRP
+ P-CEF Cap. Pharmadesh + REVOC Susp. Novo Healthcare
Cephradine 500mg/capsule Cephradine l 25mg/5ml: suspension
500mg x 20's pack: 241.00 MRP lOOml bot: 80.00 MRP
+ P-CEF Susp. Pharmadesh + REVOC DS Susp. Novo Healthcare
Cephradine l25mg/5ml: suspension Cephradine 250mg/5ml: suspension
lOOml bot: 78.00 MRP lOOml bot: 120.00 MRP
•

+ P-CEF DS Susp. Pharmadesh + REVOC Drop Novo Healthcare

Cephradine 250mg/5ml: suspension Cephradine 1 OOmg/ml: drop
lOOml bot: 120.45 MRP l5ml bot: 50.00 MRP
+ P-CEF Drop Pharmadesh + ROCEF Cap. Healthcare
Cephradine 1OOmg/ml: drop Cephradine 250mg & 500mg/capsule.
15ml bot: 50.18 MRP 250mg x 30's pack: 195.00 MRP •

t POLYCEF Cap. Renata 500mg x 24's pack: 300.00 MRP

Cephradine 250mg & 500mg/capsule + ROCEF Susp. Healthcare
250mg x 20's pack: 130.40 MRP Cephradine 125mg/5ml: suspension
500mg x 28's pack: 351.12 MRP lOOml bot: 75.00 MRP
t POLYCEF Susp. Renata + ROCEF Forte S�sp. Healthcare
Cephradine 125mg/5ml: suspension Cephradine 250mg/5ml: suspension
1OOml bot: 80.30 MRP lOOml bot: 120.00 MRP
t
.

ROXICEF Cap. Popular

t POLYCEF DS Susp. Renata
Cephradine 500mg/capsule.
Cephradine 250mg/5ml: suspension
60ml bot: 80.00 MRP
500mg x 20's pack: 251.00 MRP
1OOml bot: 132.00 MRP t ROXICEF Susp. Popular
Cephradine l 25mg/5ml: suspension
t POLYCEF Drop Renata
Cephradine I OOmg/ml: drop
lOOml bot: 80.00 MRP
l5ml bot: 62.00 MRP t ROXICEF DS Susp. Popular
 ®
QIMP-17 (242)

Cephradine 500mg/vial: i.m/ i.v injection. 1OOml bot: 80.00 MRP

Cephradine 500mg vial combipack x l's pack: 60.00 MRP
.
+ SEPTA Drop Doctor's
+ SEFRATE 500 Cap. Bristol Cephradine IOOmg/ml: drop
Cephradine 500mg/ca psule. 15ml bot: 48.90 MRP
500mg x 20's pack: 250.00 MRP + SICEF Cap. Silva
Cephradine 250mg/5ml: suspension + SEFRATE Susp. Bristol Cephradine 500mg/ca psule.
lOOml bot: 120.45 MRP Cephradine 125mg/5ml: suspension 500mg x 20's pack: 250.00 MRP
+ ROXICEF Drop Popular lOOml bot: 80.00 MRP + SICEF Susp. Silva
Cephradine 1OOmg/ml: drop + SEFRATE Drop Bristol Cephradine 125mg/5ml: suspension
15ml bot: 50.01 MRP ·Cephradine 1OOmg/ml: drop lOOml bot: 80.00 MRP
+ ROXICEF Inj. Popular 15ml bot: 50.00 MRP + SICEF DS Susp. Silva
Cephradine 500mg & 1gm/vial: i.m/i.v injection. + SEFRII, Cap. Acme Cephradine 250mg/5ml: suspension
500mg vial x l's pack: 50.01 IMRPP Cephradine 250mg & 500mg : capsule. 60ml bot: 70.00 MRP
.

1gm vial x l's pack: 80.00 IMRPP 250mg x MRP

20's pack: 130.60 1OOml bot: 120.00 MRP
+ SEFACIN Cap. Kumudini 500mg x 20's pack: 250.80 MRP + SICEF Drop Silva
Cephradine 250mg & 500mg : capsule. + SEFRIL Susp. Acme Cephradine lOOmg/ml: drop
250mg x MRP
20's pack: 155.00 Cephradine 125mg/5ml: suspension l 5ml bot: 45.00 MRP
500mg x 20's pack: 250.00 MRP IOOml bot: 80.30 MRP + SINACEPH Cap. Ibo Sina
+ SEFACIN Susp. Kumudini + SEFRIL DS Susp. Acme Cephradine 250mg & 500mg/capsule.
Cephradine l 25mg/5ml : suspension Cephradine 250mg/5ml: suspension 250mg x IP
20's pack: 1336.00
lOOml bot: 85.00 MRP lOOml bot: 120.46 MRP 500mg x 30's pack: 390.00 IP
+ SEFACIN Drop Kumudini + SEFRIL Drop Acme + SINACEPH Susp. Ibo Sina
Cephradine 1OOmg/ml: drop Cephradine IOOmg/ml: drop Cephradine 125mg/5ml: suspension
15ml bot: 50.00 MRP l 5ml bot: 50.20 MRP 1OOml bot: 85.00 IP
+ SEFCON 500 Cap. Concord + SEFRII, Inj. Acme + SINACEPH-DS Susp. Ibo Sina
Cephradine 500mg/capsule. Cephradine 500mg & 1gm/vial: i.m/i. v injection. Cephradine 250mg/5ml: suspension
500mg x 28's pack: 350.00 MRP 500mg vial x S's pack: 251.00 MRP lOOml bot: 125.00 IP
+ SEFCON DS Susp. Concord lgm vial x l's pack: 80.30 MRP + SINACEPH Drop Ibo Sina
Cephradine 250mg/5ml: suspension + SEFRO Cap. Navana Cephradine 1 OOmg/ml: drop ·

lOOml bot: 120.00 MRP Cephradine 250mg & 500mg/ca psule
+ SEFIN Cap. Orion Pharma 250mg x 24's pack: 156.72
IP
Cephradine 250mg & 500mg : capsule. 500mg x 24's pack: 300.96 IP
250mg x MRP
20's pack: 130.60 + SEFRO Susp. Navana
500mg x 20's pack: 251.00 MRP Cephradine 125mg/5ml: suspension
+ SEFIN Susp. Orion Pharma 1OOml bot: 80.29 IP
Cephradine 125mg/5ml: suspension + SEFRO HS Susp. Navana
1 OOml bot: 80.30 MRP Cephradine 250mg/5ml: suspension
+ SEFIN DS Susp. Orion Pharma lOOml bot: 120.44 IP
Cephradine 250mg/5ml: suspension + SEFRO Drop Navana
50ml bot: 60.23 MRP Cephradine 1OOmg/ml: drop
lOOml bot: 120.45 MRP l5ml bot: 60.00 IP
+ SEFIN Drop Orion Pharma + SEFfEC Cap. APC Pharma
Cephradine 1OOmg/ml: drop Cephradine 500mg/ca psule
15ml bot: 50 .19 MRP 500mg x 20's pack: 300.00
+ SEFIN Inj. Orion Pharma + SEFfEC Susp. APC Pharma
15ml bot: 55.00 IP
+ SINACEPH Inj. Ibo Sina
Cephradine 500mg & lgm/vial: i.m/i.v injection.
500mg vial x 1's pack: 55.00 IP
lgm vial x l's pack: 85.00 IP
+ SK-CEF Cap. SK+F
Cephradine 250mg & 500mg/ca psule.
250mg x MRP
48's pack: 315.36
500mg x 30's pack: 390.00 MRP
+ SK-CEF Susp. SK+F
Cephradine 125mg/5ml: suspension
IOOml bot: 82.00 MRP
t SK-CEF DS Susp. SK+F
Cephradine 250mg/5ml: suspension
MRP 60ml bot: 80.00 MRP
lOOml bot: 140.00 MRP
•

Cephradine 250mg, 500mg & 1 gm/vial: injection. Cephradine 125mg/5ml: suspension + SK-CEF Drop SK+F
250mg vial x MRP
l's pack: 35.13 lOOml bot: 86.00 IP Cephradine 1OOmg/ml: drop
500mg vial x l's pack: 50.19 MRP + SEFI'EC Drop APC Pharma l 5ml bot: 51.00 MRP
lgm vial x l's pack: 80.30 MRP Cephradine 1OOmg/ml: drop + SK-CEF Inj. SK+F
+ SEFNIN Cap. MonicoPharma l 5ml bot: 50.00 IP Cephradine 500mg & lgm/vial: i.m/i.v injection.
Cephradine 250mg & 500mg/capsule. + SEPHAR Cap. RAK Pharma 500mg vial x MRP
l's pack: 50.00
250mg x MRP
50's pack: 325.00 Cephradine 500mg/capsule. lgm vial x l's pack: 80.00 MRP
500mg x 24's pack: 300.00 MRP 500mg x 30's pack: 375.00 MRP + SUPRACEF Cap. Biopharma
+ SEFNIN Susp. MonicoPharma + SEPHAR Susp. RAK Pharma Cephradin e 250mg & 500mg/ca psule
Cephradine 125mg/5ml: Suspension Cephradine 125mg/5ml: suspension 250mg x 28's pack: 188.44 MRP
1OOml bot: 80.00 MRP l OOml bot: 80.00 MRP 500mg x 28's pack: 351.40 MRP
+ SEFRAD Cap. Sanofi-aventis + SEPHAR DS Susp. RAK Pharma + SUPRACEF Susp. Biopharma
Cephradine 250mg & 500mg/capsule. Cephradine 250mg/5ml: suspension Cephradine 125mg/5ml: suspension
250mg x MRP
20's pack: 200.00 lOOml bot: 120.00 MRP 1OOml bot: 80.30 MRP I

500mg x 20's pack: 320.00 MRP + SEPRA-S Cap. Seema + SUPRACEF-F Susp. Biopharma
+ SEFRAD Susp. Sanofi-aventis Cephradine 500mg/ca psule. Cephradine 250mg/5ml: suspension
Cephradine 125mg/5ml: suspension 500mg x 20's pack: 300.00 MRP 1OOml bot: 120.45 MRP
lOOml bot: 95.00 MRP + SEPRA-S Susp. Seema + SUPRACEF Drop Biopharma
+ SEFRAD DS Susp. Sanofi-aventis
-�

Cephradine l 25mg/5ml: suspension Cephradine lOOmg/ml: drop

Cephradine 250mg/5ml: suspension lOOml bot: 86.00 MRP 15ml bot: 50.19 MRP
1OOml bot: 130.00 MRP •

+ SEPTA 500 Cap. Doctor's + SUPRACEF Inj. Biopharma

+ SEFRAD Drop Sanofi-aventis
Cephradine 1OOmg/ml: pediatric drop
15ml bot: 65.00 MRP
+ SEFRAD Inj. Sanofi-aventis
Cephradine 500mg/ca psule.
500mg x 20's pack: 240.00
+ SEPTA Susp. Doctor's
Cephradine 125mg/5ml: suspension
Cephradine 250mg, 500mg & 1gm/vial: injection.
MRP 250mg vial x l's pack: 35.13 MRP
500mg vial x l's pack: 50.19 MRP
lgm vial x l's pack: 74.28 MRP
/
+ TYDIN Cap. Somatec
Cepbradine 500mg/capsule.
500mg x 20's pack: 250.00 IP
+ TYDIN Susp. Somatec
Cephradine l 25mg/5ml: suspension
1 OOml bot: 78.29 IP
+ TYDIN DS Susp. Somatec
Cephradine 250mg/5ml: suspension
l OOml bot: 120.46 MRP
+ TYDIN Drop Somatec
Cephradine 1 OOmg/ml: drop
l 5ml bot: 48.18 IP
+ ULTRASEF Cap. Jayson
Cephradine 250mg & 500mg: -capsule
250mg x 20's pack: 135.40 IP
500mg x 20's pack: 250.80 IP
+ ULTRASEF Susp. Jayson
Cephradine l 25mg/5ml: suspension.
l OOml bot: 90.00 IP
+ ULTRASEF Drop Jayson
Cephradine 1OOmg/ml: drop
15ml bot: 50.19 IP
+ VECEF Cap. Asiatic
Cephradine 500mg/capsule
500mg x 24's pack: 300.00 MRP
+ VECEF Susp. Asiatic
Cephradine l 25mg/5ml: suspension.
l OOml bot: 80.00 MRP
+ VECEF DS Susp. Asiatic
Cephradine 250mg/5ml: suspension
l OOml bot: 120.00 MRP . allergic reactions including urticaria, rashes,
+ VECEF Drop Asiatic
Cephradine 1OOmg/ml: drop
l 5ml bot: 50.00 MRP
+ VELOGEN Cap. General
Cephradine 250mg & 500mg/capsule
250mg x 30's pack: 195.60 MRP
500mg x 20's pack: 251.00 MRP
+ VELOGEN Susp. General
Cephradine l 25mg/5ml: suspension
1OOml bot: 82.31 MRP
+ VELOGEN Drop General
Cephradine 1OOmg/ml: drop
l 5ml bot: 50.19 MRP
+ VELOX Cap. Kemiko
Cephradine 250mg & 500mg/capsule.
250mg x 30's pack: 210.00 MRP
500mg x 20's pack: 260.00 MRP
+ VELOX Susp. Kemiko
Cephradine 125mg/5ml: suspension
1OOml bot: 80.00 MRP
+ VELOX Drop Kemiko
Cephradine 1OOmg/ml: drop
l 5ml bot: 50.00 MRP
+ WINCEF Cap. White Horse
Cephradine BP 500mg/capsule.
500mg x 20's pack: 250.00 MRP
+ WINCEF Susp. White Horse
Cephradine BP 125mg/5ml: suspension
1OOml bot: 80.30 MRP
+ ZECEF-500 Cap. Gaco
Cephradine 500mg/capsule.
20's pack: 250.00 MRP
+ ZECEF Susp. Gaco
Cephradine l 25mg/5ml: suspension
l OOml bot: 80.00 MRP
+ ZECEF Drop Gaco
Cepbradine 1OOmg/ml: drop
15ml bot: 50.00 MRP
+ ZENAF Cap. Cosmic
QIMP-17 (243) ANTIMICROBIAL DRUGS
Cephradine 250mg & 500mg/capsule. Cefaclor monohydrate 500mg/capsule
250mg x 30's pack: 201.00 MRP 500mg x 20's pack: 800.00 MRP
500mg x 20's pack: 267.60 MRP + ALCLOR Susp. Acme
+ ZENAF Susp. Cosmic Cefaclor monohydrate 125mg/5ml:suspension
Cephradine125mg/5ml: suspension 1 OOml bot: 190.00 MRP
l OOml bot: 82.00 MRP + ALCLOR Drop Acme
+ ZENAF Drop Cosmic Cefaclor monohydrate l OOmg/l ml: drop.
Cephradine I OOmg/ml: drop 15ml bot: 125.00 MRP
15ml bot: 57.00 MRP + BIOCEF Cap. Sandoz
Cefaclor monohydrate 250mg & 500mg/capsule
250mg x 20's pack: 500.00 MRP
Second generation 500mg x 20's pack: 920.00 MRP
+ BIOCEF Susp. Sandoz
Cefaclor monohydrate l 25mg/5ml:suspension
CEFACLO R21, 33 l OOml bot: 295.00 MRP
+ CEFLON Susp. SK+F
CEFACLOR: Capsuleffablet/Suspen. Cefaclor monohydrate 125mg/5ml:suspension
Cefaclor is the orally active 'second generation' l OOml bot: 200.00 MRP
cephalosporin. + CEFLON Drop SK+F
Ind: Infections due to sensitive gram-positve & Cefaclor monohydrate l OOmg/ l ml: drop.
gram-negative bacteria. It is useful for UTI which 15ml bot: 125.00 MRP
do not respond to other drugs; infections which + CEFTICLOR Cap. Renata
occur in pregnancy, respiratory-tract infections, Cefaclor monohydrate 250mg & 500mg/capsule
otitis media, sinusitis and skin & soft-tissue 250mg x l 2's pack: 252.96 MRP
infections. Cepaclor has good activity against H. 500mg x 12's pack: 457.68 MRP
influenzae, but it is associated with protracted + CEFTICLOR 375 ER Tab. Renata
skin reactions specially in children. Cefaclor monohydrate 375mg/tablet (extended
C/I: Cephalosporin hypersensitivity; porphyria. release)
S/E: Diarrhoea & rarely colitis, nausea & 375mg x 12's pack: 361.32 MRP
vomiting, abdominal discomfort, headache; t CEFTICLOR Susp. Renata
Cefaclor monohydrate 125mg/5ml:suspension
pruritus, serun sickness-like reactions with 1OOml bot: 190.72 MRP
rashes, fever and arthraliga, and anaphylaxis; + CEFTICLOR Drop Renata
erythema multiforme, toxic epidermal necrolysis Cefaclor monohydrate l OOmg/l ml: drop.
reported; disturbances in liver enzymes, transient 15ml bot: 125.47 MRP
hepatitis and cholestatic jaundice; other side + CFL Susp. Sharif
effects reported include eosinophilia and blood Cefaclor monohydrate l 25mg/5ml:suspension
disorders; reversible interstitial nephritis, IOOml bot: 190.00 MRP
hyperac-tiviy, nervousness, sleep disturbances, + CFL Drop Sharif
confusion, hypertonia, and dizziness. Cefaclor monohydrate 1OOmg/1ml: drop.
Cautions: Penicillin sensitivity; renal 15ml bot: 125.00 MRP
impairment; pregnancy and breast-feeding (but + CLOBAC Susp. Opsonin
appropriate to use); false positive urinary glucose Cefaclor monohydrate 125mg/5ml:suspension
and false positive Coomb's test (if done). l OOml bot: 158.94 MRP
Dosage & admin: Adult- 250mg 8-hourly; in + CLOBAC Drop Opsonin
severe infections, double the dose, maximum Cefaclor monohydrate l OOmg/lml: drop.
4gm daily. 15ml bot: 110.38 MRP
Child- over 1 month 20mg/kg daily in 3 + CLOCEF Cap. Amico
divided doses; in severe infections, double the Cefaclor monohydrate 500mg/capsule
dose, maximum lgm daily. Or, 1 month-I year, 500mg x 20's pack: 600.00 MRP
62.Smg 8-hourly; 1-5 years, 125mg; over 5 + CLOCEF Susp. Amico
years, 250mg; in all cases doses doubled for Cefaclor monohydrate l 25mg/5ml:suspension
severe infections. l OOml bot: 175.00 MRP
Dosage schedule for 37Smg CD/ER + CLOROCEF Cap. lbn Sina
preparation: This CD (convenient dose) or ER Cefaclor monohydrate 250mg & 500mg/capsule
(extended release) preparation of 37Smg is 250mg x 12's pack: 264.00 IP
considered as a suitable dose for the patients 500mg x 12's pack: 480.00 IP
to be given 12 hourly, if the concerned + CLOROCEF Susp. Ibo Sina
physician desires. Cefaclor monohydrate l 25mg/5ml:suspension
l OOml bot: 205.00 IP
+ ABACLOR Cap. ACI
+ CLOROCEF Drop Ibo Sina
Cefaclor monohydrate 250mg & 500mg/capsule
Cefaclor monohydrate 1 OOmg/1 ml: drop.
250mg x 20's pack: 421.60 MRP
15ml bot: 130.00 IP
500mg x 12's pack: 481.80 MRP
+ LORACEF Cap. Square
+ ABACLOR Susp. ACI
Cefaclor monohydrate 500mg/capsule
Cefaclor monohydrate 125mg/5ml:suspension
500mg x 6's pack: 228.90 MRP
1OOml bot: 200. 75 MRP
+ ABACLOR Drop ACI + LORACEF Susp. Square
Cefaclor monohydrate lOOmg/l ml: drop. Cefaclor monohydrate 125mg/5ml:suspension
15ml bot: 125.47 MRP I OOml bot: 190.72 MRP
+ ALCLOR Cap. Acme + LORACEF Drop Square
ANTIMICROBIAL DRUGS
Cefaclor monohydrate 1 OOmg/ l ml: drop.
15ml bot: 125.47 MRP
t NAVACEF Cap. Navana
Cefaclor monohydrate 250mg & 500mg/capsule
250nig x 25's pack: 505.68 MRP
500mg x 24's pack: 963.60 MRP
t NAVACEF Susp. Navana
Cefaclor monohydrate 125mg/5ml:suspension
60ml bot: 130.48 MRP
l OOml bot: 190.70 MRP
t NAVACEF Drop Navana
Cefaclor monohydrate 125mg/1.25ml: drop.
15ml bot: 125.45 MRP
t OT ICLOR Susp. lncepta
·
Cefaclor monohydrate 125mg/5ml:suspension
1 OOml bot: 180.00 MRP
t OT ICLOR Drop Incepta
Cefaclor monohydrate 1OOmg/ l ml: drop.
l 5ml bot: 125.00 MRP
t SEFALOR Cap. Techno Drugs
Cefaclor monohydrate 500mg/capsule
500mg.x 12's pack: 456.00 MRP
t SEFALOR Susp. Techno Drugs
Cefaclor monohydrate 125mg/5ml:suspension
1OOml bot: 190.00 MRP
CEFPROZIL42, 133
CEFPROZIL: Tablet/Suspension
Cefprozil is a semi-synthetic broad-spectrum
second-generation cephalosporin antibiotic.
It possesses activity against a broad range of
gram-positive and gram-negative bacteria. It is
available as tablet & dry powder for suspension;
currently presented strengths are cefprozil USP
250mg & 500mg tablet & cefprozil USP
250mg/5ml suspension. Following oral adminis­
tration of cefprozil to fasting subjects, approxi­
mately 95% of the dose is absorbed. The average
plasma half-life in normal subjects is 1.3 hours.
Mode of action: The bactericidal action of
cefprozil results from inhibition of bacterial cell
wall synthesis.
Ind: Cefprozil is indicated for the treatment of
patients with mild to moderate infections of the
following organs & systems of the body:
1. Skin and skin structure infections.
2. Upper respiratory tract infections including
pharyngitis, tonsillitis, otitis media, acute sinusitis.
3. Lower respiratory tract infections including
secondary bacterial infection of acute bronchitis,
acute bacterial exacerbation of chronic bronchitis,
•
pneumoma.
4. Acute uncomplicated urinary tract infections.
C/I: Cefprozil is contraindicated in patients with
known hypersensitivity to the cephalosporins or
to any of the ingredients of the preparations.
S/E: Cefprozil was usually well tolerated in clini­
cal trials. The most common adverse effects
observed are: Gastrointestinal- diarrhea, nausea,
vomiting and abdominal pain. Hepatobiliary- ele­
vations of AST (SOOT), ALT (SGPT), alkaline
phosphatases and bilirubin values, cholestatic
jaundice has been reported rarely.
Cefuroxime
QIMP-17 (144)
Hypersensitivity- rash, urticaria (such reactions
have been reported more frequently in children
than in adults; signs and symptoms usually occur
a few days after initiation of therapy and subside
within a few days after cessation of therapy.
CNS- dizziness, hyperactivity, headache,
nervousness, insomnia, confusion and
somnolence have been reported rarely; all were
reversible. Hematopoietic- decreased leukocyte
count, eosinophilia. Renal- elevated BUN, serum
creatinine. Other- diaper rash and superinfection,
genital pruritus and vaginitis. The following
adverse events, regardless of established causal
relationship to Cefprozil, have been rarely
reported: Anaphylaxis, angioedema, colitis
(including pseudomembranous colitis), erythema
multiforme, fever, serum-sickness like reactions,
Stevens-Johnson syndrome & thrombocytopenia.
Pregnancy· & lactation: Cefprozil is not
expected to be harmful to the fetus. Still during
pregnancy the drug should be used if it is clearly
needed.
Dosage & admin: Cefprozil is administered
orally.
Infants & children (6 months -12 years):
Upper respiratory tract infections*: Otitis
media, lSmg/kg 12 hourly for 10 days; Acute
sinusitis, 7.Smg/kg or lSmg/kg 12 hourly for
10 days, (for moderate to severe infections the
higher dose should be used).
Children (2 years -12 years):
Upper respiratory tract infections*:
Pharyngitis/fonsillitis , 7.Smg/kg 12 hourly for
10 days.
Skin structure infections*: Uncomplicated skin
and skin structure infections, 20mg/kg daily
for 10 days.
Adults (13 years & Older):
Upper respiratory tract infections:
Pharyngitis/fonsillitis , SOOmg daily for 10
days; Acute sinusitis, 2S0mg or SOOmg 12
hourly for 10 days, (for moderate to severe
infections the higher dose should be used).
Lower respiratory tract infections: Secondary
bacterial infection of acute bronchitis & acute
bacterial exacerbation of chronic bronchitis,
SOOmg 12 hourly for 10 days.
Skin & skin structure infections:
Uncomplicated skin and skin structure
infections, 2S0mg 12 hourly or SOOmg daily or
SOOmg 12 hourly for 10 days.
* In the treatment of infections due to
streptococcus pyogenes, cefprozil should be
administered for at least 10 days.
Renal impairment: Cefprozil may be
administered to patients with impaired renal
function. In that case, the following dosage
schedule should be used:
Creatinine clearance, 30-lOOml/min- standard
dose schedule may be followed.
Creatinine clearance, 0-29ml/min- so•;. of
standard dose should be given in standard
dose interval.
Cefprozil is partly removed by hemodialysis;
therefore, cefprozil should be administered
after the completion of hemodialysis.
Hepatic impairment: No dosage adjustment is
necessary for patients with impaired hepatic
function.
Drug inter: Nephrotoxicity has been reported
following concomitant administration of
aminoglycoside antibiotics and cephalosporin
antibiotics. Concomitant administration of
probenecid doubles the AUC for cefprozil. The
bioavailability of the capsule formulation
of cefprozil is not affecte.d when administered 5
minutes following an antacid.
t ZILAPRO Susp. Beximco
Cefprozil 250mg/5ml: suspension
50ml bot: 276.00 IP
•
CEFUROXJME 21,47
CE FUROXIME: Tablet/Suspension/Injection
Cefuroxime is a 'second generation'
cephalosporim. 'Cefuroxime axetil' is an ester of
'cefuroxime' but has the same antibacterial
spectrum.
Ind: See under cefaclor; surgical prophylaxis;
more active against influenza & Neisseria
gonorrhoeae.
C/I; S/E; Caution: See above under Cefaclor.
.
Dosage & adplin: By mouth: Adults: General
infection- 2S0mg twice daily, doubled in
bronchitis and pneumonia.
UTI- 12Smg twice daily, doubled in pyeloneph­
ritis. Gonorrhoea, lgm as a single dose.
Children (over 5 years)- 125 mg twice daily, if
necessary doubled in otitis media.
By i.m. or i. v. injection or infusion: Adults-
7S0mg every 6-8 hours; 1.Sgm every 6-8 hours
in severe infections; single doses over 750mg
i.v. route only.
Children- 30-1OOmg/kg daily in 3-4 divided
•
doses (2-3 divided doses in neonates).
Gonorrhoea, 1.Sgm as a single dose by i.m.
injection (divided between 2 sites).
Surgical prophylaxis, 1.S g by i.v. injection at
induction; may be supplemented with 7S0mg
i.m. 8 & 16 hours later (abdominal, pelvic, and
orthopaedic operations) or followed by 750mg
i.m. every 8 hours for further 2448 hours
(cardiac, pulmonary, oesophageal, and
vascular operations).
Meningitis- 3gm i.v every 8 hours; Child, 200-
240mg/kg daily (in 3-4 divided doses) reduced
to lOOmg/kg daily after 3 days or on clinical
improvement; Neonate, lOOmg/kg dally
reduced to SOmg/kg daily.
t ABOXII. Tab. Rephco
Cefuroxime axetil 250mg & 500mg/tablet (f.c)
250mg x 1 O's pack: 250.00 MRP
500mg x 1 O's pack: 450.00 MRP
•
t ABOXII. Susp. Rephco
Cefuroxime axetil 125mg/5ml: suspension
l OOml bot: 200.00 MRP
+ ADETIL Tab. Supreme
Cefuroxime axetil 250mg & 500mg/tablet (f.c)
•

250mg x 1O's pack: 250.00 MRP
500mg x 6's pack: 270.00 MRP
+ ADETIL Susp. Supreme
Cefuroxime axetil l 25mg/5ml: suspension
70ml bot: 198.00 MRP
+ ADROX Susp. Ad-din
Cefuroxime axetil l 25mg/5ml: suspension
70ml bot: 181.00 MRP
+ AXEFUR Tab. Amulet
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
500mg x 6's pack: 270.00 MRP
+ AXE FUR Susp. Amulet
Cefuroxime axetil l 25mg/5ml: suspension
70ml bot: 198.00 MRP
+ AXE T Tab. Orion Pharma
Cefuroxime axetil l 25mg, 250mg &
500mg/tablet (f.c ).
125mg x 20's pack: 301.20 MRP
250mg x 20's pack: 501.80 MRP
500mg x 12's pack: 542.04 MRP
+ AXE T Susp. Orion Pharma
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 215.81 MRP
+ AXE T IM/IV Inj. Orion Pharma
Cefuroxime (as sodium salt) 250mg &
750mg/vial (powder for reconstitution):i.m/i.v
injection
250mg vial x l's pack: 60.00 MRP
750mg vial x l's pack: 125.47 MRP
+ AXE TIL Tab. Alco Pharma
Cefuroxime axetil l 25mg, 250mg &
500mg/tablet (f.c).
125mg x 12's pack: 144.00 MRP
250mg x 8's pack: 300.00 MRP
500mg x 8's pack: 540.00 MRP
+ AXETIL Susp. Alco Pharma
Cefuroxime axetil l 25mg/5ml: suspension
70ml bot: 190.00 MRP
+ AXIBID Tab. N uvista
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 14's pack: 350.00 MRP
500mg x 7's pack: 315.00 MRP
+ AXIM Tab. Aristopharma
Cefuroxime axetil l 25mg, 250mg &
-
500mg/tablet (f.c).
..
125mg x lO's pack: 150.00 MRP
250mg x 20's pack: 500.00 MRP
500mg x 1O's pack: 450.00 MRP
+ AXIM Susp. Aristopharma
Cefuroxime axetil l 25mg/5ml: suspension
70ml bot: 225.00 MRP
+ AXIM IM/IV Inj. Aristopharma
Cefuroxime (as sodium salt) 750mg/vial (powder
for reconstitution): i.m/i.v injection
1 vial pack: 125.00 MRP
+ BAC'I'IKII. Tab. Edruc
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x l 8's pack: 450.00 MRP
500mg x 8's pack: 360.00 MRP
+ BACTIKIL Susp. Edruc
Cefuroxime axetil USP 125mg/5ml: suspension
I 70ml bot: 198.00 MRP
+ CEFOBAC Tab. Popular
I Cefuroxime axetil 250mg & 500mg/tablet (f.c).
I
QIMP-17 (245)
250mg x 20's pack: 501.81 MRP
500mg x 8's pack: 361.00 MRP
+ CEFOBAC Susp. Popular
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 198.75 MRP
+ CEFOBAC 750 IM/IV Inj. Popular
Cefuroxime (as sodium salt) 750mg/vial
(powder for reconstitution): i.m/i.v injection
1 vial pack: 125.00 MRP
+ CEFOBAC 1.5 IV Inj. Popular
Cefuroxime (as sodium salt) l .5gm/vial (powder
for reconstitution): i.v injection
1 vial pack: 200.00 MRP
+ CEFOTIL Tab. Square
Cefuroxime axetil l 25mg, 250mg &
500mg/tablet (f.c).
125mg x 20's pack: 301.00 MRP
250mg x 20's pack: 502.00 MRP
500mg x 12's pack: 541.92 MRP
+ CEFOTIL Susp. Square
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 198.74 MRP
+ CEFOTIL 750 IM/IV lnj. Square
Cefuroxime (as sodium salt) 750mg/vial
(powder for reconstitution): i.m/i.v injection
750mg vial x l's pack: 125.47 MRP
+ CEFOTIL 1.5 IV Inj. Square
Cefuroxime (as sodium salt) l .5gm/vial (powder
for reconstitution): i.v injection
l.5gm vial x l 's pack: 200.75 MRP
+ CEF ROXIL-250 Tab. Hallmark
Cefuroxime axetil 250mg/tablet (f.c).
250mg x 8's pack: 200.00 MRP
+ CEFROXIL Susp. Hallmark
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 195.74 MRP
+ CEFSTAR Tab. Pharmadesh
Cefuroxime axetil l 25mg, 250mg &
500mg/tablet (f.c).
125mg x lO's pack: 150.50 MRP
250mg x 8's pack: 200.64 MRP
500mg x 8's pack: 361.28 MRP
+ CEFSTAR Susp. Pharmadesh
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 190.00 MRP
+ CEFUNIX Tab. Virgo
Cefuroxime axetil USP 250mg & 500mg/tablet
250mg x S's pack: 200.00 MRP
500mg x 8's pack: 320.00 MRP
+ CEFUNIX Susp. Virgo
Cefuroxime axetil USP 125mg/5ml: suspension
70ml bot: 190.00 MRP
+ CEFURIM Tab. Somatec
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 12's pack: 301.20 MRP
500mg x 8's pack: 361.36 MRP
+ CEFURIM Susp. Somatec
.C efuroxime axetil 125mg/5ml: suspension
70ml bot: 190.72 MRP
+ CEFUXET Tab. Chemist
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 16's pack: 400.00 MRP
500mg x 16's pack: 540.00 MRP
+ CEFUXET Susp. Chemist
Cefuroxime axetil 125mg/5ml: suspension
.9'-qs.r
� ;�;;;�
•
The most dependable antibiotic
8
·
70ml bot: 198.00 MRP
+ CEF UXE T IM/IV Inj. Chemist
Cefuroxime axetil (as sodium salt) 750mg/vial
(powder for reconstitution): i.m/i.v injection
750mg x 1 vial combipack: 125.00 MRP
+ CEROX-A Tab. ACI
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x l 6's pack: 401.44 MRP
500mg x 8's pack: 361.36 MRP
+ CEROX-A Susp. ACI
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 198.75 MRP
+ CEROX-A IM/IV Inj. ACI
Cefuroxime (as sodium salt) 250mg/vial &
750mg/vial (powder for reconstitution): i.m/i.v
injection
250mg x 1 vial combipack: 55.21 MRP
750mg x 1 vial combipack: 125.47 MRP
+ CEROX-A I.V lnj. ACI
Cefuroxime (as sodium salt) l .5gm/vial (powder
for reconstitution): i.v injection
l .5gm x 1 vial pack: 200.75 MRP
+ CEROXIME Tab. Asiatic
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 8's pack: 200.00 MRP
500mg x 8's pack: 360.00 MRP
+ CEROXIME Susp. Asiatic
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 198.00 MRP
+ CEXITIL Tab. Medicon
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
500mg x 8's pack: 360.00 MRP
+ DEX ATIL-250 Tab. Doctor's
Cefuroxime axetil 250mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
+ DEX ATIL Susp. Doctor's
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 198.00 MRP
+ ELIROXIME Tab. R eliance
Cefuroxime axetil 250mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
+ ELIROXIME Susp. R eliance
Cefuroxime axetil 125mg/5ml: suspension
60ml bot: 170.34 MRP
+ FAMICEF Tab. Acme
Cefuroxime axetil 250mg & 500mg/tablet (f.c ).
250mg x 20's pack: 502.00 MRP
500mg x 8's pack: 361.28 MRP
+ FAMICEF Susp. Acme
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 198.74 MRP
+ FAMICEF Inj. Acme
Cefuroxime (as sodium salt) 750mg/vial
(powder for reconstitution): i.m/i.v injection
750mg x 1 vial pack: 120.46 MRP
+ FAMICEF I.V Inj. Acme
Cefuroxime (as sodium salt) l .5gm/vial (powder
for reconstitution): i.v injection
l .5gm x 1 vial pack: 200.75 MRP
•••
.. LS tm. www.squarepharma.com.bd
•••
•••
MUAM
 - �
--� ��---------------------
m;;; ;;;
;;;;. ____ _____________
•

250 mg & 500 mg

Film Coated Tablet & QIMP-17 (246)
. 125 mg/5ml PFS

70ml bot: 198.75 MRP 500mg x 8's pack: 360.00 MRP

An antibiotic with supreme coverage
+ FUROCEF Inj. Renata +K F ORE Susp. K emiko
Cefuroxime (as sodium salt) 250mg/vial i.m/i.v, Cefuroxime axetil 125mg/5ml: suspension
750mg/vial i.m/i.v & l .5gm/vial i.v (powder for 70ml bot: 270.00 MRP .

reconstitution): injection +KILBAC Tab. Incepta

+FIXCEF Tab. Navana 250mg vial x l's pack: 55.21 MRP Cefuroxime axetil 125mg, 250mg &
Cefuroxime axetil 250mg & 500mg/tablet (f.c). 750mg vial x l's pack: 125.47 MRP 500mg/tablet (f.c).
250mg x 14's pack: 350.00 MRP l .5gm vial x l's pack: 200.75 MRP l 25mg x 24's pack: 360.00 MRP
500mg x 14's pack: 630.00 MRP +FUROTEC 500 Tab. APC Pharma 250mg x l 8's pack: 450.00 MRP
+F'IXCEF Susp. Navana Cefuroxime axetil USP 500mg/tablet (f.c). 500mg x 8's pack: 360.00 MRP
Cefuroxime axetil 125mg/5ml: suspension 500mg x 8's pack: 360.00 MRP +KILBAC Susp. Incepta
70ml bot: 190.00 MRP +FUROTEC Susp. APC Pharma Cefuroxime axetil 125mg/5ml: suspension
+FIXCEF Inj. Navana Cefuroxime axetil 125mg/5ml: suspension 70ml bot: 198.00 MRP
·

Cefuroxime (as sodium salt) ·250mg/vial & 70ml bot: 198.00 MRP +KILBAC DS Susp. Incepta
750mg/vial (powder for reconstitution): i.m/i.v +FUROTIL Tab. Healthcare Cefuroxime axetil 250mg/5ml: suspension
injection Cefuroxime axetil l 25mg, 250mg & (double strength)
750mg x 1 vial combipack: 125.00 MRP 500mg/tablet (f.c). 50ml bot: 250.00 MRP
+FIXCEF IV Inj. Navana 125mg x 12's pack: 180.00 MRP +KII,BAC Inj. lncepta
Cefuroxime (as sodium salt) l .5gm/vial (powder 250mg x l 8's pack: 450.00 MRP Cefuroxime (as sodium salt) 250mg/vial &
for reconstitution): i.v injection 500mg x 12's pack: 540.00 MRP 750mg/vial (powder for reconstitution): i.m/i.v
l .5gm x 1 vial combipack: 200.00 MRP + FUROTIL Susp. Healthcare injection
+F UREX Tab. Drug Inter. Cefuroxime axetil l 25mg/5ml: suspension 250mg x 1 vial combipack: 55.00 MRP
Cefuroxime axetil 250mg & 500mg/tablet (f.c). 70ml bot: 200.00 MRP 750mg x 1 vial combipack: 125.00 MRP
250mg x 14's pack: 350.00 MRP +FUROTIL I.V lnj. Healthcare +KILBAC IV Inj. Incepta
500mg x 14's pack: 630.00 MRP Cefuroxime axetil (as sodium salt) 750mg & Cefuroxime (as sodium salt) l .5gm/vial (powder
+FUREX Susp. Drug Inter. l .5gm/vial (powder for reconstitution): i.v for reconstitution): i.v injection

... . ''

M.11nlf"' 1u1 t ,1 111

Dedicated Cephalosporin Plant

Cefuroxime Tablet, PFS & Injection

Maximum power, maximum killing

Cefuroxime axetil 125mg/5ml: suspension injection l .5gm x I vial combipack: 200.00 MRP
70ml bot: 225.00 MRP 750mg x l vial pack: 175.00 MRP +Kil.MAX Tab. SK+F
+FUREX I.M/l.V lnj. Drug Inter. l .5gm x 1 vial pack: 275.00 MRP Cefuroxime axetil 125mg, 250mg &
Cefuroxime (as sodium salt) USP 250mg & + FUROTIXOL Tab. Sharif 500mg/tablet (f.c).
750mg/vial (powder for reconstitution):i.m/i.v Cefuroxime axetil 250mg & 500mg/tablet (f.c). 125mg x 14's pack: 210.00 MRP
injection 250mg x 8's pack: 200.00 MRP 250mg x 14's pack: 350.00 MRP
250mg x I vial pack: 50.00 MRP 500mg x 8's pack: 360.00 MRP 500mg x 7's pack: 315.00 MRP
750mg x 1 vial pack: 125.00 MRP +FUROTIXOL Susp. Sharif +KIT.MAX Susp. SK+F
+F UREX I.V Inj. Drug Inter. Cefuroxime axetil 125mg/5ml: suspension Cefuroxime axetil 125mg/5ml: suspension
Cefuroxime (as sodium salt) USP l .5gm/vial 70ml bot: 198.00 MRP 70ml bot: 198.00 MRP
(powder for reconstitution): i.v injection +FUXTIL Tab. Pharmasia +Kii.MAX Inj. SK+F
l .5gm x I vial pack: 200.00 MRP Cefuroxime axetil 250mg & 500mg/tablet (f.c). Cefuroxime (as sodium salt) 750mg/vial i.m/i.v
+FUROCEF Tab. Renata 250mg x 18's pack: 450.00 MRP & l .5gm/vial i.v (powder for reconstitution):
Cefuroxime axetil l 25mg, 250mg & 500mg x 12's pack: 540.00 MRP injection
•

500mg/tablet (f.c). +FUXTIL Susp. Pharmasia 250mg vial x l's pack: 55.00 MRP
125mg x lO's pack: 150.60 MRP Cefuroxime axetil l 25mg/5ml: suspension 750mg vial x l's pack: 125.00 MRP
250mg x l 6's pack: 401.44 MRP 70ml bot: 198.00 MRP l .5gm vial x l's pack: 200.00 MRP
500mg x 12's pack: 542.04 MRP +K F ORE Tab. K emiko +LEPATH Tab. Amico
+FUROCEF Susp. Renata Cefuroxime axetil 250mg & 500mg/tablet (f.c). Cefuroxime axetil 250mg/tablet (f.c).
Cefuroxime axetil 125mg/5ml: suspension 250mg x l 6's pack: 400.00 MRP 250mg x IO's pack: 220.00 MRP

Cefuroxime
•

+ MENAT Tab. Mystic
Cefuroxime axetil 1 25mg & 250mg/tablet (f.c).
1 25mg x 8's pack: 1 20.00 MRP
250mg x 8's pack: 200.00 MRP
+ MENAT Susp. Mystic
Cefuroxime axetil 1 25mg/5ml: suspension
.
•
70ml bot: 1 98.00 MRP
+ MEROCEF Tab. Ibo Sina
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 8's pack: 208.00 IP
500mg x 8's pack: 368.00 IP
+ MEROCEF Susp. Ibo Sina
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 200.00 IP
+ MEROCEF Inj. Ibo Sina
Cefuroxime (as sodium salt) 750mg/vial (powder
for reconstitution): i.m/i.v injection
750mg vial x 1 's pack: 1 30.00 IP
+ MEXTIL Tab. Biopharma
Cefuroxime axetil l 25mg, 250mg &
500mg/tablet (f.c).
l 25mg x 20's pack: 301 .20 MRP
250mg x 20's pack: 501 .80 MRP
500mg x 12's pack: 542.04 MRP
+ MEX'I'IL Susp. Biopharma
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 200.75 MRP
+ MEXTIL DS Susp. Biopharma
Cefuroxime axetil 250mg/5ml: suspension
(double strength)
50ml bot: 250.94 MRP
+ MEXTIL lnj. Biopharma
Cefuroxime (as sodium salt) 250mg &
750mg/vial (powder for reconstitution): i.m/i.v
injection
250mg vial x l's pack: 55.00 MRP
750mg vial x l's pack: 1 25.00 MRP
+ MEXTIL I.V lnj. Biopharma
Cefuroxime (as sodium salt) 1 .5gm/vial (powder
for reconstitution): i.v injection
l .5gm vial x l combipack: 200.00 MRP
+ OREXTIL Tab. MonicoPharma
Cefuro�e axetil 250mg & 500mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
500mg x 12's pack: 540.00 MRP
+ PICOCEF Tab. Concord
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
I 250mg x 16's pack: 400.00 MRP
500mg x 8's pack: 360.00 MRP
+ PICOCEF Susp. Concord
Cefuroxime axetil l 25mg/5ml: suspension
70ml bot: 1 98.00 MRP
+ PRIMOCEF Tab. Novo Healthcare
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
500mg x 8's pack: 360.00 MRP
+ PRIMOCEF Susp. Novo Healthcare
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 1 98.00 MRP
+ PROBAC Tab. Silva
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 16's pack: 401 .00 MRP
500mg x 8's pack: 361.00 MRP
+ PROBAC Susp. Silva
Cefuroxime axetil 1 25mg/5ml: suspension
,,..� �)
-�
· '
- 250 mg & 500 mg
An antibiotic with supreme coverage
I
QIMP-17 (247)
70ml bot: 1 98.00 MRP
+ RECOFAST Tab. Rangs Pharma
Cefuroxime axetil l 25mg, 250mg &
500mg/tablet (f.c).
1 25mg x 8's pack: 1 20.00 MRP
250mg x 12's pack: 300.00 MRP
500mg x 8's pack: 360.00 MRP
+ RECOFAST Susp. Rangs Pharma
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 1 98.00 MRP
+ RECOFAST IM/IV lnj. Rangs Pharma
Cefuroxime (as sodium salt) 750mg/vial (powder
for reconstitution):i.m/i.v injection
750mg vial x l's pack: 1 25.00 MRP
+ ROFUROX Tab. Radiant
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x lO's pack: 350.00 MRP
500mg x 8's pack: 440.00 MRP
+ ROFUROX Susp. Radiant
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 270.00 MRP
+ ROFUROX IM/IV lnj. Radiant
Cefuroxime (as sodium salt) 750mg/vial (powder
for reconstitution):i.m/i.v injection
750mg vial x l's pack: 200.00 MRP
+ ROXCEF Tab. NIPRO JMI
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
500mg x 6's pack: 270.00 MRP
+ ROXIBAC Tab. RAK Pharma
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 1 O's pack: 250.00 MRP
500mg x 8's pack: 360.00 MRP
+ ROXILAB Tab. Labaid Pharma
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 14's pack: 350.00 MRP
500mg x 7's pack: 350.00 MRP
+ ROXII,AB Susp. Labaid Pharma
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 270.00 MRP
+ SECOMAX Tab. General
Cefuroxime axetil 250mg & 500mg/ tablet (f.c).
250mg x 12's pack: 301.08 MRP
500mg x 8's pack: 361 .36 MRP
+ SECOMAX Susp. General
· Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 200.75 MRP
+ SEFATIL Tab. Pacific
Cefuroxime axetil 1 25mg, 250mg & 500mg/
tablet (f.c).
1 25mg x 20's pack: 300.00 MRP
250mg x 20's pack: 500.00 MRP
500mg x 12's pack: 540.00 MRP
+ SEFATIL Susp. Pacific
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 1 50.00 MRP
+ SEFUR Tab. Opsonin
Cefuroxime axetil l 25mg, 250mg &
500mg/tablet (f.c).
1 25mg x 12's pack: 1 58.98 MRP
250mg x 12's pack: 264.86 MRP
500mg x 6's pack: 238.41 MRP
+ SEFUR Susp. Opsonin
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 1 74.84 MRP
Film Coated Tablet &
125 mg/5ml PFS
•
®
Cefuroxime
+ SEFUR DS Susp. Opsonin
Cefuroxime axetil 250mg/5ml: suspension
(double strength)
50ml bot: 220.75 MRP
+ SEFUR Inj. Opsonin
Cefuroxime (as sodium salt) 750mg/vial (powder
for reconstitution): i.m/i.v injection
l vial combipack: 1 1 0.38 MRP
+ SEFUR I.V Inj. Opsonin
Cefuroxime (as sodium salt) l .5gm/vial (powder
for reconstitution): i.v injection
l .5gm vial x 1 combipack: 1 75.85 MRP
+ SEFUROX Tab. Sanofi-aventis
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 20's pack: 501 .80 MRP
500mg x 12's pack: 542.04 MRP
+ SEFUROX Susp. Sanofi-aventis
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 1 98.74 MRP
+ SEFUROX Inj. Sanofi-aventis
Cefuroxime (as sodium salt) 750mg/vial
(powder for reconstitution): i.m/i.v injection
1 vial combipack: 1 25.47 MRP
+ SEFUROX I.V Inj. Sanofi-aventis
Cefuroxime (as sodium salt) l .5gm/vial (powder
for reconstitution): i.v injection
l .5gm vial x 1 combipack: 200.01 MRP
+ STAXIM Tab. Delta Pharma
Cefuroxime axetil 250mg & 500mg/tablet (f.c ).
250mg x 12's pack: 300.00 MRP
500mg x 6's pack: 270.00 MRP
+ STAXIM Susp. Delta Pharma
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 1 70.00 MRP
t TIL Tab. Apex
Cefuroxime axetil 250mg & 500mg/tablet.
250mg x 8's pack: 200.00 MRP
500mg x 8's pack: 360.00 MRP
+ TIL Susp. Apex
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 1 98.00 MRP
+ T URBOCEF Tab. Beximco
Cefuroxime axetil 250mg & 500mg/tablet (f.c ).
250mg x 14's pack: 350.00 IP
500mg x 7's pack: 31 5.00 IP
+ TURBOCEF Susp. Beximco
Cefuroxime axetil 1 25mg/5ml: suspension
70ml bot: 2 1 0.00 IP
+ TURBOCEF Inj. Beximco
Cefuroxime (as sodium salt) 750mg/vial (powder
for reconstitution): i.m/i.v injection
750mg x 1 vial pack: 1 25.00 IP
+ TURBOCEF I.V Inj. Beximco
Cefuroxime (as sodium salt) 1 .5gm/vial (powder
for reconstitution): i.v injection
l .5gm x 1 vial pack: 200.00 IP
+ UROXIME Tab. Euro Pharma
Cefuroxime axetil 250mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
+ UROXIME Susp. Euro Pharma

ANTIMICROBIAL DRUGS
Cefuroxime axetil l 25mg/5ml: suspension
70ml bot: 198.00 MRP
t VEXOTIL Tab. Organic Health
c.efuroxime axetil 250mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
+ VEXOTIL Susp. Organic Health
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 198.00 MRP
+ WINFAX-500 Tab. White Horse
Cefuroxime axetil USP 500mg/tablet (f.c).
500mg x 12's pack: 360.00 MRP
+ WINFAX Susp. White Hone
Cefuroxime axetil USP 125mg/5ml: suspension
·
70ml bot: 198.00 MRP
+ XEFRIM Tab. Beacon
Cefuroxime axetil 250mg/tablet (f.c).
250mg x 1O's pack: 250.00 MRP
+ XEFRIM Susp. Beacon
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 198.00 MRP
t XIME TIL Tab. Globe
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 16's pack: 400.00 MRP
500mg x 12's pack: 540.00 MRP
t XIME'I'IL Inj. Globe
Cefuroxime (as sodium salt) 750mg/vial (powder
for reconstitution): i.m/i.v injection
1 vial pack: 125. 00 MRP
t XIME TIL I.V lnj. Globe
Cefuroxime (as sodium salt) l .5gm/vial (powder
for reconstitution): i.v injection
l .5gm vial x 1 combipack: 200.00 MRP
t XIMOROX Tab. Kumudini
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 12's pack: 300.00 MRP
500mg x 8's pack: 360.00 MRP
t XIMOROX Susp. Kumudini
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 195.00 MRP
+ XITIL Tab. Ziska
Cefuroxime axetil 250mg/tablet.
250mg x 14's pack: 350.00 MRP
500mg x 7's pack: 315.00 MRP
t XITIL Susp. Ziska
Cefuroxime axetil 125mg/5ml: suspension
70ml bot: 198.00 MRP
+ XORIMAX Tab. Sandoz
Cefuroxime axetil 250mg & 500mg/tablet (f.c).
250mg x 14's pack: 420.00 MRP
500mg x 14's pack: 770.00 MRP
+ XORIMAX Susp. Sandoz
Cefuroxime axetil 125mg/5ml: suspension
50ml bot: 250.00 MRP
t X TIL Tab. MST Pharma
Cefuroxime axetil 250mg/tablet.
250mg x 8's pack: 200.00 MRP
t ZINATIL Tab. Everest
Cefuroxime axetil 250mg & 500mg/tablet.
250mg x 12's pack: 300.00 MRP
500mg x 6's pack: 300.00 MRP
+ ZINATIL Susp. Everest
Cefuroxime axetil l 25mg/5ml: suspension
70ml bot: 185.00 MRP
t ZINNAT Tab. GlaxoSmithKline
Cefuroxime axetil l 25mg, 250mg &
500mg/tablet.
125mg x 14's pack: 210.00 MRP
250mg x l 4's pack: 350.00 MRP
500mg x 14's pack: 630.00 MRP
QIMP-17 (248)
CEFUROXIME +
CLAVULANIC ACID26,130
CEFUROXIME + CLAVULANIC ACID:
Tablet/Suspension
This is a combination formula of cefuroxime &
clavulanic acid, where combination proportions
are expressed as- cefuroxime + clavulanic acid
respectively. The usual combinations are- l 25mg
+ 31.25mg; 250mg + 62.50mg & 500mg + 125mg.
Mode of action: Cefuroxime is one of the
bactericidal second generation cephalosporin
antibiotics which is active against a wide range
of gram-positive and gram-negative susceptible
organisms including many beta-lactamase
producing strains. Clavulanic acid has a similar
structure to the beta-lactam antibiotics but binds
irreversibly to the beta-lactamase enzymes.
The presence of clavulanic acid in these
combined formulations protects cefuroxime from
degradation by beta-lactamase enzymes and
effectively extends the antibacterial spectrum of
cefuroxime to include many bacteria normally
resistant to cefuroxime and other cephalosporins.
Ind: Cefuroxime is active against a wide range
of gram-positive and gram-negative susceptible
organisms including many beta-lactamase
producing strains. It is indicated for the treatment
of patients with mild to moderate infections
caused by susceptible strains of the designated
microorganisms in the conditions listed below:
Pharyngitis/tonsillitis, acute bacterial otitis
media, acute bacterial maxillary sinusitis, lower
respiratory tract infections including pneumoniae,
acute bacterial exacerbations of chronic
bronchitis and secondary bacterial infections of
acute bronchitis; Uncomplicated skin and skin­
structure infections; Uncomplicated urinary tract
infections; Gonorrhea- uncomplicated and
disseminated gonococcal infections due to
neiseria gonorrhoeae (penicillinase- & non­
penicillinase-producing strains) in both males and
females; Bone and joint infections caused by
staphylococcus aureus (penicillinase- and non­
penicillinase-producing strains); Septicemia
caused by staphylococcus aureus (penicillinase­
and non-penicillinase-producing strains),
streptococcus pneumoniae, escherichia coli,
hemophilus influenzae (including ampicillin­
resistant strains), and klebsiella spp; Meningitis
caused by streptococcus pneumoniae, hemophilus
influenzae (including ampicillin-resistant strains),
neisseira menintitidis, and staphylococcus aureus
(penicillinase- and non-penicillinase-producing
strains); Early Lyme disease ( erythema migrans)
caused by borrelia burgdorferi.
Surgical prophylaxis: Cefuroxime is also
indicated in the prophylaxis against infections in
abdo-minal, pelvic, orthopedic, cardiac,
pulmonary, esophageal and vascular surgery
where there is increased risk for infections.
C/I: Patients with known allergy to ephalosporins
& pseudomembranous colitis are contraindicated.
S/E: Generally cefuroxime and clavulanic acid
are well tolerated. However, a few side effects
like nausea, vomiting, diarrhea, abdominal dis­
comfort or pain may occur. As with other broad­
spectrum antibiotics, prolonged administration of
cefuroxime and clavulanic acid combination may
-
result in overgrowth of nonsusceptible microor­
ganisms. Rarely (<0.2%) renal dysfunction,
anaphylaxis, angioedema, pruritis, rash and
serum sickness like urticaria may appear.
.
Precautions: This combination should be given
with care to patients receiving concurrent
treatment with potent diuretics & who have
history of colitis.
Pregnancy & lactation: While all antibiotics
should be avoided in the first trimester if
possible. However, This combination can be
safely used in later pregnancy to treat urinary and
other infections. In nursing mothers, both the
ingredients are excreted into the breast milk in
small quantities. However, the possibility of
sensitizing the infant should be kept in mind. •
Dosage & admin: The usual course of therapy
with this combination is 5 to 7 days for
treatment of bronchitis & 7 to 10 days for
other infections with exception to Early Lyme
diseases, which requires treatment for 20 days.
Considerinrcombinationaformula;
Adolescents & adults (13 years & older):
General infection- 20mg/kg/day in 2 divided
doses for 7-10 days;
Uncomplicated urinary tract infection-30mg/
kg/day in 2 divided doses for 10 days; Uncom­
plicated skin & skin-structure infections-
30mg/kg/day in 2 divided doses for 10-14 days; I
Typhoid fever- 30mg/kg/ day in 2 divided
doses for 5-10 days;
Community acquired pneumonia-
30mg/kg/day in 2 divided doses for 10 days;
Acute bacterial maxillary sinusitis-
30mg/kg/day in 2 divided doses for 10 days;
Acute otitis media- 20mg/kg/day in 2 divided
doses for 5-10 days.
Pediatric patients (3 months to 12 years):
Acute otitis media- 20mg/kg/day in 2 divided
doses for 5-10 days.
Acute bacterial maxillary sinusitis-
30mg/kg/day in 2 divided doses for 10 days;
Consideri nrCefuroximedose:
Adolescents & adults (13 years & older):
Pharyngitis/tonsillitis- 250mg twice daily for "·
10 days;
Acute bacterial maxillary sinusitis- 250mg
twice daily for 10 days;
Acute bacterial exacerbations of chronic
bronchitis- 250mg or 500mg twice daily for 10
days;
Secondary bacterial infections of acute
bronchitis- 250mg or 500mg twice daily for 5-
10 days;
Uncomplicated sk
. in & skin structure infec­
tions- 250mg or 500mg twice daily for 10 days;
Uncomplicated urinary tract infections-
125mg or 250mg twice daily for 7-10 days;
•
Uncompl.icated gonorrhea- 1,000mg once
(single dose) only;
Early lyme disease- 500mg twice daily for 20
days.
Pediatric patients (who can swallow full tablet):
General infection- 125mg to 250mg twice daily
for 7-10 days;
Acute otitis media- 250mg twice daily for 10
days;
Acute bacterial maxillary sinusitis- 250mg
twice daily for 10 days;
Or, as directed by the physician. •

Cefuroxime + clavulanic acid combination can
be administered without regard to meals.
Drug inter: Concomitant administration of
probenecid with this combination increases the
area under the serum concentration versus time
curve by 50%. Drug that reduces gastric acidity
may result in a lower bioavailability of
cefuroxime and tend to cancel the effect of
postprandial absorption.
+ CEFACLAV 125 Tab. Incepta
Cefuroxime l 25mg as cefuroxime axetil USP &
clavulanic acid 31.25mg as clavulanate potassium
BP/tablet (film-coated).
l 25mg x 18's pack: 324.00 MRP
+ CEFACLAV 250 Tab. Incepta
Cefuroxime 250mg as cefuroxime axetil USP &
clavulanic acid 62.50mg as clavulanate potassium
BP/tablet (film-coated).
250mg x 12's pack: 360.00 MRP
+ CEFACLAV 500 Tab. Incepta
Cefuroxime 500mg as cefuroxime axetil USP &
clavulanic acid 125mg as clavulanate potassium
BP/tablet (film-coated).
500mg x 8's pack: 400.00 MRP
+ CEFUXET Plus Tab. Chemist
Cefuroxime 250mg as cefuroxime axetil USP &
clavulanic acid 62.50mg as clavulanate potassium
USP/tablet (film-coated).
250mg x 12's pack: 360.00 MRP
+ CLAVUSEF 125 Tab. Opsonin
Cefuroxime 125mg as cefuroxime axetil USP &
clavulanic acid 3 l .25mg as clavulanate potassium
USP/tablet (film-coated).
125mg x 12's pack: 190.02 MRP
+ CLAVUSEF 250 Tab. Opsonin
Cefuroxime 250mg as cefuroxime axetil USP &
clavulanic acid 62.50mg as clavulanate potassium
USP/tablet (film-coated).
250mg x 12's pack: 316.69 MRP
+ CLAVUSEF 500 Tab. Opsonin
Cefuroxime 500mg as cefuroxime axetil USP &
clavulanic acid 125mg as clavulanate potassium
USP/tablet (film-coated).
500mg x 6's pack: 263.90 MRP
+ CLAVUSEF Susp. Opsonin
Cefuroxime 12�mg as cefuroxime axetil USP &
clavulanic acid 31.25mg as clavulanate potassium
USP/5ml: suspension.
70ml bot: 221.68 MRP
+ FUCLAV-125 Tab. Drug Inter.
Cefuroxime 125mg as cefuroxime axetil USP &
clavulanic acid 3 l .25mg as clavulanate potassium
USP/tablet (film-coated).
125mg x 14's pack: 252.00 MRP
I with a history of colitis.
•
+ FUCLAV-250 Tab. Drug Inter
I In patients with transient or persistent renal
•
II Cefuroxime 250mg as cefuroxime axetil USP &
clavulanic acid 62.50mg as clavulanate potassium
USP/tablet (film-coated).
I 250mg x 14's pack: 420.00 MRP
+ FUCLAV-500 Tab. Drug Inter.
Cefuroxime 500mg as cefuroxime axetil USP &
clavulanic acid 125mg as clavulanate potassium
USP/tablet (film-coated).
500mg x l 4's pack: 700.00 MRP
+ FUCLAV Susp. Drug Inter.
Cefuroxime l 25mg as cefuroxime axetil USP &
clavulanic acid 3 l .25mg as clavulanate potassium
USP/5ml: suspension.
70ml bot: 250.00 MRP
+ FUROCLAV 250 Tab. Renata
QIMP-17 (249)
Cefuroxime 250mg as cefuroxime axetil USP &
clavulanic acid 62.50mg as clavulanate potassium
USP/tablet (film-coated).
250mg x 12's pack: 360.00 MRP
+ FUROCLAV 500 Tab. Renata
Cefuroxime 500mg as cefuroxime axetil USP &
clavulanic acid 125mg as clavulanate potassium
USP/tablet (film-coated).
500mg x 8's pack: 400.00 MRP
Third generadon
CEFDINIR42
CEFDINIR: Capsule
Cefdinir is a third generation semisynthetic
cephalosporin antibiotic. It has a broad spectrum
bactericidal activity against a wide range of
common pathogens, including b-lactamase
producing strains. Cefdinir has good stability to
bacterial b-lactamase and consequently is active
against many ampicillin-resistant and
amoxycillin-resitant strains.
Cefdinir is available as capsule of cefdinir INN
300mg and as dry powder suspension containing
cefdinir INN l 25mg/5ml; 60ml bottle.
Mode of action: See above under the text of
'cephalexin'.
Ind: Cefdinir is indicated for the treatment of- i.
community acquired pneumonia, ii. acute
exacerbation of chronic bronchitis, iii. acute
maxillary sinusitis, iv. pharyngitis, & tonsillitis,
v. uncomplicated skin & skin structure infection.
C/I: Known hypersensitivity to the cephalosporin
group of antibiotics.
S/E: In clinical trials, most adverse events were
found mild & self-limiting; about 3% of patients
discontinued medication due to adverse events
thought to be due to cefdinir therapy, the adverse
effects were primarily gastrointestinal distur­
bances, usually diarrhea or nausea; about 0.4%
patients discontinued the therapy due to rash,
thought to be related to cefdinir administration.
Precautions: As with other broad spectrum
antibiotics, prolonged treatment with cefdinir
may result in the possible emergence and over­
growth of resistant organisms. Careful observa­
tion of the patient is essential. If superinfection
occurs during therapy, appropriate alternative
antibiotic should be administered.
As with other broad spectrum antibiotics, cefdinir
should be prescribed with caution in individuals
insufficiency (creatinine clearance <30ml/min),
the total daily dose of cefdinir should be reduced.
Pregnancy & lactation: Cefdinir was not found
teratogenic in animal studies. But, there are no
adequate and well-controlled studies available in
pregnant women. Because animal reproduction
studies are not always predictive of human
response, this drug should be used during
pregnancy only if clearly needed.
Dosage & admin: Adults and adolescents (13
years and older): The recommended total
daily dose for all infections is 600mg. 600mg
once-daily dosing or 300mg twice-daily dosing
for 10 days is equally effective in all cases. The
ANTIMICROBIAL DRUGS
dosage and duration of treatment for different
infections in adults and adolescents are given
as following:
i. Community acquired pneumonia- 300mg 12
hourly for 10 days; ii. Acute exacerbation of
chronic bronchitis- 300mg 12 hourly for 5-10
days or 600mg once-daily for 10 days; iii.
Acute maxillary sinusitis- 300mg 12 hourly for
10 days or 600mg once-daily for 10 days; iv.
Pharyngitis/tonsillitis- 300mg 12 hourly for 5-
10 days or 600mg once-daily for 10 days; v.
Uncomplicated skin and skin structure
infections- .300mg 12 hourly for 10 days.
Pediatric patients (6 months through 12 yrs):
i. Acute bacterial otitis media- 7mg/kg 12
hourly for 5-10 days or 14mg/kg once-daily
for 10 days; ii. Acute maxillary sinusitis-
7mg/kg 12 hourly for 10 days or 14mg/kg
once-daily for 10 days; iii. Pharyngitis/Tonsi­
llitis- 7mg/kg 12 hourly for 5-10 days or
14mg/kg once-daily for 10 days; iv. Uncompli­
cated skin and skin structure infections- 7mg/
kg 12 hourly for 10 days.
Cefdinir may be taken without regard to meals.
+ ADINIR Cap. Acme
Cefdinir INN 300mg/capsule
300mg x 8's pack: 361.28 MRP
+ ADINIR Susp. Acme
Cefdinir INN 125mg/5ml: dry suspension
60ml bot: 175.66 MRP
+ CEFEXTA Cap. UniMed & UniHealth
Cefdinir USP 300mg/capsule
300mg x 4's pack: 228.00 MRP
+ CEFEXTA Susp. UniMed & UniHealth
Cefdinir USP l 25mg/5ml: dry suspension
60ml bot: 225.00 MRP
+ CEFEXTA Forte Susp. UniMed & UniHealth
Cefdinir USP 250mg/5ml: dry suspension
(double strength)
30ml bot: 210.00 MRP
+ CEFIDA Cap. Beximco
Cefdinir INN 300mg/capsule
300mg x 8's pack: 360.00 IP
+ CEFIDA Susp. Beximco
Cefdinir INN l 25mg/5ml: dry suspension
60ml bot: 176.00 IP
+ PALCEF Cap. Renata
Cefdinir INN 300mg/capsule
300mg x 1O's pack: 450.00 MRP
+ PALCEF Susp. Renata
Cefdinir INN l 25mg/5ml: dry suspension
60ml bot: 175.00 MRP
+ PALCEF DS Susp. Renata
Cefdinir INN 250mg/5ml: dry suspension
(double strength)
30ml bot: 160.00 MRP
CEFDITOREN87
CEFDIT OREN: Tablet
Cefditoren is a third generation broad spectrum
cephalosporin antibiotic for oral administration.
It is a bactericidal antibiotic and is stable to
hydrolysis by many beta-lactamases. It is availa­
ble as- cefditoren INN 200mg/tablet.
Mode of action: Cefditoren kills bacteria by
interfering the synthesis of the bacterial cell wall.
-
Ind: Acute bacterial exacerbation of chronic
bronchitis, community-acquired pneumonia,
ANTIMICROBIAL DRUGS
pharyngitis/tonsillitis, uncomplicated skin and
skin-structure infections.
C/I: Cefditoren is contraindicated in patients
with hypersensitivity to cefditoren, any other
cephalosporin or penicillins.
S/E: Most common side effects are mild and self­
limiting, which include- diarrhea, nausea, vaginal
-
monilisis and headache.
Precautions: Cefditoren should be prescribed
with caution in individuals with a history of
gastrointestinal colitis.
Pregnancy & lactation: Pregnancy category B.
'
There are no adequate and well-controlled studies
of cefditoren in pregnant woinen. Cefditoren
should be used during pregnancy only if clearly
needed. Cefditoren has reported to appear in
breast milk. Therefore, it is not recommended for
mursing mothers if not clearly needed.
Dosage & admin: Adults & adolescents (12
years & older):
Community-acquired pneumonia- 400mg 12
hourly for 14 days.
Acute bacterial exacerbation of chronic
bronchitis- 400mg 12 hourly for 10 days.
Pharyngitis/tonsillitis- 200mg 12 hourly for 10
days.
Uncomplicated skin & skin structure in/ections-
200mg 12 hourly for 10 days.
Children (12 years & older): Respiratory tract
infections- 6mg/kg twice daily for 10 days.
Renal impaired patients: No dose adjustment is
necessary for patients with mild renal
impairment. It is recommended that not more
than 200mg 12 hourly be administered to
patients with moderate renal impairment and
200mg QD be administered to patients with
severe renal impairment. The appropriate
dose in patients with end-stage renal disease
has not been determined.
Hepatic impaired patients: No dose adjustment
is necessary for patients with mild to moderate
hepatic impairment.
+ CEFDITOR 200 Tab. Orion Pharma
Cefditoren INN 200mg/tablet.
200mg x S's pack: 1200.00 MRP
CEFETAMET26
CEFETAME T PIVOXII, HCl: Tablet
Cefetamet pivoxil is a third-generation
cephalosporin antibiotic which is hydrolyzed to
form the active ingredient. It is available as
cefetamet pivoxil hydrochloride 250mg & 500mg
tablet for oral use.
Mode of action: Cefetamet as a cephalosporin
antibiotic, it is bactericidal in action and kills
bacteria by interfering with bacterial cell wall
synthesis due to inhibition of transpeptidase
enzyme. Cefetamet has excellent in vitro activity
against the major respiratory pathogens­
Streptococcus pneunoniae, Haemophilus
injluenzae, Moraxella catarrhalis and group A
haemolytic streptococci. It is also active against -
lactamase- producing strains of H injluenzae and
QIMP-17 (250)
M. catarrhalis. Cefetamet has marked activity
against Neisseria gonorrhoeae and possesses a
broad spectrum of activity against
Enterobacteriaceae.
Ind: Cefetamet pivoxil is indicated for the
treatment of infections caused by sensitive
microorganisms and in particular: l . Otolaryngeal
infections: Otitis media, Sinusitis, Tonsillo­
pharyngitis. 2. Infections of the lower respiratory
tract: Tracheo-bronchitis, Bronchitis, Pne11monia.
3. Infections of the complicated & uncomplicated
urinary tract: Acute pyelonephritis, Acute· " ·
gonorrhea, Urethritis.
C/I: Cefetamet is contraindicated in patients with
hypersensitivity to cefetamet, any other
cephalosporin or penicillins or any other
ingredient of this formulation.
S/E: Most common gastrointestinal side effects
may include- diarrhea, nausea & vomiting. Like
other wider spectrum antibiotics, in the course of
treatment with cefetamet internal colonization
from difficult clostridium can be observed. In
some cases, this microorganism or its toxin has
been indentified; in rare cases this reply has been
accompanied from diarrhea. Very rarely cefe­
tamet may cause gastralgia, flatulence, pyrosis,
increase in bilirubin level, transitory increase of
the transaminases, pruritus, urticaria, localized
edema, rash, weakness, fatigue, vertigo, transito­
ry leukopenia, eosinophilia, gingivitis, proctitis,
vaginitis, tendinitis, conjunctivitis, and fever.
Precautions: Cefetamet should be administered
with caution to the patients who have previously
manifested allergy phenomena or gastrointestinal
problems. An anaphylactic reaction demands an
emergency treatment. Like with other antibiotics,
cefetamet can cause the opportunistic
development of non-sensitive germs (Candida,
Enterococci, and difficile Clostridiun), in such
cases, a suitable therapy should be given.
Discontinuation of the antibiotic helps to restore
the normal microflora and the internal functions.
In presence of difficile clostridium cases, the
treatment of choice is vancomycin for oral use
and the inhibiting drug of the peristalsis are
contraindicated.
Pregnancy & lactation: The main preclinical
studies carried out with cefetamet have not evi­
denced teratogenic effects. There are no available
data regarding safe use of cefetamet during preg­
nancy & lactation. Therefore, it should be used
during pregnancy & lactation only if the potential
benefit justifies the potential risk to the fetus.
Dosage & admin: For better absorption
Cefetamet pivoxil should be taken one hour
before or after a meal.
Adults & children over 12 years: SOOmg twice
daily.
Children under 12 years: Usual dosage is
lOmg/kg twice daily. <IS kg (approximately 6
months- 3 years), 125mg twice daily; 16-30 kg
(approximately 3-9 years), 2S0mg twice daily;
- 31-40 kg (approximately 9-12 years), 37Smg
twice daily; >40 kg (approximately over 12
years), SOOmg twice daily.
Uncomplicated gonorrhea, acute urethritis,
uncomplicated cystitis: Single dose of 1500-
2000mg.
In elderly patients, dosage adjustment is not
necessary.
In the patients with renal insufficiency, dosage
modification is as following:
In patients with hepatic insufficiency, dosage
adjustment is not necessary.
Drug inter: The antacids, and/or the H2-blockers
do not alter the pharmacokinetic profile of
cefetamet; therefore, it can be administered in
combination with these drugs. Concomitant
administration with diuretic (e.g frusemide) does
not reduce renal function.
+ TENAFET Tab. Incepta
C.efetamet pivoxil hydrochloride INN 250mg &
500mg/tablet
250mg x 12's pack: 240.00 MRP
500mg x 12's pack: 420.00 MRP
+ TENAFE T Susp. Incepta
Cefetamet pivoxil hydrochloride INN
125mg/5ml: suspension.
50ml bot: 120.00 MRP
CEFIXIME42,63
CEFIXIME: Tablet/Capsule/Suspension
Ceftxime is a third generation oral cephalosporin.
It has a longer duration of action than the other
oral cephalosporins, & usually given once daily
dose, or in two divided dosage.
Ind: Upper & lower respiratory tract infections;
UTI, gonococcal urethritis; otitis media, sinusitis;
skin and soft-tissue infections.
C/I; S/E; Caution: See above under Cefetamet.
Dosage & admin: Adult & child over 10 yeras,
200-400mg daily according to the severity of
infection, given either in a single or 2 divided
doses. Elderly patients may be given the same
dose as recommended for adults. Renal
function should be assessed and dosage should
be adjusted in severe renal i.mpairment. Child
over 6 months 8mg/kg daily in single or 2
divided doses. Or as a general guide of
dosage, may be given as following- 6 months
to 1 year 7Smg daily; 1-4 years lOOmg daily;
S-10 years 200mg daily. In typhoid dosage
should be lOmg/kg/day for 14 days.
The usual course of treatment is 7 days. T his
may be continued for up to 14 days as in
typhoid or in any severe infection if the
physicians desire.
Dosage in Renal impairment: CefIXime may be
administered in the presence of impaired renal
function. Normal dose and schedule may be
maintained in patients with creatinine
clearances of 20ml/min or greater. In patients
whose creatinine clearance is less than
20ml/min, it is recommended that a dose of
200mg once daily should not be exce-eded. The
dose and regimen for patients who are main­
tained on chronic ambula-tory peritoneal dial­
ysis or haemodialysis should follow the same
 QIMP-17 (251) ANTIMICROBIAL DRUGS

recommendation as that for patients with 400mg x 8's pack: 400.00 MRP
creatinine clearances of less than 20ml/min. t BIOXIM Susp. Sharif
Cefixime trihydrate l 00mg/5ml: suspension.
30ml bot: 120.00 MRP
- .
50ml bot: 160.00 MRP.
- + CEBEX Cap. Novo Healthcare
CefIXime trihydrate 200mg & 400mg/capsule.
Cefixime USP
. . .. . 200mg x 8's pack: 240.00 MRP
,. ,1 1'1'.:: V" • • .. '.1;11
400mg x 4's pack: 200.00 MRP
� � ·� .... li""T:fl' �· t;• Al
...... ..
L"
•
..

.. "".· . • •
-
•
• - 'r4"- ..,...i
· ... ,,,.;: •

i)
•

•• • ... • . • . ·

. :>

DRUG INTEANATUUL LTD. + CEBEX Susp. Novo Healthcare

+ ADEXIM Cap. Supreme
Cefixime trihydrate 200mg/capsule.
200mg x 6's pack: 180.00 MRP
+ ADEXIM Susp. Supreme
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 160.00 MRP
+ AFIX Cap. Aristopharma
Ce fixime trihydrate 200mg & 400mg/capsule.
200mg x 12's pack: 360.00 MRP
400mg x 's pack: 200.00 MRP
+ AFIX Susp. Aristopharma
Cefixime trihydrate l 00mg/5ml: suspension.
30ml bot: 120.00 MRP
50ml bot: 195.00 MRP
+ AFIX DS Susp. Aristopharma
Cefixime trihydrate 200mg/5ml: suspension
(double strength)
30ml bot: 195.00 MRP
50ml bot: 280.00 MRP
+ Cap. Asiatic
Cefixime trihydrate 200mg & 400mg/capsule.
200mg x 12's pack: 360.00 MRP
400mg x 4's pack: 200.00 MRP
t AFIXIME Susp. Asiatic
Cefixime trihydrate 100mg/5ml: suspension.
37.50ml bot: 130.00 MRP
50ml bot: 160.00 MRP
t AMU CEF Cap. Amulet
Cefixime trihydrate 200mg & 400mg/capsule.
200mg x 12's pack: 360.00 MRP
400mg x 6's pack: 300.00 MRP
t AMUCEF Susp. A.mulet
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP
+ ANTIMA Cap. Jayson
Ceftxime trihydrate 200mg & 400mg/capsule.
200mg x 4's pack: 120.00 IP
400mg x 4's pack: 200.00 IP
+ ANTIMA Susp. Jayson
Cefixime trihydrate l 00mg/5ml: suspension.
50ml bot: 185.00 IP
+ AX 3 Cap. Apollo
Cefixime trihydrate 200mg/capsule.
200mg x 12's pack: 360.00 MRP
+ AX 3 Susp. Apollo
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 160.00 MRP
t BESTCEF Cap. Biopharma
Ce fixime trihydrate 200mg & 400mg/capsule.
200mg x 15's pack: 525.00 MRP
400mg x 8's pack: 401.52 MRP
t BESTCEF Susp. Biopharma
Cefixime trihydrate 100mg/5ml: suspension.
37:5ml bot: 13·0.49 MRP
Ce fixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP
+ C-3 Tab. Astra
Ceftxime trihydrate 200mg/capsule.
200mg x 6's pack: 180.00 MRP
+ C-3 Susp. Astra
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP
Switch thera + CEF-3 Tab. Square
Ceftxime trihydrate USP 200mg/tablet.
200mg x lO's pack: 350.00 MRP
t CEF-3 DS Tab. Square
Cefixime trihydrate USP 400mg/tablet (double
strength).
400mg x 6's pack: 300.00 MRP
+ CEF-3 Cap. Square
-
Cefixime trihydrate 200mg/capsule.
200mg x 12's pack: 420.00 MRP
Cefixime t CEF-3 DS Cap. Square
Ce fixime trihydrate 400mg/capsule (double
Sure shot strength).
to cure 400mg x 6's pack: 301.20 MRP
+ CEF-3 Susp. Square
Cefixime trihydrate 100mg/5ml: suspension.
30ml bot: 120.46 MRP
40ml bot: 150.57 MRP
50ml bot: 195.74 MRP
+ CEF-3 Forte Susp. Square
Cefixime trihydrate 200mg/5ml: suspension
50ml bot: 280.00 MRP
t CEFADYL Cap. Kumudini
Ceftxime trihydrate 200mg/capsule.
200mg x 8's pack: 240.00 MRP
t CEFADYL Susp. Kumudini
Cefixime trihydrate 100mg/5ml: suspension.
• 100% effective in Typhoid fever 50ml bot: 180.00 MRP
t CEFERON-3 Cap. Aexim
and Pneumonia
Ce fixime trihydrate 200mg/capsule.
200mg x 12's pack: 300.00 MRP
• Better choice in UTls t CEFERON-3 Susp. Aexim
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 150.00 MRP
• Wide satety margin in pregnancy
t CEFESTA-200 Cap. APC Pharma
Ceftxime trihydrate 200mg/capsule.
• Sure shot therapy in common 200mg x S's pack: 240.00 MRP
t CEFESTA Susp. APC Pharma
ENT infections Cefixime trihydrate BP 100mg/5ml: suspension.
50ml bot: 160.00 MRP
• Equal efficacy as parenteral + CEFICAP Cap. Euro Pharma
Cefixime trihydrate 200mg & 400mg/capsule.
ceftriaxoqe 200mg x 8's pack: 240.00 MRP
400mg x 8's pack: 400.00 MRP
+ CEFICAP Susp. Euro Pharma
Ceftxime trihydrate l 00mg/5ml: suspension.
50ml bot: 195.00 MRP
.
. .· t CEFmf�3 �ap. ACI ..·: ... ..
. . : . .,

.
' �-
. .
·
:· , • , · ..
· t •·. ,

50ml bot:· l 95.74' MRP .

.

·
.
·
�
·

. .�

. ·ce�� trihydrate 20omg1cap·sul e�·

" .

.�
�

' f
.• . •

,,,.,.- � • 1.
'.. . ... ·. > . -.,.
· . ... .
.,. ..
' '.

.
• -
, ,

..
g . x · 12•s
I
� . ....

· �oolli pack: 36Q.OO MRP .

• •

L. .
. •" : . ..... , .
. ;•

·
; . . .

t BIOXIM Cap. Sharif

. ·. . ,. ' ...

. . .
' ' .

. ..t .
• . . 't ,
, . ..
.
-
.

Ceftxime trihydrate 200mg & 400mg/capsule. . t CEFIJ"-3 DS Cap •. ACI .

. .
·
.

· . . .
. .

200mg
. x 8's pack: 240.00 MRP Cefixime :trihydnlte 400µig/capsule (double ·

.
. · . .

1-,.
� .. . -·
.
.
•

ANTIMICROBIAL DRUGS
strength).
400mg x 6's pack: 301.14 MRP
+ CEFIM-3 Susp. ACI
Cefixime trihydrate 100mg/5ml: suspension.
30ml bot: 120.45 MRP
50ml bot: 195.00 MRP
75ml bot: 240.90 MRP
+ CEFIM-3 DS Susp. ACI
Cefixime trihydrate 200mg/5ml: suspension
(double strength).
50ml bot: 280.00 MRP
+ CEFIX Cap. Globe
Cefixime trihydrate 200mg & 400mg/capsule.
200mg x 8's pack: 240.00 MRP
400mg x 4's pack: 180.00 MRP
t CEFIX Susp. Globe
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 180.00 MRP
+ CEFIXIM Cap. Ibo Sina
Cefixime trihydrate 200mg & 400mg/capsule.
200mg x 12's pack: 420.00 IP
400mg x 8's pack: 400.00 IP
t CEFIXIM Susp. Ibn Sina
Cefixime trihydrate 100mg/5ml: suspension.
30ml bot: 130.00 IP
40ml bot: 150.00 IP
50ml bot: 200.00 IP
+ CEFIXIME-A Cap. Ad-din
Cefixime trihydrate 200mg/capsule.
200mg x 5's pack: 125.00 MRP
+ CEFIXIME-A Susp. Ad-din
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 160.00 MRP
+ CEFMIX Cap. MonicoPharma
Cefixime trihydrate 200mg & 400mg/capsule
200mg x 12's pack: 360.00 MRP
400mg x 8's pack: 400.00 MRP
•
+ CEFMIX Susp. MonicoPharma
Cefixime trihydrate USP 100mg/5ml: suspension.
50ml bot: 180.00 MRP
+ CEFOCEF Cap. Pharmadesh
Cefixime trihydrate 200mg/capsule.
200mg x 8's pack: 200.72 MRP
+ CEFOCEF DS Cap. Pharmadesh
Cefixime trihydrate 400mg/capsule.
400mg x 4's pack: 180.64 MRP
+ CEFOCEF Susp. Pharmadesh
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 175.00 MRP
+ CEF-PLUS Cap. Hudson
Cefixime trihydrate 200mg/capsule.
200mg x 12's pack: 336.00 MRP
+ CEF-PLUS Susp. Hudson
c.efixime trihydrate 100mg/5ml: suspension.
50ml bot: 170.00 MRP
+ CEFTID Tab. Opsonin
Cefixime trihydrate 200mg & 400mg/tablet
200mg x 12's pack: 369.47 MRP
400mg x 6's pack: 264.91 MRP
+ CEFTID Cap. Opsonin
Cefixime trihydrate 200mg & 400mg/capsule.
200mg x 12's pack: 369.47 MRP
400mg x 6's pack: 264.91 MRP
+ CEFTID Susp. Opsonin
I •
------����---· iiii
... . iii
QIMP-17 (252)
Cefixime trihydrate 100mg/5ml: suspension. + ELEXIM Susp. Reliance
37.5ml bot: 114.79 MRP Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 172.19 MRP 50ml bot: 160.00 MRP
t CEFTID DS Susp. Opsonin t EMIXEF Cap. Inc_epta
Cefixime trihydrate 200mg/5ml: suspension Cefixime trihydrate 200mg & 400mg/capsule.
(double strength) 200mg x 12's pack: 360.00 MRP
50ml bot: 282.57 MRP 400mg x 4's pack: 200.00 MRP
+ CEFTID Drop Opsonin t EMIXEF Susp. Incepta
Cefixime trihydrate 25mg/ml: pediatric drop. Cefixime trihydrate 100mg/5ml: suspension.
2lml bot: 86.21 MRP 30ml bot: 120.00 MRP
+ CEMIX-3 Cap.· Seema 40ml bot: 150.00 MRP
Cefixime trihydrate 200mg/capsule. 50ml bot: 180.00 MRP
200mg x 8's pack: 240.00 MRP t EMIXEF DS Susp. Incepta
Cefixime trihydrate 200mg/5ml: suspension
+ CEMIX-3 Susp. Seema
(double strength)
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP 50ml bot: 280.00 MRP
+ CEPHORAL Cap. Labaid Pharma + ERAFIX 200 Cap. Virgo
Cefixime trihydrate 200mg & 400mg/capsule. Cefixime trihydrate USP 200mg/capsule.
200mg x 14's pack: 490.00 MRP 200mg x 8's pack: 240.00 MRP
400mg x 7's pack: 385.00 MRP + ERAFIX Susp. Virgo
Cefixime trihydrate USP 100mg/5ml: suspension.
+ CEPHORAL Susp. Labaid Pharma
Cefixime trihydrate 100mg/5ml: suspension. 30ml bot: 120.00 MRP
50ml bot: 200.00 MRP 40ml bot: 140.00 MRP
+ CEXIME Cap. GlaxoSmithKline 50ml bot: 170.00 MRP
CefIXime trihydrate 200mg & 400mg/capsule. t EVEXIM Cap. Everest
200mg x 14's pack: 421.56 MRP Cefixime trihydrate 200mg & 400mg/capsule.
400mg x 7's pack: 350.00 MRP 200mg x 6's pack: 144.00 MRP
400mg x 6's pack: 270.00 MRP
+ CEXIME Susp. GlaxoSmithKline
Cefixi�e trihydrate 100mg/5ml: suspension. + EVEXIM Susp. Everest
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.74 MRP
50ml bot: 155.00 MRP
+ DEFIM-3 Cap. Decent
Cefixime trihydrate 200mg/capsule. t EXCEF Cap. Chemist
200mg x 8's pack: 224.00 MRP Cefixime trihydrate 200mg/capsule.
200mg x l 2's pack: 360.00 MRP
+ DEFIM-3 Susp. Decent
CefIXime trihydrate 100mg/5ml: suspension. + EXCEF Susp. Chemist
60ml bot: 156.00 MRP Ce fixime trihydrate 100mg/5ml: suspe°'sion.
50ml bot: 175.00 MRP
+ DENVAR Cap. Healthcare
Cefixime trihydrate ipomg & 400mg/capsule. t FICS 200 Cap. NIPRO JMI
200mg x 12's pack: 420.00 MRP Cefixime trihydrate 200mg/capsule.
200mg x 12's pack: 361.44 MRP
400mg x 6's pack: 300.00 MRP
+ DENVAR Susp. Healthcare + FICS 400 Cap. NIPRO JMI
Cefixime trihydrate 100mg/5ml: suspension. Cefixime trihydrate 400mg/capsule.
400mg x 8's pack: 401.52 MRP
50ml bot: 195.00 MRP
+ DENVAR DS Susp. Healthcare + FICS Susp. NIPRO JMI
Cefixime trihydrate 200mg/5ml: suspension Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.74 MRP
(double strength).
37.5ml bot: 225.00 MRP + FIX-A Cap. Acme
+ D-FIX Cap. Desh Pharma Cefixime trihydrate 200mg/capsule.
200mg x 12's pack: 361.32 MRP
Cefixime trihydrate 200mg/capsule.
200mg x 6's pack: 150.00 IP + FIX-A DS Cap. Acme
200mg x 12's pack: 300.00 IP Cefixime trihydrate 400mg/capsule (double
strength).
+ D-FIX Susp. Desh Pharma
Cefixime trihydrate 100mg/5ml: suspension. 400mg x 8's pack: 401.60 MRP
50ml bot: 160.00 IP + FIX-A Susp. Acme
+ DURACEF Cap. Navana Cefixime trihydrate 100mg/5ml: suspension.
Cefixime trihydrate 200mg & 400mg/capsule. 37.5ml bot: 130.49 MRP
200mg x 12's pack: 361.32 IP 50ml bot: 175.66 MRP
400mg x 12's pack: 602.28 IP 75ml bot: 240.00 MRP
t DURACEF Susp. Navana + FIX-A DS Susp. Acme
Cefixime trihydrate 100mg/5ml: suspension. Cefixime trihydrate 200mg/5ml: suspension
30ml bot: 120.44 MRP (double strength).
50ml bot: 180.00 MRP 50ml bot: 280.00 MRP
t ELEXIM 200 Cap. Reliance + FIXBAC Cap. RAK Pharma
Cefixime trihydrate 200mg/capsule. Cefixime trihydrate 200mg & 400mg/capsule.
200mg x 12's pack: 420.00 MRP 200mg x 12's pack: 420.00 MRP
.9'- �.9-M
•••
•••
r::&l
l,gJ �!�u
•ANGt.ADCSH
LTD. www.squarepharma.com.bd •••
MCIAM
 •

QIMP-17 (253) ANTIMICROBIAL DRUGS

400mg x 6's pack: 300.00 MRP
t FIXBAC Susp. RAK Pharma
Cefixime trihydrate 100mg/5ml: suspension.
30ml bot: 140.00 MRP
50ml bot: 200.00 MRP
+ G-CEFIXIME Cap. Gonoshas
200mg x lO's pac�: 300.00 MRP
+ KEOR DS Cap. Rephco
Cefixime trihydrate 400mg/capsule.
400mg x 8's pack: 400.00 MRP
+ KEOR Susp. Rephco
Cefixime trihydrate 100mg/5ml: suspension.
.
+ NGCEF Cap. Rangs Pharma
Cefixime trihydrate 200mg/capsule.
200mg x 6's pack: 180.00 MRP
+ NGCEF Susp. Rangs Pharma
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP

Cefixime trihydrate 200mg/capsule.
200mg x 8's pack: 160.00 MRP
+ G-CEFIXIME Susp. Gonoshas
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 130.00 MRP
+ GEN-3 Cap. Amico
Cefixime trihydrate 200mg/capsule.
200mg x S's pack: 135.00 MRP
+ GEN-3 Susp. Amico
Cefixime trihydrate I 00mg/5ml: suspension.
r
-
50ml bot: 175.00 MRP
+ G-FIX Cap. Gaco
Ceftxime trihydrate 200mg/capsule.
200mg x 4's pack: 120.00 MRP
+ G-FIX Susp. Gaco
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP
t HYXIM-200 Cap. Millat
Cefixime trihydrate 200mg/capsule.
200mg x 6's pack: 180.00 MRP
50ml bot: 160.00 MRP
+ KURACEF Tab. Sanofi-aventis
Cefixime trihydrate 200mg & 400mg/tablet
200mg x 12's pack: 361.32 MRP
400mg x 8's pack: 401.52 MRP
+ KURACEF Susp. Sanofi-aventis
Cefixime trihydrate 100mg/5ml: suspension.
30ml bot: 120.00 MRP
50ml bot: 195.74 MRP
+ LOXIM Tab. Techno Drugs
Cefixime trihydrate 200mg/tablet.
200mg x 12's pack: 300.00 MRP
+ LOXIM DS Tab. Techno Drugs
Ceftxime trihydrate 400mg/tablet (double
strength).
400mg x 6's pack: 270.00 MRP
+ LOXIM Susp. Techno Drugs
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 190.00 MRP
+ MICROCEF Cap. Concord
+ NOVACEF 200 Cap. Novus
Cefixime trihydrate 200mg/capsule.
200mg x 12's pack: 360.00 MRP
+ NOVACEF Susp. Novus
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP
+ ODACEF Cap. UniMed & UniHealth
Cefixime trihydrate 200mg & 400mg/capsule.
200mg x 8's pack: 240.00 MRP
400mg x 4's pack: 200.00 MRP
+ ODACEF Susp. UniMed & UniHealth
Cefixime trihydrate 100mg/5ml: suspension.
30ml bot: 120.00 MRP
50ml bot: 195.00 MRP
+ OFEX Cap. Delta Pharma
Cefixime trihydrate 200mg & 400mg/tablet (f.c).
200mg x 12's pack: 300.00 MRP
400mg x 4's pack: 160.00 MRP
+ OFEX Susp. Delta Pharma
Cefixime trihydrate 100mg/5ml: suspension.
•

a Novarlis company

Cefixime USP

Strong & efficient

+ HYXIM Susp. Millat Cefixime trihydrate USP 200mg & 50ml bot: 170.00 MRP
Cefixime trihydrate 100mg/5ml: suspension. 400mg/capsule. + ORCEF Tab. Renata
50ml bot: 195.00 MRP 200mg x 12's pack: 360.00 MRP Cefixime trihydrate 200mg & 400mg/tablet (f.c).

+ INFA-3 Cap. Novelta
Cefixime trihydrate 200mg & 400mg/capsule.
200mg x 12's pack: 420.00 IP
400mg x 8's pack: 400.00 MRP
+ INFA-3 Susp. Novelta
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP
+ KEFIM Cap. Kemiko
400mg x 8's pack: 400.00 MRP
+ MICROCEF Susp. Concord
Cefixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP
+ NEOFEXIM Cap. Doctor's
Cefixime trihydrate 200mg/capsule.
200mg x 8's pack: 200.00 MRP
+ NEOFEXIM Susp. Doctor's
200mg x 6's pack: 180.00 MRP
200mg x 12's pack: 361.32 MRP
400mg x 6's pack: 300.00 MRP
+ ORCEF Cap. Renata
Cefixime trihydrate 200mg/capsule.
200mg x 16's pack: 481.76 MRP
+ ORCEF Susp. Renata
Cefixime trihydrate 100mg/5ml: suspension.

Cefixime trihydrate 200mg & 400mg/capsule. Cefixime trihydrate 100mg/5ml: suspension. 30ml bot: 135.51 MRP
200mg x 8's pack: 240.00 MRP 50ml bot: 175.00 MRP 40ml bot: 155.58 MRP

400mg x 4's pack: 220.00 MRP + NEOFIX Cap. Modern 50ml bot: 195.74 MRP

+ KEFIM Susp. Kemiko Cefixime trihydrate 200mg/capsule. 70ml bot: 225.00 MRP

Cefixime trihydrate 100mg/5ml: suspension. 200mg x 4's pack: 100.00 MRP + ORFIX-200 Cap. Mystic
37.Sml bot: 130.00 MRP 200mg x 8's pack: 200.00 MRP Cefixime trihydrate 200mg/capsule
50ml bot: 195.00 MRP + NEOFIX Susp. Modern 200mg x 4's pack: 100.00 MRP

+ KEOR-200 Cap. Rephco Cefixime trihydrate 100mg/5ml: suspension. + ORFIX Susp. Mystic
Cefixime trihydrate 200mg/capsule. 50ml bot: 180.00 MRP Cefixime trihydrate 100mg/5ml: suspension.

I
 QIMP-17 (254)

Ceflxlme 200 mg & 400 mg Capsule

&100 mg /5 ml PFS
t STARCEF Cap. Beacon
Ceftxime trihydrate 200mg/capsule.
® 200mg x 8's pack: 240.00 MRP
1\pex
t STARCEF Susp. Beacon
' '
�
.
. . .

Cefixime trihydrate 100mg/5ml: suspension.

50ml bot: 160.00 MRP 50ml bot: 195.00 MRP
t ORGAXIM Cap. Organic Health t SUFFIX-200 Cap. SAPL
Cefixime trihydrate USP 200mg & Cefixime trihydrate 200mg/capsule.
400mg/capsule. 200mg x 12's pack: 300.00 MRP
200mg x 12's pack: 360.00 MRP t SUFFIX Susp. SAPL
400mg x 8's pack: 400.00 MRP Cefixime trihydrate 100mg/5ml: suspension.
t ORGAXIM Susp. Organic Health 50ml bot: 160.00 MRP
Cefixime trihydrate USP 100mg/5ml: suspension. + SUP� Cap. Cosmic
50ml bot: 195.00 MRP Cefixime trihydrate 200mg/capsule.
75ml bot: 240.00 MRP 200mg x 12's pack: 360.00 MRP
t PREXIM Cap. Ziska t SUPRAX DS Cap. Cosmic
Cefixime trihydrate 200mg/capsule. Cefixime trihydrate USP 400mg/capsule (double
200mg x 12's pack: 360.00 MRP strength).
t PREXIM Susp. Ziska 400mg x 8's pack: 400.00 MRP
Cefixime trihydrate 100mg/5ml: suspension. + SUPRAX Susp. Cosmic
30ml bot: 120.00 MRP Ce fixime trihydrate 100mg/5ml: suspension.
50ml bot: 160.00 MRP 50ml bot: 180.00 MRP
t PROFIX Cap. Medicon t SUPRAXIM Cap. Silva
Cefixime trihydrate 200mg/capsule. Cefixime trihydrate 200mg/capsule.
200mg x 8's pack: 240.00 MRP 200mg x 6's pack: 210.00 MRP
t PROFIX Susp. Medicon t SUPRAXIM Susp. Silva
Cefixime trihydrate 100mg/5ml: suspension. Cefixime trihydrate 100mg/5ml: suspension.
30ml bot: 120.00 MRP
.

30ml bot: 139.00 MRP . . . ,

50ml bot: 175.00 MRP

;

50ml bot: 200.00 MRP

t ROFIXIM Cap. Radiant t T-CEF Cap. Drug Inter. . . ..

Cefixime trihydrate 200mg & 400mg/capsule.

"

Cefixime trihydrate 200mg & 400mg/capsule. ·-.

200mg x 8's pack: 280.00 MRP 200mg x l 4's pack: 420.00 MRP . ..

400mg x 8's pack: 440.00 MRP 400mg x 7's pack: 350.00 MRP ..
•
...�

t ROFIXIM Susp. Radiant

••

+
•. J

T-CEF Susp. Drug Inter.

Cefixime trihydrate 100mg/5ml: suspension. Ce fixime trihydrate 100mg/5ml: suspension.
50ml bot: 200.00 MRP 30ml bot: 130.00 MRP
t ROXIM Cap. SK+F 50ml bot: 175.00 MRP
Cefixime trihydrate 200mg & 400mg/capsule. t T-CEF DS Susp. Drug Inter.
200mg x 16's pack: 560.00 MRP Cefixime trihydrate 200mg/5ml: suspension
400mg x 8's pack: 400.00 MRP (double strength).
t ROXIM Susp. SK+F 50ml bot: 280.00 MRP
Cefixime trihydrate 100mg/5ml: suspension. t TEXIT Cap. Apex
30ml bot: 130.00 MRP Cefixime trihydrate 200mg & 400mg/capsule.
50ml bot: 195.00 MRP 200mg x 8's pack: 240.00 MRP
75ml bot: 225.00 MRP 400mg x 4's pack: 180.00 MRP
t ROXIM XL Susp. SK+F t TEXIT Susp. Apex
Cefixime trihydrate 200mg/5ml: suspension Ce fixime trihydrate 100mg/5ml: suspension.
(extended or double strength). 50ml bot: 160.00 MRP
60ml bot: 320.00 MRP t TGOCEF Cap. Somatec
t SANFIX Cap. Nuvista Cefixime trihydrate 200mg & 400mg/capsule.
Cefixime trihydrate 200mg/capsule. 200mg x l 2's pack: 301.20 MRP
200mg x 7's pack: 269.50 MRP 400mg x 4's pack: 180.68 MRP
+ SANFIX Susp. Nuvista + TGOCEF Susp. Somatec
Cefixime trihydrate 100mg/5ml: suspension. Ce fixime trihydrate 100mg/5ml: suspension.
50ml bot: 195.00 MRP 30ml bot: 130.00 MRP
+ SAVER Cap. Alco Pharma 50ml bot: 195.00 MRP
Cefixime trihydrate 200mg & 400mg/capsule. t TOCEF Cap. General
200mg x 12's pack; 360.00 MRP Cefixime trihydrate 200mg & 400mg/capsule.
400mg x 8's pack: 400.00 MRP 200mg x 12's pack: 361.32 MRP
+ SAVER Susp. Alco Pharma 400mg x 8's pack: 401.52 MRP
Cefixime trihydrate 100mg/5ml: suspension. + TOCEF Susp. General
30ml bot: 120.00 MRP Cefixime trihydrate 1OOmg/Sml: suspension.
50ml bot: 195.00 MRP 37.5ml bot: 130.49 MRP
50ml bot: 195.74 MRP
t SETIC Cap. Sandoz
Cefixime trihydrate 200mg & 400mg/capsule. t TRICEF Cap. Ambee
200mg x 14's pack: 490.00 MRP Cefixime trihydrate 200mg/capsule.
400mg x 14's pack: 770.00 MRP 200mg x 4's pack: 100.40 MRP
+ SETIC Susp. Sandoz t TRICEF Susp. Ambee
Cefixime trihydrate 100mg/5ml: suspension. Cefixime trihydrate 100mg/5ml: suspension
50ml. bot: 200.00 MRP 50ml bot: 160.61 MRP
 QIMP-17 (255) ®

t TRIFIX Cap. Pacific 50ml bot: 195.74 MRP

Cefixime trihydrate 200mg/capsule. t UNIFIX Cap. MST Pharma Cefixime
200mg x 6's pack: 210.00 MRP Cefixime trihydrate 200mg/capsule.
+ TRIFIX Susp. Pacific 200mg x S's pack: 240.00 MRP
Cefixime trihydrate 100mg/5ml: suspension + UNIFIX Susp. MST Pharma
50ml bot: 150.00 MRP Cefixime trihydrate l 25mg/5ml: suspension. Cefixime trihydrate 125mg/5ml: suspension.
t TRIOCEF-200 Cap. Nipa 50ml bot: 160.00 MRP 50ml bot: 160.00 MRP
Cefixime trihydrate 200mg/capsule. + VELOFIX Cap. Pharmasia t 3-GEOCEF Cap. Hallmark
200mg x 12's pack: 360.00 MRP Cefixime trihydrate 200mg & 400mg/capsule. Cefixime trihydrate 200mg/capsule.
t TRIOCEF Susp. Nipa 200mg x l 2's pack: 360.00 MRP. 200mg x 12's pack: 360.00 MRP
Cefixime trihydrate 100mg/5ml: suspension. 400mg x S's pack: 400.00 MRP t 3-GEOCEF Susp. Hallmark
37.5ml bot: 135.00 MRP + VELOFIX Susp. Pharmasia Cefixime trihydrate 125mg/5ml: suspension.
50ml bot: 195.00 MRP Cefixime trihydrate 100mg/5ml: suspension. 50ml bot: 175.00 MRP
t TRIOCIM Cap. Beximco 50ml bot: 195.00 MRP t 3RD CEF Tab. Medimet
Cefixime trihydrate 200mg & 400mg/tablet. t VELOFIX DS Susp. Pharmasia Cefixime trihydrate 200mg & 400mg/tablet (f.c).
200mg x 16's pack: 4SO.OO IP Cefixime trihydrate 200mg/5ml: suspension 200mg x 4's pack: 108.00 MRP
400mg x 6's pack: 300.00 IP (double strength). 400mg x 4's pack: 200.00 MRP
t TRIOCIM Susp. Beximco 37.5ml bot: 225.S5 MRP t 3RD CEF Susp. Medimet
Cefixime trihydrate 100mg/5ml: suspension. t XIFIM Cap. Bristol Cefixime trihydrate 100mg/5ml: suspension.
30ml bot: 120.00 IP Cefixime trihydrate 200mg/capsule. 37.5ml bot: 130.00 MRP
50ml bot: 195.00 IP 200mg x l 2's pack: 360.00 MRP 50ml bot: 160.00 MRP
t TRIOCIM DS Susp. Beximco t XIFIM Susp. Bristol
Cefixime trihydrate 200mg/5ml: suspension Cefixime trihydrate l 25mg/5ml: suspension.
CEFOTAXIME2t,42
(double strength). 50ml bot: 160.00 MRP
50ml bot: 320.00 IP t ZEMICEF Cap. Popular
t TRUSO Cap. Orion Pharma Ceftxime trihydrate 200mg & 400mg/capsule. CEFOTAXIME: Injection

v 200 mg Capsule �_250 mg IM

•
v:__ 400 mg Capsule L�OO mg IM/IV
IX
- �---

.../ 37.5 ml OS PFS

.
.. .../ 1 gm_ IM/IV
.../ 50 ml PFS
-
.../ 2- gm IV
Cefixime teftriaxone -
-

I
A real savior from bacterial infections Simple solution for critical infections

pharmasia A S 0 NY 1!/h RA � <; � Enterprise

Cefixime trihydrate 200mg & 400mg/tablet. 200mg x l 4's pack: 421.54 MRP Cefotaxime is a broad spectrum bactericidal

200mg x 16's pack: 4SO.OO MRP 400mg x S's pack: 401.52 MRP cephalosporin antibiotic. Cefotaxime is

400mg x S's pack: 400.00 MRP t ZEMICEF Susp. Popular exceptionally active in-vitro against gram­
+ TRUSO Susp. Orion Pharma Cefixime trihydrate 100mg/5ml: suspension. negative organisms sensitive or resistant to first

Cefixime trihydrate l 25mg/5ml: suspension. 30ml bot: 120.45 MRP or second generation cephalosporins. It is similar

37.5ml bot: 130.49 MRP 40ml bot: 150.56 MRP to other cephalosporins in activity against gram­
50ml bot: 160.60 MRP 50ml bot: 195.74 MRP positive organisms.

t TRUSO DS Susp. Orion Pharma t ZEMICEF DS Susp. Popular Ind: Respiratory infections- such as acute or
Cefi�ime trihydrate 200mg/5ml: suspension Cefixime trihydrate 200mg/5ml: suspension. chronic bronchitis, bacterial pneumonia, infected
(double strength). 50ml bot: 321.20 MRP bronchiectasis, lung abscess and post operative
50ml bot: 2SO.OO MRP t ZENICEF Cap. Zenith chest infections.Urinary tract infections- such as
+ TYFAX-3 Cap. White Horse Cefixime trihydrate 200mg/capsule. acute and chronic pyelonephritis, cystitis and
Cefixime trihydrate USP 200mg/capsule. 200mg x 4's pack: 120.00 MRP asymptomatic bacteriuria. Soft-tissue infections -
200mg x 12's pack: 300.00 MRP t ZENICEF Susp. Zenith such as cellulitis, peritonitis and wound infec­
t TYFAX DS Cap. White Horse Cefixime trihydrate 100mg/5ml: suspension. tions. Bone and joint infe·ctions- such as
Cefixime trihydrate USP 400mg/capsule (double 50ml bot: 160.00 MRP osteomyelitis, septic arthritis. Obstetric and
strength). + 3-C Cap. Edruc gynaecological infections- such as pelvic inflam­
400mg x 12's pack: 600.00 MRP Ceftxime trihydrate 200mg/capsule. matory disease. Gonorrhoea, particularly when
+ TYFAX Susp. White Horse 200mg x 4's pack: 100.00 MRP penicillin has failed or is unsuitable. Other bacte­
Cefixime trihydrate 100mg/5ml: suspension. + 3-C Susp. Edruc rial infections, such as meningitis and other sen-

200 mg & 400 mg Capsule

Apex
TYPHO/O EXIT & 100 mg/Sml PFS flh.Jtlll.l

Cefixime

I
ANTIMICROBIAL DRUGS.
sitive infections suitable for parenteral antibiotic
therapy.
Prophylaxis- the administration of cefotaxime
prophylactically may reduce the incidence of
certain post operative infections in patients
undergoing surgical procedures that are
classified as contaminated or potentially
contaminated or in clean operation where
infection would have serious effects.
C/I; S/E; Cautions: See above under Cefetamet.
Pregnancy & lactation: Although studies in
animals have not shown any adverse effect on the
developing foetus, the safety of cefotaxime in
human pregnancy has not been established.
Consequently, cefotaxime should not be
administered during pregnancy specially during
first trimester, without carefully weighing the
expected benefit against possible risks.
Cefotaxime is excreted in the milk.
Dosage & admin: Adults- in mild to moderate
infection, lgm every 12 hourly; in severe
infection dosage may be increased up to 12gm
daily given in 3 or 4 divided doses. For
infections caused by sensitive Pseudomonus
spp. daily dosage of greater than 6gm is
usually required. Children- the usual dosage
range is 100-150mg/kg/day in 2 to 4 divided
doses; in very severe infections dosage of up to
200mg/kg/day may be required. Neonates- the
recommended dosage is 50mg/kg/day in 2 to 4
divided doses; in severe infections 150-.
200mg/kg/day in divided doses may be giv.en.
Dosage in gonorrhoea- a single injection of
lgm may be administered i.m or i.v.
Dosage in renal impairment- because of extra­
renal elimination, it is only necessary to reduce
the dosage of cef otaxime in severe renal failure
(GFR<5 ml/min = serum creatinine approxi­
mately 751 micromol/litre). After an initial
loading dose of lgm, daily dose should be
halved without change in the frequency of dos­
ing. In all other patients, dosage may require
further adjustment according to the course of
infection and general condition of the patient.
Drug inter: Increased nephrotoxicity has been
reported following concomitant administration of
cephalosporins and aminoglycoside antibiotics.
+ CEFOT Inj. ACI
Cefotaxime sodium USP 250mg, 500mg &
lgm/vial (powder for reconstitution): i.m/i.v
injection.
250mg vial x l's pack: 50.00 MRP
500mg vial x l's pack: 76.00 MRP
lgm vial x l's pack: 132.00 MRP
+ CEFOT I.V Inj. ACI
Cefotaxime sodium USP 2gm/vial (powder for
reconstitution): i.v injection.
2gm vial x l's pack: 250.00 MRP
+ CEFOTAX Inj. Renata
Cefotaxime sodium USP 250mg, 500mg &
I gm/vial (powder for reconstitution): i.m/i.v
injection.
250mg vial x l's pack: 75.00 MRP
500mg vial x l's pack: 100.00 MRP
l gm vial x l's pack: 180.00 MRP
+ CEFOTIME Inj. Incepta
Cefotaxime sodium USP 250mg, 500mg &
l gm/vial (powder for reconstitution): i.m/i.v
•
injection.
250mg vial x l's pack: 50.00 MRP
QIMP-17 (256)
500mg vial x l's pack: 76.00 MRP
lgm vial x l's pack: 132.00 MRP
+ CEFTAX Inj. Opsonin
Cefotaxime sodium USP 250mg, 500mg &
l gm/vial (powder for reconstitution): i.m/i.v
injection.
250mg vial x l's pack: 44.16 MRP
500mg vial x l's pack: 67.11 MRP
lgm vial x l's pack: 116.56 MRP
+ CETAXIM lnj. Globe
Cefotaxime sodium USP 500mg & l gm/vial
(powder for reconstitution): i.m/i.v injection.
500mg vial x l's pack: 76.00 MRP
lgm vial x l's pack: 130.00 MRP
+ MAXCEF Inj. Square
Cefotaxime sodium USP 250mg, 500mg &
l gm/vial (powder for reconstitution): i.m/i.v
injection.
250mg vial x l's pack: 50.20 MRP
500mg vial x l's pack: 76.29 MRP
l gm vial x l's pack: 132.50 MRP
+ TAXCEPH Inj. Ibn Sina
Cefotaxime sodium USP 250mg, 500mg &
l gm/vial (powder for reconstitution): i.m/i.v
injection.
250mg vial x l's pack: 52.00 IP
500mg vial x l's pack: 76.00 IP
l g m vial x l's pack: 140.00 IP
+ TAXIM Inj. Acme
Cefotaxime sodium USP 250mg, 500mg &
l gm/vial (powder for reconstitution): i.m/i.v
· injection.
250mg vial x: l's pack: 50.20 MRP
500mg vial x 1's pack: 76.29 MRP
l gm vial x 1 's pack: 132.00 MRP
+ TORPED Inj. Orion Pharma
Cefotaxime sodium USP 250mg, 500mg &
l gm/vial (powder for reconstitution): i.m/i.v
injection.
250mg vial x l's pack: 50.19 MRP
500mg vial x l's pack: 75.28 MRP
l gm vial x l's pack: 130.49 MRP
CEFPODOXIME26•36
CEFPODOXIME: Capsule/Suspension
Cefpodoxime proxetil, a new 3rd generation oral
cephalosporin. It is a prodrug that is de-esterified
in the intestinal wall to release cefpodoxime. It
acts against a wide range of gram-positive &
gram-negative pathogens including good activity
against some clinically significant gram-positive
pathogens like Staph aureus, Strep pneumoniae
and S. saprophyticus.
Mode of action: Cefpodoxime is bactericidal and
kills bacteria by interfering with the synthesis of
the bacterial cell wall. Cefpodoxime binds with
high affinity to penicillin-binding proteins in the
bacterial cell wall, thus interfering in
peptidoglycan synthesis that provides the cell
wall with mechanical stability. Cefpodoxime
inhibits the transpeptidase enzyme that performs
the final stage in the synthesis of peptidoglycan.
As a result the bacterial cell wall is weakened
and the cell swells and then ruptures.
Ind: Cefpodoxime is indicated in the following
diseases: 1. Lower respiratory tract infection­
Acute community-acquired pneumonia, Acute
bacterial exacerbation of chronic bronchitis; 2.
Upper respiratory tract infection- Acute otitis
media, Acute maxillary sinusitis, Pharyngitis,
Tonsillitis; 3. Sexually transmitted diseases­
Acute uncomplicated urethral & cervical gonor­
rhoea, Acute ano-rectal infection in women
caused by N. gonorrhoeae; 4. Uncomplicated uri­
nary tract infection- Cystitis, Pyuria; 5. Skin &
soft tissue infections- Furuncle, Cellulitis,
Subcutaneous abscess, Infectious atheroma,
Periproctal abscess.
C/I: Known hypersensitivity to cefpodoxime
proxetil or to cephalosporin group of antibiotic or
any ingredient of the product.
S/E: Diarrhoea and rarely antibiotic-related coli­
tis, nausea and vomiting, abdominal discomfort,
headache; allergic reactions including rashes,
pruritus, urticaria, serum sickness-like reactions
�
.
with rashes, fever and arthralgia, and anaphylax­
is, erythema multiform, toxic epidermal necroly­
sis reported; disturbances in liver enzymes, tran­
sient hepatitis and cholestatic jaundice, etc. Other
side effects reported includeeos-inophilia and
blood disorders, reversible interstitial nephritis,
hyperactivity, nervousness, sleep disturbances,
confusion, hypertonia and dizziness etc.
Precautions: In patients with transient or persist­
ent reduction in urinary output due to renal insuf­
ficiency, the total daily dose of cefpodoxime
should be reduced because high and prolonged
serum antibiotic concentration can occur in such
individuals following usual doses. Cefpodoxime
should be administered with caution to patients
receiving concurrent treatment with potent diuret­
ics. As with other antibiotics, prolonged use of
cefpodoxime may result in overgrowth of nonsus­
ceptible organisms. If superinfection occurs during
therapy, appropriate measures should be taken.
Pregnancy & lactation: There are no adequate
and well-controlled studies on cefpodoxime
proxetil use in pregnant woman, but it was found
neither teratognic nor embryocidal in animal trial.
However, the drug should be used during
pregnancy only if clearly needed. In nursing
mother, cefpodoxime is excreted in breast milk &
• there is potential risk of serious reactions in
nursing infants, so a decision should be made
whether to discontinue breast feeding or to
disocontinue the drug.
Dosage & admin: Cefpodoxime capsule should
be administered orally with food to enhance
absorption, & suspension may be given
without regard to food.
The recommended doses, duration of treatme­
nt, applicable patient population are as below:
Adults (13 years & older):
Acute community- acquired pneumonia-
200mg 12 hourly for 14 days.
Acute bacterial exacerbation of chronic
bronchitis- 200mg 12 hourly for 10 days.
Uncomplicated gonorrhea (men/women)-
200mg single dose. •
Rectal gonococcal infection in women- 200mg
single dose.
Skin & soft tissue infection- 400mg 12 hourly
for 7 to 14 days.
Pharyngitis and/or Tonsillitis- lOOmg 12
hourly for 5 to 10 days.
Uncomplicated urinary tract infection- lOOmg
12 hourly for 7 days .
Acute maxillary sinusitis- 200mg 12 hourly for
10 days.
 QIMP-17 (257) ANTIMICROBIAL DRUGS

Infants & children: 15 days- 6 months, 4mg/kg 1OOmg x 20's p·ack: 440.00 MRP
every 12 hours; 6 months - 2 years, 40mg 200mg x l O's pack: 400.00 MRP
every 12 hours; 3-8 years, 80mg every 12 t CEFODIM Susp. Pacific
hours; Over 9 years, lOOmg every 12 hours.

The Clinically
Cefpodoxime proxetil _USP 40mg/5ml: suspension
Patients with severe renal impairment (creati­ 50ml bot: 80.00 MRP
nine clearance <30ml/min) the dosing intervals t CEFODOX Cap. Bristol

Tested Brands
shoud be increased to 24 hourly; in patients Cefpodoxime proxetil USP 1 OOmg/capsule.
with transient or persistent reduction in uri­ 4's pack: 88.00 MRP
nary output due to renal insufficiency, the t CEFODOX Susp. Bristol
total daily dose should be reduced. Cefpodoxime proxetil USP 40mg/5ml: suspension
In cirrhotic patients, phamacokinetics of 50ml bot: 95.00 MRP
Cefpodoxime are similar to those in healthy t CEFOMIN Susp. Popular
subjects, so the dose adjustment is not Cefpodoxime proxetil USP 40mg/5ml: suspension
MRP
•

necessary. 50ml bot: 96.00

Drug inter: Antacids: oncomitant administration t CEFORAN-100 Tab. Drug Inter.
of high doses of antacids (sodium bicarbonate Cefpodoxime proxetil USP 1 OOmg/tablet.
and aluminium hydroxide) or H2 blockers reduce lOOmg x 14's pack: 238.00 MRP
peak levels by 24% to 42% and the extent of t CEFORAN Cap. Drug Inter.
absorption by 27% to 32% respectively, though Cefpodoxime proxetil USP 1OOmg &
the rate of absorption is not altered by these con­ 200mg/capsule.
comitant medications. Oral anticholinergics delay l OOmg x 2 l 's pack: 420.00 MRP
peak plasma levels, but do not affect the extent of 200mg x 14's pack: 392.00 MRP
absorption. Probenecid: probenecid inhibits the t CEFORAN Susp. Drug Inter.
excretion of cefpodoxime. Nephrotoxic drugs: Cefpodoxime proxetil USP 40mg/5ml: suspension
although nephrotoxicity has not been noted when 50ml bot: 75.00 MRP
cefpodoxime was given alone, close monitoring 1 OOml bot: 120.00 MRP
of renal functionis advised when cefpodoxime is t CEFORAN DS Susp. Drug Inter.
administ-ered concomitantly with compounds of Cefpodoxime proxetil USP 80mg/5ml: suspension
known nephrotoxic potential. (double strength).
50ml bot: 175.00 MRP
t CEFPOD 100 Tab. Zenith
Cefpodoxime proxetil USP 1OOmg/tablet.
.
* �
�
,¥1;�. .. '*"��'i).. ����...-�-...
· ��,
. ��;.»°
,4>) o9ft :) �;c;.;--
_;.. '°'
.
�:.;x-
;.; � 1C>
� .:�

.
.c:>
��'*
�.c>'"
t.::li !
;.¢!
�;_c:;oc
. . ·. ��..

'
l OOmg x l O's pack: 102.00 MRP
·· . .. · ·. .. .. ·
•
· .

•. . ·.· ·•· · . ; •. · · ·.• . . · · • ' •. · . ..

ar1n® (. . t
.
. . .. CEPDOXIM Cap. Alco Pharma
. . .. . . .. . . f
• .
. . . .
· .

.. . .
I : - Met,a ...earl
�

:
· ' Cefpodoxime proxetil USP 1OOmg &
Cefpodoxime proxetil capsule, powder for suspension & paediatric drops ·
I · ' '. .
· . · •· • •
;
· ·. · , . · · ·• .·) :
· •.·

.... :;' ..· ··.•· ,,< ·. : l

:·
· l 200mg/capsule.
1 OOmg x l 6's pack: 320.00 MRP
� . : tt
SK+f :..

· �
..
.

i. .;. .
.
. . .• . . �
'. ;? \ . \_.· .. • :
.• ·
· ' .
:�: y ; 480.00 MRP
.
. . '
:·. · •
· · \· :i.
· ) ·
�.� : •� '
: : . : ·: · ·�
. 200mg x l 6's pack:
� ;;···. · : • · · . ztnmetaz1d1Ae HGI . ·
}
, {.
. : :

t
.. · ;

· • . • •. CEPDOXIM Susp. Alco Pharma

t CEDOFAX Cap. White Horse
Cefpodoxime proxetil USP 40mg/5ml: suspension
Cefpodoxime proxetil USP 1OOmg &
_ 50ml bot: 90.00 MRP
200mg/capsule. .. . . .
ir· •·. . · · .,., ,,.,
....;•;......•
,ffS · · g ·
.
, · . -: .
� · ·1· · · f).0" Y:· · C :f. ,_.;, . �8, J. '
. ....•. , . .. . ;, -
_ , . -��- c•.
j:.• ;,· . •. :·:>i·· ..·..:·1
.
. .. l OOml bot: 175.00 MRP
. .
• ·•. : ·

MRP ; · ."• <•iS:s '

: , ·1
:· ·
. .
.·

l OOmg x 12's pack: 204.00 · ' �: ·

.

: "e
' �.
, �
:'. · ·I. ,
-m· ·
; . :
.-
"
···, . :.e '
• .
z ·, �
:
a. ··,·:_,.. �·. .
·· : ·
, · • '. Y �•a n<...,.
..
n"'·, e·: ,�:,-· .· ·_·.·, �,· ".,· '. '.·i
. <

t CEPOXID Susp. Apex

�·,:·:: · · ' "�'- �, >
..

224.00 MRP . . #·
.. �

... · · '.':,
J

200mg x 8's pack: . .': \, . , . .

. .. Cefpodoxime proxetil USP 40mg/5ml: suspension
t CEFDOX Susp. ACI
50ml bot: 98.00 MRP
Cefpodoxime proxetil USP 40mg/5ml: suspension
+ CP Tab. Acme
50ml bot: 98.37 MRP
Cefpodoxime proxetil USP 200mg/tablet.
t
�"!�-:-�..;.:<���� �:S;�:;.;<�_.:�
.
� �
.;.i...
�;:.;��;;.,.�,,."-,;.,�
... . ..;..
� �-���<!;;,:$
.,.. ���

CEFIPOD Cap. Asiatic

�

200mg x 8's pack: 337.28 MRP

Cefpodoxime proxetil USP l OOmg &
+ CP Susp. Acme

;:
200mg/capsule.
c��·�1 ·�·· ·'tr" ·-�� Cefpodoxime proxetil USP 40mg/5ml: suspension
MRP (i. : _:":! _:': '-'. .. · �
l OOmg x 8's pack: 112.00
; MRP
....
·
+ ;,,
11•
'>io
"
� u -
.
�����
.. �"""'-
� �� � �
- �

":· ··

· · 50ml bot: 98.36

150.00 MRP · :
•...

200mg x 6's pack: _· . · .· · � .. _ ·

t CEFIPOD Susp. Asiatic ! · ,. ' .
• : .. · . .: :•.. ..
.
. . •. ·: !
': · � '.
.· ;. -.. .... . . .
�·� . :��
• '
t CP DS Susp. Acme
Cefpodoxime proxetil USP 80mg/5ml: suspension
Cefpodoxime proxetil USP 40mg/5ml: suspension
(double strength).
50ml bot: 98.00 MRP ·
. 50m1 bot: 175.00 MRP
t CEFIPOD DS Susp. Asiatic � -
.· . , . .I
+
··_.

CP Drop Acme
Cefpodoxime proxetil USP 80mg/5ml: suspension
Cefpodoxime proxetil USP 20mg/ml: drop
·(double strength)
15ml bot: 60.22 MRP
50ml bot: 175.00 MRP
t DESBAC Cap. General
t CEFIPOD Drop Asiatic
Cefpodoxime proxetil USP 1OOmg/capsule.
Cefpodoxime proxetil USP 20mg/ml: drop 1• •• . ,. :<;.....
. . .. . l1111��JIY: "fe�tefl.. �'ft)(tllle. .,: • ·. ·l
. ' ":.·" " a • • "•: : .....:. . . ... " •" .. .·.. : " .•· . . . . .:. ..· .. ·· 1 12's pack: 264.72 MRP
MRP
" .' '
;1>r: · ��;i:i� : �� n �l��$� ·!�1; _-
.. .

15ml bot: 60.00 i.··• .· .... ._. • · · ·

- ·• !
. · ..
... :>;
t DESBAC Susp. General
t CEFOBID Cap. UniMed & UniHealth
· · · · ·. · · · ·· . · · · · · · •· · · · "
· · · · typhoid fever .. . . .•.• . . . .•. • Cefpodoxime proxetil USP 40mg/5ml: suspension
Cefpodoxime proxetil USP 200mg/capsule.
200mg x 8's pack: 336.00 MRP
l" .· ..• .•. \ .
··

' "? •: •
., . • . . ... ••• .• . • ••.• •• • ; · • ··· .) •
•;,..;.·.:7-.'..:...,. .,..;•-. �,, '1·�.......;;.·q<;!.. .,:,., ·.,.�-..,... _�....,,�·,,.;·"*'·.,.:,,,.-f,.··M...;.,,_��..
\ 50ml bot: 98.37 MRP
... ...
--�"'':;n,,,1..,,,;.: : :. #, :; +�;;;, .. ,.::�.;,·.,.;.�;
..�;,,�qi.;.... ...,c;,.<+•�:;•

t
t DOFIXIM Cap. Ibo Sina
..

CEFOBID Susp. UniMed & UniHealth

Cefpodoxime proxetil USP 40mg/5ml: suspension Cefpodoxime proxetil USP 1 OOmg/capsule.
50ml bot: 98.00
t CEFODIM Cap. Pacific
MRP
J'd ARISTOPHARMA LTD.
1OOmg x 8's pack: 168.00 IP

t DOFIXIM Susp. Ibo Sina

Cefpodoxime proxetil USP 1 OOmg & www.a ri stopha rma .com Cefpodoxime proxetil USP 40mg/5ml: suspension
200mg/capsule. 50ml bot: 100.00 IP
ANTIMICROBIAL DRUGS QIMP-17 (258)

•DxPROXIL Susp. MonicoPharma Cefpodoxime proxetil USP 40mg/5ml: suspension •TRUCEF Susp. Renata
;
Cefpodoxime proxetil USP 40mg/5ml: suspension 50ml bot: 98.00 MRP Cefpodoxime proxetil USP 40mg/5ml: suspension
50ml bot: 98.00 MRP •ROVANTIN'Tab. Opsonin 50ml bot: 175.66 MRP
•EMIPROX Susp. Virgo Cetpodoxitne proxetil USP 1OOmg &
· lOOml bot: 190.72 MRP
Cefpodoxime proxetil USP 40mg/5ml: suspension 200mg/tablet. •TRUCEF DS Susp. Renata
50ml bot: 90.00 MRP lOOmg x lO's pack: 123.60 MRP Cefpodoxime proxetil USP 80mg/5ml: suspension
'

•EMIPROX DS Susp. Virgo 200mg x 1O's pack: 220. 72 MRP 50ml bot: 175.66 MRP
Cefpodoxime proxetil USP 80mg/5ml: suspension •ROVANTIN Susp. Opsonin •TRUCEF Drop Renata
50ml bot: 170.00 MRP Cefpodoxime proxetil USP 40mg/5ml: suspension Cefpodoxime proxetil USP 20mg/lml: suspension
•E-POD Cap. Edruc 50ml bot: 86.5.3 MRP 15ml bot: 60.23 MRP
Cefpodoxime proxetil USP 200mg/capsule. •ROVANTIN DS Susp. Opsonin •VANPROX Cap. Square
200mg x 12's pack: 480.00 MRP Cefpodoxime proxetil USP 80mg/5ml: suspension Cefpodoxime proxetil USP 1OOmg &
•E-POD Susp. Edruc (double strength). 200mg/ capsule
Cefpodoxime proxetil USP 40mg/5ml: suspension 50ml bot: 154.53 MRP lOOmg x 12's pack: 264.96 MRP
50ml bot: 96.00 MRP •ROVANTIN Drop Opsonin 200mg x 6's pack: 252.96 MRP
•EPOXIM Tab. Peoples Cefpodoxime proxetil USP 20mg/ml: drop •VANPROX Susp. Square
Cefpodoxime proxetil USP 1 OOmg & 200mg/ l 5ml bot: 52.99 MRP Cefpodoxime proxetil USP 40mg/5ml: suspension
tablet. •ROXETIL S.usp. Healthcare 50ml bot: 98.36 MRP
lOOmg x 12's pack: 240.00 MRP Cefpodoxime proxetil USP 40mg/5ml: suspension •VANPROX Forte Susp. Square
200mg x 8's pack: 280.00 MRP 50ml bot: 95. ;00 MRP
. .
Cefpodoxime proxetil USP 80mg/5ml:
•EPOXIM Susp. Peoples •S ARELOX Tab. Sanofi-aventis suspension (double strength).
Cefpodoxime proxetil USP 40mg/5ml: suspension Cefpodoxime proxetil USP 1OOmg/tablet. 50ml bot: 175.66 MRP
50ml bot: 98.00 MRP lOOmg x 12's pack: 264.96 MRP •VANPROX Drop Square
lOOml bot: 180.00 MRP •SARELOX Susp. Sanofi-aventis Cefpodoxime proxetil USP 20mg/lml: suspension
•EVEDOXIM Cap. Everest •
Cefpodo:x,im
_ e proxetil USP. 40mg/5ml� suspension 15ml bot: 60.22 MRP
Cefpodoxime proxetil USP 1OOmg/capsule. 50ml bot: 98.3 7 MRP . •VERCEF Susp. Beximco
lOOmg x 12's pack: 264.00 MRP •S ARELOX . Drop Sanofi-aventis_
.
Cefpodoxime proxetil USP 40mg/5ml: suspension
. .
•EVEDOXIM Susp. Everest Cefpodoxime proxetil USP 20mg/lml: suspension 50ml bot: 98.00 IP
Cefpodoxime proxetil USP 40mg/5ml: suspension l 5ml bot: 60.23 MRP lOOml bot: 195.00 IP
50ml bot: 85.00 MRP •SEFOX Susp. Navana Health Care •VERCEF DS Susp. Beximco
•EVEDOXIM Drop Everest Cefpodoxime proxetil USP 40mg/5ml: suspension Cefpodoxime proxetil USP 80mg/5ml:
Cefpodoxime proxetil USP 20mg/ml: drop 50ml bot: 95.35 MRP suspension (double strength).
15ml bot: 60.00 MRP •STARIN Cap. SK+F 50ml bot: 175.00 IP
•INSTINA Susp. Ziska Cefpodoxime proxetil USP 1OOmg/capsule. • VERCEF Drop Beximco
Cefpodoxime proxetil USP 40mg/5ml: suspension lOOmg x 16's pack: 352.00 MRP Cefpodoxime proxetil USP 20mg/lml: suspension
50ml bot: 98.00 MRP •STARIN Susp. SK+F l 5ml bot: 60.00 IP
•KIDCEF Susp. Beacon Cefpodoxime proxetil USP 40mg/5ml: suspension •VICTORIN Cap. Novo Healthcare
Cefpodoxime proxetil USP 50mg/5ml: suspension 50ml bot: 98.00 MRP Cefpodoxime proxetil USP 200mg/capsule.
50ml bot: 98.00 MRP •STARIN DS Susp. SK+F 200mg x 8's pack: 320.00 MRP
• LEPROX DS Susp. Amico Cefpodoxime proxetil USP 80mg/5ml: suspension •vlCTORIN Susp. Novo Healthcare
Cefpodoxime proxetil USP 80mg/5ml: suspension 50ml bot: 150.00 MRP Cefpodoxime proxetil USP 40mg/5ml: suspension
50ml bot: 175.00 MRP •STARIN Drop SK+F 50ml bot: 98.00 MRP
•METOXIM Susp. Sandoz Cefpodoxime proxetil USP 20mg/ml: drop •VICTORIN Drop Novo Healthcare
Cefpodoxime proxetil USP 40mg/5ml: suspension 15ml bot: 60.00 MRP Cefpodoxime proxetil USP 20mg/lml: suspension
50ml bot: 100.00 MRP •TAXETIL Cap. Aristopharma 15ml bot: 60.00 MRP
•NEOPROX Susp. Somatec Cefpodoxime proxetil USP 1OOmg & •XEPODOX Susp. Rangs Pharma
Cefpodoxime proxetil USP 40mg/5ml: suspension 200mg/capsule. Cefpodoxime proxetil USP 40mg/5ml: suspension
50ml bot: 98.3 7 MRP lOOmg x 18's pack: 396.00 MRP 50ml bot: 98.00 MRP
•NEOPROX Drop Somatec 200mg x 8's pack: 320.00 MRP •XEPODOX Drop Rangs. Pharma
Cefpodoxime proxetil USP 20mg/ml: drop •TAXETIL Susp. Aristopharma Cefpodoxime proxetil USP 20mg/lml: suspension
15ml bot: 60.23 MRP Cefpodoxime proxetil USP 40mg/5ml: suspension 15ml bot: 60.00 MRP
• PEDICEF Susp. Orion Pharma 50ml bot: 99.00 MRP •XIMEPROX Tab. Incepta
Cefpodoxime proxetil USP 40mg/5ml: suspension lOOml bot: 195.00 MRP Cefpodoxime proxetil USP lOOmg &
50ml bot: 98.37 MRP •TAXETIL DS Susp. Aristopharma 200mg/tablet.
•PEDICEF DS Susp. Orion Pharma Cefpodoxime proxetil USP 80mg/5ml: suspension lOOmg x 24's pack: 408.00 MRP
Cefpodoxime proxetil USP 80mg/5ml: suspension 50ml bot: 175.00 MRP 200mg x 12's pack: 336.00 MRP
50ml bot: 175.66 MRP •TAXETIL Drop Aristopharma •XIMEPROX Susp. Incepta
•PEDICEF Drop Orion Pharma Cefpodoxime proxetil USP 20mg/ml: drop Cefpodoxime proxetil USP 40mg/5ml: suspension
Cefpodoxime proxetil USP 20mg/ml: drop 15ml bot: 62.00 MRP 50ml bot: 98.00 MRP
15ml bot: 60.23 MRP •TORAXIM Susp. Delta Pharma lOOml bot: 195.00 MRP
•POD0-100 Tab. Kemiko Cefpodoxime proxetil USP 40mg/5ml: suspension •XIMEPROX DS Susp. Incepta
Cefpodoxime proxetil USP 1OOmg/tablet. 50ml bot: 98.00 MRP Cefpodoxime proxetil USP 80mg/5ml: suspension
lOOmg x lO's pack: 220.00 MRP (double strength).
•TOR AXIM Drop Delta Pharma
•PODO Susp. Kemiko Cefpodoxime proxetil USP 20mg/ml: drop 50ml bot: 175.00 MRP
Cefpodoxime proxetil USP 40mg/5ml: suspension 15ml bot: 60.00 MRP •XIMEPROX Drop lncepta
50ml bot: 98.00 MRP Cefpodoxime proxetil USP 20mg/lml: suspension
•TRUCEF Tab. Renata
•PODOXI Susp. Chemist Cefpodoxime proxetil USP lOOmg & 15ml bot: 60.00 MRP
Cefpodoxime proxetil USP 40mg/5ml: suspension 200mg/tablet. •XIMOCEF 200 Cap. Kumudini
50ml bot: 90.00 MRP lOOmg x lO's pack: 220.80 MRP Cefpodoxime proxetil USP 200mg/capsule.
•PROCTIL Susp. Medicon 200mg x IO's pack: 421.60 MRP 200mg x 8's pack: 320.00 MRP

+ XIMOCEF Susp. Kumudini
Cefpodoxime proxetil USP 40mg/5ml: suspension
50ml bot: 95.00 MRP
+ XIMOCEF Drop Kumudini
Cefpodoxime proxetil USP 20mg/ lml: suspension
50ml bot: 150.00 MRP
+ XPOTIL Susp. Cosmic
Cefpodoxime proxetil USP 40mg/5ml: suspension
50ml bot: 98.00 MRP
+ ZEDOXIM Cap. Globe
Cefpodoxime proxetil USP 1 OOmg &
200mg/capsule.
l OOmg x 12's pack: 240.00 MRP
•
200mg x 8's pack: 320.00 MRP
+ ZEDOXIM Susp. Globe
Cefpodoxime proxetil USP 40mg/5ml: suspension
50ml bot: 95.00 MRP
,
+ ZEDOXIM Drop Globe
Cefpodoxime proxetil USP 20mg/ l ml: suspension
l 5ml bot: 60.00 MRP
CEFPODOXIME + CLAVULANIC
AC1D26
CEFPODOXIME + CLAVULANIC ACID
This is a combination formula of cefpodoxime &
clavulanic acid, where combination proportions
are expressed as- cefpodoxime proxetil + this population.
clavulanic acid respectively. The available
combination preparations are- 1 OOmg + 62.50mg
& 200mg + 125mg.
Mode of action: Clavulanic acid component pro­
tects degeneration of cefpodoxime in presence of
beta-lactamase enzymes and prevents the resist­
ance to cefpodoxime that may increase with con­
tinuous usage of the drug. It has shown effective­
ness against multiple gram-positive and gram­
negative bacteria and is generally well tolerated.
Ind: URTls, such as- Pharyngitis, Tonsillitis.
LRTls, such as- Acute exacerbations of chronic
bronchitis, Acute community acquired pneumonia.
SS Tis
UTis, such as- Cystitis, Uncomplicated urinary
tract infections.
Enteric fever.
General gonorrhea and rectal gonococcal
infections.
C/I: It is contraindicated in patients with a
known allergy to cefpodoxime and clavulanic
acid or to the cephalosporin group of antibiotics.
S/E: It has very few side effects, which include
diarrhoea, nausea, skin and vaginal fungal
infection, vulvo-vaginal infections, abdominal
pain and headache.
Precautions: Cross hypersensitivity in penicillin
sensitive patients, leading to serious acute
hypersensitivity reactions may need treatment
with epinephrine along with other emergency
measures, such as- intravenous fluids, oxygen,
airway management and intravenous
antihistamine, as clinically indicated.
Pregnancy & lactation: Cefpodoxime is preg­
nancy category B. although clavulanic acid has
not been shown to have any mutagenic potential,
insufficient experimental data are available to
allow its recommendation for use in pregnancy.
Cefpodoxime is excreted in human milk. So a
decision should be made whether to discontinue
nursing or to discontinue the drug, taking into
account the importance of the drug to the mothers.
QIMP-17 (259)
Dosage & admin:
Pharyngitis antVor tonsillitis- lOOmg 12 hourly
for 5-10 days.
Acute community acquired pneumonia- 200mg
12 hourly for 14 days.
Acute bacterial exacerbations of chronic
bronchitis- 200mg 12 hourly for 10 days.
Uncomplicated gonorrhea infections
(men/women)- 200mg single dose.
Rectal gonococcal infections in women- 200mg
single dose.
Skin and skin structure- 400mg 12 hourly for
•
7-14 days.
Uncomplicated urinary tract infection- lOOmg
12 hourly for 7 days.
Acute maxillary sinusitis- 200mg 12 hourly for
10 days.
Enteric fever- 200mg 12 hourly for 7-14 days.
Patients with renal dysfunction: For patients
with severe renal impairment (< 30 ml/min
creatinine clearance), the dosing intervals
should be increased to 24 hourly. In patients
maintained on hemodialysis, the dose freque­
ncy should be 3 times/week after hemodialysis.
Patients with cirrhosis: Cefpodoxime
pharmacokinetics in cirrhotic patients (with or
without ascites) is similar to those in healthy
subjects. Dose adjustment is not necessary in
Drug inter: Antacids: Concomitant administra­
tion of high doses of antacids (sodium bicarbon­
ate and aluminum hydroxide) or H2 blockers
reduce peak plasma level by 24% to 42% and the
extent of absorption by 27% to 32o/o respectively.
Probenecid: Renal excretion of cefpodoxime
proxetil was inhibited by probenecid and resulted
in an approximately 31% increase in AUC.
Nephrotoxic drugs: Close monitoring of renal
function is advised when cefpodoxime proxetil is
administered concomitantly with compounds of
known nephrotoxic potential.
+ CEFOCLAV Tab. NIPRO JMI
Cefpodoxime 200mg as cefpodoxime proxetil
USP & clavulanic acid 125mg as diluted
potassium clavulanate BP/tablet (film-coated).
200mg x 8's pack: 240.00 MRP
+ DU0-5 LS Tab. Incepta
Cefpodoxime 1 OOmg as cefpodoxime proxetil
USP & clavulanic acid 62.5mg as diluted
potassium clavulanate BP/tablet (film-coated).
l OOmg x 12's pack: 300.00 MRP
+ DU0-5 Tab. lncepta
Cefpodoxime 200mg as cefpodoxime proxetil
USP & clavulanic acid 125mg as diluted
potassium clavulanate BP/tablet (film-coated).
200mg x 12's pack: 480.00 MRP
CEFTAZ1DIME21,47
CEFfAZIDIME: Injection
Ceftazidime pentahydrate, a 3rd generation broad
spectrum cephalosporin using parenteral route.
Ind: Broad spectrum antibiotic with greater
activity aganist certain gm-ve bacteria such as
pseudomonas and also other gm-ve bacteria.
However they are less active than 'second
generation' cephalosporins (e.g cefuroxime)
against gram-positive bacteria.
C/I; S/E; Cautions: See above under Cefetamet.
ANTIMICROBIAL DRUGS
. .
Dose: By deep i.m injection or i.v injection or
infusion, lgm every 8 hours or 2gm every 12
hours; 2gm every 8-12 hours in severe
infections; single dose� over lgm intravenous
route only;- elderly usual max. 3gm daily;
Child, up to 2 months 25-60 mg/kg daily in 2
divided doses, over 2 months 30-100 mg/kg
daily in 2-3 divided doses; up to 150mg/kg
daily if immunocompromised or meningitis;
intravenous route recommended for children.
Urinary tract and less serious infections, 0.5-
lgm every 12 hours •
Pseudomonal lung infection in cystic fibrosis­
adult with normal renal function 100-150mg/
kg daily; in 3 divided doses; child up to
150mg/kg daily; intravenous route recommen­
ded for children.
+ CEFAZID Inj. Renata
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x l's pack: 85.00 MRP
500mg vial x 1's pack: 130.00 MRP
1gm vial x 1's pack: 240.00 MRP
+ CEFfAZIM lnj. Aristopharma
Ceftazidime pentahydrate 250mg, 500mg & 1 gm
vial: i.m/i.v injection.
250mg vial x l's pack: 75.00 MRP
500mg vial x l's pack: 120.00 MRP
lgm vial x l's pack: 220.00 MRP
+ CEFZON Inj. Navana
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x l's pack: 70.26 MRP
500mg vial x l's pack: 115.43 MRP
lgm vial x l's pack: 215.80 MRP
· + LESERO Inj. Ziska
Ceftazidime pentahydrate 250mg, 500mg & l gm
vial: i.m/i.v injection.
250mg vial x l's pack: 70.00 MRP
500mg vial x l's pack: 115.00 MRP
lgm vial x l's pack: 215.00 MRP
+ MAXB AC Inj. Rangs Pharma
Ceftazidime pentahydrate 250mg, 500mg & 1 gm
vial: i.m/i.v injection.
250mg vial x l's pack: 85.00 MRP
500mg vial x l's pack: 130.00 MRP
lgm vial x l's pack: 240.00 MRP
+ MAXIDIM lnj. Beximco
Ceftazidime pentahydrate 250mg, 500mg & lgm
vial: i.m/i.v injection.
250mg vial x l's pack: 85.00 MRP
500mg vial x l's pack: 130.00 MRP
lgm vial x l's pack: 240.00 MRP
+ SEROZID Inj. Opsonin
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x l's pack: 61.81 MRP
500mg vial x l's pack: 101.54 MRP
lgm vial x l's pack: 189.84 MRP
+ SIDOBAC Inj. Incepta
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x 1 's pack: 70.00 MRP
500mg vial x l's pack: 115.00 MRP
l gm vial x l's pack: 215.00 MRP
+ T AZID Inj. Square
Ceftazidime pentahydrate 250mg, 500mg & 1 gm
vial: i.m/i.v injection.
250mg vial x l's pack: 85.00 MRP
500mg vial x l's pack: 130.00 MRP

�
<Cl
Ceftriaxone
lgm vial x l's pack: 2 40.00 MRP
+TAZIMAX Inj. SK+F
Ceftazidime pentahydrate 250mg & 1gm vial:
i.m/i.v injection.
250mg vial x l's pack: 85.00 MRP
lgm vial x l's pa�k: 2 40.00 MRP
+TIZIME Inj. Globe . exercised in pregnancy, particularly in the frrst
Ceftazidime pen�ydrate 250mg, 500mg & 1gm
·
vial: i.m/i.v injection.
250mg vial x l's pack: 70.00 MRP
500mg vial x 1's pack: 115.00 MRP
lgm vial x l's pack: 2 10.00 MRP
+TRIZIDIM Inj. Acme
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x l's pack: 70.26 MRP
500mg vial x l's pack: 115.43 MRP
lgm vial x l's pack: 215.80 MRP
+TRUM 3 Inj. Drug Inter.
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x l's pack: 70.00 MRP
500mg vial x l's pack: 120.00 MRP
lgm vial x l's pack: 225.00 MRP
+ZIDICEF I.M/I.V Inj. Popular
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x l's pack: 70.26 MRP
500mg vial x 1 's pack: 115 .43 MRP
lgm vial x l's pack: 215.80 MRP
+ZIDIM Inj. Orion Pharma
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x l's pack: 70.26 MRP
500mg vial x l's pack: 115.43 MRP
lgm vial x l's pack: 2 15.81 MRP
+ZIDIMAX lnj. Biopharma
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x l's pack: 70.00 MRP
500mg vial x l's pack: 115.00 MRP
lgm vial x l's pack: 225.00 MRP
+ZITUM Inj. ACI
Ceftazidime pentahydrate 250mg, 500mg & 1gm
vial: i.m/i.v injection.
250mg vial x l's pack: 70.26 MRP
500mg vial x l's pack: 115.43 MRP
lgm vial x l's pack: 225.85 MRP
CEFl1RIAXONE21,so
CEFI'RIAXONE: I.M/I.V Injection
Ceftriaxone is a third generation broad spectrum
cephalosporin using parenteral route. It may be
given in intram uscular or in�vascular route, but
intramuscular injection is very painful, so, in case
of i.m injection lidocaine is used as solvent.
Ind: Sepsis; m eningitis; abdomial infections;
infections of the bones, joints, soft tissue, skin
and of wounds; infections in patients with
impaired defence m echanisms; renal and urinary
tract infections; respiratory tract infections, par­
ticularly pneumonia, and ear, nose and throat
infections; genital infections, including gonor­
rhoea. Perioperative prophylaxis of infections.
-- �������----liiii---·
QIMP-17 (260)
C/I: Known hypersenitivity to cephalosporins.
Neonates with jaundice, hypoalbum inaemia,
acidosis or impaired bilirubin binding.
S/E: See under cefetamet; calcium ceftriaxone
precipitates in urine or in gall bladder
(discontinue if symptomatic).
Cautions: Hypersensitivity to penicillin (possi­
bility of allergic cross-reactions), anaphylactic
shock. Severe renal impairment; hepatic
impairment if accompanied by renal impairment.
Pregnancy & lactation: Caution should be
trim ester unless absolutely necessary; premature
neonates.
Dosage & admin: Usual dosage for adults and
children _over 12 yrs, 1-2gm o�ce �ally (every
24 hours). In severecases or infections caused
by moderatiely sensitive organisms. the
dousage may be raised to 4gm administer3d
once daily.
Neonates (up to 2 weeks): 20- SOmg/kg daily
(onces daily), not to exceed
50mg/kg. on account of the immaturity of the
infant's enzyme systems. It is not necessary to
differentiate between premature and infants
born at term.
Infants and children (3 weeks to 12 yrs): A
daily dose of 20-80mg/kg.
I. v. doses of 50mg or more per kg shoul be
given by infusion over at least 30 mins.
Meningitis: infants and children- treatment
begins with dose of lOOmg/kg (not to exceed 4
gm.) once daily. The best result have been
found with the following duration of therapy-
N. meningitidis - 4 days.
H. influenzae - 6 days.
S. pneumoniae - 7 dsys.
Enterobacteriaceae - 10-14days.
+ACIPIDN I.M lnj. ACI
Ceftriaxone 250mg, 500mg & 1gm vial: i.m
injection.
250mg vial with lidocaine: 1 00.00 MRP
500mg vial with lidocaine: 1 30.00 MRP
lgm vial with lidocaine: 190.72 MRP
+ACIPHIN I.V Inj. ACI
Ceftriaxone 250mg, 500mg & lgm vial: i.v
injection.
250mg vial with water: l 00.00 MRP
500mg vial with water: 130.00 MRP
lgm vial with water: 190.72 MRP
2gm vial with water: 301.13 MRP
+ ARIXON I.M Inj. Bex.imco
Ceftriaxone 250mg, 500mg & 1gm vial: i.m
injection.
250mg vial with lidocaine: 1 00.00 IP
500mg vial with lidocaine: 1 30.00 IP
lgm vial with lidocaine: 190.00 MRP
+ARIXON I.V Inj. Beximco
Ceftriaxone 250mg, 500mg, lgm & 2gm vial: i.v
injection.
250mg vial with water: 100.00 IP
500mg vial with water: 1 30.00 IP
lgm vial with water: 190.00 MRP
2gm vial with water: 300.00 IP
+ AXON I.M Inj. Aristopharma
Ceftriaxone 250mg, 500mg & 1gm vial: i.m
injection.
250mg vial with lidocaine: 90.00 MRP
500mg vial with lidocaine: 120.00 MRP
lgm vial with lidocaine: 150.00 MRP
+AXON I.V Inj. Aristopharma
Ceftriaxone 250mg, 500mg, lgm & 2gm vial: i.v
injection.
250mg vial with water:. 90.00 MRP
500mg vial with water: 12 0.00 MRP
lgm vial with water: 150.00 MRP
2gm vial with water: 260.00 MRP
+AXOSIN I.M Inj. Ibn Sina
Ceftriaxone 250mg, 500mg & lgm vial: i.m
injection.
250mg vial with lidocaine: 90.00 IP
500mg vial with lidocaine: 12 0.46 IP
lgm vial with lidocaine: 1 80.00 IP
+ AXOSIN I.V Inj. lbn Sina
Ceftriaxone 250mg, 500mg, lgm & 2gm vial: i.v
injection.
250mg vial with water: 90.00 IP
500mg vial with water: 12 0.46 IP
lgm vial with water: 1 80.00 IP
2gm vial with water: 290.00 IP
+CEFAZ I.V lnj. Astra
Ceftriaxone lgm & 2gm vial with water: i.v
injection
1gm vial with water: 190.00 MRP
2gm vial with water: 300.00 MRP
+CEFIXON I.M Inj. Techno Drugs
Ceftriaxone 250mg, 500mg & 1gm vial with
lidocaine: i.m injection
250mg vial with lidocaine: 80.00 MRP
500mg vial with lidocaine: 120.00 MRP
lgm vial with lidocaine: 160.00 MRP
+CEFIXON I.V Inj. Techno Drugs
Ceftriaxone 250mg, 500mg, 1gm & 2gm vial
with water: i.v Injection
250mg vial with water: 80.00 MRP
500mg vial with water: 12 0.00 MRP
1gm vial with water: 160.00 MRP
2gm vial with water: 250.00 MRP
+CEFTIZONE I.M lnj. Renata
Ceftriaxone 250mg, 500mg & 1gm. vial:
i.m injection.
250mg vial with lidocaine: 1 00.38 MRP
500mg vial with lidocaine: 140.53 MRP
lgm vial with lidocaine: 2 00.75 MRP
+CEFTIZONE I.V Inj. Renata
Ceftriaxone 250mg, 500mg, lgm & 2gm vial: i.v
injection.
250mg vial with water: 100.38 MRP
500mg vial with water: 140.53 MRP
lgm vial with water: 2 00.75 MRP
2gm vial with water: 341.2 8 MRP
+CEFTRIX I.M Inj. Novo Healthcare
Ceftriaxone 250mg & 500mg vial with lidocaine:
i.m injection
250mg vial with lidocaine: 90.00 MRP
500mg vial with lidocaine: 1 30.00 MRP
+CEFTRIX I.V lnj. Novo Healthcare
Ceftriaxone lgm & 2gm vial with water: i.v
Injection
lgm vial with water: 160.00 MRP
2gm vial with water: 300.00 MRP
+CEFTRON I.M Inj. Square
Ceftriaxone 250mg, 500mg & 1gm vial with
lidocaine: i.m injection
250mg vial with lidocaine: 1 00.00 MRP
500mg vial with lidocaine: 1 30.00 MRP
lgm vial with lidocaine: 190.00 MRP
+CEFTRON I.V lnj. Square
Ceftriaxone 250mg, 500mg lgm & 2gm vial with
water: i.v Injection
 QIMP-17 (261)

250mg vial with water: 100.00 MRP 250mg vial with lidocaine: 90.34 MRP
500mg vial with water: 130.00 MRP 500mg vial with lidocaine: 120.48 MRP
lgm vial with water: 190.00 MRP lgm vial with lidocaine: 160.60 MRP
2gm vial with water: 301.14 MRP +IMACEF I.V Inj. General
+DICEPHIN I.M lnj. Drug Inter. Ceftriaxone lgm & 2gm vial with water: i.v
Ceftriaxone 250mg, 500mg & 1gm vial with Injection 500mg vial with lidocaine: 150.00 MRP
lidocaine: i.m injection lgm vial with water: 160.60 MRP lgm vial with lidocaine: 200.00 MRP
250mg vial with lidocaine: 100.00 MRP 2gm vial with water: 301.13 MRP +ORYX I.V Inj. Rangs Pharma
500mg vial with lidocaine: 130.00 MRP +INOXON I.M Inj. Rephco Ceftriaxone 250mg, 500mg & lgm vial:
lgm vial with lidocaine: 190.00 MRP Ceftriaxone USP 250mg, 500mg & lgm. vial: i.v injection.
+DICEPHIN I.V Inj. Drug Inter. i.m injection. 250mg vial with water: 100.00 MRP
Ceftriaxone 250mg, 500mg & 1gm vial with 250mg vial with lidocaine: 90.00 MRP 500mg vial with water: 150.00 MRP
water: i.v Injection 500mg vial with lidocaine: 120.00 MRP lgm vial with water: 200.00 MRP
250mg vial with water: 100.00 MRP lgm vial with lidocaine: 180.00 MRP lgm vial with water x lO's pack: 1000.00 MRP
500mg vial with water: 130.00 MRP +INOXON I.V Inj. Rephco 2gm vial with water: 350.00 MRP
lgm vial with water: 190.00 MRP Ceftriaxone SOOmg, lgm & 2gm. vial: i.v +PARCEF I.M lnj. Jayson
2gm vial with water: 300.00 MRP injection. Ceftriaxone 250mg, 500mg & 1 gm vial:
+ENOCEF I.V Inj. Sanofi-aventis 500mg vial with water: 120.00 MRP i.m injection.
Ceftriaxone SOOmg & 1gm vial with water: i.v lgm vial with water: 180.00 MRP 250mg vial with lidocaine: 80.00 IP
injection. 2gm vial with water: 300.00 MRP 500mg vial with lidocaine: 120.00 IP
500mg vial with water: 150.57 MRP + KEPTRIX I.M Inj. Apex lgm vial with lidocaine: 160.00 IP
lgm vial with water: 200.75 MRP Ceftriaxone 250mg, 500mg & lgm vial: i.m +PARCEF I.V Inj. Jayson·
+ERACEF I.M lnj. Popular injection. Ceftriaxone 250mg, 500mg & 1gm vial:
Ceftriaxone 250mg, 500mg & 1gm vial with 250mg vial with lidocaine: 90.00 MRP i.v injection.
lidocaine: i.m injection. 500mg vial with lidocaine: 120.00 MRP 250mg vial with water: 80.00 IP
250mg vial with lidocaine: 100.00 MRP lgm vial with lidocaine: 160.00 MRP 500mg vial with water: 120.00 IP
500mg vial with lidocaine: 130.00 MRP +KEPTRIX I.V Inj. Apex lgm vial with water: 160.00 IP
lgm vial with lidocaine: 190.00 MRP Ceftriaxone 500mg, lgm & 2gm vial: +PERIX I.M Inj. MonicoPharma
+ERACEF I.V lnj. Popular i.v injection. Ceftriaxone 250mg, 500mg & lgm vial:
Ceftriaxone 250mg, 500mg, 1gm & 2gm vial 500mg vial with water: 120.00 MRP i.m injection.
with water: i.v injection. lgm vial with water: 160.00 MRP 250mg vial with lidocaine: 90.00 MRP
250mg vial with water: 100.00 MRP 2gm vial with water: 300.00 MRP 500mg vial with lidocaine: 120.00 MRP
500mg vial with water: 130.00 MRP + MEGION l.M Inj. Sandoz lgm vial with lidocaine: 160.00 MRP
1 gm vial with water: 190.00 MRP Ceftriaxone 250mg, SOOmg & 1gm vial with +PERIX I.V Inj. MonicoPharma
lgm vial with water x lO's pack: 1806.81 MRP lidocaine: i.m injection Ceftriaxone 250mg, 500mg & lgm vial:
2gm vial with water: 301.13 MRP 250mg vial with lidocaine: 125.00 MRP i.v injection.
+EXEPIDN I.M lnj. lncepta 500mg vial with lidocaine: 175.00 MRP 250mg vial with water: 90.00 MRP
Ceftriaxone 250mg, 500mg & 1 gm vial with lgm vial with lidocaine: 320.00 MRP 500mg vial with water: 120.00 MRP
lidocaine: i.m injection. +MEGION I.V Inj. Sandoz lgm vial with water: 160.00 MRP
250mg vial with lidocaine: 90.00 MRP Ceftriaxone 1gm vial with water: i.v Injection 2gm vial with water: 300.00 MRP
500mg vial with lidocaine: 120.00 MRP lgm vial with water: 320.00 MRP +POWERCEF I.M Inj. Chemist
lgm vial with lidocaine: 190.00 MRP + ODATRIX I.M Inj. UniMed & UniHealth Ceftriaxone 250mg, 500mg & lgm vial:
+EXEPHIN I.V Inj. Incepta Ceftriaxone 500mg vial: i.m injection. i.m injection.
Ceftriaxone 250mg, SOOmg, lgm & 2gm vial 500mg vial with lidocaine: 120.00 MRP 250mg vial with lidocaine: 80.00 MRP
with water: i.v injection. +ODATRIX I.V Inj. UniMed & UniHealth 500mg vial with lidocaine: 130.00 MRP
250mg vial with water: 90.00 MRP Ceftriaxone lgm & 2gm vial: i.v injection. lgm vial with lidocaine: 160.00 MRP
SOOmg vial with water: 120.00 MRP lgm vial with water: 160.00 MRP +POWERCEF I.V Inj. Chemist
lgm vial with water: 190.00 MRP 2gm vial with water: 300.00 MRP Ceftriaxone lgm & 2gm vial: i.v injection.
2gm vial with water: 300.00 MRP + ORICEF I.M lnj. Healthcare lgm vial with water: 160.00 MRP
•

+G-CEFTRIAX I.M Inj. Gonoshastha Ceftriaxone 250mg, 500mg & lgm. vial: i.m
•

2gm vial with water: 300.00 MRP

Ceftriaxone 250mg, 500mg & 1gm vial with injection. +RAKXON I.M Inj. RAK Pharma
lidocaine: i.m injection 250mg vial with lidocaine: 130.00 MRP Ceftriaxone 250mg, 500mg & 1gm vial with
250mg vial with lidocaine: 75.00 MRP SOOmg vial with lidocaine: 200.00 MRP lidocaine: i.m injection
SOOmg vial with lidocaine: 120.00 MRP lgm vial with lidocaine: 320.00 MRP 250mg vial with lidocaine: 95.00 MRP
lgm vial with lidocaine: 150.00 MRP + ORICEF I.V Inj. Healthcare 500mg vial with lidocaine: 130.00 MRP
+G-CEFTRIAX I.V Inj. Gonoshastha Ceftriaxone 250mg, 500mg, lgm & 2gm vial: lgm vial with lidocaine: 180.00 MRP
Ceftriaxone 250mg, 500mg, lgm & 2gm vial: i.v i.v injection. +RAKXON l.V lnj. RAK Pharma
injection. 250mg vial with water: 130.00 MRP Ceftriaxone lgm & 2gm vial with water:
250mg vial with water: 75.00 MRP 500mg vial with water: 200.00 MRP i.v Injection
500mg vial with water: 120.00 MRP lgm vial with water: 320.00 MRP lgm vial with water: 180.00 MRP
lgm vial with water: 150.00 MRP 2gm vial with water: 490.00 MRP 2gm vial with water: 300.00 MRP
2gm vial with water: 200.00 MRP +ORYX I.M Inj. Rangs Pharma +RIT I.M Inj. Kemiko
+IMACEF I.M Inj. General Ceftriaxone 250mg, 500mg & lgm vial: Ceftriaxone 250mg, 500mg & lgm vial:
Ceftriaxone 250mg, 500mg & 1gm vial with i.m injection. i.m injection.
lidocaine: i.m injection 250mg vial with lidocame: 100.00 MRP 250mg vial with lidocaine: 95.00 MRP

. �-·- 3rd qeneration <Parentera[ Cepfia{osporin

.; .
.
;..

. -.. , .
: : ;
.. . : .-. . .Jln a(f-rountfer anti6iotic
;;;40 ���1Jf:l., �H.��; �· 9!!P�L§:. · bID ·.
;

.·
}; � :1��}.c : �:f��� . ··
, �-:� ·- � ,;,; :·l .,.:; : .�f�:.,;:� ; _::.: ·. ;:;:. » ' :::: :�-:�;, ,,.··
.
:: · L:· ;
.·.
::; ··
· :
..
.
.
'.< - bo1·11 to cure

I
 QIMP-17 (262)
'

+ TRIJECT I.V lnj. SK+F

Ceftriaxone
500mg vial with lidocaine: 120.00 MRP
lgm vial with lidocaine: 190.00 MRP
t RIT I.V Inj. Kemiko
Ceftriaxone 250mg, 500mg, lgm & 2gm/vial
with water: i.v injection
250mg vial with water: 95.00 MRP
500mg vial with water: 120.00 MRP
lgm vial with water: 190.00 MRP
2gm vial with water: 300.00 MRP
t ROFECIN I.M Inj. Radiant
Ceftriaxone 500mg & lgm vial: i.m injection.
• ®
Azithromycin 500 mg Table t ,
20 & 35 ml PFS
The novel antibiotic of today's
clinical practice
Ceftriaxone 250mg, 500mg, 1 gm & 2gm/vial
with water: i.v injection
250mg vial with water: 100.00 MRP
500mg vial with water: 130.00 MRP
lgm vial with water: 190.00 MRP
2gm vial with water: 300.00 MRP
+ TRIMAX I.M Inj. Pharmasia
Ceftriaxone 250mg, 500mg & 1gm vial with
lidocaine: i.m injection
250mg vial with lidocaine: 90.00 MRP
500mg vial with lidocaine: 120.00 MRP
lgm vial with lidocaine: 160.00 MRP
+ TRIMAX I.V Inj. Pharmasia
Ceftriaxone 250mg, 500mg 1 gm & 2gm vial with
water: i.v Injection '

500mg vial with lidocaine: 220.00 MRP
lgm vial with lidocaine: 360.00 MRP
t ROFECIN I.V Inj. Radiant
Ceftriaxone 500mg, 1 gm & 2gm/vial with water:
i. v injection
500mg vial with water: 220.00 MRP
lgm vial with water: 360.00 MRP
2gm vial with water: 680.00 MRP
t TOPCEF I.M lnj. Navana
Ceftriaxone 250mg, 500mg & 1 gm vial with 1 o/o
lidocaine: i.m injection
250mg vial with lidocoine: 90.33 MRP
500mg vial with lidocaine: 130.48 MRP
lgm vial with lidocaine: 190.00 MRP
t TOPCEF I.V Inj. Navana
Ceftriaxone 250mg, 500mg & lgm vial with
water: i.v injection
• lgm vial with water: 160.00 MRP
Cefuroxime 250 & 500 mg Tablet,
70 ml PFS, 750 mg IV/IM,
1.5 g IV Injection
Power of spectrum balance
to treat infections
®
250mg vial with water: 90.00 MRP
500mg vial with water: 120.00 MRP
2gm vial with water: 300.00 MRP
t TRIPHIN I.M Inj. Ziska
Ceftriaxone 250mg, 500mg & lgm vial with 1 %
lidocaine: i.m injection
250mg vial with lidocoine: 80.00 MRP
500mg vial with lidocaine: 120.00 MRP
lgm vial with lidocaine: 160.00 MRP
t TRIPIDN I.V lnj. Ziska
Ceftriaxone 250mg, 500mg & 1gm vial with
water: i. v injection
250mg vial with water: 80.00 MRP
500mg vial with water: 120.00 MRP
lgm vial with water: 160.00 MRP
2gm vial with water: 250.00 MRP

250mg vial with water: 90.33 MRP t TRIZON I.M Inj. Acme
500mg vial with water: 130.48 MRP Ceftriaxone 250mg, 500mg, & l gm vial with 1 %

lgm vial with water: 190.00 MRP 250mg IV/ IM, 500mg IV/ IM, lidocaine: i.m injection

2gm vial with water: 301.12 MRP
t TRAXON I.M Inj. Opsonin
Ceftriaxone 250mg, 500mg & 1 gm vial with 1 %
lidocaine: i.m injection
250mg vial with lidocoine: 87 .97 MRP
500mg vial with lidocaine: 114.36 MRP
lgm vial with lidocaine: 167.15 MRP
t TRAXON I.V Inj. Opsonin
Ceftriaxone 250mg, 500mg lgm & 2gm/vial with
water: i.v injection
250mg vial with water: 87.97 MRP
500mg vial with water: 114.36 MRP
lgm vial with water: 167.15 MRP
2gm vial with water: 264.90 MRP
t TRIBAC I.M Inj. Globe
Ceftriaxone 250mg, 500mg & 1gm vial with 1 %
lidocaine: i.m injection
250mg vial with lidocoine: 90.00 MRP
500mg vial with lidocaine: 120.00 MRP
lgm vial with lidocaine: 160.00 MRP
+ TRIBAC I.V Inj. Globe
Ceftriaxone 250mg, 500mg lgm & 2gm/vial with
water: i.v injection
250mg vial with water: 90.00 MRP
500mg vial with water: 120.00 MRP
lgm vial with water: 160.00 MRP
2gm vial with water: 300.00 MRP
t TRIJECT I.M lnj. SK+F
Ceftriaxone 250mg, 500mg & 1gm vial with 1 %
lidocaine: i.m injection
250mg vial with lidocoine: 100.00 MRP
500mg vial with lidocaine: 130.00 MRP
lgm vial with lidocaine: 190.00 MRP
•
1 gm IV / IM, 2 gm IV 250mg vial with lidocoine: 100.00 MRP
500mg vial with lidocaine: 130.00 MRP
Ensures wide coverage for lgm vial with lidocaine: 190.00 MRP
\ bacterial infections t TRIZON I.V Inj. Acme
.....,,
Ceftriaxone 250mg, 500mg, 1gm & 2gm vial
�, with water: i.v injection
�-� �
»··
-I
� --.,
1Q<Wt)
*' i-,,.
":
:.» ;
·
1·�
_. ., �
250mg vial with water: 100.00 MRP
�'.�"'""' 500mg vial with water: 130.00 MRP
lgm vial with water: 190.00 MRP
2gm vial with water: 300.00 MRP
Cefixime ®
+ VERTEX I.M Inj. Orion Pharma
Ceftriaxone 250mg, 500mg, & l gm vial with 1 %
lidocaine: i.m injection
250mg vial with lidocoine: l00.00 MRP
200& 400 mg Capsule,
500mg vial with lidocaine: 130.00 MRP
30& 50ml PFS
lgm vial with lidocaine: 190.00 MRP
The 3rd generation power + VERTEX I.V Inj. Orion Pharma
to cure infections Ceftriaxone 250mg, 500mg & 1gm vial with
water: i.v injection
250mg vial with water: 100.00 MRP
500mg vial with water: 1300.00 MRP
lgm vial with water: 190.00 MRP
2gm vial with water: 301.14 MRP
+ WINNER I.M Inj. Biopharma
• Ceftriaxone 250mg, 500mg, & 1gm vial with 1 %
lidocaine: i.m injection
250mg vial with lidocoine: 90.34 MRP
500mg vial with lidocaine: 120.45 MRP
lgm vial with lidocaine: 180.68 MRP
+ WINNER I.V Inj. Biopharma
Ceftriaxone 250mg, 500mg, 1gm & 2gm vial
with water: i.v injection
250mg vial with water: 90.34 MRP
500mg vial with water: 120.45 MRP
 QIMP-17 (263) ANTIMICROBIAL DRUGS

l gm vial with water: 180.68 MRP Complicated intra-abdominal infections: 2gm

2gm vial with water: 300.00 MRP i.v 12 hourly for 7-10 days;
Empiric therapy for febrile neutropenic
High-end antibiotic patients: 2gm i.v 8 hourly for 7 days;
Fourth generation Septicaemia: 2gm i.v 12 hourly for 7-10 days.
injections for critical Pediatric patients (2 months up to 16 years; in
weight up to 40kg):
CEFEPIME26,62
infections The maximum dose for pediatric patients
should not exceed the recommended adult
CEFEPIME HCI: Injection dose.
Cefepime hydrochloride is a semi-synthetic Pneumonia: 50mg/kg i.v or i.m 12 hourly for
fourth generation broad-spectrum cephalosporin 10 days;
antibiotic for parenteral administration. It is Bacterial meningitis: 50mg/kg i.v or i.m 8
available as cefepime hydrochloride USP 500mg hourly for 7-10 days;
vial and 1gm vial with L-arginine sterile powder Uncomplicated or complicated urinary tract
r
for i.m & i.v injection. infections (including pyelonephritis): 50mg/kg
... .

Mode of action: See above under the text of i.v or i.m 12 hourly for 7-10 days;
cephalosporins. Uncomplicated skin & skin structure infections:
Ind: Cefepime is indicated in the treatment of the 50mg/kg i. v or i.m 12 hourly for 10 days;
I . .
following infections: Meropenem Febrile neutropenic patients: 50mg/kg i.v or i.m
i. Pneumonia (moderate to severe); 8 hourly for 7 days;
ii: Uncomplicated and complicated urinary tract Impaired hepatic function:
infections (including pyelonephritis); No adjustment is necessary for patients with
iii. Uncomplicated skin and skin structure impaired hepatic function.
infections; iv. Complicated intra-abdominal Impaired renal function:
infections; v. Empiric therapy for febrile -
In patients with impaired renal function (crea­

I neutropenic patients.
Cefepime has been shown to be active against
tinine clearance 60ml/min), the dose of
cefepime should be adjusted. The recommend­
most strains of the gram-positive Staphylococcus ed initial dose of cef epime should be the same
and Streptococcus microorganisms and most of as in patients with normal renal function
the gram-negative microorganisms, and also except in patients undergoing hemodialysis.
Cefepime
active against some of the anaerobes such as. Drug inter: Renal function should be monitored
clostridium perfringens and mobiluncus spp. carefully if high doses of aminoglycosides are to
C/I: Cefepime is contraindicated in patients who be administered with cefepime because of the
have shown hypersensitivity reactions to the increased potential of nephrotoxicity and ototoxi­
cephalosporin class of antibiotics, penicillins or
•

city of aminoglycoside antibiotics.

other beta-lactam antibiotics & any component of Nephrotoxicity has been reported following con­
the formulation.
I comitant administration of other cephalosporins

'f
S/E: Generally cefepime is well tolerated.
�:·....
,, with potent diuretics such as frusemide.
However, few side-effects including rash, pruritus, ,

urticaria, fever, headache, nausea, vomiting, + CEFA-4 IM/IV lnj. Popular

Ceftriaxo·ne
diarrhea, dizziness, oral moniliasis may occur. Cefepime hydrochloride 500mg & 1gm vial with
Precautions: In patients with impaired renal water: i.m/i.v injection.
function (creatinine clearance ?60ml/min), the 500mg vial with water: 300.00 MRP
dose of cefepime should be adjusted. Cefepime l g m vial with water: 550.00 MRP
should be advised with caution in individuals t CEFA-4 2gm I.V Inj. Popular
with a history of gastrointestinal diseases, Cefepime hydrochloride 2gm vial with water: i.v
particularly colitis. injection.
Pregnancy & lactation: There are no adequate 2gm vial with water: 1100.00 MRP
and well-controlled studies of cefepime use in t CEFTIPIME IM/IV lnj. Renata
pregnant women, so it should be used during Cefepime hydrochloride 500mg & 1gm vial with
pregnancy only if clearly needed. water: i.m/i.v injection.
Cefepime is excreted in human breast milk in 500mg vial with water: 301.13 MRP
very low concentrations, so caution should be lgm vial with water: 552.08 MRP
exercised if it is administered to a nursing t CEFTIPIME 2gm I.V Inj. Renata
woman. Cefepime hydrochloride 2gm vial with water: i.v
Dosage & admin: injection.
Recommended dosage schedule for adults with 2gm vial with water: 1104.15 MRP
normal renal function: t EFEPIME IM/IV lnj. Ziska
Moderate to severe pneumonia: lgm to 2gm i.v Cefepime hydrochloride 500mg & 1gm vial with
12 hourly for 10 days; ..,
,,
water: i.m/i.v injection.
··
.
.

Mild to moderate uncomplicated or complicated ·

,;, ' Cefuroxime 500mg vial with water: 300.00 MRP
urinary tract infections (including
.. . lgm vial with water: 550.00 MRP
pyelonephritis): O.Sgm to lgm i.v or i.m 12 .'
.
t EFEPIME 2gm I.V lnj. Ziska
hourly for 7-10 days; Cefepime hydrochloride 2gm vial with water: i.v
Severe uncomplicated or complicated urinary injection.
tract infections (including pyelonephritis): 2gm 2gm vial with water: 1100.00 MRP
- . 1:
� q
.

i.v 12 hourly forlO days; � + FORGEN IM/IV lnj. Aristopharma

.

Moderate to severe uncomplicated skin and skin .· · ARISTOPHARMA LTD .

.
Cefepime hydrochloride 500mg & 1gm vial
structure infections: 2gm i.v 12 hourly for 10 www.a ri stop ha rma .com with water: i.m/i. v injection.
days; 500mg vial with water: 300.00 MRP
 ANTIMICROBIAL DRUGS QIMP-17 (264)

l gm vial with water: 550.00 MRP with water: i.m/i.v injection. reported in 3.86% of the patients. Superficial
+ FORGEN 2gm I.V lnj. Aristopharma 500mg vial with water: 300.00 MRP phlebitis, thrombophlebitis and infection site
Cefepime hydrochloride 2grn vial with water: lgm vial with water: 500.00 MRP reaction have been noted in 2.31 % of patients
i.v injection. + WINNIPIME I.M/l.V Inj. Sanofi-aventis receiving intraveno�s cefpirome.
2gm vial with water: 1100.00 MRP Cefepime hydrochloride 500mg & 1gm vial Precaution: There are no special precautions for
+ GEN-4 IM/IV Inj. lbn Sina with water: i.m/i.v injection. its use in the elderly provided dosage is adjusted
Cefepime hydrochloride 500mg & 1 gm vial 500mg vial (combipack): 300.00 MRP accordingly to renal function.
with water: i.m/i.v injection. 1 gm vial (combipack): 550.00 MRP Pregnancy & lactation: The safety of cefpirome
500mg vial with water: 305.00 IP + WINNIPIME 2gm I.V Inj. Sanofi-aventis has not been established in pregnancy and as
lgm vial with water: 555.00 IP Cefepime hydrochloride 2gm vial with water: with all agents it should be administered with
+ GEN-4 2gm I.V Inj. lbn Sina i.v injection. caution, specially during the early months of
Cefepime hydrochloride 2gm vial with water: 2gm vial (combipack): 1100.00 MRP pregnancy. As cefpirome is excreted in human
i.v injection. . + XENIM I.M/l.V Inj. Opsonin breast milk, either cefpirome treatment should be
2gm vial with water: 1010.00 IP Cefepime hydrochloride 500mg & 1gm vial discontinued or breast feeding ceased.
+ JAPIME IM/IV lnj. Jayson with water: i.m/i.v injection. Dosage & admin: Cefpirome is administered
Cefepime hydrochloride 1gm vial with water: 500mg vial with water: 264.90 MRP only through the parenteral route. The dosage
i.m/i.v injection. l gm vial with water: 485.66 MRP is dependent upon the severity and site of
lgm vial (combipack): 526.98 IP + XIMEPIME I.M/l.V Inj. Globe infection, the susceptibility of the infecting
+ MAXPIME IM/IV lnj. Square Cefepime hydrochloride 500mg & 1gm vial microorganisms and age, weight and renal
Cefepime hydrochloride 500mg & 1gm vial with water: i.m/i.v injection. function of the patient. The drug is adminis­
with water: i.m/i.v injection. 500mg vial x l's combipack: 300.00 MRP tered through intravenous injection or infusion.
500mg vial with water: 300.00 MRP lgm vial x l's combipack: 550.00 MRP The following dosages are recommended for
l gm vial with water: 550.00 MRP + XIMEPIME 2gm I.V Inj. Globe moderate to severe infections in adult patients
+ MAXPIME I.V lnj. Square Cefepime hydrochloride 2gm vial with water: with normal renal function:
Cefepime hydrochloride 2gm vial with water: i.v injection.
1. Complicated upper & lower urinary tract
i.v injection. 2gm vial x l's combipack: 1100.00 MRP
·

infections- lgm 12 hourly twice daily; 2. Skin

2gm vial with water: 1100.00 MRP + ZOPIME I.M/l.V lnj. Healthcare
& soft tissue infections- lgm 12 hourly twice
+ PIME-4 IM/IV Inj. ACI Cefepime hydrochloride 500mg & 1gm vial
daily; 3. Lower respiratory tract infections- 1
Cefepime hydrochloride 500mg & 1 gm vial with water: i.m/i.v injection.
to 2gm 12 hourly twice daily;
with water: i.m/i.v injection. 500mg vial with water: 300.00 MRP
4. Bacteremia/septicemia and severe
500mg vial with water: 301.13 MRP l gm vial with water: 550.00 MRP
infections- 2gm 12 hourly twice daily;
l gm vial with water: 552.07 MRP
5. Infections in neutropen.ic patients- 2gm 12
+ PIME-4 2gm I.V Inj. ACI
Cefepime hydrochloride 2gm vial with water: CEFPIROM E42 hourly twice daily.

i.v injection. Dose reduction is necessary in patients with

•

2gm vial with water: 1104.15 MRP CEFPIROME: I.V Injection markedly reduced renal function. After an

+ SUPERPIME IM/IV Inj. Acme Cefpirome is a fourth generation cephalosporin initial dose of 0.5-2gm to establish a high

Cefepime hydrochloride 500mg & 1 gm vial antibiotic that has an extended spectrum of activ­ serum concentration, the dose should be
with water: i.m/i.v injection. ity to include pseudomonas aeruginosa and gram­ reduced by SOo/o for clearances of 49-21ml in
500mg vial with water: 300.00 MRP positive organisms including methicillin-sensitive min-1 or 75°/o for clearances of 20ml in min-1.

1gm vial with water: 550.00 MRP staphylococcus aureus, coagulase-negative In end-stage renal disease, a supplementary

+ SUPERPIME 2gm IV Inj. Acme staphylococci and enterococcus faecalis. dose equal to SOo/o of the recommended daily

Cefepime hydrochloride 2gm vial with water: Cefpirome is available as cefpirome sulphate dose should be administered after each

i.v injection. INN equivalent to 1gm of cefpirome in vial for hemodialysis treatment.

2gm vial with water: 1100.00 MRP intravenous injection. The duration of treatment depends on the
+ TETRACEF IM/IV Inj. Beximco Mode of action: See above under the text of patient's clinical and bacteriological response.
Cefepime hydrochloride 500mg & 1gm vial cephalosporins.
Drug inter: There are no significant drug
with water: i.m/i.v injection. Ind: I. Severe infection, such as septicemia, bac­
interactions have been observed with cefpirome.
500mg vial with water: 300.00 MRP teremia & infections in immunosuppressed neutr­
Storage: Cefpirome vial should be stored below
•

lgm vial with water: 550.00 MRP openic patients with hematological malignancies.
25°C protected from light. Freshly reconstituted
+ TETRACEF 2gm I.V Inj. Beximco 2. Lower respiratory tract infections including
solution is always recommended. Reconstituted
Cefepime hydrochloride 2gm vial with water:
•

pneumonia.
solution can be stored for up to 6 hours at room
i.v injection. 3. Severe urinary tract infections including
temperature and 24 hours in refrigerator (at 2-
2gm vial with water: 1100.00 MRP pyelonephritis.
80C) when prepared in water for injection BP.
+ TUPIME Inj. Kemiko 4. Skin and soft tissue infections.
Cefepime hydrochloride 1gm vial with water: 5. Bone and joint infections. + FORCE Inj. Square
i.m/i.v injection. 6. Infections in immunocompromised patients. Cefpirome sulphate INN equivalent to 1 gm of
lgm vial with water: 550.00 MRP 7. Other infections. cefpirome in vial with water: i.v injection
+ ULTRAPIME Inj. Incepta C/I: Known hypersensitivity to the cephalosporin 1 gm vial with water: 401.51 MRP '

Cefepime hydrochloride 500mg & 1gm vial group of antibiotics. ..

with water: i.m/i.v injection. S/E: Cefpirome is generally well tolerated. There
500mg vial with water: 300.00 MRP are no predictable life threatening effects of cef­ Other beta-lactam Antibiotics
lgm vial with water: 550.00 MRP pirome. Adverse gastrointestinal reactions
+ UNIPIM Inj. Drug Inter. include- diarrhea, nausea, vomiting, pseudomem­
,
Cefepime hydrochloride 500mg & 1 gm vial braneous colitis, abdominal pain, have been CARBAPENEMs21,s2,9s 134
; .
.·
.

An antipseudomonal weapon . · _._- ..:.·- �:_: --·(:efepime USP 1 gm I v ia l

. . ·

. ·
j

IV/ IM
.. •
·

. in l·ife threatening infec�i()n ..

e Injection
'

I
.

. -- · . .
.
.

. ;-,;:_

KEMIKO·.PHARMACEUTICALS LTD.
--
4th. #en.e'C.ation rfa't.en.te'C.al t:..epla.alo�po't.in.
-
. · - .. --·
- :
. . ;. .;;· . � :
.

. .-::-- . ....:_ ·· . . ' .

· .
··. . .

I
•

•

Carbapenems: Carbapenem antibiotics belong to
beta-lactam antibiotics. The important carbapen­
em antibiotics currently available are- Imipenem,
Meropenem, Doripenem & Ertapenem. All these
carbapenem antibiotics are active against a broad
spectrum of pathogens, which include the majori­
ty of clinically significant gram-positive and
gram-negative, aerobic and anaerobic strains of
bacteria. This broad spectrum antibacterial activi­
ty makes these antibiotics particularly useful in
the treatment of polymicrobic mixed infections,
as well as initial therapy prior to the identifica­
tion of the causative organisms. Among these,
imipenem, meropenem & doripenem have good
activity against pseudomonas aeruginosa and
acinetobacter spp; these are used for the treat­
ment of severe infections including septicemia,
hospital-acquired penumonia, intra-abdominal
infections, skin and soft-tissue infections and
complicated urinary-tract infections. Ertapenem
has found effective in the treatment of abdominal
and gynecological infections and community
acquired pneumonia, but not active against
atypical respiratory infections, pseudomonas
aeruginosa and acinetobacter spp. infections.
I The important difference in pharmacokinetics of
I
I these products is that, imipenem is inactivated in
I the kidney by an enzymatic activity, that is why,
I a specific renal enzyme inhibitor- cilastatin is
added with imipenem to make it stable to the
renal enzyme. But, unlike imipenem, meropen­
em, doripenem and ertapenem are not inactivated
in the kidney by enzymatic activity, so, these do
not require any cilastatin supplement.
II Mode of action: Like other beat-lactam antibio­
I tics, carbapenems are also bactericidal and act by
r interfering the synthesis of bacterial cell wall.
I
I Ind: See below under the text of individual
products.
C/I: Patients with history of hypersensitivity to
I
carbapenems or other beta-lactam antibiotics.
S/E: See below under the text of individual
products
Precautions: If an allergic reaction to any of the
carbapenem occurs, the drug should be discontin­
ued and appropriate measures to be taken.
Monitor transaminase and bilirubin levels when
used in hepatic disease. Monitor for over growth
of non-susceptible organisms as with other antibi­
otics. Caution in individuals with a history of
gastro-intestinal complaints, particularly colitis.
In patients who develop diarrhoea, consider diag­
nosis of pseudomembranous colitis. Caution, if to
be co-administered with potentially nephrotoxic
drugs. Carbapenem therapy may reduce serum
valproic acid levels, sub-therapeutic levels may
occur. As with other antibiotics, caution may be
required in using meropenem as monotherapy in
critically ill patients with known or suspected
pseudomonas aeruginosa lower respiratory tract
infection. Regular sensitivity testing is recom­
mended when treating pseudomonas aeruginosa
infection.
Pregnancy & lactation: Safety in pregnancy and
breast-feeding mothers not established.
Dosage & admin: See below under the text of
individual products.
I� IMIPENEM + CILASTATIN134
QIMP-17 (265)
IMIPENEM + CILASTATIN: IV/IM Injection
Imipenem, a semi-synthetic derivative of
thienamycin, the parent compotind produced by
the filamentous bacterium streptomyces catteleya.
As imipenem is inactivated in the kidney by an
enzyme activity, a specific renal enzyme
inhibitor- cilastatin is added with imipenem to
make it stable to the renal enzyme. That is why,
imipenem injection is produced as a combined
preparation with cilastatin. The available
combined preparations are- i. 250mg of
imipenem equivalent & 250mg of cilastatin
equivalent as white dry powder in vials; ii.
SOOmg of imipenem equivalent & 500mg of
cilastatin equivalent as white dry powder in vials;
iii. 750mg of imipenem equivalent & 750mg of
cilastatin equivalent as white dry powder in vials.
Mode of action: Imipenem is one of the widest
spectrum of the beta-lactam antibiotics. It is
active against nearly all common bacterial
sj>ecies, including those resistant to
aminoglycosides and newer cephalosporins.
· Ind: The activity of imipenem against a widest
spectrum of pethogens makes it particularly
useful in the treatment of polymicrobic mixed
aerobic/anaerobic infections as well as initial
therapy prior to the identification of the causative
organisms. Imipenem is used as empirical
monotherapy in intensive care unit (ICU) patients
with nosocomial infections.
Imipenem is indicated for the treatment of the
following infections due to susceptible organi­
sm�: 1. Intra-abdominal infections, 2. Lower
respiratory tract infections, 3. Gynaecological
infections, 4. Septicaemia, 5. Genitourinary tract
infections, 6. Bone & joint infections, 7. Skin &
soft tissue infections,
8. Endocarditis.
C/I: Patients with history of hypersensitivity to
carbapenems or other beta-lactam antibiotics.
S/E: Please consult the manufacturer's literature.
Precautions: See under the text of carbapenems.
Pregnancy & lactation: Safety in pregnancy and
breast-feeding mothers not established.
Dosage & ad.min: The dosage recommenda­
tions for imipenem + cilastatin (for i.v & i.m
use only) represent the quantity of imipenem
to be administered. An enquivalent amount of
cilastatin is also present. The total daily
dosage of imipenem bases on the type or
severity of infection & is given in equally
divided doses based on consideration of degree
of susceptibility of the pathogens, renal
function & body weight.
Adult dosage schedule for patients with normal
renal function:
Doses based on a patient with normal renal
function (creatinine clearance
>70ml/min/1.73m2) & a body weight >70kg. A
reduction in doses must be made for a patient
with a creatinine clearance <70ml/min/1. 73m2
& /or a body weight <70kg. The reduction of
doses for body weight is specially important
for patients with much lower body weights
and/or moderate/severe renal insufficiency. In
most infections due to less susceptible organi­
sms, the daily dose of 1-2gm should be admin­
istered in 3-4 divided doses. For the treatment
of moderate infection, 1gm b.i.d dosage
regimen may also be used. In infections due to
ANTIMICROBIAL DRUGS
less susceptible organisms, the daily dosage of
imipenem may be increased to a maximum of
4gm/day or 50mg/kg/day, whichever is lower.
Each dose of imipenem <500mg should be
given by i.v infusion over 20-30 minutes. Each
dose >SOOmg should be infused over 40-60
minutes. In patients who develop nausea
during the infusion, the rate of infusion may
be slowed.
Paediatric dosing schedule (3 months or older):
For children & infants, the following schedule
is recommended: a) Children >40kg body
weight showd receive adult doses; b) Children
and infants <40kg body weight should receive
15mg/kg at six-hour intervals. The total daily
dose should not exceed 2gm. Clinical data are
insufficient to recommend dosing for children
less than 3 months of age, or pediatric patients
with impaired renal function (serum
creatinine >2mg/dl). Im.ipenem is not
recommended for the therapy of meningitis. If
meningitis is suspected, an appropriate
antibiotic should be used. Imipenem may be
used in children with sepsis as long as they are
not suspected of having meningitis.
Drug inter: Consult manufacturer's literature.
Note: For further information, please consult
manufacturer's literature.
t CISPENAM 250 I.V Inj. Incepta
Imipenem 250mg + cilastatin 250mg/vial;
powder for reconstitution: i.v injection.
250mg vial x l's pack: 650.00 MRP
t CISPENAM 500 I.V Inj. Incepta
lmipenem 500mg + cilastatin 500mg/vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 1195.00 MRP
t CISPENAM 750 I.M Inj. lncepta
Imipenem 750mg + cilastatin 750mg/vial;
powder for reconstitution: i.m injection.
750mg vial x l's pack: 1650.00 MRP
t IMBAC 500 I.V Inj. Popular
Imipenem SOOmg + cilastatin 500mg/vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 1199.51 MRP
t IMINEM 500 I.V Inj. ACI
Imipenem 500mg + cilastatin 500mg/vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 1199.51 MRP
+ IMIPEN 500 I. V Inj. Techno Drugs
Imipenem 500mg + cilastatin 500mg/vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 1195.00 MRP
t IROPEN 500 I.V Inj. Renata
Imipenem 500mg + Cilastatin 500mg/vial;
powder for reconstitution: i.v injection.
500mg vial x 1's pack: 1195.00 MRP
MEROPENEM95
MEROPENEM: I.V Injection
Meropenem, a carbapenem group, initially identi­
fied as olivanic acid, which is a beta-lactamase
inhibitor. Meropenem as a beta-lactam antibiotic,
its antibacterial spectrum (broad spectrum)
includes the majority of clinically significant
gram-positive & gram-negative, aerobic &
anaerobic strains of bacteria. Unlike imipenem,
meropenem is not inactivated in the kidney by
enzymatic activity, that is why, it is stable to the
•
 1 gm
ene
QIMP-17 (266)
IV
•-----· Meropenem
-Astra
• Biophar uticafs
maa ltd.
renal enzyme (which inactivates imipenem) and
therefore can be given without cilastatin (a
specific renal enzyme inhibitor). Meropenem has
less seizure-inducing potential, & good
tolerability at high doses, which makes it
particularly useful for the treatment of meningitis
& other CNS infections.
Mode of action: Like other beat-lactam
•
antibiotics, it is a bactericidal antibiotic and acts
by interfering the synthesis of bacterial cell wall.
Ind: Pne\1monias including nosocomial
pneumonias. Urinary tract infections. Intra­
abdominal infections. Gynaecological infections
such as endometritis and pelvic inflammatory
disease. Skin and soft tissue infections.
Meningitis. Septicaemia.
Besides, empiric treatment for presumed
infections in adult patients with febrile
neutropenia used as monotherapy or in
combination with anti-viral or anti-fungal agents.
There is no experience in paediatric patients with
neutropenia or primary or secondary
immunodeficiency.
C/I: Patients with history of hypersensitivity to
carbapenems or other beta-lactam antibiotics.
S/E: Meropenem i.v therapy is generally well
tolerated. Local injection site reactions­
inflammation, thrombophlebitis, pain at the site
of injection. Skin reactions- rash, pruritus,
urticaria. Gastrointestinal- abdominal pain,
nausea, vomiting, diarrhoea, pseudomembranous
colitis. Blood- reversible thrombocythaemia,
eosinophilia, thrombocytopenia and neutropenia.
Positive Coombs test. Reduction in partial
thromboplastin time. Rarely systemic allergic
reactions (hypersensitivity), which may include­
angioedema and manifestations of anaphylaxis.
Liver function- reversible increases in serum
bilirubin, transaminases, alkaline phosphatase &
lactic dehydrogenase. CNS- headache,
paraesthesia and infrequently convulsions
(although no casual relationship has been
established). Other- oral and vaginal candidosis.
Precautions: See under the text of carbapenems.
Pregnancy & Lactation: Safety in pregnancy
and breast-feeding mothers not established.
Dosage & Admin: Adults: The dosage and
duration of therapy should be established
depending on the type and severity of infection
and the condition of the patient. The
recommended daily dosage is as follows:
Pneumonia, urinary tract infections,
gynaecological infections such as endometritis,
skin and skin structure infections- 500mg i.v
every 8 hours. Nosocomial pneumonias,
peritonitis, presumed infections in neutropenic
patients and septicaemia- lgm i.v every 8
hours. Meningitis- 2gm i.v every 8 hours.
Hepatic impairment: No dosage adjustment is
necessary in patients with hepatic insufficiency.
Elderly patients: No dosage adjustment is
requi.red for the elderly with normal renal
function or creatinine clearance values above
50ml/min.
Renal impairment: Dosage should be reduced
in p�tients with creatinine clearance less than
Simi/min, as scheduled below.
Children: 0-3 months- not recommended; 3
months-12 years- 10-20mg/kg i.v every 8 hours
depending on type and severity of infection,
susceptibility of the pathogens and the
condition of the patient. Children over 50kg
weight- adult dosage.
Meningitis- 40mg/kg i. v every 8 hours. There
is no experience in children with hepatic or
renal impairment.
Administration: Following reconstitution (Sml
per 250mg) meropenem should be given as an
intravenous bolus injection over approx. 5
minutes or by intravenous infusion (dilution in
50-200ml) over approx. 15 to 30 minutes.
Drug inter: Probenecid competes with
meropenem for active tubular secretion and thus
inhibits the renal excretion, with the effect of
increasing the elimination half-life and plasma
concentration of meropenem. As the potency and
duration of action of meropenem dosed without
probenecid are adequate, the co-administration
of probenecid with meropenem is not
recommended. However, no specific drug
interaction data are available.
+ ARONEM I. V Inj. ACI
Meropenem trihydrate SOOmg & 1gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 652.45 MRP
lgm vial x l's pack: 1204.52 MRP
+ AROPEN I.V Inj. Aristopharma
Meropenem trihydrate 500mg & 1gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 650.00 MRP
lgm vial x l's pack: 1200.00 MRP
+ CARBANE M I.V lnj. Sanofi-aventis
Meropenem trihydrate SOOmg & 1gm vial;
powder for reconstitution: i.v injection.
SOOmg vial x l's pack: 700.01 MRP
l gm vial x l's pack: 1300.00 MRP
+ FULSPEC I.V Inj. Acme
Meropenem trihydrate 500mg & 1gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 652.46 MRP
lgm vial x l's pack: 1204.53 MRP
+ 1-PENAM I.V Inj. Incepta
Meropenem trihydrate 500mg & lgm vial;
powder for reconstitution: i.v injection.
SOOmg vial x l's pack: 700.00 MRP
lgm vial x l's pack: 1300.00 MRP
+ MENEM I.V Inj. Astra
Meropenem trihydrate 1gm vial; powder for
reconstitution: i. v injection.
lgm vial x l's combipack: 1300.00 MRP
t MEROBAC I.V Inj. Popular
Meropenem trihydrate 500mg & 1gm vial;
powder for reconstitution: i.v injection. •
500mg vial x l's pack: 652.45 MRP
lgm vial x l's pack: 1204.53 MRP
+ MEROCAR I.V Inj. Globe
Meropenem trihydrate 500mg & 1gm vial;
powder for reconstitution: i.v injection.
SOOmg vial x l's pack: 650.00 MRP
lgm vial x l's pack: 1200.00 MRP
+ MEROCON I.V Inj. Beacon
Meropenem trihydrate 500mg/10ml & l gm/20ml
vial; powder for reconstitution: i.v injection.
SOOmg ( l Oml) vial x l's pack: 700.00 MRP
lgm (20ml) vial x l's pack: 1300.00 MRP

+MEROJECT I. V Inj. SK+F
Meropenem trihydrate 500mg & 1gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 700.00 MRP
lgm vial x l's pack: 1300.00 MRP
+MEROM I.V Inj. Techno Drugs
Meropenem trihydrate 500mg & lgm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 650.00 MRP
l gm vial x l's pack: 1200.00 MRP
+MEROMAX I.V lnj. Orion Pharma
Meropenem trihydrate 500mg & lgm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 652.45 MRP
lgm vial x l's pack: 1204.45 MRP
+MERONIX I.V Inj. Novo Healthcare
Meropenem trihydrate 500mg & 1gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 650.00 MRP
l gm vial x l's pack: 1200.00 MRP
+MEROPEN I.V lnj. Renata
Meropenem trihydrate 500mg & 1gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 700.00 MRP
l gm vial x l's pack: 1300.00 MRP
The latest carbapenem, the broadest coverage
+MEROTRAX I.V Inj. lbn Sina
Meropenem trihydrate 500mg & 1 gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 700.00 IP
lgm vial x l's pack: 1300.00 IP
+NEOPENEM I.V Inj. Healthcare
Meropenem trihydrate 500mg & l gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 750.00 MRP
l gm vial x l's pack: 1350.00 MRP
+RONEM I.V Inj. Opsonin
Meropenem trihydrate 500mg & 1gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 573.95 MRP
lgm vial x l's pack: 1103.77 MRP
+ROPENEM I.V Inj. Drug Inter.
Meropenem trihydrate 500mg & l gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 501.64 MRP
l gm vial x l's pack: 1000.00 MRP
QIMP-17 (267)
+R-PENEM I.V Inj. RAK Pharma
Meropenem trihydrate 500mg & l gm vial;
powder for reconstitution: i. v injection.
500mg vial x l's pack: 700.00 MRP
l gm vial x l's pack: 1300.00 MRP
+SPECBAC I.V Inj. Square
Meropenem trihydrate 500mg & 1gm vial;
powder for reconstitution: i.v injection.
500mg vial x l's pack: 652.45 MRP
l gm vial x l's pack: 1204.53 MRP
DORIPENEM52
DORIPENEM: I.V Injection
Doripenem is a synthetic broad spectrum
carbapenem antibiotic structurally related to P­
lactum antibiotics. It is available as- doripenem
monohydrate INN 500mg/vial for i. v infusion.
Mode of action: Doripenem exerts its bacterici­
dal activity by inhibiting cell wall biosynthesis.
Ind: Doripenem has a potent broad spectrum
antibacterial activity against aerobic and anaero­
bic gram postitive and gram negative bacteria
including pseudomonas aeruginosa and acineto­
bacter spp. Doripenem is used for the treatment
Doripenem Injection 250 & 500 mg
of severe infections including- i. hospital­
acquired penumonia, ii. complicated intra­
abdominal infections, and iii. complicated
urinary-tract infections.
C/I: Doripenem is contraindicated in patients
with known serious hypersensitivity to
doripenem and who have demonstrated
anaphylactic reactions to P-lactam antibiotics. It
is also contraindicated in patients with known
serious hypersensitivity to other carbapenems.
S/E: The common side effects involving the skin­
rash and pruritus; the gastrointestinal system­
including nausea, vomiting and diarrhea; nervous
system disorder- headache; vascular disorder­
phlebitis.
Precautions: Serious and occasionally fatal
hypersensitivity reactions have occurred in
patients receiving P-lactam antibiotics. Before
therapy with doripenem is started, careful inquiry
should be made concerning a previous history of
.9"- �u
SQUARE
PHAllMAClfUTIC4/..S I.TD,
•ANOLAOE!SH
ANTIMICROBIAL DRUGS
hypersensitivity reactions to other active
substances of this class or other P-lactam
antibiotics. Seizures have infrequently been
reported during treatment with other
carbapenems. Pseudornembranous colitis due to
c/ostridium difficile has been reported with
doripenem and many range of severity from mild
to life-threatening. Therefore, it is important to
consider this diagnosis in patients who present
with diarrhea during or subsequent to the
administration of doripenem. Administration of
doripenem, like other antibiotics has been
associated with emergence and selection of
strains with reduced susceptibility.
Pregnancy & lactation: Doripenem is drug of
pregnancy category B. For doripenem, limited
clinical data on exposed pregnancies are
available. It is unknown whether doripenem is
excreted in breast milk or not. A study in rats has
shown that doripenem and its metabolite are
excreted in breast milk. A decision whether to
continue/discontinue breast feeding or to
continue/discontinue therapy with doripenem
should be made taking into account that the
benefit of breast feeding in child and the benefit
of doripenem therapy to nursing mother.
Dosage & admin:
Adults & children (of 18 years & over):
1. Nosocomial (hospital-acquired) pneumonia:
500mg or lgm every 8 hours to be infused
ov�r 1 or 4 hours (in case of lgm 4-hour
infusion time is advised) for 7-14 days;
2. Complicated UTI, including pyelonephritis:
500mg every 8 hours to be infused over 1 hour
for 10 days;
3. Complicated intra-abdominal infection:
500mg every 8 hours to be infused over 1 hour
for 5-14 days.
Dosage in patients with renal impairment: The
following dosage of doripenem should be used
for patient with renal impaired function:
i. Creatinine clearance >50ml/min- no dosage
adjustment is necessary;
ii. Creatinine clearance �30-SOml/min- 250mg
i.v over 1 hour, every 8 hours;
iii. Creatinine clearance >10 to< 30ml/min-
.
.. ••• •
••• ••
.
www.squarepharma.com.bd
• •
'
·
Ill
ANTIMICROBIAL DRUGS
250mg i.v over 1 hour, every 12 hours;
Dosage in patients with renal impainnent:
Doripenem dosing and administration
recommended for patients on continuous renal
replacement therapies (CRRT) are as following:
i. Continuous venovenous hemofdtration
(CVVH):
Glomerular filtration rate: 30ml/min- 250mg
i.v infusion over 4 hours, every 12 hours;
ii. Continuous venovenous hemodiflltration
(CVVHDF): Glomerular filtration rate: < cloacae, Klebsiella oxytoca, Citrobacter species
Sml/min- 250mg i. v infusion over 4 hours,
every 12 hours;
' '
iii. Continuous venovenous hemodiflltration
(CVVHDF): Glomerular filtration rate: S-
30ml/min- SOOmg i. v infusion over 4 hours,
every 12 hours.
Dose in elderly patients (65 years of age): No
dose adjustment is necessary in elderly
patients, except in cases of moderate to severe
renal impai.rment.
Dose in patients with impaired hepatic function:
No dose adjustment is necessary.
Children below 18 years: Doripenem is not
recommended for children below 18 years of
age due to a lack of safety and efficacy data.
Drug inter: Please consult manufacturer's
literature.
t DORIBAX I.V Inj. UniMed & UniHealth
Doripenem monohydrate INN 500mg/vial: for i.v
infusion.
500mg vial x l O's pack: 29378.90 MRP
t DORINEM I.V Inj. ACI
Doripenem monohydrate INN 500mg/vial: for i.v
infusion.
500mg vial x l's pack: 2000.00 MRP
t DORIPEN I.V lnj. SK+F
Doripenem monohydrate INN 250mg & 500mg/
vial: for i.v infusion.
250mg vial x l's pack: 1300.00 MRP
500mg vial x l's pack: 2000.00 MRP
MonobacUlms
AZ'.IU. ONAM 21,26,5 l
AZTREONAM: I.M/l.V Injection
It is a synthetic monocyclic beta-lactam
(monobactam) antibiotic with an antibacterial
spectrum limited to gm-negative aerobic bacteria.
It is available as- 500mg & lgm vial for i.m/i.v
injection, & 2gm vial for i.v injection.
Mode of action: Like other beat-lactam antibi­
otics, it is a bactericidal antibiotic and acts by
interfering the synthesis of bacterial cell wall.
It inhibits bacterial cell wall synthesis by block­
ing peptidoglycan crosslinking. The inhibition of
bacterial cell wall synthesis occurs due to a high
affinity of aztreonam for penicillin binding pro­
tein 3 (PBP3). By binding to PBP3, aztreonam
inhibits the third and last stage of bacterial cell
wall synthesis. Cell lysis is then mediated by
bacterial cell wall autolytic enzymes such as
QIMP-17 (268)
autolysins. It is possible that aztreonam interferes
with an autolysin inhibitor.
Ind: Aztreonam is indicated for the treatment of
the following infections caused by only
susceptible gram -negative microorganisms:
• Urinary tract infections (complicated and
uncomplicated), including pyelonephritis and
cystitis (initial and recurrent) caused by
Escherichia coli, Klebsiella pneumoniae, Proteus
mirabilis, Pseudomonas aeruginosa, Enterobacter
and Serratia marcescens. It is also effective
against N. gonorrhoeae.
• Lower respiratory tract infections, including
pne11monia and bronchitis caused by escherichia
coli, Klebsiella pneumoniae, Pseudomonas aerug­
inosa, Haemophilus influenzae, Proteus mirabilis,
Enterobacter species and Serratia marcescens.
• Septicemia caused by Escherichia coli,
Klebsiella pneumoniae, Pseudomonas aeruginosa,
Proteus mirabilis, Serratia marcescens and
Enterobacter species.
• Skin and Skin-Structure Infections, including
those associated with postoperative wounds,
ulcers and burns caused by Escherichia coli,
Proteus mirabilis, Serrati a marcescens,
Enterobacter species, Pseudomonas aeruginosa,
Klebsiella pneumoniae and Citrobacter species.
• Intra-abdominal Infections, including peritonitis
caused by Escherichia coli, Klebsiella species
including K. pneumoniae, Enterobacter species
including E. cloacae, Pseudomonas aeruginosa,
Citrobacter species including C. freundii and
Serratia species including S. marcescens.
• Gynecologic infections, including endometritis
and pelvic cellulitis caused by Escherichia coli,
Klebsiella pneumoniae, Enterobacter species
including E. cloacae and Proteus mirabilis.
It is also effective against N. meningitidis.
•
Aztreonam is indicated for adjunctive therapy to
surgery in the management of infections caused
by susceptible organisms.
Aztreonam should not be used alone for 'blind'
treatment since it is not active against Gram­
positive organisms.
C/I: This preparation is contraindicated in
patients with known hypersensitivity to
aztreonam or any other component in the
formulation. Pregnancy and breast-feeding.
S/E: Systemic side-effects like diarrhea, nausea
and/or vomiting, and rash may occur. Other side
effects include anaphylaxis, angioedema, bron­
chospasm, pancytopenia, neutropenia, thrombo­
cytopenia, anemia, eosinophilia, leukocytosis,
thrombocytosis, abdominal cramp s, mouth ulcers,
altered taste; jaundice and hepatitis; dermatitis,
urticaria, pruritus, hypotension, flushing, seizure,
weakness, headache, fever, malaise may occur.
Precautions: Hypersensitivity to beta-lactam
antibiotics. In patients with impaired hepatic or
renal function, appropriate monitoring is
recommended during therapy; reduce dose in
?
renal impairment.
Pregnancy & lactation: Aztreonam is a preg­
nancy category B drug. There are no adequate
��
and well-controlled studies in pregnant women.
Aztreonam is excreted in human milk in
concentrations less than 1 %; consideration should
be given to temporary discontinuation of nursing.
Dosage & admin: Adult patients: By i.m
injection or i.v injection or infusion:
.
Moderately severe systemic infections- lgm 8
hourly or 2gm 12 hourly;
Severe systemic or life-threatening infections
(including systemic Pseudomonas aeruginosa
and lung infections in cystic fibrosis)- 2gm 6 or
8 hourly;
Urinary tract infections- SOOmg or lgm 8 or
12 hourly;
Maximum recommended dose for adult is 8gm
per day; single doses over lgm i.v route only.
Gonorrhoea/cystitis, by i.m injection, lgm as a
single dose.
•
Pediatric patients:
Children, over 1 week- by i.v injection or
infusion, JOmg/kg 6-8 hourly, increased in
severe infections; dosage information for new
born less than one week is not yet available;
For children of 2 years or older- SOmg/kg 6-8
hourly;
Maximum recommended dose for pediatric
patient is 120mg/kg/day.
Renal impairment in adult patients:
The dosage of aztreonam should be halved in
patients with estimated creatinine clearances
between lOml/min/1.73 m2 and 30ml/min/1.73
m2 after an initial loading dose of lgm or 2gm.
When only the serum creatinine concentration
is available, the following formula (based on
sex, weight, and age of the patient) may be
used to approximate the creatinine clearance:
Cler: weight (kg) x (140-age)72 x serum
creatinine (mg/di) Males: Cler =
Females: Cler 0.85 above value.
x
=
In patients with severe renal failure (creatinine
clearance less than 10 ml/mi.n/1.73 m2), the
usual dose of 500 mg, 1 g or 2 g should be
given initially. The maintenance dose should
be one-fourth of the usual initial dose given at
the usual fixed interval of 6, 8 or 12 hours. For
serious or life-threatening infections, in •
addition to the maintenance doses, one-eighth
of the initial dose should be given after each
hemodialysis session.
Direction for reconstitution of injection vial &
administration:
Bolus injection: lgm injection should be
reconstituted in 6-1Oml. The dose should be
slowly injected directly into a vein, or the
tubing of a suitable administration set, over a
period of 3 to 5 minutes.
Intravenous infusion: Initially lgm injection
vial should be reconstituted in 3ml water for •
injection. The reconstituted solution must be
further diluted with an appropriate infusion
•
solution to final concentration less than 2 °/o
w/v (at least SOml solution per gram of
aztreonam).
Appropriate infusion solution may be 0.9°/o
•••
•..1'1. www.squarepharma.com.bd
•••
•••
····--
•
 •

QIMP-17 (269) ANTIMICROBIAL DRUGS

sodium chloride injection BP, 5°/o glucose +BACTOCYCLINE Cap. Medicon Oxytetracycline hydrochloride USP equivalent to
intravenous infusion BP, 5% or 10°/o mannitol Tetracycline 250mg/capsule oxytetracycline 500mg/tablet
intravenous infusion BP. IOO's pack: 180.00 MRP 500mg x 20's pack: 60.00 IP
Infusion should be completed within a 20-60 +BPTE TRA Cap. Bristol +OXECYLIN Cap. Acme
minutes period. Tetracycline 250mg/capsule Oxytetracycline 250mg/capsule
Intramuscular administration: 0.5gm injection IOO's pack: 100.00 MRP 250mg x l OO's pack: 122.00 MRP
)
vial should be reconstituted in 1.5ml or lgm in +JMYCIN Cap. Jayson +OXYTETRACYCLINE Cap. Reliance
3ml water for injection. The dose should be Tetracycline 250mg/capsule Oxytetracycline 250mg/capsule
given by deep injection into a large muscle 1OO's pack: 131.00 MRP 250mg x 60's box: 135.00 MRP
mass. Aztreonam is well tolerated and should +MONATREX DS Cap. Amico +RENAMYCIN Cap. Renata
not be admixed with any local anesthetic Tetracycline 500mg/capsule Oxytetracycline 250mg/capsule
agent. 500mg x IOO's pack: 200.00 MRP 250mg x 60's pack: 120.00 MRP

Drug inter: Concomitant administration of +OMNIMYCIN Cap. Desh Pharma +RENAMYCIN I.M lnj. Renata

probenecid or frusemide and aztreonam causes Tetracycline 500mg/capsule Oxytetracycli.ne 50mg/ml: i.m injection.

clinically insignificant increases in the serum IOO's pack: 215.00 IP l Oml vial: 16.19 MRP

levels of aztreonam. +RANDAMYCIN Cap. Desh Pharma

Tetracycline 250mg/capsule.
Storage: Aztreonam solutions for i. v infusion at
IOO's pack: 100.00 IP DOXYCYCLJNE2I,33
concentrations not exceeding 2% w/v must be
+TETCLIN Cap. Pacific
used within 48 hours following constitution if
Tetracycline 250mg/capsule DOXYCYCLINE: Capsule/Injection
kept at controlled room temperature (15°-30°C)
IOO's pack: 100.00 MRP Ind: Broad spectrum antibiotic i.e infections due
or within 7 days if refrigerated (2°-8°C).
+TETRACYCLINE Cap. Reliance to gram+ve and gram-ve bacteria, brucella,

• ATREON 500mg I.M/I.V Inj. Square Tetracycline 500mg/capsule chlamydia, mycoplasma, rickettsiae, spirochetes

Aztreonam 500mg vial: i.m/i.v injection 500mg x IOO's pack: 234.00 MRP & large viruses; severe acne vulgaris, resistant
500mg vial x l's combipack: 300.00 MRP +TETRACYCLINE Cap. Pharmadesh malaria; and also chronic prostatitis and sinusitis.

+ATREON lgm I.M/I.V lnj. Square Tetracycline 250mg/capsule C/I; S/E & Caution: See above under

Aztreonam lgm vial: i.m/i.v injection 1OO's pack: 132.00 MRP tetracycline, but may be used in renal

lgm vial x l ' s combipack: 450.00 MRP +TETRACYCLINE-H Cap. Hudson impairment; avoid in porphyria.

• ATREON 2gm I.V Inj. Square Tetracycline 250mg/capsule Dosage & admin: 200 mg on 1st day, then 100

Aztreonam 2gm vial: i.v injection IOO's pack: 100.00 MRP mg (1 cap) daily (twice in severe infections

2gm vial x l's combipack: 650.00 MRP • TETRACYN Cap. Renata including chronic UTI).

+ AZONAM I.M/I.V lnj. Incepta Tetracycline 250mg & 500mg/capsule Acne, 50mg daily for 6-12 weeks or longer

Aztreonam USP l gm/vial: i.m/i.v injection. 250mg x IOO's pack: 122.00 MRP
+BPDOX Cap. Bristol
l gm vial x I combipack: 400.00 MRP 500mg x I OO's pack: 202.00 MRP
Doxycycline 1OOmg/capsule
• TETRAM Cap. Ambee
1 OO's pack: 150.00 MRP
Tetracycline 250mg/capsule
• COSDOX Cap. Cosmo Pharma
1.3 Tetracycline Group of Drugs l OO's pack: 133.00 MRP
Doxycycline 1OOmg/capsule
+TETRAM Cap. Modern
1 OO's pack: 200.00 IP
Tetracycline 250mg/capsule
TETRACYCLJNE2I,33 l OO's pack: 132.00 MRP
+DOPAC Cap. Pacific
Doxycycline 1 OOmg/capsule
+TETRAMET Cap. Medimet
1OO's pack: 200.00 MRP
TETRACYCLINE: Capsule/ Syrup/ Injection Tetracycline 250mg/capsule
+ DOXACIL Cap. Square
Ind: Broad spectrum antibiotic i. e. infections IOO's pack: 137.00 MRP
Doxycycline 1OOmg/capsule
due to gram+ve and gram-ve bacteria, brucella, +TETRASINA Cap. Ibo Sina
I OO's pack: 200.00 MRP
chlamydia, mycoplasma, rickettsiae, spirochetes Tetracycline 250mg & 500mg/capsule
+ DOXACIN Cap. Desh Pharma
'

& large viruses; severe acne vulgaris, resistant 250mg x l OO's pack: 137.00 MRP
Doxycycline 1OOmg/capsule
malaria. 500mg x 50's pack: 112.50 MRP
l OO's pack: 155.00 IP
C/I: Hypersensitivity to any tetracycline; renal + TETRAX Cap. Square
+DOXCLINE Cap. Alco Pharma
failure; pregnancy; infants & young children Tetracycline 500mg/capsule
Doxycycline 1OOmg/capsule
under 12 yrs. of age; SLE. 500mg x l OO's pack: 228.00 MRP
l OO's pack: 200.00 MRP
S/E: Gastro-intestinal tract discomforts; over­ +TETRAZEN Cap. Zenith.
growth of commensal organisms, superinfection
• DOXICAP Cap. Renata
Tetracycline 250mg/capsule
Doxycycline 50mg & 1 OOmg/capsule
with resistant organisms; staining of bone & 250mg x IOO's pack: 100.00 MRP
50mg x SO's pack: 71.00 MRP
teeth; rarely allergic reactions; nausea, vomiting,
l OOmg x IOO's pack: 220.00 MRP
diarrhoea.
OXYTET.RACYCLINE21,33
II
Cautions: Incompatible with penicillins &_other • DOXICEN Cap. CPL
Doxycycline 1OOmg/capsule
bactericidal antimicrobial agents; renal
lOO's pack: 220.00 MRP
impairment; pregnancy & childhood. OXYTETRACYCLINE: Capsule/
Syrup/Injection +DOXICLINE Cap. Ziska
Dosage & admin: By mouth, 250-SOOmg every
Ind: Broad spectrum antibiotic i.e. infections due Doxycycline 1OOmg/capsule
6 hrs; By i.m. inj, 100-200mg every 6-8 hrs; By
to gram+ve and gram-ve bacteria, brucella, IOO's pack: 200.00 MRP
i. v. infusion, 500mg every 12 hrs.
chlamydia, mycoplasma, rickettsiae, spirochetes
Early Syphilis, SOOmg every 6 hrs. for 15 days. + DOXICO Cap. Supreme
& large viruses; severe acne vulgaris, resistant Doxycycline 1OOmg/capsule
Non gonococcal urethritis, 500mg every 6
malaria. l OO's pack: 215.00 MRP
hours for 7-21 days.
C/I; S/E; Caution: See above under tetracycline.
+ DOXICON Cap. Medicon
+ A-TETRA Cap. Acme Dosage & admin: By mouth, 250-500 mg every
J
Doxycycline 1OOmg/capsule
Tetracycline 500mg/capsule 6 hours. BY i. m injection, 100 mg every 8-12
I OO's pack: 220.00 MRP
IOO's pack: 203.00 MRP hours. By slow i. v injection, 250-500 mg every
+A-TETRA Tab. Acme 12 hours. + DOXILIN Cap. Ambee
Tetracycline 500mg/tablet Doxycycline 1 OOmg/capsule
l OO's pack: 229.00 MRP +ORAVET Tab. Desh Pharma IOO's pack: 213.00 MRP

I
ANTIMICROBIAL DRUGS QIMP-17 (270)

t DOXIMET Cap. Medimet in adulls).

Doxycycline 1OOmg/capsule AMIKACIN52 lnpaired renal function: In patient with
l OO's pack: 2SO.OO MRP impaired renal function the daily dose should
t DOXIN Cap. Opsonin AMIKACIN: Injection be reduced and/or the intervals between doses
Doxycycline SOmg & 1OOmg/capsule Amikacin is a semi-synthetic aminoglycosidic increased to avoid accumulation of the drug.
SOmg x SO's pack: 62.90 MRP antibiotic. Simple doses schedule for renal impairment is
l OOmg x l OO's pack: 194.42 MRP Ind: Amikacin is indicated in the short-term given below-
t DOXIZEN Cap. Zenith treatment of serious infections due to susceptible Mild impairment- 500mg every 18 hours.
Doxycycline 1OOmg/capsule strains of Gram-negative bacteria. It is effective Moderate impairment- 500mg every 24 hours.
l OO's pack: 216.00 MRP in bacterial septicemia (including neonatal sep­ Severe impairment- 250mg every 24 hours.
sis); in serious infections of the respiratory tract, Administration: In most infections the
t DOXSEEM Cap. Seema
Doxycycline 1OOmg/capsule bones and joints, central nervous system (includ­ intramuscular route is preferred, but in life­
1OO's pack: 2SO.OO MRP ing meningitis) and skin and soft tissue; intra­ threatening infections, or in patients in whom
abdominal infections (including peritonitis); and intramuscular injection route is not feasible
t DOXY-A Cap. Acme
Doxycycline 1OOmg/capsule in bums and post-operative infections (including the intravenous route may be used.
l OO's pack: 219.00 MRP post-vascular surgery). Amikacin is also effective Intraperitoneal use- Amikacin may be used as
in serious complicated and recurrent urinary tract an irrigant after recovery from anaesthesia in
t DOXYCIN Cap. Cosmic
infections due to susceptible Gram-negative concentration of 0.25°/o.
Doxycycline 1OOmg/capsule ,
'

organisms. Amikacin may be considered as initial

-

l OO's pack: 216.00 MRP Other route of administration: Amikacin in

therapy in suspected Gram-negative infections & concentration of 0.25°/o may be used
t DOXYSINA Cap. Ibo Sina
therapy may be started before obtaining the satisfactorily as irrigation solution in abscess
Doxycycline 1OOmg/capsule
results of susceptibility. Amikacin is also e cavities, the pleural space, the peritoneum and
l OO's pack: 203.00 IP
ffective in infections caused by Gentamycin the cerebral ventricles.
t DOXYSON Cap. Hudson
and/or Tobramycin resistant strains of Gram­ Overdose: In the event of overdose or toxic
Doxycycline 1OOmg/capsule
negative organisms. Amikacin has also been reaction, peritoneal dialysis or haemodialysis will
l OO's pack: 190.00 MRP
shown to be effective in Staphylococcal aid in the removal of Amikacin from the blood.
t E-DOXY Cap. Edruc
infection and may be considered as initial Phamaceutical precautions: Amikacin should be
Doxycycline 1OOmg/capsule
therapy under certain condition in the treatment stored in a cool dry place, protected from light.
l OO's pack: 21S.00 MRP
of known suspected Staphylococcal disease such
t ELIDOX Cap. Reliance
as, severe infections where the causative t AMIBAC Inj. Popular
Doxycycline 1OOmg/capsule
organism may either a Gram-negative bacterium Amikacin sulphate USP I 00mg/2ml ampoule &
60's pack: 13S.OO MRP
or Staphylococcus infection due to susceptible SOOmg/2ml ampoule: i.m/i.v injection.
t FARDOX Cap. Pharmadesh
strains of Staphylococcal/ Gram-negative l OOmg (2ml) amp x I O's pack: 160.60 MRP
Doxycycline 1OOmg/capsule
infections. In certain severe infections such as SOOmg (2ml) amp x I O's pack: 481.80 MRP
1OO's pack: 2SO.OO MRP
neonatal sepsis, concomitant therapy with a t AMIKIN Inj. Incepta
t IMPEDOX Cap. ACI
penicillin type drug may be indicated because of Amikacin sulphate USP 100mg/2ml ampoule &
Doxycycline 1 OOmg/capsule
the possibility of infections due to Gram-positive SOOmg/2ml ampoule: i.m/i,v injection.
l OO's pack: 216.00 MRP
organism such as Streptococci or Pneumococci. l OOmg (2ml) amp x l O's pack: 160.00 MRP
t MEGADOX Cap. Beximco
C/I: A history of hypersensitivity or serious toxic SOOmg (2ml) amp x 1 O's pack: 480.00 MRP
Doxycycline 1OOmg/capsule
reaction to aminoglycosides is contraindicated. t Inj. Biopharma
lOO's pack: 216.00 IP
Pregnancy & lactation: The safety of amikacin in Amikacin sulphate USP 100mg/2ml ampoule &
t MONADOX Cap. Amico
pregnancy & lactation has not yet been SOOmg/2ml ampoule: i.m/i.v injection.
Doxycycline 1OOmg/capsule
established. l OOmg (2ml) amp x lO's pack: 160.00 MRP
lOO's pack: 2SO.OO MRP
S/E: When the recommended precautions & 500mg (2ml) amp x lO's pack: 480.00 MRP
t MYDOX Cap. Mystic
dosages are followed the incidence of toxic t AMISTAR Inj. Square
Doxycycline 1OOmg/capsule ..

reactions, such as tinnitus, vertigo, and partial Amikacin sulphate USP 100mg/2ml ampoule &
1OO's pack: 200.00 MRP
reversible or irreversible deafness, skin rash, SOOmg/2ml ampoule: i.m/i.v injection.
t ORIODOX Cap. Orion Pharma
drug fever, heada-che, paraesthesia, nausea and l OOmg (2ml) amp x lO's pack: 160.00 MRP
Doxycycline 1OOmg/capsule
vomiting is low. Urinary signs of renal irritation, SOOmg (2ml) amp x 1O's pack: 480.00 MRP
1OO's pack: 211.00 MRP
azo-taemia and oliguria have been reported. t CINAMAK Inj. Techno Drugs
t UNIDOX Cap. Globe Dosage & admin: Adults & children: Amikacin sulphate USP 2SOmg/2ml ampoule &
Doxycycline 1OOmg/capsule
• 15mg/kg/day in two equally divided doses S00mg/2ml ampoule: i.m/i.v injection.
1 OO's pack: 200.00 MRP
(equivalent to 500mg bid in adults). Use of the 2S0mg (2ml) amp x lO's pack: 120.00 MRP
tVIB Cap. Modern 100mg/2ml strength is recommended for SOOmg (2ml) amp x lO's pack: 210.00 MRP
Doxycycline 1OOmg/capsule children for the accurate measurement of the t KACIN lnj. ACI
l OO's pack: 200.00 MRP appropriate dose. Amikacin sulphate USP 100mg/2ml ampoule &
Neonates & premature children: An initial 500mg/2ml ampoule: i.m/i. v injection.
tVIDOX Cap. Jayson
Doxycycline 1OOmg/capsule loading dose of lOmg/kg followed by 1OOmg (2ml) amp x 20's pack: 381.20 MRP

SO's pack: 100.00 MRP 15mg/kg/day in two equally divided doses.
Elderly: Doses should be adjusted under
tVITROCIN Cap. Nipa
impaired renal function in elderly.
Doxycycline 1OOmg/capsule
Life-threatening infections and/or those caused
1OO's pack: 200.00 MRP
by pseudomonas: The adult dose may be
increased to 500mg every eight hours but
should neither exceed 1.Sgm/day nor be
1.4 Aminoglycosides
administered for a period longer than 10 day.
A maximum total adult dose of 15gm should
Aminoglycosides that are used as bactericidal not be exceeded.
antibiotics include21_ Urinary tract infections (other than pseudomon­
Amikacin, Gentamicin, Kanamycin, Neomycin, al infections): 7.Smg/kg/day in two equally
Netilmicin, Tobram �. divided doses (equivalent to 250mg twice daily
SOOmg (2ml) amp x lO's pack: 481.80 MRP
t MIKACIN Inj. Aristopharma
Amikacin sulphate USP I 00mg/2ml ampoule &
SOOmg/2ml ampoule: i.m/i.v injection.
l OOmg (2ml) amp x lO's pack: 160.00 MRP
SOOmg (2ml) amp x S's pack: 240.00 MRP
t PSUDONIL lnj. Drug Inter.
Amikacin sulphate USP 100mg/2ml ampoule,
2SOmg/ampoule & SOOmg/ampoule: i.m/i.v
injection.
1OOmg (2ml) amp x S's pack: 80.00 MRP
2S0mg amp x 5's pack: l S0.00 MRP
SOOmg amp x S's pack: 22S.OO MRP

GENTAMICIN21,33
GENTAMICIN: Injection/Infusion
Ind: Septicaemia & neonatal sepsis; meningitis
and other CNS infections; chest infections;
biliary tract infections; acute pyelonephritis or
prostatitis; endocarditis caused by Strep. viridens
or faecalis (with a penicillin); wound infection &
bums; gonorrhoea & persistant strains of both
gram+ve & gram-ve organisms.
C/I: Hypersensitivity to gentamycin; pregnancy;
pre-existing neurogenic disorder of the ear,
myasthenia gravis.
S/E: Nephrotoxicity, Ototoxicity.
Cautions: Renal impairmen� early pregnancy,
premature infants & neonates.
Dosage & admin: By i.m. or slow i.v. injection
or infusion: severe infections, 5mg/kg daily in
divided doses at 6 or 8 hourly; other systemic
infections 2-5mg/kg daily at divided doses.
In renal impairment the interval between
successive doses should be increased to 12
hours when creatinine clearence is 30-
70ml/min. 24 hours for 10-30ml/min. 48 hours
for 5-10 ml/min. 3-4 days after dialysis for less
than 5ml/min.
Gonorrhoea, 240mg as a single dose.
Child, up to 2 wks. 3mg/kg 12 hourly; 2 wks to
12 yrs, 2mg/kg every 8 hours.
By intrathecal injection: lmg daily, with
2-4mg/kg daily by i.m injection in divided
doses every 8 hours.
+ EGEN Inj. Edruc
Gentamicin 80mg/2ml ampoule: injection
5 amps pack: 47.50 MRP
+ GENACYN lnj. Square
Gentamicin 80mg/2ml ampoule: injection
10 amps pack: 101.48 MRP
+ GENACYN Inj. Square
Gentamicin 20mg/2ml ampoule: injection
10 amps pack: 60.90 MRP
+ GENTASOL Inj. Techno Drugs
Gentamicin 80mg/2ml ampoule: injection
10 amps pack: 110.00 MRP
+ GEN'I'IN Inj. Opsonin -
Gentamicin sulph. 20mg & 80mg/2ml ampoule:
injection
20mg (2ml) x 25 amps: 133.72 MRP
80mg (2ml) x 25 amps: 307.69 MRP
+ G-GENTAMICIN lnj. Gonoshas
Gentamicin sulph. 40mg & 80mg/2ml ampoule:
injection
40mg (2ml) x 25 amps pack: 150.00 MRP
80mg (2ml) x 10 amps pack: 120.00 MRP
+ INTAMYCIN lnj. lncepta
Gentamicin sulph. 20mg & 80mg/2ml ampoule:
injection
20mg (2ml) x 10 amps pack: 60.00 MRP
80mg (2ml) x 10 amps pack: 100.00 MRP
+ INVIGEN l.V Inf. Beximco
Gentamicin sulph. 80mg/l OOml (i.e 0.08% w/v):
i.v infusion.
l OOml bot for i.v infusion: 47.22 MRP
+ OPTIMYCIN Inj. Aristopharma
Gentamicin sulph. 80mg/2ml ampoule: injection
80mg (2ml) x 10 amps pack: 100.00 MRP
STREPT.OMYCIN
QIMP-17 (271) ANTIMICROBIAL DRUGS
STREPTOMYCIN: Streptomycin now a day 1OO's pack: 400.00 MRP
almost entirely reserved for the treatment of + ECIN Susp. Gaco
tuberculosis so, this has been discussed under the Erythromycin 125mg/5ml: suspension
group of anti-tubercular drugs. I OOml bot: 60.00 MRP
+ EDRY Susp. Edruc
Erythromycin 125mg/5ml: suspension
1.5 Macrolides lOOml bot: 60.00 MRP
+ EM-500 Tab. Modern
Erythromycin 500mg/tablet
Macrolides include-
20's pack: 160.00 MRP
Azithromycin, Clarithromycin, Erythromycin,
Roxithromycin, Spiramycin. + EM Susp. Modern
Erythromycin 125mg/5ml: suspension
1 OOml bot: 60.00 MRP
ERY'I'HROMYCIN21,33
.
+ EMYCIN Tab. Medimet
Erythromycin 250mg/tablet.
ERYTHROMYCIN STE ARATE: Tablet/ 50's pack: 237.50 MRP
Suspension/Injection + EMYCIN Susp. Medimet
Ind: An alternative to penicillin in hypersensitive Erythromycin 125mg/5ml: suspension
patients (such as in streptococcal, pneumococcal­ lOOml bot: 61.00 MRP
as in resp. tract infections, staphylococcal, + ERIXIN Susp. Amico
treponemal & gonorrhoeal infections; sinusitis). Erythromycin l 25mg/5ml: suspension
An alternative to tetracycline, in mycoplasma lOOml bot: 60.00 MRP
+
•
pneumoniae infection; also recommended for E RIXIN Drop Amico
diphtheria, pertusis and clostridial infections. Erythromycin 200mg/5ml: drop
C/I: Pre-existing hepatic disorder; history of 60ml drop: 60.00 MRP
hypersensitivity. + ERMAC Susp. Opsonin
S/E: Nausea, vomiting, abdominal discomfort, Erythromycin 125mg/5ml: suspension
diarrhoea (antibiotic-associated colitis reported); lOOml bot: 53.93 MRP
urticaria, rashes and other allergic reactions; + ERO Susp. Hudson
reversible hearing loss reported after large doses; Erythromycin 125mg/5ml: suspension
cholestatic jaundice and cardiac effects (including 1 OOml bot: 60.00 MRP
chest pain and arrhythmias) repored. + EROCIN Tab. Acme
Cautions: Hepatic and renal impairment; Erythromycin 250mg & 500mg/tablet
prolongation of QT interval (ventricular 250mg x 50's pack: 243.50 MRP
500mg x 30's pack: 258.90 MRP
tachycardia reported); porphyria; pregn-ancy (not
known to be harmful) and breast feeding (only + EROCIN Susp. Acme
small amounts in milk). Erythromycin l 25mg/5ml: suspension
l OOml bot: 69.32 MRP
Arrhythmias: avoid concomitant administration
with astemizole, terfenadine or cisapride. + EROM Tab. Kemiko
Dosage & admin: By mouth: Adult, 250- Erythromycin 250mg & 500mg/tablet
250mg x l OO's pack: 485.00 MRP
500mg every 6 hours; serious infections, upto
4 gm daily. Child, upto 2 years 125mg every 6 500mg x 50's pack: 430.00 MRP
hours, 2-8 years 250mg every 6 hours. + EROM Susp. Kemiko
Erythromycin 125mg/5ml: suspension
Acne, 2S0mg twice daily; maintenance, 250mg
once daily. 1OOml bot: 60.00 MRP
Early syphilis, 500mg 4 times daily for 14 days. + EROMAC Susp. General
Erythromycin l 25mg/5ml: suspension
By i.m or i.v. injection: Adult-100 mg every 4
to 8 hours. Child-25-SO mg/kg body-wt. i.m or l OOml bot: 61.33 MRP
i.v daily in divided doses. + EROMYCIN Tab. Square
Erythromycin 250mg/tablet
+ ACRYTH Susp. MonicoPharma 50's pack: 218.50 MRP
Erythromycin 125mg/5ml: suspension
+ EROMYCIN DS Tab. Square
l OOml bot: 60.00 MRP
Erythromycin 500mg/tablet
+ A-MYCIN Tab. Aristopharma
30's pack: 243.90 MRP
Erythromycin 250mg & 500mg/tablet
+ EROMYCIN Susp. Square
250mg x 1 OO's pack: 480.00 MRP
Erythromycin 125mg/5ml: suspension
500mg x 50's pack: 450.00 MRP
lOOml bot: 69.32 MRP
+ A-MYCIN Susp. Aristopharma
t EROMYCIN Drop Square
Erythromycin 125mg/5ml: suspension
Erythromycin 200mg/5ml: drop
l OOml bot: 69.30 MRP
60ml drop: 60.22 MRP
+ A-MYCIN DS Susp. Aristopharma
+ ERONIX Susp. Ziska
Erythromycin 250mg/5ml: suspension
Erythromycin 125mg/5ml: suspension
l OOml bot: 104.20 MRP
1 OOml bot: 60.00 MRP
+ A-MYCIN Paediatric Susp. Aristopharma
Erythromycin 200mg/5ml: suspension + EROSA Tab. Biopharma
Erythromycin 250mg & 500mg/tablet
60ml bot: 60.00 MRP
250mg x 1 OO's pack: 452.00 MRP
+ ARIG RAM Susp. CPL
500mg x 50's pack: 401.50 MRP
Erythromycin 125mg/5ml: suspension
l OOml bot: 60.00 MRP + EROSA Susp. Biopharma
+ CPMYCIN Tab. Cosmo Pharma Erythromycin 125mg/5ml: suspension
Erythromycin 250mg/tablet l OOml bot: 55.21 MRP
 ANTIMICROBIAL DRUGS QIMP-17 (272)

t EROSITE Susp. Sharif 1OOml bot: 61.22 MRP
Erythromycin 125mg/5ml: suspension t ETHROLEX 500 Tab. Mystic
lOOml bot: 69.32 MRP Erythromycin 500mg/tablet
+ E -ROX 500 Tab. Desh Pharma 30's pack: 217.50 MRP
Erythromycin 500mg/tablet t ETHROLEX Susp. Mystic
50's pack: 350.00 IP Erythromycin l 25mg/5ml: suspension
+ E -ROX Susp. Desh Pharma l OOml bot: 54.50 MRP
Erythromycin 125mg/5ml: suspension t ETROCIN Tab. Beximco
1 OOml bot: 70.00 MRP Erythromycin 250mg & 500mg/tablet
+ ERY-250 Tab. Alco Pharma 250mg x l OO's pack: 480.00 MRP
Erythromycin 250mg/tablet 500mg x 50's pack: 450.00 MRP
50's pack: 200.00 MRP t ETROCIN Susp. Beximco
+ ERY-500 Tab. Alco Pharma Erythromycin 125mg/5ml: suspension
Erythromycin 500mg/tablet lOOml bot: 60.25 MRP
.
50's pack: 350.00 MRP t EURO Tab. Nipa
+ ERY Susp. Alco Pharma Erythromycin 250mg & 500mg/tablet
Erythromycin 125mg/5ml: suspension 250mg x 50's pack: 212.50 MRP
l OOml bot: 50.00 MRP 500mg x 30's pack: 240.00 MRP
Erythromycin 250mg & 500mg/tablet
250mg x 30's pack: 136.50 MRP
500mg x 20's pack: 170.20 MRP
t MITROCIN Susp. Millat
Erythromycin 125mg/5ml: suspension.
1OOml bot: 60.00 MRP
t MITROCIN DS Susp. Millat
Erythromycin 250mg/5ml: suspension
l OOml bot: 103.00 MRP
t MYCIN Tab. Ambee
Erythromycin 500mg/tablet
500mg x 50's pack: 401.50 MRP
+ MYCIN Susp. Ambee
Erythromycin 125mg/5ml: suspension.
lOOml bot: 60.22 MRP
t ORGAMYCIN Susp. Organic H e alth
Erythromycin l 25mg/5ml: suspension.
l OOml bot: 57.00 MRP ,

t ERYBAC Tab. Drug Inter. t EURO Susp. Nipa + PEDICIN Susp. Rangs Pharma
Erythromycin 250mg & 500mg/tablet Erythromycin 125mg/5ml: suspension Erythromycin l 25mg/5ml: suspension.
250mg x 50's pack: 200.00 MRP 1OOml bot: 60.00 MRP 1OOml bot: 61.25 MRP
500mg x 30's pack: 240.00 MRP + FIRMAC Tab. lncepta t 'I'HROCIN Susp. Globe
t Erythromycin 250mg & 500mg/tablet Erythromycin l 25mg/5ml: suspension.
•

ERYBAC Susp. Drug Inter.

Erythromycin 125mg/5ml: suspension 250mg x 50's pack: 225.00 MRP lOOml bot: 56.00 MRP
1OOml bot: 60.00 MRP 500mg x 30's pack: 258.00 MRP t ZEROBAC Susp. Chemist
+ ERYCIN Susp. Somatec + FI RMAC Susp. Incepta Erythromycin l 25mg/5ml: suspension.
Erythromycin 125mg/5ml: suspension Erythromycin 125mg/5ml: suspension l OOml bot: 55.00 MRP
lOOml bot: 56.21 MRP l OOml bot: 60.00 MRP t ZURACIN Susp. Rephco
+ ERYLIN Susp. Cosmic + ILOCIN Tab. Doctor's Erythromycin 125mg/5ml: suspension.
Erythromycin 125mg/5ml: suspension Erythromycin 500mg/tablet 1 OOml bot: 61.07 MRP
lOOml bot: 61.00 MRP 20's pack: 160.00 MRP
t ERYMEX Tab. Ibo Sina + ILOCIN Susp. Do ctor's
Erythromycin 500mg/tablet Erythromycin 125mg/5ml: suspension
AZITHROMYCIN2 l ,26,33
30's pack: 243.00 MRP lOOml bot: 60.00 MRP
t ERYMEX Susp. Ibo Sina t KUMU CIN Susp. Kumudini AZITHROMYCIN: Capsule/ Suspension/
Erythromycin 125mg/5ml: suspension Erythromycin 125mg/5ml: suspension Injection
lOOml bot: 60.50 MRP lOOml bot: 55.00 MRP Azithromycin is an azalide, a subclass of
t ERYNET Susp. Bris tol + MAC Susp. Orion Pharma macrolide antibiotic. It is a broad-spectrum
Erythromycin 125mg/5ml: suspension Erythromycin 125mg/5ml: suspension antibiotic and has been shown to be active
1OOml bot: 60.00 MRP lOOml bot: 60.27 MRP against most strains of susceptible gram-positive
t ERYTH IN Susp. ACI + MAC DS Susp. Orion Pharma and gram-negative microorganisms. It is
Erythromycin 125mg/5ml: suspension Erythromycin 250mg/5ml: suspension available as- capsule, suspension, and injection in
1OOml bot: 61.29 MRP 70ml bot: 74.27 MRP different strengths.
t ERYTHRO Susp. Medicon lOOml bot: 103.39 MRP Mode of action: Azithromycin acts by binding to
Erythromycin 125mg/5ml: suspension t MACAS Susp. As iatic the 50s ribosomal subunit of susceptible microor­
•

l OOml bot: 57.00 MRP
t ERYTHROM YCIN-A Susp. Ad-din
Erythromycin 125mg/5ml: suspension
l OOml bot: 60.00 MRP
t ERYTHROX Tab. Renata
Erythromycin stearate 250mg & 500mg/tablet (f.c)
250mg x 50's pack: 257.50 MRP
500mg x 50's pack: 515.00 MRP
t ERYTHROX Susp. Renata
Erythromycin succinate 125mg/5ml: suspension
1 OOml bot: 69.32 MRP
t ERYZEN Tab. Zenith
Erythromycin 250mg & 500mg/tablet
250mg x 60's pack: 262.20 MRP
500mg x 20's pack: 172.60 MRP
t ERYZEN Susp. Zenith
Erythromycin 125mg/5ml: suspension
1OOml bot: 56.85 MRP
+ ETHRO Susp. Pharmades h
Erythromycin 125mg/5ml: suspension
Erythromycin 125 mg/5ml: suspension
lOOml bot: 56.85 MRP
t MACERY Tab. Pacific
Erythromycin 250mg & 500mg/tablet
250mg x 50's pack: 225.00 MRP
500mg x 30's pack: 246.00 MRP
t MACERY Susp. Pacific
Erythromycin 125mg/5ml: suspension.
lOOml bot: 46.00 MRP
+ MACROCIN Tab. Sanofi- aventis
Erythromycin stearate 250mg & 500mg/tablet
250mg x IOO's pack: 487.00 MRP
500mg x 50's pack: 432.92 MRP
+ MACROCIN Susp. Sanofi-aventis
Erythromycin stearate 125mg/5ml: suspension.
1OOml bot: 61.00 MRP
+ MAKCIN Susp. Techno Drugs
Erythromycin 125mg/5ml: suspension.
lOOml bot: 60.00 MRP
t MITROCIN Tab. Millat
ganisms and thus interfering with microbial pro­
tein synthesis. It is a broad-spectrum antibiotic
and has been shown to be active against most
strains of the following microorganisms.
Gram-positive: Staphylococcus aureus,
Streptococcus agalactiae, Streptococcus
pneumoniae, Streptococcus pyogenes.
Gram-negative: Haemophilus ducreyi,
Haemophilus injluenzae, Moraxella catarrhalis,
Neisseria gonorrhoeae, Escherichia coli.
Others: Chlamydia pneumoniae, Chlamydia
trachomatis, Mycoplasma pneumoniae,
Bacteroides fragilis, Legionella pneumophila,
Toxoplasma gondii.
Ind: Respiratory tract infections; otitis media;
skin and soft-tissue infections; non-gonococcal
urethritis and cervicitis due to chlamydia tra­
chomatis; gonococcal urethritis and cervicitis due
to neisseria gonorrhoeae; genital ulcer disease in
men due to haemophilus ducreyi (chancroid);
.
.
.;·
-
. ..
.
� "

. "

·- ···--

. ,

. .
... ...

. . :
,;

:-
�czwa:a:c
.

.
. .

:
·

:. :
:

I
 QIMP-17 (273) ANTIMICROBIAL DRUGS

cholera; shigellosis; typhoid. a single, daily dose of 250mg to complete a 7- 500mg x 12's pack: 420.00 MRP
C/I: Patients with known hypersensitivity to day course. t ASIZITH Susp. Asiatic
azithromycin, erythromycin, or any macrolide or Children: Use of azithromycin by i.v route Azithromycin 200mg/5ml: suspension.
ketolide antibiotic. Hepatic impairment. althugh not yet approved by the FDA, the i.v 15ml bot: 85.00MRP
S/E; Cautions: See under erythromycin. Mild preparation has been studied in children using 30ml bot: 130.00 MRi>
neutropenia reported. a dose of lOmg/kg administered over 1 hour + ATM 500 Tab. Everest
Pregnancy & lactation: Pregnancy category B. once daily. I.V therapy should be followed by Azithromycin 500mg/tablet
In the animal studies, no evidence of harm to the oral therapy as desired, in accordance with 500mg x 6's pack: 180.00 MRP
fetus due to azithromycin was found. Animal clinical response. + ATM Susp. Everest
reproduction studies are not always predictive of Drug inter: Avoid concomitant administration Azithromycin USP 200mg/5ml: suspension.
human response; therefore, azithromycin should with astemizole or terfenadine. 15ml bot: 85.00 MRP
be used during pregnancy only if clearly needed. 35ml bot: 130.00 MRP
It is not known whether azithromycin is excreted t ACOS Tab. Radiant t AVALON 500 Tab. Techno Drugs
in human milk. Because many drugs are excreted Azithromycin USP 500mg/tablet Azithromycin USP 500mg/tablet
in human milk, caution should be exercised when 500mg x 6's pack: 330.00 MRP 500mg x 6's pack: 180.00 MRP
azithromycin is administered to a nursing woman. t ACOS Susp. Radiant t AVALON Susp. Techno Drugs
Dosage & admin: By mouth: Adult: For Azithromycin USP 200mg/5ml: suspension. Azithromycin USP 200mg/5ml: suspension.
respiratory tract infections, otitis media and 30ml bot: 175.00 MRP 15ml bot: 85.00 MRP
skin & soft tissue infections: 500mg once daily + ADIZ Tab. Euro Pharma 30ml bot: 130.00 MRP
for 3 days. For sexually transmitted diseases Azithromycin 500mg/tablet t AVALON I.V lnj. Techno Drugs
like genital ulcer, non-gonococcal urethritis 500mg x S's pack: 240.00 MRP Azithromycin dihydrate USP 500mg/5ml vial
and cervicitis due to chlamydia trachomatis: a + ADIZ Susp Euro Pharma
•. (powder for reconstitution): i.v injection.
single lgm (lOOOmg) dose. For the treatment Azithromycin 200mg/5ml: suspension. 500mg (5ml vial) x l's pack: 250.00 MRP
of urethritis and cervicitis due to neisseria 15ml bot: 85.00 MRP + AZ-250 Cap. Aristopharma
gonorrhoeae: a single 2gm (2000mg) dose. In 30ml bot: 130.00 MRP Azithromycin 250mg/capsule
typhoid, 500mg once daily for 7 days. In + AM-500 Tab. Reliance 250mg x lO's pack: 250.00 MRP

'
'

cholera, a single lgm (lOOOmg) dose. In Azithromycin 500mg/tablet + AZ-500 Cap. Aristopharma
shigellosis, 500mg once on first day, followed 500mg x 1O's pack: 360.00 MRP Azithromycin 500mg/capsule
by 250mg once daily for next 4 days. + AM Susp. Reliance 500mg x 9's pack: 315.00 MRP
Children: Over 6 months, lOmg/kg once daily Azithromycin 200mg/5ml: suspension. + AZ Susp. Aristopharma
for 3 days; or body-weight 15-25 kg, 200mg 30ml bot: 130.00 MRP Azithromycin 200mg/5ml: suspension.
once daily for 3 days; body-weight 26-35 kg, t AMZITH Cap. Amulet 20ml bot: 100.00 MRP
300mg once daily for 3 days; body-weight 36- Azithromycin 250mg/capsule 35ml bot: 140.00 MRP
45 kg, 400mg once daily for 3 days. 250mg x 6's pack: 120.00 MRP 50ml bot: 200.00 MRP
Azithromycin tablet can be taken with or t AMZITH Tab. Amulet
•
+ AZALID Cap. Orion Pharma
without food; suspension should be taken at Azithromycin 500mg/tablet
Azithromycin 250mg/capsule
least 1 hour before or 2 hours after meal. 500mg x 12's pack: 360.00 MRP
250mg x 8's pack: 160.64 MRP
Injection: t AMZITH Susp. Amulet
Adults: Community-acquired pneumonia: Azithromycin 200mg/5ml: suspension. + AZALID 500 Tab. Orion Pharma
500mg as a single daily dose by i.v route for at 30ml bot: 130.00 MRP Azithromycin USP 500mg/tablet

least two -days. I. V therapy sho.uld be followed t APOZYTH Tab. Apollo . 500mg x 8's pack: 280.00
..
MRP
.
. � �

by oral therapy at a single, daily dose of Azithromycin 500mg/tablet + AZALID Susp. Orion Pharma
500mg tablet to complete a 7 tO 10-day course. 500mg x 12's pack: 360.00 MRP Azithromycin 200mg/5ml: suspension.
Pelvic inflammatory disease: 500mg as a single t ASIZITH Tab. Asiatic 15ml bot: 85.32 MRP .
daily dose by i.v route for one or two days. I. V Azithromycin 250mg & 500mg/tablet 35ml bot: 130.49 MRP
therapy should be foilowed by oral therapy at 250mgx 6's pack: 120.00 MRP 50ml bot: 160.00 MRP

.
.

.
. .

•
• •

. .
.
•
• •

500 mg Tablet
.
• •
• •

I
.·:·2somgTablet •• .

35mlPFS ·.: 500 mg Tablet .:.:

20mlPFS
pharmasia -�. . 70mlPFS.··
.
. .

Azithromycin
. •
. .
• •
•
. .
• . .
•

A Enterprise
 • •
ZIDI
Azithromycin
250 mg& 500mgRmC..ed1•'-. 200 n9'Sml Pf5
•
t AZALTIC Tab. NIPRO JMI
Azithromycin USP 500mg/tablet
500mg x 9's pack: 270.00 MRP
t AZALTIC Sosp. NIPRO JMI
Azithromycin 200mg/5ml: suspension.
15ml bot: S5.00 MRP
35ml bot: 130.00 MRP
t AZASI'fE Tab. Sharif
Azithromycin 500mg/tablet
500mg x S's pack: 240.00 MRP
t AZASI'fE Sosp. Sharif
Azithromycin 200mg/5ml: suspension.
20ml bot: S5.00 MRP
35ml bot: 130.00 MRP
t AZEXIA Tab. Pharmasia
Azithromycin 500mg/tablet
500mg x 6's pack: l S0.00 MRP
t AZEXIA Sup. Pharmasia
Azithromycin 200mg/5ml: suspension.
20ml bot: 85.00 MRP
35ml bot: 130.00 MRP
t AZICIN Cap. Opsonin
Azithromycin 250mg & 500mg/capsule
250mg x 6's pack: 105.99 MRP
500mg x 6's pack: 158.35 MRP
t AZICIN Tab. Opsonin
Azithromycin 250mg & 500mg/tablet
250mg x 6's pack: 105.99 MRP
_s_oonig x 6's pack: 184.73 MRP
t .AilCTN lgm Sachet Opsonin
Azithromycin lgm (lOOOmg)/sachet
lgm (lOOOmg) sachet x S's pack: 351.SS MRP
t AZICIN Sup. Opsonin
Azithromycin 200mg/5ml: suspension.
20ml bot: 75.06 MRP
35ml bot: 114.79 MRP
50ml bot: 163.36 MRP .
.
I t AZD,AB 500 Tab. Labaid Pharma
Azithromycin 500mg/tablet
6's pack: 300.00 MRP
t AZII.AB Sosp. Labaid Pharma
Azithromycin 200mg/5ml: suspension.
35ml bot: 165.00 MRP
t AZILIT-500 Tab. Desh Pharma
Azithromycin 500mg/tablet
3's pack: 90.00 MRP
t AZILIT Susp. Desh Pharma
Azithromycin 200mg/5ml: suspension.
15ml bot: SS.00 MRP
t AZIMET-500 Tab. Medimet
Azithromycin 500mg/tablet
500mg x 4's pack: 120.00 MRP
t AZIMET Sosp. Medimet
Azithromycin 200mg/5ml: suspension.
15ml bot: 85.00 MRP
30ml bot: 130.00 MRP
t AZIMEX Tab. Drug Inter.
Azithromycin 250mg &. 500mg/tablet
250mg x 20's pack: 400.00 MRP
500mg x 9's pack: 270.00 MRP
t AZIMEX Susp. Drug Inter.
Azithromycin 200mg/5ml: suspension.
l 5ml bot: 90.00 MRP
30ml bot: 130.00 MRP
t AZIMON 500 Tab. MonicoPharma
QIMP-17 (274)
Azithromycin USP 500mg/tablet
12's pack: 360.00 MRP
t AZIMON Susp. MonicoPharma
Azithromycin 200mg/?ml: suspension.
l 5ml bot: 90.00 MRP
30ml bot: 130.00 MRP
t AZIN Tab. Acme
Azithromycin 500mg/tablet
500mg x 6's pack: 180.66 MRP
t AZIN Cap. Acme
Azithromycin 250mg/capsule
250mg x 6's pack: 150.00 MRP
t AZIN Susp. Acme
Azithromycin 200mg/5ml: suspension.
15ml bot: 95.00 MRP
30ml bot: 140.00 MRP
50ml bot: 185.00 MRP
t AZINIL Tab. Apex
Azithromycin 250mg & 500mg/tablet
250mg x 6's pack: 120.00 MRP
500mg x S's pack: 240.00 MRP
t AZINIL Sosp. Apex
Azithromycin 200mg/5ml: suspension.
20ml bot: 85.00 MRP
35ml bot: 130.00 MRP
t AZIROX Tab. Navana
Azithromycin 500mg/tablet
500mg x 12's pack: 361.32 MRP
t AZIROX Susp. Navana .
Azithromycin 200mg/5ml: suspension. ·
20ml bot: 85.00 MRP
35ml bot: 130.00 MRP
t AZI-S 500 Tab. Seema
Azithromycin 500mg/tablet
500mg x 6's pack: 180.00 MRP
t AZI-S Susp. Seema
Azithromycin 200mg/5ml: suspension.
15ml bot: 100.00 MRP
t AZl'l'EL-500 Cap. Cosmic
Azithromycin 500mg/capsule
·
500mg x S's pack: 240.00 MRP
t AZl'I'EL Susp. Cosmic .
AzithrOmycin 200mg/5ml: suspension.
15ml bot: 85.00 MRP
35ml bot: 134.00 MRP
t AZITHIN Tab. Chemist
Azithromycin 500mg/tablet
500mg x 12's pack: 360.00 MRP
t AZITHIN Susp. Chemist \
Azithromycin 200mg/5ml: suspension.
15ml bot: 85.00 MRP
35ml bot: 130.00 MRP
t AZI'I'HRO Tab. Astra
Azithromycin 500mg/tablet
500mg x 6's pack: 180.00 MRP
t AZIT BRO Susp. Astra
Azithromycin l 25mg/5ml: suspension.
15ml bot: 85.00 MRP
t AZIT HROCIN Cap. Beximco
Azithromycin 250mg/capsule
250mg x lO's pack: 250.00 IP
t AZITHROCIN 500 Tab. Beximco
Azithromycin 500mg/tablet
500mg x 9's pack: 315.00 IP
t AZITHROCIN Susp. Beximco
Azithromycin 200mg/5ml: suspension.
15ml bot: 85.00 IP
30ml bot: 130.00 IP .
50ml bot: 185.00 MRP
t AZimROCIN 500 I.V Inj. Beximco
 -

QIMP-17 (275) ANTIMICROBIAL DRUGS

Azithromycin dihydrate USP 500mg/5ml vial 500mg x 6's pack: 495.00 MRP t MACAZI Sup. Pacific
(powder for reconstitution): i.v injection. t AZYTH Sup. Sandoz Azithromycin 200mg/5ml: suspension.
500mg (5ml vial) x l's pack: 460.00 MRP Azithromycin 200mg/5ml: suspension. 15ml bot: 64.00 MRP
t AZITHROMAX SOO Tab. Ziska 15ml bot: 115.00 MRP 35ml bot: 118.00 MRP
Azithromycin 500mg/tablet 30ml bot: 155.00 MRP t MACROBAC Tab. Coacord
500mg x 1O's pack: 300.00 MRP 50ml bot: 220.00 MRP Azithromycin 500mg/tablet
t AZITHROMAX Susp. Ziska t BP-Z Cap. Bristol 500mg x 9's pack: 270.00 MRP
Azithromycin 200mg/5ml: suspension. Azithromycin 500mg/capsule t MACROBAC Susp. Coacord
15ml bot: 85.00 MRP 500mg x 3's pack: 90.00 MRP Azithromycin 200mg/5ml: suspension.
35ml bot: 130.00 MRP t BP-Z Tab. Bristol 15ml bot: 85.00 MRP
t AZITOR-SOO Tab. CPL Azithromycin 500mg/tablet 25ml bot: 120.00 MRP
Azithromycin 500mg/tablet 500mg x 6's pack: 180.00 MRP 35ml bot: 135.00 MRP
500mg x S's pack: 150.00 MRP t BP-Z Susp. Bristol 50ml bot: 185.00 MRP
t AZITOR Susp. CPL Azithromycin 200mg/5ml: suspension. t MACROZim Cap.Silva
Azithromycin dihydrate USP 200mg/5ml: 15ml bot: 85.00 MRP Azithromycin 250mg & 500mg/capsule
suspension. t CINAIJD Tab. Jayson 250mg x 6's pack: 120.00 MRP
•

35ml bot: 140.00 MRP Azithromycin 500mg/tablet
t AZITRA Tab. MST Pharma 500mg x 3's pack: 90.00 IP
Azithromycin 500mg/tablet 500mg x 6's pack: 180.00 IP
500mg x 6's pack: 180.00 MRP t CINAI.ID Susp. Jayson
t AZIX Tab. Amico Azithromycin 200mg/5ml: suspension.
Azithromycin 500mg/tablet 15ml bot: 75.28 IP
500mg x 6's pack: 180.00 MRP tc Tab. Sanofi-aventis
500mg x 3's pack: 90.00 MRP
t MACROZI'l"H Tab.Silva
Azitbromycin 500mgltablet
500mg x 6's pack: 180.00 MRP
t MACROZITH GFS Silva
Azitbromycin 200mg/5ml: granules for
•

suspenslOD.
t AZIX Susp. Amico Azithromycin 250mg & 500mg/tablet 15ml (GFS) bot: 85.00 MRP
Azithromycin 200mg/5ml: suspension. 250mg x 6's pack: 120.00 MRP 25ml (GFS) bot: 115.00 MRP
15ml bot: 85.00 MRP 500mg x 12's pack: 360.00 MRP t MACROZl'l'H PFS SDva
t AZMIN-SOO Tab. Modem t Sasp.Sanofi-aveatis Azithromycin 200mg/5ml: powder for
Azithromycin 500mg/tablet J_\zithromycm 200mg/5ml: suspension. suspenston.
•

500mg x 4's pack: 112.00 MRP 15ml bot: 85.00 MRP 15ml (PFS) bot: 85.00 MRP
500mg x 8's pack: 224.00 MRP 30ml bot: 130.00 MRP.
25ml (PFS) bot: 99.00 MRP
t AZMIN Susp. Modem t DEMACR0-500 Tab. Deceat t MACZI'ffi Cap. Bioplaar•••a
Azithromycin 200mg/5ml: suspension. Azithromycin 500mg/tablet Azithromycin 250mg/capsule
15ml bot: 95.00 MRP 8's pack: 240.00 MRP 250mg x 6's pack: 120.48 MRP
35ml bot: 130.00 MRP t DEMACRO Sup. Decent t MACZim Tab. Bioplaarma
t AZO SOO Tab. Delta Pharma Azithromycin 200mg/5ml: suspension. Azithromycin 500mg/tablet
Azithromycin 500mg/tablet 15ml bot: 85.00 MRP 500mg x 12's pack: 420.00 MRP
500mg x 9's pack: 270.00 MRP 30ml bot: 120.00 MRP t MACZim Susp. Bioplaarma
t AZO Susp. Delta Pharma t EZITH Tab. Edruc Azithromycin 200mg/5ml: suspension.
Azithromycin 200mg/5ml: suspension. Azithromycin 500mg/tablet 15ml bot: 95.00 MRP
15ml bot: 85.00 MRP 500mg x 3's pack: 90.00 MRP 35ml bot: 130.49 MRP
30ml bot: 130.00 MRP t EZlffi Sup. Ednie t MAZITH 500 Tab. Hallmark
t AZOMAC SOO Tab. General Azithromycin 200mg/5ml: suspension. Azitbromycin 500mg/tablet
Azithromycin 500mg/tablet 15ml bot: 85.00 MRP 500mg x 12's pack: 360.00 MRP
500mg x 12's pack: 360.00 MRP t FIZYTH Tab. Peoples t MAZITH Susp. BaDmark
t AZOMAC Susp. General Azithromycin USP 500mgltablet Azithromycin 200mg/5ml: suspension.
Azithromycin 200mg/5ml: suspension. 500mg x 12's pack: 360.00 MRP 15ml bot: 85.00 MRP
20ml bot: 100.00 MRP t HYZI'I"H-SOO Tab. Millat 25ml bot: 110.00 MRP
35ml bot: 140.00 MRP Azithromycin 500mg/tablet 35ml bot: 130.00 MRP
50ml bot: 185.00 MRP 500mg x 3's pack: 90.00 MRP t MYZlll Tab. Ambee
t AZOMAC Susp. (Taste masked) General 500mg x 6's pack: 180.00 MRP Azithromycin dihydrate 250mg & SOOmg/tablet
Azithromycin USP 200mg/5ml: suspension (taste t BYZITH Susp. Millat 250mg x 12's pack: 240.00 MRP
masked). Azithromycin 200mg/5ml: suspension. 500mg x 12's pack: 360.00 MRP
20ml bot: 85.00 MRP 15ml bot: 85.00 MRP t N-Zlm 500 Tab. Novas
t AZRO Tab. Nipa 30ml bot: 130.00 MRP Azithromycin 500mg/tablet
Azithromycin 500mg/tablet t ILOZIN Tab. Doctor's SOOmg x 6's pack: 180.00 MRP
500mg x 12's pack: 360.00 MRP Azithromycin 500mg/tablet t ODAZ-SOO Tab. UlliMed & UaiHealth
t AZRO Susp. Nipa 500mg x 8's pack: 240.00 MRP Azithromycin 500mg/tablet
Azithromycin 200mg/5ml: suspension. t ILOZIN Susp. Doctor's 500mg x 6's pack: 180.00 MRP
l 5ml bot: 85.00 MRP Azithromycin 200mg/5ml: suspension. • ODAZ Sup. UaiMed & uamealtll
30ml bot: 130.00 MRP 15ml bot: 85.00 MRP Azithromycin 200mg/5ml: suspension.
t AZY'I'H Cap. Sandoz 30ml bot: 130.00 MRP 1Sml bot: 85.00 MRP
Azithromycin 250mg/capsule t MACAZI Tab. Pacific 30ml bot: 130.00 MRP
250mg x 1O's pack: 300.00 MRP Azithromycin 500mg/tablet t ODAZIN Tab. Beagal Drop
t AZY'I'H Tab. Sandoz 500mg x 3's pack: 105.00 MRP Azithromycin BP 500mg/tablet
Azithromycin 500mg/tablet 500mg x 6's pack: 210.00 MRP 500mg x 12's pack: 360.00 MRP

• •
250 mg Tablet
500 mg Tablet Apex
ph.tr IY1d
200 mg/5ml PFS
Azithromycin

I
ANTIMICROBIAL DRUGS QIMP-17 (276)
•
•

t ODAZYTH Tab. ACI 20ml bot: 100.00 IP

Azithromycin 500mg/tablet 35ml bot: 135.00 IP
500mg x 12's pack: 361.32 MRP 50ml bot: 190.00 IP
t ODAZYTH Susp. ACI + ROZITH Tab. Healthcare
.
Azithromycin 200mg/5ml: suspension. Azithromycin 250mg/tablet
15ml bot: 85.32 MRP 250mg x 6's pack: 150.00 MRP
•

30ml bot: 130.49 MRP t ROZITH Cap. Healthcare

50ml bot: 185.70 MRP Azithromycin 500mg/capsule
t ORGAZITH Cap. Organic Health 500mg x l 2's pack: 420.00 MRP
Azithromycin USP 250mg & 500mg/capsule + ROZITH Susp. Healthcare
250mg x 6's pack: 120.00 MRP Azithromycin 200mg/5ml: suspension.
500mg x 12's pack: 360.00 MRP 15ml bot: 95.00 MRP
t ORGAZITH Susp. Organic Health 22.5ml bot: 105.00 MRP
Azithromycin USP 200mg/5ml: suspension. 35ml bot: 140.00 MRP
20ml bot: 85.00 MRP 50ml bot: 185.00 MRP
35ml bot: 130.00 MRP + ROZITH SR 2gm Susp. Healthcare •

50ml bot: 185.00 MRP Rozith SR is a sustained release microsphere

t PENALOX Cap. Rephco formulation, containing azithromycin dihydrate '•

Azithromycin 500mg/capsule equivalent to azithromycin USP 2gm in bottle.

500mg x 8's pack: 240.00 MRP Each bottle to be constituted with 60ml of water
t PENALOX Susp. Rephco to make suspension.
Azithromycin 200mg/5ml: suspension. Ind: This formulation is particularly indicated for
15ml bot: 95.00 MRP the treatment of- acute bacterial sinusitis, and
30ml bot: 130.00 MRP
.\

comm11nity acquired pneumonia.

-
•

t PHAGOCIN-500 Tab. SAPL Dosage & admin: Adult dose: Rozith SR '

Azithromycin 500mg/tablet should be taken as a single 2gm dose. This

500mg x 8's pack: 240.00 MRP preparation provides a full course of
t PHAGOCIN Susp. SAPL antibacterial therapy in a single oral dose.
Azithromycin 200mg/5ml: suspension. Pediatiric dose (for pediatric patients 6 month &
15ml bot: 85.00 MRP older): Rozith SR should be taken as a single
35ml bot: 130.00 MRP dose of 60mg/kg body weight. Pediatric
+ RANZI'I'H Cap. Rangs Pharma patients weighing 34kg or more should receive
Azithromycin 250mg & 500mg/capsule the adult dose. Shake bottle well before
250mg x 6's pack: 120.00 MRP dispensing. Constituted suspension should be
500mg x 6's pack: 210.00 MRP consumed within 12 hours. Incase of children
+ RANZITH Susp. Rangs Pharma remaining suspension after dosing must be •

Azithromycin 200mg/5ml: suspension. discarded.

15ml bot: 85.00 MRP 2gm bot: 250.00 MRP
30ml bot: 130.00 MRP
t ROZITH I.V Inj. Healthcare
t RAZI'I'HRO Susp. RAK Pharma .
Azithromycin dihydrate USP 500mg/5ml vial
•

Azithromycin 200mg/5ml: suspension.

(powder for reconstitution): i. v injection.
15ml bot: 85.00 MRP ·

500mg (5ml vial) x l's pack: 460.00 MRP

35ml bot: 130.00 MRP
t SIMPLI-3 Tab. Beacon
50ml bot: 186.00 MRP
Azithromycin 500mg/tablet
t RESPAZIT Cap. Somatec
500mg x 8's pack: 280.00 MRP
Azithromycin 250mg/capsule
+ SIMPLI-3 Susp. Beacon
250mg x 6's pack: 120.48 MRP
Azithromycin l 25mg/5ml: suspension.
t RESPAZIT Tab. Somatec
20ml bot: 85.00 MRP .
Azithromycin 500mg/tablet
•

35ml bot: 130.00 MRP

500mg x 6's pack: 168.60 MRP
+ SIMPLI-3 Inj. Beacon
+ RESPAZIT Susp. Somatec
Azithromycin dihydrate USP 500mg/5ml vial
Azithromycin 200mg/5ml: suspension.
(powder for reconstitution): i.v injection.
l 5ml bot: 80.30 MRP
500mg (5ml vial) x l's pack: 450.00 MRP
30ml bot: 130.49 MRP
t SOTO Tab. Hudson
t RIBOZITH Tab. Novelta
Azithromycin USP 500mg/tablet
Azithromycin USP 500mg/tablet
500mg x 8's pack: 240.00 MRP
500mg x 6's pack: 180.00 MRP
+ SOTO Susp. Hudson
t RIBOZITH Susp. Novelta
Azithromycin USP 200mg/5ml: suspension.
•

Azithromycin USP 200mg/5ml: suspension.

35ml bot: 130.00 MRP
25ml bot: 115.00 MRP
t THIZA Tab. Kumudini
35ml bot: 130.00 MRP
Azithromycin 500mg/tablet
t ROMYCIN Cap. lbn Sina
500mg x 12's pack: 360.00 MRP
Azithromycin 250mg/capsule
+ T HIZA Susp. Kumud.ini
250mg x 8's pack: 160.00 IP
Azithromycin 200mg/5ml: suspension.
t ROMYCIN Tab. lbn Sina 15ml bot: 85.00 MRP
Azithromycin 500mg/tablet 30ml bot: 130.00 MRP
500mg x 12's pack: 360. IP
+ THROMAX Tab. Novo Healthcare
t ROMYCIN Susp. Ibo Sina Azithromycin 250mg & 500mg/tablet
Azithromycin 200mg/5ml: suspension. 250mg x 6's pack: 120.00 MRP
l Sml bot: 90.00 IP 500mg x 6's pack: 180.00 MRP

•
 ®
QIMP-17 (277)

+ THROMAX Susp. Novo H ealthcare 50ml bot: 185.07 MRP Azithromycin

Azithromycin 200mg/5ml: suspension. t ZIBAC I.V Inj. Popular
15ml bot: 90.00 MRP Azithromycin dihydrate USP 500mg/Sml vial
25ml bot: 120.00 MRP (powder for reconstitution): i.v injection.
35ml bot: 140.00 MRP 500mg (5ml vial) x 1's pack: 461.74 MRP
t 'I'RIDOSIL Tab. Incepta + ZIMAX 250 Cap. Square + ZI'I'HRO Susp. Pharmadesh
Azithromycin 250mg & SOOmg/tablet Azithromycin 250mg/capsule Azithromycin 200mg/5ml: suspension.
2SOmg x 6's pack: 120.00 MRP 250mg x l 2's pack: 300.00 MRP 15ml bot: 86.11 MRP
SOOmg x 6's pack: 180.00 MRP t ZIMAX 500 Tab. Square 30ml bot: 125.47 MRP
t TRIDOSIL Susp. Incepta Azithromycin 500mg/tablet t ZITHROLEX Tab. Mystic
Azithromycin 200mg/5ml: suspension. 500mg x 12's pack: 420.00 MRP Azithromycin 250mg & 500mg/tablet
l Sml bot: 8S.OO MRP + ZIMAX Susp. Square 250mg x 6's pack: 114.00 MRP
30ml bot: 130.00 MRP Azithromycin 200mg/5ml: suspension. 500mg x 3's pack: 84.00 MRP
35ml bot: 140.00 MRP 15ml bot: 85.33 MRP t ZITHROLEX Susp. Mystic
SOml bot: 18S.OO MRP 30ml bot: 130.49 MRP Azithromycin 200mg/5ml: suspension.
t TRIDOSIL I.V lnj. Incepta 50ml bot: 185.69 MRP 15ml bot: 84.00 MRP
Azithromycin dihydrate USP SOOmg/Sml vial t ZIMAX I.V Inj. Square t ZITHROX Tab. SK+F
(powder for reconstitution): i.v injection. Azithromycin dihydrate USP 500mg/5ml vial Azithromycin 250mg & 500mg/tablet
500mg (Sml vial) x l's pack: 350.00 MRP (powder for reconstitution): i. v injection/infusion. 250mg x 6's pack: 120.00 MRP
t TRUZl'I'H Tab. White Horse SOOmg (5ml vial) x l's pack: 460.00 MRP 500mg x 12's pack: 420.00 MRP
Azithromycin USP SOOmg/tablet + ZINEX Tab. Alco Pharma t ZITHROX Susp. SK+F
500mg x 12's pack: 360.00 MRP Azithromycin 250mg & 500mg/tablet Azithromycin 200mg/5ml: suspension.
t VINZAM Tab. Ad-din 250mg x 12's pack: 240.00 MRP 20ml bot: 85.00 MRP
Azithromycin SOOmg/tablet 500mg x 12's pack: 360.00 MRP 35ml bot: 130.00 MRP
SOOmg x S's pack: 12S.OO MRP + ZINEX Susp. Alco Pharma 50ml bot: 180.00 MRP
t VINZAM Susp. Ad-din Azithromycin 200mg/5ml: suspension. t ZITREX 500 Tab. Medicon
Azithromycin 200mg/Sml: suspension. 15ml bot: 85.00 MRP Azithromycin 500mg/tablet
l Sml bot: 7S.OO MRP 30ml bot: 130.00 MRP 500mg x 8's pack: 240.00 MRP
t VIRZITH Tab. Virgo + ZITA-500 Tab. Kemiko t ZITREX Susp. Medicon
Azithromycin USP SOOmg/tablet Azithromycin 500mg/tablet Azithromycin 200mg/5ml: suspension.
500mg x 9's pack: 270.00 MRP 500mg x 6's pack: 180.00 MRP 20ml bot: 85.00 MRP
t VIRZITH Susp. Virgo + ZITA Susp. Kemiko 35ml bot: 130.00 MRP
Azithromycin USP 200mg/5ml: suspension. Azithromycin 200mg/5ml: suspension. t ZUNAMI F.C Tab. Nuvista
15ml bot: 90.00 MRP 15ml bot: 85.00 MRP Azithromycin 500mg/tablet (film-coated)
30ml bot: 130.00 MRP 30ml bot: 130.00 MRP SOOmg x S's pack: 275.00 MRP
t ZEMYCIN Tab. Gaco 50ml bot: 185.00 MRP t ZYCIN-500 Tab. Globe
Azithromycin 500mg/tablet t ZIT HRACIN Tab. Supreme Azithromycin 500mg/tablet
SOOmg x 3's pack: 180.00 MRP Azithromycin USP 500mg/tablet 500mg x 6's pack: 180.00 MRP
t ZEMYCIN Susp. Gaco 500mg x 6's pack: 210.00 MRP t ZYCIN Susp. Globe
Azithromycin 200mg/5ml: suspension. t ZIT HRACIN Susp. Supreme Azithromycin 200mg/5ml: suspension.
15ml bot: 8S.OO MRP Azithromycin USP 200mg/5ml: suspension. 15ml bot: 80.00 MRP
t ZENICIN 500 Tab. Zenith l 5ml bot: 85 .25 MRP 30ml bot: 120.00 MRP
Azithromycin SOOmg/tablet 35ml bot: 130.00 MRP 50ml bot: 18S.OO MRP
SOOmg x 6's pack: 180.00 MRP t ZIT HRIN Tab. Renata
+ ZENICIN Susp. Zenith Azithromycin 250mg & 500mg/tablet
CLARITHROMYCJN 2t,49
Azithromycin 200mg/5ml: suspension. 250mg x 12's pack: 300.00 MRP
15ml bot: 82.00 MRP 500mg x 12's pack: 420.00 MRP
50ml bot: 200.00 MRP CLARITHROMYCIN: Tablet/
t ZITHRIN Cap. Renata
Azithromycin 250mg/capsule Suspension/Infusion
t ZEOCIN-500 Tab. APC Pharma
Azithromycin 500mg/tablet 12's pack: 240.84 MRP Ind: Respiratory tract infections (acute & chronic

500mg 3's pack: 90.00 MRP bronchitis, pneumonia); sinusitis, pharyngitis;

x + ZITHRIN Susp. Renata
Azithromycin 200mg/5ml: suspension. otits media; skin & soft tissue infections.
t ZEOCIN Susp. APC Pharma
Azithromycin USP 200mg/5ml: suspension. 15ml bot: 80.30 MRP Eeradication of H. pylori for the treatment of

30ml bot: 130.00 MRP 20ml bot: 85.32 MRP duodenal ulcers.

30ml bot: 125.00 MRP C/I: Hypersensitivity to clarithromycin or any

t ZIBAC Tab. Popular
Azithromycin 250mg & 500mg/tablet 35ml bot: 130.00 MRP other macrolide antibiotics.

250mg x 8's pack: 160.66 MRP 50ml bot: 185.00 MRP S/E; Cautions: See under Erythromycin; reduce
500mg x 12's pack: 361.32 MRP t ZIT HRIN I.V Inj. Renata dose in renal impairment; caution in heapatic
SOOmg x 18's pack: S41.98 MRP Azithromycin dihydrate USP 500mg/5ml vial impairment, pregnancy and breast feeding; also
t ZIBAC Susp. Popular (powder for reconstitution): i.v injection. reported, headache, taste disturbances, stomatitis,
Azithromycin 200mg/5ml: suspension. 500mg (5ml vial) x l's pack: 460.00 MRP glossitis, cholestasis, jaundice, hepatitis and
15ml bot: 85.32 MRP + ZITHRO Cap. Pharmadesh Stevens-Johnson syndrome; on i.v infusion, local
20ml bot: 100.00 MRP Azithromycin 250mg & 500mg/capsule tenderness, phlebitis.
25ml bot: 115.00 MRP 250mg x 6's pack: 120.36 MRP Arrhythmias- avoid concomitant administration
35ml bot: 130.49 MRP 500mg x 6's pack: 180.66 MRP with astemizole, terfenadine or cisapride.

fl'rustedmacrofitfefor treatment
ofvarious infectious aiseases
KEMIKO PHARMACEUTICALS LTD.

I
ANTIMICROBIAL DRUGS
Dosage & admin: By mouth, 250mg every 12
hours for 7 days, increased in severe infections
to SOOmg every 12 hours for up to 14 days.
Child- body weight under 8kg, 7.Smg/kg twice
daily; 8-11 kg (1-2 years), 62.Smg twice daily;
12-19 kg (3-6 years), 125mg twice daily; 20-29
kg (7-9 years), 187.Smg twice daily; 30-40kg
(10-12 years), 250mg twice daily.
Eradication of H. pylori- SOOmg twice daily
for 7 days in combination with other
preparations of the recomme-nded regimens.
By i. v infusion into larger proximal vein,
SOOmg twice daily; Child not recommended.
t BINOCLAR Tab. Sandoz
Clarithromycin 500mg/tablet
500mg x' 14's pack: 924.00 MRP
t BINOCLAR Susp. Sandoz
Clarithromycin l 25mg/5ml: suspension
60ml bot: 395.00 MRP
t CLACIN Tab. Medimet
Clarithromycin 500mg/tablet
500mg x 4's pack: 160.00 MRP
t CLARICIN Tab. Acme
Clarithromycin 250mg & 500mg/tablet
250mg x S's pack: 200.SO MRP
500mg x S's pack: 321.20 MRP
+ CLARIN Tab. Drug Inter
Clarithromycin 250mg & 500mg/tablet
250mg x lO's pack: 250.00 MRP
500mg x 1O's pack: 400.00 MRP
t CLARISON Tab. Hudson
Clarithromycin 500mg/tablet
500mg x l O's pack: 450.00 MRP
t CLAROCIN-500 Tab. Desh Pharma
Clarithromycin USP 500mg/tablet
500mg x 12's pack: 360.00 IP
t CLAROX Tab. Renata
Clarithromycin 250mg & 500mg/tablet
250mg x 20's pack: 500.00 MRP
500mg x 12's pack: 4SO.OO MRP
t KLABEX Tab. Opsonin
Clarithromycin 250mg & 500mg/tablet
250mg x 12's pack: 263.90 MRP
500mg x 6's pack: 211.13 MRP
t KLABID Tab. UniMed & UniHealth
Clarithromycin BP 250mg & 500mg/tablet
250mg x 14's pack: 420.00 IP
500mg x 14's pack: 700.00 IP
t KLABID ER Tab. UniMed & UniBealth
Clarithromycin BP 500mg/tablet (extended
release)
500mg x 7's pack: 455.00 MRP
+ KLABID Susp. UniMed & UniHealth
Clarithromycin BP 125mg/5ml: suspension
70ml bot: 340.00 MRP
t KLARICID I.V Inj. AbboWUniMed &
UniHealth
Clarithromycin lactobionate 500mg/vial: i.v
injection
1 vial pack: 623.73 MRP
+ MACLAR Tab. Techno Drugs
Clarithromycin 250mg & 500mg/tablet
250mg x 6's pack: l S0.00 MRP
500mg x 6's pack: 240.00 MRP
QIMP-17 (278)
+ MACLAR Susp. Techno Drugs
Clarithromycin 125mg/5ml: suspension
60ml bot: 330.00 MRP
t MACLAR I..V Inj. Techno Drugs
Clarithromycin lactobionate 500mg/vial: i.v inj.
l vial pack: 300.00 MRP
t MACROBID Tab. General
Clarithromycin 500mg/tablet
500mg x 4's pack: 200.76 MRP
+ REMAC Tab. Square
Clarithromycin 500mg/tablet
500mg x 6's pack: 240.90 MRP
ROXITHROMYCJN2t,26
ROXITHROMYCIN: Tablet/Suspension
Roxithromycin is a macrolide with antibacterial
properties similar to erythromycin. It is a broad
spectrum antibiotic and effective against a good
range of gram positive & gram negative bacteria
including atypical pathogens like mycoplasma
and chlamydia. It is well-tolerated by adults and
children.
Roxithromycin is well absorbed on oral
administration. It has a mean plasma half-life of
9-16 hours and once or twice daily dosing is
sufficient to maintain adequate bactericidal
activity in plasma and tissues. It is metabolized
in the liver; excretion occurs mainly through
faeces and also through respiratory tract & urine.
Ind: Roxithromycin is indicated in the treatment
of infections caused by susceptible
rmcroorgan1sms:
• •
Respiratory infections like pneumonia, acute and
chronic bronchitis, bronchopne\1monia; ENT
infections like tonsillitis, pharyngitis, sinusitis
and otitis media; Skin infections like folliculitis,
furuncles, cellulitis, carbuncles, pyoderma,
impetigo and infected dermatitis; Genital
infections like urethritis, prostatitis, cervicitis and
salpingitis specially if produced by chlamydia
trachomatis.
C/I: History of hypersensitivity to the drug.
S/E: Roxithromycin is well-tolerated by patients
of all age groups. Less than 4% of treated
patients complain of side-effects mainly nausea,
abdominal pain, diarrhoea and hypersensitivity
rash. Other side-effects reported include
vomiting, dizziness, headache, pruritus,
dyspepsia, flatulence, tinnitus, vertigo and
constipation. These are in general minor and do
not necessitate withdrawal of therapy.
Precautions: In patients with hepatic diseases the
dose of roxithromycin should not exceed l 50mg
twice a day. The safety of roxithromycin in
pregnancy has not been established. It appears in
breast milk in small amounts and does not
produce adverse effects in the breast fed infant.
Accumulation does not occur in patients with
compromised renal function and dosage
adjustment is not necessary. Roxithromycin
should not be administered simultaneously with
ergotamine or its derivatives as it may provoke
arterial spasm and severe ischaemia.
,,
' -'.
,. . . ' . :: .
;.; , .
' '' ' '' '
. .
: .
·: : :� -�
: : �
; : � ;
; : ; : · : :
'
: : :
"·
· ' ''' " _,, ''
.. .
. ...
Mol.e·:·than an antibiotic - · - :
•
,
Tablet 5QO:mg
Capsul8 250-mg
Dosage & admin: Adult dose- 300mg once
daily or 150mg twice daily for at least two
days after resolution of symptoms; a normal
course of therapy is between 5 and 10 days. In
severe hepatic impairment the dose is lSOmg
once daily. Roxithromycin is best administered
on empty stomach.
Children: 2.5-Smg/kg body weight twice a day.
The following general guidelines can be fol­
lowed- 6-llkg, 2Smg 12 hourly; 12-23kg, SOmg
12 hourly; 24-40kg, lOOmg 12 hourly. A nor­
mal course of therapy is between S & 10 days.
Drug Inter: Roxithromycin shows mild
interaction with theophylline though this has not
been found to produce clinically relevant effects.
Antacids, H2-receptor antagonists and food has
no effect on the absorption of roxithromycin.
t A-ROX Tab. Ambee
Roxithromycin BP l 50mg & 300mg/tablet
150mg x 30's pack: 195.90 MRP
300mg x 20's pack: 220.SO MRP
t A-ROX Susp. Ambee
Roxithromycin BP 50mg/5ml: suspension
50ml bot: 45.17 MRP
t PEDILID Tab. Incepta
Roxithromycin BP 150mg & 300mg/tablet
150mg x 50's pack: 350.00 MRP
300mg x 30's pack: 420.00 MRP
t PEDILID Susp. Incepta
Roxithromycin BP 50mg/5ml: suspension
50ml bot: 50.00 MRP
+ ROCKY Susp. Amico
Roxithromycin BP 50mg/5ml: suspension
50ml bot: 40.00 MRP
t ROLID Tab. Globe
Roxithromycin BP 150mg & 300mg/tablet
150mg x 50's pack: 350.00 MRP
300mg x 30's pack: 420.00 MRP
t ROLID Susp. Globe
Roxithromycin BP 50mg/5ml: suspension
50ml bot: 45.00 MRP
t ROTOMYCIN-300 Tab. Kemiko
Roxithromycin BP 300mg/tablet
300mg x 30's pack: 420.00 MRP
+ ROXCIN Tab. Alco Pharma
Roxithromycin BP 150mg & 300mg/tablet
150mg x 20's pack: 120.00 MRP
300mg x 20's pack: 240.00 MRP '
+ ROXCIN Susp. Alco Pharma
Roxithromycin BP 50mg/5ml: suspension
50ml bot: 45.00 MRP
+ RYTH Tab. Navana
Roxithromycin BP 150mg & 300mg/tablet
150mg x 18's pack: 126.54 IP
300mg x 1S's pack: 252.90 IP
+ RYTH Susp. Navana
Roxithromycin BP 50mg/5ml: suspension
50ml bot: 50.19 IP
,.
SPIRAMYCIN2 t,35
+ ROVAMYCINE Tab. Sanofi-aventis
Spiramycin 1.5 MIU & 3 MIU/tablet
-
· ' _ .
,- :;·" '
: ; '':
Powder for suspension 15 ml,
··
30 ml & 50 ml (200 mg/5 ml)

Ind: Species usually sensitive- streptococcus,
pne11mococcus (as in resp. tract infections),
meningococcus, gonococcus, bordetella pertussis,
. c.diphtheriae, listeria monocytogenes,
clostridit1m, mycoplasma pnet1moniae, chlamydia
trachomatis, legionella pneumophilia, treponema,
leptospira, campylobacter, toxoplasma gondii.
Species inconsistently sensitive-
h. influenzae, vibrio cholerae, staph. aureus.
Infections due to organisms mentioned above to
be sensitive, particularly in the following clinical
situations:
E.N.T, bronchopulmonary, dermatolo-gical,
genital (following prostatic) and bone infections.
- Prophylaxis of meningo-coccal meningitis in
l
contact subjects. Chemoprophylaxis of recurrence
of rheumatic fever.
Toxoplasmosis in pregnant women and in
immunodepressed subjects.
C/I: Known hypersensitivity to macrolides.
S/E: Gastro-intestinal effects- nausea, vomiting,
diarrhoea, sometimes leading to withdrawal of
treatment. Allergic skin reactions.
Precautions & warnings: The dosage does not
need to be modified in patients with renal
inpairment, because of the absence of renal
Clindamycin Hydrochloride USP capsule
excretion of the active molecule.
As spiramycin passes into the maternal milk,
using a milk substitute, or should not be given
during breast-feeding if there is alternative
antimicrobial is available.
In pregnancy spiramycin can safely be
I
prescribed.
Dosage & Admin: Adults- 6 to 9 MIU/day to
•
be divided in 2 or 3 doses.
Children- weight more than 20kg, 1.S MIU per
1Okg of body weight per day, to be divided in 2
or 3 doses.
Prophylaxis of meningococcal meningitis­
adults, 3 MIU/12 hours for S days; children,
75,000 IU/12 hours for S days.
Price: 3 MIU x 20's pack: 401.40 MRP
1.6 Clindamycin
I
QIMP-17 (279)
CLINDAMYCIN
CLINDAMYCIN: Tablet/Injection
Clindamycin is a semi-synthetic antibiotic produ­
ced by chlorosubstitution of the hydroxylgroup of
the parent compound lincomycin. It is available
as- i. Clindamycin hydrochloride BP l 50mg &
300mg capsule; ii. Clindamycin phosphate BP/
USP equivalent to clindamycin 300mg in 2ml &
600mg in 4ml ampoule for i.m/i.v injection.
Mode of action: Clindamycin may be either bac­
tericidal or bacteriostatic depending on the sensi­
tivity of the micro-organism & the concentration
of the antibiotic at the site of action.
Ind: Clindamycin has been found active against­
Gram-positive cocci including penicillin-resistant
Staphylo cocci, Streptococci (except S. faecalis),
Pneumoccoci; also many anaerobes specially
Bacteroides fragilis.
Clindamycin is indicated in the following
infections caused by the susceptible strains of
above bacteria.
1. Upper respiratory infections & lower respirato­
ry infections including bronchitis, pneumonia,
empyema. and lung abscess.
Wide Spectrum with real power
2. Skin and soft tissue infections including acne.
3. Bone adn joint infections including
osteomyelitis and septic arthritis.
4. Gynaecological infections including pelvic
inflammatory diseases when given in conjunction
with an antibiotic of appropriate garm-negative
spectrum.
5. Intra-abdominal infections including peritonitis
and abdominal abscess given with an appropriate
gram-negative aerobic antibiotic.
6. Septicemia and endocarditis.
7. Dental infections such as periodontal abscess
and periodontitis, etc.
C/I: Previously found to be sensitive to
clindamycin or lincomycin. Diarrhoeal diseases.
S/E: Abdominal pain, nausea, vomiting, diar­
rhoea, pseudo-membranous colitis; jaundice &
abnormalities in liver function tests; hypersensi­
tivity reactions such as, maculopapular rash and
urticaria, generalized mild to moderate morbilli
form-like skin rashes; transient neutropenia and
eosinophilia, agranulocytosis and thrombocytope­
nia have been reported.
Cautions: Discontinue immediately if diarrhoea
or colitis develops; impaired hepatic or renal
functions.
Pregnancy & lactation: Safety of clindamycin
for use in pr�gnancy has not been established. It
also appears in the breast milk from 0.7 to
3.8mcg/ml.
Dosage & admin: By mouth: The usual adult
dosage for patients with serious infections is
150-300mg every 6 hours. For more severe
infections 300-450mg every 6 hours is advised.
For acute pharyngitis/tonsillitis, the recom­
mended dosage is 300mg every 12 boon for 10
days. To avoid the possibility of esophageal
irritation, capsules should be taken with a full
glass of water.
By injection: The usual adult daily dosage for
infections of the intra-abdominal area, female
pelvis and other complicated or serious inf ec­
tions is 2400-2700mg/day given divided in 2, 3
or 4 equal doses. Less complicated infections
due to more susceptible microorganisms may
respond to lower doses such as 1200mg/day
given divided in 3 or 4 equal doses.
For children over 1 month of age, the dosage
is 20-40mg/kg/day divided in 3 or 4 equal dose.
In neonates (under 1 month of age), the dose is
1S-20mg/kg/day divided in 2, 3 or 4 equal
doses. Single intramuscular doses of greater
than 600mg are not recommended. The con­
centration of clindamycin in diluent for infu­
sion should not exceed 18mg per ml and infu­
sion rates should not exceed 30mg per minute.
Administration of more than 1200mg in a sin­
gle infusion is not recommended. If significant
diarrhea occurs during therapy, this antibiotic
should be discontinued. For certain indica­
tions, parenteral therapy may be changed to
 •
® QIMP-17 (280)

1n a max
Clindamycin 300mg/capsule. l SOmg x 30's pack: 240.00 MRP
l SOmg x 30's pack: 211.92 MRP 300mg x 30's pack: 4SO.OO MRP
300mg x 30's pack: 397.4S MRP
t CLINDAX Oral Soln. Opsonin
Clindamycin hydrochloride 7Smg/Sml: 1.7 Some other antibacterials21
oral when the condition warrants and at the suspension.
•

discretion of the physician.
Drug inter: A ntagonism has been demonstrated
between clindamycin and erythromycin.
t CINAMYCIN Cap. lbn Sina
Clindamycin hydrochloride l SOmg &
300mg/capsule.
l SOmg x 30's pack: 240.00 IP
300mg x 30's pack: 4SO.OO IP
t CLEODIN Cap. General
lOOml bot: 220.7S MRP
t CLINDAX 300 Inj. Opsonin
Clindamycin phosphate BP equivalent to clin­
damycin 300mg/2ml ampoule: i.m/i.v injection.
300mg (2ml) amp x S's pack: 176.60 MRP
t CLINDAX 600 Inj. Opsonin
Clindamycin phosphate BP equivalent to clin­
damycin 600mg/4ml ampoule: i.m/i.v injection.
600mg (4ml) amp x S's pack: 309.04 MRP
Drugs discussed under 'some other antibacte­
rials' include- chloramphenicol, daptomycin,
fidaxomicin, fusidic acid, glycopeptide
antibiotics (vancomycin & teicoplanin),
oxazolidinone group (linezolid), spectinomycin,
the polymyxins (colistimethate sodium,
polymyxin-B), the ri/amycin (ri/aximin).
CHLORAMPHENICOVt,33 \

+ CLINEX Cap. Aristopharma

Clindamycin hydrochloride l 50mg &
300mg/capsule.
l SOmg x 30's pack: 240.00 MRP
300mg x 30's pack: 4SO.OO MRP
t CLEODIN 300 Inj. General
Clindamycin phosphate BP equivalent to clin­
damycin 300mg/2ml ampoule: i.m/i.v injection.
300mg (2ml) amp x S's pack: 200.00 MRP
t CLEODIN 600 lnj. General
Clindamycin phosphate BP equivalent to clin­
damycin 600mg/4ml ampoule: i.m/i. v injection.
600mg (4ml) amp x S's pack: 3SO.OO MRP
t CLIMYCIN Cap. Square
Clindamycin hydrochloride 1SOmg &
300mg/capsule.
1SOmg x 30's pack: 241.20 MRP
300mg x 30's pack: 4S l .SO MRP
t CLINCIN Cap. Navana
Clindamycin hydrochloride BP l SOmg &
300mg/capsule.
l SOmg x 30's pack: 240.00 MRP
300mg x 30's pack: 4SO.OO MRP
t CLINDABAC Cap. Popular
Clindamycin hydrochloride 1SOmg &
300mg/capsule.
1SOmg x 30's pack: 240.00 MRP
300mg x 30's pack: 450.00 MRP
t CLINDABAC 300 Inj. Popular
Clindamycin phosphate BP equivalent to clin­
damycin 300mg/2ml ampoule: i.m/i.v injection.
300mg (2ml) amp x S's pack: 200.00 MRP
t CLINDABAC 600 Inj. Popular
Clindamycin phosphate BP equivalent to clin­
damycin 600mg/4ml ampoule: i.m/i.v injection.
600mg (4ml) amp x S's pack: 3SO.OO MRP
t CLINDACIN Cap. lncepta
Clindamycin hydrochloride 1SOmg &
300mg/capsule.
l SOmg x 30's pack: 240.00 MRP
300mg x 30's pack: 450.00 MRP
t CLINDACIN 300 Inj. Incepta
Clindamycin phosphate BP equivalent to clin­
damycin 300mg/2ml ampoule: i.m/i.v injection.
300mg (2ml) amp x S's pack: 200'.00 MRP
t CLINDACIN 600 Inj. Incepta
Clindamycin phosphate BP equivalent to clin­
damycin 600mg/4ml ampoule: i.m/i.v injection.
600mg (4ml) amp x S's pack: 3SO.OO MRP
t CLINDAMET Cap. Somatec
Clindamycin hydrochloride l SOmg &
300mg/capsule.
l SOmg x 30's pack: 240.00 MRP
300mg x 30's pack: 4SO.OO MRP
t CLINDAX Cap. Opsonin
Clindamycin hydrochloride l SOmg &
Clindamycin hydrochloride l SOmg &
300mg/capsule. CHLORAMPHENICOL: Capsule/ Syrup/
l SOmg x 30's pack: 240.00 MRP Injection.
Ind: Broad spectrum antibiotic, is a potent &
300mg x 30's pack: 4SO.OO MRP
t DACLIN Cap. ACI
potentially toxic, which should be reserved for
the treatment of life threatening infections,
Clindamycin hydrochloride l SOmg &
particularly those caused by haemophylus
300mg/capsule.
influenuie or klebsiella penumoniae & also for
l SOmg x 30's pack: 240.00 MRP
300mg x 30's pack: 4SO.OO MRP typhoid fever (salmonella group).
S/E: Leucopenia, thrombocytopenia, irreversible
t DALACIN-300 Cap. Drug Inter.
aplastic anaemia, peripheral neuritis, optic
Clindamycin hydrochloride 300mg/capsule.
neuritis, erythema multiforme; nausea, vomiting,
300mg x 14's pack: 210.00 MRP
t DALACIN Inj. Drug Inter.
diarrhoea.
Clindamycin phosphate USP 300mg/2ml Cautions: Avoid repeated courses & prolonged
treatment; reduce doses in hepatic & renal
ampoule & 600mg/4ml ampoule: i.m/i. v
impairment; periodic blood counts required;
injection.
interferes with development of immunity; caution
300mg (2ml) amp x S's pack: 200.00 MRP
600mg (4ml) amp x 3's pack: 210.00 MRP
in neonates (may cause grey daby syndrome).
Dosage & admin: By mouth, 250-SOOmg every
+ DALACIN C Cap. Pharmacia-Pfizer/Janata
6 houn, or SO mg/kg/day in divided doses.
Clindamycin hydrochloride 300mg/capsule.
By i.v. or i.m. injection 1 gm every 6-8 hours.
300mg x l 6's pack: 848.16 MRP
Child, pyogenic meningitis, S0-1 OOmg/kg daily
+ DALACIN lnj. Pharmacia-Pfizer/Janata
Clindamycin phosphate BP equivalent to clin­
in divided doses every 6 hours.
Neoborn & premature infants, 2Smg/kg wt.
damycin 600mg/4ml ampoule: i.m/i.v injection.
600mg (4ml) amp x l 's pack: 332.03 MRP
t CHLORAMPHENICOL Cap. Hudson
t LINACIN Cap. Sharif
Chloramphenicol 2SOmg/capsule.
Clindamycin hydrochloride l SOmg &
l OO's pack: 220.00 MRP
300mg/capsule.
t CHLORPHEN Cap. Nipa
ISOmg x 30's pack: 240.00 MRP
Chloramphenicol 2SOmg/capsule
300mg x 30's pack: 4SO.OO MRP.
l OO's pack: 200.00 MRP
t LINCOCIN Cap. Acme
t EDRUMYCETIN Cap. Edruc
Clindamycin hydrochloride l SOmg &
Chloramphenicol 2S0mg/capsule.
300mg/capsule.
IOO's pack: 2SO.OO MRP
ISOmg x 30's pack: 240.00 MRP
t OPSOMYCETIN Susp. Opsonin
300mg x 30's pack: 4SO.OO MRP
Chloramphenicol 12Smg/Sml: suspension
t LINDAMAX Cap. SK+F
60ml bot: 39.33 MRP
Clindamycin hydrochloride l SOmg &
300mg/capsule.
FUSIDIC ACil)2t,73
1SOmg x 30's pack: 240.00 MRP
300mg x 30's pack: 4SO.OO MRP
+ QCIN Cap. Renata + FUCIDIN Tab. Leo Pharma/Kapricorn
Clindamycin hydrochloride 1SOmg & Sodium fusidate 2SOmg/tablet
300mg/capsule. Ind: Infections caused by penicillin resistant
l SOmg x 30's pack: 240.00 MRP staphylococci (specially osteomyelitis, as they are
300mg x 30's pack: 4SO.OO MRP well concentrated in bone; a second anti-staphy­
+ QCIN Inj. Renata lococcal antibiotic is usually required.)
Clindamycin phosphate USP 300mg/2ml S/E: Nausea, vomiting, rashes, jaundice,
ampoule & 600mg/4ml ampoule: i.m/i.v reversible change in liver function.
injection. Cautions: Hepatic insufficiency.
300mg (2ml) amp x S's pack: 200.00 MRP Dosage & admin: 250-SOOmg every 8 hourly.
600mg (4ml) amp x S's pack: 3SO.OO MRP 20's pack: 2220.40 MRP
+ XINDAL Cap. Orion Pharma
Clindamycin hydrochloride l SOmg &
Oxazolidinones2,62;120
300mg/capsule.

Oxazolidinone is a new class of antibiotics
belonging to the miscellaneous antimicrobials.
The drugs of this group are organically
synthesised and absorbed excellently by oral
administration. The mechanism of action of this
class of antibiotics differs from that of existing
antimicrobial agents. Therefore, cross resistance
to other antimicrobials is less likely and has been
shown to date. There is only one preparation of
this group, currently available for clinical use­
Linezolid.
•
LINEZOLJD62,120
LINEZOLID: Tablet/Suspension/Injection
Linezolid is the first and only product of
oxazolidinone group currently available for
clinical use. It is active against a wide range of
gram-positive bacteria including methicillin­
resistant staphylococcus aureus (MRSA),
vancomycin-resistant enterococci (VRE) and
penicillin-resistant pneumococci, but not against
any gram-negative pathogens.
Mode of action: Linezolid is a bacteriostatic
antibiotic. It selectively inhibits bacterial protein
synthesis by binding to a site on the bacterial
ribosome and preventing the formation of the
functional complex which is an essential
component of the translation process.
Ind: Linezolid is indicated for the treatment of
severe infections of different organs and systems
of the body caused by most gram-positive
bacteria, viz. vancomycin-resistant enterococcus
faecium infections, nosocomial or community
acquired pneumonia and uncomplicated or
complicated skin and skin structure infections.
C/I: Known case of hypersensitivity to linezolid
or any of the other product components.
S/E: Linezolid is well tolerated. The most com-
mon adverse events in patients treated with line­
zolid are- diarrhoea, headache and nausea. Other
adverse events reported are- insomnia, constipa­
tion, dizziness, oral moniliasis, vaginal monilia­
sis, hypertension, dyspepsia, localised abdominal
pain, rash, pruritus, tongue discolouration, pseu­
domembranous colitis and myelosuppression.
Precautions: If superinfection occurs during
/
therapy, appropriate measures should be taken.
Linezolid has not been studied in patients with
uncontrolled hypertension, pheochromocytoma,
carcinoid syndrome or untreated hyperthy­
-·
roidism. The safety and efficacy of linezolid .
formulations given for longer than 28 days have
not been evaluated in controlled clinical trials.
Platelet counts should be monitored in patiynts
who are at increased risk of bleeding, who have
pre-existing thrombocytopenia, who receive
concomitant medications that may decrease
platelet count or function or who may require
longer than 2 weeks of linezolid therapy.
Pregnancy & lactation: Linezolid is not
teratogenic and still like all other drugs it should
be used during pregnancy only if the potential
benefit justifies the potential risk to the foetus.
Although it is known not to be excreted in breast
milk, caution should be exercised when linezolid
is administered to a nursing woman.
Dosage & admin: Patients who commence
treatment on the parenteral formulation may
QIMP-17 (281)
be switched to either oral presentation when
clinically indicated. In such circumstances, no
dose adjustment is required as Linezolid has
an oral bioavailability of approximately 100°/o.
The oral preparation (film coated tablets or
suspension) may be taken with or without food.
T he injection should be administered over a
period of 30 to 120 minutes.
Adultdosare; The usual adult dose of Iinezolid
is 400-600mg 12 hourly regardless of meals for
7-28 days depending on the type and severity
of the infection and the patients clinical
response. The recommended dosage for
specific indications are as below:
Vancomycin-resistant enterococcus faecium
infection including concurrent bacteremia:
600mg 12 hourly for 14 to 28 days.
Nosocomial pneumonia, community-acquired
pneumonia including concurrent bacteremia &
complicated skin and skin structure infection:
600mg 12 hourly for 10 to 14 days.
Uncomplicated skin & skin structure infection:
400mg 12 hourly for 10 to 14 days.
Elderly patients: No dose adjustment is
required for elderly patients.
Neonates< 7 days: Most pre-term neonates< 7
days of age (gestational age< 34 weeks) have
lower systemic linezolid clearance values and
larger AUC values than many full-term
neonates and older infants. T hese neonates
should be initiated with a dosing regimen of
1Omg/kg every 12 hours. Consideration may
be given to the use of 1Omg/kg in every eight
hours regimen in neonates with a sub-optimal
clinical response. All neonatal patients should
receive 1Omg/kg t.i.d. by 7 days of life.
Overdose: In the event of overdosage, supportive
care is advised with maintenance of glomerular
filtration. Haemodialysis may facilitate more
rapid elimination of linezolid.
·
Drug inter: Line?'.olid is a reversible, nonselec­
tive inhibitor of monoamine oxidase. Therefore,
linezolid has the potential for interaction with
adrenergic and serotonergic agents. Patients
receiving linezolid need to avoid consuming large
amounts of foods or beverages with high
tyramine content. A reversible enhancement of
the pressor response of either pseudoephedrine
hydrochloride or phenylpropanolamine
hydrochloride is observed when linezolid is
administered to healthy normotensive.
+ ARLIN-600 Tab. Beximco
Linezolid INN 600mg/tablet (film coated).
600mg x 20's pack: 1700.00 IP
+ ARLIN Susp. Beximco
Linezolid INN 100mg/5ml: suspension.
l OOml bot: 280.00 IP
t LINEZ Tab. Renata
Linezolid INN 400mg & 600mg/tablet (f.c ).
400mg x lO's pack: 600.00 MRP
600mg x 1O's pack: 850.00 MRP
+ LINEZ Susp. Renata
Linezolid INN 100mg/5ml: suspension.
60ml bot: 175.00 MRP
1OOml bot: 280.00 MRP
l 50ml bot: 420.00 MRP
t LINZOLID Tab. Incepta
Linezolid INN 600mg/tablet (film coated).
600mg x 1 O's pack: 850.00 MRP
t LINZOLID Susp. Incepta
ANTIMICROBIAL DRUGS
Linezolid INN 100mg/5ml: suspension.
1 OOml bot: 280.00 MRP
t LINZOLID 600 I.V Inf. Incepta
Linezolid INN 600mg_in 300ml solution: injection
for i.v infusion.
600mg (300ml solution) x l 's pack: 450.00 MRP
RIFAXIMJN2l,154,155
RIFAXIMIN: Tablet (f.c)
Rifaximin is a gastrointestinal selective, rifamycin
derivative s_emi-synthetic, non-systemic antibiotic
which is a structural analog of rifampin. It has a
broad spectrum anti-microbial activity against a
variety of enteropathogens causing acute
infectious diarrhea including traveler's diarrhea,
diarrhea predominant irritable bowel syndrome
(IBS-D) & hepatic encephalopathy (HE). It is
available as- rifaximin BP 200mg & 550mg per
tablet (film-coated).
Mode of action: Rifaximin is not (or poorly)
absorbed from gastrointestinal tract, so, it has
been found useful in the treatment of patients
with acute infectious diarrhea including traveler's
diarrhea caused by noninvasive strains of
escherichia coli, and 'diarrhea predominant irrita­
ble bowel syndrome (IBS-D)'; but, not useful in
the treatment of systemic infections, so that, not
recommended for diarrhea associated with inva­
sive organisms such as campylobacter & shigella.
Rifaximin acts by binding to the beta-subunit of
bacterial DNA-dependent RNA polymerase
enzyme resulting in inhibition of bacterial RNA
synthesis, thus interferes with protein synthesis &
inhibits growth of causative bactaria.
Ind: Rifaximin is indicated for-
i. the treatment of patients (over 12 years of age)
with acute infectious diarrhea including traveler's
diarrhea caused by noninvasive strains of
escherichia coli at lower dose (200mg);
ii. the treatment of 'diarrhea predominants
irritable bowel syndrome (IBS-D)' at higher dose
(550mg); and
iii. the treatment for reduction in risk of overt
hepatic encephalopathy (HE) at higher dose
(550mg).
C/I: Rifaximin is contraindicated in patients with
a hypersensitivity to rifaximin or any of the com­
ponents or any of the rifamycin antimicrobial age­
nts. Hypersensitivity reactions include exfoliat-ive
dermatitis, angioneurotic edema & anaphylaxis.
•
S/E: Most common side effects in traveler's diar­
rhea are- flatulence, headache, abdominal pain,
rectal tenesmus, defecation urgency and nausea.
Most common side effects in hepatic
encephalopathy are- peripheral edema, nausea,
dizziness, fatigue, ascites, flatulence & headache.
Precautions: Rifaximin is not effective in diar­
rhea complicated by fever or blood in the stool or
diarrhea due to pathogens other than escherichia
coli. If diarrhea symptoms get worse or persist
for more than 24-48 hours, discontinue rifaximin
and consider alternative antibiotics. Rifaximin
should be used with caution in patients with
severe hepatic impaionent.
Pregnancy & lactation: Pregnancy catergory C.
There are no adequate and well controlled studies
in pregnant women. Based on animal data, rifaxi­
min may cause fetal harm. It should be used dur­
ing pregnancy only if the potential benefit out-
•
 ANTIMICROBIAL DRUGS
•
weighs the probable risk to the fetus.
In case of nursing mother, discontinue nursing or
drug, taking into account the importance of the
drug to the mother.
Dosage & admin: Acute infectious diarrhea
including Traveler's diarrhea (over 12 years of
age): The recommended dose is 200mg taken
orally 3 times a day for 3 days.
Diarrhea predominant irritable bowel syndrome
(IBS-D): The recommended dose is 550mg
taken orally 2 times a day for 14 days.
Hepatic encephalopathy (over 18 years of age):
The recommended dose is 550mg taken orally
2 times a day for required days.
Rifaximin can be administered orally, with or
without fo�d.
Drug inter: Rifaximin does not inhibit cytoch­
rome P-450 isoenzymes at concentration ranging
from 2 to 200ng/ml.
+ HEPAXIMIN Tab. Aristopharma
Rifaximin BP 200mg & 550mg/tablet (f.c).
200mg x 20's pack: 400.00 MRP
550mg x IO's pack: 450.00 MRP
+ RIFABAC Tab. Popular
Rifaximin BP 200mg/tablet (f.c).
200mg x 1O's pack: 250.00 MRP
t RIFACOL Tab. Sharif
Rifaximin BP 200mg & 550mg/tablet (f.c).
200mg x 20's pack: 400.00 MRP
550mg x 1O's pack: 450.00 MRP
+ RIFAGUT Tab. Opsonin
Rifaximin BP 200mg & 550mg/tablet (f.c).
200mg x IO's pack: 175.94 MRP
550mg x lO's pack: 395.87 MRP
t RIFAGYL Tab. Globe
Rifaximin BP 200mg & 550mg/tablet (f.c).
200mg x 1O's pack: 200.00 MRP
550mg x 6's pack: 270.00 MRP
+ RIFAXIN Tab. Ziska
Rifaximin BP.200mg & 550mg/tablet (f.c).
200mg x 16's pack: 320.00 MRP
550mg x 8's pack: 360.00 MRP . Adults with impaired renal function and the
+ XIFAMIN 200 Tab. NIPRO JMI
Rifaximin BP 200mg/tablet (f.c).
200mg x 1O's pack: 200.00 MRP
SPECTINOMYCIN 21,60
SPECTINOMYCIN: Injection
•
Spectinomycin is an antibiotic belonging to the
miscellaneous antimicrobials. It is available as
2gm vial for intramuscular injection.
Ind: Acute go. norrhoeal urethritis, cervicitis and
proctitis.
,
C/I: Pregnancy & brest-feeding; children below
two years.
S/E: Nausea, dizziness, urticaria, fever.
Dose: Male- single 2gm dose (Sml); Female­
single 4gm dose (1Oml) i.m deep in the
buttock.
Children: Not recommended; but, if no
alternative, 40mg/kg over 2 years of age.
+ TINOBAC Inj. Incepta
Spectinomycin 2gm vial: injection.
2gm vial: 250.00 MRP
VANCOMYCIN121
·
QIMP-17 (282)
VANCOMYCIN: Injection.
Vancomycin is an amphoteric glycopeptide
antimicrobial substance produced by the growth
of certain strains of Nocardia orientalis. It is
bactericidal aganist many gram positive
organisms including staphylococci, streptococci,
corynebacterium and clostridium, including
clostridium difficile. Gram negative bacteria,
mycobacteria and fungi are resistant.
Vancomycin is available as vancomycin hydro­
chloride 500mg vial injection for i.v infusion.
Mode of action: Vancomycin is bactericidal
against many gram positive organisms. It appears
to act by inhibiting the production of bacterial
cell wall mucopeptide. Gram-negative bacteria,
mycobacteria and fungi are found resistant to
vancomycm.
•
Ind: Potentially life-threatening infections which
cannot be treated with another effective, less
toxic antimicrobial drug, including the penicillins
and cephalosporins.
Vancomycin injection is useful in therapy of
severe staphylococcal (including methicillin
resistant staphylococcal) infections.
Vancomycin injection is effective alone or in
combination with an aminoglycoside for endo­
carditis caused by Strep. viridans or Strep. bovis.
For endocarditis caused by enterococci (e.g Strep.
faecalis), Vancomycin is effective only in combi­
nation with an aminoglycoside. Vancomycin is
effective for the treatment of diptheroid endocar­
ditis. Vancomycin injection is used in combina­
tion with rifampicin, an aminoglycoside, or both
in early onset prosthetic valve endocarditis
caused by staph. epidermidis or diphtheroids.
Vancomycin injection should be administered
orally for the treatment of staphylococcal entero­
colitis and antibiotic associated pseudomembra­
nous colitis (produced by Cl. difficile). For oral
administration the parenteral formulation may be
used.
•
C/I: Known hypersensitivity to this drug.
Adverse reactions:
Infusion related events: During or soon after
infusion of vancomycin injection, patients may
develop anaphylactoid reactions including
hypotension, palpitations, substemal pressure,
tachycardia, wheezing, dyspnoea, urticaria, or
pruritus. Rapid infusion may cause flushing of
the upper body ("red neck") or pain and muscle
spasm of the chest and back. These reactions
usually resolve within 20 minutes, but may
persist for sveral hours.
Auditory & Vestibular: Sensorineural deafness
which may be accompanied by tinnitus may
occur but the incidence is low. Vertigo and
dizziness have also been reported.
Cardiovascular: Hypotension, palpitations,
substemal pressure, tachycardia (see infusion
related events).
Gastrointestinal: Oral doses are extremely
unpalatable. In leukaemic patients, oral dosing
regimens are associated with frequent nausea,
diarrhoea and occasional vomiting.
Haematological: Eosinophilia, thrombocytopenia
and neutropenia.
Immunological: Hypersensitivity reacitons with
chills, nausea, urticaria, macular rash, fever and
rigors. Anaphylactoid reactions have been
reported infrequently.
Renal: Cases of interstitial nephritis and renal
failure have been reported.
Precautions: Vancomycin i.v should be
administered in a dilute solution at a rate not
exceeding 500mg/hour to avoid rapid-inusion­
related reactions.
Because of its ototoxicity and nephroto-xicity,
vancomycin should be used with care in patients
with renal insufficiency.
The use of vancomycin may result in overgrowth
of nonsusceptible organisms. IQ rare instances
there have been reports of pseudomembranous
colitis due to C. difficile.
Since vancomycin is irritating to tissue and
causes drug fever, pain and possibly necrosis it
should never be injected I.M; it must be
administered l.V. Pain and thrombophlebitis
occur in many patients receiving vancomycin a.nd
are occasionally severe. The frequency and
severity of thrombophlebitis can be minimised if
the drug is administered in a volume of at least
200ml of glucose or saline solution and if the
injection sites are rotated.
Patients taking oral vancomycin should be
warned of its offensive taste.
Pregnancy & lactation: As there is little
information on the use of vancomycin in
pregnancy, the drug should not be used in
pregnant women or those likely to become
pregnant unless the expected benefits outweigh
any potential risk. Vancomycin is excreted in
breast milk, but not known whether harmful to
the newborn. Therefore, it is not recommended
for nursing mothers unless the expected benefits
outweigh any potential risk.
Dosage & admin: Adults: The usual i.v dose is
500mg for every 6 hours or lgm every 12
hours. A 500mg dose of vancomycin should be
infused over a period of at least 50 minutes,
whereas a lgm dose should be administered
over a period of at least 2 hours .
elderly: Dose adjustment must be made in
patients with impaired renal function. For
most patients with renal impairment or the
elderly, the dosage calculations may be made
by using the following table.
Vancomycin injection: Dosage in patients with
impaired renal function:
Loaing dose: The initial dose should be not less
than 15mg/kg, even in patients with mild to
moderate renal insufficiency.
Anephric patients:
The table is not valid for functionally anephric
patients.
The majority of patients with infections
caused by organisms susceptible to the
antibiotic show a therapeutic response by 48- •
72 hours. The total duration of therapy is
determined by the type and severity of the
infection and the clinical response of the
patient. In staphylococcal endocarditis,
therapy for 3 weeks or longer is recommended.
Children: The paediatric dosage of vancomy­
cin is calculated on the basis of 1Omg/kg body
weight every 6 hours after an initial loading
dose of 15mg/kg. Each dose should be
administered over a period of at least 60
minutes.
Infants & Neonates: In neonates and young

infants, the total daily i.v dosage may be
lower. An initial dose of 15mg/kg is suggested,
followed by 1Omg/kg every 12 hours in the
first week of life and every eight hours there­
after until one month of age. Close monitoring
of serum vancomycin concentrations is
mandatory in these patients.
Oral administration: The usual adult total
daily dosage for antibiotic associated
pseudomembranous colitis produced by C.
difficile is 500mg to 2gm given in 3 or 4
divided doses for 7 to 10 days. The total daily
dosage in children is 40mg/kg body-weight in 3
or 4 divided doses. The total daily dosage
should not exceed 2gm.
The contents of 1 vial (500mg or 500,000 i.u)
may be diluted in 30ml of distilled or deionised
water and given to the patient to drink, or the
diluted material may be administered via
nasogastric tube. Common flavouring syrups
may be added to the solution to improve the
taste for a oral administration.
Preparation of solution for injection: At the
time of use, the 500mg (or 500,000 i.u) vials
•
should be reconstituted with 1Oml of water for
injection. The resulting solution contains
vancomycin 50mg/ml. The l gm (1,000,000 i.u)
vial should be reconsituted with 20ml of water
for injection. Tlie resulting solution contains
vancomycin 50mg/ml. The reconstituted solution
must be further diluted with Sodi11m chloride i.v
infusion 0.9% or Glucose i.v infusion 5% to a
concentration of not more than 1Omg/ml. The
resulting solution should be infused over a period
of at least 60 minutes when 500mg of
vancomycin is to be administered, or at least 2
hours when 1gm of vancomycin is to be given.
Stability of reconstituted solution: Solutions of
vancomycin 50mg/ml (50,000 i.u/ml) in water for
injection do not show significant loss of potency
when stored at 2°C-8°C for 96 hours.
When diluted to a concentration of either
lOmg/ml or l mg/ml with Sodium chloride i.v
infusion 0.9% or Glucose i.v infusion 5o/o
vancomycin was chemically stable for 24 hours
at 25°C and 28 days at 2-8°C.
However to avoid microbial contamination all
solutions should be used as soon as practicable
after reconstituted and within 24 hours of
preparation.
Drug inter: Careful monitoring is required for
the following: Streptomycin, neomycin, gentam­
icin, kanamycin, amikacin, polymyxin b, colistin,
ethacrynic acid, frusemide & cholestyramine.
+ COVAN Inj. Renata
Vancomycin hydrochloride USP 500mg/vial &
l gm/vial: injection for i.v infusion.
500mg vial x 1's pack: 250.00 MRP
l l gm vial x l's pack: 480.00 MRP
+ VANCARD Inj. Techno Drugs
Vancomycin hydrochloride USP 500mg/vial &
l gm/vial: injection for i.v infusion.
500mg vial x l's pack: 245.00 MRP
l gm vial x l's pack: 460.00 MRP
+ VANCOBAC Inj. Popular
Vancomycin hydrochloride USP 500mg/vial &
l gm/vial: injection for i.v infusion.
500mg vial x 1's pack: 320.00 MRP
l gm vial x l's pack: 552.08 MRP
'
'
I
QIMP-17 (283)
+ VANCOMIN lnj. Opsonin
Vancomycin hydrochloride USP 500mg/vial &
l gm/vial: injection for i.v infusion.
500mg vial x l's pack: 220. 75 MRP
l gm vial x l's pack: 423.84 MRP
+ VANMYCIN Inj. lncepta
Vancomycin hydrochloride USP 500mg/vial &
l gm/vial: injection for i.v infusion.
500mg vial x 1's pack: 250.00 MRP
l gm vial x l's pack: 480.00 MRP
TEICOPLANIN26
TEICOPLANIN: Injection
Teicoplanin is a glycopeptide bactericidal
antibiotic, which is active against both anaerobic
and aerobic gram-positive organisms. It is
available as teicoplanin INN 200mg lyophilized
powder in vial for i.m or i.v injection.
Mode of action: Teicoplanin inhibits the growth
of susceptible organisms by interfering with cell­
wall bisynthesis at a site different from that
affected by beta-lactams. It is active against
staphylococci (including those resistant to
methicillin and other beta-lactam antibiotics),
streptococci, enterococci, listeria monocytogenes,
micrococci, group J/K corynebacteria and gram­
positive anaerobes including clostridium difficile
and peptococci.
C/I: Known hypersensitivity to teicoplanin or its
any ingredients.
S/E: Teicoplanin is generally well tolerated.
Serious side-effects are rare. General side-effects
are gastrointestinal like nausea, vomiting, diarrhea;
CNS associated with urticaria, rash, anaphylactic
shock as well as hearing problems like vertigo,
tinnitus and vestibular disorder may occur.
Precautions: Teicoplanin should be administered
with caution in patients with renal insufficiency,
patients who require concurrent use of drugs
which have ototoxic &/or nephrotoxic properties.
Pregnancy & lactation: There are no adequate
and well-controlled studies of teicoplanin in
pregnant women, therefore, this drug should be
used during pregnancy only if clearly needed.
Information about the excretion of teicoplanin in
milk is not known.
.
Dosage & admin: 3ml water for injection from
the accompanying diluent water ampoule
should be added slowly down the side wall of
the vial of teicoplanin 200mg. The vial shoo.Id
be rolled gently between the palms until the
powder is completely dissolved. During the
rolling, we have to be cautious about the
solution that it does not become foamy. The
solution must not be shaken. If foam formed
then it should be allowed to stand for 15
minutes for the foam to be subsided. The
entire contents from the vial should be
withdrawn slowly into a syringe.
The reconstituted solution can be administered
either by i.m or i.v route. I.V injection may be
administered by rapid injection over 3-5
minutes, or slowly over a 30 minutes infusion
by diluting with 0.9°/o sodium chloride or
Hartmann's solution or 5°/o dextrose etc. An
i.m injection of teicoplanin should not exceed
3ml at a single site.
•
ANTIMICROBIAL DRUGS
Patients with renal impairment: For patients
with impaired renal function, reduction of
dosage is not required until the fourth day of
teicoplanin treatment. From the fourth day of
•
treatment- in mild renal insu.fficiency-
teicoplanin dose should be halved either by
administering the initial unit dose every two
days, or by administering half of this dose
once a day when creatinine clearance is 40-
60ml/min; in severe renal insufficiency­
teicoplanin dose should be 1/3 the normal
either by administering the initial unit dose
every third day or by administering 1/3 of the
•
dose once a day when creatinine clearance is
<40ml/min and in haemodialysed patients.
Teicoplanin is not removed by dialysis.
Drug inter: Teicoplanin should be administered
with caution in patients receiving concurrent
nephrotoxic or ototoxic drugs such as
aminoglycosides, amphotericin B, cyclosporine
and frusemide.
+ TARGOCID 200 Inj. Sanofi-aventis
Teicoplanin INN 200mg lyophilized powder in
vial for i.m or i.v injection.
200mg vial x 1's pack: 872.08 MRP
+ TARGOCID 400 Inj. Sanofi-aventis
Teicoplanin INN 400mg lyophilized powder in
vial for i.m or i.v injection.
400mg vial x l's pack: 1568.62 MRP
TIGECYCLINE26
TIGECYCLINE: I.V Infusion
Tigecycline is a glycylcycline antibacterial agent.
Structurally, it is similar to tetracycline-class of
antibiotics. Tigecycline is available as tigecycline
INN 50mg as lyophilized powder in vial for i. v
infusion.
Mode of action: Tigecycline inhibits protein
translation in bacteria by binding to the 30S
ribosomal subunit and blocking entry of amino­
acyl tRNA molecules into the A site of the
ribosome. This prevents incorporation of amino
·
acid residues into elongating peptide chains. To
date there has been no cross-resistance observed
between tigecycline and other antibacterials.
Tigecycline is not affecte� by the two major
tetracycline-resistance mechanisms- ribosomal
protection and efflux. Additionally, tigecycline is
not affected by resistance mechanisms such as
beta-lactamases (including extended spectrum
beta-lactamases), target-site modifications,
macrolide effiux pumps. or enzyme target changes
(e.g gyrase/topoisomerases).
Ind: Tigecycline is indicated for the treatment of
infections caused by susceptible strains of the
designated microorganisms in the conditions
listed below:
i. Complicated skin and skin structure infections
caused by- escherichia coli, enterococcus faecalis
(vancomycin-susceptible isolates only),
staphylococcus aureus (methicillin-susceptible
and -resistant isolates), streptococcus agalactiae,
streptococcus anginosus grp. (includes s.
anginosus, s. intermedius, and s. constellatus),
streptococcus pyogenes, snterobacter cloacae,
klebsiella pneumoniae and bacteroides fragilis.
ii. Complicated intra-abdominal infections caused
ANTIMICROBIAL DRUGS
by- citrobacter freundii, enterobacter cloacae,
escherichia coli, klebsiella oxytoca, klebsiella
pneumoniae, enterococcus faecalis (vancomycin­
susceptible isolates only), staphylococcus aureus
(methicillin-susceptible and -resistant isolates),
streptococcus anginosus grp. (includes s. angi­
nosus, s. intermedius, and s. constellatus), bac­
teroides fragilis, bacteroides thetaiotaomicron,
bacteroides uniformis, bacteroides vulgatus,
clostridium perfringens, and peptostreptococcus
micros.
.
iii. Community-acquired bacterial pneumonia
caused by- streptococcus pne\1moniae (penicillin­
susceptible isolates), including cases with concur­
rent bacteremi, haemophilus influenzae (beta-lac­
tamase negative isolates), and legionella
pneumophila.
C/I: Tigecycline is contraindicated in patients
who have known hypersensitivity to this drug.
S/E: The most common adverse events are nau­
sea and vomiting which generally occur during
the first 1-2 days of therapy. The following drug­
related adverse events are reported infrequently
in patients receiving tigecycline:
Injection site inflammation & pain,· septic shock,
allergic reaction, chills, thrombophlebitis, brady­
cardia, tachycardia, vasodilatation, anorexia, dry
mouth, hypoglycemia, hyponatremia, prolonged
prothrombin time, eosinophilia, thrombocytope­
nia, vaginal moniliasis, vaginitis, leukorrhea.
Precautions: As tigecycline has structural
similarity to tetracycline-class of antibiotics, it
should be administered with caution in patients
with known hypersensitivity to tetracycline-class
of antibiotics.
Pregnancy & lactation: Tigecycline should be
used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.
Caution should also be exercised when
tigecycline is administered to a nursing woman.
Dosage & admin:
Adults: The recommended dosage regimen is
an initial dose of 1OOmg, followed by SOmg
every 12 hours. Intravenous infusions of tige­
cycl.ine should be administered over approxi­
mately 30 to 60 minutes every 12 hours.
Geriatric use: No unexpected overall differe­
nces in safety or effectiveness were observed
between these subjects and younger subjects.
Pediatric use: Safety and effectiveness in
pediatric patients below the age of 18 years
have not been established.
Method of reconstitution:
Each vial of tigecycline should be reconstituted
with 5.3 ml of 0.9°/o sodium chloride injection
to achieve a concentration of 1 Omg/ml of
tigecycline. The vial should be gently swirled
until the drug dissolves. Withdraw 5ml of the
reconstituted solution from the vial and add to
a lOOml intravenous bag of 0.9°/o sodium
chloride or So/o dextrose or lactated Ringer's
solution for infusion (for a lOOmg dose,
reconstitute two vials; for a 50mg dose,
reconstitute one vial). The maximum concen­
tration of i.v solution should be lmg/ml. If the
same intravenous line is used for sequential
infusion of several drugs, the line should be
flushed before and after infusion of tigecycline
with either 0.9o/o sodium chloride injection or
5o/o dextrose injection.
QIMP-17 (284)
Duration of therapy: The duration of therapy
should be guided by the severity and site of
the infection and the patient's clinical and
bacteriological progress. The recommended
duration of treatment with tigecycline for
complicated skin and skin structure infections
or for complicated intra-abdominal infections
is 5 to 14 days and for community-acquired
bacterial pneumonia is 7 to 14 days.
Drug inter: Drug interaction of tigecycline with
digoxin and warfarin is observed.
Storage: Prior to reconstitution, tigecycline
should be stored at 20°C to 25°C. Once
reconstituted, tigecycline may be stored at room
temperature for up to 24 hours (up to 6 hours in
the vial and the remaining time in the intravenous
bag). Reconstituted solution may be stored
refrigerated at 2°C to 8°C for up to 48 hours
following immediate transfer of reconstituted
solution into the intravenous bag.
t TIGACIL lnj. Incepta
Tigecycline INN 50mg as lyophilized powder in
vial, with 1 ampoule containing 5.3ml of 0.9%
sodium chloride BP and one 5ml sterile
disposable syringe for injection preparation for
i.v infusion.
50mg vial in combipack: 500.00 MRP
1.8 Sulphonamides &
Trimethoprim
SULPHADIAZINE2I
SULPHADIAZINE: Tablet/Injection
Ind: Meningococcal meningitis.
C/I: Pregnancy, infants under 6 wks; renal & leukopenia & megaloblastic anaemia due to
hepatic failure, Jaundice & blood disorder.
S/E: Nausea, vomiting, rashes, eosinophilia,
agranulocytosis, granulocytopenia, purpura,
leukopenia.
Cautions: Blood counts in prolonged treatment;
maintain adequate fluid intake; renal impairment.
Dose: By deep i.m inj. or i.v infusion 2gm
initially then lgm every 6 hours for 2 days,
followed by oral treatment for a further 5 days.
If injection is not available, by mouth, 2gm (4
tab) on the first time there after lgm (2 tab) 4-
6 hourly for 7 days.
Preparation: May not be available
SULPHADIMIDJNE21
SULPHADIMIDINE: Tablet/Injection
Ind: Specially for urinary tract infections.
C/I; S/E; Cautions: Same as sulphadiazine.
Dose: By mouth, initially 2gm (4 tabs.) then
4gm daily in divided doses. By i.m or i.v
injection, 2gm initially, then 0.5-lgm every 6-8
hours.
•
Preparation: May not be available
SULPHASALAZINE 2 t ,6o
SULPHASALAZINE: Tablet/Suppository
Ind: Ulcerative colitis, Crohn's disease,
rheumatoid arthritis.
S/E: Nausea, headache, rash, fever, loss of
appetite.
Cautions: Impaired renal or hepatic function.
Regular blood check and liver function test
should be done.
Dosage & admin: Adults: 2-4 tablets 4 times
daily; maintenance, 4 tablets daily in divided
doses.
Rheumatoid arthritis- initially 1 tablet daily for
one week increasing by one each week to
maximum 6 daily in divided doses.
Children: Under 2 years not recommended.
Over 2 years 40-60mg/kg daily; maintenance,
20-30mg/kg daily.
Preparations: See under the 'drugs for chronic
inflammatory bowel disease' in the chapter- I of
gastro-intestinal drugs.
CO-TRIMOXAZOLE2t,33
CO-TRIMOXAZOLE: Tablet/Suspn/ Injection
A mixture preparation of trimethoprim &
sulphamethoxazole in the proportions of 1 parts
to 5 parts (i.e 1: 5; such as, trimethoprim 20mg &
sulpbamethoxazole 1OOmg; or, 80mg & 400mg;
or, 160mg & 800mg respectively).
Ind: Broad spectrum chemotherapeutic agent
specially in typhoid fever, respiratory tract,
genito-urinary tract, skin and soft tissue
infections, bone and joint infections due to
haemophilus influenzae, sinusitis, exacerbation
of chronic bronchitis, gonorrhoea in penicillin­
allergic patient.
C/I: Pregnancy, infants under 6 wks; renal &
hepatic failure, Jaundice & blood disorder.
S/E: Nausea, vomiting, rashes, eosinoph-ilia,
agranulocytosis, granulocytopenia, purpura,
trimethoprim.
Cautions: Blood counts in prolonged treatment;
maintain adequate fluid intake; renal
impairment; drug interactions.
Dosage & admin: By mouth, 960mg·(2 tab or
20 ml) twice daily (12 hourly). Child- under 6
wks. not recommended; 6 wks. to 5 months,
120mg (2.5 ml); 6 months to 5 yrs. 240mg (Sml);
6 yrs. to 12 yrs. 480mg ( lOml), all twice daily.
By i.m injection or i.v infusion, 960mg every
12 hours.
t ACTRIM-DS Tab. Globe
Co-trimoxazole 960mg I tablet
lOO's pack: 140.00 MRP
t ACTRIM Susp. Globe
Cotrimoxazole 240mg/5ml: suspension
60ml bot: 22.00 MRP
t ALCOT Tab. Pacific
Cotrimoxazole 480mg/tablet
•
l OO's pack: 100.00 MRP
t ALCOT-DS Tab. Pacific
Co-trimoxazole 960mg (double strength)/tablet
lOO's pack: 200.00 MRP
+ ALCOT Susp. Pacific
Cotrimoxazole 240mg/5ml: suspension
60ml bot: 20.00 MRP
t APCETRIM Susp. APC Pharma
Co-trimoxazole 240mg/5ml: suspension
60ml bot: 20.00 MRP
t APTRIM Susp. Apollo
Co-trimoxazole 240mg/5ml: suspension
 -

QIMP-17 (285) ANTIMICROBIAL DRUGS

60ml bot: 20.54 MRP + DEOTRIM-DS Tab. Desh Pharma + NAVATRIM Susp. Navana
+ AVLOTRIN DS Tab. ACI Co-trimoxazole 960mg (double strength)/tablet Co-trimoxazole 240mg/5ml: suspension
Co-trimoxazole 960mg (double strength)/ tablet 1OO's pack: 180.00 IP 60ml bot: 21.06 MRP
lOO's pack: 201.00 MRP + DEOTRIM Susp. Desh Pharma + NEOSET Tab. Alco Pharma
+ AV LOTRIN Susp. ACI Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 480mg/tablet.
Co-trimoxazole 240mg/5ml: suspension 60ml bot: 17.50 IP IOO's pack: 142.00 MRP.
,

60ml bot: 21.57 MRP + DOCTRIM Susp. Doctor's + NEOTRIM Susp. Medicon
+ BACTIPRONT Tab. Renata Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 240mg/5ml: suspension
Co-trimoxazole 480mg/tablet 60ml bot: 21.00 MRP 60ml bot: 22.00 MRP
lOO's pack:148.00 MRP + EDITRIM-DS Tab. Edruc + OCTRIM Susp. Orion Pharma
+ BACTIPRONT DS Tab. Renata Co-trimoxazole 960mg /tablet Co-trimoxazole 240mg/5ml: suspension
Co-trimoxazole 960mg/tablet 1OO's pack: 304.00 MRP 60ml bot: 21.08 MRP
1OO's pack: 202.00 MRP + EDITRIM Susp. Edruc + PHARMATRIM Tab. Pharmadesh
+ BACTIPRONT P-120 Tab. Renata Co-trimoxazole 240mg/5ml: suspension _Co-trimoxazole 480mg/tablet
Co-trimoxazole 120mg/tablet (pediatric prepn.) 60ml bot: 25.00 MRP lOO's pack: 130.00 MRP
lOO's pack: 48.00 MRP + GENTRIM Tab. General + PHARMATRIM-DS Tab. Pharmadesh
+ BACTIPRONT Susp. Renata Co-trimoxazole 480mg/tablet Co-trimoxazole 960mg/tablet
Co-trimoxazole 240mg/5ml: suspension lOO's pack: 149.00 MRP 1OO's pack: 260.00 MRP
60ml bot: 22.06 MRP + GENTRIM Susp. Gener al + PHARMATRIM Susp. Pharmadesh
+ BENTRIM Susp. Bengal Drugs Co-trimoxazole 240m/5ml: suspension Co-trimoxazole 240mg/5ml: suspension
Co-trimoxazole 240mg/5ml: suspension 60ml bot: 22.13 MRP 60ml bot: 21.58 MRP
60ml bot: 20.00 MRP + G-COTRIMOXAZOLE Tab. Gonoshas + P OLITRIM Tab. A cme
+ BIOTRIM Tab. Biopharma Co-trimoxazole 480mg/tablet. Co-trimoxazole 480mg/tablet
Co-trimoxazole 480mg/tablet lOO's pack: 120.00 MRP 1OO's pack: 124.00 MRP
lOO's pack: 149.00 MRP + G-COTRIMOXAZOLE Susp. Gonoshas + P OLITRIM-DS Tab. Acme
+ BIOTRIM-DS Tab. Biopharma Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 960mg/tablet (double strength)
Co-trimoxazole 960mg (double strength)/tablet 50ml bot: 19.60 MRP 1OO's pack: 230.00 MRP
lOO's pack: 201.00 MRP lOOml bot: 28.00 MRP + P OLITRIM Susp. Acme '
+ BIOTRIM Susp. Biopharma + JASOTRIM Tab. Jayson Co-trimoxazole 240mg/5ml: suspension
· Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 480mg/tablet 60ml bot: 18.82 MRP
60ml bot: 21.56 MRP lOO's pack: 149.00 MRP + SEEMATRIN Susp. Seema
+ CENTRIM-DS Tab. CPL + JASOTRIM Susp. Jayson Co-trimoxazole 240mg/5ml: suspension
Co-trimoxazole 960mg/tablet (double strength) Co-trimoxazole 240mg/5ml: suspension 60ml bot: 24.00 MRP
1OO's pack: 200.00 MRP 60ml bot: 21.61 MRP + SEFTRIM-DS Tab. Hudson
+ CENTRIM Susp. CPL + LITRIM-DS Tab. Millat Co-trimoxazole 960mg/tablet
Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 960mg (double strength)/tablet lOO's pack: 150.00 MRP
60ml bot: 20.00 MRP lOO's pack: 202.00 MRP + SEFTRIM Susp. Hudson
+ COTRAZEN Tab. Zenith + LITRIM Susp. Millat Co-trimoxazole 240mg/5ml: suspension
Co-trimoxazole 480mg/tablet Co-trimoxazole 240mg/5ml: suspension 60ml bot: 17.00 MRP
1OO's pack: 140.00 MRP 60ml bot: 21.50 MRP + SEMOTRIM DS Tab. Reliance
+ COTRAZEN DS Tab. Zenith + MEDITRIM Tab. Medimet Co-trimoxazole 960mg/tablet
Co-trimoxazole 960mg (double strength)/tablet Co-trimoxazole 480mg/tablet 60's pack: 121.80 MRP
1OO's pack: 201.00 MRP lOO's pack: 148.00 MRP + SEMOTRIM Susp. Reliance
+ COTRAZEN Susp. Zenith + MEDITRIM-960 Tab. Medimet Co-trimoxazole 240mg/5ml: suspension
Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 960mg/tablet (double strength) 60ml bot: 21.50 MRP
-

.)

60ml bot: 21.30 MRP 50's pack: 130.00 MRP + SINATRIM-DS Tab. Ibo Sina
+ COTRIM Tab. Square + MEDITRIM Susp. Medimet Co-trimoxazole 960mg/tablet (double strength)
Co-trimoxazole 480mg/tablet Co-trimoxazole 240mg/5ml: suspension lOO's pack: 210.00 MRP
lOO's pack: 149.00 MRP . 60ml bot: 20.00 MRP + SINATRIM Susp. lbn Sina
+ COTRIM DS Tab. Square + MEGASET Tab. Alco Pharma Co-trimoxazole 240mg/5ml: suspension
Co-trimoxazole 960mg (double strength)/tablet Co-trimoxazole 960mg/tablet (double strength) 60ml bot: 22.00 MRP
lOO's pack: 203.00 MRP lOO's pack: 202.00 MRP + SITRIM DS Tab. Silva
+ COTRIM Susp. Square + MEGATRIM-DS Tab. Beximco Co-trimoxazole 960mg/tablet (double strength)
Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 960mg/tablet (double strength) 1OO's pack: 200.00 MRP
60ml bot: 21.58 MRP 150's pack: 390.00 MRP + SITRIM Susp. Silva
+ CO-TRY Susp. A d-din + MEGATRIM Susp. Beximco Co-trimoxazole 240mg/5ml: suspension
Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 240mg/5ml: suspension 60ml bot: 20.00 MRP
60ml bot: 21.50 MRP 60ml bot: 22.10 MRP + SOMA-DS Tab. Ambee
+ COTS Susp. Opsonin + M-TRIM Tab. Modern Co-trimoxazole 960mg/tablet (double strength)
Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 480mg/tablet. lOO's pack: 203.00 MRP
·

60ml bot: 19.48 MRP lOO's pack: 146.00 MRP + SULPHATRIM Tab. Amico
t DECATRIM DS Tab. Decent + M-TRIM DS Tab. Modern Co-trimoxazole 480mg/tablet
Co-trimoxazole 960mg (double strength)/tablet Co-trimoxazole 960mg/tablet (double strength) lOO's pack: 149.00 MRP
lOO's pack: 150.00 MRP 1OO's pack: 202.00 MRP + SULPHATRIM-DS Tab. Amico
Co-trimoxazole 960mg/tablet (double strength)
+ DECATRIM Susp. Decent + M-TRIM Susp. Modern
Co-trimoxazole 240mg/5ml: suspension Co-trimoxazole 240mg/5ml: suspension 1OO's pack: 250.00 MRP

60ml bot: 21.83 MRP 60ml bot: 23.96 MRP + SULPHATRIM Susp. Amico
Co-trimoxazole 240mg/5ml: suspension
+ DEOTRIM Tab. Desh Pharma + NAVATRIM DS Tab. Navana
Co-trimoxazole 480mg/tablet Co-trimoxazole 960mg/tablet (double strength) 60ml bot: 22.10 MRP

lOO's pack: 120.00 IP 1OO's pack: 201.00 MRP + SUMETROLIM Susp. Ambee

I
 ANTIMICROBIAL DRUGS
Co-trimoxazole 240mg/5ml: suspension
60ml bot: 21.61 MRP
+ SUPRIM-DS Tab. Nipa
Co-trimoxazole 960mg/tablet
SO's pack: 101.00 MRP
+ SUP RIM Susp. Nipa
Co-trimoxazole 240mg/5ml: suspension
60ml bot: 20.00 MRP
+ TRICOT-DS Tab. Reman
Co-trimoxazole 960mg/tablet
IOO's pack: 210.00 MRP
+ TRICOT Susp. Reman
Co-trimoxazole 240mg/5ml: suspension
60ml bot: 21.50 MRP
+ TRIPRIM-DS Tab. Supreme
Co-trimoxazole 960mg/tablet
'
1 OO's pack: 200.00 MRP
+ TRIPRIM Susp. Supreme
Co-trimoxazole 240mg/5ml: suspension
60ml bot: 21.00 MRP
1.9 4-Quinolone prepns.
CIPROFLOXACIN21,26,33,86,101
CIPROFLOX ACIN: Tablet/Suspension/
Sachet/Injection
Ciprofloxacin is a synthetic 4-quinolone
derivative. It has bactericidal activity against a
wide range of gram-positive and gram-negative
orgamsms.
•
Mode of action: The mode of action of the
quinolones is not fully known. In susceptible bac-.
teria, quinolones inhibit the activity of DNA
gyrase (topoisomerase-II), an essential bacterial
enzyme required for DNA replication, transcrip­
tion, repair, and recombination. The drugs are
bactericidal during the stationary growth phase,
as well as in the logarith mic growth phase of
certain bacteria (other anti-infective agents are
most active during the logarithmic growth phase).
Quinolones also inhibit topoisomerase-IV, an
enzyme structurally similar to DNA gyrase and
·essential for bacterial DNA replication.
Topoisomerase-IV may be the primary target of
major quinolones in gram-positive bacteria,
(DNA gyrase appears to be the main target in
gram-negative bacteria). The targets of older
quinolones (ciprofloxacin, and other second
generation agents) probably are different from the
targets of the newer agents.
Ind: UTI, respiratory tract infection, infections of
ear, nose, throat, eyes, skin & soft tissue, bone,
joints, and g.i tract. Gonorrhoea, severe systemic
infection & gram negative pneumonia.
Ciprofloxacin is particularly active against gram
negative bacteria, including salmonella, shigella,
camphylobacter, neisseria and pseudomonas. It
only has moderate activity against gram positive
bacteria such as streptococcus pneumoniae and
streptococcus faecalis.
C/I: Growing adolescents, except where benefits
exceed risks; pregnancy and lactation; epilepsy
and history of CNS disorders.
'
\
S/E: Nausia, vomiting, diarrhoea, dyspepsia,
\ abdominal pian, dizziness, headache, restlessness,
rash, pruritus, tremor, confusion, convulsions,
hallucinations, somnolence, blurred vision, mus­
cle and joint pain, photosensitivity; blood disor-
QIMP-17 (286)
ders including eosinophilia, leucopenia thromoo­
cytopenia, thrombocytosis, pseudpmembranous
colitis, vasculitis, Steven-Johnson., syndrome and
•.
tachycardia reported.
Cautions: 4-quinolones should be used with
caution in patients with epilepsy or a history of
epilepsy, in hepatic or renal impairment, in
pregnancy, during breast-feeding, and in children
or adolescents (arthropathy has developed in
weight-bearing joints in young animals). 4-
quinolones may induce convulsions in patients
with or without a history of convulsions; taking
NSAIDs at the same time may also induce them.
• The drug should be discontinued if mental,
neurological or hypersensitivity reactions occur
with the first dose.
Dosage & admin: By mouth: Adult:
Urinary tract infections: Mild to moderate
infection, 250mg every 12 hours; complicated
infections, caused by organisms not highly
susceptible to drug, 500mg every 12 hours.
Infectious diarrhoea: 500mg every 12 hrs.
Lower respiratory tract, skin & soft tissue, bone
& joint infections: In mild to moderate
infections in all cases, usual dosage is 500mg
every 12 hours; a dosage of 750mg every 12
hours may be needed, specially in bone and
joint infections or when infections are severe
or complicated.
In severe infections, particularly due to
pseudomonas, staphylococcus and
streptococci, the higher dosage of ciprofloxacin
750mg tablet twice daily should be used.
The duration of therapy depends on the type
& severity of infection and should be determi­
ned by the clinical and bacteriologic response
of the patients. For most infections, usual dur­
ation is 1-2 weeks but severe or complicated
infections may require more prolonged therapy.
Gonorrhoea: A single SOOmg oral dose of
ciprofloxacin followed by oral doxycycline
therapy for possible coexisting chlamydia
infection. In the treatment of chancroid,
500mg orally twice daily for 3 days is required.
Surgical prophylaxis: A single dose of
ciprofloxacin 750mg is given 60-90 minutes
before the procedure.
Children: Not recommended but where benefit
outweighs risk, by mouth 7.S-lSmg/kg daily in
2 divided doses.
Dosage of XR Tablets: Ciprofloxacin XR
(extended-release) SOOmg tablet is specially
formulated only for the treatment of
uncomplicated urinary tract infections (acute
cystitis) to be taken once daily, usually for 3
days with or without food and drinking water
liberally. No dosage adjustment is needed for
renally impaired patients.
In patients with complicated urinary tract
infections and acute uncomplicated
pyelonephritis, who have a creatinine
clearance of <30ml/mi11, ciprofloxacin XR
500mg can be used for 7-14 days.
Ciprofloxacin XR SOOmg tablet and
ciprofloxacin immediate release tablets are not
interchangeable.
The tablet should be swallowed whole and it is
advised not to split, crush or chew the tablet.
Patients whose therapy is started with ciprofl­
oxacin i.v for. UTls may be switched to ciprofl-
oxacin XR SOOmg tablet when clinically
indicated.
By i.v infusion (over 30-60 mins):
Ciprofloxacin i.v infusion is indicated for
patients with severe· infections or where oral
administration is not possible. Intravenous '
therapy should be replaced by oral tablets at
the appropriate time.
The usual recommended dosage schedule for
adults is as following:
UTI & GI infections: 100-200mg i.v 12 hourly.
Gonorrhoea: lOOmg i.v single dose.
Other inf�ctions: 200mg i.v 12 hourly.
Children: Not recommended, but where
benefit outweighs risk, 5-1Omg/kg daily in 2
divided doses.
•
In case of marked renal impairment
( creatinine clearance <20ml/min), the total
daily dosage should be halved.
Duration of treatment: For acute infection the
usual treatment period is S to 7 days (i.v), then
if required to continue the therapy may be
changed to oral tablet.
+ ADECIN Tab. Supreme
Ciprofloxacin 500mg/tablet.
500mg x 30's pack: 420.00 MRP
+ AMIFLOX Tab. Amico
Ciprofloxacin 250mg, 500mg & 750mg/tablet
250mg x 30's pack: 180.00 MRP •
500mg x 30's pack: 300.00 MRP
750mg x 1 O's pack: 160.00 MRP
+ AMIFLOX DS Susp. Amico
Ciprofloxacin 250mg/5ml: suspension (double
strength).
60ml bot: 85.00 MRP
+ ANCIPRO Tab. UniMed & UniHealth
Ciprofloxacin 250mg, 500mg & 750mg/tab.
250mg x 20's pack: 170.00 MRP
500mg x 20's pack: 280.00 MRP
750mg x 20's pack: 360.00 MRP
t ANGYR Tab. SAPL
Ciprofloxacin 250mg & SOOmg/tablet.
250mg x SO's pack: 425.00 MRP
500mg x 30's pack: 360.00 MRP
+ APROCIN Tab. Aristopharma
•
Ciprofloxacin 250mg, SOOmg & 750mg/tab.
250mg x 30's pack: 255.00 MRP
SOOmg x 30's pack: 420.00 MRP
750mg x 20's pack: 360.00 MRP
+ APROCIN Susp. Aristopharma
Ciprofloxacin 250mg/5ml (taste masked pellets
for suspension): suspension.
60ml bot: 100.00 MRP
+ BACTIN Tab. Ibn Sina
Ciprofloxacin 250mg, 500mg & 750mg/tablet.
250mg x 20's pack: 170.80 IP
500mg x 20's pack: 281.20 IP
SOOmg x 30's pack: 421.80 IP
750mg x 20's pack: 361.20 IP
+ BEUFLOX Tab. Incepta .
Ciprofloxacin 250mg, SOOmg & 750mg/tablet.
250mg x 18's pack: 153.00 MRP
500mg x 20's pack: 280.00 MRP
750mg x 20's pack: 360.00 MRP
+ BEUFLOX Sachet Incepta
Ciprofloxacin 250mg granules/sachet: suspension.
Dose & admin: For dosage: See above under
the text.
Preparation of suspension: Whole contents of
the sachet should be taken into a small glass
\
\
 -

QIMP-17 (287) ANTIMICROBIAL DRUGS

containing 2-3 tsf of water. Other liquids or t CIPLON Tab. Techno Drugs 60ml bot: 90.00 MRP
foods should not be used. The mixer should Ciprofloxacin 500mfg & 750mg/tablet. t CIPROLEX Tab. Mystic
be stirred well and drink immediately. The 500mg x 30's pack: 420.00 MRP Ciprofloxacin 250mg & 500mg/tablet.
glass should be refdled with water and drink. 750mg x 20's pack: 360.00 MRP 250mg x 30's pack: 210.00 MRP
If the suspension is to be administered through t CIPLON I.V Inf. Techno Drugs 500mg x 20's pack: 240.00 MRP
a nasogastric or orogastric tube, the Ciprofloxacin 200mg in l OOml bottle: i.v + CIPROLYN Tab. Cosmic
suspension should be constituted with about infusion. Ciprofloxacin 250mg & 500mg/tablet.
· 20ml of water, and an approximately sized l OOml bot: 75.00 MRP 250mg x 50's pack: 309.00 MRP
syringe should be used to instill the suspension + CIPLON DS I.V Inf. Techno Drugs 500mg x 30's pack: 369.00 MRP
in the tube. The suspension should be washed Ciprofloxacin 400mg in 1 OOml bottle (double t CIPROLYN Susp. Cosmic
through the tube with about 20ml of water. strength): i.v infusion. Ciprofloxacin 250mg/5ml: suspension.
250mg sachet x 14's pack: 168.00 MRP l OOml bot: 145.00 MRP 60ml bot: 90.00 MRP
t CIPOXIA-500 Tab. Pharmasia t CIPROM·Tab. Millat
t BEUFLOX Paed Sachet Incepta
Ciprofloxacin 500mg/tablet. Ciprofloxacin 250mg & 500mg/tablet.
Ciprofloxacin l 25mg granules/sachet: for
500mg x 20's pack: 280.00 MRP 250mg x 30's pack: 150.00 MRP
paediatric suspension.
t CIPOXIA Susp. Pharmasia 500mg x 20's pack: 240.00 MRP
Dose & admin: For dosage: See above under
Ciprofloxacin 250mg/5ml: suspension. t CIPROM Susp. Millat
the text.
60ml bot: 100.00 MRP Ciprofloxacin 250mg/5ml: suspension.
Preparation of suspension: Same as above
t CIPRIN Tab. Nipa l OOml bot: 80.00 MRP
(Beuflox sechet).
Ciprofloxacin 500mg/tablet. + CIPRO-M Tab. Modern
125mg sachet x 14's pack: 112.00 MRP
500mg x 30's pack: 360.00 MRP Ciprofloxacin 500mg & 750mg/tablet.
t BEUFLOX I.V Inf. Incepta
t CIPR0-500 Tab. Apollo 500mg x 20's pack: 200.00 MRP
Ciprofloxacin 200mg in 1OOml bottle & 400mg
Ciprofloxacin 500mg/tablet. 500mg x 30's pack: 300.00 MRP
in 200ml bottle: i.v infusion.
500mg x 30's pack: 300.00 IP 500mg x 40's pack: 400.00 MRP
IOOml (200mg) bot: 70.00 MRP
t CIPRO Susp. Apollo 750mg x 20's pack: 361.20 MRP
200ml (400mg) bot: 130.00 MRP
Ciprofloxacin 250mg/5ml: suspension. + CIPROMET Tab. Medimet
t CEPROCON-500 Tab. Concord
60ml bot: 80.00 IP Ciprofloxacin 250mg & 500mg/tablet.
Ciprofloxacin 500mg/tablet.
t CIPRO-A Tab. Acme 250mg x 30's pack: 180.00 MRP
500mg x 30's pack: 360.00 MRP
Ciprofloxacin 250mg, 500mg & 750mg/tablet 500mg x 20's pack: 200.00 MRP
t CEPROCON Susp. Concord
250mg x 30's pack: 255.90 MRP t CIPRON Tab. Edruc
Ciprofloxacin 250mg/5ml: suspension.
500mg x 20's pack: 281.20 MRP Ciprofloxacin 500mg/tablet.
60ml bot: 90.00 MRP
750mg x 20's pack: 361.20 MRP 500mg x 30's pack: 364.50 MRP
t CERO Tab. Gaco
t CIPRO-A Susp. Acme t CIPRON Susp. Edruc
Ciprofloxacin 500mg/tablet.
Ciprofloxacin 250mg/5ml: suspension. Ciprofloxacin 250mg/5ml: suspension.
500mg x 20's pack: 280.00 MRP
60ml bot: 90.34 MRP 60ml bot: 90.00 MRP
t CIBACT Tab. Euro Phrama
t CIPRO-A Inf. Acme + CIPRONIL Tab. Silva
Ciprofloxacin 500mg/tablet.
Ciprofloxacin 200mg in l OOml bot: i.v infusion. Ciprofloxacin 500mg/tablet.
500mg x 30's pack: 420.00 MRP
200mg x l OOml bot: 90.34 MRP 500mg x 30's pack: 421.00 MRP
t CIFLOCIN Tab. Astra
t CIPROAID 500 Tab. Labaid Pharma + CIPRONIL Susp. Silva
Ciprofloxacin 500mg/tablet.
Ciprofloxacin 500mg/tablet. Ciprofloxacin 250mg/5ml: suspension.
500mg x 20's pack: 240.00 MRP
500mg x 20's pack: 300.00 MRP 60ml bot: 90.00 MRP
t CIFLOX Tab. Reman
t CIPROBAC 500 Tab. Bristol t CIPRONOR Tab. Novelta
Ciprofloxacin 500mg/tablet.
Ciprofloxacin 500mg/tablet. Ciprofloxacin hydrochloride BP 500mg/tablet.
500mg x 20's pack: 250.00 MRP
500mg x 20's pack: 200.00 MRP 500mg x 20's pack: 280.00 MRP
t CILOCIN Tab. Pacific
t CIPROBAC DS Susp. Bristol + CIPRONOR Susp. Novelta
Ciprofloxacin 500mg/tablet.
Ciprofloxacin 250mg/5ml: suspension. Ciprofloxacin hydrochloride BP 250mg/Sml:
500mg x 20's pack: 160.00 MRP
60ml bot: 80.00 MRP suspension.
•

500mg x 50's pack: 400.00 MRP

t CIPRO-C Tab. Chemist 60ml bot: 90.00 MRP
500mg x 1OO's pack: 800.00 MRP
Ciprofloxacin 500mg/tablet. t CIPRO-S Tab. Seema
+ CILOCIN XR Tab. Pacific
500mg x 50's pack: 500.00 MRP Ciprofloxacin 500mg/tablet
Ciprofloxacin 500mg/tablet (extended release).
+ CIPROCAP Tab. Sonear 500mg x 50's pack: 700.00 MRP
500mg x 30's pack: 240.00 MRP
Ciprofloxacin 250mg & 500mg/tablet. + CIPRO-S Susp. Seema
t CILOCIN Susp. Pacific
250mg x 30's pack: 261.30 MRP Ciprofloxacin 250mg/5ml: suspension.
Ciprofloxacin 250mg/5ml: suspension.
500mg x 16's pack: 229.60 MRP 60ml bot: 90.00 MRP
60ml bot: 100.00 MRP
t CIPROCIN Tab. Square + CIPROTEC-500 Tab. APC Pharma
t CIP Tab. Asiatic
Ciprofloxacin 250mg, 500mg & 750mg/ tablet. Ciprofloxacin 500mg/tablet
Ciprofloxacin 500mg & 750mg/tablet.
250mg x 50's pack: 427.00 MRP 500mg x 20's pack: 160.00 MRP
500mg x 30's pack: 420.00 MRP
500mg x 30's pack: 450.00 MRP t CIPROTEC Susp. APC Pharma
750mg x 12's pack: 216.00 MRP
750mg x 20's pack: 361.20 MRP Ciprofloxacin 250mg/5ml: suspension.
+ CIPCIN Tab. Biopharma
+ CIPROCIN XR lgm Tab. Square 60ml bot: 80.00 MRP
Ciprofloxacin 250mg, 500mg & 750mg/tablet.
Ciprofloxacin 1gm/tablet (extended release). t CIPROX Tab. Opsonin
250mg x 30's pack: 255.90 MRP
l gm x 12's pack: 240.84 MRP Ciprofloxacin 250mg, 500mg & 750mg/tablet.
500mg x 30's pack: 421.50 MRP
t CIPROCIN Susp. Square 250mg x 30's pack: 125.12 MRP
750mg x 12's pack: 216.84 MRP
Ciprofloxacin 250mg/5ml: suspension. 500mg x 20's pack: 247.20 MRP
t CIPCIN Susp. Biopharma
60ml bot: 100. 00 MRP 750mg x 18's pack: 286.13 MRP
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 90.34 MRP t CIPROL 500 Tab. Medicon t CIPROX XR 1000 Tab. Opsonin
Ciprofloxacin 500mg/tablet. Ciprofloxacin 1OOOmg/tablet (extended release).
t CIPCIN I.V Inf. Biopharma
50Qmg x 30's pack: 360.00 MRP l OOOmg x 6's pack: 105.99 MRP
Ciprofloxacin 200mg in 1 OOml bottle: i. v
infusion. + CIPROL-DS Susp. Medicon t CIPROX Susp. Opsonin
1OOml bot: 100.00 MRP Ciprofloxacin 250mg/5ml: suspension. Ciprofloxacin 250mg/5ml: powder for suspension.

I

ANTIMICROBIAL DRUGS
60ml bot: 79.47 MRP
+ CIPROX DS Susp. Opsonin
Ciprofloxacin 250mg/5ml: granules for suspension.
60ml bot: 79.47 MRP
+ CIPROX I.V Inf. Opsonin
Ciprofloxacin 200mg in 1OOml bot: i.v infusion.
l OOml bot: 61.81 MRP
+ CIPROXEN Tab. Ad-din
Ciprofloxacin 250mg & 500mg/tablet.
250mg x 30's pack: 210.00 MRP
500mg x 14's pack: 196.00 MRP .
+ CIPROXIM Tab. White Horse
Ciprofloxacin USP 500mg/tablet.
500mg x 24's pack: 288.00 MRP
+ CIPROXY I.V Inf. Opso Saline
Ciprofloxacin 200mg in l OOml bot: i.v infusion.
l OOml bot: 70.26 MRP
+ CIPROZEN Tab. Zenith
Ciprofloxacin 250mg/tablet.
250mg x 50's pack: 401.50·MRP
+ CIPROZEN DS Tab. Zenith
Ciprofloxacin 500mg/tablet.
500mg x 50's pack: 703.00 MRP
+ CIPROZEN Susp. Zenith
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 75.25 MRP
+ CIPROZID Tab. Drug Inter.
Ciprofloxacin 250mg/tablet.
50's pack: 400.00 MRP
+ CIPROZID-DS Tab. Drug Inter.
Ciprofloxacin 500mg/tablet.
30's pack: 420.00 MRP
+ CIPROZID-750 Tab. Drug Inter.
Ciprofloxacin 750mg/tablet.
30's pack: 480.00 MRP
+ CIPROZID-XR- 1000 Tab. Drug Inter.
Ciprofloxacin l OOOmg/tablet (extended release).
lOOOmg x 14's pack: 280.00 MRP
+ CIPROZID Susp. Drug Inter.
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 90.00 MRP
+ CIPROZID Inf. Drug Inter.
Ciprofloxacin 200mg in 1 OOml bot: i.v infusion.
200mg x l OOml bot: 70.00 MRP
+ CIPTEC Tab. Everest
Ciprofloxacin 500mg & 750mg/tablet.
500mg x 30's pack: 360.00 MRP
750mg x 24's pack: �6.00 MRP
+ CIPTEC Susp. Everest
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 80.00 MRP
+ CIVOX Tab. Popular
Ciprofloxacin 500mg/tablet.
24's pack: 337.20 MRP
+ CIVOX Susp. Popular
Ciprofloxacin 200mg/5ml: suspension.
60ml bot: 90.34 MRP
+ CIVOX Inf. Popular
Ciprofloxacin 200mg in l OOml bot: i.v infusion.
200mg x lOOml bot: 75.00 MRP
+ CPFLOX Tab. Cosmo Pharma
Ciprofloxa.cin 500mg/tablet.
500mg x 20's pack: 202.20 MRP
+ DEFLOX Tab. Desh Pharma.
Ciprofloxacin 500mg & 750mg/tablet.
500mg x 30's p·ack: 315.00 MRP
750mg x 20's pack: 260.00 MRP
+ DEFLOX-DS Susp. Desh Pharma
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 80.00 MRP
QIMP-17 (288)
+ D-FLOXIN Tab. Doctor's
Ciprofloxacin 250mg & 500mg/tablet.
250mg x 30's pack: 136.50 MRP
500mg x 30's pack: 360.00 MRP
+ DFX Tab. Delta Pharma
Ciprofloxacin 500mg tablet.
500mg x 32's pack: 320.00 MRP
+ DFX Susp. Delta Pharma
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 90.00 MRP
+ DOQUIN Tab. Hallmark
Ciprofloxacin 500mg/tablet.
30's pack: 361.50 MRP
+ DUMAFLOX Tab. Alco Pharma
Ciprofloxacin 250mg, 500mg & 750mg/tablet
250mg x 30's pack: 225.00 MRP
500mg x 30's pack: 300.00 MRP
750mg x 20's pack: 240.00 MRP
+ DUMAFLOX Susp. Alco Pharma
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 65.00 MRP
+ ELIPROX Tab. Reliance
Ciprofloxacin SOOmg/tablet
500mg x 30's pack: 420.00 MRP
+ FIPROX Tab. Sanofi-aventis
Ciprofloxacin 250mg, 500mg & 750mg/tablet.
250mg x 30's pack: 255.90 MRP
500mg x 30's pack: 421.50 MRP
750mg x 20's pack: 361.40 MRP
t FLOCIP Tab. Amulet
Ciprofloxacin USP SOOmg/tablet.
500mg x 30's pack: 420.00 MRP
+ FLOCIP Susp. Amulet
Ciprofloxacin USP 250mg/5ml: suspension.
60ml bot: 90.00 MRP
+ FLON'I'IN Tab. Renata
Ciprofloxacin 250mg, SOOmg & 750mg/tablet.
250mg x 20's pack: 170.60 MRP
500mg x 30's pack: 450.00 MRP
750mg x 20's pack: 361.20 MRP
t FLONTIN Susp. Renata
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 100.00 MRP
t FLQNTIN I.V Inj. Renata
Ciprofloxacin 200mg in l OOml bot: i.v injection.
l OOml bot: 145.54 MRP
t FLOROCIN Tab. NIPRO JMI
Ciprofloxacin USP SOOmg/tablet.
500mg x 30's pack: 361.50 MRP
+ FLOROCIN Susp. NIPRO JMI
Ciprofloxacin USP 250mg/5ml: suspension.
60ml bot: 90.00 MRP
t FLOXABID Tab. ACI
Ciprofloxacin 250mg, 500mg & 750mg/tablet.
250mg x 50's pack: 426.50 MRP
500mg x 30's pack: 421.50 MRP
750mg x 20's pack: 361.40 MRP
+ FLOXABID SR Tab. ACI
Ciprofloxacin l OOOmg/tablet (sustained release).
l OOOmg x 8's pack: 160.56 MRP
t FLOXA.BID DS Susp. ACI
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 90.34 MRP
t FLOXACIN Tab. Navana
Ciprofloxacin 250mg & 500mg/tablet.
250mg x 50's pack: 350.00 IP
500mg x 30's pack: 360.00 IP
+ FLOXIN Tab. Pharmadesh
Ciprofloxacin 250mg & 500mg/tablet.
250mg x 50's pack: 250.00 MRP
-
500mg x 30's pack: 360.00 MRP
+ FLOXIN-DS Susp. Pharmadesh
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 90.00 MRP
•
+ G-CIPRO Tab. Gonoshas
Ciprofloxacin 500mg/tablet.
30's pack: 300.00 MRP
+ G-CIPRO I.V Inf. Gonoshas
Ciprofloxacin 250mg in 1OOml bot: i.v infusion.
1OOml bot: 50.00 MRP
t GEFLOX Tab. General
Ciprofloxacin 250mg & 500mg/tablet.
250mg x 30's pack: 255.00 MRP
500mg x 30's pack: 421.50 MRP
+ GEFLOX XR Tab. General
Ciprofloxacin 500mg/tablet (extended release).
500mg x 20's pack: 240.00 MRP •
t GEFLOX Susp. General
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 80.30 MRP
+ GEFLOX 200 I.V Inf. General
Ciprofloxacin 200mg in 1OOml bot: i.v infusion.
200mg (1 OOml bot) x l's pack: 70.00 MRP
t GLAXIPRO Tab. GlaxoSmithKline
Ciprofloxacin 500mg/tablet.
500mg x 30's pack: 421.58 MRP
t HIFLOX Tab. Ambee
Ciprofloxacin 500mg & 750mg/tablet.
500mg x 30's pack: 261.00 MRP
750mg x 20's pack: 241.00 MRP
t HIFLOX XR 1000 Tab. Ambee
Ciprofloxacin 1OOOmg/tablet (extended release).
1OOOmg x l 2's pack: 240.00 MRP
t HIFLOX Susp. Ambee
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 70.26 MRP
+ m-FLOXIN Tab. Hudson
Ciprofloxacin 500mg/tablet.
500mg x 30's pack: 360.00 MRP
+ KAPRON Tab. Globe
Ciprofloxacin 250mg, 500mg & 750mg/tablet.
250mg x 30's pack: 180.00 MRP
500mg x 30's pack: 360.00 MRP
750mg x 20's pack: 300.00 MRP
•
+ KAPRON Susp. Globe
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 90.00 MRP
t LIBRACIN I.V Inf. Libra
Ciprofloxacin 200mg in 1OOml bot: i.v infusion.
200mg (l OOml bot) x l's pack: 70.26 MRP
+ LIBRACIN-400 I.V Inf. Libra
Ciprofloxacin 400mg in 1OOml bot: i.v infusion
l OOml bot: 146.30 MRP
t MAPROCIN Tab. Orion Pharma
Ciprofloxacin 500mg & 750mg/ tablet.
500mg x 30's pack: 421.50 MRP
750mg x 20's pack: 361.20 MRP
+ MAPROCIN Susp. Orion Pharma •
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 90.34 MRP
t MAPROCIN I.V Inf. Orion Infusion
Ciprofloxacin 200mg in 1OOml bot: i.v infusion.
200mg ( l OOml bot) x l's pack: 70.26 MRP
t MAPROCIN-DS I.V Inf. Orion Infusion
Ciprofloxacin 400mg in 1OOml bot: i.v infusion
(double strength).
lOOml bot: 130.49 MRP
+ MONIPRO Tab. MonicoPharma
Ciprofloxacin 500mg/tablet.
500mg x 24's pack: 336.00 MRP
 • ®
QIMP-17 (289)

Ciprofloxacin
+ MONIPRO Susp. MonicoPharma 60ml bot: 90.00 MRP
Ciprofloxacin 250mg/5ml: suspension. t PROFLOX Tab. Kumudini Gold standard antibiotic
60ml bot: 90.00 MRP Ciprofloxacin 250mg & 500mg/tablet
t NEOFLOX Tab. CPL 250mg x 30's pack: 180.00 MRP
Ciprofloxacin 500mg/tablet. 500mg x 30's pack: 360.00 MRP
500mg x 30's pack: 360.00 MRP t PROQUIN 500 Tab. Sharif 750mg x 20's pack: 360.00 MRP
t NEOFLOXIN Tab. Beximco Ciprofloxacin 500mg/tablet. t ROCIPRO Tab. Healthcare
Ciprofloxacin 250mg, 500mg & 750mg/ tablet. 500mg x 30's pack: 420.00 MRP Ciprofloxacin 500mg & 750mg/tablet.
250mg x 50's pack: 425.00 IP t PROQUIN Susp. Sharif 500mg x 30's pack: 420.00 MRP
500mg x 20's pack: 280.00 IP Ciprofloxacin 250mg/5ml: suspension. 750mg x 16's pack: 288.00 MRP
500mg x 50's pack: 700.00 IP 60ml bot: 90.00 MRP t SERVIFLOX Tab. Sandoz
750mg x 30's pack: 540.00 IP + Q-NOL-500 Tab. Decent Ciprofloxacin 500mg & 750mg/tablet.
t NEOFLOXIN XR Tab. Beximco Ciprofloxacin 500mg/tablet. 500mg x 30's pack: 420.00 MRP
Ciprofloxacin 500mg/tablet (extended release). 500mg x 30's pack: 330.00 MRP 750mg x 20's pack: 360.00 MRP
500mg x 20's pack: 220.00 IP t QUINOBID Tab. Nuvista t SPECTRA-500 Tab. Jayson
t NEOFLOXIN XR 1000 Tab. Beximco Ciprofloxacin 500mg/tablet (f.c). Ciprofloxacin 500mg/tablet.
Ciprofloxacin I OOOmg/tablet (extended release). 500mg x 20's pack: 320.00 MRP 500mg x 20's pack: 203.20 IP
l OOOmg x I O's pack: 250.00 IP t QUINOX Tab. SK+F t SYPRON Tab. MST Pharma
t NEOFLOXIN Susp. Beximco Ciprofloxacin 250mg, 500mg & 750mg/tablet. Ciprofloxacin 500mg/tablet.
Ciprofloxacin 250mg/5ml: suspension. 250mg x 30's pack: 255.00 MRP 500mg x 30's pack: 375.00 MRP
60ml bot: l 00.00 IP 500mg x 20's pack: 280.00 MRP + TYFLOX Tab. Somatec
t NEOFLOXIN lnj. Beximco 500mg x 40's pack: 560.00 MRP Ciprofloxacin 250mg, 500mg & 750mg/tablet
Ciprofloxacin 200mg in I OOml bot: i.v infusion. 750mg x lO's pack: 180.00 MRP 250mg x 30's pack: 255.90 MRP
200mg ( lOOml bot) x l's pack: 146.50 IP t QUINOX DS Susp. SK+F 500mg x 30's pack: 361.20 MRP
t NEWCIP Tab. Bengal Drugs Ciprofloxacin hydrochloride monohydrate 750mg x I O's pack: 180.70 MRP
Ciprofloxacin hydrochloride USP 500mg/tablet. 250mg/5ml: suspension. + TYFLOX Susp. Somatec

I
- . � ' - _;;,.
I
'�

II ®
I

Ciprofloxacin

The

500mg x 30's pack: 420.00 MRP 60ml bot: 90.00 MRP Ciprofloxacin 250mg/5ml: suspension.
t NOVACIN-500 Tab. Novus t QUINOX I.V Inf. SK+F 60ml bot: 90.34 MRP
Ciprofloxacin hydrochloride 500mg/tablet. Ciprofloxacin 200mg in 1OOml bot: i.v infusion. t UNIFLOX-500 Tab. Aexim
500mg x 20's pack: 280.00 MRP 200mg (IOOml bot) x l's pack: 100.00 MRP Ciprofloxacin 500mg/tablet.
t OCTABID Tab. Rephco t QUINTOR Tab. Ziska 500mg x 30's pack: 240.00 MRP
Ciprofloxacin 500mg/tablet. Ciprofloxacin 500mg & 750mg/tablet. t VIRFLOX 500 Tab. Virgo
500mg x 30's pack: 360.00 MRP 500mg x 24's pack: 240.00 MRP Ciprofloxacin USP 500mg/tablet.
t ORCIPRO 500 Tab. Organic Health 750mg x 20's pack: 280.00 MRP 500mg x 30's pack: 420.00 MRP
Ciprofloxacin USP 500mg/tablet. t QUINTOR Susp. Ziska t VIRFLOX Susp. Virgo
500mg x 30's pack: 420.00 MRP Ciprofloxacin 250mg/5ml: suspension. Ciprofloxacin USP 250mg/5ml: suspension.
t PEOFLOX Tab. Peoples 60ml bot: 60.00 MRP 60ml bot: 80.00 MRP
Ciprofloxacin USP 500mg/tablet. t RACIPROX 500 Tab. RAK Pharma t WINBAC Tab. Radiant
500mg x 30's pack: 360.00 MRP Ciprofloxacin 500mg/tablet. Ciprofloxacin 500mg/tablet.
t PROCIN Tab. Kemiko MRP
500mg x 20's pack: 280.00 500mg x 20's pack: 320.00 MRP
Ciprofloxacin 250mg, 500mg & 750mg/tablet t RACIPROX Susp. RAK Pharma 500mg x 28's pack: 448.00 MRP
250mg x 30's pack: 255.00 MRP Ciprofloxacin 250mg/5ml: suspension. + XBAC Tab. Beacon
500mg x 30's pack: 420.00 MRP 60ml bot: 80.00 MRP Ciprofloxacin 500mg & 750mg/tablet.
750mg x 20's pack: 360.00 MRP + RANFLOX Tab. Rangs Pharma 500mg x 30's pack: 420.00 MRP
t PROCIN Susp. Kemiko Ciprofloxacin 500mg & 750mg/tablet. 750mg x 20's pack: 360.00 MRP
Ciprofloxacin 250mg/5ml: suspension. 500mg x 20's pack: 280.00 MRP + XBAC Susp. Beacon

.9'- � •••
rai
� !��! !�
·�NGLAOl!SH
Al• LJD. www.squarepharma.com.bd •••
•••
MUA•
..,.L

Oprofloxacin
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 90.00 MRP
t XBAC I.V Inf. Beacon
Ciprofloxacin 200mg in 1OOml bot: i. v infusion.
l OOml bot: 145.00 MRP
+ XIROCIP Tab. Novo Healthcare
Ciprofloxacin 500mg/tablet.
500mg x 20's pack: 280.00 MRP
+ XIROCIP XR 1000 Tab. Novo Healthcare
Ciprofloxacin USP I OOOmg/tablet (extended
release).
lOOOmg x 8's pack: 200.00 MRP
+ XIROCIP Susp. Novo Healthcare
Ciprofloxacin 250mg/5ml: suspension.
60ml bot: 90.00 MRP
lOOml bot: 140.00 MRP
+ XIROCIP Inj. Novo Healthcare
Ciprofloxacin 200mg in IOOml bot: i.v infusion.
1OOml bot: 70.00 MRP
G
. . .. � .�y, .. �
. '1:12,134
�·· • ., ��'-'·\l.
.
�"
GATIFLOXACIN: Tablet/Injection
Gatifloxacin is a synthetic broad spectrum 8-
,
methoxyfluoroquinolone antibacterial agent. It is
available as gatifloxacin (as sesquihydrate) INN
400mg film-coated tablet & 200ml (400mg) i.v
infusion.
Mode of action: See above under the text of
ciprofloxacin.
Ind: Gatifloxacin is indicated for the treatment of
infections due to susceptible strains of gram+ve
and gram-ve microorganisms in the following
infection diseases, viz: i. Acute bacterial
exacerbation of chronic bronchitis, ii. Acute
sinusitis, iii. Community-acquired pneumonia, iv.
Uncomplicated skin & skin structure infections
(i.e simple abscesses, furuncles, folliculitis,
wound infections, & cellulitis), v. Uncomplicated
urinary tract infections (cystitis), vi. Complicated
urinary tract infections, vii. Pyelonephritis (due
to E. coli), viii. Uncomplicated urethral and
cervical gonorrhea (due to neisseria gonorrhoeae),
ix. Acute, uncomplicated rectal infections in
women (due to neisseria gonorrhoeae).
C/I: Patients with a history of hypersensitivity to
gatifloxacin or any member of the quinolone
class of antimicrobial agents. Growing adoles­
cents (less than 18 years of age), except where
benefits exceed risks. Pregnancy & lactation.
S/E: Gatifloxacin is generally well tolerated. The
most common side effects that can occur while
taking this drug are usually mild and include
nausea, vomting, stomach pain, diarrhoea,
dizziness, and headache.
Precautions: Gatifloxacin should be used with
caution in patients receiving drugs that may
affect the QTc interval in ECG, such as cisapride,
erythromycin, antipsychotics, and tricyclic
antidepressants.
In patients with impaired renal function
(creatinine clearance <40ml/min), adjustment of
the dosage regimen is necessary.
As gatifloxacin may cause disturbances in blood
glucose levels, careful monitoring of blood
QIMP-17 (290)
glucose is recommended when this drug is
administered in diabetic patients.
Pregnancy & lactation: The safety and
Best-in-Taste effectiveness of gatifloxacin in pregnant women,
•
and lactating mothers have not been established.
antibiotic suspensions Dosage & admin: By mouth;
1. Acute bacterial exacerbation of chronic
for child patients bronchitis- 400mg once daily for 5 days.
2. Acute sinusitis- 400mg once daily for 10 days.
3. Community-acquired pneumonia- 400mg
once daily for 7-14 days.
4. Uncomplicated skin & skin structure
infections-. 400mg once daily for 7-10 days.
5. Uncomplicated urinary tract infections (cysti­
tis)- 400mg or 200mg single dose for 3 days.
6. Complicated urinary tract infections- 400mg
.
once daily for 7-10 days
Azithromycin
•
7. Pyelonephritis- 400mg once daily for 7-10
days.
Banana flavored_Taste 8. Uncomplicated urethral and cervical
Masked Suspension gono"hea- 400mg single dose.
9. Acute, uncomplicated rectal infections in
;.
. . women- 400mg single dose.
The drug may be taken with or without meals.
• ••
ByI.V infusion;
. ·roc1n 1. Acute bacterial exacerbation of chronic bron­
Ciprofloxacin chitis- 400mg i.v once daily for S days.
2. Acute sinusitis- 400mg i.v once daily for 10
Truly bitterless Taste Masked days.
3. Com•11nlty-acquired pneumonia- 400mg i.v
Suspension
once daily for 7-14 days.
4. Uncomplicated skin & skin structure infec­
tions- 400mg i.v once daily for 7-10 days.
5. Uncomplicated urinary tract infections
(cystitis)- 400mg i.v or 200mg i.v single dose
for 3 days.
6. Complicated urinary tract infections- 400mg
Cefuroxime i.v once daily for 7-10 days.
-
7. Pyelonephritis- 400mg i.v once daily for 7-10
Bitterless suspension manufactured days.
8. Uncomplicated urethral and cervical
with· coated granules
gonorrhea- 400mg i.v single dose.
9. Acute, uncomplicated rectal infections in
women- 400mg Lv single dose.
•
'
Incase of renal ins11fficiency: If the creatinine
••
clearance is <40ml/min and hemodialysis
occurred or continuous peritoneal dialysis is
going on, the starting dose will be 400mg and
subsequent daily dose will be 200mg.
Impaired hepatic function: No adjustment in ,
Clinically tested mixed banana & the dosage is necessary in patients with
orange flavored Ceflxlme moderate hepatic impairment. T here are no
data in patients with severe hepatic impairment.
Drug inter: Probenecid: Concomitant
administration of gatifloxacin with probenecid
resulted in increase in AUC and a longer half-life
of gatifloxacin.
Iron: When gatifloxacin is administered
concomitantly with ferrous sulfate, bioavailability
of gatifloxacin is reduced. Administration of
gatifloxacin 2 hours after or 2 hours before
. .Mixed orange & banana flavored .:.
.
ferrous sulfate does not significantly alter the oral
clinically tested Cefpodoxlme bioavailability of gatifloxacin.
Antacids: Antacids contaning aluminium/
magnesium component do not cause a clinically
.. ,
.. �:.: '
.
:'
.
.
. significant effect on the pharmacokinetics of
.
- gatifloxacin when administer 4 hours after
ARISTOPHARMA tTD. gatifloxacin administration.
www.a ristopha rma�com Milk, calcium, and calcium-containing antacids:
No significant pharmacokinetic interactions occur
-
.......
.
.

when milk or calcium carbonate is administered
concomitantly with gatifloxacin.
Zinc, magnesium, or iron: Gatifloxacin can be
administered 4 hours before the administration of
dietary supplements containing zinc, magnesi\1rn,
or iron (such as multivitamins & multiminerals).
Digoxin, cimetidine, midazolam, theophyline,
warfarin, or glyburide: No significant
pharmacokinetic interactions occur when digoxin,
cimetidine, midazolam, theophyline, warfarin, or
glyburide is administered concomitantly with
gatifloxacin.
t AMIQUIN Tab. Amico
Gatifloxacin INN 400mg/tablet (film-coated).
400mg x 20's pack: 200.00 MRP
t ATAQ Tab. Orion Pharma
Gatifloxacin INN 400mg/tablet (f.c).
400mg x 20's pack: 200.80 MRP
t GATFO Tab. Alco Pharma
Gatifloxacin INN 400mg/tablet (f.c).
400mg x 20's pack: 200.00 MRP
t GATIFLOX Tab. Incepta
Gatifloxacin INN 400mg/tablet (film-coated).
400mg x 20's pack: 200.00 MRP
t GATILEX 400 Tab. Mystic
Gatifloxacin INN 400mg/tablet (film-coated).
400mg x 20's pack: 200.00 MRP
t GATINOX Tab. SK+F
Gatifloxacin INN 400mg/tablet (film-coated).
400mg x 20's pack: 200.00 MRP
t GATIZEN Tab. Zenith
Gatifloxacin INN 200mg & 400mg/tablet (f.c).
200mg x 30's pack: 180.60 MRP
400mg x18's pack: 180.72 MRP
t GATLIN Tab. Renata
Gatifloxacin INN 200mg & 400mg/tablet (f.c).
200mg x 20's pack: 120.00 MRP
400mg x lO's pack: 100.00 MRP
400mg x 30's pack: 300.00 MRP
t GATOX Tab. Acme
Gatifloxacin INN 400mg/tablet (film-coated).
400mg x 20's pack: 200.80 MRP
t GATPR0-400 Tab. Desh Pharma
Gatifloxacin INN 400mg/tablet (film-coated).
400mg x 30's pack: 300.00 MRP
t GATSINA Tab. Ibo Sina
Gatifloxacin INN 400mg/tablet (film-coated).
400mg x 20's pack: 220.00 IP
t LOGAT-400 Tab. Kemiko
Gatifloxacin INN 400mg/tablet (film-coated).
400mg x 20's pack: 200.00 MRP
t XEGAL Tab. Beximco
Gatifloxacin INN 400mg/tablet (film-coated).
400mg x 30's pack: 302.10 IP
GEMIFLOX ACIN: Tablet
•
Gemifloxacin is a synthetic broad spectrum 4th
generation fluoroquinolone antibiotic for oral
administration. It is available as gemifloxacin
mesylate INN equivalent to 320mg
gemifloxacin/tablet.
QIMP-17 (291)
Mode of action: See under the text of
ciprofloxacin.
Ind: Gemifloxacin is indicated for the treatment
of infections caused by susceptible strains of the
designated microorganisms in the conditions
listed as following:
Acute bacterial exacerbation of chronic
bronchitis caused by streptococcus pneumoniae,
haemophilus influenzae, haemophilus
parainfluenzae, or moraxella catarrhalis.
Community-acquired pneumonia (of mild to
moderate severity) caused by streptococcus
pneumoniae (including multi-drug resistant
strains-MDRSP*), haemophilus influenzae,
moraxella catarrhalis, mycoplasma pne\1moniae,
chlamydia pneumoniae, or klebsiella pneumoniae.
Acute sinusitis.
Uncomplicated urinary tract infections.
Acute pyelonephritis.
C/I: History of hypersensitivity to gemifloxacin,
fluoroquinolone antibiotic agents, or any of the
product components.
S/E: Nausea, stomach upset, loss of appetite,
diarrhea, drowsiness, dizziness, headache, dry
mouth, altered taste, constipation, or trouble
sleeping may occur. This medication may rarely
cause a severe intestinal condition (pseudomem­
branous colitis) due to a resistant bacteria. This
condition may occur while receiving therapy or
even weeks after treatment has stopped. Do not
use anti-diarrhea products or narcotic pain medi­
cations if you have the following symptoms
because these products may make them worse.
Seek immediate medical attention if you develop:
abdominal or stomach pain/cramping, blood/
mucus in your stool, persistent diarrhea. A
serious allergic reaction to this drug is unlikely,
but seek immediate medical attention if it occurs.
Symptoms of a serious allergic reaction include:
rash, hives, itching, swelling, severe dizziness,
trouble breathing.
Precautions: Before taking gemifloxacin, tell
your doctor if you have any history of allergy;
any medical history, specially of- brain or nerv­
ous system disorders (e.g cerebral arteriosclero­
sis, tumors, increased intracranial pressure), heart
problems (e.g cardiomyopathy, slow heart rate,
torsades de pointes, QTc prolongation), history of
seizures, kidney disease, liver disease, muscle/
joint/tendon problems, untreated mineral
imbalance (e.g low potassium or magnesium).
This drug may make the patient dizzy or drowsy;
use caution engaging in activities requiring alert­
ness such as driving or using machinery. This
medication may make the patient more sensitive
to the sun. Avoid prolonged sun exposure,
tanning booths or sunlamps. Caution is advised
when using this drug in the elderly because they
may be more sensitive to its side effects. Caution
is advised when using this drug in children.
Contact your doctor for more information.
Pregnancy & lactation: This medication should
be used only when clearly needed during preg­
nancy. It is not known if this medication passes
into breast milk. So, consultation is necessary
ANTIMICROBIAL DRUGS
before breast-feeding.
Dosage & Admin: Gemifloxacin can be taken
with or without food and should be swallowed
whole with a liberal amount of liquid. The
recommended dose of·gemifloxacin is 320mg
daily, and given as following:
1. Acute bacterial exacerbation of chronic
bronchitis (AECB)- 320mg daily for 5 days.
2. Community-acquired pneumonia (CAP) of
mild to moderate severity- 320mg daily for
7 days. (Therapy may be extended to 14
days incases of serious pneumonia).
3. Acute sinusitis- 320mg daily for S days.
4. Uncomplicated urinary tract infections-
320mg daily for 3 days.
S. Acute pyelonephritis- 320mg daily for 10
days.
The recommended dose and duration of gemi
floxacin should not be exceeded.
(*MDRSP, multi-drug resistant Streptococcus pneu­
moniae, includes isolates previously known as PRSP
(penicillin-resistant Streptococcus pneumoniae), and
are strains resistant to two ot more of the followlng
antibiotics: penicillin (MIC= 2 pg/mL), 2nd genera­
tion cephalosporins (e.g., cefuronme), macrolides,
tetracyclines and trimetboprim/sulfametboxazole.)
Use in renally impaired patients: Dose adjust­
ment in patients with creatinine clearance >
40ml/min is not required. Modification of the
dosage is recommended for patients with crea­
tinine clearance � 40ml/min. In these patients
recommended dose is t60mg every 24 hours.
Use in hepaticaUy impaired patients: No dosage
adjustment is recommended in patients with
mild, moderate or severe hepatic impairment.
Use in elderly: No dosage adjustment is
necessary.
Drug inter: May interact with 'blood thinners'
(e.g warfarin), corticosteroids (e.g prednisone),
diabetes medications (e.g glyburide, insulin),
probenecid, live vaccines. Report the use of
drugs which might increase seizure risk (decrease
seizure threshold) when combined with
gemifloxacin, such as phenothiazines (e.g
thioridazine), tricyclic antidepressants (e.g
amitriptyline), isoniazid (INH), or theophylline.
Note: For further information please consult
manufacturer's literature.
Gemiftoxacin Film Coated Tablet
SK•F
t FACTICIN Tab. Square
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 6's pack: 390.00 MRP
t FACTIQ Tab. MonicoPharma
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
www.squarepharmacom.bd
 ANTIMICROBIAL DRUGS
320mg x 8's pack: 520.00 MRP
t FLOGEM Tab. Opsonin
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 6's pack: 344.40 MRP
t GELCIN Tab. Drug Inter.
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 7's pack: 455.00 MRP
t GEMELON Tab. Navana
Gemifloxacin 320mg/tablet (film-coated).
320mg x 6's pack: 390.00 MRP
+ GEMICIN Tab. Healthcare
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 7's pack: 455.00 MRP
+ GEMIF Tab. Beacon
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 8's pack: 520.00 MRP
t GEMIFLOX Tab. Popular
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 1O's pack: 552.50 MRP
t GEMIN OX Tab. SK+F
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 8's pack: 520.00 MRP
t GEMIQUIN Tab. RAK Pharma
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 8's pack: 520.00 MRP
t GEMITAB-320 Tab. lbn S.ina
Gemifloxacin mesylate sesquihydrate INN equiv­
alent to 320mg gemifloxacin/tablet (film-coated).
320mg x I O's pack: 350.00 IP
t GEOFLOX Tab. Sharif
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 8's pack: 520.00 MRP
t GEPCIN Tab. Biopharma
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 8's pack: 520.00 MRP
t RTNOR Tab. Novelta
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 6's pack: 390.00 MRP
+ TOPLON Tab. Renata
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 6's pack: 390.00 MRP
+ XEMI Tab. Orion Pharma
Gemifloxacin mesylate INN equivalent to 320mg
gemifloxacin/tablet (film-coated).
320mg x 8's pack: 400.00 MRP
LEVOFLOXACIN26,42,134
LEVOFLOXACIN: Tablet/Injection
Levofloxacin is a synthetic, broad-spectrum
antibacterial agent for oral use, belonging to the
third generation fluoroquinolone derivative.
Chemically it is a chiral fluorinated carboxy-
I
QIMP-17 (292)
quinolone.
Mode of action: See above under the text of
ciprofloxacin.
Ind: Levofloxacin is indicated in the treatment of
mild, moderate and severe infections caused by
susceptible strains of the designated micro­
organisms in the following diseases: acute
maxillary sinusitis; acute bacterial exacerbation
of chronic bronchitis; comm11nity-acquired
pneumonia; complicated urinary tract infections,
acute pyelonephritis; uncomplicated &
complicated skin & soft tissue infections
including abscesses, cellulitis, furuncles,
impetigo, pyoderma, wound infections.
C/I: Patients with a history of hypersensitivity to
levofloxacin or any member of the quinolone
class of antimicrobial agents. Growing adoles­
cents (less than 18 years of age), except where
benefits exceed risks. Pregnancy & lactation.
S/E: Side-effects may include- nausea, vomiting,
diarrhoea, abdominal pain, flatulence and rare
occurrence of phototoxicity (o. l %). Very rarely
there may be tremor, depression, anxiety,
confusion etc.
Precautions: W hile taking levofloxacin, adeq­
uate amount of water should be taken to avoid
concentrated form of urine. Dose adjustment
should be exercised during levofloxacin ingestion
in presence of renal insufficiency.
Pregnancy & lactation: Levofloxacin is not
recommended in pregnancy or nursing mother, as
the effects on the foetus or nursing infant are
unknown.
Dosage & Adm.in: Bymouth:
1. Exacerbation of chronic bronchitis: 2S0-
500mg daily for 7 days.
2. Acute sinusitis: 500mg once daily for 10-14
days.
3. Community-acquired pneumonia: 500mg
once or twice daily for 7-14 days.
4. Complicated urinary tract infections & acute
pyelonephritis: 250mg daily for 7-10 days.
5. Uncomplicated skin and soft-tissue
infections: SOOmg once daily for 7-10 days.
6. Complicated skin and soft-tissue infections:
750mg once daily for 7-14 days.
Children: Not recommended for children (<18
years of age).
Byi.yinfusion;
1. Exacerbation of chronic bronchitis: 2S0-
500mg i.v once or twice daily for 7 days.
2. Acute sinusitis: 500mg i.v once daily for 10-
14 days.
3. Community-acquired pneumonia: SOOmg i. v
once or twice daily for 7-14 days.
4. Complicated urinary tract infections: 250mg
i.v once or twice daily for 7-10 days.
S. Acute pyeloneplrritis: 2SOmg i.v once daily
for 7-10 days.
6. Uncomplicated skin and soft-tissue
infections: SOOmg i.v once or twice daily for 7-
10 days.
7. Complicated skin and soft-tissue infections:
7S0mg i.v once or twice daily for 7-14 days.
Children: Not recommended for children (<18
years of age).
Overdosage: Levofloxacin exhibits a low
potential for acute toxicity, however, in the
events of an acute ove�dosage, the stomach
should be emptied. The patients should be kept
under observation and appropriate hydration
should be maintained.
Drug interaction: Antacids, iron and adsorbents
reduce absorption of levofloxacin. NSAID may
increases the risk of CNS stimulation. Warfarin
may increase the risk of bleeding.
t ASILEE-.500 Tab. Asiatic
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 24's pack: 360.00 MRP
+ AVELOX-500 Tab. SAPL
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 260.00 MRP
t BACNIL Tab. Rephco
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
+ CORBIC Tab. Novo Healthcare
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 1O's pack: 150.00 MRP
+ COSLEV Tab. Cosmo Pharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 280.00 MRP
+ EVO Tab. Beximco
Levofloxacin hemihydrate USP 250mg, 500mg &
750mg/tablet.
250mg x 30's pack: 270.00 MRP
500mg x 20's pack: 320.00 IP
750mg x I O's pack: 200.00 IP
+ EVO Oral Solo. Beximco
Levofloxacin hemihydrate USP 125mg/5ml: syrup
lOOml bot: 75.00 IP
+ EVO Inf. Beximco
Levofloxacin hemihydrate USP 500mg/100ml
bottle: i.v infusion.
500mg ( l OOml) bot: x l's pack: 100.00 MRP
t EVOCIN Tab. Hudson
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 240.00 MRP
_
t EVOLOXIN 500 Tab. Hallmark
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 261.00 MRP
t EVONEX Tab. Jayson
Levofloxacin hemihydrate USP 250mg &
500mg/tablet.
250mg x 30's pack: 210.90 MRP
500mg x 20's pack: 261.00 MRP
t EXOLEV Tab. Sandoz
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 320.00 MRP
t FLOVO Tab. Decent
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
t LAXOD-500 Tab. Millat
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 30's pack: 450.00 MRP
+ LEEVOTIN-500 Tab. MST Pharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 18's pack: 270.00 MRP
+ LEFEX SOO Tab. Doctor's
Levofloxacin hemihydrate USP 500mg/tablet.

500mg x 30's pack: 420.00 MRP
t LEFLOX Tab. ACI
Levofloxacin hemihydrate USP 500mg &
750mg/tablet.
500mg x 20's pack: 301.20 MRP
750mg x lO's pack: 200.70 MRP
t LEO Tab. Acme
'
Levofloxacin hemihydrate USP 250mg, 500mg &
750mg/tablet.
250mg x 32's pack: 257.28 MRP
500mg x 20's pack: 301.00 MRP
750mg x 12's pack: 240.84 MRP
t LEO I.V Inf. Acme
Levofloxacin hemihydrate USP 500mg/1OOml
bottle: i. v infusion.
500mg (lOOml) bot: x l ' s pack: 100.00 MRP
.
t LEOFLOX Tab. Alco Pharma
Levofloxacin hemihydrate USP 250mg &
500mg/tablet.
250mg x 1O's pack: 70.00 MRP
500mg x 20's pack: 300.00 MRP
t LEQUIN Tab. Apex
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 200.00 MRP
t LETAB Tab. Chemist
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 240.00 MRP
t LETIDQUIN 500 Tab. Rangs Pharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
t LEVIN Tab. Amico
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x l O's pack: 140.00 MRP
t LEVOBAC Tab. Popular
Levofloxacin hemihydrate USP 500mg &
750mg/tablet.
500mg x 24's pack: 361.44 MRP
750mg x 24's pack: 481.92 MRP
t LEVOBAC Inf. Popular
Levofloxacin hemihydrate USP 500mg/l OOml
bottle: i.v infusion.
500mg (lOOml) bot: x l 's pack: 100.38 MRP
t LEVOCIN-500 Tab. Desh Pharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 30's pack: 360.00 MRP
t LEVOCOS Tab. Cosmic
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 30's pack: 432.00 MRP
t LEVODON Tab. Apollo
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x l 6's pack: 240.00 MRP
t LEVOFLOX Tab. Drug Inter.
Levofloxacin hemihydrate USP 500mg &
750mg/tablet.
500mg x 20's pack: 300.00 MRP
750mg x l O's pack: 200.00 MRP
t LEVOFLOX Inf. Drug Inter.
Levofloxacin hemihydrate USP 500mg/ l OOml
bottle: i. v infusion.
-
•
500mg (lOOml) bot: x l 's pack: 100.00 MRP
t LEVOGEN Tab. General
Levofloxacin hemihydrate USP 250mg &
500mg/tablet.
250mg x 30's pack: 240.90 MRP
500mg x 20's pack: 301.20 MRP
QIMP-17 (293)
t LEVOKING Tab. Renata
Levofloxacin hemihydrate USP 250mg, 500mg &
750mg/tablet (f.c ).
250mg x 30's pack: 240.90 MRP
500mg x 30's pack: 451.80 MRP
750mg x 18's pack: 361.26 MRP
t LEVOLEX Tab. Pharmadesh
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 280.00 MRP
t LEVOLO 500 Tab. Pacific
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 30's pack: 450.00 MRP
t LEVOLON Tab. Peoples
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 30's pack: 420.00 MRP
t LEVOMAX Tab. SK+F
Levofloxacin hemihydrate USP 500mg &
750mg/tablet.
500mg x 20's pack: 300.00 MRP
750mg x 1O's pack: 200.00 MRP
t LEVONCE Tab. Bristol
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
t LEVONIX 500 Tab. Ziska
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 2 l 's pack: 294.00 MRP
t LEVONOR Tab. Novelta
Levofloxacin hemihydrate USP 500mg &
750mg/tablet.
500mg x 20's pack: 300.00 MRP
750mg x 1O's pack: 200.00 MRP
t LEVOQUIN Tab. Navana
Levofloxacin hemihydrate USP 250mg &
500mg/tablet.
250mg x 20's pack: 160.60 IP
500mg x 24's pack: 361.44 IP
t LEVORA Tab. Somatec
L.evofloxacin hemihydrate USP 500mg &
750mg/tablet.
500mg x 20's pack: 281.00 MRP
750mg x l O's pack: 180.70 MRP
t LEVOSEEM-500 Tab. Seema
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 320.00 MRP
t LEVOSINA Tab. Ibo Sina
Levofloxacin hemihydrate USP 250mg, 500mg &
750mg/tablet.
250mg x 20's pack: 160.00 IP
500mg x 20's pack: 310 IP
750mg x 20's pack: 420.00 IP
t LEVOSTIN Tab. Aexim
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 250.00 MRP
t LEVOX Tab. Opsonin
Levofloxacin hemihydrate USP 250mg, 500mg &
750mg/tablet.
250mg x 30's pack: 211.92 MRP
500mg x 20's pack: 264.97 MRP
750mg x 12's pack: 211.97 MRP
t LEVOX Oral Solo. Opsonin
Levofloxacin hemihydrate USP l 25mg/5ml: syrup
IOOml bot: 66.22 MRP
t LEVOX I.V Inf. Opsonin
Levofloxacin hemihydrate USP 500mg/l OOml
bottle: i.v infusion.
Levofloxacin
500mg (lOOml) bot: x l ' s pack: 88.30 MRP
t LEVOXIN Tab. Incepta
Levofloxacin hemihydrate USP 250mg, 500mg
& 750mg/tablet.
250mg x 30's pack: 240.00 MRP
500mg x 20's pack: 300.00 MRP
750mg x 1O's pack: 200.00 MRP
t LEVOXIN Syp. Incepta
Levofloxacin hemihydrate USP 125mg/5ml: syrup
1OOml bot: 75.00 MRP
t LEVOXIN I. V Inf. Incepta
Levofloxacin hemihydrate USP 500mg/l OOml
bottle: i.v infusion.
500mg (1OOml) bot: x 1's pack: 100.00 MRP
t LEXAZE N Tab. Zenith
Levofloxacin hemihydrate USP 250mg &
500mg/tablet.
250mg x 30's pack: 240.90 MRP
500mg x 18's pack: 253.08 MRP
t LEXLO Tab. Ambee
Levofloxacin hemihydrate USP 250mg &
500mg/tablet.
250mg x 20's pack: 161.00 MRP
500mg x 20's pack: 260.60 MRP
t LEXV0-500 Tab. Modern
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
t LEZON Tab. Euro Pharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
t LIFCIN Tab. Biopharma
Levofloxacin hemihydrate USP 500mg &
750mg/tablet.
500mg x 20's pack: 301.20 MRP
750mg x 12's pack: 240.96 MRP
t LIFCIN Syp. Biopharma
Levofloxacin hemihydrate USP 125mg/5ml: syrup
l OOml bot: 75.28 MRP
t LIFCIN I.V Inf. Biopharma
Levofloxacin hemihydrate USP 500mg/l OOml
bottle: i.v infusion.
500mg (lOOml) bot: x l 's pack: 100.00 MRP
t LIN Tab. Kemiko
Levofloxacin hemihydrate USP 250mg &
500mg/tablet.
250mg x 30's pack: 300.00 MRP
500mg x 20's pack: 300.00 MRP
t LIVACIN-500 Tab. Gaco
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
t LIVODON Tab. Apollo
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x l 6's pack: 240.00 MRP
t LOCE 500 Tab. Everest
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 24's pack: 288.00 MRP
t LOCIN Tab. Globe
Levofloxacin hemihydrate USP 250mg &
500mg/tablet.
250mg x 20's pack: 140.00 MRP
ANTIMICROBIAL DRUGS
500mg x 20's pack: 280.00 MRP
t LOVICIN Tab. Nipa
Levofloxacin hemihydrate USP 500mg/tablet.
500mg-x 30's pack: 450.00 MRP
+ LOXIN Tab. Medicon
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
t MAXLEV 500 Tab. Novus
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 240.00 MRP
t NEOVOX 500 Tab. RAK Pharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
t NIVOLOC 500 Tab. Kumudini
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
+ OLCIN Tab. Delta Pharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 240.00 MRP
t ORGALEV 500 Tab. Organic Health
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 30's pack: 450.00 MRP
+ ORLEV Tab. Orion Pharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 301.20 MRP
+ ORLEV IV Inj. Orion Infusion
Levofloxacin hemihydrate 500mg/ l OOml bottle:
i. v infusion.
500mg (1OOml) bot: x l 's pack: 100.38 MRP
+ OVEL-500 Tab. Aristopharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 30's pack: 450.00 MRP
+ QUILEV Tab. MonicoPharma
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 24's pack: 360.00 MRP
t QUIVA Tab. Ad-din
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 1O's pack: 130.00 MRP
+ QUIXIN Tab. Beacon
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 30's pack: 450.00 MRP
+ RADIBAC 500 Tab. Concord
Levofloxacin hemihydrate 500mg/tablet.
500mg x 20's pack: 300.00 MRP
+ RESQUIN Tab. Healthcare
Levofloxacin hemihydrate USP 250mg, 500mg &
750mg/tablet.
250mg x 30's pack: 240.00 MRP
500mg x 24's pack: 360.00 MRP
750mg x l 8's pack: 360.00 MRP
t T IVANIK Tab. Silva
Levofloxacin hemihydrate USP 250mg &
500mg/tablet.
250mg x 30's pack: 240.00 MRP
500mg x 20's pack: 301.00 MRP
t T OPLEVO 500 Tab. NIPRO JMI
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 30's pack: 450.00 MRP
t T REVOX Tab. Square
Levofloxacin hemihydrate USP 500mg &
750mg/tablet.
500mg x 30's pack: 451.50 MRP
750mg x 20's pack: 401.40 MRP
t T REVOX Syp. Square
Levofloxacin hemihydrate USP 125mg/5ml: syrup
1OOml bot: 80.00 MRP
t T REVOX 500 I.V Inf. Square
Levofloxacin hemihydrate 500mg/l OOml bottle:
i.v infusion.
500mg ( lOOml) bot: x l 's pack ·: 100.00 MRP
QIMP-17 (294)
t T RILON 500 Tab. White Horse
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 24's pack: 360.00 MRP
+ URILEV Tab. Techno Drugs
Levofloxacin hemihydrate USP 500mg &
750mg/tablet.
500mg x 20's pack: 300.00 MRP
750mg x l 8's pack: 360.00 MRP
t URILEV I. V Inf. Techno Drugs
Levofloxacin hemihydrate USP 500mg/l OOml
bottle: i.v infusion.
500mg ( l OOml) bot: x l ' s pack: 100.00 MRP
+ XELEV0-500 Tab. Pharmasia
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
t XENOLEV 500 Tab. Virgo
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 300.00 MRP
+ 3-F 500 Tab. Edruc
Levofloxacin hemihydrate USP 500mg/tablet.
500mg x 20's pack: 280.00 MRP
LOMEFLOXACIN: Tablet
Lomefloxacin is a synthetic quinolone broad­
spectrum antimicrobial agent.
Mode of action: See above under the text of
ciprofloxacin.
Ind: lit is indicated in the treatment of infections
of lower respiratory tract & urinary tract, caused
by susceptible organisms and prophylaxis in
patients undergoing transurethral surgical
procedures.
C/I: Patients with a history of hypersensitivity to
lomefloxacin or any member of the quinolone
class of antimicrobial agents. Growing adoles­
cents (less than 18 years of age), except where
benefits exceed risks. Pregnancy & lactation.
S/E: There may be mild to moderate and
transient development of some side-effects such
as, nausea, headache, photosensitivity, dizziness
and diarrhoea.
Precautions & Warnings:
Patient should be advised to avoid the maximum
extent possible direct or indirect sunlight during
and several days after therapy; to discontinue
therapy if any sign/symptom of phototoxicity
reaction such as sensation of skin burning,
redness, swelling, blisters, rash, itching or
dermati�is appears; to drink fluids liberally.
Dosage & Admin: For treatment of lower
respiratory tract infections or uncomplicated
and complicated urinary tract infections, the
usual adult dose is 400mg once daily for 10
days (14 days for complicated UTI).
For prophylaxis in patients undergoing
transurethral surgical procedures- a single
dose of 400mg 2-6 hours prior to the
procedure in adults.
Geriatric patients generally can receive usual
adult dosages unless creatinine clearance is
less than 40ml/min. No dosage adjustment is
needed for elderly patients with normal renal
function.
In patients with a creatinine clearance
>lOml/min but <40ml/min, the recommended
dosage is an initial loading dose of 400mg
followed by daily maintenance dose of 200mg
· once daily for the duration of treatment.
t LOMEFLOX Tab. Aristopharma
Lomefloxacin 400mg/tablet.
400mg x 20's pack: 300.00 MRP
t MEXLO Tab. Square
L.omefloxacin 400mg/tablet.
400mg x 20's pack: 301.00 MRP
t NAMICIN Tab. Nipa
Lomefloxacin 400mg/tablet.
400mg x 20's pack: 300.00 MRP
MOXD"LOXA.C.lN87,120,133
MOXIFLOXACIN: Tablet/Injection
Moxifloxacin is a new fourth generation
synthetic 8-methoxy-fluoroquinolone ..
antibacterial agent with a broad spectrum activity
and bactericidal action. This is found effective in
the treatment of acute bacterial sinusitis, acute
bacterial exacerbation of chronic bronchitis and
community acquired pneumonia in adults.
It is available as- moxifloxacin INN 400mg tablet
for oral administration and moxifloxacin
hydrochloride BP equivalent to 400mg
moxifloxacin in 250ml glass bottle
(160mg/100ml) for i.v infusion.
Mode of action: As there is development of
cross-resistance among the quinolones, primarily
as a result of mutation affecting DNA gyrase,
moxifloxacin and other newer quinolones don't
exhibit cross-resistance with some single mutati­
ons that developed resistance to older quinolones.
For further information, please see above under
the text of ciprofloxacin.
Ind: Acute bacterial sinusitis; acute bacterial
exacerbation of chronic bronchitis; community­
acquired pneumonia; skin and skin structure
infections.
C/I: Patients with a history of hypersensitivity to
moxifloxacin or any member of the quinolone
class of antimicrobial agents. Growing
adolescents (less than 18 years), except where
benefits exceed risks. Pregnancy & lactation.
S/E: Adverse e.ffects include- nausea, diarrhea,
dizziness, headache, abdominal pain, vomiting,
dyspepsia, taste perversion and abnormal liver
function tests.
Precautions: Safety and effectiveness in
paediatric patients and adolescents less than 18
years of age have not been established. Patient
should be instructed to drink fluid liberally
during treatment with any fluoroquinolone in
order to prevent crystal formation in the urine.
Pregnancy & lactation: Moxifloxacin should
not be used in pregnant women and breast­
feeding mothers.
Dosage & admin: By mouth:
Acute bacterial sinusitis: 400mg orally once
daily for 10 days; Or, 400mg (250ml) once
daily by i.v infusion, followed by oral therapy
for 7-10 days.
\
Acute bacterial exacerbation of chronic
brochitis: 400mg orally once daily for 5 days;
Or, 400mg (250ml) once daily by i.v infusion
for 5 days.
Community-acquired pneumonia: 400mg orally
once daily for 10 days; Or, 400mg (250ml)
once"1aily by i.v infusion, followed by oral
therapy for 7-14 days.
Skin and skin structure infection: 400mg once
daily for 7 days; Or, 400mg (250ml) once daily

by i.v infusion, followed by oral therapy for 7
days, in case of complicated infection may be
given upto 21 days.
Complicated intra-abdominal infections:
400mg (250ml) once daily by i. v infusion,
followed by oral therapy for 5-14 days.
Moxitloxacin tablet may be taken with or
without food.
Moxitloxacin i.v infusion can be administered
for the entire treatment duration.
Alternatively, therapy may be initial i.v admi­
nistration, followed by oral administration
when clinically indicated. The recommended
duration of treatment for the indication being
treated should not be exceeded. The solution
for infusion should be infused i. v over 60
minutes.
Elderly: No adjustment of dosage is required
in the elderly.
Children: Efficacy and safety of moxifloxacin
in children and adolescents have not been
established.
Drug inter: Antacids containing magnesium or
aluminium, sucralfate, metal cations such as iron
or zinc may interfere with oral absorption of
moxifloxacin. These age�ts should be given 2
hours after or 6 hours before moxifloxacin.
t IVENTI 400 I.V Inf. Square
Moxifloxacin hydrochloride BP equivalent to
400mg moxifloxacin in 250ml bottle
(160mg/100ml): injection for i.v infusion.
250ml (400mg) x l 's pack: 175.00 MRP
t MOXIBAC I.V Inf. Popular
Moxifloxacin hydrochloride BP equivalent to
400mg moxifloxacin in 250ml glass bottle
(160mg/100ml): injection for i.v infusion.
250ml (400mg) x l's pack: 350.00 MRP
t MOXIBAC Tab. Popular
Moxifloxacin 400mg/tablet
400mg x 1O's pack: 700.00 MRP
t MOXIFLOX Tab. Alco Pharma
Moxifloxacin INN 400mg/tablet
400mg x 8's pack: 680.00 MRP
I t MOXQUIN 400 Tab. Incepta
1 be diluted in any solution containing chloride
Moxifloxacin INN 400mg/tablet
400mg x 8's pack: 680.00 MRP
OFLOXACIN: Tablet/Injection
Ofloxacin is a synthetic antibacterial drug which
belongs to the 4-quinolone family.
Ind: UTI, lower respiratory tract infections,
uncomplicated gonorrhoea, non-gonococcal
urethritis & cervicitis, septicaemia, severe or
complicated infections.
C/I; S/E: See under Ciprofloxacin (which are
almost common in all 4-quinolones ). Other side
effects include haemolytic anaemia, renal
impairment, hepatic dysfunction, anaphylaxis &
hypoglycaemia.
Cautions: See under Ciprofloxacin
Dosage & admin: By mouth, U.T.1- 200-400mg
daily preferably in the morning, increased if
I
-
QIMP-17 (295) ANTIMICROBIAL DRUGS
necessary in upper U.T.I to 400mg twice daily. SPARFLOXACIN: Tablet
Lower R.T.I, 400mg daily preferably in the Sparfloxacin is a synthetic, broad-spectrum
morning, increased if necessary to 400mg bactericidal agent from the fluoroquinolone
twice daily. family of antibacterial�.
Uncomplicated gonorrhoea, 400mg as a single Ind: Upper and lower respiratory tract infections
dose. including sinusitis, acute exacerbation of chronic
Non-gonococcal urethritis and cervicitis, bronchitis, pneumonia due to atypical organisms;
400mg daily in single or divided doses. urinary tract infections including gonococcal and
By I.V infusion (over at least 30 minutes), nongonococcal urethritis, chancroid and other
complicated U.T.I, 200mg daily. sexually transmitted diseases; skin & soft tissue
Lower R.T.I, 200mg twice daily. infections; prophylactic use in different
Septicaemia, 200mg twice daily. urological & ophthalmic operations.
Severe or complicated infections, dose may be C/I: Hypersensitivity to any of fluoroquinolones;
increased to 400mg twice daily. pregnacy and lactaion; history of achilles
tendinits following the use of fluoroquninolones;
t FLOCET Tab. Opsonin glucose-6 phosphate dehydrogenase (G-6PD)
Ofloxacin 200mg & 400mg/tablet deficiency.
200mg x 20's pack: 212.00 MRP S/E: Side-effects are mild and transient and
400mg x lO's pack: 194.24 MRP seldom result in cessation of therapy with
t OFLACIN Tab. Drug Inter. sparfloxacin. Nausea, vomiting, diarrhoea, sleep
Ofloxacin 200mg & 400mg/tablet disturbances, allergy, pain, tendinitis,
200mg x 20's pack: 240.00 MRP phototoxicity, cardiac rhythm disturbances, have
400mg x 20's pack: 400.00 MRP been reported in some patients.
t RUTIX Tab. Square Precautions: Renal disease, gastric ulcers,
Ofloxacih 200mg & 400mg/tablet concomitant use of NSAIDs.
200mg x 30's pack: 361.50 MRP Dosage: Depending on the severity of
400mg x 20's pack: 441.60 MRP infection, causative pathogen and clinical
response, the dosage is to be individualised.
For most of the infections in majority of
clinical practices the following dosage regimen
is sufficient- 400mg on day 1, followed by
PEFLOXACINE MESYLATE: Tablet/ 200mg/day for 5 to 7 days. In renal failure of
injection third degree severity (creatinine clearance <
Pefloxacine is a synthetic antibacterial drug 30ml/min) dosage modification is
which belongs to the quinolone family. recommended- 400mg on day 1, 200mg/day on
Ind: Sevre infections in adults, caused by gram­ day 2 & 3 followed by 200mg every 48 hours.
negative and staphylococci organisms. Children: below 12 years not recommended.
C/I; S/E: Please see above under ciprofloxacin.
Cautions: Please see above under ciprofloxacin. t ACIFLOX Tab. ACI
Sparfloxacin INN 200mg/tablet.
Dosage & admin: Adult: 400 mg 12 hourly
lO's pack: 150.60 MRP
with meals to avoid g.i symptoms. By
injection, 400mg (lamp.) diluted in 250ml of t ASAF Tab. Asiatic
Sparfloxacin INN 200mg/tablet.
5�. glucose in aqua, as a slow one-hour
20's pack: 375.00 MRP
infusion, twice daily. (Pefloxacine should not
t FLOXIPAR Tab. Acme
Sparfloxacin INN 200mg/tablet.
ions. Initial dose may be 800mg.
lO's pack: 155.60 MRP
t ISOFLOXIN Tab. Beximco t MEGA-FLOX Tab. Hudson
Pefloxacine 400mg/tablet Sparfloxacin INN 200mg/tablet.
50's pack: 602.50 IP 20's pack: 300.00 MRP
t NOBAC Tab. Ibo Sina t OMNIFLOX Tab. Aristopharma
Pefloxacine 400mg/tablet Sparfloxacin INN 200mg/tablet.
20's pack: 240.00 IP lO's pack: 180.00 MRP
+ PEFLA Tab. Sonear t PARFLOX Tab. Somatec
Pefloxacine 400mg/tablet Sparfloxacin INN 200mg/tablet.
20's pack: 307.60 MRP lO's pack: 150.60 MRP
t PARLOX Tab. SK+F
t PEFLACINE Tab. Sanofi-aventis
Sparfloxacin INN 200mg/tablet.
Pefloxacine 400mg/tablet
lO's pack: 150.00 MRP
30's pack: 456.90 MRP.
t PIOCIN-200 Tab. Millat
t PEFLOX Tab. Drug Inter.
Sparfloxacin INN 200mg/tablet.
Pefloxacine 400mg/tablet
6's pack: 108.00 MRP
20's pack: 220.00 MRP
+ QUINOFLOX Tab. Healthcare
Sparfloxacin INN 200mg/tablet.
lO's pack: 150.00 MRP
.9'-Hs' •••
•••
rai
� ���!ALS
IJAHOLA06$11
�T,,. www.squarepharma.com.bd •••
HUfl9

ANTIMICROBlAL DRUGS
t ROXIPAR Tab. Cosmic
Sparfloxacin INN 200mg/tablet.
lO's pack: 154.00 MRP
t SAGA Tab. Square
Sparfloxacin INN 200mg/tablet.
15's pack: 225.00 MRP
t SALOCIN Tab. Kemiko
Sparfloxacin INN 200mg/tablet.
lO's pack: 170.00 MRP
t SPACIN Tab. Sandoz
Sparfloxacin INN 200mg/tablet.
l O's pack: 260.00 MRP
t SPALOCIN Tab. Pacific
Sparfloxacin INN 200mg/tablet.
IO's pack: 200.00 MRP
t SPALOX Tab. Edruc
Sparfloxacin INN 200mg/tablet.
lO's pack: 160.00 MRP
t SPAR Tab. Globe
Sparfloxacin INN 200mg/tablet.
lO's pack: 150.00 MRP
t SPARCIN-200 Tab. Chemist
Sparfloxacin INN 200mg/tablet.
20's pack: 300.00 MRP
t SPARDON Tab. Apollo
Sparfloxacin INN 200mg/tablet.
12's pack: 192.00 IP
t SPARFLOX Tab. Alco Pharma
Sparfloxacin INN 200mg/tablet.
IO's pack: 160.00 MRP
t SPARFLOXIN-200 Tab. Desh Pharma
Sparfloxacin INN 200mg/tablet.
20's pack: 240.00 MRP
+ SPARK Tab. Navana
Sparfloxacin INN 200mg/tablet.
lO's pack: 150.00 IP
t SPARLIN Tab. Beximco
Sparfloxacin INN 200mg/tablet.
lO's pack: 150.60 IP
t SPARONEX Tab. Drug Inter.
Sparfloxacin INN 200mg/tablet.
20's pack: 360.00 MRP
Anti-Tuberculer Antibiotics
STREPTOMYCIN 2t,33
STREPTOMYCIN: Injection
Ind: Tuberculosis in combination with other
drugs; some gram-ve infections such as,
klebsiella pneumoniae, E. coli, tularaemia,
plague, brucellosis etc but usually not used.
C/I: Streptomycin hypersensitivity, diseases of
the ear particularly suppurative otitis media,
labyrinthine disturbances.
S/E: Ototoxicity and vestibular damage
usually preceded by dizziness, headache, nausea,
vomiting, nystagmus & ataxia; allergic rashes
and fever with eosinophilia; paraesthesia of
mouth.
Cautions: If symptoms of ototoxicity occur, must
stop the drug.
Dosage & admin: Tuberculosis: Adult, 0.75-1
gm. daily or 0.75-lgm 3 times a week (for fully
supervised intermittent therapy) i.m. injec­
tion; Child, usually 30 mg/kg upto lgm daily.
Non-tuberculous infections: Adult, I gm/ day
i.m inj. for 3-7 days; Child, 22 to 40 mg/kg
daily may be given in divided doses.
QlMP-17 (296)
t STREPTOMYCIN Inj. Renata
Streptomycin l gm/vial: injection
l gm vial: 9.19 MRP
RIFAMPICJN 2t,33
RIFAMPICIN: Tablet/capsule/syrup
Ind: Tuberculosis (in combination with other
drugs, usually isoniazid & ethambutol); Leprosy;
Brucellosis, Legionnaires; prophylaxis of
meningo-coccal meningitis and haemophilus
influenzae infection.
C/I: Pregenancy, Jaundice.
S/E: GI symptoms including anorexia, nausea,
vomiting, diarrhoea; hepatic reactions with
alterations of liver-functions, jaundice; acute
renal failure; thrombocytopenic purpura; urticaria
& rashes; pink colouration of urine and other
body secretions. Other side effects like muscular
weakness, myopathy, leucopenia, oesinophilia,
menstrual disturbance.
Cautions: Hepatic impairment, alcoholism, drug
interactions.
Dose: Adult, under 50kg 450mg daily· before
breakfast; 50kg and over 600mg daily.
Child, 1Omg/kg daily.
Brucellosis & Legionnaires, by mouth or by i.v
infusion, 0.6-1.2gm daily in 2-4 divided doses.
Leprosy, 600mg once monthly (450mg for
those weighing less than 35kg) along with
other antileprotic drug/drugs.
+ RIFCIN Cap. Pharmadesh
Rifampicin 450mg/capsule
450mg x 40's pack: 441.20 MRP
+ RIFCIN Syp. Pharmadesh
Rifampicin 100mg/5ml: syrup
60ml bot: 80.00 MRP
Anti-Tuberculer
Chemotherapeutics
ISONIAZ1D21,33
(Isonicotinic acid hydrazide)
ISONIAZID: Tablet/Elixir/Injection
Ind: Tuberculosis (in combination with other
drugs).
C/I: Hepatic damage (Jaundice) .
S/E: Nausea, vomiting; allergic reactions includ­
ing rashes; peripheral neuropathy with high doses
(treat with pyridoxine 10-20 mg daily); mental
disturbances, convulsions & incoordination;
alcoholic intolerence, hypertoxicity;
agranulocytosis and rarely anaemia and pellagra.
Dose: Adult, 300mg daily; child, lOmg/kg
(max. 300mg) daily or lSmg/kg 3 times a week
(both adult and child) for intermittent
supervised therapy.
Preparations: Individual preparation may not be
available; available as combined preparations.
ETHAMBUTO L2t, 33
ET HAMBUTOL: Tablet
Ind: Tuberculosis (in combination with other
drugs, usually isoniazid and rifampicin).
-
'
•
• •
C/I: Young children, elderly patients, optic
neuritis.
S/E: Optic neuritis, red/green colour blindness,
peripheral neuritis.
Caution: Reduced dose in renal impairment;
warn patients to report any visual change;
lactation.
Dosage & admin: Adults, prophylaxis &
treatment- 15 mg/kg daily as a single dose or
2Smg/kg daily in the initial phage followed by
15mg/kg daily in the continuous phage. Or for
supervised intermittent treatment- 30mg/kg 3
times a �eek or 45mg/kg 2 times a week.
Children: treatment, 25 mg/kg daily as a single
dose for 2 months, then 15mg/kg body-wt.
daily as a single dose. Prophylaxis-IS mg/kg
'
daily as a single dose.
Tuberculous meningitis, 25mg/kg daily •
+ FIAMBUTOL Tab. Sanofi-aventis
Ethambutol 400mg/tablet
1OO's pack: 341.28 MRP
t SERVAMBUTOL Tab. Sandoz
Ethambutol 400mg/tablet
IOO's pack: 344.00 MRP
+ SURAL Tab. Ambee
Ethambutol 400mg/tablet
lOO's pack: 166.00 MRP
PYRAZINAMIDE2t ,33
PYRAZINAMIDE: Tablet
Ind: Tuberculosis, specially tuberculous
meningitis.
C/I: Liver damage, pregnancy & children.
S/E: Hepatotoxicity, occasional mild fever,
malaise, liver tenderness, hepatomegaly, jaundice
and fulminating liver failure; gastro-intestinal
disturbances are anorexia, nausea, vomiting,
diarrhoea & aggravation of peptic ulcer; acute
gout, arthralgia; sideroblastic anaemia & urticaria.
Dosage & admin: Adult, under SOkg l.5gm,
50kg and over 2gm daily.
Child, 35 mg/kg daily for first 2 months only.
Intermittent supervised therapy- adult, under
50kg 2gm 3 times a week, 50kg and over
2.Sgm; child, 50mg/kg 3 times a week. Or
adult, under 50kg 3gm 2 times a week, SOkg
and above 3.Sgm; child, 75mg/kg 2 times a
week.
Preparations: Not available at this moment.
Combined anti-TB prepns.
RIFAMPICIN + ISONIAZID2I,33
RIFAMPICIN + ISONIAZID: Tablet/ Capsule
Ind: Tuberculosis.
C/I; S/E: See above under Rifampicin & INH.
Dose: See below, under individual drug.
t RIFAGEN 450 Tab. Pharmadesh
Rifampicin 450mg + Isoniazid 300mg/tablet
Dose: 1 tab. daily in a single dose before
breakfast for the patients under 50kg body-wt.
20's pack: 349.80 MRP
+ RIFAZID 150 Tab. Sanofi-aventis
Rifampicin l 50mg + Isoniazid 1OO mg/tablet
Dose: Under 50 kg body-wt. 3 tabs. daily as a
 QIMP-17 (297) ANTIMICROBIAL DRUGS

single dose before breakfast.
lOO's pack: 423.47 MRP
+ RIFAZID 300 Tab. Sanofi-aventis
Rifampicin 300mg+ Isoniazid 150mg/tablet.
Dose: Over 50 kg. 2 tabs. daily as a single dose
before breakfast.
60's pack: 462.60 MRP
+ RIFAZID 450 Tab. Sanofi-aventis
Rifampicin 450mg + Isoniazid 300mg/tablet
Dose: 1 tablet daily in a single dose before
breakfast for the patients under 50kg body-wt.
30's pack: 351.12 MRP
t RIMACTAZID 300 Tab. Sandoz
Rifampicin 300mg+ Isoniazid 150mg/tablet.
Dose: Over 50kg 2 tablets daily as a single
dose before breakfast.
50's pack: .418.50 MRP
t RIMACTAZID 450 Tab. Sandoz
Rifampicin 450mg + Isoniazid 300mg/tablet
Dose: 1 tablet daily in a single dose before
breakfast for the patients under 50kg body-wt.
50's pack: 585.50 MRP
Body weight > 50kg, initial 2 months- Rimstar ii. Drugs for Cytomegalovirus: Such as­
4-FDC 4 tablets at a time daily; next 4 Cidofovir, Foscarnet, Ganciclovir,
months- continuation dose Rifampicin 600mg Valganciclovir.
+ Isoniazid 300mg (or Rimactazid-300 two
2.2. Drugs for Human immunodeficiency
tablets) at a time daily.
virus (HIV):.See below under
Retreatmentpatients:
antiretroviral drugs.
Body weight< 50kg, initial 2 months- Rimstar
2.3. Drugs for Viral hepatitis infection:
4-FDC 3 tablets at a time daily, &
i. Chronic hepatitis B: Such as­
Streptomycin 15mg/kg daily; next 1 month­
Lamivudine, Adefovir dipivoxil,
Rimstar 4-FDC 3 tablets at a time daily; next
Entecavir, Telbivudine.
5 months- continuation dose Rifampicin
ii. Chronic hepatitis C: Such as­
450mg + Isoniazid 300mg (or Rimactazid-450
Peginterferon a/fa, Ribavirin (in
one tablet) daily, & Ethambutol 400mg 2
combination with Peginterferon alfa).
tablets (800mg) at a time daily.
2.4. Drugs for Influenza virus: Such as­
Body weight > 50kg, initial 2 months- Rimstar
Amantadine, Oseltamivir, Zanamivir
4-FDC 4 tablets at a time daily, &
2.5. Drugs for Respiratory syncytial virus:
Streptomycin 15mg/kg daily; next 1 month­
Such as- Palivizumab, Ribavirin
Rimstar 4-FDC 4 tablets at a time daily; next
5 months- continuation dose Rifampicin
600mg + Isoniazid 300mg (or Rimactazid-300 2.1 Drugs for Herpes simplex &
two tablets) at a time daily, & Ethambutol
400mg 21/2 tablets (lOOOmg) at a time daily.
Varicella-zoster
Rimstar 4-FDC x 50's pack: 600.00 MRP

RIFAMPICIN + ISONIAZID + PYRAZI­ •

Drugs for Herpes simplex &
NAMB>E + ETHAMBUTO L21,54 Varicella-zoster
1.11 Anti-Leprotic drugs
RIFAMPICIN + ISONIAZID +
PYRAZINAMIDE + ET HAMBUTOL: Tablet DAPSONE2 1,33 ACY CL OVIR21,47, 138
Ind: Tuberculosis, where combination of three or
ACYCLOVIR: Tablet/Syrup/I.V Infusion
•

four drugs required. DAPSONE: Tablet.

C/I; S/E: See above under Rifampicin, INH,
Pyrazinamide & Ethambutol.
Dose: See below, under individual drug.
t RIMSTAR 4-FDC Tab. Sandoz
Rimstar 4-FDC presents- Rifampicin 150mg +
Isoniazid 75mg + Pyrazinamide 400mg +
Ethambutol 275mg/tablet.
Ind: Rifampicin, isoniazid, pyrazinamide and
ethambutol are major drugs in the management
of tuberculosis and in certain opportunist
mycobacterial infections. Rifampicin is also
effective in the cases resistant to other anti­
tuberculous agents.
C/I: In known or suspected hypersensitivity to
rifampicin and/or to isoniazid, pyrazinamide and
ethambutol and/or to any of the excipients,
including, a history of drug induced hepatitis,
acute liver diseases, peripheral neuritis and optic
neuritis.
S/E: Please see under individual preparation.
Precautions: Caution is advised in patients with
impaired renal, liver and visual function, diabetes
mellitus, gout.
Pregnancy: Should not be given during
pregnancy unless the potential benefit justifies
the potential risk to the foetus.
Dosage: The total dosage requirement of
rifampicin is 10 (8 to 12) mg/kg/day, of
isoniazid 5 (4 to 6) mg/kg/day, of pyrazinamide
25 (20 to 30) mg/kg/day and of ethambutol 15
(15-20) mg/kg/day.
Calculating the daily dosage as above, a treat­
ment schedule has been prepared as below:
Newpatients:
Body weight< 50kg, initial 2 months- Rimstar
4-FDC 3 tablets at a time daily; next 4
months- continuation dose Rifampicin 450mg
+ Isoniazid 300mg (or Rimactazid-450 one
tablet) daily.
Ind: Leprosy; Dermatitis herpetiformis, (and also
malaria).
S/E: Anaemia (mild to severe); allergic
dermatitis, hepatitis, psychosis; anorexia, nausea,
vomiting; headache, insomnia, tachycardia;
agranulocytosis; Lepra reactions (discontinue if
eye or nerve trunks affected).
Dose: Treatment of leprosy started on a low
dose (1/4 th of the standard) which then
gradually increased so as to take 6 or 8 weeks
to reach the standard. The following regimens
have been used; 100-200 mg once a day or
200-400 mg twice a week or 300-600 mg once a
week or 1-2mg/kg/day.
Dermatitis herpetiformis- adult, initially 50-
1 OOmg daily modified according to response.
t DAPSONE Tab. Clonmel
Dapsone BP 1OOmg/tablet
l OOO's pack: 210.00 MRP (previous price).
Preparation: May not be available; price could
not be revised.
OTHER PREPNS.
IUFAMPICIN: See under anti- T.B drugs.
2. ANTI-VIRAL DRUGS/ANTI­
AIDS DRUGS
Anti-viral drugs that are available now a day may
be classified as below: 1,21
2.1 Drugs for Herpes virus infection:
i. Herpes simplex & Varicella-zoster:
Such as-Acyclovir, Famciclovir, Inosine
pranobex, Va/acyclovir.
Ind: Treatment of herpes simplex virus infections
of the skin & mucous membrane. Initial &
recurrent episodes of herpes genitalis. Severe
initial clinical episodes of herpes genitalis in
immunocompetent patients. Herpes simplex
encephalitis. Neonatal herpes simplex virus
infection. Varicella-zoster infection in
immunocompromised patients. Prophylaxis in
immunocompromised patients.
C/I: Patients known to be hypersensitive to
acyclovir or valacyclovir.
S/E: Events occuring during acyclovir therapy
are not different in nature, incidence or severity
from events occuring in patients receiving
placebo.
Cautions: In patients with severe renal
impairment (creatinine clearance less than
1Oml/min), a dose of 200mg every 12 hourly is
recommended. No more information is available.
Dosage & admin: By mouth: Adult:
Treatment- 1 tablet (or 5ml syrup) 5 times
daily at 4 hourly intervals (omitting the night
time-dose) for 5 days. Prophylaxis- 1 tablet or
5ml 4 times daily at 6 hourly intervals.
Child: Treatment- under 2 years, 112 tablet or
2.5ml 5 times daily at 4 hourly intervals for 5
days. Over 2 years, same as adult.
Prophylaxis- under 2 years, 112 tablet or 2.5ml
4 times dalily at 6 hourly intervals; over 2
years, same as adult.
By i. v infusion: See under the individual
preparation.
t ACERUX Tab. Opsonin
Acyclovir 200mg & 400mg/tablet
200mg x 30's pack: 370.79 MRP
400mg x 20's pack: 387.07 MRP
t CLOVIR Tab. Ibo Sina
Acyclovir 200mg & 400mg/tablet
200mg x 30's pack: 420.00 IP
ANTIMICROBIAL DRUGS
400mg x 20's pack: 440.00 IP
t NOVIREX Tab. Drug Inter.
Acyclovir 200mg & 400mg/tablet
200mg x 30's pack: 420.00 MRP
400mg x 20's pack: 440.00 MRP
t VIRUX Tab. Square
Acyclovir 200mg & 400mg/tablet
200mg x 30's pack: 421.80 MRP
400mg x 20's pack: 441.60 MRP
t VIRUX Susp. Square
Acyclovir 200mg/5ml: suspension
70ml bot: 125.47 MRP
t XOVIR I.V Inf. Beacon
Acyclovir sodium equivalent to acyclovir USP
250mg/vial & 500mg/vial: injection for i.v
infusion.
Dosage & admin: Method of preparation:
Reconstitution: The required dose of acyclovir
injection should be administered by slow i.v
infusion over a one-hour period. 250mg vial
should be reconstituted using 1 Oml of solvent
(e.g water for injection, sodium chloride solu­
tion 0.9°o
/ , 0.45°/o, 0.18°/o w/v or glucose 4°/o
w/v, or Hartman's solution) to provide a solu­
tion containing 25mg acyclovir per ml. To
reconstitute each vial add 1 Oml of infusion
fluid and shake gently untill the contents of
the vial have dissolved completely.
Administration: After reconstitution acyclovir
may be administered by a controlled rate infu­
sion pump. Alternatively the reconstituted
solution may be further diluted to give an acy­
clovir concentration of not greater than
5mg/ml (0.5°/o w/v) for administration by infu­
sion. Add the required volume of rec�nstituted
solution to the chosen infusion solution, as rec­
ommended below and shake well to ensure
adequate mixing occurs.
For children and neonates, where it is advis­
able to keep the volume of infusion fluid to
minimum, it is recommended that dilution is
on the basis of 4ml reconstituted solution
(lOOmg acyclovir) added to 20ml of infusion
fluid. Acyclovir i.v infusion after reconstitution
may be injected directly into a vein over one
hour by a controlled-rate infusion pump, or be
further diluted for administration by infusion.
For i.v injection by a controlled-rate infusion
pump a solution containing 25mg acyclovir
per ml is used. For i.v infusion each vial of
acyclovir should be reconstituted and then
wholly or in part according to the dosage
required, added to and mixed with at least 50-
100ml infusion solution. A maximum of 250mg
of acyclovir may be added to 50ml infusion
solution. After addition of acyclovir to an infu­
sion solution the mixture should be shaken to
ensure thorough mixing. Acyclovir injection
when diluted in accordance with the above
schedule will give an acyclovir concentration
not greater than 0.5o/o w/v. Acyclovir i.v infu­
sion is known to be compatible with the fol­
lowing infusion fluids and stable for up to 12
hours at room temperature (below 25oC) when
diluted to a concentration not. greater than
0.5°/o w/v acyclavir. Acyclovir injection when
diluted in accordance with the above schedule
will give an acyclovir concentration not
greater than 0.5°o
/ w/v. Since no antimicrobial
preservative is included, reconstitution and
QIMP-17 (298)
dilution must be corried out under full aseptic
conditions immediately before use and any
unused solution discarded. Reconstituted or
diluted solution should not be refrigerated.
Hemodialysis: For patients who require
dialysis, the mean plasma half-life of acyclovir
during hemodialysis is approximately S hours.
This results in a 50°/o decrease in plasma
concentration following a 6-hour dialysis
period. Therefore, the patients dosing schedule
should be adjusted so that an additional dose
is administered after each dialysis.
Peritoneal dialysis: No supplemental dose is
necessary after adjustment of the dosing
interval.
250mg vial x 1 's pack: 400.00 MRP
500mg vial x l's pack: 700.00 MRP
FAMCICLOVIR54
FAMCICLOVIR: Tablet
Famciclovir is the orally administered pro-drug
of the antiviral agent penciclovir. Famciclovir
itself has no antiviral activity until it is biotrans­
formed to penciclovir. Following oral administra­
tion, famciclovir is rapidly absorbed and convert­
ed to the antivirally active compound, penci­
clovir. Studies have shown that famciclovir is
well absorbed and produces plasma penciclovir
concentrations superior to those obtained
following oral administration of penciclovir alone.
The mean bioavailability of penciclovir after oral
administration of famciclovir is about 77%.
Mode of action: Penciclovir is a substituted
guanine analogue with potent and selective
antiviral activity against varicella zoster virus and
other human herpes viruses. Penciclovir is in the
same class of antiviral drugs as acyclovir, and
both are phosphorylated b.y viral thymidine
kinase and then by cellular enzymes to the active
triphosphate form in virus-infected cells..
•
Penciclovir triphosphate inhibits viral DNA poly-
merase competitively with deoxyguanosine
triphosphate and is incorporated into the extend­
ing DNA chain, preventing significant chain
elongation. Consequently, viral DNA synthesis
and, therefore, viral replication are inhibited.
Inhibition of the virus reduces the period of viral
shedding, limits the degeree of spread and level
of pathology, and thereby facilitates healing.
Penciclovir is not readily phosphorylated in
uninfected cells and does not inhibit cellular
DNA synthesis even at concentrations> 20 times
those achieved in clinical usage.
Ind: Famciclovir is indicated: 1. For the
treatment of acute herpes zoster (shingles).
2. For the treatment or suppression of recurrent
•
episodes of genital herpes in immunocompetent
adults. 3. For the treatment of recurrent episodes
of mucocutaneous herpes simplex infections in
RN-infected patients.
C/I: Patients who have known hypersensitivity to
famciclovir or to any ingredient in the
formulation or component of the container. For a
complete information, please see the
manufacturer's literature.
Precautions & warnings: The efficacy of famci­
clovir has not been established for first episode
genital herpes infections, disseminated zoster, or
in immuncompromised patients with herpes
zoster. Dosage adjustment is required when
administrering famciclovir to patients with '
moderate or severe renal dysfunction.
Genital herpes is a sexually transmitted disease
with an increased risk of transmission during
acute episodes. There are no data evaluating
whether famciclovir will prevent transmission of
infection to others. Patients should be advised to
avoid intercourse when lesions and/or symptoms
are present (even if treatment with an anti-viral
has been initiated) in order to avoid infecting
partners. Genital herpes can aslo be transmitted
in the absence of symptoms through
asymptomatic viral shedding.
Famciclovir 125mg, 250mg and 500mg tablets
contain lactose (26.9mg, 53.7mg and 107.4mg,
respectively). Patients with rare heredity
problems of galactose intolerance, a severe case
of lactase deficiency or glucose-galactose
malabsorption should not take famciclovir tablets.
Pregnancy & lactation: Although animal studies
have not shown any embryotoxic or teratogenic
effects with famciclovir or penciclovir, the safety
of famciclovir in human pregnancy has not been
established. Because animal reproducti tudies
are not always predictive of human response,
famciclovir should, therefore, not be used in
pregnancy unless the potential benefits are
considered to outweigh the potential risks
associated with treatment.
Following oral administration of famciclovir to
lactating rats, penciclovir is excreted in milk. It is
not known whether it (penciclovir) is excreted in
human milk, thus a decision should be made
whether to discontinue nursing or to discontinue
the drug, taking into account the importance of
the drug ,to the mother.
Adverse reactions: The following adverse events
have been reported during post-approval use of
famci�lovir (frequency has been estimated from
spontaneous and literature reports): Rare cases of
headache, nausea and confusion (including
'
delirium, disorientation, confusional state,
occuring predominantly in the elderly), and very
rare cases of rash, urticaria, pruritus, serious skin
reactions (e.g erythema multiforme, Steven
Johnson syndrome, toxic epidermal necrolysis ),
vomiting, dizziness, somnolence (predominantly
in the elderly), hallucinations and jaundice.
However, reporting rates determined on the basis
of spontaneously reported post-marketing adverse
events are generally presumed to underestimate
the risks associated with drug treatment.
Abnormal haematological and clinical chemistry
findings: In post-market experience,
thrombocytopenia has been reported very rarely.
Dosage & admin:
Herpes zoster infections: The recommended
dose is 500mg 3 times per day for 7 days.
Therapy should be initiated within 72 hours of
the onset of the rash.
Herpes simplex infections: lmmunocompetent
patients.
Recurrent genital herpes episodes: The
recommended dosage is 125mg twice a day for
5 days. Initiation of treatment is recommended
during the prodromal period or as soon as ·
possible after onset of lesions.
Suppression of recurrent genital herpes
episodes: The recommended dosage is 250mg
 I
twice daily for up to 1 year. The safety and
efficacy of famciclovir therapy beyond one
year of treatment has not been established.
•
HIV-infected patients: For recurrent episodes
I of mucocutaneous herpes simplex infection,
I
the recommended dosage is SOOmg twice a day
for 7 days.
Famciclovir tablets should be swallowd whole
and may be taken with or without food.
Missed dose: If a dose of famciclovir is missed,
it should be taken as soon as the patient
remembers. The next dose should be taken at
the normal time. The patient should carry on
as normal until they have finished all the
tablets.
Do not double-dose.
Use in children: Safety and efficacy in children
under the age of 18 years has not been
established.
Drug inter: No clinically significant drug
interactions have been observed in any study of
coadministration of any drugs with pamciclovir
therapy.
+ FAMVIR Tab. Novartis
Famciclovir 125mg & 250mg/tablet
125mg x lO's pack: 1310.00 MRP
250mg x 21's pack: 4263.00 MRP
VALACYCLOVI R26
VALACYCLOVIR HCl: Tablet
Valacyclovir hydrochloride is a nucleoside
analogue DNA polymerase inhibitor. It is
available as valacyclovir hydrochloride INN
equivalent to valacyclovir 500mg and 1gm tablet.
Mode of action: Valacyclovir hydrochloride after
oral administration rapidly converts to acyclovir
which has demonstrated antiviral activity against
HSV types 1 (HSV-1) and 2 (HSV-2) and VZV.
Viral enzyme converts acyclovir to acyclovir
triphosphate which inhibits viral DNA synthesis.
Ind: Adult patients: Cold sores (Herpes labialis),
Genital herpes, treatment in immunocompetent
patients (initial or recurrent episode), suppression
in immunocompetent or HIV-infecte.d patients,
reduction of transmission, herpes zoster.
Pediatric patients: Cold sores (Herpes labialis)
and Chickenpox.
C/I: Hypersensitivity to valacyclovir, acyclovir,
or any component of the formulation.
S/E: The most common adverse reactions
reported in adult patients (>10% ·patients) are
headache, nausea, and abdominal pain.
(> 10% of)
The only adverse reaction reported in
paediatric patients (<18 years of age) was
headache.
Precautions: Dosage reduction is recommended
when administering valacyclovir to.patients with
renal impairment. Similar caution should be
exercised when administering valacyclovir to
geriatric patients (over 65 years), and patients
receiving potentially nephrotoxic agents. The
safety and efficacy of vaiacyclovir have not been
established in immuno-compromised patients
other than for the suppression of genital herpes in
HIV-infected patients.
Pregnancy & lactation: Pregnancy category B.
Valacyclovir should be used during pregnancy
only if the potential benefit justifies the potential
QIMP-17 (299) ANTIMICROBIAL DRUGS
risk to the fetus. women of childbearing potential should be
Caution should be exercised when Valacyclovir is advised to use effective contraceptive during
administered to a lactating woman. treatment. Similarly, men should be advised to
Dosage & admin: Adult patients: practice barrier contraceptive during and for at
Cold sores: 2gms every 12 hours for 1 day. least 90 days following treatment with
Genital herpes: ganciclovir.
Initial episode- lgm twice daily for 10 days. Dosage & admin: Treatment of CMV infec­
Recurrent episodes- 500mg twice daily for 3 tion: Initial (induction) treatment: 5mg/kg
days. infused at a constant rate over 1 hour every 12
Suppressive therapy- immunocmpetent hours (lOmg/kg/day) for 14 to 21 days. Long­
patients, lgm once daily term (maintenance) treatment: For immuno­
Alternate doses in patients with =s 3? compromised patients at risk of relapse of
recurrences/year, 500mg once daily. CMV retinitis- a course of maintenance
HIV- infected patients, 500mg twice daily. therapy may be given. I.V infusion of 6mg/kg
Reduction of transmission, 500mg once daily. once daily, 5 days per week, or 5mg/kg once
Herpes zoster, lgm 3 times daily for 7 days. daily, 7 days per week is recommended.
Pediatric patients:
Prevention of CMV disease: Induction
Cold sores: �12 years of age, 2gms every 12 regimen: Smg/kg infused every 12 hours
hours for 1 day. . (lOmg/kg/day) for 7 to 14 days. Maintenance
Chickenpox: 2 to <18 years of age, 20mg/kg 3 regimen: l.V infusion of 6mg/kg once daily, 5
times daily for S days; not to exceed lgm 3 days per week, or Smg/kg once daily, 7 days
times daily. every 12 hours for 1 day. per week is recommended.
500mg ( lOml) vial x 1's pack: 4750.00 TP
Drug inter: No clinically significant drug-drug
or drug-food interactions with valacyclovir are
known.
2.2 Drugs for Human immuno­
+ ALACLOV Tab. ACI deficiency virus (HIV) I
Valacyclovir hydrochloride INN equivalent to
Antiretroviral drugs1,21
valacyclovir 500mg/tablet.
500mg x lO's pack: 401.50 MRP
The antiretroviral drugs available now-a-day, are
+ REVIRA Tab. Square
classified into three main categories-
Valacyclovir hydrochloride INN equivalent to
valacyclovir 500mg & 1gm/tablet. 1. Nucleoside & nucleotide reverse
500mg x lO's pack: 401.50 MRP transcriptase inhibitors:
1gm x 12's pack: 900.00 MRP a. Zidovdine
+ VALOVIR Tab. Incepta b. Didanosine
Valacyclovir hydrochloride INN equivalent to c. Zalcitabine
valacyclovir 500mg & 1 gm/tablet. d. Stavudine
500mg x lO's pack: 400.00 MRP e. Lamivudine
l gm x 8's pack: 600.00 MRP f. Abacavir
g. Adefovir
2. Nonnucleoside reverse transcriptase
Drugs for Cytomegalovirus inhibitors:
a. Nevirapine &
b. Delavirdine
+ CYMEVENE lnj. Roche/Radiant50
Ganciclovir sodium salt equivalent to 500mg c. Efavirenz
ganciclovir in IOml vial: i.v injection. 3. Protease inhibitors:
.. Mode of action: Ganciclovir is an antiviral drug. a. Indinavir
It works by blocking the action of a viral b. Nelfinavir
component called DNA polymerase. This c. Ritonavir
compound ·is required by the virus for it to copy d. Saquin�vir
genetic material ( from RNA to DNA), a process
that is needed for the virus to multiply & survive.
Ganciclovir is also incorporated into the viral
Nucleoside & nucleotide
reverse transcriptase
•
DNA. By blocking the action of DNA
polymerase & disrupting virul DNA, ganciclovir
prevents CMV from multiplying. inhibitors
Ind: I. Treatment of cytomegalovirus (CMV)
infections in immunocompromised individuals.
2. Prevention of cytomegalovirus (CMV) disease,
LAMIVUDINE47
in patients receiving immunosuppressive therapy
secondary to organ transplantation. The text of Lamivudine has been. discussed
.
below under the drugs of 'chronic hepatitis B'.
AIR: In patients ·who were being treated with
ganciclovir the most common haematological
side effects were neutropenia, anaemia and ZIDOVUDINE
thrombocytopenia.
.
Precautions: Ganciclovir i.v injection should not ZIDOVUDINE: Capsule
be administered if the absolute neutrophil count Zidovudine is a synthetic nucleoside analogue. It
is less than 500 cells/ml. Because of the muta­ is presented as 1OOmg capsule for oral adminis­
genic and teratogenic potential of ganciclovir, tration. But recently not available in our market.
•
ANTIMICROBIAL DRUGS
Nonnucleoside reverse
transcriptase inhibitors
EFAVIRENZ48
EFAVIRENZ: Tablet
Efavirenz is a synthetic anti-retroviral agent. It is
available as Efavirenz INN 600mg tablet.
Mode of action: Efavirenz is a non-nucleoside
reverse transcriptase inhibitor. Although efavirenz
is pharmacologically related to other non­
nucleoside reverse transcriptase inhibitors, it
differs structurally from this group of drugs and
other currently available anti-retroviral agents.
Ind: Efavirenz is indicated in combination with
other anti-retroviral agents for the treatment of
HIV-1 infection. This indication is based on
analysis of plasma HIV-RNA levels and CD4 cell
counts in controlled studies of up to 24 weeks in
duration. At present, there are no results from
controlled trials evaluating long-term
suppression of HIV-RNA with efavirenz.
C/I: Efavirenz is contraindicated in patients
with known hypersensitivity to the drug or any
ingredient in formulation.
S/E: CNS effects: CNS effects including dizzi­
ness, impaired concentration, abnormal dreams
and insomnia have been reported in about 52% of
adults receiving efavirenz 600mg once daily.
These CNS effects were described as mild (do
not interfere with daily activities) in 31.4%, mod­
erate (may interfere with daily activities) in
17.8% or severe (interrupt usual daily activities)
in 2.6% cases. Adverse CNS effects generally
begin during the frrst 1-2 days of efavirenz thera­
py, improve with continued therapy and usually
resolve after the frrst 1-2 days of efavirenz
therapy. These effects may be more tolerable if
the daily dose of efavirenz is administered at bed­
time, specially during the first 2-4 weeks of ther­
apy and in patients who continue to experience
such effects. Fatigue has been reported in up to
7% of adults receiving efavirenz Severe acute
depression, sometimes accompanied by suicidal
ideation/ attempts, has been reported rarely in
patients receiving efavirenz.
Adverse CNS effects reported in less than
2% of patients receiving efavirenz include- atax­
ia, confusion, impaired coordination, migraine
headache, neuralgia, paresthesia, peripheral
neuropathy, seizures, speech disorder, tremor, or
vertigo. In addition, aggravated depression,
agitation, amnesia, anxiety, apathy, emotional
liability, euphoria, hallucination, or psychosis
has occurred in less than 2% of efavirenz-treated
patients. Adverse CNS effects occurred in 9% of
children receiving efavirenz in clinical studies.
Dermatolgic and sensitivity reactions: Rash has
occurred in 27.3% of adults receiving efavirenz
in clinical studies. Pruritus or increased sweating
has been reported in 1-2% of patients receiving
efavirenz. Allergic reaction, alopecia, eczema,
folliculitis, skin exfoliation or urticaria has
occurred in lees than 2% of patients receiving
the drug.
GI effects: Nausea or diarrhoea has been reported
in up to 12% of adults receiving efavirenz.
Vomiting, dyspepsia, abdominal pain, or
QIMP-17 (300)
flatulence has occurred in some efavirenz-treated
adults. Dry mouth or taste change has been repor­
ted in up to 2o/o of patients receiving efavirenz.
Hepatic effects: Hepatitis occurred in less than
2% of patients receiving efavirenz.
Cardiovascular effects: Total serum cholesterol
level increases 10-20% in healthy individuals
receiving efavirenz. Hot flushes, flushing,
palpitations, tachycardia, or thrombophlebitis has
been reported in less than 2% of patients
receiving efavirenz.
Precautions & warning: Warnings: As high fat
foods may cause unwanted increase in drug
effect, avoid taking with high-fat foods and also
in an empty stomach.
Regular, periodic measurement of plasma HIV- I
RNA levels and CD4+ T-cell count is necessary
to determine the risk of disease progression and
to determine when to modify anti-retroviral agent
regimens. Patients should be advised that
efavirenz has not been shown to reduce the risk
of transmission of HIV to others via sexual
contact or blood contamination, and that is why
practices designed to prevent transmission of
HIV should be maintained during anti-retroviral
therapy.
Efavirenz should always be administered in
conjunction with other anti-retroviral agent and
should not be used alone in the treatment of HIV
infection. Although efavirenz used in combina­
tion with other anti-retroviral agents appears to
be well tolerated, patients should be monitored
closely for adverse effects during combination
therapy. The usual precautions and contraindica­
tions of the other anti-retroviral agents in the reg­
imen should be considered during combination
therapy; efavirenz should not be added as sole
agent to a failing regimen. Whenever a change in
anti-retroviral therapy is considered because of
therapeutic failure, at least 2 components of the
previous regimen should be changed since
adding a single new agent may predispose to the
development of viral resistance. Use of an
entirely new regimen containing at least 3 drugs
is preferred. The effect of efavirenz therapy on
subsequent therapy with other non-nucleoside
reverse transcriptase inhibitors remains to be
determined. As cross-resistance occurs among
non-nucleoside reverse transcriptase inhibitors,
most clinicians suggest that individuals who
experience disease progression while receiving
one of the agents (e.g delavirdine, efavirenz,
nevirapine) should not be switched to another
agent in the class. Patients taking efavirenz
should not involve in any hazardous activities
requiring mental alertness or physical coordina­
tion such as operating machinery or driving a
motor vehicle. Patients should be advised to
contact their clinician if they experience
delusions, inappropriate behavior, or acute
depression while receiving efavirenz;
discontinuance of efavirenz may be necessary in
patients who experience such CNS effects.
Efavirenz is metabolized in the liver, so the drug
should be used with caution in patients with
hepatic impairment. Serum hepatic enzyme
concentrations should be monitored during
efavirenz therapy in patients who have, or may
have, hepatitis Band/or C virus infection, in
patients receiving concomitant ritonavir and in
patients receiving concomitant therapy with
hepatotoxic drugs. In· patients with serum hepatic
enzyme concentrations more than 5 times the
upper limit of normal, the benefits of continued
efavirenz therapy versus the risks of
hepatotoxicity should be considered. As increases
in serum cholesterol concentration have occurred
in individuals receiving efavirenz, cholesterol
monitoring should be considered in patients
receiving the drug.
Precautions: Efavirenz may cause drowsiness or
dizziness. Al�ohol may intensify this effect.
Pediatric precautions: Safety and efficacy of
efavirenz in neonates and children younger than
3 years of age or who weigh less than l 3kg have
not been evaluated. Adverse effects reported in
children receiving efavirenz are similar to those
reported in adults including CNS, GI and
dennatologic effects. But, in children rashes and
dermatologic reactions have been reported more
frequently than adults. Antihistamines may be
used for the prevention of rash when initiating
efavirenz therapy in children.
Pregnancy & lactation: Should not use in
pregnant, planning to become pregnant or breast­
feeding women.
Dosage & admin: Adults: The recommended
dosage of efavirenz is 600mg orally, once daily,
in combination with a protease inhibitor
and/or nucleoside analogue reverse
transcriptase inhibitors (NRTls ). Efavirenz
may be taken with or without food; however, a
high fat meal may increase the absorption of
efavirenz and should be avoided.
In order to improve the tolerability of nervous
system side effects, bedtime dosing is
recommended during the first 2 to 4 weeks of
therapy and in patients who continue to
experience these symptoms.
Pediatric patients: The pediatric patients
include 3 years of age or older and weighing
between 10 and 40kg. The recommended
dosage of efavirenz is given orally, once daily
at a rate- body weight 10 to< 15kg, 200mg; 15
to < 20kg, 250mg; 20 to< 25kg, 300mg; 25 to
< 32.5kg, 350mg; 32.5 to< 40kg, 400mg. The
recommended dosage for pediatric patients
weighing greater than 40kg is 600mg (as
adult), once daily.
Drug inter: Please see the manufacturer's
literature.
Note: For further information please consult
manufacturer's literature.
t AVIFANZ Tab. Beximco
Efavirenz INN 600mg/tablet
I O's pack: 2000.00 IP
Protease Inhibitors
NELFINAVIR48
NELFINAVIR: Tablet
Nelfinavir is a human immunodeficiency virus
(HIV) protease inhibitor. It is available as
Nelfinavir mesylate 250mg film-coated tablet.
Ind: Indicated for the treatment of HIV infection
when antiretroviral therapy is warranted.
C/I: Nelfmavir is contraindicated in patients with
 \
clinically significant hypersensitivity to any of its
components. Co-administration of nelfinavir is
contraindicated with drugs that are highly
dependent on CYP3A for clearnace and for
which elevated plasma concentrations are
associated with serious and/or life-threatening
adverse events.
S/E: The majority of adverse events found with
nelfinavir therapy either alone or in combination
with nucleoside analogues were mild in intensity.
The most fequently reported adverse event was
diarrhoea, of mild to moderate intensity.
Adverse events occurring in less than 2% of
patients receiving nelfinavir treatment and of at
least moderate severity are listed as below.
Body as a whole: abdominal pain, accidental
injury, allergic reaction, asthenia, back pain,
fever, headache, malaise, pain and redistribu­
tion/accumulation of body fat.
Digestive system: Anorexia, dyspepsia, epigas­
tric pain, gastrointestinal bleeding, hepatitis,
mouth ulceration, pancreatitis and vomiting.
Hemic/lympathic system: Anemia, leukopenia
and thrombocytopenia.
Metabolic/nutritional: Increase in alkaline
phosphatase, amylase, creatine phosphokinase,
lactic dehydrogenase, SGOT, SGPT and gamma
glutamyl transpeptidase, hyperlipemia,
hyperuricemia, hyperglycemia, hypoglycemia,
dehydration and abnormal liver function tests .
Musculoskeletal system: Arthralgia, arthritis,
cramps, myalgia, myasthenia and myopathy.
Nervous system: Anxiety, depression, dizziness,
emotional liability, hyperkinesia, insomnia,
migraine, paresthesia, seizures, sleep disorder,
somnolence and suicide ideation.
Respiratory system: Dyspnea, pharyngitis,
rhinitis and sinusitis.
Special senses: Acute iritis and eye disorder.
Urogenital system: Kidney calculus, sexual
dysfunction and urine abnormality.
Skin/appendages: Dermatitis, folliculitis, fungal
dermatitis, maculopapular rash, pruritus,
sweating, and urticaria.
• Warnings: Nelfinavir should not be administered
concurrently with terfenadine, astemizole,
cisapride, triazolam, midazolam, ergot
derivatives, amiodarone or quinidine because
nelfmavir may affect the hepatic metabolism of
these drugs and create potential for serious and/or
life-threatening adverse events.
New onset diabetes mellitus, exacerbation of pre­
existing diabetes mellitus and hyperglycemia
have been reported in HIV-infected patients
receiving protease inhibitor therapy. Some
patients required either initiation or dose
adjustments of insulin or oral hypoglycemic
•
agents for treatment of these events. In some
cases diabetic ketoacidosis has occurred. In those
patients who discontinued protease inhibitor
therapy, hyperglycemia persisted in some cases.
Precautions: General: Nelfinavir is principally
metabolized by the liver, therefore, caution
should be exercised when administering this drug
to patients with hepatic impairment.
Hemophilia: There have been reports of
increased bleeding, including spontaneous skin
hematomas and hemarthrosis in patients with
hemophilia type A and B treated with protease
imhibitors. In some patients, additional factor
QIMP-17 (301)
VIII has to be given. In more than half of the
reported cases, treatment with protease inhibitors
was continued or reintroduced. A causal
relationship has not been established.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women.
HIV-infected women are advised not to breast­
feed to avoid postnatal transmission of HIV to
the newborn and infants who may not yet been
infected. Studies in lactating rats have
demonstrated that nelfmavir is excreted in milk,
but it is yet not known whether nelfinavir is
excreted in human milk.
Dosage & admin: Adults: The recommended
dose is 1250mg (250mg x 5 tabs.) twice daily
or 750mg (250mg x 3 tabs.) three times daily.
Nelfinavir should be taken with a meal.
Antiviral activity is enhanced when nelfinavir
is administered in combination with nucleo­
side analogues (e.g lamivudine). Therefore, it
is recommended that nelfinavir be used in
combination with nucleoside analogues.
Children (2-13 years): The recommended oral
dose is 20-30mg/kg per dose, 3 times daily with
a meal.
Pediatric use: The safety, effectiveness and
pharmacokinetics of nelfinavir have not been
evaluated yet in pediatric patients below the
age 2 years.
Drug inter: Please see the manufacturer's
literature.
Note: For further information please consult
manufacturer's literature.
t AVIFIX Tab. Beximco
Nelfinavir mesylate 250mg/tablet (film-coated).
I O's pack: 450.00 IP
Combined Preparations
LAMIVUDINE + ZIDOVUDINE48
LAMIVUDINE + ZIDOVUDINE: Tablet
This combined preparation contains lamivudine
INN l 50mg and zidovudine USP 300mg/tablet.
Mode of action: Please see under the text of
lamivudine & zidovudine given separately.
Ind: This is indicated for the treatment of HIV
infection, where combined preparation is thought
necessary.
C/I; S/E; Precautions: Please see under the text
of lamivudine & zidovudine given separately.
Dosage & admin: The recommended oral dose
of lamivudine and zidovudine combined prepa­
ration is as follows: For adults and adolescents
of age 12 years and above- 1 tablet (lamivu­
dine 150mg + zidovudine 300mg) twice daily.
Dose adjustment: As this is a fixed-dose
combination, it should not be prescribed for
patients requiring dosage adjustment such as
those with reduced renal function (creatinine
clearance< 50ml/min), those with low body­
weight (50kg or 110 lb), or those experiencing
dose-limiting adverse events.
This is also not recommended for patients with
impaired hepatic function.
Overdose: There is no experience of overdosage
with lamivudine and zidovudine combination.
However, there are limited data available on the
ANTIMICROBIAL DRUGS
consequences of ingestion of acute overdoses of
lamivudine and zidovudine in humans. No
fatalities occurred, and all patients recovered. No
special signs or symptoms have been identified
following such overdosage.
t DIAVIX Tab. Beximco
Lamivudine INN l 50mg and zidovudine USP
300mg/tablet.
IO's pack: 450.00 IP
LAMIVUDINE + ZIDOVUDINE +
NEVIRAPINE48
t TRIOVIX Tab. Beximco
Triovix is a combined preparation, containing
Lamivudine INN l 50mg, Zidovudine USP
300mg & Nevirapine INN 200mg/tablet.
Ind & use: This is a fixed dose combination of
lamivudine, zidovudine and nevirapine,
recommended for human immunodeficiency
virus (HIV- I) infected patients who are able to
tolerate standard doses of lamivudine, zidovudine
and nevirapine separately for at least 2 weeks
prior to switching over to this fixed dose
combination. Patients should have demonstrated
adequate tolerability to nevirapine i.e who are
able to tolerate maintenance therapy with
nevirapine 200mg twice daily.
This three-drug combined preparation is
administered twice daily and each tablet contains
half of the daily dose for each component. Twice
daily formulation in single tablet for three drugs
is convenient for patients to take and also ensures
higher rate of compliance.
C/I: Please see above under the text of
lamivudine & zidovudine. For nevirapine- history
of hypersensitivity; not to be used as initial
therapy, because initial therapy requires 200mg
once daily, whereas fixed dose combination
allows for 200mg twice daily.
S/E: Please see above under the text of lamivu­
dine & zidovudine. For nevirapine: more ferquent
incidence- skin rash, diarrhea, gastrointestinal
problems, headache, nausea, stomach pain; less
frequent incidence- aphthous stomatitis, fever,
hepatitis, Stevens- Johnson syndrome.
Warnings & precautions: For the following
conditions, assess risk to the patient and take
action as needed- chronic hepatitis B,
hepatomegaly with steatosis, lactic acidosis, liver
function impairment, severe renal function
impairment, peripheral neuropathy.
•
Dosage & admin: For treatment of HIV infec-
tion: Adult dosage- 1 tablet twice daily.
This fixed dose combination is not recom­
mended for patients who have not been on
initial lower dose of nevirapine 200mg once
daily for 2 weeks and/or have not tolerated
this dose. After successful therapy with low
dose nevirapine for two weeks, patients can be
switched over to 200mg b.i.d dose provided
they have not demonstrated any hypersensitiv­
ity reaction (rash, abnormal liver function
tests) during their initial exposure to nevirap­
ine. Monitoring of patients for their liver
function tests etc is desirable prior to initiating
therapy with nevirapine and monitoring at
frequent intervals once therapy with fixed
dose combination is continued.

ANTIMICROBIAL DRUGS
Dosage adjustment: As this is a fixed-dose
combination, it should not be prescribed for
patients requiring dosage adjustment such as
those with reduced renal function (creatinine
clearance < 50ml/min), those with low body­
weight (SOkg or 110 lb), or those experiencing
dose-limiting adverse events.
This is also not recommended for patients with
impaired hepatic function.
lO's pack: 700.00 IP
2.3.1 Drugs for Chronic Viral
Hepatitis B
LAMIVUDINE42,47
LAMIVUDINE: Tablet/Syrup
Lamivudine is a synthetic nucleoside analogue. It
is available as 150mg film-coated tablet &
1Omg/ml syrup in 1OOml bottle.
Mode of action: Intracellularly, lamivudine is
phosphorylated to its active 5' -triphosphate
metabolite, lamivudine triphosphate (L-TP). The
principal mode of action of L-TP is inhibition of
RT (HIV-1 reverse transcriptase) via DNA chain
termination after incorporation of the nucleoside
analogue. L-TP is a weak inhibitor of mammalian
DNA polymerases.
Ind: 1. Lamivudine is used to treat patients 16
years of age or over with long term (chronic)
hepatitis B. It reduces the amount of hepatitis B
virus in the body and thus prevents liver damage
and improves liver function.
2. Lamivudine is also used in combination
therapy with Zidovudine in the management of
HIV-infection & AIDS.
C/I: It must not be taken if any hypersensitivity
to the active substance lamivudine or to any
ingedients found in the preparation.
S/E: The most commonly reported undesirable
effects are- tiredness, respiratory tract infections,
throat discomfort, headache, stomach discomfort
and pain, nausea, vomiting and diarrhoea. These
are generally mild in severity.
Some patients may be allergic to the medicine,
and if there is any of the following symptoms
soon after taking the drug, stop further taking and
tell the physician immediately-
- sudden wheeziness and chest pain or
tightening.
- swelling of eyelids, face or lips.
•
- skin rash or 'hives' any where on the body.
Precautions: Please see the manufactu-rer's
literature.
Dosage & Admin: Treatment of chronic
hepatitis-B: The recommended dose of
Iamivudine is lOOmg once a day. The-tablet
should be swallowed whole with water and can
be taken with or without food. Doses can be
adjusted by the physician if there is any renal
impairment. The duration of treatment will be
decided by the physician depending on the
clinical condition of the patient.
If the patient forgets to take the schedule dose
in time, take it as soon as remembered & then
continue to take it as instructed .
•
Treatment of HIV-infection & AIDS:
Lamivudine is also used in the management of
QIMP-17 (302)
HI V-infection & AIDS in combination therapy
with Zidovudine. Lamivudine is given 150mg
twice daily in combination with Zidovudine
600mg daily in 2 or 3 divided doses.
Drug inter: Trimethoprim (TMP} 160mg/
sulfamethoxazole (SMX) 800mg once daily has
been shown to increase lamivudine exposure
(AUC). The effect of higher doses of TMP/SMX
on lamivudine pharmacokinetics has not been
studied. Lamivudine and zalcitabine may inhibit
the intracellular phosphorylation of one another.
Therefore, use of this combination in combination
with zalcitabine is not recommended.
+ AVILAM Tab. Beximco
Lamivudine INN 150mg/tablet (f.c).
1O's pack: 250.00 IP
t HEPAVIR Tab. Square
Lamivudine INN lOOmg/tablet (f.c).
20's pack: 502.00 MRP
t LAMIDI N Tab. SK+F
Lamivudine INN 150mg/tablet (f.c).
lO's pack: 253.00 MRP
+ LAMIVIR Tab. Incepta
Lamivudine INN 150mg/tablet (f.c).
20's pack: 500.00 MRP
ADEFOVIR DIPIVOXI L2 6
ADEFOVI R DIPI VOXIL: Tablet
Adefovir is an acyclic nucleotide analog of
adenosine monophosphate. It is available as
adefovir dipivoxil INN 1Omg/tablet.
Mode of action: Adefovir is phosphorylated to
its active metabolite, adefovir diphosphate, by
cellular kinases. Adefovir diphosphate inhibits·
HBV DNA polymerase(reverse transcriptase) by
competing with the natural substrate deoxyadeno­
sine triphosphate and by causing DNA chain ter­
mination after its incorporation into viral DNA.
Ind: Adefovir is indicated for the treatment of
chronic hepatitis B in adults with evidence of
active viral replication and either evidence of
persistent elevations in serum aminotransferases
(ALT or AST) or histologically active disease.
C/I: Known hypersensitivity to any of the
components of the product.
S/E: Treatment related clinical adverse events
that occurrd in 3% or greater number of patients
are asthenia, headache, abdominal pain, nausea,
•
flatulence, diarrhea, dyspepsia ..
Precautions: Severe acute exacerbation of hepa­
titis has been reported in patients who have dis-.
continued anti-hepatitis B therapy, including ther­
apy with adefovir dipivoxil. Patients who discon­
tinue adefovir dipivoxil should be monitored at
rei)eated intervals over a period of time for
hepatic function. If appropriate, res11mption of
anti-hepatitis B therapy may be warranted.
Chronic administration of adefovir dipivoxil
(1Omg once daily) may result in nephrotoxicity.
The overall risk of nephrotoxicity in patients with
adequate renal function is low. However, this is
of special importance in patients at risk of or
having underlying renal dysfunction and patients
taking concomitant nephrotoxic agents such as
cyclosporine, tacrolimus, aminoglycosides,
vancomycin and NSAIDs.
Elderly patients: In general, caution should be
exercised when prescribing elderly patients since
\
they have greater frequency of decreased renal or
cardiac function due to concomitant disease or
other durg therapy.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women.
Therefore, adefovir dipivoxil should be used '-
during pregnancy only if clearly needed and after
careful consideration of the risks and benefits.
It is not known whether adefovir is excreted in
human milk. Mothers should be instructed not to
breast feed if they are taking adefovir dipivoxil.
Dosage & admin: The recommeded dose of
.
adef ovir in chronic hepatitis B patients is
lOmg once daily, taken orally, without regard
to food.
Dose adjustment in renal impairment:
Significantly increased drug exposures are
seen when adefovir dipivoxil is administered to
patients with renal impairment. Therefore,
the dosing interval of adefovir dipivoxil should
be adjusted in patients with baseline creatinine
clearance <SOml/min using the following
suggested guidelines:
- if creatinine clearance is ?50ml/min, the dose
of adefovir dipivoxil should be adjusted as
lOmg in every 24 hours.
- if creatinine clearance is 20-49ml/min, the
dose of adefovir dipivoxil should be adjusted
as lOmg in every 48 hours.
- if creatinine clearance is 10- 19ml/min, the
dose of adefovir dipivoxil should be adjusted
as lOmg in every 72 hours.
- if the patient is under haemodialysis, the
dose of adefovir dipivoxil should be adjusted
as lOmg in every 7 days following dialysis.
Pediatric use: Safety and effectiveness in
pediatric patients have not been established.
Drug inter: When adefovir dipivoxil is
co-administered with lamivudine, trimethoprim/
sulfamethoxazole and acetaminophen, the
pharmacokinetics of adefovir remain unchanged
and vice-versa.
When adefovir dipivoxil is co-administered with
ibuprofen (800mg 3 times daily), there is no
change in pharmacokinetics of ibuprofen but,
there is increase in adefovir Cmax (33%), AUC
(23%) and urinary recovery are observed.
+ ADFOVIR Tab. Sun Pharma
Adefovir dipivoxil INN I Omg/tablet.
lO's pack: 251.00 MRP
t ADOVIR Tab. Renata
Adefovir dipivoxil INN 1Omg/tablet.
30's pack: 300.00 MRP
t A NT IVA Tab.- Square
Adefovir dipivoxil INN I Omg/tablet.
lO's pack: 351.40 MRP
t INFOVI R Tab. Incepta
•
Adefovir dipivoxil INN 1Omg/tablet.
20's pack: 700.00 MRP
ENTECAVIR26,52
E NTECAVI R : Tablet/Syrup.
Entecavir is a guanosine nucl�oside analogue
with selective activity against hepatitis B virus
(HBV) polymerase. It is available as entecavir
INN 0.5mg & lnig tablet & as syrup.
Mode of action: Entecavir functionally inhibits
all activities of the hepatitis B virus (HBV) poly-

merase (reverse transcriptase).
Entecavir is effectively phosphorylated to the
active triphosphate form and competes with the
natural substrate deoxyguanosine triphosphate
which functionally inhibits reverse transcription
actions of HBV polymerase; including base
priming, reverse transcription of the negative
strand from the pregenomic messenger RNA and
synthesis of the positive strand of HBV DNA.
Entecavir produces only weak inhibition of
normal cellular DNA polymerases and
mitochondrial DNA polymerase.
Ind: Entecavir is indicated for the treatment of
chronic hepatitis B virus infection in adults with
evidence of active viral replication and either
evidence of persistent elevation in serum
aminotransferases (ALT or AST) or histologically
active disease.
C/I: Entecavir is contraindicated in patients with
previously demonstrated hypersensitivity to
entecavir or any component of the product.
S/E: The most common adverse events are
headache, fatigue, dizziness and nausea.
Precautions: Lactic acidosis: Lactic acidosis and
severe hepatomegaly with steatosis, including
fatal cases have been reported with the use of
nucleoside analogues alone or in combination
with antiretrovirals.
Exacerbations of hepatitis after discontinuation
of treatment: Severe acute exacerbations of
hepatitis B have been reported in patients who
have discontinued anti-hepatitis B therapy,
including entecavir.
Pregnancy & lactation: There are no data on the
effect of entecavir on transmission of HBV from
. .
mother to infant. Therefore, appropriate care sho-
uld be taken. It is not known whether it is excre­
ted in human milk. Mothers should be inst-ructed
not to breast feed if they are taking entecavir.
Doslge & admin: The recommended dose of
entecavir for chronic hepatitis B virus
infection in nucleoside-treatment-naive adults
and adolescents 16 years of age is 0.5mg once
daily. Entecavir should be administered.on an
empty stomach (at least 2 hours before or 2
hours after a meal).
-
' infection or chronic hepatitis B virus infection
Children: Below the age of 16 years not
recommended.
Dose adjustment in renal impairment: Dose
adjustment is recommended for patients with
creatinin e clearance <50ml/min, including pat­
I ients on hemodialysis or continuous ambulato­
ry peritoneal dialysis (CAPD) is as following:
Creatinine clearance 30 to < 50ml/min, the
dose is O.Smg every 48 hours;
Creatinine clearance 10 to < 30ml/min, the
dose is O.Smg every 72 hours;
Creatinine clearance < 1Oml/min, or
hemodialysis or CAPD patient, the dose is
O.Smg every 7 days.
Missed dose: If it is almost time for next dose,
skip the missed dose and take the next dose at
the proper time. Nobody should take a double
dose to make up for the missed dose.
Drug Inter: Coadministration of entecavir with
lamivudine or adefovir dipivoxil did not result in
significant drug interactions. The effects of coad­
ministration of entecavir with other drugs that are
renally eliminated or are known to affect renal
function have not been evaluated.
I
QIMP-17 (303)
+ BARCAVIR Tab. Incepta
Entecavir INN O.Smg/tablet.
0.Smg x IO's pack: 6SO.OO MRP
+ CAVIR Tab. Square
Entecavir INN O.Smg & !mg/tablet.
0.5mg x S's pack: 240.00 MRP
lmg x S's pack: 4SO.OO MRP
+ ENTA VIR Tab. Drug Inter.
Entecavir INN 0.5mg & !mg/tablet.
O.Smg x IO's pack: 450.00 MRP
l mg x !O's pack: 900.00 MRP
+ EN VIRAL Tab. Opsonin
Entecavir INN 0.5mg & !mg/tablet.
0.5mg x IO's pack: 423.84 MRP
l mg x IO's pack: 794.72 MRP
+ TECAVIR Tab. Aristopharma
Entecavir INN 0.5mg & !mg/tablet.
O.Smg x IO's pack: 480.00 MRP
l m g x IO's pack: 900.00 MRP
+ TE VIRAL Tab. ACI
Entecavir INN 0.5mg & !mg/tablet.
0.5mg x IO's pack: 481.80 MRP
l mg x !O's pack: 900.00 MRP
+ VIR Tab. Acme
Entecavir INN O.Smg/tablet.
0.5mg x 1 O's pack: 480.00 MRP
+ VIRENTA Tab. SK+F
Entecavir INN 0.5mg/tablet.
0.5mg x IO's pack: 480.00 MRP
TELBIVUDINE54
+ SEBIVO Tab. Novartis
Telbivudine 600mg/tablet (film-coated).
Ind: Treatment of chronic hepatitis B in adults
with evidence of viral replication and active liver
inflammation.
C/I: Hypersensitivity to telbivudine or to any of
the excipients.
•.
S/E: Common side-effects are- dizziness,
headache, blood amylase increased, diarrhoea,
lipase increased, nausea, alanine
aminotransferase increased, rash, blood creatine
phosphokinase increased, fatigue. Rare side­
effects are- aspartate aminotransferase increased,
myopathy, arthralgia, myalgia, malaise.
Precautions & warnings: Risk of post-treatment
severe acute exacerbation of hepatitis B. Hepatic
function must be monitored for at least several
months after treatment discontinuation. Risks of
lactic acidosis and hepatomegaly with steatosis.
Risk of myopathy. Treatment discontinuation if
myopathy is diagnosed. Caution with co-adminis­
tration of agents associated with myopathy.
Caution in patients with impaired renal function,
and with drugs that affect renal function. Limited
data available in elderly patients. Use in children
under 16 years not recommended.
Pregnancy & lactation: Use during pregnancy
only if clearly necessary. Avoid breast-feeding.
Dosage: The recommended dose is 600mg
daily. Dose must be reduced in patients with
renal impairment.
Drug inter: Caution with concomitant use of
drugs affecting renal function.
Note: Before prescribing, please read full
prescribing information.
600mg x 28's pack: 7308.00 MRP
ANTIMICROBIAL DRUGS
TENOFOVIR26, 129
TENOFOVIR DISOPROXII. FUMARATE:
Tablet
Tenofovir disoproxil fuinarate is an acyclic
nucleotide analog of adenosine monophosphate.
It is a prodrug of tenofovir. The product is avail­
able as- tenofovir disoproxil fumarate INN
·24Smg & 300mg in film-coated tablet.
Mode of action: Tenofovir disoproxil fumarate,
which is an acyclic nucleotide analog of adeno­
sine monophosphate, shows its activity against
HBV polymerase and HIV reverse transcriptase
after phosphorylation to the active diphosphate
form. Tenofovir diphosphate inhibits viral poly­
merase (reverse transcriptase) by directly com­
peting with the natural substrate deoxyribonu­
cleotide and by causing DNA chain termination
after its incorporation into viral DNA.
Ind: Tenofovir is indicated for the treatment of-
1. Chronic hepatitis B virus infection in adults;
2. HIV-I infected adults in combination with
other anti-retroviral agents.
C/I: Known hypersensitivity to tenofovir or any
component of the product.
S/E: The most common side effects are nausea,
vomiting, diarrhoea and flatulence.
Precautions: Tenofovir should not be
administered concurrently with emtricitabine &
tenofovir combination or adefovir dipivoxil.
Though the risk of occurrence of lactic acidosis
is low for tenofovir, treatment should be
suspended in any patient who develops lactic
•
acidosis or hepatotoxicity.
Discontinuation of tenofovir therapy may be
associated with severe acute exacerbation of
hepatitis.
Pregnancy & lactation: No clinical data are
available for pregnant women or breast-feed
mothers being treated with tenofovir. It should be
used during pregnancy only if clearly needed,
and mothers should be instructed not to breast
feed if they are taking tenofovir.
Dosage & admin: Dosage in adults: The
recommended dose of 'tenofovir' i.n HIV-1
in adults 18 years of age and older with
adequate renal function is 245mg or 300mg
once daily orally without regard to food. In
the treatment of chronic hepatitis B, the
optimal duration of treatment is unknown.
Dose interval adjustment in renal impairment:
Tenof ovir is eliminated by renal excretion, so
the exposure to tenofovir increases in patients
with renal dysfunction. Dosing interval should
be adjusted in all patients with creatinine
clearance <50ml/min, as detailed below-
Creatinine clearance- >50ml/min
-
- recommended 300mg dosing interval
every 24 hours;
Creatinine clearance- 30-49ml/min
- recommended 300mg dosing interval •
every 48 hours;
Creatinine clearance- 10-29ml/min
- recommended 300mg dosing interval
every 72-96 hours;
In cases of hemodialysis patients
- recommended 300mg dosing interval is
every 7 days or after a total of approxi­
mately 12 hours of dialysis.
ANTIMICROBIAL DRUGS
Dose adjustment in hepatic impairment: No
dose adjustment is required in patients with
hepatic impairment.
Geriatric patients: No sufficient clinical data
are available for elderly patients aged 65 years
and over. So, care should be taken in dose
selection.
Recommeded dosage in pediatric patients:
Children: Safety and effectiveness of tenofovir
in patients under the age of 18 years have not
been establ.ished. However, for the treatment
of HIV- 1 in pediatric patients 12 years of age
and older with body weight greater than or
equal to 35kg, the dose is one 245mg tablet
once daily taken orally, without regard to
food.
Drug inter: Co-administration of tenofovir with
anti-retroviral, entecavir, lamivudine, methadone,
oral contraceptives, ribavirin and tacrolimus did
not result in significant drug interactions. The
effects of co-administration of tenofovir with
other drugs that are renally eliminated or are
known to affect renal function have not been
evaluated.
t FOVIRAL Tab. ACI
Tenofovir disoproxil fumarate INN 300mg/tablet
(film-coated)
300mg x 8's pack: 680.00 MRP
t PROXIVIR Tab. Square
Tenofovir disoproxil fumarate INN 300mg/tablet
(film-coated)
300mg x 12's pack: 1020.00 MRP
t TAFOVIR Tab. Popular
Tenofovir disoproxil fumarate INN 300mg/tablet
(film-coated)
300mg x 12's pack: 1020.00 MRP
t T E NVIRA Tab. Aristopharma
Tenofovir disoproxil fumarate INN 300mg/tablet
(film-coated)
300mg x 1O's pack: 850.00 MRP
t T-FOVIR Tab. Drug Inter.
Tenofovir disoproxil fumarate INN 300mg/tablet
(film-coated)
300mg x 7's pack: 595.00 MRP
t VIRONIL Tab. UniMed & UniHealth
Tenofovir disoproxil INN equivalent to tenofovir
disoproxil 245mg/tablet (film-coated)
245mg x 1O's pack: 950.00 MRP
+ XYNOVIR Tab. Incepta
Tenofovir disoproxil fumarate INN 300mg/tablet
(film-coated)
300mg x 12's pack: 1020.00 MRP
2.3.2 Drugs for Chronic Viral
Hepatitis C
PEGINTERFERON ALFA-2a/2b21,26,50
PEGINTERFERON ALFA-2a/2b: Injection
Peginterferon alfa, a pegylated interferon alfa-
2a/2b with increase in mean molecular weight of
approximately 60,000 daltons.
Peginterferon alfa-2a is available as 135mcg/ml
vial & l 80mcg/ml vial for subcutaneous injection.
Peginterferon alfa-2b is available as 50mcg/vial,
80mcg/vial, 1 OOmcg/vial, l 20mcg/vial and
l 50mcg/vial for subcutaneous injection.
QIMP-17 (304)
Description & mode of action: Peginterferon
alfa (2a/2b) is a derivative of natural interferon
alfa. Pegylation (polyethylene glycol­
conjugation) increases the mean molecular
weight and thus persistence of the interferon in
the blood. The molecular weight of the PEG
fraction of peginterferon is about 40,000 daltons,
which has a direct effect on the clinical
pharmacology because the size and branching of
the PEG component determines the absorption,
distribution and elimination characteristics of
peginterferon. Peginterferons bind to specific
interferon alfa-receptors on the cell surface,
initiating complex intracellular signal
transduction and inducing activation of gene
transcription. This influences various biological
processes, such as inhibition of viral replication
in infected cells, inhibition of cell proliferation
and immunomodulation. Like non-PEG
conjugated alfa-interferon, peginterferon displays
antiviral and antiproliferative activity in vitro.
Ind: Peginterferon alfa-2a/2b are indicated for
the treatment of chronic hepatitis C, and chronic
hepatitis B, usually in combination with ribavirin
if available and indicated or as monotherapy if
ribavirin is not available or not tolerated.
C/I: Hypersensitivity to alfa-interferons or any of
its ingredients; autoimmune chronic hepatitis,
cirrhotic patients; existing or previous severe
psychiatric disorders, organ transplantation (other
than liver).
S/E: The frequency and severity of reported
undesirable effects in patients treated with
peginterferon alfa are similar to those observed
during treatment with interferon alfa (see product
literature). In clinical trial treatment with
peginterferon alfa was associated with clinically
significant changes in thyroid function tests that
necessitated clinical intervention.
Precautions: Treatment should be started only
by physicians experienced in the treatment of
hepatitis C (in non cirrhotic patients or cirrhotic
patients with compensated liver diseases).
Pregnancy & lactation: Safe use in human
pregnancy has not yet been established, therefore
alfa-interferon should be used during pregnancy
only if the potential benefit justifies the potential
risk to the fetus. It is not known whether alfa­
interferon is excreted in breast milk. Because
many drugs are excreted in human milk, caution
should be exercised if peginterferon alfa (2a/2b)
is administered to a nursing woman.
Dosage & admin: The recommended duration
of treatment: Patients infected with hepatitis
C virus (genotype 2 and/or 3) previously
untreated with interferon, should be treated
with interferon or peginterferon alfa and
ribavirin for 24 weeks.
Patients infected with hepatitis C virus
(genotype 1 and/or 4) previously untreated
with interferon, should be treated with
interferon or peginterferon alfa and ribavirin
for 12 to 48 weeks. After 12 weeks (or 24
weeks) of treatment virologic response should
be assessed, and if the viral load has been
reduced to less than 1°/o of the load at the start
of treatment, the combination should be
continued for a total of 48 weeks; but, if the
viral load exceeds 1 °/o of the load at the start
of treatment, therapy should be discontinued.
There are no safety and efficacy data on
treatment for longer than 48 weeks in the
previously untreated patient population.
In patients who relapse following interferon
therapy, the recommended duration of
•
treatment is 24 weeks. There are no safety and
efficacy data on treatment for longer than 24
'
weeks in the relapse patient populations.
Dosage schedule of Peginterferon + Ribavirin:
Ribavirin: Chronic hepatitis C (genotypes 1 &
4): Adult, body weight < 75kg, ribavirin daily
400mg in the morning and 600mg in the
evening; body weight ? 75kg, ribavirin daily
600mg in the morning and 600mg in the
evening.
•
Chronic hepatitis C (genotypes 2 & 3): Adult
(of any body weight), ribavirin daily 400mg in
the morning and 400mg in the evening.
Peginterferon alfa 2a/2b: Chronic hepatitis C
(genotypes 1, 2, 3 & 4): Adult (of any body
weight), 180mcg once weekly subcutaneously.
Duration: 48 weeks in cases of genotype 1 & 4;
24 weeks in cases of genotype 2 & 3.
Ribavirin may be administered without regard
to food, but should be administered in a
consistent manner. Drink plenty of water
while being treated with this medication;
drinking water will decrease the risk of serious
side effects.
Missed dose: If any dose is missed, it should
be taken as soon as remembered. If it is near
the time of the next dose, skip the missed dose
and resume usual dose schedule. Do not
double the dose to catch up.
•
Patients under 18 years: The safety and
efficacy of peginterferon alfa has not yet been
established in these patients.
Patients with renal impairment: No special
dose adjustment is required in patients with
renal dysfunction. Peginterferon alfa has not
been studied in patients requiring
haemodialysis.
Patients with hepatic impairment: No special
dosage modification is required in patients
with Child's Class A cirrhosis. Peginterferon
alfa has not been studied in patients with
decompensated liver disease.
Storage: Store the product away from light in the
sealed original package at a temperature of 2° -
8°C in refrigerator.
t PEGASYS Inj. Roche/Radiant
-
.
Peginterferon alfa-2a 135mcg/ l ml vial &
180mcg/ l ml vial: solution for subcutaneous
injection.
Dosage & admin: See above under the text of
Peginterferon alfa, and consult manufacturer's
literature.
•
135mcg vial x l's pack: 16,500.00 TP
180mcg vial x l's pack: 20,000.00 TP
t PEG-INTRON Inj. Schering Plough/Janata
Healthcare
Peginterferon alfa-2b 80mcg/vial: solution for
subcutaneous injection.
Dosage & admin: See above under the text of
Peginterferon alfa-2a/2b, and consult
manufacturer's literature.
80mcg vial x l's pack: 20145.22 MRP
RIBAVIRIN2 l ,26,50

RIBAVIRIN: Capsule
Ribavirin is a nucleoside analog with antiviral
activity. It is available as ribavirin BP 200mg
capsule.
Ind: Ribavirin is indicated in combination with
peginterferon alfa-2a, 2b or interferon alfa
injection for the treatment of chronic hepatitis C
virus (genotype 1, 2, 3 and 4) in patients with
compensated liver disease previously untreated
with alfa interferon or who have relapsed
following alfa interferon therapy.
Ribavirin alone is ineffective in hepatitis C virus
infection.
C/I: Ribavirin is conraindicated in patients with
known hypersensitivity to ribavirin or any
components of the capsule, women who are
pregnant, men whose female partners are
pregnant, patients with haemoglobinopathies (e.g
thalassemia major or sickle cell anemia),
'•
autoimmune hepatitis or hepatic decompensation
before or during treatment.
S/E: Nausea, vomiting, headache, dizziness,
blurred vision, stomach upset or pain, trouble
sleeping, and flu-like symptoms (e.g fever, chills,
sore throat, muscle aches) may occur. Other
severe side effects include hair loss, loss of
appetite, weight loss, rash, itching, fatigue, dark
urine, yellow eyes, mood changes (including
severe depression or suicidal thoughts), rapid or
trouble breathing, chest pain, muscle pain, joint
pain, easy bruising or unusual bleeding.
Precautions: Before using this drug, following
things should be considered: Patients suffering
from severe heart disease, kidney disease, blood
disorders (e.g sickle cell anemia, low
haemoglobin), other types of hepatitis ( e.g
autoimmune hepatitis), other liver problems,
breathing problems, pancreas problems (e.g
. ataxia, orthostatic hypotension, headache,
" , pancreatitis), diabetes, any allergy. Caution
·
should be taken in activities requiring alertness
such as driving or using machinery. Caution is
advised when using this drug in the elderly
because they may be more sensitive to its effects.
Pregnancy & lactation: This medication must
not be used during pregnancy. It is not known
whether this drug passes into breast milk.
Because of the potential risk to the infant, breast­
feeding is not recommended while using this drug.
Dosage & admin:
Dosage schedule of Ribavirin+Peginterferon:
See above under the text of peginterferon alfa.
Dosage schedule of Ribavirin +Interferon:
Ribavirin: Chronic hepatitis C (all genotypes
1, 2, 3 & 4): Adult, body weight < 75kg,
ribavirin daily 400mg in the morning and
600mg in the evening; body weight ? 75kg,
ribavirin daily 600mg in the morning and
600mg in the evening.
Interferon alfa 2a/2b: Chronic hepatitis C (all
genotypes 1, 2, 3 & 4): Adult (of any body
weight), 3 MIU 3 times weekly subcutaneously.
Duration: 48 weeks in cases of genotype 1 & 4;
24 weeks in cases of genotype 2 & 3.
Pediatric patients: Safety and efficacy of
ribavirin has not been established in patients
below the age of 18 yrs.
Drug inter: This drug should not be used with
the following medications because very serious
interactions may occur, viz: didanosine,
stavudine, zidovudine.
QIMP-17 (305) ANTIMICROBIAL DRUGS
No pharmacokinetic interactions were noted doses.
between interferon alfa and ribavirin. Elderly: In persons 65 years of age or older,
the daily dosage of amantadine hydrochloride
t CELBARIN Cap. Incepta is 100mg.
Ribavirin BP 200mg/capsule
Children: 1-9 years o·f age- the total daily dose
20's pack: 700.00 MRP
is 4.4-8.8mg/kg/day, but should not exceed
t CELBARIN Cap. Roche
150mg/day; 9-12 years of age- the total daily
Ribavirin BP 200mg/capsule
dose is 200mg given in two divided doses. The
20's pack: 528.30 TP
1 OOmg daily dose has not been studied in
children.
Dosage for parkinsonism: Adult: The usual
2.4 Drugs for Influenza virus
dose of amantadine hydrochloride is 1OOmg
twice daily.when used alone. The initial dose
AMANTADINE128 of amantadine hydrochloride is 1OOmg daily
for patients with serious associated medical
illnesses or who are receiving high doses of
AMAN TADINE: Syrup
other antiparkinson drugs. After one to
Amantadine hydrochloride is chemically known
several weeks at 1OOmg once daily, the dose
as 1-adamantanamine hydrochloride. Amantadine
may be increased to 1OOmg twice daily, if
has pharmacological actions both as an antiviral
necessary. Dosage for concomitant therapy:
and an anti-parkinson's drug. It is available as
Some patients who do not respond to
amantadine hydrochloride USP 1 OOmg/capsule
anticholinergic antiparkinson drugs, may
and amantadine hydrochloride USP 50mg/5ml
respond to amantadine. When amantadine or
syrup.
anticholinergic, antiparkinson drugs are each
Ind: Amantadine is indicated for the prophylaxis
used alone with marginal benefit, concomitant
and treatment of signs and symptoms of infection
use may produce additional benefit. When
caused by various strains of influenza-A virus.
amantadine and levodopa are initiated
Amantadine hydrochloride is also indicated in the
concurrently, the patient can exhivit rapid
treatment of parkinsonism and drug-induced
therapeutic benefits. Amantadine should be
extrapyramidal reactions.
held constant at 1OOmg daily or twice daily
C/I: Patients with known hypersensitivity to the
while the daily dose of levodopa is gradually
drug.
increased to optimal
S/E: The adverse reactions reported most
benefit.
frequently (5-10%) are: nausea, dizziness
Dosage for durg induced extrapyramidal
(lightheadedness), and insomnia. Adverse
reactions: Adult: The usual dose of
reactions reported less frequently (1-5%) are:
amantadine hydrochloride is 1OOmg twice
depression, anxiety, irritability, hallucinations,
daily. Occasionally patients whose responses
confusion, anorexia, dry mouth, constipation,
are not optimal with amantadine 200mg daily
dose, an increase up to 300mg daily in divided
nervousness, dream abnormality, agitation, dry
doses may be benefited.
nose, diarrhea and fatigue. Rare side effects (0.1-
Dosage for impaired renal function: Depending
1% ) are: congestive heart failure, urinary
upon creatinine clearance, the following
retention, dyspnoea, skin rash, vomiting,
dosage adjustments are recommended:
weakness, confusion, hyperkinesia, hypertension,
C. clearance 30-50mL/min/1.73m2- 200mg 1st
decreased libido, and visual disturbance.
day and 1OOmg each day thereafter.
Precautions: Amantadine should not be
C. clearance 15-29mL/min/1.73m2- 200mg 1st
discontinued abruptly in patients with Parkinson's
day followed by 1 OOmg on alternate days.
disease since a few patients have experienced a
C. clearance <15mL/min/1.73m2 - 200mg
parkinsoninan crisis, i.e a sudden marked clinical
every 7 days.
deterioration when this medication is suddenly
The recommended dosage for patients on
stopped. The dose of anticholinergic drugs or of
hemodialysis is 200mg every 7 days.
amantadine should be reduced if atropine-like
Drug inter: Careful observation is required when
. effects appear when these drugs are used
amantadine is administered concurrently with
concurrently. Neuroleptic malignant syndrome
central nervous system stimulants. Co­
(NMS): Sporadic cases of possible neuroleptic
administration of thioridazine has been reported
malignant syndrome (NMS) characterized by
to worsen the tremor in elderly patients with
fever or hyperthermia, muscle rigidity,
Parkinson's disease; however, it is not known if
involuntary movements, tachycardia, tachypnea,
other phenothiazines produce a similar response.
hyper-or hypotension.
Pregnancy & lactation: There are no adequate
t INFLU Cap. Peoples
and well-controlled studies in pregnant women.
Amantadine hydrochloride USP 1OOmg/capsule
So, a�antadine should be used during pregnancy
60's pack: 180.00 MRP
only 1f the potential benefit justifies the potential
risk to the embryo or fetus.
Amantadine is excreted in human milk; so, it's OSELTAMJVJR48
use is not recommended in nursing mothers.
Dosage & admin: Prophylaxis and treatment OSELTAMIVIR: Capsule/Suspension
of uncomplicated influenza-A Virus illness: Oseltamivir phosphate is an ethyl ester prodrug
Adult: The daily dosage of amantadine which undergoes ester hydrolysis by hepatic
hydrochloride is 200mg (2 capsules or 4 tsf of esterases to form active ingredient, oseltamivir
syrup) given as a single dose or in two divided carboxylate. It is available as oseltamivir
 ANTIMICROBIAL DRUGS QIMP-17 (306)

75mg/capsule & 60mg/5ml of suspension.
Mode of action: Oseltamivir carboxylate acts by
selective inhibition of influenza viral
neuraminidase with the possibility of alteration of
virus particle aggregation and release.
A lipophilic side chain of the active drug binds to
the virus enzyme, blocking its ability to cleave
sialic acid residues on the surface of the infected
cell and resulting in an inability to release
progeny vmons.
• •
13 yean & older: The recommended standard lOO's pack: 532.00 MRP
oral dose of oseltamivir for prophylaxis of + GRISEOFULVIN-FP Tab. Bristol
influenza following close contact with an Griseofulvin 500mg/tablet.
infected individual is 7Smg once daily for at lOO's pack: 500.00 MRP
least 7 days. Therapy should begin within 2 + GRISO 500 Tab. Ziska
days of exposure. The recommended dose for Griseofulvin 500mg/tablet.
prophylaxis during a community outbreak of lOO's pack: 350.00 MRP
influenza is 7Smg once daily for up to 6 weeks, + GRISOFULVIN-M Tab. Modern
because safety and efficacy have been demon­ Griseofulvin 500mg/tablet.
strated for up to 6 weeks. The duration of pro­ IOO's pack: 694.00 MRP

Ind: 1. Prophylaxis of influenza: Oseltamivir is
indicated for prevention of influenza (including
Pandemic influenza or Bird flu, strain- HSN1) in
adults and adolescents aged 13 years and over
who have been in contact with someone
diagnosed with flu.
2. Treatment ofinfluenza: In adults and in
children over 1 year of age when the influenza
virus is circulating in the community.
3. WHO recommended oseltamivir for
prophylaxis and treatment of Pandemic influenza
(Bird Flu). WHO also prescribed oseltamivir as
the drug for treatment and prophylaxis of
seasonal influenza, to reduce the complications.
tection lasts for. as long as dosing is continued. + GRISOVIN FP GlaxoSmithKli.ne
Pediatric use: The safety and efficacy of Griseofulvin 500mg: tablet
oseltamivir for prophylaxis of influenza in l OO's pack: �58.33 MRP
pediatric patients younger than 13 years of age + GRISOZEN Tab. Zenith
have not been established. Griseofulvin 500mg: tablet
Oseltamivir phosphate may be taken with or 50's pack: 334.00 MRP
without food. However, when taken with food, + GROVIN Tab. Nipa
tolerability may be enhanced in some patients. Griseofulvin 500mg/tablet.
Drug inter: Information derived from 1OO's pack: 556.00 MRP
phamacology and pharmacokinetic studies of
oseltamivir suggests that clinically significant
drug interactions are unlikely. Co-administration NYSTATIN21•33
with amoxicillin does not alter plasma levels of
either compound. NYSTA'.I'IN: Tablet/Drop

C/I: This product is contraindicated in patients Ind: Intestinal candidosis. (Drop, usually used
with known hypersensitivity to any of the + OSEFLU Cap. Beximco for oral & oesophageal candidosis.)
components of the product. Oseltamivir phosphate INN equivalent to S/E: Nausea, vomiting, diarrhoea.

S/E: The most frequently reported adverse events oseltamivir 75mg/capsule. Dosage: Tablet, adult- 1-2 tabs. 4 times daily.
are nausea and vomiting. These events generally lO's pack: 1500.00 IP Drop, adult- lml 4 times daily; child- lml 4

of mild to moderate degree and usually occur on + TAMIFLU Cap. Roche/Radiant times daily.
the first 2 days of administration. Additional Ose ltamivir phosphate INN equivalent to Prophylaxis in neonates, lml daily. For oral

adverse events may occur (in <1% of patients) oseltamivir 75mg/capsule. lesions retain suspension in the mouth for a
include- unstable angina, anemia, 1O's pack: 2,220.45 TP while.

pseudomembranous colitis, humerus fracture,

+ CANDEX Drop Square
pneumonia, pyrexia, and peritonsillar abscess.

Precautions & warnings: General: There is no

3. SYSTEMIC ANTI-FUNGAL Nystatin 100,000 11nits/lml: drop
12ml bot: 22.73 MRP
evidence for efficacy of oseltamivir phosphate in DRUGS + CANSTAT Tab. Jayson
any illness caused by agents other than influenza Nystatin 500,000 units/tablet.
viruses types A and B. Efficacy of oseltamivir Systemic antifungal preparations belong to 1OO's pack: 278.00 MRP •

phosphate in patients who begin treatment after different groups:21 + CANSTAT Drop Jayson
48 hours of symptoms has not been established. Nystatin 100,000 units/lml: drop
1. Polyene aotifungals: Such as Amphotericin,
Hepatic impairment: The safety and phamacoki­ I Oml bot: 17.20 MRP
Nystatin.
netics in patients with hepatic impairment have
2. Imidazole antifungals: Such as + FEFUN Drop Amico
not been evaluated. Nystatin 100,000 units/l ml: drop
Clotrimazole, Econazole, F enticonazole,
Renal impairment: Dose adjustment is recom­ 12ml bot: 21.00 MRP
lsoconazole, Ketoconazole, Miconazole,
mended for patients with a serum creatinine
Sulconazole &: Tioconazole. + FUNGISTIN Drop Beximco
clearance <30ml/min. Nystatin 100,000 units/lml: drop
3. Triazole antifungals: Such as Fluconazole,
Geriatric use: The safety of oseltamivir phoshate 12ml bot: 22.74 MRP
ltraconazole.
has been established in clinical studies.
4. Other antifungals: Such as Flucytosine, + MYCOCIN Tab. Ibo Sina
Pregnancy & lactation: There are insufficient Nystatin 500,000 \1nits/tablet.
Griseofulvin &: Terbinafine etc.
human data upon which evaluation of risk of 28's pack: 141.40 MRP
oseltamivir phosphate to the pregnant woman or + MYCOCIN Drop Ibo Sina
developing fetus can be based. �.u.�����"-1.Y.� '33
�b��lr.ii" lr* :r-,�2
!r l Nystatin 100,000 l1nits/ lml: drop
It is also not known whether oseltamivir is 12ml bot: 21.00 MRP
excreted in human milk. Oseltamivir phosphate GRISEOFULVIN: Tablet/ Suspension + NAF Drop Opsonin
should, therefore, be used only if the potential Ind: Fungal (dermatophyte) infections of skin, Nystatin 100,000 units/ l ml: drop
benefit for the lactating mother justifies the hands, nails and scalp. 12ml bot: 18.01 MRP
potential risk to the breast-fed infant.
C/I: Porphyria, severe liver disease. + NYSOL Drop Edruc
Dosage & admin: Treatment of influenza: Nystatin BP 100,000 units/ l ml: drop
S/E: Headache, nausea, vomiting, gastric
Adults & adolescents 13 years & older: The l 2ml bot: 23.00 MRP
discomport, urticarial reactions, erythematous
recommended standard oral dose is 7Smg
rashes, photosensitivity. + NYST Drop Somatec
twice daily for 5 days. Treatment should begin
Cautions: Pregnancy, drug interactions (specially Nystatin 100,000 units/ l ml: drop
within 2 days of onset of symptoms of
coumarin anticoagulant admn.}. 12ml bot: 20.59 MRP
influenza. Pediatric use: The safety and
Dose: Adult, SOOmg-lgm daily preparably in + NYSTAT Tab. Acme
efficacy of oseltamivir phosphate in pediatric
divided doses (or as single dose) after meals. Nystatin 500,000 units/tablet.
patietns younger than 1 year of age have not
Children, 10 mg/kg body-wt. daily in divided 50's pack: 287.28 MRP
been studied. Oseltamivir phosphate is not
doses.
recommended for treatment of influenza in + NYSTAT Drop Acme
pediatric patients younger than 1 year of age. + AFUVIN Tab. Ambee Nystatin 100,000 units/lml.
Prophylaxis of influenza: Adults & adolescents Griseofulvin 500mg/tablet. 12ml bot: 22.73 MRP

t'
-
•

I

t ORNY S Drop Kemiko
Nystatin 100,000 units/l ml: drop
12ml bot: 20.46 MRP
t ZENISTIN Drop Zenith
Nystatin 100,000 units/ lml: drop
12ml bot: 20.11 MRP
FLUCONAZOLE21 ,33,42
FLUCONAZOLE: Tablet/Capsule/
Suspension/I.V infusion
Fluconazole is a triazole antifungal drug. It is
active against a broad spectrum of fungal
pathogens. It is available as- tablet, capsule and
suspension for oral administration; and parenteral
preparation for i.v infusion.
Mode of action: Fluconazole acts by inhibiting
the synthesis of ergosterol, a major component of
the cell membrane of yeast and fungi.
Ind: It is indicated in the treatment of acute or
recurrent vaginal candidiasis, mucosa! candidiasis
(a.s oropharyngeal candidiasis, oesophagitis,
candiduria), systemic candidiasis and
cryptococcal infections (including meningitis).
C/I: It is contraindicated to patients hypersensi­
tive to this drug and in advanced liver disease.
S/E: Nausea, abdominal discomfort, diarrhoea,
and flatulence; occasionally abnormalities of
liver enzymes; rarely rash (discontinue
treatment); angioedema, anaphylaxis and
Stevens-Johnson syndrome reported; fixed drug
eruption also reported.
Precaution: Caution should be taken in renal
impairment, pregnancy and breast feeding and in
raised liver enzymes; children (use only if
imperative and if no alternative treatment; not
recommended under 1 year). Avoid concomitant
administration with astemizole or terfenadine.
Pregnancy & lactation: Caution should be taken
during pregnancy (toxicity at high doses in ani­
mal studies) & breast-feeding. The use of flucon­
azole in lactating mothers is not recommended.
Dosage & admin : Acute or recurrent vaginal
candidiasis, by mouth, a single dose of lSOmg.
Mucosal candidiasis (except vaginal), by
mouth, SOmg daily (lOOmg daily in unusually
difficult infections) given for 7-14 days in
oropharyngeal candidiasis (max. 14 days
except in severely immunocompromised
patients); for 14 days in atrophic oral candidi­
asis associated with dentures; for 14-30 days in
other mucosal infections (e.g. oesophagitis,
candiduria).
Tinea pedis, corporis, cruris, versicolor, and
dermal candidiasis, by mouth, SOmg daily for
2-4 weeks (for up to 6 weeks in tinea pedis);
max. duration of treatment 6 weeks.
Systemic candidiasis and cryptococcal infec­
tions (including meningitis), by mouth or i.v
infusion, 400mg initially then 200mg daily,
increased if necessary to 400mg daily; treat­
ment continued according to response (at least
6-8 weeks for cryptococcal meningitis).
Prevention of relapse of cryptococcal meningi­
tis in AIDS patients after completion of pri­
mary therapy, 100-200mg daily.
Prevention of fungal infections in immuno­
compromised patients following cytotoxic
chemotherapy or radiotherapy, S0-400mg
daily adjusted according to risk; 400mg daily
QIMP-17 (307)
if high risk of systemic infections e.g. following
bone-marrow transplantation; commence
treatment before anticipated onset of
neutropenia and continue for 7 days after
neutrophil count in desirable range.
Children- over 1 year (see cautions), by mouth
or by i. v infusion, superficial candidal
infections, 1-2 mg/kg daily; systemic
candidiasis and cryptococcal infections, 3-
6mg/kg daily (in serious life-threatening
infections up to 12mg/kg daily has been given
to children aged 5-13 years- max. 400mg daily)
Drug inter: Rifampicin reduces plasma concen­
tration of fluconazole. Effect of nicoumalone,
phenytoin and warfarin is enhanced. Plasma
concentrations of sulphonylureas & theophyline
is possibly increased.
Fluconazole USP capsule
Sl<•F
t AFL UZOLE Cap. Ambee
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 240.90 MRP
150mg x lO's pack: 220.80 MRP
t AFLUZOLE Susp. Ambee
Fluconazole 50mg/5ml: suspension
35ml bot: 78.30 MRP
t ANFASIL Tab. Silva
Fluconazole 50mg & 150mg/tablet
50mg x 30's pack: 210.00 MRP
150mg x 12's pack: 240.00 MRP
t ANFASIL Susp. Silva
Fluconazole 50mg/5ml: suspension
35ml bot: 75.00 MRP
t APICON SO Cap. APC Pharma
Fluconazole 50mg/capsule
50mg x 30's pack: 240.00 MRP
t CANAZOLE Tab. ACI
Fluconazole 50mg, 150mg & 200mg/tablet
50mg x 30's pack: 240.90 MRP
150mg x lO's pack: 220.80 MRP
200mg x 1O's pack: 250.00 MRP
t CANAZOLE Susp. ACI
Fluconazole 50mg/5ml: suspension
35ml bot: 78.29 MRP
t CANDID Tab. Amico
Fluconazole 50mg & 150mg/tablet
50mg x 30's pack: 210.00 MRP
150mg x lO's pack: 220.00 MRP
t CANDIDAL Cap. Radiant Pharma
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 240.00 MRP
150mg x 12's pack: 270.00 MRP
t CANDINIL Cap. Healthcare
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 240.00 IP
150mg x 12's pack: 264.00 IP
t CANDINIL Susp. Healthcare
Fluconazole 50mg/5ml: suspension
35ml bot: 78.00 MRP
t CON-50 Tab. Reliance
Fluconazole 50mg/tablet
50mg x 30's pack: 241.50 MRP
• SO mg tablet • 1 SO mg tablet
• 200 mg tablet • 3S ml suspension
t CONAZ Cap. Orion Pharma
Fluconazole 50mg & l 50mg/capsule
50mg x 20's pack: 160.60 MRP
150mg x 12's pack: 264.96 MRP
t CONAZOLE Cap. Apollo
Fluconazole 50mg/capsule
50mg x 30's pack: 240.00 IP
t COSFLU 50 Tab. Cosmo Pharma
Fluconazole· 50mg/tablet
50mg x 30's pack: 240.00 IP
t DEFUNGI Cap. NIPRO JMI
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 241.20 MRP
150mg x lO's pack: 220.90 MRP
t DERMA Cap. Alco Pharma
Fluconazole 50mg & 150mg/capsule
50mg x 24's pack: 192.00 MRP
150mg x 12's pack: 240.00 MRP
t DIFLU Cap. Aristopharma
Fluconazole 50mg, 150mg & 200mg/capsule.
50mg x 48's pack: 384.00 MRP
150mg x 12's pack: 264.00 MRP
200mg x 12's pack: 300.00 MRP
t DIFLU Susp. Aristopharma
Fluconazole 50mg/5ml: suspension
35ml bot: 78.00 MRP
t DIFLUCON Cap. Aexim
Fluconazole 50mg/capsule.
50mg x 50's pack: 250.00 MRP
t FCON Tab. Everest
Fluconazole 50mg & 150mg/tablet
50mg x 30's pack: 240.00 MRP
150mg x 12's pack: 240.00 MRP
t FLUCANEX Cap. RAK Pharma
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 240.00 MRP
150mg x 6's pack: 132.00 MRP
t FLUCODER Cap. SK+F
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 243.00 MRP
150mg x lO's pack: 220.00 MRP
t FLUCODER Susp. SK+F
Fluconazole 50mg/5ml: suspension
35ml bot: 78.00 MRP
t FLUCOLET Cap. Amulet
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 240.00 MRP
150mg x lO's pack: 200.00 MRP
t FLUCOLET Susp. Amulet
Fluconazole 50mg/5ml: suspension
35ml bot: 75.00 MRP
t FLUCON Cap. Opsonin
Fluconazole 50mg, 150mg & 200mg/capsule
50mg x 30's pack: 211.92 MRP
150mg x lO's pack: 194.24 MRP
200mg x IO's pack: 219.92 MRP
t FLUCONAL Tab. Acme
Fluconazole 50mg & 150mg/tablet
50mg x 20's pack: 160.80 MRP
150mg x 12's pack: 220.80 MRP
t FLUCONAL Susp. Acme
Fluconazole 50mg/5ml: suspension
35ml bot: 78.30 MRP
t FLUCONAZOLE Cap. Bristol
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 240.00 MRP
 r

•
•
.
•

.
. .

-
.
•

ANTIMIC�OBIAI.DRUGS. QIMP-17 (308) •

. ..
..
••
... ....
. .
• .
.. ·�
�

.
• v .. .�

'
.
'
.
, ��

150mg x lO's pack: 220.00 MRP Fluconazole 50mg/5ml : suspension 20ml bot: 60.00 MRP
t FLUCO-S Cap. Seema 35ml bot: 75.00 MRP 35ml bot: 78.29 MRP
Fluconazole 50mg & l 50mg/capsule t FLUNOL Cap. Somatec t F-ZOL I.V Inf. Popular
50mg x 30's pack: 240.00 MRP Fluconazole 50mg & l 50mg/capsule Fluconazole 200mg/100ml: i.v infusion
150mg x 1O's pack: 220.00 MRP 50mg x 32's pack: 224.96 MRP 1OOml bot x 1's pack:-200.00 MRP
t FLUCOSTAN Cap. Ziska 150mg x lO's pack: 200.80 MRP t GALFIN Cap. General
Fluconazole INN 50mg/capsule + FLUNOL Susp. Somatec Fluconazole 50mg & 150mg/capsule
•

50mg x 20's pack: 100.00 MRP Fluconazole 50mg/5ml: suspension 50mg x 30's pack: 240.90 MRP
•

'

+ FLUDA Cap. Novo Healthcare 35ml bot: 75.28 MRP 150mg x lO's pack: 220.80 MRP
Fluconazole INN 50mg/capsule t FLUSAF Cap. White Horse t ILUCA Cap. Ibo Sina
50mg x 30's pack: 240.00 MRP Fluconazole USP 50mg & 150mg/capsule Fluconazole 50mg & 150mg/capsule
+ FLUDA Susp. Novo Healthcare 50mg x 30's pack: 240.00 MRP 50mg 20's pack: 180.00 IP
. .

Fluconazole 50mg/5ml: suspension 150mg x 30's pack: 396.00 MRP 150mg x 12's pack: 276.00 IP
.

35ml bot: 78.00 MRP t FLUTINEX Cap. Organic Health t LEUCODAR Tab. Chemist •

t FLUDEX Cap. Medicon Fluconazole BP 50mg & 150mg/capsule Fluconazole 50mg/tablet

Fluconazole INN 50mg/capsule 50mg 30's pack: 240.00 MRP 50mg 20's pack: 120.00 MRP
•

x x •
.

50mg 30's pack: 240.00 MRP 150mg 12's pack: 264.00 MRP t LUCAN-R Cap. Renata
•

x x

t FLUFUN Cap. Astra t FLUVIN-OD Tab. GlaxoSmithKline
Fluconazole 50mg & 150mg/capsule Fluconazole 50mg & 150mg/tablet
50mg x lO's pack: 80.00 MRP 50mg x 30's pack: 240.90 MRP
150mg x lO's pack: 220.00 MRP 150mg x lO's pack: 200.75 MRP
t FLUGAL Cap. Square t FLUZO Tab. Pacific
Fluconazole 50mg, 150mg & 200mg/capsule Fluconazole 50mg & l 50mg/tablet
50mg x 30's pack: 241.40 MRP 50mg x 30's pack: 240.00 MRP
150mg x 20's pack: 441.60 MRP 150mg x lO's pack: 220.00 MRP
200mg x 1O's pack: 251.00 MRP t FLUZOLE Tab. Globe
t FLUGAL Susp. Square Fluconazole 50mg & 150mg/tablet
Fluconazole 50mg/5ml : suspension 50mg x 30's pack: 240.00 MRP
35ml bot: 78.30 MRP 150mg x 20's pack: 400.00 MRP
+ FLUGARD Cap. Pharmasia t FUNCID Cap. MST Pharma
Fluconazole 50mg & 150mg/capsule Fluconazole 50mg/capsule
Fluconazole 50mg & 150mg/capsule
50mg x 40's pack: 321.20 MRP
150mg x lO's pack: 264.96 MRP
t LUCAN-R Susp. Renata
Fluconazole 50mg/5ml: suspension
35ml bot: 78.30 MRP
t LUCON Cap. Navana
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 240.90 IP
150mg x lO's pack: 220.80 IP
t MYCODER Tab. UniMed & UniHealth
Fluconazole 50mg & l 50mg/tablet
50mg x 30's pack: 210.00 MRP
l 50mg IO's pack: 200.00 MRP
•

x •

50mg x 30's pack: 240.00 MRP 50mg x 30's pack: 240.00 MRP
150mg x 12's pack: 264.00 MRP + FUNGA Cap. Doctor's
+ FLUGARD Susp. Pharmasia Fluconazole 50mg & 150mg/capsule
Fluconazole 50mg/5ml : suspension 50mg x 50's pack: 325.00 MRP
35ml bot: 78.80 MRP 150mg x 20's pack: 360.00 MRP
t FLUJALE Cap. CPL + FUNGARD Cap. Cosmic
Fluconazole USP 50mg/capsule Fluconazole 50mg/capsule
t MYCODER Susp. UniMed & UniHealth
Fluconazole 50mg/5ml: suspension
35ml bot: 70.00 MRP
t NISPORE Cap. Incepta
Fluconazole 50mg, 150mg & 200mg/capsule
50mg x 30's pack: 240.00 MRP
150mg x lO's pack: 220.00 MRP •

50mg x 30's pack: 240.00 MRP 50mg x 30's pack: 246.90 MRP 200mg x 1O's pack: 250.00 MRP
t FLUKZOL Cap. Sharif t FUNGATA Tab. Biopharma t NISPORE Susp. Incepta
Fluconazole 50mg/capsule Fluconazole 50mg & 150mg/tablet Fluconazole 50mg/5ml: suspension
50mg x 30's pack: 240.00 MRP 50mg x 30's pack: 240.90 MRP 35ml bot: 78.00 MRP
t FLUMA Cap. Modern l 50mg x 1O's pack: 220.80 MRP t NOGAL Tab. Kumudini
Fluconazole 50mg & 150mg/capsule t FUNGATA Susp. Biopharma Fluconazole 50mg & 150mg/capsule
50mg x 20's pack:_160.00 MRP Fluconazole 50mg/5ml: suspension 50mg x 20's pack: 160.00 MRP
150mg x 20's pack: 400.00 MRP 35ml bot: 78.29 MRP 150mg x lO's pack: 220.00 MRP
+ FLUMART Cap. Desh Pharma t FUNGI-F Cap. Edruc t OLIF Cap. Kemiko
Fluconazole 50mg & l 50mg/capsule Fluconazole 50mg/capsule Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 210.00 MRP 50mg x 30's pack: 240.00 MRP 50mg x 50's pack: 400.00 MRP
150mg x 12's pack: 240.00 MRP t FUNGITROL Cap. Rangs Pharma 150mg x lO's pack: 220.00 MRP
+ FLUMYC Cap. Euro Pharma Fluconazole 50mg & l 50mg/capsule t OMAS'l'IN Cap. Beximco
Fluconazole 50mg & l 50mg/capsule 50mg x 20's pack: 160.00 MRP Fluconazole 50mg, l 50mg & 200mg/capsule
,

50mg x 30's pack: 240.00 MRP 150mg x 12's pack: 264.00 MRP 50mg x 50's pack: 400.00 IP •

150mg x lO's pack: 220.00 MRP + FUNGITROL Susp. Rangs Pharma 150mg x 20's pack: 440.00 IP
t FLUNAC Cap. Drug Inter. Fluconazole 50mg/5ml: suspension 200mg x 1O's pack: 250.00 MRP
Fluconazole 50mg & 150mg/capsule 35ml bot: 78.00 MRP + OMASTIN Susp. Beximco •

50mg x 30's pack: 240.00 MRP + FUNZOLE Cap. MonicoPharma
150mg x 20's pack: 400.00 MRP Fluconazole 50mg & 150mg/capsule
t FLUNAC Susp. Drug Inter. 50mg x 30's pack: 240.00 MRP
Fluconazole 50mg/5ml : suspension 150mg x 12's pack: 264.00 MRP
35ml bot: 70.00 MRP + FUNZOLE Susp. MonicoPharma
t FLUNAPEN Cap. Concord Fluconazole 50mg/5ml: suspension
Fluconazole 50mg & 150mg/capsule 35ml bot: 78.00 MRP
50mg x 30's pack: 240.00 MRP
t F-ZOL Cap. Popular
150mg x lO's pack: 220.00 MRP
Fluconazole 50mg, 150mg & 200mg/capsule
t FLUNAZOL Cap. Pharmadesh 50mg x 30's pack: 240.90 MRP
Fluconazole 50mg & 150mg/capsule 150mg x 12's pack: 264.96 MRP
50mg x 30's pack: 210.00 MRP 200mg x 12's pack: 300.00 MRP
150mg x 12's pack: 240.00 MRP
+ F-ZOL Susp. Popular
+ FLUNAZOL Susp. Pharmadesh Fluconazole 50mg/5ml: suspension
Fluconazole 50mg/5ml: suspension.
35ml bot: 78.00 IP
t OMASTIN I.V Inf. Beximco
Fluconazole USP 200mg/100ml: i.v infusion
lOOml bot x 1 's pack: 200.00 MRP
t ONICON Tab. Zenith
Fluconazole 50mg/tablet
50mg x 50's pack: 300.00 MRP
t ONICON Susp. Zenith
Fluconazole 50mg/5ml: suspension.
35ml bot: 65.24 MRP
+ ORAF Cap. Hallmark
Fluconazole 50mg & 150mg/capsule
50mg x 30's pack: 240.00 MRP

150mg x 20's pack: 400.00 MRP
+ ORAF Susp. Hallmark
Fluconazole 50mg/5ml: suspension.
35ml bot: 70.00 MRP
t SACONA Cap. SAPL
Fluconazole 50mg & l 50mg/capsule
50mg x 30's pack: 240.00 MRP
150mg x 12's pack: 192.00 MRP
t SEGAL Cap. Supreme
Fluconazole 50mg & l 50mg/capsule
50mg x 20's pack: 160.00 MRP
l 50mg x l O's pack: 220.00 MRP
•
+ SEGAL Susp. Supreme
Fluconazole 50mg/5ml: suspension
35ml bot: 78.00 MRP
t TRIGAL Cap. Ad-din
-
Fluconazole USP 50mg & 150mg/capsule
50mg x 30's pack: 210.00 MRP
l 50mg x 20's pack: 360.00 MRP
t XERODER Cap. Beacon
Fluconazole 50mg/capsule
50mg x 30's pack: 240.00 MRP
t XERODER I.V Inf. Beacon
Fluconazole 200mg/100ml: i.v infusion
l OOml bot x l's pack: 200.00 MRP
t ZOLEN Cap. Apex
Fluconazole 50mg & l 50mg/capsule
50mg x 50's pack: 400.00 MRP
150mg x IO's pack: 180.00 MRP
ITRACONAZOLE 21•42
ITRACONAZOLE: Capsule
Itraconazole is a broad spectrim, orally active
triazole antifungal drug.
Mode of action: ltraconazole inhibits
cytochrome P-450 dependent enzymes resulting
in impairment of the biosynthesis of ergosterol, a
major component of the cell membrane of yeasts
and fungal cells.
Inhibition of the synthesis of ergosterol leads to
formation of defective cell membrane, inhibition
of growth, and accumulation of intracellular
lipids and membranous vesicles.
Ind: Itraconazole is used for the treatment of
oropharyngeal candidiasis, vulvovaginal candidi­
asis, pityriasis versicolor, tinea pedis, tinea cruris,
tinea corporis, tinea manuum, onychomycosis,
histoplasmosis. It is indicated in the treatment of
systemic candidiasis, aspergillosis, and crypto­
coccosis (including cryptococcal meningitis). It is
also used for maintenance therapy in AIDS
patients to prevent relapse of underlying fungal
infections and in the prevention of fungal
infection during prolonged neutropenia.
C/I: Known hypersensitivity to the drug or any
ingredient in the formulation. Patients who have
severe hepatic disease are not advised to take
..
•
itraconazole. It is not advisable to use the drug in
patients taking rifampicin which appears to
initially inhibit and then enhance the metabolism
of itraconazole.
S/E: Nausea, abdominal pain, dyspepsia, consti­
pation, headache, dizziness, raised liver enzymes,
menstrual disorder, allergic reactions (including
pruritus, rash, urticaria and angioedema),
hepatitis and cholestatic jaundice, & peripheral
neuropathy reported. On prolonged use hypoka­
lemia, edema and hair loss are also reported.
Precaution: Absorption is impaired when gastric
QIMP-17 (309)
acidity is reduced. In patients receiving acid
neutralizing medicines (e.g antacids), these
should be administered at least two hours after
the intake of itraconazole. The drug should be
administered after a full meal. Rarely, cases of
hepatitis and jaundice have been reported mainly
in patients treated for longer than one month. It is
therefore advised to monitor liver function in
patients receiving continuous treatment of more
than one month.
Pregnancy & lactation: ltraconazole is contra­
indicated in pregnancy. Breast feeding while
receiving itraconazole is not recommended.
Dosage & admin: Oropharyngeal candidiasis­
lOOmg daily (200mg daily in AIDS or
neutropenia) for 15 days.
Vulvovaginal candidiasis- 200mg twice daily
for 1 day.
Pityriasis versicolor- 200mg daily for 7 days.
Tinea corpris & tinea cruris- 1OOmg daily for
15 days or 200mg daily for 7 days. Tinea pedis
& tinea manuum- 1OOmg daily for 30 days or
200mg twice daily for 7 days.
Onychomycosis- 200mg daily for 3 months or
a course of 200mg twice daily for 7 days;
subsequent courses should be repeated after
21 day interval; fingernails- two courses;
toenails- three courses.
Systemic infections (aspergillosis, candidiasis,
cryptococcosis including crytococcal meningi­
tis) where other antifungal drugs are inappro­
priate or ineffective- 200mg once daily, increa­
sed in invasive or diseminated disease and in
cryptococcal meningitis to 200mg twice daily.
Histoplasmosis- 200mg 1-2 times daily.
Maintenance in AIDS patients to prevent
relapse of underlying fungal infection and
prophylaxis in neutropenia when standard
therapy is inappropriate- 200mg once daily,
increased to 200mg twice daily if low plasma
concentration is detected.
Children- the recommended dose is 3 to
Smg/kg/day.
Drug Inter: The drug astemizole, HMG-CoA
reductase inhibitors such as simvastatin, oral
midazolam or triazolam should not be given con­
currently with itraconazole. Significant interac­
tions are also observed during co-administration
of rifampicin, phenytoin, phenobarbital, digoxin,
and calcium channel blockers.
t ICONAL Cap. Kemiko
ltraconazole INN I OOmg/capsule
12's pack: 180.00 MRP
• ITRA Cap. Square
ltraconazole INN I OOmg/capsule
24's pack: 361.20 MRP
t ITRACON Cap. Navana
Itraconazole INN I OOmg/capsule
12's pack: 180.72 IP
KE10CONAZOLE21,33
KETOCONAZOLE: Tabtet/ Suspension
Ind: Systemic mycoses, prophylaxis of mycoses
in patients with reduced immune responses.
Serious chronic mucocutaneous candidosis &
serious mycoses of the g. i tract not responsive to
other therapy. Dermatophyte infections not
responsive to other therapy excluding infection of
ANTIMICROBIAL DRUGS
the toe nails or for pityriasis versicolor.
Chronic vaginal candidosis not responsive to
other therapy.
C/I: Hypersensitivity to ketoconazole or other
imidazole. Pre-existing liver disease or
significant abnormalities on liver function tests.
Pregnancy.
S/E: Rarely nausea, rashes, pruritus, hepatitis
(discontinue treatment if signs of hepatitis
develop).
Precautions: Monitor patients for signs of liver
disease during & after treatment. Concurrent
admn. Of drugs that reduce gastric acid secretion
or that are plasma protein bound.
Dosage & admin: Adult: 200-400 mg once
daily with meals. Continue for at least one
week after symptoms have cleared.
Children: 3mg/kg daily with food.
Vaginal candidiasis: 200mg with food every 12
hours for 5 days.
t KETOCON Tab. Opsonin
Ketoconazole 200mg/tablet.
30's pack: 211.92 MRP
• KETOFUN Tab. Amico
Ketoconazole 200mg/tablet
30's pack: 249.90 MRP
• KETORAL Tab. Square
Ketoconazole 200mg/tablet.
40's pack: 361.20 MRP
MICONAZOLE21·52
MICONAZOLE: Oral gel
Miconazole (and Econazole) are the members of
broad-spectrum synth�tic imidazole class of
antifungal agents. Miconazole oral gel is
available as miconazole base USP 2% w/w.
Ind: Treatment and prevention of fungal
infection & gram positive bacterial superinfection
of the oropharynx and gastro-intestinal tract.
C/I: No known contra-indications.
S/E: No major side-effe.cts have been reported in
using miconazole oral gel. Occasional mild
gastrointestinal side-effect is seen.
Cautions: Systemic miconazole may potentiate
the activity of anti-coagulants, anti-epileptics, or
hypoglycaemic drugs, the dosage of which may
require adjustment.
Pregnancy & lactation: In pregnancy no
significant teratogenic affect is reported,
however, as with other imidazole, it should be
avoided in pregnant women.
Dosage & admin: Miconazol oral gel should be
taken after meals. The recommended dosage is
lSmg/kg/day.
Adult: 1 to 2 tsf (5 to tOml) of gel 4 times daily.
Children: Age 6 years and over, 1 tsf of gel 4
times daily; age 2-6 years, 1 tsf (5ml) of gel
twice daily; infants under 2 years, half tsf
(2.5ml) of gel twice daily.
Alternatively, for localised lesions of the
mouth, a small amount of gel may be applied
directly to the affected area with a clean
fmger, 2 to 4 times daily. For best results in the
treatment of oral lesions, Miconazol oral gel
should be kept in contact with the affected
area for as long as possible. This can be
achieved by retaining the gel in the mouth for
the maximum time possible.

®
oralg�I
..;
: ·- • "'
;
_ .,
Treatment should be continued for upto 2 days
after symptoms have cleared.
+
A-MIGEL Oral Gel Acme
Miconazole base USP 2% w/w: Oral gel.
l 5gm tube: 52.00 MRP
+ CANDORAL Oral Gel Beximco
Miconazole base USP 2% w/w: Oral gel.
15gm tube: 52.00 MRP
+ DAKRIN Oral Gel General
Miconazole base USP 2% w/w: Oral gel.
15gm tube: 50.19 MRP
+ GELORA Oral Gel Square
Miconazole base USP 2% w/w: Oral gel.
l 5gm tube: 60.00 MRP
+ MICODERM-Gel Drug Inter.
Miconazole base USP 2% w/w: Oral gel.
15gm tube: 50.00 MRP
+ MICORAL Oral Gel ACI
Miconazole base USP 2% w/w: Oral gel.
l 5gm tube: 60.00 MRP
+ MIZOL Oral Gel Medicon
Miconazole base USP 2% w/w: Oral gel.
15gm tube: 50.00 MRP
+ MYCON Oral Gel Aristopharma
Miconazole base USP 2% w/w: Oral gel.
15gm tube: 60.00 MRP
+ MYCO-OG Oral Gel Pharmasia
Miconazole base USP 2% w/w: Oral gel.
15gm tube: 50.00 MRP
+ ORAGEL-M Gel UniMed & UniHealth
Miconazole USP 2% w/w: Oral gel.
15gm tube: 50.00 MRP
+ ORMICO Oral Gel Pacific
Miconazole base USP 2% w/w: Oral gel.
l 5gm tube: 50.00 MRP
+ OROCARE Oral Gel Novo Healthcare
Miconazole base USP 2% w/w: Oral gel.
15gm tube: 50.00 MRP
+ OROCONAZOL Oral Gel Incepta
Miconazole base USP 2% w/w: Oral gel.
15gm tube: 50.00 MRP
+ OROGURD Oral Gel SK+F
Miconazole base USP 2% w/w: Oral gel.
15gm tube: 50.00 MRP
+ UNIGAL Oral Gel Opsonin
Miconazole 2% w/w: Oral gel.
15gm tube: 44.16 MRP
TERBINAFINE21,54
T ERBINAFINE HCI: Tablet
Ind: Fungal infections of the skin and nails
(dermatophyte & ringworm infections).
C/I: Hypersensitivity to terbinafine.
S/E: Gastrointestinal symptoms (feeling of
fullness, loss of appetite, nausea, mild abdominal
pain, diarrhoea); skin reactions (rashes, urticaria).
Cautions: Pregnant and breast-feeding women;
hepatic & renal impairment.
Dosage: Ringworm infection-250mg daily
usually for 2-6 weeks in tinea pedis, 2-4 weeks
in tinea cruris, 4 weeks in tinea corporis; nail
infection- 6 weeks-3 months or longer in nail
infections.
Child- not recommended.
QIMP-17 (310)
+ INFUD Tab. General
Terbinafine hydrochloride 250mg/tablet.
4's pack: 160.60 MRP
+ MYCOFIN Tab. SK+F
Terbinafine hydrochloride 250mg/tablet.
1O's pack: 400.00 MRP
+ T ELFIN Tab. UniMed & UniHealth
Terbinafme hydrochloride 250mg/tablet.
lO's pack: 500.00 MRP
+ T ERBEX Tab. Beximco
Terbinafme hydrochloride 250mg/tablet.
1O's pack: 500.00 IP
+ T ERBIFIN Tab. Aristopharma
Terbinafine hydrochloride 250mg/tablet.
12's pack: 600.00 MRP
*
Topical antifungal preparations can be
found in Dermatology sections.
*
Urogenital anti-fungal drugs can be found
in Urogenital section.
4. ANTI- PROTOZOAL
DRUGS
Amoebicidal/Anti-giardial/
Trichomonacidal drugs
METRONIDAZOLE21,33
MET RONIDAZOLE: Tablet/ Susp/ Injection/
Suppositories.
Ind: Amoebiasis, liver abceess; giardiasis; tri­
chomonal vaginitis; colonic anaerobes (specially
bacteroides fragilis), ulcerative stomatitis and
amoebic infections of other organs.
Intravenous (i.v) preparations are indicated and
prepared specially for curative and preventive
treatment against anaerobic infections during
colonic surgery.
C/I: Pregnancy (1st trimester), active CNS
disease.
S/E: Nausea, headache, drowsiness, dizziness;
rashes, leucopenia, darkening of urine, peripher­
al neuropathy in prolonged treatment, ataxia and
transient epileptic seizures with high doses.
Cautions: Blood dyscrasias; pregnancy,
lactation; avoid alcohol.
Dosage & admin: Oral preparation:
Amoebiasis, 800 mg thrice daily for 5 days.
Child, 7-10 yrs. 400 mg; 3-7 yrs. 200mg tds.;
1-3 years lOOmg every 8 hours for 5 days.
Giardiasis, 2gm daily for 3 days.
Child, 1-3 yrs. SOOmg daily; 3-7 yrs. 600-
800mg daily; 7-10 yrs. lgm daily for 3 days.
Trichomoniasis, 200mg 3 times daily for 7 days
or 400mg every 12 hours for 7 days or 800mg
in the morning and 1.2gm at night for 2 days,
or 2gm as a single dose. Child, SOmg 8 hourly
(1-3 yrs.), l OOmg 12 hourly (3-7 yrs.), lOOmg 8
hourly (7-10 yrs.). All for 7 days.
Anaerobic infections, 400mg 3 times daily for
7 days. Child, 7.5mg/kg every 8 hours.
Amoebic abscess, 400mg 3 times daily for 5-
10 days. The course may be repeated after 2
weeks if necessary.
L V preparation: 1 OOml injection is given by i.v
infusion immediately before, during or after
-
colonic operation at the rate of 5ml per
minute. This should be repeated 8 hourly until
oral medication can be given to complete a 7
day course of treatment.
Suppository: Use rectally.
+ AMEZOL Tab. Cosmic
Metronidazole 400mg/tablet
•
1OO's pack: 101.00 MRP
+ AMEZOL Susp. Cosmic
Metronidazole 200mg/5ml: suspension
60ml bot: 24.21 MRP
+ AMORIN Tab. Doctor's
Metronidazole 400mg/tab1et.
400mg x lOO's pack: 114.00 MRP
+ AMORIN Susp. Doctor's
Metronidazole 200mg/ 5ml : suspension
60ml bot: 24.00 MRP
+ AMODIS Tab. Square
Metronidazole 400mg & 500mg/tablet.
400mg x 200's pack: 202.00 MRP
500mg x lOO's pack: 135.00 MRP
+ AMODIS Susp. Square
Metronidazole 200mg/ 5ml: suspension
60ml bot: 24.84 MRP
+ AMODIS I.V Inf. Square
Metronidazole 500mg in 1OOml bottle: i.v infusion
.
lOOml bot: 53.40 MRP
+ AMOTREX Tab. ACI
Metronidazole 200mg & 400mg/tablet
200mg x lOO's pack: 66.00 MRP
400mg x lOO's pack: 115.00 MRP
+ AMOTREX Syp. ACI
Metronidazole 200mg/5ml: suspension
60ml bot: 25.09 MRP
+ ANAMET Tab. Navana
Metronidazole 400mg/tablet
lOO's pack: 114.00 MRP
+ ANAMET Susp. Navana
Metronidazole 200mg/5ml: suspension
60ml bot: 25.50 MRP
+ ANTIPRO 400 Tab. Rangs Pharma
Metronidazole 400mg/tablet
lOO's pack: 114.00 MRP
+ ANTIPRO Susp. Rangs Pharma
Metronidazole 200mg/5ml: suspension
60ml bot: 25.00 MRP
+ ANZOLE 400 Tab. MonicoPharma
Metronidazole 400mg/tablet
1OO's pack: 101.00 MRP
+ ANZOLE Susp. MonicoPharma
Metronidazole 200mg/5ml: suspension
60ml bot: 25.00 MRP
+ APETRYL-400 Tab. APC Pharma
Metronidazole 400mg/tablet
IOO's pack: 113.00 MRP
+ APE'I'RYL Susp. APC Pharma
Metronidazole 200mg/5ml: suspension
60ml bot: 20.00 MRP
+ APZYL Susp. Apollo
Metronidazole 200mg/5ml: suspension
60ml bot: 24.00 MRP
+ BENMET Tab. Pacific
Metronidazole 400mg/tablet
1OO's pack:. 114.00 MRP •
+ BENMET Susp. Pacific
Metronidazole 200mg/5ml suspension
60ml bot: 20.00 MRP
+ BEZOL Tab. Bengal Drugs
Metronidazole 400mg/tablet
lOO's pack: 100.00 MRP
 QIMP-17 (311) ANTIMICROBIAL DRUGS

+ BEZOL Susp. Bengal Drugs 60ml bot: 21.00 MRP

t FLAGYL I.V Inj. Sanofi-aventis
Metronidazole 200mg/5ml suspension t MELAGYL Tab. Reliance
Metronidazole 500mg in 1OOml bottle (0.5%
60ml bot: 22.00 MRP Metronidazole 400mg/tablet
w/v): i.v injection.
t BIOZYL Tab. Biopharma 1 OOml bot: 85.22 MRP I OO's pack: I 02.00 MRP
Metronidazole 400mg/tablet • MELAGYL Susp. Reliance
+ FLAMYD Tab. Incepta
lOO's pack: 100.00 MRP Metronidazole 200mg/5ml: suspension
Metronidazole 250mg & 500mg: tablet (f.c)
t BIOZYL Susp. Biopharma 250mg x 1 OO's pack: 78.00 MRP 60ml bot: 25.75 MRP
Metronidazole 200mg/5ml suspension 500mg x lOO's pack: 135.00 MRP t MENILET Tab. Alco Pharma
60ml bot: 25.09 MRP t FLAMYD I.V Inf. Incepta Metronidazole 400mg/tablet
t BIOZYL I.V Inf. Biopharma Metronidazole 500mg in 1 OOml bottle: i.v infusion 400mg x lOO's pack: 101.00 MRP
Metronidazole 500mg in lOOml bottle : i.v infusion lOOml bot: 53.18 MRP t MENILET Susp. Alco Pharma
lOOml bot: 52.59 MRP t FLORAZOL Tab. NIPRO JMI Metronidazole 200mg/5ml: suspension
t CEDOL Tab. CPL Met ronidazole BP 400mg/tablet 60ml bot: 21.24 MRP
Metronidazole 400mg/tablet 400mg x 200's pack: 228.00 MRP t MENOL Tab. Supreme
lOO's pack: 100.00 MRP t FLORAZOL Susp. NIPRO JMI Metronidazole 400mg/tablet
t CEDOL Susp. CPL Metronidazole BP 200mg/5ml: suspension . 400mg x lOO's pack: 114.00 MRP
Metronidazole 200mg/5ml suspension 60ml bot: 24.94 MRP + MENOL Susp. Supreme
60ml bot: 22.00 MRP Metronidazole 200mg/5ml: suspension
t G-METRONIDAZOLE Tab. Gonoshas
t DECAGYL Tab. Decent Metronidazole 400mg/tablet (f.c) 60ml bot: 25.75 MRP
Metronidazole 400mg/tablet. 400mg x 1 OO's pack: 100.00 MRP t METASON Tab. Jayson
400mg x lOO's pack: 100.00 MRP t G-METRONIDAZOLE Susp. Gonoshas Metronidazole 400mg/tablet.
t DECAGYL Syp. Decent Metronidazole 125mg/5ml: suspension 400mg x lOO's pack: 115.00 MRP
.

Metronidazole 200mg/5ml: suspension 60ml bot: 21.00 MRP t METASON Susp. Jayson
60ml bot: 25.50 MRP lOOml bot: 30.25 MRP Met ronidazole 200mg/5ml: suspension
t DIROZYL Tab. Acme t G-METRONIDAZOLE I.V Inf. Gonoshas 60ml bot: 25.10 MRP
Metronidazole 200mg & 500mg/tablet. Metronidazole 500mg in 1 OOml vial: i.v infusion t METCO Tab. SK+F
200mg x lOO's pack: 67.00 MRP lOOml bot: 35.53 MRP Metronidazole 400mg/tablet
500mg x 500's pack: 400.00 MRP 400mg lOO's pack: 114.00 MRP
t KEMET Tab. Kemiko x

t DIROZYL Susp. Acme Metronidazole 400mg/tablet t METCO Susp. SK+F

Metronidazole 200mg/5ml: suspension 400mg x lOO's pack: 112.00 MRP Metronidazole 200mg/5ml: suspension
60ml bot: 25.10 MRP t KEMET Susp. Kemiko 60ml bot: 25.12 MRP
t DIROZYL Suppo. Acme Metronidazole 200mg/5ml: suspension t METCO I.V Inf. SK+F
Metronidazole 500mg/stick: supposito ry. 60ml bot: 25.75 MRP Metronidazole 500mg in lOOml vial: i.v infusion
10 sticks pack: 120.50 MRP 1 OOml bot: 60.00 MRP
+ KILPRO Tab. Techno Drugs
t DIROZYL I.V Inf. Acme Metronidazole 400mg/tablet t METFIL Tab. Bristol
Metronidazole 500mg in lOOml vi al: i.v infusion 400mg x lOO's pack: 114.00 MRP Metronidazole 400mg/tablet
1OOml vial: 50.20 MRP t KILPRO I.V Inf. Techno Drugs 400mg x lOO's pack: 100.00 MRP
t D-METR0-400 Tab. Desh Pharma Metronidazole 500mg in 1 OOml vial: i.v infusion t METONID Tab. Popular
Metronidazole 400mg/tablet. lOOml bot: 65.00 MRP Metronidazole 400mg/tablet
400mg x lOO's pack: 80.00 IP 400mg x lOO's pack: 114.00 MRP
t KLION Tab. Ambee
+ D-METRO Susp. Desh Pharma Metronidazole 200mg & 400mg/tablet t METONID Susp. Popular
Metronidazole 20Cfmg/5ml: suspension 200mg x lOO's pack: 67.00 MRP Metronidazole 200mg/5ml: suspension
60ml bot: 16.80 IP 400mg x lOO's pack: 109.00 MRP 60ml bot: 25 .24 MRP
+ EGYL Tab. Euro Pharma t KLION Susp. Ambee t METONID I.V Inf. Popular
Metronidazole 400mg/tablet. Metronidazole 125mg/5ml: suspension Metronidazole 500mg in lOOml vial: i.v infusion
400mg x lOO's pack: 114.00 MRP 60ml bot: 23.35 MRP lOOml bot: 52.79 MRP
+ EGYL Susp. Euro Pharma t LIBRAZOL I.V Inf. Libra t METRA Tab. Ad-din
Metronidazole 200mg/5ml: suspension Metronidazole 500mg in lOOml bot: i.v infusion Metronidazole 400mg/tablet
60ml bot: 24.85 MRP lOOml bot: 49.76 MRP 400mg x lOO's pack: 105.00 MRP
t FILMET Tab. Beximco + M-400 Tab. Pharmasia t METRA Susp. Ad-din
Metronidazole 200mg & 400 mg/tablet. Metronidazole 400mg/tablet Metronidazole 200mg/5ml: suspension
200mg x 200's pack: 138.00 MRP 400mg x lOO's pack: 114.00 MRP 60ml bot: 24.00 MRP
400mg x lOO's pack: 101.00 MRP t M-DAZOLE Tab. Modern t METRION Tab. General
400mg x 250's pack: 252.50 MRP
• Metronidazole 200mg & 400mg/tablet Metronidazole 400mg/tablet
t FILMET-DS Tab. Beximco 200mg x I OO's pack: 66.00 MRP 400mg x lOO's pack: 114.00 MRP
Metronidazole 800 mg/tablet (double str ength). 400mg x lOO's pack: 114.00 MRP + METRION Susp. General
800mg x lOO's pack: 201.00 MRP t M-DAZOLE Susp. Modern Metronidazole 200mg/5ml: suspension
t FILMET Susp. Beximco Metronidazole 200mg/5ml: suspension 60ml bot: 25.76 MRP
Metronidazole 200mg/5ml 60ml bot: 25.67 MRP t METRION I.V Inf. General
60ml bot: 25.75 MRP Metronidazole 500mg in 1OOml bot: i.v infusion
t MECOZOL Tab. Amico
t FILMET I.V Inj. Beximco Metronidazole 400mg/tablet I OOml bot: 80.00 MRP
Metronidazole 500mg in lOOml bottle: i.v infusion lOO's pack: 100.00 MRP t METRIZOL Tab. Cosmo Pharma
lOOml bot: 53.88 MRP t MECOZOL Susp. Amico Metronidazole 400mg/tablet
400mg x lOO's pack: 101.00 MRP
+ FLAGYL Tab. Sanofi-aventis Metronidazole 200mg/5ml: suspension
Metronidazole 200mg & 400mg: tablet 60ml bot: 25.00 MRP t METRO I.V Inf. Opso Saline
200mg x 500's pack: 335.00 MRP t MEDIZOL Tab. Medicon Metronidazole 500mg in I OOml bot: i.v infusion
400mg x 250's pack: 285.00 MRP Metronidazole 400mg/tablet lOOml bot: 35.13 MRP
1 OO's pack: 110.00 MRP
+ FLAGYL Susp. Sanofi-aventis t METROCON-400 Tab. Concord
Metronidazole 200mg/5ml: suspension t MEDIZOL Susp. Medicon Metronidazole 400mg/tablet.
60 ml bot: 24.94 MRP Metronidazole 200mg/5ml: suspension 400mg x 200's pack: 200.00 MRP

•
ANTIMICROBIAL DRUGS QIMP-17 (312)

t METROGYL Tab. Rephco + NIDA Tab. Sonear

Metronidazole 400mg/tablet
400mg x lOO's pack: 110.00 MRP
+ METROMAX 500 Tab. Novo Healthcare
Metronidazole 500mg/tablet.
500mg x lOO's pack: 13 5.00 MRP
+ METROMAX I.V Inf. Novo Healthcare
Metronidazole 400mg/tablet.
400mg x 1OO's pack: 82.00 MRP
+ NIDAZYL Tab. Orion Pharma
Metronidazole 400mg/tablet
400mg x lOO's pack: 114.00 MRP
+ NIDAZYL Susp. Orion Pharma
ORNIDAZOLE35,45
ORNIDAZOLE: Tablet
Omidazole belongs to 5-nitroimidazole group of
drugs. It is an antiprotozoal and antimicrobial
agent for the treatment of infections due to •

Metronidazole 500mg in lOOml vial: i. v infusion Metronidazole 200mg/5ml: suspension Trichomonas vaginalis, Entamoeba histolytica,
1OOml bot: 52.00 MRP 60ml bot: 21.08 MRP Giardia lamblia and certain anaerobic bacteria
t METROPILL Tab. Medimet t NIDAZYL I.V Inf. Orion Pharma such as bacteroides and Clostridium spp,
Metronidazole 200mg & 400mg/tablet Metronidazole 500mg in lOOml bottle: i.v infusion Fusobacterium spp. and anaerobic cocci.
200mg x 1OO's pack: 60.00 MRP 1 OOml bot: 52.20 MRP Mode of action: The antimicrobial activity of
400mg x lOO's pack: 110.00 MRP t ONIDA Tab. Mystic omidazole is due to the reduction of the nitro
t METROPILL Susp. Medimet Metronidazole 400mg/tablet group to a more reactive amine that attacks
Benzoyl metronidazole 200mg/5ml: suspension 400mg x lOO's pack: 100.00 MRP microbial DNA, brings about loss of helical
60ml bot: 22.00 MRP + ONIDA Susp. Mystic sructure of DNA and subsequent DNA breakage,
t METROSIL Tab. Silva Metronidazole 200mg/5ml: suspension thus inhibiting further synthesis and causing
Metronidazole 400mg/tablet 60ml bot: 21.00 MRP degradation of existing DNA of the microbes.
400mg x lOO's pack: 100.00 MRP + ORZYL Tab. Organic Health Ind: Omidazole is used in the treatment of
t METROSIL Susp. Silva Metronidazole BP 400mg/tablet hepatic and intestinal amoebiasis, giardiasis, tri­
Benzoyl metronidazole 200mg/5ml: suspension 400mg x 200's pack: 228.00 MRP chomoniasis of urogenital tract and bacterial
60ml bot: 19.00 MRP + PHIDAZOLE Tab. Pharmadesh vaginosis; also used in the treatment and prophy­
t METROSON Tab. Hudson Metronidazole 400mg/tablet. laxis of susceptible anaerobic infections in den­
Metronidazole 400mg/tablet 400mg x 200's pack: 220.00 MRP tal and gastrointestinal surgery & in other mixed
400mg x lOO's pack: 10 5.00 MRP + PHIDAZOLE Susp. Pharmadesh aerobic-anaerobic infections. Omidazole is also
t METROSON Susp. Hudson Metronidazole 200mg/5ml: suspension advocated in the management of H. pylori induced
Metronidazole 200mg/5ml: suspension 60ml bot: 24.50 MRP duodenal ulcer in combination with other drugs
60ml bot: 18.00 MRP + PROZOL Tab. SAPL C/I; Warnings: First trimester of pregnancy,
t METROZEN Tab. Zenith Metronidazole 400mg/tablet. nursing mothers, known hypersensitivity to
Metronidazole 400mg/tablet 400mg x lOO's pack: 100.00 MRP imidazole derivatives.
400mg x 200's pack: 214.00 MRP t SEEMAGYL Susp. Seema S/E: The following side-effects are common to
t METROZEN Susp. Zenith Metronidazole 200mg/5ml: suspension all nitroimidazoles & are rarely serious:
Metronidazole 200mg/5ml: suspension 60ml bot: 24.00 MRP gastroi ntestinal disturbances, nausea, epigastric
60ml bot: 21.38 MRP t STRAZYL Tab. Asiatic pain, metallic taste, glossitis.
+ METRYL Tab. Opsonin Metronidazole 400mg/tablet Dosage & Admin: Amoebiasis- adults, SOOmg
Metronidazole 200mg, 400mg & 500mg/tablet. 400mg x lOO's pack: 102.00 MRP twice daily for 5-7 days; children, 25mg/kg
200mg x lOO's pack: 58.94 MRP + STRAZYL Susp. Asiatic once daily for 5-10 days. Amoebic dysentery­
400mg x lOO's pack: 100.28 MRP Metronidazole 200mg/5ml: suspension adults, l.Sgm as a single dose for 3 days;
500mg x lOO's pack: 135.47 MRP 60ml bot: 24.84 MRP children, 40mg/kg once daily for 3 days.
t METRYL Susp. Opsonin t TRICOZYL Tab. Edruc Giardiasis- adults, l.5gm once daily for 1-2
Metronidazole 200mg/5ml: suspension Metronidazole 400mg/tablet days; children, 40mg/kg daily for 2 days.
60ml bot: 22.66 MRP 400mg x lOO's pack: 126.00 MRP Trichomoniasis- adults, l.5gm as a single dose
t METRYL I.V Inf. Opsonin + TRICOZYL Susp. Edruc or SOOmg twice daily for 5 days, sexual
Metronidazole 500mg in lOOml bottle: i.v infusion Metronidazole 200mg/5ml: suspension partner should be simultaneously treated;
1OOml bot: 46.99 MRP 60ml bot: 2 5 .00 MRP children, 25mg/kg as a single dose. Bacterial
t METSINA Tab. Ibo Sina + VARIZIL Tab. Drug Inter. vaginosis- adults, l.Sgm once or SOOmg twice
Metronidazole 200mg & 400mg/tablet. Metronidazole 400mg/tablet daily for S-7 days.
200mg x lOO's pack: 63.00 MRP 400mg x lOO's pack: 86.00 MRP Anaerobic bacterial infections- initiate oral
400mg x lOO's pack: 11 5.00 MRP + VARIZIL I.V Inf. Drug Inter. therapy as soon as possible.
t METSINA Susp. Ibo Sina Metronidazole 500mg in lOOml bottle: i. v infusion.
Metronidazole 200mg/5rnl: suspesion lOOml bot: 4 5.00 MRP
t OR-500 Tab. Zenith
Ornidazole INN 500mg/tablet (f.c).
60ml bot: 25.75 MRP
30's pack: 195.60 MRP
+ MEZ Tab. Renata
DILOXANIDE FUROATE21,75 + ORNID Tab. Drug Inter.
Metronidazole 400mg/tablet.
Omidazole INN 500mg/tablet (f.c).
400mg x lOO's pack: 125.00 MRP
DILOXANIDE FUROATE: Tablet/Suspension 50's pack: 3 50.00 MRP
+ MEZ I. V Inf. Renata
Metronidazole 500mg in lOOml bottle: i. v infusion. Ind: Chronic intestinal amoebiasis in which + ORNIL Tab. Opsonin
only cyst and non-vegetative forms of E. Ornidazole INN 500mg/tablet (f. c) .
lOOml bot: 70.00 MRP
histolytica are present in the faeces. 20's pack: 114.89 MRP
t MICOGYL-400 Tab. Globe
Metronidazole 400mg/tablet S/E: Flatulence, vomiting, urticaria, pruritus. t ORNIZOL Tab. Alco Pharma
Dose: 500mg 3 times (every 8 hours) daily for Omidazole INN 500mg/tablet (f. c).
400mg x lOO's pack: 100.00 MRP
10 days, give alone for chronic infection or 30's pack: 180.00 MRP
+ MICOGYL Susp. Globe
Metronidazole 200mg/5ml: suspension following 5 days of metronidazole treatment in t ROBIC Tab. Square
Omidazole INN 500mg/tablet (f. c).
60ml bot: 22.00 MRP acute dysenteric infection.
30's pack: 195 .90 MRP
t NEOGYL-400 Tab. Millat t DILAMIDE Tab. Pharmadesh + TRONIZ Tab. UniMed & UniHealth
Metronidazole 400mg/tablet. Diloxanide Furoate 500mg/tablet Omidazole INN 500mg/tablet (f.c).
400mg x lOO's pack: 114.00 MRP 1OO's pack: 500.00 MRP 30's pack: 195.00 MRP
+ NEOGYL Susp. Millat + DILAMIDE Susp. Pharmadesh + XYNOR Tab. Beximco
Metronidazole 200mg/5ml: suspension Diloxanide Furoate BP 2 50mg/5ml: suspension. Omidazole INN 500mg/tablet (f. c).
60rnl bot: 24.88 MRP 60ml bot: 60 .00 MRP 30's pack: 195.00 IP

SECNIDAZOLE21,35
SECNIDAZOLE: Tablet/Syrup
Secnidazole is a synthetic derivative of the
nitroimidazole series of antiprotozoal drugs.
Ind: Intestinal amoebiasis, hepatic amoebiasis,
urethritis and vaginitis dueto Trichomonas
vaginalis, giardiasis.
C/I; Warnings: First trimester of pregnancy,
nursing mothers, known hypersensitivity to
imidazole derivatives.
S/E: The following side-effects are common to
all nitroimidazoles & are rarely serious: gastroin­
testinal disturbances, nausea, epigastric pain,
metallic taste, glossitis. With secnidazole, gas­
trointestinal disorders (nausea, vomiting, epigas­
tric pain) have been reported in very rare cases.
Dosage & Admin: The usual adult dosage is
2gm once only, just before meals. For hepatic
amoebiasis, the adult dosage is 1.5gm/day, in a
single or divided dose, just before meals, for 5
days.
+ PRONIL-DS Tab. Acme
Secnidazole 1gm/tablet (double strength).
8's pack: 128.48 MRP
+ SECNID DS Tab. Square
Secnidazole l gm/tablet (double strength).
lO's pack: 160.60 MRP
+ SECNID Susp. Square
Secnidazole 500mg (as granules) in IO ml single
dose bottle: suspension
500mg (lO ml) dose bot: 25.10 MRP
+ SECNIDAL-DS Tab. Sanofi-aventis
Secnidazole I gm/tablet (double strength).
lO's pack: 253.80 MRP
+ SECNIZOL DS Tab. Incepta
Secnidazole l gm/tablet (double strength).
6's pack: 96.00 MRP
+ SEZOL-DS Tab. ACI
Secnidazole l gm/tablet (double strength).
IO's pack: 170.00 MRP
TINIDAZOLE21,62
TINIDAZOLE: Tablet/ Injection
Ind: Amoebiasis; Giardiasis; Urogenital
trichomoniasis; prophylaxis and treatment of
Anaerobic infections.
C/I: Blood dyscrasias; Neurological disorders.
Cautions: Pregnancy, lactation; concurrent use
with alcohol:
Dose: Amoebiasis, 2gm daily in a single dose
for 3 days.
Giardiasis, 2gm as a single dose.
Trichomoniasis, 2gm as a single dose.
Anaerobic infections, by mouth, 2gm initially
then lgm daily for minimum 5-6 days;
prophylaxis- 2gm as a single dose.
Or,
By injection, treatment- 800mg by slow i.v
infusion followed by 800mg i.v daily (until oral
maintenance) & prophylaxis, 1600mg by slow
i.v infusion.
Children, 50-60mg/kg/day.
+ PROTOGYN Tab. Renata
Tinidazole 500mg & l gm/tablet (f.c).
500mg x lOO's pack: 400.00 MRP
l gm x 20's pack: 120.00 MRP
QIMP-17 (313)
+ TINIZOL DS Tab. Beacon
Tinidazole lgm/tablet (f.c).
l gm x 50's pack: 285.00 MRP
+ T-ZOL Tab. Popular
Tinidazole 500mg & l gm/tablet (f.c).
500mg x 30's pack: 82.80 MRP
l gm x 32's pack: 183.36 MRP
+ T-ZOL I.V Inf. Popular
Tinidazole 0.4% (400mg/100ml): i.v infusion.
lOOml (400mg) bot x 1 's pack: 120.00 MRP
Antimalarials
CHLOROQUINE21, 33
CHLOROQUINE: Tablet/Syrup/ Injection
Ind: Prophylaxis and treatment of malaria; extra­
intestinal amoebiasis (amoebic hepatitis),
giardiasis, rheumatoid arthritis, SLE.
S/E: Headache, nausea, vomiting, diarrhoea;
rashes; rarely psychotic episodes) convulsions;
corneal and retinal changes with prolonged high
doses.
Cautions: Impaired renal and hepatic functions,
psoriasis, porphyria; ocular change.
Dosage & admin: Malaria- Adult, 600mg (of
base) stat then 300mg (base) after 6 to 8
hours, then 300mg daily (single dose) for 2
days. (Approx. total cumulative dose of
25mg/kg of base).
Child, initial dose of lOmg/kg (of base) then a
single dose of 5mg/kg after 6-8 hours then a
single dose of 5mg/kg daily for 2 days.
Prophylaxis- adult, 2 tabs. as a single dose on
the same day each week; start 2 weeks before
entering endemic area and continue for 4
weeks after leaving. Child, 5 mg/kg (of base) at
weekly intervals; start 2 weeks before entering
epidemic area and continue for 4 weeks after
leaving.
Amoebic hepatitis: Adult, 4 tab. daily for 2
days then 1 tab 2 times daily for 2-3 weeks.
Child, not recommended;
Chloroquine better take after meal.
+ AVLOQUIN Tab. ACI
Chloroquine phosphate 250mg/tablet.
lOO's pack: 122.00 MRP
+ AVLOQUIN Syp. ACI
Chloroquine 80mg (base 50mg)/5ml: syrup
Dosage: For children, Prophylaxis- under 1
year not recommended; 1-4 yars. 2 tsf; 4-8 yrs.
3 tsf; 8-12 yrs. 4-5 tsf.
Treatment- under 1 year , initial 1-2 tsf ·
followed by 1 tsf after 6 hours, then 1 tsf daily
for 4 days: 1-4 yrs. 3-4 tsf.+ 2 tsf then 2 tsf
daily for four days; 4-8 yrs. 4-6 tsf. 3 tsf then
+ departure and continued for 4 weeks after
3 tsf daily for 4 days; 8-12 yrs. 6-9 tsf+ 3 tsf
then 4 tsf daily for 4 days.
60ml bot: 14.87 MRP
+ CLIT Tab. Hudson
Chloroquine phosphate 250mg/tablet.
lOO's pack: 120.00 MRP
+ JASOCHLOR Tab. Jayson
Chloroquine phosphate 250mg/tablet.
lOO's pack: 121.00 MRP
+ JASOCHLOR Syp. Jayson
Chloroquine 80mg/5ml: syrup
60ml bot: 14.87 MRP
•
ANTIMICROBIAL DRUGS
+ QUINOLEX Tab. Globe
Chloroquine phosphate 250mg/tablet.
lOO's pack: 100.00 MRP
+ QUINOLEX Syp. Globe
Chloroquine phosphate 80mg/5ml: syrup
60ml bot: 12.00 MRP
+ ZENOQUINE Tab. Zenith
Chloroquine phosphate 250mg/tablet.
lOO's pack: 130.00 MRP
• ZENOQUINE Syp. Zenith
Chloroquine phosphate 80mg/5ml: syrup
60ml bot: 14.65 MRP
MEFLOQUINE21,50
MEFLOQUINE: Tablet
Ind: Chemoprophylaxis of malaria, (in
areas of the world where there is a high risk of
chloroquine-resistant falciparum malaria);
treatment of uncomplicated falciparum malaria
and chloroquine-resistant vivax malaria. It is also
effective in the treatment of benign malarias, but
is not required as chloroquine is usually efective.
Mefloquine should not be used for treatment if it
has been used for prophylaxis.
C/I: Chemoprophylaxis in first trimester of preg­
nancy (teratogenic in animals, avoid pregnancy
during and for·3 months after), breast-feeding,
and history of serious psychiatric disorders or
convulsions (or family history of epilepsy);
hypersensitivity to quinine.
S/E: Nausea, vomiting, diarrhoea, abdominal
pain; dizziness, loss of balance, headache, som­
nolence, sleep disorders (insommia, abnormal
dreams); also neuropsychiatric reactions (includ­
ing sensory and motor neuropathies, anxiety,
depression, hallucinations, overt psychosis,
convulsions), tinnitus and vestibular disorders,
visual disturbances, circulatory disorders
(hypotension and hypertension), tachycardia,
bradycardia, cardiac conduction disorders,
muscle weakness, myalgia, arthralgia, rash,
urticaria, pruritus, alopecia, asthenia, malaise,
fatigue, fever, loss of appetite, leucopenia or
leucocytosis, thrombocytopenia; disturbances in
liver function tests; rarely Stevens-Johnson
syndrome, AV block and encephalopathy.
Cautions: Exclude pregnancy before starting
chemoprophylaxis; avoid chemoprophylaxis in
severe hepatic impairment; renal impairment;
cardiac conduction disorder; epilepsy; not recom­
mended in young children (under 15kg).
May affect performance of skilled tasks e.g
driving; effects may persist for upto 3 weeks.
Dosage & admin: Chemoprophylaxis: Adult,
250mg each week starting 1-2 weeks before
leaving malarious area; Child, 2-5 years (15-
19kg) quarter adult dose, 6-8 years (20-30kg)
half adult dose, 9-llyears (31-45kg) three­
quarters adult dose.
Treatment: Adult, by mouth, 20mg/kg (of
base) as a single dose (up to max. 1.5gm) or
preferably in 2 divided doses 6-8 hours apart;
Children, by mouth 20mg/kg as a single dose
or preferably in 2 divided doses 6-8 hrs. apart.
Drug inter: Halofantrine must not be given with
or after mefloquine therapy (danger of fatal
arrhythmias).

ANTIMICROBIAL DRUGS
.
+ MEF-Q Tab. Renata
Mefloquine 250mg/tablet
1OO's pack: 3200.00 MRP
HYDROXYCHLOROQUINE
Preparations: See in the chapter of 'antirheumatic
& anti-inflammatory drugs' under 'disease­
modifying antirheumatic drugs'.
PRIMAQUINE21,33
PRIMAQUINE Phosphate: Tablet
Ind: Radical cure of malaria (pl. vivax & ovale
malaria).
C/I: Haemolytic anaemia.
S/E: Anorexia, nausea, vomiting, jaundice; less
commonly mild diarrhoea; haemolytic anaemia
and bone marrow depression.
Dosage & admin: Adult, 15 mg (1 tablet) daily
for 14-21 days following a course of chloroqu­
ine or amodiaquine. Child, half the adult dose.
+ JASOPRIM Tab. Jayson
Primaquine phosphate 15mg/tablet
lOO's pack: 126.00 IP
+ KANAPRIM Tab. Globe
Primaquine phosphate 15mg/tablet
1OO's pack: 62.00 MRP
+ P-PHOS Tab. Hudson
Primaquine phosphate 15mg/tablet
1OO's pack: 62.00 MRP
+ REMAQUIN Tab. ACI
Primaquine phosphate 15mg/tablet
lOO's pack: 151.00 MRP
I sleep disorder, etc.
PYRIMETHAMINE21,33
PYRIMETHAMINE: Tablet
Ind: Chemprophylaxis of malaria.
S/E; Cautions: See above (sulphadoxine +
pyri.methamine prepn.)
Dose: prophylaxis, 25-50mg, once a week.
Child, 5-12 yrs. haH adult dose; under 5 yrs.
quarter adult dose.
+ PYRISON Tab. Jayson
Pyrimethamine 25mg/tablet
1OO's pack: 28.00 JP
Q UININE2 l ,33
QUININE: Tablet/Syrup/ Injection
Ind: Malignant tertian malaria; nocturnal leg
cramps.
S/E: Cinchonism, including tinitus, headache,
nausea, abdominal pain, rashes, visual
disturbances, blindness, hypersensitivity reactions
including angioneurotic oedema.
C/I: Haemoglobinuria, optic neuritis.
Dosage & admin: By mouth: Adult, 600 mg
every 8 hours for 7 days. Child, 1 Omg/kg 8
hourly for 7 days.
By injection: If the patient is seriously ill, i.v
quinine should be given- loading dose 20mg/kg
infuse over 4 hours; then maintenance dose-
1 Omg/kg infuse over 4 hours, every 8-12
hourly followed by oral quinine.
QIMP-17 (314)
+ JASOQUIN Tab. Jayson
Quinine sulphate 300mg/tablet
lOO's pack: 642.00 MRP
+ JASOQUIN Inj. Jayson
Quinine dihydrochloride 300mg/5ml ampoule:
injection.
I 0 amps pack: 205.90 MRP
+ KANAQUINE Tab. Globe
Quinine sulphate 300mg/tablet
1OO's pack: 640.00 MRP
+ KANAQUINE Inj. Globe
Quinine dihydrochloride 300mg/5ml ampoule:
injection.
I 0 amps pack: 205.00 MRP
+ QUIN-ff Tab. Hudson
Quinine sulphate 300mg/tablet
lOO's pack: 347.00 MRP
SULFADOXIN +
PYRIMETHAMINE21,33
PYRIMETHAMINE: Tablet
Ind: Malarial attacks and symptoms; suppressant
in malaria (chemoprophylaxis); Chloroquine­
resistant falciparum malaria.
S/E: Depression of haemopoesis with prolonged
treatment, rashes.
Cautions: Hepatic or renal impairment; folate
supplements in pregnancy; blood counts required
with high doses.
Dosage & admin: Adult: over 14 yrs. 2-3 tabs.
as a single dose. Child: under 4 yrs. 1/2 tab; 4-
8 yrs.I tab; 9-14 yrs. 2 tabs. All as a single dose.
Prophylaxis: over 14 yrs. 1 tab. weekly; child,
under 4 yrs. 1/4 adult dose; 4-8 yrs. 1/2 adult
dose; 9-14 yrs. 3/4 adult dose.
+ MALACIDE Tab. Square
Sulfadoxine 500mg + pyrimethamine 25mg/tablet.
60's pack: 265.20 MRP . other severe manifestations of complicated
+ MALASON Tab. Hudson
Sulfadoxine 500mg + pyrimethamine 25mg/tablet.
IOO's pack: 380.00 MRP
+ MALEX Tab. Ibo Sina
Sulfadoxine 500mg + pyrimethamine 25mg/tablet.
30's pack: 123.00 MRP
+ SULFAMIN Tab. Jayson
Sulfadoxine 500mg + pyrimethamine 25mg/tablet.
30's pack: 132.30 MRP
Other Preparations
ARTEMETHER/LUMEFANT RINE26,s2,s4
ARTEMETHER + LUMEFANTRINE: Tablet/
Syrup
This is a combined preparation of artemether and
lumefantrine which contains a fixed ratio of 1 :6
parts of artemether and lumefantrine respectively.
Artemether is a sesquiterpene lactone derived
from methyl ether artemisinin. Lumefantrine is a
synthetic aryl-amino alcohol family like other
antimalarials (e.g quinine, matloquine,
halofantrine).
The combination provides the rapid antimalarial
effects of artemether, while reducing the incidence
of recrudescence because of the prolonged effect
of lumefantrine.
•
The two components may act synergistically both
in vitro and in vivo. There appears to be a
correlation between efficacy and AUC (area
under the plasma concentration) for lumefantrine
regardless of the initial parasite load.
Mode of action: The site of antiparasitic action
of both components of the combination is the
food vacuole of the malarial parasite, where they
are thought to interfere with the conversion of
haem, a toxic intermediate produced during
hemoglobin breakdown, to the non-toxic hemo­
zoin, malaria pigment. Artemether is concentrat­
ed in the food vacuole. It then splits its endoper­
oxide bridge as it interacts with haem, blocking
conversion to haemozoin, destroying existing
haemozoin and releasing haem and a cluster of
free radicals into the parasite. Lumefantrine is
•
thought to interfere with the haem polymerisation
process, a critical detoxifying pathway for the
malaria parasite. Both artemether and
lumefantrine have a secondary action involving
inhibition of nucleic acid and protein synthesis
within the malarial parasite. Free radicals that
are generated catalyse various biological
processes and can result in parasite death.
Ind: Treatment and stand-by emergency treat­
ment of non-immune adults and children with
malaria due to plasmodium falciparum infection
or mixed infection including P. falciparum. This
combination is also recommended for malaria
infections acquired in areas where the parasites
may be resistant to other antimalarials.
C/I: Hypersensitivity to the active substances or
any of the excipients. Pregnancy, unless the
doctor considers it essential.
S/E: Headache, anorexia, abdominal pain,
dizziness, asthenia, cough, myalgia, arthralgia,
Precautions & warnings: Cerebral malaria or
malaria including pulmonary oedema or renal
failure. QTc prolongation. Patients with food
aversion. Pregnancy, lactation. Drivers &
machinery users.
Dosage & admin: Adults: J. Treatment, gene­
ral: 4 tablets (or equivalent syrup) at initial
diagnosis and then after 8, 24 and 48 hours.
2. Treatment of multi-drug resistant malaria
and non-immune patients: A 3-day course
comprising 4 tablets (or equivalent syrup) at
initial diagnosis, again after 8 hours, and then
twice daily for the following two .days.
3. Stand-by emergency treatment: A 3-day
course comprising 4 tablets (or equivalent
syrup) at the onset of symptoms, again after 8
hours, and then twice daily for the following
two days.
Children: 1. Treatment, general: 1 to 3 tablets
(or equivalent syrup) at initial diagnosis •
(depending on body-weight) and then after 8,
24 and 48 hours.
2. Treatment of multi-drug-resistant malaria
and non-immune patients: A 3-day course
comprising 1 to 3 tablets (or equivalent syrup)
at initial diagnosis (depending on body-weight)
again after 8 hours and then twice daily on
th� followint two days.
3. Stand-by emergency treatment: A 3-day
course comprising 1 to 3 tablets (or equivalent
syrup) at the onset of symptoms (depending
 QIMP-17 (315) ANTIMICROBIAL DRUGS

on body-weight), again after 8 hours, and then

(Leishmaniacides) +LIVAMISOLE-M Tab. Modern
twice daily on the following two days. Levamisole 40mg/tablet
Drug inter: Interaction studies in healthy volun­ 1 OO's pack: 40.00 MRP
teers who have received high levels of meflo­ SODIUM STIBOGLUCONATE21,47 460ml bot: 70.26 MRP •

quine with this combination, & studies in the +VERMICOM Syp. Opsonin
field, when enrolled patients on this combination Levamisole 40mg/5ml: syrup
SODIUM STIB OGLUCONATE (An antimony
had been previously treated with quinine, there 30ml bot: 8.17 MRP
compound): Injection .
were no evidence of drug interactions.
Preparation: Stibatin injection

+AREXEL Tab. Jayson

(GlaxoSmithkline)- may not be available. ME BENDAZOLE21,33
Artemether 20mg & lumefantrine 120mg/tablet.
24's pack: 409.44 IP MEBENDAZOLE: Tablet/Syrup
•

5. ANTHELMINTICS
+COARTEM Tab. Novartis Ind: Roundworm, threadworm, common &
Artemether 20mg & lumefantrine 120mg/tablet. American hookworm and whipworm.
16's pack: 346.40 MRP C/I: Pregnancy; children under 2 yrs.
Drugs for Round worms Hook
24's pack: 519.60 MRP S/E: Diarrhoea and rarely abdominal pain.
+COAV L ON Tab. ACI worms Thread worms Whip Dosage & admin: Adult and children over 2
Artemether 20mg & lumefantrine 120mg/tablet. years, roundworm, hookworm & whipworm-
24's pack: 481.92 MRP
worms 1OOmg twice daily (morning & evening) for 3
+L UMER TAM Tab. Square days. Threadworm- lOOmg in a single dose for

LEVAMISOLE 21,33
Artemether 20mg & lumefantrine 120mg/tablet. all age, a second dose may be given after 2-3
24's pack: 481.68 MRP wks. if not cured.

LEVAMISOLE: Tablet/Syrup +BENDEX Tab. Gaco

ARTESUNATE136 Ind: Roundworm, Hookworm (and Thread or Mebendazole 1OOmg & 500mg/tablet
Pinworm). 1OOmg x 30's pack: 22.20 MRP
ARTESUNATE: Tablet. C/I: Severe liver and kidney disease. 500mg x 60's pack: 165.00 MRP
Artesunate INN 50mg/tablet. S/E: Nausea, vomiting , abdominal·discomport,
+ BENDEX Susp. Gaco
Artesunate is an antimalarial drug with high headache, dizziness etc. Mebendazole 100mg/5ml: suspension
degree of etlicacy on malarial parasites and no Dosage & admin: 1-4 years 40-50mg; 5-12 30ml bot: 14.83 MRP
cross resista11ce to chloroquine. It is available as years 80-1 OOmg ; above 12 years and adult,
+ HELBEN Susp. Ad-din
artesunate INN 50mg/tablet. 120-150mg in a single dose at night may be Mebendazole 100mg/5ml: suspension
Ind: Artesunate can quickly and reliably control repeated after 1 week. 30ml·bot: 14.80 MRP
the acute attack of malaria. It is suitable to sal­ Syrup: 1-4 yrs. 1 tsf. 5-12 yrs. 2 tsf; above 12 + MEBANTRIN Tab. Pharmadesh
vage the patients with pernicious malaria and years and adult, 3 tsf in a single dose at night. Mebendazole 1OOmg/tablet
treat p. falciparum malaria and p. vivax malaria. 30's pack: 22.50 MRP
+BIOTREX Syp. B iopharma
It is effective against malaria caused by chloro­ +MEBANTRIN Susp. Pharmadesh
Levamisole 40mg/5ml: syrup
quine resistant strain of plasmodium falciparum. Mebendazole 100mg/5ml: suspension
l 5ml bot: 8.03 MRP
S/E: No adverse reactions were observed with 30ml bot: 15.00 MRP
30ml bot: 15.00 MRP
recommended dose uptill now. + MEBENDOL Tab. Doctor's
+DEOTREX Tab. Desh Pharma
Precaution: Artesunate should be used carefully Mebendazole 1OOmg/tablet
Levamisole 40mg/tablet
in pregnant women during the first tri-mester of 60's pack: 42.00 MRP
l OO's strip pack: 35.00 IP
pregnancy. + MEBENDOL Susp. Doctor's
+ DEOTREX Syp. Desh Pharma
Pregnancy & lactation: See above under Mebendazole I 00mg/5ml: syrup.
Levamisole 40mg/5ml: syrup
'precaution'. 30ml bot: 13.65 MRP
30ml bot: 11.00 IP '

Dosage & admin: Adult: 5 days treatment- on + MEBREX Tab. M edimet

+ETRAX Tab. ACI
the 1st day 2 tablets twice and 2nd day Meberldazole 1OOmg/tablet
Levamisole 40mg/tablet
onward 1 tablet twice daily for remaining 4 60's pack: 44.40 MRP
1OO's strip pack: I 00.00 MRP
days (i.e total 12 ta�lets). + MEBREX Susp. M edimet
+ETRAX Syp. ACI
Children: 1-3 years: 5 days treatment- on the Mebendazole 100mg/5ml: syrup.
Levamisole 40mg/5ml: syrup
1st day 1/2 tablet twice and 2nd day onward 30 ml bot: 14.83 MRP
30ml bot: 24.00 MRP
1/ 4 tablet twice daily for remaining 4 days (i.e +PANAMOX Tab. Jayson
+ G-LEVAMIZOLE Syp. Gonoshas.
total 3 tablets). Mebendazole 1OOmg/tablet
Levamisole 40mg/5ml: syrup
4-5 years: 5 days treatment- on the· 1st day 1 ·
120's pack: 88.80 MRP
30ml bot: 9.50 MRP
tablet twice and 2nd day onward 1/2 tablet +PANAMOX Syp. Jayson
+HELMISOLE Tab. Gaco
twice daily for remaining 4 days (i.e total 6 Mebendazole 100mg/5ml: syrup.
Levamisole 40mg/tablet
tablets). 30ml bot: 14.75 MRP
1 OO's pack: 41.08 MRP
6-12 years: 5 days treatment- on the 1st day +SOLAS Tab. Opsonin
+HEL MISOLE Syp. Gaco
11/2 tablet twice, 2nd day 1 tablet twice and Mebendozole1OOmg/tablet.
Levamisole 40mg/5ml: syrup.
3rd day onward 1/2 tablet twice daily for 60's pack: 39.06 MRP
30ml bot: 15.00 MRP
remaining 3 days (i.e total 8 tablets). +SOLAS Syp. Opsonin
+ LEMOX Syp. B engal Drugs
Prophylaxis: 1OOmg tablet once a week, from Mebendozolel 00mg/5ml: suspension
Levamisole 40mg/5ml: syrup.
1 week before entering malarial areas, to 4 30ml bot: 13.09 MRP
15ml bot: 9.00 MRP
weeks after leaving the area.
30ml bot: 15.00 MRP

+ARTEX-50 Tab. Jayson +LEVAMIN Tab. Pharmadesh ALBENDAZOLE21,33

Artesunate INN 50mg/tablet. Levamisole 40mg/tablet
12's pack: 144.60 IP l OO's pack: 46.00 MRP
ALBENDAZOLE: Tablet/Suspension
+LEVAMIN Syp. Pharrnadesh Ind: It is a broad spectrum anthelmintic for ·the
Levamisole 40mg/5ml: syrup treatment of - pinworm or theradworm, whip­
Anti-kala-azar drugs 30ml bot: 13.07 MRP worm, large roundworm, hookworm & tape-

I

ANTIMICROBIAL DRUGS QIMP-17 (316)
worm, in single or mixd infestations of any of the +AL-DS Tab. Globe
above. Albendazole 400mg/tablet
C/I; Warnings: Use in pregnancy- because 40's pack: 152.00 MRP
albendazole was found to be embryotoxic and +ALDA-DS Tab. Supreme
teratogenic in the rat and rabbit, its use is con­ Albendazole 400mg/tablet
traindicated in pregnant women or those likely to 25's pack: 100.00 MRP
be pregnant. for women of child-bearing age (15- +ALDA Susp. Supreme
40 yrs) 'albendazole' should be administered Albendazole 200mg/5ml: suspension.
within 7 days of the start of normal menstruation. lOml bot: 15.00 MRP
Dosage & admin: Usual dose in both adutls +ALDABEN-DS Tab. Ad-din
and children over 2 years of'age, 400mg(two Albendazole 400mg/tablet
tablets) as a single dose in cases of Enterobius 25's pack: 100.00 MRP
vermicularis, Trichuris trichiura, Ascaris +ALDABEN Susp. Ad-din
lumbricoides, Ancylostoma duodenale and Albendazole 200mg/5ml: suspension.
Necator americanus. lOml bot: 15.00 MRP
In cases of Strongyloidiasis or Taeniasis +ALDES DS Tab. Desh Pharma
'albendazole' 400mg as a single dose should Albendazole 400mg/tablet
be given for 3 consecutive days. 50's pack: 150.00 IP
Children under 2 yrs. a single dose of 200mg IOO's pack: 300.00 IP
is effective in common infections. In +ALDES Susp. Desh Pharma
hymenolepis nana infections a dose of 400mg Albendazole 200mg/5ml: suspension.
for 3 consecutive days has been found to be 1Oml bot: 15.00 IP
effective. +ALDEX-DS Tab. Gaco
If the patients is not cured on follow-up after Albendazole 400mg/tablet
three weeks, a second course of treatment is 20's pack: 80.00 MRP
indicated. +ALDEX Susp. Gaco
Albendazole 200mg/5ml: suspension.
IOml bot: 15.00 MRP
+ALDIN DS Tab. Techno Drugs
®
Albendazole 400mg/tablet
60's pack: 240.00 MRP
Albendazole chewable tablet & suspension +ALENT IN-DS Tab. Renata
Albendazole 400mg/tablet
25's pack: 83.75 MRP
Sl<•F +ALMEX Tab. Square
Albendazole 400mg/tablet.
+ABENTEL Tab. Aristopharma 48's pack: 240.00 MRP
Albendazole 400mg/tablet lOO's pack: 500.00 MRP
50's pack: 250.00 MRP + ALMEX Susp. Square
+ADZE-400 Tab. Kemiko Albendazole 200mg/5ml: suspension.
Albendazole 400mg/tablet lOml bot: 18.00 MRP
50's pack: 200.00 MRP +ALMIN Tab. Kumudini
+ALARM Tab. Decent Albendazole 400mg/tablet.
Albendazole 400mg/tablet 50's pack: 200.00 MRP
30's pack: 120.00 MRP +ALMIN Susp. Kumudini
+ALBAMAX DS Tab. Ziska Albendazole 200mg/5ml: suspension.
Albendazole 400mg/tablet. lOml bot: 15.00 MRP
lOO's pack: 456.00 MRP +ALPHIN DS Tab. Beximco
+ALBAZOLE-DS Tab. CPL ' Albendazole 400mg/tablet
Albendazole 400mg/tablet. 50's pack: 250.00 IP
50's pack: 200.00 MRP + ALPRO Tab. Pharmadesh
+ALBEN-DS SK+F Albendazole 400mg/tablet
Albendazole 400mg/tablet. 30's pack: 120.00 MRP
48's pack: 240.00 MRP +ALZED Tab. General
1OO's pack: 500.00 MRP Albendazole 400mg/tablet
+ALBEN Susp. SK+F 20's pack: 66.20 MRP
Albendazole 200mg/5ml: suspension. +ANTHEL DS Tab. Seema
1Oml bot: 18.00 MRP Albendazole 400mg/tablet
+ALBENDA-DS Tab. Aexim 50's pack: 210.00 MRP
Albendazole 400mg/tablet +AZOLE Tab. Biopharma
20's pack: 68.00 MRP Albendazole 400mg/tablet
+ ALBEZEN Tab. Zenith 30's pack: 120.60 MRP
Albendazole 400mg/tablet +AZOLE Susp. Biopharma
60's pack: 180.60 MRP Albendazole 200mg/5ml: suspension.
lOml bot: 15.06 MRP
+ALBEZOLE Tab. Apollo
Albendazole 400mg/tablet + BENDA-DS Tab. Bristol
40's pack: 152.00 IP Albendazole 400mg/tablet
+ALBREX Tab. Medimet 50's pack: 175.00 MRP
Albendazole 400mg/tablet +BENFAST Tab. Novo Healthcare
50's pack: 175.00 MRP Albendazole 400mg/tablet
•
-4oomg x 50's pack: 200.00 MRP
+ CIDR-DS Tab. Reliance
Albendazole 400mg/tablet
1O's pack: 51.00 MRP
• CHUBEN Tab. Alco Pharma
Albendazole 400mg/tablet
50's pack: 192.50 MRP
+COLAZ-400 Tab. Cosmic
Albendazole 400mg/tablet
30's pack: 150.00 MRP
•
+COLAZ Susp. Cosmic
Albendazole 200mg/5ml: suspension.
1Oml bot: 15..44 MRP
+COSBEN 400 Tab. Cosmo Pharma
Albendazole 400mg/tablet
50's pack: 150.00 IP
+DURAZOL-400 Tab. Millat
•
Albendazole 400mg/tablet
50's pack: 200.00 MRP
+DURAZOL Susp. Millat
Albendazole 200mg/5ml: suspension.
lOml bot: 15.00 MRP
+EBEN-DS Tab. Edruc
Albendazole 400mg/tablet
25's pack: 100.00 MRP
+EBEN Susp. Edruc
Albendazole 200mg/5ml: suspension.
lOml bot: 15.00 MRP
+ELMIN Tab. Jayson
Albendazole 400mg/tablet
25's pack: 82.75 IP
+ESTAZOL-400 Tab. Ibo Sina
Albendazole 400mg/tablet
50's pack: 200.00 IP
+ESTAZOL Susp. Ibo Sina
Albendazole 200mg/5ml: suspension.
1Oml bot: 20.00 IP •
+G-ALBENDAZOLE Tab. Gonoshas.
Albendazole 400mg/tablet
400mg x lOO's pack: 325.00 MRP
400mg x lOOO's pack: 1600.00 MRP
+H-BEN Tab. Hudson
Albendazole 400mg/tablet
40's pack: 144.00 MRP
I
+HELBEN DS Tab. Modern
Albendazole 400mg/tablet
25's pack: 75.00 MRP
50's pack: 150.00 MRP
+INFESEN Tab. Drug Inter.
Albendazole 400mg/tablet
60's pack: 210.00 MRP
+ INFESEN Susp. Drug Inter.
Albendazole 200mg/5ml: suspension.
lOml bot: 15.00 MRP
+KRIMIZOLE-DS Tab. Mystic
Albendazole 400mg/tablet
25's pack: 81.25 MRP
+KRIMIZOLE Susp. Mystic
Albendazole 200mg/5ml: suspension. •
lOml bot: 15.00 MRP
+ MEBEL DS Tab. Medicon
Albendazole USP 400mg/tablet
50's pack: 265.00 MRP
+MEBEL Susp. Medicon
Albendazole 200mg/5ml: suspension.
lOml bot: 20.00 MRP
+NEMATOX-DS Tab. Chemist
Albendazole 400mg/tablet
50's pack: 177.00 MRP
+NT-PAR 400 Tab. Rangs Pharma
 I
I
•

'

QIMP-17 (317) ANTIMICROBIAL DRUGS

•

Albendazole 400mg/tablet
50's pack: 200.00MRP
+NT-PAR Susp. Rangs Pharma
Albendazole 200mg/5ml: suspension.
lOml bot: 15.00MRP
+ OLV 400 Tab. Organic ·Health
Albendazole USP 400mg/tablet
400mg x 50's pack: 190.00 MRP
t PAM IL DS Tab. Euro Pharma
Albendazole
. 400mg/tablet
400mg x 50's pack: 190.00 MRP
t PARN IL DS Tab. Euro Pharma
Albendazole 400mg/tablet
400mg x 50's pack: 250.00MRP
250mg (2 tabs or 1 tsf); 11 to 15 yrs . 375mg (3 and other lymph node enlargement and
tabs. or 1.5 tsf); adult 625mg (5 tabs or 3 tsf) tenderness; pruritus; skin involvement including
in a single dose. edema, papular and pustular or frank urticaria!
Children, before 6 months- not recommended. ra�, and fever; abnormal sensation in the eyes,
eyelid edema, anterior uveitis, conjunctivitis,
t DELENTIN Syp. Renata limbitis, keratitis, and chorioretinitis or
Pyrantel pamoate 50mg/ml: Syrup choroiditis. These have rarely been severe or
lOml bot: 16.05MRP associated with loss of vision and have generally
t MELPHIN Tab Beximco resolved without corticosteroid treatment. There
Pyrantel pamoate 125mg/tablet are some other adverse reactions have been
lOO's pack: 166.00MRP reported since the drug was registered, such as­
t MELPHIN Syp. B eximco hypotension (mainly orthostatic hypotension),
Pyrantel pamoate 50mg/ml: syrup worsening of bronchial asthma, toxic epidermal
1Oml bot: 11.45MRP necrolysis, an� Stevens-Johnson syndrome.
.

t Q BEN DS Tab. Concord

t PYROPIN Syp. Organic Health Precaution & \Warnings: After treatment with
Albendazole 400mg/tablet Pyrantel pamoate USP 50mg/ml: syrup microfilarici� drugs, patients with hyperreactive
\
400mg x 60's pack: 240.00MRP lOml bot: l l .50MRP ,
11 onchodermatitl� (sowda) may be more likely than
I
others to experie
: nce, severe adverse reactions,
+R-ZOL Tab. Reman \\
Albendazole 400mg/tablet specially edem� and aggravation of
'

Ii!
400mg x 25's pack: 100.00 MRP
FilaricidaI Drugs..
I

(>nchodermatiti� rarely, patietns with

t SINTEL Tab. ACI
I
�nchocerciasis t� are al�o heavily infected with
Albendazole 400mg/tablet oa loa may dev� lop a serious or even fatal
DIETHYL CARBAMAZ E21,33\ f
400mg x 50's pack: 250.00 MRP ,ncephalopathy itbl et sponta11eously or followin�
�
t SINTEL Susp. ACI tteatment with aq eff4ctive m�crofilaricide. ,i
DIET HYL CARB AMAZINE� Tablet/
Albendazole USP 200mg/5ml: suspension. Warning: Histori¢al data have shown that ·�
Injection.
lOml bot: 15.06MRP �icrofilarcidal drugs, I such as1 diethylcarbamazine \
Ind: Filariasis; (Onchocerciasis loiasis).
I I .

citrate, might cause cutaneous and/or systemic

1

t TRIBEN Tab. Ambee

C/I: Pregnancy.
Albendazole 400mg/tablet reactiOl1$ of varying severity (theMazzotti
S/E: Headache, nausea, sedation & malaise;
400mg x 25's pack: 83.75MRP reaction) and ophthalmological reactions in
severe skin reactions may appear.
+TRIBEN Susp. Ambee patients with onchocerciasis.
Cautions: Monitor onchocerciasis patients for
Albendazole 200mg/5ml: suspension. Pregnancy & lactation: lvermectin does not
eye changes.
lOml bot: 13.97 MRP appear to be selectively fetotoxic to the
Dose: 6mg/kg body-wt daily in divided doses
t VERDEN Tab. Astra developing fetus. There are, however, no
for 3-4 weeks.
Albendazole 400mg/tablet adequate and well-controlled studies in pregnant
To minimise reactions treatment is
20's pack: 80 . 00MRP women, so, ivermectin should not be used during
commenced with a dose of lmg/kg and
+VE RMID Tab. Somatec pregnancy since safety in pregnancy has not been
increase gradually over 3 days to 6mg/kg.
Albendazole 400mg/tablet established. In nursing mothers, ivermectin is
Close medical supervision is necessary
25's pack: 95.50 IP excreted in breast milk in low concentrations, so,
particularly in the early phage of treatment.
t VERMIKIL Chew. Tab. NIPRO JMI treatment of mothers who intend to breast feed
Albendazole USP 400mg/tablet (chewable) should only be undertaken when the risk of
t REMAZIN Tab. Reman
50's pack: 176.00MRP Diethylcarbamazine citrate 50mg/tablet delayed treatment to the mother outweighs the
t VERMIKIL Susp. NIPRO JMI lOO's pack: 75.00MRP possible risk to the newborn.
Albendazole 200mg/5ml: suspension. Dosage & admin: The recommended dosages
' 1Oml bot: 15.06MRP of ivermectin are as following:
t VERMIN-DS Tab. Nipa Parasiticidal Drugs 1. Scabies: Dose of 200mcg/kg repeated in 7 to
Albendazole 400mg/tablet 14 days.
25's pack: 88.75MRP 2. Pediculosis: Dose of 200mcg/kg repeated in

t ZOBEN Tab. Amico IVERMECTIN48 7 to 14 days.

Albendazole 400mg/tablet 3. Strongyloidiasis: Single dose of 200mcg/kg
50's pack: 150.00MRP IVERMECTIN: Tablet body-wt.
t ZOBEN Susp. Amico Ivermectin is a semisynthetic, avermectin­ 4. Onchocerciasis: Single dose of 150mcg/kg
Albendazole 200mg/5ml: suspension. derivative anthelmintic and antiectoparasitic (may be repeated every 3 to 12 months).
lOml bot: 14.00MRP agent. It is available as ivermectin BP 6mg/tablet. 5. Filariasis: Single dose of 200mcg/kg.

Ind: 1. Scabies, an infestation with the mite 6. Cutaneous larva migrans: Single dose of

sarcoptes scabiei. 2. Pediculosis, the three lice 200mcg/kg.

PYRANTEL PAMOATE21,33
species that infest humans are- Pediculus Pediatric use: Safety and effectiveness in

PYRANTEL PAMOATE: Table.ti Suspension.
Ind: Threadworm, roundworm, hookworm and
whipworm; Trichostrongyliasis.
C/I: Hepatic dysfunction .
humanus capitis (head louse), Phthirus pubis pediatric patients weighing less than 15kg
(crab or pubic louse), and Pediculus humanus have not been established.
corpus (body louse). 3. Strongyloidiasis of the
intestinal tract (nondisseminated) due to the
+IVERA 6 Tab. B eximco
Ivermectin BP 6mg/tablet
nematode parasite strongyloides stercoralis. 4.
lO's pack: 150.00 IP
Onchocerciasis due to the nematode parasite
..

S/E: Gastro- intestinal disturbances, headache,

dizziness, drowsiness, insomnia and rashes. onchocerca volvulus. 5. Cutaneous larva migrans.

Dosage & admin: Adult and children over 6 C/I: It is contraindicated in patients who are
hypersensitive to any component of this product.
.

months - Ascaris lumbricoides alone, a single

dose of 5 mg/kg; mixed infections involving
ascaris lumbricoides, a single dose of 10 mg/kg
is given. Or,
Adult & children (over 6 months): 6 months to
4 yrs. 125mg (1 tab. or 0.5 tsf); 5 to 10 yrs.
S/E: Strongyloidiasis: Asthenia/fatigue, abdomi­
nal pain, anorexia, constipation, diarrhea, nausea,
• • •
vomiting; dizziness, somnolence, vertigo, tremor;
pruritus, rash and urticaria, Onchocerciasis:
Arthralgia/synovitis; axillary, cervical, inguinal

ANALGESICS
Analgesics are broadly classified in the
following groups:
1. Non-opioid analgesics
2. Opioid analgesics
3. Anti-migraine drugs·
4. Drugs used in Trigeminal neuralgia
5. Drugs used in oral & dental pain
6. Embrocations
1. NON-OPIOID ANALGESICS
Non-opioid analgesics are suitable for mild to
moderate pain of musculoskeletal origin. They
are also effective as antipyretic drugs. Whereas
the opioid drugs are more suitable for moderate
to severe visceral pain & play no role in pyrexia.
Non-opioid analgesics include:
1. Aspirin
2. Paracetamol
3. Nefopam
4. Other NSAIDs (discussed under anti­
inflammatory drugs)
ASPIRIN33,52
ASPIRIN: Tablet
Ind: Analgesic (mild to moderate pain including
headache), antipyretic, anti-inflammatory and
antirheumatic, anti-thro�bosis (reduce platelet
adhesion).
Prophylaxis of cerebrovascular disease or
myocardial infarction; to reduce the risk of
myocardial infarction in patients who have had a
previous attack or in patients with unstable
angina. Prevention of graft occlusion following
aortocoronary by-pass surgery.
C/I: Children under 12 years (unless specially
indicated) and in breast feeding mother, active
peptic ulceration, haemophilia and other bleeding
disorders. Aspirin should not be given to patients
with asthma.
S/E: Side-effects are mild for usual dosage of
aspirin. These are nausea, dyspepsia,
gastrointestinal ulceration & bronchospasm.
Aspirin may induce gastric irritation and
gastrointestinal haemorrtage. There may be skin
reactions in hypersensitive patients. Prolonged
administration may give rise to hearing
disturbances, such as tinnitus.
Cautions: Asthma or history of brochospasm;
Precautios: Aspirin should be administered
cautiously in uncontrolled blood pressure & in
patients with history of brochospasm or asthma
(if clearly needed); impaired renal or hepatic
function; dyspepsia & dehydration.
I
It should be given with caution to patients with
nasal polyps and nasal allergy.
Pregnancy & lactation: It is evident that aspirin
is safe in pregnancy, but it may prolong labour
and contribute to maternal and neonatal bleeding
and is best avoided in the last trimester of
pregnancy unless recommended by the physician.
Aspirin is excreted in low concentration in breast
milk, but, is unlikely to adversely affet the breast­
fed infant.
Dose: Adult- 300-900mg in water, 4 to 6 hourly
when necessary (usually after
meal); max. 4gm daily.
Angina pectoris- 150-3QOm
. g daily (after meal).
Acute myocardial infarction- 300mg stat &
then 75-150mg daily for atleast 4 weeks.
Child under 12 years: Not recommended.
Drug Inter: Aspirin may enhance the effects of
anticoagulants, oral hypoglycaemics and
methotrexate and decreases the action of
uricosuric drugs.
+ ECOSPRIN 300 Tab. Acme
Aspirin 300mg/tablet (e.c)
300mg x 1 OO's: 172.00 MRP
PARACETAMOL26,42,5 2
PARACETAMOL: Tablet/Dispersible Tablet/
Suspension/Syrup/ Drop/IV Infusion/
Suppository
Paracetamol is a fast acting and safe non-opioid
analgesic & antipyretic drug. It is available as­
tablet, suspension, syrup, drop, i. v infusion &
suppository.
Mode of action: The precise mechanism of the
analgesic properities of paracetamol is unknown;
it may involve central and peripheral effects.
Ind: All kinds of mild to moderate pain
(analgesic) and fever (antipyretic), including
neuritis, neuralgia, headache, toothache, earache,
body ache, myalgia, minor arthritic pain, pain
due to rheumatic disorder, cold, influenza,
dysmenorrhoea etc.
C/I: Severe renal function impairment & hepatic
disease; known hypersensitivity to paracetamol.
S/E: Side-effects are usually mild, though
haematological reactions including thrombocy­
topenia, leukopenia, pancytopenia, neutropenia,
and agranulocytosis have been reported.
Pancreatitis; and in very rare cases, hypersensi­
tivity reactions ranging from simple skin rash or
urticaria to anaphylactic shock have been report­
ed, while discontinuation of treatment is required.
Precautions: Paracetamol should be given with
care to patients with impaired kidney or liver
function.
Pregnancy & lactation: Paracetamol is safe in
all stages of pregnancy and lactation.
Dosage & Admin: Adult:, 0.5-lgm (1-2 tablets
or 4-8 tsf syrup) 4-6 times daily, upto a
maximum of 4gm in 24 hours.
Children: Syrup: Under 3 months, usually not
recommended; only can be given on doctor's
-
'
advice, as for post immunization pyrexia at 2
months age- 60mg (or 1/2 tst) or l Omg/kg (or
5mg/kg if jaundiced); 3 months to lyear- 60-
120mg (1/2-1 tst); 1 to 5 years- 1-2 tsf; 6 to 12
years- 2-4 tsf.
These doses may be repeated every 4-6 hours
when necessary (maximum of 4 doses in 24
hours).
Children: Paediatric drop: Under 3 months,
usually not recommended; only can be given
on doctor's advice, as for post immunization
pyrexia at 2 months age- 40mg to 60mg (or
0.5-0.75ml) or lOmg/kg (or Smg/kg if jaun­
diced); 3 months to 1 year- 60mg to 120mg
(0.75-1.Sml); 1 to 2 years- 120mg (1.Sml).
These doses may be repeated every 4-6 hours
when necessary (max. of 4 doses in 24 hours).
Dispersible tablet: Dispersible tablets are a bet­
ter way of replacing other liquid preparations
(such as syrup, suspension, drop). At the time
of giving medicine to the patient one or more
dispersible tablet to be placed in a teaspoon or
cup, add adequate amount of water; the tablet
will dissolve instantly, then give the amount
(as advised or required) to the baby or patient.
IV Infusion: Paracetamol i.v infusion provides
onset of pain relief within 5-10 minutes and
reduces fever within 30 minutes after the start
of administration. The peak analgesic effect is
obtained in 1 hour and the duration of this
effect is usually 4-6 hours. Paracetamol i.v
infusion is indicated where an intravenous
route of administration is considered
necessary. Dosages as below:
Adult >50 kg- lgm/lOOml, up to 4 times a day.
Adult 33 to 50 kg- 15mg/kg body wt, up to 4
times a day.
Neonates, Infants and Children up to 33kg-
15mg/kg body wt, up to 4 times a day.
Neonates, Infants and Children less than 10
kg� 7.5mg/kg body wt, up to 4 times a day.
The minimum interval between each
administration must be 4 hours in patients
without hepatic or renal impairment. In
patients with renal and/or hepatic impairment
the minimum interval between doses must not
be less than 6 hours.
The paracetamol solution is administered as a
15-minutes i.v infusion. Paracetamol solution
for infusion can be diluted in a 0.9°/o sodium
•
chloride or 5o/o glucose solution up to one
tenth. In this case, use the diluted solution
within the hour following its preparation
(infusion time included).
Suppository: Children below 5 years- 125-
250mg suppository 2-3 times a day; 6-12 y�ars
250-SOOmg suppository 2-3 times a day; Adult-
500mg suppository 2-3 times a day. In all cases
suppository should be used rectally.
Overdosage: Moderate overdose: 4-l Ogm/day.
Excessive overdose: More th.an 1Ogm/day.
Symptoms of paracetamol overdose in the first
24 hours are pallor, nausea, vomiting, anorexia
and abdominal pain. Liver damage may become
 QIMP-17 (319) ANALGESICS & ANTIPYRETICS
•

apparent 12 to 48 hours after ingestion. 500's pack: 375.00 MRP · 200's pack: 160.00 MRP
Abnormalities of glucose metabolism & metabo­ +ANALPAIN Susp. Pharmadesh +DOLA Susp. Millat
lic acidosis may occur. Paracetamol l 20mg/5ml: suspension Paracetamol l 20mg/5ml: Suspension
In severe poisoning hepatic failure may progress 60ml bot: 20.63 MRP 60ml bot: 20.00 MRP
to encephalopathy, coma & death. +ANALPAIN Drop Pharmadesh +ENYL Tab. Euro Pharma
Drug inter: Paracetamol should be given with Paracetamol 80mg/ml: paediatric drop. Paracetamol 500mg/tablet.
care to patients taking other drugs that affect the 15ml bot: 12.25 MRP SOO's pack: 400.00 MRP
•

liver. +ASMOL Tab. Sharif +ENYL Susp. Euro Pharma

Paracetamol 500mg/tablet Paracetamol l 20mg/5ml: suspension •

+ ACE Tab. Square l OO's pack: 80.00 MRP 60ml bot: 20.00 MRP
Paracetamol 500mg/tablet
+ASMOL Susp. Sharif +FAST Tab. Acme
500's pack: 400.00 MRP
Paracetamol 120mg/5ml: suspension Paracetamol SOOmg/tablet.
+ACE XR Tab. Square 60ml bot: 21.00 MRP 500's pack: �00.00 MRP
Paracetamol 665mg/tablet (extended release)
+ASTA Susp. Rephco +FAST XR Tab. Acme
1 OO's pack: 150.00 MRP
Paracetamol 120mg/5ml: suspension Paracetamol 665mg/tablet (extended release)
+ACE Susp. Square 60ml bot: 18.00 MRP · l OO's pack: 150.00 MRP
Paracetamol 120mg/5ml: suspension
+ATOPEN Tab. Kemiko +FAST Susp. Acme
60ml bot: 16.35 MRP Paracetamol 500mg/tablet Paracetamol 120mg/5ml: suspension
+ ACE Syp. Square 200's pack: 160.00 MRP 60ml bot: 20.63 MRP
Paracetamol 120mg/5ml: syrup
+ATOPEN Susp. Kemiko +FAST Drop Acme
60ml bot: 20.64 MRP Paracetamol 120mg/5ml: suspension Paracetamol 80mg/ml: paediatric drop.
l OOml bot: 31.78 MRP 60ml bot: 20.63 MRP 15ml bot: 12.27 MRP
+ACE Drop Square l OOml bot: 24.62 MRP +FAST Suppo. Acme
Paracetamol 80mg/ml: paediatric drop.
+ATP Tab. General Paracetamol l 25mg, 250mg & 500mg/stick:
15ml bot: 12.31 MRP Paracetamol 500mg/tablet suppository
30ml bot: 15.73 MRP 250's pack: 200.00 MRP 125mg x lO's pack: 40.10 MRP
+ACE Suppo. Square 250mg x 1O's pack: 50.10 MRP
+ATP Susp. General
Paracetamol 60mg, 125mg, 250mg & Paracetamol l 20mg/5m1: suspension 500mg x 1O's pack: 80.40 MRP
500mg/stick: suppository 60ml bot: 20.63 MRP +FEA Tab. Navana
60mg x l O's pack: 35.10 MRP
+ BEPOL Susp. Bengal Drugs Paracetamol 500mg/tablet.
125mg x 20's pack: 80.20 MRP Paracetamol 120mg/5ml: suspension 200's pack: 160.00 MRP
250mg x 20's pack: 100.20 MRP 60ml bot: 18.00 MRP +FEA-XR Tab. Navana
500mg x 20's pack: 160.80 MRP
+CENTAMOL Tab. CPL Paracetamol BP 665mg/tablet (extended release)
+ACEP Tab. Zenith Paracetamol 500mg/tablet l OO's pack: 150.00 MRP
Paracetamol 500mg/tablet 200's pack: 160.00 MRP + FEA Susp. Navana
200's pack: 160.00 MRP Paracetamol 120mg/5ml: suspension
+CENTAMOL Susp. CPL
+ACEP Susp. Zenith Paracetamol 120mg/5ml: suspension 60ml bot: 20.00 MRP
Paracetamol l 20mg/5ml: suspension
60ml bot: 16.00 MRP •
+FEVA Tab. Ad-din
60ml bot: 16.06 MRP
+CETADOL Susp. Doctor's Paracetamol 500mg/tablet
+ ACEP Drop Zenith Paracetamol 120mg/5ml: suspension 200's pack: 150.00 MRP
Paracetamol 80mg/ml: paediatric drop.
60ml bot: 16.28 MRP +FEVA Susp. Ad-din
l 5ml bot: 10.91 MRP
+CETAL Tab. Sup reme Paracetamol 120mg/5ml: suspension
+ACETA Tab. Biopharma Paracetamol 500mg/tablet 60ml bot: 18.00 MRP
Paracetamol 500mg/tablet
240's pack: 192.00 MRP +FEVA Drop Ad-din
200's pack: 160.00 MRP
+CETAL Susp. Sup reme Paracetamol 80mg/ml: paediatric drop.
+ACETA Susp. Biopharma Paracetamol 120 mg/5ml: suspension 15ml bot: 12.27 MRP
Paracetamol 120mg/5ml: suspension
60ml bot: 20.63 MRP + FEVA Suppo. Ad-din
60ml bot: 16.34 MRP
+CETAM Tab. Pacific Paracetamol 125mg, 250mg & 500mg/stick:
+ACETA Drop Biopharma Paracetamol 500mg/tablet suppository
Paracetamol 80mg/ml: paediatric drop.
500's pack: 300.00 MRP 125mg x lO's pack: 40.00 MRP
15ml bot: 12.30 MRP
+CETAM Susp. P acific 250mg x 1 O's pack: 50.00 MRP
+ACETO 500 Tab. Reliance Paracetamol l 20mg/5ml: suspension 500mg x l O's pack: 80.00 MRP
Paracetamol 500mg/tablet
60ml bot: 20.00 MRP +FEVAC Susp. Orion Pharma
I OO's pack: 79.00 MRP
+CPMOL Tab. Cosmo Pharma Paracetamol 120mg/5ml: suspension
+ACT Tab. Ambee Paracetamol 500mg/tablet 60ml bot: 20.00 MRP
Paracetamol 500mg/tablet 250's pack: 150.00 MRP +FIBI Tab. MST Pharma
250's pack: 200.00 MRP
+ D-CETAMOL Tab. Decent Paracetamol 500mg/tablet
+ ACT Susp. Ambee Paracetamol 500mg/tablet 200's pack: 160.00 MRP
Paracetamol 120mg/5ml: suspension
250's pack: 200.00 MRP +G-PARACETAMOL Tab. Gonoshas.
60ml bot: 16.34 MRP
+D-CETAMOL Susp. Decent Paracetamol 500mg/tablet
+ ACT Drop Ambee Paracetamol 120mg/5ml: suspension l OO's pack: 60.00 MRP
Paracetamol 80mg/ml: paediatric drop. 60ml bot: 16.00 MRP +G-PARACETAMOL Syp. Gonoshas.
15ml bot: 12.31 MRP
+DEPOL Tab. Desh Pharma Paracetamol 250mg/5ml: syrup.
+ACTOL Tab. Somatec
Paracetamol 500mg/tablet 50ml bot: 15.00 MRP
Paracetamol 500mg/tablet
400's pack: 240.00 IP l OOml bot: 27.00 MRP
200's pack: 160.00 MRP .

+ACTOL Susp. Somatec +DEPOL Susp. Desh Pharma +G-PARACETAMOL Susp. Gonoshas.

Paracetamol 120mg/5ml: suspension Paracetamol 120mg/5ml: suspension Paracetamol 250mg/5ml: suspension.

60ml bot: 20.63 MRP 60ml bot: 16.00 IP 60ml bot: 16.00 MRP

+ANALPAIN Tab. Pharmadesh + DOLA Tab. Millat +HEPA Tab. Huds o n

Paracetamol 500mg/tablet Paracetamol 500mg/tablet Paracetamol 500mg/tablet
 I
•
I
I
l
'
ANALGESICS & ANTIPYRETICS QIMP-17 (320)
500's pack: 275.00 MRP 500's pack: 325.00 MRP
+HEPA Susp. Hudson +PANOL Susp. Virgo
Paracetamol l20mg/5ml: Suspension Paracetamol 120mg/5ml: Suspension
60ml bot: 16.28 MRP 60ml bot: 20.00 MRP
+LONGPARA Tab. lbn Sina + PARA Tab. Amico
Paracetamol 665mg/tablet (extend ed rele ase) Paracetamol 500mg/tablet
l20's pack: 181.20 IP 200's pack: 160.00 MRP
+M-POL Tab. Modern +PARA Susp. Amico
Paracetamol 500mg/tablet Paracetamol 120mg/5ml: Suspension
200's pack: 160.00 MRP 60ml bot: 16.00 MRP
+M-POL Susp. Modern +PARA Drop Amico
Paracetamol 120mg/5ml: suspension Paracetamol 80mg/ml: paedi atric drop.
60ml bot: 20.00 MRP 15ml bot: 12.00 MRP
+NAPA Tab. Beximco +PARACETAMOL Tab. Bengal Drugs
Paracetamol 500mg/tablet Paracetamol 500mg/tablet
500's pack: 400.00 MRP 500's pack: 300.00 MRP
+NAPA DT Tab. Beximco +PARACETAMOL Tab. SAPL
Paracetamol 500mg/tablet (dispersible) Paracetamol 500mg/tablet
200's pack: 256.00 MRP 200's pack: 160.00 MRP
+NAPA Extend Tab. Beximco +PARACETAMOL Tab. Ziska
Paracetamol 665mg/tablet (extend ed dose) Paracetamol 500mg/tablet
120's pack: 180 .00 MRP 200's pack: 115.00 MRP
+NAPA Susp. Beximco +PARAFEN Susp. Ziska
Paracetamol 120mg/5ml: suspension Paracetamol 120mg/5ml: suspension
50ml bot: 18.23 MRP 60ml bot: 16.28 MRP •
60ml bot: 20.63 MRP +PARAMOL Susp. Seema
+NA.PA Syp. Beximco Paracetamol 120mg/5ml: suspension
Paracetamol 120mg/5ml: syrup 60ml bot: 20.90 MRP
50ml bot: 18.24 MRP + PARAPYROL Tab. Glaxosmithkline
60ml bot: 20.64 MRP Paracetamol 500mg/tablet
1 OOml bot: 31.77 MRP 500's pack: 360.56 MRP
+NAPA Drop Beximco +PARAPYROL Susp. Glaxosmithkline
Paracetamol 80mg/ml: paediatric drop. Paracetamol 120mg/5ml: suspension
15ml bot: 12.30 MRP lOOml bot: 30.00 MRP
+NAPA Suppo. Beximco +PARAXIA Tab. Pharmasia
Paracetamol 60mg,125mg & 250mg/stick: Paracetamol 500mg/tablet
suppository 200's pack: 160.00 MRP
60mg x 20's pack: 70.00 IP +PARAXIA Sus� Pharmasia
l 25mg x 20's pack: 80.00 IP Paracetamol 120mg/5ml: suspension
250mg x 20's pack: 100.00 IP 60ml bot: 20.50 MRP
+ NAPA IV Inf. Beximco +PM Susp. Reliance
Paracetamol BP lgm/lOOml: solution for i.v Paracetamol 120mg/5ml: suspension
infusion 60ml bot: 20.00 MRP
lOOml bot: 120.00 MRP - +POL Tab. Globe
+NEOPARA Tab. Bristol Paracetamol 500mg/tablet
Paracetamol 500mg/tablet 200's pack·: 130.00 MRP
lOO's pack: 50.00 MRP + POL Susp. Globe
+NIPA Tab. Nipa Paracetamol 120mg/5ml: suspension
I Paracetamol 500mg/tablet
lOO's pack: 65.00 MRP
60ml bot: 20.56 MRP
+PREDUET Tab. Silva
+NIPA Susp. Nipa Paracetamol 500mg/tablet
Paracetamol l 50mg/5ml: suspension 250's pack: 200.00 MRP
60ml bot: 12.66 MRP +PREDUET Susp. Silva
+ NIPA Drop Nipa Paracetamol 120mg/5ml: suspension
-
Paracetamol 80mg/ml: paediatric drop. 60ml bot: 16.00 MRP
15ml bot: 10.87 MRP +PROMEL Syp. Apollo
+NOVA Tab. Cosmic Paracetamol 120mg/5ml: syrup
Paracetamol 500mg/tablet 60ml bot: 20.00 MRP
200's pack: 160.00 MRP +PYRAC Tab. Medimet
+NOVA Susp. Cosmic Paracetamol 500mg/tablet
Paracetamol 120mg/5ml: suspension 200's pack: 160.00 MRP
60ml bot: 20.00 MRP 500's pack: 400.00 MRP
+PAINIL Tab. Kumudini +PYRAC Susp. Medimet
Paracetamol 500mg/tablet Paracetamol 120mg/5ml: suspension
500's pack: 325.00 MRP 50ml bot: 18.25 MRP
60ml bot: 200.00 MRP
+PAINIL Susp. Kumudini
Paracetamol 120mg/5ml: suspension +PYRALGIN Tab. Renata
60ml bot: 16.34 MRP Paracetamol 500mg/tablet
500's pack: 400.00 MRP.
+ PANOL Tab. V irgo
Paracetamol BP 500mg/tablet +PYRALGIN Susp. Renata
Paracetamol 120mg/5ml: Suspension
60ml bot: 20.64 MRP
+REMALGIN Tab. Reman
Paracetamol 500mg/tablet
250's pack: 200.00 MRP
+REMALGIN Susp. Reman
Paracetamol 125mg/5ml: suspension •
...
_
60ml bot: 20.00 MRP
+ RE�OVA Tab. Opsonin
Paracetamol 500mg/tablet •
250's pack: 175.94 MRP
+RENOVA XR Tab. Opsonin
•
Paracetamol 665mg/tablet (extend ed rele ase) •
1 OO's pack: 131.95 MRP
+RENOVA Susp. Opsonin
Paracetamol 120mg/5ml: suspension
60ml bot: 18.16 MRP
1 OOml bot: 21.58 MRP
+RENOVA Syp. Opsonin
Paracetamol 120mg/5ml: syrup
60ml bot: 18.16 MRP
lOOml bot: 27.80 MRP
+RENOVA Drop Opsonin
Paracetamol 80mg/ml: paedi atric drop.
15ml bot: 10.83 MRP
+RENOVA IV Inf. Opsonin
Paracetamol BP lgm/lOOml: solution for i.v •
infusion
lOOml bot: 105.57 MRP
+RENOVA Suppo. Opsonin
Paracetamol 60mg·, 125mg, 250mg &
500mg/stick: suppository
60mg x !O's pack: 30.88 MRP
125mg x I O's pack: 35.35 MRP
250mg x I O's pack: 44.16 MRP
500mg x 1O's pack: 70.64 MRP
+RESET Tab. Incepta
Paracetamol 500mg/tablet
200's pack: 160.00 MRP
+RESET Susp. lncepta
Paracetamol 125mg/5ml: suspension
60ml bot: 20.64 MRP
+RESET Drop Incepta
Paracetamol 80mg/ml: paedi atric drop.
15ml bot: 12.30 MRP
+RESET IV Inf. lncepta
Paracetamol BP lgm/lOOml: solution for i.v
infusion
lOOml bot: 120.00 MRP
+ SERIDOL Tab. Sonear
Paracetamol 500mg/tablet
lOO's pack: 80.00 MRP
+SILPA Tab. Silva
Paracetamol 500 mg/tablet.
250's pack: 150.00 MRP
+SILPA Susp. Silva
Paracetamol 125mg/5ml: suspension
60ml bot: 1 &00 MRP
+SINAPOL Tab. Ibo Sina •
Paracetamol 500mg/tablet.
250's pack: 200.00 MRP
+SINAPOL Susp. Ibo Sina
Paracetamol l 25mg/5ml: suspension
60ml bot: 20.00 MRP
+TAMEN Tab. SK+F
Paracetamol 500mg/tablet
200's pack: 160.00 MRP
t TAMEN Syp. SK+F --,
Paracetamol 120mg/5ml: syrup
60ml bot: 20.56 MRP •
•
 QIMP-17 (321) ANALGESICS & ANTIPYRETICS

lOOml bot: 31.66 MRP 30ml bot: 15.73 MRP Paracetamol l 25mg, 250mg & 500mg/stick:
t TAMEN Drop SK+F t 'I'IMIDAL Tab. Gaco suppository
Paracetamol 80mg/ml: paediatric drop. Paracetamol 500mg/tablet 125mg x lO's pack: 50.00 MRP
15ml bot: 12.26 MRP 250's pack: 200.00 MRP 250mg x 20's pack: 120.00 MRP
+ TAMEN I.V Inf. SK+F t TIMIDAL Susp. Gaco 500mg x 20's pack: 180.00 MRP
Paracetamol BP lgm/lOOml: solution for i.v Paracetamol 120mg/5ml: Suspension + ZERIN Tab. Jayson
infusion 60ml bot: 20.00 MRP Paracetamol 500mg/tablet
lOOml bot: 120.00 MRP + TYDENOL Tab. Edruc 500's pack: 400.00 MRP
+ TAMINO Tab. NIPRO JMI Paracetamol 500mg/tablet + ZERIN Susp. Jayson
Paracetamol BP 500mg/tablet. 200's pack: 160.00 MRP Paracetamol 120mg/5ml: suspension
200's pack: 160.00 MRP t TYDENOL Susp. Edruc 60ml bot: 20.00 MRP
t TAMINO ER Tab. NIP RO JMI Paracetamol 120mg/5ml: suspension + ZERIN Drop Jayson
Paracetamol 665mg/tablet (extended release) 60ml bot: 21.00 MRP Paracetamol 80mg/ml: paediatric drop.
lOO's pack: 150.00 MRP + TYLEN Tab. RAK Pharma 15ml bot: 12.30 MRP
t TAMINO Susp. NIPRO JMI Paracetamol 500mg/tablet + 2 A Tab. Mystic
Paracetamol 120mg/5ml: suspension 200's pack: 160.00 MRP Paracetamol 500mg/tablet
60ml bot: 20.63 MRP t TYLEN Susp. RAK Pharma 500's pack: 325.00 MRP
+ TAMOL Tab. Apex Paracetamol 120mg/5ml: suspension
+ 2 A Susp. M ystic
Paracetamol 500mg/tablet. 60ml bot: 20.63 MRP Paracetamol 120mg/5ml: suspension
200's pack: 160.00 MRP t XCEL Tab.ACI 60ml bot: 16.28 MRP
+ TAMOL Susp. Apex Paracetamol 500mg/tablet
Paracetamol 120mg/5ml: suspension 500's pack: 400.00 MRP
60ml bot: 16.34 MRP + XCEL DT Tab. ACI PARACETAMOL+ CAFFE INE124
+ TANDAMOL Tab. M edicon Paracetamol 120mg/tablet (dispersible)
Paracetamol 500mg/tablet. lOO's pack: 128.00 MRP PARACETAMOL+ CAF FEINE: Tablet
300's pack: 225.00 MRP t XCEL ER Tab. ACI Pracetamol BP 500mg and caffeine BP

Paracetamol 1000 mg /100 ml IV Infusion

For rapid post-operative pain management

+ TANDAMOL Susp. Medicon Paracetamol 665mg/tablet (extended release) 65mg/tablet (film-coated).

Paracetamol 120mg/5ml: suspension 120's pack: 180.00 MRP Ind: It is indicated for the relief of fever, migra­

60ml bot: 20.00 MRP t XCEL Susp. ACI ine and headache, common colds and flu, sore

t TEMPAC Tab. Hallmark Paracetamol l 20mg/5ml: suspension throat, earache, toothache, backache, rheumatic
Paracetamol 500mg/tablet. 60ml bot: 20.63 MRP and muscular pain, neuralgia and menstrual pain.
200's pack: 160.00 MRP t XCEL Syp. ACI C /I: Patients with known hypersensitivity to

t TEMPAC Susp. Hallmark Paracetamol 120mg/5ml: syrup paracetamol, caffeine or any other components of
Paracetamol 120mg/5ml: suspension 60ml bot: 20.64 MRP the product.
60ml bot: 20.00 MRP + XCEL Drop ACI P recaution: It should be used with caution in

+ TEMPANIL Tab. Amulet Paracetamol 80mg/ml: drop. severe liver or kidney disease.
Paracetamol 500mg/tablet. 15ml bot: 12.31 MRP S/E: In recommended doses, it is usually free
250's pack: 200.00 MRP + XPA Tab. Aristopharma from side effects. However, skin reactions such
+ TEMPIL Tab. Alco Pharma Paracetamol 500mg/tablet as urticaria have been reported rarely.
Acetaminophen 500mg/tablet. 250's pack: 200.00 MRP
Pregnancy & lactation: Although there is
200's pack: 160.00 MRP + XPA XR Tab. Aristopharma
epidemiological evidence of the safety of
500's pack: 400.00 MRP Paracetamol 665mg4ablet (extended release)
paracetamol in pregnancy and lactation, medical
+ TEMPIL Susp. Alco Pharma lOO's pack: 150.00 MRP
advice should be sought before using this product.
Acetaminophen 120mg/5ml: suspension + XPA Susp. Aristopharma
Dosage & admin: Adults & adolescents over
1OOml bot: 24.53 MRP Paracetamol l 20mg/5ml: suspension
60ml bot: 20.60 MRP 12 years: 1-2 tablets in every 4 hours, or as
t TEMPOL Susp. Asiatic needed. Maximum dose is 8 tablets in 24 hours.
l OOml bot: 24.60 MRP
Paracetamol l 20mg/5ml: Suspension
Drug inter: The ingredients of this combina­
60ml bot: 16.34 MRP + XPA Drop Aristopharma .
tion may interact w ith anticoagulant agents on
Paracetamol 80mg/ml: paediatric drop.
t TEMPOL Drop Asiatic prothrombin time. The liver effects of it may
l5ml bot: 12.30 MRP
Paracetamol 80mg/ml: paediatric drop. b e increased b y the use of alcohol and con­
15ml bot: 12.31 MRP + XPA Suppo. Aristopharma comitant use of certain drugs which enhance
ANALGESICS & ANTIPYRETICS QIMP-17 (322)

the metabolism of paracetamol in the liver (i.e 65mg/tablet (film-coated).
barbiturates, tricyclic antidepressants). 200's pack: 300.00 MRP
+CETAL Plus Tab. Supreme
+ACE Plus Tab. Square Paracetamol BP 500mg +caffeine BP
Paracetamol BP 500mg +caffeine USP 65mg/tablet (film-coated).
65mg/tablet (film-coated). IOO's pack: 190.00 MRP
200's pack: 380.00 MRP
t CETAM Plus Tab. Pacific
t ACEP Plus Tab. Zenith Paracetamol BP 500mg +caffeine USP
Paracetamol BP 500mg + caffeine USP 65mg/tablet (film-coated).
65mg/tablet (film-coated). 200's pack: 470.00 MRP
1OO's pack: 151.00 MRP
t CLOFAMOL Tab. Ziska
t ACETA-X Tab. Biopharma Paracetamol BP 500mg + caffeine USP
Paracetamol BP 500mg +caffeine USP 65mg/tablet (film-coated).
65mg/tablet (film-coated). 200's pack: 300.00 MRP
lOO's pack: 191.00 MRP
+CPMOL Plus Tab. Cosmo Pharma
+ACT Plus Tab. Ambee Paracetamol BP 500mg + caffeine USP
Paracetamol BP 500mg +caffeine USP 65mg/tablet (film-coated).
65mg/tablet (film-coated). 1OO's pack: 150.00 IP
lOO's pack: 151.00 MRP
+DC-Plus Tab. D ecent
t ARCHI Extra Tab. Aexim Paracetamol BP 500mg +caffeine USP
Paracetamol BP 500mg +caffeine USP 65mg/tablet (film-coated).
65mg/tablet (film-coated). 1OO's pack: 200.00 MRP
lOO's pack: 150.00 MRP
t DEPOL EXTRA Tab. Desh Pharma
t ASMOL Plus Tab. Sharif Paracetamol BP 500mg +caffeine BP
Paracetamol BP 500mg + caffeine USP 65mg/tablet (film-coated).
65mg/tablet (film-coated). lOO's pack: 160.00 IP
lOO's pack: 150.00 MRP 200's pack: 320.00 IP
t ASTA Plus Tab. Rephco t DOLA EXTRA Tab. M illat
Paracetamol BP 500mg + caffeine USP Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated). 65mg/tablet (film-coated).
lOO's pack: 200.00 MRP lOO's pack: 190.00 MRP
t ATOPEN Plus Tab. Kemiko +DUAL Tab. M edicon
·
Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated). 65mg/tablet (film-coated).
I OO's pack: 190.00 MRP 1OO's pack: 200.00 MRP
+BEPOL Plus Tab. Bengal Drugs t DUET Tab. Silva
Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated). 65mg/tablet (film-coated).
lOO's pack: 150.00 MRP 200's pack: 380.00 MRP
t CAFCETA Tab. Peoples +ENYL Plus Tab. Euro P hrama
_
65mg/tablet (film-coated).
lOO's pack: 151.00 MRP
t HEDEX Tab. Orion Pharma
Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated).
lOO's pack: 151.00 MRP
+HEPA-Plus Tab. Hudson
Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated).
lOO's pack: 150.00 MRP
t K-POL Tab. M odern
Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated).
lOO's pack: 190.00 MRP
t NAPA EXTRA Tab. Beximco
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
200's pack: 500.00 IP
240's pack: 600.00 IP
t NEOPARA Plus Tab. Bristol
Paracetamol BP 500mg + caffeine USP
65mg/tablet (film-coated).
lOO's pack: 150.00 MRP
+NOR Plus Tab. Novelta
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
200's pack: 380.00 MRP
+NOVA Plus Tab. Cosmic
Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated).
1OO's pack: 180.00 MRP
+ORPA Plus Tab. Belsen
Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated).
1OO's pack: 190.00 MRP
t PAC-2 Tab. Ibo Sina
Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated)
200's pack: 400.00 IP
+PAINIL Plus Tab. Kumudini

Paracetamol BP 500mg +caffeine 65mg/tablet Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg +caffeine USP
(film-coated). 65mg/tablet (film-coated). 65mg/tablet (film-coated).
200's pack: 300.00 MRP lOO's pack: 200.00 MRP 200's pack: 400.00 MRP
t CAFEDON Tab. Healthcare +FAP Plus Tab. Beacon t PANADOL Extra Tab. GlaxoSmithKline
Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg + caffeine USP Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated). 65mg/tablet (film-coated). 65mg/tablet (film-coated).
200's pack: 380.00 MRP
200's pack: 300.00 MRP 200's pack: 381.42 MRP
t CAFENOL Tab. General t FAST Plus Tab. Acme t PANOL Plus Tab. Virgo
Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg +caffeine BP
65mg/tablet (film-coated). 65mg/tablet (film-coated). 65mg/tablet (film-coated).
lOO's pack: 191.00 MRP
lOO's pack: 190.00 MRP 200's pack: 380.00 MRP
t CAFFO Tab. Somatec +FEA Plus Tab. N avana t PARA-C Tab. Amico
Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated). 65mg/tablet (film-coated). 65mg/tablet (film-coated).
IOO's pack: 190.00 MRP
1OO's pack: 200.00 MRP lOO's pack: 190.00 MRP
+CAPDOL Tab. Novo Healthcare t FEVA Plus Tab. Ad-din t PARACAF Tab. Seema
Paracetamol BP 500mg +caffeine BP Paracetamol BP 500mg + caffeine USP Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated). 65mg/tablet (film-coated). 65mg/tablet (film-coated).
50's pack: 100.00 MRP
lOO's pack: 150.00 MRP lOO's pack: 190.00 MRP
t CENTAMOL Plus Tab. CPL t FIBI-Plus Tab. MST P harma t PARACET Plus Tab. White Horse
Paracetamol BP 500mg +caffeine BP
Paracetamol BP 500mg + caffeine USP Paracetamol BP 500mg +caffeine USP
65mg/tablet (film-coated).
65mg/tablet (film-coated). 65mg/tablet (film-coated).
lOO's pack: 190.00 MRP
lOO's pack: 200.00 MRP lOO's pack: 150.00 MRP
t CETADOL Plus Tab. D octor's t GESIC Plus Tab. Popular +PARACIN Tab. P harmadesh
Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg +caffeine USP Paracetamol BP 500mg +caffeine USP

US Tablet

Paracetamol BP 500 mg & Caffeine USP 65 mg

KEMIKO PHARMACEUTICALS LTD. (f'or rapid rd'ieffront fever & pcain

65mg/tablet (film-coated).
200's pack: 300.00 MRP
t PARA FAST Tab. APC Pharma
Paracetamol BP 500mg + caffeine USP
65mg/tablet (film-coated).
lOO's pack: 150.00 MRP
+ PARA.XIA Plus Tab. Pharmasia
Paracetamol BP 500mg + caffeine USP
65mg/tablet (film-coated).
1OO's pack: 190.00 IP
t PAX Tab. SAPL
Paracetamol BP 500mg + caffeine USP
65mg/tablet (film-coated).
200's pack: 300.00 MRP
+ P+C Tab. Alco Pharma
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
lOO's pack: 190.00 MRP
+ PCAF Tab. Everest
Paracetamol BP 500mg +caffeine BP
65mg/tablet (film-coated).
lOO's pack: 190.00 MRP
+ PM Plus Tab. Reliance
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
lOO's pack: 150.00 MRP
t POL Plus Tab. Globe
Paracetamol BP 500mg +caffeine BP
65mg/tablet (film-coated).
lOO's pack: 150.00 MRP
t PROMEL Plus Tab. Apollo
Paracetamol BP 500mg +caffeine BP
65mg/tablet (film-coated).
1OO's pack: 190.00 MRP
+ PYRA Plus Tab. Renata
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
150's pack: 300.00 MRP
t PYRENOL Tab. Delta Pharma
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
' �
200's pack: 380.00 MRP
+ PYREX Plus Tab. Concord
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
200's pack: 360.00 MRP
t RELIV Plus Tab. Astra
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
1OO's pack: 190.00 MRP
t REMALGIN Plus Tab. Reman
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
lOO's pack: 150.00 MRP
t RENOVA Plus Tab. Opsonin
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
1OO's pack: 167 .15 MRP
+ RESET Plus Tab. Incepta
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
1OO's pack: 190.00 MRP
+ TACS Tab. Rangs Pharma
Paracetamol BP 500mg +caffeine BP
65mg/tablet (film-coated).
200's pack: 380.00 MRP
t TAMEN X Tab. SK+F
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
lOO's pack: 190.00 MRP
-
QIMP-17 (323) ANALGESICS & ANTIPYRETICS
150's pack: 285.00 MRP
t TAMINO Plus Tab. NIPRO JMI
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
lOO's pack: 150.00 MRP
t TAMOL Plus Tab. Apex
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
lOO's pack: 150.00 MRP
+ TEMFIN Tab. Organic He alth
Paracetamol BP 500mg +caffeine BP
65mg/tablet (film-coated).
lOO's pack: 180.00 MRP
t TEMPANIL Extra Tab. Amulet
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
200's pack: 380.00 MRP
t TEMPOL Plus Tab. Asiatic
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
1OO's pack: 190.00 MRP
+ TEMRIF Plus Tab. MonicoPharma
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
1OO's pack: 150.00 MRP
t TIMIDAL Plus Tab. Gaco
Paracetamol BP 500mg + caffeine BP
Blla�tablet�gives bOth quick and .
:
65mg/tablet (film-coated).
1OO's pack: 200.00 MRP
.
-
.. Lil' pro.l�gged effects
.
�
':..
��
:�....
��.·
... .
,
. + TYLEN Plus Tab. RAK Pharma
:�. �
....
....... �·")':
;� '.:+·
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
1OO's pack: 150.00 MRP
t TY- PLUS Tab. Edruc
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
lOO's pack: 190.00 MRP
t XCEL Plus Tab. ACI
Paracetamol BP 500mg +caffeine BP
"
65mg/tablet (film-coated).
-r
'
..
...
.;. "
.
200's pack: 382.00 MRP
'. .
'.
. . ..
"
. . ..
...
+ XPA-C Tab. Aristopharma
. .
.
·­
,
�
Paracetamol BP 500mg +caffeine BP
65mg/tablet (film-coated).
200's pack: 400.00 MRP
+ ZERIN-XP Tab. Jayson
Paracetamol BP 500mg + caffeine BP
65mg/tablet (film-coated).
lOO's pack: 190.00 IP
PARACETAMOL+
DL�METRIONINE124
PARACETAMOL+ DL-METIDONINE:
Tablet
This is a fixed dose combination formula of
paracetamol (an analgesic and antipyretic) and
di-methionine (its antidote); this mixture is called
co methiamol. This combined preparation is
available as- paracetamol BP 500mg and
di-methionine BP 1OO mg/tablet.
Mode of action: Paracetamol is used in the treat­
ment of mild to moderate pain and fever.
Paracetamol is broken down to toxic compounds
which are normally neutralised by a substance in
the liver called glutathione. Glutathione is only
produced in limited amounts, so the body cannot
neutralise the excessive toxins resulting from a
paracetamol overdose. This leads to liver dam­
age. Methionine is a substance obtained from the
ANALGESICS & ANTIPYRETICS
diet and used by the body to produce glutathione.
It is included in this preparation to ensure levels
of glutathione in the liver are maintained in order
to minimize the liver damage caused if a
paracetamol overdose is taken.
Ind: This combined preparation is indicated for
the treatment of pain and fever in patients
with the risk of liver toxicity.
C/I: Children under 12 years of age; known sen­
sitivity or allergy to any ingredient; liver disease.
S/E: Side effects of recommended doses (up to 8
tablets/capsules a day in adults) are rare, but
blood disorders, skin rashes are. known to be
associated with this preparation.
Precautions & warnings: This preparation
should be used with caution in alcoholism and
decreased kidney function. In cases of overdose,
immediate advice should be sought from a
physician. Alcohol increases the risk of liver
damage that can occur if an overdose of
paracetamol is taken. The haz,ards of paracetamol
overdose are greater in persistent heavy drinkers
and in people with alcoholic liver disease.
Pregnancy & lactation: Since this preparation is
a fixed dose combination of paracetamol and
methionine, it is advised to consult with
physician before use during the period of
pregnancy and lactation. This preparation should
be used with caution during pregnancy and
breastfeeding mothers, and only if the expected
benefit to the mother is greater than any possible
risk to the fetus or baby.
Dosage & admin: Adult dosage: 2 tablets every
4 hours; maximum 8 tablets daily.
Child dosage: Not recommended for children
under 12 years of age.
Drug inter: Paracetamol should not be used with
monoamine oxidase inhibitor (MAOI),
antidepressants (e.g phenelzine). Prolonged use
of paracetamol may enhance the effects of
anti clotting/blood thinning medicinessuch as
warfarin, leading to an increased risk of bleeding.
Methionine may reduce the effect of levodopa.
Metoclopramide and domperidone increase the
rate of absorption of paracetamol from the gut.
The absorption of paracetamol is decreased if
cholestyramine is taken at the same time.
t ACTOL M Tab. Somatec
Paracetamol BP 500mg + di-methionine BP
l OOmg/tablet.
l OO's pack: 250.00 MRP
t NAPASOFT Tab. Beximco
Paracetamol BP 500mg + di-methionine BP
l OOmg/tablet.
50's pack: 125.00 IP
t NORSOFT Tab. Novelta
Paracetamol BP 500mg + di-methionine BP
1 OOmg/tablet.
l OO's pack: 250.00 MRP
t PAMIX-M Tab. Ziska
Paracetamol BP 500mg + dl-methionine BP
I OOmg/tablet.
IOO's pack: 250.00 MRP
t PARADOT E Tab. Renata
Paracetamol BP 500mg + di-methionine BP
I OOmg/tablet.
IOO's pack: 250.00 MRP
- t PARAMIN Tab. Sharif
Paracetamol BP 500mg + dl-methionine BP
1OOmg/tablet.
QIMP-17 (324)
1 OO's pack: 250.00 MRP
t RENOMET Tab. Opsonin
Paracetamol BP 500mg + di-methionine BP
I OOmg/tablet.
l OO's pack: 219.92 MRP
t TAMEPRO Tab. SK+F
Paracetamol BP 500mg + di-methionine BP
1 OOmg/tablet.
l OO's pack: 250.00 MRP
NEFOPAM42
NEFOPAM: Tablet/Injection
Nefopam is a centrally acting mild to moderate
non-opioid analgesic with a rapid onset of action.
The main site of action appears to be in the
central nervous system both at the brain and
spinal levels.
Nefopam is totally different from the other
centrally acting opioid analgesics such as
morphine, codeine, pentazocine and
propoxyphene. Unliike the narcotic agents,
nefopam has been shown not to cause respiratory
depression. There is no evidence for pre-clinical
research of habituation occurring with nefopam.
Nefopam is available as: 1. Nefopam
hydrochloride INN 30mg film coated tablet; 2.
Nefopam hydrochloride INN 20mg/ l ml ampoule
for injection.
Mode of action: Nefopam is a centrally acting
analgesic. In vitro experiments have shown that,
nefopam inhibits the re-uptake of various
catecholamines (including noradrenaline,
serotonin and dopamine). It is possible that, the
mechanism of action of nefopam is at least in
part by altering the levels of these neuromodu­
lators in the brain and at the spinal level.
Ind: Nefopam is most commonly used to treat
pain after surgery, dental pain, muscular pain and
pain associated with cancer.
Nefopam should not be used to treat the pain
from a heart attack.
C/I: Nefopam is contraindicated in patients with
a history of convulsive disorders and should not
be given to patients taking monoamine oxidase
(MAO) inhibitors.
Nefopam should not be used in the treatment of
myocardial infarction. This advice is based on the
lack of clinical experience for this indication.
S/E: More commonly- nausea, nervousness, dry
mouth, lightheadedness and urinary retention
may occur. Less commonly- vomiting blurred
vision, drowsiness, sweating, insomnia,
headache, confusion, hallucinations, tachycardia
and aggravation of angina have been reported.
Rarely a temporary harmless pink discolouration
of the urine has occurred.
Precautions & warnings: Hepatic and renal
insufficiency may interfere with the metabolism
and excretion of nefopam. Nefopam should be
used with caution in patients with glaucoma and
with or at risk of urinary retention. Nefopam may
cause adverse sympathomimetic effects including
tachycardia and aggravation or precipitation of
angina. Caution should be exercised in patients
with a history of ischaemic heart disease.
Pregnancy & lactation: Nefopam is not
recommended for pregnant women or those
likely to become pregnant unless the expected
benefit to the mother outweighs any potential risk
to the foetus.
Nefopam is excreted in human milk. A decision
should be made whether to discontinue nursing or
discontinue the medication, taking into account
the potential for adverse effects for the foetus and
the importance of treatment to the mother.
Dosage & admin: By injection: 20mg (lml) i.m
or i.v, repeated if necessary every six hours.
Onset of effect after i.m injection is within 15
to 20 minutes and peak effect is reached 1 to
1 Yz hours after administration.
Nefopam injection should always be given with
the patient lying down and after injection the
patient should remain lying down for 15 to 20
minutes. The patient should then get up slowly.
Treatment started with nefopam injection may
be continued with nefopam tablets. 60mg
nefopam (2 tablets) is approximately bioequiv­
alent to 20mg (1 ampoule) given by injection.
By mouth (tablet): Adults: The usual starting
dose is 60mg (2 tablets) taken three times
daily. This may be increased up to a maximum
of 90mg (3 tablets) taken 3 times a day.
Elderly: Elderly patients may require reduced
dosage due to slower metabolism. It is strongly
recommended that the starting dose does not
exceed 30mg (1 tablet) 3 times daily as the
elderly appear more susceptible to, in
particular, the CNS side effects of nefopam
and some cases of hallucination and confusion
have been reported in this age group.
Children: Nefopam is not recommended for
children under the age of 12 years.
Missing dose: If there in missing a dose, it
should be taken as soon as it is remembered.
Then carry on taking the tablets as
recommended by the doctor.
Overdose: Symptoms and signs: Nefopam
toxicity is manifested by neurological symptoms
(convulsions, hallucinations, agitation) and
cardiovascular response (tachycardia with
hyperdynamic circulation).
Treatment: Supportive treatment is suggested
including gastric lavage, forced emesis and
diuresis. Oral administration of activated charcoal
may help prevent absorption. Convulsions and
hallucinations may be controlled (e.g. with
diazepam i.v or i.m or p.r). Beta-adrenergic
blockers may be of use in controlling the
cardiovascular complications.
Drug inter: The side effects of nefopam may be
additive to those of other agents with
anticholinergic or sympathomimetic activity.
Nefopam should be used with caution in patients
on tricyclic anti-depressants and is
contraindicated in patients on MAO inhibitors.
t NEFOREX Tab. Incepta
Nefopam hydrochloride INN 30mg/tablet (f.c)
30mg x 30's pack: 90.00 MRP
t NEFOREX lnj. Incepta
Nefopam hydrochloride INN 20mg/1ml ampoule:
i.rn/i.v injection.
l ml amp x S's pack: 75.00 MRP
01'HEKS
t NOVALGIN Inj. Sanofi aventis/Hoechst21,4 I
Metamizol (Dypirone) 500mg/ml; 2ml ampoule:
injection
 f
I
Ind: Hyperpyrexia, acute articular rheumatism
and its complications.
Dosage & admin: Adult: 2-3gm (4-6ml) daily
i.m in divided doses. The solution should
always be warmed to body temperature before
injection. I.v. may be given slowly (2ml/min) if
required.
Child: 2-12 years O.S-2ml daily in divided doses
or as required.
2ml amp x 2S's pack: 253.75 MRP
2. OPIOID ANALGESICS21
Opioid analgesics: opioid analgesics are used to
relieve moderate to severe pain particularly of
visceral origin. Repeated use of these drugs may
cause dependence and tolerence.
Opioid analgesics have got many side-effects
common to all though qualitative & quantitative
differences exist. The most commons include­
nausea, vomiting, constipation, and drowsiness.
Larger doses produce respiratory depression and
hypotension. Among the opioid analgesics,
morphine remains the most valuable and standard
one, against which other opioid analgesics are
compared.
Opioid analgesics include:
Morphine, Buprenorphine Codeine & dihy­
drocodeine, Dextromoramide,
Dextropropoxyphene, Diamorphine (heroin),
Diphenoxylate, Dipipanone,
Fentanyl, alfentanil & remifentanil (used/or
intra-operative analgesia), Meptazinol,
Methadone, Nalbuphine, Oxycodone,
Papaveretum, Pentazocine, Pethidine,
Phenazocine, Tramadol
MORPHIN_E2 I ,33
MORP HINE : Tablet/Syrup/ Injection.
Ind: Severe and intractable pain (e.g. pain of
myocardial infarction, acute pancreatitis etc); pre­
operative & post-operative medication, enhance­
men of anaesthesia; acute pulmonary oedema.
C/I: Acute respiratory depression, obstructive
airway diseases; hepatic insu fficiency; acute
abdomen; raised intracranial pressure, head
injury; acute alcoholism; concurrent admin. of
other opiates; with or within 2 weeks of MAOIs.
S/E: Drug dependence and addiction; nausea,
vomiting, severe constipation, respiratory
depression, drawsiness, difficulty in micturition,
ureteric and biliary spasm, sweating, dry mouth,
facial flushing, vertigo, bradycardia, palpitation,
postural hypotension, hypothermia, hallucination,
mode change, miosis, articaria, pruritus.
Cautions: Hypotension., hypothyroidism, asthma,
(avoid during attack) and decreased respiratory
/
- 4
reserve, prostatic hypertrophy; pregnancy, labour
and breast-feeding; may precipitate coma in
hepatic impairment (reduce dose or avoid but
many such patients tolerate morphine well);
reduce dose or avoid in renal impairment; elderly
and debilitated (reduce dose); convulsive disor­
ders, dependence (severe withdrwal symptoms if
withdrawn abruptly); use of cough suppressants
containing opioid analgesics not generally recom­
mended in children and should be avoided alto­
gether in those under at least 1 year; concurrent
QIMP-17 (325)
admin.of CNS depressants.
Dosage & admin: Parenteral preparation:
Acute pain- By s.c or by i.m injection, lOmg
every 4 hours (if necessary, lSmg for heavier
patients); Child, up to 1 month lSOmcg/kg, 1-
12 months 200mcg/kg, 1-5 years 2.S-Smg, 6-12
years S-lOmg. By slow i.v injection, quarter to
half corresponding i.m dose.
Pre-operative sedation: By s.c or i.m injection
up to lOmg 60-90 minutes before operation;
Child, by i.m injection lSOmcg/kg.
Post-operative pain: By s.c or i.m injection,
lOmg every 2-4 hours (if necessary, lSmg for
heavier patients); Child up to 1 month
lSOmcg/kg, 1-12 months 200mcg/kg, 1-S years
2.S-Smg, 6-12 years S-lOmg.
Myocardial infarction: By slow i. v injection
(2mg/minute), 1Omg followed by a further S-
1Omg if necessary; elderly or frail patients,
reduce dose by half.
Acute pulmonary oedema: By slow i.v injection
(2mg/minute) S-lOmg.
Chronic pian: By s.c or i.m injection S-20mg
regularly every 4 hours dose may be increased
according to needs.
Oral preparation: Dosage- see below under the
individual product.
+ G-MORPHINE SR Tab. Gonoshasthaya21
Morphine sulphate 1 Smg/tablet (sustained
release).
Dosage & admin: 1 tablet every 12 hourly;
dose adjusted according to daily morphine
requirements.
For further information- please consult
manufacturer's literature.
30's pack: 300.00 MRP
+ G-MORPHINE lnj. Gonoshasthaya
Morphine sulphate 15mg/l ml ampoule: injection.
Dosage & admin: See above under the text.
5 amps pack: 200.00 MRP
t MORPHINE-R Inj. Renata
Morphine sulphate 15mg/l ml ampoule: injection.
Dosage & admin: See above under the text.
5 amps pack: 111.55 MRP
NALBUPlllNE26
NALBUPHINE HCl: Injection
Nalbuphine is a synthetic opioid analgesic. It is
available as nalbuphine hydrochloride INN 1Omg
in 1ml ampoule and 20mg in 2ml ampoule for
i.m and i.v injection.
Mode of action: Nalbuphine hydrochloride binds
with mu, kappa and delta receptor. Its analgesic
potency is equivalent to morphine on a milligram
basis and 10 times more than that of pentazocine
but has lower side effects and less abuse potential
than morphine. The onset of action of nalbuphine
occurs within 2 to 3 minutes after i.v
administration and in less than 15 minutes
following i.m injection.
Ind: i. Relief of moderate to severe pain
associated with myocardial infarction (Ml); ii. as
a supplement of balanced anesthesia; iii. pre­
operative and post-operative analgesia; iv.
obstetrical analgesia during labor and delivery.
C/I: Known hypersensitivity to nalbuphine
hydrochloride.
S/E: Generally nalbuphine is well tolerated.
.-
ANALGESICS & ANTIPYRETICS .
However, few side-effects like sedation, ..
sweating, nausea, vomiting,. dizziness, vertigo,
dry mouth, headache, respiratory depression,
dyspnea and asthma may be seen$
Precautions: Caution should be taken in the
following conditions: impaired respiration,
impaired renal or hepatic function, billiary tract
surgery, myocardial infarction and hypotension.
Pregnancy & lactation: The placental transfer of
nalbuphine is high and rapid. There are no
adequate and well-controlled studies in pregnant
women. This drug should be used during
pregnancy only if clearly needed.
Less than 1% of the administered dose is
excreted in the breast-milk. However, cautions
should be exercised when nalbuphine is
administered to a nursing mother.
•
Dosage & admin: Moderate to severe pain: By
i. v or i.m injection 10-20mg for 70kg patients,
adjusted as required. Child up to 0.3mg/kg
repeated once or twice as necessary.
In balanced anesthesia: By i.v or i.m injection
O.l-0.2mg/kg.
Obstetrical analgesia during labor and delivery:
By i.v injection 0.3-lmg/kg over 10-15 minutes
with maintenance dose of 0.25-0.Smg/kg in
single i.v administration as required.
Intra-operative analgesia: By i.v injection 0.25-
0.Smg/kg at 30 minutes intervals.
Myocardial infarction: By slow i.v injection 10-
20mg repeated after 30 minutes if necessary.
Larger dose is required when used as
supplement of anesthesia than that required
for analgesia.
Children from 18 months to 15 years old:
Usually 0.2mg/kg given preferably by i.v or
i.m injection. Maintenance doses may be given
at intervals of 4 to 6 hours or the doses must
be determined by the physician.
Drug inter: No hazardous interactions have been
identified with nalbuphine; however, interactions
described with other opioids may be anticipated.
Patient receiving a narcotic analgesic, general
anesthesia, phenothiazines or other tranquilizers,
sedatives, hypnotics, or other CNS depressants
(including alcohol) concomitantly with
nalbuphine may exhibit an additive effect.
+ NALBUN lnj. lncepta
Nalbuphine hydrochloride INN lOmg in lml
ampoule and 20mg in 2ml ampoule: i.m/i.v
injection.
lml ( lOmg) amp x S's pack: 300.00 MRP
2ml (20mg) amp x S's pack: 500.00 MRP
t NALBUTIN lnj. ACI
Nalbuphine hydrochloride INN lOmg in lml
ampoule and 20mg in 2ml ampoule: i.m/i. v
injection.
lml ( lOmg) amp x S's pack: 300.00 MRP
2ml (20mg) amp x S's pack: 500.00 MRP
t NALPHIN Inj. Acme
Nalbuphine hydrochloride INN lOmg in lml
ampoule and 20mg in 2ml ampoule: i.m/i.v
injection.
lml ( lOmg) amp x S's pack: 301.10 MRP
2ml (20mg) amp x 5's pack: SO l .90 MRP
+ RADIRIF lnj. Square
Nalbuphine hydrochloride INN 20mg in 2ml
ampoule: i.m/i.v injection.
2ml (20mg) amp x 4's pack: 401.52 MRP

• SK•F
+RALTROX Inj. Opsonin
Nalbuphine hydrochloride INN l Omg in l ml
ampoule and 20mg in 2ml ampoule: i.m/i.v
injection.
lml ( l Omg) amp x 3's pack: 1S8.96 MRP
2ml (20mg) amp x 1's pack: 88.30 MRP
PETHIDINE21·33
•
, PETHIDINE HCI: Injection.
Ind: Moderate to severe pain; pre-anaesthetic
medication; post-operative pain; obstetrical
analgesia.
C/I: Comatose states; respiratory depression;
obstructive airway disease; with or within 2
weeks. of MAOls.
S/E: Dependence & addiction; dizziness, nausea,
vomiting, tachycardia. Cardiovascular and resp.
depression.
Cautions: Severe renal or hepatic impairment;
head injury; hypothyroidism; pregnancy &
labour; concurrent admn. of alcohol and CNS
depressants.
Dosage & admin: Adult: General analgesia:
50-100 mg i.m daily four to six hourly or as
reqd. 25-50 mg by slow i.v. injection.
Pre-anaesthetic: lOOmg i.m.
Obstetrical analgesia: 50-100 mg. i.m. repeat 1-
3 hours later if necessary. Max. 400mg. in 24
hours.
Children: General analgesia: Upto 1 year 1-
_ Tramadol hydrochloride SOmg/capsule
2mg/kg; 1-5 years, 12.5-25mg; 6-12 years, 25-
50mg by i.m injection as or when required.
Pre-anaesthetic: Under 8 years, not recom­
mended; 8-12 years, 50mg intramuscularly.
+G-PETHIDINE Inj. Gonoshasthaya
Pethidine hydrochloride 100mg/2ml ampoule:
i.m/i.v injection.
2ml amp x S's pack: 124.80 MRP
+ PETHIDINE-R Inj. Renata
Pethidine hydrochloride 100mg/2ml ampoule:
i.m/i.v injection.
2ml amp x S's pack: 99.40 MRP
TRAMADOL21,11
T RAMADOL HCl: Tablet/Sachet/Capsule/
Injection
Tramadol is an opioid analgesic. It is available
as- tablet, capsule, sachet, injection &
suppositories.
Mode of action: Tramadol hydrochloride exarts
its analgesic effect by two ways- an opioid effect
and an enhancement of serotoninergic and
adrenergic pathways. It acts on the central nevous
system. It is a pure non selective agonists of the
m,d, and k opioid receptors with a higher affinity
for the m receptors. Unlike morphine, a broad
range of analgesic doses of tramadol hydrochlo­
ride has no respiratory depressant effect.
Ind: Moderate to severe acute pain, chronic pain,
diagnostic procedures and surgical pain.
C/I: Hypersensitivity to tramadol hydrochloride.
Acute intoxication with alcohol, hypnotic drugs,
QIMP-17 (326)
centrally acting analgesics, opioids or +DOLONIL Cap. Acme
psychotropic drugs. Narcotic withdrawal Tramadol hydrochloride SOmg/capsule
treatment. This combination should not be 20's pack: l S0.60 MRP
administered to patients who are receiving t DOLONIL SR Tab. Acme
monoamine oxidase inhibitors or within 2 weeks Tramadol hydrochloride 1OOmg/tablet (sustained
of their withdrawal. Severe hepatic impaiment. release)
Epilepsy not controlled with treatment. l 6's pack: 400.00 MRP
S/E: It is repoted to have fewer of the typical +DOLONIL Inj. Acme
opioid side-effects notably, less respiratory Tramadol hydrochloride 100mg/2ml ampoule:
depression, less constipation and less addiction i.m/i.v injection
potential; hypotension and occasionally S amps pack: 100.3S MRP
hypertension also reported; sweating, dizziness, +DOLORAN Cap. Sandoz
nausea, vomiting, dry mouth and fatigue; In rare Tramadol hydrochloride SOmg/capsule
cases, headache retching, g.i irritation, skin SOmg x 30's pack: 2SS.OO MRP
reactions, motorial weakness, appetite changes, t DOLORAN lnj. Sandoz
micturition disorders, psychic side effects e.g Tramadol hydrochloride 100mg/2ml ampoule:
(_
mood, perception & activity changes. injection
Precautions: Opioid dependence; reduced level l OOmg (2ml amp) x S amps pack: 200.00 MRP
of consciousness of unclear origin; respiratory t DOLORAN P R Tab. Sandoz
disorders; increased intracranial pressure. Patients Tramadol hydrochloride 1OOmg/tablet (per rectal)
known to suffer from convulsions. Capacity to 30's pack: 4SO.OO MRP
drive or operate machines may be impaired, +DOLORAN Suppo. Sandoz
specially if taken with alcohol. Tramadol hydrochloride 1OOmg/suppository
Not suitable as subsitute in opioid dependent l O's pack: 200.00 MRP
patients. General anaesthesia, not recommended +DOLOREX Cap. Biopharma
for analgesia during potentially very light planes Tramadol hydrochloride SOmg & 1 OOmg/capsule
of general anaesthesia (possibly increased SOmg x 30's pack: 22S.90 MRP
operative recall reported). l OOmg x lO's pack: 130.SO MRP
Pregnancy & lactation: Tramadol hydrochloride +DOLOREX Inj. Biopharma
should not be used during pregnancy & lactation. Tramadol hydrochloride 100mg/2ml ampoule:
Dosage & admin: Adults & adolescents over injection
14 years of age: By mouth, 50-lOOmg not more S amps pack: 100.40 MRP
often than every 4 hours; total of more than t DOLOT RAM Cap. Sun Pharma
400mg daily not usually required; Tramadol hydrochloride SOmg/capsule
By suppository (rectal use), 50-lOOmg not 30's pack: 19S.OO MRP
more often than every 4 hours; total of more +FUDOL Cap. Pharmasia
than 400mg daily not usually required;
By i.m injection or by slow i. v injection (over 30's pack: 240.00 MRP
2-3 minutes) or by i. v infusion, 50-1 OOmg +IMADOL 50 Cap. Delta Pharma
every 4-6 hours. Tramadol hydrochloride SOmg/capsule
Post-operative pain, 1 OOmg initially then 50mg 30's pack: 225.00 MRP
every 10-20 minutes if necessary during first +KADOL Cap. Kemiko
hour to total max. 250mg (including initial Tramadol hydrochloride SOmg/capsule
dose) in first hour, then 50-1OOmg every 4-6 30's pack: 240.00 MRP
hours, maximum 600mg daily. +LUCIDOL Cap. Beximco
Children: Not recommended. Tramadol hydrochloride SOmg/capsule
Drug inter: Sedative effects of some CNS drugs SOmg x 30's pack: 22S.00 IP
may be enhanced. Avoid concurrent t LUCIDOL Suppo. Beximco
administration of MAO ls. Tramadol hydrochloride 1OOmg/suppository
.
S's pack: 7S.00 MRP
+ANADOL Cap. Square
+MURTRUM Inj. MonicoPharma
Tramadol hydrochloride SOmg/capsule
Tramadol hydrochloride 100mg/2ml ampoule:
SO's pack: 321.60 MRP
injection
+ANADOL SR Cap. ·square
S amps pack: 100.00 MRP
Tramadol hydrochloride 1OOmg/capsule
+PENDOL Cap. Alco Pharma
(sustained release).
Tramadol hydrochloride SOmg/capsule
30's pack: 361.SO MRP
SOmg x 30's pack: 180.00 MRP
+ANADOL Inj. Square
t RAPIDOL Cap. Renata
Tramadol hydrochloride 100mg/2ml ampoule:
Tramadol hydrochloride SOmg/capsule
injection
SOmg x 30's pack: 210.60 MRP
10 amps pack: 200.70 MRP
+RAPIDOL Inj. Renata
+ANADOL Suppo. Square
Tramadol hydrochloride 100mg/2ml ampoule:
Tramadol hydrochloride 1OOmg/suppository
injection
20's pack: 301.00 MRP
5 amps pack: 12S.SO MRP
+DOLAN Cap. Techno Drugs
Tramadol hydrochloride INN SOmg/capsule +RELADOL Inj. Globe
30's pack: 180.00 MRP Tramadol hydrochloride 100mg/2ml ampoule:
injection
+DOLAN Inj. Techno Drugs
Tramadol hydrochloride INN 100mg/2ml S amps pack: 100.00 MRP
ampoule: i.m/i.v injection + RETRAM Cap. Rephco
10 amps pack: 180.00 MRP Tramadol hydrochloride SOmg/capsule

50mg x 30's pack: 240.00 MRP
+ RET RAM lnj. Rephco
Tramadol hydrochloride 100mg/2ml ampoule:
injection
5 amps pack: 125.00 MRP
+ SYNDOL Cap. Healthcare
Tramadol hydrochloride 50mg/capsule
50mg x 30's pack: 255.00 MRP
+ SYNDOL lnj. Healthcare
Tramadol hydrochloride 100mg/2ml ampoule:
injection
5 amps pack: 125.00 MRP
t TAMADOL Cap. Mystic
Tramadol hydrochloride 50mg/capsule
50mg x 30's pack: 217 .50 MRP
t T ENDIA Cap. ACI
Tramadol hydrochloride 50mg/capsule
30's pack: 225.90 MRP
+ TENDIA Inj. ACI
•
Tramadol hydrochloride 100mg/2ml ampoule:
injection
l OOmg (2ml) amp x 5's pack: 100.35 MRP
I + T RAMADOL Cap. Amico
Tramadol hydrochloride 50mg/capsule
50mg x 30's pack: 180.00 MRP
+ T RAMAL Suppo. Grunentbal/Unimed &
Unihealth
Tramadol hydrochloride 1OOmg/suppository.
•
5's·pack: 204.02 MRP
+ TRAMANIL lnj. Ziska
Tramadol hydrochloride 100mg/2ml ampoule:
injection
5 amps pack: 100.00 MRP
+ T RAMAVIR 50 Cap. Virgo
Tramadol hydrochloride BP 50mg/capsule
50mg x 30's pack: 225.00 MRP
+ T RANAL Cap. Opsonin
Tramadol hydrochloride 50mg/capsule
50mg x 20's pack: 132.48 MRP
....
•
+ TRANAL Inj. Opsonin
Tramadol hydrochloride 100mg/2ml ampoule:
injection
5 amps pack: 88.32 MRP
t T RANAL Suppo. Opsonin
Tramadol hydrochloride 1OOmg/suppository.
1 O's pack: 132.48 MRP
+ TRUMEN Cap. General
Tramadol hydrochloride 50mg/capsule
50mg x 30's pack: 225.90 MRP
+ TRUMEN Inj. General
QIMP-17 (327)
Tramadol hydrochloride 100mg/2ml ampoule:
i.m/i.v injection
5 amps pack: 110.00 MRP
t ULT RADOL Cap. Ad-din
Tramadol hydrochloride 50mg/capsule
50mg x 30's pack: 225.00 MRP
t UT RAMAL Cap. UniHealth
Tramadol hydrochloride 50mg/capsule
50mg x 30's pack: 255.00 MRP
+ UTRAMAL Rtd. Tab. UniHealth
Tramadol hydrochloride 50mg & 1 OOmg/tablet
(retard).
50mg x 20's pack: 200.00 MRP
l OOmg x lO's pack: 200.00 MRP
+ UTRAMAL Inj. UniHealth
Tramadol hydrochloride 100mg/2ml ampoule:
injection
lOOmg (2ml) amp x S's pack: 125.QO MRP
+ UT RAMAL Suppo. UniHealth
Tramadol hydrochloride 1OOmg/suppository.
5's pack: 125.00 MRP
t WINPAIN Cap. Incepta
Tramadol hydrochloride SOmg/capsule
50mg x 40's pack: 300.00 MRP
+ WINPAIN ER Cap. Incepta
Tramadol hydrochloride 1OOmg/capsule
(extended release).
20's pack: 280.00 MRP
+ WINPAIN Inj. Incepta
Tramadol hydrochloride SOmg/ l ml &
100mg/2ml ampoule: injection
50mg ( l ml) amp x 5's pack: 75.00 MRP
l OOmg (2ml) amp x 5's pack: 100.00 MRP
+ XTRAPEL Cap. Beacon
Tramadol hydrochloride 50mg & 1 OOmg/capsule
50mg x 20's pack: 160.00 MRP
1 OOmg x 30's pack: 360.00 MRP
+ ZYDOL 50 Cap. Novo Healthcare
Tramadol hydrochloride 50mg/capsule
SOmg x 30's pack: 22S.OO MRP
+ ZYDOL SR Cap. Novo Healthcare
Tramadol hydrochloride 1OOmg/capsule
(sustained release).
30's pack: 360.00 MRP
+ ZYDOL Inj. Novo Healthcare
Tramadol hydrochloride 100mg/2ml ampoule:
injection
I OOmg (2ml) amp x S's pack: 90.00 MRP
TAPENTADOL 42
ANALGESICS & ANTIPYRETICS
TAPENTADOL: Tablet
Tapentadol is a centrally-acting synthetic
analgesic, useful in the treatment of moderate to
severe acute pa.in in patients 18 years of age or
older. It is available as- tapentadol hydrochloride
INN equivalent to tapentadol 50mg, 75mg &
•
1OOmg/tablet (film coated).
Mode of action: As tapentadol is a centrally­
acting synthetic analgesic, its exact mechanism is
unknown. Analgesic efficacy is thought to be due
to µ opioid agonist activity and the inhibition of
norepinephrine reuptake.
Ind: Tapentadol tablet is indicated for the relief
of moderate ·to severe acute pain in patients 18
years of age or older.
C/I: This drug is contraindicated in patients with
impaired pulmonary function, it is also con­
traindicated in patients with acute or severe
bronchial asthma or hypercapnia in unmonitored
settings or the absence of resuscitative equip­
ment. This drug is contraindicated in any patient
who has or is suspected of having paralytic ileus.
S/E: The following treatment-emergent adverse
events may happen: heart rate increased or
decreased, visual disturbance, abdominal discom­
fort, impaired gastric emptying, irritability,
edema, drug withdrawal synrome, hypersensitivi­
ty, involuntary muscle contractions, sensation of
heaviness, hypoesthesia, paresthesia, disturbance
in attention, sedation, dysarthria, memory impair­
ment, ataxia, presyncope, syncope, coordination
abnormal, seizure, urticaria, blood pressure
decreased etc.
Precautions: Tapentadol should be administered
with caution to patients with conditions accompa­
nied by hypoxia, hypercapnia, respiratory prob­
lems such as- asthma, chronic obstructive pul­
monary disease etc. Besides this, in case of
patient with sleep apnea syndrome, myxedema,
kyphoscoliosis, central nervous system (CNS)
depression should have to be cautious prior
administration of tapentadol. Patients receiving
other µ-opioid agonist analgesics, general anes­
thetics, phenothiazines, other tranquilizers, seda­
tives, hypnotics, or other CNS depressants
(including alcohol) concomitantly with tapenta­
dol may exhibit additive CNS depression.
Pregnancy & lactation: Pregnancy category C.
There are no adequate and well-controlled studies
in pregnant women. This preparation should be
used during pregnancy only if the potential
 I

®
QIMP-17 (328)

+ T RAMP Tab. General

Fastacting & safercombination Paracetamol 325mg + tramadol 37 .5mg/tablet
tor moderate to sevete pain SO's pack: 300.00 MRP
PARACETAMOL+ T RAMADOL: Tablet
t UTRACET Tab. UniMed & UniHealth
This formula of above two drugs is found in a Paracetamol 325mg + tramadol 37.Smg/tablet
fixed-dose combination, viz: paracetamol 325mg 30's pack: 240.00 MRP
benefit justifies the potential risk to the fetus.
& tramadol 37.5mg as tablet. t XCEL MAX Tab. ACI
Neonates whose mothers have been taking tapen­
Mode of action: See above under the text of Paracetamol 325mg + tramadol 37.5mg/tablet
tadol should be monitored for respiratory
individual drug. 30's pack: 240.00 MRP
depression.
Ind: Symptomatic treatment of moderate to
Dosage & admin: As with many centrally­
severe acute pain, chronic pain.
acting analgesic medications, the dosing
C/I; S/E; Precaution: See above under the text 3. ANTI-MIG DRUGS21
regimen should be individualized according to
of individual drug.
the severity of pain being treated, the previous
Pregnancy & lactation: Since, this combination
experience with similar drugs and the ability 3.1 Drugs for acute migraine attack
includes tramadol hydrochloride, it should not be
to monitor the patient. 3.2 Prophylactics of migraine
used during pregnancy & lactation. (
.

The dose is SOmg, 75mg, or 1 OOmg every 4 to 6
hours depending upon pain intensity.
On the first day of dosing, the second dose
may be administered as soon as one hour after
the first dose, if adequate pain relief is not
attained with the first dose.
Subsequent dosing is SOmg, 75mg, or 1 OOmg
every 4 to 6 hours and should be adjusted to
maintain adequate analgesia with acceptable
tolerability.
Daily doses greater than 700mg on the first
day of therapy and 600mg on subsequent days
have not been studied and •re not
3.3 Drugs for cluster headache
Dosage & admin: Treatment of pain- the
recommended dose is 1 or 2 tablets every 4 to
7 hours as needed for pain relief up to
Drugs for Acute Migraine
maximum of 8 tablets per day. The dosing
interval should not be less than 6 hours. This Attack21
combination is not recommended in patients
below 18 years of age.
Drugs used in the treatment of acute migraine
attack include:
t ACETRAM Tab. Square
Paracetamol 325mg + tramadol 37.Smg/tablet 1. Analgesics: Such as- Aspirin, Paracetamol,
30's pack: 240.00 MRP or an NSAID (e.g Tolfenamic acid, Diclo/enac
+ ALKAFEN Tab. �avana sodium, Ibuprofen, Naproxen etc)
�aracetamol 325mg. + tramadol 37.Smg/tablet 2. SH'I'l agonists (triptans): Such as-
. .

recommended. 20's pack: 160.00 MRP Almo�tan, Eletriptan, Frovatriptan,

Pediatric use: The safety and effectiveness of t ATOPEN-X Tab. K emiko Naratriptan, Rizatriptan, Sumatriptan,
·

tapentadol in pediatric p�tients.less than 18 Paracetamol BP 325mg + tramadol 37.Smg/tablet Zolmitriptan

years of age have not been established. 20's pack: 160.00 MRP 3. Ergot alkaloids: such as-.Ergotamine tartrate
Geriatric use; In general, recommended dosing +. FASTDOL Tab. Acme 4. Other drugs for migraine: such as­
for elderly patient$ with normal. renal and Paracetamol BP 325mg + tramadol 37.5mg/tablet Isometlteptene mucate
hepatic func�on is· the same as for younger 30's pack: 240.00 MRP
·

adult patients with normal renal and hepatic .

+ NAPADOL Tab. Bexlmco .

function. consideration should be given to

. .
Paracetamol 325mg + tramadol 37.5mg/tablet Analgesics in Migraine
starting elderly patients with the lower range 30's pack: 240.00 MRP
of recommended doses. t NOR DOL Tab. Novelta Analgesics that are used in the treatment ·of �cute
Renal disease: In patients with severe renal Paracetamol BP 325mg + tramadol BP
migraine such as Aspirin, Paracetamol and
impairment, the safety and eectiveness of 37.Smg/tablet
NSAIDs, are discussed separately in the .
tapentadol has not been established. 30's pack: ·240.00 MRP respective class of drugs. ·

t NOVODOL Tab. Orion Pharma

.

Hepatic disease: Tapentadol should be used

·

Paracetamol 325mg + tramadol 37.5mg/tablet

with caution in patients with moderate hepatic
50's pack: 400.00 MRP
impairment. Tapentadol has not been studied 5HT1 Agonists (Triptans)
t PANOL-T Tab. Virgo
in patients with severe hepatic impairment.
Paracetamol BP 325mg + tramadol BP

+ CYNTA Tab. Healthcare

37.5mg/tablet
30's pack: 240.00 MRP
Tapentadol hydrochloride INN equivalent to
tapentadol 50mg & 75mg/tablet (film-coated). t P-DOL Tab. Popular
Paracetamol 325mg + tramadol 37.Smg/tablet
50mg x 20's pack: 280.00 MRP
75mg x l O's pack: 200.00 MRP 30's pack: 150.00 MRP
t PYREDOL Tab. Delta Pharma
t PENTADOL Tab. Square Paracetamol 325mg + tramadol 37.5mg/tablet
Tapentadol hydrochloride INN equivalent to
30's pack: 240.00 MRP
tapentadol 50mg, 75mg & lOOmg/tablet (f.c).
t PYREX T Tab. Concord
50mg x 20's pack: 240.00 MRP
Paracetamol 325mg + tramadol 37.5mg/tablet
75mg x lO's pack: 170.00 MRP
30's pack: 240.00 MRP
lOOmg x lO's pack: 250.00 MRP
t RESADOL Tab. Incepta
t TAPENDOL Tab. Opsonin Paracetamol 325mg + tramadol 37.5mg/tablet
Tapentadol hydrochloride INN equivalent to 30's pack: 240.00 MRP
tapentadol 50mg & 75mg/tablet (film-coated). t SYNDOL PLUS Tab. Healthcare
50mg x 20's pack: 211.13 MRP Paracetamol 325mg + tramadol 37.5mg/tablet
75mg x 20's pack: 299.10 MRP 30's pack: 240.00 MRP
t TAPENTA Tab. SK+F t TAMENOL Tab. SK+F
Tapentadol hydrochloride INN equivalent to Paracetamol 325mg + tramadol 37.5mg/tablet
tapentadol 50mg, 75mg & lOOmg/tablet (f.c). 20's pack: 160.00 MRP
50mg x 20's pack: 240.00 MRP t TRACET Tab. Opsonin
75mg x lO's pack: 170.00 MRP Paracetamol 325mg + tramadol 37.Smg/tablet
lOOmg x lO's pack: 200.00 MRP 30's pack: 211.13 MRP
ALMOTRIPTAN•3s,1s4
ALMOTRIPTAN: Tablet (f.c)
Almotriptan is a selective and potent serotonin
(5-HT1) agonist (triptan), useful in the treatment
of acute migraine attack. It is available as- almo­
triptan malate USP equivalent to almotriptan
6.25mg/tablet (film-coated).
Mode of action: Almotriptan and other triptans
bind to specific serotonin receptors 5-HT1B/1D
(5-hydroxytryptamine) on intracranial (meningeal)
blood vessels and in sensory nerves of trigeminal
system, inhibiting the release of vasoactive
peptides. This results in constriction of the
cranial arteries, but very little effect on cardiac
and pulmonary vessels.
Ind: Almotriptan is effective in the treatment of
acute headache phase of migraine attacks with or
without aura. Almotriptan is the only oral triptan
approved for the treatment of migraine in
adolescents from 12-17 years of age.
C/I: As with other 5-HT1B/1D receptor agonists,
almotriptan should not be used in patients with a
Il
f-
history of symptoms or signs of ischemic heart
disease (myocardial infarction, angina pectoris,
documented silent ischemia, Prinzmetal's angina)
or severe hypertension and uncontrolled mild or
moderate hypertension. Concomitant administra­
tion with ergotamine, ergotamine derivatives
(including methysergide) and other 5-HT1B/1D
agonists is contraindicated.
S/E: Serious cardiac reactions including
myocardial infarction may occur following the
use of almotriptan malate. These reactions are
extlemely rare and most have been reported in
-
patients with risk factors predictive of CAD
(coronary artery disease).
Precautions: Hypersensitivity to the active ingre­
dient or to any of the excipients. Patients with
severe hepatic impairment, with a previous cere­
brovascular accident (CVA) or transient ischemic
attack (TIA), or peripheral vascular disease.
Pregnancy & lactation: Pregnancy category C.
There is no data regarding excretion of
almotriptan in human milk.
Dosage & admin: Treatment of acute migraine
attacks: The recommended dose of almotriptan
in adults and adolescents age 12-17 years is
6.2Smg to 12.Smg; 12.Smg is considered to be
a more effective dose in adults. If the headache
is relieved after the initial dose but returns,
the dose may be repeated after 2 hours. The
maximum daily dose should not exceed 2Smg.
The safety of treating an average of more than
four migraine attacks in a 30 day period has
not been established.
Hepatic & renal impllirment: The recommend­
ed starting dose of almotriptan malate in
patients with hepatic & severe renal impair­
ment is 6.2Smg. The maximum daily dose in
both cases should not exceed 12.Smg over a 24
hour period.
Drug inter: These drugs have been reported to
cause prolonged vasospastic reactions. Cases of
life threatening serotonin syndrome have been
reported during combined use of triptans and
selective serotonin reuptake inhibitors (SSRis) or
serotonin norepinephrine reuptake inhibitors
(SNRls).
t ALTRIP Tab. NIPRO JMI
Almotriptan malate USP equivalent to
almotriptan 6.25mg/tablet (film-coated).
IO's pack: 250.00 MRP
RIZATRIPTAN135
RIZATRIPTAN: Tablet
Rizatriptan is a 5-HTt agonist (triptan), useful in
the treatment of acute migraine attack. It is
available as rizatriptan benzoate equivalent to
rizatriptan INN 5mg/tablet.
Mode of action: See above under the text of
almotriptan.
Ind: Rizatriptan is indicated for the treatment of
acute migraine attacks with or without aura in
· If a patient does not achieve satisfactory relief
adults.
C/I: See above under the text of almotriptan.
S/E: Rizatriptan is generally well-tolerated. The
most common adverse events during treatment
with rizatriptan were asthenia/fatigue, somno­
lence, pain/pressure sensation and dizziness.
Precautions: See above under the text of
QIMP-17 (329)
almotriptan.
Dosage & admin: Single doses of S or 1 Omg of
rizatriptan is indicated for the treatment of
acute migraine attacks in adults. Doses should
be separated by at least 2 hours; no more than
30mg should be given in any 24-hour period.
t RIZAMIG Tab. Healthcare
Rizatriptan benzoate equivalent to rizatriptan
INN 5mg/tablet.
5nig x IO's pack: 355.00 MRP
t RIZAT Tab. Acme
Rizatriptan benzoate equivalent to rizatriptan
INN 5mg/tablet.
5mg x 1O's pack: 162.60 MRP
SUMATRIPTAN34
SUMATRIPTAN: Tablet
Sumatriptan is a 5-HTI agonist (triptan), useful
in the treatment of acute migraine attack. It is
available as sumatriptan succinate INN
equivalent to sumatriptan INN 50mg/tablet.
Mode of action: See above under the text of
almotriptan.
Ind: Treatment of acute migraine attacks.
C/I: See above under the text of almotriptan.
S/E: Side-effects of the sumatriptan include sen­
sations of tingling, heat, heaviness, pressure, or
tightness of any part of the body including throat
and chest, flushing, dizziness, feeling of weak­
ness; fatigue; nausea and vomiting also reported.
Precautions: See above under the text of
almotriptan.
Pregnancy & lactation: Though sumatriptan has
no teratogenic effects, its use in pregnancy
should be considered only if the benefits are
expected to outweigh the possible risks to the
fetus. Sumatriptan is excreted in h11man breast
milk. Therefore, caution should be exercised
when considering the administration of
sumatriptan succinate to a nursing woman.
Dosage & admin: Adult: SOmg (some patients
may require 1OOmg) as soon as possible after
onset; dose may be repeated after not less than
2 hours if migraine recurs; maximum 300mg
in 24 hours.
Child & adolescent: Under 18 years not
recommended.
Drug inter: As the drug may cause drowsiness,
patients taking other drugs having this effect
should be warned to take care when driving or
using dangerous machinery. Concurrent
administration with ergotamine increased risk of
vasospasm. Sumatriptan should not be given to
patients taking monoamine oxidase inhibitors,
selective 5-HT reuptake inhibitors or lithi11m.
t NOMIGRAN Tab. Ambee
Sumatriptan succinate INN equivalent to
s11matriptan INN 50mg & 1OOmg/tablet.
50mg x 4 tabs pack: 180.68 MRP
1 OOmg x 4 tabs pack: 361.40 MRP
ZOLMITRIPTAN21•42
ZOLMITRIPTAN: Tablet
Zolmitriptan is a 5-HTI agonist (triptan), useful
in the treatment of acute migraine. attack. It is
available as 2.5mg film-coated tablet.
ANALGESICS & ANTIPYRETICS
Mode of action: See above under the text of
almotriptan.
Ind: Zolmitriptan is indicated for the treatment
of acute migraine attack with or without aura.
Zolmitriptan is not indicated for prophylaxis of
m1grame.
• •
C/I: See above under the text of almotriptan.
S/E: Zolmitriptan is well tolerated. Adverse reac­
tions are typically mild to moderate, transient,
not serious and resolve spontaneously without
additional treatment. Possible adverse reactions
tend to occur within 4 hours of dosing and are
no more frequent following repeated dosing. The
following adverse reactions have been the most
commonly reported, are: nausea, dizziness, som­
nolence, warm sensation, asthenia, & dry mouth.
Abnormalities or disturbances of sensation have
been reported, such as- heaviness, tightness or
pressure may occur in the throat, neck, limbs and
chest (with no evidence of ischaemic changes on
ECG); myalgia, muscle weakness, paraesthesia
and dysaesthesia may also occur.
Precautions & Warnings: Zolmitriptan should
only be used where a clear diagnosis of migraine
has been established. Care should be taken to
exclude other potentially serious neurological
conditions. There are no data on the use of
zolmitriptan in hemiplegic or basilar migraine.
Zolmitriptan should not be given to patients with
symptomatic Wolff-Parkinson-White syndrome
or arrhythmias associated with other cardiac
accessory conduction pathways. This class of
compounds (5HT 1 D agonists) has been found
associated with coronary vasospasm; therefore,
zolmitriptan is not recommended in patients with
ischaemic heart disease. The patients in whom
unrecognised coronary artery disease is likely,
cardiovascular evaluation is recommended prior
to commencement of treatment with 5HT1D
agonists. As with other 5HTID agonists, atypical
sensations over the precordium (see undesirable
effects) have been reported after the administra­
tion of zolmitriptan, but in clinical trials these
have not been associated with arrhythmias or
ischaemic changes on ECG Zolmitriptan may
cause mild, transient increases in blood pressure
(which may be more pronounced in the elderly),
however, this has not been associated with
clinical sequelae in the clinical trial progr amme.
Pregnancy & lactation: Safety and efficacy of
5HTI agonists in pregnancy and lactation have
not been established. Therefore, zolmitriptan
should be used with caution in pregnancy and
nursing mothers only if the benefits outweigh the
potential risk to the fetus and child or
discontinue the breast-feeding during medication.
Dosage & admin: The recommended dose of
zolmitriptan to treat a migraine attack is
2.Smg. If symptoms persist or return within 24
hours, a second dose has been shown to be
effective. If a second dose is required, it should
not be taken within 2 hours of the initial dose.
with 2.Smg doses, subsequent attacks can be
treated with Smg doses of zolmitriptan. In
those patients who respond, significant
efficacy is apparent within 1 hour of dosing,
zolmitriptan is equally effective whenever the
tablets are taken during a migraine attack;
although it is advisable that zolmitriptan

The sure shot solution
.
tablets are taken as early as possible after the
onset of migraine headache.
In the event of recurrent attacks, it is recom­
mended that the total intake of zolmitriptan in
a 24-hour period should not exceed lSmg.
Zolm.itriptan is not indicated for prophylaxis
of migraine.
Use in children: Safety and efficacy of
zolmitriptan in paediatric patients have not
been established.
Use in patients aged over 65 years: Safety and
efficacy of zolmitriptan in individuals aged
over 65 yean have not been systematically
evaluated.
Patients with hepatic impainnent: T here is no
clinical or pharmacokinetic experience in
patients with hepatic impairment treated with
zolmitriptan.
Patients with renal impairment: No dosage
adjustment is required.
Drug inter: There is no evidence that
concomitant use of migraine prophylactic
medications has any effect on the efficacy or
unwanted effects of zolmitriptan (for example
beta blockers, oral dihydroergotamine, pizotifen).
The pharmacokinetics and tolerability of
zolmitriptan ere unaffected by acute symptomatic
treatment such as paracetamol, metoclopramide
and ergotamine. However, it is recommended that
patients should leave at least 6 hours between
taking an ergotamine preparation and starting
zolmitriptan, and vice versa. Concomitant
administration of other 5HTID agonists within 12
hours of zolmitriptan treatment should be
avoided. Following administration of
moclobemide, a specific MAO-A inhibitor, there
was a small increase (26%) in AUC for
zolmitriptan and a 3-fold increase in AUC of the
active metabolite. Therefore, a maximum intake
of 7.5mg zolmitriptan in 24 hours is recom­
mended in patients taking an MAO-A inhibitor.
+ MIOTROL Tab. Drug Inter.
Zolmitriptan INN 2.5mg/tablet
50's pack: 750.00 MRP
+ NOMI Tab. Square
Zolmitriptan INN 2.5mg/tablet
l 2's pack: 301.20 MRP
+ NOMITEN Tab. Rephco
Zolmitriptan INN 2.5mg/tablet
50's pack: 1000.00 MRP
+ ZOMITAN 2.S Tab. lncepta
Zolmitriptan INN 2.5mg/tablet
1O's pack: 250.00 IP
Ergot Alkaloids
.
ERGOTAMINl: TARTRAT.£2t,33
ERGOTAMINE TARTRAT E: Tablet/
Suppositories/ Inhalation.
Ind: Migraine attack and other headaches of
vascular origin.
C/I: Pregnancy and lactation; coronary, periphe-
QIMP-17 (330)
ral or occlussive vascular disease; severe hyper­
tension; impaired hepatic or renal function; sepsis
S/E: Headache, nausea and vomiting, abdominal
pain; repeated dsoage may cause ergotism with
gangrene and mental derangement. Pleural and
peritonial fibrosis may occur with excessive use.
Precautions: Renal, hepatic and cardiovascular
disease; hyperthyroidism; unsuitable for prophy­
lais. Concomitant admin. of erythromycin should
be avoided. Withdraw the treatment immediately
if numbness and tingling of extremities develops.
Dosage & admin: Adult: Oral, 2mg at onset of
attack repeated every 30 minutes if necessary;
max. 6mg daily (per attack), lOmg in any one
week.
Child: Not recommended.
Preparations: May be available in the market.
Prophylactics of migraineii
1. Antihistamine prepn.- such as pizotifen
2. Beta-blocken- such propranolol,
as
metoprolol, nadolol and timolol
3. liicyclic antidepressants-such as
amitriptyline
4. Miscellaneous preparations- such as
flunariz.ine
PIZOTIFEN21,1s
PIZOTIFE N: Tablet/Syrup
Ind: Prevention of vascular headache including
clas-sical migraine, common migraine & cluster
headache.
C/I: Better to avoid in narrow-angle glaucoma,
prostate hypertrophy and lactation.
S/E: Drowsiness, increased appetite and weight
gain; rarely nausea, dininess, dry mouth, consti­
pation; CNS stimulation may occur in children.
P recautions: Urinary retention; renal
impairment; pregnancy and breast feeding;
drowsiness may affect performance of skilled
tasks (e.g driving); effects of alcohol enhanced.
Dosage & admin: l.Smg at night or SOOmcg 3
times daily, and if necessary, may be increased
gradually to 3mg daily; max. single dose 3mg
max. daily dose may be upto 4.Smg.
Child- up to 1.Smg daily in divided doses;
max. single dose at night lmg.
Drug inter: Pizotifen may increase the
drowsiness effects of tranquillizers, hypnotics &
antidepressants. MAOis.
+ ANTIGRAIN Tab. Ibo Sina
Pizotifen malate BP 0.5mg/tablet
50's pack: 162.50 IP
+ ANTIGRAIN-TS Tab. lbn Sina
Pizotifen malate BP l .5mg/tablet (triple strength).
30's pack: 217.50 IP
+ AVIDRO Tab. Beximco
Pizotifen malate BP 0.5mg & l . 5mg/tablet
0.5mg x 1OO's pack: 300.00 IP
l .5mg x 50's pack: 350.00 IP
+ D-FEN Tab. Drug Inter.
Pizotifen malate BP 0.5mg & l .5mg/tablet
0.5mg x 50's pack: 150.00 MRP
l .5mg x 50's pack: 250.00 MRP
+ DMIGRAIN Tab. NIPRO JMI .
Pizotifen malate BP 0.5mg & l .5mg/tablet
0.5mg x 50's pack: 150.00 MRP
l .5mg x 50's pack: 350.00 MRP
+ MIGOFEN Tab. Techno Drugs
Pizotifen malate 0.5mg & l .5mg/tablet
0.5mg x 30's pack: 90.00 MRP
l .5mg x 30's pack: 180.00 MRP
+ MIGRANEX Tab. Edruc
Pizotifen malate BP 0.5mg & l .5mg/tablet
0.5mg x 50's pack: 150.00 MRP
l .5mg x 30's pack: 210.00 MRP
+ MIGRANIL Tab. Square
Pizotifen malate BP 0.5mg & l .5mg/tablet
0.5mg x 50'� pack: 150.50 MRP
l .5mg x 30's pack: 210.60 MRP
+ PIFEN Tab. Opsonin
Pizotifen malate BP 0.5mg & l .5mg/tablet
0.5mg x 50's pack: 131.84 MRP
l .5mg x 30's pack: 185.53 MRP
•
+ PITOFEN Tab. Medicon
Pizotifen malate BP 0.5mg/tablet
1OO's pack: 300.00 MRP
+ P IZO-A Tab. Acme
Pizotifen malate BP 0.5mg & l .5mg/tablet
0.5mg x lOO's pack: 262.00 MRP
l .5mg x 50's pack: 306.00 MRP
+ PIZOFEN Tab. Navana
Pizotifen malate BP 0.5mg/tablet
lOO's pack: 301.00 IP
+ PIZOFEN-TS Tab. Navana
Pizotifen malate BP l .5mg/tablet (triple strength).
50's pack: 351.50 IP
+ PIZOTIN Tab. Nipa
Pizotifen malate BP 0.5mg & l .5mg/tablet
0.5mg x lOO's pack: 300.00 MRP
l .5mg x 30's pack: 210.00 MRP
+ ZEROMIG Tab. SK+F
Pizotifen malate BP 0.5mg & l .5mg/tablet
0.5mg x 50's pack: 150.00 MRP
l.5mg x 30's pack: 210.00 MRP
+ ZOFEN Tab. Aristopharma
Pizotifen malate BP 0.5mg/tablet
50's pack: 155.00 MRP
+ ZOFEN TS Tab. Aristopharma
Pizotifen malate BP l .5mg/tablet (triple strength).
50's pack: 360.00 MRP
PROPRANOLOL 801
PROP RANOLOL HCl: Tablet
Ind: Prophylaxis or prevention of severe
recurrent migraine
C/I; S/E; Cautions: See in the section of
Cardiovascular drugs; caution also necessary
with concurrent admin. of ergotamine
Dosage & admin: Adult: 40 mg 2 or 3 times
daily.
Child : Half adult dose.
•
Preparations: See under the section of
cardiovascular drugs.
Tricyclic Antidepressant drug.1
Antidepressant drugs may be useful, for example­
Amitriptyline 1 Omg at night, increasing to a
maintenance dose of 50 to 7Smg at night.
(For detail see Antidepressant drugs under CNS
drugs).

jfiscellaneouspreparadons
FLUNARIZINE65
FLUNARIZINE: Tablet
Flunarizine is the difluorinated derivative of
cinnarizine. It is available as- flunarizine INN
5mg & 1Omg tablet & capsule.
Mode of action: Flunarizine is a selective calci­
um channel antagonist. It prevents cellular calci­
um overload by reducing excessive transmem­
brane influxes of calcium. It does not interfere
with normal cellular calcium homeostasis. It also
has antihistaminic and sedative properties.
Ind: Prophylaxis of classic (with aura) or com­
mon (without aura) migraine.
Symptomatic treatment of vestibular vertigo,
dizziness. Preripheral vascular disease (intermit­
tent claudication, Raynaud's phenomenon, pares­
thesiae, cold extremities, nocturnal cramp and
trophic disorders owing to ischaemia of limbs).
Refractory epilepsy resistant to conventional
antiepileptic therapy Alternating hemplegia of
childhood.
C/I: Hypersensitivity to flunarizine or structural­
ly similar calcium channel blocker. Patients with
a history of depressive illness. Patients with pre­
existing symptoms of Parkinson's disease or other
extra-pyramidal disorders. Hepatic insufficiency
(relatively contraindicated).
S/E: Flunarizine is well tolerated and seldom
causes serious side effects. The main adverse
effects experienced by the patients are­
depression, drowsiness, sedation, anxiety; heart
burn, nausea, vomiting, dry mouth, gastralgia;
weight gain, and/or increased appetite, asthenia,
muscle aches, skin rash, and galactorrhea in
female patients on oral contraceptives.
Precautions: Since sedation or drowsiness occur
in some patients during treatment with flunar­
izine hydrochloride, patients should be cautioned
against activities which require alertness or rapid,
I -
precise responses ( e.g operating machinery or a
motor vehicle) until the response to the drug has
been determined.
Elderly: The efficacy of flunarizine in the prophy­
laxis of migraine has not been established in elder­
ly subjects. Moreover, treatment with flunarizine
may give rise to extrapyramidal & depressive
symptoms & reveal parkinsonism, specially in the
elderly. Therefore, it should be used with caution.
Patients with impaired hepatic function:
Flunarizine is metabolised by the liver, therefore
care should be exercised when flunarizine is
given to patients with compromised liver function.
Pregnancy & lactation: There is no data to
support the use of flunarizine during pregnancy.
Therefore it should not be administered to
pregnant women unless the anticipated benefits
outweigh the potential risks. As animal studies
have shown that flunarizine is excreted in breast
milk, therefore, breast-feeding should be
discouraged in women taking flunarizine.
I
QIMP-17 (331)
Dosage & admin: The usual dose is 5 to lOmg
daily, usually given at night to minimize the
effects of drowsbiess.
Migraine prophyla:ds: Starting dose is lOmg
daily (at night) for patients less than 65 years
and 5mg daily for patients older than 65 years.
Maintenance treatment: If a patient's response
is satisfactory and if a maintenance treatment
is needed, the dose should be decreased so that
each week the patient has 5 days treatment at
the same daily dose and 2 successive drug free
days. Treatment should be interrupted after 6
months and re-initiated only if the patient
relapses. The recommended maximum dose is
1Omg daily in adults and Smg daily in children
(<40kg).
Vertigo: The recommended maximum dose is
1Omg daily in adults and Smg daily in children
(<40kg).
Epilepsy: An optimal therapeutic dosage in
epileptic patients receiving other antiepileptic
drugs is 15mg to 20mg daily in adults and 5 to
1Omg daily in children.
Peripheral vascular disorders: The recomm­
ended daily dose is 5-1Omg in the evening.
Drug inter: Galactorrhea has been reported in
few women on oral contraceptives within the first
two months of flunarizine treatment. Hepatic
enzyme inducers such as carbamazepine and
phenytoin increase the metabolism of flunarizine
and thus reduce its steady state level. So, an
increase in dose of the drug may be required.
Concomitant use of a calci11m-channel blocker
and amiodarone has been reported to result in
sinus arrest and atrioventricular block. Excessive
sedation can occur when alcohol, hypnotics or
tranquilizers are taken simultaneously with
flunarizine.
+ FLUNARIN Tab. Apex
Flunarizine 5mg & 1Omg/tablet.
5mg x 50's pack: 100.00 MRP
lOmg x 30's pack: 90.00 MRP
+ FLURIUM Tab. Beximco
Flunarizine 5mg & 1Omg/tablet.
5mg x 30's pack: 90.00 IP
lOmg x 30's pack: 150.00 IP
+ FLURIZIN Tab. Square
Flunarizine 5mg & 1Omg/tablet.
5mg x 50's pack: 150.50 MRP
lOmg x 50's pack: 200.50 MRP
+ FLUVER Tab. ACI
Flunarizine 5mg & 1Omg/tablet.
5mg x lOO's pack: 350.00 MRP
1Omg x 80's pack: 400.00 MRP
+ FLUZIN Tab. Acme
Flunarizine 5mg & 1Omg/tablet.
5mg x 50's pack: 150.00 MRP
1Omg x 50's pack: 250.00 MRP
+ IMIGRA Cap. Navana
Flunarizine 5mg & lOmg/capsule.
5mg x 50's pack: 200.00 IP
1Omg x 30's pack: 150.00 IP
+ MINIUM Tab. Opsonin
Flunarizine 5mg & 1Omg/capsule.
-
•
Flunarizine
5mg x 50's pack: 132.40 MRP
1Omg x 50's pack: 176.82 MRP
+ NORIUM Tab. SK+F
Flunarizine 5mg & 1Omg/capsule.
5mg x 1OO's pack: 350.00 MRP
1Omg x 60's pack: 300.00 MRP
+ RIZELIUM Cap. UniMed & UniHealth
Flunarizine ·smg & 1Omg/capsule.
.5mg x 30's pack: 105.00 MRP
lOmg x 30's pack: 150.00 MRP
+ VERTIG-5 Cap. Alco Pharma
Flunarizine 5mg/capsule.
5mg x 30's pack: 105.00 MRP
4. TRIGEMINAL NEURALGIA
The drugs commonly used in trigeminal
neuralgia include: Carbamazepine, phenytoin­
which are discussed in the section of anti­
epileptic drugs.
5. DRUGS USED IN ORAL &
DENTAL PAIN
BENZOCAINE42
+ OROGEL Dental Gel Square
Benzocaine is a local anesthetic. It is available as
gel preparation containing benzocaine USP 20%
w/w for dental use.
Mode of acti�n: Local anesthetics inhibit
conduction of nerve impulses from sensory
nerves. This action results from an alteration of
the cell membrane permeability to ions.
Benzocaine has low solubility in water and it is
absorbed too slowly to be toxic. Although poorly
absorbed through the intact epidermis, this is
absorbed from mucous membranes. When skin
permeability has been increased by abrasions or
ulcers, the absorption and, subsequently, the
efficacy of local anesthetics improves; however,
the incidence of side effects also increases.
Ind: For the temporary relief of pain due to
minor injury or irritation of the mouth and gums
like- toothache, sore gums, canker sores, braces,
minor dental procedures, dentures.
C/I: In patients who are hypersensitive to this
medication or to any of its ingredients, or to other
'caine' anesthetics.
S/E: Side effects are less common; these include,
allergies, swelling in the mouth or throat etc.
Precaution: Not for prolonged use. The product
should not be used more than 7 days unless
directed by a physician or dentist. If condition
persists or irritation develops, use of the product
should be discontinued. Contact with eyes should
ANALGESICS & ANTIPYRETICS
be avoided. Food should not be taken for 1 hour
after use of this medication in mouth. Some of
these medications can block swallowing reflex if
ingested which may cause the patient to choke.
Pregnancy & lactation: Bezocaine has not been
reported to cause birth defe�ts or other problems
in pregnant women, as well as, in nursing babies.
Dosage & admin: Apply to the affected area
up to 4 times daily or as directed by the
physician. Children under 12 years of age:
should be supervised in the use of this
product. Children under 2 years of age: should
be consulted with a physician or dentist prior
to the use of this product. A small amount of
gel should be applied either by the tip of a
fi.nger or by the applicator to the affected area
and wait for 2-3 minutes for the action of the
drug. When pain is gone mouth cavity should
be rinsed with water.
Drug inter: Information regarding durg
interaction is not known.
5gm tube: 50.00 MRP
CEIJ\LKONIUM cm,
.
'-!'
� .. ... . ,,.,,.
�- ��.. .. �
�, 34
I .
CETALKONIUM CHLORIDE +CHOLINE
SALICYLATE: Oral gel
This combination of cetalkonium chloride and
choline salicylate is prepared for analgesic and
anti-inflammatory action in the cases of inflam­
matory infections on the mucosa of the oral cavi­
ty and throat. This combined preparation is avail
able as oral gel, 1gm of which contains­
cetalkonium chloride Ph. Gr. O. l mg and choline
salicylate BP 87. l 4mg.
Mode of action: Choline salicylate has an
analgesic anti inflammatory effect. Like salicylic
acid choline salicylated has no antithrombotic
activity. The pharmacological actions of choline
salicylate are thought to be primarily medicated
through inhibiton of prostaglandin production.
Cetalkonium chloride is an antiseptic, being
bactericidal towards both gram positive and gram
negative organisms.
Ind: This combined oral gel is indicated for the
fast relief of pain, discomfort and inflammation
caused by mouth infection or ulcer/aphthous
ulcer/canker sore, cold sore/fever blister, denture
sore, irritation from braces, gum swelling, and
sore spots due to othodonitic device.
.
C/I: Not to be used in- if allergic to salicylates,
e.g aspirin, if have an active peptic ulcer.
S/E: Salicylates may produce bronchospasm and
induce asthma attacks in susceptible patients.
Precautions: Do not exceed the recommended
dose.
Pregnancy & lactation: there is clinical
evidence of the safety of salicylates in pregnancy.
This medicine may pass into breast milk in very
small amounts, but is unlikely to have any
adverse effects on a mursing infant.
Dosage & admin: Adult: Wash hands, apply 112
inch of gel on to the sore area. T his can be
repeated after every 3 hours.
Drug inter: Salicylates may enhance the effect
of anticoagulants. and inhibit the action of
uncosuncs.
• •
QIMP-17 (332)
+ BONGEL Oral Gel General
This oral gel is a combined preparation of cetalk­
onium chloride & choline salicylate. 1gm of this
gel contains- cetalkonium chloride Ph. Gr. 0.1mg
(0.01 %) & choline salicylate BP 87.14mg
(8.714%).
1Ogm tube: 80.00 MRP
RHUBARB EXTRACT+ SAJ,JCYLIC·
AClll I4s
RHUBARB EXTRACT+ SALICYLIC ACID:
. Oral Snlution.
This combination of rhubarb extract and
salicylic acid is prepared for anti-inflammatory
and analgesic action in the cases of inflammatory
infections on the mucosa of the mouth or throat.
This combined preparation is available as oral
solution, l ml of which contains- rhubarb extract
BP 0.05gm (equivalent to anthraquinone
glycosides 0.005gm) & salicylic acid BP O.Ol gm.
Mode of action: This combined preparation
exerts an anti-inflammatory action in the cases of
£+ •
inflammatory infections on the mucosa of the
mouth or throat. Its analgesic properties allow to
rapidly suppressing pains and the sensitivity of
the tissues submitted to inflammatory processes.
This combined oral preparation also allows that,
after a short time, mucosas res11me their normal
physiological functions, without exerting any
harmful action on the tissues.
Ind: This combined oral solution is indicated in
the treatment of acute and chronic inflammations
of the mucosas of the mouth & throat (Aphthous
ulcer, gingivitis, periodontitis and denture
irritation).
C/I: Hypersensitivity to any of the components.
S/E: A transient local burning sensation at the
site of application occurs very commonly.
Temporary discoloration of teeth or oral mucosa
following administration of oral solution.
Precautions: One bottle of oral solution should
be used by only one person.
Pregnancy & lactation: The potential risk for
human pregnancy is unknown. However, caution
should be exercised when prescribing to pregnant
women.
Anthranoid glycosides derived from rhubarb may
be excreted in breast milk; but, it is not known
whether salicylic acid is excreted in breast milk.
In this context, a decision is to be taken whether
to continue breast-feeding or to continue therapy
with oral solution considering the benefit of
breast-feeding to the child and benefit of oral
solution therapy to the mother.
Dosage & admin: Adults (including the
elderly): To be applied to the inflamed oral
mucosa (after removing any dentures) 3 or 4
times daily using the brush provided. Avoid
rinsing the mouth or eating for 15 minutes
after application. Always keep the mouth
closed immediately after every use.
Children: Not recommended below the age of
12 years.
Drug inter: There are no known interactions
with the preparation documented.
+ OROFRESH Oral Solo. Ziska
This oral solution is a combined preparation of
rhubarb extract and salicylic acid. 1 ml of this
solution contains- rhubarb extract BP 0.05gm
(equivalent to anthraquinone glycosides 0.005gm)
& salicylic acid BP O.Ol gm.
1Oml bot: 120.00 MRP
6. EMBROCATIONS
Analgesic & Muscle relaxants
for topical use
CAPSAICIN: Cream
Topical capsaicin has been used to treat different
types of pain. It is available as capsaicin USP
0.25mg/gm (i.e 0.025% w/w).
Mode of action: Although the precise
mechanism of action of capsaicin is not fully
understood, current evidence suggests that
capsaicin exerts an analgesic effect by rendering
skin insensitive to pain by depleting and
preventing reaccumulation of substance P in
peripheral sensory neurons. Substance P is the
principal chemomediator of pain impulses from
the periphery to the central nervous system.
Ind: Rhe11matoid arthritis, osteoarthritis, pain due
to diabetic neuropathy, joint pain, post-herpetic
neuralgia, post-surgical neuropathic pain, nerve
pain, back pain, muscle pain, fibromyalgia,
bursitis & pruritis (itching).
C/I: Capsaicin cream is contraindicated for use
on broken or irritated skin or known
hypersensitivity to this medication.
S/E: Capsaicin may cause transient burning on
application. This burning is observed more
frequently when the application schedules are
more than 3-4 times daily. The burning can be
enhanced if too much cream is used and if it is
applied just before or after a bath or shower. But,
this burning sensation generally disappears with
regular use.
Precautions: Capsaicin cream should not be
applied to broken or irritated skin or on mucous
membranes or into eyes or on contact lenses.
Applied area should not be tightly bandaged. Do
not apply the cream on the heat treated area as
this may increase the burning sensation.
Pregnancy & lactation: The safety of capsaicin
during pregnancy or lactation has not been
established in either humans or animals.
Dosage & admin: Persons 18 years of age and
older: Apply a thin film of capsaicin cream to
affected area 3 to 4 times daily. Use for 2
weeks provides optimum pain relief.
Drug inter: There are no reported drug
interactions with topical capsaicin cream.
t OSTOCIN Cream General
Each gram of cream contains capsaicin USP
0.25mg (i.e 0.025% w/w).
20gm tube: 50.19 MRP
t TOPICACIN Cream Incepta
Each gram of cream contains capsaicin USP
0.25mg (i.e 0.025% w/w).
MRP
20gm tube: 50.00

METHYL SALICYLATE+
MENmOL26
METHYL SALICYLATE + MENTHOL:
Cream
This is a specially formulated combined
preparation of methyl salicylate and menthol
available as topical cream.
Comp: See below under individual product.
Mode of action: The ingredients of this product
penetrate into skin to provide fast relief from
pain and stiffness of minor arthritis and muscle
aches. This cream preparation is fast acting,
strong medicine that penetrates deep down to
provide long lasting and effective relief. Methyl
salicylate has been shown that first pass
metabolism exists in the skin and rapidly
hydrolyzing salicylate ester to release the active
salicylate in both epidermis and dermis. It
alleviates pain and inflammation by inhibiting the
synthesis of drugs when applied on the skin to
give a faster onset of action. It dilates the blood
vessels causing a sensation of coldness followed
by an analgesic effect.
Ind: It is indicated for the fast relief of minor
aches and pains of muscles and joints associated
with- arthritis, bursitis, rhel1matism, tendonitis,
simple backache, strains, sprains, leg cramps.
C/I: Hypersensitivity to salicylate or any of its
ingredients.
S/E: Redness or irritation may occur, specially in
persons with sensitive skin. Adverse reactions
possibly involved are mild to moderate local
irritation, erythema, rash, desquamation, pruritis
and relative local reaction at the application site.
Precautions: Avoid contact with the eyes and
mucous membranes. Do not bandage tightly,
wrap or cover until washing the area. It should
not be applied to wounds or scraped, irritated or
damaged skin & should not be used immediately
after bath. Wash hand thoroughly after applying.
Pregnancy: Its safety in human pregnancy has
not been established. This preparation should
therefore be given to pregnant women only if
clearly needed.
Use & application: For external use only.
•
Adult & children 2 years of age and older:
Apply a thin layer of cream to the affected
I
area and gently massage until cream disap­
pears; apply not more than 3 to 4 times daily.
+ BANGAY Cream Sharif
Each gram of 'lnstacool cream' contains methyl
salicylate BP 0.30gm (30%) and menthol BP
0.08gm (8%).
15gm tube: 40.00 MRP
25gm tube: 60.00 MRP
+ FASTCUT Cream Pacific
Each gram of cream contains methyl salicylate
BP 300mg (0.30gm or 30%) and menthol BP
80mg (0.08gm or 8%).
20gm tube: 60.00 MRP
+ ICYKOOL Cream Beximco
Each gram of cream contains methyl salicylate
BP 150mg (0.15gm or 15%) and menthol BP
lOOmg (O. lOgm or 10%).
25gm tube: 40.00 IP
+ ICYKOOL MAX Cream Beximco
Each gram of cream contains methyl salicylate
BP 300mg (0.30gm or 30%) and menthol BP
I
QIMP-17 (333)
80mg (0.08gm or 8%).
25gm tube: 60.00 IP
+ INSTACOOL Cream Medicon
Each gram of 'Instacool cream' contains methyl
salicylate BP 0.30gm (30%) and menthol BP
0.08gm (8%).
25gm tube: 60.00 MRP
+ P-COOL Cream Alco Pharma
Each gram of cream contains methyl salicylate
BP 150mg (i.e 0.15gm or 15%) and menthol BP
lOOmg (i.e O.lOgm or 10%).
lOgm tube: 25.00 MRP
25gm tube: 40.00 MRP
+ PENRIF IS Cream Square
Each gram of 'Penrif 15 cream' contains methyl
salicylate BP 0.15gm (15%) and menthol BP
O.lOgm (10%).
20gm tube: 40.15 MRP
+ PENRIF30 Cream Square
Each gram of 'Penrif 30 cream' contains methyl
salicylate BP 0.30gm (30%) and menthol BP
0.08gm (8%).
20gm tube: 60.22 MRP
+ SALINIX IS Cream Incepta
Each gram of 'Salinix 15 cream' contains methyl
salicylate BP 0.15gm (15%) and menthol BP
O.lOgm (10%).
20gm tube: 40.00 MRP
+ SALINIX 30 Cream Incepta
Each gram of 'Salinix 30 cream' contains methyl
salicylate BP 0.30gm and menthol BP 0.08gm.
20gm tube: 60.00 MRP
t VISCON IS Cream ACI
Each gram of 'Viscon 15 cream' contains methyl
salicylate BP 0.15gm (15%) and menthol BP
O.lOgm (10%).
20gm tube: 40.15 MRP
+ VISCON30 Cream ACI
Each gram of 'Viscon 30 cream' contains methyl
salicylate BP 0.30gm (30%) and menthol BP
0.08gm (8%).
20gm tube: 60.23 MRP
+ XENTHOL30 Cream SK+F
Each gram of 'Xenthol 30 cream' contains methyl
salicylate BP 0.30gm (30o/o) and menthol BP
0.08gm (8%).
15gm tube: 40.00 MRP
CAMPHOR+MENTHOL+METHYL
SALICYLATE 155
CAMPHOR+ MENTHOL + METHYL
SALICYLATE: Cream
This is a combined formulation of three
ingredients, viz: camphor, menthol & methyl
salicylate; used for reduction of pain. It is
available as- cream for topical use.
Comp: Each gram of the cream contains- cam­
phor USP 0.04gm (4%), menthol USP O.lOgm
(10%), and methyl salicylate BP 0.30gm (30%).
Mode of action: Each of the ingredients in the
combination shows distinct function in reduction
of pain. Camphor, which shows spasmolytic
action on smooth muscles; it causes reduction of
Ca2+ influx in the smooth muscles and thus
reduces the contraction of muscles, and muscle
spasm. Another action of camphor is to reduce
the pain by increasing the threshold level. Pain
stimuli are not enough to be transmitted to brain
because of increased threshold level. Menthol
ANALGESICS & ANTIPYRETICS
exerts cooling and soothing effect by stimulating
the cold receptor and thus causes reduction of
pain. Methyl salicylate is converted to salicylic
acid and causes the inhibition of cyclooxygenase
enzyme. As a result prostaglandin synthesis is
inhibited and that ultimately results in reduction
of pain.
Ind: This combined preparation provides
temporary relief of minor aches and pains of
muscles and joints associated with backache,
lumbago, strains, bruises, sprains and arthritis or
rheumatic pain, pain of tendons and ligaments.
C/I: Contraindicated in patients with bleeding
disorders, allergy to salicylate or sensitivity to
any of the components. Application to broken
skin or raw surfac.es is not recommended.
S/E: Redness or irritation may occur, specially in
persons with sensitive skin. Adverse reactions
possibly involved are mild to moderate local irri­
tation, erythema, rash, desquamation, pruritis and
relative local reaction at the site of application.
Precautions: For external use only. Use only as
directed. Should not use with a heating pad. Keep
away from children to avoid accidental poison­
ing. Do not use tight bandage. Do not swallow. If
swallowed, induce vomiting and call a physician.
Keep away from eyes, mucous membranes,
broken or inflamme d skin. Long term and excess
administration may cause skin irritation and
redness. Therapy might be hazzardous for
patients with impaired kidney or liver function.
Dosage & application: Adults & children 2
years of age & older: Apply generously to the
painful area and gently massage until the
cream disappears. Apply to the affected area
not more than 3 to 4 times daily. If condition
worsens, or if symptoms persist for more than
7 days or clear-up and occur again within a
few days, discontinue use of this product and
consult a doctor. Children below 2 years of age:
Sufficient data is not available for use of this
product in children below 2 years of age.
Drug inter: Methyl salicylate is systemically
absorbed through the skin in measurable amounts
..
and may increase warfarin action by affecting
vitamin K metabolism or by displacing warfarin
from protein-binding sites.
+ BANGAY ULTRA Cream Sharif
This is a combined formulation of three
ingredients, viz: camphor, menthol & methyl
salicylate. Each gram of which contains­
camphor USP 0.04gm (4°/o), menthol USP
O.lOgm (10%), and methyl salicylate BP 0.30gm
(30%): cream for topical use.
15gm tube: 95.00 MRP
25gm tube: 120.00 MRP
+ FREEFAST Cream Pacific
This is a combined formulation of three
ingredients, viz: camphor, menthol & methyl
salicylate. Each gram of which contains­
camphor USP 0.04gm (4%), menthol USP
0.lOgm (10%), and methyl salicylate BP 0.30gm
(30%): cream for topical use.
25gm tube: 120.00 MRP
CAMPHOR+EUCALYPTUS OIL+
MENTHOL+THYMOL132
 ANALGESICS & ANTIPYRETICS
CAMPHOR+ EUCALYPTUS OIL+
MENTHOL+ TH YMOL: Ointment
This is a combined formulation of four ingredi­
ents, viz: camphor, eucalyptus oil, menthol &
thymol; presented as vaporising ointment for
topical use.
Comp: See below under individual product.
Ind: It can be used in all types of colds, flu, resp­
iratory affections and as counter irritant in aches
and pains.
ANTIRHEUMATIC &
ANTI-INFLAMMA­
TORY DRUGS21
Antirheumatic & anti-inflammatory drugs are
discussed under the following headings:
1. Drugs used in rheumatic diseaeses & gout.
2. Drugs used in neuromuscular disorders.
3. Drugs used in soft-tissue inflammation
1. DRUGS USED IN
RHEUMATIC DISEAESES
& GOUT21
1.1 Non steroidal anti-in tlammatory drugs
1.2 Corticosteroids
1.3 Drugs which suppress the rheumatic
<lisease process
1.4 Drugs used in the treatment of gout &
cytotoxic-induced hyperuricaem.ia
Non-steroidal anti­
injlammatory drugs (NSAJD)
The non-steroidal anti-inflammatory drugs
{NSAIDs) that are used up to currrent time
include: Aspirin, Aceclo/enac, Acemetacin,
Celecoxib, Dexibupro/en, Dexketoprofen,
Diclofenac sodium, Diflunisal, Etodolac,
Etoricoxib, •Fenbu/en, F enoprofen,
Flurbiprofen, Ibuprofen, lndomethacin,
Ketopro/en, Lumiracoxib, Me/enamic acid,
Meloxicam, Nabumetone, Naproxen, Piroxicam,
Sulindac, Tenoxicam, Tiaprofenic acid.
ASPIRIN
Aspirin and other salicylate preparations- see in
the section of analgesics & antipyretics
I
QIMP-17 (334)
C/I: Children under 3 years; history of
convulsions.
Use & application: Rub on gently for 3-S
minutes on the chest & back 2-3 times daily &
cover the rubbed area with warm clothes. Use
as inhalation- 1 tsf of ointment tobe dissolved
in boiled water & inhale the steam by mouth
or nose as required.
+ SINEX Oint. Cosmic
ACECLOFENAC26•42
ACECLOFENAC: Tablet
Aceclofenac is a non-steroidal agent with
antiinflammatory and analgesic properties. It is
available as- Aceclofenac BP 1 OOmg film-coated
tablet.
Mode of action: Its mode of action is largely
based on inhibition of prostaglandin synthesis.
Aceclofenac is a potent inhibitor of the enzyme
cyclooxygenase, which is involved in the
production of prostaglandins. Aceclofenac
penetrates into the synovial fluid, where the
concentrations reach approximately 57% of those
in plasma. The mean plasma elimination half-life
is around 4 hours. It also stimulates cartilage
matrix (glycosaminogly-cans) synthesis.
Ind: Aceclofenac is indicated for the relief of
pain and inflammation in both acute and chronic
pain like osteoarthritis, rheumatoid arthritis, ank­
ylosing spondy-litis, dental pain, post-tratimatic
pain, low back pain, gynaecological pain etc.
C/I: Known hypersensitivity to aceclofenac or
aspirin or other NSAIDs. Patients with active or
suspected peptic ulcer or gastrointestinal bleeding
and moderate to severe renal impairment.
S/E: Generally ac.eclofenac is well tolerated. The
majority of side effects observed have been
reversible and of a minor nature and include
gastrointestinal disorders (dyspepsia, abdominal
pain, nausea and diarrhoea) and occasional
occurance of dizziness. Dermatological side
effects include pruritus and rash. Abnormal
hepatic enzyme levels and raised serum
creatinine have occasionally been reported.
Precaution: Aceclofenac should be administered
with caution to patients with symptoms indicative
of gastrointestinal disorders, with a history of
peptic ulceration, ulcerative colitis, Crohn's
disease, hepatic porphyria, and coagulation
disorders. Patients suffering from severe hepatic
impairment must be monitored.
Pregnancy & lactation: There is no information
on the use of aceclofenac during pregnancy & in
nursing mother. Therefore, aceclofenac should
not be administered during pregnancy & breast
feeding, unless the potential benefits to the
mother outweigh the possible risks to the fetus
& child respectively. In that cases the lowest
effective doses should be administered.
Dosage & admin: Adults & elderly: The maxi-
Each 1OOgm contains camphor BP 1Ogm,
menthol BP 2.Sgm, eucalyptus oil BP 2.Sgm &
thymol BP 1gm: vaporising ointment
Price: lOgm x 12's pack: 144.00 MRP
t VAPOREX Oint. Hallmark
Each 1 OOgm contains camphor BP 1Ogm,
•
menthol BP 2.Sgm, eucalyptus oil BP 2.Sgm &
-
thymol BP 1 gm: vaporising ointment
Price: 30gm pack: 35.00 MRP
mum recommended dose is 200mg daily, taken
in two divided doses in the morning and in the
evening.
•
Children: There is no clinical data on the use
of aceclofenac in children.
Renal insufficiency: T here is no evidence that
the dosage of aceclofenac needs to be modified
in patients with mild renal impairment.
Hepatic insufficiency: The dose of aceclofenac
should be reduced in patients with hepatic
impairment. An initial daily dose of 1OOmg
should be administered.
Drug inter: Lithium & digoxin: Aceclofenac,
like other NSAIDs, may increase plasma
concentrations of lithium and digoxin.
Diuretics: Aceclofenac, like other NSAIDs, may
inhibit the activity of diuretics.
Anticoagulants:
Like other NSAIDs, aceclofenac
may enhance the activity of anticoagulants.
Quinolones: Convulsion may occur due to an
interaction between quinolones and NSAIDs.
Other NSAIDs and steroids: Concomitant therapy
with aspirin, other NSAIDs and steroids may
increase the frequency of side effects.
Overdosage: There is no human data available
on the consequences of aceclofenac overdosage.
However, after any overdosage, following
therapeutic measures to be taken- absorption
should be prevented as soon as possible by
means of gastric lavage and treatment with
activated charcoal. Supportive and symptomatic
treatment should be given for complications.
t ACEBID Tab. Beacon
Aceclofenac BP lOOmg/tablet (f.c).
SO's pack: 200.00 MRP
t ACECLOFEN Tab. Astra
Aceclofenac BP 1OOmg/tablet (f.c).
30's pack: 90.00 MRP
t ACECOL Tab. Ziska
Aceclofenac BP 1OOmg/tablet (f.c).
50's pack: 100.00 MRP
+ ACEDOL Tab. Concord
Aceclofenac BP l OOmg/tablet (f.c).
1OO's pack: 300.00 MRP
t ACEFENAC Tab. General
Aceclofenac BP l OOmg/tablet (f.c).
50's pack: 200.00 MRP
t ACEGIC Tab. Belsen
Aceclofenac BP l OOmg/tablet (f.c).
1OO's pack: 300.00 MRP
t ACELOCK Tab. Bristol
 QIMP-17 (335)

Aceclofenac BP lOOmg/tablet (f.c). 1OO's pack: 300.00 MRP

1OO's pack: 300.00 MRP t ECENA Tab. Edruc
t ACELON Tab. CPL Aceclofenac BP 1OOmg/tablet (f.c)
Aceclofenac BP lOOmg/tablet (f.c). 50's pack: 150.00 MRP
1OO's pack: 300.00 MRP t ENA Tab. Asiatic
t ACENAC Tab. Medicon Aceclofenac BP lOOtng/tablet (f.c) + PANKIL Tab. Everest
,
Aceclofenac BP lOOmg/tablet (f.c). 50's pack: 150.00 MRP Aceclofenac BP lOOmg/tablet (f.c)
I

50's pack: 200.00 MRP t FIXONAC Tab. Euro Pharma

l OO's pack: 250.00 MRP
t ACEPRO Tab. White Horse Aceclofenac BP lOOmg/tablet (f.c) t PENAC-AC Tab. APC Pharma

Aceclofenac BP lOOmg/tablet (f.c). lOO's pack: 300.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

50's pack: 150.00 MRP t FLECO Tab. Ad-din

lOO's pack: 300.00 MRP
t ACF Tab. Decent Aceclofenac BP lOOmg/tablet (f.c) + PRESERVIN Tab. lbn Sina

Aceclofenac BP lOOmg/tablet (f.c). lOO's pack: 250.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

MRP 50's pack: 175.00 IP

1OO's pack: 300.00 t FLEXI Tab. Square
t ACFLAM Tab. Apollo Aceclofenac BP lOOmg/tablet (f.c) t PRO'I'ILEZ Tab. Reliance

1OO's pack: 400.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

Aceclofenac BP lOOtng/tablet (f.c).
1OO 's pack: 400.00 IP t FLEXIVAN Tab. NIPRO JMI
l OO's pack: 400.00 MRP
+ ACLO Tab. Alco Pharma Aceclofenac BP lOOtng/tablet (f.c) + QRIP Tab. Sanofi aventis

50's pack: 151.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

Aceclofenac BP lOOmg/tablet (f.c).
lOO's pack: 300.00 MRP + FREEMAX F.C Tab. Nuvista
1OO's pack: 400.00 MRP
t ACLONAC Tab. Pharmasia Aceclofenac BP 1OOtng/tablet (film-coated) t R APIDOR Tab. Rephco

50's pack: 247.50 MRP Aceclofenac BP lOOmg/tablet (f.c)

Aceclofenac BP lOOmg/tablet (f.c).
50's pack: 150.00 MRP t INTAS Tab. Virgo
l OO's pack: 300.00 MRP
t ACLOPAIN Tab. RAK Pharma Aceclofenac USP lOOmg/tablet (f.c) + RESERVIX Tab. Incepta

Aceclofenac BP lOOmg/tablet (f.c). 1OO's pack: 350.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

1OO 's pack: 400.00 MRP t LOFENS Tab. Zenith

1OO's pack: 300.00 MRP
t ACLOVIX Tab. Aexim Aceclofenac BP lOOmg/tablet (f.c) + RHlt:UMA 100 Tab. Mystic

Aceclofenac BP lOOmg/tablet (f.c) lOO's pack: 151.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

1OO's pack: 250.00 MRP + LOFLAM-100 Tab. Millat

l OO's pack: 280.00 MRP
+ ACN Tab. Modem Pharma Aceclofenac BP lOOmg/tablet (f.c) + RHEUNIL Tab. Amulet
Aceclofenac BP lOOtng/tablet (f.c). l OO's pack: 300.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

1OO's pack: 300.00 MRP + MACL0-100 Tab. Doctor's

l OO's pack: 300.00 MRP
t AC PR Tab. Pacific Aceclofenac BP lOOtng/tablet (f.c) t SAPCLO Tab. SAPL

50's pack: 125.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

Aceclofenac BP lOOtng/tablet (f.c)
50's pack: 200.00 MRP + MERVAN Tab. Aristophar1na
50's pack: 150.00 MRP
t ALONA-100 Tab. Kemiko Aceclofenac BP lOOmg/tablet (f.c) + SENAC-A Tab. Seema

Aceclofenac BP lOOmg/tablet (f.c) l OO's pack: 400.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

50's pack: 200.00 MRP t MOTIFEN Tab. Pharmadesh

l OO's pack: 300.00 MRP
t ANALGEN Tab. Cosmo Pharma Aceclofenac BP lOOmg/tablet (f.c) + SERVEX Tab. Novo Healthcare

Aceclofenac BP lOOmg/tablet (f.c). 50's pack: 175.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

50's pack: 150.00 MRP + MOVEX Tab. Opsonin 50's pack: 200.00 MRP
t APECLO Tab. Apex Aceclofenac BP lOOmg/tablef (f.c) + SYCLOFEN Tab. MST Pharma

Aceclofenac BP lOOmg/tablet (f.c). IOO's pack: 351.88 MRP Aceclofenac BP lOOmg/tablet (f.c)

lOO's pack: 150.00 MRP t MOVON Tab. Hallmark

lOO's pack: 300.00 MRP
t APITAC Tab. Acme Aceclofenac BP lOOmg/tablet (f.c) + T ERNILLA Tab. Healthcare

Aceclofenac BP lOOmg/tablet (f.c) 50's pack: 150.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

lOO's pack: 400.00 MRP + NOAK Tab. Orion Pharma

50's pack: 200.00 MRP
t AROS Tab. Globe Aceclofenac BP 1OOmg/tablet (f.c) + VAX'I'IN Tab. Sandoz

Aceclofenac BP lOOmg/tablet (f.c) 50's pack: 200.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

50's pack: 150.00 MRP t NOFENAC Tab. Drug Inter.

60's pack: 300.00 MRP
+ AVENAC Tab. Radiant Pharma Aceclofenac BP lOOmg/tablet (f.c) + XE-FAST Tab. Desh Pharma

Aceclofenac BP lOOmg/tablet (f.c) 50's pack: 200.00 MRP Aceclofenac BP l OOmg/tablet (f.c)

50's pack: 250.00 MRP + NOSTRIN Tab. MonicoPharma

80's pack: 160.00 MRP
t CECLOFEN Tab. Renata Ace.clofenac BP lOOmg/tablet (f.c) t XERIFEN Tab. Peoples

Aceclofenac BP 1OOmg/tablet (e.c) 50's pack: 150.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

50's pack: 200.00 MRP t ORCENAC Tab. Organic Health

lOO's pack: 300.00 MRP
t CECONAC Tab. Hudson Aceclofenac BP l OOmg/tablet (f.c) + XERIFLAM Tab. Kumudini

50's pack: 200.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

Aceclofenac BP 1OOmg/tablet (e.c)
MRP 50's pack: 150.00 MRP
1OO's pack: 300.00 + ORIFEN Tab. Silva
t CELOFEN Tab. ACI Aceclofenac BP l OOtng/tablet (f.c) + XEROLIN Tab. Novelta

lOO's pack: 250.00 MRP Aceclofenac BP lOOmg/tablet (f.c)

Aceclofenac BP lOOmg/tablet (f.c)
SO's pack: 200.00 MRP 50's pack: 150.00 MRP
+ OSTOFLEX Tab. Somatec
+ CLOF Tab� Biopharma Aceclofenac BP 1OOmg/tablet (f.c)
+ XPAIN Tab. Gaco
Aceclofenac BP lOOmg/tablet (f.c)
Aceclofenac BP lOOmg/tablet (f.c) 1OO's pack: 400.00 MRP
1OO's pack: 400.00 MRP 50's pack: 150.00 MRP
t PAINEX Tab. Chemist
+ XYFEN Tab. Supreme
t CLOFENTA Tab. Amico Aceclofenac BP lOOmg/tablet (f.c)
Aceclofenac BP lOOtng/tablet (f.c)
Aceclofenac BP lOOmg/tablet (f.c) 50's pack: 150.00 MRP 30's pack: 90.00 MRP
50's pack: 150.00 MRP
t PAINO Tab. SK+F + ZERODOL Tab. Navana
t DOLONAC Tab. Cosmic Aceclofenac BP lOOtng/tablet (f.c) Aceclofenac BP lOOmg/tablet (f.c)
Aceclofenac BP 1OOmg/tablet (f.c) 1OO's pack: 400.00 MRP 50's pack: 150.50 MRP

I
ANTIRHEUMATIC & ANTI-
·. '
t ZOLFIN Tab. Beximco
'
Aceclofenac BP 1OOmg/tablet (f.c)
1OO's pack: 400.00 IP
l 50's pack: 600.00 IP
t ZOLONAC Tab. Sharif
Aceclofenac BP l OOmg/tablet (f.c)
50's pack: 200.00 MRP
ACEMETACIN87
ACEMETACIN: Capsule
Acemetacin is a non-steroidal anti-inflammatory
drug. It is a potent gastroprotective NSAID. It is
available as- acemetacin BP 60mg/capsule.
Mode of action: Acemetacin works by blocking
cyclooxygenase (COX), which is involved in the
production of certain irritant chemicals in respo­
nse to injury or rheumatic disease. By blocking
the action of COX, acemetacin reduces the
symptoms of pain and inflammation. Acemetacin
also produces another substance, lipoxin which
guards gastric mucosa and exerts very potent
mucosal protective effects in the stomach.
Ind: i. Pain & inflammation associated with
musculoskeletal & joint disorders, such as­
rheumatoid arthritis, osteoarthritis, low back pain.
ii. Pain relief after an operation.
C/I: Acemetacin is contraindicated to known
hypersensitivity to acemetacin or indomethacin;
peptic ulcer; safety in children is not established.
S/E: Common side effects are- anorexia, nausea,
vomiting, diarrhea and constipation, peptic
ulceration, headache, dizziness & vertigo. Rarely
confusion, depressed mood, edema, chest pain,
blood urea elevation may occur.
Precautions: Caution should be taken in elderly
people; history of disorders affecting the stomach
or intestines, in.flammatory bowel disease such as
crohn's disease or ulcerative colitis; kidney
disease; liver disease; heart failure.
Pregnancy & lactation: The safety of acemetacin
in human pregnancy and lactation has not been
established. Some animal reproduction studies
showed some toxic/teratogenic effects on fetus.
Therefore, use of this drug during pregnancy and
lactation period is not recommended.
Dosage & admin: The recommended starting
dose is 120mg/day in divided doses, increasing
to 180mg/day in divided doses, depending on
patient response. For the treatment of elderly
patients, adjustment of dosage i s not normally
required. However, NSAIDs should be used
with particular care in older patients who may
be more prone to adverse reactions.
Acemetacin should be taken with food, milk or
an antacid to reduce the possibility of gastro­
intestinal disturbance.
Drug inter: Acemetacin reduces the
antihypertensive effect of fl-blockers. Increase
risk of convulsion when �ed with quinolone.
Concurrent use with aspirin, NSAIDs, SSRis or
corticosteroids may increase risk of gastro­
intestinal bleeding. Increased risk of methotrexate
toxicity when used together.
t TENDONIL Cap. Orion Pharma
Acemetacin BP 60mg/capsule
60mg x 30's pack: 240.00 MRP
QIMP-17 (336)
CELECOXJB26
CELECOXIB: Capsule
Celecoxib is a non-steroidal anti-inflammatory
agent (specific COX-2 inhibitor) having marked
anti-inflammatory, analgesic and antipyretic
properties with lower incidence of
gastrointestinal adverse effects. It is available as
celecoxib INN 1OOmg & 200mg capsule.
Mode of action: It is a selective COX-2 inhibitor.
lnd:Celecoxib is indicated for the relief of pain
and inflammation of rheumatoid arthritis &
osteoarthritis; it is also indicated to reduce the
number of adenomatous colorectal polyps in
familial adenomatous polyposis (FAP); as an
adjunct to usual care (e.g endoscopic
surveillance, surgery).
C/I: Known case of hypersensitivity to
celecoxib; patients who have experienced asthma,
urticaria or allergic type reactions after taking
aspirin or other NSAIDs or sulfonamideslater
period of pregnancy; nursing mother.
S/E: GI side-effects include- abdominal pain,
diarrhoea, dyspepsia, flatulence and nausea. CNS
side-effects include- dizziness, headache and
insomnia. Other side-effects include- upper
respiratory tract infection, skin rash, back pain
and peripheral oedema.
Precautions: Celecoxib cannot be a substitute for
any corticosteroid, or to treat any corticosteroid
insufficiency. Celecoxib should be prescribed
with extreme caution in patients with a prior
history of peptic ulcer disease or gastrointestinal
bleeding, hepatic and renal insufficiency, heart
failure, those taking diuretics and ACE inhibitors,
pre-existing asthma, elderly patients.
Pregnancy & lactation: Celecoxib should be
used during pregnancy only if the potential
benefit justifies the potential risk to foetus. But in
late pregnancy celecoxib should be av�ided,
because it may cause premature closure of ductus
arteriosus. It is not known whether celecoxib is
excreted in human milk or not, if excreted, it may
cause serious adverse reaction in nursing infants,
so decision shoud be made in such a case
whether to discontinue nursing or to discontinue
the drug, taking into account the inportance of
the drug to the mother.
Dosage & Admin: Rheumatoid arthritis &
osteoarthritis, the lowest dose of Celenta 100
should be sought for each patient. These doses
can be given without regard to timing of meals.
Rheumatoid arthritis: The recommended oral
dose is 100-200mg twice daily.
Osteoarthritis: The recommended oral dose is
200mg per day as a single dose or as lOOmg
twice daily. These doses can be given without
regard to timing of meals.
Familial adenomatous polyposis (FAP): To
reduce the number of adenomatous colorectal
polyps, the recommended oral dose is 400mg
twice daily to be taken with food; usual
medical care for FAP patients should be
continued with lOOmg dose.
In moderate hepatic impairment, the daily
recommended dose should be reduced
approximately by 50o/o.
Children: Not recommended below the age of
18 years.
Over dosage: Patients should be managed by
.'
symptomatic arid supportive care following an
•
NSAID overdose. There is no specific antidote.
Drug inter: Celcoxib may diminish the
antihypertensive effects of ACE inhibitors,
reduces natriuretic effect of furosemide &
thriazide, increase blood lithium level, accentuate
the haematologic toxicity of methotrexate &
increase the risk of bleeding while giving with
warfarin and similar agents. Fluconazole
increases plasma concentration of celecoxib.
t CELECO Cap. Medimet
Celecoxib INN 1 OOmg & 200mg/capsule
l OOmg x 50's pack: 225.00 MRP
200mg x 30's pack: 240.00 MRP
t CELENTA Cap. Incepta
Celecoxib INN 1OOmg & 200mg/capsule
l OOmg x 50's pack: 225.00 MRP
200mg x 40's pack: 320.00 MRP •
t CELOXIB Cap. Ziska
Celecoxib INN 1OOmg/capsule
l OOmg x 30's pack: 135.00 MRP
t CELOX-R Cap. Renata
Celecoxib INN 1OOmg & 200mg/capsule
1OOmg x 50's pack: 228 MRP
200mg x 50's pack: 406.50 MRP
+COX B-100 Cap. Be:ximco
Celecoxib INN 1 OOmg/capsule
l OOmg x 50's pack: 225.00 IP
+ COX B-200 Cap. Beximco
Cel�coxib INN 200mg/capsule
200mg x 50's pack: 400.00 IP
DEXIBUPROFEN26 ,87
DEXIBUPROFEN: Tablet/suspension
Dexibuprofen is a non-steroidal anti­
inflammatory drug (NSAID) and is the active
form of ibuprofen with better pharmacological
profile. It is available as dexibuprofen INN
300mg & 400mg film-coated tablet and
100mg/5ml suspension.
Mode of action: Dexibuprofen reduces pain and
inflammation by blocking the action of cyclo­
oxygenase (COX) which is responsible for
production of prostaglandins.
Ind: 1. For the relief of sign and symptoms of
osteoarthritis, rheumatoid arthritis,
musculoskeletal disorder such as ankylosing
spondylitis, low back pain or other forms of mild
to moderate pain, muscular rheumatism,
degenerative joint diseases. 2. Acute symptomatic
treatment of painful menstruation (primary
dysmenorrhoea). 3. Common headache and fever
4. Symptomatic treatment of mild to moderate
pain, such as muscle pain, dental pain. 5. As
adjuvant with common cold and influenza
associated with headache.
C/I: Dexibuprofen is contrain�icated in patients
with previous history of hypersensitivity to
dexibuprofen or any other component of the
product. It is also contraindicated in patients with
active or suspected hemorrhage, Crohn's disease
or ulcerative colitis, patients with serious heart
disease, renal impairment (GFR<30ml/min) and
serious hepatic impairment.
S/E: Common side effects are- dyspepsia,
diarrhoea, fatigue, headache, nausea, vomiting
and abdominal pain.
Precautions: Dexibuprofen should be used with

caution in patients with bronchial asthma or other
chronic disease of the pulmonary tract as well as
in persons prone to allergy. Caution is also
required in patients with hepatic, renal or cardiac
insufficiency and patients with peptic ulceration.
Pregnancy & lactation: Although no teratogenic
impact has been observed in the animal study, the
use of dexibuprofen should be avoided during the
pregnancy.
Very small amount of dexibuprofen may pass
into breast milk. So, dexibuprofen should be used
with caution in nursing mothers.
Dosage & admin: The recommended dosage is
600-900mg per day, at 2-3 divided doses. The
dosage can be raised temporarily· up to
1200mg per day in patients with acute disor­
ders or exacerbations. The maximum daily
dose is 1200mg.
At dysmenorrhea, a dosage of 600 up to
900mg per day, at divided dose • .
At elderly people, lowest effective dose is reco­
mmended. The dosage can be raised to adult
dosage if well tolerated.
The dosage must be adjusted to the serious­
ness of the syndrome and the complaints of the
patient. During chronic pain, the dosage must
be adapted to the lowest effective dose.
Hepatic impairment: Patients with mild to
moderate liver function impairments must
start with low dose and closely be monitored.
Dexibuprofen should not be used in patients
with serious liver function impairments.
Renal impairment: The starting dose must be
reduced in patients with mild to moderate
kidney function impairments. Dexibuprofen
cannot be used in patients with serious kidney
function impairments.
Drug inter: Drug interactions are noticed with
simultaneous use of anticoagulant, ACE
inhibitors, beta-blockers, cyclosporine, corticos­
teroids, digoxin, methotrexate, phenytoin, probe­
necid, sulfonylurea and thiazide type diuretics.
t ARTOFLEX Tab. Opsonin
Dexibuprofen INN 300mg & 400mg/tablet.
300mg x 30's pack: 106.09 MRP
400mg x 30's pack: 132.48 MRP
t DEX-I Tab. Edruc
Dexibuprofen INN 300mg/tablet.
300mg x 20's pack: 60.00 MRP
t DEXIBU Tab. General
Dexibuprofen INN 200mg, 300mg &
400mg/tablet.
200mg x 42's pack: 126.42 MRP
300mg x 35's pack: 140.70 MRP
400mg x 28's pack: 140.56 MRP
t DEXIFEN Tab. Beximco
Dexibuprofen INN 200mg, 300mg &
400mg/tablet.
200mg x 1OO's pack: 300.00 IP
300mg x lOO's pack: 400.00 IP
400mg x lOO's pack: 500.00 IP
t DEXIFEN Susp. Beximco
Dexibuprofen INN 100mg/5ml: suspension.
lOOml bot: 40.00 MRP
t DEXPRO Tab. Orion Pharma
Dexibuprofen INN 300mg & 400mg/tablet.
300mg x 50's pack: 201.00 MRP
400mg x 30's pack: 150.60 MRP
+ DIP Tab. Alco Pharma
Dexibuprofen INN 200mg & 400mg/tablet.
QIMP-17 (337)
200mg x 50's pack: 150.00 MRP
400mg x 30's pack: 150.00 MRP
t FL AMEX-DX Tab. ACI
Dexibuprofen INN 300mg/tablet.
300mg x 50's pack: 201.00 MRP
+ INFLAM-D Tab. Sanofi aventis
Dexibuprofen INN 200mg, 300mg &
400mg/tablet.
200mg x lOO's pack: 301.01 MRP
300mg x 1OO's pack: 402.01 MRP
400mg x 50's pack: 251.00 MRP
t PURIFEN Tab. Incepta
Dexibuprofen INN 300mg/tablet.
300mg x 20's pack: 80.00 MRP
+ PURIFEN Susp. Incepta
Dexibuprofen INN 100mg/5ml: suspension.
lOOml bot: 40.00 MRP
t SERIFEN Tab. Silva
Dexibuprofen INN 300mg & 400mg/tablet.
300mg x 50's pack: 200.00 MRP
400mg x 50's pack: 250.00 MRP
+ XFLAM Tab. Square
Dexibuprofen INN 300mg & 400mg/tablet.
300mg x 48's pack: 192.48 MRP
400mg x 48's pack: 240.48 MRP
DEXKETOPROFEN42
DEXKETOPROFEN: Tablet
Dexketoprofen trometamol is available as
dexketoprofen INN 25mg flim-coated tablet.
Dexketoprofen is the S(+)-enantiomer of
ketoprofen and is responsible for the analgesic
and anti-inflammatory activity of ketoprofen. The
inactive R(-)-enantiomer does not contribute to
the therapeutic properties of ketoprofen but adds
to the metabolic load.
Mode of action: Dexketoprofen has been formu­
lated as a trometamol salt. Its high solubility in
water means a rapid absorption through the gut
wall which results in a more rapid onset of action
than ketoprofen. Peak plasma concentrations are
attained more quickly than other widely used
analgesics with an onset of action of 30 minutes.
The anti-inflammatory potency of dexketoprofen
was always equivalent to that demonstrated by
twice the dose of ketoprofen.
Ind: Symptomatic treatment of pain and inflam­
mation of mild or moderate intensity, such as
musculo-skeletal pain, menstrual pain & dental
pain.
•
C/I: Dexketoprofen is not recommended in
patients who are allergic to this product or aspirin
or other NSAIDs; who have suffered attacks of
asthma, brochospasm, acute rhinitis, nasal
polyps, urticaria, angioedema (swollen face, eyes,
lips, or tongue, or difficulty in breathing) after
taking aspirin or other non-steroidal anti­
inflammatory drugs; who have or previously
suffered from a peptic ulcer or chronic gastro­
intestinal disorders; who had previously gastro­
intestinal haemorrhage (bleeding); who have
suffered bronchial asthma; who have severe heart
failure, moderate to severe renal dysfunction or
severely impaired hepatic function; who hav.e a
bleeding disorder, a blood clotting disorder or are
taking an anticoagulant; and who are pregnant or
breast-feeding.
S/E: As with all medicines, dexketoprofen may
cause some unwanted affects in some patients,
ANTIRHEUMATIC & ANTI-INFLAMMATORY DRUGS
which are characteristics of non-steroidal anti­
inflammatory drugs. These are:
commonly (1-10%)- nausea, vomiting, diarrhoea,
stomach pain or heartburn; rarely (0.1-1%)- sleep
disorders, nervousness, headache, dizziness, ver­
tigo, palpitations, constipation, dry mouth, flatu­
lence, skin rash, fatigue, hot flushes, shivering,
general malaise; very rarely (0.01 0.1%)- stom­
ach ulceration, gastric haemorrhage or perfora­
tion, pins and needles, high blood pressure, water
retention, slowed -breathing rate, hepatic enzymes
increased, increased sweating.
In isolated-cases (<0.01%)- blurred vision, ring­
ing in the ear, low blood pressure, haematological
reactions, hepatic or renal damage, dermatologi­
cal and photosensitivity reactions, bronchospasm
or anaphylaxis. In patients with systemic lupus
erythematosus or mixed connective tissue
disease, anti-inflammatory medicines may rarely
cause isolated cases of fever, headache and
rigidity of the nape (back of the neck).
Precautions: Precaution should be exercised
during using dexketoprofen in patients who are
allergic to any other NSAIDs; who have kidney
disease, liver disease, heart disease or fluid
retention conditions; and who have blood
disorder, systemic lupus erythematosus or mixed
connective tissue disease.
Pregnancy & lactation: The use of dexketo­
profen during pregnancy or breast-feeding is not
recommended.
Dosage & admin: The dose of dexketoprofen
depends on the type, severity and duration of
pain. The recommended dose is generally
25mg every 8 hours, with no more than 75mg
(3 tablets) daily. The elderly and patients with
renal or hepatic impairment should start
treatment with a total daily dose of no more
than 50mg (2 tablets). Normally it is recom­
mended to take the tablets with food. In the
case of acute pain, it is recommended to take
at least 30 minutes before meals.
Child: Dexketoprofen is not recommended for
children.
Drug inter: Any of the following drugs cannot
be used at the same time while taking dexketo­
profen: other NSAIDs; anticoagulant medicines;
lithium; methotrexate; hydantoins; some
sulphonamide antibiotics (e.g sulfamethoxazole);
medications used to treat high blood pressure
(ACE inhibitors, diuretics and beta-blockers);
pentoxifylline; zidovudine; cyclosporine or
tacrolimus; sulphonylureas; thrombolytic
medicines; probenecid; cardiac glycosides;
mifepristone; and quinolone antibiotics.
t ACTIDEX Tab. Incepta
Dexketoprofen trometamol equivalent to
dexketoprofen INN 25mg/tablet.
50's pack: 200.00 MRP
t KETO-D Tab. Acme
Dexketoprofen trometamol equivalent to
dexketoprofen INN 25mg/tablet.
30's pack: 120.30 MRP
DICLOFENAC SODIUM21,33
DICLOFENAC SODIUM: Tablet/
Injection/Gel/Suppository
Diclofenac sodium is a non-steroidal anti-inflam-
 AN'I'IRBEUMATIC & ANTI-INFLAMMATORY DRUGS QIMP-17 (338)

matory agent having marked anti-inflammatory, +A-FENAC lnj. Acme +CLOFENAC Tab. Square
analgesic and antipyretic properties. Diclofenac sodium 25mg/ml; 3ml ampoule, for Diclofenac sodium 25mg & 50mg/tablet.
Mode of action: Diclofenac sodium works by deep i.m injection. 25mg x lOO's pack: 100.00 MRP.
blocking the action of a substance (enzyme) in 10 amps. pack: 140.60 MRP 50mg x 200's pack: 300.00 MRP
the body called cyclo-oxygenase. Cyclo­ +A-FENAC Plus Inj. Acme +CLOFENAC SR Tab. Square ·

oxygenase is involved in the production of
various chemicals in the body, some of which are
known as prostaglandins. Prostaglandins are
produced in response to injury or certain diseases
and would otherwise go on to cause pain,
swelling and infl ammation.
Ind: Rheumatoid arthritis, osteoarthrosis,
ankylosing spondylitis, acute gout; chronic
Diclofenac sodium 75mg & lidocaine hydrochlo­ Diclofenac sodium lOO mg/tablet (s.r)
ride 20mg/2ml ampoule: deep i.m injection lOO's pack: 400.00 MRP.
2ml amp x lO's pack: 140.60 MRP +CLOFENAC T R Cap. Square
+A-FENAC Suppo. Acme Diclofenac sodium lOOmg/capsule (t.r).
Diclofenac sodium 12.5mg & 50mg/stick 50's pack: 200.00 MRP
(suppository) +CLOFENAC lnj. Square
12.5mg x lO's pack: 80.40 MRP Diclofenac sodium 75mg/3ml ampoule: deep i.m
50mg x lO's pack: 140.60 MRP injection. ·

juvenile arthritis. Relief of pain in musculoskeletal + ALCOFEN Tab. Aexim 10 amps pack: 150.50 MRP
& soft-tissue inflammations such as sprains, Diclofenac sodium 50mg/tablet +CLOFENAC Plus lnj. Square
strains, bruises, traumatic inflammation of 50mg x 1OO's pack: 70.00 MRP Diclofenac sodium 75mg & lidocaine hydrochlo­
tendons, ligaments, muscles & joints. +ALCOFEN SR Cap. Aexim ride 20mg/2ml ampoule: deep i.m injection.
C/I: Active peptic ulcer; as thma, aspirin or any Diclofenac sodium lOO mg/capsule (s.r). 10 amps pack: 150.50 MRP
non-steroid anti-inflammatroy induced allergy lOO's pack: 150.00 MRP +CLOFENAC Suppo. Square
S/E: Mild and infrequent gastro-intestinal dis­ +ALTERIN Tab. Euro Pharma Diclofenac sodium 12.5mg, 25mg, 50mg &
comport, bleeeding, nausea, vertigo, headache, Diclofenac sodium 50mg/tablet lOOmg/stick (suppository)
hearing disturbances such as tinnitus; thrombo­ lOO's pack: 100.00 MRP 12.5mg x lO's pack: 90.30 MRP
cytopenia; hypersensitivity reactions (bron­ +ALTERIN TR Cap. Euro Pharma 25mg x 15's pack: 180.75 MRP
chospasm, angioneurotic oedema, rashes). Diclofenac sodium 1OO mg/capsule (t.r). 50mg x 20's pack: 301.00 MRP
Cautions: History of gastro- intestinal lesions; 50's pack: 150.00 MRP lOOmg x lO's pack: 200.00 MRP
impaired renal function; asthma; pregnancy & +ANODYNE Tab. Ibo Sina +CLONAC T R Cap. Somatec
;
lactation; concurrent administration of plasma Diclofenac sodium 50mg/tablet Diclofenac sodium 1OO mg/capsule (t.r)
protein-bound drugs, lithium, beta-blockers or lOO's pack: 100.00 IP 50's pack: 150.50 MRP
frusemide. +ANODYNE-SR Cap. Ibo Sina +COSFENAC SR Cap. Cosmo Pharma
Pregnancy & lactation: Diclofenac is not Diclofenac sodium lOO mg/tablet (s.r). Diclofenac sodium 1OO mg/capsule (s.r)
recommended for use in pregnancy, particularly 50's pack: 162.50 IP 50's pack: 150.00 IP
the third trimester, unless considered essential by +ANODYNE Gel Ibo Sina +DCF Tab. Decent
the physician. Diclofenac sodium 1% w/w (i.e 1O mg/gm): gel Diclofenac sodium 50mg/tablet
The medicine passes into the breast milk, but at lOgm tube: 13.00 IP lOO's pack: 60.00 MRP
normal doses it is unlikely to harm the baby. +ANODYNE Plus Inj. lbn Sina +DECAFEN Tab. Renata
Dosage & admin: Adult: By mouth: 75-lSOmg Diclofenac sodium 75mg & lidocaine hydrochlo­ Diclofenac sodium 50mg/tablet (e.c)
as enteric-coated (e.c) tablet daily in 2 or 3 ride 20mg/2ml ampoule: deep i.m injection. lOO's pack: 84.00 MRP
divided doses, preferably after food. 10 amps pack: 120.00 IP +DECAFEN SR Tab. Renata
Dosage of TR (timed release) capsule or SR +APAIN-TR Cap. Kemiko Diclofenac sodium lOO mg/tablet (s.r)
(sustained release) capsule or tablet: lOOmg Diclofenac sodium lOOmg/capsule (t.r). lOO's pack: 289.00 MRP
(1 capsule or tablet) once daily, preferably 50's pack: 150.00 MRP +DFC T R Cap. Amulet
with food. +APAIN Plus lnj. Kemiko Diclofenac sodium 1OO mg/capsule (t.r)
By deep i.m injection into the gluteal muscle:
.

Acute exacerbations and post-operative-
75mg once daily (twice daily in severe cases)
for maximum of 2 days;
Ureteric colic, 75mg then a further 75mg after
30 minutes if necessary.
Gel preparation: Apply 3-4 times daily with
gentle massage.
By rectum as suppositories: 75-lSOmg daily in
divided doses.
Maximum total daily dose by any route
lSOmg.
Children & adolescents: 1-12 years, juvenile
arthritis, by mouth or by rectum, 1-3mg/kg
daily in divided doses (25mg tablets, 12.Smg
and 25mg suppositories only).
Drug inter: Diclofenac may increase the blood
levels of lithium, digoxin and methotrexate.
There may be an increased risk of bleeding from
the gut if diclofenac is taken with blood thinning
or anticlotting medicines such as warfarin.
+A-FENAC Tab. Acme
Diclofenac sodium 25mg & 50mg/tablet (e.c).
25mg x lOO's pack: 55.00 MRP
50mg x 1OO's pack: 84.00 MRP
+A-FENAC SR Tab. Acme
Diclofenac sodium 1OO mg/tablet (s.r)
lOO's pack: 300.00 MRP
Diclofenac sodium 75mg & lidoc.aine hydrochlo­
ride 20mg/2ml ampoule: deep i.m injection.
10 amps pack: 150.00 MRP
+APNAC SR Cap. Supreme
Diclofenac sodium lOO mg/capsule (s.r)
50's pack: 150.00 MRP
+ARTHROFEN PLUS I.M Inj. Healthcare
Diclofenac sodium 75mg & lidocaine hydrochlor.
20mg/2ml ampoule: for deep i.m injection.
2ml amp x lO's pack: 230.00 MRP
+C-FENAC Tab. Chemist
Diclofenac sodium 50mg/tablet
lOO's pack:·3o.oo MRP
+C-FENAC Inj. Chemist
Diclofenac sodium 75mg/3ml ampoule: deep i.m
injection.
10 amps pack: 111.30 MRP
+C-FENAC Plus lnj. Chemist
Diclofenac sodi11m 75mg & lidocaine hydrochlo­
ride 20mg/2ml ampoule: deep i.m injection.
10 amps pack: 119.30 MRP
+CLOFEN Tab. Cosmic
Diclofenac sodium 50mg/tablet
50mg x 1OO's pack: 75.00 MRP
+CLOFEN-T R Cap. Cosmic
Diclofenac sodium 1OO mg/capsule (t.r).
50's pack: 154.50 MRP
1OO's pack: 250.00 MRP
+DICLO SO Tab. Apollo
Diclofenac sodium USP 50mg/tablet
lOO's pack: 125.00 MRP
+DICLO T R Cap. Apollo
Diclofenac sodium 1OO mg/capsule (t.r)
lOO's pack: 300.00 MRP
+DICLOFEN Tab. Opsonin
Diclofenac sodium 25mg & 50mg/tablet
25mg x lOO's pack: 45.73 MRP
50mg x lOO's pack: 77.42 MRP
+DICLOFEN-SR Tab. Opsonin
Diclofenac sodium lOOmg/tablet (s.r)
lOO's pack: 264.79 MRP
+DICLOFEN Gel Opsonin
Diclofenac sodium 1 % w/w (i.e lOmg/gm): gel
lOgm tube: 11.40 MRP
+DICLOFEN Inj. Opsonin
Diclofenac sodium 75mg/3ml ampoule, for deep
i.m injection.
3ml amp x IO's pack: 132.48 MRP
+DICLOFEN Plus IM Inj. Opsonin
Diclofenac sodium 75mg & lidocaine hydrochlor.
20mg/2ml ampoule: for deep i.m injection.
2ml amp x 15's pack: 198.72 MRP
+DICLOFEN Suppo. Opsonin
Diclofenac sodium 12.5mg, 25mg & 50mg/stick
suppository
 QIMP-17 (339) ANTIRHEUMATIC & ANTI-INFLAMMATORY DRUGS

12.5mg x 25's pack: 198.59 MRP t DIX-TR Cap. Apex

25mg x lO's pack: 106.00 MRP Diclofenac sodium lOO mg/capsule (t.r)
50mg x 25's pack: 329.72 MRP lOO's pack: 150.00 MRP
t DICLON Tab. CPL t EDIFENAC Tab. Edruc
Diclofenac sodium 50mg/tablet Diclofenac sodium 50mg/tablet
50mg x lOO's pack: 85.00 MRP lOO's pack: 83.00 MRP
t DICLON SR Tab. CPL t E DIFENAC TR Cap. Edruc
Diclofenac sodium 1OO mg/tablet (s.r) Diclofenac sodium lOO mg/capsule (t.r)
lOO's pack: 300.00 MRP 50's pack: 150.00 MRP
t DICLONAC 50 Tab. Ziska t E DIFENAC Inj. Edruc
Diclofenac sodium 50mg/tablet Diclofenac sodium 75mg/3ml ampoule: deep i.m
50mg x lOO's pack: 83.00 MRP •
injection.
t DICLONAC 100 TR Cap. Ziska 8 amps pac�: 120.00 MRP
Diclofenac sodium 1OO mg/capsule (t.r). t E DIFENAC Plus Inj. Edruc
50's pack: 100.00 MRP Diclofenac sodium 75mg & lidocaine hydrochlor.
t DICLONAC Inj. Zis·ka 20mg/2ml ampoule: for deep i.m injection.
Diclofenac sodium 75mg/3ml ampoule: deep i.m 2ml amp x lO's pack: 150.00 MRP
injection. t E -FENAC-50 Tab. Reliance
10 amps pack: 85.00 MRP Diclofenac sodium 50mg/tablet (e.c)
t DICLONAC Plus Inj. Ziska lOO's pack: 50.00 MRP
Diclofenac sodium 75mg & lidocaine hydrochlo­ t ERDON 100 TR Cap. Aristopharma
ride 20mg/2ml ampoule: deep i.m injection. Diclofenac sodium lOO mg/capsule (t.r)
10 amps pack: 95.00 MRP lOO's pack: 300.00 MRP
t DICLONIL Tab. Zenith t ERDON-Plus Inj. Aristopharma
Diclofenac sodium 50mg/tablet (e.c ). Diclofenac sodium 75mg & lidocaine hydrochlo­
50mg x lOO's pack: 80.00 MRP ride 20mg/2ml ampoule: deep i.m injection
t DICLONIL SR Tab. Zenith 2ml amp x lO's pack: 150.00 MRP
t
-
Diclofenac sodium lOO mg/tablet (s.r). ERDON Gel Cream Aristopharma
lOO's pack: 301.00 MRP Diclofenac sodi11m 1% w/w (i.e 1O mg/gm): gel
t DICLOREX Tab. Medimet lOgm tube: 12.90 MRP
Diclofenac sodium 25mg & 50mg/tablet t ERDON Suppo. Aristopharma
25mg x 1OO's pack: 54.00 MRP Diclofenac sodium 50mg/stick: suppository
50mg x lOO's pack : 70.00 MRP 50mg x 20's pack: 300.00 MRP
t DICLOREX Rtd. Tab. Medimet t FENGEL Gel Pharmadesh
Diclofenac sodium 1OO mg/tablet (retard) Diclofenac sodium 1% w/w: gel preparation.
50's pack: 150.00 MRP 15gm tube: 19.68 MRP
t DICLOREX Inj. Medimet t FENTAB Tab. Pharmadesh
Diclofenac sodium 75mg/3ml ampoule, for deep Diclofenac sodium 50mg/tablet
i.m injection. 50mg x lOO's pack: 100.00 MRP
10 amps pack: 95.00 MRP t FENTAB SR Tab. Pharmadesh
t DICLOVIR 50 Tab. Virgo Diclofenac sodium lOOmg/ tablet (s.r)
Diclofenac sodium USP 50mg/tablet 50's pack: 150.00 MRP
lOO's pack: 75.00 MRP t FICLON Inj. S anofi aventis
t Diclofenac sodium 75mg/3ml ampoule: 1.m
•

DICLOVIR 100 SR Cap. Virgo

Diclofenac sodium BP lOOmg/capsule (s.r) injection.
50's pack: 150.00 MRP 10 amps pack: 152.30 MRP
t DIFENAC Tab. Rephco t FICLON Suppo. Sanofi aventis
Diclofenac sodium 50mg/tablet Diclofenac sodium 50mg/stick: suppository
1OO's pack: 90.00 MRP 50mg x lO's pack: 120.46 MRP
t t
'

DIFENAC Plus Inj. Rephco G-DICLOFENAC Tab. Gonoshastha.

Diclofenac sodium 75mg & lidocaine hydrochlor. Diclofenac sodium 50mg/tablet
20mg/2ml ampoule: for deep i.m injection. 1OO's pack: 60.00 MRP
2ml amp x lO's pack: 100.00 MRP
t G-DICLOFENAC Inj. Gonoshastha.
t DILOCK 50 Tab. Bristol Diclofenac sodium 75mg/3ml ampoule: i.m
Diclofenac sodium 50mg/tablet injection.
1OO's pack: 50.00 MRP 5 amps pack: 45.00 MRP
t DILOCK-SR Tab. Bristol t GENAC-50 Tab. Globe
Diclofenac sodium lOO mg/tablet (s.r) Diclofenac sodium 50mg/tablet
lOO's pack: 300.00 MRP lOO's pack: 60.00 MRP
t DILOCK-TR Cap. Bristol
t GENAC Inj. Globe
Diclofenac sodium 1OO mg/capsule (t.r)
Diclofenac sodium 75mg/3ml ampoule: deep i.m
50's pack: 150.00 MRP injection.
t DINAC-TR Cap. Navana 10 amps pack: 95.00 MRP
Diclofenac sodium lOOmg/capsule (t.r) t GENAC-Plus lnj. Globe
I OO's pack: 300.00 IP Diclofenac sodium 75mg & lidocaine hydrochlo­

t DIX Plus Inj. Apex ride 20mg/2ml ampoule: deep i.m injection.
ARISTOPHARMA LTD.
Diclofenac sodium 75mg & lidocaine hydrochlor. 2ml amp x lO's pack: 150.00 MRP
www.a ri stop ha rma .com
20mg/2ml ampoule: for deep i.m injection. t ID-FENAC Tab. Hudson
2ml amp x IO's pack: 95.00 MRP Diclofenac sodium 50mg/tablet
ANTIRHEUMATIC & ANTI- QIMP-17 (340)

1OO's pack: 50.00 MRP + MOOV SR Cap. A.stra + PENAC-TR Cap. APC Pharma
+ ID-FENAC-TR Cap. Hudson Diclofenac sodium 1 OOmg/capsule (s.r) Diclofenac sodium 1OOmg/capsule (t.r)
Diclofenac sodium 1OOmg/capsule (t.r) 50's pack: 75.00 MRP 50's pack: 150.00 MRP
1OO's pack: 300.00 MRP + MOVONAC Tab. Sharif + PROFENAC L Inj. Popular
+ IDTFLAM Tab. Ambee Diclofenac sodium 50mg/tablet Diclofenac sodium 75mg & lidocaine hydrochlo­
Diclofenac sodium 50mg/tablet 50mg x 1OO's pack: 80.00 MRP ride 20mg/2ml amp oule: deep i.m injection.
1OO's pack: 84.00 MRP + MOVONAC TR Cap. Sharif 2ml amp x 5's pack: 47.70 IP
+ HITFLAM-SR Tab. Ambee Diclofenac sodium 1OOmg/capsule (t.r) + PROFENAC Gel Popular
Diclofenac sodium lOOmg/tablet (s.r) 50's pack: 150.00 MRP Diclofenac sodium 1 % w/w (i.e 1 Omg/gm): gel
50's pack: 152.50 MRP + NASIDA SR Cap. Delta Pharma 1 O gm tube: 12.95 MRP
+ HITFLAM Gel Ambee Diclofenac sodium lOOmg/capsule (s.r) + PROFLAM Tab. Novo Healthcare
Diclofenac sodium 1 % w/w (i. e 1 Omg/gm): gel lOO's pack: 150.00 MRP Diclofenac sodium 50mg/tablet
•

1 O gm tube: 12.95 MRP + NE OFENAC Tab. Ad-din
+ IDTFLAM Inj. Ambee Diclofenac sodium 50mg/tablet
Diclofenac sodium 75mg/3ml amp oule: deep i.m 50mg x lOO's pack: 60.00 MRP
injection. + NE OFENAC Suppo. Ad-din
10 amps pack: 76.20 MRP Diclofenac sodium BP 12.5mg & 50mg/stick:
+ INTAFENAC SO Tab. Incepta su p p ository
Diclofenac sodium 50mg/tablet 12.5mg x IO's pack: 75.00 MRP
1 OO's pack: 75.00 MRP 50mg x lO's pack: 120.00 MRP
+ INTAFENAC lnj. Incepta + NEOFENAC Tab. Modern
Diclofenac sodium 75mg/3ml amp oule: deep i.m Diclofenac sodium 50mg/tablet
injection. 50mg x lOO's pack: 84.00 MRP
10 amps pack: 95.00 MRP + NE OFENAC SR Cap. Modern
+ INTAFENAC Plus Inj. Incepta Diclofenac sodium 1OOmg/capsule (s.r)
Diclofenac sodium 75mg & lidocain e hydrochlo­ 40's pack: 120.00 MRP
ride 20mg/2ml amp oule: deep i.m injection. + NIRO TR Cap. Everest
2ml amp x lO's pack: 95.00 MRP Diclofenac sodium 1OOmg/capsule (t.r)
+ JEFENAC-TR Cap. Ad-din 50's pack: 106.26 MRP
Diclofenac sodium 1 OOmg/capsule (t.r) + NORFEN Tab. Kumudini
lOO's pack: 300.00 MRP Diclofenac sodi11m 50mg/tablet
+ LARDON-TR Cap. Desh Pharma 50mg x 1OO's pack: 80.00 MRP
Diclofenac sodium 1 OOmg/capsule (t.r) + NORFEN SR Cap. Kumudini
1 OO's pack: 200.00 MRP Diclofenac sodium lOOmg/capsule (s.r)
+ LOCOPAIN-TR Cap. Asiatic 50's pack: 200.00 MRP
Diclofenac sodium lOOmg/capsule (t.r) + NOVARIN SR Cap. Amico
lOO's pack: 300.00 MRP Diclofenac sodium 1OOmg/capsule (s.r)
+ MEDIFEN Tab. Medicon 1OO's pack: 250.00 MRP
Diclofenac sodium 50mg/tablet + NOVARIN Gel Amico ·
lOO's pack: 100.00 MRP Diclofenac sodium 1 % w/w (i. e lOmg/gm): gel
+ MEDIFEN-TR Cap. Medicon 1O gm tube: 12.90 MRP
Diclofenac sodium 1OOmg/capsule (t.r) + ORAFEN SR Tab. Rangs Pharma
50's pack: 150.00 MRP Diclofenac sodium lOOmg/tablet (s.r)
+ MEGAFEN Tab. Jayson 50's pack: 150.00 MRP
Diclofenac sodium 50mg/tablet + ORAFEN Plus IM Inj. Rangs Pharma
1 OO's pack: 8 1.00 IP Diclofenac sodium 75mg & lidocaine hydrochlo­
+ MEGAFEN-SR Tab. Jayson ride 20mg/2ml ampoule: deep i.m injection.
Diclofenac sodium 1OOmg/tablet (s.r) 2ml amp x lO's pack: 150.00 MRP
50's pack: 15 1.00 IP + ORFENAC Tab. Orion Pharma
1OO's pack: .50.00 MRP
+ PROFLAM SR Tab. Novo Healthcare
Diclofenac sodium lOOmg/tablet (s.r)
lOO's pack: 140.00 MRP
+ PROFLAM Lido lnj. Novo Healthcare
Diclofenac sodium 75mg & lidocain e hydrochlo­
ride 20mg/2ml amp oule: deep i.m injection.
5 amps. pack: 75.00 MRP
+ PROLADIN Tab. Alco Pharma
Diclofenac sodium 50mg/tablet.
lOO's pack: 75.00 MRP
+ PROLADIN-TR Cap. Alco Pharma
Diclofenac sodium 1 OOmg/capsule (t.r)
50's pack: 150.00 MRP
+ PRONAC-SR Tab. Hallmark
Diclofenac sodium lOOmg/tablet (s.r)
50's pack: 125.50 MRP
+ REFAIN Tab. MonicoPharma
Diclofenac sodium 50mg/tablet.
IOO's pack: 8 3.00 MRP
+ REFAIN TR Cap. MonicoPharma
Diclofenac sodium 1OOmg/capsule (t.r)
48's pack: 144.00 MRP
+ REFAIN Inj. MonicoPharma
Diclofenac sodium 75mg/3ml amp oule: deep i.m
injection.
3ml amp x lO's pack: 95.00 MRP
+ RENAC-TR Cap. Reman
Diclofenac sodium lOOmg/capsule (t.r)
50's pack: 150.00 MRP
+ REUTREN-SR Tab. Gaco
Diclofenac sodium 1 OOmg/tablet (s.r)
50's pack: 150.00 MRP
+ REUTREN Inj. Gaco
Diclofenac sodium 75mg/3ml ampoule: deep i.m
injection.
1 amp pack: 7.74 MRP •

+ MEGAFEN Inj. Jayson
Diclofenac sodium 75mg/3ml amp oule: deep i.m
injection.
20 amps pack: 203.00 IP
+ MEGAFEN Plus Inj. Jayson
Diclofenac sodium 75mg & lidocaine hydrochlo­
ride 20mg/2ml amp oule: deep i.m injection.
2ml amp x lO's pack: 150.00 MRP
+ MICLOFEN-SO Tab. Millat
Diclofenac sodium 50mg/tablet
lOO's pack: 8 3.00 MRP
+ MICLOFEN-100 TR Cap. Millat
Diclofenac.sodium lOOmg/capsule (t.r)
50's pack: 151.50 MRP
+ MOBIF'EN Tab. ACI
Diclofenac sodium 50mg/tablet
50mg x 1 OO's pack: 88.00 MRP
+ MOBIFEN Plus Inj. ACI
Diclofenac sodium 75mg & lidocaine hydrochlo­
ride 20mg/2ml amp oule: deep i.m injection.
10 amps. pack: 95.40 MRP
Diclofenac sodium 50mg/tablet.
1 OO's pack: 80.00 MRP
+ ORFENAC TR Cap. Orion Pharma
Diclofenac sodium 1 OOmg/capsule (t.r)
50's pack: 150.50 MRP
+ ORFENAC Plus Inj. Orion Pharma
Diclofenac sodium 75mg & lidocain e hydrochlo­
ride 20mg/2ml amp oule: deep i.m injection.
2ml amp x 1 O's pack: 90.30 MRP
+ ORGAFEN TR Cap. Organic Health
Diclofenac sodium BP lOOmg/capsule (t.r)
1 OO's pack: 300.00 MRP
+ PAIN ZERO TR Cap. Reliance
Diclofenac sodium lOOmg/capsule (t.r)
50's pack: 150.00 MRP
+ PANFRE SR Cap. Pacific
Diclofenac sodi11m 1OOmg/capsule (s.r)
50's pack: 150.00 MRP
+ PENAC-SO Tab. APC Pharma
Diclofenac sodium 50mg/tablet.
lOO's pack: 85.00 MRP
+ RONAC Plus I.M Inj. Gener al
Diclofenac sodium 75mg & lidocaine hydrochlo­
ride 20mg/2ml amp oule: deep i.m injection.
10 amps pack: 150.00 MRP
+ SAFENAC-TR Cap. SAPL
Diclofenac sodium 1OOmg/capsule (t.r)
50's pack: 125.00 MRP
+ S-FENAC-TR Cap. S eema
Diclofenac sodium 1OOmg/capsule (t.r)
50's pack: 150.00 MRP
+ SIFEN TR Cap. Silva
Diclofenac sodium lOOmg/capsule (t.r)
1OO's pack: 250.00 MRP
+ ULT RAFEN Tab. Beximco
Diclofenac sodium 25mg & 50mg/tablet
25mg x 1OO's pack: 54.00 IP
25mg x 200's pack: 108.00 IP
50mg x 200's pack: 166.00 IP
+ ULTRAFEN-100 SR Tab. Beximco
Diclofenac sodium lOOmg/tablet (s.r)
1 OO's pack: 300.00 IP

t ULTRAFEN S uppo. Beximco
Diclofenac sodium 12.5mg & 50mg/stick:
suppository
12.5mg x 1O's pack: 90.00 IP
50mg x lO's pack: 150.00 IP
t ULTRAFEN lnj. Beximco
Diclofenac sodium 75mg/3ml ampoule: deep i.m
injection.
3ml amp x lO's pack: 150.00 IP
t ULTRAFEN Extra Inj. Beximco
Diclofenac sodium 75mg & lignocaine
hydrochloride 1Omg/2ml ampoule: deep i.m
injection.
2ml amp x lO's pack: 150.00 IP
t VOLCAN Tab. Biopharma
Diclofenac sodium 50mg/tablet
1OO's pack: 80.00 MRP
t VOLCAN SR Tab. Biopharma
Diclofenac sodium 1OOmg/tablet (s.r)
50's pack: 150.50 MRP
t VOLCAN TR Cap. Biopharma
Diclofenac sodium lOOmg/capsule (t.r)
lOO's pack: 301.00 MRP
t VOLMAX SR Tab. SK+F
Diclofenac sodium 1OOmg/tablet (s.r)
60's pack: 180.00 MRP
t VOLPRO SO Tab. Mystic
Diclofenac sodium 50mg/tablet
1OO's pack: 80.00 MRP
t VOLTALIN Tab. Novartis
Diclofenac sodium 25mg/tablet
1OO's pack: 400.00 MRP
t VOLTALIN Forte Tab. Novartis
Diclofenac sodium 50mg/tablet
1OO's pack: 700.00 MRP
t VOLTALIN SR 75 Tab. Novartis
Diclofenac sodium 75mg/tablet (s.r)
50's pack: 550.00 MRP
t VOLTALIN SR 100 Tab. Novartis
Diclofenac sodium 1OOmg/tablet (s.r)
50's pack: 750.00 MRP
t VOLTALIN Inj. Novartis
Diclofenac sodium 75mg/3ml ampoule: for deep
i.m injection
5 amps pack: 550.00 MRP
t VOLTALIN S uppo. Novartis
Diclofenac sodium 12.5mg & 50mg/stick:
suppository
12.5mg x lO's pack: 260.00 MRP
50mg x 1O's pack: 500.00 MRP
t VOLTAROL lnj. Techno Drugs
Diclofenac sodium 75mg/3ml ampoule: for deep
i.m injection.
8 amps pack: 75.00 MRP
t VOLTID-SO Tab. Pharmasia
Diclofenac sodium 50mg/tablet
50mg x 1OO's pack: 60.00 MRP
t VOLTID-SR Cap. Pharmasia
Diclofenac sodium 1OOmg/capsule (s.r)
1OOmg x 50's pack: 151.00 MRP
t VURDON SR Cap. NIPRO JMI
Diclofenac sodium 1OOmg/capsule (s.r)
lOOmg x 50's pack: 150.00 MRP
DICLOFENAC DIETHYLAMINE/
DICLOFENAC DIETHYL­
AM MONIUM SALT48,54
QIMP-17 (341)
DICLOFENAC DIETHYLAMINE/
DIET HYL-AMMONIUM SALT: Emulgel/Gel
preparation
Diclofenac diethylamine/diethyl-ammonium salt
BP 1.16% (1 l .6mg/gm) equivalent to diclofenac
sodium l % (i.e 1Omg/gm): emulgel/gel
preparation.
Mode of action: Diclofenac diethylamine/diethyl­
ammonium salt is systemically absorbed through
the skin. It inhibits the enzyme cyclooxygenase,
thus reducing the formation of PGE2. It also
increases the uptake of arachidonic acid into the
cellullar pool. Oleum lini contains predominantly
essential fatty acids
i.e 11 linolenic acid. On percutaneous absorbtion,
11 - linolenic acid gets converted to elcosapenta­
noic acid (EPA). EPA is acted upon by cyclo­
oxyganase enzyme to produce prostaglandin E3
which is a weak inflammatory agent. Presence of
EPA prevents the action of cyclo-oxygenase on
archidonic acid which reduces its conversion to
PGE2 (a highly inflammatory agent). Presence of
PGE3 itself modulates the inflammatory response
through a feedback mechanism.
Ind: Relief of pain in musculoskeletal & soft­
tissue inflammations such as sprains, strains,
bruises, hands, neck & shoulder pain, sciatica,
back ache, lumbago, muscle stiffness and joint
pain; soft tissue rheumatism, osteoarthrosis;
periarthropathy; traumatic inflammation of
tendons, ligaments, muscles & joints.
C/I: Hypersensitivity to diclofenac sodi11m or
aspirin & other drugs opposing prostaglandin
synthesis.
S/E: Usually well tolerated. However, mild
rashes, itching, redness or smarting at the site.
Cautions: For NSAIDs asthma warning. Avoid
contact with eyes, mucous membranes & injured
or broken skin.
Dosage & use: Approximately one inch band of
cream should be applied to the affected site 3 to
4 times daily with. gentle rubbing till the film
disappears. Therapy should be reviewed after
14 days.
t A-FENAC Gel Acme
Diclofenac diethylamine BP 1.16% ( l l .6mg/gm)
equivalent to diclofenac sodium l % (i.e 1Omg/gm):
gel preparation.
lOgm tube: 13.05 MRP
t CLOFENAC Emulgel Square
Diclofenac diethylamine BP 1.16% ( l 1.6mg/gm)
equivalent to diclofenac sodium 1% (i.e lOmg/gm):
gel preparation.
20gm tube: 40.15 MRP
t CLOFENAC Gel Square
Diclofenac diethyl-ammonium salt BP 1.16%
( l l .6mg/gm) equivalent to diclofenac sodium 1%
(i.e 1Omg/gm): gel preparation.
1Ogm tube: 12.95 MRP
t D-FENAC Gel Doctor's
Diclofenac diethylamine BP 1.16% ( l l .6mg/gm)
equivalent to diclofenac sodium 1% (i.e lOmg/gm):
gel preparation.
20gm tube: 25.00 MRP
t EMOV Gel Edruc
Diclofenac diethylamine BP 1.16% (11.6mg/gm)
equivalent to diclofenac sodium 1% (i.e 1Omg/gm):
gel preparation.
25gm tube: 25.00 MRP
ANTIRHEUMATIC & ANTI-INFLAMMATORY DRUGS
t MOOV Gel Astra
Diclofenac diethylamine BP 1.16% (11.6mg/gm)
equivalent to dic�ofenac sodium 1% (i.e lOmg/gm):,
gel preparation.
1Ogm tube: 60.00 MRP
t NEOFENAC Gel Ad-din
Diclofenac diethylamine BP 1.16% ( l l .6mg/gm)
equivalent to diclofenac sodium 1% (i.e lOmg/gm):
gel preparation.
lOgm tube: 12.90 MRP
t REUTREN Gel Gaco
Diclofenac diethylamine BP 1.16% ( l l .6mg/gm)
equivalent to �clofenac sodium 1% (i.e lOmg/gm):
gel preparation.
lOgm tube: 12.14 MRP
t ULTRAFEN Gel Beximco
Diclofenac diethylamine BP 1.16% (11.6mg/gm)
equivalent to diclofenac sodium 1% (i.e 1Omg/gm):
gel preparation.
lOgm tube: 13.00 IP
25mg tube: 35.00 IP
t VOLIGEL Gel Beximco
Diclofenac diethylamine BP 1.16% ( l l .6mg/gm)
equivalent to diclofenac sodium 1% (i.e 1Omg/gm):
gel preparation.
30gm tube: 80.00 MRP
50gm tube: 97.00 IP
t VOLTID Gel Pharmasia
Diclofenac diethylamine BP 1.16% ( l l .6mg/gm)
equivalent to diclofenac sodium 1% (i.e 1Omg/gm):
gel preparation.
lOgm tube: 12.95 MRP
DICLOFENAC FREE ACJD21,33
DICLOFENAC FREE ACID: Dispersible
tablet
Diclofenac free acid, available as 46.5mg
dispersible tablet (corresponding to 50mg of
diclofenac sodium).
Ind: Dispersible tablets are suitable for short­
term use in acute painful condisions, such as,
painful syndromes of vertebral column, myalgia,
sprains & strains, fractures, wounds & injuries,
non-articular rheumatism, acute gout, dental or
orthopaedic surgery, primary dysmenorrhoea or
adnexitis; as an adjuvant in severe infections of
the ear, nose or throat.
C/I; S/E; Caution: See under diclofenac sodium;
but it's gastric irritation is less as it disperses
immediately (within 15 seconds) & acts speedily
(20-30 min) due to it's quick absorption.
Dosage: adults: The recommended initial daily
dosage is 2-3 dispersible tablets; in milder
cases & for children over 14 years of age, 2
dispersible tablets daily are usually sufficient.
In dysmenorrhoea 2 to max. 4 tablets (if
necessary) may be given per day.
Children: Not recommended below 14 years.
t CLOFENAC D T Tab. Square
Diclofenac free acid 46.5mg (corresponding to
50mg of diclofenac sodium)/tablet (dispersible).
lOO's pack: 400.00 MRP
t VOLTALIN D Tab. Novartis
Diclofenac free acid 46.5mg (corresponding to
50mg of diclofenac sodium)/tablet (dispersible).
1OO's pack: 650.00 MRP
 QIMP-17 (342)

C'ai11 /tee slffik rouib tlte clot"
®
DICLOFENAC POTASSWM21,54
DICLOFENAC POTASSIUM: Tablet
Diclofenac potassium BP 25mg and 50mg tablet.
Ind: Short-term treatment in the following acute
conditions: post-traumatic & post-operative pain
and inflammation, dysmenorrhoea, adnexitis and
non-articular rheumatism; rheumatoid arthritis;
osteoarthritis; ankylosing spondylitis; acute gout;
disorders of the muscles and skeleton, such as
tendinitis, sprains, strains, dislocations, fractures;
lower back pain; pain relief in migraine; as an
adjuvant in severe infections of the ear, nose or
throat.
C/I; S/E; Cautions: See under the text of
diclofenac sodium.
Pregnancy & lactation: See under the text of
diclofenac sodium.
Dosage: Usual dosage, 100-lSOmg daily in
divided doses. In mild cases, 75-lOOmg daily in
divided doses. In primary dysmenorrhoea,
initially 50-lOOmg daily in divided doses; if
necessary, dose can be increased during the
course of several cycles to a maximum of
200mg/day.
Drug inter: See under the text of diclofenac
sodium.
experienced asthma, urticaria or other allergic-type
reactions after taking aspirin or other NSAIDs.
S/E: Like other NSAIDs etodolac also causes
gastrointestinal symptoms, such as- abdominal
pain, constipation, diarrhea, dyspepsia, flatulence,
heartburn, nausea, GI ulcers, vomiting. Other
events include- abnormal renal function, anemia,
dizziness, edema, elevated liver enzymes,
headache, increased bleeding time, pruritis,
rashes, tinnitus etc.
Precautions: Etodolac should be given with
caution in patients with severe hepatic reactions,
pre-existing asthma, fluid retention, hypertension
or heart failure. If clinical sings and symptoms
consistent with liver disease develop, or if
systemic manifestations occur (e.g. eosinophilia,
rash etc.), it should be discontinued.
Pregnancy & lactation: There are no adequate
and well-controlled studies in pregnant women. It
should be used in pregnancy only if the potential
benefit justifies the potential risk to the fetus. It is
not known whether etodolac is excreted in h11man
milk. A decision should be made whether to
discontinue nursing or to discontinue the drug
takin g into account the importance of the drug to
the mother.
Dosage & admin: Adults & over 18 years:
300mg capsule, 2 capsule (600mg) daily in 1-2
divided doses; Or, Etodolac 600mg ER tablet
once daily.
Children: Below 18 years, not recommended.
Drug inter: Reports suggest that NSAIDs may
diminish the antihypertensive effect of ACE­
inhibitors. This interaction should be given
bleeding, severe hepatic dysfunction. Children
and adolescents under 16 years of age. Patients
with inflammatory bowel disease and severe
congestive heart failure.
S/E: Common side effects are dizziness,
headache, gostro-intestinal disorders ( e.g
abdominal pain, flatulence, heartburn), diarrhoea,
dyspepsia, nausea, asthenia, fatigue, flu-like
symptoms. Rare side effects are oedema, weight
gain, anxiety, blurred vision, hypertension,
epistaxis, dyspnoea, constipation, vomiting,
muscle cramps, chest pain.
Precautions: Decreased kidney function and
liver function, dehydration, hypertension, history
of heart failure, perforation, and people over 65
years of age.
Pregnancy & lactation: Not recommended.
Dosage & admin: Adult and adolescent over
16 years: Arthritis/osteoarthritis- 60mg once
daily; Rheumatoid arthritis- 90mg once daily;
Acute gouty arthritis- 120mg once daily;
Analgesia, acute pain associated with dental
surgery- 120mg once daily; Primary
dysmenorrhoea, chronic musculo-skeletal
pain, including chronic low back pain- 60mg
once daily.
Drug inter: Warfari n, ACE inhibitors, rifampicin,
lithium, birth control pills, methotrexate, digoxin.
+ ALGIREX Tab. Ibo Sina
Etoricoxib INN 60mg, 90mg & l 20mg/tablet (f.c)
60mg x 30's pack: 210.00 IP
90mg x 20's pack: 240.00 IP
120mg x 20's pack: 285.00 IP

t A-FENAC-K Tab. Acme consideration in patients taking NSAIDs t AROXIA Tab. Ad-din
Diclofenac potassium 50mg/tablet concomita-ntly with ACE-inhibitors. As with Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)

50mg x 50's pack: 150.00 MRP other NSAIDs, concomitant administration of 60mg x 30's pack: 180.00 MRP
90mg x 20's pack: 160.00 MRP
t CATAFLAM Tab. Novartis etodolac and aspirin is not recommended because
Diclofenac potassium 25mg & 50mg/tablet of the potential of increased adverse effects. 120mg x 20's pack: 200.00 MRP

25mg x 50's pack: 200.00 MRP t ARTORIX Tab. Asiatic

50mg x 50's pack: 325.00 MRP t EDOLAC Cap. Opsonin Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
I
t KALINAC Tab. Square Etodol�c BP 300mg/capsule 60mg x 30's pack: 210.00 MRP
I
300mg x 30's pack: 211.92 MRP 90mg x 20's pack: 240.00 MRP
1 Diclofenac potassium 50mg/tablet
50mg x 50's pack: 200.50 MRP t EDOLAC 600 ER Tab. Opsonin 120mg x 20's pack: 280.00 MRP

t INTAFENAC K Tab. Incepta Etodolac USP 600mg/tablet (extended release) t COX-E Tab. Popular
Diclofenac potassium 50mg/tablet 600mg x 12's pack: 190.76 MRP Etoricoxib INN 60mg, 90mg & l 20mg/tablet (f.c)

50mg x 50's pack: 150.00 MRP t EDOPAIN Cap. Incepta 60mg x 30's pack: 210.00 MRP
Etodolac BP 300mg/capsule 90mg x 30's pack: 360.00 MRP
t NOPAIN Tab. Drug Inter.
Diclofenac potassium 25mg & 50mg/ tablet 300mg x 30's pack: 240.00 MRP 120mg x 30's pack: 420.00 MRP

25mg x 1OO's pack: 200.00 MRP t EDOPAIN 600 ER Tab. Incepta t COXET Tab. Pacific
50mg x 50's pack: 200.00 MRP Etodolac USP 600mg/tablet (extended release) Etoricoxib INN 90mg & 120mg/tablet (f.c)
600mg x 20's pack: 360.00 MRP 90mg x 30's pack: 360.00 MRP
t PANODIN SR Tab. Square 120mg x 20's pack: 280.00 MRP
ETODOLAC26 Etodolac USP 600mg/tablet (sustained release) t COXETORI Tab. Amulet
600mg x 30's pack: 451.50 MRP Etoricoxib INN 60mg & 120mg/tablet (f.c)

ETODOLAC: Tablet/Capsule 60mg x 30's pack: 210.00 MRP

Etodolac is a nonsteroidal anti-inflammatory drug 120mg x 20's pack: 280.00 MRP

ETORICOXIB34 t COXFREE Tab. Kemiko
(NSAIDs) that exhibits anti-inflammatory,
analgesic and antipyretic activities. It is available Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
as etodolac BP 300mg capsule & etodolac USP ETORICOXIB: Tablet 60mg x 30's pack: 210.00 MRP •

600mg extended release (ER) tablet. Etoricoxib is a non-steroidal anti-inflammatory 90mg x 30's pack: 360.00 MRP

Mode of action: Like that of other NSAIDs, the
mechanism of action of etodolac is also mediated
through inhibition of prostaglandin synthesis.
Ind: For acute and long-term use in the
management of signs and symptoms of 1.
Osteoarthritis, 2. Rheumatoid arthritis; for the
management of acute pain in acute gout.
C/I: Etodolac is contraindicated in patients with
known hypersensitivity to etodolac. Etodolac
should not be given to patients who have
drug available as etoricoxib INN 60mg, 90mg & 120mg x 20's pack: 280.00 MRP
l 20mg film-coated tablet. t COXIA Tab. ACI
Mode of action: It is a selective COX-2 inhibitor. Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
Ind: Acute pain and inflammation, chronic 60mg x 30's pack: 210.90 MRP
musculo-skeletal pain, osteoarthritis, rheumatoid 90mg x 30's pack: 361.50 MRP
arthritis, acute gouty arthritis, primary 120mg x 20's pack: 281.00 MRP
dysmenorrhoea, ankylosing spondylitis. t COXITOR Tab. Beacon
C/I: Patients with known hypersensitivity to Etoricoxib INN 60mg & 90mg/tablet (f.c)
etoricoxib or any ingredient of the product. 60mg x 30's pack: 210.00 MRP
Active peptic ulceration or gastro-intestinal 90mg x 20's pack: 240.00 MRP

+ COXPAIN Tab. Novo Healthcare
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 20's pack: 240.00 MRP
120mg x lO's pack: 140.00 MRP
+ ECOX Tab. Alco Pharma
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 20's pack: 240.00 MRP
120mg x 20's pack: 280.00 MRP
t EFLAM Tab. Apex
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 20's pack: 240.00 MRP
120mg x 20's pack: 280.00 MRP
t EROFLAM Tab. Orion Pharma
Etoricoxib INN 60mg & 90mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 30's pack: 360.00 MRP
+ ETO Tab. Delta Pharma
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 50's pack: 350.00 MRP
90mg x 30's pack: 300.00 MRP
120mg x 20's pack: 240.00 MRP
t ETOCOX Tab. General
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 50's pack: 350.50 MRP
90mg x 30's pack: 361.50 MRP
120mg x 20's pack: 181.00 MRP
t ETOFLAM Tab. RAK Pharma
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 30's pack: 300.00 MRP
120mg x 20's pack: 240.00 MRP
t ETORGIN Tab. Cosmic
Etoricoxib INN 90mg & 120mg/tablet (f.c)
90mg x 30's pack: 360.00 MRP
120mg x 30's pack: 420.00 MRP
t ETORIFLEX Tab. Somatec
Etoricoxib INN 60mg & 90mg/tablet (f.c)
•
60mg x 30's pack: 180.00 MRP
I 90mg x 30's pack: 270.00 MRP
t ETORIX Tab. SK+F
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 40's pack: 280.00 MRP
90mg x 30's pack: 360.00 MRP
120mg x 20's pack: 280.00 MRP
t ETOX Tab. Hallmark
Etoricoxib INN 60mg & 90mg/tablet (f.c)
60mg x 30's pack: 210.60 MRP
90mg x 30's pack: 360.00 MRP
I
QIMP-17 (343)
t ETOXIB Tab. Globe
Etoricoxib INN 60mg & 90mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 30's pack: 360.00 MRP
t ETRIB Tab. Ni pro JMI
Etoricoxib INN 60mg & 90mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 30's pack: 360.00 MRP
t KINGCOX Tab. Medicon
Etoricoxib INN 60mg & 90mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 30's pack: 360.00 MRP
t ORICOX Tab. Incepta
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 30's pack: 360.00 MRP
120mg x 20's pack: 280.00 MRP
+ RIBOX Tab. Beximco
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 30's pack: 210.00 IP
90mg x 30's pack: 360.00 IP
120mg x 20's pack: 280.00 MRP
+ RITO Tab. Opsonin
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 30's pack: 185.49 MRP
90mg x 30's pack: 318.01 MRP
120mg x 20's pack: 247.20 MRP
t SETORIB Tab. Acme
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 40's pack: 280.80 MRP
90mg x 30's pack: 361.50 MRP
l 20mg x 20's pack: 281.20 MRP
t TORIMON F.C Tab. Nuvista
Etoricoxib INN 90mg & 120mg/tablet (f.c)
90mg x 30's pack: 360.00 MRP
120mg x 20's pack: 280.00 MRP
t TORY Tab. Square
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 30's pack: 210.60 MRP
90mg x 30's pack: 361.50 MRP
l 20mg x 20's pack: 281.20 MRP
t VARGUS Tab. Sandoz
Etoricoxib INN 60mg, 90mg & l 20mg/tablet (f.c)
60mg x 28's pack: 252.00 MRP
90mg x 30's pack: 450.00 MRP
120mg x 20's pack: 340.00 MRP
+ XIBRA Tab. Aristopbarma
Etoricoxib INN 60mg, 90mg & 120mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 30's pack: 360.00 MRP
120mg x 20's pack: 280.00 MRP
. .
•
®
'
. .
Etoricoxib
+ X DOL Tab. Concord
Etoricoxib INN 60mg, 90mg & l 20mg/tablet (f.c)
60mg x 30's pack: 210.00 MRP
90mg x 30's pack: 360.00 MRP
120mg x 20's pack: 280.00 MRP
FLURBIPROFEN34
.
t URBIFEN Tab. General
Flurbiprofen BP 50mg/tablet (film-coated).
Flurbiprofen is a potent non-steroidal anti­
inflammatory drug with antipyretic and analgesic
activity.
Mode of action: Flurbiprofen is a
cyclooxygenase inhibitor. It inhibits
prostaglandin and thromboxane biosynthesis. It
inhibits vasodilatation and also prevents the
sensitization of pain fibers by prostaglandins.
Ind: Pain and inflammation in rheumatic disease
and other musculoskeletal disorders such as
rheumatoid arthritis, osteoarthritis, ankylosing
spondylitis, frozen shoulder, low back pain,
sprains & strains; mild to moderate pain including
dysmenorrhoea; migraine; post-operative
analgesia, dental pain; relief of sore throat.
C/I: Active peptic ulceration or recent
gastrointestinal hemorrhage, ulcerative colitis.
Bronchospasm and other hypersensitivity-type
reactions with aspirin and other non-steroidal
agents. Relative contraindications are anticoagu­
lant therapy, diuretic therapy and patients with
history of heart failure/hypertension and non­
allergic asthma. Patients with a prior hypersen­
sitivity to flurbiprofen or any other ingredient in
the formulation.
S/E: The most important side effects are peptic
ulceration, hemorrhage and perforation.
Gastrointestinal adverse effects include­
dyspepsia, nausea, vomiting, constipation and
diarrhea. There may be peripheral edema due to
salt and water retention. Some neurological
reactions such as dizziness, tinnitus, deafness and
blurred vision have been reported which have
disappeared on withdrawal of the drug.
Prec autions: Flurbiprofen has not been exten-
 '

QIMP-17 (344)

t CPFEN Tab. Cosmo Pharma t SIFLAM Tab. Silva

Ibuprofen 400mg/tablet
400mg x 1OO's pack: 131.00 MRP
t DEFLAM-400 Tab. Desh Pharma
Ibuprofen 400mg/tablet.
sively studied in children. If is not recommended 400mg x lOO's pack: 100.00 IP
Ibuprofen 400mg/tablet
400mg x lOO's pack: 120.00 MRP
t T RUFEN 400 Tab. Modern
Ibuprofen 400mg/tablet
400mg x lOO's pack: 126.00 MRP •

for children under 12 years of age. t EROFEN Tab. Edruc t UNIFLAM 400 Tab. Bristol
Pregnancy & lactation: The safety of Ibuprofen 400mg/tablet Ibuprofen 400mg/tablet
flurbiprofen during pregnancy has not been 400mg x lOO's pack: 135.00 MRP 400mg x lOO's pack: 100.00 MRP
established. Breast feeding is not contraindication t FLAMEX Tab. ACI
but sa.fety is not declared. Ibuprofen 200mg & 400mg/tablet
INDOMETHACIN21,33
Dosage: 150-200mg daily in divided doses, 200mg x 1OO's pack: 88.00 MRP
increased in acute conditions to 300mg daily. 400mg x lOO's pack: 143.00 MRP
INDOMETHACIN: Capsule/ Suppository.
In dysmenorrhoea, initially 1OOmg, then 50- t FLAMEX SR Cap. ACI
1OOmg every 4-6 hours; maximum 300mg daily. Ibuprofeµ 300mg/capsule (sustained release). Ind: Rheumatoid arthritis, osteoarthrosis, anky­

Missed dose: Take the missed dose as soon as 300mg x 50's pack: 200.00 MRP losing spondylitis, acute gout, degenerative joint '

diseases of the hip and serious acute peri-articu­

remembered. However, if it is almost time for t FLAMEX Susp. ACI
the next dose, skip the missed dose and Ibuprofen BP 100mg/5ml: suspension. lar disorders. Lumbago, and other musculo-skele­

continue regular dosing schedule. Do not take
a double dose to make up for a missed one.
..
lOOml bot: 33.71 MRP tal disorders ( e.g. bursitis, tendinitis, synovitis
etc), orthopaedic procedures, dysmenorrhoea.
t FLAMPEN Tab. Alco Pharma
C/I: Active peptic ulcer, history of gastro-intes­

Drug inter: Care should be taken in patients Ibuprofen 400mg/tablet

treated with any of the following drugs as 400mg x lOO's pack: 130.00 MRP tinal lesions; aspirin/ anti-inflammatory induced
allergy; recent proctitis; pregnancy and lactation
interactions have been reported in some patients­ t G-IBUPROFEN Tab. Gonoshas.
antihypertensives, diuretics, cardiac glycosides, Ibuprofen 400mg/tablet S/E: Headache, dizziness , nausea, vomiting, epi­

lithium, methotrexate etc. 400mg x lOO's pack: 120.00 MRP gastric and abdominal pain and discomfort, diar­
rhoea, ulceration of oesophagus, stomach & duo­
30's pack: 150.60 MRP t IBEN Tab. Zenith
Ibuprofen 400mg/tablet denum including haemorrhage or even perfora­

400mg x lOO's pack: 130.00 MRP tion; hepatitis, jaundices; raised blood pressure;
IBUPROFEN21,33 haematuria; dermatological hypersensitivity reac­
t IBF Tab. Decent
tions. Acute resp. distress including sudden dys­
_ Ibuprofen
. . 400mg/tablet
pnoea and asthma; Leucopenia, purpura, aplastic
,-

IBUPROFEN: Tablet/Capsul�/ Suspension 400mg x lOO's pack: 125.00 MRP

Ind: Rheumatoid arthritis (including stilt's and haemolytic anaemia and thrombocytopenia;
t IBUREX Tab. Medimet
disease), osteoarthrosis, anylosing spondylitis, rarely ophthalmological problems & deafness.
Ibuprofen 200mg & 400mg/tablet.
non-rheumatoid arthropathies, peri-articular Cautions: Renal or hepatic insufficiency; discon­
200mg x lOO's pack: 80.00 MRP
disorders, frozen shoulder ( capsulitis), bursitis, tinue if gastro- intestinal bleeding or persistent
400mg x lOO's pack: 120.00 MRP
tendinitis and low back pain, soft tissue headache occurs; carry out periodic ophthalmo­
. t IFEN Tab. Cosmic
.inflammation such as sprains and strains . ligical examination during long -term therapy.
Ibuprofen 400mg/tablet
C/I: Active peptic ulceration. Dosage & admin: Adult: Oral, 50-200mg daily
.400mg x lOO's pack: 141.00 MRP
S/E: GaStro- intestinal discomport and bleeding; in divided doses with food, milk or antacid
t INFLAM Tab. Sanofi aventis
•

precipitation 9f bronchia
. l asthma or allergic Dysmenorrhoea, up to 75mg daily.
. .
.

Ibuprofen 200mg & 400mg/tablet

diseases. Suppository, 1 at night plus one in the
200mg x ·lOO's pack: 87.78 MRP
Cautions: Asthma; pregnancy; aspirin/anti­ 400mg x lOO's pack: 142.31 MRP
morning if necessary or 1 at night
inflammatroy induced allergies. supplemented during the day with caps or
t INFLAM Susp. Sanofi aventis .
Dosage & admin: Adult: 600-1200 mg .daily in Ibuprofen BP 100mg/5ml: suspension.
suspn. upto a total of 200mg daily.
divided doses. Max. 2400mg daily. Children: Child: Not recommended.
lOOml bot: 18.65 MRP
usual dose 20mg/kg in divided doses, which Overdose: Over dosage may be managed by
t IRUFEN 400 Tab. Ziska
may be achieved as: 1-2 yrs. half tsf 3-4 times gastric lavage. Antacids may be helpful.
Ibuprofen 400mg/tablet.
daily; 3-7 yrs. 1 tsf 3-4 times daily; 8-12 yrs. 2
400mg x lOO's pack: 100.00 MRP
tsf 3-4 times daily; below 1 year, not indicated. t IMET Cap. Pacific
t NEUROFEN Tab. Globe lndomethacin 25mg/capsule.
Dose should not exceed SOOmg daily for
Ibuprofen 400mg/tablet (f.c).
lOO's pack: 100.00 MRP
children weighing less than 30kg.
400mg x lOO's pack: 100.00 MRP
t IMET SR Cap. Pacific
t PROFEN Tab. Acme
t ADVEL Tab. Opsonin Indomethacin 75mg/capsule (sustained release)
Ibuprofen 400mg/tablet (f.c).
Ibuprofen 200mg & 400mg/tablet 50's pack: 200.00 MRP
400mg x 1OO's pack: 142.00 MRP
200mg x 1OO's pack: 77.00 MRP t INDO-A Suppo. Acme
400mg x lOO's pack: 125.80 MRP
t PROFEN Susp. Acme lndomethacin 1OO mg/stick: suppository.
Ibuprofen BP 100mg/5ml: suspension.
t ADVEL Susp. Opsonin lO's pack: 70.20 MRP
lOOml bot: 33.70 MRP
Ibuprofen BP 100mg/5ml: suspension. t INDOMET Cap. Opsonin
lOOml bot: 29.66 MRP
t RAPOFEN Tab. Pharmadesh Indomethacin 25mg/capsule
Ibuprofen 400mg/tablet (f.c).
lOO's pack: 87.97 MRP
•

t ANAFEN Tab. Nipa •

400mg x lOO's pack: 133.00 MRP

Ibuprofen 400mg/tablet. t INDOMET SR Cap. Opsonin
400mg x lOO's pack: 142.00 MRP
t REBUPROFEN Tab. Renata lndomethacin 75mg/capsule (sustained release)
Ibuprofen 400mg/tablet (f.c).
t ARAFA Tab. Hudson 50's pack: 175.94 MRP
400mg x lOO's pack: 145.00 MRP
Ibuprofen 400mg/tablet. t INDOMET Suppo. Opsonin
400mg x lOO's pack: 100.00 MRP t REUMAFEN Tab. Beximco lndomethacin 1OO mg/stick: suppository.
t BEFLAM Tab. Bengal Drugs Ibuprofen 200mg & 400mg/tablet 25's pack: 153.93 MRP
Ibuprofen BP 400mg/tablet. 200mg x 1OO's pack: 88.00 MRP t INDOMETHACIN Cap. Bristol
400mg x 1OO's pack: 182.00 MRP 400mg x 1OO's pack: 142.00 MRP lndomethacin 25mg/capsule.

t REUMAFE N Susp. Beximco IOO's pack: 50.00 MRP

t BUFEN-SR Cap. Drug Inter.
Ibuprofen 300mg/capsule (sustained release). Ibuprofen l 00mg/5ml BP: suspension. t INDOMIN Cap. Reliance
300mg x lOO's pack: 405.00 MRP lOOml bot: 33.71 MRP Indomethacin 25mg/capsule.
 QIMP-17 (345) ANTIRHEUMATIC & ANTI-INFLAMMATORY DRUGS

'

1OO's pack: 100.00 MRP gently but massage well to ensure gel
t INDOREX Cap. Medimet penetration. Should be avoided in children
Indomethacin 25mg/capsule under 5 years of age. The gel can be used with
1OO's pack: 100.00 MRP occlusive dressing.
•
+ INDOXYL Cap. Jayson
lndomethacin 25mg/ca psule. t FESTAM Gel Pacific
Ketoprofen 2.5% w/w: gel prepa ra tion
1OO's pack: 63.00 IP
Dosage & admin: See above under the text.
t METHACIN Cap. Nipa
30gm tube: 120.00 MRP
Indomethacin 25mg/ca psule.
lOO's pack: 61.00 MRP
'
. . ..'
.(. '
"

.
.
.. + KEFEN Inj. Techno Drugs
Ketoprofen 100mg/2ml ampoule:i.m injection
+ REUMACAP Cap. Aristopharma
10 amps pack: 150.00 MRP
lndomethacin 25mg/capsule
lOO's pack: 100.00 MRP t KETO-A Tab. Acme
Ketoprofen 50mg & 1OOmg/ tablet.
+ REUMACAP SR Cap. Aristopharma
50mg x 50's pack: 175.50 MRP
I ndomethacin 75mg/ca psule (sustained release)
lOOmg x 50's pack: 276.00 MRP
lOO's pack: 400.00 MRP
t KETO-A Inj. Acme
+ REUMACID Suppo. Aristopharma
Ketoprofen 100mg/2ml ampoule: i.m injection
Indomethacin 1OOmg/ stick: suppository.
10 amps pack: 195.80 MRP
20's pack: 180.00 MRP
+ KETO-A Suppo. Acme
+ RHEUMET Cap. Pharmadesh
Ketoprofen 1 OOmg/ stick: suppository.
Indomethacin 25mg/ca psule.
lO's pack: 120.50 MRP
lOO's pack: 62.00 MRP
t KONTROL T R 100 Cap. Silva
t SERVIMETA Cap. Sandoz
Ketoprofen lOOmg/capsule (timed release).
! lndometh acin 25mg/ca psule. '

lOOmg x 30's pack: 180.00 MRP

) "

I lOO's pack: 180.00 MRP

I + KOP Tab. Square
I
Ketoprofen 50mg/tablet
I N21 ,35, 79
KETOPROFE 50mg x 50's pack: 175.50 MRP
t KOP SR Cap. Square
Ketoprofen lOOmg & 200mg/capsule (s. r)
I KETOPROFEN: Capsuleffablet/

I
Injection/Gel/ Suppositories
Ind: Rheuma toid arthri tis, osteoarthrosis,
E·SO & 100 tablets lOOmg x 50's pack: 351.00 MRP
200mg x 30's pack: 301.20 MRP
'

I
a nkylosing spondylitis, acute a rticula r and peri­ t KOP IM Inj. Square
I a rticula r disorders; soft tissue inflamm a tion; Ketoprofen 100mg/2ml ampoule: i.m injection

I dysmenorrhoea. 10 amps pack: 200.70 MRP

I C/I: Active peptic ulcer or history of recurrent

peptic ulcer; a sthma; recent proctitis; a spirin or
+ KOP Gel Square
Ketoprofen 2.5% w/w gel, a lso containing ethyl
a lcohol, trietha nolamine & la vender oil: gel
j a ny non-steroidal a nti- inflammatory induced
a llergy. Dosage & admin: See above under the text.
S/E: Ga stro-intestina l discomport or 20gm tube: 58.21 MRP
: .. :
'.: .: ..:
. ...
. .
· :: : :
...
,
"

.
. ..
....
.
.

t KYNOL TR Cap. SK+F

:- .

ha emorrhage (rare), skin rash.

·-
'�

Cautions: Impaired hepa tic function; pregnancy Ketoprofen 1OOmg & 200mg/capsule (t. r).
& lactation; concurrent a dministration of plasma lOOmg x 50's pack: 350.00 MRP
protein-bound drugs. 200mg x 30's pack: 300.00 MRP
Pregnancy & lactation: Exercise ca ution during + ORKET Inj. Orion Pharma
pregna ncy & lacta tion. Ketoprofen l00mg/2ml ampoule: i.m injection
Dosage & admin: Oral preparations: 5 amps pack: 75.30 MRP
Plain capsule or tablet: Rheumatic disease, + PROFENID-E Tab. Sanofi-aventis
100-200mg daily in 2-4 divided doses with Ketoprofen 50mg & 1 OOmg/tablet (e.c).
food; pain & dysmenorrhoea, SOmg upto 3 50mg x 50's pack: 300.00 MRP
times daily with food. lOOmg x 50's pack: 450.00 MRP
CRISR/l'R capsules: 100-200mg capsule once
. ;.;. .
t PROFENID CR Cap. Sanofi-aventis
.
Ketoprofen 1OOmg & 200mg/capsule (consta nt
'•

daily with food. These preparations are more .. .

. , ...·: ... _'.::·. ·· :.- ; �-.-

: .
..... . .... . . . ..,,

adventageous, because, acid environment in release).

. . :� : . '. � ··-· '
. .
- . .
... ..
'

. :
. .. .. - .
.. ··
..

. - · .. . .. ...

the stomach prevents release of active drug, -�·-· -·· .

thus mi.nimising gastric irritation. The pellets
release ketoprofen in solution only when they
reach the alkaline environment of the
intestine. The continuous slow release,
sustained release or timed release capsules
ensure full 24 hours relief of symptoms.
By deep i.m injection into the gluteal muscle:
50-lOOmg every 4 hours (maximum 200mg in
24 hours) for upto 3 days.
By rectum in suppositories: Rheumatic disease,
1 OOmg at bed time. Combined oral & rectal
treatment, max. total daily dose 200mg.
Child: not recommended.
Use ofgel preparation: Adults & children
5 years- to be applied several times daily to
skin in the painful & inflammed region. Apply
l OOmg x 50's pack: 550.00 MRP
· 'CR-100 l 200 200mg x 50's pack: 1000.00 MRP
+ PROFENID Inj. Sanofi-aventis
·capsules Ketoprofen l00mg/2ml ampoule: i.m injection
10 amps pack: 500 .00 MRP
+ PROFENID Gel Sanofi-aventis
Ketoprofen 2.5% w/w gel, a lso containing ethyl
a lcohol, trietha nolamine & lavender oil: gel
Dosage & admin: See above under the text.
30gm tube: 120.00 MRP
+ TOP Tab. Biopharma
Ketoprofen 50mg & lOOmg/ tablet.
50mg x 50's pack: 175.50 MRP
�
over
SANOFI V lOOmg x 30's pack: 180.60 MRP
t T RAMP CR Cap. Bristol
Ketoprofen 1 OOmg/ca psule (constant release).
lOOmg x 50's pack: 505.50 MRP
AN'l'IRHEUMATIC & ANTI-INFLAMMATORY DRUGS
t XYNOFEN SR Cap. Beximco
Ketoprofen 1OOmg/capsule (sustained release).
50's pack: 377.00 IP
MEFENAMIC ACJD21,33
MEFENAMIC ACID: Tablet/Capsule/Syrup.
Ind: Mild to moderate pain in rheumatoid
arthritis (including Still's disease); osteoarthritis;
headache; dysmenorrhoea. Menorrhagia
(including IUD users).
C/I: Peptic ulcerations, inflammatory bowel
disease; Renal or hepatic impairment; pregnancy.
S/E: Drowsiness, dizziness; g.i disturbances,
heeding, nausea, occasional ulceration. Withdraw
treatment in severe diarrhoea, hypersensitivity,
bronchospasm, rashes, cholestatic jaundice,
thrombocytopenia, haemolytic anaemia.
Cautions: Bronchial asthma & allergic disorders.
Concurrent administration of plasma protein­
bound drugs specially coumarin anticoagulants.
Elderly patient.
Dosage & admin: Adult: 500mg 3 times daily
after food; Incase of menorrhagia starting on
first day of menses.
Child: Use paed. suspen. Under 6 months not
recommended; Over 6 months, 25 mg/kg daily
in divided doses for not longer than 7days,
except in juvenile chronic arthritis (still's
disease), after food.
t AMIFEN Tab. Opsonin
Mefenamic acid 500mg/tablet
500mg x 50's pack: 220.80 MRP
+ AMIFEN Susp. Opsonin
Mefenamic acid 50mg/5ml: suspension.
60ml bot: 24.73 MRP
t DYSMEN Tab. Renata
Mefenamic acid 250mg & 500mg/tablet
250mg x 1OO's pack: 280.00 MRP
500mg x 50's pack: 250.00 MRP
t FENAMIC Cap. Beximco
Mefenamic acid 250mg & 500mg/capsule
250mg x lOO's pack: 201.00 IP
500mg x 30's pack: 114.60 IP
+ FENAMIC Susp. Beximco
Mefenamic acid 50mg/5ml: suspension.
60ml bot: 15 .00 IP
t FENATON Tab. Drug Inter.
Mefenamic acid 500mg/tablet
lOO's pack: 150.00 MRP
t FLAMIC Tab. Globe
Mefenamic acid 250mg & 500mg/tablet.
250mg x lOO's pack: 125.00 MRP
500mg x 50's pack: 125.00 MRP
t FLAMIC Susp. Globe
Mefenamic acid 50mg/5ml: suspension.
60ml bot: 22.00 MRP
+ HPR Tab. Pacific
Mefenamic acid 250mg/tablet
1OO's pack: 300.00 MRP
t HPR-DS Tab. Pacific
Mefenamic acid 500mg/tablet
50's pack: 290.00 MRP
+ HPR Susp. Pacific
Mefenamic acid 50mg/5ml: suspension
60ml bot: 40.00 MRP
t MEFALGIN Tab. Cosmic
Mefenamic acid 250mg & 500mg/tablet
250mg x l OO's pack: 180.00 MRP
QIMP-17 (346)
500mg x lOO's pack: 257.00 MRP
t MEFALGIN Susp. Cosmic
Mefenamic acid 50mg/5ml: suspension
60ml bot: 22.00 MRP
t MEFEPAIN Tab. RAK Pharma
Mefenamic acid 250mg & 500/tablet
250mg x l OO's pack: 200.00 MRP
500mg x 50's pack: 150.00 MRP
+ NAM 2SO Tab. Everest
Mefenamic acid 250mg/tablet
250mg x l OO's pack: 120.00 MRP
+ NAM 500 Tab. Everest
Mefenamic acid 500mg/tablet
500mg x 50's pack: 117.50 MRP
MELOX ICAM21,42
MELOXICAM: Tablet
Meloxicam is a non-steroidal anti-inflammatory
drug (NSAID) of the oxicam family, with anti­
inflammatory, analgesic and antipyretic
properties.
Ind: Osteoarthritis (short-term treatment),
rhe\1matoid arthritis (long-term teratment),
ankylosing spondylitis.
C/I & Precaution: Meloxicam is contraindicated
to patients hypersensitive to it. Meloxicam should
not be given to patients who have developed
signs of asthma, nasal polyps, angioneurotic
oedema or urticaria following the administration
of aspirin or NSAIDs. Meloxicam is also
contraindicated to patients with active peptic
ulcer during the last six months or a history of
recurrent peptic ulcer disease, severe hepatic
failure, non-dialysed severe renal failure,
gastrointestinal bleeding, cerebrovascular
bleeding or other bleeding disorders.
Pregnancy & lactation: It is advisable to avoid
meloxicam during pregnancy & breast-feeding.
S/E: Nausea, vomiting, abdominal pain,
dyspepsia, constipation or diarrhoea may occur.
Ulcers or gastrointestinal bleeding may rarely
occur. Skin rash or urticaria may occur in some
individuals. Oedema of the lower limbs may
occur during treatment. Onset of an asthma attack
has been reported in certain individuals allergic
to aspirin or to other NSAIDs. Headache, vertigo,
or drowsiness may occur.
Dosage & admin: Adults: Osteoarthritis:
7.Smg/day; if necessary, may be increased to
lSmg/day. Rheumatoid arthritis: lSmg/day; in
elderly patients the recommended dose for
long term treatment is 7 .Smg/day. Anlcylosing
spondylitis: 15mg/day; in elderly patients the
recommended dose is 7.Smg/day.
Do not exceed the dose of 15mg/day. The total
daily amount should be taken as a single dose.
Patients with increased risks for adverse
reactions should start treatment with 7.5mg/
day. In dialysis patients with severe renal
failure the dose should not exceed 7.Smg/day.
Children: The pharmacokinetics of meloxicam
in paediatric patients under 18 years of age
has not been established.
Drug inter: Administration of other NSAIDs
together may increase the risk of ulcers and
gastrointestinal bleeding, via a synergistic effect.
Concomitant use of oral anticoagulants, heparin
and ticlopidine incresase the risk of bleeding via
inhibition of platelet function and damage to the
gastroduodenal mucosa. Use of lithium or
methotrexate with NSAIDs increase their levels
in the blood, which may then reach toxic values.
NSAIDs appear to decrease the efficacy of
intrauterine contraceptive devices.
t MELCAM Tab Square
Meloxicam BP l 5mg/tablet.
15mg x 50's pack: 200.50 MRP
NAPROXEN21,33,52
NAPROXEN SODIUM: Tablet/Capsule/Gel/
Suspension/Suppositories.
Ind: Rheumatoid arthritis, osteoarthrosis,
ankylosing spondylitis; acute gout.
C/I: Active peptic ulcer; aspirin or any non­
steroid anti- inflammatory induced allergy.
\
S/E: Mild and infrequent gastro-intestinal
discomport, bleeeding, nausea, vertigo, headache,
hearing disturbances such as tinnitus;
thrombocytopenia; hypersensitivity reactions
(bronchospasm, angioneurotic oeden1a, rashes).
Precutions: History of gastro-intestinal lesions;
impaired renal function; asthma; pregnancy &
lactation; concurrent ad111in. of plasma protein­
bound drugs, lithi11m, beta-blockers or frusemide.
Dosage & admin: Adult: RllelUIUlto id arthritis,
osteoarthritis, tutkylosing spotUlyli.tis: The usual
dose is 250-SOOm g twice daily or as a single
dose of SOOmg tablet or SOOmg SR tablet daily
in the morning or evening after meal.
Ae11te goat: 7S0mg initially then 2S0mg eight
hourly until the attack subsides.
Juvadk tutlttitis: lOmg/kg daily in divided
doses.
Acute musculo-skeletal disorders: SOOmg ini­
tially, then 2S0mg every 6-8 hours as required.
Child: Under S years, not recommended; for
the treatment of juvenile rheumatoid arthritis
in children over S years of age, the usual
dosage is 1Omg/kg body-wt daily in two
divided doses. Naproxen is not recommended
for use in any other indication in children
under 16 years of age.
SR/CR Preparation: SOOmg SR or CR tablet
once daily in the morning or evening after
meal.
Gel preparatio n: Gel is to be applied locally 2-6
times a day as required with gentle massage
and is not recommended for use in children.
t ANAFLEX Tab. ACI
Naproxen sodi\1m 250mg & 500mg/tablet
250mg x 50's pack: 251.00 MRP
250mg x 1 OO's pack: 502.00 MRP
500mg x 30's pack: 270.90 MRP
t ANAFLEX SR Tab. ACI
\
Naproxen sodium 500mg/tablet (sustained
release).
500mg x 20's pack: 281.00 MRP
t ANAFLEX Gel ACI
Naproxen 10% w/w: gel preparation
15gm pack: 62.23 MRP
30gm pack: 116.00 MRP
• ARNEX Tab. Silva
Naproxen sodium 500mg/tablet
500mg x 30's pack: 180.00 MRP
t BPXEN Tab. Bristol
Naproxen sodium 250mg & 500mg/tablet

250mg x 50's pack: 200.00 MRP
500mg x 30's pack: 225.00 MRP
+ COSNAP Tab. Cosmo Pharma
Naproxen sodium 250mg/tablet
250mg x 50's pack: 150.00 MRP
t DIPROXEN Tab. Drug Inter.
Naproxen sodit1m 250mg & 500mg/tablet
250mg x l OO's pack: 425.00 MRP
500mg x 50's pack: 350.00 MRP
t DIPROXEN CR-500 Tab. Drug Inter.
Naproxen sodi11m 500mg/tablet (controlled
release).
500mg x 30's pack: 300.00 MRP
t DIPROXEN Gel Drug Inter.
Naproxen 10% w/w gel preparation
Use: Apply locally 3-4 times daily with gentle
massage.
l 5gm pack: 60.00 MRP
+ EPROX Tab. Euro Pharma
Naproxen sodium 500mg/tablet
500mg x 50's pack: 400.00 MRP
+ FRITI Tab. Somatec
Naproxen sodi11m 250mg & 500mg/tablet
250mg x 50's pack: 200.50 MRP
500mg x 50's pack: 351.50 MRP
t GLOXEN-250 Tab. Globe
Naproxen sodium 250mg/tablet
250mg x 30's pack: 120.00 MRP
t GLOXEN-500 Tab. Globe
Naproxen sodi11m 500mg/tablet
500mg x 30's pack: 210.00 MRP
+ NAID Tab. Pacific
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 200.00 MRP
500mg x SO's pack: 376.00 MRP
+ NAN 500 Tab. Reliance
Naproxen sodium 500mg/tablet
50's pack: 231.90 MRP
+ NAPIER 500 Tab. Concord
Naproxen sodium 500mg/tablet
30's pack: 210.00 MRP
+ NAPIUM Tab. Kumudini
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 200.00 MRP
500mg x 30's pack: 210.00 MRP
+ NAPIX-500 Tab. Modern
Naproxen sodium 500mg/tablet
500mg x 20's pack: 140.00 MRP
t NAPOXEN Tab. Edruc
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 200.00 MRP
500mg x 30's pack: 210.00 MRP
+ NAPRO Tab. Aristopharma
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 210.00 MRP
500mg x 30's pack: 210.00 MRP
t NAPRO-A Tab. Acme
Naproxen sodium 250mg & 500mg/tablet
250mg x l OO's pack: 101.00 MRP
500mg x 30's pack: 210.60 MRP
t NAPROCID Tab. Gaco
Naproxen sodi11m 250mg & 500mg/tablet
250mg x 30's pack: 120.00 MRP
SOOmg x 30's pack: 210.00 MRP
t NAPRONIL-500 Tab. Pharmasia
Naproxen sodium 500mg/tablet
500mg x 30's pack: 210.00 MRP
t NAPROPAIN Tab. RAK Pharma
Naproxen sodi11m 250mg & 500mg/tablet
250mg x 50's pack: 300.00 MRP
QIMP-17 (347)
500mg x 30's pack: 240.00 MRP
t NAPROSON Tab. Jayson
Naproxen sodium 250mg & 500mg/tablet ·
250mg x 50's pack: 203.00 IP
500mg x 30's pack: 210.90 IP
t NAPROSYN Tab. Radiant Pharma
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 400.00 MRP
500mg x 50's pack: 750.00 MRP
t NAPROSYN Susp. Radiant
Naproxen sodium 125mg/5ml: suspension
50ml bot: 120.00 MRP
t NAPROX Tab. SK+F
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 250.00 MRP
500mg x 50's pack: 450.00 MRP
t NAPROX Susp. SK+F
Naproxen sodi11m 125mg/5ml: suspension
50ml bot: 50.00 MRP
t NAPROX Gel SK+F
Naproxen 10% w/w gel preparation
Use: Apply locally 3-4 times daily with gentle
massage.
15gm pack: 60.00 MRP
t NAPROXEN Tab. Amico
Naproxen sodi11m 500mg/tablet
500mg x 30's pack: 210.00 MRP
t NAPROXEN 500 Tab. Organic Health
Naproxen sodium USP 500mg/tablet
500mg x 30's pack: 210.00 MRP
t NAPROXIN Tab. Ambee
Naproxen sodi11m 250mg & 500mg/tablet
250mg x 30's pack: 127.80 MRP
500mg x 30's pack: 207.60 MRP
+ NAPRYN Tab. Healthcare
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 350.00 MRP
500mg x 30's pack: 550.00 MRP
+ NAPRYN Gel Healthcare
Naproxen 10% w/w: gel preparation
Use & admin: Apply locally 3-4 times daily
with gentle massage.
l 5gm pack: 70.00 MRP
t NAPSOD Tab. UniMed & UniHealtb
Naproxen sodium 275mg & 550mg/tablet
275mg x 30's pack: 150.00 MRP
550mg x 30's pack: 270.00 MRP
t NAPTODIN 500 Tab. Desh Pharma
Naproxen sodium 500mg/tablet
500mg x 50's pack: 450.00 IP
t NASOX Tab. Seema
Naproxen sodium 500mg/tablet
500mg x 20's pack: 300.00 MRP
t NASPRO Tab. Pop,Ular
Naproxen sodil1m 250mg & 500mg/tablet
250mg x SO's pack: 251.00 MRP
500mg x 30's pack: 270.90 MRP
+ NAXIN Tab. Opsonin
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 219 .92 MRP
500mg x 30's pack: 237.39 MRP
+ NAXO Tab. Navana
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 201.00 MRP
500mg x 50's pack: 351.51 MRP
t NEPROXEN SR Tab. Zenith
Naproxen sodi11m 500mg/tablet (sustained,
release). _
500mg x 30's pack: 300.00 MRP
Naproxen
t NIPOXEN 250 Tab. NIPRO JMI
Naproxen sodium 250mg/tablet
250mg x 50's pack: 250.00 MRP
t NIPOXEN 500 SR Tab. NIPRO JMI
Naproxen sodi11m 500mg/tablet (s.r)
30's pack: 420.00 MRP
t NOZEE 500 Tab. MST Pharma
Naproxen sodium 500mg/tablet
500mg x 30's pack: 210.00 MRP
t NUPRAFEN Tab. Beximco
Naproxen sodium 250mg & 500mg/tablet
250mg x 1OO's pack: 420.00 IP
500mg x 50's pack: 392.50 IP
t NUPRALGIN Tab. Ibo Sina
Naproxen sodium 250mg & 500mg/tablet
250mg x 48's pack: 240.00 IP
500mg x 24's pack: 216.00 IP
t PAIROX Tab. Asiatic
Naproxen sodium BP 250mg & 500mg/tablet
250mg x 50's pack: 250.00 MRP
500mg x 30's pack: 240.00 MRP
+ PROXEN 500 Tab. MonicoPharma
Naproxen sodium BP 500mg/tablet
250mg x 50's pack: 350.00 MRP
+ RANOXEN Tab. Rangs Pharma
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 200.00 IP
500mg x 30's pack: 210.00 IP
t REPKO 500 Tab. Doctor's
Naproxen sodium 500mg/tablet
500mg x 30's pack: 210.00 MRP
t ROXEN Tab. Hallmark
Naproxen sodi11m 250mg & 500mg/tablet.
250mg x 50's pack: 200.00 MRP
500mg x 30's pack: 210.00 MRP
t SERVINAPROX Tab. Sandoz
Naproxen sodium 250mg & 500mg/tablet.
250mg x 50's pack: 350.00 MRP
500mg x 30's pack: 360.00 MRP
+ SONAP Tab. Square
Naproxen sodi11m 250mg & 500mg/tablet
250mg x 50's pack: 200.50 MRP
500mg x 30's pack: 210.60 MRP
+ SONAP Suppo. Square
Naproxen sodium 500mg/suppository.
500mg x 1O's pack: 120.50 MRP
t SONAP Gel Square
Naproxen 10% w/w: gel preparation
Use & admin: Apply locally 3-4 times daily
with gentle massage.
15gm pack: 60.22 MRP
+ SUXEN Gel Supreme
Naproxen 10% w/w: gel preparation
Use & admin: Apply locally 3-4 times daily
with gentle massage.
l 5gm pack: 62.00 MRP
t TICOFLEX Tab. Incepta
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 200.00 MRP
500mg x SO's pack: 350.00 MRP
t TICOFLEX SR Tab. Incepta
Naproxen sodium 500mg/tablet (s.r)
30's pack: 240.00 MRP
t TICOFLEX Susp. I.ncepta
Naproxen sodium 125mg/5ml: suspension

ANTIRHEUMATIC & ANTI-INFLAMMATORY DRUGS
50ml bot: 35-.00 MRP ·
• T ICOFLEX Gel Incepta
Naproxen 10% w/w: gel preparation
Use: Apply locally 3-4 times daily with gentle
massage.
l 5gm pack: 60.00 MRP
• TOFA Tab. Kemiko
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 200.00 MRP
500mg x 50's pack: 400.00 MRP
• ULT RANAX Tab. Ad-din
Naproxen sodium 500mg/tablet
500mg x 30's pack: 240.00 MRP
• XENAPRO Tab. Renata
Naproxen sodium 250mg & 500mg/tablet
250mg x 50's pack: 250.00 MRP
500mg x 30's pack: 240.90 MRP
• XPRO Tab. Apex
Naproxen sodium 500mg/tablet
500mg x 30's pack: 210.00 MRP
• ZENOSYN Tab. Sharif
Naproxen sodium 500mg/tablet
500mg x 30's pack: 210.00 MRP
NAPROXEN + ESOMEPRAZOLE26
NAPROXEN + ESOMEPRAZOLE: Tablet
Combination preparations of naproxen and
esomeprazole are available in two fixed-dose
presentations, viz: i. Naproxen BP 375mg +
Esomeprazole magnesium trihydrate BP
equivalent to esomeprazole 20mg/tablet; and
ii. Naproxen BP 500mg + Esomeprazole
magnesit1m trihydrate BP equivalent to
esomeprazole 20mg/tablet.
In these preparations esomeprazole magnesium
forms an immediate release outer layer and
naproxen forms an enteric coated delayed release
inner core. As a result esomeprazole is released
frrst into the stomach, prior to the dissolution of
naproxen in the small intestine.
Mode of action: Naproxen is an NSAID with
analgesic and antipyretic properties. Naproxen
acts by inhibiting the synthesis of prostaglandin.
Esomeprazole is a proton pump inhibitor that
suppresses gastric acid secretion by specific
inhibition of the H+/K+-ATPase in the gastric
parietal cell. By acting specifically on the proton
pump, esomeprazole blocks the fmal step in acid
production, thus reducing gastric acidity.
Ind: This combination is indicated for the relief
of signs and symptoms of osteoarthritis, rehuma­
toid arthritis and ankylosing spondylitis, dysmen­
orrhoea and at the same time to decrease the risk
of developing gastric ulcers in patients at risk of
developing NSAID associated gastric ulcers.
C/I: Known hypersensitivity to any component
of these combinations. History of asthma,
urticaria, or other allergic-type reactions after
taking aspirin or other NSAIDs. Use during the
peri-operative period in the setting of coronary
artery bypass graft (CABG) surgery. Late
pregnancy.
S/E: In general, this combination is well
tolerated. The most common adverse reactions in
clinical trials (>5%) are erosive gastritis,
dyspepsia, gastritis, diarrhea, gastric ulcer, upper
abdominal pain, nausea etc.
Precautions: Patients with known CV disase/
risk factors may be at greater risk. These
r
QIMP-17 (348)
preparations should be used with caution in
patients with fluid retention or heart failure.
Pregnancy & lactation: Pregnancy category C.
In late pregnancy, it should be avoided because it
may cause premature closure of the ductus arter­
iosus. These combinations should not be used in
ex®
Naproxen SOOmg + Esomeprazole 20mg
nursing mothers due to the naproxen component.
Dosage & admin: In rheumatoid arthritis,
Naproxen 375mg + Esomeprazole 20mg
osteoarthritis, ankylosing spondylitis and
dysmenorrhoea- the recommended dosages of
these combined preparations (naproxen 375mg
Approved & recommended therapy for + esomeprazole 20mg, or naproxen 500mg +
esomeprazole 20mg) are same i.e 1 tablet
twice daily.
• Osteoarthritis Bu� before prescribing these combinations
carefully consider the potential benefits and
• Rheumatoid arthritis risks of these preparations and other
treatment options. Use the lowest effective I
• Ankylosing spondylitis dose for the shortest duration consistent with
individual patient treatment goals. If a dose of
esomeprazole lower than a total daily dose of
• Patients at risk of developing 40mg is more appropriate, a different ·
NSAID induced ulcer treatment should be considered.
Do not spli� chew, crush or dissolve the tablet.
T hese drugs are to be taken at least 30
minutes before meals.
Children: Dosage in children less than 18 years
has not been established.
Renal impairment: Naproxen-contain.ing prod­
ucts are not recommended for use in patients
with moderate to severe or severe renal
impairment (creatinine clearance <30ml/min).
Hepatic insufficiency: Monitor patients with
mild to moderate hepatic impairment closely
and consider a possible dose reduction based
on the naproxen component. These drug
•
combinations are not recommended in patients
_
s.r-c
-,r
"...,.
• ,.
's
.
__
.4
____.
.... .. ·�
with severe hepatic impairment because
esomeprazole dosa.ge should not exceed 20mg
daily in these patients.
Drug inter: Concomitant use of NSAIDs may
reduce the antihypertensive effect of ACE
inhibitors, diuretics, and beta-blockers.
• Protects stomach during effective Concomitant use of these combinations and
warfarin may result in increased risk of bleeding
management of pain complications.
Esomeprazole inhibits gastric acid secretion and
may interfere with the absorption of drugs where
• Minimum chance of developing gastric pH is an important determinant of bioava­
NSAID induced ulcer ilability (eg, ketoconazole, iron salts & digoxin).
• ANAFLEX Max 375 Tab. ACI
• Provides cardio protection Naproxen sodium 375mg + esomeprazole 20mg/
tablet
375mg x 32's pack: 256.00 MRP
• Requires only one tablet instead • ANAFLEX Max 500 Tab. ACI
Naproxen sodium 500mg + esomeprazole 20mg/
of two tablet
500mg x 32's pack: 320.00 MRP
• DEMOVO 375 Tab. Delta Pharma
• Economic treatment option Naproxen sodium 375mg + esomeprazole 20mg/
tablet
375mg x 24's pack: 192.00 MRP
•· DEMOVO 500 Tab. Delta Pharma
ACI Naproxen sodium 500mg + esomeprazole 20mg/
tablet
� 500mg x 24's pack: 240.00 MRP
• DINOVO 375/20 Tab. Beximco
Naproxen sodium 375mg + esomeprazole 20mg/
tablet
375mg x 50's pack: 400.00 MRP
 QIMP-17 (349) AN'l'IRHEUMATIC & ANTI-INFLAMMATORY DRUGS

t DINOVO 500/20 Tab. Beximco tablet

Naproxen sodium 500mg + esomeprazole 20mg/ 375mg x 30's pack: 240.00 MRP
tablet t NAPROXEN Plus 50o+20 Tab. Zenith
500mg x 50's pack: 500.00 MRP Naproxen sodium 500mg + esomeprazole 20mg/
t ESONA 375/20 Tab. Navana tablet

)
Naproxen sodium 375mg + esomeprazole 20mg/
® 500mg x 30's pack: 300.00 MRP
tablet t NAPSEC-375 Tab. Drug Inter.
375mg x 30's pack: 240.00 MRP Naproxen sodium USP 375mg + esomeprazole
t ESONA 500/20 Tab. Navana Naproxen 375 mg & Esomeprazole 20 mg Tablet USP 20mg/tablet
Naproxen 500 mg & Esomeprazole 20 mg Tablet
Naproxen sodium 500mg + esomeprazole 20mg/ 375mg x 30's pack: 240.00 MRP
tablet t NAPSEC-500 Tab. Drug Inter.
500mg x 30's pack: 300.00 MRP Managing pain ensuring Naproxen sodium USP 500mg + esomeprazole
t INFLECT-375 Tab. Kemiko GI & Cardiac safety USP 20mg/tablet
Naproxen sodi11m 375mg + esomeprazole 20mg/ 500mg x 30's pack: 300.00 MRP
tablet t NAPXON 375 Tab. Ziska
375mg x 20's pack: 160.00 MRP Naproxen sodium 375mg + esomeprazole 20mg/
t INFLECT-500 Tab. ·Kemiko tablet
Naproxen sodium 500nasonexmg + esomeprazole
�'''''
� 375mg x 32's pack: 256.00 MRP
®
20mg/ tablet ·
t NAPXON 500 Tab. Ziska
500mg x 20's pack: 200.00 MRP Naproxen sodium 500mg + esomeprazole 20mg/
t NAMESO 375 Tab. Opsonin tablet
Naproxen sodium 375mg + esomeprazole 20mg/
Ketorolac Tromethamine 500mg x 32's pack: 320.00 MRP
30 mg IV/IM & 60 mg IM Injection
tablet 10 mg Tablet t NASOPAIN 375/20 Tab. RAK Pharma
375mg x 30's pack: 211.13 MRP Naproxen sodium 375mg + esomeprazole 20mg/
t NAMESO 500 Tab. Opsonin
• •

tablet
Excellent in Acute Pain
Naproxen sodium 500mg + esomeprazole 20mg/ 375mg x 30's pack: 300.00 MRP
tablet Management t NASOPAIN 500/20 Tab. RAK Pharma
500mg x 30's pack: 263.90 MRP Naproxen sodium 500mg + esomeprazole 20mg/
t NAPRO-A Plus 375 Tab. Acme tablet
Naproxen sodium 375mg + esomeprazole 20mg/ 500mg x 30's pack: 360.00 MRP
tablet + NES0-375 Tab. Aristopharma
375mg x 30's pack: 240.00 MRP Naproxen sodium 375mg + esomeprazole 20mg/
t NAPRO-A Plus 500 Tab. Acme tablet
Naproxen sodium 500mg + esomeprazole 20mg/ 375mg x 40's pack: 320.00 MRP
tablet + NES0-500 Tab. Aristopharma
500mg x 30's pack: 300.00 MRP Naproxen 250 & 500 mg Tablet Naproxen sodium 500mg + esomeprazole 20mg/
t NAPROFLEX 375 Tab. Somatec tablet
Naproxen sodium 375mg + esomeprazole 20mg/ Cardiac friendly NSAID 500mg x 40's pack: 400.00 MRP
tablet t NOVOXEN 375 Tab. Orion Pharma
375mg x 32's pack: 256.00 MRP Naproxen sodium 375mg + esomeprazole 20mg/
t NAPROFLEX 500 Tab. Somatec tablet
Naproxen sodium 500mg + esomeprazole 20mg/ 375mg x 20's pack: 160.00 MRP
·
tablet t NOVOXEN 500 Tab. Orion Pharma
500mg x 32's pack: 320.00 MRP Naproxen sodium 500mg + esomeprazole 20mg/
t NAPROSYN Plus 375/20 Tab. Radiant tablet
Naproxen sodit1m 375mg + esomeprazole 20mg/ 500mg x 20's pack: 200.00 MRP
tablet ® t NUPRALGIN PLUS 375 Tab. lbn Sina
MRP
ero Naproxen sodium 375mg + esomeprazole 20mg/
375mg x 48's pack: 768.00
t NAPROSYN Plus 500/20 Tab. Radiant tablet
Aceclofenac 100 mg Tablet
Naproxen sodium 500mg + esomeprazole 20mg/ 375mg x 30's pack: 240.00 IP
tablet t NUPRALGIN PLUS 500 Tab. Ibn Sina
An NSAID that rebuild the cartilage
•

500mg x 24's pack: 480.00 MRP Naproxen sodium 500mg + esomeprazole 20mg/
t NAPROTEC 375 Tab. Sharif tablet·
Naproxen sodium 375mg + esomeprazole 20mg/
'
500mg x 30's pack: 300.00 IP
tablet t PROGESIC 375 Tab. Incepta
375mg x 30's pack: 240.00 MRP Naproxen �odium 375mg + esomeprazole 20mg/
t NAPROTEC 500 Tab. Sharif tablet
Naproxen sodium 500mg + esomeprazole 20mg/ 375mg x 30's pack: 240.00 MRP
tablet t PROGESIC 500 Tab. Incepta
500mg x 30's pack: 300.00 MRP Naproxen sodiym 500mg + esomeprazole 20mg/
t NAPROX Plus 375 Tab. SK+F tablet .: •

Naproxen sodium 375mg + esomeprazole 20mg/ 500mg x 28's pack: 280.00 MRP
tablet
t PROGUT-N 375 Tab. Popular
375mg x 30's pack: 240.00 MRP Naproxen sodium 375mg + esomeprazole 20mg/
·

t NAPROX Plus 500 Tab. SK+F tablet

Naproxen sodium 500mg + esomeprazole 20mg/ 375mg x 30's pack: 240.00
.
MRP
tablet
-� PROGUT-N 500 Tab. Popular
�

500mg x 30's pack: 300.00 MRP

Naproxen sodium 500mg + esomeprazole 20mg/
t NAPROXEN Plus 375+20 Tab. Zenith .
•

tablet
Naproxen sodium 375mg + esomeprazole 20mg/ 500mg x 28's pack: 300.00 MRP

L
 ANTIRHEUMATIC & ANTI-INFLAMMATORY DRUGS QIMP-17 (350)

+ SOLIVO 375 Tab. Healthcare with oxaprozin in patients with considerable Suppository
Naproxen sodium 375mg + esomeprazole 20mg/ dehydration. It is advisable to rehydrate patients Ind: Rhe11matoid arthritis, osteoarthrosis,
tablet first and then start therapy with oxaprozin. ankylosing spondylitis, acute musculo-skeletal
375mg x 30's pack: 390.00 MRP Caution is also recommended in patients with disorders and acute gout.
t SOLIVO 500 Tab. Healthcare preexisting kidney disease. Fluid retention and C/I: Active peptic ulcer, history of recurrent
Naproxen sodium 500mg + esomeprazole 20mg/ edema: Fluid retention and edema have been ulceration; recent proctitis, aspirin or any non­
,_

tablet observed in some patients taking NSAIDs. steroidal anti-inflammatory induced allergy.
500mg x 30's pack: 450.00 MRP Therefore, as with other NSAIDs, oxaprozin S/E: See under Naproxen; also rarely oedema.
t TWIST Tab. Chemist should be used with caution in patients with fluid Cautions: Pregnancy, lactation, impaired hepatic
Naproxen sodium BP 500mg + esomeprazole retention, hypertension or heart failure. Warnings: function; oedematous states; concurrent admin.
20mg/ tablet Serious GI toxicity, such as peptic ulceration, of plasma protien-bound drugs; proctitis &
500mg x 50's pack: 500.00 MRP perforation and GI bleeding, sometimes severe haemorrhoids
t XENOLE 375 Tab. Square and occasionally fatal, can occur at any time, Dosage & admin: By mouth: Adult,general
Naproxen sodium 375mg + esomeprazole 20mg/ with or without symptoms in patients treated with use- 20mg daily as a single dose.
oxaproz1n.
•

tablet Musculo-skeletal disorders: Initially 40mg daily

375mg x 30's pack: 240.00 MRP Pregnancy & lactation: There are no adequate for 2 days then 20mg. daily for 7-14 days.
t XENOLE 500 Tab. Square or well-controlled studies in pregnant women. Gout,initially 40mg, as a single dose,then
Naproxen sodium 500mg + esomeprazole 20mg/ So, oxaprozin should be used during pregnancy 40mg, daily in single or divided doses for next
tablet only if the potential benefits justify the potential 4-6 days
500mg x 30's pack: 300.00 MRP risks to the fetus. It is not known whether this Juvenile arthritis: Less than 15 kg body wt.
drug is excreted in h11man milk. Because many 5mg daily; 16-25kg lOmg daily; 20-4Skg 15mg
drugs are excreted in human milk, therefore daily; over 46kg,20mg daily.
OXAPROZIN52 oxaprozin is not recommended for lactating Child: Not recommended.
mothers. By deep i.m injection:
OXAPROZIN: Tablet Dosage & admin: Adult: Rheumatoid arthritis, Rheumati.c disease: Initially 20mg daily,
Oxaprozin is a non-steroidal anti-inflammatory 1200mg (two 600mg tablets) once daily; maintenance 10-30mg daily,in single or
drug that exhibits anti-inflammatory, analgesic Osteoarthritis,1200mg (two 600mg tablets) divided doses.
and antipyretic properties. Oxaprozin is available once daily. Juveenile RA: Child- >46kg body wt. 20mg
as oxaprozin USP 600mg film coated tablet. Children: Juvenile rheumatoid arthritis (6-16 daily,26-4Skg body wt. 15mg once daily,16-
Mode of action: The mechanism of action of years of age), the recommended dose based on 2Skg body wt. lOmg once daily,<lSkg body
oxaprozin is like that of other NSAIDs, that are the body weight is given bellow: wt. 5mg once daily.
related to prostaglandin synthesis. Child's weight 22-31 kg,600mg once daily; 32- Acute musculoslceletal disorders: 40mg daily in
Ind: Oxaprozin is indicated for relief of the signs 54 kg, 900mg once daily; >SS kg, 1200mg once single or divided doses for 2 days,then 20mg
and symptoms of: osteoarthritis, rheumatoid daily. daily for 7-14 days; child not recommended.
arthritis & juvenile rheumatoid arthri tis, ankylos­ The maximum recommended total daily dose Actue gout: 40mg initially,then 40mg daily in
ing spondylitis, tendonitis, bursitis & acute gout. of oxaprozin in adults is 1800mg (or 26mg/kg, single or divided doses for 4-6 days; child not
C/I: Oxaprozin is contraindicated in patients with whichever is lower),to be given in divided recommended.
known hypersensitivity to any of the components doses. In children,doses greater than 1200mg
of the formulation. It should not be given to pati­ have not been studied. Patients of low body
t FLEXICAM Cap. Renata
Piroxicam 1Omg/capsule
ents who have experienced asthma, urticaria, or weight and patients with severe renal
IOO's pack: 167.00 MRP
allergic-type reactions after taking aspirin or other impairment or on dialysis should initiate
NSAIDs. Oxaprozin should be avoided in those therapy with 600mg once daily.
t FLEXICAM I.M lnj. Renata
Piroxicam 40mg/2ml ampoule: i.m injection
with a history of peptic ulcer or GI bleeding. Drug inter: Oxaprozin and other NSAIDs can
2ml amp x 1 's pack: 14.72 MRP
S/E: The more frequent reactions are nausea, reduce the anti-hypertensive effect of propranolol
vomiting, abdominal discomfort and epigastric and other beta-blockers. The natriuretic effects of
t RHEUDENE Cap. Gaco
Piroxicam 1Omg/capsule
distress, skin rashes, urticaria, tinnitus, edema, frusemide have been reported to be inhibited by
IOO's pack: 175.00 MRP
headache, insomnia, cognitive dysfunction, ane­ some drugs of this class. Concurrent
mia etc. The more serious reactions like gastroin­ administration of methotrexate may enhance its
testinal bleeding, peptic ulceration, haemorrhage, toxicity due to reduce tubular secretion. Animal SULINDAC133
perforation, colitis etc may occur occasionally. studies indicate that the prompt administration of

Precautions & warnings: General: Oxaprozin activated charcoal in adequate amounts would SULINDAC: Tablet
cannot be expected to substitute for corticos­ tend to reduce markedly the absorption of the drug. Sulindac is a non-steroidal antirheumatic agent
teroids or to treat corticosteroid insufficiency. Overdose: In cases of accidental overdoses, possessing anti-inflammatory, analgesic and anti­
Abrupt discontinuation of corticosteroids may patients should be managed by symptomatic and pyretic properties. It is available as sulindac BP
lead to disease exacerbation. Patients on prologed supportive care following an NSAID overdose. 1OOmg tablet.
cortiosteroid therapy should have their therapy Storage: Store in a cool dry place. Protect from Ind: Sulindac is indicated for the symptomatic
tapered slowly if a decision is made to discontin­ light. treatment of the rheumatoid arthri tis, osteoarthri­
ue corticosteroids. Hepatic effects: Borderline tis, ankylosing spondylitis, periarticular inflam­
t DAYPROX Tab. SK+F
elevations of one or more liver tests may occur in Oxaprozin USP 600mg/tablet (film coated).
matory disorders, acute painful shoulder (acute
up to 15% of patients taking NSAIDs including subacromial bursitis/supraspinatus tendinitis), and
600mg x 30's pack: 210.01 MRP
oxaprozin. Notable elevations of ALT or AST acute gouty arthritis.
(approximately three or more times the upper C/I: Patients with known allergy to sulindac.
limit of normal) have been reported in approxi­ PIROXICAM21,33 Patients in whom acute asthmatic attacks,
mately 1% of patients in NSAIDs. Renal effects: urticaria or rhinitis have been precipitated by
Caution should be used when initiating treatment PIROXICAM: Capsule/ Injection/ aspirin or other NSAIDs. Sulindac is also con-

.. .
The· World Wide Accepted
eombin.atlon of NSAID-f! R l. !gs'
lnflect�3.751500 Tablet
. , :_;.: "-' · . .
·
_ 375 mg 20 mg & 500 mg 20 mg
•

+ +

;�}�· ����1%���'t,nt�i'*c·eU.l. fe&Ls:['tjj�, �H(::·:" _-.� ,, .

: .,.,,.,.,..�. Naproxen BP & Esomeprazole USP
.
. . •:·: �. : .
.
·
· :
r ' M).;�� . . :..
:n
'
�;
·
·..,..
·....; :.... _:--..;It
ir : . .. ..:·.:::· .: � i.
� ¥: ·. · :.-"· ;.::
-;:· ---�·

_
. .· .
'* •: _;� -� : i :; : �
.:�-·
:?:. �
..... J :
�:-:-: . -. · -: ·�
�m:--
i�:-�
�:�1-
::·:..;�
::
-�-
.... - ..:··.
�-
: =:..:� ;;.·
�: :
· .-�··z.a.. -
jl;
.
•

traindicated in patients with a history of active
gastro-intestinal bleeding or peptic ulceration.
S/E: Gastro-intestinal side effects are the most
common and consist of abdominal pain, nausea
and constipation. Gastro-intestinal ulceration and
bleeding may also occur. The most frequently
reported central nervous system side effects are
-
•
drowsiness, dizziness, headache and nervousness.
Other adverse effects include depression, tinnitus,
confusion, light-headedness, insomnia,
•
psychiatric disturbances, syncope, convulsions,
coma, peripheral neuropathy, blurred vision and
other ocular effects, oedema and mass gain,
hypertension, hematuria, skin rashes, pruritus,
urticaria, stomatitis, alopecia and hypersensitivity
reactions. A hypersensitivity syndrome consisting
of fever and chills, skin rashes or other cutaneous
manifestations, hepatotoxicity, renal toxicity
(including renal failure), leukopenia,
thrombocytopenia, eosinophilia, inflamed glands
or lymph nodes, and arthralgia has been reported.
Precautions: Patients intolerant to one of the
non-steroidal anti-inflammatory ana_lgesics,
including aspirin, may be intolerant to sulindac.
Sulindac should be administered with caution to
patients with impaired renal function and to those
with bleeding disorders, epilepsy, Parkinsonism
or psychiatric disorders. In the presence of liver
function impairment the halflife of sulindac is
prolonged and a reduction of daily dosage may
be required.
Pregnancy & lactation: Sulindac should be used
during the first two trimesters of pregnancy only
if the potential benefit justifies the potential risk
to the foetus. Use of sulindac during the third
trimester of pregnancy is not recommended. It is
not known whether sulindac is excreted in human
milk. So, a decision should be made whether to
•
discontinue nursing or discontinue the medicine
taking into acconut the importance of the
medicine to the mother.
Dosage & ad min: The usual dosage is 1 OOmg
to 200mg twice a day; although dosages should
be optimized for each individual. The maximal
daily dose is 400mg. Therapy for 7 days in
acute gouty arthritis and for 7 to 14 days in
-
•
acute painful shoulder is usually sufficient.
After a satisfactory response has been
achieved, the dosage may be reduced
according to the response. Sulindac should be
taken with food.
Drug inter: Sulindac and its sulphide metabolite
are highly protein bound. Patients should be
monitored carefully until it is certain that no
change in their anticoagulant or hypoglycaemic
dosage is required.
t CLINOREL Tab. Opsonin
Sulindac BP 1OOmg & 200mg/tablet.
IOOmg x 50's pack: 219.92 MRP
200mg x 30's pack: 251. 77 MRP
t L IND AC Tab. Popular
Sulindac BP 1 OOmg & 200mg/tablet.
l OOmg x 50's pack: 251.00MRP
200mg x 50's pack: 477.00 MRP
t SULIDAC Tab. SK+F
Sulindac BP 1 OOmg/tablet.
IOOmg x SO's pack: 250.00 MRP
+ SULIN Tab. Alco Pharma
Sulindac BP 1 OOmg/tablet.
lOOmg x l OO's pack: 250.00 MRP
QIMP-17 (351)
TM
Naproxen 375 mg+ Esomeprazole 20 mg &
Naproxen 500 mg+ Esomeprazole 20 mg Tablet
Naproxen with built-in
GI protection
• Provides pain relief with
excellent GI protection
• Provides better cardiovascular
safety profile
• Convenient twice daily dosing
PHARMACEUTICALS LTD.
BANGLADESH
•
AN'I'IRHEUMATIC & ANTI-INFLAMMATORY DRUGS
TENOXICAM50
TENOXICAM: Tablet
Tenoxicam is a non-steroidal agent with
antiinflammatory and analgesic properties. It is
available as- Tenoxicam 20mg tablet.
Ind: Symptomatic treatment of the following
painful inflammatory and degenerative disorders
of the musculoskeletal system- rheumatoid
arthritis, osteoarthritis, arthrosis, ankylosing
spondylitis; extra-articular disorders, e.g tendinitis,
bursitis, periarthritis of shoulders (shoulder-hand
syndrome) or· hips, strains & sprains.
C/I: Known hypersensitivity to the drug. Patients
in whom salicylates or other nonsteroidal anti­
inflammatory drugs (NSAIDs) induce symptoms
of asthma, rhinitis or urticaria. Patients who are
suffering or have suffered from severe dseases of
the upper gastrointestinal tract, including
gastritis, gastric and duodenal ulcer. Concurrent
treatment with salicylates or other NSAIDs
should be avoided.
S/E: Tenoxicam was found well tolerated in the
recommended dosage.
Undesirable effects that reported were mild and
transient. Frequency greater than 1%:
Gastrointestinal tract- gastric, epigastric and
abdominal discomfort, dyspepsia, heartburn, nau­
sea; Central nervous system- dizziness, headache.
Frequency less than 1%: Gastrointestinal tract­
constipation, diarrhea, stomatitis, gastritis, vomit­
ing, ulcers, GI-bleeding including hematemesis
and melena; Central nervous system- fatigue,
sleep disturbances, appetite loss, dry mouth, ver­
tigo; Skin- itching, erythema, exanthema, rash,
urticaria; Urinary tract and kidneys- increase in
BUN or creatinine, edema; Liver and biliary
tract- increased liver enzyme activity;
Cardiovascular system- palpitations. In a small
proportion of patients the interruption of treat­
ment due to undesirable effects was necessary.
Precautions: Monitor cardiac and renal function
in patients with conditions that could increase
their risk of developing renal failure, sub as pre­
existing renal disease, impaired renal function in
diabetics, hepatic cirrhosis, congestive heart
failure, volume depletion or concomitant
treatment with potentially nephrotoxic drugs,
diuretics and corticosteroids. Patients having
coagulation disorders or receiving drug therapy
that interferes with haemostasis. Any patient with
symptoms of gastrointestinal disease should be
closely monitored. If peptic ulceration or
gastrointestinal bleeding occurs, tenoxicam
should be immediately withdrawn. If severe skin
reactions (e.g Lyell's or Stevens-Johnosn
syndrome) occur, the treatment should be
discontinued immediately.
Pregnancy & lactation: Chronic treatment
during the third trimester of pregnancy should be
avoided. Infants should be weaned or the drug
discontinued.
Dosage & admin: 20mg at the same time of
the day.
t ENOCAM Tab. Acme
Tenoxicam 20mg/tablet.
20mg x 30's pack: 240.00 MRP
t INOTEN Tab. Opsonin
Tenoxicam 20mg/tablet.
 •
®
Tenoxicam 20mg tab
Ideal NSAID for long term use in
• Osteoarthritis
• Rheumatoid arthritis
8 • Ankylosing spondylitis
20mg x 30's pack: 211.92 MRP
t MOBICAM Tab. Beximco
Tenoxicam 20mg/tablet.
20mg x 30's pack: 240.00 MRP
t OXICAM Tab. ACI
Tenoxicam 20mg/tablet.
20mg x 30's pack: 240.90 MRP
t TENOFLEX Tab. Beacon
Tenoxicam 20mg/tablet.
20mg x 30's pack: 240.00 MRP
t TENORIX Tab. Orion Pharma
Tenoxicam 20mg/tablet.
20mg x 30's pack: 240.90 MRP
t TEXICAM Tab. Apex
Tenoxicam 20mg/tablet.
20mg x 20's pack: 160.00 MRP
t TILCOTIL Tab. Radiant
Tenoxicam 20mg/tablet.
20mg x 50's pack: 850.50 MRP
t XICO'I'IL Tab. Aristopharma
Tenoxicam 20mg/tablet.
20mg x 30's pack: 240.00 MRP
t XTEN Tab. Square
Tenoxicam 20mg/tablet.
20mg x 30's pack: 240.00 MRP
TOJ,fE.NAMIC ACID65
TOLFENAMIC ACID: Tablet
Tolfenamic acid is an NSAID with anti­
inflammatory, analgesic and antipyretic effects. It
is available as tolfenamic acid BP 200mg tablet
Mode of action: Tolfenamic acid acts by
inhibiting prostaglandin and leukotriene synthesis.
Ind: Acute migraine.
C/I: Tolfenamic acid is contraindicated in active
peptic ulceration, significantly impaired kidney
or liver function and in patients in whom attacks
of asthma, urticaria or acute rhinitis are
precipitated by aspirin or other NSAIDs.
S/E: Tolfenamic acid is well tolerated at the
recommended dosage. The side effects include­
diarrhoea, nausea, epigastric pain, vomiting,
dyspepsia, isolated reports of gastric ulceration,
drug exanthema, erythema, pruritus, urticaria and
occasional harmless dysuria in the form of
smarting during urination in males. The
occurrence is correlated with the concentration of
a metabolite and is most probably due to local
irritation of the urethra. Increased consumption of
liquid or reduction of the dose diminishes the risk
of smarting. The urine may, due to coloured
metabolites, become a little more lemon­
coloured. As is the case with the use of other
NSAIDs, the occasional side effects includde
headache, vertigo, tremor, euphoria, fatigue,
isolated cases of dyspnoea, pulmonary
infiltration, bronchospasm and asthma attack,
isolated cases of thrombocytopenia, anemia and
leucopenia, isolated cases of reversible liver
function disturbances and toxic hepatitis.
Precautions: As is the case with other NSAIDs,
tolfenamic acid should be used with caution in
patients with a history of gastrointestinal
ulceration, or impaired liver or kidney function.
QIMP-17 (352)
Pregnancy & lactation: Studies in pregnant
women are not available. As is the case with ·the
use of other NSAIDs, tolfeamic acid should not
be given in the last trimester, due to risks of pre­
mature closure of the ductus arteriosus and pro­
longed parturi tion. Tolfenamic acid is excreted to
such a very small extent in mothers' milk that it
should be without risk to the breast-fed baby.
D�sage & admin: Adults: 200mg when the
first symptoms of migraine appear. The
treatment can be repeated once after 1-2 hours
if a satisfactory response in not obtained.
.
Elderly: Normal adult dose.
Children: Paediatric use yet not been
established.
Drug inter: In patients treated with
anticoagulants, close monitoring of blood
coagulation is recommended. The effect of loop
diuretics may be reduced. The effect of lithium
may be increased.
• ®
Tolfenarnic acid tablet
SK•F
t ARAIN Tab. Opsonin
Tolfenamic acid BP 200mg/tablet
200mg x 30's pack: 211.92 MRP
t NAMITOL Tab. ACI
Tolfenamic acid BP 200mg/tablet
200mg x 30's pack: 240.00 MRP
t TOLMIC Tab. Benmco
Tolfenamic acid BP 200mg/tablet
200mg x 30's pack: 240.90 IP
t T UFNIL Tab. SK+F
Tolfenamic acid BP 200mg/tablet
200mg x 40's pack: 400.00 MRP
Combined Preparations
DICLOFENAC SODIUM +
MISOPROSTOL48
DICLOFENAC SODIUM +MISOPROSTOL:
Tablet
It is a combination product containing diclofenac
sodium, a nonsteroidal anti-inflammatory drug
(NSAID) with analgesic properties, and
misoprostol, a gastrointestinal mucosal protective
prostaglandin E1 analog.
The combined preparations are available as
enteric-coated tablets in two strengths, viz: i.
tablets containing diclofenac sodium BP 50mg in
the core surrounded by an outer mantle of
misoprostol INN 200mcg; ii. tablets containing
diclofenac sodium BP 75mg in the core
surrounded by an outer mantle of misoprostol
INN 200mcg.
Mode of action: The mechanism of action of
diclofenac sodium, like other NSAIDs, is not
completely understood but may be related to
prostaglandin synthetase inhibition. NSAIDs
inhibit prostaglandin synthesis. A deficiency of
prostaglandins within the gastric and duodenal
mucosa may lead to diminish bicarbonate and
mucous secretion and may contribute to the
mucosal damage caused by NSAIDs. Misoprostol
can increase bicarbonate and mucous production
& prevents gastric and duodenal ulcers.
Ind: This combination is indicated for treatment
of the signs and symptoms of osteoarthritis or
rheumatoid arthritis in patients at high risk of
developing NSAID-induced gastric and duodenal
ulcers and their complications.
C/I: Diclofenac sodium and misoprostol
combination, because of the abortifacient
property of the misoprostol component, is
contraindicated in women who are pregnant.
S/E: The most common reported side-effects are
abdominal pain, diarrhoea and other g.i
symptoms. Diarrhoea and abdominal pain
developed early in the course of therapy, and are
usually self-limited (resolve after 2 to 7 days).
Rare instances of profound diarrhoea leading to
severe dehydration have been reported in patients
receiving misoprostol.
Precautions: Patients with an underlying
condition such as inflammatory bowel disease, or
those in whom dehydration should be monitored
carefully if diclofenac sodium and misoprostol
combination is prescribed.
Geriatric use: No overall differences in safety or
effectiveness were observed between these
subjects and younger subjects, and other reported
clinical experience has not identified differences
in responses between the elderly and younger
patients, but greater sensitivity of some older
individuals cannot be ruled out. As with any
NSAID, the elderly are likely to tolerate adverse
events less well than younger patients.
Pregnancy & lactation: Diclofenac sodium has
been found in the milk of nursing mothers. It is
unlikely that misoprostol is excreted into milk
since the drug is rapidly metabolized throughout
the body. Excretion of the active metabolite
(misoprostol acid) into milk is possible, but has
not been studied. Because of the potential for
serious adverse reactions in nursing infants,
• •
diclofenac sodium and misoprostol combination
is not recommended for use by nursing mothers.
Dosage & admin: Osteoarthritis: The recom­
mended dosage for maximal g.i mucosal pro­
tection is diclofenac sodium SOmg plus miso­
prostol 200mcg 3 times daily. For patients who
experience intolerance, diclofenac sodium
7Smg plus misoprostol 200mcg 2 times daily or
diclofenac sodium SOmg plus misoprostol
200mcg 2 times daily can be given.
Rheumatoid arthritis: The recommended
dosage is diclofenac sodium SOmg plus miso­
prostol 200mcg 3 or 4 times daily. For patients
'
who experience intolerance, diclofenac sodium
7Smg plus misoprostol 200mcg 2 times daily or
diclofenac sodium SOmg plus misoprostol
200mcg 2 times daily can be given.
Paediatric use: Safety & effectiveness of diclo­
f enac sodium & misoprostol combination in
paediatric patients have not been established.
Drug inter: Aspirin: Concomitant administration
with aspirin is not recommended because
diclofenac sodium is displaced from its binding
sites by aspirin, resulting in lower plasma con­
centrations, peak plasma levels and AUC values.

Digoxin: Elevated digoxin levels have been
reported in patients receiving digoxin and
diclofenac sodium. Antihypertensive: NSAIDs
can inhibit the activity of antihypertensives,
including ACE inhibitors. Thus, caution should
be taken when administering it with such agents.
Warfarin: The effects of warfarin and NSAIDs
on GI bleeding are synergistic, such that users of
both drugs together have a risk of serious bleed­
ing greater than users of either drug alone. Oral
hypoglycaemics: Diclofenac sodium does not
alter glucose metabolism in healthy people nor it
alters the effects of oral hypoglycaemics. There
are rare reports, however, from marketing expe­
rience, of changes in effects of insulin or oral
hypoglycaemics in the presence of diclofenac
sodium that necessitated change in the doses of
such agents. Both hypo- and hyperglycaemic
effects have been reported. A direct causal
relationship has not been established, but
physicians should consider the possibility that
diclofenac sodium may alter a diabetic patient's
response to insulin or oral hypoglycaemics.
Antacids: Antacids reduce the bioavailability of
misoprostol acid. Antacids may also delay
absorption of diclofenac sodium. Magnesium­
containing antacids exacerbate misoprostol­
associated diarrhea. So, it is not recommended to
be coadministered with magnesium-containing
antacids. Diuretics: The diclofenac sodium
component like other NSAIDs, can inhibit the
activity of diuretics. Concomitant therapy with
potassium-sparing diuretics may be associated
with increased serum potassium levels.
+ APAIN-MS Tab. Kemiko
Diclofenac sodium BP 75mg + misoprostol INN
200mcg/tablet
30's pack: 330.00 MRP
+ ARTHROFEN 50 Tab. Healthcare
Diclofenac sodium BP 50mg + misoprostol INN
200mcg/tablet
30's pack: 300.00 MRP
+ ARTHROFEN 75 Tab. Healthcare
Diclofenac sodium BP 75mg + misoprostol INN
200mcg/tablet
30's pack: 360.00 MRP
+ ERDON SUPER-SO Tab. Aristopharma
Diclofenac sodium BP 50mg + misoprostol INN
200mcg/tablet
30's pack: 300.00 MRP
+ ERDON SUPER-75 Tab. Aristopharma
Diclofenac sodium BP 75mg + misoprostol INN
200mcg/tablet
30's pack: 330.00 MRP
+ MICLOFENAC 50 Tab. Square
Diclofenac sodium BP 50mg + misoprostol INN
200mcg/tablet
30's pack: 301.20 MRP
+ MICLOFENAC 75 Tab. Square
Diclofenac sodium BP 75mg + misoprostol INN
200mcg/tablet
30's pack: 331.20 MRP
+ MIFENAC-50 Tab. Rephco
Diclofenac sodium BP 50mg + misoprostol INN
200mcg/tablet
1 OO's pack: 800.00 MRP
+ MIFENAC-75 Tab. Rephco
Diclofenac sodium BP 75mg + misoprostol INN
200mcg/tablet
lOO's pack: 1000.00 MRP
QIMP-17 (353)
+ MISOCLO Tab. General
Diclofenac sodium BP 50mg + misoprostol INN
200mcg/tablet
20's pack: 200.80 MRP
+ MISOCLO-75 Tab. General
Diclofenac sodium BP 75mg + misoprostol INN
200mcg/tablet
20's pack: 220.80 MRP
+ MISOFEN Tab. Somatec
Diclofenac sodium BP 75mg + misoprostol INN
200mcg/tablet
30's pack: 331.20 IP
+ NOPAIN Extra 50 Tab. Drug Inter.
Diclofenac sodium USP 50mg + misoprostol BP
200mcg/tablet
20's pack: 200.00 MRP
+ NOPAIN Extra 75 Tab. Drug Inter.
Diclofenac sodium USP 75mg + misoprostol BP
200mcg/tablet
30's pack: 330.00 MRP
+ PANFRE Plus 50 Tab. Pacific
Diclofenac sodium BP 50mg + misoprostol INN
200mcg/tablet
30's pack: 300.00 MRP
+ PROFENAC Plus Tab. Popular
Diclofenac sodium BP 50mg + misoprostol INN
200mcg/tablet
20's pack: 200.80 MRP
+ ULT RAFEN Plus Tab. Beximco
Diclofenac sodium BP 50mg + misoprostol INN
200mcg/tablet
50's pack: 500.00 IP
+ ULTRAFEN Plus 75 Tab. Beximco
Diclofenac sodium BP 75mg + misoprostol INN
200mcg/tablet
30's pack: 330.00 IP
Cordcosteroids
Systemic and local corticosteroids used in rheu­
matic & inflammatory musculoskeletal disaeses
such as, dexamethasone, hydrocortisone, pred­
nisolone & methyl prednisolone, triamcinolone
discussed in the section of corticosteroid drugs
under endocrine system.
Drugs which suppress the
Rheumadc disease processi•
or
Disease-modifying
Andrheumadc drug
There are some drugs such as, gold, penicil­
lamine, hydroxychloroquine, chloroquine, sul­
phasalazine, immunosuppressants (e.g lefluno­
mide, methotrexate) & cytoldne modulators (e.g
tocilizumab) may suppress the disease process in
rheumatic arthritis. They are sometimes known as
second-line or disease-modifying antirheumatic
drugs. Unlike NSAIDs they do not produce an
immediate therapeutic effect but require 4-6
months of treatment for a full response. If one of
these drugs does not lead to objective benefit
within 6 months, it should be discontinued.
HYDROXYCHLOROQUINE26
ANTIRHEUMATIC & ANTI-INFLAMMATORY DRUGS
HYDROXYCHLOROQUINE SULPHATE:
Tablet
Hydroxychloroquine sulphate is a synthetically
produced derivative of quinine, acting as an
immunosuppressant. It is available as hydroxy­
chloroquine sulphate BP 200mg tablet (f.c).
Mode of action: Hydroxychloroquine sulphate
acts as an immunosuppressant by inhibiting pro­
duction of rheumatoid and acute phase reactants.
It also accumulates in white blood cells,
stabilizing lysosomal membranes & inhibiting the
activity of many enzymes, including collagenase
and the proteases that cause cartilage breakdown.
It also acts by disrupting cell walls of infected
red blood cells and kills the developing malarial
parasites.
Ind: 1. Acute and chronic rheumatoid arthri tis, 2.
Systemic lupus erythematosus (SLE), 3. Malaria.
C/I: The presence of retinal or visual field changes
attributable to any 4-aminoquinoline compound;
patients with known hypersensitivity to 4-aminoq­
uinoline compounds; long term therapy in children.
S/E: Generally hydroxychloroquine sulphate is
well tolerated. However, few side effects like
nausea, vomiting, stomach upset, loss of appetite,
diarrhea, tiredness, weakness or headache and
visual problem may occur the first several days.
Precautions: Children are specially sensitive to
the 4- aminoquinoline compounds. Patients should
be strongly warned to keep these drugs out of
the reach of children. Opthalmologic examination
requires in every 12 months.
Pregnancy & lactation: During pregnancy, this
drug should be used only if clearly needed. Since
small amount of this drug is found in the breast
milk, it should not be given a nursing mother
without consulting the concerned physician.
Dosage & admin: Hydroxychloroquine
sulphate tablets are taken orally with food to
avoid stomach upset.
Acute and chronic rheumatoid arthritis: 400 to
600mg daily. When good response is obtained
(usually 4-8 wks.), dose can be reduced to 50o/'o.
Systemic Lupus Erythematosus (SLE): 400mg
once or twice daily for several weeks or
months depending on response of the patients.
Maintenance dose is 200 to 400mg daily.
Malaria: Adults, an initial dose of 800mg
followed by 400mg in 6-8 hours and 400mg on
each of two consecutive days. Children, a total
dose calculating 2Smg/kg is administered in 3
days as follows: First dose- lOmg base/kg (but
not exceeding a single dose of 620mg base);
Second dose- 5mg base/kg (but not exceeding a
si.ngle dose of 31Omg base) 6 hours after first
dose; Third dose- 5mg base/kg 18 hours after
second dose; Fourth dose- Smg base/kg 24
hours after third dose.
* Hydroxychloroquine sulphate BP 200mg
equivalent to 15Smg of base.
Overdosage: Symptoms of overdose consist of
headache, drowsiness, visual disturbances, car­
diovascular collapse, and convulsions, followed
by sudden and early respiratory and cardiac
arrest. Gastric lavage until the stomach is com­
pletely emptied.
Drug inter: Antibiotics, neostigmine,
chloroquine, antacids.
+ RECONIL Tab. Incepts
Hydroxychloroquine sulphate BP 200mg/tablet
ANTIRHEUMATIC & ANTI-INFLAMMATORY DRUGS
30's pack: 360.00 MRP
t ROQUIN Tab. Zenith
Hydroxychloroquine sulphate BP 200mg/ tablet
30's pack: 360.00 MRP
LEFLUNOMJDE26
LEFLUNOMIDE: Tablet
Leflunomide is an isoxazole immunomodulatory
agent which acts on the immune system, has been
introduced recently as a disease-modifying
antirheumatic drug (DMARD).
Mode of action: In rheumatoid arthritis,
inflammation and subsequent degradation of
synovial tissues are initiated by the influx of
lymphocytes (B cells, CD4+, and CDS+ T cells)
into the synovial tissue.
Leflunomide inhibits lymphocyte proliferation by
blocking dihydroorotate dehydrogenase, an
enzyme involved in de novo pyrimidine
production necessary for DNA synthesis. In this
way, leflunomide inhibits the lymphocyte
proliferation associated with the clonal expansion
of T cells in rheumatoid arthritis.
Ind: Leflunomide is indicated in adults for the
treatment of active 'rheumatoid arthritis' to reduce
signs and symptoms and to retard structural
damage as manifested by x-ray erosions and joint
.
space narrowmg.
.
C/I: Known hypersensitivity to leflunomide or
any of the other components; hepatic impairment;
severe uncontrolled infections; and bone marrow
dysplasia.
S/E: Adverse reactions associated with the use of
leflunomide include- diarrhea, nausea, vomiting,
abdominal pain, headache, respiratory infection,
bronchitis, elevated liver enzymes, aggravation of
pre-existing hypertension, alopecia, and rash.
Precautions: Caution should be taken for those
female with child bearing potential who are not
using reliable contraception and for the subject of
renal insufficiency. Leflunomide should be
stopped before becoming pregnant. Liver function
should be monitored before starting treatment.
Pregnancy & lactation: Leflunomide is not
recommended for pregnant women. Pregnancy
must be avoided during leflunomide treatment or
prior to the completion of the drug elimination
procedure after leflunomide treatment. It is not
known whether leflunomide is excreted in human
milk, but there is a potential for serious adverse
reactions in nursing infants from leflunomide.
Therefore, leflunomide should not be used by
nursing mothers. Incas·e of therapeutic
importance of the drug to the mother, a decision
should be made whether to proceed with nursing
or initiate treatment with leflunomide.
Dosage & admin: Initially a loading dose of
lOOmg once daily for 3 days. T hen a
maintenance dose of 20mg once daily. The
dose may be decreased to 1 Omg daily if
tolerability issues arise.
Children: Not recommended for children
below 18 years of age.
Drug inter: Cholestyramine and activated
charcoal help rapid elimination of leflunomide
from the body. Increased side effects may occur
when leflunomide given concomitantly with
hepatotoxic substances.
Overdosage: There is no human experience
QIMP-17 (354)
regarding leflunomide overdosage. In the event
of a significant overdose or toxicity,
cholestyramine or charcoal administration is
recommended to accelerate elimination.
t NODIA Tab. Incepta
Leflunomide INN lOmg &lOOmg/tablet (f.c).
1Omg x 1OO's pack: 300.00 MRP
lOOmg x 3's pack: 60.00 MRP
METHOTREXATE
Methotrexate preparations are discussed under
cytotoxic antimetabolites in the chapter-16 for
carcinochemotherapy.
TOCILIZUMAB21•50
TOCILIZU MAB: Injection for i.v infusion
Tocilizumab is a cytokine modulator; it inhibits
interleukin-6 (IL-6) receptor. It is available as-
80mg/4ml, 200mg/lOml & 400mg/20ml (i.e
20mg/ml) in single-dose vials; injection for i.v
infusion.
Mode of action: Tocilizumab antagonises the
action of interleukin-6 receptor.
Ind: Tocilizumab is indicated for treatment of:
1. Rheumatoid Arthritis (RA): Tocilizumab is
indicated for adult patients with moderately to
severely active rheumatoid arthritis when
response to at least one disease-modifying
antirheumatic drug (DMARD) or tumour necrosis
factor ( T NF) inhibitor has been inadequate, or in
those who are intolerant of those drugs.
Tocilizumab can be used in combination with
methotrexate, or as monotherapy if methotrexate
is not tolerated or is contraindicated.
2. Systemic Juvenile Idiopathic Arthritis (SJIA):
Patients 2 years of age and older with active
systemic juvenile idiopathic arthritis.
C/I: Tocilizumab should not be administered to
patients with known hypersensitivity to
tocilizumab.
S/E: Most common adverse reactions (incidence
of at least 5%): Upper respiratory tract
infections, nasopharyngitis, headache,
hypertension, increased ALT.
Precautions & warnings: Serious infections
such as- tuberculosis (TB), bacterial, invasive
fungal, viral, and other opportunistic infections
have occurred in patients receiving tocilizumab.
If a serious infection develops, interrupt
tocilizumab until the infection is controlled.
Perform test for latent TB; if positive, start treat­
ment for TB prior to starting tocilizumab.
Monitor all patients for active TB during treat­
ment, even if initial latent TB test is negative.
Gastrointestinal (GI) perforation- use with
caution in patients who may be at increased risk.
Laboratory monitoring- recommended due to
potential consequences of treatment-related
changes in neutrophils, platelets, lipids, and liver
function tests.
Hypersensitivity reactions, including anaphylaxis
and death have occurred.
Live vaccines- should not be given with
tocil izumab.
Pregnancy & lactation: Based on animal data,
may cause fetal harm. Therefore, it is not recom­
mended during pregnancy & breast-feeding.
Dosage & admin: Tocilizumab may be used
alone or in combination with methotrexate,
and in RA, other DMARDs.
Rheumatoid arthritis: Recommended adult
dosage every 4 weeks. Patients who have had
an inadequate response to one or more TNF
'
antagonists when used in combination with
DMARDs or as monotherapy the recommend­
ed starting dose is 4mg/kg followed by an
increase to 8mg/kg based on clinical response.
Systemic Juvenile Idiopathic Arthritis:
Recommended dosage every 2 weeks.
Patients less than 30kg weight 12mg/kg.
Patients at or above 30kg weight 8mg/kg.
General dosing information: It is recommend­
ed that tocilizumab not be initiated in patients
with an absolute neutrophil count (ANC)
below 2000/mmJ, platelet count below
100,000/mmJ, or who have ALT or AST above
1.5 times the upper limit of normal (ULN).
Tocilizumab doses exceeding 800mg per infu­
sion are not recommended in RA patients.
Method of administration: For adults and SJIA
·
patients at or above 30kg, dilute to 1 OOml of
0.9°/o sodium chloride for intravenous infusion
using aseptic technique.
For SJIA patients less than 30kg, dilute to.
50ml of 0.9o/o sodium chloride for intravenous
infusion using aseptic technique.
Administer as a single i.v drip infusion over 1
hour; do not administer as bolus or push.
Dose modifications: Recommended for
management of certain dose-related
laboratory changes including elevated liver
enzymes, neutropenia, and thrombocytopenia.
+ ACTEMRA Inj. Roche/Radiant
Tocilizumab 80mg/4ml & 200mg/lOml (i.e
20mg/ml) in single-use vials; injection for i.v
infusion.
80mg (4ml) vial x l 's pack: 11,500.00 TP
200mg ( lOml) vial x l's pack: 28,750.00 TP
OTHER PRODUCTS
Chloroquine: See under anti-malarial drugs.
Sulphasalazine: See under antibacterial
chemotherapeutics.
Drugs used in Gout
ALLOPURINOVI,33
ALLOPURINOL: Tablet.
Ind: Gout; primary and secondary hyperuri­
cemia; prophylaxis of uric acid and calcium
oxalate stones
C/I: Acute gout.
S/E: Rashes, sometimes with fever, gastro­
intestinal disordesr, drowsiness; rarely malaise,
headache, vertigo, taste disturbances;
hypertension; symptomless zanth.ine deposists in
muscle; alopecia; hepatitis; (Sometimes rashes
may be the sign of impending hypersensitivity
reaction- withdraw therapy but when rash is
mild reintroduce cautiously, discontinue
immediately on recurrence).
Caution: Pregnancy; renal or hepatic dysfunc­
tion. When initiating therapy also give colchicine

or an anti-inflammatory agent for 1 month.
Concurrent admin. of anticoagulants, 6-mercap­
topurine or azathioprine.
Dosage & admin: Adult: initially 100-300mg
daily in divided doses; maintenance, 200-
600mg daily in divided doses.
Child: Not recommended.
+ ALURIC Tab. Sonear
Allopurinol 1OOmg/tablet
1OOmg x 1OO's pack: 410.00 MRP
+ ALUROL Tab. Incepta
Allopurinol 1OOmg/tablet
l OOmg x l OO's pack: 400.00 MRP
+ DURIC Tab. Opsonin
Allopurinol 1OOmg/tablet
l OOmg x 50's pack: 176.82 MRP
+ ESLORIC Tab. Square
Allopurinol 1OOmg & 300mg/tablet
l OOmg x l OO's pack: 401.00 MRP
300mg x 30's pack: 241.20 MRP
+ GOUTEX Tab. Biopharma
Allopurinol 1OOmg/tablet
1OOmg x 1OO's pack: 402.00 MRP
+ PURINOL Tab. Unimed & unihealth
Allopurinol 1OOmg & 300mg/tablet
IOOmg x 30's pack: 120.00 MRP
300mg x 30's pack: 360.00 MRP
COLCIDCINE26•129
COLCHICINE: Tablet.
Colchicine is used to help prevent gout and to
treat sudden severe attacks of gout. It is available
as colchicine USP 0.5mg and 0.6mg/tablet.
Mode of action: In gout, crystals of uric acid are
deposited in certain joints of the body, where
white blood cells migrate to that areas of uric
acid deposition. They attempt to engulf the crys­
tals, as a result, lactic acid and pro-inflammatory
enzymes are released. These substances give rise
to the characteristic pain and swelling of gout.
Colchicine inhibits the migration of the white
blood cells to the inflammed areas, causing a
reduction in pain and inflama
m tion.
Ind: i. Prophylaxis and treatment of gout flares
in adults. ii. Familial Mediterranean fever (FMF)
in adults and children 4 years or older
C/I: Blood disorders
S/E: Nausea, vomiting, and abdominal pain.
Excessive doses may cause profuse diarrhea,
Precaution: Pregnancy & lactation.
Pregnancy & lactation: There are no adequate
studies of colchicine in pregnant women.
Colchicine is excreted into human milk and may
cause adverse effects in the infant.
Dosage & admin: Gout flares:
QIMP-17 (355)
swelling typically reduced within12 hours and
are usually gone in 24 to 48 hours, An interval
of 3 days between colchicine courses is advised
in order to minimize the possibility of
cumulative toxicity. The total amount of
colchicine needed to control pain and
inflammation during an attack usually ranges
from 4 to 8mg. First dose-1 to1.2mg (two
0.5mg or two 0.6mg tablets) at a time every 2
hours until pain and inflammation relieved;
maximum 6mg per course; course not be
repeated within 3 days.
Colchicine is administered orally without
regard to meals.
Pediatric patients: Gout is rare in pediatric
patients, safety and effectiveness of colchicine
in pediatric patients has not been established.
So, colchicine is not recommended for
pediatric use in gout flares.
Familial mediterranean fever (FMF) in adults
& children 4 years or older: The recommended
dosage:
Children 4-6 years, 0.3mg to1.8mg daily;
Children 6-12 years, 0.9mg to1.8mg daily;
Older than 12 years, 1.2mg to 2.4mg daily.
Drug inter: Co-administration with clarithro­
mycin or cyclosporine have been demonstrated to
alter the concentration of colchicine.
+ COLURIC Tab. UniMed & UniHealth
Colchicine USP 0.6mg/tablet.
0.6mg x 14's pack: 105.00 MRP
+ KOLCHIN Tab. Incepta
Colchicine USP 0.5mg and 0.6mg/tablet.
0.5mg x 30's pack: 120.00 MRP
0.6mg x 30's pack: 150.00 MRP
FEBUXOSTAT26
FEBUXOSTAT: Tablet
Febuxostat is a non-purine selective xanthine
oxidase (XO) inhibitor, approved for the chronic
management of hyperuricemia in patients with
gout. It is available as febuxostat INN 40mg &
80mg in tablet form.
Mode of action: Febuxostat lowers serum uric
acid levels by blocking xanthine oxidase- the
enyzme responsible for uric acid production.
Xanthine oxidase breaks down hypoxantine (a
natural-occurring purine derivative) to xanthine
and then to uric acid.
Ind: Febuxostat is indicated for the chronic
management of hyperuricemia in patients with
gout. It is not recommended for the treatment of
asymptomatic or secondary hyperuricemia, nor is
indicated for treatment of acute gout.
C/I: Febuxostat is contraindicated in patients
-
sta
ACME
Monitor for signs and symptoms of MI and
stroke and discuss with physician.
Liver enzyme elevation: Transaminase elevations
have been observed in febuxostat treated patients.
Monitor liver function tests periodically.
Pregnancy & lactation: Pregnancy category C:
There are no adequate and well-controlled studies
in pregnant women. Febuxostat should be used
during pregnancy only if the potential benefit
justifies the potential risk to the fetus.
It is not known whether this drug is excreted in
hl1man milk. Because many drugs are excreted in
human milk, caution should be exercised when
febuxostat is administered to a nursing woman.
Dosage & admin: Febuxostat is recommended
at 40mg-80mg once daily. The starti.ng dose
recommended as 40mg once daily. For patients
who do not achieve a serum uric acid (sUA)
less than 6mg per di after 2 weeks with 40mg,
febuxostat 80mg is recommended.
Febuxostat can be taken without regard to
food or antacid use.
�o dose adjustment is necessary in patients
with mild to moderate renal or hepatic
impairment.
Children: Not recommended under12 years.
Drug inter: Concomitant administration of
febuxostat with azathioprine, mercaptopurine or
theophylline could increase plasma concentrations
of these drugs resulting in severe toxicity.
+ BARIF Tab. Square
Febuxostat INN 40mg & 80mg/tablet.
40mg x 30's pack: 360.00 MRP
80mg x l O's pack: 220.00 MRP
+ FEBURIC 40 Tab. Beximco
Febuxostat INN 40mg/tablet.
40mg x 30's pack: 360.00 MRP
+ FEBUS Tab. ACI
Febuxostat INN 40mg & 80mg/tablet.
40mg x 30's pack: 360.00 MRP
80mg x 30's pack: 660.00 MRP
+ FEBUSTAT Tab. Incepta
Febuxostat INN 40mg & 80mg/tablet.
40mg x 30's pack: 360.00 MRP
80mg x 30's pack: 660.00 MRP
,
+ FEBUX Tab. Aristopharma
Febuxostat INN 40mg & 80mg/tablet.
40mg x 30's pack: 360.00 MRP
80mg x 1O's pack: 220.00 MRP
+ FEBUX 40 Tab. MonicoPharma
Febuxostat INN 40mg/tablet.
40mg x 20's pack: 240.00 MRP